PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Jiang, PH; Cui, M; Zhao, BH; Liu, Z; Snyder, LA; Benard, LMJ; Osman, R; Margolskee, RF; Max, M				Jiang, PH; Cui, M; Zhao, BH; Liu, Z; Snyder, LA; Benard, LMJ; Osman, R; Margolskee, RF; Max, M			Lactisole interacts with the transmembrane domains of human T1R3 to inhibit sweet taste	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; CONFORMATIONAL-CHANGES; ALLOSTERIC MODULATOR; MAMMALIAN SWEET; RECEPTOR GENE; SODIUM-SALT; HORMONE TRH; IDENTIFICATION; ENERGY; ACID	The detection of sweet-tasting compounds is mediated in large part by a heterodimeric receptor comprised of T1R2+T1R3. Lactisole, a broad-acting sweet antagonist, suppresses the sweet taste of sugars, protein sweeteners, and artificial sweeteners. Lactisole's inhibitory effect is specific to humans and other primates; lactisole does not affect responses to sweet compounds in rodents. By heterologously expressing interspecies combinations of T1R2+T1R3, we have determined that the target for lactisole's action is human T1R3. From studies with mouse/human chimeras of T1R3, we determined that the molecular basis for sensitivity to lactisole depends on only a few residues within the transmembrane region of human T1R3. Alanine substitution of residues in the transmembrane region of human T1R3 revealed 4 key residues required for sensitivity to lactisole. In our model of T1R3's seven transmembrane helices, lactisole is predicted to dock to a binding pocket within the transmembrane region that includes these 4 key residues.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai	Max, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1677,1425 Madison Ave, New York, NY 10029 USA.	max@inka.mssm.edu		Margolskee, Robert/0000-0002-9572-2887	NIDCD NIH HHS [1 F32 DC007021-01, DC003155, DC003055] Funding Source: Medline; NIMH NIH HHS [MH58811] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F32DC007021, R01DC003155, R01DC003055] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bachmanov AA, 2001, CHEM SENSES, V26, P925, DOI 10.1093/chemse/26.7.925; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Binet V, 2004, J BIOL CHEM, V279, P29085, DOI 10.1074/jbc.M400930200; BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Damak S, 2003, SCIENCE, V301, P850, DOI 10.1126/science.1087155; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Frisch G.W., 2016, GAUSSIAN 16 REVISION; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Jiang P, 2005, CHEM SENSES, V30, pI17, DOI 10.1093/chemse/bjh091; Jiang PH, 2004, J BIOL CHEM, V279, P45068, DOI 10.1074/jbc.M406779200; JOHNSON C, 1994, CHEM SENSES, V19, P349, DOI 10.1093/chemse/19.4.349; Kitagawa M, 2001, BIOCHEM BIOPH RES CO, V283, P236, DOI 10.1006/bbrc.2001.4760; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; Malherbe P, 2001, MOL PHARMACOL, V60, P944, DOI 10.1124/mol.60.5.944; Manivet P, 2002, J BIOL CHEM, V277, P17170, DOI 10.1074/jbc.M200195200; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270; Montmayeur JP, 2001, NAT NEUROSCI, V4, P492, DOI 10.1038/87440; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perlman JH, 1996, BIOCHEMISTRY-US, V35, P7643, DOI 10.1021/bi952202r; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schiffman SS, 1999, CHEM SENSES, V24, P439, DOI 10.1093/chemse/24.4.439; Schmidt C, 2003, J BIOL CHEM, V278, P30248, DOI 10.1074/jbc.M304991200; Sclafani A, 1997, PHYSIOL BEHAV, V61, P25, DOI 10.1016/S0031-9384(96)00316-2; Strader C D, 1991, Adv Exp Med Biol, V287, P209; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueda T, 2003, J NEUROSCI, V23, P7376; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; Xu H, 2004, P NATL ACAD SCI USA, V101, P14258, DOI 10.1073/pnas.0404384101; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	43	220	233	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15238	15246		10.1074/jbc.M414287200	http://dx.doi.org/10.1074/jbc.M414287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15668251	hybrid			2022-12-25	WOS:000228236800109
J	Liu, W; Yang, N; Ding, JJ; Huang, RH; Hu, Z; Wang, DC				Liu, W; Yang, N; Ding, JJ; Huang, RH; Hu, Z; Wang, DC			Structural mechanism governing the quaternary organization of monocot mannose-binding lectin revealed by the novel monomeric structure of an orchid lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES LISTERA-OVATA; ANTIFUNGAL PROTEIN; EPIPACTIS-HELLEBORINE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SNOWDROP LECTIN; PLANT-LECTINS; BULB LECTIN; ANGSTROM; AGGLUTININ	Two isoforms of an antifungal protein, gastrodianin, were isolated from two subspecies of the orchid Gastrodia elata, belonging to the protein superfamily of monocot mannose-specific lectins. In the context that all available structures in this superfamily are oligomers so far, the crystal structures of the orchid lectins, both at 2.0 angstrom, revealed a novel monomeric structure. It resulted from the rearrangement of the C-terminal peptide inclusive of the 12th beta-strand, which changes from the "C-terminal exchange" into a "C-terminal self-assembly" mode. Thus, the overall tertiary scaffold is stabilized with an intramolecular beta-sheet instead of the hybrid observed on subunit/subunit interface in all known homologous dimeric or tetrameric lectins. In contrast to the constrained extended conformation with a cis peptide bond between residues 98 and 99 commonly occurring in oligomers, a beta-hairpin forms from position 97 to 101 with a normal trans peptide bond at the corresponding site in gastrodianin, which determines the topology of the C-terminal peptide and thereby its unique fold pattern. Sequence and structure comparison shows that residue replacement and insertion at the position where the beta-hairpin occurs in association with cis-trans inter-conversion of the specific peptide bond (97-98) are possibly responsible for such a radical structure switch between monomers and oligomers. Moreover, this seems to be a common melody controlling the quaternary states among bulb lectins through studies on sequence alignment. The observations revealed a structural mechanism by which the quaternary organization of monocot mannose binding lectins could be governed. The mutation experiment performed on maltose-binding protein-gastrodianin fusion protein followed by a few biochemical detections provides direct evidence to support this conclusion. Potential carbohydrate recognition sites and biological implications of the orchid lectin based on its monomeric state are also discussed in this paper.	Chinese Acad Sci, Inst Biophys, Ctr Struct & Mol Biol, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China; Chinese Acad Sci, Kunming Inst Bot, Kunming 650204, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Kunming Institute of Botany, CAS	Wang, DC (corresponding author), Chinese Acad Sci, Inst Biophys, Ctr Struct & Mol Biol, Beijing 100101, Peoples R China.	dcwang@sun5.ibp.ac.cn	Huang, Ren-Huai/B-3610-2010	Ding, Jingjin/0000-0001-9941-7997				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bachhawat K, 2001, BIOCHEMISTRY-US, V40, P7291, DOI 10.1021/bi0027783; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410; Barre A, 1996, PLANT PHYSIOL, V112, P1531, DOI 10.1104/pp.112.4.1531; Barre A, 1999, PLANT MOL BIOL, V39, P969, DOI 10.1023/A:1006133527621; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chandra NR, 1999, J MOL BIOL, V285, P1157, DOI 10.1006/jmbi.1998.2353; Chantalat L, 1996, ACTA CRYSTALLOGR D, V52, P1146, DOI 10.1107/S090744499600546X; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Dam TK, 1998, J BIOL CHEM, V273, P5528, DOI 10.1074/jbc.273.10.5528; DRICKAMER K, 1995, NAT STRUCT BIOL, V2, P437, DOI 10.1038/nsb0695-437; HESTER G, 1995, NAT STRUCT BIOL, V2, P472, DOI 10.1038/nsb0695-472; Hester G, 1996, J MOL BIOL, V262, P516, DOI 10.1006/jmbi.1996.0532; HILDER VA, 1995, TRANSGENIC RES, V4, P18, DOI 10.1007/BF01976497; Hu Zhong, 1999, Acta Botanica Yunnanica, V21, P131; Hu Zhong, 1994, Acta Botanica Yunnanica, V16, P169; JIANG L, 1993, ACTA BOT SIN, V35, P593; JONES TA, 1993, O VERSION 5 9 MANUAL; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAH R, 1991, J BIOL CHEM, V266, P1564; Liu W, 2002, ACTA CRYSTALLOGR D, V58, P1833, DOI 10.1107/S0907444902014701; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARCHETTI M, 1995, RES VIROLOGY, V146, P211, DOI 10.1016/0923-2516(96)80581-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V42, P140; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347; RAHDE Y, 1995, ENTOMOL EXP APPL, V76, P143; RAIKHEL NV, 1993, ANNU REV PLANT PHYS, V44, P591, DOI 10.1146/annurev.pp.44.060193.003111; Ramachandraiah G, 2000, PROTEINS, V39, P358, DOI 10.1002/(SICI)1097-0134(20000601)39:4<358::AID-PROT80>3.0.CO;2-M; Ramachandraiah G, 2002, ACTA CRYSTALLOGR D, V58, P414, DOI 10.1107/S0907444901021497; Sauerborn MK, 1999, J MOL BIOL, V290, P185, DOI 10.1006/jmbi.1999.2862; SCHLUMBAUM A, 1986, NATURE, V324, P365, DOI 10.1038/324365a0; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; Srinivas VR, 2001, BBA-GEN SUBJECTS, V1527, P102, DOI 10.1016/S0304-4165(01)00153-2; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; Van Damme EJM, 2000, EUR J BIOCHEM, V267, P5067, DOI 10.1046/j.1432-1327.2000.01563.x; VANDAMME EJM, 1994, EUR J BIOCHEM, V221, P769, DOI 10.1111/j.1432-1033.1994.tb18790.x; VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52, DOI 10.1111/j.1399-3054.1988.tb09192.x; VANDAMME EJM, 1987, FEBS LETT, V215, P140, DOI 10.1016/0014-5793(87)80129-1; VANDAMME EJM, 1994, GLYCOCONJUGATE J, V11, P321, DOI 10.1007/BF00731205; VANPARIJS J, 1991, PLANTA, V183, P258, DOI 10.1007/BF00197797; VANPARIJS J, 1992, ARCH MICROBIOL, V158, P19, DOI 10.1007/BF00249060; Wang XC, 1999, ACTA BOT SIN, V41, P1041; Wang XC, 2001, PLANT J, V25, P651, DOI 10.1046/j.1365-313x.2001.00999.x; Wood SD, 1999, ACTA CRYSTALLOGR D, V55, P1264, DOI 10.1107/S0907444999005326; Wright CS, 1996, STRUCTURE, V4, P1339, DOI 10.1016/S0969-2126(96)00141-4; Wright LM, 2000, FEBS LETT, V468, P19, DOI 10.1016/S0014-5793(00)01109-1; Xu Q, 1998, PLANT PHYSIOL BIOCH, V36, P899, DOI 10.1016/S0981-9428(99)80008-4; YANG Z, 1990, Acta Botanica Yunnanica, V12, P421	55	25	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14865	14876		10.1074/jbc.M411634200	http://dx.doi.org/10.1074/jbc.M411634200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15649901	hybrid			2022-12-25	WOS:000228236800065
J	White, D; Aghigh, S; Magder, I; Cosson, J; Huitorel, P; Gagnon, C				White, D; Aghigh, S; Magder, I; Cosson, J; Huitorel, P; Gagnon, C			Two anti-radial spoke monoclonal antibodies inhibit Chlamydomonas axonemal motility by different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER DYNEIN ARMS; PARALYZED FLAGELLA; SEA-URCHIN; SEQUENCE-ANALYSIS; BENDING PATTERNS; WILD-TYPE; PROTEINS; MUTANTS; INNER; PHOSPHORYLATION	In the 9 + 2 axoneme, radial spokes are structural components attached to the A-tubules of the nine outer doublet microtubules. They protrude toward the central pair microtubule complex with which they have transient but regular interactions for the normal flagellar motility to occur. Flagella of Chlamydomonas mutants deficient in entire radial spokes or spoke heads are paralyzed. In this study the importance of two radial spoke proteins in the flagellar movement is exemplified by the potent inhibitory action of two monoclonal antibodies on the axonemal motility of demembranated-reactivated Chlamydomonas models. We show that one of these proteins is localized on the stalk of the radial spokes, whereas the other is a component of the head of the same structure and most likely correspond to radial spoke protein 2 and 1, respectively. Fine motility analysis by videomicrography further indicates that these two anti-radial spoke protein antibodies at low concentration affect motility of demembranated-reactivated Chlamydomonas by changing the flagellar waveform without modifying axonemal beat frequency. They also modify wave amplitude differently during motility inhibition. This brings more direct evidence for the involvement of both radial spoke stalk and head in the fine tuning of the waveform during flagellar motility.	McGill Univ, Ctr Hlth, Fac Med, Urol Res Lab, Montreal, PQ H3A 1A1, Canada; Univ Paris 06, Observ Oceanol, Stn Zool, Dept Biol Dev,CNRS,UMR 7009, F-06230 Villefranche Sur Mer, France	McGill University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite	White, D (corresponding author), McGill Univ, Ctr Hlth, Fac Med, Urol Res Lab, Montreal, PQ H3A 1A1, Canada.	dan7white@yahoo.ca						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROKAW CJ, 1985, CELL MOTIL CYTOSKEL, V5, P195, DOI 10.1002/cm.970050303; BROKAW CJ, 1990, CELL MOTIL CYTOSKEL, V17, P309, DOI 10.1002/cm.970170406; BROKAW CJ, 1982, J CELL BIOL, V92, P722, DOI 10.1083/jcb.92.3.722; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; Cosson J, 1996, CELL MOTIL CYTOSKEL, V35, P100, DOI 10.1002/(SICI)1097-0169(1996)35:2<100::AID-CM3>3.3.CO;2-U; CURRY AM, 1992, MOL CELL BIOL, V12, P3967, DOI 10.1128/MCB.12.9.3967; DIENER DR, 1993, J CELL BIOL, V123, P183, DOI 10.1083/jcb.123.1.183; Frey E, 1997, CELL MOTIL CYTOSKEL, V38, P91; Gagnon C, 1996, J CELL SCI, V109, P1545; GAGNON C, 1994, MOL BIOL CELL, V5, P1051, DOI 10.1091/mbc.5.9.1051; Gaillard AR, 2001, J CELL BIOL, V153, P443, DOI 10.1083/jcb.153.2.443; Galfre G, 1981, Methods Enzymol, V73, P3; GIBBONS IR, 1995, CELL MOTIL CYTOSKEL, V32, P136, DOI 10.1002/cm.970320214; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; Gingras D, 1996, J BIOL CHEM, V271, P12807, DOI 10.1074/jbc.271.22.12807; Gingras D, 1998, MOL BIOL CELL, V9, P513, DOI 10.1091/mbc.9.2.513; GOODENOUGH UW, 1985, J CELL BIOL, V100, P2008, DOI 10.1083/jcb.100.6.2008; Habermacher G, 1997, J CELL BIOL, V136, P167, DOI 10.1083/jcb.136.1.167; Hayashibe K, 1997, CELL MOTIL CYTOSKEL, V37, P232, DOI 10.1002/(SICI)1097-0169(1997)37:3<232::AID-CM5>3.0.CO;2-8; HUANG B, 1982, CELL, V28, P115, DOI 10.1016/0092-8674(82)90381-6; HUANG B, 1981, J CELL BIOL, V88, P80, DOI 10.1083/jcb.88.1.80; Kamiya R, 2002, INT REV CYTOL, V219, P115; KAMIYA R, 1995, CELL MOTIL CYTOSKEL, V32, P98, DOI 10.1002/cm.970320205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindemann CB, 2003, BIOPHYS J, V84, P4115, DOI 10.1016/S0006-3495(03)75136-4; LUCK DJL, 1984, J CELL BIOL, V98, P789, DOI 10.1083/jcb.98.3.789; Mitchell DR, 2000, J PHYCOL, V36, P261, DOI 10.1046/j.1529-8817.2000.99218.x; Omoto CK, 1996, CELL MOTIL CYTOSKEL, V33, P88; Omoto CK, 1999, MOL BIOL CELL, V10, P1; Patel-King RS, 2004, MOL BIOL CELL, V15, P3891, DOI 10.1091/mbc.E04-04-0352; PIPERNO G, 1977, P NATL ACAD SCI USA, V74, P1600, DOI 10.1073/pnas.74.4.1600; PIPERNO G, 1981, J CELL BIOL, V88, P73, DOI 10.1083/jcb.88.1.73; Porter ME, 1996, CURR OPIN CELL BIOL, V8, P10, DOI 10.1016/S0955-0674(96)80042-1; Porter ME, 2000, J CELL BIOL, V151, pF37, DOI 10.1083/jcb.151.5.F37; SAGER R, 1953, ANN NY ACAD SCI, V56, P831, DOI 10.1111/j.1749-6632.1953.tb30261.x; Satir P., 1979, The spermatozoon. Maturation, motility, surface properties and comparative aspects. Proceedings of the Third International Symposium on the Spermatozoon, held at the American Academy of Arts and Sciences, Boston, and the Swope Conference Center, Marine Biological Laboratories, Woods Hole, Massachusetts, May 2-5, 1978., P81; Smith EF, 2004, CELL MOTIL CYTOSKEL, V57, P8, DOI 10.1002/cm.10155; Smith EF, 2002, MOL BIOL CELL, V13, P3303, DOI 10.1091/mbc.E02-04-0185; SMITH EF, 1992, SCIENCE, V257, P1557, DOI 10.1126/science.1387971; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; WITMAN GB, 1978, J CELL BIOL, V76, P729, DOI 10.1083/jcb.76.3.729; Witman George B., 1993, Trends in Cell Biology, V3, P403, DOI 10.1016/0962-8924(93)90091-E; Yagi T, 2000, CELL MOTIL CYTOSKEL, V46, P190, DOI 10.1002/1097-0169(200007)46:3<190::AID-CM4>3.0.CO;2-#; Yang PF, 2000, J BIOL CHEM, V275, P18905, DOI 10.1074/jbc.M002134200; Yang PF, 2004, EUKARYOT CELL, V3, P72, DOI 10.1128/EC.3.1.72-81.2004; Yang PF, 2000, J CELL SCI, V113, P91; Yang PF, 2001, J CELL BIOL, V153, P1315, DOI 10.1083/jcb.153.6.1315	49	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14803	14810		10.1074/jbc.M414114200	http://dx.doi.org/10.1074/jbc.M414114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15664983	hybrid			2022-12-25	WOS:000228236800058
J	Hoque, M; Tian, B; Mathews, MB; Pe'ery, T				Hoque, M; Tian, B; Mathews, MB; Pe'ery, T			Granulin and granulin repeats interact with the Tat center dot P-TEFb complex and inhibit Tat transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; VIRUS TYPE-1 TAT; GROWTH-FACTOR; CYCLIN T1; EPITHELIN PRECURSOR; TERMINAL DOMAIN; HIV-1 TAT; GRANULIN/EPITHELIN PRECURSOR; DEPENDENT TRANSCRIPTION; GENE-EXPRESSION	The cellular positive transcription elongation factor b (P-TEFb), containing cyclin T1 and cyclin-dependent kinase 9 (CDK9), interacts with the human immunodeficiency virus, type 1 (HIV-1) regulatory protein Tat to enable viral transcription and replication. Cyclin T1 is an unusually long cyclin and is engaged by cellular regulatory proteins. Previous studies showed that the granulin/epithelin precursor (GEP) binds the histidine-rich region of cyclin T1 and inhibits P-TEFb function. GEP is composed of repeats that vary in sequence and properties. GEP also binds directly to Tat. Here we show that GEP and some of its constituent granulin repeats can inhibit HIV-1 transcription via Tat without directly binding to cyclin T1. The interactions of granulins with Tat and cyclin T1 differ with respect to their binding sites and divalent cation requirements, and we identified granulin repeats that bind differentially to Tat and cyclin T1. Granulins DE and E bind Tat but do not interact directly with cyclin T1. These granulins are present in complexes with Tat and P-TEFb in which Tat forms a bridge between the cellular proteins. Granulins DE and E repress transcription from the HIV-1 LTR and gene expression from the viral genome, raising the possibility of developing granulin-based inhibitors of viral infection.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Pe'ery, T (corresponding author), Univ Med & Dent New Jersey, NJMS, Dept Biochem, 185 S Orange Ave,MSB E615B, Newark, NJ 07013 USA.	peeryts@umdnj.edu		Tian, Bin/0000-0001-8903-8256	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031802, R21AI055331] Funding Source: NIH RePORTER; NIAID NIH HHS [AI055331, AI31802] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANAKWE OO, 1990, BIOL REPROD, V42, P317, DOI 10.1095/biolreprod42.2.317; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Brigati C, 2003, FEMS MICROBIOL LETT, V220, P57, DOI 10.1016/S0378-1097(03)00067-3; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Hoque M, 2003, MOL CELL BIOL, V23, P1688, DOI 10.1128/MCB.23.5.1688-1702.2003; Hrabal R, 1996, NAT STRUCT BIOL, V3, P747, DOI 10.1038/nsb0996-747; Ivanov D, 1999, J MOL BIOL, V288, P41, DOI 10.1006/jmbi.1999.2663; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Lu RQ, 2001, P NATL ACAD SCI USA, V98, P142, DOI 10.1073/pnas.011525198; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Ong CHP, 2003, HISTOL HISTOPATHOL, V18, P1275, DOI 10.14670/HH-18.1275; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 1999, J VIROL, V73, P5448, DOI 10.1128/JVI.73.7.5448-5458.1999; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Reza SM, 2003, VIROLOGY, V310, P141, DOI 10.1016/S0042-6822(03)00106-5; Serrero G, 2003, BIOCHEM BIOPH RES CO, V308, P409, DOI 10.1016/S0006-291X(03)01452-9; Shoham N, 2003, INTERVIROLOGY, V46, P239, DOI 10.1159/000072434; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Tolkatchev D, 2000, BIOCHEMISTRY-US, V39, P2878, DOI 10.1021/bi992130u; Trinh DP, 1999, BIOCHEM BIOPH RES CO, V256, P299, DOI 10.1006/bbrc.1999.0317; Vranken WF, 1999, J PEPT RES, V53, P590, DOI 10.1034/j.1399-3011.1999.00048.x; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xia XM, 1998, BIOCHEM BIOPH RES CO, V245, P539, DOI 10.1006/bbrc.1998.8498; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200; Young TM, 2003, MOL CELL BIOL, V23, P6373, DOI 10.1128/MCB.23.18.6373-6384.2003; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; Zheng YH, 2003, NAT CELL BIOL, V5, P611, DOI 10.1038/ncb1000; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	45	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13648	13657		10.1074/jbc.M409575200	http://dx.doi.org/10.1074/jbc.M409575200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15653695	hybrid			2022-12-25	WOS:000228095500059
J	Jacobs, MD; Black, J; Futer, O; Swenson, L; Hare, B; Fleming, M; Saxena, K				Jacobs, MD; Black, J; Futer, O; Swenson, L; Hare, B; Fleming, M; Saxena, K			Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; TRANSCRIPTIONAL ACTIVITY; PROTEIN; PHOSPHORYLATION; 3-KINASE; PEPTIDE; BINDING; DOMAIN; IDENTIFICATION	Pim-1 is an oncogene-encoded serine/threonine kinase primarily expressed in hematopoietic and germ cell lines. Pim-1 kinase was originally identified in Maloney murine leukemia virus-induced T-cell lymphomas and is associated with multiple cellular functions such as proliferation, survival, differentiation, apoptosis, and tumorigenesis (Wang, Z., Bhattacharya, N., Weaver, M., Petersen, K., Meyer, M., Gapter, L., and Magnuson, N. S. ( 2001) J. Vet. Sci. 2, 167-179). The crystal structures of Pim-1 complexed with staurosporine and adenosine were determined. Although a typical two-domain serine/threonine protein kinase fold is observed, the inter-domain hinge region is unusual in both sequence and conformation; a two-residue insertion causes the hinge to bulge away from the ATP-binding pocket, and a proline residue in the hinge removes a conserved main chain hydrogen bond donor. Without this hydrogen bond, van der Waals interactions with the hinge serve to position the ligand. The hinge region of Pim-1 resembles that of phosphatidylinositol 3-kinase more closely than it does other protein kinases. Although the phosphatidylinositol 3-kinase inhibitor LY294002 also inhibits Pim-1, the structure of the LY294002.Pim-1 complex reveals a new binding mode that may be general for Ser/Thr kinases.	Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals	Jacobs, MD (corresponding author), 130 Waverly St, Cambridge, MA 02139 USA.	marc_jacobs@vrtx.com	Jacobs, Marc/GYU-0672-2022	Jacobs, Marc/0000-0003-4153-3930				AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; BERG MM, 1992, J BIOL CHEM, V267, P13; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Chambers SP, 2004, PROTEIN EXPRES PURIF, V36, P40, DOI 10.1016/j.pep.2004.03.003; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DOMEN J, 1993, LEUKEMIA, V7, pS108; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Dumas J, 2001, EXPERT OPIN THER PAT, V11, P405, DOI 10.1517/13543776.11.3.405; El-Kholy W, 2003, FASEB J, V17, P720, DOI 10.1096/fj.02-0802fje; Ethier MF, 2002, CELL CALCIUM, V32, P31, DOI 10.1016/S0143-4160(02)00111-2; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; Fox T, 1999, FEBS LETT, V461, P323, DOI 10.1016/S0014-5793(99)01488-X; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Harris TE, 1996, BIOCHEM BIOPH RES CO, V227, P672, DOI 10.1006/bbrc.1996.1567; HASHIMOTO Y, 1991, BIOCHEM BIOPH RES CO, V181, P423, DOI 10.1016/S0006-291X(05)81436-6; HOOVER D, 1991, J BIOL CHEM, V266, P14018; Ishibashi Y, 2001, FEBS LETT, V506, P33, DOI 10.1016/S0014-5793(01)02881-2; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Krishnan N, 2003, ENDOCRINE, V20, P123, DOI 10.1385/ENDO:20:1-2:123; Krumenacker JS, 2001, J NEUROIMMUNOL, V113, P249, DOI 10.1016/S0165-5728(00)00430-6; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Limon AMP, 2003, MOL CELL ENDOCRINOL, V200, P199, DOI 10.1016/S0303-7207(02)00421-5; Maita H, 2000, EUR J BIOCHEM, V267, P5168, DOI 10.1046/j.1432-1327.2000.01585.x; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MIZUNO K, 1993, FEBS LETT, V330, P114, DOI 10.1016/0014-5793(93)80254-R; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P2556, DOI 10.1073/pnas.83.8.2556; Nagata Yuka, 1997, Leukemia (Basingstoke), V11, P435; Narayana N, 1997, BIOCHEMISTRY-US, V36, P4438, DOI 10.1021/bi961947+; OTWINOSKI Z, 1993, OSCILLATION DATA RED; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; PADMA R, 1991, CANCER RES, V51, P2486; Palaty CK, 1997, J BIOL CHEM, V272, P10514; Palaty CK, 1997, BIOCHEM CELL BIOL, V75, P153, DOI 10.1139/bcb-75-2-153; Pierce AC, 2002, PROTEINS, V49, P567, DOI 10.1002/prot.10259; Prade L, 1997, STRUCTURE, V5, P1627, DOI 10.1016/S0969-2126(97)00310-9; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; *RIG MSC, 1997, CRYSTALCLEAR INT PRO; Roversi P, 2000, ACTA CRYSTALLOGR D, V56, P1316, DOI 10.1107/S0907444900008490; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Tereshko V, 2001, NAT STRUCT BIOL, V8, P899, DOI 10.1038/nsb1001-899; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wang Z, 2001, J Vet Sci, V2, P167; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Wang ZP, 2001, ARCH BIOCHEM BIOPHYS, V390, P9, DOI 10.1006/abbi.2001.2370; Winn LM, 2003, CELL CYCLE, V2, P258, DOI 10.4161/cc.2.3.383; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	60	155	166	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13728	13734		10.1074/jbc.M413155200	http://dx.doi.org/10.1074/jbc.M413155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15657054	hybrid			2022-12-25	WOS:000228095500068
J	Jensen, SA; Corbett, AR; Knott, V; Redfield, C; Handford, PA				Jensen, SA; Corbett, AR; Knott, V; Redfield, C; Handford, PA			Ca2+-dependent interface formation in fibrillin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE DOMAINS; NEONATAL MARFAN-SYNDROME; CALCIUM-BINDING PROPERTIES; EXTRACELLULAR-MATRIX; BACKBONE DYNAMICS; FBN1 MUTATIONS; MICROFIBRILS; ORGANIZATION; PROTEIN; PAIR	The calcium-binding epidermal growth factor-like (cbEGF) domain is a common structural motif in extracellular and transmembrane proteins. K-d values for Ca2+ vary from the millimolar to nanomolar range; however the molecular basis for this variation is poorly understood. We have measured K-d values for six fibrillin-1 cbEGF domains, each preceded by a transforming growth factor beta-binding protein-like (TB) domain. Using NMR and titration with chromophoric chelators, we found that K-d values varied by five orders of magnitude. Interdomain hydrophobic contacts between TB-cbEGF domains were studied by site-directed mutagenesis and could be correlated directly with Ca2+ affinity. Furthermore, in TB-cbEGF pairs that displayed high-affinity binding, NMR studies showed that TB-cbEGF interface formation was strongly Ca2+-dependent. We suggest that Ca2+ affinity is a measure of interface formation in both homologous and heterologous cbEGF domain pairs, thus providing a measure of flexibility in proteins with multiple cbEGF domains. These data highlight the versatile role of the cbEGF domain in fine tuning the regional flexibility of proteins and provide new constraints for the organization of fibrillin-1 within 10-12-nm microfibrils of the extracellular matrix.	Univ Oxford, Dept Biochem, Oxford OX1 3TA, England; Univ Oxford, Dept Biochem, Div Mol & Cellular Biochem, Oxford OX1 3QU, England; Univ Oxford, Oxford Ctr Mol Sci, Chem Res Lab, Oxford OX1 3TA, England	University of Oxford; University of Oxford; University of Oxford	Redfield, C (corresponding author), Univ Oxford, Dept Biochem, Mansfield Rd, Oxford OX1 3TA, England.	christina.redfield@bioch.ox.ac.uk; penny.handford@bioch.ox.ac.uk	Jensen, Sacha A./AAB-4034-2019	Jensen, Sacha A./0000-0002-0560-9531; Redfield, Christina/0000-0001-7297-7708				Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; Cardy CM, 1998, J MOL BIOL, V276, P855, DOI 10.1006/jmbi.1997.1593; Collod-Beroud G, 1998, NUCLEIC ACIDS RES, V26, P229, DOI 10.1093/nar/26.1.229; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Handford PA, 2000, BBA-MOL CELL RES, V1498, P84, DOI 10.1016/S0167-4889(00)00085-9; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; Kettle S, 1999, J MOL BIOL, V285, P1277, DOI 10.1006/jmbi.1998.2368; KIELTY CM, 1993, MATRIX, V13, P103, DOI 10.1016/S0934-8832(11)80069-7; KIELTY CM, 1993, FEBS LETT, V336, P323, DOI 10.1016/0014-5793(93)80829-J; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; LINSE S, 1991, J BIOL CHEM, V266, P8050; Liu WO, 1997, GENET TEST, V1, P237, DOI 10.1089/gte.1997.1.237; Lonnqvist L, 1996, GENOMICS, V36, P468, DOI 10.1006/geno.1996.0492; NIJBROEK G, 1995, AM J HUM GENET, V57, P8; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Smallridge RS, 2003, J BIOL CHEM, V278, P12199, DOI 10.1074/jbc.M208266200; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; Stenberg Y, 1997, J BIOL CHEM, V272, P23255, DOI 10.1074/jbc.272.37.23255; Suk JY, 2004, J BIOL CHEM, V279, P51258, DOI 10.1074/jbc.M408156200; Tiecke F, 2001, EUR J HUM GENET, V9, P13, DOI 10.1038/sj.ejhg.5200582; Werner JM, 2000, J MOL BIOL, V296, P1065, DOI 10.1006/jmbi.1999.3513; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807; WILLIAMSON MP, 1992, J BIOMOL NMR, V2, P83, DOI 10.1007/BF02192802; Yuan XM, 2002, J MOL BIOL, V316, P113, DOI 10.1006/jmbi.2001.5329; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659	39	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14076	14084		10.1074/jbc.M412832200	http://dx.doi.org/10.1074/jbc.M412832200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15649891	hybrid			2022-12-25	WOS:000228095500110
J	Piszczek, G; Rozycki, J; Singh, SK; Ginsburg, A; Maurizi, MR				Piszczek, G; Rozycki, J; Singh, SK; Ginsburg, A; Maurizi, MR			The molecular chaperone, ClpA, has a single high affinity peptide binding site per hexamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; ESCHERICHIA-COLI; SUBSTRATE-RECOGNITION; CRYSTAL-STRUCTURE; HSP100 CHAPERONE; QUALITY-CONTROL; AAA+ ATPASE; PROTEIN; DEGRADATION; TRANSLOCATION	Substrate recognition by Clp chaperones is dependent on interactions with motifs composed of specific peptide sequences. We studied the binding of short motif-bearing peptides to ClpA, the chaperone component of the ATP-dependent ClpAP protease of Escherichia coli in the presence of ATP gamma S and Mg2+ at pH 7.5. Binding was measured by isothermal titration calorimetry (ITC) using the peptide, AANDENYALAA, which corresponds to the SsrA degradation motif found at the C terminus of abnormal nascent polypeptides in vivo. One SsrA peptide was bound per hexamer of ClpA with an association constant (K-A) of 5 x 10(6) M-1. Binding was also assayed by changes in fluorescence of an N-terminal dansylated SsrA peptide, which bound with the same stoichiometry of one per ClpA hexamer (K-A similar to 1 x 10(7) M-1). Similar results were obtained when ATP was substituted for ATP gamma S at 6 degrees C. Two additional peptides, derived from the phage P1 RepA protein and the E. coli HemA protein, which bear different substrate motifs, were competitive inhibitors of SsrA binding and bound to ClpA hexamers with K-A' > 3 x 10(7) M-1. DNS-SsrA bound with only slightly reduced affinity to deletion mutants of ClpA missing either the N-terminal domain or the C-terminal nucleotide-binding domain, indicating that the binding site for SsrA lies within the N-terminal nucleotide-binding domain. Because only one protein at a time can be unfolded and translocated by ClpA hexamers, restricting the number of peptides initially bound should avoid nonproductive binding of substrates and aggregation of partially processed proteins.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Piszczek, G (corresponding author), NHLBI, Biochem Lab, NIH, 50 S Dr,Bldg 50,Rm 2341, Bethesda, MD 20892 USA.	grzegorz_piszczek@nih.gov	Piszczek, Grzegorz/GYU-2029-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000338, ZICHL000338] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bolon DN, 2004, MOL CELL, V13, P443, DOI 10.1016/S1097-2765(04)00027-9; Dougan DA, 2003, MOL CELL, V12, P373, DOI 10.1016/j.molcel.2003.08.012; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glover JR, 2001, BIOCHEM CELL BIOL, V79, P557, DOI 10.1139/bcb-79-5-557; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Gonciarz-Swiatek M, 1999, J BIOL CHEM, V274, P13999, DOI 10.1074/jbc.274.20.13999; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Guo FS, 2002, J BIOL CHEM, V277, P46753, DOI 10.1074/jbc.M208104200; Hengge-Aronis R, 2002, MICROBIOL MOL BIOL R, V66, P373, DOI 10.1128/MMBR.66.3.373-395.2002; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; Ishii Y, 2000, J BIOCHEM-TOKYO, V127, P837, DOI 10.1093/oxfordjournals.jbchem.a022677; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kwon AR, 2004, J STRUCT BIOL, V146, P141, DOI 10.1016/j.jsb.2003.11.003; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PISZCZEK G, 2002, PROTEIN SCI, V11, pS76; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; Siddiqui SM, 2004, GENE DEV, V18, P369, DOI 10.1101/gad.1170304; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Singh SK, 1999, BIOCHEMISTRY-US, V38, P14906, DOI 10.1021/bi991615f; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; Wah DA, 2003, MOL CELL, V12, P355, DOI 10.1016/S1097-2765(03)00272-7; Wah DA, 2002, CHEM BIOL, V9, P1237, DOI 10.1016/S1074-5521(02)00268-5; Wang LY, 1999, J BACTERIOL, V181, P6033, DOI 10.1128/JB.181.19.6033-6041.1999; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	51	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12221	12230		10.1074/jbc.M411733200	http://dx.doi.org/10.1074/jbc.M411733200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15657062	hybrid			2022-12-25	WOS:000227922000020
J	Pushkar, YN; Karyagina, I; Stehlik, D; Brown, S; van der Est, A				Pushkar, YN; Karyagina, I; Stehlik, D; Brown, S; van der Est, A			Recruitment of a foreign quinone into the A(1) site of photosystem I Consecutive forward electron transfer from A(0) TO A(1) to F-X with anthraquinone in the A(1) site as studied by transient EPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORRELATED RADICAL PAIRS; PHOTOSYNTHETIC REACTION CENTERS; BIOSYNTHETIC-PATHWAY MUTANTS; BACTERIAL REACTION CENTERS; SYNECHOCOCCUS SP PCC-7002; IRON-SULFUR CENTERS; HIGH-FIELD EPR; W-BAND EPR; SPIN POLARIZATION; RHODOBACTER-SPHAEROIDES	In photosystem I ( PS I), phylloquinone (PhQ) acts as a low potential electron acceptor during light-induced electron transfer ( ET). The origin of the very low midpoint potential of the quinone is investigated by introducing anthraquinone (AQ) into PS I in the presence and absence of the iron-sulfur clusters. Solvent extraction and reincubation is used to obtain PS I particles containing AQ and the iron-sulfur clusters, whereas incubation of the menB rubA double mutant yields PS I with AQ in the PhQ site but no iron-sulfur clusters. Transient electron paramagnetic resonance spectroscopy is used to investigate the orientation of AQ in the binding site and the ET kinetics. The low temperature spectra suggest that the orientation of AQ in all samples is the same as that of PhQ in native PS I. In PS I containing the iron sulfur clusters, (i) the rate of forward electron transfer from the AQ(.-) to F-X is found to be faster than from PhQ(.-) to F-X, and (ii) the spin polarization patterns provide indirect evidence that the preceding ET step from A(0)(.-) to quinone is slower than in the native system. The changes in the kinetics are in accordance with the more negative reduction midpoint potential of AQ. Moreover, a comparison of the spectra in the presence and absence of the iron-sulfur clusters suggests that the midpoint potential of AQ is more negative in the presence of FX. The electron transfer from the AQ(.-) to F-X is found to be thermally activated with a lower apparent activation energy than for PhQ in native PS I. The spin polarization patterns show that the triplet character in the initial state of P(700)(.+)AQ(.-) increases with temperature. This behavior is rationalized in terms of a model involving a distribution of lifetimes/redox potentials for A(0) and related competition between charge recombination and forward electron transfer from the radical pair P(700)(.+)A(0)(.-).	Free Univ Berlin, Inst Expt Phys, D-14195 Berlin, Germany; Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada	Free University of Berlin; Brock University	Stehlik, D (corresponding author), Free Univ Berlin, Inst Expt Phys, Arnimallee 14, D-14195 Berlin, Germany.	stehlik@physik.fu-berlin; avde@brocku.ca						Agalarov R, 2003, BBA-BIOENERGETICS, V1604, P7, DOI 10.1016/S0005-2728(03)00024-0; BIGGINS J, 1988, BIOCHEMISTRY-US, V27, P1494, DOI 10.1021/bi00405a015; Bixon M, 1999, ADV CHEM PHYS, V106, P35, DOI 10.1002/9780470141656.ch3; BLANKENSHIP RE, 2002, MOL MECH PHOTOSYNTHE, P95; BONNERJEA J, 1982, FEBS LETT, V148, P313, DOI 10.1016/0014-5793(82)80831-4; Bratt PJ, 1997, J PHYS CHEM B, V101, P9686, DOI 10.1021/jp9725238; BURGHAUS O, 1993, J PHYS CHEM-US, V97, P7639, DOI 10.1021/j100131a037; Carrington A., 1967, INTRO MAGNETIC RESON; Cohen RO, 2004, BIOCHEMISTRY-US, V43, P4741, DOI 10.1021/bi035633f; Cramer W.A., 1990, ENERGY TRANSDUCTION; Edens GJ, 2000, J AM CHEM SOC, V122, P1479, DOI 10.1021/ja991791b; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fursman CE, 2002, J PHYS CHEM B, V106, P9679, DOI 10.1021/jp0257202; Golbeck JH, 1999, PHOTOSYNTH RES, V61, P107, DOI 10.1023/A:1006281802710; GUIGLIARELLI B, 1993, J BIOL CHEM, V268, P900; GUNNER MR, 1991, CURR TOP BIOENERG, V16, P319; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; Hartwich G, 1998, J PHYS CHEM B, V102, P3815, DOI 10.1021/jp973472h; Hore PJ, 1996, MOL PHYS, V89, P1195, DOI 10.1080/002689796173598; Hulsebosch RJ, 2001, J PHYS CHEM B, V105, P10146, DOI 10.1021/jp012272+; Hulsebosch RJ, 1999, J PHYS CHEM B, V103, P6815, DOI 10.1021/jp990677c; Itoh S, 2001, BBA-BIOENERGETICS, V1507, P115, DOI 10.1016/S0005-2728(01)00199-2; Iwaki M, 1996, J PHYS CHEM-US, V100, P10802, DOI 10.1021/jp960221k; Johnson TW, 2001, J BIOL CHEM, V276, P39512, DOI 10.1074/jbc.M104040200; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Jortner J., 1999, ADV CHEM PHYS, V107; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kamlowski A, 1998, J PHYS CHEM B, V102, P8266, DOI 10.1021/jp9817022; Kamlowski A, 1998, J PHYS CHEM B, V102, P8278, DOI 10.1021/jp9824611; Kandrashkin Y, 2001, SPECTROCHIM ACTA A, V57, P1697, DOI 10.1016/S1386-1425(01)00436-X; Kandrashkin YE, 1998, APPL MAGN RESON, V15, P417, DOI 10.1007/BF03162027; Kandrashkin YE, 2002, MOL PHYS, V100, P1431, DOI 10.1080/00268970110118240; Kandrashkin YE, 1997, APPL MAGN RESON, V12, P141, DOI 10.1007/BF03162183; Li JL, 2000, BIOCHEMISTRY-US, V39, P7445, DOI 10.1021/bi992591f; Link G, 2001, J AM CHEM SOC, V123, P4211, DOI 10.1021/ja003382h; Lubitz W, 1999, APPL MAGN RESON, V17, P1, DOI 10.1007/BF03162067; LUNEBERG J, 1994, FEBS LETT, V338, P197, DOI 10.1016/0014-5793(94)80364-1; MacMillan F, 1997, BIOCHEMISTRY-US, V36, P9297, DOI 10.1021/bi971097d; MCCRACKEN JL, 1983, BIOCHIM BIOPHYS ACTA, V724, P83, DOI 10.1016/0005-2728(83)90028-2; MOENNELOCCOZ P, 1994, BIOCHEMISTRY-US, V33, P10037, DOI 10.1021/bi00199a030; MORRIS AL, 1995, J PHYS CHEM-US, V99, P3854, DOI 10.1021/j100011a063; NORRIS JR, 1990, J CHEM PHYS, V92, P4239, DOI 10.1063/1.457782; O'Malley PJ, 1999, BBA-BIOENERGETICS, V1411, P101, DOI 10.1016/S0005-2728(99)00036-5; PEDERSEN JB, 1979, FEBS LETT, V97, P305, DOI 10.1016/0014-5793(79)80108-8; Poluektov OG, 2002, J PHYS CHEM B, V106, P8911, DOI 10.1021/jp021465+; PRISNER TF, 1993, P NATL ACAD SCI USA, V90, P9485, DOI 10.1073/pnas.90.20.9485; Pushkar YN, 2004, J MOL STRUCT, V700, P233, DOI 10.1016/j.molstruc.2004.02.015; Pushkar YN, 2004, J PHYS CHEM B, V108, P9439, DOI 10.1021/jp0361879; Pushkar YN, 2002, J PHYS CHEM B, V106, P12052, DOI 10.1021/jp0265743; Rigby SEJ, 1996, BIOCHEMISTRY-US, V35, P6651, DOI 10.1021/bi952619x; RUSTANDI RR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P311, DOI 10.1016/0005-2728(92)90087-I; Sakuragi Y, 2005, J BIOL CHEM, V280, P12371, DOI 10.1074/jbc.M412943200; Sakuragi Y, 2002, BIOCHEMISTRY-US, V41, P394, DOI 10.1021/bi011297w; Salikhov KM, 2003, APPL MAGN RESON, V24, P467, DOI 10.1007/BF03166949; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; Schlodder E., 2001, PS2001 P 12 INT C PH, pS6; Semenov AY, 2000, J BIOL CHEM, V275, P23429, DOI 10.1074/jbc.M000508200; Shen GZ, 2002, J BIOL CHEM, V277, P20355, DOI 10.1074/jbc.M201104200; Shen GZ, 2002, J BIOL CHEM, V277, P20343, DOI 10.1074/jbc.M201103200; SIECKMAN I, 1991, FEBS LETT, V284, P98, DOI 10.1016/0014-5793(91)80771-T; SNYDER S, 1993, BIOPHYS J, V64, pA216; STEHLIK D, 1989, J PHYS CHEM-US, V93, P1612, DOI 10.1021/j100341a084; STEHLIK D, 1992, PHOTOSYNTH RES, V34, P129; Tang J, 1999, J PHYS CHEM B, V103, P5145, DOI 10.1021/jp990236t; Tang J, 1996, CHEM PHYS LETT, V253, P293, DOI 10.1016/0009-2614(96)00176-5; Utschig LM, 1997, BIOCHEMISTRY-US, V36, P8548, DOI 10.1021/bi9630319; van der Est A, 2004, BIOCHEMISTRY-US, V43, P1264, DOI 10.1021/bi035431j; van der Est A, 2001, BBA-BIOENERGETICS, V1507, P212, DOI 10.1016/S0005-2728(01)00204-3; VANDEREST A, 1995, CHEM PHYS, V194, P349, DOI 10.1016/0301-0104(95)00046-Q; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; vanderEst A, 1997, J PHYS CHEM B, V101, P1437, DOI 10.1021/jp9622086; Xu Q, 2000, J PHYS CHEM B, V104, P8035, DOI 10.1021/jp000543v; Xu Q, 2002, BIOCHEMISTRY-US, V41, P10021, DOI 10.1021/bi025573y; Xu W, 2003, J BIOL CHEM, V278, P27876, DOI 10.1074/jbc.M302965200; Xu W, 2003, J BIOL CHEM, V278, P27864, DOI 10.1074/jbc.M302962200; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; Zech SG, 2000, J PHYS CHEM B, V104, P9728, DOI 10.1021/jp002125w; Zech SG, 1997, BIOCHEMISTRY-US, V36, P9774, DOI 10.1021/bi970754z; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	79	17	18	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12382	12390		10.1074/jbc.M412940200	http://dx.doi.org/10.1074/jbc.M412940200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15640524	hybrid			2022-12-25	WOS:000227922000039
J	Choi, J; Rees, HD; Weintraub, ST; Levey, AI; Chin, LS; Li, L				Choi, J; Rees, HD; Weintraub, ST; Levey, AI; Chin, LS; Li, L			Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; SUPEROXIDE-DISMUTASE; CELL-DEATH; PROTEIN; IDENTIFICATION; INCLUSIONS; STRESS; MICE; NEURODEGENERATION	Although oxidative stress has been strongly implicated in the pathogenesis of Alzheimer disease ( AD) and Parkinson disease (PD), the identities of specific protein targets of oxidative damage remain largely unknown. Here, we report that Cu, Zn-superoxide dismutase (SOD1), a key antioxidant enzyme whose mutations have been linked to autosomal dominant neurodegenerative disorder familial amyotrophic lateral sclerosis (ALS), is a major target of oxidative damage in AD and PD brains. By using a combination of two-dimensional gel electrophoresis, immunoblot analysis, and mass spectrometry, we have identified four human brain SOD1 isoforms with pI values of 6.3, 6.0, 5.7, and 5.0, respectively. Of these, the SOD1 pI 6.0 isoform is oxidatively modified by carbonylation, and the pI 5.0 isoform is selectively accumulated in AD and PD. Moreover, Cys-146, a cysteine residue of SOD1 that is mutated in familial ALS, is oxidized to cysteic acid in AD and PD brains. Quantitative Western blot analyses demonstrate that the total level of SOD1 isoforms is significantly increased in both AD and PD. Furthermore, immunohistochemical and double fluorescence labeling studies reveal that SOD1 forms proteinaceous aggregates that are associated with amyloid senile plaques and neurofibrillary tangles in AD brains. These findings implicate, for the first time, the involvement of oxidative damage to SOD1 in the pathogenesis of sporadic AD and PD. This work suggests that AD, PD, and ALS may share a common or overlapping pathogenic mechanism(s) that could potentially be targeted by similar therapeutic strategies.	Emory Univ, Sch Med, Dept Pharmacol, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Emory University; Emory University; University of Texas System; University of Texas Health San Antonio	Li, L (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Ctr Neurodegenerat Dis, 1510 Clifton Rd, Atlanta, GA 30322 USA.	lianli@pharm.emory.edu	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X; Li, Lian/0000-0003-4700-1134; Chin, Lih-Shen/0000-0002-0817-0368	NIA NIH HHS [AG021489] Funding Source: Medline; NIEHS NIH HHS [ES012068] Funding Source: Medline; NINDS NIH HHS [NS047575] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021489] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Choi JG, 2002, BIOCHEM BIOPH RES CO, V293, P1566, DOI 10.1016/S0006-291X(02)00420-5; Choi JG, 2002, BBA-GEN SUBJECTS, V1571, P201, DOI 10.1016/S0304-4165(02)00217-9; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Conrad CC, 2001, PROTEOMICS, V1, P829, DOI 10.1002/1615-9861(200107)1:7<829::AID-PROT829>3.0.CO;2-R; DEBELLEROCHE J, 1995, J MED GENET, V32, P841, DOI 10.1136/jmg.32.11.841; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FURUTA A, 1995, AM J PATHOL, V146, P357; GEARING M, 1995, NEUROLOGY, V45, P1985, DOI 10.1212/WNL.45.11.1985; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Guegan C, 2003, J CLIN INVEST, V111, P153, DOI 10.1172/JCI200317610; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jaarsma D, 2000, NEUROBIOL DIS, V7, P623, DOI 10.1006/nbdi.2000.0299; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kato S, 2000, AMYOTROPH LATERAL SC, V1, P163, DOI 10.1080/14660820050515160; Kurahashi T, 2001, J AM CHEM SOC, V123, P9268, DOI 10.1021/ja015953r; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; NISHIYAMA K, 1995, ACTA NEUROPATHOL, V89, P471; OKAMOTO K, 1991, NEUROSCI LETT, V129, P233, DOI 10.1016/0304-3940(91)90469-A; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Petrovic N, 1996, J BIOL CHEM, V271, P28331, DOI 10.1074/jbc.271.45.28331; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; UCHIDA K, 1994, J BIOL CHEM, V269, P2405; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273	41	226	241	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11648	11655		10.1074/jbc.M414327200	http://dx.doi.org/10.1074/jbc.M414327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659387	hybrid			2022-12-25	WOS:000227761800093
J	Chondrogianni, N; Tzavelas, C; Pemberton, AJ; Nezis, IP; Rivett, AJ; Gonos, ES				Chondrogianni, N; Tzavelas, C; Pemberton, AJ; Nezis, IP; Rivett, AJ; Gonos, ES			Overexpression of proteasome beta(5) subunit increases the amount of assembled proteasome and confers ameliorated response to oxidative stress and higher survival rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENESCENCE-LIKE PHENOTYPE; HUMAN BJ FIBROBLASTS; 20S PROTEASOME; PROTEIN OXIDATION; PEPTIDASE ACTIVITIES; CELLULAR SENESCENCE; OXIDIZED PROTEINS; 26S PROTEASOME; DEGRADATION; INHIBITION	The proteasome is the major cellular proteolytic machinery responsible for the degradation of both normal and damaged proteins. Proteasomes play a fundamental role in retaining cellular homeostasis. Alterations of proteasome function have been recorded in various biological phenomena including aging. We have recently shown that the decrease in proteasome activity in senescent human fibroblasts relates to the down-regulation of beta-type subunits. In this study we have followed our preliminary observation by developing and further characterizing a number of different human cell lines overexpressing the beta(5) subunit. Stable overexpression of the beta(5) subunit in WI38/T and HL60 cells resulted in elevated levels of other beta-type subunits and increased levels of all three proteasome activities. Immunoprecipitation experiments have shown increased levels of assembled proteasomes in stable clones. Analysis by gel filtration has revealed that the recorded higher level of proteasome assembly is directly linked to the efficient integration of "free" (not integrated) beta-type subunits identified to accumulate in vector-transfected cells. In support we have also found low proteasome maturation protein levels in beta(5) transfectants, thus revealing an increased rate/level of proteasome assembly in these cells as opposed to vector-transfected cells. Functional studies have shown that beta(5)-overexpressing cell lines confer enhanced survival following treatment with various oxidants. Moreover, we demonstrate that this increased rate of survival is due to higher degradation rates following oxidative stress. Finally, because oxidation is considered to be a major factor that contributes to aging and senescence, we have overexpressed the beta(5) subunit in primary IMR90 human fibroblasts and observed a delay of senescence by 4-5 population doublings. In summary, these data demonstrate the phenotypic effects following genetic up-regulation of the proteasome and provide insights toward a better understanding of proteasome regulation.	Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, GR-11635 Athens, Greece; Univ Bristol, Sch Med, Dept Biochem, Bristol BS8 1TD, Avon, England	National Hellenic Research Foundation; University of Bristol	Gonos, ES (corresponding author), Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, 48 Vasileos Constantinou Ave, GR-11635 Athens, Greece.	sgonos@eie.gr	Nezis, Ioannis/AAE-8625-2020; Nezis, Ioannis/Q-6124-2019; Nezis, Ioannis P/I-4910-2014	Nezis, Ioannis/0000-0003-0233-7574; Nezis, Ioannis P/0000-0003-0233-7574				AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; Apcher GS, 2004, FEBS LETT, V569, P211, DOI 10.1016/j.febslet.2004.05.067; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bildirici L, 2000, NATURE, V405, P298, DOI 10.1038/35012701; Bulteau AL, 2002, ARCH BIOCHEM BIOPHYS, V397, P298, DOI 10.1006/abbi.2001.2663; Bulteau AL, 2000, EXP GERONTOL, V35, P767, DOI 10.1016/S0531-5565(00)00136-4; Burri L, 2000, P NATL ACAD SCI USA, V97, P10348, DOI 10.1073/pnas.190268597; Chondrogianni N, 2004, BIOGERONTOLOGY, V5, P55, DOI 10.1023/B:BGEN.0000017687.55667.42; Chondrogianni N, 2003, J BIOL CHEM, V278, P28026, DOI 10.1074/jbc.M301048200; Chondrogianni N, 2002, BIOGERONTOLOGY, V3, P121, DOI 10.1023/A:1015236203379; Chondrogianni N, 2000, EXP GERONTOL, V35, P721, DOI 10.1016/S0531-5565(00)00137-6; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Doyle A, 1998, CELLS TISSUE CULT; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; Friguet B, 2000, ANN NY ACAD SCI, V908, P143; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; Gaczynska M, 2001, MECH AGEING DEV, V122, P235, DOI 10.1016/S0047-6374(00)00246-3; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Gerards WLH, 1997, J BIOL CHEM, V272, P10080; Gerards WLH, 1998, J MOL BIOL, V275, P113, DOI 10.1006/jmbi.1997.1429; Gonos ES, 2000, EXP GERONTOL, V35, P15, DOI 10.1016/S0531-5565(99)00075-3; Griffin Thomas A., 2000, Molecular Cell Biology Research Communications, V3, P212, DOI 10.1006/mcbr.2000.0213; Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Harlow E., 1999, USING ANTIBODIES LAB; Heinemeyer W, 2004, CELL MOL LIFE SCI, V61, P1562, DOI 10.1007/s00018-004-4130-z; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; Jayarapu K, 2004, BIOCHEM BIOPH RES CO, V314, P523, DOI 10.1016/j.bbrc.2003.12.119; Jorgensen L, 1999, MOL BIOL REP, V26, P119, DOI 10.1023/A:1006965602142; Kruger E, 2001, BIOCHIMIE, V83, P289, DOI 10.1016/S0300-9084(01)01241-X; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Merker K, 2000, EXP GERONTOL, V35, P779, DOI 10.1016/S0531-5565(00)00140-6; Merker K, 2000, ARCH BIOCHEM BIOPHYS, V375, P50, DOI 10.1006/abbi.1999.1657; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; Owsianik G, 2002, MOL MICROBIOL, V43, P1295, DOI 10.1046/j.1365-2958.2002.02823.x; Petropoulos I, 2000, J GERONTOL A-BIOL, V55, pB220, DOI 10.1093/gerona/55.5.B220; Petropoulou C, 2000, ANN NY ACAD SCI, V908, P133; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RIVETT AJ, 1993, BIOCHEM J, V291, P1; Rivett AJ, 2002, EXP GERONTOL, V37, P1217, DOI 10.1016/S0531-5565(02)00127-4; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Sitte N, 2000, FREE RADICAL BIO MED, V28, P701, DOI 10.1016/S0891-5849(99)00279-8; Tanaka K, 1998, J BIOCHEM-TOKYO, V123, P195; Trougakos IP, 2003, BIOL AGING MODULAT, V5, P65; Tzavelas C, 2004, BIOTECHNIQUES, V37, P276, DOI 10.2144/04372RR05; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Ustrell V, 2002, EMBO J, V21, P3516, DOI 10.1093/emboj/cdf333; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Witt E, 2000, J MOL BIOL, V301, P1, DOI 10.1006/jmbi.2000.3959; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	59	161	167	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11840	11850		10.1074/jbc.M413007200	http://dx.doi.org/10.1074/jbc.M413007200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15661736	hybrid			2022-12-25	WOS:000227761800113
J	Yu, WX; Gong, JS; Ko, MH; Garver, WS; Yanagisawa, K; Michikawa, M				Yu, WX; Gong, JS; Ko, MH; Garver, WS; Yanagisawa, K; Michikawa, M			Altered cholesterol metabolism in Niemann-Pick type C1 mouse brains affects mitochondrial function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-DERIVED CHOLESTEROL; DISEASE TYPE-C; ALZHEIMERS-DISEASE; INTRACELLULAR-TRANSPORT; NEUROFIBRILLARY TANGLES; TAU-PHOSPHORYLATION; LIVER MITOCHONDRIA; CULTURED NEURONS; PLASMA-MEMBRANE; LIPID RELEASE	Niemann- Pick type C1 (NPC1) disease is a fatal hereditary disorder characterized by a defect in cholesterol trafficking and progressive neurodegeneration. Although the NPC1 gene has been identified, the molecular mechanism responsible for neuronal dysfunction in brains of patients with NPC1 disease remains unknown. This study demonstrates that the amount of cholesterol within mitochondria membranes is significantly elevated in NPC1 mouse brains and neural cells. In addition, the mitochondrial membrane potential, the activity of ATP synthase, and henceforth the level of ATP are markedly decreased in NPC1 mouse brains and neurons. Importantly, reducing the level of cholesterol within mitochondrial membranes using methyl-beta-cyclodextrin can restore the activity of ATP synthase. Finally, NPC1 neurons show an impaired neurite outgrowth, which can be rescued by exogenous ATP. These results suggest that mitochondrial dysfunctions and subsequent ATP deficiency, which are induced by altered cholesterol metabolism in mitochondria, may be responsible for neuronal impairment in NPC1 disease.	Natl Inst Longev Sci, Dept Alzheimers Dis Res, Obu, Aichi 4748522, Japan; Pharmaceut & Med Devices Agcy, Tokyo 1000013, Japan; Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA	University of Arizona	Michikawa, M (corresponding author), Natl Inst Longev Sci, Dept Alzheimers Dis Res, 36-3 Gengo, Obu, Aichi 4748522, Japan.	michi@nils.go.jp						AUER IA, 1995, ACTA NEUROPATHOL, V90, P547; Bu BT, 2002, J NEUROSCI, V22, P6515; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Colell A, 2003, J BIOL CHEM, V278, P33928, DOI 10.1074/jbc.M210943200; Fan QW, 2001, J NEUROCHEM, V76, P391, DOI 10.1046/j.1471-4159.2001.00063.x; Garren L D, 1971, Recent Prog Horm Res, V27, P433; Garver WS, 2000, J LIPID RES, V41, P673; Garver WS, 2002, J LIPID RES, V43, P579; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; Gong JS, 2002, J NEUROSCI RES, V70, P438, DOI 10.1002/jnr.10347; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; HIGASHI Y, 1993, ACTA NEUROPATHOL, V85, P175; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kuge O, 2003, J BIOCHEM, V133, P397, DOI 10.1093/jb/mvg052; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOVE S, 1995, BRAIN, V118, P119, DOI 10.1093/brain/118.1.119; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Mattson MP, 1999, J NEUROSCI RES, V56, P8, DOI 10.1002/(SICI)1097-4547(19990401)56:1<8::AID-JNR2>3.3.CO;2-7; Michikawa M, 2003, J NEUROSCI RES, V72, P141, DOI 10.1002/jnr.10585; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; MORRIS MD, 1982, AM J PATHOL, V108, P140; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; Ribeiro I, 2001, HUM GENET, V109, P24, DOI 10.1007/s004390100531; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; RINDINA FC, 1986, FEBS LETT, V198, P353, DOI 10.1016/0014-5793(86)80435-5; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Sawamura N, 2001, J BIOL CHEM, V276, P10314, DOI 10.1074/jbc.M009733200; Sawamura N, 2003, J NEUROCHEM, V84, P1086, DOI 10.1046/j.1471-4159.2003.01596.x; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Simons M, 2001, NEUROLOGY, V57, P1089, DOI 10.1212/WNL.57.6.1089; Skladchikova G, 1999, J NEUROSCI RES, V57, P207; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SUZUKI K, 1995, ACTA NEUROPATHOL, V89, P227; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; Walkley SU, 1998, ANN NY ACAD SCI, V845, P188, DOI 10.1111/j.1749-6632.1998.tb09671.x; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; ZHENG X, 1989, NEUROLOGY, V39, P1203, DOI 10.1212/WNL.39.9.1203	46	152	160	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11731	11739		10.1074/jbc.M412898200	http://dx.doi.org/10.1074/jbc.M412898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644330	hybrid			2022-12-25	WOS:000227761800102
J	Wang, L; Haeusler, RA; Good, PD; Thompson, M; Nagar, S; Engelke, DR				Wang, L; Haeusler, RA; Good, PD; Thompson, M; Nagar, S; Engelke, DR			Silencing near tRNA genes requires nucleolar localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR UAF; SACCHAROMYCES-CEREVISIAE; POLYMERASE-I; RIBOSOMAL DNA; YEAST RDNA; CHROMATIN; ELEMENTS; SUBUNIT; REPLICATION; EXPRESSION	Transcription by RNA polymerase II is antagonized by the presence of a nearby tRNA gene in Saccharomyces cerevisiae. To test hypotheses concerning the mechanism of this tRNA gene-mediated (tgm) silencing, the effects of specific gene deletions were determined. The results show that the mechanism of silencing near tRNA genes is fundamentally different from other forms of transcriptional silencing in yeast. Rather, tgm silencing is dependent on the ability to cluster the dispersed tRNA genes in or near the nucleolus, constituting a form of three-dimensional gene control.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Michigan Technol Univ, Dept Chem, Houghton, MI 49931 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Michigan Technological University	Engelke, DR (corresponding author), Univ Michigan, Dept Biol Chem, 1150 W Med Ctr Dr,3200 MSRB 3, Ann Arbor, MI 48109 USA.	engelke@umich.edu		Haeusler, Rebecca/0000-0002-6973-9845	NIGMS NIH HHS [GM063142, R01 GM063142, T32 GM007544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063142, T32GM007544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; BOEKE JD, 1991, MOL CELLULAR BIOL YE, P193; Bolton EC, 2003, GENOME RES, V13, P254, DOI 10.1101/gr.612203; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Cioci F, 2003, MOL CELL, V12, P135, DOI 10.1016/S1097-2765(03)00262-4; Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402; Dror V, 2004, MOL CELL BIOL, V24, P8227, DOI 10.1128/MCB.24.18.8227-8235.2004; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Heun P, 2001, SCIENCE, V294, P2181, DOI 10.1126/science.1065366; HIPSKIND RA, 1983, CELL, V34, P881, DOI 10.1016/0092-8674(83)90545-7; Huang Y, 2002, NUCLEIC ACIDS RES, V30, P1465, DOI 10.1093/nar/30.7.1465; HULL MW, 1994, MOL CELL BIOL, V14, P1266, DOI 10.1128/MCB.14.2.1266; Kendall A, 2000, P NATL ACAD SCI USA, V97, P13108, DOI 10.1073/pnas.240454997; Keys DA, 1996, GENE DEV, V10, P887, DOI 10.1101/gad.10.7.887; Kim JM, 1998, GENOME RES, V8, P464, DOI 10.1101/gr.8.5.464; KINSEY PT, 1991, NUCLEIC ACIDS RES, V19, P1317, DOI 10.1093/nar/19.6.1317; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; LILJELUND P, 1992, P NATL ACAD SCI USA, V89, P9302, DOI 10.1073/pnas.89.19.9302; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; Oakes M, 1999, MOL CELL BIOL, V19, P8559; Siddiqi IN, 2001, EMBO J, V20, P4512, DOI 10.1093/emboj/20.16.4512; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Thompson M, 2003, SCIENCE, V302, P1399, DOI 10.1126/science.1089814; ZOU S, 1995, P NATL ACAD SCI USA, V92, P920, DOI 10.1073/pnas.92.3.920	26	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8637	8639		10.1074/jbc.C500017200	http://dx.doi.org/10.1074/jbc.C500017200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15654076	hybrid, Green Accepted			2022-12-25	WOS:000227453100003
J	LeMaoult, J; Zafaranloo, K; Le Danff, C; Carosella, ED				LeMaoult, J; Zafaranloo, K; Le Danff, C; Carosella, ED			HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells	FASEB JOURNAL			English	Article						inhibitory receptors; immune cells; human leukocyte antigen	G MESSENGER-RNA; NATURAL-KILLER-CELLS; G EXPRESSION; CLASS-I; G MOLECULE; INHIBITORY RECEPTORS; PROLIFERATIVE RESPONSE; MYELOMONOCYTIC CELLS; HUMAN TROPHOBLASTS; DENDRITIC CELLS	The nonclassical HLA class I antigen HLA-G is an inhibitory molecule involved in immune tolerance and immune escape. HLA-G exerts its inhibitory functions via interaction with inhibitory receptors ILT2, ILT4, and KIR2DL4, differentially expressed by NK, T, and antigen-presenting cells. Cells expressing HLA-G and cells expressing its receptors are often found in the vicinity of each other, but the mechanisms responsible for this colocalization are still unknown. We report that ILT2, ILT3, ILT4, and KIR2DL4 expression is up-regulated by HLA-G in antigen-presenting cells, NK cells, and T cells. Because this up- regulation seems not to require antigenic costimulation, it might precede an immune response. Functionally, up- regulation of inhibitory receptors in immune cells before stimulation might increase their activation thresholds and participate in immune escape mechanisms.	Hop St Louis, Inst Univ Hematol, CEA DRM DSV, Serv Rech Hematoimmunol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; CEA; UDICE-French Research Universities; Universite Paris Cite	Carosella, ED (corresponding author), Hop St Louis, Inst Univ Hematol, CEA DRM DSV, Serv Rech Hematoimmunol, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	carosella@dsvidf.cea.fr	LeMaoult, Joel/E-9583-2011	LeMaoult, Joel/0000-0002-4513-9482				Allan DSJ, 1999, J EXP MED, V189, P1149, DOI 10.1084/jem.189.7.1149; Aractingi S, 2001, AM J PATHOL, V159, P71, DOI 10.1016/S0002-9440(10)61675-6; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; Bukur J, 2003, CANCER RES, V63, P4107; Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760; Colonna M, 1998, J IMMUNOL, V160, P3096; COLONNA M, 1997, J EXP MED, V186, P1803; Contini P, 2003, EUR J IMMUNOL, V33, P125, DOI 10.1002/immu.200390015; Costa P, 2001, AIDS, V15, P965, DOI 10.1097/00002030-200105250-00004; Creput C, 2003, J HEPATOL, V39, P587, DOI 10.1016/S0168-8278(03)00354-4; Crisa L, 1997, J EXP MED, V186, P289, DOI 10.1084/jem.186.2.289; ELLIS SA, 1986, IMMUNOLOGY, V59, P595; Fainardi E, 2003, J NEUROIMMUNOL, V142, P149, DOI 10.1016/S0165-5728(03)00266-2; FUJII T, 1994, J IMMUNOL, V153, P5516; Ibrahim EC, 2001, CANCER RES, V61, P6838; ISHITANI A, 1992, P NATL ACAD SCI USA, V89, P3947, DOI 10.1073/pnas.89.9.3947; Khalil-Daher I, 1999, J REPROD IMMUNOL, V43, P175, DOI 10.1016/S0165-0378(99)00032-7; Khosrotehrani K, 2001, J INVEST DERMATOL, V117, P750, DOI 10.1046/j.0022-202x.2001.01487.x; KIRSZENBAUM M, 1994, P NATL ACAD SCI USA, V91, P4209, DOI 10.1073/pnas.91.10.4209; Le Discorde M, 2003, HUM IMMUNOL, V64, P1039, DOI 10.1016/j.humimm.2003.08.346; Le Gal FA, 1999, INT IMMUNOL, V11, P1351, DOI 10.1093/intimm/11.8.1351; Lefebvre S, 2002, J PATHOL, V196, P266, DOI 10.1002/path.1039; LeMaoult J, 2004, P NATL ACAD SCI USA, V101, P7064, DOI 10.1073/pnas.0401922101; Lila N, 2000, LANCET, V355, P2138, DOI 10.1016/S0140-6736(00)02386-2; Lila N, 2002, CIRCULATION, V105, P1949, DOI 10.1161/01.CIR.0000015075.89984.46; Lila N, 2001, P NATL ACAD SCI USA, V98, P12150, DOI 10.1073/pnas.201407398; Lozano JM, 2002, AIDS, V16, P347, DOI 10.1097/00002030-200202150-00005; Manavalan JS, 2004, INT IMMUNOL, V16, P1055, DOI 10.1093/intimm/dxh107; Menier C, 2000, HUM IMMUNOL, V61, P1118, DOI 10.1016/S0198-8859(00)00194-4; MOREAU P, 1995, HUM IMMUNOL, V43, P231, DOI 10.1016/0198-8859(95)00009-S; Pangault C, 2002, HUM IMMUNOL, V63, P83, DOI 10.1016/S0198-8859(01)00373-1; Paul P, 1998, P NATL ACAD SCI USA, V95, P4510, DOI 10.1073/pnas.95.8.4510; Paul P, 2000, HUM IMMUNOL, V61, P1138, DOI 10.1016/S0198-8859(00)00197-X; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; Riteau B, 2001, J IMMUNOL, V166, P5018, DOI 10.4049/jimmunol.166.8.5018; Riteau B, 1999, J REPROD IMMUNOL, V43, P203, DOI 10.1016/S0165-0378(99)00034-0; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P5249, DOI 10.1073/pnas.94.10.5249; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Urosevic M, 2001, AM J PATHOL, V159, P817, DOI 10.1016/S0002-9440(10)61756-7; UROSEVIC M, 2003, BLOOD; Vlad G, 2003, HUM IMMUNOL, V64, P483, DOI 10.1016/S0198-8859(03)00040-5; Wiendl H, 2000, ANN NEUROL, V48, P679, DOI 10.1002/1531-8249(200010)48:4<679::AID-ANA19>3.3.CO;2-M; Wiendl H, 2003, BRAIN, V126, P176, DOI 10.1093/brain/awg017; Wiendl H, 2002, J IMMUNOL, V168, P4772, DOI 10.4049/jimmunol.168.9.4772	45	225	242	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					662	+		10.1096/fj.04-1617fje	http://dx.doi.org/10.1096/fj.04-1617fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15670976				2022-12-25	WOS:000226576600010
J	Gowher, H; Liebert, K; Hermann, A; Xu, GL; Jeltsch, A				Gowher, H; Liebert, K; Hermann, A; Xu, GL; Jeltsch, A			Mechanism of stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA-(cytosine-C5)-methyltransferases by Dnmt3L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA CYTOSINE-5 METHYLTRANSFERASES; DE-NOVO METHYLATION; TRANSCRIPTIONAL REPRESSOR; IMMUNODEFICIENCY SYNDROME; MAMMALIAN DEVELOPMENT; ENZYMATIC-PROPERTIES; HISTONE DEACETYLASE; IN-VIVO; BINDING; GENE	Dnmt3L has been identified as a stimulator of the catalytic activity of de novo DNA methyltransferases. It is essential in the development of germ cells in mammals. We show here that Dnmt3L stimulates the catalytic activity of the Dnmt3A and Dnmt3B enzymes by directly binding to their respective catalytic domains via its own C-terminal domain. The catalytic activity of Dnmt3A and -3B was stimulated similar to 15-fold, and Dnmt3L directly binds to DNA but not to S-adenosyl-L-methionine (AdoMet). Complex formation between Dnmt3A and Dnmt3L accelerates DNA binding by Dnmt3A 20-fold and lowers its Km for DNA. Interaction of Dnmt3L with Dnmt3A increases the binding of the coenzyme AdoMet to Dnmt3A, and it lowers the Km of Dnmt3A for AdoMet. On the basis of our data we propose a model in which the interaction of Dnmt3A with Dnmt3L induces a conformational change of Dnmt3A that opens the active site of the enzyme and promotes binding of DNA and the AdoMet. We demonstrate that the interaction of Dnmt3A and Dnmt3L is transient, and after DNA binding to Dnmt3A, Dnmt3L dissociates from the complex. Following dissociation of Dnmt3L, Dnmt3A adopts a closed conformation leading to slow rates of DNA release. Therefore, Dnmt3L acts as a substrate exchange factor that accelerates DNA and AdoMet binding to de novo DNA methyltransferases.	Int Jacobs Univ Bremen, Sch Sci & Engn, D-28759 Bremen, Germany; Univ Giessen, FB 08, Inst Biochem, D-35392 Giessen, Germany; Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China	Justus Liebig University Giessen; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Jeltsch, A (corresponding author), Int Jacobs Univ Bremen, Sch Sci & Engn, Campus Ring 1, D-28759 Bremen, Germany.	a.jeltsch@iu-bremen.de	Jeltsch, Albert/O-7404-2014; Gowher, Humaira/AAG-7112-2019	Jeltsch, Albert/0000-0001-6113-9290; 				Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Aapola U, 2002, NUCLEIC ACIDS RES, V30, P3602, DOI 10.1093/nar/gkf474; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886; Chedin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999; Chen TP, 2004, CURR TOP DEV BIOL, V60, P55; Chen TP, 2004, MOL CELL BIOL, V24, P9048, DOI 10.1128/MCB.24.20.9048-9058.2004; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8; Fatemi M, 2001, J MOL BIOL, V309, P1189, DOI 10.1006/jmbi.2001.4709; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Ge YZ, 2004, J BIOL CHEM, V279, P25447, DOI 10.1074/jbc.M312296200; Gowher H, 2002, J BIOL CHEM, V277, P20409, DOI 10.1074/jbc.M202148200; Gowher H, 2001, J MOL BIOL, V309, P1201, DOI 10.1006/jmbi.2001.4710; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hata K, 2002, DEVELOPMENT, V129, P1983; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200; Hermann A, 2003, J BIOL CHEM, V278, P31717, DOI 10.1074/jbc.M305448200; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jeltsch A, 1998, J MOL BIOL, V275, P747, DOI 10.1006/jmbi.1997.1492; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Jeltsch Albert, 2002, Methods Mol Biol, V182, P85; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Kunert N, 2003, DEVELOPMENT, V130, P5083, DOI 10.1242/dev.00716; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Liu K, 2003, MOL CELL BIOL, V23, P2709, DOI 10.1128/MCB.23.8.2709-2719.2003; Nelson D.L., 2004, PRINCIPLES BIOCH, V4th; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PINGOUD A, 2002, BIOCH METHODS, P327; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Reither S, 2003, J MOL BIOL, V329, P675, DOI 10.1016/S0022-2836(03)00509-6; Roth M, 2000, BIOL CHEM, V381, P269, DOI 10.1515/BC.2000.035; Suetake I, 2004, J BIOL CHEM, V279, P27816, DOI 10.1074/jbc.M400181200; Tang LY, 2003, J BIOL CHEM, V278, P33613, DOI 10.1074/jbc.C300255200; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	49	208	223	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13341	13348		10.1074/jbc.M413412200	http://dx.doi.org/10.1074/jbc.M413412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15671018	hybrid			2022-12-25	WOS:000228095500020
J	Davies, JP; Scott, C; Oishi, K; Liapis, A; Ioannou, YA				Davies, JP; Scott, C; Oishi, K; Liapis, A; Ioannou, YA			Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL; EXPRESSION	NPC1L1, a recently identified relative of Niemann-Pick C1, was characterized to determine its subcellular location and potential function(s). NPC1L1 was highly expressed in HepG2 cells and localized in a subcellular vesicular compartment rich in the small GTPase Rab5. mRNA expression profiling revealed significant differences between mouse and man with highest expression found in human liver and significant expression in the small intestine. In contrast, liver expression in mouse was extremely low with mouse small intestine exhibiting the highest NPC1L1 expression. A mouse knock-out model of NPC1L1 was generated and revealed that mice lacking a functional NPC1L1 have multiple lipid transport defects. Surprisingly, lack of NPC1L1 exerts a protective effect against diet-induced hyperlipidemia. Further characterization of cell lines generated from wildtype and knock-out mice revealed that in contrast to wild-type cells, NPC1L1 cells exhibit aberrant plasma membrane uptake and subsequent transport of various lipids, including cholesterol and sphingolipids. Furthermore, lack of NPC1L1 activity causes a deregulation of caveolin transport and localization, suggesting that the observed lipid transport defects may be the indirect result of an inability of NPC1L1 null cells to properly target and/or regulate caveolin expression.	CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ioannou, YA (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, Box 1498,1 Gustave Levy Pl, New York, NY 10029 USA.	yiannis.ioannou@mssm.edu		Oishi, Kimihiko/0000-0001-9446-8912	NCI NIH HHS [CA88302] Funding Source: Medline; NIDDK NIH HHS [R01 DK54736, R01 DK065793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA088302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054736, R01DK065793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Davies JP, 2000, GENOMICS, V65, P137, DOI 10.1006/geno.2000.6151; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; Fu Y, 2004, J BIOL CHEM, V279, P14140, DOI 10.1074/jbc.M311061200; GARMY N, 2004, J LIPID RES; Higgins ME, 2001, J LIPID RES, V42, P1939; Loura LMS, 2001, BBA-BIOMEMBRANES, V1511, P236, DOI 10.1016/S0005-2736(01)00269-3; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; Pohl J, 2004, BIOCHEMISTRY-US, V43, P4179, DOI 10.1021/bi035743m; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schmitt M, 1999, J LIPID RES, V40, P39; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Smart EJ, 2004, P NATL ACAD SCI USA, V101, P3450, DOI 10.1073/pnas.0400441101; Walter M, 2003, J LIPID RES, V44, P243, DOI 10.1194/jlr.M200230-JLR200; Weiss D, 2001, CIRCULATION, V103, P448; Westermann M, 1999, HISTOCHEM CELL BIOL, V111, P71, DOI 10.1007/s004180050335	18	219	244	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12710	12720		10.1074/jbc.M409110200	http://dx.doi.org/10.1074/jbc.M409110200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15671032	hybrid			2022-12-25	WOS:000227922000078
J	Fujii-Yamamoto, H; Kim, JM; Arai, K; Masai, H				Fujii-Yamamoto, H; Kim, JM; Arai, K; Masai, H			Cell cycle and developmental regulations of replication factors in mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MCM HETEROHEXAMERIC COMPLEXES; MESSENGER-RNA STABILITY; MAMMALIAN CDC7 KINASE; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; DNA-REPLICATION; REPRESSES TRANSCRIPTION; GENE-EXPRESSION; BINDING; E2F	Embryonic stem (ES) cells can grow rapidly and permanently while maintaining their differentiation capacity. To gain insight into how the cell cycle progression of undifferentiated murine ES cells is regulated, we have examined the expression patterns of various replication and cell cycle regulators. Most factors including cyclins, Cdc6, and geminin are rather constitutively expressed during the cell cycle of ES cells. Furthermore, the transcript levels of almost all the cell cycle regulators we investigated except for p21 and p27 are higher in undifferentiated ES cells than in murine embryonic fibroblasts ( MEFs), and the increased stability of mRNA in ES cells may be partially responsible for this at least with some of the factors. More strikingly, the transcriptional levels of these factors are strongly correlated with the acetylated state of histone H3 at their promoter regions. However, the methylation state of histone or CpG methylation of the promoter region is not generally correlated significantly with the expression pattern of these factors in both cell types. On the protein level, Cdc6, ASK, cyclin A2, and cyclin B1 are extremely abundant in ES cells compared with MEFs. Furthermore, they are rapidly down-regulated upon induction of differentiation of ES cells. The significance of these findings is discussed in relation to the unusual proliferative properties of ES cells in an undifferentiated state.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Integrat Life Sci, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	hmasai@rinshoken.or.jp						Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; Feng Q, 2001, GENE DEV, V15, P827; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Fujita M, 1997, J BIOL CHEM, V272, P10928; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Geng Y, 1996, ONCOGENE, V12, P1173; Gidekel S, 2002, J BIOL CHEM, V277, P34521, DOI 10.1074/jbc.M203338200; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kim JM, 2004, CELL CYCLE, V3, P300; Kim JM, 2003, MUTAT RES-FUND MOL M, V532, P29, DOI 10.1016/j.mrfmmm.2003.08.008; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lee JH, 2004, GENESIS, V38, P32, DOI 10.1002/gene.10250; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Mattick JS, 2004, NAT REV GENET, V5, P316, DOI 10.1038/nrg1321; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Nakatsuka SI, 2003, INT J ONCOL, V22, P561; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; PROSPERI E, 1994, EXP CELL RES, V215, P257, DOI 10.1006/excr.1994.1341; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Santos F, 2004, REPRODUCTION, V127, P643, DOI 10.1530/rep.1.00221; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; SAVATIER P, 1994, ONCOGENE, V9, P809; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sclafani RA, 2000, J CELL SCI, V113, P2111; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith A, 2001, COLD SPRING HARBOR M, P205; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yamada M, 2002, J BIOL CHEM, V277, P27668, DOI 10.1074/jbc.M202884200; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	71	88	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12976	12987		10.1074/jbc.M412224200	http://dx.doi.org/10.1074/jbc.M412224200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15659392	hybrid			2022-12-25	WOS:000227922000107
J	Johans, M; Milanesi, E; Franck, M; Johans, C; Liobikas, J; Panagiotaki, M; Greci, L; Principato, G; Kinnunen, PKJ; Bernardi, P; Costantini, P; Eriksson, O				Johans, M; Milanesi, E; Franck, M; Johans, C; Liobikas, J; Panagiotaki, M; Greci, L; Principato, G; Kinnunen, PKJ; Bernardi, P; Costantini, P; Eriksson, O			Modification of permeability transition pore arginine(s) by phenylglyoxal derivatives in isolated mitochondria and mammalian cells - Structure-function relationship of arginine ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; CYCLOSPORINE-A; MATRIX PH; MODULATION; APOPTOSIS; DEATH; PROTEINS; COMMON; HYDROXYPHENYLGLYOXAL; TRANSLOCATOR		Univ Helsinki, Inst Biomed Biochem, Helsinki Biophys & Biomembrane Grp, FIN-00014 Helsinki, Finland; Univ Padua, Dept Biomed Sci, I-35131 Padua, Italy; Univ Padua, Dept Biol, I-35131 Padua, Italy; Kibron Inc, FIN-00171 Helsinki, Finland; Polytech Univ Marche, Dept Mat & Earth Sci, I-60131 Ancona, Italy	University of Helsinki; University of Padua; University of Padua; Marche Polytechnic University	Eriksson, O (corresponding author), Univ Helsinki, Inst Biomed Biochem, Helsinki Biophys & Biomembrane Grp, POB 63, FIN-00014 Helsinki, Finland.	ove.eriksson@helsinki.fi	Liobikas, Julius/J-4278-2016; Bernardi, Paolo/C-3656-2008; Franck, Marina/A-9498-2008; Eriksson-Rosenberg, Ove/GVU-6692-2022	Liobikas, Julius/0000-0001-6314-9898; Bernardi, Paolo/0000-0001-9187-3736; Franck, Marina/0000-0002-2174-6392; PRINCIPATO, Giovanni/0000-0001-8800-0301				ABRAHAM MH, 1989, J CHEM SOC PERK T 2, P1355, DOI 10.1039/p29890001355; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cesura AM, 2003, J BIOL CHEM, V278, P49812, DOI 10.1074/jbc.M304748200; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Eriksson O, 1999, AM J PHYSIOL-CELL PH, V276, pC1297, DOI 10.1152/ajpcell.1999.276.6.C1297; Eriksson O, 1997, FEBS LETT, V409, P361, DOI 10.1016/S0014-5793(97)00549-8; Eriksson O, 1998, J BIOL CHEM, V273, P12669, DOI 10.1074/jbc.273.20.12669; Fischer H, 1998, J MEMBRANE BIOL, V165, P201, DOI 10.1007/s002329900434; FODOR G, 1949, J AM CHEM SOC, V71, P1045, DOI 10.1021/ja01171a079; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Linder MD, 2002, J BIOL CHEM, V277, P937, DOI 10.1074/jbc.M107610200; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SEELIG A, 1994, P NATL ACAD SCI USA, V91, P68, DOI 10.1073/pnas.91.1.68; Speer O, 2003, J BIOL CHEM, V278, P34757, DOI 10.1074/jbc.M301990200; Suomalainen P, 2004, J MED CHEM, V47, P1783, DOI 10.1021/jm0309001; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; THORNALLEY PJ, 1995, CRIT REV ONCOL HEMAT, V20, P99, DOI 10.1016/1040-8428(94)00149-N; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; YAMASAKI RB, 1980, ANAL BIOCHEM, V109, P32, DOI 10.1016/0003-2697(80)90006-8; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	40	31	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12130	12136		10.1074/jbc.M413454200	http://dx.doi.org/10.1074/jbc.M413454200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15671016	hybrid			2022-12-25	WOS:000227922000010
J	Zhang, L; Joshi, AK; Hofmann, J; Schweizer, E; Smith, S				Zhang, L; Joshi, AK; Hofmann, J; Schweizer, E; Smith, S			Cloning, expression, and characterization of the human mitochondrial beta-ketoacyl synthase - Complementation of the yeast cem1 knock-out strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER PROTEIN; FATTY-ACID SYNTHASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; LIPOIC ACID; CONDENSING ENZYMES; FUNCTIONAL EXPRESSION; NEUROSPORA-CRASSA; IN-VITRO	A human beta-ketoacyl synthase implicated in a mitochondrial pathway for fatty acid synthesis has been identified, cloned, expressed, and characterized. Sequence analysis indicates that the protein is more closely related to freestanding counterparts found in prokaryotes and chloroplasts than it is to the beta-ketoacyl synthase domain of the human cytosolic fatty acid synthase. The full-length nuclear-encoded 459-residue protein includes an N-terminal sequence element of similar to 38 residues that functions as a mitochondrial targeting sequence. The enzyme can elongate acyl-chains containing 2-14 carbon atoms with malonyl moieties attached in thioester linkage to the human mitochondrial acyl carrier protein and is able to restore growth to the respiratory-deficient yeast mutant cem1 that lacks the endogenous mitochondrial beta-ketoacyl synthase and exhibits lowered lipoic acid levels. To date, four components of a putative type II mitochondrial fatty acid synthase pathway have been identified in humans: acyl carrier protein, malonyl transferase, beta-ketoacyl synthase, and enoyl reductase. The substrate specificity and complementation data for the beta-ketoacyl synthase suggest that, as in plants and fungi, in humans this pathway may play an important role in the generation of octanoyl-acyl carrier protein, the lipoic acid precursor, as well as longer chain fatty acids that are required for optimal mitochondrial function.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Erlangen Nurnberg, Lehrstuhl Biochem, D-91058 Erlangen, Germany	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of Erlangen Nuremberg	Smith, S (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	ssmith@chori.org		Hofmann, Joerg/0000-0001-7387-1569	NIDDK NIH HHS [DK 16073] Funding Source: Medline; NIGMS NIH HHS [GM 69717] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069717] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; BRODY S, 1988, EUR J BIOCHEM, V173, P353, DOI 10.1111/j.1432-1033.1988.tb14005.x; Edwards P, 1997, FEBS LETT, V402, P62, DOI 10.1016/S0014-5793(96)01437-8; Fujiwara K, 2001, J BIOL CHEM, V276, P28819, DOI 10.1074/jbc.M101748200; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; HARINGTON A, 1993, MOL MICROBIOL, V9, P545, DOI 10.1111/j.1365-2958.1993.tb01715.x; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; Jordan SW, 2003, J BACTERIOL, V185, P1582, DOI 10.1128/JB.185.5.1582-1589.2003; Joshi AK, 2003, J BIOL CHEM, V278, P33142, DOI 10.1074/jbc.M305459200; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Moche M, 2001, J MOL BIOL, V305, P491, DOI 10.1006/jmbi.2000.4272; Morikawa T, 2001, FEBS LETT, V498, P16, DOI 10.1016/S0014-5793(01)02469-3; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; Olsen JG, 2001, STRUCTURE, V9, P233, DOI 10.1016/S0969-2126(01)00583-4; OLSEN JG, 2001, THESIS U COPENHAGEN; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; Price AC, 2003, J BACTERIOL, V185, P4136, DOI 10.1128/JB.185.14.4136-4143.2003; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Rangan VS, 1997, PROTEIN ENG, V10, P561, DOI 10.1093/protein/10.5.561; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; Schneider R, 1997, FEBS LETT, V407, P249, DOI 10.1016/S0014-5793(97)00360-8; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Schneider R, 1997, CURR GENET, V32, P384, DOI 10.1007/s002940050292; TOMODA H, 1984, J BIOCHEM-TOKYO, V95, P1705, DOI 10.1093/oxfordjournals.jbchem.a134784; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; Triepels R, 1999, J INHERIT METAB DIS, V22, P163, DOI 10.1023/A:1005402020569; Wada M, 2001, PLANT CELL PHYSIOL, V42, P650, DOI 10.1093/pcp/pce081; Wang HP, 1999, J BIOL CHEM, V274, P14875, DOI 10.1074/jbc.274.21.14875; Wrenger C, 2004, MOL MICROBIOL, V53, P103, DOI 10.1111/j.1365-2958.2004.04112.x; Yasuno R, 2004, J BIOL CHEM, V279, P8242, DOI 10.1074/jbc.M308894200; Zhang L, 2003, J BIOL CHEM, V278, P40067, DOI 10.1074/jbc.M306121200	43	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12422	12429		10.1074/jbc.M413686200	http://dx.doi.org/10.1074/jbc.M413686200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668256	hybrid			2022-12-25	WOS:000227922000044
J	Hwang, JJ; Park, MH; Choi, SY; Koh, JY				Hwang, JJ; Park, MH; Choi, SY; Koh, JY			Activation of the Trk signaling pathway by extracellular zinc - Role of metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CORTICAL-NEURONS; INTRACELLULAR FREE ZINC; LONG-TERM POTENTIATION; NEUROTROPHIC FACTOR; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHATASES; SYNAPTIC-TRANSMISSION; HIPPOCAMPAL SLICES; GROWTH-FACTOR; FAMILY	In certain brain regions, extracellular zinc concentrations can rise precipitously as intense neuronal activity releases large amounts of zinc from the nerve terminals. Although zinc release has been suggested to play a pathological role, its precise physiological effect is poorly understood. Here, we report that exposure to micromolar quantities of zinc for only a few minutes robustly and specifically activated tropomyosin-related kinase (Trk) receptors, most likely TrkB, in cultured cortical neurons. We further found that Trk activation by zinc is extracellularly mediated by activation of metalloproteinases, which release pro-BDNF from cells and convert pro-BDNF to mature BDNF. These results suggest that activity-dependent release of extracellular zinc leads to metalloproteinase activation, which plays a critically important role in Trk receptor activation at zinc-containing synapses.	Univ Ulsan, Coll Med, Natl Creat Res Initiat Ctr Study CNS Zinc, Dept Neurol, Seoul 138736, South Korea	University of Ulsan	Koh, JY (corresponding author), Univ Ulsan, Coll Med, Natl Creat Res Initiat Ctr Study CNS Zinc, Dept Neurol, Seoul 138736, South Korea.	jkko@amc.seoul.kr	Hwang, Jung Jin/F-3424-2014; Koh, Jae-Young/C-9014-2011	Koh, Jae-Young/0000-0002-4318-495X				ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Canzoniero LMT, 1999, J NEUROSCI, V19; Chen GQ, 1999, J NEUROSCI, V19, P7983; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Hwang JJ, 2002, J NEUROCHEM, V82, P894, DOI 10.1046/j.1471-4159.2002.01040.x; Iwasaki Y, 1998, J NEUROCHEM, V71, P106; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kim CH, 1999, BIOCHEM BIOPH RES CO, V259, P505, DOI 10.1006/bbrc.1999.0814; Kim TY, 2002, SYNAPSE, V46, P49, DOI 10.1002/syn.10118; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kossel AH, 2001, P NATL ACAD SCI USA, V98, P14702, DOI 10.1073/pnas.251326998; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li Y, 2001, J NEUROSCI, V21, P8015, DOI 10.1523/JNEUROSCI.21-20-08015.2001; Manzerra P, 2001, P NATL ACAD SCI USA, V98, P11055, DOI 10.1073/pnas.191353598; Minami A, 2002, BRAIN RES, V936, P91, DOI 10.1016/S0006-8993(02)02499-X; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; Mowla SJ, 2001, J BIOL CHEM, V276, P12660, DOI 10.1074/jbc.M008104200; Park JA, 2000, J NEUROSCI, V20, P9096; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Ross GM, 1997, NAT MED, V3, P872, DOI 10.1038/nm0897-872; Samet JM, 1999, AM J RESP CELL MOL, V21, P357, DOI 10.1165/ajrcmb.21.3.3656; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; TAPLEY P, 1992, ONCOGENE, V7, P371; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; Wu WD, 2004, AM J RESP CELL MOL, V30, P540, DOI 10.1165/rcmb.2003-0233OC	37	169	172	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11995	12001		10.1074/jbc.M403172200	http://dx.doi.org/10.1074/jbc.M403172200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659400	hybrid			2022-12-25	WOS:000227761800132
J	Tiedemann, K; Sasaki, T; Gustafsson, E; Gohring, W; Batge, B; Notbohm, H; Timpl, R; Wedel, T; Schlotzer-Schrehardt, U; Reinhardt, DP				Tiedemann, K; Sasaki, T; Gustafsson, E; Gohring, W; Batge, B; Notbohm, H; Timpl, R; Wedel, T; Schlotzer-Schrehardt, U; Reinhardt, DP			Microfibrils at basement membrane zones interact with perlecan via fibrillin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; GROWTH-FACTOR-BETA; DENSITY-LIPOPROTEIN-RECEPTOR; EXTRACELLULAR-MATRIX PROTEINS; CELL-ADHESION MOLECULES; BINDING PROTEIN-1; MARFAN-SYNDROME; CORE PROTEIN; DOMAIN-I; MONOCLONAL-ANTIBODIES	Mutational defects in fibrillin-rich microfibrils give rise to a number of heritable connective tissue disorders, generally termed microfibrillopathies. To understand the pathogenesis of these microfibrillopathies, it is important to elucidate the supramolecular composition of microfibrils and their interaction properties with extracellular matrix components. Here we demonstrate that the proteoglycan perlecan is an associated component of microfibrils typically close to basement membrane zones. Double immunofluorescence studies demonstrate colocalization of fibrillin-1, the major backbone component of microfibrils, with perlecan in fibroblast cultures as well as in dermal and ocular tissues. Double immunogold labeling further confirms colocalization of perlecan to microfibrils in various tissues at the ultrastructural level. Extraction studies revealed that perlecan is not covalently associated with microfibrils. High affinity interactions between fibrillin-1 and perlecan were found by kinetic binding studies with dissociation constants in the low nanomolar range. A detailed mapping study of the interaction epitopes by solid phase binding assays primarily revealed interactions of perlecan domains I and II with a central region of fibrillin-1. Analysis of perlecan null embryos showed less microfibrils at the dermal-epidermal junction as compared with wild-type littermates. The data presented indicate a functional significance for perlecan in anchoring microfibrils to basement membranes and in the biogenesis of microfibrils.	McGill Univ, Dept Anat & Cell Biol, Fac Med, Montreal, PQ H3A 2B2, Canada; McGill Univ, Fac Dent, Fac Med, Montreal, PQ H3A 2B2, Canada	McGill University; McGill University	Reinhardt, DP (corresponding author), McGill Univ, Dept Anat & Cell Biol, Fac Med, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.	reinhardt@mcgill.ca	Reinhardt, Dieter P/A-3102-2008; Wedel, Thilo/B-1247-2010; Tiedemann, one/A-9739-2016	Reinhardt, Dieter P/0000-0001-6535-9872; Wedel, Thilo/0000-0002-8146-2711				AJIRI T, 1978, ACTA ANAT, V102, P433; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; Collod-Beroud G, 2003, HUM MUTAT, V22, P199, DOI 10.1002/humu.10249; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; Costell M, 1996, FEBS LETT, V396, P127, DOI 10.1016/0014-5793(96)01082-4; Costell M, 1997, EUR J BIOCHEM, V243, P115, DOI 10.1111/j.1432-1033.1997.t01-1-00115.x; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; COUCHMAN JR, 1989, MATRIX, V9, P311, DOI 10.1016/S0934-8832(89)80007-1; Dallas SL, 2000, J BONE MINER RES, V15, P68, DOI 10.1359/jbmr.2000.15.1.68; DAVIS EC, 1994, J CELL SCI, V107, P727; Dzamba BJ, 2001, J INVEST DERMATOL, V117, P1612, DOI 10.1046/j.0022-202x.2001.01588.x; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; Gleizes PE, 1996, J BIOL CHEM, V271, P29891, DOI 10.1074/jbc.271.47.29891; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; Groffen AJA, 1996, EUR J BIOCHEM, V241, P827, DOI 10.1111/j.1432-1033.1996.00827.x; Gupta PA, 2002, HUM MUTAT, V19, P39, DOI 10.1002/humu.10017; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; HEREMANS A, 1988, J BIOL CHEM, V263, P4731; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HEREMANS A, 1989, J CELL BIOL, V109, P3199, DOI 10.1083/jcb.109.6.3199; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; INOUE S, 1995, CELL TISSUE RES, V279, P303, DOI 10.1007/s004410050285; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; Kassner A, 2004, J MOL BIOL, V339, P835, DOI 10.1016/j.jmb.2004.03.042; Kassner A, 2003, MATRIX BIOL, V22, P131, DOI 10.1016/S0945-053X(03)00008-8; Kielty CM, 1996, FEBS LETT, V386, P169, DOI 10.1016/0014-5793(96)00423-1; KIELTY CM, 1994, MATRIX BIOL, V14, P191, DOI 10.1016/0945-053X(94)90008-6; Kielty CM, 2002, J CELL SCI, V115, P2817; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; KORTE GE, 1991, ACTA ANAT, V142, P49; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Lin GQ, 2002, J BIOL CHEM, V277, P50795, DOI 10.1074/jbc.M210611200; LOW FN, 1961, ANAT RECORD, V139, P105, DOI 10.1002/ar.1091390203; MALAK TM, 1994, AM J OBSTET GYNECOL, V171, P195, DOI 10.1016/0002-9378(94)90469-3; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; Mongiat M, 2003, J BIOL CHEM, V278, P17491, DOI 10.1074/jbc.M210529200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nakajima Y, 1997, J CELL BIOL, V136, P193, DOI 10.1083/jcb.136.1.193; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; Pan TC, 2003, AM J HUM GENET, V73, P355, DOI 10.1086/377107; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Piecha D, 2002, BIOCHEM J, V367, P715, DOI 10.1042/BJ20021069; PUTNAM EA, 1995, NAT GENET, V11, P456, DOI 10.1038/ng1295-456; Pyeritz RE, 2000, ANNU REV MED, V51, P481, DOI 10.1146/annurev.med.51.1.481; Raghunath M, 1998, J INVEST DERMATOL, V111, P559, DOI 10.1046/j.1523-1747.1998.00339.x; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Ritty TM, 2003, BIOCHEM J, V375, P425, DOI 10.1042/BJ20030649; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI T, 1987, ANAT EMBRYOL, V176, P373; Sasaki T, 1998, FEBS LETT, V435, P169, DOI 10.1016/S0014-5793(98)01063-1; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; SchlotzerSchrehardt U, 1997, INVEST OPHTH VIS SCI, V38, P970; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; Schulze B, 1996, MATRIX BIOL, V15, P349, DOI 10.1016/S0945-053X(96)90138-9; SINGER II, 1987, EXP CELL RES, V173, P558, DOI 10.1016/0014-4827(87)90295-3; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TANGEMANN K, 1995, FEBS LETT, V358, P179, DOI 10.1016/0014-5793(94)01411-S; Tiedemann K, 2004, MED INTELL UNIT, P130; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; TSUJI T, 1980, BRIT J DERMATOL, V102, P413, DOI 10.1111/j.1365-2133.1980.tb06554.x; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	80	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11404	11412		10.1074/jbc.M409882200	http://dx.doi.org/10.1074/jbc.M409882200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657057	Green Published, hybrid			2022-12-25	WOS:000227761800063
J	Wilkinson, B; Xiao, RY; Gilbert, HF				Wilkinson, B; Xiao, RY; Gilbert, HF			A structural disulfide of yeast protein-disulfide isomerase destabilizes the active site disulfide of the N-terminal thioredoxin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE RESIDUES; FOLDING CATALYST; IN-VIVO	Protein-disulfide isomerase (PDI) is an essential catalyst of disulfide formation and isomerization in the eukaryotic endoplasmic reticulum. PDI has two active sites at either end of the molecule, each containing two cysteines that facilitate thiol-disulfide exchange. In addition to its four catalytic cysteines, PDI possesses two non-active site cysteines whose location and separation distance varies by organism. In higher eukaryotes, the non-active site cysteines are located in the C-terminal half of the protein sequence and are separated by 30 amino acids. In contrast, the internal cysteines of PDI from lower eukaryotes are located near the N-terminal active site and are much closer together in sequence. The function of these cysteines and the significance of their unique location in yeast PDI have been unclear. Previous data (Xiao, R., Wilkinson, B., Solovyov, A., Winther, J. R., Holmgren, A., Lundstrom-Ljung, J., and Gilbert, H. F. (2004) J. Biol. Chem. 279, 49780-49786) suggest that the internal cysteines exist as a disulfide in the endoplasmic reticulum of Saccharomyces cerevisiae. By coupling mass spectrometry with a gel-shift technique that allows us to measure the redox potentials of the PDI active sites in the presence and absence of the non-active site cysteines, we find that the non-active site cysteines form a disulfide that is stable even in a very reducing environment and demonstrate that this disulfide exists to destabilize the N-terminal active site disulfide, making it a better oxidant by 18-fold. Consistent with this finding, we show that mutating the non-active site cysteines to alanines disrupts both the oxidase and isomerase activities of PDI in vitro.	Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Baylor College of Medicine; Karolinska Institutet	Gilbert, HF (corresponding author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	hgilbert@bcm.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379, T32GM008280] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008280, T32-GM-08280, GM-40379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bevington PR, 1969, DATA REDUCTION ERROR; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Luz JM, 1998, BIOCHEM BIOPH RES CO, V248, P621, DOI 10.1006/bbrc.1998.8992; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Schwaller M, 2003, J BIOL CHEM, V278, P7154, DOI 10.1074/jbc.M211036200; Solovyov A, 2004, PROTEIN SCI, V13, P1902, DOI 10.1110/ps.04716104; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Westphal V, 1999, J MOL BIOL, V286, P1229, DOI 10.1006/jmbi.1999.2560; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Wu HH, 2000, BIOCHEM J, V351, P87, DOI 10.1042/0264-6021:3510087; Xiao RY, 2004, J BIOL CHEM, V279, P49780, DOI 10.1074/jbc.M409210200	15	47	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11483	11487		10.1074/jbc.M414203200	http://dx.doi.org/10.1074/jbc.M414203200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15649885	hybrid			2022-12-25	WOS:000227761800072
J	Ying, BW; Taguchi, H; Kondo, M; Ueda, T				Ying, BW; Taguchi, H; Kondo, M; Ueda, T			Co-translational involvement of the chaperonin GroEL in the folding of newly translated polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGGER FACTOR; IN-VIVO; SUCCESSIVE ACTION; PROTEIN; DNAK; IDENTIFICATION; HSP70; CHAIN; FLUX	A large fraction of the newly translated polypeptides emerging from the ribosome require certain proteins, the so-called molecular chaperones, to assist in their folding. In Escherichia coli, three major chaperone systems are considered to contribute to the folding of newly synthesized cytosolic polypeptides. Trigger factor (TF), a ribosome-tethered chaperone, and DnaK are known to exhibit overlapping co-translational roles, whereas the cage-shaped GroEL, with the aid of the co-chaperonin, GroES, and ATP, is believed to be implicated in folding only after the polypeptides are released from the ribosome. However, the recent finding that GroEL-GroES overproduction permits the growth of E. coli cells lacking both TF and DnaK raised questions regarding the separate roles of these chaperones. Here, we report the puromycin-sensitive association of GroEL-GroES with translating ribosomes in vivo. Further experiments in vitro, using a reconstituted cell-free translation system, clearly demonstrate that GroEL associates with the translation complex and accomplishes proper folding by encapsulating the newly translated polypeptides in the central cavity formed by GroES. Therefore, we propose that GroEL is a versatile chaperone, which participates in the folding pathway co-translationally and also achieves correct folding post-translationally.	Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Kashiwa, Chiba 2778562, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Ueda, T (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, FSB 401,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	ueda@k.u-tokyo.ac.jp	Taguchi, Hideki/B-6946-2009; Ueda, Takuya/K-5217-2014; taguchi, hideki/AAM-2663-2021; Ying, Bei-Wen/Q-9750-2019	Taguchi, Hideki/0000-0002-6612-9339; Ueda, Takuya/0000-0002-7760-8271; taguchi, hideki/0000-0002-6612-9339; Ying, Bei-Wen/0000-0003-2517-5686				Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Dunn AY, 2001, J STRUCT BIOL, V135, P176, DOI 10.1006/jsbi.2001.4380; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Fedorov AN, 1998, METHOD ENZYMOL, V290, P1, DOI 10.1016/S0076-6879(98)90003-9; FLESSEL CP, 1967, SCIENCE, V158, P658, DOI 10.1126/science.158.3801.658; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Hardesty Boyd, 1999, Current Opinion in Structural Biology, V9, P111, DOI 10.1016/S0959-440X(99)80014-1; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; KOHLER RE, 1968, J MOL BIOL, V36, P71, DOI 10.1016/0022-2836(68)90220-9; Kolb VA, 2000, J BIOL CHEM, V275, P16597, DOI 10.1074/jbc.M002030200; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; McCallum CD, 2000, J CELL BIOL, V149, P591, DOI 10.1083/jcb.149.3.591; McLennan N, 1998, NATURE, V392, P139, DOI 10.1038/32317; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; NETZER JW, 2000, TRENDS BIOCHEM SCI, V23, P68; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Taguchi H, 2001, NAT BIOTECHNOL, V19, P861, DOI 10.1038/nbt0901-861; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Ueno T, 2004, MOL CELL, V14, P423, DOI 10.1016/S1097-2765(04)00261-8; Vorderwulbecke S, 2004, FEBS LETT, V559, P181, DOI 10.1016/S0014-5793(04)00052-3; Wei YH, 2002, MOL MICROBIOL, V43, P1651, DOI 10.1046/j.1365-2958.2002.02856.x; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Ying BW, 2004, BIOCHEM BIOPH RES CO, V320, P1359, DOI 10.1016/j.bbrc.2004.06.095; Ying BW, 2003, J BIOCHEM, V133, P485, DOI 10.1093/jb/mvg064	39	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					12035	12040		10.1074/jbc.M500364200	http://dx.doi.org/10.1074/jbc.M500364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15664980	hybrid			2022-12-25	WOS:000227761800137
J	Reagan-Shaw, S; Ahmad, N				Reagan-Shaw, S; Ahmad, N			Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer	FASEB JOURNAL			English	Article						cell cycle; cytokinesis; centrosome	DOWN-REGULATION; PLK1; INHIBITION; CENTROSOME; EXPRESSION; TARGET	Prostate cancer (PCa) is one of the most common cancers in men. Each year similar to 543,000 new cases are reported worldwide, and the disease kills 200,000 ( mostly older men) in developed countries. The existing treatment approaches and surgical intervention have not been able to effectively manage this dreaded cancer and, therefore, continuing efforts are ongoing to explore novel targets and strategies for the management of PCa. The activity of polo-like kinase 1 (Plk1) is elevated in tissues and cells with a high mitotic index, including cancer cells. An increasing body of evidence suggests that the level of Plk1 expression has prognostic value for predicting outcomes in patients with some cancers. A close correlation between Plk1 expression and carcinogenesis has been documented. However, the role of Plk1 in PCa is not known. We propagated a hypothesis that Plk1 inhibition will result in elimination of human PCa cells via a mitotic arrest followed by apoptosis ( 1). To define the role of Plk1 in PCa, we used the technique of RNA silencing via small interfering RNA ( siRNA). First, using a series of human prostate carcinoma cells and normal human prostate epithelial (PrEC) cells, we assessed Plk1 levels in PCa. Immunoblot analyses clearly showed a significant expression of Plk1 in LNCaP, DU145, and PC3 human PCa cells. Interestingly, Plk1 was not detectable in normal PrEC cells. Next, we transfected the PCa cells with Plk 1 siRNA, which resulted in a significant inhibition in Plk1 protein in all PCa cells. Plk1 depletion resulted in a decrease in cell viability and induction of apoptosis in PCa cells but had no appreciable effect in normal PrEC cells. Our data also demonstrated that Plk1 siRNA transfection of PCa cells resulted in 1) a mitotic cell cycle arrest, 2) failure of cytokinesis, and 3) defects in centrosome integrity and maturation. Thus, our study suggested that 1) Plk1 plays a critical role in the process of PCa development and 2) gene therapeutic approaches aimed at Plk1 or the pharmacological inhibitors of Plk1 may be developed for the management of PCa.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, Madison, WI 53706 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, 1300 Univ Ave,MSC 25B, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887				Ahmad N, 2004, FASEB J, V18, P5, DOI 10.1096/fj.03-0848hyp; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Donaldson MM, 2001, J CELL SCI, V114, P2357; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Golsteyn R M, 1996, Prog Cell Cycle Res, V2, P107; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Masuda Y, 2003, ONCOGENE, V22, P1012, DOI 10.1038/sj.onc.1206200; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; Pereira G, 2001, CURR OPIN CELL BIOL, V13, P762, DOI 10.1016/S0955-0674(00)00281-7; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Yuan JP, 2002, CANCER RES, V62, P4186	23	117	132	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					611	+		10.1096/fj.04-2910fje	http://dx.doi.org/10.1096/fj.04-2910fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15661849				2022-12-25	WOS:000226576600018
J	Slepkov, ER; Rainey, JK; Li, XJ; Liu, YS; Cheng, FJ; Lindhout, DA; Sykes, BD; Fliegel, L				Slepkov, ER; Rainey, JK; Li, XJ; Liu, YS; Cheng, FJ; Lindhout, DA; Sykes, BD; Fliegel, L			Structural and functional characterization of transmembrane segment IV of the NHE1 isoform of the Na+/H+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; MEMBRANE-PROTEIN STRUCTURE; COUPLING-CONSTANTS; LACTOSE PERMEASE; BINDING-SITE; NMR; PEPTIDES; RESIDUES; HELIX; EXPRESSION	The Na+/H+ exchanger isoform 1 is a ubiquitously expressed integral membrane protein that regulates intracellular pH in mammals. We characterized the structural and functional aspects of the critical transmembrane (TM) segment IV. Each residue was mutated to cysteine in cysteineless NHE1. TM IV was exquisitely sensitive to mutation with 10 of 23 mutations causing greatly reduced expression and/or activity. The Phe(161) --> Cys mutant was inhibited by treatment with the water-soluble sulfhydryl-reactive compounds [2-( trimethylammonium) ethyl] methanethiosulfonate and [ 2- sulfonatoethyl] methanethiosulfonate, suggesting it is a pore-lining residue. The structure of purified TM IV peptide was determined using high resolution NMR in a CD3OH: CDCl3: H2O mixture and in Me2SO. In CD3OH: CDCl3: H2O, TM IV was structured but not as a canonical alpha-helix. Residues Asp(159) - Leu(162) were a series of beta-turns; residues Leu(165) - Pro(168) showed an extended structure, and residues Ile(169) - Phe(176) were helical in character. These three structured regions rotated quite freely with respect to the others. In Me2SO, the structure was much less defined. Our results demonstrate that TM IV is an unusually structured transmembrane segment that is exquisitely sensitive to mutagenesis and that Phe(161) is a pore-lining residue.	Univ Alberta, Dept Biochem, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta; University of Alberta	Fliegel, L (corresponding author), Univ Alberta, Dept Biochem, Membrane Prot Res Grp, 347 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	lfliegel@ualberta.ca	Rainey, Jan K/C-1927-2008	Rainey, Jan K/0000-0003-0793-5573				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMBLER RP, 1965, BIOCHEM J, V96, pP32; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *COMM COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760; Counillon L, 1997, BIOCHEMISTRY-US, V36, P2951, DOI 10.1021/bi9615405; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dibrov P, 1998, FEBS LETT, V424, P1, DOI 10.1016/S0014-5793(98)00119-7; Dibrov P, 1998, BIOCHEMISTRY-US, V37, P8282, DOI 10.1021/bi9801457; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; Fliegel L, 2001, BASIC RES CARDIOL, V96, P301, DOI 10.1007/s003950170036; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; Huth JR, 1997, PROTEIN SCI, V6, P2359; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Katragadda M, 2001, BIOPHYS J, V81, P1029, DOI 10.1016/S0006-3495(01)75760-8; Kelley LA, 1997, PROTEIN ENG, V10, P737, DOI 10.1093/protein/10.6.737; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Kleywegt G. J., 1995, CCP4 ESF EACBM NEWSL, V31, P45; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lindhout DA, 2003, PROTEIN SCI, V12, P1786, DOI 10.1110/ps.0376003; Liu J, 2000, NEURON, V28, P899, DOI 10.1016/S0896-6273(00)00162-8; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Marassi FM, 2002, CONCEPT MAGNETIC RES, V14, P212, DOI 10.1002/cmr.10022; MATTSON G, 1993, MOL BIOL REP, V17, P167, DOI 10.1007/BF00986726; Mentzer RM, 2003, ANN THORAC SURG, V75, pS700, DOI 10.1016/S0003-4975(02)04700-8; MURTAZINA BR, 2001, EUR J BIOCHEM, V268, P1; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; POUCHERT CJ, 1983, ALDRICH LIB NMR SP A, V4, P450; POUCHERT CJ, 1983, ALDRICH LIB NMR SP A, V21, P978; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Slepkov ER, 2004, BIOCHEM J, V379, P31, DOI 10.1042/BJ20030884; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Spadaccini R, 2001, CELL MOL LIFE SCI, V58, P1572, DOI 10.1007/PL00000797; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Tang XB, 1999, J BIOL CHEM, V274, P3557, DOI 10.1074/jbc.274.6.3557; Touret N, 2001, BIOCHEMISTRY-US, V40, P5095, DOI 10.1021/bi0025464; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WANG JJ, 1995, J AM CHEM SOC, V117, P8627, DOI 10.1021/ja00138a019; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; Yeagle PL, 2001, BIOCHEMISTRY-US, V40, P11932, DOI 10.1021/bi015543f	52	79	81	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17863	17872		10.1074/jbc.M409608200	http://dx.doi.org/10.1074/jbc.M409608200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15677483	hybrid			2022-12-25	WOS:000228807200039
J	Chenette, EJ; Abo, A; Der, CJ				Chenette, EJ; Abo, A; Der, CJ			Critical and distinct roles of amino- and carboxyl-terminal sequences in regulation of the biological activity of the Chp atypical Rho GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATIONS; GERANYLGERANYLTRANSFERASE-I; PROTEIN PALMITOYLATION; CDC42; FAMILY; INHIBITORS; FARNESYLTRANSFERASE; PRENYLATION; MECHANISM; RAC	Chp (Cdc42 homologous protein) shares significant sequence and functional identity with the human Cdc42 small GTPase, and like Cdc42, promotes formation of filopodia and activates the p21-activated kinase serine/threonine kinase. However, unlike Cdc42, Chp contains unique amino- and carboxyl-terminal extensions. Here we determined whether Chp, like Cdc42, can promote growth transformation and evaluated the role of the amino- and carboxyl-terminal sequences in Chp function. Surprisingly, we found that a GTPase-deficient mutant of Chp exhibited low transforming activity but that deletion of the amino terminus of Chp greatly enhanced its transforming activity. Thus, the amino terminus may serve as a negative regulator of Chp function. The carboxyl terminus of Cdc42 contains a CAAX ( where C is cysteine, A is aliphatic amino acid, X is terminal amino acid) tetrapeptide sequence that signals for the post-translational modification critical for Cdc42 membrane association and biological function. Although Chp lacks aCAAXmotif, we found that Chp showed carboxylterminus-dependent localization to the plasma membrane and to endosomes. Furthermore, an intact carboxyl terminus was required for Chp transforming activity. However, treatment with inhibitors of protein palmitoylation, but not prenylation, caused Chp to mislocalize to the cytoplasm. Thus, Chp depends on palmitoylation, rather than isoprenylation, for membrane association and function. In summary, Chp is implicated in cell transformation, and the unique amino and carboxyl termini of Chp represent atypical mechanisms of regulation of Rho GTPase function.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; SalutariX Inc, Oakland, CA 94606 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB7295,102 Mason Farm Rd, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Chenette, Emily/0000-0003-0393-395X; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA063071, U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA63071, CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; COX AD, 1994, METHOD ENZYMOL, V238, P277; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Drisdel RC, 2004, BIOTECHNIQUES, V36, P276, DOI 10.2144/04362RR02; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fransson A, 2003, J BIOL CHEM, V278, P6495, DOI 10.1074/jbc.M208609200; Ivanchenko M, 2000, PLANT J, V24, P79, DOI 10.1046/j.1365-313x.2000.00855.x; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Katoh M, 2002, INT J ONCOL, V20, P977; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Lavy M, 2002, PLANT CELL, V14, P2431, DOI 10.1105/tpc.005561; Lawrence DS, 1999, J MED CHEM, V42, P4932, DOI 10.1021/jm980591s; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Mayer BJ, 2001, J CELL SCI, V114, P1253; METZ SA, 1993, BIOCHEM J, V295, P31, DOI 10.1042/bj2950031; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; MITCHELL DA, 1994, J BIOL CHEM, V269, P21540; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Shutes A, 2004, CURR BIOL, V14, P2052, DOI 10.1016/j.cub.2004.11.011; Solski PA, 2002, CELL GROWTH DIFFER, V13, P363; Sun JZ, 1999, CANCER RES, V59, P4919; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Veit M, 2001, EMBO J, V20, P3145, DOI 10.1093/emboj/20.12.3145; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wherlock M, 2002, J CELL SCI, V115, P239; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Zarrinpar A., 2003, SCI STKE, V2003, DOI [10.1126/stke.2003.179.re8, DOI 10.1126/STKE.2003.179.RE8]	50	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13784	13792		10.1074/jbc.M411300200	http://dx.doi.org/10.1074/jbc.M411300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15664990	hybrid			2022-12-25	WOS:000228095500075
J	Shi, T; Wang, F; Stieren, E; Tong, Q				Shi, T; Wang, F; Stieren, E; Tong, Q			SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; DEPENDENT DEACETYLASE; CALORIE RESTRICTION; CELL-SURVIVAL; TRANSCRIPTION FACTORS; UNCOUPLING PROTEIN; INSULIN-RESISTANCE; COACTIVATOR PGC-1; WHITE ADIPOCYTES	SIRT3 is one of the seven mammalian sirtuin homologs of the yeast Sir2 gene, which mediates the effect of caloric restriction on life span extension in yeast and Caenorhabditis elegans. Because adipose tissue is essential in energy homeostasis and also plays a role in life span determination, we decided to investigate the function of sirtuin members in fat. We report here that murine SIRT3 is expressed in brown adipose tissue and is localized on the mitochondria inner membrane. Caloric restriction activates SIRT3 expression in both white and brown adipose. Additionally, cold exposure up-regulates SIRT3 expression in brown fat, whereas elevated climate temperature reduces the expression. Enforced expression of SIRT3 in the HIB1B brown adipocytes enhances the expression of the uncoupling protein PGC-1 alpha, UCP1, and a series of mitochondria-related genes. Both ADP-ribosyltransferase and deacetylase activities of SIRT3 are required for this action. Furthermore, the SIRT3 deacetylase mutant exhibits a dominant negative effect by inhibiting UCP1 expression. This inhibitive effect can be abolished by the coexpression of PGC-1 alpha, indicating a major role of PGC-1 alpha in the SIRT3 action. In addition, SIRT3 stimulates CREB phosphorylation, which reportedly activates PGC-1 alpha promoter directly. Functionally, sustained expression of SIRT3 decreases membrane potential and reactive oxygen species production while increasing cellular respiration. Finally, SIRT3, along with genes related to mitochondrial function, is down-regulated in the brown adipose tissue of several genetically obese mice. In summary, our results demonstrate that SIRT3 activates mitochondria functions and plays an important role in adaptive thermogenesis in brown adipose.	Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA	Baylor College of Medicine; United States Department of Agriculture (USDA)	Tong, Q (corresponding author), Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, 1100 Bates St, Houston, TX 77030 USA.	qtong@bcm.tmc.edu	Wang, Fei/F-8015-2010					APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Barzilai N, 2001, J NUTR, V131, p903S, DOI 10.1093/jn/131.3.903S; BASS DA, 1983, J IMMUNOL, V130, P1910; Baumruk F, 1999, FEBS LETT, V444, P206, DOI 10.1016/S0014-5793(99)00053-8; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Dubey A, 1996, ARCH BIOCHEM BIOPHYS, V333, P189, DOI 10.1006/abbi.1996.0380; Dutnall RN, 2001, CELL, V105, P161, DOI 10.1016/S0092-8674(01)00305-1; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; HIMMSHAGEN J, 1985, INT J OBESITY, V9, P17; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kobayashi T, 2004, CELL, V117, P441, DOI 10.1016/S0092-8674(04)00414-3; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lee D W, 1990, Aging (Milano), V2, P357; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; Masaki T, 2000, AM J PHYSIOL-REG I, V279, pR1305, DOI 10.1152/ajpregu.2000.279.4.R1305; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; RINE J, 1987, GENETICS, V116, P9; Rose G, 2003, EXP GERONTOL, V38, P1065, DOI 10.1016/S0531-5565(03)00209-2; ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H; San-Segundo PA, 2000, MOL BIOL CELL, V11, P3601, DOI 10.1091/mbc.11.10.3601; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; Speakman JR, 2004, AGING CELL, V3, P87, DOI 10.1111/j.1474-9728.2004.00097.x; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vergnes B, 2002, GENE, V296, P139, DOI 10.1016/S0378-1119(02)00842-9; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang YH, 2000, GENOMICS, V69, P355, DOI 10.1006/geno.2000.6360; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	66	542	569	1	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13560	13567		10.1074/jbc.M414670200	http://dx.doi.org/10.1074/jbc.M414670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15653680	hybrid			2022-12-25	WOS:000228095500048
J	Testa, A; Donati, G; Yan, P; Romani, F; Huang, THM; Vigano, MA; Mantovani, R				Testa, A; Donati, G; Yan, P; Romani, F; Huang, THM; Vigano, MA; Mantovani, R			Chromatin immunoprecipitation (ChIP) on chip experiments uncover a widespread distribution of NF-Y binding CCAAT sites outside of core promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUE INHIBITOR; DNA-BINDING; CBF/NF-Y; CELL-CYCLE; FUNCTIONAL-CHARACTERIZATION; SEQUENCE ELEMENTS; REGULATORY REGION; GENE-EXPRESSION; HUMAN CANCER; CPG ISLANDS	The CCAAT box is a prototypical promoter element, almost invariably found between -60 and -100 upstream of the major transcription start site. It is bound and activated by the histone fold trimer NF-Y. We performed chromatin immunoprecipitation (ChIP) on chip experiments on two different CpG islands arrays using chromatin from hepatic HepG2 and pre-B cell leukemia NALM-6 cell lines, with different protocols of probe preparation and labeling. We analyzed and classified 239 known or predicted targets; we validated several by conventional ChIPs with anti-YB and anti-YC antibodies, in vitro EMSAs, and ChIP scanning. The importance of NF-Y binding for gene expression was verified by the use of a dominant negative NF-YA mutant. All but four genes are new NF-Y targets, falling into different functional categories. This analysis reinforces the notion that NF-Y is an important regulator of cell growth, and novel unexpected findings emerged from this unbiased approach. (i) A remarkable proportion of NF-Y targets, 40%, are complex transcriptional units composed of divergent, convergent, and tandem promoters. (ii) 40-50% of NF-Y sites are not in core promoters but are in introns or at distant 3' or 5' locations. The abundance of "unorthodox" CCAAT positions highlights an unexpected complexity of the NF-Y-mediated transcriptional network.	Univ Modena & Reggio Emilia, Dipartimento Biol Anim, I-41100 Modena, Italy; Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20143 Milan, Italy; Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA	Universita di Modena e Reggio Emilia; University of Milan; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Mantovani, R (corresponding author), Dipartimento Sci Biomol & Biotecnol, Via Celoria 26, I-20133 Milan, Italy.	mantor@unimi.it	Yan, Pearlly S/E-4339-2011	Yan, Pearlly S/0000-0003-1965-4920; DONATI, Giacomo/0000-0002-0370-8288; vigano, maria alessandra/0000-0003-2009-0384				Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; ALDER H, 1992, NUCLEIC ACIDS RES, V20, P1769, DOI 10.1093/nar/20.7.1769; Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bhattacharya A, 2003, CANCER RES, V63, P8167; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; Cappabianca L, 2003, EXP CELL RES, V286, P209, DOI 10.1016/S0014-4827(03)00072-7; Caretti G, 1999, MOL CELL BIOL, V19, P8591; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Caretti G, 2000, J MOL BIOL, V302, P539, DOI 10.1006/jmbi.2000.4028; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Coustry F, 2001, J BIOL CHEM, V276, P40621, DOI 10.1074/jbc.M106918200; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DORN A, 1988, MOL CELL BIOL, V8, P3975, DOI 10.1128/MCB.8.10.3975; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FitzGerald PC, 2004, GENOME RES, V14, P1562, DOI 10.1101/gr.1953904; Gilthorpe J, 2002, DEVELOPMENT, V129, P3887; Gowri PM, 2003, MOL CELL BIOL, V23, P815, DOI 10.1128/MCB.23.3.815-825.2003; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; Ioshikhes IP, 2000, NAT GENET, V26, P61, DOI 10.1038/79189; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Izumi H, 2001, J CELL SCI, V114, P1533; KADARIYA Y, 2004, IN PRESS BIOCH J; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Meccia E, 2003, BBA-GENE STRUCT EXPR, V1626, P1, DOI 10.1016/S0167-4781(03)00018-6; Meergans T, 1998, EUR J BIOCHEM, V256, P436, DOI 10.1046/j.1432-1327.1998.2560436.x; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200; Okladnova O, 1997, GENOMICS, V42, P452, DOI 10.1006/geno.1997.4735; Okladnova O, 1999, GENOMICS, V57, P110, DOI 10.1006/geno.1998.5711; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; Scheef G, 2002, J VIROL, V76, P12553, DOI 10.1128/JVI.76.24.12553-12563.2002; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Suzuki Y, 2001, GENOME RES, V11, P677, DOI 10.1101/gr.GR-1640R; Syagailo YV, 2002, GENE, V294, P259, DOI 10.1016/S0378-1119(02)00798-9; TASANEN K, 1992, J BIOL CHEM, V267, P11513; Trappe R, 1999, BBA-GENE STRUCT EXPR, V1446, P341, DOI 10.1016/S0167-4781(99)00107-4; Trinklein ND, 2003, GENOME RES, V13, P308, DOI 10.1101/gr.794803; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Watada H, 2000, J BIOL CHEM, V275, P34224, DOI 10.1074/jbc.M004981200; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Young DA, 2002, BIOCHEM J, V364, P89, DOI 10.1042/bj3640089; Zhong ZD, 2000, J BIOL CHEM, V275, P18602, DOI 10.1074/jbc.M001389200; Zhu J, 2003, BLOOD, V102, P2420, DOI 10.1182/blood-2003-01-0251; ZWARTKRUIS F, 1992, NUCLEIC ACIDS RES, V20, P1599, DOI 10.1093/nar/20.7.1599	59	71	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13606	13615		10.1074/jbc.M414039200	http://dx.doi.org/10.1074/jbc.M414039200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15647281	hybrid, Green Published			2022-12-25	WOS:000228095500054
J	Mori, T; Sakaue, H; Iguchi, H; Gomi, H; Okada, Y; Takashima, Y; Nakamura, K; Nakamura, T; Yamauchi, T; Kubota, N; Kadowaki, T; Matsuki, Y; Ogawa, W; Hiramatsu, R; Kasuga, M				Mori, T; Sakaue, H; Iguchi, H; Gomi, H; Okada, Y; Takashima, Y; Nakamura, K; Nakamura, T; Yamauchi, T; Kubota, N; Kadowaki, T; Matsuki, Y; Ogawa, W; Hiramatsu, R; Kasuga, M			Role of Kruppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-GAMMA; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; C/EBP-BETA; GENE-EXPRESSION; 3T3 FIBROBLASTS; PROMOTER; FAMILY; ORGANIZATION; CONVERSION	Kruppel-like zinc finger transcription factors (KLFs) play diverse roles during cell differentiation and development in mammals. We have now shown by microarray analysis that expression of the KLF15 gene is markedly up-regulated during the differentiation of 3T3-L1 preadipocytes into adipocytes. Inhibition of the function of KLF15, either by expression of a dominant negative mutant or by RNA interference, both reduced the expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) and blocked adipogenesis in 3T3-L1 preadipocytes exposed to inducers of adipocyte differentiation. However, the dominant negative mutant of KLF15 did not affect the expression of CCAAT/enhancer-binding protein beta (C/EBP beta) elicited by inducers of differentiation in 3T3-L1 preadipocytes. In addition, ectopic expression of KLF15 in NIH 3T3 or C2C12 cells triggered both lipid accumulation and the expression of PPAR gamma in the presence of inducers of adipocyte differentiation. Ectopic expression of C/EBP beta, C/EBP delta, or C/EBP alpha in NIH 3T3 cells also elicited the expression of KLF15 in the presence of inducers of adipocyte differentiation. Moreover, KLF15 and C/EBP alpha acted synergistically to increase the activity of the PPAR gamma 2 gene promoter in 3T3-L1 adipocytes. Our observations thus demonstrate that KLF15 plays an essential role in adipogenesis in 3T3-L1 cells through its regulation of PPAR gamma expression.	Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Sumitomo Pharmaceut Co Ltd, Genom Sci Labs, Takarazuka, Hyogo 6650051, Japan; Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo 1138655, Japan	Kobe University; University of Tokyo	Sakaue, H (corresponding author), Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	hsakaue@med.kobe-u.ac.jp	Sakaue, Hiroshi/ABE-2337-2021; Kubota, Naoto/N-7892-2015; OGAWA, Wataru/AAQ-9586-2020	Sakaue, Hiroshi/0000-0002-2468-2363; 				Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; BERNLOHR DA, 1985, BIOCHEM BIOPH RES CO, V132, P850, DOI 10.1016/0006-291X(85)91209-4; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Gray S, 2002, J BIOL CHEM, V277, P34322, DOI 10.1074/jbc.M201304200; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Inuzuka H, 1999, BBA-GENE STRUCT EXPR, V1447, P199, DOI 10.1016/S0167-4781(99)00161-X; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Sakaue H, 2004, J BIOL CHEM, V279, P39951, DOI 10.1074/jbc.M407353200; Sakaue H, 2002, GENE DEV, V16, P908, DOI 10.1101/gad.983202; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tzameli I, 2004, J BIOL CHEM, V279, P36093, DOI 10.1074/jbc.M405346200; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	39	259	277	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12867	12875		10.1074/jbc.M410515200	http://dx.doi.org/10.1074/jbc.M410515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15664998	hybrid			2022-12-25	WOS:000227922000095
J	Gao, H; Jin, SQ; Song, YM; Fu, M; Wang, MR; Liu, ZH; Wu, M; Zhan, QM				Gao, H; Jin, SQ; Song, YM; Fu, M; Wang, MR; Liu, ZH; Wu, M; Zhan, QM			B23 regulates GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle G(2)-M arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR PROTEIN B23; P53; NUCLEOPHOSMIN/B23; INHIBITION; ACTIVATION; EXPRESSION; INDUCTION; APOPTOSIS; TRANSPORT; INTERACTS	Gadd45a is an important player in cell cycle G(2)-M arrest in response to genotoxic stress. However, the underlying mechanism(s) by which Gadd45a exerts its role in the control of cell cycle progression remains to be further defined. Gadd45a interacts with Cdc2, dissociates the Cdc2-cyclin B1 complex, alters cyclin B1 nuclear localization, and thus inhibits the activity of Cdc2/ cyclin B1 kinase. These observations indicate that Gadd45a nuclear translocation is closely associated with its role in cell cycle G(2)-M arrest. Gadd45a has been characterized as a nuclear protein, but it does not contain a classical nuclear localization signal, suggesting that Gadd45a nuclear translocation might be mediated through different nuclear import machinery. Here we show that Gadd45a associates directly with B23 (nucleophosmin), and the B23-interacting domain is mapped at the central region (61- 100 amino acids) of the Gadd45a protein using a series of Myc tag-Gadd45a deletion mutants. Deletion of this central region disrupts Gadd45a association with B23 and abolishes Gadd45a nuclear translocation. Suppression of endogenous B23 through a short interfering RNA approach disrupts Gadd45a nuclear translocation and results in impaired Gadd45a-induced cell cycle G(2)-M arrest. These findings demonstrate a novel association of B23 and Gadd45a and implicate B23 as an important regulator in Gadd45a nuclear import.	Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Inst Canc, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhan, QM (corresponding author), Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.	Zhanqimin@chinalab.gov.cn		song, yongmei/0000-0002-7789-0158	NCI NIH HHS [R01 CA93640] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093640] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carrier F, 1999, MOL CELL BIOL, V19, P1673; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1990, PROG CLIN BIOL RES, V340, P315; HALL PA, 1995, ONCOGENE, V10, P2427; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Huang WH, 2001, J BIOL CHEM, V276, P25166, DOI 10.1074/jbc.M010087200; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OConnor PM, 1997, CANCER SURV, V29, P151; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; SIPOS K, 1991, BIOCHEM BIOPH RES CO, V177, P673, DOI 10.1016/0006-291X(91)91841-Y; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; Szebeni A, 1999, PROTEIN SCI, V8, P905; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yun JP, 2003, J CELL BIOCHEM, V90, P1140, DOI 10.1002/jcb.10706; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, CANCER RES, V54, P2755; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906	43	52	65	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10988	10996		10.1074/jbc.M412720200	http://dx.doi.org/10.1074/jbc.M412720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644315	hybrid			2022-12-25	WOS:000227761800015
J	Li, YP; Keller, DM; Scott, JD; Lu, H				Li, YP; Keller, DM; Scott, JD; Lu, H			CK2 phosphorylates SSRP1 and inhibits its DNA-binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CK2; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; NUCLEAR-MATRIX; IN-VIVO; FACT; TRANSCRIPTION; COMPLEX; ELONGATION; P53	We have previously shown that CK2 associates with the human high-mobility group protein SSRP1 and that this association increases in response to UV irradiation. CK2 also phosphorylates SSRP1 in vitro. Here we extend this work by investigating CK2 regulation of SSRP1 function through phosphorylation. Phosphorylation of SSRP1 by CK2 inhibited the nonspecific DNA-binding activity of SSRP1 and FACT (facilitating chromatin-mediated transcription) complex in vitro. Using a serine/threonine-scanning Auto-spot peptide array coupled with a filter-based kinase assay with synthetic peptides as substrates, we identified serines 510, 657, and 688 as phosphorylation targets of CK2 in vitro. Mutagenesis of the three serines revealed that serine 510 was more important for the regulation of SSRP1 DNA-binding activity. Furthermore, we found that SSRP1 was phosphorylated in cells in response to UV (but not gamma) irradiation. These results suggest that CK2 regulates the DNA-binding ability of SSRP1 and that this regulation may be responsive to specific cell stresses.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Howard Hughes Med Inst, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Howard Hughes Medical Institute; Oregon Health & Science University	Lu, H (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	luh@ohsu.edu			NATIONAL CANCER INSTITUTE [R01CA093614, R01CA079721, R01CA095441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER; NCI NIH HHS [CA095441, R01 CA079721, CA079721, R01 CA093614, R01 CA095441, CA93614] Funding Source: Medline; NIGMS NIH HHS [R37 GM048231, GM48231, R01 GM048231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; Buchou T, 2003, MOL CELL BIOL, V23, P908, DOI 10.1128/MCB.23.3.908-915.2003; Cao S, 2003, MOL CELL BIOL, V23, P5301, DOI 10.1128/MCB.23.15.5301-5307.2003; Carnegie GK, 2004, MOL CELL, V15, P889, DOI 10.1016/j.molcel.2004.09.015; FLORES O, 1992, J BIOL CHEM, V267, P2786; Gariglio M, 1997, EXP CELL RES, V236, P472, DOI 10.1006/excr.1997.3742; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; Guo CH, 1999, CANCER RES, V59, P1146; Guo CH, 1998, J BIOL CHEM, V273, P13675, DOI 10.1074/jbc.273.22.13675; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Krohn NM, 2003, J BIOL CHEM, V278, P12710, DOI 10.1074/jbc.M300250200; Mason PB, 2003, MOL CELL BIOL, V23, P8323, DOI 10.1128/MCB.23.22.8323-8333.2003; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Schlesinger MB, 2000, GENETICS, V155, P1593; Shimojima T, 2003, GENE DEV, V17, P1605, DOI 10.1101/gad.1086803; SHIRAKATA M, 1991, MOL CELL BIOL, V11, P4528, DOI 10.1128/MCB.11.9.4528; Spencer JA, 1999, J BIOL CHEM, V274, P15686, DOI 10.1074/jbc.274.22.15686; Stemmer C, 2002, J BIOL CHEM, V277, P1092, DOI 10.1074/jbc.M109503200; TAKEDA S, 1967, NATURE, V213, P696, DOI 10.1038/213696a0; Tawfic S, 1997, J CELL BIOCHEM, V64, P499; Tegge WJ, 1998, METH MOL B, V87, P99; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Yabuta Y, 2003, J BIOL CHEM, V278, P15246, DOI 10.1074/jbc.M212003200; Yarnell AT, 2001, J BIOL CHEM, V276, P25736, DOI 10.1074/jbc.M101208200; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540; Zeng XY, 1998, P NATL ACAD SCI USA, V95, P6681, DOI 10.1073/pnas.95.12.6681	32	45	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11869	11875		10.1074/jbc.M413944200	http://dx.doi.org/10.1074/jbc.M413944200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659405	Green Accepted, hybrid			2022-12-25	WOS:000227761800116
J	Ohkawara, H; Ishibashi, T; Sakamoto, T; Sugimoto, K; Nagata, K; Yokoyama, K; Sakamoto, N; Kamioka, M; Matsuoka, I; Fukuhara, S; Sugimoto, N; Takuwa, Y; Maruyama, Y				Ohkawara, H; Ishibashi, T; Sakamoto, T; Sugimoto, K; Nagata, K; Yokoyama, K; Sakamoto, N; Kamioka, M; Matsuoka, I; Fukuhara, S; Sugimoto, N; Takuwa, Y; Maruyama, Y			Thrombin-induced rapid geranylgeranylation of RhoA as an essential process for RhoA activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TISSUE FACTOR; ADHESION; PHOSPHORYLATION; SIGNALS; GTPASES; KINASE; RAC; SPHINGOSINE-1-PHOSPHATE; CYTOSKELETON	RhoA plays a critical signaling role in thrombin-induced endothelial dysfunction. The possible thrombin regulation of geranylgeranylation, a lipid modification, of unprocessed RhoA and the significance of the geranylgeranylation in RhoA activation in endothelial cells (ECs) are not well understood. The amounts of the unprocessed and geranylgeranylated forms of RhoA in non-stimulated cultured human aortic ECs were 31 +/- 8 and 69 +/- 8% total cellular RhoA, respectively (n = 6, p < 0.0001), as determined by the Triton X-114 partition method. Thrombin-induced rapid conversion of most of the unprocessed RhoA into the geranylgeranylated form within 1 min through stimulating geranylgeranyltransferase I ( GGTase I) activity. Thrombin-induced rapid geranylgeranylation was inhibited by acute short term ( 3 min) pretreatment with atorvastatin as well as by an inhibitor of GGTase I (GGTI-286). Thrombin also rapidly stimulated GTP loading of RhoA, which was blocked by acute pretreatment with either atorvastatin or GGTI-286. These observations indicate the dependence of thrombin stimulation of RhoA on the rapid geranylgeranylation of unprocessed RhoA. Importantly, the addition of geranylgeranylpyrophosphate to ECs pretreated with atorvastatin quickly reversed the atorvastatin inhibition of thrombin stimulation of RhoA. These results suggest that geranylgeranylation of unprocessed RhoA may limit thrombin-induced full activation of RhoA in ECs. Cytoskeleton analysis demonstrated that atorvastatin and GGTI-286 inhibited thrombin-induced stress fiber formation. We provide the evidence that, in thrombin-stimulated ECs, the unprocessed form of RhoA is rapidly geranylgeranylated to become the mature form, which then is converted into GTP-bound active RhoA.	Fukushima Med Univ, Dept Internal Med 1, Fukushima 9601295, Japan; Fukushima Med Univ, Dept Pharmacol, Fukushima 9601295, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, Osaka 5658565, Japan; Kanazawa Univ, Grad Sch Med, Dept Physiol, Kanazawa, Ishikawa 9208640, Japan	Fukushima Medical University; Fukushima Medical University; National Cerebral & Cardiovascular Center - Japan; Kanazawa University	Ishibashi, T (corresponding author), Fukushima Med Univ, Dept Internal Med 1, 1 Hikarigaoka, Fukushima 9601295, Japan.	masaishi@fmu.ac.jp	Sugimoto, Naotoshi/C-4739-2015	Sugimoto, Naotoshi/0000-0003-1995-5002; Kamioka, Masashi/0000-0001-6588-0764; Matsuoka, Isao/0000-0002-7170-3630; Ohkawara, Hiroshi/0000-0002-3129-1977				Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Ardissino D, 2001, BLOOD, V98, P2726, DOI 10.1182/blood.V98.9.2726; Begum N, 2002, DIABETES, V51, P2256, DOI 10.2337/diabetes.51.7.2256; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chappell J, 2000, J BIOL CHEM, V275, P31792, DOI 10.1074/jbc.M004798200; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Eto M, 2001, CIRC RES, V89, P583, DOI 10.1161/hh1901.097084; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Golovchenko I, 2000, CIRC RES, V87, P746, DOI 10.1161/01.RES.87.9.746; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Ishibashi T, 2003, ARTERIOSCL THROM VAS, V23, P681, DOI 10.1161/01.ATV.0000065194.00822.C7; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Liu L, 1999, J BIOL CHEM, V274, P33334, DOI 10.1074/jbc.274.47.33334; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Nagata K, 2001, J HYPERTENS, V19, P775, DOI 10.1097/00004872-200104000-00015; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C; Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Sonel A, 2000, CIRCULATION, V102, P1107, DOI 10.1161/01.CIR.102.10.1107; VAN AL, 1997, GENE DEV, V11, P2295; Wolfrum S, 2003, ARTERIOSCL THROM VAS, V23, P729, DOI 10.1161/01.ATV.0000063385.12476.A7; Yokoyama K, 2002, CIRCULATION, V105, P962, DOI 10.1161/hc0802.104457	35	39	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10182	10188		10.1074/jbc.M409547200	http://dx.doi.org/10.1074/jbc.M409547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640525	hybrid			2022-12-25	WOS:000227559600055
J	Qing, GL; Xiao, GT				Qing, GL; Xiao, GT			Essential role of I kappa B kinase alpha in the constitutive processing of NF-kappa B2 p100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-ALPHA; GENE; PROTEINS; BETA; P100; ACTIVATION; EXPRESSION; DEREGULATION; PRECURSOR; SUBUNIT	Processing of NF-kappa B2 precursor protein p100 to generate p52 is tightly controlled, which is important for proper function of NF-kappa B. Accordingly, constitutive processing of p100, caused by the loss of its C-terminal processing inhibitory domain due to nf kappa b2 gene rear-rangements, is associated with the development of various lymphomas and leukemia. In contrast to the physiological processing of p100 triggered by NF-kappa B-inducing kinase (NIK) and its downstream kinase, I kappa B kinase alpha (IKK alpha), which requires the E3 ligase, beta-transducin repeat-containing protein (beta-TrCP), and occurs only in the cytoplasm, the constitutive processing of p100 is independent of beta-TrCP but rather is regulated by the nuclear shuttling of p100. Here, we show that constitutive processing of p100 also requires IKK alpha, but not IKK beta (I kappa B kinase beta) or IKK gamma (I kappa B kinase gamma). It seems that NIK is also dispensable for this pathogenic processing of p100. These results demonstrate a general role of IKK alpha in p100 processing under both physiological and pathogenic conditions. Additionally, we find that IKK alpha is not required for the nuclear translocation of p100. Thus, these results also indicate that p100 nuclear translocation is not sufficient for the constitutive processing of p100.	Rutgers State Univ, Nelson Biol Lab, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Xiao, GT (corresponding author), Rutgers State Univ, Nelson Biol Lab, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.	xiao@biology.rutgers.edu						Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Liao GX, 2003, ONCOGENE, V22, P4868, DOI 10.1038/sj.onc.1206761; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Qing GL, 2005, J BIOL CHEM, V280, P18, DOI 10.1074/jbc.M406619200; Qu ZX, 2004, J BIOL CHEM, V279, P44563, DOI 10.1074/jbc.M403689200; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; THAKUR S, 1994, ONCOGENE, V9, P2335; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576	33	40	43	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9765	9768		10.1074/jbc.C400502200	http://dx.doi.org/10.1074/jbc.C400502200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15677466	hybrid			2022-12-25	WOS:000227559600003
J	Sengupta, S; Shimamoto, A; Koshiji, M; Pedeux, R; Rusin, M; Spillare, EA; Shen, JC; Huang, LE; Lindor, NM; Furuichi, Y; Harris, CC				Sengupta, S; Shimamoto, A; Koshiji, M; Pedeux, R; Rusin, M; Spillare, EA; Shen, JC; Huang, LE; Lindor, NM; Furuichi, Y; Harris, CC			Tumor suppressor p53 represses transcription of RECQ4 helicase	ONCOGENE			English	Article						repression; histone deacetylases; trichostatin A; Rothmund-Thomson syndrome; SP1; promoter	ROTHMUND-THOMSON-SYNDROME; WILD-TYPE P53; TATA-BINDING PROTEIN; CELL-CYCLE; FUNCTIONAL INTERACTION; HISTONE DEACETYLASE; REPLICATION FORKS; FAMILY HELICASES; GENE-EXPRESSION; BREAST-CANCER	RECQ4 is a member of the RecQ helicase family, which has been implicated in the regulation of DNAreplication, recombination and repair. p53 modulates the functions of RecQ helicases including BLM and WRN. In this study, we demonstrate that p53 can regulate the transcription of RECQ4. Using nontransformed, immortalized normal human fibroblasts, we show that p53-dependent downregulation of RECQ4 expression occurred in G1-arrested cells, both in the absence or presence of exogenous DNA damage. Wild-type p53 ( but not the tumor-derived mutant forms) repressed RECQ4 promoter activity. The camptothecin or etoposide-dependent p53-mediated repression was attenuated by trichostatin A (TSA), an inhibitor of histone deacetylases (HDACs). Repression of the RECQ4 promoter was accompanied with an increased accumulation of HDAC1, and the loss of SP1 and p53 binding to the promoter. The simultaneous formation of a camptothecin-dependent p53-SP1 complex indicated its occurrence outside of the RECQ4 promoter. These data suggest that p53-mediated repression of RECQ4 transcription during DNA damage results from the modulation of the promoter occupancy of transcription activators and repressors.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Gene Care Res Inst, Kamakura, Kanagawa, Japan; Mayo Clin, Dept Med Genet, Rochester, MN 55905 USA; Marie Sklodowska Curie Mem Inst, Ctr Oncol, Dept Tumor Biol, PL-44101 Gliwice, Poland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; Maria Sklodowska-Curie National Research Institute of Oncology	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,Bldg 37,Room 3068, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov	PEDEUX, Rémy M/I-2603-2014; Sengupta, Sagar/AGR-1063-2022	PEDEUX, Rémy M/0000-0002-2553-7934; Sengupta, Sagar/0000-0002-6365-1770; Huang, Eric/0000-0002-6444-1708; Rusin, Marek/0000-0002-0143-9192	NATIONAL CANCER INSTITUTE [Z01BC005795, ZIABC005795] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; DROUIN CA, 1993, J AM ACAD DERMATOL, V28, P301, DOI 10.1016/0190-9622(93)70040-Z; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ElKhoury JM, 1997, BRIT J RADIOL, V70, P215, DOI 10.1259/bjr.70.830.9135453; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Fuchs B, 2002, CLIN ORTHOP RELAT R, P40; Furuichi Y, 2001, ANN NY ACAD SCI, V928, P121; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Hoki Y, 2003, HUM MOL GENET, V12, P2293, DOI 10.1093/hmg/ddg254; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kawabe T, 2000, ONCOGENE, V19, P4764, DOI 10.1038/sj.onc.1203841; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mishra SK, 2001, FEBS LETT, V507, P88, DOI 10.1016/S0014-5793(01)02951-9; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Pal S, 2001, CANCER RES, V61, P6952; PERREM K, 1995, ONCOGENE, V11, P1299; PuvionDutilleul F, 1997, GENE EXPRESSION, V6, P315; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shimamoto Akira, 2004, Int J Clin Oncol, V9, P288, DOI 10.1007/s10147-004-0426-0; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; VENNOS EM, 1995, DERMATOL CLIN, V13, P143, DOI 10.1016/S0733-8635(18)30117-7; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LL, 2003, J NATL CANCER I, V95, P669, DOI 10.1093/jnci/95.9.669; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Webster NJG, 1996, CANCER RES, V56, P2781; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yin JH, 2004, HUM MOL GENET, V13, P2421, DOI 10.1093/hmg/ddh269; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zhao RB, 2000, GENE DEV, V14, P981	66	57	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1738	1748		10.1038/sj.onc.1208380	http://dx.doi.org/10.1038/sj.onc.1208380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674334				2022-12-25	WOS:000227345100010
J	Trauzold, A; Roder, C; Sipos, B; Karsten, K; Arlt, A; Jiang, P; Martin-Subero, JI; Siegmund, D; Muerkoster, S; Raluy, LP; Siebert, R; Wajant, H; Kalthoff, H				Trauzold, A; Roder, C; Sipos, B; Karsten, K; Arlt, A; Jiang, P; Martin-Subero, JI; Siegmund, D; Muerkoster, S; Raluy, LP; Siebert, R; Wajant, H; Kalthoff, H			CD95 and TRAF2 promote invasiveness of pancreatic cancer cells	FASEB JOURNAL			English	Article						apoptosis; invasion; uPA; MMP; IL-8	NF-KAPPA-B; CLASSICAL HODGKIN LYMPHOMA; PROTEIN-KINASE-C; CARCINOMA CELLS; CD95-MEDIATED APOPTOSIS; PLASMINOGEN-ACTIVATOR; ADENOCARCINOMA CELLS; FAS LIGAND; SIGNAL-TRANSDUCTION; MEDIATED APOPTOSIS	Pancreatic adenocarcinoma represents a tumor type with extremely poor prognosis. High apoptosis resistance and a strong invasive and early metastatic potential contribute to its highly malignant phenotype. Here we identified the death receptor adaptor molecule TRAF2 as a key player in pancreatic cancer pathophysiology. Using immunohistochemistry and Western blot analysis we found TRAF2 overexpressed in 34 of 36 pancreatic tumor samples as well as in pancreatic tumor cell lines resistant to CD95-mediated apoptosis. The high TRAF2 protein level was not related to chromosomal changes, as monitored by FISH analysis. Instead, the NF-kappaB- and MEK-signaling pathways were involved. Introduction of a TRAF2 expression vector in CD95-sensitive Colo357 cells resulted in (i) resistance to CD95-induced apoptosis; (ii) increased constitutive NF-kappaB and AP-1 activity; and (iii) higher basal secretion of matrix metalloproteinases ( MMPs), urokinase-type plasminogen activator (uPA), and IL-8, leading to increased invasiveness. High apoptosis resistance and uPA secretion could be reverted by TRAF2-specific siRNA. Stimulation of TRAF2-overexpressing cells with CD95 ligand led to induction of NF-kappaB and AP-1, enhanced IL-8- and uPA-secretion, and a further increased invasiveness. Thus, TRAF2 overexpression does not only block apoptosis induction by CD95 but also converts this death receptor into a mediator of invasiveness.	Univ Hosp Schleswig Holstein, Clin Gen Surg, Mol Oncol Unit, D-24105 Kiel, Germany; Univ Hosp Schleswig Holstein, Inst Pathol, D-24105 Kiel, Germany; Univ Hosp Schleswig Holstein, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Univ Hosp Schleswig Holstein, Inst Human Genet, D-24105 Kiel, Germany; Univ Wurzburg, Dept Mol Internal Med, Med Polyclin, Wurzburg, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Wurzburg	Kalthoff, H (corresponding author), Univ Hosp Schleswig Holstein, Clin Gen Surg, Mol Oncol Unit, Campus Kiel Arnold Heller Str 7, D-24105 Kiel, Germany.	hkalthoff@email.uni-kiel.de	Wajant, Harald/A-3020-2017; Sebens, Susanne/C-1222-2010; Trauzold, Anna/P-4398-2014; Roeder, Christian/F-1068-2010; Arlt, Alexander/G-7308-2019; Siebert, Reiner/A-8049-2010; Kalthoff, Holger/B-1618-2010	Wajant, Harald/0000-0002-2005-3949; Roeder, Christian/0000-0001-7881-9110; Arlt, Alexander/0000-0002-6160-1059; Martin-Subero, Jose Ignacio/0000-0001-8809-5195				Ademmer K, 1998, CLIN EXP IMMUNOL, V112, P21; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Arlt A, 2002, CANCER RES, V62, P910; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Bellone G, 2000, CLIN CANCER RES, V6, P2448; Butler LM, 1998, BRIT J CANCER, V77, P1454, DOI 10.1038/bjc.1998.239; Casey RC, 2003, CLIN EXP METASTAS, V20, P343, DOI 10.1023/A:1024009131191; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Chung JY, 2002, J CELL SCI, V115, P679; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; Eggert A, 2001, CANCER RES, V61, P1314; Elnemr A, 2001, INT J ONCOL, V18, P311; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Harvey SR, 2003, CLIN CANCER RES, V9, P4935; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Irisarri M, 2000, LEUKEMIA, V14, P2149, DOI 10.1038/sj.leu.2401954; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jobin C, 1999, J IMMUNOL, V162, P4447; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Koshiba T, 1998, CANCER, V82, P642, DOI 10.1002/(SICI)1097-0142(19980215)82:4<642::AID-CNCR5>3.0.CO;2-N; Kuwada Y, 2003, INT J ONCOL, V22, P765; Loro LL, 1999, J ORAL PATHOL MED, V28, P82; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Martin-Subero JI, 2002, AM J PATHOL, V161, P413, DOI 10.1016/S0002-9440(10)64197-1; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Satoh K, 1999, PANCREAS, V19, P339, DOI 10.1097/00006676-199911000-00004; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Sliva D, 2002, BIOCHEM BIOPH RES CO, V290, P552, DOI 10.1006/bbrc.2001.6225; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Trauzold A, 2003, ONCOGENE, V22, P8939, DOI 10.1038/sj.onc.1207001; Trauzold A, 2003, BRIT J CANCER, V89, P1714, DOI 10.1038/sj.bjc.6601330; Ungefroren H, 2001, J CELL SCI, V114, P2735; Ungefroren H, 1998, CANCER RES, V58, P1741; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wajant H, 2003, CYTOKINE GROWTH F R, V14, P53, DOI 10.1016/S1359-6101(02)00072-2; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zhu YM, 2003, J BIOL CHEM, V278, P29366, DOI 10.1074/jbc.M301785200	52	78	80	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					620	+		10.1096/fj.04-2984fje	http://dx.doi.org/10.1096/fj.04-2984fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15670977				2022-12-25	WOS:000226576600011
J	Gaildrat, P; Moller, M; Mukda, S; Humphries, A; Carter, DA; Ganapathy, V; Klein, DC				Gaildrat, P; Moller, M; Mukda, S; Humphries, A; Carter, DA; Ganapathy, V; Klein, DC			A novel pineal-specific product of the oligopeptide transporter PepT1 gene - Circadian expression mediated by cAMP activation of an intronic promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; O-METHYLTRANSFERASE GENE; ORPHAN NUCLEAR RECEPTOR; MESSENGER-RNA; H+/PEPTIDE COTRANSPORTER; DIURNAL RHYTHM; MELATONIN SYNTHESIS; NOCTURNAL INCREASE; HOMEOBOX GENE; GLAND	The oligopeptide transporter 1, PepT1, is a member of the Slc15 family of 12 membrane-spanning domain transporters; PepT1 has proton/peptide cotransport activity and is selectively expressed in intestinal epithelial cells, where it is responsible for the nutritional absorption of di- and tri-peptides. Here, a novel PepT1 gene product has been identified in the rat pineal gland, termed pgPepT1. It encodes a 150-amino acid protein encompassing the C-terminal 3 membrane-spanning domains of intestinal PepT1 protein, with 3 additional N-terminal residues. Expression of pgPepT1 appears to be restricted to the pineal gland and follows a marked circadian pattern with > 100-fold higher levels of mRNA occurring at night; this is accompanied by an accumulation of membrane-associated pgPepT1 protein ( similar to 16 kDa). The daily rhythm in pgPepT1 mRNA is regulated by the well described neural pathway that controls pineal melatonin production. This includes the retina, the circadian clock in the suprachiasmatic nucleus, central structures, and projections from the superior cervical ganglia; activation of this pathway results in the release of norepinephrine. Here it was found that pgPepT1 expression is mediated by a norepinephrine 3 cyclic AMP mechanism that activates an alternative promoter located in intron 20 of the gene. pgPepT1 protein was found to have transporter-modulator activity; it could contribute to circadian changes in pineal function through this mechanism.	NICHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA; Univ Copenhagen, Panum Inst, Inst Med Anat, DK-2200 Copenhagen, Denmark; Mahidol Univ, Neurobehav Biol Ctr, Inst Sci & Technol Res & Dev, Nakhon Pathom 73170, Thailand; Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Copenhagen; Mahidol University; Cardiff University; University System of Georgia; Augusta University	Klein, DC (corresponding author), NICHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bldg 49,Rm 6A-82, Bethesda, MD 20892 USA.	klein@helix.nih.gov	Carter, David/A-4479-2010	Carter, David/0000-0002-8419-3975; Klein, David/0000-0002-1792-5806	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000095, Z01HD000095] Funding Source: NIH RePORTER; MRC [G9724886] Funding Source: UKRI; Medical Research Council [G9724886] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Appelbaum L, 2004, MOL ENDOCRINOL, V18, P1210, DOI 10.1210/me.2003-0439; Arendt J., 1995, MELATONIN MAMMALIAN; Bailey MJ, 2003, MOL ENDOCRINOL, V17, P2084, DOI 10.1210/me.2003-0121; BALER R, 1995, J BIOL CHEM, V270, P27319, DOI 10.1074/jbc.270.45.27319; Baler R, 1997, J BIOL CHEM, V272, P6979, DOI 10.1074/jbc.272.11.6979; Baler R, 1996, BIOCHEM BIOPH RES CO, V220, P975, DOI 10.1006/bbrc.1996.0517; Bernard M, 2001, J NEUROCHEM, V79, P248, DOI 10.1046/j.1471-4159.2001.00555.x; Borjigin J, 1999, J NEUROSCI, V19, P1018; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Coon SL, 2001, J BIOL CHEM, V276, P24097, DOI 10.1074/jbc.M011298200; Coon SL, 1997, MOL PHARMACOL, V51, P551, DOI 10.1124/mol.51.4.551; Daniel H, 2004, ANNU REV PHYSIOL, V66, P361, DOI 10.1146/annurev.physiol.66.032102.144149; Fei YJ, 2000, BBA-GENE STRUCT EXPR, V1492, P145, DOI 10.1016/S0167-4781(00)00101-9; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Fukuhara C, 2003, J PINEAL RES, V35, P196, DOI 10.1034/j.1600-079X.2003.00078.x; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Ganguly S, 2001, P NATL ACAD SCI USA, V98, P8083, DOI 10.1073/pnas.141118798; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; Humphries A, 2004, J NEUROCHEM, V91, P946, DOI 10.1111/j.1471-4159.2004.02777.x; Humphries A, 2002, J NEUROENDOCRINOL, V14, P101, DOI 10.1046/j.0007-1331.2001.00738.x; Jaramillo AM, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-3; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; Kim JS, 2005, J BIOL CHEM, V280, P677, DOI 10.1074/jbc.M408438200; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1985, CIBA F SYMP, V117, P38; Klein DC, 2004, J BIOL RHYTHM, V19, P264, DOI 10.1177/0748730404267340; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Li XD, 1998, P NATL ACAD SCI USA, V95, P1876, DOI 10.1073/pnas.95.4.1876; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Moller M, 2002, CELL TISSUE RES, V309, P139, DOI 10.1007/s00441-002-0580-5; Moller M, 1997, CELL TISSUE RES, V288, P279, DOI 10.1007/s004410050813; Murakami M, 1997, NEUROSCI LETT, V227, P65, DOI 10.1016/S0304-3940(97)00298-X; Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155; Ogihara H, 1996, BIOCHEM BIOPH RES CO, V220, P848, DOI 10.1006/bbrc.1996.0493; Pan XY, 2004, J NUTR, V134, P2211, DOI 10.1093/jn/134.9.2211; Pan XY, 2003, J PHARMACOL EXP THER, V307, P626, DOI 10.1124/jpet.103.055939; Pan XY, 2002, AM J PHYSIOL-GASTR L, V283, pG57, DOI 10.1152/ajpgi.00545.2001; PARFITT A, 1976, NEUROPHARMACOLOGY, V15, P353, DOI 10.1016/0028-3908(76)90083-6; PARFITT AG, 1976, ENDOCRINOLOGY, V99, P840, DOI 10.1210/endo-99-3-840; Price DM, 2004, FEBS LETT, V577, P220, DOI 10.1016/j.febslet.2004.09.083; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RODRIGUEZ IR, 1994, J BIOL CHEM, V269, P31969; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; Saito H, 1995, J PHARMACOL EXP THER, V275, P1631; Saito H, 1997, BIOCHEM BIOPH RES CO, V237, P577, DOI 10.1006/bbrc.1997.7129; SCHAAD NC, 1993, BRAIN RES, V614, P251, DOI 10.1016/0006-8993(93)91042-Q; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Shiraga T, 1999, GASTROENTEROLOGY, V116, P354, DOI 10.1016/S0016-5085(99)70132-0; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0	53	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16851	16860		10.1074/jbc.M414587200	http://dx.doi.org/10.1074/jbc.M414587200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15684415	hybrid			2022-12-25	WOS:000228615500039
J	Kaeberlein, M; McDonagh, T; Heltweg, B; Hixon, J; Westman, EA; Caldwell, SD; Napper, A; Curtis, R; DiStefano, PS; Fields, S; Bedalov, A; Kennedy, BK				Kaeberlein, M; McDonagh, T; Heltweg, B; Hixon, J; Westman, EA; Caldwell, SD; Napper, A; Curtis, R; DiStefano, PS; Fields, S; Bedalov, A; Kennedy, BK			Substrate-specific activation of sirtuins by resveratrol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTENDS LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; CALORIE RESTRICTION; SIR2 FAMILY; PROTEIN DEACETYLASES; RIBOSOMAL DNA; NAD(+)-DEPENDENT DEACETYLASES; HISTONE/PROTEIN DEACETYLASES; DROSOPHILA-MELANOGASTER	Resveratrol, a small molecule found in red wine, is reported to slow aging in simple eukaryotes and has been suggested as a potential calorie restriction mimetic. Resveratrol has also been reported to act as a sirtuin activator, and this property has been proposed to account for its anti-aging effects. We show here that resveratrol is a substrate-specific activator of yeast Sir2 and human SirT1. In particular, we observed that, in vitro, resveratrol enhances binding and deacetylation of peptide substrates that contain Fluor de Lys, a non-physiological fluorescent moiety, but has no effect on binding and deacetylation of acetylated peptides lacking the fluorophore. Consistent with these biochemical data we found that in three different yeast strain backgrounds, resveratrol has no detectable effect on Sir2 activity in vivo, as measured by rDNA recombination, transcriptional silencing near telomeres, and life span. In light of these findings, the mechanism accounting for putative longevity effects of resveratrol should be reexamined.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Elixir Pharmaceut, Cambridge, MA 02139 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bedalov, A (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.	abedalov@fhcrc.org; bkenn@u.washington.edu		Kennedy, Brian/0000-0002-5754-1874	NIA NIH HHS [P30 AG013280] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG013280] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Armstrong CM, 2002, MOL BIOL CELL, V13, P1427, DOI 10.1091/mbc.01-10-0482; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bhat KPL, 2002, ANN NY ACAD SCI, V957, P210, DOI 10.1111/j.1749-6632.2002.tb02918.x; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Borra MT, 2004, METHOD ENZYMOL, V376, P171; Borra MT, 2004, BIOCHEMISTRY-US, V43, P9877, DOI 10.1021/bi049592e; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Brack C, 1997, CELL MOL LIFE SCI, V53, P960, DOI 10.1007/PL00013199; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Buck SW, 2004, J LEUKOCYTE BIOL, V75, P939, DOI 10.1189/jlb.0903424; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Gledhill JR, 2005, BIOCHEM J, V386, P591, DOI 10.1042/BJ20041513; Goldberg DM, 1996, CLIN CHEM, V42, P113; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; Granados-Soto V, 2003, DRUG NEWS PERSPECT, V16, P299, DOI 10.1358/dnp.2003.16.5.829318; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2001, TRENDS GENET, V17, P391, DOI 10.1016/S0168-9525(01)02339-3; HARRINGTON LA, 1988, MECH AGEING DEV, V43, P71, DOI 10.1016/0047-6374(88)90098-X; Hirao M, 2003, J BIOL CHEM, V278, P52773, DOI 10.1074/jbc.M308966200; HIXON J, 2004, SOC BIOM SCREEN 10 A; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Jordens RG, 1999, NEUROCHEM RES, V24, P227, DOI 10.1023/A:1022510004220; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2005, MECH AGEING DEV, V126, P17, DOI 10.1016/j.mad.2004.09.013; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kaeberlein M, 2004, GENETICS, V166, P1661, DOI 10.1534/genetics.166.4.1661; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; KAUR M, 1989, GERONTOLOGY, V35, P188, DOI 10.1159/000213021; KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P275; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lamming DW, 2004, MOL MICROBIOL, V53, P1003, DOI 10.1111/j.1365-2958.2004.04209.x; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MCDONAGH T, 2005, IN PRESS METHODS; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; MILLER NJ, 1995, CLIN CHEM, V41, P1789; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Park PU, 1999, MOL CELL BIOL, V19, P3848; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Posakony J, 2004, J MED CHEM, V47, P2635, DOI 10.1021/jm030473r; RINE J, 1987, GENETICS, V116, P9; ROGINA B, 2004, P NATL AC SCI US; Schouten A, 2002, MOL MICROBIOL, V43, P883, DOI 10.1046/j.1365-2958.2002.02801.x; SHARMA SP, 1983, MECH AGEING DEV, V23, P67, DOI 10.1016/0047-6374(83)90099-4; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; WADHWA R, 1986, GERONTOLOGY, V32, P141, DOI 10.1159/000212780; Wegener D, 2003, CHEM BIOL, V10, P61, DOI 10.1016/S1074-5521(02)00305-8; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu ZX, 2002, CELL MOL BIOL, V48, P725; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397; Zheng JB, 1999, BIOCHEM BIOPH RES CO, V261, P499, DOI 10.1006/bbrc.1999.1063; Zini R, 1999, DRUG EXP CLIN RES, V25, P87	70	617	651	2	76	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17038	17045		10.1074/jbc.M500655200	http://dx.doi.org/10.1074/jbc.M500655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15684413	hybrid			2022-12-25	WOS:000228615500061
J	Kuratani, M; Ishii, R; Bessho, Y; Fukunaga, R; Sengoku, T; Shirouzu, M; Sekine, S; Yokoyama, S				Kuratani, M; Ishii, R; Bessho, Y; Fukunaga, R; Sengoku, T; Shirouzu, M; Sekine, S; Yokoyama, S			Crystal structure of tRNA adenosine deaminase (TadA) from Aquifex aeolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE DEAMINASE; BACILLUS-SUBTILIS; ENZYME; ANTICODON; MECHANISM; SEQUENCE; STRATEGIES; PROVIDES; ORPHAN; FOLD	The bacterial tRNA adenosine deaminase ( TadA) generates inosine by deaminating the adenosine residue at the wobble position of tRNA(Arg-2). This modification is essential for the decoding system. In this study, we determined the crystal structure of Aquifex aeolicus TadA at a 1.8-angstrom resolution. This is the first structure of a deaminase acting on tRNA. A. aeolicus TadA has an alpha/beta/alpha three-layered fold and forms a homodimer. The A. aeolicus TadA dimeric structure is completely different from the tetrameric structure of yeast CDD1, which deaminates mRNA and cytidine, but is similar to the dimeric structure of yeast cytosine deaminase. However, in the A. aeolicus TadA structure, the shapes of the C-terminal helix and the regions between the beta 4 and beta 5 strands are quite distinct from those of yeast cytosine deaminase and a large cavity is produced. This cavity contains many conserved amino acid residues that are likely to be involved in either catalysis or tRNA binding. We made a docking model of TadA with the tRNA anticodon stem loop.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; RIKEN Harima Inst SPring8, Mikazuki, Hyogo 6795148, Japan	University of Tokyo; RIKEN; RIKEN	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Sekine, Shun-ichi/N-5450-2015; Shirouzu, Mikako/A-6521-2016; Bessho, Yoshitaka/K-7702-2012; Fukunaga, Ryuya/AAK-8609-2020; Yokoyama, Shigeyuki/N-6911-2015; Sengoku, Toru/E-4304-2013	Sekine, Shun-ichi/0000-0001-8174-8704; Bessho, Yoshitaka/0000-0001-9297-7473; Fukunaga, Ryuya/0000-0002-5814-8206; Yokoyama, Shigeyuki/0000-0003-3133-7338; Sengoku, Toru/0000-0001-9461-8714; Ishii, Ryohei/0000-0003-2486-1393				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Auxilien S, 1996, J MOL BIOL, V262, P437, DOI 10.1006/jmbi.1996.0527; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; Dance GSC, 2001, NUCLEIC ACIDS RES, V29, P1772, DOI 10.1093/nar/29.8.1772; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HOLLEY RW, 1965, J BIOL CHEM, V240, P2122; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Johansson E, 2002, BIOCHEMISTRY-US, V41, P2563, DOI 10.1021/bi011849a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Ko TP, 2003, J BIOL CHEM, V278, P19111, DOI 10.1074/jbc.M300874200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liaw SH, 2004, J BIOL CHEM, V279, P35479, DOI 10.1074/jbc.M405304200; Marck C, 2002, RNA, V8, P1189, DOI 10.1017/S1355838202022021; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POULSEN LK, 1992, MOL MICROBIOL, V6, P895, DOI 10.1111/j.1365-2958.1992.tb01540.x; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wolf J, 2002, EMBO J, V21, P3841, DOI 10.1093/emboj/cdf362; Xie KF, 2004, P NATL ACAD SCI USA, V101, P8114, DOI 10.1073/pnas.0400493101; Zaim J, 2003, NAT IMMUNOL, V4, P1153, DOI 10.1038/ni1203-1153	30	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16002	16008		10.1074/jbc.M414541200	http://dx.doi.org/10.1074/jbc.M414541200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15677468	hybrid			2022-12-25	WOS:000228444800067
J	George, CX; Wagner, MV; Samuel, CE				George, CX; Wagner, MV; Samuel, CE			Expression of interferon-inducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involves tissue-selective promoter utilization and alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EDITING ENZYME ADAR1; PRE-MESSENGER-RNA; GAMMA-INTERFERON; BINDING DOMAINS; SITE VARIANTS; HUMAN-CELLS; Z-DNA; EXPORT SIGNAL; IN-VITRO; GENE	ADAR1 ( adenosine deaminase acting on RNA) is widely expressed in adult mammals and has a critical role during embryogenesis. Two size forms of ADAR1 are known that possess adenosine-to-inosine editing activity: an interferon (IFN)-inducible similar to 150-kDa protein and a constitutively expressed N-terminally truncated similar to 110-kDa protein. We defined the structure of the 5'-flanking region of the mouse Adar1 gene, and we show here that mouse Adar1 transcripts possess alternative exon 1 structures (1A, 1B, and 1C) that initiate from unique promoters and are spliced to a common exon 2 junction. Exon 1A-containing transcripts encoding p150 were expressed in all tissues examined from adult mice ( brain, cecum, heart, kidney, liver, lung, spleen, and Peyer's patches) and were elevated most significantly in liver but remained lowest in brain following oral infection with Salmonella. Exon 1B-containing RNA was most abundant in brain and was not increased in any tissue examined following infection. Exon 1C-containing RNA was very scarce. Exon 1A, but not exon 1B or 1C, expression was increased in fibroblast L cells treated with IFN, and a consensus ISRE element was present in the promoter driving exon 1A expression. Exon 1B, but not 1A, was detectable in embryonic day 10.5 embryos and was abundantly expressed in embryonic day 15 embryos. Furthermore, the ADAR1 p110 protein isoform was detected in embryonic tissue, whereas both p110 and the inducible p150 proteins were found in IFN-treated L cells. Finally, the presence of alternative exon 7a correlated with exon 1B-containing RNA, and alternative exon 7b correlated with exon 1A-containing RNA. These results establish that multiple promoters drive the expression of the Adar1 gene in adult mice, that the IFN inducible promoter and exon 1A-containing RNA are primarily responsible for the increased ADAR1 observed in Salmonella-infected mice, and that the constitutive exon 1B-containing transcript and encoded p110 protein product are abundantly expressed both in adult brain and during embryogenesis.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	samuel@lifesci.ucsb.edu			NIAID NIH HHS [AI-12520] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012520, R01AI012520] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; Bass BL, 1997, RNA, V3, P947; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; CATTANEO R, 1994, CURR OPIN GENET DEV, V4, P895, DOI 10.1016/0959-437X(94)90076-0; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; George CX, 1999, GENE, V229, P203, DOI 10.1016/S0378-1119(99)00017-7; Gott JM, 2000, ANNU REV GENET, V34, P499, DOI 10.1146/annurev.genet.34.1.499; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; Hartner JC, 2004, J BIOL CHEM, V279, P4894, DOI 10.1074/jbc.M311347200; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Kallman AM, 2003, NUCLEIC ACIDS RES, V31, P4874, DOI 10.1093/nar/gkg681; Kawakubo K, 2000, GENE, V258, P165, DOI 10.1016/S0378-1119(00)00368-1; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kim YG, 2000, J BIOL CHEM, V275, P26828; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kumar M, 1997, P NATL ACAD SCI USA, V94, P3542, DOI 10.1073/pnas.94.8.3542; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; Lei M, 1998, VIROLOGY, V245, P188, DOI 10.1006/viro.1998.9162; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Liu Y, 1996, J VIROL, V70, P1961, DOI 10.1128/JVI.70.3.1961-1968.1996; Liu Y, 2000, P NATL ACAD SCI USA, V97, P12541, DOI 10.1073/pnas.97.23.12541; Liu Y, 1999, J BIOL CHEM, V274, P5070, DOI 10.1074/jbc.274.8.5070; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; Maas S, 2003, J BIOL CHEM, V278, P1391, DOI 10.1074/jbc.R200025200; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; O'Connell RM, 2004, J EXP MED, V200, P437, DOI 10.1084/jem.20040712; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Poulsen H, 2001, MOL CELL BIOL, V21, P7862, DOI 10.1128/MCB.21.22.7862-7871.2001; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LAB MANU, P382; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SAMUEL CE, 1982, J BIOL CHEM, V257, P1791; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Seeburg PH, 2003, CURR OPIN NEUROBIOL, V13, P279, DOI 10.1016/S0959-4388(03)00062-X; Shtrichman R, 2002, INFECT IMMUN, V70, P5579, DOI 10.1128/IAI.70.10.5579-5588.2002; Shtrichman R, 2001, CURR OPIN MICROBIOL, V4, P251, DOI 10.1016/S1369-5274(00)00199-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Strehblow A, 2002, MOL BIOL CELL, V13, P3822, DOI 10.1091/mbc.E02-03-0161; THOMIS DC, 1992, J BIOL CHEM, V267, P10723; VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200; Weier HUG, 2000, CYTOGENET CELL GENET, V89, P214, DOI 10.1159/000015615; Wong SK, 2001, RNA, V7, P846, DOI 10.1017/S135583820101007X; Yang JH, 2003, J BIOL CHEM, V278, P45833, DOI 10.1074/jbc.M308612200; Yang JH, 2003, IMMUNOLOGY, V109, P15, DOI 10.1046/j.1365-2567.2003.01598.x	60	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15020	15028		10.1074/jbc.M500476200	http://dx.doi.org/10.1074/jbc.M500476200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15677478	hybrid			2022-12-25	WOS:000228236800084
J	Arevalo, E; Chiara, DC; Forman, SA; Cohen, JB; Miller, KW				Arevalo, E; Chiara, DC; Forman, SA; Cohen, JB; Miller, KW			Gating-enhanced accessibility of hydrophobic sites within the transmembrane region of the nicotinic acetylcholine receptor's delta-subunit - A time-resolved photolabeling study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID TYPE-A; CHANNEL-LINING RESIDUES; GATED ION CHANNELS; BINDING-SITE; NONCOMPETITIVE ANTAGONIST; GENERAL-ANESTHETICS; GLYCINE RECEPTORS; ALPHA-SUBUNIT; RESTING STATE; M1 SEGMENT	General anesthetics often interact more strongly with sites on open than on closed states of ligand-gated ion channels. To seek such sites, Torpedo membranes enriched in nicotinic acetylcholine receptors (nAChRs) were preincubated with the hydrophobic probe 3-(trifluoromethyl)3-(m-iodophenyl) diazirine ([I-125]TID) and exposed to agonist for either 0 ms (closed state), 1.5 and 10 ms (activated states), 1 s (fast desensitized state), or >= 1 h (equilibrium or slow desensitized state) and then rapidly frozen (<1 ms) and photolabeled. Within 1.5 ms, the fractional change in photoincorporation relative to the closed state decreased to 0.7 in the beta- and gamma-subunits, whereas in the alpha-subunit, it changed little. The most dramatic change occurred in the delta-subunit, where it increased to 1.6 within 10 ms but fell to 0.7 during fast desensitization. Four residues in the delta-subunit's transmembrane domain accounted for the enhanced photoincorporation induced by a 10-ms agonist exposure both when TID was added simultaneously with agonist and when it was preincubated with membranes. In the published closed state structure, two residues (delta Thr(274) and delta Leu(278)) are situated toward the extracellular end of helix M2, both contralateral to the ion channel and adjacent to the third residue (delta Phe(232)) on M1. The fourth labeled residue (delta Ile(288)) is toward the end of the M2-M3 loop. Contact with these residues occurs on the time scale of a rapid phase of TID inhibition in Torpedo nAChRs, suggesting the formation of a transient hydrophobic pocket between M1, M2, and M3 in the delta-subunit during gating.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu	Forman, Stuart/Q-6590-2019	Forman, Stuart/0000-0001-6340-2478	NIGMS NIH HHS [GM-58448] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058448] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addona GH, 2002, J BIOL CHEM, V277, P25685, DOI 10.1074/jbc.M201303200; Addona GH, 1999, ANAL BIOCHEM, V267, P135, DOI 10.1006/abio.1998.2959; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; Arias HR, 2003, INT REV NEUROBIOL, V54, P1, DOI 10.1016/S0074-7742(03)54002-8; Arias HR, 2001, MOL PHARMACOL, V60, P497; Bali M, 2004, MOL PHARMACOL, V65, P68, DOI 10.1124/mol.65.1.68; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; Borghese CM, 2002, ALCOHOL CLIN EXP RES, V26, P1764, DOI 10.1097/01.ALC.0000042012.58231.D9; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Chen J, 1998, BIOPHYS J, V75, P218, DOI 10.1016/S0006-3495(98)77508-3; Chiara DC, 2003, BIOCHEMISTRY-US, V42, P13457, DOI 10.1021/bi0351561; Chiara DC, 2001, BIOCHEMISTRY-US, V40, P296, DOI 10.1021/bi0021481; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; COX RN, 1985, J BIOL CHEM, V260, P7186; Dahan DS, 2004, P NATL ACAD SCI USA, V101, P10195, DOI 10.1073/pnas.0301885101; Dilger JP, 2002, BRIT J ANAESTH, V89, P41, DOI 10.1093/bja/aef161; Downie DL, 2002, J BIOL CHEM, V277, P10367, DOI 10.1074/jbc.M107847200; Forman SA, 1999, BIOCHEMISTRY-US, V38, P14559, DOI 10.1021/bi9914457; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FORMAN SA, 1987, BIOCHEMISTRY-US, V26, P2807, DOI 10.1021/bi00384a023; FORMAN SA, 1988, BIOPHYS J, V54, P149, DOI 10.1016/S0006-3495(88)82939-4; Grosman C, 2000, J GEN PHYSIOL, V115, P637, DOI 10.1085/jgp.115.5.637; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; HEIDMANN T, 1984, P NATL ACAD SCI-BIOL, V81, P1897, DOI 10.1073/pnas.81.6.1897; Jung SW, 2005, J BIOL CHEM, V280, P308, DOI 10.1074/jbc.M409871200; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; LINGLE CJ, 1992, J MEMBRANE BIOL, V126, P195; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; Pratt MB, 2000, J BIOL CHEM, V275, P29441, DOI 10.1074/jbc.M004710200; Rusch D, 2004, J BIOL CHEM, V279, P20982, DOI 10.1074/jbc.M400472200; Sawyer GW, 2002, J BIOL CHEM, V277, P50036, DOI 10.1074/jbc.M209281200; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; WU G, 1994, BIOCHEMISTRY-US, V33, P15375, DOI 10.1021/bi00255a018; Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23; Zhang H, 1997, BIOCHEMISTRY-US, V36, P15856, DOI 10.1021/bi972357u; Zhou QL, 2000, BIOCHEMISTRY-US, V39, P14920, DOI 10.1021/bi001281q; Ziebell MR, 2004, J BIOL CHEM, V279, P17640, DOI 10.1074/jbc.M313886200	52	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13631	13640		10.1074/jbc.M413911200	http://dx.doi.org/10.1074/jbc.M413911200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15664985	hybrid			2022-12-25	WOS:000228095500057
J	Gondeau, C; Gerbal-Chaloin, S; Bello, P; Aldrian-Herrada, G; Morris, MC; Divita, G				Gondeau, C; Gerbal-Chaloin, S; Bello, P; Aldrian-Herrada, G; Morris, MC; Divita, G			Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE INHIBITORS; RECRUITMENT PEPTIDES; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; MECHANISM; PHOSPHORYLATION; SPECIFICITY; SUBSTRATE; SITE; ANTAGONISTS	Cyclin dependent kinases (CDKs) are key regulators of the cell cycle progression and therefore constitute excellent targets for the design of anticancer agents. Most of the inhibitors identified to date inhibit kinase activity by interfering with the ATP-binding site of CDKs. We recently proposed that the protein/protein interface and conformational changes required in the molecular mechanism of CDK2-cyclin A activation were potential targets for the design of specific inhibitors of cell cycle progression. To this aim, we have designed and characterized a small peptide, termed C4, derived from amino acids 285-306 in the alpha 5 helix of cyclin A. We demonstrate that this peptide does not interfere with complex formation but forms stable complexes with CDK2-cyclin A. The C4 peptide significantly inhibits kinase activity of complexes harboring CDK2 in a competitive fashion with respect to substrates but does not behave as an ATP antagonist. Moreover, when coupled with the protein transduction domain of Tat, the C4 peptide blocks the proliferation of tumor cell lines, thereby constituting a potent lead for the development of specific CDK-cyclin inhibitors.	Ctr Rech Biochim Macromol, Dept Mol Biophys & Therapeut, CNRS, FRE 2593, F-34293 Montpellier, France; Monash Univ, LPO, Stem Cell Sci Ltd, Clayton, Vic 3168, Australia	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Monash University	Divita, G (corresponding author), Ctr Rech Biochim Macromol, Dept Mol Biophys & Therapeut, CNRS, FRE 2593, 1919 Route Mende, F-34293 Montpellier, France.	gilles.divita@crbm.cnrs.fr	DIVITA, GILLES/AAV-9214-2021; GERBAL-CHALOIN, sabine/M-8783-2017; MORRIS, May C/J-5940-2016; MORRIS, May/ABB-2629-2021	GERBAL-CHALOIN, sabine/0000-0002-2549-7899; MORRIS, May C/0000-0001-8106-9728; MORRIS, May/0000-0001-8106-9728; Aldrian, Gudrun/0000-0002-7899-0572				Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Barr RK, 2004, J BIOL CHEM, V279, P36327, DOI 10.1074/jbc.M402181200; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; Ferguson M, 2004, CELL CYCLE, V3, P80; Fischer Peter M, 2003, Prog Cell Cycle Res, V5, P235; Fischer PM, 2004, CELL CYCLE, V3, P742; Gali-Muhtasib H, 2002, CURR CANCER DRUG TAR, V2, P309, DOI 10.2174/1568009023333809; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; Huwe A, 2003, ANGEW CHEM INT EDIT, V42, P2122, DOI 10.1002/anie.200200540; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Lowe ED, 2002, BIOCHEMISTRY-US, V41, P15625, DOI 10.1021/bi0268910; Malumbres Marcos, 2003, Prog Cell Cycle Res, V5, P5; McInnes Campbell, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P57, DOI 10.2174/1568011033353506; Mendoza N, 2003, CANCER RES, V63, P1020; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morris MC, 2002, J BIOL CHEM, V277, P23847, DOI 10.1074/jbc.M107890200; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SERENDOWICZ AM, 2003, ONCOGENE, V22, P6606; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996	35	48	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13793	13800		10.1074/jbc.M413690200	http://dx.doi.org/10.1074/jbc.M413690200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15649889	hybrid, Green Published			2022-12-25	WOS:000228095500076
J	Mayr, GW; Windhorst, S; Hillemeier, K				Mayr, GW; Windhorst, S; Hillemeier, K			Antiproliferative plant and synthetic polyphenolics are specific inhibitors of vertebrate inositol-1,4,5-trisphosphate 3-kinases and inositol polyphosphate multikinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEIN-KINASE-C; TUMOR-CELL LINES; HUMAN CARCINOMA-CELLS; MESSENGER-RNA EXPORT; 1,4,5-TRISPHOSPHATE 3-KINASE; AURINTRICARBOXYLIC ACID; IN-VITRO; ELLAGIC ACID; GREEN TEA; PHOTODYNAMIC THERAPY	Inositol-1,4,5-trisphosphate 3-kinases (IP3K) A, B, and C as well as inositol polyphosphate multikinase (IPMK) catalyze the first step in the formation of the higher phosphorylated inositols InsP(5) and InsP(6) by metabolizing Ins(1,4,5)P-3 to Ins(1,3,4,5)P-4. In order to clarify the special role of these InsP(3) phosphorylating enzymes and of subsequent anabolic inositol phosphate reactions, a search was conducted for potent enzyme inhibitors starting with a fully active IP3K-A catalytic domain. Seven polyphenolic compounds could be identified as potent inhibitors with IC50 < 200 nM (IC50 given): ellagic acid (36 nM), gossypol (58 nM), (-)-epicatechin-3-gallate (94 nM), (-)-epigallocatechin-3-gallate (EGCG, 120 nM), aurintricarboxylic acid (ATA, 150 nM), hypericin (170 nM), and quercetin (180 nM). All inhibitors displayed a mixed-type inhibition with respect to ATP and a noncompetitive inhibition with respect to Ins(1,4,5) P3. Examination of these inhibitors toward IP3K-A, - B, and - C and IPMK from mammals revealed that ATA potently inhibits all kinases while the other inhibitors do not markedly affect IPMK but differentially inhibit IP3K isoforms. We identified chlorogenic acid as a specific IPMK inhibitor whereas the flavonoids myricetin,3',4',7,8-tetrahydroxyflavone and EGCG inhibit preferentially IP3K-A and IP3K-C. Mutagenesis studies revealed that both the calmodulin binding and the InsP(3) binding domain in IP3K are involved in inhibitor binding. Their absence in IPMK and the presence of a unique insertion in IPMK were found to be important for selectivity differences from IP3K. The fact that all identified IP3K and IPMK inhibitors have been reported as anti-proliferative agents and that IP3Ks or IPMK often are the best binding targets deserves further investigation concerning their antitumor potential.	Univ Hamburg, Hosp Eppendorf, Inst Biochem & Mol Biol Zellulare Signaltransdukt, D-20246 Hamburg, Germany	University of Hamburg	Mayr, GW (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Biochem & Mol Biol Zellulare Signaltransdukt, Martinistr 52, D-20246 Hamburg, Germany.	mayr@uke.uni-hamburg.de						Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Alecu M, 1998, ANTICANCER RES, V18, P4651; ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; Ali SM, 2001, J PHOTOCH PHOTOBIO B, V65, P59, DOI 10.1016/S1011-1344(01)00252-4; ANDREONI A, 1994, PHOTOCHEM PHOTOBIOL, V59, P529, DOI 10.1111/j.1751-1097.1994.tb02978.x; Andrew DJ, 1999, IMMUNOPHARMACOLOGY, V41, P1, DOI 10.1016/S0162-3109(98)00049-6; Asano Y, 1996, LIFE SCI, V60, P135, DOI 10.1016/S0024-3205(96)00603-0; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Bai JZ, 1999, BIOCHEM J, V343, P53, DOI 10.1042/0264-6021:3430053; Barch DH, 1996, CARCINOGENESIS, V17, P265, DOI 10.1093/carcin/17.2.265; Beery R, 2001, ENDOCRINOLOGY, V142, P3098, DOI 10.1210/en.142.7.3098; BENCHOKROUN Y, 1995, BIOCHEM PHARMACOL, V49, P305, DOI 10.1016/0006-2952(94)00465-X; BENEZRA M, 1994, ARTERIOSCLER THROMB, V14, P1992, DOI 10.1161/01.ATV.14.12.1992; Bertsch U, 1999, GENE, V228, P61, DOI 10.1016/S0378-1119(99)00018-9; Bertsch U, 2000, J BIOL CHEM, V275, P1557, DOI 10.1074/jbc.275.3.1557; Blank M, 2003, CANCER RES, V63, P8241; Borska S, 2003, FOLIA HISTOCHEM CYTO, V41, P229; Brehm MA, 2004, BIOCHEM J, V382, P353, DOI 10.1042/BJ20031751; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; Bushunow P, 1999, J NEURO-ONCOL, V43, P79, DOI 10.1023/A:1006267902186; Casagrande F, 2001, BIOCHEM PHARMACOL, V61, P1205, DOI 10.1016/S0006-2952(01)00583-4; CATCHPOOLE DR, 1994, ANTICANCER RES, V14, P853; Chen B, 2002, INT J CANCER, V98, P284, DOI 10.1002/ijc.10175; Chen TC, 2003, CANCER-AM CANCER SOC, V97, P2363, DOI 10.1002/cncr.11307; Chiang LC, 2003, AM J CHINESE MED, V31, P37, DOI 10.1142/S0192415X03000825; Chung LY, 2001, LIFE SCI, V68, P1207, DOI 10.1016/S0024-3205(00)01020-1; CONSTANTINOU A, 1995, NUTR CANCER, V23, P121, DOI 10.1080/01635589509514368; COYLE T, 1994, J NEURO-ONCOL, V19, P25, DOI 10.1007/BF01051046; DASILVA CP, 1994, J BIOL CHEM, V269, P12521; Dewaste V, 2003, BIOCHEM J, V374, P41, DOI 10.1042/BJ20021963; Dewaste V, 2002, BIOCHEM BIOPH RES CO, V291, P400, DOI 10.1006/bbrc.2002.6456; Dewaste V, 2000, BIOCHEM J, V352, P343, DOI 10.1042/0264-6021:3520343; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; El Bakkoury M, 2000, MOL MICROBIOL, V35, P15, DOI 10.1046/j.1365-2958.2000.01665.x; ESCARGUEILBLANC I, 1997, THROMB VASC BIOL, V17, P331; Facino RM, 1995, PLANTA MED, V61, P510, DOI 10.1055/s-2006-959359; FLACK MR, 1993, J CLIN ENDOCR METAB, V76, P1019, DOI 10.1210/jc.76.4.1019; Fraifeld V, 2001, ANTICANCER RES, V21, P1975; Freire ACG, 2003, PLANTA MED, V69, P67, DOI 10.1055/s-2003-37036; FREW T, 1994, ANTICANCER RES, V14, P2425; Gerhauser C, 2003, MUTAT RES-FUND MOL M, V523, P163, DOI 10.1016/S0027-5107(02)00332-9; Gonzalez B, 2004, MOL CELL, V15, P689, DOI 10.1016/j.molcel.2004.08.004; GOPALAKRISHNA R, 1992, FEBS LETT, V314, P149, DOI 10.1016/0014-5793(92)80962-G; Goswami R, 2002, NEUROCHEM RES, V27, P735, DOI 10.1023/A:1020292504535; Grimley PM, 1998, BLOOD, V91, P3017, DOI 10.1182/blood.V91.8.3017.3017_3017_3027; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GUTFREUND H, 1971, ENZYMES PHYS PRINCIP; Hadjur C, 1996, PHOTOCHEM PHOTOBIOL, V64, P375, DOI 10.1111/j.1751-1097.1996.tb02474.x; Hamilton HB, 1996, J NEUROSURG, V85, P329, DOI 10.3171/jns.1996.85.2.0329; Heiduschka P, 2000, NEUROPHARMACOLOGY, V39, P889, DOI 10.1016/S0028-3908(99)00245-2; Hoy M, 2003, J BIOL CHEM, V278, P35168, DOI 10.1074/jbc.M303927200; Hoy M, 2002, P NATL ACAD SCI USA, V99, P6773, DOI 10.1073/pnas.102157499; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; JOSEPHY PD, 1990, MUTAT RES, V242, P143; Jun KS, 1998, LEARN MEMORY, V5, P317; Karni R, 2003, FEBS LETT, V537, P47, DOI 10.1016/S0014-5793(03)00069-3; Kavutcu M, 1999, PHARMAZIE, V54, P457; Khanduja KL, 1999, FOOD CHEM TOXICOL, V37, P313, DOI 10.1016/S0278-6915(99)00021-6; Kim JH, 2001, ARCH PHARM RES, V24, P292, DOI 10.1007/BF02975094; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Koren H, 1996, J PHOTOCH PHOTOBIO B, V36, P113, DOI 10.1016/S1011-1344(96)07357-5; LAUGHTON MJ, 1989, BIOCHEM PHARMACOL, V38, P2859, DOI 10.1016/0006-2952(89)90442-5; Lavie G, 1999, BRIT J CANCER, V79, P423, DOI 10.1038/sj.bjc.6690066; Lee HS, 1996, PLANTA MED, V62, P293, DOI 10.1055/s-2006-957887; Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V; Lin CM, 2002, PLANTA MED, V68, P365, DOI 10.1055/s-2002-26753; Luksiene Zivile, 2003, Medicina (Kaunas), V39, P677; Lyn-Cook BD, 1999, NUTR CANCER, V35, P80, DOI 10.1207/S1532791480-86; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; Marchisio M, 2003, BIOCHEM PHARMACOL, V66, P1973, DOI 10.1016/S0006-2952(03)00583-5; Martinez C, 2003, MELANOMA RES, V13, P3, DOI 10.1097/00008390-200302000-00002; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; Mertens-Talcott SU, 2003, J NUTR, V133, P2669, DOI 10.1093/jn/133.8.2669; Middleton E, 2000, PHARMACOL REV, V52, P673; Miller GJ, 2004, MOL CELL, V15, P703, DOI 10.1016/j.molcel.2004.08.005; MIURA S, 1994, BIOL PHARM BULL, V17, P1567; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; Mori H, 2000, BIOFACTORS, V12, P101, DOI 10.1002/biof.5520120116; Nalaskowski MM, 2004, CURR MOL MED, V4, P277, DOI 10.2174/1566524043360726; Nalaskowski MM, 2003, J BIOL CHEM, V278, P19765, DOI 10.1074/jbc.M211059200; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Olivo M, 2003, INT J ONCOL, V23, P1501; ONO K, 1990, J BIOCHEM-TOKYO, V108, P609, DOI 10.1093/oxfordjournals.jbchem.a123251; Paschka AG, 1998, CANCER LETT, V130, P1, DOI 10.1016/S0304-3835(98)00084-6; PERCHELLET JP, 1992, BASIC LIFE SCI, V59, P783; Pouillon V, 2003, NAT IMMUNOL, V4, P1136, DOI 10.1038/ni980; Raboy V, 2003, PHYTOCHEMISTRY, V64, P1033, DOI 10.1016/S0031-9422(03)00446-1; Rando OJ, 2003, NAT STRUCT BIOL, V10, P81, DOI 10.1038/nsb0203-81; RAO L, 1995, CHEM RES TOXICOL, V9, P16; Rodgers EH, 1998, CHEM-BIOL INTERACT, V116, P213, DOI 10.1016/S0009-2797(98)00092-1; Rosenbaum DM, 1998, ANN NEUROL, V43, P654, DOI 10.1002/ana.410430515; RUCKSTUHL M, 1979, BIOCHEM PHARMACOL, V28, P535, DOI 10.1016/0006-2952(79)90249-1; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; Schempp H, 2003, ARZNEIMITTELFORSCH, V53, P568; SEGEL HI, 1993, ENZYME KINETICS BEHA, P125; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Shelley MD, 1999, CANCER LETT, V135, P171, DOI 10.1016/S0304-3835(98)00302-4; Shidaifat F, 1997, ANTICANCER RES, V17, P1003; Simmen U, 2001, PHARMACOPSYCHIATRY, V34, pS137, DOI 10.1055/s-2001-15475; Soriano S, 1997, BIOCHEM J, V324, P579, DOI 10.1042/bj3240579; SPINOZZI F, 1994, LEUKEMIA RES, V18, P431, DOI 10.1016/0145-2126(94)90079-5; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; Stevenson-Paulik J, 2002, J BIOL CHEM, V277, P42711, DOI 10.1074/jbc.M209112200; Stoner GD, 1997, CANCER LETT, V114, P113, DOI 10.1016/S0304-3835(97)04639-9; Suganuma M, 1999, MUTAT RES-FUND MOL M, V428, P339, DOI 10.1016/S1383-5742(99)00059-9; TAKAHASHI I, 1989, BIOCHEM BIOPH RES CO, V165, P1207, DOI 10.1016/0006-291X(89)92730-7; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM BIOPH RES CO, V174, P529, DOI 10.1016/0006-291X(91)91449-M; TAKAZAWA K, 1989, BIOCHEM J, V261, P483, DOI 10.1042/bj2610483; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Tao P, 1992, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V14, P334; Theodossiou T, 2003, CANCER RES, V63, P1818; Umekawa H, 1999, BIOCHEM MOL BIOL INT, V47, P795; Valastro B, 2001, HIPPOCAMPUS, V11, P673, DOI 10.1002/hipo.1082; Van Poznak C, 2001, BREAST CANCER RES TR, V66, P239, DOI 10.1023/A:1010686204736; Vandenbogaerde AL, 1996, ANTICANCER RES, V16, P1619; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; VANWEYENBERG V, 1995, BIOCHEM J, V306, P429, DOI 10.1042/bj3060429; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Weller M, 1997, NEUROL RES, V19, P459; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yang SN, 2001, FASEB J, V15, P1753, DOI 10.1096/fj.00-0799com; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Yu J, 2003, J BIOL CHEM, V278, P46210, DOI 10.1074/jbc.M303743200; Zhang MC, 2003, BIOCHEM PHARMACOL, V66, P93, DOI 10.1016/S0006-2952(03)00248-X; Zhang ZZ, 2003, J NAT PROD, V66, P548, DOI 10.1021/np020442j; Zhao Y, 1997, CANCER LETT, V121, P163, DOI 10.1016/S0304-3835(97)00348-0	135	67	71	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13229	13240		10.1074/jbc.M500545200	http://dx.doi.org/10.1074/jbc.M500545200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15659385	hybrid			2022-12-25	WOS:000228095500006
J	Zhou, HY; Xu, YQ; Yang, YD; Huang, AD; Wu, JH; Shi, YY				Zhou, HY; Xu, YQ; Yang, YD; Huang, AD; Wu, JH; Shi, YY			Solution structure of AF-6 PDZ domain and its interaction with the C-terminal peptides from neurexin and Bcr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL JUNCTIONS; CRYSTAL-STRUCTURE; TARGET RECOGNITION; EPITHELIAL-CELLS; BINDING PROTEIN; AFADIN; ADHESION; DYNAMICS; REVEALS; COMPLEX	AF-6 is a key molecule essential for structure organization of cell-cell junction of polarized epithelia. It belongs to a novel cell-cell adhesion system. The AF-6 PDZ domain mediates interactions by binding to a specific amino acid sequence in target proteins. Here we report the solution structure of the AF-6 PDZ domain determined by NMR. Previously, the AF-6 PDZ domain was considered to be a class II PDZ domain. However we found that a unique hydrophilic amino acid, Gln(70), at position alpha B1 makes the alpha B/beta B groove of the AF-6 PDZ domain significantly different from that of the canonical class II PDZ domain. The AF-6 PDZ domain does not have the second hydrophobic binding pocket, and the N-terminal end of alpha B is closer to beta B. Using BIACORE and NMR chemical shift perturbation experiments, we have studied the binding characteristics of the PDZ domain to the C-terminal peptide of Neurexin, KKNKD-KEYYV, and that of Bcr, KRQSILFSTEV. The C-terminal peptide of Neurexin is a class II ligand, whereas that of Bcr is a class I ligand. The dissociation constants of these ligands were 4.08 x 10(-7) and 2.23 x 10(-6) M, respectively. Each of the four C-terminal positions in Neurexin and Bcr may contribute to the interaction. The three-dimensional models of the AF-6 PDZ-Neurexin C-terminal peptide complex and the AF-6 PDZ-Bcr C-terminal peptide complex were built up by molecular dynamics simulations. Unlike the canonical class II PDZ domain, Ala(74) at alpha B5 rather than the residue at beta B1 makes direct hydrophobic contact with the side chain of Tyr at the -2 position of the ligand.	Univ Sci & Technol China, Sch Life Sci, Hefei Natl Lab Phys Sci Microscale, Anhua 230026, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wu, JH (corresponding author), Univ Sci & Technol China, Sch Life Sci, Hefei Natl Lab Phys Sci Microscale, Anhua 230026, Peoples R China.	wujihui@ustc.edu.cn; yyshi@ustc.edu.cn	Yang, Yuedong/C-9394-2009; Shi, Yunyu/B-3240-2009	Yang, Yuedong/0000-0002-6782-2813; Shi, Yunyu/0000-0002-1348-4759				Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fuentes EJ, 2004, J MOL BIOL, V335, P1105, DOI 10.1016/j.jmb.2003.11.010; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Harris BZ, 2001, J CELL SCI, V114, P3219; Hata Y, 1996, J NEUROSCI, V16, P2488; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Im YJ, 2003, J BIOL CHEM, V278, P8501, DOI 10.1074/jbc.M212263200; Karthikeyan S, 2002, J BIOL CHEM, V277, P18973, DOI 10.1074/jbc.M201507200; Kozlov G, 2002, J MOL BIOL, V320, P813, DOI 10.1016/S0022-2836(02)00544-2; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Piserchio A, 2002, J BIOL CHEM, V277, P6967, DOI 10.1074/jbc.M109453200; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; PRASAD R, 1993, CANCER RES, V53, P5624; Radziwill G, 2003, MOL CELL BIOL, V23, P4663, DOI 10.1128/MCB.23.13.4663-4672.2003; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; VANGUNSTERN WF, 1996, BIOMOLECULAR SIMULAT; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3; Zhu JA, 2002, J PHYS CHEM B, V106, P4844, DOI 10.1021/jp020058v	38	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13841	13847		10.1074/jbc.M411065200	http://dx.doi.org/10.1074/jbc.M411065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15684424	hybrid			2022-12-25	WOS:000228095500082
J	Kawar, ZS; Haslam, SM; Morris, HR; Dell, A; Cummings, RD				Kawar, ZS; Haslam, SM; Morris, HR; Dell, A; Cummings, RD			Novel poly-GalNAc beta 1-4GlcNAc (LacdiNAc) and fucosylated poly-LacdiNAc N-glycans from mammalian cells expressing beta 1,4-N-acetylgalactosaminyltransferase and alpha 1,3-fucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; NORMAL HUMAN-LEUKOCYTES; CIRCULATORY HALF-LIFE; E-SELECTIN-BINDING; MOLECULAR-CLONING; LINKED OLIGOSACCHARIDES; SCHISTOSOMA-MANSONI; ANTIBODY-RESPONSES; DIFFERENTIAL EXPRESSION	Glycans containing the GalNAc beta 1-4GlcNAc (LacdiNAc or LDN) motif are expressed by many invertebrates, but this motif also occurs in vertebrates and is found on several mammalian glycoprotein hormones. This motif contrasts with the more commonly occurring Gal beta 1-4GlcNAc (LacNAc or LN) motif. To better understand LDN biosynthesis and regulation, we stably expressed the cDNA encoding the Caenorhabditis elegans beta 1,4-N-acetylgalactosaminyltransferase (GalNAcT), which generates LDN in vitro, in Chinese hamster ovary (CHO) Lec8 cells, to establish L8-GalNAcT CHO cells. The glycan structures from these cells were determined by mass spectrometry and linkage analysis. The L8-GalNAcT cell line produces complex-type N-glycans quantitatively bearing LDN structures on their antennae. Unexpectedly, most of these complex-type N-glycans contain novel "poly-LDN" structures consisting of repeating LDN motifs (-3GalNAc beta 1-4GlcNAc beta 1-)(n). These novel structures are in contrast to the well known poly-LN structures consisting of repeating LN motifs (-3Gal beta 1-4GlcNAc beta 1-)(n). We also stably expressed human alpha 1,3-fucosyltransferase IX in the L8-GalNAcT cells to establish a new cell line, L8-GalNAcT-FucT. These cells produce complex-type N-glycans with alpha 1,3-fucosylated LDN (LDNF) GalNAc beta 1-4(Fuc beta 1-3) GlcNAc beta 1-R as well as novel "poly-LDNF" structures (-3GalNAc beta 1-4(Fuc beta 1-3)GlcNAc beta 1-)(n). The ability of these cell lines to generate glycoprotein hormones with LDN-containing N-glycans was studied by expressing a recombinant form of the common alpha-subunit in L8-GalNAcT cells. The alpha-subunit N-glycans carried LDN structures, which were further modified by co-expression of the human GalNAc 4-sulfotransferase I, which generates SO4-4GalNAc beta 1-4GlcNAc- R. Thus, the generation of these stable mammalian cells will facilitate future studies on the biological activities and properties of LDN-related structures in glycoproteins.	Univ Oklahoma, Hlth Sci Ctr, OK Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; M SCAM Mass Spectrometry Res & Training Ctr, Ascot SL5 7PZ, Berks, England	University of Oklahoma System; University of Oklahoma Health Sciences Center; Imperial College London	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, OK Ctr Med Glycobiol, Dept Biochem & Mol Biol, 975 NE 10th St,BRC Rm 417, Oklahoma City, OK 73104 USA.	richard-cummings@ouhsc.edu			NICHD NIH HHS [R01 CH/HD54832-01] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; Baenziger JU, 1996, ENDOCRINOLOGY, V137, P1520, DOI 10.1210/en.137.5.1520; Baenziger JU, 2003, BIOCHEM SOC T, V31, P326, DOI 10.1042/BST0310326; BRILES EB, 1977, J BIOL CHEM, V252, P1107; Cailleau-Thomas A, 2000, GLYCOBIOLOGY, V10, P789, DOI 10.1093/glycob/10.8.789; CHIU MH, 1994, J BIOL CHEM, V269, P16195; de Vijver KKV, 2004, INT J PARASITOL, V34, P951, DOI 10.1016/j.ijpara.2004.04.009; Delahaye R, 1996, J MOL ENDOCRINOL, V16, P141, DOI 10.1677/jme.0.0160141; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; Dell A, 2003, P NATL ACAD SCI USA, V100, P15631, DOI 10.1073/pnas.2635507100; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Do KY, 1997, GLYCOBIOLOGY, V7, P183, DOI 10.1093/glycob/7.2.183; DO SI, 1992, J BIOCHEM BIOPH METH, V24, P153, DOI 10.1016/0165-022X(94)90068-X; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218; Gotoh M, 2004, FEBS LETT, V562, P134, DOI 10.1016/S0014-5793(04)00219-4; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; Ishida H, 2005, FEBS LETT, V579, P71, DOI 10.1016/j.febslet.2004.11.037; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; LEE EU, 1989, J BIOL CHEM, V264, P13848; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; Mercier D, 1999, GLYCOBIOLOGY, V9, P851, DOI 10.1093/glycob/9.9.851; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; Morelle W, 2000, GLYCOBIOLOGY, V10, P941, DOI 10.1093/glycob/10.9.941; NEMANSKY M, 1992, BIOCHEM J, V287, P311, DOI 10.1042/bj2870311; Nyame AK, 2004, ARCH BIOCHEM BIOPHYS, V426, P182, DOI 10.1016/j.abb.2004.04.004; Nyame AK, 1999, GLYCOBIOLOGY, V9, P1029, DOI 10.1093/glycob/9.10.1029; Nyame AK, 2000, EXP PARASITOL, V96, P202, DOI 10.1006/expr.2000.4573; Ohkura T, 2002, J BIOCHEM, V132, P891, DOI 10.1093/oxfordjournals.jbchem.a003302; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; Saarinen J, 1999, EUR J BIOCHEM, V259, P829, DOI 10.1046/j.1432-1327.1999.00105.x; Salo H, 2002, GLYCOBIOLOGY, V12, P217, DOI 10.1093/glycob/12.3.217; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sato T, 2003, J BIOL CHEM, V278, P47534, DOI 10.1074/jbc.M308857200; Schlenke P, 1999, CYTOTECHNOLOGY, V30, P17, DOI 10.1023/A:1008049603947; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STROUD MR, 1995, BIOCHEM BIOPH RES CO, V209, P777, DOI 10.1006/bbrc.1995.1568; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; Toivonen S, 2002, GLYCOBIOLOGY, V12, P361, DOI 10.1093/glycob/12.6.361; Ujita M, 2001, TRENDS GLYCOSCI GLYC, V13, P177, DOI 10.4052/tigg.13.177; van den Berg TK, 2004, J IMMUNOL, V173, P1902, DOI 10.4049/jimmunol.173.3.1902; Van den Nieuwenhof IM, 2000, EUR J BIOCHEM, V267, P4753, DOI 10.1046/j.1432-1327.2000.01528.x; van Die I, 2003, GLYCOBIOLOGY, V13, P471, DOI 10.1093/glycob/cwg052; van Remoortere A, 2003, EXP PARASITOL, V105, P219, DOI 10.1016/j.exppara.2003.12.005; VANDENEIJNDEN DH, 1995, BIOCHEM SOC T, V23, P175, DOI 10.1042/bst0230175; VandenEijnden DH, 1997, BIOCHEM SOC T, V25, P887, DOI 10.1042/bst0250887; Vervelde L, 2003, GLYCOBIOLOGY, V13, P795, DOI 10.1093/glycob/cwg107; Woodworth A, 2002, J BIOL CHEM, V277, P50941, DOI 10.1074/jbc.M209876200; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597	60	50	51	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12810	12819		10.1074/jbc.M414273200	http://dx.doi.org/10.1074/jbc.M414273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15653684	hybrid			2022-12-25	WOS:000227922000089
J	Kim, JY; Sharma, S; Li, YM; Cobos, E; Palvimo, JJ; Williams, SC				Kim, JY; Sharma, S; Li, YM; Cobos, E; Palvimo, JJ; Williams, SC			Repression and coactivation of CCAAT/enhancer-binding protein epsilon by sumoylation and protein inhibitor of activated STATx proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-C/EBP; LACTOFERRIN GENE-EXPRESSION; GRANULE DEFICIENCY; DNA-BINDING; ANDROGEN RECEPTOR; ATTENUATOR DOMAIN; SUMO; FAMILY; UBIQUITIN; MOTIF	CCAAT/enhancer-binding protein epsilon (C/EBP epsilon) is a neutrophil-specific transcription factor whose activity is controlled by juxtaposed activating and regulatory domains. We previously determined that the function of the major regulatory domain (RD1) in C/EBP epsilon was dependent on the integrity of a five-amino acid motif that was identical to the recognition site for members of the small ubiquitin-like modifier (SUMO) family of ubiquitin-related proteins. We show here that the SUMO attachment site (the regulatory domain motif) is necessary and sufficient both for the intrinsic inhibitory function of RD1 and for coactivation by PIASx alpha and PIASx beta, two members of the protein inhibitor of activated STAT (PIAS) family of SUMO E3 ligases. PIASx beta was a more potent coactivator than PIASx alpha of both full-length C/EBP epsilon and fusion proteins containing the N-terminal portion of C/EBP epsilon, whereas PIASx alpha was more active on fusion proteins containing a heterologous activation domain. Two modes of coactivation were observed, one that was dependent on the integrity of the RING finger (RF) domain and was shared by both PIASx alpha and PIASx beta and a second mode that was independent of the RF and was only observed with PIASx beta. Sumoylation of C/EBP epsilon was enhanced by coexpression of PIASx alpha, suggesting that this modification is associated with the enhanced activity of the target protein. These results suggest that a complex interplay of accessory factors, including SUMO and PIAS proteins, modulates the activity of C/EBP epsilon.	Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lubbock, TX 79430 USA; Univ Kuopio, Dept Med Biochem, FIN-70211 Kuopio, Finland; Univ Med Ctr, SW Canc Ctr, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; University of Eastern Finland; Texas Tech University System; Texas Tech University Health Science Center	Williams, SC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, 3601 4th St, Lubbock, TX 79430 USA.	simon.williams@ttuhsc.edu		Palvimo, Jorma/0000-0003-2373-0578				Angerer ND, 1999, J BIOL CHEM, V274, P4147, DOI 10.1074/jbc.274.7.4147; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Chih DY, 1997, BLOOD, V90, P2987, DOI 10.1182/blood.V90.8.2987; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Gombart AF, 2002, CURR OPIN HEMATOL, V9, P36, DOI 10.1097/00062752-200201000-00007; Gombart AF, 2001, BLOOD, V97, P2561, DOI 10.1182/blood.V97.9.2561; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; Guo DH, 2004, NAT GENET, V36, P837, DOI 10.1038/ng1391; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; Khanna-Gupta A, 2001, P NATL ACAD SCI USA, V98, P8000, DOI 10.1073/pnas.141229598; Khanna-Gupta A, 2003, BLOOD, V101, P3460, DOI 10.1182/blood-2002-09-2767; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Kubota T, 2000, BLOOD, V96, P3953, DOI 10.1182/blood.V96.12.3953.h8003953_3953_3957; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Pascual-Le Tallec L, 2003, MOL ENDOCRINOL, V17, P2529, DOI 10.1210/me.2003-0299; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Prado F, 2002, J BIOL CHEM, V277, P16383, DOI 10.1074/jbc.M200418200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Tavor S, 2002, BLOOD, V99, P1794, DOI 10.1182/blood.V99.5.1794; Tussie-Luna MI, 2002, J BIOL CHEM, V277, P43185, DOI 10.1074/jbc.M207635200; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Verbeek W, 1999, BLOOD, V94, P3141, DOI 10.1182/blood.V94.9.3141.421k41_3141_3150; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Williams SC, 1998, J BIOL CHEM, V273, P13493, DOI 10.1074/jbc.273.22.13493; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187	44	17	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12246	12254		10.1074/jbc.M413771200	http://dx.doi.org/10.1074/jbc.M413771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15661739	hybrid			2022-12-25	WOS:000227922000023
J	Yun, CH; Kim, KH; Calcutt, MW; Guengerich, FP				Yun, CH; Kim, KH; Calcutt, MW; Guengerich, FP			Kinetic analysis of oxidation of coumarins by human cytochrome P450 2A6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LIVER MICROSOMAL CYTOCHROME-P-450; COMPOUND-I FORMATION; RATE-LIMITING STEPS; GENETIC-POLYMORPHISM; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; ESCHERICHIA-COLI; TRANSITION-STATE; MAJOR CATALYSTS; O-DEALKYLATION	Human cytochrome P450 (P450) 2A6 catalyzes 7-hydroxylation of coumarin, and the reaction rate is enhanced by cytochrome b(5) (b(5)). 7-Alkoxycoumarins were O-dealkylated and also hydroxylated at the 3-position. Binding of coumarin and 7-hydroxycoumarin to ferric and ferrous P450 2A6 are fast reactions (k(on) similar to 10(6) M-1 s(-1)), and the k(off) rates range from 5.7 to 36 s(-1) (at 23 degrees C). Reduction of ferric P450 2A6 is rapid (7.5 s(-1)) but only in the presence of coumarin. The reaction of the ferrous P450 2A6 substrate complex with O-2 is rapid (k >= 10(6) M-1 s(-1)), and the putative Fe2+center dot O-2 complex decayed at a rate of similar to 0.3 s(-1) at 23 degrees C. Some 7-hydroxycoumarin was formed during the oxidation of the ferrous enzyme under these conditions, and the yield was enhanced by b5. Kinetic analyses showed that similar to 1/3 of the reduced b(5) was rapidly oxidized in the presence of the Fe2+center dot O-2 complex, implying some electron transfer. High intrinsic and competitive and non-competitive intermolecular kinetic deuterium isotope effects (values 6-10) were measured for O-dealkylation of 7-alkoxycoumarins, indicating the effect of C-H bond strength on rates of product formation. These results support a scheme with many rapid reaction steps, including electron transfers, substrate binding and release at multiple stages, and rapid product release even though the substrate is tightly bound in a small active site. The inherent difficulty of chemistry of substrate oxidation and the lack of proclivity toward a linear pathway leading to product formation explain the inefficiency of the enzyme relative to highly efficient bacterial P450s.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA; Chonnam Natl Univ, Hormone Res Ctr, Sch Biol Sci & Technol, Kwangju 500757, South Korea	Vanderbilt University; Vanderbilt University; Chonnam National University	Guengerich, FP (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu		Yun, Chul-Ho/0000-0003-2685-2968	NATIONAL CANCER INSTITUTE [R01CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES012123, P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90426] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267, F32 ES12123] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ariyoshi N, 2002, CANCER EPIDEM BIOMAR, V11, P890; ATKINSON JK, 1994, BIOCHEMISTRY-US, V33, P10630, DOI 10.1021/bi00201a009; Bell-Parikh LC, 1999, J BIOL CHEM, V274, P23833, DOI 10.1074/jbc.274.34.23833; Born SL, 2002, DRUG METAB DISPOS, V30, P483, DOI 10.1124/dmd.30.5.483; BURLEIGH BD, 1969, ANAL BIOCHEM, V27, P536, DOI 10.1016/0003-2697(69)90067-0; Calcutt MW, 2003, FASEB J, V17, pA1325; Chandrasena REP, 2004, J AM CHEM SOC, V126, P115, DOI 10.1021/ja038237t; Chauret N, 1998, DRUG METAB DISPOS, V26, P1; CREAVEN PJ, 1965, BIOCHEM J, V96, P390, DOI 10.1042/bj0960390; Cryle MJ, 2003, AUST J CHEM, V56, P749, DOI 10.1071/CH03040; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; DALY AK, 1993, PHARMACOL THERAPEUT, V57, P129, DOI 10.1016/0163-7258(93)90053-G; de Montellano O., 2005, CYTOCHROME P450 STRU; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; Denisov IG, 2001, J INORG BIOCHEM, V87, P215, DOI 10.1016/S0162-0134(01)00328-2; Ding XX, 2003, ANNU REV PHARMACOL, V43, P149, DOI 10.1146/annurev.pharmtox.43.100901.140251; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; Fersht A., 1999, STRUCTURE MECH PROTE, P125; Fisher MB, 2002, DRUG METAB DISPOS, V30, P270, DOI 10.1124/dmd.30.3.270; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; FOUST GP, 1969, ANAL BIOCHEM, V27, P530, DOI 10.1016/0003-2697(69)90066-9; FURNISS BS, 1978, VOGELS TXB PRACTICAL, P753; GELB MH, 1982, BIOCHEMISTRY-US, V21, P370, DOI 10.1021/bi00531a026; Gellman AJ, 2000, J PHYS CHEM A, V104, P2476, DOI 10.1021/jp993474x; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; Gillam EMJ, 1999, BIOCHEM BIOPH RES CO, V265, P469, DOI 10.1006/bbrc.1999.1702; GILLETTE JR, 1991, LIFE SCI, V49, P1, DOI 10.1016/0024-3205(91)90573-T; GILLETTE JR, 1994, BIOCHEMISTRY-US, V33, P2927, DOI 10.1021/bi00176a024; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; Guengerich F. P., 2001, PRINCIPLES METHODS T, P1625; Guengerich FP, 1996, J BIOL CHEM, V271, P27321, DOI 10.1074/jbc.271.44.27321; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1976, BIOCHEM BIOPH RES CO, V70, P951; Guengerich FP, 2004, J MED CHEM, V47, P3236, DOI 10.1021/jm030561b; Guengerich FP, 2004, BIOCHEMISTRY-US, V43, P10775, DOI 10.1021/bi0491393; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; Guengerich FP, 2002, BIOL CHEM, V383, P1553, DOI 10.1515/BC.2002.175; Guengerich FP, 2002, J BIOL CHEM, V277, P33711, DOI 10.1074/jbc.M205146200; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; GUENGERICH FP, 2004, CYTOCHROME P450 STRU, P377; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; HANZLIK RP, 1985, J AM CHEM SOC, V107, P7164, DOI 10.1021/ja00310a066; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; Hinterding K, 1998, BIOORGAN MED CHEM, V6, P1153, DOI 10.1016/S0968-0896(98)00070-4; INDAHL S R, 1971, Xenobiotica, V1, P13; ISHIFUKU K, 1953, YAKUGAKU ZASSHI, V73, P332; ISHIMURA Y, 1971, BIOCHEM BIOPH RES CO, V42, P140, DOI 10.1016/0006-291X(71)90373-1; Johnson Kenneth A., 2003, P1; JONES JP, 1987, J AM CHEM SOC, V109, P2171, DOI 10.1021/ja00241a040; JUNG B, 1985, BIOL CHEM H-S, V366, P23, DOI 10.1515/bchm3.1985.366.1.23; KADKHODAYAN S, 1995, J BIOL CHEM, V270, P28042; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; KEREKJARTO BV, 1964, BIOCHEM Z, V339, P460; Kolliker S, 1998, ANAL CHEM, V70, P1979, DOI 10.1021/ac9709458; Krauser JA, 2004, FASEB J, V18, pC238; London SJ, 1999, LANCET, V353, P898, DOI 10.1016/S0140-6736(98)04984-8; Lowe LG, 1996, BIOCHEMISTRY-US, V35, P9840, DOI 10.1021/bi960485x; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; Matsson O, 1998, ADV PHYS ORG CHEM, V31, P143; MILES JS, 1990, BIOCHEM J, V267, P365, DOI 10.1042/bj2670365; MIWA GT, 1987, BIOESSAYS, V7, P215, DOI 10.1002/bies.950070506; Mueller Ernest J., 1995, P83; Munro AW, 1996, MOL MICROBIOL, V20, P1115, DOI 10.1111/j.1365-2958.1996.tb02632.x; Nakamura K, 2001, ARCH BIOCHEM BIOPHYS, V395, P25, DOI 10.1006/abbi.2001.2569; Neubauer O, 1907, H-S Z PHYSIOL CHEM, V52, P375, DOI 10.1515/bchm2.1907.52.3-4.375; NORTHROP DB, 1981, J AM CHEM SOC, V103, P1208, DOI 10.1021/ja00395a035; NORTHROP DB, 1981, BIOCHEMISTRY-US, V20, P4056, DOI 10.1021/bi00517a017; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; NOSHIRO M, 1978, J BIOCHEM, V83, P61, DOI 10.1093/oxfordjournals.jbchem.a131913; Nunoya K, 1999, J PHARMACOL EXP THER, V289, P437; OHAVER TC, 1976, ANAL CHEM, V48, P312, DOI 10.1021/ac60366a016; OKAZAKI O, 1993, J BIOL CHEM, V268, P1546; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; Ost TWB, 2004, J BIOL CHEM, V279, P48876, DOI 10.1074/jbc.M408601200; Palfey Bruce A., 2003, P203; Patten CJ, 1997, CARCINOGENESIS, V18, P1623, DOI 10.1093/carcin/18.8.1623; PETERSON JA, 1976, J BIOL CHEM, V251, P4010; PETERSON JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P654, DOI 10.1016/0003-9861(92)90738-I; PHILLIPS IR, 1985, P NATL ACAD SCI USA, V82, P983, DOI 10.1073/pnas.82.4.983; Pianezza ML, 1998, NATURE, V393, P750, DOI 10.1038/31623; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAJYALAKSHMI K, 1978, INDIAN J CHEM B, V16, P156; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; SEVRIOUKOVA IF, 1995, ARCH BIOCHEM BIOPHYS, V317, P397, DOI 10.1006/abbi.1995.1180; SHIMADA T, 1986, J BIOL CHEM, V261, P909; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; Soucek P, 1999, ARCH BIOCHEM BIOPHYS, V370, P190, DOI 10.1006/abbi.1999.1388; Soucek P, 1999, J CHROMATOGR B, V734, P23; Tan YZ, 1997, ARCH BIOCHEM BIOPHYS, V342, P82, DOI 10.1006/abbi.1997.9995; Tipson RS, 1944, J ORG CHEM, V9, P235, DOI 10.1021/jo01185a005; TYSON CA, 1972, J BIOL CHEM, V247, P5777; ULLRICH V, 1972, H-S Z PHYSIOL CHEM, V353, P1171, DOI 10.1515/bchm2.1972.353.2.1171; VANIERSEL MLPS, 1994, XENOBIOTICA, V24, P795, DOI 10.3109/00498259409043279; WALSH C, 1979, ENZYMATIC REACTION M, P368; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; YAMANO S, 1990, BIOCHEMISTRY-US, V29, P1322, DOI 10.1021/bi00457a031; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yamazaki H, 2002, PROTEIN EXPRES PURIF, V24, P329, DOI 10.1006/prep.2001.1578; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789; Yamazaki T, 1998, BIOCHEMISTRY-US, V37, P2800, DOI 10.1021/bi9715066; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; YANO JK, 2004, 15 INT S MICR DRUG O; YUN CH, 1991, MOL PHARMACOL, V40, P679; Yun CH, 2001, BIOCHEMISTRY-US, V40, P4521, DOI 10.1021/bi002906n; ZUBIA E, 1992, TETRAHEDRON, V48, P4239, DOI 10.1016/S0040-4020(01)92200-8	109	74	75	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12279	12291		10.1074/jbc.M411019200	http://dx.doi.org/10.1074/jbc.M411019200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15665333	hybrid			2022-12-25	WOS:000227922000027
J	Bourguignon, LYW; Gilad, E; Rothman, K; Peyrollier, K				Bourguignon, LYW; Gilad, E; Rothman, K; Peyrollier, K			Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA TRANSMEMBRANE GLYCOPROTEIN; TUMOR-CELL MIGRATION; CD44 INTERACTION; ESTROGEN-RECEPTOR; CYCLIN D1; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; SMALL GTPASES; IP3 RECEPTOR; RHO GTPASES	In this study, we have examined the interaction of hyaluronan (HA)-CD44 with IQGAP1 (one of the binding partners for the Rho GTPase Cdc42) in SK-OV-3.ipl human ovarian tumor cells. Immunological and biochemical analyses indicated that IQGAP1 (molecular mass of similar to 190 kDa) is expressed in SK-OV-3.ipl cells and that IQGAP1 interacts directly with Cdc42 in a GTP-dependent manner. Both IQGAP1 and Cdc42 were physically linked to CD44 in SK-OV-3.ipl cells following HA stimulation. Furthermore, the HA-CD44-induced Cdc42-IQGAP1 complex regulated cytoskeletal function via a close association with F-actin that led to ovarian tumor cell migration. In addition, the binding of HA to CD44 promoted the association of ERK2 with the IQGAP1 molecule, which stimulated both ERK2 phosphorylation and kinase activity. The activated ERK2 then increased the phosphorylation of both Elk-1 and estrogen receptor-alpha (ER alpha), resulting in Elk-1- and estrogen-responsive element-mediated transcriptional up-regulation. Down-regulation of IQGAP1 (by treating cells with IQGAP1-specific small interfering RNAs) not only blocked IQGAP1 association with CD44, Cdc42, F-actin, and ERK2 but also abrogated HA-CD44-induced cytoskeletal function, ERK2 signaling (e.g. ERK2 phosphorylation/activity, ERK2-mediated Elk-1/ER alpha phosphorylation, and Elk-1/ER alpha-specific transcriptional activation), and tumor cell migration. Taken together, these findings indicate that HA-CD44 interaction with IQGAP1 serves as a signal integrator by modulating Cdc42 cytoskeletal function, mediating Elk-1-specific transcriptional activation, and coordinating "cross-talk" between a membrane receptor ( CD44) and a nuclear hormone receptor (ER alpha) signaling pathway during ovarian cancer progression.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA.	lillyb@itsa.ucsf.edu			NCI NIH HHS [R01 CA66163, R01 CA 78633] Funding Source: Medline; NIAMS NIH HHS [P01 AR39448] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066163, R01CA078633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bali A, 2004, CLIN CANCER RES, V10, P5168, DOI 10.1158/1078-0432.CCR-03-0751; Barbieri F, 2004, ONCOLOGY-BASEL, V66, P310, DOI 10.1159/000078332; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Brill S, 1996, MOL CELL BIOL, V16, P4869; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CANNISTRA SA, 1995, CLIN CANCER RES, V1, P333; CANNISTRA SA, 1993, CANCER RES, V53, P3830; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Givant-Horwitz V, 2003, GYNECOL ONCOL, V91, P160, DOI 10.1016/S0090-8258(03)00434-7; GREEN SJ, 1988, EXP CELL RES, V178, P224, DOI 10.1016/0014-4827(88)90393-X; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Haslinger B, 2001, CELL TISSUE RES, V305, P79, DOI 10.1007/s004410100409; Havrilesky LJ, 2001, J SOC GYNECOL INVEST, V8, P104, DOI 10.1016/S1071-5576(01)00093-4; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katso RMT, 1997, CANCER METAST REV, V16, P81, DOI 10.1023/A:1005796307286; Kirker KR, 2002, BIOMATERIALS, V23, P3661, DOI 10.1016/S0142-9612(02)00100-X; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; LIAO HX, 1995, J IMMUNOL, V155, P3938; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; Luo Y, 2002, PHARM RES-DORDR, V19, P396, DOI 10.1023/A:1015170907274; Luo Y, 1999, BIOCONJUGATE CHEM, V10, P755, DOI 10.1021/bc9900338; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Nicosia SV, 2003, HEMATOL ONCOL CLIN N, V17, P927, DOI 10.1016/S0889-8588(03)00056-X; Parker MG, 1998, BIOCHEM SOC SYMP, P45; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; Steinmetz R, 2004, MOL ENDOCRINOL, V18, P2570, DOI 10.1210/me.2004-0082; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; UNDERHILL C, 1992, J CELL SCI, V103, P293; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Yeo TK, 1996, AM J PATHOL, V148, P1733; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342	81	130	137	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11961	11972		10.1074/jbc.M411985200	http://dx.doi.org/10.1074/jbc.M411985200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15655247	hybrid			2022-12-25	WOS:000227761800128
J	Flatley, J; Barrett, J; Pullan, ST; Hughes, MN; Green, J; Poole, RK				Flatley, J; Barrett, J; Pullan, ST; Hughes, MN; Green, J; Poole, RK			Transcriptional responses of Escherichia coli to S-nitrosoglutathione under defined chemostat conditions reveal major changes in methionine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE DIOXYGENASE; HYBRID-CLUSTER PROTEIN; SIGNAL-TRANSDUCTION; NITROSATIVE STRESS; GENE-EXPRESSION; REDUCTASE; NITROGEN; DETOXIFICATION; GROWTH; NORR	Nitric oxide and nitrosating agents exert powerful antimicrobial effects and are central to host defense and signal transduction. Nitric oxide and S-nitrosothiols can be metabolized by bacteria, but only a few enzymes have been shown to be important in responses to such stresses. Glycerol-limited chemostat cultures in defined medium of Escherichia coli MG1655 were used to provide bacteria in defined physiological states before applying nitrosative stress by addition of S-nitrosoglutathione (GSNO). Exposure to 200 mu M GSNO for 5 min was sufficient to elicit an adaptive response as judged by the development of NO-insensitive respiration. Transcriptome profiling experiments were used to investigate the transcriptional basis of the observed adaptation to the presence of GSNO. In aerobic cultures, only 17 genes were significantly up-regulated, including genes known to be involved in NO tolerance, particularly hmp (encoding the NO-consuming flavohemoglobin Hmp) and norV (encoding flavorubredoxin). Significantly, none of the up-regulated genes were members of the Fur regulon. Six genes involved in methionine biosynthesis or regulation were significantly up-regulated; metN, metI, and metR were shown to be important for GSNO tolerance, because mutants in these genes exhibited GSNO growth sensitivity. Furthermore, exogenous methionine abrogated the toxicity of GSNO supporting the hypothesis that GSNO nitrosates homocysteine, thereby withdrawing this intermediate from the methionine biosynthetic pathway. Anaerobically, 10 genes showed significant upregulation, of which norV, hcp, metR, and metB were also up-regulated aerobically. The data presented here reveal new genes important for nitrosative stress tolerance and demonstrate thatmethionine biosynthesis is a casualty of nitrosative stress.	Univ Sheffield, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England; Kings Coll London, Dept Chem, London WC2R 2LS, England	University of Sheffield; University of London; King's College London	Poole, RK (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Western Bank, Firth Court, Sheffield S10 2TN, S Yorkshire, England.	r.poole@sheffield.ac.uk		Pullan, Steven/0000-0002-8983-599X	Biotechnology and Biological Sciences Research Council [P18939] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; Castro LA, 1998, ARCH BIOCHEM BIOPHYS, V359, P215, DOI 10.1006/abbi.1998.0898; CECCHINI G, 1986, J BIOL CHEM, V261, P1808; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; D'Autreaux B, 2002, P NATL ACAD SCI USA, V99, P16619, DOI 10.1073/pnas.252591299; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; DEMPLE B, 1983, NATURE, V304, P466, DOI 10.1038/304466a0; Ding HG, 2000, P NATL ACAD SCI USA, V97, P5146, DOI 10.1073/pnas.97.10.5146; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; Escolar L, 1997, MOL MICROBIOL, V26, P799, DOI 10.1046/j.1365-2958.1997.6211987.x; Fillebeen C, 2002, REDOX REP, V7, P15, DOI 10.1179/135100002125000136; Gardner AM, 2003, J BIOL CHEM, V278, P10081, DOI 10.1074/jbc.M212462200; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; GARLAND PB, 1962, NATURE, V196, P987, DOI 10.1038/196987a0; Gomes CM, 2002, J BIOL CHEM, V277, P25273, DOI 10.1074/jbc.M203886200; GREENE RC, 1996, ESCHERICHIA COLI SAL, P542; HADDOCK BA, 1976, BIOCHEM J, V154, P285, DOI 10.1042/bj1540285; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hidalgo E, 1997, TRENDS BIOCHEM SCI, V22, P207, DOI 10.1016/S0968-0004(97)01068-2; Hua Q, 2004, APPL ENVIRON MICROB, V70, P2354, DOI 10.1128/AEM.70.4.2354-2366.2004; HUBBARD JAM, 1986, ARCH MICROBIOL, V146, P80, DOI 10.1007/BF00690163; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; HUGHES MN, 1991, J GEN MICROBIOL, V137, P725, DOI 10.1099/00221287-137-4-725; Hutchings MI, 2002, J BACTERIOL, V184, P4640, DOI 10.1128/JB.184.16.4640-4643.2002; JUSTINO MC, 2004, J BIOL CHEM; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Membrillo-Hernandez J, 1998, MOL MICROBIOL, V29, P1101, DOI 10.1046/j.1365-2958.1998.01000.x; Merlin C, 2002, J BACTERIOL, V184, P5513, DOI 10.1128/JB.184.19.5513-5517.2002; Mills CE, 2001, BIOCHEM J, V353, P207, DOI 10.1042/0264-6021:3530207; Moore CM, 2004, J BACTERIOL, V186, P4655, DOI 10.1128/JB.186.14.4655-4664.2004; Mukhopadhyay P, 2004, P NATL ACAD SCI USA, V101, P745, DOI 10.1073/pnas.0307741100; Patel RP, 1999, BBA-BIOENERGETICS, V1411, P385, DOI 10.1016/S0005-2728(99)00028-6; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; Poock SR, 2002, J BIOL CHEM, V277, P23664, DOI 10.1074/jbc.M200731200; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Rozen S, 2000, Methods Mol Biol, V132, P365; Sambrook J, 2001, MOL CLONING LAB MANU; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; St John G, 2001, P NATL ACAD SCI USA, V98, P9901; Stevanin TM, 2000, J BIOL CHEM, V275, P35868, DOI 10.1074/jbc.M002471200; van den Berg WAM, 2000, EUR J BIOCHEM, V267, P666, DOI 10.1046/j.1432-1327.2000.01032.x; Wolfe MT, 2002, J BACTERIOL, V184, P5898, DOI 10.1128/JB.184.21.5898-5902.2002; WU G, 2004, RESPIRATION ARCHAEA, V1, P251; Wu GH, 2003, ADV MICROB PHYSIOL, V47, P255, DOI 10.1016/S0065-2911(03)47005-7	51	100	105	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10065	10072		10.1074/jbc.M410393200	http://dx.doi.org/10.1074/jbc.M410393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647275	hybrid			2022-12-25	WOS:000227559600041
J	Rodriguez, A; Martinez-Martinez, S; Lopez-Maderuelo, D; Ortega-Perez, I; Redondo, JM				Rodriguez, A; Martinez-Martinez, S; Lopez-Maderuelo, D; Ortega-Perez, I; Redondo, JM			The linker region joining the catalytic and the regulatory domains of CnA is essential for binding to NFAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; CYCLOSPORINE-A; CALCINEURIN; TARGET	Calcineurin (CN) is an important regulator of developmental processes and in adults controls the immune response through its regulation of nuclear factor of activated T cells (NFAT). The physical interaction between CN and NFATs is an essential step in the activation of NFAT-dependent genes by calcium signals. Using deletional and substitutional analyses, we have identified a 13-amino acid region within CN that is essential for the interaction with NFAT and with two other CN-binding proteins, AKAP79 and Cabin-1. The interaction of CN with these proteins is selectively disrupted by substitution of specific amino acid residues within this region, indicating that NFAT and other CN-interacting proteins bind differentially to CN. This selectivity suggests that the region identified in CN could be a potential molecular target for immunosuppressive and other therapeutic interventions in diseases involving the CN/NFAT pathway.	CNIC, Madrid 28760, Spain; Univ Autonoma Madrid, CSIC, CBM, E-28049 Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Redondo, JM (corresponding author), CNIC, Ronda Poniente 5, Madrid 28760, Spain.	jmredondo@cbm.uam.es	Marquez, Antonio A. Rodriguez/L-2422-2013; Redondo, Juan Miguel/H-6351-2015	Marquez, Antonio A. Rodriguez/0000-0003-2455-6583; Redondo, Juan Miguel/0000-0001-5779-9122				Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Dell'Acqua ML, 2002, J BIOL CHEM, V277, P48796, DOI 10.1074/jbc.M207833200; Dodge KL, 2003, BIOCHEM BIOPH RES CO, V311, P1111, DOI 10.1016/j.bbrc.2003.09.040; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Jiang B, 1999, J BIOL CHEM, V274, P18543, DOI 10.1074/jbc.274.26.18543; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Li HM, 2004, J MOL BIOL, V342, P1659, DOI 10.1016/j.jmb.2004.07.068; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu JO, 2003, BIOCHEM BIOPH RES CO, V311, P1103, DOI 10.1016/j.bbrc.2003.10.020; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rodriguez A, 1999, ANAL BIOCHEM, V272, P171, DOI 10.1006/abio.1999.4156; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0	20	25	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9980	9984		10.1074/jbc.C400401200	http://dx.doi.org/10.1074/jbc.C400401200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15671033	hybrid			2022-12-25	WOS:000227559600030
J	Neben, K; Schnittger, S; Brors, B; Tews, B; Kokocinski, F; Haferlach, T; Muller, J; Hahn, M; Hiddemann, W; Eils, R; Lichter, P; Schoch, C				Neben, K; Schnittger, S; Brors, B; Tews, B; Kokocinski, F; Haferlach, T; Muller, J; Hahn, M; Hiddemann, W; Eils, R; Lichter, P; Schoch, C			Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype	ONCOGENE			English	Article						acute myeloid leukemia; normal karyotype; gene expression profiling; FLT3-activating mutations; NRAS-activating mutations	INTERNAL TANDEM DUPLICATION; HIGH-DOSE CYTARABINE; PROGNOSTIC-SIGNIFICANCE; NORMAL CYTOGENETICS; ADULT PATIENTS; AML 10; FLT3; APOPTOSIS; IDENTIFY; CYCLE	In acute myeloid leukemia (AML), constitutive activation of the FLT3 receptor tyrosine kinase, either by internal tandem duplications (FLT3-ITD) of the juxtamembrane region or by point mutations in the second tyrosine kinase domain (FLT3-TKD), as well as point mutations of the NRAS gene (NRAS-PM) are among the most frequent somatic gene mutations. To elucidate whether these mutations cause aberrant signal transduction in AML, we used gene expression pro. ling in a series of 110 newly diagnosed AML patients with normal karyotype. The different algorithms used for data analysis revealed highly concordant sets of genes, indicating that the identified gene signatures are specific for each analysed subgroup. Whereas samples with FLT3-ITD and FLT3-TKD could be separated with up to 100% accuracy, this did not apply for NRAS-PM and wild-type samples, suggesting that only FLT3-ITD and FLT3-TKD are associated with an apparent signature in AML. The set of discriminating genes included several known genes, which are involved in cell cycle control (CDC14A, WEE1), gene transcription (HOXB5, FOXA1), and signal transduction (SMG1). In conclusion, we showed that unique gene expression patterns can be correlated with FLT3-ITD and FLT3-TKD. This might lead to the identification of further pathogenetic relevant candidate genes particularly in AML with normal karyotype.	Deutsch Krebsforschungszentrum, Div Mol Genet B060, D-69120 Heidelberg, Germany; Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Lab Leukemia Diagnost, D-81366 Munich, Germany; Deutsch Krebsforschungszentrum, Div Intelligent Bioinformat Syst B080, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ)	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Genet B060, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	k.neben@dkfz.de	Eils, Roland/B-6121-2009; Brors, Benedikt/E-5620-2013	Eils, Roland/0000-0002-0034-4036; Brors, Benedikt/0000-0001-5940-3101; Kokocinski, Felix/0000-0002-8472-9207				BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Bishop C. M., 1995, NEURAL NETWORKS PATT; Bloomfield CD, 1998, CANCER RES, V58, P4173; Buchner T, 2003, J CLIN ONCOL, V21, P4496, DOI 10.1200/JCO.2003.02.133; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Dohner K, 2002, J CLIN ONCOL, V20, P3254, DOI 10.1200/JCO.2002.09.088; Epstein DJ, 1999, DEVELOPMENT, V126, P281; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Griswold IJ, 2004, BLOOD, V104, P2912, DOI 10.1182/blood-2003-05-1669; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Kelly LM, 2002, CANCER CELL, V1, P421, DOI 10.1016/S1535-6108(02)00070-3; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Korshunov A, 2003, AM J PATHOL, V163, P1721, DOI 10.1016/S0002-9440(10)63530-4; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Li YW, 2004, BLOOD, V104, P1137, DOI 10.1182/blood-2003-07-2585; Lin L, 2002, CANCER RES, V62, P5273; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Mitelman F, 1995, INT SYSTEM HUMAN CYT; Nabney I, 2002, NETLAB ALGORITHMS PA; Neben K, 2004, CANCER RES, V64, P3103, DOI 10.1158/0008-5472.CAN-03-3968; NEUBAUER A, 1994, BLOOD, V83, P1603; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ragg T, 2002, AI COMMUN, V15, P61; Reuter CWM, 2000, BLOOD, V96, P1655, DOI 10.1182/blood.V96.5.1655.h8001655_1655_1669; Schnittger S, 2000, LEUKEMIA, V14, P796, DOI 10.1038/sj.leu.2401773; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	42	54	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1580	1588		10.1038/sj.onc.1208344	http://dx.doi.org/10.1038/sj.onc.1208344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674343				2022-12-25	WOS:000227218200011
J	Bechmann, I; Goldmann, J; Kovac, AD; Kwidzinski, E; Simburger, E; Naftolin, F; Dirnagl, U; Nitsch, R; Priller, J				Bechmann, I; Goldmann, J; Kovac, AD; Kwidzinski, E; Simburger, E; Naftolin, F; Dirnagl, U; Nitsch, R; Priller, J			Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transform into microglia	FASEB JOURNAL			English	Article						glial fibrillary acidic protein; caspase inhibitors	CENTRAL-NERVOUS-SYSTEM; GREEN FLUORESCENT PROTEIN; ENTORHINAL CORTEX LESION; MARROW-DERIVED CELLS; ADHESION MOLECULE EXPRESSION; BLOOD-BRAIN-BARRIER; RAT FASCIA-DENTATA; WALLERIAN DEGENERATION; HEMATOPOIETIC-CELLS; GLIAL-CELLS	In this study, we demonstrate the infiltration of blood-derived monocytic cells and their morphologic transformation into microglia in zones of acute, anterograde ( Wallerian) axonal degeneration induced by entorhinal cortex lesion (ECL). ECL was performed in mice which had received green fluorescent protein (GFP)-transduced bone marrow grafts allowing identification of blood-derived elements within the brain. While in the unlesioned hemisphere GFP(+) cells were restricted to perivascular and leptomeningeal sites, many round fluorescent cells appeared in hippocampal zones of axonal degeneration at 24 h post lesion (hpl). Within 72 hpl, these GFP(+) cells acquired ramified, microglia-like morphologies, which persisted for at least 7 days post ECL. Differentiation of GFP(+) cells into glial fibrillary acidic protein (GFAP)(+) astrocytes was never observed. To exclude that this recruitment is an artifact of irradiation or bone marrow transplantation, the fluorescent cell tracker 6-carboxylfluorescein diacetate (CFDA) was injected into spleens of normal mice 1 day before ECL. Again, fluorescent cells appeared at the lesion site and along the layers of axonal degeneration at 48 hpl and CFDA(+)/ MAC-1(+), cells exhibited amoeboid and ramified morphologies. Thus, blood-derived cells infiltrate not only the site of mechanical lesion, but also the layers of anterograde axonal degeneration, where they readily transform into microglia-like elements. A role for infiltrating leukocytes in facilitating or modulating postlesional plasticity, e.g., by phagocytosis of growth-inhibiting myelin should now be considered. Moreover, monocytic cells may serve as vehicles to transport therapeutic substances such as neurotrophic factors or caspase inhibitors to zones of axonal degeneration.	Charite, Ctr Anat, Inst Cell Biol & Neurobiol, D-10098 Berlin, Germany; Carl Zeiss Jena GmbH Div, Adv Imaging Microscopy, Jena, Germany; Yale Univ, Dept Obstet & Gynecol, New Haven, CT USA; Charite, Dept Neurol, D-10098 Berlin, Germany; Charite, Dept Psychiat, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Carl Zeiss AG; Yale University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Bechmann, I (corresponding author), Charite, Ctr Anat, Inst Cell Biol & Neurobiol, D-10098 Berlin, Germany.	ingo.bechmann@charite.de	Priller, Josef/ABW-3835-2022; Nitsch, Robert/AAI-9129-2021	Glumm, Jana/0000-0001-5756-3718; Dirnagl, Ulrich/0000-0003-0755-6119; Priller, Josef/0000-0001-7596-0979				Babcock AA, 2003, J NEUROSCI, V23, P7922; Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y; Bechmann I, 1997, HISTOCHEM CELL BIOL, V107, P391, DOI 10.1007/s004180050125; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Bechmann I, 2002, J NEUROIMMUNOL, V132, P60, DOI 10.1016/S0165-5728(02)00311-9; Bechmann I, 2001, EXP NEUROL, V168, P242, DOI 10.1006/exnr.2000.7618; Bechmann I, 2001, EUR J NEUROSCI, V14, P1651, DOI 10.1046/j.0953-816x.2001.01793.x; BECHMANN I, 2004, NEUROGLIA, P302; Beck H, 2003, J CEREBR BLOOD F MET, V23, P709, DOI 10.1097/01.WCB.0000065940.18332.8D; Buss A, 2003, GLIA, V42, P424, DOI 10.1002/glia.10220; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; de Vos AF, 2002, J IMMUNOL, V169, P5415, DOI 10.4049/jimmunol.169.10.5415; Deller T, 1997, NEUROSCIENCE, V81, P829, DOI 10.1016/S0306-4522(97)00194-2; Deller T, 2001, RESTOR NEUROL NEUROS, V19, P159; Dong JH, 2004, GLIA, V47, P102, DOI 10.1002/glia.10355; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Eglitis MA, 1999, NEUROREPORT, V10, P1289, DOI 10.1097/00001756-199904260-00025; Eyupoglu IY, 2003, FASEB J, V17, P1110, DOI 10.1096/fj.02-0825fje; FAGAN AM, 1994, NEUROSCIENCE, V58, P705, DOI 10.1016/0306-4522(94)90449-9; Finsen B, 1999, ADV EXP MED BIOL, V468, P157; Frotscher M, 1997, TRENDS NEUROSCI, V20, P218, DOI 10.1016/S0166-2236(96)01018-1; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; GRIFFIN JW, 1992, J NEUROIMMUNOL, V40, P153, DOI 10.1016/0165-5728(92)90129-9; Haas CA, 1999, J NEUROSCI, V19, P9953; Hailer NP, 1997, EUR J NEUROSCI, V9, P863, DOI 10.1111/j.1460-9568.1997.tb01436.x; Hailer NP, 1999, EUR J NEUROSCI, V11, P3359, DOI 10.1046/j.1460-9568.1999.00808.x; Hailer NP, 1998, BRAIN PATHOL, V8, P459; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hailer NP, 1997, HIPPOCAMPUS, V7, P341, DOI 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; JENSEN MB, 1994, EXP BRAIN RES, V98, P245; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kovac AD, 2004, BRAIN PATHOL, V14, P249; KRALL WJ, 1994, BLOOD, V83, P2737; KREUTZBERG GW, 1978, J NEUROCYTOL, V7, P601, DOI 10.1007/BF01260892; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Li YQ, 2004, RADIAT RES, V161, P143, DOI 10.1667/RR3117; LYNCH G, 1972, BRAIN RES, V42, P311, DOI 10.1016/0006-8993(72)90533-1; McMahon EJ, 2002, J NEUROIMMUNOL, V130, P32, DOI 10.1016/S0165-5728(02)00205-9; NITSCH R, 1991, BRAIN RES, V554, P304, DOI 10.1016/0006-8993(91)90205-A; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; NITSCH R, 1993, HIPPOCAMPUS, V3, P481, DOI 10.1002/hipo.450030409; PAPALINO O, 1998, NAT MED, V4, P814; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Ramirez JJ, 2001, RESTOR NEUROL NEUROS, V19, P237; RENNO T, 1995, J IMMUNOL, V154, P944; Samms M, 2001, CELL IMMUNOL, V212, P16, DOI 10.1006/cimm.2001.1836; Schilling M, 2003, EXP NEUROL, V183, P25, DOI 10.1016/S0014-4886(03)00082-7; SCHMIDTMAYER J, 1994, GLIA, V12, P259, DOI 10.1002/glia.440120403; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; SIMARD AR, 2004, FASEB J         0414; Skutella T, 2001, TRENDS NEUROSCI, V24, P107, DOI 10.1016/S0166-2236(00)01717-3; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; THANOS S, 1991, NEUROSCI LETT, V127, P108, DOI 10.1016/0304-3940(91)90906-A; Thon N, 2000, EUR J NEUROSCI, V12, P2547, DOI 10.1046/j.1460-9568.2000.00109.x; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Vallieres L, 2003, J NEUROSCI, V23, P5197; Wehner T, 2003, J NEUROSCI, V23, P5004; Yuan H, 2003, BRAIN RES, V969, P59, DOI 10.1016/S0006-8993(03)02278-9	65	92	96	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					647	+		10.1096/fj.04-2599fje	http://dx.doi.org/10.1096/fj.04-2599fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15671154				2022-12-25	WOS:000226576600008
J	Chinami, M; Yano, Y; Yang, X; Salahuddin, S; Moriyama, K; Shiroishi, M; Turner, H; Shirakawa, T; Adra, CN				Chinami, M; Yano, Y; Yang, X; Salahuddin, S; Moriyama, K; Shiroishi, M; Turner, H; Shirakawa, T; Adra, CN			Binding of HTm4 to cyclin-dependent kinase (cdk)-associated phosphatase (KAP)center dot cdk2 center dot cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP dephosphorylation of cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; BETA-SUBUNIT; FAMILY; IDENTIFICATION; INHIBITORS; EXPRESSION; CLONING; CANCER; CD20	Cyclin-dependent kinase 2 (cdk2) activation requires phosphorylation of Thr(160) and dissociation from cyclin A. The T-loop of cdk2 contains a regulatory phosphorylation site at Thr(160). An interaction between cdc-associated phosphatase (KAP) and cdk2 compromises the interaction between cdk2 and cyclin A, which permits access of KAP, a Thr(160)-directed phosphatase, to its substrate, cdk2. We have reported that KAP is bound and activated by a nuclear membrane protein, HTm4. Here, we present in vitro data showing the direct interaction between the HTm4 C terminus and KAP Tyr(141). We show that this interaction not only facilitates access of KAP to Thr(160) and accelerates KAP kinetics, but also forces exclusion of cyclin A from the KAP.cdk2 complex.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Kyushu Womens Univ, Dept Nutr, Kitakyushu, Fukuoka 8078586, Japan; Harvard Univ, Sch Med, Childrens Hosp, Dept Med, Boston, MA 02215 USA; Fukuoka Dent Sch, Dept Internal Med, Fukuoka 8140193, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Queens Med Ctr, Queens Ctr Biomed Res, Honolulu, HI 96813 USA; Kyoto Univ, Grad Sch Publ Hlth, Dept Hlth Promot & Human Behav, Kyoto 6068501, Japan; RIKEN SNP Typing Ctr, Tokyo 1088639, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Fukuoka Dental College (FDC); Kyushu University; The Queen's Medical Center; Kyoto University; RIKEN	Adra, CN (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, 99 Brookline Ave, Boston, MA 02215 USA.	cadra@caregroup.harvard.edu		Shiroishi, Mitsunori/0000-0002-3133-157X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043663] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 43663] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADRA CN, 1994, P NATL ACAD SCI USA, V91, P10178, DOI 10.1073/pnas.91.21.10178; Barnhill JC, 2004, J CELL BIOCHEM, V91, P808, DOI 10.1002/jcb.10775; Donato JL, 2002, J CLIN INVEST, V109, P51, DOI 10.1172/JCI14025; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HARPER JW, 1993, CELL, V75, P805; Hulett MD, 2001, IMMUNOL CELL BIOL, V79, P345, DOI 10.1046/j.1440-1711.2001.01017.x; Ishibashi K, 2001, GENE, V264, P87, DOI 10.1016/S0378-1119(00)00598-9; Kutok JL, 2005, J MOL HISTOL, V36, P77, DOI 10.1007/s10735-004-3913-8; Lee SW, 2000, MOL CELL BIOL, V20, P1723, DOI 10.1128/MCB.20.5.1723-1732.2000; Liang YH, 2001, GENOMICS, V72, P119, DOI 10.1006/geno.2000.6472; Liang YH, 2001, IMMUNOGENETICS, V53, P357, DOI 10.1007/s002510100339; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; TSAI LH, 1993, ONCOGENE, V8, P1593; Yeh CT, 2003, BIOCHEM BIOPH RES CO, V305, P311, DOI 10.1016/S0006-291X(03)00757-5	22	24	27	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17235	17242		10.1074/jbc.M413437200	http://dx.doi.org/10.1074/jbc.M413437200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15671017	hybrid			2022-12-25	WOS:000228615500086
J	Hijazi, N; Kariv-Inbal, Z; Gasset, M; Gabizon, R				Hijazi, N; Kariv-Inbal, Z; Gasset, M; Gabizon, R			PrPSc incorporation to cells requires endogenous glycosaminoglycan expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-INFECTED HAMSTERS; CELLULAR PRION PROTEIN; CONGO RED; INCUBATION PERIOD; SURFACE RECEPTOR; LAMININ RECEPTOR; CULTURED-CELLS; RESISTANT; MICE; IDENTIFICATION	Many lines of evidence suggest an interaction between glycosaminoglycans (GAGs) and the PrP proteins as well as a possible role for GAGs in prion disease pathogenesis. In this work, we sought to determine whether the PrP-GAG interaction affects the incorporation of PrPSc (the scrapie isoform of PrP) to normal cells. This may be the first step in prion disease pathogenesis. To this effect, we incubated proteinase K-digested hamster scrapie brain homogenates with several lines of Chinese hamster ovary (CHO) cells in the presence or absence of heparin. Our results show that over a large range of PrPSc concentrations the binding of PrPSc to wild type CHO cells, which do not express detectable PrP, was equivalent to the binding of PrPSc to CHO cells overexpressing PrP. A significant part of PrPSc binding to both lines could be inhibited by heparin. Additional evidence that PrPSc binding to cells was dependent on the presence of GAGs could be concluded from the fact that the binding of PrPSc to CHO cells missing GAGs on the cell surface was significantly reduced. Interestingly, preincubation of scrapie brain homogenate with heparin before intraperitoneal inoculation into normal hamsters resulted in a significant delay in prion disease manifestation.	Hadassah Univ Hosp, Dept Neurol, Agnes Ginges Ctr Human Neurogenet, IL-91120 Jerusalem, Israel; Consejo Super Invest Cient, Inst Quim Fis Rocasolano, Madrid 28006, Spain	Hebrew University of Jerusalem; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Gabizon, R (corresponding author), Hadassah Univ Hosp, Dept Neurol, Agnes Ginges Ctr Human Neurogenet, IL-91120 Jerusalem, Israel.	gabizonr@hadassah.org.il	Gasset, Maria/I-2050-2014; Gasset, Maria/K-4339-2012	Gasset, Maria/0000-0001-6436-4055; Gasset, Maria/0000-0001-6436-4055				BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; Beringue V, 2000, J VIROL, V74, P5432, DOI 10.1128/JVI.74.12.5432-5440.2000; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Caspi S, 1998, J BIOL CHEM, V273, P3484, DOI 10.1074/jbc.273.6.3484; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; DeArmond SJ, 2003, CLIN LAB MED, V23, P1, DOI 10.1016/S0272-2712(02)00041-0; Diaz-Nido J, 2002, PEPTIDES, V23, P1323, DOI 10.1016/S0196-9781(02)00068-2; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; ELIMOVA E, 2004, FASEB J; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Hijazi N, 2003, BRAIN RES, V993, P192, DOI 10.1016/j.brainres.2003.09.014; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; INGROSSO L, 1995, J VIROL, V69, P506, DOI 10.1128/JVI.69.1.506-508.1995; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Leucht C, 2003, EMBO REP, V4, P290, DOI 10.1038/sj.embor.embor768; May BCH, 2004, TRENDS BIOCHEM SCI, V29, P162, DOI 10.1016/j.tibs.2004.02.008; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Peters PJ, 2003, J CELL BIOL, V162, P703, DOI 10.1083/jcb.200304140; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Schonberger O, 2003, BIOCHEM BIOPH RES CO, V312, P473, DOI 10.1016/j.bbrc.2003.10.150; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; Shaked GM, 2001, J BIOL CHEM, V276, P14324, DOI 10.1074/jbc.M007815200; SNOW AD, 1990, LAB INVEST, V63, P601; Tatzelt J, 1998, CELL MOL NEUROBIOL, V18, P721, DOI 10.1023/A:1020282205041; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Yanai A, 1999, FEBS LETT, V460, P11, DOI 10.1016/S0014-5793(99)01316-2; Yehiely F, 1997, NEUROBIOL DIS, V3, P339, DOI 10.1006/nbdi.1997.0130	35	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17057	17061		10.1074/jbc.M411314200	http://dx.doi.org/10.1074/jbc.M411314200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15668233	hybrid			2022-12-25	WOS:000228615500063
J	Zaccagnini, G; Gaetano, C; Della Pietra, L; Nanni, S; Grasselli, A; Mangoni, A; Benvenuto, R; Fabrizi, M; Truffa, S; Germani, A; Moretti, F; Pontecorvi, A; Sacchi, A; Bacchetti, S; Capogrossi, MC; Farsetti, A				Zaccagnini, G; Gaetano, C; Della Pietra, L; Nanni, S; Grasselli, A; Mangoni, A; Benvenuto, R; Fabrizi, M; Truffa, S; Germani, A; Moretti, F; Pontecorvi, A; Sacchi, A; Bacchetti, S; Capogrossi, MC; Farsetti, A			Telomerase mediates vascular endothelial growth factor-dependent responsiveness in a rat model of hind limb ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMOPERFUSED SKELETAL-MUSCLE; CELL-PROLIFERATION; GENE-TRANSFER; LIFE-SPAN; IN-VIVO; EXPRESSION; ANGIOGENESIS; REGENERATION; SURVIVAL; MICROVASCULATURE	Telomere dysfunction contributes to reduced cell viability, altered differentiation, and impaired regenerative/proliferative responses. Recent advances indicate that telomerase activity confers a pro-angiogenic phenotype to endothelial cells and their precursors. We have investigated whether telomerase contributes to tissue regeneration following hind limb ischemia and vascular endothelial growth factor 165 (VEGF(165)) treatment. VEGF delivery induced angiogenesis and increased expression of the telomerase reverse transcriptase (TERT) and telomerase activity in skeletal muscles and satellite and endothelial cells. Adenovirus-mediated transfer of wild type TERT but not of a dominant negative mutant, TERTdn, significantly induced capillary but not arteriole formation. However, when co-delivered with VEGF, TERTdn abrogated VEGF-dependent angiogenesis, arteriogenesis, and blood flow increase. This effect was paralleled by in vitro evidence that telomerase inhibition by 3'-azido-3'-deoxythymidine in VEGF-treated endothelial cells strongly reduced capillary density and promoted apoptosis in the absence of serum. Similar results were obtained with adenovirus-mediated expression of TERTdn and AKTdn, both reducing endogenous TERT activity and angiogenesis on Matrigel. Mechanistically, neo-angiogenesis in our system involved: (i) VEGF-dependent activation of telomerase through the nitric oxide pathway and (ii) telomerase-dependent activation of endothelial cell differentiation and protection from apoptosis. Furthermore, detection of TERT in activated satellite cells identified them as VEGF targets during muscle regeneration. Because TERT behaves as an angiogenic factor and a downstream effector of VEGF signaling, telomerase activity appears required for VEGF-dependent remodeling of ischemic tissue at the capillaries and arterioles level.	Regina Elena Inst Canc Res, CRS, Dept Expt Oncol, Mol Oncogenesis Lab, I-00158 Rome, Italy; Cardiol Ctr I Monzino, Lab Vasc Biol & Gene Therapy, I-20138 Milan, Italy; Ist Dermopat Immacolata, Lab Vasc Pathol, I-00167 Rome, Italy; Univ Sacred Heart, Inst Med Pathol, I-00168 Rome, Italy; CNR, Inst Neurobiol & Mol Med, I-00137 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR)	Farsetti, A (corresponding author), Regina Elena Inst Canc Res, CRS, Dept Expt Oncol, Mol Oncogenesis Lab, Via Messi Oro 156, I-00158 Rome, Italy.	farsetti@ifo.it	Gaetano, Carlo/P-9997-2019; Moretti, Fabiola/I-5647-2013; Zaccagnini, Germana/J-7722-2016; Farsetti, Antonella/I-8710-2018	Gaetano, Carlo/0000-0002-5238-1832; Moretti, Fabiola/0000-0002-2691-1254; Zaccagnini, Germana/0000-0002-9441-4735; Farsetti, Antonella/0000-0002-8603-7925				BAUTERS C, 1994, AM J PHYSIOL-HEART C, V267, pH1263, DOI 10.1152/ajpheart.1994.267.4.H1263; BODINEFOWLER S, 1994, J VOICE, V8, P53, DOI 10.1016/S0892-1997(05)80319-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CHADENEAU C, 1995, ONCOGENE, V11, P893; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Chang E, 2002, J INVEST DERMATOL, V118, P752, DOI 10.1046/j.1523-1747.2002.01714.x; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Emanueli C, 2000, ARTERIOSCL THROM VAS, V20, P2379, DOI 10.1161/01.ATV.20.11.2379; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Germani A, 2003, AM J PATHOL, V163, P1417, DOI 10.1016/S0002-9440(10)63499-2; Giampietri C, 2000, CELL DEATH DIFFER, V7, P292, DOI 10.1038/sj.cdd.4400654; Gowdak LHW, 2000, CIRCULATION, V102, P565; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Isner JM, 1998, AM J CARDIOL, V82, p63S, DOI 10.1016/S0002-9149(98)00764-4; Isner JM, 2000, J INVASIVE CARDIOL, V12, p14A; JENNISCHE E, 1986, ACTA PHYSIOL SCAND, V128, P409, DOI 10.1111/j.1748-1716.1986.tb07994.x; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61; Larrivee B, 2000, INT J MOL MED, V5, P447; Leri A, 2003, EMBO J, V22, P131, DOI 10.1093/emboj/cdg013; Leri A, 2001, P NATL ACAD SCI USA, V98, P8626, DOI 10.1073/pnas.151013298; LOUD AV, 1984, LAB INVEST, V50, P250; Maida Y, 2002, ONCOGENE, V21, P4071, DOI 10.1038/sj.onc.1205509; MATSUMOTO T, 2001, SCI STKE; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; MUHLHAUSER J, 1995, CIRC RES, V77, P1077, DOI 10.1161/01.RES.77.6.1077; Murasawa S, 2002, CIRCULATION, V106, P1133, DOI 10.1161/01.CIR.0000027584.85865.B4; Namba T, 2003, CIRCULATION, V108, P2250, DOI 10.1161/01.CIR.0000093190.53478.78; Oh H, 2002, J MOL CELL CARDIOL, V34, P717, DOI 10.1006/jmcc.2002.2018; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Strahl C, 1996, MOL CELL BIOL, V16, P53; Teupe C, 2002, CIRCULATION, V105, P1104, DOI 10.1161/hc0902.104720; TORELLA D, 2004, CIRC RES, V15, P15; Trivier E, 2004, ANN NY ACAD SCI, V1019, P111, DOI 10.1196/annals.1297.020; Vale P R, 2001, J Interv Cardiol, V14, P511, DOI 10.1111/j.1540-8183.2001.tb00367.x; Vasa M, 2000, CIRC RES, V87, P540, DOI 10.1161/01.RES.87.7.540; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yang JW, 2001, NAT BIOTECHNOL, V19, P219, DOI 10.1038/85655; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375	45	60	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14790	14798		10.1074/jbc.M414644200	http://dx.doi.org/10.1074/jbc.M414644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15687494	hybrid			2022-12-25	WOS:000228236800056
J	Humtsoe, JO; Kim, JK; Xu, Y; Keene, DR; Hook, M; Lukomski, S; Wary, KK				Humtsoe, JO; Kim, JK; Xu, Y; Keene, DR; Hook, M; Lukomski, S; Wary, KK			A streptococcal collagen-like protein interacts with the alpha(2)beta(1) integrin and induces intracellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; AMINO-ACID-SEQUENCE; SURFACE PROTEIN; INTEGRINS ALPHA(1)BETA(1); BINDING-SITES; CELL; IDENTIFICATION; RECOGNITION; RECEPTOR; ACTIVATION	The streptococcal collagen-like proteins Scl1 and Scl2 are prokaryotic members of a large protein family with domains containing the repeating amino acid sequence (Gly-Xaa-Yaa)(n) that form a collagen-like triple-helical structure. Here, we test the hypothesis that Scl variant might interact with mammalian collagen-binding integrins. We show that the recombinant Scl protein p176 promotes adhesion and spreading of human lung fibroblast cells through an alpha(2)beta(1) integrin-mediated interaction as shown in cell adhesion inhibition assays using anti-alpha(2)beta(1) and anti-beta(1) integrins monoclonal antibodies. Accordingly, C2C12 cells stably expressing alpha(2)beta(1) integrin as the only collagen-binding integrin show productive cell adhesion activities on p176 that can be blocked by an anti-alpha(2)beta(1) integrin antibody. In addition, p176 promotes tyrosine phosphorylation of p125(FAK) of C2C12 cells expressing alpha(2)beta(1) integrin, whereas parental C2C12 cells do not. Furthermore, adhesion of human lung fibroblast cells to p176 induces phosphorylation of p125(FAK), p130(CAS), and p68(Paxillin) proteins. In a domain swapping experiment, we show that integrin binds to the collagenous domain of the Scl protein. Moreover, the recombinant inserted domain of the alpha(2) integrin interacts with p176 with a relatively high affinity (K-D = 17 nM). Attempts to identify the integrin sites in p176 suggest that more than one site may be involved. These studies, for the first time, suggest that the collagen-like proteins of prokaryotes retained not only structural but also functional characteristics of their eukaryotic counterparts.	W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Sch Med, Morgantown, WV 26506 USA; Texas A&M Univ Syst, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Hlth Sci Ctr, Houston, TX 77030 USA; Shriners Hosp Children, Portland, OR 97201 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Sch Med, Morgantown, WV 26506 USA	West Virginia University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; West Virginia University	Lukomski, S (corresponding author), W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Sch Med, Morgantown, WV 26506 USA.	slukomski@hsc.wvu.edu; kwary@ibt.tamhsc.edu		Wary, Kishore/0000-0001-8851-8565	NIAID NIH HHS [AI50666] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Aquilina A, 2002, EUR J BIOCHEM, V269, P1136, DOI 10.1046/j.0014-2956.2001.02740.x; Assoian RK, 1996, J CLIN INVEST, V98, P2436, DOI 10.1172/JCI119059; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Brodsky B, 1995, FASEB J, V9, P1537, DOI 10.1096/fasebj.9.15.8529832; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; CHARALAMBOUS BM, 1988, EMBO J, V7, P2903, DOI 10.1002/j.1460-2075.1988.tb03148.x; CHERESH DA, 1992, CLIN LAB MED, V12, P217, DOI 10.1016/S0272-2712(18)30514-6; Cue D, 2000, P NATL ACAD SCI USA, V97, P2858, DOI 10.1073/pnas.050587897; Cywes C, 2001, NATURE, V414, P648, DOI 10.1038/414648a; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Engel J, 1997, SCIENCE, V277, P1785, DOI 10.1126/science.277.5333.1785; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Fowler T, 2003, CELL MICROBIOL, V5, P417, DOI 10.1046/j.1462-5822.2003.00290.x; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gullberg DE, 2002, PROG HISTOCHEM CYTO, V37, P9; He L, 2003, BLOOD, V102, P3652, DOI 10.1182/blood-2003-04-1323; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; Humtsoe JO, 2003, EMBO J, V22, P1539, DOI 10.1093/emboj/cdg165; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEBLOND CP, 1989, ANAT REC, V224, P123, DOI 10.1002/ar.1092240204; Liddington R, 1998, STRUCT FOLD DES, V6, P937, DOI 10.1016/S0969-2126(98)00094-X; Lukomski S, 2001, INFECT IMMUN, V69, P1729, DOI 10.1128/IAI.69.3.1729-1738.2001; Lukomski S, 2000, INFECT IMMUN, V68, P6542, DOI 10.1128/IAI.68.12.6542-6553.2000; Onley DJ, 2000, J BIOL CHEM, V275, P24560, DOI 10.1074/jbc.M004111200; Perret S, 2003, J BIOL CHEM, V278, P29873, DOI 10.1074/jbc.M304073200; PIHLAJANIEMI T, 1981, BIOCHEMISTRY-US, V20, P7409, DOI 10.1021/bi00529a014; Prockop DJ, 1998, MATRIX BIOL, V16, P519, DOI 10.1016/S0945-053X(98)90064-6; RAMACHANDRAN GN, 1988, INT J PEPT PROT RES, V31, P1; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Rasmussen M, 2000, INFECT IMMUN, V68, P6370, DOI 10.1128/IAI.68.11.6370-6377.2000; Rasmussen M, 2003, J BIOL CHEM, V278, P32313, DOI 10.1074/jbc.M304709200; Rasmussen M, 2001, MOL MICROBIOL, V40, P1427, DOI 10.1046/j.1365-2958.2001.02493.x; REID KBM, 1993, BIOCHEM SOC T, V21, P464, DOI 10.1042/bst0210464; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Rohde M, 2003, CELL MICROBIOL, V5, P323, DOI 10.1046/j.1462-5822.2003.00279.x; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; Sambrook J, 2001, MOL CLONING LAB MANU; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; Siljander PRM, 2004, J BIOL CHEM, V279, P47763, DOI 10.1074/jbc.M404685200; Smith MCM, 1998, SCIENCE, V279, P1834; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; UITTO J, 1974, BIOCHEMISTRY-US, V13, P4586, DOI 10.1021/bi00719a018; UITTO J, 1973, BIOCHEM BIOPH RES CO, V55, P904, DOI 10.1016/0006-291X(73)91229-1; Wary KK, 1999, METH MOL B, V129, P35; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Whatmore AM, 2001, MICROBIOL-UK, V147, P419, DOI 10.1099/00221287-147-2-419; Xiong JP, 2003, J THROMB HAEMOST, V1, P1642, DOI 10.1046/j.1538-7836.2003.00277.x; Xu Y, 2002, J BIOL CHEM, V277, P27312, DOI 10.1074/jbc.M201163200; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Yamada KM, 1997, MATRIX BIOL, V16, P137, DOI 10.1016/S0945-053X(97)90001-9; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	57	89	95	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13848	13857		10.1074/jbc.M410605200	http://dx.doi.org/10.1074/jbc.M410605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15647274	hybrid			2022-12-25	WOS:000228095500083
J	Moucadel, V; Constantinescu, SN				Moucadel, V; Constantinescu, SN			Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD CELLS; SINGLE AMINO-ACID; ERYTHROPOIETIN RECEPTOR; GENE-EXPRESSION; FACTOR INDEPENDENCE; KINASE-ACTIVITY; POINT MUTATION; GROWTH-HORMONE; ACTIVATION; PROTEINS	Many leukemia and cancer cells exhibit constitutive activation of STAT5, which was suggested to provide an anti-apoptotic advantage. Transformation of cytokine-dependent hematopoietic cells, such as Ba/F3 cells to autonomous growth and tumorigenicity equally results in selection for constitutive activation of STAT5. We compared STAT5 signaling between erythropoietin (Epo)-dependent cells and cells that were transformed by oncogenic activation of the erythropoietin receptor (EpoR) by coexpression of the gp55-P envelope protein of the spleen focus forming virus or by expression of the R129C constitutively active EpoR mutant. In transformed cells it was mainly STAT5B that was constitutively activated. In contrast, Epo stimulation activated both STAT5A and STAT5B. In transformed cells, chromatin immunoprecipitation (ChIP) showed STAT5 to be physically bound to promoters of STAT5 target genes, such as Bcl(XL), and to be able to promote transactivation of the Bcl(XL) promoter in a constitutive fashion. Sequencing of native sequences after ChIP with anti-STAT5 antibodies in Epo-dependent and -transformed cells indicated that in gp55-transformed cells, STAT5B bound in the chromatin not only to N3 high affinity, but also to low affinity N4 GAS sites. Transactivation for N3 GAS sites in luciferase reporters was specific to gp55 transformation. Because we also found preferential constitutive STAT5B activation after transformation of cells by a truncated form of the G-CSF-R that produces severe neutropenia (Kostmann syndrome) and favors leukemia in humans, we discuss the potential role of STAT5B in oncogenic transformation of hematopoietic cells.	Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Louvain, Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium; Univ Louvain, MEXP Unit, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	Constantinescu, SN (corresponding author), Ludwig Inst Canc Res, B-1200 Brussels, Belgium.	stefan.constantinescu@bru.licr.org	Constantinescu, Stefan N/E-5277-2012	Constantinescu, Stefan N./0000-0002-8599-2699				Arcasoy MO, 1999, EXP HEMATOL, V27, P63, DOI 10.1016/S0301-472X(98)00003-4; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Buettner R, 2002, CLIN CANCER RES, V8, P945; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; Chai SK, 1997, J IMMUNOL, V159, P4720; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Constantinescu SN, 1999, EMBO J, V18, P3334, DOI 10.1093/emboj/18.12.3334; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dong F, 1997, LEUKEMIA, V11, P120, DOI 10.1038/sj.leu.2400537; DONG F, 1995, BLOOD, V85, P902, DOI 10.1182/blood.V85.4.902.bloodjournal854902; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Gewinner C, 2004, J BIOL CHEM, V279, P3563, DOI 10.1074/jbc.M306449200; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Hayakawa F, 1998, BRIT J HAEMATOL, V101, P521, DOI 10.1046/j.1365-2141.1998.00720.x; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Jegalian AG, 2002, J BIOL CHEM, V277, P2345, DOI 10.1074/jbc.M105575200; Kelly JA, 2003, J EXP MED, V198, P79, DOI 10.1084/jem.20021548; Ketteler R, 2003, J BIOL CHEM, V278, P2654, DOI 10.1074/jbc.M211236200; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Liu RY, 1999, BLOOD, V93, P2369, DOI 10.1182/blood.V93.7.2369.407k18_2369_2379; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Mitsui T, 2003, BLOOD, V101, P2990, DOI 10.1182/blood.V101.8.2990; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Ohashi Takashi, 1997, Leukemia (Basingstoke), V11, P251; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; RUSCETTI SK, 1995, BAILLIERE CLIN HAEM, V8, P225, DOI 10.1016/S0950-3536(05)80239-2; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; Shuai K, 1996, ONCOGENE, V13, P247; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; Stephanou A, 2004, J CELL MOL MED, V8, P519, DOI 10.1111/j.1582-4934.2004.tb00476.x; Storz P, 1999, ANAL BIOCHEM, V276, P97, DOI 10.1006/abio.1999.4345; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tidow N, 1997, BLOOD, V89, P2369, DOI 10.1182/blood.V89.7.2369; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; van de Geijn GJM, 2004, BLOOD, V104, P667, DOI 10.1182/blood-2003-08-2913; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Ward AC, 1999, BLOOD, V93, P447, DOI 10.1182/blood.V93.2.447; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; WeberNordt RM, 1996, BLOOD, V88, P809; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Xia Z, 1998, CANCER RES, V58, P3173; Yamamura Y, 1998, MOL CELL BIOL, V18, P1172, DOI 10.1128/MCB.18.3.1172; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	77	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13364	13373		10.1074/jbc.M407326200	http://dx.doi.org/10.1074/jbc.M407326200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677477	hybrid			2022-12-25	WOS:000228095500023
J	Murakami, MT; Fernandes-Pedrosa, MF; Tambourgi, DV; Arni, RK				Murakami, MT; Fernandes-Pedrosa, MF; Tambourgi, DV; Arni, RK			Structural basis for metal ion coordination and the catalytic mechanism of sphingomyelinases D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOXOSCELES-INTERMEDIA; PHOSPHOLIPASE-D; CRYSTAL-STRUCTURE; SPIDER; PROTEIN; VENOM; ERYTHROCYTES; MUTAGENESIS; RESIDUES; CLONING	Sphingomyelinases D (SMases D) from Loxosceles spider venom are the principal toxins responsible for the manifestation of dermonecrosis, intravascular hemolysis, and acute renal failure, which can result in death. These enzymes catalyze the hydrolysis of sphingomyelin, resulting in the formation of ceramide 1-phosphate and choline or the hydrolysis of lysophosphatidyl choline, generating the lipid mediator lysophosphatidic acid. This report represents the first crystal structure of a member of the sphingomyelinase D family from Loxosceles laeta (SMase I), which has been determined at 1.75-angstrom resolution using the "quick cryo-soaking" technique and phases obtained from a single iodine derivative and data collected from a conventional rotating anode x-ray source. SMase I folds as an (alpha/beta)(8) barrel, the interfacial and catalytic sites encompass hydrophobic loops and a negatively charged surface. Substrate binding and/or the transition state are stabilized by a Mg2+ ion, which is coordinated by Glu(32), Asp(34), Asp(91), and solvent molecules. In the proposed acid base catalytic mechanism, His(12) and His(47) play key roles and are supported by a network of hydrogen bonds between Asp(34), Asp(52), Trp(230), Asp(233), and Asn(252).	Univ Estadual Paulista, IBILCE, Dept Phys, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil; Butantan Inst, Immunochem Lab, BR-05503900 Sao Paulo, Brazil	Universidade Estadual Paulista; Instituto Butantan	Arni, RK (corresponding author), Univ Estadual Paulista, IBILCE, Dept Phys, Rua Cristovao Colombo 2265, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil.	arni@df.ibilce.unesp.br	Murakami, Mario T/F-5640-2016; Tambourgi, Denise/H-7114-2016; Arni, Raghuvir K/N-9338-2018; Arni, Raghuvir K/B-2222-2013; Murakami, Mario T/C-2087-2012; Fernandes-Pedrosa, Matheus/C-6398-2014	Murakami, Mario T/0000-0002-0405-8010; Tambourgi, Denise/0000-0003-1896-9074; Arni, Raghuvir K/0000-0003-2460-1145; Arni, Raghuvir K/0000-0003-2460-1145; Fernandes-Pedrosa, Matheus/0000-0003-4221-9580				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ALLEN PBR, 1988, CAN MED ASSOC J, V138, P792; ATKINS JA, 1958, AM J TROP MED HYG, V7, P165, DOI 10.4269/ajtmh.1958.7.165; BARRETTO OCO, 1985, REV INST MED TROP SP, V27, P264, DOI 10.1590/S0036-46651985000500006; BERNHEIMER AW, 1985, SCIENCE, V228, P590, DOI 10.1126/science.3983643; Bey TA, 1997, ANN EMERG MED, V30, P701, DOI 10.1016/S0196-0644(97)70092-1; CARNE HR, 1978, NATURE, V271, P246, DOI 10.1038/271246a0; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Claus R., 2000, Current Drug Targets, V1, P185, DOI 10.2174/1389450003349272; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; FERNANDESPEDROS.MF, 2002, BIOCHEM BIOPH RES CO, V298, P638; FORRESTER LJ, 1978, ARCH BIOCHEM BIOPHYS, V187, P355, DOI 10.1016/0003-9861(78)90046-2; FUTRELL JM, 1992, AM J MED SCI, V304, P261, DOI 10.1097/00000441-199210000-00008; GENDRON BP, 1990, AM J EMERG MED, V8, P51, DOI 10.1016/0735-6757(90)90297-D; GINSBURG CM, 1988, J PEDIATR-US, V112, P496, DOI 10.1016/S0022-3476(88)80348-2; Jones SJ, 1996, J MOL BIOL, V264, P1154, DOI 10.1006/jmbi.1996.0703; KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leiros I, 2004, J MOL BIOL, V339, P805, DOI 10.1016/j.jmb.2004.04.003; Matsuo Y, 1996, PROTEIN SCI, V5, P2459, DOI 10.1002/pro.5560051208; MCNAMARA PJ, 1995, GENE, V156, P113, DOI 10.1016/0378-1119(95)00002-N; MCNAMARA PJ, 1994, MOL MICROBIOL, V12, P921, DOI 10.1111/j.1365-2958.1994.tb01080.x; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagem RAP, 2001, ACTA CRYSTALLOGR D, V57, P996, DOI 10.1107/S0907444901007260; NELSON J, 1988, CAN MED ASSOC J, V138, P888; O'Sullivan O, 2004, J MOL BIOL, V340, P385, DOI 10.1016/j.jmb.2004.04.058; Obama T, 2003, BIOL PHARM BULL, V26, P920; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ramos-Cerrillo B, 2004, TOXICON, V44, P507, DOI 10.1016/j.toxicon.2004.06.013; SCHENONE H, 1989, REV INST MED TROP SP, V31, P403, DOI 10.1590/S0036-46651989000600007; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sezerino UM, 1998, T ROY SOC TROP MED H, V92, P546, DOI 10.1016/S0035-9203(98)90909-9; Songer JG, 1997, TRENDS MICROBIOL, V5, P156, DOI 10.1016/S0966-842X(97)01005-6; SOUCEK A, 1967, BIOCHIM BIOPHYS ACTA, V144, P180; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; Tambourgi DV, 1998, BIOCHEM BIOPH RES CO, V251, P366, DOI 10.1006/bbrc.1998.9474; Tambourgi DV, 2004, MOL IMMUNOL, V41, P831, DOI 10.1016/j.molimm.2004.03.027; Tambourgi DV, 2002, IMMUNOLOGY, V107, P93, DOI 10.1046/j.1365-2567.2002.01483.x; TAMBOURGI DV, 1995, J IMMUNOL, V155, P4459; Tambourgi DV, 2000, BLOOD, V95, P683, DOI 10.1182/blood.V95.2.683; Tambourgi DV, 1998, TOXICON, V36, P391, DOI 10.1016/S0041-0101(97)00063-9; TRUETT AP, 1993, ADV LIPID RES, V26, P275; van Meeteren LA, 2004, J BIOL CHEM, V279, P10833, DOI 10.1074/jbc.C300563200; WASSERMAN GS, 1984, J TOXICOL-CLIN TOXIC, V21, P451, DOI 10.3109/15563658308990434; Zela SP, 2004, ACTA CRYSTALLOGR D, V60, P1112, DOI 10.1107/S090744490400678X	50	77	79	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13658	13664		10.1074/jbc.M412437200	http://dx.doi.org/10.1074/jbc.M412437200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15654080	hybrid			2022-12-25	WOS:000228095500060
J	Palacios, VG; Robinson, LJ; Borysenko, CW; Lehmann, T; Kalla, SE; Blair, HC				Palacios, VG; Robinson, LJ; Borysenko, CW; Lehmann, T; Kalla, SE; Blair, HC			Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 cells by estrogen and phytoestrogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ALPHA; BONE MASS; EXPRESSION; GENISTEIN; BETA; ESTRADIOL; APOPTOSIS; OSTEOPROTEGERIN; INHIBITOR; PATHWAYS	We studied estrogen effects on osteoclastic differentiation using RAW264.7, a murine monocytic cell line. Differentiation, in response to RANKL and colony-stimulating factor 1, was evaluated while varying estrogen receptor (ER) stimulation by estradiol or nonsteroidal ER agonists was performed. The RAW264.7 cells were found to express ER alpha but not ER beta. In contrast to RANKL, which decreased ER alpha expression and induced osteoclast differentiation, 10 nM estradiol, 3 mu M genistein, or 3 mu M daidzein all increased ER alpha expression, stimulated cell proliferation, and decreased multinucleation, with the effects of estrogen >= daidzein > genistein. However, no estrogen agonist reduced RANKL stimulation of osteoclast differentiation markers or its down-regulation of ER alpha expression by more than similar to 50%. Genistein is also an Src kinase antagonist in vitro, but it did not decrease Src phosphorylation in RAW264.7 cells relative to other estrogen agonists. However, both phytoestrogens and estrogen inhibited RANKL-induced I kappa B degradation and NF-kappa B nuclear localization with the same relative potency as seen in proliferation and differentiation assays. This study demonstrates, for the first time, the direct effects of estrogen on osteoclast precursor differentiation and shows that, in addition to effecting osteoblasts, estrogen may protect bone by reducing osteoclast production. Genistein, which activates ERs selectively, inhibited osteoclastogenesis less effectively than the nonselective phytoestrogen daidzein, which effectively reproduced effects of estrogen.	Univ Pittsburgh, Dept Pathol & Cell Biol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Physiol, Pittsburgh, PA 15261 USA; Vet Affairs Med Ctr, Pittsburgh, PA 15243 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Blair, HC (corresponding author), Univ Pittsburgh, Dept Pathol & Cell Biol, 705 Scaife Hall, Pittsburgh, PA 15261 USA.	hcblair@imap.pitt.edu		Kalla, Sara/0000-0003-2437-5352	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012951] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47700] Funding Source: Medline; NIA NIH HHS [AG12951] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Anderson JJB, 1998, BAILLIERE CLIN ENDOC, V12, P543, DOI 10.1016/S0950-351X(98)80003-7; Barnes S, 2000, J NUTR, V130, p656S, DOI 10.1093/jn/130.3.656S; Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165; Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756-3282(02)00953-5; Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309; Braidman IP, 2001, J BONE MINER RES, V16, P214, DOI 10.1359/jbmr.2001.16.2.214; Brubaker KD, 1999, J BONE MINER RES, V14, P1861, DOI 10.1359/jbmr.1999.14.11.1861; Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025; Cao LH, 2003, J CELL BIOCHEM, V89, P152, DOI 10.1002/jcb.10486; Cuzzocrea S, 2003, ENDOCRINOLOGY, V144, P1098, DOI 10.1210/en.2002-220597; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; FIORELLI G, 1995, P NATL ACAD SCI USA, V92, P2672, DOI 10.1073/pnas.92.7.2672; Fonseca D, 2004, BONE, V35, P489, DOI 10.1016/j.bone.2004.03.031; FOX MH, 1980, CYTOMETRY, V1, P71, DOI 10.1002/cyto.990010114; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gao YH, 1999, BIOL PHARM BULL, V22, P805, DOI 10.1248/bpb.22.805; Guo ZY, 2002, J BIOL CHEM, V277, P7044, DOI 10.1074/jbc.M109808200; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakamura I, 2003, ENDOCRINOLOGY, V144, P4739, DOI 10.1210/en.2003-0615; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oreffo ROC, 1999, HISTOCHEM CELL BIOL, V111, P125, DOI 10.1007/s004180050342; Ramalho AC, 2002, EUR CYTOKINE NETW, V13, P39; Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539; Rickard DJ, 1999, J CELL BIOCHEM, P123; Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S; Shevde NK, 1996, BLOOD, V87, P2683, DOI 10.1182/blood.V87.7.2683.bloodjournal8772683; Su SJ, 2000, CLIN CANCER RES, V6, P230; Tobe H, 1997, BIOSCI BIOTECH BIOCH, V61, P370, DOI 10.1271/bbb.61.370; Vegeto E, 2004, J STEROID BIOCHEM, V91, P59, DOI 10.1016/j.jsbmb.2004.02.004; Viereck V, 2002, J CELL BIOCHEM, V84, P725, DOI 10.1002/jcb.10087; Wersto RP, 2001, CYTOMETRY, V46, P296, DOI 10.1002/cyto.1171; Williams JP, 1998, AM J CLIN NUTR, V68, p1369S, DOI 10.1093/ajcn/68.6.1369S	36	103	109	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13720	13727		10.1074/jbc.M410995200	http://dx.doi.org/10.1074/jbc.M410995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15644335	hybrid			2022-12-25	WOS:000228095500067
J	Pope, SM; Fulkerson, PC; Blanchard, C; Akei, HS; Nikolaidis, NM; Zimmermann, N; Molkentin, JD; Rothenberg, ME				Pope, SM; Fulkerson, PC; Blanchard, C; Akei, HS; Nikolaidis, NM; Zimmermann, N; Molkentin, JD; Rothenberg, ME			Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-4 MESSENGER-RNA; T-CELLS; MAST-CELLS; FUNCTIONAL-CHARACTERIZATION; EOSINOPHIL ACCUMULATION; AIRWAY EOSINOPHILIA; CHEMOKINE RECEPTORS; ATOPIC-DERMATITIS; IGE SYNTHESIS; CC-CHEMOKINE	Pulmonary eosinophilia, a hallmark pathologic feature of allergic lung disease, is regulated by interleukin-13 (IL-13) as well as the eotaxin chemokines, but the specific role of these cytokines and their cooperative interaction are only partially understood. First, we elucidated the essential role of IL-13 in the induction of the eotaxins by comparing IL-13 gene-targeted mice with wild type control mice by using an ovalbumin-induced model of allergic airway inflammation. Notably, ovalbumin-induced expressions of eotaxin-1 and eotaxin-2 mRNA in the lungs were almost completely dependent upon IL-13. Second, in order to address the specific role of eotaxin-2 in IL-13-induced pulmonary eosinophilia, we generated eotaxin-2 gene-deficient mice by homologous recombination. Notably, in contrast to observations made in eotaxin-1-deficient mice, eotaxin-2-deficient mice had normal base-line eosinophil levels in the hematopoietic tissues and gastrointestinal tract. However, following intratracheal IL-13 administration, eotaxin-2-deficient mice showed a profound reduction in airway eosinophilia compared with wild type mice. Most interestingly, the level of peribronchial lung tissue eosinophils in IL-13-treated eotaxin-2-deficient mice was indistinguishable from wild type mice. Furthermore, IL-13 lung transgenic mice genetically engineered to be deficient in eotaxin-2 had a marked reduction of luminal eosinophils. Mechanistic analysis identified IL-13-induced eotaxin-2 expression by macrophages in a distinct lung compartment ( luminal inflammatory cells) compared with eotaxin-1, which was expressed solely in the tissue. Taken together, these results demonstrate a cooperative mechanism between IL-13 and eotaxin-2. In particular, IL-13 mediates allergen-induced eotaxin-2 expression, and eotaxin-2 mediates IL-13-induced airway eosinophilia.	Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp,Med Ctr, Dept Pediat,Div Allergy & Immunol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp,Med Ctr, Dept Pediat,Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp,Med Ctr, Dept Pediat,Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org		Pope, Sam/0000-0002-7724-9141; Molkentin, Jeffery/0000-0002-3558-6529	NIAID NIH HHS [R01 AI45898, R01 AI42242, R01 AI57803] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057803, R01AI042242, R01AI045898] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akdis M, 1997, J IMMUNOL, V159, P4611; AlGhamdi K, 1997, J OTOLARYNGOL, V26, P160; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Broide D, 2001, IMMUNOL REV, V179, P163, DOI 10.1034/j.1600-065X.2001.790116.x; Campbell EM, 1998, J IMMUNOL, V161, P7047; DISCOMBE G, 1946, LANCET, V250, P195; Foster PS, 2001, IMMUNOL REV, V179, P173, DOI 10.1034/j.1600-065X.2001.790117.x; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; Hoeck J, 2001, J IMMUNOL, V167, P3216, DOI 10.4049/jimmunol.167.6.3216; Hogan SP, 1998, IMMUNOL CELL BIOL, V76, P454, DOI 10.1046/j.1440-1711.1998.00766.x; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; Lai SY, 1996, EMBO J, V15, P4506, DOI 10.1002/j.1460-2075.1996.tb00828.x; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Lee NA, 1997, J IMMUNOL, V158, P1332; Li L, 1999, J IMMUNOL, V162, P2477; Matsukura S, 1999, J IMMUNOL, V163, P6876; Mattes Joerg, 2003, Current Drug Targets - Inflammation and Allergy, V2, P169, DOI 10.2174/1568010033484214; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Murata T, 1996, J IMMUNOL, V156, P2972; Ono SJ, 2003, J ALLERGY CLIN IMMUN, V111, P1185, DOI 10.1067/mai.2003.1594; Onuffer JJ, 2002, TRENDS PHARMACOL SCI, V23, P459, DOI 10.1016/S0165-6147(02)02064-3; Patel VP, 1997, J EXP MED, V185, P1163, DOI 10.1084/jem.185.7.1163; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Saito H, 2002, J IMMUNOL, V168, P3017, DOI 10.4049/jimmunol.168.6.3017; Taha RA, 1999, J ALLERGY CLIN IMMUN, V103, P476, DOI 10.1016/S0091-6749(99)70474-4; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Terada N, 2000, CLIN EXP ALLERGY, V30, P348; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Tiffany HL, 1998, J IMMUNOL, V160, P1385; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Watanabe K, 2002, J IMMUNOL, V168, P1911, DOI 10.4049/jimmunol.168.4.1911; Weller PF, 1996, EUR RESPIR J, V9, pS109; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang M, 2003, J ALLERGY CLIN IMMUN, V112, P935, DOI 10.1016/j.jaci.2003.08.010; Ying S, 1997, J IMMUNOL, V158, P5050; Ying S, 1997, J IMMUNOL, V158, P3539; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336; Zhu Z, 2002, J IMMUNOL, V168, P2953, DOI 10.4049/jimmunol.168.6.2953; Zimmermann N, 2000, J IMMUNOL, V165, P5839, DOI 10.4049/jimmunol.165.10.5839; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	68	128	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13952	13961		10.1074/jbc.M406037200	http://dx.doi.org/10.1074/jbc.M406037200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15647285	hybrid			2022-12-25	WOS:000228095500097
J	Scott, RP; Eketjall, S; Aineskog, H; Ibanez, CF				Scott, RP; Eketjall, S; Aineskog, H; Ibanez, CF			Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ENTERIC NERVOUS-SYSTEM; TYROSINE KINASE; C-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING COMPLEXES; BINDING DOMAIN; DOCKING SITE; CELL-LINE; GRB2	Alternative splicing of transcripts encoding the RET kinase receptor leads to isoforms differing in their cytoplasmic tail. Although in vitro studies have demonstrated a higher transforming activity of the long RET isoform (RET51), only the short isoform (RET9) can rescue the effects of a RET null mutation in the enteric nervous system and kidney development. The molecular basis underlying the distinct functions of the two RET isoforms is not understood. Here we demonstrated that activated RET51 associated more strongly with the ubiquitin ligase Cbl than did RET9, leading to increased ubiquitylation and faster turnover of RET51. The association of Cbl with RET was indirect and was mediated through Grb2. A constitutive complex of Grb2 and Cbl could be recruited to both receptor isoforms via docking of Shc to phosphorylated Tyr-1062 in RET. A mutant Shc protein unable to recruit the Grb2.Cbl complex decreased the turnover and prolonged the half-life of RET9, thus ascribing a previously unknown negative role to the Shc adaptor molecule. In addition, phosphorylation of Tyr-1096, which is present in RET51 but absent in RET9, endowed the longer isoform with a second route to recruit the Grb2.Cbl complex. These findings establish a mechanism for the differential down-regulation of RET9 and RET51 signaling that could explain the apparently paradoxical activities of these two RET isoforms. More generally, these results illustrate how alternative splicing can regulate the half-life and function of a growth factor receptor.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Retzius Vag 8, S-17177 Stockholm, Sweden.	carlos.ibanez@neuro.ki.se	Scott, Rizaldy/AAC-5264-2020; Scott, Rizaldy/Y-7584-2019	Scott, Rizaldy/0000-0002-0288-8862				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Barlow A, 2003, NEURON, V40, P905, DOI 10.1016/S0896-6273(03)00730-X; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Carniti C, 2003, CANCER RES, V63, P2234; Carter MT, 2001, CYTOGENET CELL GENET, V95, P169, DOI 10.1159/000059341; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Ivanchuk SM, 1998, ONCOGENE, V16, P991, DOI 10.1038/sj.onc.1201622; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Matera I, 2000, DNA SEQUENCE, V11, P405, DOI 10.3109/10425170009033991; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; MYERS SM, 1995, ONCOGENE, V11, P2039; Natarajan D, 2002, DEVELOPMENT, V129, P5151; Parisi MA, 2000, CURR OPIN PEDIATR, V12, P610, DOI 10.1097/00008480-200012000-00017; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; TAHIRA T, 1990, ONCOGENE, V5, P97; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899	45	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13442	13449		10.1074/jbc.M500507200	http://dx.doi.org/10.1074/jbc.M500507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677445	hybrid			2022-12-25	WOS:000228095500032
J	Vertino, AM; Bula, CM; Chen, JR; Almeida, M; Han, L; Bellido, T; Kousteni, S; Norman, AW; Manolagas, SC				Vertino, AM; Bula, CM; Chen, JR; Almeida, M; Han, L; Bellido, T; Kousteni, S; Norman, AW; Manolagas, SC			Nongenotropic, anti-apoptotic signaling of 1 alpha,25(OH)(2)-Vitamin D-3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes - Mediation by Src, phosphatidylinositol 3-, and Jnk kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; BIOLOGICAL RESPONSES; LEUKEMIA-CELLS; DNA-BINDING; ESTROGEN; MECHANISMS; PHOSPHORYLATION; STIMULATION	Because sex steroids regulate the life span of bone cells by modulating cytoplasmic kinase activity via a nongenotropic action of their classical receptors, we have explored the possibility that the vitamin D nuclear receptor ( VDR) might exhibit similar nongenotropic actions. We report that the conformationally flexible full VDR agonist, 1 alpha,25( OH) (2)- vitamin D-3 ( 1 alpha, 25( OH)(2)D-3), and the 6- s-cis-locked 1 alpha, 25( OH)(2)- lumisterol(3) ( JN) analog, also acting through the VDR but with poor transcriptional activity, protected murine osteoblastic or osteocytic cells from apoptosis. This effect was reproduced in HeLa cells transiently transfected with either wild type VDR or a mutant consisting of only the VDR ligand binding domain. The VDR ligand binding domain bound [ H-3] 1 alpha, 25( OH)(2)D-3 as effectively as wild type VDR but did not induce vitamin D response element- mediated transcription. The antiapoptotic effects of 1 alpha, 25( OH)(2)D-3 and the 6- s- cis- locked 1 alpha, 25( OH)(2)- lumisterol(3) analog in calvaria cells were blocked by three cytoplasmic kinase inhibitors: Src kinase inhibitor 4- amino- 5-( 4- methylphenyl)- 7-( t- butyl) pyrazolo[ 3,4- d] pyrimidine ( PP1), phosphatidylinositol 3 kinase inhibitor Wortmannin, and the JNK kinase inhibitor SP600125. However, inhibition of p38 with SB203580 or ERK with either U0126 or a transfected dominant negative MEK did not interfere with these anti- apoptotic actions. Further, 1 alpha, 25( OH)(2)D-3 induced rapid ( 5 min) association of VDR with Src kinase in OB- 6 cells. Finally, actinomycin D or cycloheximide prevented the anti- apoptotic effect of 1 alpha, 25( OH)(2)D-3, indicating that transcriptional events are also required. These findings suggest that nongenotropic modulation of kinase activity is also a general property of the VDR and that ligands that activate nongenotropic signals, but lack transcriptional activity, display different biological profiles from the steroid hormone 1 alpha, 25( OH)(2)D-3.	Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72205 USA; Cent Arkansas Vet Hlth Care Syst, Little Rock, AR 72205 USA; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of California System; University of California Riverside; University of California System; University of California Riverside	Manolagas, SC (corresponding author), Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, 4301 W Markham St,Slot 587, Little Rock, AR 72205 USA.	manolagasstavros@uams.edu		Almeida, Maria/0000-0002-6722-9200	NIAMS NIH HHS [K02-AR02127] Funding Source: Medline; NIA NIH HHS [P01-AG13918] Funding Source: Medline; NIDDK NIH HHS [DK-09012-37] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009012, R37DK009012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Boyan BD, 2004, STEROIDS, V69, P591, DOI 10.1016/j.steroids.2004.05.008; Boyan BD, 2004, J STEROID BIOCHEM, V89-90, P309, DOI 10.1016/j.jsbmb.2004.03.027; Buitrago CG, 2003, J BIOL CHEM, V278, P2199, DOI 10.1074/jbc.M205732200; Bula CM, 2000, MOL ENDOCRINOL, V14, P1788, DOI 10.1210/me.14.11.1788; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; De Haes P, 2003, J CELL BIOCHEM, V89, P663, DOI 10.1002/jcb.10540; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Huhtakangas JA, 2004, MOL ENDOCRINOL, V18, P2660, DOI 10.1210/me.2004-0116; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kajikawa M, 1999, ENDOCRINOLOGY, V140, P4706, DOI 10.1210/en.140.10.4706; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261; Kousteni S, 2003, J BONE MINER RES, V18, pS28; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Liu YY, 1997, J BIOL CHEM, V272, P3336, DOI 10.1074/jbc.272.6.3336; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MANOLAGAS SC, 2004, P END SOC 86 ANN M N, P30; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Miura D, 1999, FEBS LETT, V460, P297, DOI 10.1016/S0014-5793(99)01347-2; Mizwicki MT, 2004, P NATL ACAD SCI USA, V101, P12876, DOI 10.1073/pnas.0403606101; NEMERE I, 1984, ENDOCRINOLOGY, V115, P1476, DOI 10.1210/endo-115-4-1476; Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283; Norman AW, 2002, STEROIDS, V67, P457, DOI 10.1016/S0039-128X(01)00167-2; Norman AW, 2002, BIOCHEM BIOPH RES CO, V298, P414, DOI 10.1016/S0006-291X(02)02482-8; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Norman AW, 1997, MOL ENDOCRINOL, V11, P1518, DOI 10.1210/me.11.10.1518; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Schwartz Z, 2002, ENDOCRINOLOGY, V143, P2775, DOI 10.1210/en.143.7.2775; Schwartz Z, 2001, J BIOMED MATER RES, V56, P417, DOI 10.1002/1097-4636(20010905)56:3<417::AID-JBM1111>3.0.CO;2-K; Shibusawa N, 2003, J CLIN INVEST, V112, P588, DOI 10.1172/JCI200318377; Song XD, 1998, ENDOCRINOLOGY, V139, P457, DOI 10.1210/en.139.2.457; Tuohimaa P, 2001, J STEROID BIOCHEM, V76, P125, DOI 10.1016/S0960-0760(00)00141-2; Wang SH, 1999, ENDOCRINOLOGY, V140, P1649, DOI 10.1210/en.140.4.1649; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Zanello LP, 1997, J BIOL CHEM, V272, P22617, DOI 10.1074/jbc.272.36.22617; Zanello LP, 2004, P NATL ACAD SCI USA, V101, P1589, DOI 10.1073/pnas.0305802101	46	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14130	14137		10.1074/jbc.M410720200	http://dx.doi.org/10.1074/jbc.M410720200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15671029	hybrid			2022-12-25	WOS:000228095500116
J	Dennes, A; Cromme, C; Suresh, K; Kumar, NS; Eble, JA; Hahnenkamp, A; Pohlmann, R				Dennes, A; Cromme, C; Suresh, K; Kumar, NS; Eble, JA; Hahnenkamp, A; Pohlmann, R			The novel Drosophila lysosomal enzyme receptor protein mediates lysosomal sorting in mammalian cells and binds mammalian and Drosophila GGA adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; SECRETASE CYTOSOLIC DOMAIN; CYTOPLASMIC TAIL; VHS DOMAIN; STRUCTURAL BASIS; CLATHRIN; TRANSPORT; GOLGI; RECOGNITION; MEMAPSIN-2	Biogenesis of lysosomes depends in mammalian cells on the specific recognition and targeting of mannose 6-phosphate-containing lysosomal enzymes by two mannose 6-phosphate receptors (MPR46, MPR300), key components of the extensively studied receptor-mediated lysosomal sorting system in complex metazoans. In contrast, the biogenesis of lysosomes is poorly investigated in the less complex metazoan Drosophila melanogaster. We identified the novel type I transmembrane protein lysosomal enzyme receptor protein (LERP) with partial homology to the mammalian MPR300 encoded by Drosophila gene CG31072. LERP contains 5 lumenal repeats that share homology to the 15 lumenal repeats found in all identified MPR300. Four of the repeats display the P-lectin type pattern of conserved cysteine residues. However, the arginine residues identified to be essential for mannose 6-phosphate binding are not conserved. The recombinant LERP protein was expressed in mammalian cells and displayed an intracellular localization pattern similar to the mammalian MPR300. The LERP cytoplasmic domain shows highly conserved interactions with Drosophila and mammalian GGA adaptors known to mediate Golgi-endosome traffic of MPRs and other transmembrane cargo. Moreover, LERP rescues missorting of soluble lysosomal enzymes in MPR-deficient cells, giving strong evidence for a function that is equivalent to the mammalian counterpart. However, unlike the mammalian MPRs, LERP did not bind to the multimeric mannose 6-phosphate ligand phosphomannan. Thus ligand recognition by LERP does not depend on mannose 6-phosphate but may depend on a common feature present in mammalian lysosomal enzymes. Our data establish a potential important role for LERP in biogenesis of Drosophila lysosomes and suggest a GGA function also in the receptor-mediated lysosomal transport system in the fruit fly.	Univ Klinikum Muenster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Hyderabad, Dept Biochem, Hyderabad 500046, Andhra Pradesh, India	University of Munster; University of Hyderabad	Dennes, A (corresponding author), Univ Klinikum Muenster, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.	dennes@uni-muenster.de						AEED PA, 1994, BIOCHEMISTRY-US, V33, P8793, DOI 10.1021/bi00195a022; Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; DAHMS N, 2002, BIOCHIM BIOPHYS ACTA, V1572, P31; Dennes A, 2002, J BIOL CHEM, V277, P12288, DOI 10.1074/jbc.M112295200; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; DURESH K, 2004, GLYCOCONJ J, V20, P257; GASZNER M, 1991, BIOCHEM BIOPH RES CO, V181, P44, DOI 10.1016/S0006-291X(05)81379-8; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; He XY, 2003, BIOCHEMISTRY-US, V42, P12174, DOI 10.1021/bi035199h; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Le Borgne R, 1998, CURR OPIN CELL BIOL, V10, P499; LeBorgne R, 1997, J CELL BIOL, V137, P335; Luzio JP, 2000, J CELL SCI, V113, P1515; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Nakayama K, 2003, CELL STRUCT FUNCT, V28, P431, DOI 10.1247/csf.28.431; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Tryselius Y, 1997, INSECT MOL BIOL, V6, P173, DOI 10.1111/j.1365-2583.1997.tb00085.x; VONFIGURA K, 1985, BIOCHEM J, V225, P543, DOI 10.1042/bj2250543; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; Xu H, 2004, EMBO J, V23, P811, DOI 10.1038/sj.emboj.7600112; Yeyeodu S, 2000, TRAFFIC, V1, P724, DOI 10.1034/j.1600-0854.2000.010905.x; Zhu GY, 2003, FEBS LETT, V537, P171, DOI 10.1016/S0014-5793(03)00095-4; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	38	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12849	12857		10.1074/jbc.M410626200	http://dx.doi.org/10.1074/jbc.M410626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15664992	hybrid			2022-12-25	WOS:000227922000093
J	Fujikane, R; Komori, K; Shinagawa, H; Ishino, Y				Fujikane, R; Komori, K; Shinagawa, H; Ishino, Y			Identification of a novel helicase activity unwinding branched DNAs from the hyperthermophilic archaeon, Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTION RESOLVASE; HOMOLOGOUS RECOMBINATION; BIOCHEMICAL-CHARACTERIZATION; POLYMERASE; RESOLUTION; PROTEIN; RUVABC; MIGRATION; GENE; HJC	To identify the branch migration activity in archaea, we fractionated Pyrococcus furiosus cell extracts by several chromatography and assayed for ATP-dependent resolution of synthetic Holliday junctions. The target activity was identified in the column fractions, and the optimal reaction conditions for the branch migration activity were determined using the partially purified fraction. We successfully cloned the corresponding gene by screening a heat-stable protein library made by P. furiosus genomic DNA. The gene, hjm (Holliday junction migration), encodes a protein composed of 720 amino acids. The Hjm protein is conserved in Archaea and belongs to the helicase superfamily 2. A homology search revealed that Hjm shares sequence similarity with the human Pol Theta, HEL308, and Drosophila Mus308 proteins, which are involved in a DNA repair, whereas no similar sequences were found in bacteria and yeast. The Hjm helicase may play a central role in the repair systems of organisms living in extreme environments.	Kyushu Univ, Dept Genet Resources Technol, Fac Agr, Higashi Ku, Fukuoka 8128581, Japan; Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Osaka Univ, Dept Mol Microbiol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan	Kyushu University; Osaka University	Ishino, Y (corresponding author), Kyushu Univ, Dept Genet Resources Technol, Fac Agr, Higashi Ku, 6-10-1 Hakozaki 4217, Fukuoka 8128581, Japan.	ishino@agr.kyushu-u.ac.jp		Fujikane, Ryosuke/0000-0002-6621-3848; Ishino, Yoshizumi/0000-0001-9419-0826				BOYD JB, 1990, GENETICS, V125, P813; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; Davies AA, 1998, CURR BIOL, V8, P725, DOI 10.1016/S0960-9822(98)70282-9; DiRuggiero J, 1998, NEW DEVELOPMENTS IN MARINE BIOTECHNOLOGY, P193; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hayashi I, 1999, NUCLEIC ACIDS RES, V27, P4695, DOI 10.1093/nar/27.24.4695; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Hopfner KP, 2000, J BACTERIOL, V182, P6036, DOI 10.1128/JB.182.21.6036-6041.2000; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; HYDE H, 1994, J BIOL CHEM, V269, P5202; ISHINO Y, 1992, BIOCHIMIE, V74, P131, DOI 10.1016/0300-9084(92)90036-E; Komori K, 2000, J BIOL CHEM, V275, P33791, DOI 10.1074/jbc.M004556200; Komori K, 2002, GENES GENET SYST, V77, P227, DOI 10.1266/ggs.77.227; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; Komori K, 2000, NUCLEIC ACIDS RES, V28, P4544, DOI 10.1093/nar/28.22.4544; Komori K, 2001, J BIOL CHEM, V276, P25654, DOI 10.1074/jbc.M102423200; Komori K, 2000, J BIOL CHEM, V275, P40385, DOI 10.1074/jbc.M006294200; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Lilley DMJ, 2000, P NATL ACAD SCI USA, V97, P9351, DOI 10.1073/pnas.97.17.9351; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; Marini F, 2002, J BIOL CHEM, V277, P8716, DOI 10.1074/jbc.M110271200; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; Nishino T, 2001, STRUCTURE, V9, P197, DOI 10.1016/S0969-2126(01)00576-7; Ohnishi T, 2000, GENES GENET SYST, V75, P233, DOI 10.1266/ggs.75.233; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; Oshige M, 1999, MUTAT RES-DNA REPAIR, V433, P183, DOI 10.1016/S0921-8777(99)00005-1; Seki M, 2003, NUCLEIC ACIDS RES, V31, P6117, DOI 10.1093/nar/gkg814; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; UEMORI T, 1993, NUCLEIC ACIDS RES, V21, P259, DOI 10.1093/nar/21.2.259; van Gool AJ, 1999, GENE DEV, V13, P1861, DOI 10.1101/gad.13.14.1861; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Yamada K, 1999, MOL GEN GENET, V261, P1001, DOI 10.1007/s004380051049; Zerbib D, 1998, J MOL BIOL, V281, P621, DOI 10.1006/jmbi.1998.1959	41	38	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12351	12358		10.1074/jbc.M413417200	http://dx.doi.org/10.1074/jbc.M413417200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677450	hybrid			2022-12-25	WOS:000227922000036
J	Pessi, G; Choi, JY; Reynolds, JM; Voelker, DR; Ben Mamoun, C				Pessi, G; Choi, JY; Reynolds, JM; Voelker, DR; Ben Mamoun, C			In vivo evidence for the specificity of Plasmodium falciparum phosphoethanolamine methyltransferase and its coupling to the Kennedy pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; MALARIA PARASITE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; INFECTED ERYTHROCYTES; ANTIMALARIAL ACTIVITY; N-METHYLTRANSFERASE; METABOLISM; GENE; METHYLATION; INHIBITION	Unlike humans and yeast, Plasmodium falciparum, the agent of the most severe form of human malaria, utilizes host serine as a precursor for the synthesis of phosphatidylcholine via a plant-like pathway involving phosphoethanolamine methylation. The monopartite phosphoethanolamine methyltransferase, Pfpmt, plays an important role in the biosynthetic pathway of this major phospholipid by providing the precursor phosphocholine via a three-step S-adenosyl-L-methionine-dependent methylation of phosphoethanolamine. In vitro studies showed that Pfpmt has strong specificity for phosphoethanolamine. However, the in vivo substrate ( phosphoethanolamine or phosphatidylethanolamine) is not yet known. We used yeast as a surrogate system to express Pfpmt and provide genetic and biochemical evidence demonstrating the specificity of Pfpmt for phosphoethanolamine in vivo. Wild-type yeast cells, which inherently lack phosphoethanolamine methylation, acquire this activity as a result of expression of Pfpmt. The Pfpmt restores the ability of a yeast mutant pem1 Delta pem2 Delta lacking the phosphatidylethanolamine methyltransferase genes to grow in the absence of choline. Lipid analysis of the Pfpmt-complemented pem1 Delta pem2 Delta strain demonstrates the synthesis of phosphatidylcholine but not the intermediates of phosphatidylethanolamine transmethylation. Complementation of the pem1 Delta pem2 Delta mutant relies on specific methylation of phosphoethanolamine but not phosphatidylethanolamine. Interestingly, a mutation in the yeast choline-phosphate cytidylyltransferase gene abrogates the complementation by Pfpmt thus demonstrating that Pfpmt activity is directly coupled to the Kennedy pathway for the de novo synthesis of phosphatidylcholine.	Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Univ Connecticut, Dept Genet & Dev Biol, Ctr Hlth, Farmington, CT 06030 USA; Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA	University of Connecticut; University of Connecticut; National Jewish Health	Ben Mamoun, C (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, 263 Farmington Ave, Farmington, CT 06030 USA.	choukri@up.uchc.edu	Pessi, Gabriella/AGW-2342-2022	Pessi, Gabriella/0000-0002-8138-5541	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI058962, R01AI030060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453] Funding Source: NIH RePORTER; NIAID NIH HHS [AI058962, AI051507, AI030060] Funding Source: Medline; NIGMS NIH HHS [2R37-GM32453] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; ANCELIN ML, 1989, BIOCHIM BIOPHYS ACTA, V1001, P82, DOI 10.1016/0005-2760(89)90310-X; Bahl A, 2002, NUCLEIC ACIDS RES, V30, P87, DOI 10.1093/nar/30.1.87; Biagini GA, 2004, BLOOD, V104, P3372, DOI 10.1182/blood-2004-03-1084; BLIGH EG, 1959, CAN J MED SCI, V37, P911, DOI DOI 10.1139/O59-099; Bolognese CP, 2000, PLANT PHYSIOL, V124, P1800, DOI 10.1104/pp.124.4.1800; Calas M, 2000, J MED CHEM, V43, P505, DOI 10.1021/jm9911027; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Charron JBF, 2002, PLANT PHYSIOL, V129, P363, DOI 10.1104/pp.001776; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Guthrie C, 1991, GUIDE YEAST GENETICS; Howe AG, 2002, J BIOL CHEM, V277, P44100, DOI 10.1074/jbc.M206643200; Kanipes MI, 1998, GENETICS, V150, P553; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; KODAKI T, 1987, J BIOL CHEM, V262, P15428; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Lehane AM, 2004, BIOCHEM BIOPH RES CO, V320, P311, DOI 10.1016/j.bbrc.2004.05.164; Nuccio ML, 2000, J BIOL CHEM, V275, P14095, DOI 10.1074/jbc.275.19.14095; Pessi G, 2004, P NATL ACAD SCI USA, V101, P6206, DOI 10.1073/pnas.0307742101; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; Roggero R, 2004, ANTIMICROB AGENTS CH, V48, P2816, DOI 10.1128/AAC.48.8.2816-2824.2004; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Santiago TC, 2004, J BIOL CHEM, V279, P9222, DOI 10.1074/jbc.M310502200; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; SUMMERS EF, 1988, GENETICS, V120, P909; Vial H., 1998, MALARIA PARASITE BIO, P159; VIAL HJ, 1982, J PARASITOL, V68, P379, DOI 10.2307/3280946; VIAL HJ, 1982, J PROTOZOOL, V29, P258, DOI 10.1111/j.1550-7408.1982.tb04023.x; Wengelnik K, 2002, SCIENCE, V295, P1311, DOI 10.1126/science.1067236; White NJ, 2004, J CLIN INVEST, V113, P1084, DOI [10.1172/JCI21682, 10.1172/JCI200421682]; WHO Expert Committee on Malaria, 2000, WHO TECH REP SER, V892, P1	32	63	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12461	12466		10.1074/jbc.M414626200	http://dx.doi.org/10.1074/jbc.M414626200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15664981	hybrid			2022-12-25	WOS:000227922000049
J	Preuss, M; Ott, M; Funes, S; Luirink, J; Herrmann, JM				Preuss, M; Ott, M; Funes, S; Luirink, J; Herrmann, JM			Evolution of mitochondrial Oxa proteins from bacterial YidC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI YIDC; SYNTHASE SUBUNIT-C; SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; CYTOCHROME-OXIDASE; ATP SYNTHASE; NEUROSPORA-CRASSA; EXPORT MACHINERY; NUCLEAR GENE	Members of the Oxa1/ YidC family are involved in the biogenesis of membrane proteins. In bacteria, YidC catalyzes the insertion and assembly of proteins of the inner membrane. Mitochondria of animals, fungi, and plants harbor two distant homologues of YidC, Oxa1 and Cox18/ Oxa2. Oxa1 plays a pivotal role in the integration of mitochondrial translation products into the inner membrane of mitochondria. It contains a C-terminal ribosome-binding domain that physically interacts with mitochondrial ribosomes to facilitate the cotranslational insertion of nascent membrane proteins. The molecular function of Cox18/ Oxa2 is not well understood. Employing a functional complementation approach with mitochondria- targeted versions of YidC we show that YidC is able to functionally replace both Oxa1 and Cox18/ Oxa2. However, to integrate mitochondrial translation products into the inner membrane of mitochondria, the ribosome- binding domain of Oxa1 has to be appended onto YidC. On the contrary, the fusion of the ribosome- binding domain onto YidC prevents its ability to complement COX18 mutants suggesting an indispensable post- translational activity of Cox18/ Oxa2. Our observations suggest that during evolution of mitochondria from their bacterial ancestors the two descendents of YidC functionally segregated to perform two distinct activities, one co-translational and one post- translational.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany; Free Univ Amsterdam, Inst Mol Cell Biol, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands	University of Munich; Vrije Universiteit Amsterdam	Herrmann, JM (corresponding author), Univ Munich, Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	hannes.herrmann@bio.med.uni-muenchen.de	Funes, Soledad/A-1278-2010; Luirink, Joen/AAB-8658-2021	Funes, Soledad/0000-0003-1815-1977; Luirink, J./0000-0001-8431-0804; Ott, Martin/0000-0001-6367-3091				Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; Bonnefoy N, 2000, MOL MICROBIOL, V35, P1135, DOI 10.1046/j.1365-2958.2000.01781.x; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x; Dalbey RE, 2004, J CELL BIOL, V166, P769, DOI 10.1083/jcb.200405161; de Gier JWL, 2003, EMBO REP, V4, P939, DOI 10.1038/sj.embor.embor921; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; Funes S, 2004, FEBS LETT, V569, P89, DOI 10.1016/j.febslet.2004.05.055; Funes S, 2004, MOL BIOL CELL, V15, P1853, DOI 10.1091/mbc.e03-11-0789; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GLICK BS, 1996, PROTEIN SCI, V5, P1; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Herrmann JM, 2003, TRENDS MICROBIOL, V11, P74, DOI 10.1016/S0966-842X(02)00033-1; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Herrmann JM, 2001, METHOD CELL BIOL, V65, P217, DOI 10.1016/S0091-679X(01)65013-1; Jia LX, 2003, EMBO J, V22, P6438, DOI 10.1093/emboj/cdg624; Jiang FL, 2002, J BIOL CHEM, V277, P19281, DOI 10.1074/jbc.M110857200; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; Nagamori S, 2004, J CELL BIOL, V165, P53, DOI 10.1083/jcb.200402067; Nargang FE, 2002, J BIOL CHEM, V277, P12846, DOI 10.1074/jbc.M112099200; Preuss M, 2001, J CELL BIOL, V153, P1085, DOI 10.1083/jcb.153.5.1085; Pugsley AP, 2004, MOL MICROBIOL, V52, P3, DOI 10.1111/j.1365-2958.2003.03966.x; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Sharma MR, 2003, CELL, V115, P97, DOI 10.1016/S0092-8674(03)00762-1; Sherman F., 1986, METHODS YEAST GENETI; Souza RL, 2000, J BIOL CHEM, V275, P14898, DOI 10.1074/jbc.275.20.14898; Szyrach G, 2003, EMBO J, V22, P6448, DOI 10.1093/emboj/cdg623; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Urbanus ML, 2002, J BIOL CHEM, V277, P12718, DOI 10.1074/jbc.M200311200; van Bloois E, 2005, J BIOL CHEM, V280, P12996, DOI 10.1074/jbc.M414094200; van Bloois E, 2004, FEBS LETT, V576, P97, DOI 10.1016/j.febslet.2004.08.069; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; Westermann B, 2001, METHOD CELL BIOL, V65, P429, DOI 10.1016/S0091-679X(01)65025-8	53	77	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13004	13011		10.1074/jbc.M414093200	http://dx.doi.org/10.1074/jbc.M414093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15654078	hybrid, Green Published			2022-12-25	WOS:000227922000110
J	Wang, YM; Chen, WD; Simpson, DM; Elion, EA				Wang, YM; Chen, WD; Simpson, DM; Elion, EA			Cdc24 regulates nuclear shuttling and recruitment of the Ste5 scaffold to a heterotrimeric G protein in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; BUD-SITE SELECTION; PLECKSTRIN HOMOLOGY DOMAINS; GTPASE-ACTIVATING PROTEINS; BETA-GAMMA-SUBUNITS; CELL POLARITY; SIGNAL-TRANSDUCTION; BUDDING YEAST; MAPK CASCADE; PHEROMONE RESPONSE	The Saccharomyces cerevisiae guanine nucleotide exchange factor Cdc24 regulates polarized growth by binding to Cdc42, a Rho- type GTPase that has many effectors, including Ste20 kinase, which activates multiple MAPK cascades. Here, we show that Cdc24 promotes MAPK signaling during mating through interactions with Ste5, a scaffold that must shuttle through the nucleus and bind to the beta subunit ( Ste4) of a G protein for Ste20 to activate the tethered MAPK cascade. Ste5 was basally recruited to growth sites of G(1) phase cells independently of Ste4. Loss of Cdc24 inhibited nuclear import and blocked basal and pheromone- induced recruitment of Ste5. Ste5 was not basally recruited and the MAPK Fus3 was not basally activated in the presence of a Cdc24 mutant ( G168D) that still activates Cdc42, suggesting that Cdc24 regulates Ste5 and the associated MAPK cascade through a function that is not dependent on its guanine nucleotide exchange factor activity. Consistent with this, Cdc24 bound Ste5 and coprecipitated with Ste4 independently of Far1 and Ste5. Loss of Cdc24 decreased Ste5- Ste4 complex formation, and loss of Ste4 stimulated Cdc24- Ste5 complex formation. Collectively, these findings suggest that Cdc24 mediates site- specific localization of Ste5 to a heterotrimeric G protein and may therefore ensure localized activation of the associated MAPK cascade.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Elion, EA (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	elaine_elion@hms.harvard.edu			NIGMS NIH HHS [GM69462] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069462] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Andersson J, 2004, EMBO J, V23, P2564, DOI 10.1038/sj.emboj.7600250; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Ayscough KR, 1998, CURR BIOL, V8, P927, DOI 10.1016/S0960-9822(07)00374-0; Bardwell L, 2005, PEPTIDES, V26, P337, DOI 10.1016/j.peptides.2004.10.001; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; Blondel M, 1999, GENE DEV, V13, P2284, DOI 10.1101/gad.13.17.2284; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; Casamayor A, 2002, CURR OPIN MICROBIOL, V5, P179, DOI 10.1016/S1369-5274(02)00300-4; Caviston JP, 2003, MOL BIOL CELL, V14, P4051, DOI 10.1091/mbc.E03-04-0247; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; Elion EA, 2001, J CELL SCI, V114, P3967; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; Farley FW, 1999, GENETICS, V151, P1425; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Flotho A, 2004, J BIOL CHEM, V279, P47391, DOI 10.1074/jbc.M405681200; GIMENO CJ, 1992, SCIENCE, V257, P626, DOI 10.1126/science.1496375; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Irazoqui JE, 2003, NAT CELL BIOL, V5, P1062, DOI 10.1038/ncb1068; Kim JA, 2000, MOL CELL BIOL, V20, P8826, DOI 10.1128/MCB.20.23.8826-8835.2000; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Krapivinsky G, 2003, NEURON, V40, P775, DOI 10.1016/S0896-6273(03)00645-7; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; Matheos D, 2004, J CELL BIOL, V165, P99, DOI 10.1083/jcb.200309089; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Miller PJ, 1997, YEAST, V13, P561; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Moskow JJ, 2000, MOL CELL BIOL, V20, P7559, DOI 10.1128/MCB.20.20.7559-7571.2000; Nern A, 2000, MOL CELL, V5, P853, DOI 10.1016/S1097-2765(00)80325-1; Nern A, 2000, J CELL BIOL, V148, P1115, DOI 10.1083/jcb.148.6.1115; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; Reiser V, 2000, NAT CELL BIOL, V2, P620, DOI 10.1038/35023568; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; Shimada Y, 2004, EMBO J, V23, P1051, DOI 10.1038/sj.emboj.7600124; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; Smith GR, 2002, EUKARYOT CELL, V1, P469, DOI 10.1128/EC.1.3.469-480.2002; Toenjes KA, 1999, CURR BIOL, V9, P1183, DOI 10.1016/S0960-9822(00)80022-6; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; van Drogen F, 2001, NAT CELL BIOL, V3, P1051, DOI 10.1038/ncb1201-1051; WANG DS, 1995, BIOCHEM BIOPH RES CO, V209, P622, DOI 10.1006/bbrc.1995.1545; Wang YM, 2003, MOL BIOL CELL, V14, P2543, DOI 10.1091/mbc.E02-10-0699; Wiget P, 2004, EMBO J, V23, P1063, DOI 10.1038/sj.emboj.7600123; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZIMAN M, 1994, YEAST, V10, P463, DOI 10.1002/yea.320100405	71	14	14	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13084	13096		10.1074/jbc.M410461200	http://dx.doi.org/10.1074/jbc.M410461200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15657049	hybrid			2022-12-25	WOS:000227922000119
J	Zhang, XL; Topley, N; Ito, T; Phillips, A				Zhang, XL; Topley, N; Ito, T; Phillips, A			Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta 1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULAR EPITHELIAL-CELLS; INFLAMMATORY-BOWEL-DISEASE; TGF-BETA; EXPERIMENTAL GLOMERULONEPHRITIS; DIABETIC-NEPHROPATHY; SMAD PROTEINS; T-CELLS; EXPRESSION; KIDNEY; MEMBRANES	Transforming growth factor (TGF)-beta 1 is a key cytokine involved in the pathogenesis of fibrosis in many organs, whereas interleukin (IL)-6 plays an important role in the regulation of inflammation. Recent reports demonstrate interaction between the two cytokines in disease states. We have assessed the effect of IL-6 on TGF-beta 1 signaling and defined the mechanism by which this occurred. Stimulation of Smad-responsive promoter (SBE)(4)-Lux activity by TGF-beta 1 was significantly greater in the presence of IL-6 than that induced by TGF-beta 1 alone. Augmented TGF-beta 1 signaling following the addition of IL-6 appeared to be mediated through binding to the cognate IL-6 receptor, the presence of which was confirmed by fluorescence-activated cell sorting and Stat-specific signaling. TGF-beta 1 receptors internalize by both caveolin-1 (Cav-1) lipid raft and early endosome antigen 1 (EEA-1) non-lipid raft pathways, with non-lipid raft-associated internalization increasing TGF-beta 1 signaling. Affinity labeling of TGF-beta 1 receptors demonstrated that IL-6 stimulation resulted in increased partitioning of TGF-beta receptors to the non-lipid raft fraction. There was no change in expression of Cav-1; however, following IL-6 stimulation, co-immunoprecipitation demonstrated decreased association of IL-6 receptor with Cav-1. Increased TGF-beta 1-dependent Smad signaling by IL-6 was significantly attenuated by inhibition of clathrin-mediated endocytosis and augmented by depletion of membrane cholesterol. These results indicate that IL-6 increased trafficking of TGF-beta 1 receptors to non-lipid raft-associated pools results in augmented TGF-beta 1 Smad signaling.	Cardiff Univ, Inst Nephrol, Sch Med, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Phillips, A (corresponding author), Cardiff Univ, Inst Nephrol, Sch Med, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	PhillipsAO@cf.ac.uk						Akagi Y, 1996, KIDNEY INT, V50, P148, DOI 10.1038/ki.1996.297; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P975, DOI 10.1053/gast.1996.v110.pm8613031; Basile DP, 1998, AM J PHYSIOL-RENAL, V275, pF894, DOI 10.1152/ajprenal.1998.275.6.F894; Basile DP, 1996, AM J PHYSIOL-RENAL, V270, pF500, DOI 10.1152/ajprenal.1996.270.3.F500; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BORDER WA, 1992, KIDNEY INT, V41, P566, DOI 10.1038/ki.1992.83; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Fraser D, 2002, AM J PATHOL, V161, P1039, DOI 10.1016/S0002-9440(10)64265-4; Fujita Y, 2004, KIDNEY INT, V66, P1794, DOI 10.1111/j.1523-1755.2004.00954.x; FUKATSU A, 1993, LAB INVEST, V69, P58; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOLZ RW, 1974, ANN NY ACAD SCI, V235, P469, DOI 10.1111/j.1749-6632.1974.tb43284.x; HORII Y, 1993, KIDNEY INT, V43, pS71; HORII Y, 1989, J IMMUNOL, V143, P3949; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Isaka Y, 2000, KIDNEY INT, V58, P1885, DOI 10.1046/j.1523-1755.2000.00360.x; Ito T, 2004, J BIOL CHEM, V279, P25326, DOI 10.1074/jbc.M403135200; Ito T, 2004, AM J PATHOL, V164, P1979, DOI 10.1016/S0002-9440(10)63758-3; Janssen U, 2001, KIDNEY INT, V60, P126, DOI 10.1046/j.1523-1755.2001.00779.x; Jones S, 2001, KIDNEY INT, V59, P1739, DOI 10.1046/j.1523-1755.2001.0590051739.x; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KULKARNI AB, 1993, AM J PATHOL, V143, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; MCCABE RP, 1993, CLIN IMMUNOL IMMUNOP, V66, P52, DOI 10.1006/clin.1993.1007; Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485; Morrisey K, 2001, AM J PATHOL, V159, P1905, DOI 10.1016/S0002-9440(10)63037-4; Orphanides C, 1997, KIDNEY INT, V52, P637, DOI 10.1038/ki.1997.377; Piek E, 1999, J CELL SCI, V112, P4557; Pitts RL, 2001, J BIOL CHEM, V276, P19966, DOI 10.1074/jbc.M011759200; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Walia B, 2003, FASEB J, V17, P2130, DOI 10.1096/fj.02-1211fje; YAMAMOTO T, 1994, KIDNEY INT, V45, P916, DOI 10.1038/ki.1994.122; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280	51	150	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12239	12245		10.1074/jbc.M413284200	http://dx.doi.org/10.1074/jbc.M413284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15661740	hybrid			2022-12-25	WOS:000227922000022
J	Law, PY; Erickson-Herbrandson, LJ; Zha, QQ; Solberg, J; Chu, J; Sarre, A; Loh, HH				Law, PY; Erickson-Herbrandson, LJ; Zha, QQ; Solberg, J; Chu, J; Sarre, A; Loh, HH			Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; 3RD INTRACELLULAR LOOP; COUPLED RECEPTORS; DOPAMINE D2; BETA(2)-ADRENERGIC RECEPTOR; CROSS-TALK; TRAFFICKING; DIMERIZATION; SUBUNITS; OLIGOMERIZATION	Homo- and heterodimerization of the opioid receptors with functional consequences were reported previously. However, the exact nature of these putative dimers has not been identified. In current studies, the nature of the heterodimers was investigated by producing the phenotypes of the 1: 1 heterodimers formed between the constitutively expressed mu- opioid receptor ( MOR) and the ponasterone A- induced expression of delta- opioid receptor ( DOR) in EcR293 cells. By examining the trafficking of the cell surface- located MOR and DOR, we determined that these two receptors endocytosed independently. Using cell surface expression- deficient mutants of MOR and DOR, we observed that the corresponding wild types of these receptors could not rescue the cell surface expression of the mutants, whereas the antagonist naloxone could. Furthermore, studies with constitutive or agonist- induced receptor internalization also indicated that MOR and DOR endocytosed independently and could not "drag in" the corresponding wild types or endocytosis- deficient mutants. Additionally, the heterodimer phenotypes could be eliminated by the pretreatment of the EcR293 cells with pertussis toxin and could be modulated by the deletion of the RRITR sequence in the third intracellular loop that is involved in the receptor- G protein interaction and activation. These data suggest that MOR and DOR heterodimerize only at the cell surface and that the oligomers of opioid receptors and heterotrimeric G protein are the bases for the observed MOR- DOR heterodimer phenotypes.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Law, PY (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St S-E, Minneapolis, MN 55455 USA.	lawxx001@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHS [DA007339, DA015091, DA016674, K05 DA70544, DA011806] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016674, R01DA007339, P50DA011806, P01DA015091] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Calver AR, 2001, J NEUROSCI, V21, P1203; Chaipatikul V, 2003, J PHARMACOL EXP THER, V305, P909, DOI 10.1124/jpet.102.046219; Chaipatikul V, 2003, MOL PHARMACOL, V64, P32, DOI 10.1124/mol.64.1.32; Chakrabarti S, 1997, MOL PHARMACOL, V52, P105, DOI 10.1124/mol.52.1.105; Chalecka-Franaszek E, 2000, J NEUROCHEM, V74, P1068, DOI 10.1046/j.1471-4159.2000.0741068.x; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Dean MK, 2001, J MED CHEM, V44, P4595, DOI 10.1021/jm010290+; Filippov AK, 2000, J NEUROSCI, V20, P2867; Filizola M, 2002, BIOPOLYMERS, V66, P317, DOI 10.1002/bip.10311; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Georgoussi Z, 1997, BBA-MOL CELL RES, V1359, P263, DOI 10.1016/S0167-4889(97)00097-9; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Gouldson PR, 1997, J MED CHEM, V40, P3871, DOI 10.1021/jm960647n; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; HERBERT TE, 1996, J BIOL CHEM, V271, P16384; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; JRODAN BA, 2000, P NATL ACAD SCI USA, V98, P343; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Martin NA, 2001, MOL PHARMACOL, V59, P774, DOI 10.1124/mol.59.4.774; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Pagano A, 2001, J NEUROSCI, V21, P1189; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Salim K, 2002, J BIOL CHEM, V277, P15482, DOI 10.1074/jbc.M201539200; Sawyer GW, 1999, J PHARMACOL EXP THER, V289, P464; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Tsu RC, 1997, MOL PHARMACOL, V52, P38, DOI 10.1124/mol.52.1.38; Wang W, 2003, J BIOL CHEM, V278, P36848, DOI 10.1074/jbc.M301540200; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Xie XD, 1999, FEBS LETT, V456, P63, DOI 10.1016/S0014-5793(99)00918-7; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	62	97	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11152	11164		10.1074/jbc.M500171200	http://dx.doi.org/10.1074/jbc.M500171200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657030	hybrid			2022-12-25	WOS:000227761800036
J	Schalm, SS; Tee, AR; Blenis, J				Schalm, SS; Tee, AR; Blenis, J			Characterization of a conserved c-terminal motif (RSPRR) in ribosomal protein S6-kinase-1 required for its mammalian target of rapamycin-dependent regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; CELL-CYCLE PROGRESSION; INITIATION-FACTOR 4E; PHOSPHORYLATION SITE; TRANSLATION INITIATION; TOS MOTIF; MTOR; P70(S6K); GROWTH; DOMAIN	The mammalian target of rapamycin, mTOR, is a Ser/Thr kinase that promotes cell growth and proliferation by activating ribosomal protein S6 kinase 1 (S6K1). We previously identified a conserved TOR signaling (TOS) motif in the N terminus of S6K1 that is required for its mTOR-dependent activation. Furthermore, our data suggested that the TOS motif suppresses an inhibitory function associated with the C terminus of S6K1. Here, we have characterized the mTOR-regulated inhibitory region within the C terminus. We have identified a conserved C-terminal "RSPRR" sequence that is responsible for an mTOR-dependent suppression of S6K1 activation. Deletion or mutations within this RSPRR motif partially rescue the kinase activity of the S6K1 TOS motif mutant (S6K1-F5A), and this rescued activity is rapamycin resistant. Furthermore, we have shown that the RSPRR motif significantly suppresses S6K1 phosphorylation at two phosphorylation sites (Thr-389 and Thr-229) that are crucial for S6K1 activation. Importantly, introducing both the Thr-389 phosphomimetic and RSPRR motif mutations into the catalytically inactive S6K1 mutant S6K1-F5A completely rescues its activity and renders it fully rapamycin resistant. These data show that the N-terminal TOS motif suppresses an inhibitory function mediated by the C-terminal RSPRR motif. We propose that the RSPRR motif interacts with a negative regulator of S6K1 that is normally suppressed by mTOR.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	john_blenis@hms.harvard.edu		Tee, Andrew/0000-0002-5577-4631	NIGMS NIH HHS [GM51405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Martin KA, 2001, J BIOL CHEM, V276, P7892, DOI 10.1074/jbc.M009972200; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687	21	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11101	11106		10.1074/jbc.M413995200	http://dx.doi.org/10.1074/jbc.M413995200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659381	hybrid			2022-12-25	WOS:000227761800028
J	Watts, BA; George, T; Good, DW				Watts, BA; George, T; Good, DW			The basolateral NHE1 Na+/H+ exchanger regulates transepithelial HCO3- absorption through actin cytoskeleton remodeling in renal thick ascending limb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; APICAL MEMBRANE; BICARBONATE ABSORPTION; MOLECULAR PHYSIOLOGY; PRIMARY HYPERTENSION; PROXIMAL TUBULE; ION-TRANSPORT; H+ EXCHANGE; F-ACTIN; MICE	In the renal medullary thick ascending limb ( MTAL), inhibiting the basolateral NHE1 Na+/H+ exchanger with amiloride or nerve growth factor (NGF) results secondarily in inhibition of the apical NHE3 Na+/H+ exchanger, thereby decreasing transepithelial HCO3- absorption. MTALs from rats were studied by in vitro microperfusion to identify the mechanism underlying cross-talk between the two exchangers. The basolateral addition of 10 mu M amiloride or 0.7 nM NGF decreased HCO3- absorption by 27-32%. Jasplakinolide, which stabilizes F-actin, or latrunculin B, which disrupts F-actin, decreased basal HCO3- absorption by 30% and prevented the inhibition by amiloride or NGF. Jasplakinolide had no effect on HCO3- absorption in tubules bathed with amiloride or a Na+-free bath to inhibit NHE1. Jasplakinolide and latrunculin B did not prevent inhibition of HCO3- absorption by vasopressin or stimulation by hyposmolality, factors that regulate HCO3- absorption through primary effects on apical Na+/H+ exchange. Treatment of MTALs with amiloride or NGF for 15 min decreased polymerized actin with no change in total cell actin, as assessed both by fluorescence microscopy and by actin Triton X-100 solubility. Jasplakinolide prevented amiloride-induced actin remodeling. Vasopressin, which inhibits HCO3- absorption by an amount similar to that observed with amiloride and NGF but does not act via NHE1, did not affect cellular F-actin content. These results indicate that basolateral NHE1 regulates apical NHE3 and HCO3- absorption in the MTAL by controlling the organization of the actin cytoskeleton.	Univ Texas, Med Branch, Dept Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Good, DW (corresponding author), Univ Texas, Med Branch, Dept Med, 4-200 John Sealy Annex,301 Univ Blvd, Galveston, TX 77555 USA.	dgood@utmb.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038217] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38217] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpern RJ, 2000, KIDNEY, P455; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BIEMESDERFER D, 1997, AM J PHYSIOL, V273, P289; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF83; BORENSZTEIN P, 1993, AM J PHYSIOL, V264, pF354, DOI 10.1152/ajprenal.1993.264.2.F354; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CHALUMEAU C, 2001, AM J PHYSIOL, V49, pF283; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Donowitz M, 2001, CURR TOP MEMBR, V50, P437; DRENCKHAHN D, 1993, RENAL PHYSIOL BIOCH, V16, P6; Frank AE, 2002, AM J PHYSIOL-RENAL, V282, pF1120, DOI 10.1152/ajprenal.00266.2001; Good DW, 2004, AM J PHYSIOL-RENAL, V287, pF1244, DOI 10.1152/ajprenal.00176.2004; Good DW, 1996, AM J PHYSIOL-RENAL, V270, pF691, DOI 10.1152/ajprenal.1996.270.4.F691; GOOD DW, 1993, SEMIN NEPHROL, V13, P225; GOOD DW, 1990, J CLIN INVEST, V85, P1006, DOI 10.1172/JCI114530; Good DW, 2000, AM J PHYSIOL-CELL PH, V279, pC1443, DOI 10.1152/ajpcell.2000.279.5.C1443; Good DW, 1995, P NATL ACAD SCI USA, V92, P12525, DOI 10.1073/pnas.92.26.12525; Goyal S, 2003, AM J PHYSIOL-RENAL, V284, pF467, DOI 10.1152/ajprenal.00352.2002; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Karmazyn M, 1999, CIRC RES, V85, P777, DOI 10.1161/01.RES.85.9.777; KRAPF R, 1991, J CLIN INVEST, V88, P783, DOI 10.1172/JCI115377; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; KUROO M, 1995, CIRC RES, V76, P148, DOI 10.1161/01.RES.76.1.148; Mills J W, 1994, Curr Opin Nephrol Hypertens, V3, P529, DOI 10.1097/00041552-199409000-00009; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Orlando RA, 2001, J AM SOC NEPHROL, V12, P1589, DOI 10.1681/ASN.V1281589; Orlov SN, 1999, AM J PHYSIOL-CELL PH, V276, pC511, DOI 10.1152/ajpcell.1999.276.3.C511; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Park K, 2001, J BIOL CHEM, V276, P27042, DOI 10.1074/jbc.M102901200; Peng Y, 2001, AM J PHYSIOL-RENAL, V280, pF34, DOI 10.1152/ajprenal.2001.280.1.F34; Prat AG, 1999, AM J PHYSIOL-CELL PH, V277, pC1160, DOI 10.1152/ajpcell.1999.277.6.C1160; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; SIFFERT W, 1995, HYPERTENSION, V26, P649, DOI 10.1161/01.HYP.26.4.649; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Szaszi K, 2001, J BIOL CHEM, V276, P40761, DOI 10.1074/jbc.M106724200; Szaszi K, 2000, CELL PHYSIOL BIOCHEM, V10, P265, DOI 10.1159/000016358; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Wang T, 1999, AM J PHYSIOL-RENAL, V277, pF298, DOI 10.1152/ajprenal.1999.277.2.F298; Wang YG, 2003, CIRC RES, V93, P776, DOI 10.1161/01.RES.0000094746.24774.DC; Watts BA, 2002, AM J PHYSIOL-RENAL, V282, pF1056, DOI 10.1152/ajprenal.00133.2001; Watts BA, 1999, J CLIN INVEST, V104, P1593, DOI 10.1172/JCI7332; Watts BA, 1999, J BIOL CHEM, V274, P7841, DOI 10.1074/jbc.274.12.7841; Wei Y, 2002, AM J PHYSIOL-RENAL, V282, pF680, DOI 10.1152/ajprenal.00229.2001; Weinman EJ, 2001, KIDNEY INT, V60, P450, DOI 10.1046/j.1523-1755.2001.060002450.x; WU MS, 1994, J MEMBRANE BIOL, V142, P323	54	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11439	11447		10.1074/jbc.M410719200	http://dx.doi.org/10.1074/jbc.M410719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644322	hybrid			2022-12-25	WOS:000227761800067
J	Yang, CR; Shapiro, BE; Hung, SP; Mjolsness, ED; Hatfield, GW				Yang, CR; Shapiro, BE; Hung, SP; Mjolsness, ED; Hatfield, GW			A mathematical model for the branched chain amino acid biosynthetic pathways of Escherichia coli K12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBAL GENE-EXPRESSION; THREONINE DEAMINASE; COLI; 2-KETOBUTYRATE; METABOLISM; ISOLEUCINE; MECHANISM	As a first step toward the elucidation of the systems biology of the model organism Escherichia coli, it was our goal to mathematically model a metabolic system of intermediate complexity, namely the well studied end product-regulated pathways for the biosynthesis of the branched chain amino acids L-isoleucine, L-valine, and L-leucine. This has been accomplished with the use of kMech (Yang, C.-R., Shapiro, B. E., Mjolsness, E. D., and Hatfield, G. W. (2005) Bioinformatics 21, in press), a Cellerator (Shapiro, B. E., Levchenko, A., Meyerowitz, E. M., Wold, B. J., and Mjolsness, E. D. (2003) Bioinformatics 19, 677-678) language extension that describes a suite of enzyme reaction mechanisms. Each enzyme mechanism is parsed by kMech into a set of fundamental association-dissociation reactions that are translated by Cellerator into ordinary differential equations. These ordinary differential equations are numerically solved by Mathematica (TM). Any metabolic pathway can be simulated by stringing together appropriate kMech models and providing the physical and kinetic parameters for each enzyme in the pathway. Writing differential equations is not required. The mathematical model of branched chain amino acid biosynthesis in E. coli K12 presented here incorporates all of the forward and reverse enzyme reactions and regulatory circuits of the branched chain amino acid biosynthetic pathways, including single and multiple substrate (Ping Pong and Bi Bi) enzyme kinetic reactions, feedback inhibition ( allosteric, competitive, and non-competitive) mechanisms, the channeling of metabolic flow through isozymes, the channeling of metabolic flow via transamination reactions, and active transport mechanisms. This model simulates the results of experimental measurements.	Univ Calif Irvine, Inst Genom & Bioinformat, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Informat & Comp Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Mjolsness, ED (corresponding author), Univ Calif Irvine, Inst Genom & Bioinformat, Irvine, CA 92697 USA.	emj@uci.edu; gwhatfie@uci.edu			NIGMS NIH HHS [GM55073, GM68903] Funding Source: Medline; NLM NIH HHS [T15 LM-07443] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068903] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ADAMS CW, 1985, J BIOL CHEM, V260, P8538; Arfin SM, 2000, J BIOL CHEM, V275, P29672, DOI 10.1074/jbc.M002247200; BARAK Z, 1987, J BACTERIOL, V169, P3750, DOI 10.1128/jb.169.8.3750-3756.1987; CALHOUN DH, 1973, J BIOL CHEM, V248, P3511; CHANGEUX JP, 1963, COLD SPRING HARB SYM, V28, P497, DOI 10.1101/SQB.1963.028.01.066; DANCHIN A, 1984, MOL GEN GENET, V193, P473, DOI 10.1007/BF00382086; DANIEL J, 1983, MOL GEN GENET, V190, P452, DOI 10.1007/BF00331076; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Epelbaum S, 1998, J BACTERIOL, V180, P4056, DOI 10.1128/JB.180.16.4056-4067.1998; Falk S, 1998, BIOPHYS J, V74, P816, DOI 10.1016/S0006-3495(98)74006-8; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gillespie DT, 2000, J CHEM PHYS, V113, P297, DOI 10.1063/1.481811; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Hashiguchi K, 1999, BIOSCI BIOTECH BIOCH, V63, P672, DOI 10.1271/bbb.63.672; HATFIELD GW, 1970, J BIOL CHEM, V245, P1742; Hatfield GW, 2002, ANNU REV GENET, V36, P175, DOI 10.1146/annurev.genet.36.032902.111815; HATFIELD GW, 1970, THESIS PURDUE U PURD, P103; HERRING PA, 1995, BIOCHEM BIOPH RES CO, V207, P48, DOI 10.1006/bbrc.1995.1151; Hung SP, 2002, J BIOL CHEM, V277, P40309, DOI 10.1074/jbc.M204044200; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; JACKSON JH, 1993, BIOCHIMIE, V75, P759, DOI 10.1016/0300-9084(93)90125-C; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karp PD, 2002, NUCLEIC ACIDS RES, V30, P56, DOI 10.1093/nar/30.1.56; LAWTHER RP, 1982, J BACTERIOL, V149, P294, DOI 10.1128/JB.149.1.294-298.1982; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P1310; QUAY SC, 1977, J BACTERIOL, V129, P1257, DOI 10.1128/JB.129.3.1257-1265.1977; Reed JL, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r54; Schomburg I, 2004, NUCLEIC ACIDS RES, V32, pD431, DOI 10.1093/nar/gkh081; SEGEL IH, 1993, ENZYME KINETICS BEHA, P427; Selkov E, 1996, NUCLEIC ACIDS RES, V24, P26, DOI 10.1093/nar/24.1.26; Shapiro BE, 2003, BIOINFORMATICS, V19, P677, DOI 10.1093/bioinformatics/btg042; Umbarger H. E., 1996, ESCHERICHIA COLI SAL, P442; UMBARGER HE, 1955, J BACTERIOL, V70, P241, DOI 10.1128/JB.70.2.241-248.1955; UMBARGER HE, 1978, ANNU REV BIOCHEM, V47, P533, DOI 10.1146/annurev.bi.47.070178.002533; YANG CR, 2005, IN PRESS BIOINFORMAT, V21	38	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11224	11232		10.1074/jbc.M411471200	http://dx.doi.org/10.1074/jbc.M411471200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657047	Green Published, hybrid			2022-12-25	WOS:000227761800043
J	Bremer, E; Samplonius, DF; van Genne, L; Dijkstra, MH; Kroesen, BJ; de Leij, LFMH; Helfrich, W				Bremer, E; Samplonius, DF; van Genne, L; Dijkstra, MH; Kroesen, BJ; de Leij, LFMH; Helfrich, W			Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv : sTRAIL fusion protein with specificity for human EGFR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE INHIBITOR; CELL LUNG-CANCER; MONOCLONAL-ANTIBODY; PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA CELLS; HIGH-LEVEL; IN-VIVO; CASPASE-8; ZD1839; SENSITIVITY	Epidermal growth factor receptor (EGFR) signaling inhibition by monoclonal antibodies and EGFR-specific tyrosine kinase inhibitors has shown clinical efficacy in cancer by restoring susceptibility of tumor cells to therapeutic apoptosis induction. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anti-cancer agent with tumor-selective apoptotic activity. Here we present a novel approach that combines EGFR-signaling inhibition with target cell-restricted apoptosis induction using a TRAIL fusion protein with engineered specificity for EGFR. This fusion protein, scFv425:sTRAIL, comprises the EGFR-blocking antibody fragment scFv425 genetically fused to soluble TRAIL (sTRAIL). Treatment with scFv425: sTRAIL resulted in the specific accretion to the cell surface of EGFR-positive cells only. EGFR-specific binding rapidly induced a dephosphorylation of EGFR and downstream mitogenic signaling, which was accompanied by cFLIP(L) down-regulation and Bad dephosphorylation. EGFR-specific binding converted soluble scFv425: sTRAIL into a membrane-bound form of TRAIL that cross-linked agonistic TRAIL receptors in a paracrine manner, resulting in potent apoptosis induction in a series of EGFR-positive tumor cell lines. Co-treatment of EGFR-positive tumor cells with the EGFR-tyrosine kinase inhibitor Iressa resulted in a potent synergistic pro-apoptotic effect, caused by the specific down-regulation of c-FLIPL. Furthermore, in mixed culture experiments binding of scFv425: sTRAIL to EGFR-positive target cells conveyed a potent apoptotic effect toward EGFR-negative bystander tumor cells. The favorable characteristics of scFv425: sTRAIL, alone and in combination with Iressa, as well as its potent anti-tumor bystander activity indicate its potential value for treatment of EGFR-expressing cancers.	Univ Groningen, Inst Drug Explorat, Univ Med Ctr Groningen, Dept Pathol & Lab Med,Sect Med Biol,Lab Tumor Imm, NL-9713 GZ Groningen, Netherlands	University of Groningen	Helfrich, W (corresponding author), Univ Groningen Hosp, Dept Pathol & Lab Med, Sect Med Biol, Lab Tumor Immunol, Bldg CMC VII,Rm T2-228,Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	w.helfrich@med.rug.nl	Bremer, Edwin S/B-7508-2016	Bremer, Edwin S/0000-0002-0325-7376; Helfrich, Wijnand/0000-0001-7004-3995				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barker AJ, 2001, BIOORG MED CHEM LETT, V11, P1911, DOI 10.1016/S0960-894X(01)00344-4; Bremer E, 2004, NEOPLASIA, V6, P636, DOI 10.1593/neo.04229; Bremer E, 2004, INT J CANCER, V109, P281, DOI 10.1002/ijc.11702; Chan KC, 2002, CANCER RES, V62, P122; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; Gabler B, 1997, ANTICANCER RES, V17, P3157; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Herberman RB, 2002, SEMIN ONCOL, V29, P27, DOI 10.1053/sonc.2002.33079; Herbst RS, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.35644; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Jonsson G, 2003, ANTICANCER RES, V23, P1213; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Kim KH, 2000, CLIN CANCER RES, V6, P335; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kortt AA, 2001, BIOMOL ENG, V18, P95, DOI 10.1016/S1389-0344(01)00090-9; Leverkus M, 2000, CANCER RES, V60, P553; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Muller KM, 1998, FEBS LETT, V432, P45, DOI 10.1016/S0014-5793(98)00829-1; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Normanno N, 2003, J CELL PHYSIOL, V194, P13, DOI 10.1002/jcp.10194; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Osaki M, 2004, J CANCER RES CLIN, V130, P8, DOI 10.1007/s00432-003-0505-z; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Park SY, 2002, BIOCHEM BIOPH RES CO, V295, P515, DOI 10.1016/S0006-291X(02)00719-2; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Power BE, 2000, J IMMUNOL METHODS, V242, P193, DOI 10.1016/S0022-1759(00)00201-5; Raben D, 2002, SEMIN ONCOL, V29, P37, DOI 10.1053/sonc.2002.31521; RODECK U, 1987, J CELL BIOCHEM, V35, P315, DOI 10.1002/jcb.240350406; RODECK U, 1987, CANCER RES, V47, P3692; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Sedger LM, 1999, J IMMUNOL, V163, P920; Solomon B, 2003, INT J RADIAT ONCOL, V55, P713, DOI 10.1016/S0360-3016(02)04357-2; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Wajant H, 2001, ONCOGENE, V20, P4101, DOI 10.1038/sj.onc.1204558; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	57	78	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10025	10033		10.1074/jbc.M413673200	http://dx.doi.org/10.1074/jbc.M413673200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644326	hybrid			2022-12-25	WOS:000227559600036
J	Chen, ZH; Stokes, DL; Jones, LR				Chen, ZH; Stokes, DL; Jones, LR			Role of leucine 31 of phospholamban in structural and functional interactions with the Ca2+ pump of cardiac sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; INTERACTION SITE; CROSS-LINKING; CALCIUM-PUMP; CA2+-ATPASE; ATPASE; DOMAIN; INHIBITION; FORMS; THAPSIGARGIN	The ability of two loss-of-function mutants, L31A and L31C, of phospholamban (PLB) to bind to and inhibit the Ca2+ pump of cardiac sarcoplasmic reticulum (SERCA2a) was investigated using a molecular cross-linking approach. Leu(31) of PLB, located at the cytoplasmic membrane boundary, is a critical amino acid shown previously to be essential for Ca2+-ATPase inhibition. We observed that L31A or L31C mutations of PLB prevented the inhibition of Ca2+-ATPase activity and disabled the cross-linking of N27C and N30C of PLB to Lys(328) and Cys(318) of SERCA2a. Although L31C-PLB failed to cross-link to any Cys or Lys residue of wild-type SERCA2a, L31C did cross-link with high efficiency to T317C of SERCA2a with use of the homobifunctional sulfhydryl cross-linking reagent, 1,6-bismaleimidohexane. This places Leu(31) of PLB within 10 angstrom of Thr(317) of SERCA2a in the M4 helix. Thus, contrary to previous suggestions, PLB with loss-of-function mutations at Leu(31) retains the ability to bind to SERCA2a, despite losing inhibitory activity. Cross-linking of L31C-PLB to T317C-SERCA2a occurred only in the absence of Ca2+ and in the presence of nucleotide and was prevented by thapsigargin and by anti-PLB antibody, demonstrating for a fourth cross-linking pair that PLB interacts near M4 only when the Ca2+ pump is in the Ca2+-free, nucleotide-bound E2 conformation, but not in the E2 state inhibited by thapsigargin. L31I-PLB retained full functional and cross-linking activity, suggesting that a bulky hydrophobic residue at position 31 of PLB is essential for productive interaction with SERCA2a. A model for the three-dimensional structure of the interaction site is proposed.	Krannert Cardiovasc Res Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Indiana University System; Indiana University-Purdue University Indianapolis; New York University; New York University	Chen, ZH (corresponding author), Krannert Cardiovasc Res Inst, 1800 N Capitol Ave, Indianapolis, IN 46202 USA.	lrjones@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049428, R01HL049428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056960] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49428] Funding Source: Medline; NIGMS NIH HHS [GM56960] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; Chen ZH, 2003, J BIOL CHEM, V278, P48348, DOI 10.1074/jbc.M309545200; Cornea RL, 2002, BIOPHYS J, V82, p527A; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; Haghighi K, 2004, BIOCHEM BIOPH RES CO, V322, P1214, DOI 10.1016/j.bbrc.2004.07.164; Hutter MC, 2002, CHEMBIOCHEM, V3, P1200, DOI 10.1002/1439-7633(20021202)3:12<1200::AID-CBIC1200>3.0.CO;2-H; INESI G, 1994, J MEMBRANE BIOL, V141, P1; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; Jones LR, 2002, J BIOL CHEM, V277, P28319, DOI 10.1074/jbc.M204085200; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Lamberth S, 2000, HELV CHIM ACTA, V83, P2141, DOI 10.1002/1522-2675(20000906)83:9<2141::AID-HLCA2141>3.0.CO;2-W; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SIMMERMAN HKB, 1989, BIOCHIM BIOPHYS ACTA, V997, P322, DOI 10.1016/0167-4838(89)90203-3; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; TATULIAN SA, 1995, BIOCHEMISTRY-US, V34, P4448, DOI 10.1021/bi00013a038; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2003, P NATL ACAD SCI USA, V100, P467, DOI 10.1073/pnas.0237326100; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WEGENER AD, 1986, J BIOL CHEM, V261, P5154	29	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10530	10539		10.1074/jbc.M414007200	http://dx.doi.org/10.1074/jbc.M414007200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644311	hybrid			2022-12-25	WOS:000227559600097
J	Hytonen, VP; Maatta, JAE; Nyholm, TKM; Livnah, O; Eisenberg-Domovich, Y; Hyre, D; Nordlund, HR; Horha, J; Niskanen, EA; Paldanius, T; Kulomaa, T; Porkka, EJ; Stayton, PS; Laitinen, OH; Kulomaa, MS				Hytonen, VP; Maatta, JAE; Nyholm, TKM; Livnah, O; Eisenberg-Domovich, Y; Hyre, D; Nordlund, HR; Horha, J; Niskanen, EA; Paldanius, T; Kulomaa, T; Porkka, EJ; Stayton, PS; Laitinen, OH; Kulomaa, MS			Design and construction of highly stable, protease-resistant chimeric avidins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN AVIDIN; THERMAL-STABILITY; HIGH-AFFINITY; GLUTAMATE-DEHYDROGENASE; CRYSTAL-STRUCTURE; BIOTIN-BINDING; LOOP-DELETION; HOT-SPOTS; KEY ROLE; STREPTAVIDIN	The chicken avidin gene family consists of avidin and seven separate avidin-related genes (AVRs) 1-7. Avidin protein is a widely used biochemical tool, whereas the other family members have only recently been produced as recombinant proteins and characterized. In our previous study, AVR4 was found to be the most stable biotin binding protein thus far characterized (T-m = 106.4 degrees C). In this study, we studied further the biotin-binding properties of AVR4. A decrease in the energy barrier between the biotin-bound and unbound state of AVR4 was observed when compared with that of avidin. The high resolution structure of AVR4 facilitated comparison of the structural details of avidin and AVR4. In the present study, we used the information obtained from these comparative studies to transfer the stability and functional properties of AVR4 to avidin. A chimeric avidin protein, ChiAVD, containing a 21-amino acid segment of AVR4 was found to be significantly more stable (T-m = 96.5 degrees C) than native avidin (T-m = 83.5 degrees C), and its biotin-binding properties resembled those of AVR4. Optimization of a crucial subunit interface of avidin by an AVR4-inspired point mutation, I117Y, significantly increased the thermostability of the avidin mutant (Tm = 97.5 degrees C) without compromising its high biotin-binding properties. By combining these two modifications, a hyperthermostable ChiAVD( I117Y) was constructed (T-m = 111.1 degrees C). This study provides an example of rational protein engineering in which another member of the protein family has been utilized as a source in the optimization of selected properties.	Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40014 Jyvaskyla, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland; Hebrew Univ Jerusalem, Dept Biol Chem, Inst Life Sci, Wolfson Ctr Appl Stuct Biol, IL-91904 Jerusalem, Israel; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ Kuopio, Dept Mol Med, AI Virtanen Inst, FIN-70211 Kuopio, Finland	University of Jyvaskyla; Abo Akademi University; Hebrew University of Jerusalem; University of Washington; University of Washington Seattle; Finland National Institute for Health & Welfare; University of Eastern Finland	Kulomaa, MS (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35 YAB, FIN-40014 Jyvaskyla, Finland.	markku.kulomaa@uta.fi	Määttä, Juha/A-6629-2016; Hytonen, Vesa P./E-8855-2013; Kulomaa, Markku S/C-9063-2014; Stayton, Patrick/C-1975-2018; Laitinen, Olli H/A-6618-2016; Niskanen, Einari/O-1379-2019; Niskanen, Einari A/F-2883-2017	Määttä, Juha/0000-0003-3885-6149; Hytonen, Vesa P./0000-0002-9357-1480; Stayton, Patrick/0000-0001-6939-6371; Laitinen, Olli H/0000-0002-3751-9952; Niskanen, Einari A/0000-0001-9471-7026				Ahlroth MK, 2001, BIOCHEM BIOPH RES CO, V288, P400, DOI 10.1006/bbrc.2001.5760; Ahlroth MK, 2000, ANIM GENET, V31, P367, DOI 10.1046/j.1365-2052.2000.00681.x; Backmann J, 1998, J MOL BIOL, V284, P817, DOI 10.1006/jmbi.1998.2216; Britton KL, 1999, J MOL BIOL, V293, P1121, DOI 10.1006/jmbi.1999.3205; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; Chu V, 1998, PROTEIN SCI, V7, P848; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; Ferrin T. E., 1988, J MOL GRAPHICS, V6, P36; Gonzalez M, 1999, BIOMOL ENG, V16, P67, DOI 10.1016/S1050-3862(99)00041-8; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; Hu ZJ, 2000, PROTEINS, V39, P331, DOI 10.1002/(SICI)1097-0134(20000601)39:4<331::AID-PROT60>3.0.CO;2-A; Hyre DE, 2000, PROTEIN SCI, V9, P878, DOI 10.1110/ps.9.5.878; Hyre DE, 2002, NAT STRUCT BIOL, V9, P582, DOI 10.1038/nsb825; Hytonen VP, 2004, J BIOL CHEM, V279, P9337, DOI 10.1074/jbc.M310989200; Hytonen VR, 2004, BIOCHEM J, V384, P385, DOI 10.1042/BJ20041114; JOHNSON MS, 1993, J MOL BIOL, V231, P735, DOI 10.1006/jmbi.1993.1323; Kannan N, 2000, PROTEIN ENG, V13, P753, DOI 10.1093/protein/13.11.753; Klumb LA, 1998, BIOCHEMISTRY-US, V37, P7657, DOI 10.1021/bi9803123; Knapp S, 1997, J MOL BIOL, V267, P916, DOI 10.1006/jmbi.1996.0900; KUNNAS TA, 1993, BIOCHIM BIOPHYS ACTA, V1216, P441, DOI 10.1016/0167-4781(93)90012-3; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; Laitinen OH, 2002, BIOCHEM J, V363, P609, DOI 10.1042/0264-6021:3630609; Laitinen OH, 2001, J BIOL CHEM, V276, P8219, DOI 10.1074/jbc.M007930200; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Nordlund HR, 2003, J BIOL CHEM, V278, P2479, DOI 10.1074/jbc.M210721200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; TUOHIMAA P, 1989, International Journal of Developmental Biology, V33, P125; Vetriani C, 1998, P NATL ACAD SCI USA, V95, P12300, DOI 10.1073/pnas.95.21.12300; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wilchek M, 1999, BIOMOL ENG, V16, P1; WILCHEK M, 1990, METHOD ENZYMOL, V184, P5	39	46	47	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10228	10233		10.1074/jbc.M414196200	http://dx.doi.org/10.1074/jbc.M414196200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15649900	hybrid			2022-12-25	WOS:000227559600061
J	Jin, ZH; Kurosu, T; Yamaguchi, M; Arai, A; Miura, O				Jin, ZH; Kurosu, T; Yamaguchi, M; Arai, A; Miura, O			Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis	ONCOGENE			English	Article						cell cycle checkpoints; hematopoietic cytokines; Chk1; Akt; GSK3	ACUTE MYELOID-LEUKEMIA; GLYCOGEN-SYNTHASE KINASE-3; CELL-CYCLE ARREST; COLONY-STIMULATING FACTOR; DNA-DAMAGE; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE PHOSPHORYLATION; ERYTHROPOIETIN RECEPTOR; SIGNALING PATHWAY; CHK1	Hematopoietic cytokines play crucial roles in regulation of cell cycle progression and apoptosis of hematopoietic cells. However, the effects of cytokines on cellular responses to chemotherapeutic agents and the mechanisms involved have remained elusive. Here we report that erythropoietin or IL-3 promotes G2/M arrest and prevents apoptosis induced by the topoisomerase II inhibitor etoposide in murine hematopoietic 32D cells and human leukemic UT7 cells. Erythropoietin or IL-3 significantly enhanced etoposide-induced activation-specific phosphorylation of Chk1, a checkpoint kinase that inhibits Cdc2 activation by Cdc25 phosphatases, and led to the inhibition of Cdc2 kinase activity with the persistent inhibitory phosphorylation on Tyr15. The inhibitory Cdc2 phosphorylation and G2/M block by etoposide were enhanced or inhibited by overexpression of Chk1 or by the specific Chk1 inhibitor SB218078, respectively. The G2/M arrest induced by etoposide was also enhanced or inhibited by expression of a constitutively activated or dominant-negative Akt mutant, respectively. Furthermore, SB216763 or LiCl, a specific inhibitor for the GSK3 kinase inhibited by Akt, enhanced the Chk1 phosphorylation and G2/M arrest by etoposide. These results indicate that hematopoietic cytokines protect etoposide-treated cells from DNA damage-induced apoptosis by promoting, through the PI3K/Akt/GSK3 signaling pathway, G2/M checkpoint that is dependent on Chk1-mediated inhibition of Cdc2.	Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Cheong JW, 2003, LEUKEMIA RES, V27, P1159, DOI 10.1016/S0145-2126(03)00102-4; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Eapen AK, 2001, MOL CELL BIOL, V21, P6113, DOI 10.1128/MCB.21.18.6113-6121.2001; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Henry MK, 2001, BLOOD, V98, P834, DOI 10.1182/blood.V98.3.834; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jackson JR, 2000, CANCER RES, V60, P566; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; King FW, 2004, CELL CYCLE, V3, P634; KOMATSU N, 1991, CANCER RES, V51, P341; Kubota Y, 2004, LEUKEMIA, V18, P1438, DOI 10.1038/sj.leu.2403402; Lowenberg B, 2003, NEW ENGL J MED, V349, P743, DOI 10.1056/NEJMoa025406; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; Nimbalkar D, 2003, CANCER RES, V63, P1034; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; Sramkoski RM, 1999, CYTOMETRY, V35, P274, DOI 10.1002/(SICI)1097-0320(19990301)35:3<274::AID-CYTO11>3.0.CO;2-O; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	38	40	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1973	1981		10.1038/sj.onc.1208408	http://dx.doi.org/10.1038/sj.onc.1208408			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15674326				2022-12-25	WOS:000227681900002
J	Coll, MAL; Perera, S; Shi, W; Filmus, J				Coll, MAL; Perera, S; Shi, W; Filmus, J			A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells	ONCOGENE			English	Article						anoikis; c-Src; caveolin-1; IEC-18; colon cancer	HUMAN BREAST-CANCER; C-SRC; INDUCED APOPTOSIS; TYROSINE KINASES; DOWN-REGULATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; ACTIVATED RAS; DEATH; ADHESION	Detachment of epithelial cells from the basement membrane ( BM) induces apoptosis, a phenomenon now widely known as anoikis. Studies in mammary and intestinal epithelial cells have shown that the loss of attachment to the BM rapidly triggers reversible proapoptotic events from which the cells can recover if they reattach within a certain period. Thus, cells seem to be transiently protected from the initial detachment-induced proapoptotic events. The molecular mechanisms underlying such transient protection against anoikis are unknown. In this paper, we present evidence indicating that detachment of intestinal epithelial cells triggers a transient, yet significant increase in the activity of the tyrosine kinases c-Src and c-Fyn, and that this activation of Src-family kinases (SFK) contributes to the transient protection against anoikis in these cells. The protective signals from SFK are mediated by the PI3K pathway, and caveolin-1. In addition, we show that the MEK1-ERK1/2 pathway acts in a synergistic manner with SFK to protect intestinal epithelial cells from anoikis.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Filmus, J (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Mol & Cellular Biol, 2075 Bayview Ave,S Wing,Room S218, Toronto, ON M4N 3M5, Canada.	jorge.filmus@sw.ca		Perera, Sheron/0000-0001-8048-0611; Loza Coll, Mariano/0000-0002-3123-1229				Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Carver LA, 2003, CANCER RES, V63, P6571; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Ishida K, 2003, BIOCHEM BIOPH RES CO, V300, P201, DOI 10.1016/S0006-291X(02)02790-0; JAMAL HH, 1994, ONCOGENE, V9, P417; Krestow JK, 1999, BIOCHEM BIOPH RES CO, V260, P48, DOI 10.1006/bbrc.1999.0863; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin EH, 2004, EXP CELL RES, V293, P1, DOI 10.1016/j.yexcr.2003.09.008; LOZA CM, 2002, ONCOGENE, V21, P2908; Maher PA, 2000, EXP CELL RES, V260, P189, DOI 10.1006/excr.2000.5009; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Quaroni A, 1980, Methods Cell Biol, V21B, P403; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Reed BH, 2004, CURR BIOL, V14, P372, DOI 10.1016/j.cub.2004.02.029; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sevignani C, 1998, J CLIN INVEST, V101, P1572, DOI 10.1172/JCI919; STRANGE R, 1992, DEVELOPMENT, V115, P49; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zheng XM, 2002, J BIOL CHEM, V277, P21922, DOI 10.1074/jbc.M201394200; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037	50	51	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1727	1737		10.1038/sj.onc.1208379	http://dx.doi.org/10.1038/sj.onc.1208379			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674335				2022-12-25	WOS:000227345100009
J	Bhatia, M; Wong, FL; Fu, D; Lau, HY; Moochhala, SM; Moore, PK				Bhatia, M; Wong, FL; Fu, D; Lau, HY; Moochhala, SM; Moore, PK			Role of hydrogen sulfide in acute pancreatitis and associated lung injury	FASEB JOURNAL			English	Article						inflammation cystathionine-gamma-lyase; DL-propargylglycine; myeloperoxidase; caerulein	SMOOTH-MUSCLE RELAXANT; NITRIC-OXIDE SYNTHASE; INFLAMMATORY MEDIATORS; GAMMA-LYASE; IN-VITRO; H2S; MICE; INACTIVATION; INHIBITION; METABOLISM	Hydrogen sulfide (H2S) is a naturally occurring gas with potent vasodilator activity. Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S. Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system. Whilst H2S has been reported to relax precontracted rat arteries in vitro and to lower blood pressure in the rat, its effect in an inflammatory condition such as acute pancreatitis has not previously been reported. In this paper, we report the presence of H2S synthesizing enzyme activity and CSE ( as determined by mRNA signal) in the pancreas. Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204 +/- 59); prophylactic treatment: placebo, 10635 +/- 305; PAG, 7904 +/- 495; therapeutic treatment: placebo, 10427 +/- 470; PAG, 7811 +/- 428; P< 0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) ( prophylactic treatment: placebo, 5.78 +/- 0.63; PAG, 2.97 +/- 0.39; therapeutic treatment: placebo, 5.48 +/- 0.52; PAG, 3.03 +/- 0.47; P< 0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/ necrosis; 4) lung MPO activity ( fold increase over control) [ prophylactic treatment: placebo, 1.99 +/- 0.16; PAG, 1.34 +/- 0.14; therapeutic treatment: placebo, 2.03 +/- 0.12; PAG, 1.41 +/- 0.97; P< 0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury. These effects of CSE blockade suggest an important proinflammatory role of H2S in regulating the severity of pancreatitis and associated lung injury and raise the possibility that H2S may exert similar activity in other forms of inflammation.	Natl Univ Singapore, Fac Med, Dept Pharmacol, Singapore 117597, Singapore; Def Sci Org, Def Med & Environm Res Inst, Ctr Biomed Sci, Singapore 0511, Singapore	National University of Singapore	Bhatia, M (corresponding author), Natl Univ Singapore, Fac Med, Dept Pharmacol, Bldg MD2,18 Med Dr, Singapore 117597, Singapore.	mbhatia@nus.edu.sg		MOOCHHALA, SHABBIR/0000-0003-4521-3192				Abe K, 1996, J NEUROSCI, V16, P1066; Bhatia M, 2000, J PATHOL, V190, P117; Bhatia M, 1998, P NATL ACAD SCI USA, V95, P4760, DOI 10.1073/pnas.95.8.4760; Bhatia M., 2002, Current Drug Targets - Inflammation and Allergy, V1, P343; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; Bhatia M, 2003, AM J PHYSIOL-GASTR L, V284, pG830, DOI 10.1152/ajpgi.00140.2002; Bhatia M, 2001, Curr Opin Investig Drugs, V2, P496; Bhatia M, 2000, GUT, V47, P838, DOI 10.1136/gut.47.6.838; BHATIA M, 2004, MED CHEM REV ONLINE, V1, P25, DOI DOI 10.2174/1567203043480395; Chen P, 1999, ADV ENZYME REGUL, V39, P93, DOI 10.1016/S0065-2571(98)00029-6; Cheng YQ, 2004, AM J PHYSIOL-HEART C, V287, pH2316, DOI 10.1152/ajpheart.00331.2004; Cuzzocrea S, 2002, SHOCK, V17, P416, DOI 10.1097/00024382-200205000-00013; DiMagno MJ, 2004, AM J PHYSIOL-GASTR L, V287, pG80, DOI 10.1152/ajpgi.00525.2003; Geng B, 2004, BIOCHEM BIOPH RES CO, V313, P362, DOI 10.1016/j.bbrc.2003.11.130; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Hui Y, 2003, J INFECTION, V47, P155, DOI 10.1016/S0163-4453(03)00043-4; JOHNSTON M, 1979, BIOCHEMISTRY-US, V18, P4690, DOI 10.1021/bi00588a033; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lau HY, 2005, BIOCHEM BIOPH RES CO, V327, P509, DOI 10.1016/j.bbrc.2004.12.030; Moore PK, 2003, TRENDS PHARMACOL SCI, V24, P609, DOI 10.1016/j.tips.2003.10.007; Ogasawara Y, 1997, BBA-GEN SUBJECTS, V1334, P33, DOI 10.1016/S0304-4165(96)00072-4; Patacchini R, 2004, BRIT J PHARMACOL, V142, P31, DOI 10.1038/sj.bjp.0705764; PIERRE KJ, 1976, CLIN CHEM, V22, P1219; REED DJ, 1995, METHOD ENZYMOL, V252, P92; Sanchez-Bernal C, 2004, PANCREAS, V28, pE9, DOI 10.1097/00006676-200401000-00021; Steegborn C, 1999, J BIOL CHEM, V274, P12675, DOI 10.1074/jbc.274.18.12675; Teague B, 2002, BRIT J PHARMACOL, V137, P139, DOI 10.1038/sj.bjp.0704858; UREN JR, 1978, BIOCHEM PHARMACOL, V27, P2807, DOI 10.1016/0006-2952(78)90194-6; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; WASHTIEN W, 1977, BIOCHEMISTRY-US, V16, P2485, DOI 10.1021/bi00630a026; Zhang CY, 2003, BIOCHEM BIOPH RES CO, V302, P810, DOI 10.1016/S0006-291X(03)00256-0; Zhang QY, 2004, BIOCHEM BIOPH RES CO, V317, P30, DOI 10.1016/j.bbrc.2004.02.176; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008; Zhong GZ, 2003, J HYPERTENS, V21, P1879, DOI 10.1097/00004872-200310000-00015	34	251	280	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					623	+		10.1096/fj.04-3023fje	http://dx.doi.org/10.1096/fj.04-3023fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15671155				2022-12-25	WOS:000226576600009
J	Kumar, A; Kingdon, E; Norman, J				Kumar, A; Kingdon, E; Norman, J			The isoprostane 8-iso-PGF(2 alpha) suppresses monocyte adhesion to human microvascular endothelial cells via two independent mechanisms	FASEB JOURNAL			English	Article						inflammation; monocyte adhesion; thromboxane receptor; signaling	LIPID-PEROXIDATION; EXPRESSION; RECEPTORS; F-2-ISOPROSTANES; PROLIFERATION; MIGRATION; CYTOKINE; BIOLOGY; MARKER; ALPHA	Isoprostanes, produced in vivo by non-enzymatic free-radical-induced lipid peroxidation, are markers of oxidative stress. Elevated serum and urine levels of 8-iso-PGF(2alpha) have been reported in a variety of diseases, many of which are characterized by early perivascular inflammatory infiltrates. It has been suggested that, in addition to being markers of oxidative stress, isoprostanes may have pathogenic functions. In this study, we investigated the potential role of 8-iso-PGF(2alpha) in inflammation, focusing on its effects on adhesion of monocytes to microvascular endothelial cells, an early event in the inflammatory response. In monocyte adhesion assays, 8-iso- PGF(2alpha) (> 10(-8)M) suppressed both basal and TNF-alpha-induced monocyte adhesion to quiescent or proliferating human dermal (HMEC) and rat renal microvascular endothelial cells. In contrast, 8-iso-PGF(2alpha) stimulated monocyte adhesion to human umbilical vein endothelial cells ( HUVEC) as also reported by others. 8-Iso-PGF(2alpha) had no effect on the viability (Trypan Blue exclusion) of U937 monocytes or HMEC. 8-Iso-PGF(2alpha) also had no effect on HMEC surface expression of ICAM-1 or VCAM-1. Exposure of HMEC to 8-iso-PGF(2alpha) for 1-2 h was sufficient to reduce monocyte adhesion to the cell surface, and this effect was independent of de novo protein synthesis by HMEC. The effect of 8-iso-PGF(2alpha) was mimicked by a thromboxane receptor (TP) agonist (U46619) and blocked by a TP antagonist (SQ29548), indicating a TP-mediated process. Signal transduction pathway inhibitors (SB203580, curcumin, and PD98059) implicated p38 and JNK, but not ERK, in 8-iso-PGF(2alpha)-induced suppression of monocyte adhesion. In addition to a direct effect, conditioned medium (CM) transfer experiments suggest that 8-iso-PGF(2alpha) induces a secondary mediator, which also suppresses monocyte adhesion but via an alternative mechanism initiated between 3 - 4 h, which is TP-independent, requires new protein synthesis, and is primarily dependent on activation of p38. The data show that 8-iso-PGF(2alpha) can suppress the attachment of monocytes to HMECs via two independent pathways, indicating a potential anti-inflammatory effect of 8-iso-PGF(2alpha) in the microvasculature.	UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, Div Med, Ctr Nephrol, London NW3 2PF, England; Brighton & Sussex Univ Hosp Trust, Sussex Kidney Unit, Brighton, E Sussex, England	University of London; University College London; UCL Medical School	Norman, J (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, Div Med, Ctr Nephrol, 2nd Floor,Hampstead Campus,Rowland Hill St, London NW3 2PF, England.	j.norman@rfc.ucl.ac.uk						Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Chana RS, 2003, KIDNEY INT, V63, P889, DOI 10.1046/j.1523-1755.2003.00828.x; Cracowski JL, 2001, J VASC RES, V38, P93, DOI 10.1159/000051036; Delanty N, 1997, CIRCULATION, V95, P2492, DOI 10.1161/01.CIR.95.11.2492; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; FAN JL, 1993, BIOL CELL, V79, P17, DOI 10.1016/0248-4900(93)90258-G; Floris S, 2003, J NEUROPATH EXP NEUR, V62, P780, DOI 10.1093/jnen/62.7.780; Fukunaga M, 1997, AM J PHYSIOL-RENAL, V272, pF477, DOI 10.1152/ajprenal.1997.272.4.F477; GOPAUL NK, 1995, FEBS LETT, V368, P225, DOI 10.1016/0014-5793(95)00649-T; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Hart CM, 1998, PROSTAG LEUKOTR ESS, V58, P9, DOI 10.1016/S0952-3278(98)90124-7; Hellewell PG, 1999, PULM PHARMACOL THER, V12, P137, DOI 10.1006/pupt.1999.0189; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL1067, DOI 10.1152/ajplung.2001.280.6.L1067; Janssen LJ, 2002, J PHARMACOL EXP THER, V301, P1060, DOI 10.1124/jpet.301.3.1060; Janssen LJ, 2001, BRIT J PHARMACOL, V132, P127, DOI 10.1038/sj.bjp.0703784; Kinsella BT, 2001, BIOCHEM SOC T, V29, P641, DOI 10.1042/BST0290641; Leitinger N, 2001, FASEB J, V15, P1254, DOI 10.1096/fj.00-0498fje; LONGMIRE AW, 1994, PROSTAGLANDINS, V48, P247, DOI 10.1016/0090-6980(94)90011-6; Mayer K, 2002, AM J PHYSIOL-HEART C, V283, pH811, DOI 10.1152/ajpheart.00235.2002; Mene P, 1996, KIDNEY INT, V50, P417, DOI 10.1038/ki.1996.331; Mohler ER, 1996, BIOCHEM BIOPH RES CO, V225, P915, DOI 10.1006/bbrc.1996.1272; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; Nonaka-Sarukawa M, 2003, HEART, V89, P871, DOI 10.1136/heart.89.8.871; Pratico D, 1999, ATHEROSCLEROSIS, V147, P1, DOI 10.1016/S0021-9150(99)00257-9; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; ROBERTS LJ, 1994, ANN NY ACAD SCI, V744, P237, DOI 10.1111/j.1749-6632.1994.tb52741.x; Rodriguez E, 2002, LIFE SCI, V71, P2181, DOI 10.1016/S0024-3205(02)01999-9; Stein CM, 1996, ARTHRITIS RHEUM-US, V39, P1146, DOI 10.1002/art.1780390711; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; Teupser D, 2001, BIOCHEM BIOPH RES CO, V289, P838, DOI 10.1006/bbrc.2001.6066; Theriault A, 2002, ATHEROSCLEROSIS, V160, P21, DOI 10.1016/S0021-9150(01)00540-8; Witztum JL, 1998, CURR OPIN LIPIDOL, V9, P441, DOI 10.1097/00041433-199810000-00008; Yura T, 1999, KIDNEY INT, V56, P471, DOI 10.1046/j.1523-1755.1999.00596.x; Zahler S, 1999, PROSTAG OTH LIPID M, V57, P319, DOI 10.1016/S0090-6980(98)00079-3; Zhang H, 2002, AM J PATHOL, V160, P2219, DOI 10.1016/S0002-9440(10)61169-8	40	28	33	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					443	+		10.1096/fj.03-1364fje	http://dx.doi.org/10.1096/fj.03-1364fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15640282	Bronze			2022-12-25	WOS:000226576600026
J	Papaharalambus, C; Sajjad, W; Syed, A; Zhang, C; Bergo, MO; Alexander, RW; Ahmad, M				Papaharalambus, C; Sajjad, W; Syed, A; Zhang, C; Bergo, MO; Alexander, RW; Ahmad, M			Tumor necrosis factor alpha stimulation of rac1 activity - Role of isoprenylcysteine carboxylmethyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; HUMAN ENDOTHELIAL-CELLS; KINASE-C-ALPHA; NADPH OXIDASE; CARBOXYL METHYLTRANSFERASE; DIFFERENTIAL ACTIVATION; MEMBRANE TRANSLOCATION; ENDOPLASMIC-RETICULUM; ACTIN CYTOSKELETON	We have previously demonstrated that both isoprenylcysteine carboxylmethyltransferase (ICMT) and one of its substrates, the RhoGTPase Rac1, are critical for the tumor necrosis factor alpha (TNF alpha) stimulation of vascular cell adhesion molecule-1 expression in endothelial cells (EC). Here, we have shown that ICMT regulates TNF alpha stimulation of Rac1 activity. TNF alpha stimulation of EC increased the membrane association of Rac1, an event that is essential for Rac1 activity. ICMT inhibitor Nacetyl-S-farnesyl-L-cysteine (AFC) blocked the accumulation of Rac1 into the membrane both in resting and TNF alpha-stimulated conditions. Similarly, the membrane-associated Rac1 was lower in Icmt-deficient versus wildtype mouse embryonic fibroblasts (MEFs). TNF alpha also increased the level of GTP-Rac1, the active form of Rac1, in EC. AFC completely suppressed the TNF alpha stimulation of increase in GTP-Rac1 levels. Confocal microscopy revealed resting EC Rac1 was present in the plasma membrane and also in the perinuclear region. AFC mislocalized Rac1, both from the plasma membrane and the perinuclear region. Mislocalization of Rac1 was also observed in Icmt-deficient versus wild-type MEFs. To determine the consequences of ICMT inhibition, we investigated the effect of AFC on p38 mitogen-activated protein ( MAP) kinase phosphorylation, which is downstream of Rac1. AFC inhibited the TNF alpha stimulation of p38 MAP kinase phosphorylation in EC. TNF alpha stimulation of p38 MAP kinase phosphorylation was also significantly attenuated in Icmt-deficient versus wild-type MEFs. To understand the mechanism of inhibition of Rac1 activity, we examined the effect of ICMT inhibition on the interaction of Rac1 with its inhibitor, Rho guanine nucleotide dissociation inhibitor ( RhoGDI). The association of Rac1 with its inhibitor RhoGDI was dramatically increased in the Icmt-deficient versus wild-type MEFs both in resting as well as in TNF alpha-stimulated conditions, suggesting that RhoGDI was involved in inhibiting Rac1 activity under the conditions of ICMT inhibition. These results suggest that ICMT regulates Rac1 activity by controlling the interaction of Rac1 with RhoGDI. We hypothesize that ICMT regulates the release of Rac1 from RhoGDI.	Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30322 USA; Sahlgrens Univ Hosp, Dept Internal Med, Wallenberg Lab, S-41345 Gothenburg, Sweden	Emory University; Sahlgrenska University Hospital	Ahmad, M (corresponding author), Emory Univ, Sch Med, Dept Med, Div Cardiol, 1639 Pierce Dr,WMB 319, Atlanta, GA 30322 USA.	mahmad@emory.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066508, R01HL060728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66508, HL60728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; AHMAD M, 1991, CURR EYE RES, V10, P35, DOI 10.3109/02713689109007609; Ahmad M, 2002, ARTERIOSCL THROM VAS, V22, P759, DOI 10.1161/01.ATV.0000015884.61894.DC; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dusi S, 1996, J IMMUNOL, V157, P4615; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hanna AN, 2001, MOL BIOL CELL, V12, P3618, DOI 10.1091/mbc.12.11.3618; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; HORI Y, 1991, ONCOGENE, V6, P515; ISOMURA M, 1991, ONCOGENE, V6, P119; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; Lian LY, 2000, STRUCT FOLD DES, V8, P47, DOI 10.1016/S0969-2126(00)00080-0; Longenecker K, 1999, ACTA CRYSTALLOGR D, V55, P1503, DOI 10.1107/S090744499900801X; Meacci E, 2001, CELL SIGNAL, V13, P593, DOI 10.1016/S0898-6568(01)00177-2; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Min W, 1997, J IMMUNOL, V159, P3508; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Niu JX, 2003, CIRC RES, V93, P848, DOI 10.1161/01.RES.0000097607.14733.0C; Nomanbhoy T, 1998, METH MOL B, V84, P237; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Pietersma A, 1997, BIOCHEM BIOPH RES CO, V230, P44, DOI 10.1006/bbrc.1996.5886; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; SASAKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1188, DOI 10.1006/bbrc.1993.1948; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Sohn HY, 2000, J BIOL CHEM, V275, P18745, DOI 10.1074/jbc.M000026200; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Symons M, 2000, CURR BIOL, V10, pR535, DOI 10.1016/S0960-9822(00)00588-1; TAKAISHI K, 1995, METHOD ENZYMOL, V256, P336; Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Young S. G., 2001, ENZYMES, V21, P156; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	63	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18790	18796		10.1074/jbc.M410081200	http://dx.doi.org/10.1074/jbc.M410081200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15647276	hybrid			2022-12-25	WOS:000228932300030
J	Japelj, B; Pristovsek, P; Majerle, A; Jerala, R				Japelj, B; Pristovsek, P; Majerle, A; Jerala, R			Structural origin of endotoxin neutralization and antimicrobial activity of a lactoferrin-based peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; PROTEIN STRUCTURES; ANTIBACTERIAL; LIPOPOLYSACCHARIDE; BINDING; NMR; PROGRAM; DODECYLPHOSPHOCHOLINE; INDOLICIDIN; TRYPTOPHAN	Treatment of Gram-negative bacterial infections with antimicrobial agents can cause release of the endotoxin lipopolysaccharide (LPS), the potent initiator of sepsis, which is the major cause of mortality in intensive care units worldwide. Structural information on peptides bound to LPS can lead to the development of more effective endotoxin neutralizers. Short linear antimicrobial and endotoxin-neutralizing peptide LF11, based on the human lactoferrin, binds to LPS, inducing a peptide fold with a "T-shaped" arrangement of a hydrophobic core and two clusters of basic residues that match the distance between the two phosphate groups of LPS. Side chain arrangement of LF11 bound to LPS extends the previously proposed LPS binding pattern, emphasizing the importance of both electrostatic and hydrophobic interactions in a defined geometric arrangement. In anionic micelles, the LF11 forms amphipathic conformation with a smaller hydrophobic core than in LPS, whereas in zwitterionic micelles, the structure is even less defined. Protection of tryptophan fluorescence quenching in the order SDS> LPS> DPC and hydrogen exchange protection indicates the decreasing extent of insertion of the N terminus and potential role of peptide plasticity in differentiation between bacterial and eukaryotic membranes.	Natl Inst Chem, Dept Biotechnol, Ljubljana 1000, Slovenia	National Institute of Chemistry - Slovenia	Jerala, R (corresponding author), Natl Inst Chem, Dept Biotechnol, Ljubljana 1000, Slovenia.	roman.jerala@ki.si	Jerala, Roman/H-9850-2015	Jerala, Roman/0000-0002-6337-5251				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Andra J, 2005, BIOCHEM J, V385, P135, DOI 10.1042/BJ20041270; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; ARNOLD RR, 1977, SCIENCE, V197, P263, DOI 10.1126/science.327545; BELLAMY W, 1992, J APPL BACTERIOL, V73, P472, DOI 10.1111/j.1365-2672.1992.tb05007.x; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; CHEN CP, 1995, FEBS LETT, V370, P46, DOI 10.1016/0014-5793(95)00792-8; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Damberg P, 2001, METHOD ENZYMOL, V339, P271, DOI 10.1016/S0076-6879(01)39318-7; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DAVIS DG, 1994, J MAGN RESON SER B, V104, P266, DOI 10.1006/jmrb.1994.1084; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; Deininger S, 2003, J IMMUNOL, V170, P4134, DOI 10.4049/jimmunol.170.8.4134; Eisenmesser EZ, 2000, J BIOMOL NMR, V17, P17, DOI 10.1023/A:1008311703619; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, STRUCTURE, V8, P585; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hsu STD, 2003, J BIOL CHEM, V278, P13110, DOI 10.1074/jbc.M211144200; Hwang PM, 1998, BIOCHEMISTRY-US, V37, P4288, DOI 10.1021/bi972323m; KESSLER H, 1992, BIOPOLYMERS, V32, P427, DOI 10.1002/bip.360320420; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laederach A, 2002, BIOCHEMISTRY-US, V41, P12359, DOI 10.1021/bi026185z; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lohner K., 2001, DEV NOVEL ANTIMICROB; Majerle A, 2003, J ANTIMICROB CHEMOTH, V51, P1159, DOI 10.1093/jac/dkg219; Nagpal S, 2002, PROTEIN SCI, V11, P2158, DOI 10.1110/ps.0211602; Neidigh JW, 2002, BIOPOLYMERS, V65, P354, DOI 10.1002/bip.10272; Odell EW, 1996, FEBS LETT, V382, P175, DOI 10.1016/0014-5793(96)00168-8; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Powers JPS, 2003, PEPTIDES, V24, P1681, DOI 10.1016/j.peptides.2003.08.023; Pristovsek P, 1999, J MED CHEM, V42, P4604, DOI 10.1021/jm991031b; Pristovsek P, 2002, J COMPUT CHEM, V23, P335, DOI 10.1002/jcc.10011; PRISTOVSEK P, 2002, BIOM HLTH R, V55, P161; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIFKIND D, 1967, J BACTERIOL, V93, P1463, DOI 10.1128/JB.93.4.1463-1464.1967; Rozek A, 2000, BIOCHEMISTRY-US, V39, P15765, DOI 10.1021/bi000714m; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; Schibli DJ, 1999, FEBS LETT, V446, P213, DOI 10.1016/S0014-5793(99)00214-8; Schibli DJ, 1999, BIOCHEMISTRY-US, V38, P16749, DOI 10.1021/bi990701c; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; WILKINSON SC, 1998, MICROBIAL LIPIDS; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	44	74	80	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16955	16961		10.1074/jbc.M500266200	http://dx.doi.org/10.1074/jbc.M500266200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15687491	hybrid			2022-12-25	WOS:000228615500051
J	Morel, J; Audo, R; Hahne, M; Combe, B				Morel, J; Audo, R; Hahne, M; Combe, B			Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; MEDIATED APOPTOSIS; TNF-FAMILY; RECEPTORS; DR5; IDENTIFICATION; EXPRESSION; MATURATION; INHIBITOR	A hallmark of rheumatoid arthritis ( RA) is the pseudotumoral expansion of fibroblast- like synoviocytes ( FLSs), and the RA FLS has therefore been proposed as a therapeutic target. Tumor necrosis factor ( TNF)- related apoptosis- inducing ligand ( TRAIL) has been described as a pro- apoptotic factor on RA FLSs and, therefore, suggested as a potential drug. Here we report that exposure to TRAIL- induced apoptosis in a portion ( up to 30%) of RA FLSs within the first 24 h. In the cells that survived, TRAIL induced RA FLS proliferation in a dose-dependent manner, with maximal proliferation observed at 0.25 nM. This was blocked by a neutralizing anti- TRAIL antibody. RA FLSs were found to express constitutively TRAIL receptors 1 and 2 ( TRAIL- R1 and TRAIL- R2) on the cell surface. TRAIL- R2 appears to be the main mediator of TRAIL- induced stimulation, as RA FLS proliferation induced by an agonistic anti-TRAIL- R2 antibody was comparable with that induced by TRAIL. TRAIL activated the mitogen- activated protein kinases ERK and p38, as well as the phosphatidylinositol 3- kinase ( PI3K)/ Akt signaling pathway with kinetics similar to those of TNF-alpha. Moreover, TRAIL-induced RA FLS proliferation was inhibited by the protein kinase inhibitors PD98059, SB203580, and LY294002, confirming the involvement of the ERK, p38, and PI3 kinase/ Akt signaling pathways. This dual functionality of TRAIL in stimulating apoptosis and proliferation has important implications for its use in the treatment of RA.	Ctr Hosp Univ Arnaud de Villeneuve, INSERM, U454, F-34295 Montpellier, France; Ctr Hosp Univ Lapeyronie, Dept Immunorheumatol, F-34295 Montpellier, France; Inst Genet Mol Montpellier, CNRS, UMR5535, F-34293 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Morel, J (corresponding author), CHU Montpellier, Serv Immunorhumatol, 371 Av Doyen Gaston Giraud, F-34295 Montpellier, France.	j-morel@chu-montpellier.fr	AUDO, Rachel/AAD-6091-2020	AUDO, Rachel/0000-0002-0021-5349				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baetu TM, 2002, CYTOKINE GROWTH F R, V13, P199, DOI 10.1016/S1359-6101(02)00006-0; Firestein GS, 1999, ARTHRITIS RHEUM-US, V42, P609, DOI 10.1002/1529-0131(199904)42:4<609::AID-ANR3>3.0.CO;2-I; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Ichikawa K, 2003, J IMMUNOL, V171, P1061, DOI 10.4049/jimmunol.171.2.1061; KOCH AE, 1986, ARTHRITIS RHEUM, V29, P471, DOI 10.1002/art.1780290403; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Miranda-Carus ME, 2004, ARTHRITIS RHEUM-US, V50, P2786, DOI 10.1002/art.20501; Miyashita T, 2003, BIOCHEM BIOPH RES CO, V312, P397, DOI 10.1016/j.bbrc.2003.10.141; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Morel JCM, 2001, J BIOL CHEM, V276, P37069, DOI 10.1074/jbc.M103574200; Palao G, 2004, ARTHRITIS RHEUM-US, V50, P2803, DOI 10.1002/art.20453; Perlman H, 2003, ARTHRITIS RHEUM, V48, P3096, DOI 10.1002/art.11302; Pope RM, 2002, NAT REV IMMUNOL, V2, P527, DOI 10.1038/nri846; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Schedel J, 2002, ARTHRITIS RHEUM, V46, P1512, DOI 10.1002/art.10309; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Screaton G, 2000, CURR OPIN IMMUNOL, V12, P316, DOI 10.1016/S0952-7915(00)00093-5; Secchiero P, 2003, CIRCULATION, V107, P2250, DOI 10.1161/01.CIR.0000062702.60708.C4; Secchiero P, 2004, CELL MOL LIFE SCI, V61, P1965, DOI 10.1007/s00018-004-4197-6; Secchiero P, 2004, BLOOD, V103, P517, DOI 10.1182/blood-2003-06-2137; Secchiero P, 2002, BLOOD, V100, P2421, DOI 10.1182/blood-2002-01-0047; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; Suzuki I, 2000, P NATL ACAD SCI USA, V97, P1707, DOI 10.1073/pnas.97.4.1707; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang HG, 2001, ARTHRITIS RHEUM-US, V44, P1555, DOI 10.1002/1529-0131(200107)44:7<1555::AID-ART279>3.0.CO;2-M	33	141	163	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15709	15718		10.1074/jbc.M414469200	http://dx.doi.org/10.1074/jbc.M414469200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15684417	Green Published, hybrid			2022-12-25	WOS:000228444800032
J	Mansharamani, M; Wilson, KL				Mansharamani, M; Wilson, KL			Direct binding of nuclear membrane protein MAN1 to emerin in vitro and two modes of binding to barrier-to-autointegration factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; TRANSCRIPTIONAL REPRESSOR; INTEGRAL PROTEIN; INNER MEMBRANE; LEM DOMAIN; BAF; LAMIN; INTERACTS; CHROMATIN; ELEGANS	MAN1 is a vertebrate nuclear inner membrane protein that inhibits Smad signaling downstream of transforming growth factor beta. MAN1 has an exposed LEM domain-containing N-terminal region ("MAN1-N"), two transmembrane domains, and an exposed C-terminal domain ("MAN1-C"). Many regions of human MAN1 are homologous to emerin, a LEM domain nuclear protein, loss of which causes Emery-Dreifuss muscular dystrophy ( EDMD). To test the hypothesis that MAN1 function might overlap with emerin, we tested different polypeptide fragments of MAN1 for binding to selected partners of emerin. Our findings support this hypothesis. Blot overlay assays and co-immunoprecipitation studies showed that MAN1-C binds the transcription regulators GCL, Btf, and barrier-to-autointegration factor (BAF). BAF binding to this region, which has no LEM domain, was notable. Sequence alignments identified a potential BAF-binding motif, characterized by the conserved residues Ser-Arg-Val, in MAN1-C and two other BAF-binding proteins. The other region, MAN1-N, bound directly to BAF, lamin A, and lamin B1, supporting functional overlap with emerin. Unexpectedly, three independent assays showed that MAN1-N also bound directly to emerin. Proposed MAN1-emerin complexes are discussed in the context of EDMD disease mechanisms and potential in vivo functions.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, WBSB, Baltimore, MD 21205 USA	Johns Hopkins University	Wilson, KL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, WBSB, Rm G-10,725 N Wolfe St, Baltimore, MD 21205 USA.	klwilson@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064535] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM64535] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bengtsson L, 2004, CURR OPIN CELL BIOL, V16, P73, DOI 10.1016/j.ceb.2003.11.012; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Gruenbaum Y, 2002, J CELL SCI, V115, P923; Haraguchi T, 2004, EUR J BIOCHEM, V271, P1035, DOI 10.1111/j.1432-1033.2004.04007.x; Harris D, 2000, J BIOL CHEM, V275, P39671, DOI 10.1074/jbc.M002626200; Hellemans J, 2004, NAT GENET, V36, P1213, DOI 10.1038/ng1453; Holaska JM, 2004, PLOS BIOL, V2, P1354, DOI 10.1371/journal.pbio.0020231; Holaska JM, 2003, J BIOL CHEM, V278, P6969, DOI 10.1074/jbc.M208811200; Lee KK, 2004, EXPTL BIOL REV, P329; Lee KK, 2001, J CELL SCI, V114, P4567; Lin F, 2005, HUM MOL GENET, V14, P437, DOI 10.1093/hmg/ddi040; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Liu J, 2003, P NATL ACAD SCI USA, V100, P4598, DOI 10.1073/pnas.0730821100; Manilal S, 1996, HUM MOL GENET, V5, P801, DOI 10.1093/hmg/5.6.801; Mansharamani M, 2003, J VIROL, V77, P13084, DOI 10.1128/JVI.77.24.13084-13092.2003; Mislow JMK, 2002, FEBS LETT, V525, P135, DOI 10.1016/S0014-5793(02)03105-8; Mounkes L, 2003, CURR OPIN GENET DEV, V13, P223, DOI 10.1016/S0959-437X(03)00058-3; Osada SI, 2003, DEVELOPMENT, V130, P1783, DOI 10.1242/dev.00401; Raju GP, 2003, J BIOL CHEM, V278, P428, DOI 10.1074/jbc.M210505200; Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019; Segura-Totten M, 2004, TRENDS CELL BIOL, V14, P261, DOI 10.1016/j.tcb.2004.03.004; Umland TC, 2000, BIOCHEMISTRY-US, V39, P9130, DOI 10.1021/bi000572w; Wang XJ, 2002, J BIOL CHEM, V277, P43288, DOI 10.1074/jbc.M207952200; Wilkinson FL, 2003, EUR J BIOCHEM, V270, P2459, DOI 10.1046/j.1432-1033.2003.03617.x; Wu W, 2002, J CELL SCI, V115, P1361; Zastrow MS, 2004, J CELL SCI, V117, P979, DOI 10.1242/jcs.01102	28	100	107	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13863	13870		10.1074/jbc.M413020200	http://dx.doi.org/10.1074/jbc.M413020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15681850	hybrid			2022-12-25	WOS:000228095500085
J	Kim, SA; Yoon, JH; Lee, SH; Ahn, SG				Kim, SA; Yoon, JH; Lee, SH; Ahn, SG			Polo-like kinase 1 phosphorylates heat shock transcription factor 1 and mediates its nuclear translocation during heat stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; ACTIVATION DOMAIN; PROTEIN; COMPLEX; LOCALIZATION; PURIFICATION; PROTECTION; HSP70; PLK1	Heat shock transcription factor 1 (HSF1) is activated by pathophysiologic stresses and activation leads to an increased cellular level of heat shock proteins (Hsp(s)). Although the activation of HSF1 occurs via multiple stress-induced processes such as hyperphosphorylation, the exact cellular mechanism of HSF1 activation is still unclear. Here we show polo-like kinase 1 (PLK1) and HSF1 interact in vivo using the tandem affinity purification system. Although the interaction between HSF1 and PLK1 is increased by thermal stress, overexpression of PLK1 did not affect HSF1 trimerization or DNA binding activity. This interaction results in the phosphorylation of HSF1 on serine 419 by PLK1. Interestingly, mutation of serine 419 to alanine inhibited heat-stress induced HSF1 nuclear translocation. Our results suggest that the phosphorylation of HSF1 by PLK1 is an essential step for HSF1 nuclear translocation by heat stress.	Chosun Univ, Coll Dent, Oral Biol Res Inst, Kwangju 501759, South Korea; Chosun Univ, Coll Dent, Dept Pathol, Kwangju 501759, South Korea	Chosun University; Chosun University	Ahn, SG (corresponding author), Chosun Univ, Coll Dent, Oral Biol Res Inst, Kwangju 501759, South Korea.	ahnsg@chosun.ac.kr		Kim, Soo-A/0000-0001-6777-739X				Ahn SG, 2001, GENE DEV, V15, P2134, DOI 10.1101/gad.894801; Ahn SG, 2003, GENE DEV, V17, P516, DOI 10.1101/gad.1044503; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Liu PCC, 1999, J BIOL CHEM, V274, P17219, DOI 10.1074/jbc.274.24.17219; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; Morimoto R I, 1996, EXS, V77, P139; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Park JH, 2001, J CELL BIOCHEM, V82, P326, DOI 10.1002/jcb.1163; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; POLLA BS, 1996, STRESS INDUCIBLE CEL, P375; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Zhang XD, 2002, CURR OPIN STRUC BIOL, V12, P231, DOI 10.1016/S0959-440X(02)00315-9	39	66	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12653	12657		10.1074/jbc.M411908200	http://dx.doi.org/10.1074/jbc.M411908200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15661742	hybrid			2022-12-25	WOS:000227922000071
J	Makowski, L; Brittingham, KC; Reynolds, JM; Suttles, J; Hotamisligil, GKS				Makowski, L; Brittingham, KC; Reynolds, JM; Suttles, J; Hotamisligil, GKS			The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity - Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and I kappa B kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THP-1 MACROPHAGES; NITRIC-OXIDE SYNTHASE; PPAR-GAMMA; TNF-ALPHA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); LIPID-METABOLISM; OXIDIZED LDL; CYCLOPENTENONE PROSTAGLANDINS; GENE-EXPRESSION; DEFICIENT MICE	Fatty acid-binding proteins are cytosolic fatty acid chaperones, and the adipocyte isoform, aP2, plays an important role in obesity and glucose metabolism. Recently, this protein has been detected in macrophages where it strongly contributes to the development of atherosclerosis. Here, we investigated the role of aP2 in macrophage biology and the molecular mechanisms underlying its actions. We demonstrate that aP2-deficient macrophages display defects in cholesterol accumulation and alterations in pro-inflammatory responsiveness. Deficiency of aP2 alters the lipid composition in macrophages and enhances peroxisome proliferator-activated receptor gamma activity, leading to elevated CD36 expression and enhanced uptake of modified low density lipoprotein. The increased peroxisome proliferator-activated receptor gamma activity in aP2-deficient macrophages is also accompanied by a significant stimulation of the liver X receptor alpha-ATP-binding cassette transporter A1-mediated cholesterol efflux pathway. In parallel, aP2-deficient macrophages display reduced I kappa B kinase and NF-kappa B activity, resulting in suppression of inflammatory function including reduced cyclooxygenase-2 and inducible nitric-oxide synthase expression and impaired production of inflammatory cytokines. Our results demonstrate that aP2 regulates two central molecular pathways to coordinate macrophage cholesterol trafficking and inflammatory activity.	Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40292 USA; Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	University of Louisville; Harvard University; Harvard T.H. Chan School of Public Health	Suttles, J (corresponding author), Univ Louisville, Sch Med, Dept Microbiol & Immunol, 319 Abraham Flexner Way, Louisville, KY 40292 USA.	jill.suttles@louisville.edu	Eckhardt, Erik/G-1567-2010	Reynolds, Joseph/0000-0003-3490-0544; Makowski, Liza/0000-0002-5337-8037	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL075970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048850] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL075970, F32 HL075970-01] Funding Source: Medline; NIAID NIH HHS [R01 AI048850, R01 AI48850] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Baccam M, 1999, EUR J IMMUNOL, V29, P3855, DOI 10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO;2-S; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; Boord JB, 2002, ARTERIOSCL THROM VAS, V22, P1686, DOI 10.1161/01.ATV.0000033090.81345.E6; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen SY, 2001, SPECTROSC SPECT ANAL, V21, P377; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Clemons-Miller AR, 2000, IMMUNOBIOLOGY, V202, P477, DOI 10.1016/S0171-2985(00)80105-9; Collins AR, 2001, ARTERIOSCL THROM VAS, V21, P365, DOI 10.1161/01.ATV.21.3.365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING AH, 1988, J IMMUNOL, V141, P2407; Fu YC, 2002, ATHEROSCLEROSIS, V165, P259, DOI 10.1016/S0021-9150(02)00305-2; Fu YC, 2000, J LIPID RES, V41, P2017; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Inoue H, 2000, J BIOL CHEM, V275, P28028; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Llaverias G, 2004, BIOCHEM BIOPH RES CO, V318, P265, DOI 10.1016/j.bbrc.2004.04.021; Lutgens E, 2002, TRENDS CARDIOVAS MED, V12, P27, DOI 10.1016/S1050-1738(01)00142-6; Makowski L, 2004, J NUTR, V134, p2464S, DOI 10.1093/jn/134.9.2464S; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; McLeish KR, 1996, KIDNEY INT, V50, P407, DOI 10.1038/ki.1996.330; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Scheja L, 1999, DIABETES, V48, P1987, DOI 10.2337/diabetes.48.10.1987; SHIMANO K, 2001, THROMB VASC BIOL, V21, P365; STOUT RD, 1992, CELL IMMUNOL, V139, P363, DOI 10.1016/0008-8749(92)90078-4; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Watkins SM, 2002, J LIPID RES, V43, P1809, DOI 10.1194/jlr.M200169-JLR200; Welch JS, 2003, P NATL ACAD SCI USA, V100, P6712, DOI 10.1073/pnas.1031789100; Zhang WJ, 2001, FASEB J, V15, P2423, DOI 10.1096/fj.01-0260com	48	301	318	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12888	12895		10.1074/jbc.M413788200	http://dx.doi.org/10.1074/jbc.M413788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15684432	hybrid, Green Accepted			2022-12-25	WOS:000227922000097
J	Matuszewska, M; Kuczynska-Wisnik, D; Laskowska, E; Liberek, K				Matuszewska, M; Kuczynska-Wisnik, D; Laskowska, E; Liberek, K			The small heat shock protein IbpA of Escherichia coli cooperates with IbpB in stabilization of thermally aggregated proteins in a disaggregation competent state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; IN-VIVO; CHAPERONE ACTIVITY; CLPB; DNAK; SYSTEM; HSP104; GRPE; INACTIVATION; EXPRESSION	The small heat shock proteins are ubiquitous stress proteins proposed to increase cellular tolerance to heat shock conditions. We isolated IbpA, the Escherichia coli small heat shock protein, and tested its ability to keep thermally inactivated substrate proteins in a disaggregation competent state. We found that the presence of IbpA alone during substrate thermal inactivation only weakly influences the ability of the bi-chaperone Hsp70-Hsp100 system to disaggregate aggregated substrate. Similar minor effects were observed for IbpB alone, the other E. coli small heat shock protein. However, when both IbpA and IbpB are simultaneously present during substrate inactivation they efficiently stabilize thermally aggregated proteins in a disaggregation competent state. The properties of the aggregated protein substrates are changed in the presence of IbpA and IbpB, resulting in lower hydrophobicity and the ability of aggregates to withstand sizing chromatography conditions. IbpA and IbpB form mixed complexes, and IbpA stimulates association of IbpB with substrate.	Univ Gdansk, Dept Mol & Cellular Biol, Intercollegiate Fac Biotechnol, PL-80822 Gdansk, Poland; Univ Gdansk, Dept Biochem, PL-80822 Gdansk, Poland	Fahrenheit Universities; University of Gdansk; Fahrenheit Universities; University of Gdansk	Liberek, K (corresponding author), Univ Gdansk, Dept Mol & Cellular Biol, Intercollegiate Fac Biotechnol, Kladki 24, PL-80822 Gdansk, Poland.	liberek@biotech.univ.gda.pl	Liberek, Krzysztof/F-5812-2011	Laskowska, Ewa/0000-0002-7138-1125; Kuczynska-Wisnik, Dorota/0000-0002-3678-2660; Liberek, Krzysztof/0000-0002-7532-9279				ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992; Basha E, 2004, J BIOL CHEM, V279, P7566, DOI 10.1074/jbc.M310684200; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Bukach OV, 2004, EUR J BIOCHEM, V271, P291, DOI 10.1046/j.1432-1033.2003.03928.x; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; Cobb BA, 2000, J BIOL CHEM, V275, P6664, DOI 10.1074/jbc.275.9.6664; DIAMANT S, 1995, J BIOL CHEM, V270, P28387; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Friedrich KL, 2004, J BIOL CHEM, V279, P1080, DOI 10.1074/jbc.M311104200; Fu L, 2003, BIOCHEM BIOPH RES CO, V302, P710, DOI 10.1016/S0006-291X(03)00257-2; Germaniuk A, 2002, J BIOL CHEM, V277, P27801, DOI 10.1074/jbc.M201756200; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kitagawa M, 2000, FEMS MICROBIOL LETT, V184, P165, DOI 10.1111/j.1574-6968.2000.tb09009.x; Kitagawa M, 2002, EUR J BIOCHEM, V269, P2907, DOI 10.1046/j.1432-1033.2002.02958.x; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Kuczynska-Wisnik D, 2002, MICROBIOL-SGM, V148, P1757, DOI 10.1099/00221287-148-6-1757; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Laskowska E, 1996, MOL MICROBIOL, V22, P555, DOI 10.1046/j.1365-2958.1996.1231493.x; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Nakamoto H, 2000, FEBS LETT, V483, P169, DOI 10.1016/S0014-5793(00)02097-4; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Shearstone JR, 1999, J BIOL CHEM, V274, P9937, DOI 10.1074/jbc.274.15.9937; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Studer S, 2000, J BIOL CHEM, V275, P37212, DOI 10.1074/jbc.M004701200; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	48	76	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12292	12298		10.1074/jbc.M412706200	http://dx.doi.org/10.1074/jbc.M412706200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15665332	hybrid			2022-12-25	WOS:000227922000028
J	Birtley, JR; Knox, SR; Jaulent, AM; Brick, P; Leatherbarrow, RJ; Curry, S				Birtley, JR; Knox, SR; Jaulent, AM; Brick, P; Leatherbarrow, RJ; Curry, S			Crystal structure of foot-and-mouth disease virus 3C protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRREVERSIBLE INHIBITORS; PROTEINASE; CLEAVAGE; SERINE; REVEALS; SITE; RNA; IDENTIFICATION; DESIGN; FOLD	Foot-and-mouth disease virus ( FMDV) causes a widespread and economically devastating disease of domestic livestock. Although FMDV vaccines are available, political and technical problems associated with their use are driving a renewed search for alternative methods of disease control. The viral RNA genome is translated as a single polypeptide precursor that must be cleaved into functional proteins by virally encoded proteases. 10 of the 13 cleavages are performed by the highly conserved 3C protease (3C(pro)), making the enzyme an attractive target for antiviral drugs. We have developed a soluble, recombinant form of FMDV 3Cpro, determined the crystal structure to 1.9-angstrom resolution, and analyzed the cleavage specificity of the enzyme. The structure indicates that FMDV 3C(pro) adopts a chymotrypsin-like fold and possesses a Cys-His-Asp catalytic triad in a similar conformation to the Ser-His-Asp triad conserved in almost all serine proteases. This observation suggests that the dyad-based mechanisms proposed for this class of cysteine proteases need to be reassessed. Peptide cleavage assays revealed that the recognition sequence spans at least four residues either side of the scissile bond (P4-P4') and that FMDV 3C(pro) discriminates only weakly in favor of P1-Gln over P1-Glu, in contrast to other 3C(pro) enzymes that strongly favor P1-Gln. The relaxed specificity may be due to the unexpected absence in FMDV 3C(pro) of an extended beta-ribbon that folds over the substrate binding cleft in other picornavirus 3C(pro) structures. Collectively, these results establish a valuable framework for the development of FMDV 3C(pro) inhibitors.	Univ London Imperial Coll Sci Technol & Med, Dept Chem, Biol & Biophys Chem Sect, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Biophys Sect, Div Cell & Mol Biol, Blackett Lab, London SW7 2AZ, England	Imperial College London; Imperial College London	Leatherbarrow, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Chem, Biol & Biophys Chem Sect, S Kensington Campus,Exhibit Rd, London SW7 2AZ, England.	r.leatherbarrow@imperial.ac.uk; curry@imperial.ac.uk	Leatherbarrow, Robin J/H-3070-2014	Leatherbarrow, Robin J/0000-0001-8193-5964; BIRTLEY, JAMES/0000-0002-8159-4060; Curry, Stephen/0000-0002-0552-8870				ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Atherton E., 1990, SOLID PHASE PEPTIDE; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belsham GJ, 2000, J VIROL, V74, P272, DOI 10.1128/JVI.74.1.272-280.2000; Bergmann EM, 1997, J VIROL, V71, P2436, DOI 10.1128/JVI.71.3.2436-2448.1997; Bergmann EM, 1999, VIROLOGY, V265, P153, DOI 10.1006/viro.1999.9968; Blom N, 1996, PROTEIN SCI, V5, P2203, DOI 10.1002/pro.5560051107; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Debreczeni JE, 2003, ACTA CRYSTALLOGR D, V59, P393, DOI 10.1107/S0907444902020917; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7; DOUGHERTY WG, 1988, EMBO J, V7, P1281, DOI 10.1002/j.1460-2075.1988.tb02942.x; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; GANDOUR RD, 1990, J AM CHEM SOC, V112, P7816, DOI 10.1021/ja00177a064; GRUBMAN MJ, 1995, VIROLOGY, V213, P581, DOI 10.1006/viro.1995.0030; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Hakansson K, 2000, P NATL ACAD SCI USA, V97, P14097, DOI 10.1073/pnas.260376797; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; JEWELL DA, 1992, BIOCHEMISTRY-US, V31, P7862, DOI 10.1021/bi00149a017; Johnson TO, 2002, J MED CHEM, V45, P2016, DOI 10.1021/jm010435c; KEAN KM, 1993, VIROLOGY, V194, P360, DOI 10.1006/viro.1993.1268; Knowles NJ, 2003, VIRUS RES, V91, P65, DOI 10.1016/S0168-1702(02)00260-5; Lall MS, 2002, J ORG CHEM, V67, P1536, DOI 10.1021/jo0109016; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; LAWSON MA, 1992, VIROLOGY, V191, P309, DOI 10.1016/0042-6822(92)90193-S; Lin W, 2001, FEBS LETT, V507, P1, DOI 10.1016/S0014-5793(01)02885-X; LONG AC, 1989, FEBS LETT, V258, P75, DOI 10.1016/0014-5793(89)81619-9; MALCOLM BA, 1995, PROTEIN SCI, V4, P1439, DOI 10.1002/pro.5560040801; Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; Meijers R, 2004, BIOCHEMISTRY-US, V43, P2784, DOI 10.1021/bi035354s; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Mosimann SC, 1997, J MOL BIOL, V273, P1032, DOI 10.1006/jmbi.1997.1306; NIENABER VL, 1993, BIOCHEMISTRY-US, V32, P11469, DOI 10.1021/bi00094a001; Ohlenschlager O, 2004, STRUCTURE, V12, P237, DOI 10.1016/j.str.2004.01.014; PALLAI PV, 1989, J BIOL CHEM, V264, P9738; Phan J, 2002, J BIOL CHEM, V277, P50564, DOI 10.1074/jbc.M207224200; Prasad L, 2004, ACTA CRYSTALLOGR D, V60, P256, DOI 10.1107/S090744490302599X; Ryan MD, 1997, J GEN VIROL, V78, P699, DOI 10.1099/0022-1317-78-4-699; Seipelt J, 1999, VIRUS RES, V62, P159, DOI 10.1016/S0168-1702(99)00043-X; STANWAY G, 1984, NUCLEIC ACIDS RES, V12, P7859, DOI 10.1093/nar/12.20.7859; Sutmoller P, 2003, VIRUS RES, V91, P101, DOI 10.1016/S0168-1702(02)00262-9; TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6; van Rensburg H, 2002, GENE, V289, P19, DOI 10.1016/S0378-1119(02)00471-7; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; Waugh SM, 2000, NAT STRUCT BIOL, V7, P762, DOI 10.1038/78992; Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	55	110	125	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11520	11527		10.1074/jbc.M413254200	http://dx.doi.org/10.1074/jbc.M413254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15654079	hybrid			2022-12-25	WOS:000227761800077
J	Harvat, EM; Zhang, YM; Tran, CV; Zhang, ZG; Frank, MW; Rock, CO; Saier, MH				Harvat, EM; Zhang, YM; Tran, CV; Zhang, ZG; Frank, MW; Rock, CO; Saier, MH			Lysophospholipid flipping across the Escherichia coli inner membrane catalyzed by a transporter (LplT) belonging to the major facilitator superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN N-ACYLTRANSFERASE; CARRIER PROTEIN SYNTHETASE; ABC TRANSPORTERS; MYCOBACTERIUM-TUBERCULOSIS; 2-ACYL LYSOPHOSPHOLIPIDS; PHOSPHOLIPID SCRAMBLASE; MSBA; IDENTIFICATION; GENE; PHOSPHATIDYLETHANOLAMINE	The transfer of phospholipids across membrane bilayers is protein-mediated, and most of the established transporters catalyze the energy-dependent efflux of phospholipids from cells. This work identifies and characterizes a lysophospholipid transporter gene (lplT, formally ygeD) in Escherichia coli that is an integral component in the 2-acylglycerophosphoethanolamine (2-acyl-GPE) metabolic cycle for membrane protein acylation. The lplT gene is adjacent to and in the same operon as the aas gene, which encodes the bifunctional enzyme 2-acyl-GPE acyltransferase/acyl-acyl carrier protein synthetase. In some bacteria, acyltransferase/acyl-ACP synthetase (Aas) and LplT homologues are fused in a single polypeptide chain. 2-Acyl-GPE transport to the inside of the cell was assessed by measuring the Aas-dependent formation of phosphatidylethanolamine. The Aas-dependent incorporation of [H-3]palmitate into phosphatidylethanolamine was significantly diminished in Delta lplT mutants, and the LplT-Aas transport/acylation activity was independent of the proton motive force. The Delta lplT mutants accumulated acyl-GPE in vivo and had a diminished capacity to transport exogenous 2-acylglycerophosphocholine into the cell. Spheroplasts prepared from wild-type E. coli transported and acylated fluorescent 2-acyl-GPE with an apparent K-d of 7.5 mu M, whereas this high-affinity process was absent in Delta lplT mutants. Thus, LplT catalyzes the transbilayer movement of lysophospholipids and is the first example of a phospholipid flippase that belongs to the major facilitator superfamily.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	St Jude Children's Research Hospital; University of California System; University of California San Diego	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	charles.rock@stjude.org		Frank, Matthew/0000-0002-4914-1440	NIGMS NIH HHS [GM 34496, GM 64368] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064368, R01GM034496, R37GM034496] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; COOPER CL, 1989, J BIOL CHEM, V264, P7384; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; Dassa E, 1999, MOL MICROBIOL, V32, P887, DOI 10.1046/j.1365-2958.1999.01392.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Domenech P, 2004, J BIOL CHEM, V279, P21257, DOI 10.1074/jbc.M400324200; GUPTA SD, 1993, J BIOL CHEM, V268, P16551; GUPTA SD, 1991, FEMS MICROBIOL LETT, V78, P37; GUPTA SD, 1991, J BIOL CHEM, V266, P9983; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOMMA H, 1981, BIOCHIM BIOPHYS ACTA, V663, P1, DOI 10.1016/0005-2760(81)90189-2; HOMMA H, 1982, J BIOCHEM, V91, P1093, DOI 10.1093/oxfordjournals.jbchem.a133791; HOMMA H, 1982, J BIOCHEM, V91, P1103, DOI 10.1093/oxfordjournals.jbchem.a133792; HSU L, 1991, J BIOL CHEM, V266, P13783; HSU L, 1989, J BACTERIOL, V171, P1203, DOI 10.1128/jb.171.2.1203-1205.1989; JACKOWSKI S, 1986, J BIOL CHEM, V261, P1328; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KARASAWA K, 1985, J BIOCHEM, V98, P1117, DOI 10.1093/oxfordjournals.jbchem.a135360; KOBAYASHI T, 1984, J BIOCHEM, V96, P137, DOI 10.1093/oxfordjournals.jbchem.a134805; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; Locher KP, 2004, CURR OPIN STRUC BIOL, V14, P426, DOI 10.1016/j.sbi.2004.06.005; Miller J.H., 1972, EXPT MOL GENETICS; MUNOA FJ, 1991, J BIOL CHEM, V266, P17667; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Saier MH, 2000, MICROBIOL MOL BIOL R, V64, P354, DOI 10.1128/MMBR.64.2.354-411.2000; Sambrook J., 2002, MOL CLONING LAB MANU; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Suhre K, 2004, NUCLEIC ACIDS RES, V32, pD273, DOI 10.1093/nar/gkh053; SWEET G, 1990, J BACTERIOL, V172, P424, DOI 10.1128/JB.172.1.424-430.1990; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Wang XY, 2004, J BIOL CHEM, V279, P49470, DOI 10.1074/jbc.M409078200; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Zhai YF, 2001, J MOL MICROB BIOTECH, V3, P285; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	47	46	47	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					12028	12034		10.1074/jbc.M414368200	http://dx.doi.org/10.1074/jbc.M414368200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15661733	hybrid			2022-12-25	WOS:000227761800136
J	Wang, R; Cherukuri, P; Luo, JY				Wang, R; Cherukuri, P; Luo, JY			Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER; GENE-EXPRESSION; CELL-SURVIVAL; P53; ASSOCIATION; GROWTH; CANCER	Signal transducers and activators of transcription (Stat) belong to a family of latent cytoplasmic factors that can be activated by tyrosine phosphorylation by members of the Jak tyrosine kinase family in response to a variety of cytokines and growth factors. Activated Stats form dimers and translocate into nucleus to induce expression of critical genes essential for normal cellular events. Here we report for the first time that Stat3 can be modified by acetylation both in vivo and in vitro. A major site of Stat3 that is acetylated by its coactivator, p300/CREB-binding protein (CBP), resides in the C-terminal transcriptional activation domain at lysine 685. Furthermore, the acetylation of Stat3 can stimulate its sequence-specific DNA binding ability and transactivation activity. Inhibition of histone deacetylase activity in cells results in increased Stat3 nuclear localization. These observations clearly indicate a novel mechanism for Stat3 activation in mammalian cells.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Luo, JY (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 422 LRB,364 Plantat St, Worcester, MA 01605 USA.	Jianyuan.luo@umassmed.edu	Luo, Jianyuan/ABI-7585-2020	Luo, Jianyuan/0000-0001-6057-2914				Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chung YH, 2004, J VIROL, V78, P6489, DOI 10.1128/JVI.78.12.6489-6497.2004; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pranada AL, 2004, J BIOL CHEM, V279, P15114, DOI 10.1074/jbc.M312530200; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Shankaranarayanan P, 2001, J BIOL CHEM, V276, P42753, DOI 10.1074/jbc.M102626200; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhukovskaya NV, 2004, DEVELOPMENT, V131, P447, DOI 10.1242/dev.00927	32	203	212	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11528	11534		10.1074/jbc.M413930200	http://dx.doi.org/10.1074/jbc.M413930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15649887	hybrid			2022-12-25	WOS:000227761800078
J	De Nardo, D; Masendycz, P; Ho, S; Cross, M; Fleetwood, AJ; Reynolds, EC; Hamilton, JA; Scholz, GM				De Nardo, D; Masendycz, P; Ho, S; Cross, M; Fleetwood, AJ; Reynolds, EC; Hamilton, JA; Scholz, GM			A central role for the Hsp90(.)Cdc37 molecular chaperone module in interleukin-1 receptor-associated-kinase-dependent signaling by toll-like receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; COMPLEX-FORMATION; CO-CHAPERONE; HSP90; ACTIVATION; LIPOPOLYSACCHARIDE; TOLERANCE; LPS; MACROPHAGES; INHIBITION	Toll-like receptors (TLRs) serve crucial roles in innate immunity by mediating the activation of macrophages by microbial pathogens. The protein kinase interleukin-1 receptor associated kinase (IRAK-1) is a key component of TLR signaling pathways via its interaction with TRAF6, which subsequently leads to the activation of MAP kinases and various transcription factors. IRAK-1 is degraded following TLR activation, and this has been proposed to contribute to tolerance in macrophages by limiting further TLR-mediated signaling. Using a mass spectrometric-based approach, we have identified a cohort of chaperones and co-chaperones including Hsp90 and Cdc37, which bind to IRAK-1 but not IRAK-4 in 293T cells. Pharmacologic inhibition of Hsp90 led to a rapid decline in the expression level of IRAK-1, whereas overexpression of Cdc37 enhanced the activation and oligomerization of IRAK-1 in 293T cells. Significantly, the inhibition of Hsp90 in macrophages resulted in the destabilization and degradation of IRAK-1 but not IRAK-4. Concomitant with the loss of IRAK-1 expression was a reduction in the activation of p38 MAP kinase and Erk1/2 following stimulation with the bacterially derived TLR ligands, lipopolysaccharide and CpG DNA. Moreover, TLR ligand-induced expression of proinflammatory cytokines was also reduced. Thus we conclude that the level of on-going support provided to IRAK-1 by the Hsp90-Cdc37 chaperone module directly influences the magnitude of TLR-mediated macrophage activation. In addition, because further TLR signaling depends on the synthesis of new IRAK-1, the Hsp90-Cdc37 chaperone module could also contribute to tolerance in macrophages by controlling the rate at which nascent IRAK-1 is folded into a functional conformation.	Univ Melbourne, Royal Melbourne Hosp, Dept Med, Cooperat Res Ctr Chron Inflammatory Dis, Parkville, Vic 3010, Australia; Univ Melbourne, Royal Melbourne Hosp, Sch Dent Sci, Parkville, Vic 3010, Australia	Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; University of Melbourne	Scholz, GM (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Cooperat Res Ctr Chron Inflammatory Dis, Parkville, Vic 3010, Australia.	glenms@unimelb.edu.au	Fleetwood, Andrew/AAB-4743-2019	Fleetwood, Andrew/0000-0002-6803-3533; Hamilton, John A/0000-0002-9493-9224; Scholz, Glen/0000-0003-2722-6344; De Nardo, Dominic/0000-0002-7045-4695; Reynolds, Eric/0000-0002-6618-4856				Adib-Conquy M, 2002, J BIOL CHEM, V277, P27927, DOI 10.1074/jbc.M200705200; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; GEPPERT TD, 1994, MOL MED, V1, P93; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Heine H, 1999, J BIOL CHEM, V274, P21049, DOI 10.1074/jbc.274.30.21049; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jaworowski A, 1999, J BIOL CHEM, V274, P15127, DOI 10.1074/jbc.274.21.15127; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Mead JR, 2003, J BIOL CHEM, V278, P17741, DOI 10.1074/jbc.M301602200; Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209; Medzhitov R, 1998, SEMIN IMMUNOL, V10, P351, DOI 10.1006/smim.1998.0136; Miyata Y, 2004, MOL CELL BIOL, V24, P4065, DOI 10.1128/MCB.24.9.4065-4074.2004; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; REIMANN T, 1994, J IMMUNOL, V153, P5740; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Sato S, 2002, INT IMMUNOL, V14, P783, DOI 10.1093/intimm/dxf046; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; Scholz GM, 2001, CELL GROWTH DIFFER, V12, P409; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; Shao JY, 2003, BIOCHEMISTRY-US, V42, P12577, DOI 10.1021/bi035138j; Shao JY, 2003, J BIOL CHEM, V278, P38117, DOI 10.1074/jbc.C300330200; Shiotsu Y, 2000, BLOOD, V96, P2284, DOI 10.1182/blood.V96.6.2284; Siedlar M, 2004, J IMMUNOL, V173, P2736, DOI 10.4049/jimmunol.173.4.2736; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Thomas JA, 1999, J IMMUNOL, V163, P978; Vega VL, 2003, MOL BIOL CELL, V14, P764, DOI 10.1091/mbc.E02-08-0498; Wax S, 2003, ARTHRITIS RHEUM, V48, P541, DOI 10.1002/art.10780; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zeisberger E, 1998, ANN NY ACAD SCI, V856, P116, DOI 10.1111/j.1749-6632.1998.tb08320.x; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200; Zhu FG, 2001, INFECT IMMUN, V69, P5546, DOI 10.1128/IAI.69.9.5546-5552.2001	56	45	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9813	9822		10.1074/jbc.M409745200	http://dx.doi.org/10.1074/jbc.M409745200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647277	hybrid			2022-12-25	WOS:000227559600010
J	Zhou, JL; Herring, BP				Zhou, JL; Herring, BP			Mechanisms responsible for the promoter-specific effects of myocardin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE DIFFERENTIATION; TERNARY COMPLEX FACTORS; LIGHT-CHAIN KINASE; GENE-EXPRESSION; CELL DIFFERENTIATION; CARG ELEMENTS; IN-VIVO; TRANSCRIPTION; COACTIVATOR; ACTIVATION	Understanding the mechanism of smooth muscle cell (SMC) differentiation will provide the foundation for elucidating SMC- related diseases such as atherosclerosis, restenosis, and asthma. Recent studies have demonstrated that the interaction of SRF with the co-activator myocardin is a critical determinant of smooth muscle development. It has been proposed that the specific transcriptional activation of smooth muscle-restricted genes (as opposed to other SRF-dependent genes) by myocardin results from the presence of multiple CArG boxes in smooth muscle genes that facilitate myocardin homodimer formation. This proposal was further tested in the current study. Our results show that the SMC-specific telokin promoter, which contains only a single CArG box, is strongly activated by myocardin. Furthermore, myocardin and a dimerization defective mutant myocardin induce expression of endogenous telokin but not c-fos in 10T1/2 fibroblast cells. Knocking down myocardin by small interfering RNA decreased telokin promoter activity and expression in A10 SMCs. A series of telokin and c-fos promoter chimeric and mutant reporter genes was generated to determine the mechanisms responsible for the promoter- specific effects of myocardin. Data from these experiments demonstrated that the ets binding site in the c-fos promoter partially blocks the activation of this promoter by myocardin. However, the binding of ets factors alone was not sufficient to explain the promoter- specific effects of myocardin. Elements 3' of the CArG box in the c-fos promoter act in concert with the ets binding site to block the ability of myocardin to activate the promoter. Conversely, elements 5' and 3' of the CArG box in the telokin promoter act in concert with the CArG box to facilitate myocardin stimulation of the promoter. Together these data suggest that the promoter specificity of myocardin is dependent on complex combinatorial interactions of multiple cis elements and their trans binding factors.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Herring, BP (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pherring@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061130, R01DK065644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58571] Funding Source: Medline; NIDDK NIH HHS [DK61130, DK65644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; Herring BP, 2001, AM J PHYSIOL-CELL PH, V280, pC12, DOI 10.1152/ajpcell.2001.280.1.C12; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; Herring BP, 2000, AM J PHYSIOL-CELL PH, V279, pC1656, DOI 10.1152/ajpcell.2000.279.5.C1656; Hoggatt AM, 2002, CIRC RES, V91, P1151, DOI 10.1161/01.RES.0000047508.30800.4F; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; SMITH AF, 1998, AM J PHYSIOL, V274, pR1188; Springer ML, 2002, CELL MOTIL CYTOSKEL, V51, P177, DOI 10.1002/cm.10022; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Yoshida T, 2004, ARTERIOSCL THROM VAS, V24, P1596, DOI 10.1161/01.ATV.0000137190.63214.c5; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhou JL, 2004, J BIOL CHEM, V279, P15929, DOI 10.1074/jbc.M313822200	26	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10861	10869		10.1074/jbc.M411586200	http://dx.doi.org/10.1074/jbc.M411586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15657056	hybrid			2022-12-25	WOS:000227559600135
J	Foster, KW; Liu, ZL; Nail, CD; Li, XN; Fitzgerald, TJ; Bailey, SK; Frost, AR; Louro, ID; Townes, TM; Paterson, AJ; Kudlow, JE; Lobo-Ruppert, SM; Ruppert, JM				Foster, KW; Liu, ZL; Nail, CD; Li, XN; Fitzgerald, TJ; Bailey, SK; Frost, AR; Louro, ID; Townes, TM; Paterson, AJ; Kudlow, JE; Lobo-Ruppert, SM; Ruppert, JM			Induction of KLF4 in basal keratinocytes blocks the proliferation - differentiation switch and initiates squamous epithelial dysplasia	ONCOGENE			English	Article						KLF4; squamous cell carcinoma; dysplasia; doxycycline; MMTV	KRUPPEL-LIKE FACTOR; TRANSGENIC MICE; BREAST-CANCER; NECK-CANCER; MALIGNANT PROGRESSION; COLORECTAL-CANCER; GENE-EXPRESSION; MOUSE MODEL; C-MYC; SKIN	KLF4/GKLF normally functions in differentiating epithelial cells, but also acts as a transforming oncogene in vitro. To examine the role of this zinc finger protein in skin, we expressed the wild-type human allele from inducible and constitutive promoters. When induced in basal keratinocytes, KLF4 rapidly abolished the distinctive properties of basal and parabasal epithelial cells. KLF4 caused a transitory apoptotic response and the skin progressed through phases of hyperplasia and dysplasia. By 6 weeks, lesions exhibited nuclear KLF4 and other morphologic and molecular similarities to squamous cell carcinoma in situ. p53 determined the patch size sufficient to establish lesions, as induction in a mosaic pattern produced skin lesions only when p53 was deficient. Compared with p53 wild-type animals, p53 hemizygous animals had early onset of lesions and a pronounced fibrovascular response that included outgrowth of subcutaneous sarcoma. A KLF4-estrogen receptor fusion protein showed tamoxifen-dependent nuclear localization and conditional transformation in vitro. The results suggest that KLF4 can function in the nucleus to induce squamous epithelial dysplasia, and indicate roles for p53 and epithelial mesenchymal signaling in these early neoplastic lesions.	Univ Alabama Birmingham, Med Sch Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Ruppert, JM (corresponding author), Univ Alabama Birmingham, Med Sch Birmingham, Dept Med, Room 570 WTI,1824 6th Ave S, Birmingham, AL 35294 USA.	mruppert@uab.edu	Louro, Iuri D/I-8641-2012	Kammerud, Sarah/0000-0002-4808-1618; Louro, Iuri/0000-0001-5160-9615	NCI NIH HHS [CA094030, P50 CA089019, P30 CA013148, R01 CA094030, R29 CA065686, CA89019, R01 CA065686, P30CA13148, CA65686] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148, P50CA089019, R01CA094030, R01CA065686, R29CA065686] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BOYLE JO, 1993, CANCER RES, V53, P4477; Brash DE, 1998, CANCER SURV, V32, P69; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coussens LM, 1996, AM J PATHOL, V149, P1899; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; DEAMANT FD, 1987, J CELL SCI, V88, P305; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Engel ME, 1998, J CELL BIOCHEM, P111; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; Gao XH, 2002, J INVEST DERMATOL, V118, P998, DOI 10.1046/j.1523-1747.2002.01778.x; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hann B, 2001, CURR OPIN CELL BIOL, V13, P778, DOI 10.1016/S0955-0674(00)00283-0; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; Hinnebusch BF, 2004, AM J PHYSIOL-GASTR L, V286, pG23, DOI 10.1152/ajpgi.00203.2003; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; HORN TD, 1998, CUTANEOUS ONCOLOGY, P361; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Katz JP, 2002, DEVELOPMENT, V129, P2619; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; King KE, 2003, J BIOL CHEM, V278, P11661, DOI 10.1074/jbc.M211337200; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu LH, 2001, J BIOL CHEM, V276, P26737, DOI 10.1074/jbc.C100275200; Louro ID, 2002, CANCER RES, V62, P5867; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Maillard I, 2003, CANCER CELL, V3, P203, DOI 10.1016/S1535-6108(03)00052-7; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; NG YK, 1990, CELL DIFFER DEV, V30, P27, DOI 10.1016/0922-3371(90)90071-4; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; vanderVelden LA, 1997, EUR ARCH OTO-RHINO-L, V254, P376, DOI 10.1007/BF01642554; WEINBERG RA, 1989, CANCER RES, V49, P3713; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Wu XM, 2001, TRENDS CELL BIOL, V11, pS2, DOI 10.1016/S0962-8924(01)82000-6; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	63	160	171	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1491	1500		10.1038/sj.onc.1208307	http://dx.doi.org/10.1038/sj.onc.1208307			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674344	Green Accepted			2022-12-25	WOS:000227218200002
J	Gery, S; Tanosaki, S; Hofmann, WK; Koppel, A; Koeffler, HP				Gery, S; Tanosaki, S; Hofmann, WK; Koppel, A; Koeffler, HP			C/EBP delta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation	ONCOGENE			English	Article						C/EBP delta; BCR-ABL; granulocytic differentiation	CCAAT/ENHANCER-BINDING PROTEINS; CHRONIC MYELOCYTIC-LEUKEMIA; C-MYC; TRANSCRIPTION-FACTOR; ADIPOCYTE DIFFERENTIATION; HEMATOPOIETIC-CELLS; ALPHA EXPRESSION; CYCLIN-E; GENE; EPSILON	CCAAT/enhancer-binding proteins (C/EBPs) are a family of highly conserved transcription factors that have important roles in normal myelopoiesis as well as associated with myeloid disorders. The chronic myelogenous leukemia (CML) cell lines, KCL22 and K562, express exceptionally low levels of endogenous C/EBPs and provide a good model to test the effects of C/EBPs on myeloid differentiation. To explore the possibility that C/EBPdelta can promote differentiation in BCR-ABL-positive cells, we generated stable KCL22 and K562 clones that expressed an inducible C/EBPdelta gene. C/EBPdelta expression resulted in G0/G1 proliferative arrest and a moderate increase in apoptosis of the KCL22 and the K562 cells. Within 4 days of inducing expression of C/EBPdelta, myeloid differentiation of the CML blast cells occurred as shown by morphologic changes and induction of secondary granule-specific genes. We also showed that during granulocytic differentiation of KCL22 cells, the C/EBPdelta protein was detected in immunocomplexes with both Rb and E2F1. Furthermore, expression of C/EBPdelta was associated with downregulation of c-Myc and cyclin E and upregulation of the cyclin-dependent kinase inhibitor p27(Kip1) in both the KCL22 and K562 cell lines. These results show that expression of C/EBPdelta in BCR-ABL-positive leukemic cells in blast crisis is sufficient for neutrophil differentiation and point to the therapeutic potential of ectopic induction of C/EBPdelta in the acute phase of CML.	Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Hosp, Dept Hematol, D-60596 Frankfurt, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Gery, S (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Davis Bldg 5066,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	gerys@cshs.org						AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; Asimakopoulos FA, 1999, BLOOD, V94, P2452, DOI 10.1182/blood.V94.7.2452.419k23_2452_2460; Billiard J, 2001, J BIOL CHEM, V276, P15354, DOI 10.1074/jbc.M009973200; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159; Gheorghiu I, 2001, J BIOL CHEM, V276, P44331, DOI 10.1074/jbc.M107591200; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Kubota T, 2001, LEUKEMIA RES, V25, P981, DOI 10.1016/S0145-2126(01)00065-0; Mori N, 1997, BLOOD, V90, P2010, DOI 10.1182/blood.V90.5.2010; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Schuster C, 2003, BLOOD, V101, P655, DOI 10.1182/blood-2002-01-0043; SCOTT LM, 1992, BLOOD, V80, P1725; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tavor S, 2003, J BIOL CHEM, V278, P52651, DOI 10.1074/jbc.M307077200; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Vegesna VA, 2002, LEUKEMIA RES, V26, P451, DOI 10.1016/S0145-2126(01)00150-3; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Yamanaka R, 1998, INT J MOL MED, V1, P213; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245	38	57	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2005	24	9					1589	1597		10.1038/sj.onc.1208393	http://dx.doi.org/10.1038/sj.onc.1208393			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674331				2022-12-25	WOS:000227218200012
J	Frantz, S; Calvillo, L; Tillmanns, J; Elbing, I; Dienesch, C; Bischoff, H; Ertl, G; Bauersachs, J				Frantz, S; Calvillo, L; Tillmanns, J; Elbing, I; Dienesch, C; Bischoff, H; Ertl, G; Bauersachs, J			Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose	FASEB JOURNAL			English	Article						diabetes mellitus; myocardial infarction; inflammation; oxidative stress	ISCHEMIA-REPERFUSION INJURY; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RISK-FACTOR; IN-VIVO; DIABETES-MELLITUS; OXIDATIVE STRESS; HEART; TOLERANCE; MORTALITY	Protective effects of the alpha-glucosidase inhibitor acarbose have been reported for various diabetic complications. In the STOP-NIDDM study, even patients without overt diabetes, but with impaired glucose tolerance, had a reduction in cardiovascular events when treated with acarbose. Therefore, we investigated the effect of repetitive postprandial hyperglycemia on the cardiac ischemia/reperfusion injury in vivo. Mice were treated daily by single applications of placebo, sucrose ( 4 g/kg body weight), or sucrose + acarbose ( 10 mg/kg body weight) by gavage for 7 days. Acarbose treatment significantly reduced the sucrose-induced increase in plasma glucose concentration. Subsequently, animals underwent 30 min of ischemia by coronary artery ligation and 24 h of reperfusion in vivo. In the sucrose group, ischemia/reperfusion damage was significantly increased (infarct/area at risk, placebo vs. sucrose, 38.8 +/- 7.5% vs. 62.2 +/- 4.8%, P< 0.05). This was prevented by acarbose treatment (infarct/area at risk 30.7 +/- 7.2%). While myocardial inflammation was similar in all groups, oxidative stress as indicated by a significant increase in lipid peroxides was enhanced in the sucrose, but not in the sucrose + acarbose group. In summary, repetitive postprandial hyperglycemia increases ischemia/reperfusion damage. This effect can be prevented by treatment with the alpha-glucosidase inhibitor acarbose.	Univ Wurzburg, Med Klin, D-97080 Wurzburg, Germany; Bayer AG, BHC PH R EU CV III, D-5600 Wuppertal, Germany	University of Wurzburg; Bayer AG	Bauersachs, J (corresponding author), Univ Wurzburg, Med Klin, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	bauersachs_j@medizin.uni-wuerzburg.de	Frantz, Stefan/G-1723-2012; calvillo, laura/K-1901-2019	calvillo, laura/0000-0002-5151-8243				Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; CARREA FP, 1991, CIRC RES, V68, P1652, DOI 10.1161/01.RES.68.6.1652; Ceriello A, 2001, DIABETOLOGIA, V44, P834; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486; Ebel D, 2003, PFLUG ARCH EUR J PHY, V446, P175, DOI 10.1007/s00424-003-1051-x; Feuvray D, 1997, CARDIOVASC RES, V34, P113, DOI 10.1016/S0008-6363(97)00037-0; Frantz S, 2004, BRIT J PHARMACOL, V141, P9, DOI 10.1038/sj.bjp.0705585; Frantz S, 2003, CARDIOVASC RES, V57, P749, DOI 10.1016/S0008-6363(02)00723-X; Frantz S, 2003, J MOL CELL CARDIOL, V35, P685, DOI 10.1016/S0022-2828(03)00113-5; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Jones SP, 2003, AM J PHYSIOL-HEART C, V284, pH277, DOI 10.1152/ajpheart.00236.2002; Jones SP, 1999, AM J PHYSIOL-HEART C, V277, pH763, DOI 10.1152/ajpheart.1999.277.2.H763; Kersten JR, 1998, AM J PHYSIOL-HEART C, V275, pH721, DOI 10.1152/ajpheart.1998.275.2.H721; King GL, 2004, HISTOCHEM CELL BIOL, V122, P333, DOI 10.1007/s00418-004-0678-9; Lefer DJ, 2001, FASEB J, V15, P1454, DOI 10.1096/fj.00-0819fje; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Oyama J, 2004, CIRCULATION, V109, P784, DOI 10.1161/01.CIR.0000112575.66565.84; Paulson DJ, 1997, CARDIOVASC RES, V34, P104, DOI 10.1016/S0008-6363(97)00018-7; PULS W, 1977, NATURWISSENSCHAFTEN, V64, P536, DOI 10.1007/BF00483562; Rodriguez BL, 1996, DIABETES CARE, V19, P587, DOI 10.2337/diacare.19.6.587; Schafer A, 2004, THROMB HAEMOSTASIS, V92, P97, DOI 10.1160/th04-02-0118; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Tominaga M, 1999, DIABETES CARE, V22, P920, DOI 10.2337/diacare.22.6.920; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Vinten-Johansen J, 2004, CARDIOVASC RES, V61, P481, DOI 10.1016/j.cardiores.2003.10.011; Wolever TMS, 1998, DIABETES CARE, V21, P336, DOI 10.2337/diacare.21.3.336; WONG SHY, 1987, CLIN CHEM, V33, P214; Ye F, 2002, PHYTOMEDICINE, V9, P161, DOI 10.1078/0944-7113-00065; ZUANETTI G, 1993, J AM COLL CARDIOL, V22, P1788, DOI 10.1016/0735-1097(93)90758-S	30	52	55	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					591	+		10.1096/fj.04-2459fje	http://dx.doi.org/10.1096/fj.04-2459fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15671153				2022-12-25	WOS:000226576600007
J	Barre, B; Vigneron, A; Coqueret, O				Barre, B; Vigneron, A; Coqueret, O			The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; REPRESSES TRANSCRIPTION; FUNCTIONAL INTERACTION; BREAST-CANCER; ACTIVATION; TRANSFORMATION; PHOSPHATASE; CELLS; GENE; PHOSPHORYLATION	The STAT3 ( signal transducer and activator of transcription) transcription factor functions as downstream effector of growth factor signaling. Whereas STAT3 activation is transient in normal cells, constitutively activated forms of the transcription factor have been detected in several cancer cell lines and primary tumors. Through the up-regulation of cell cycle and survival genes, STAT3 plays important roles in cell growth, anti-apoptosis, and cell transformation yet the molecular basis for this behavior is poorly understood. In this study, we show that STAT3 and its transcriptional cofactors are recruited to the promoter of the Cdc25A gene to activate its expression. Using chromatin immunoprecipitations, we observed that Myc is recruited to this promoter following STAT3 DNA binding. Moreover, small interfering RNA-mediated knockdown of Myc specifically inhibits the STAT3-mediated activation of Cdc25A. Reduction in Myc protein level results in defective recruitment of the CREB-binding protein, Cdk9, and RNA polymerase complexes, indicating that Myc is necessary for STAT3 transcription. Surprisingly, the association of STAT3 with the Cdc25A promoter does not necessarily lead to transcriptional induction because this protein also functions as a transcriptional repressor of the Cdc25A gene. Following hydrogen peroxide stimulation, STAT3 forms a repressor complex with the retinoblastoma (Rb) tumor suppressor to occupy the Cdc25A promoter and block its induction. In coimmunoprecipitations and ChIP experiments, Rb was found to associate with STAT3 on DNA and we provide evidence that Rb binds directly to the transcription factor. Thus, we propose that Myc and STAT3 cooperate to induce the expression of Cdc25A and that their transcriptional activity is normally regulated by the Rb tumor suppressor gene.	Ctr Reg Lutte Canc Paul Papin, INSERM, U564, F-49033 Angers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Universite d'Angers	Coqueret, O (corresponding author), Ctr Reg Lutte Canc Paul Papin, INSERM, U564, 2 Rue Moll, F-49033 Angers, France.	olivier.coqueret@univ-angers.fr	Coqueret, Olivier/K-9660-2015; Vigneron, Arnaud/ABC-7306-2021	Coqueret, Olivier/0000-0002-2843-7867; Vigneron, Arnaud/0000-0003-4161-0676				Barre B, 2003, J BIOL CHEM, V278, P2990, DOI 10.1074/jbc.M210422200; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Carballo M, 1999, J BIOL CHEM, V274, P17580, DOI 10.1074/jbc.274.25.17580; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Giraud S, 2004, ONCOGENE, V23, P7391, DOI 10.1038/sj.onc.1207972; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lin JY, 2002, CANCER RES, V62, P376; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338	45	70	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15673	15681		10.1074/jbc.M413203200	http://dx.doi.org/10.1074/jbc.M413203200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15677471	hybrid			2022-12-25	WOS:000228444800028
J	Luciano, F; Zhai, DY; Zhu, XW; Maitre, BB; Ricci, JE; Satterthwait, AC; Reed, JC				Luciano, F; Zhai, DY; Zhu, XW; Maitre, BB; Ricci, JE; Satterthwait, AC; Reed, JC			Cytoprotective peptide humanin binds and inhibits proapoptotic Bcl-2/Bax family protein BimEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; FOCAL CEREBRAL-ISCHEMIA; BAX-DEPENDENT APOPTOSIS; RESCUE FACTOR HUMANIN; NEURONAL CELL-DEATH; MEMBER BIM; NEUROPROTECTIVE FACTOR; CONFORMATIONAL-CHANGE; BH3-ONLY PROTEINS; INDUCE APOPTOSIS	Humanin (HN) is a recently identified endogenous peptide that protects cells against cytotoxicity induced by various stimuli. Recently, we showed that HN binds to and inhibits Bax, a proapoptotic Bcl-2 family protein, suggesting a mechanism for HN action. In this study, we identified Bim, a Bcl-2 homology 3-only member of the Bcl-2/Bax family, as an additional HN target protein. Using in vitro protein binding, immunoprecipitation, and coimmunolocalization assays, we demonstrated that HN binds directly to the extra long isoform of Bim (BimEL) but not the long (BimL) or short (BimS) isoforms. HN also protects cells against apoptosis induced by BimEL but not BimL and BimS in gene transfection studies. In contrast, mutants of HN which failed to bind BimEL failed to protect from BimEL-induced cell death. Moreover, HN inhibited BimEL-induced release of SMAC and cytochrome c from mitochondria isolated from bax-/- cells, indicating that HN can suppress BimEL independently of its effect on Bax. Finally, we demonstrate that HN prevents BimEL-induced oligomerization of Bak using isolated mitochondria. Taken together, our results indicate that the inhibition of BimEL may contribute to the antiapoptotic properties of the HN peptide.	Burnham Inst, La Jolla, CA 92037 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute; La Jolla Institute for Immunology	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org	luciano, frederic/P-6264-2016; RICCI, Jean Ehrland/AAS-4379-2020; Ricci, Jean Ehrland/I-7117-2016	luciano, frederic/0000-0001-9253-4998; RICCI, Jean Ehrland/0000-0003-1585-8117; Ricci, Jean Ehrland/0000-0003-1585-8117; Bailly-Maitre, Beatrice/0000-0002-8389-8498	NIGMS NIH HHS [GM60554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hashimoto Y, 2001, J NEUROSCI, V21, P9235, DOI 10.1523/JNEUROSCI.21-23-09235.2001; Hashimoto Y, 2001, BIOCHEM BIOPH RES CO, V283, P460, DOI 10.1006/bbrc.2001.4765; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Linseman DA, 2002, J NEUROSCI, V22, P9287; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Niikura T, 2002, J NEUROSCI RES, V70, P380, DOI 10.1002/jnr.10354; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; RATHMELL JC, 2002, CELL S, V109, P97; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Shinoda S, 2004, J CLIN INVEST, V113, P1059, DOI 10.1172/JCI200419971; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Tajima H, 2002, NEUROSCI LETT, V324, P227, DOI 10.1016/S0304-3940(02)00199-4; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Yamagishi Y, 2003, PEPTIDES, V24, P585, DOI 10.1016/S0196-9781(03)00106-2; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yin KJ, 2002, J NEUROSCI, V22, P9764; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200; Zhai DY, 2005, J BIOL CHEM, V280, P15815, DOI 10.1074/jbc.M411902200; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	49	82	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15825	15835		10.1074/jbc.M413062200	http://dx.doi.org/10.1074/jbc.M413062200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15661735	hybrid			2022-12-25	WOS:000228444800046
J	Spreter, T; Pech, M; Beatrix, B				Spreter, T; Pech, M; Beatrix, B			The crystal structure of archaeal nascent polypeptide-associated complex (NAC) reveals a unique fold and the presence of a ubiquitin-associated domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN FAMILIES; ALPHA-SUBUNIT; BETA-NAC; RECOGNITION; SEQUENCE; IDENTIFICATION; DEGRADATION; EVOLUTION; APOPTOSIS	Nascent polypeptide-associated complex (NAC) was identified in eukaryotes as the first cytosolic factor that contacts the nascent polypeptide chain emerging from the ribosome. NAC is highly conserved from yeast to humans. Mutations in NAC cause severe embryonically lethal phenotypes in mice, Drosophila, and Caenorhabditis elegans. NAC was suggested to protect the nascent chain from inappropriate early interactions with cytosolic factors. Eukaryotic NAC is a heterodimer with two subunits sharing substantial homology with each other. All sequenced archaebacterial genomes exhibit only one gene homologous to the NAC subunits. Here we present the first archaebacterial NAC homolog. It forms a homodimer, and as eukaryotic NAC it is associated with ribosomes and contacts the emerging nascent chain on the ribosome. We present the first crystal structure of a NAC protein revealing two structural features: (i) a novel unique protein fold that mediates dimerization of the complex, and (ii) a ubiquitin-associated domain that suggests a yet unidentified role for NAC in the cellular protein quality control system via the ubiquitination pathway. Based on the presented structure we propose a model for the eukaryotic heterodimeric NAC domain.	Free Univ Berlin, Inst Chem Crystallog, D-14195 Berlin, Germany	Free University of Berlin	Beatrix, B (corresponding author), Free Univ Berlin, Inst Chem Crystallog, Takustr 6, D-14195 Berlin, Germany.	bbeatrix@chemie.fu-berlin.de						Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Arcus V, 2002, CURR OPIN STRUC BIOL, V12, P794, DOI 10.1016/S0959-440X(02)00392-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Beatrix B, 2000, J BIOL CHEM, V275, P37838, DOI 10.1074/jbc.M006368200; Bloss TA, 2003, NATURE, V424, P1066, DOI 10.1038/nature01920; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; DENG JM, 1995, TRANSGENIC RES, V4, P264, DOI 10.1007/BF01969120; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim SH, 2002, J INVEST MED, V50, P293, DOI 10.2310/6650.2002.33287; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kroes RA, 2000, CANCER LETT, V156, P191, DOI 10.1016/S0304-3835(00)00462-6; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Macario AJL, 2001, FRONT BIOSCI-LANDMRK, V6, pD262, DOI 10.2741/Macario; Makarova KS, 1999, GENOME RES, V9, P608; Markesich DC, 2000, DEVELOPMENT, V127, P559; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moller I, 1998, P NATL ACAD SCI USA, V95, P13425, DOI 10.1073/pnas.95.23.13425; Moller I, 1998, FEBS LETT, V441, P1, DOI 10.1016/S0014-5793(98)01440-9; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rees B, 2000, J MOL BIOL, V299, P1157, DOI 10.1006/jmbi.2000.3792; Reimann B, 1999, YEAST, V15, P397, DOI 10.1002/(SICI)1097-0061(19990330)15:5<397::AID-YEA384>3.3.CO;2-L; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scheuring UJ, 1998, AIDS, V12, P563, DOI 10.1097/00002030-199806000-00004; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yotov WV, 1998, MOL CELL BIOL, V18, P1303, DOI 10.1128/MCB.18.3.1303	47	54	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15849	15854		10.1074/jbc.M500160200	http://dx.doi.org/10.1074/jbc.M500160200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15665334	hybrid			2022-12-25	WOS:000228444800049
J	Dey, S; Hu, ZQ; Xu, XL; Sacchettini, JC; Grant, GA				Dey, S; Hu, ZQ; Xu, XL; Sacchettini, JC; Grant, GA			D-3-phosphoglycerate dehydrogenase from Mycobacterium tuberculosis is a link between the Escherichia coli and mammalian enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOGLYCERATE DEHYDROGENASE; PHOSPHOGLYCERATE DEHYDROGENASE; SERINE BIOSYNTHESIS; CHLORIDE-ION; HYBRID TETRAMERS; ANIMAL TISSUES; PURIFICATION; DOMAIN; COOPERATIVITY; INHIBITION	D-3-Phosphoglycerate dehydrogenase (PGDH) from Mycobacterium tuberculosis has been isolated to homogeneity and displays an unusual relationship to the Escherichia coli and mammalian enzymes. In almost all aspects investigated, the M. tuberculosis enzyme shares the characteristics of the mammalian PGDHs. These include an extended C-terminal motif, substrate inhibition kinetics, dependence of activity levels and stability on ionic strength, and the inability to utilize alpha-ketoglutarate as a substrate. The unique property that the M. tuberculosis enzyme shares with E. coli PGDH that it is very sensitive to inhibition by L-serine, with an I-0.5 = 30 mu M. The mammalian enzymes are not inhibited by L-serine. In addition, the cooperativity of serine inhibition appears to be modulated by chloride ion, becoming positively cooperative in its presence. This is modulated by the gain of cooperativity in serine binding for the first two effector sites. The basis for the chloride modulation of cooperativity is not known, but the sensitivity to serine inhibition can be explained in terms of certain amino acid residues in critical areas of the structures. The differential sensitivity to serine inhibition by M. tuberculosis and human PGDH may open up interesting possibilities in the treatment of multidrug-resistant tuberculosis.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Washington University (WUSTL); Washington University (WUSTL); Texas A&M University System; Texas A&M University College Station	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	ggrant@molecool.wustl.edu	Dey, Sanghamitra/AAV-7921-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achouri Y, 1997, BIOCHEM J, V323, P365, DOI 10.1042/bj3230365; Ali V, 2004, EUR J BIOCHEM, V271, P2670, DOI 10.1111/j.1432-1033.2004.04195.x; Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Chipman DM, 2001, CURR OPIN STRUC BIOL, V11, P694, DOI 10.1016/S0959-440X(01)00272-X; Cigic B, 1999, EUR J BIOCHEM, V264, P944, DOI 10.1046/j.1432-1327.1999.00697.x; Dey S, 2005, J BIOL CHEM, V280, P14892, DOI 10.1074/jbc.M414489200; Grant GA, 2000, BIOCHEMISTRY-US, V39, P7316, DOI 10.1021/bi000218y; Grant GA, 2004, METHOD ENZYMOL, V380, P106; Grant GA, 2004, J BIOL CHEM, V279, P13452, DOI 10.1074/jbc.M313593200; Grant GA, 2003, J BIOL CHEM, V278, P18170, DOI 10.1074/jbc.M213050200; GRANT GA, 1989, BIOCHEM BIOPH RES CO, V165, P1371, DOI 10.1016/0006-291X(89)92755-1; ICHIHARA A, 1957, J BIOL CHEM, V224, P331; MCKITRICK JC, 1980, J BACTERIOL, V141, P235, DOI 10.1128/JB.141.1.235-245.1980; MEIJER AJ, 1992, J BIOL CHEM, V267, P5823; Pederson BA, 1998, ARCH BIOCHEM BIOPHYS, V353, P141, DOI 10.1006/abbi.1998.0642; Peters-Wendisch P, 2002, APPL MICROBIOL BIOT, V60, P437, DOI 10.1007/s00253-002-1161-y; PIZER LI, 1963, J BIOL CHEM, V238, P3934; ROSENBLUM IY, 1970, ARCH BIOCHEM BIOPHYS, V137, P91, DOI 10.1016/0003-9861(70)90414-5; SASKI R, 1975, EUR J BIOCHEM, V51, P415, DOI 10.1111/j.1432-1033.1975.tb03941.x; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Slaughter J C, 1975, Methods Enzymol, V41, P278; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; VANBEEK GGM, 1980, EUR J BIOCHEM, V105, P353; WALSH DA, 1966, J BIOL CHEM, V241, P4068; WALSH DA, 1965, BIOCHEMISTRY-US, V4, P1076, DOI 10.1021/bi00882a015; WILLIS JE, 1964, BIOCHIM BIOPHYS ACTA, V81, P39, DOI 10.1016/0926-6569(64)90333-5; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	28	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14884	14891		10.1074/jbc.M414488200	http://dx.doi.org/10.1074/jbc.M414488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15668250	hybrid			2022-12-25	WOS:000228236800067
J	Federici, L; Du, DJ; Walas, F; Matsumura, H; Fernandez-Recio, J; McKeegan, KS; Borges-Walmsley, MI; Luisi, BF; Walmsley, AR				Federici, L; Du, DJ; Walas, F; Matsumura, H; Fernandez-Recio, J; McKeegan, KS; Borges-Walmsley, MI; Luisi, BF; Walmsley, AR			The crystal structure of the outer membrane protein VceC from the bacterial pathogen Vibrio cholerae at 1.8 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-EFFLUX PUMP; MULTIDRUG EFFLUX; PSEUDOMONAS-AERUGINOSA; TUNNEL ENTRANCE; TOLC; RESISTANCE; ACRB; ASSOCIATION; TRANSPORTER; REFINEMENT	Multidrug resistance in Gram-negative bacteria arises in part from the activities of tripartite drug efflux pumps. In the pathogen Vibrio cholerae, one such pump comprises the inner membrane proton antiporter VceB, the periplasmic adaptor VceA, and the outer membrane channel VceC. Here, we report the crystal structure of VceC at 1.8 angstrom resolution. The trimeric VceC is organized in the crystal lattice within laminar arrays that resemble membranes. A well resolved detergent molecule within this array interacts with the transmembrane beta-barrel domain in a fashion that may mimic protein-lipopolysaccharide contacts. Our analyses of the external surfaces of VceC and other channel proteins suggest that different classes of efflux pumps have distinct architectures. We discuss the implications of these findings for mechanisms of drug and protein export.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Durham, Wolfson Res Inst, Ctr Infect Dis, Stockton On Tees TS17 6BH, England	University of Cambridge; Durham University	Luisi, BF (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	ben@cryst.bioc.cam.ac.uk; a.r.walmsley@durham.ac.uk		Fernandez-Recio, Juan/0000-0002-3986-7686; Matsumura, Hiroyoshi/0000-0003-0361-3796				Akama H, 2004, J BIOL CHEM, V279, P52816, DOI 10.1074/jbc.C400445200; Akama H, 2004, J BIOL CHEM, V279, P25939, DOI 10.1074/jbc.C400164200; Andersen C, 2002, MOL MICROBIOL, V44, P1131, DOI 10.1046/j.1365-2958.2002.02898.x; Andersen C, 2002, P NATL ACAD SCI USA, V99, P11103, DOI 10.1073/pnas.162039399; Borges-Walmsley MI, 2003, BIOCHEM J, V376, P313, DOI 10.1042/BJ20020957; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choudhury P, 1996, INDIAN J MED RES, V104, P148; Colmer JA, 1998, MOL MICROBIOL, V27, P63, DOI 10.1046/j.1365-2958.1998.00657.x; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Federici L, 2004, CURR SCI INDIA, V87, P190; Fernandez-Recio J, 2004, FEBS LETT, V578, P5, DOI 10.1016/j.febslet.2004.10.097; FERNANDEZRECIO J, 2004, PROTEINS, V58, P134; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Higgins MK, 2004, P NATL ACAD SCI USA, V101, P9994, DOI 10.1073/pnas.0400375101; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Li XZ, 2001, J BACTERIOL, V183, P12, DOI 10.1128/JB.183.1.12-27.2001; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Sharff A, 2001, EUR J BIOCHEM, V268, P5011, DOI 10.1046/j.0014-2956.2001.02442.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tikhonova EB, 2004, J BIOL CHEM, V279, P32116, DOI 10.1074/jbc.M402230200; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; ZAKHAROV SD, 2002, BIOCHIM BIOPHYS ACTA, V1165, P333; ZHU ZY, 1992, PROTEIN ENG, V5, P43, DOI 10.1093/protein/5.1.43	32	80	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15307	15314		10.1074/jbc.M500401200	http://dx.doi.org/10.1074/jbc.M500401200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15684414	Green Accepted, hybrid			2022-12-25	WOS:000228236800116
J	Jiang, HY; Wek, RC				Jiang, HY; Wek, RC			Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2 alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; INDUCED GENE-EXPRESSION; NF-KAPPA-B; MESSENGER-RNA TRANSLATION; TARGETED DISRUPTION; BINDING PROTEIN; CELL-SURVIVAL; KINASE GCN2; ACTIVATION; TRANSCRIPTION	Protein ubiquitination and subsequent degradation by the proteasome are important mechanisms regulating cell cycle, growth and differentiation, and apoptosis. Recent studies in cancer therapy suggest that drugs that disrupt the ubiquitin/ proteasome pathway induce apoptosis and sensitize malignant cells and tumors to conventional chemotherapy. In this study we addressed the role of phosphorylation of the alpha- subunit eukaryotic initiation factor- 2 ( eIF2), and its attendant regulation of gene expression, in the cellular stress response to proteasome inhibition. Phosphorylation of eIF2 alpha in mouse embryo fibroblast ( MEF) cells subjected to proteasome inhibition leads to a significant reduction in protein synthesis, concomitant with induced expression of the bZIP transcription regulator, ATF4, and its target gene CHOP/ GADD153. The primary eIF2 alpha kinase activated by exposure of these fibroblast cells to proteasome inhibition is GCN2 ( EIF2AK4), which has a central role in the recognition of cytoplasmic stress signals. Endoplasmic reticulum ( ER) stress is not effectively induced in MEF cells subjected to proteasome inhibition, with minimal activation of the ER stress sensory proteins, eIF2 alpha kinase PEK ( PERK/ EIF2AK3), IRE1 protein kinase and the transcription regulator ATF6 following up to 6 h of proteasome inhibitor treatment. Loss of eIF2 alpha phosphorylation thwarts caspase activation and delays apoptosis. Central to this pro- apoptotic function of eIF2 alpha kinases during proteasome inhibition is the transcriptional regulator CHOP, as deletion of CHOP in MEF cells impedes apoptosis. We conclude that eIF2 alpha kinases are integral to cellular stress pathways induced by proteasome inhibitors, and may be central to the efficacy of anticancer drugs that target the ubiquitin/ proteasome pathway.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Jiang, HY (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	hjiang@iupui.edu	Longo, Kenneth A/A-5631-2010; 高, 雨莉/HGU-8187-2022		NIGMS NIH HHS [R01GM49164, R01GM64350] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049164, R01GM064350] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Anthony TG, 2004, J BIOL CHEM, V279, P36553, DOI 10.1074/jbc.M404559200; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Iakova P, 2004, EMBO J, V23, P406, DOI 10.1038/sj.emboj.7600052; Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Katayama T, 2001, J BIOL CHEM, V276, P43446, DOI 10.1074/jbc.M104096200; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Narasimhan J, 2004, J BIOL CHEM, V279, P22820, DOI 10.1074/jbc.M402228200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Ryu EJ, 2002, J NEUROSCI, V22, P10690; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Schauer SL, 1996, J IMMUNOL, V157, P81; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Senee V, 2004, DIABETES, V53, P1876, DOI 10.2337/diabetes.53.7.1876; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wek RC, 2004, TOP CURR GENET, V7, P171; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200; Yu CR, 2004, EXP CELL RES, V295, P555, DOI 10.1016/j.yexcr.2004.02.001; Zhan K, 2004, GENETICS, V168, P1867, DOI 10.1534/genetics.104.031443; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; Zimmermann J, 2000, ONCOGENE, V19, P2913, DOI 10.1038/sj.onc.1203606; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	81	246	257	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14189	14202		10.1074/jbc.M413660200	http://dx.doi.org/10.1074/jbc.M413660200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15684420	hybrid			2022-12-25	WOS:000228095500122
J	Massenet, C; Chenavas, S; Cohen-Addad, C; Dagher, MC; Brandolin, G; Pebay-Peyroula, E; Fieschi, F				Massenet, C; Chenavas, S; Cohen-Addad, C; Dagher, MC; Brandolin, G; Pebay-Peyroula, E; Fieschi, F			Effects of p47(phox) C terminus phosphorylations on binding interactions with p40(phox) and p67(phox) - Structural and functional comparison of p40(phox) and p67(phox) SH3 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; SRC HOMOLOGY-3 DOMAINS; PX DOMAIN; CRYSTAL-STRUCTURE; CYTOSOLIC COMPONENTS; INDUCED ACTIVATION; PC MOTIF; COMPLEX	The neutrophil NADPH oxidase produces superoxide anions in response to infection. This reaction is activated by association of cytosolic factors, p47(phox) and p67(phox), and a small G protein Rac with the membranous flavocytochrome b(558). Another cytosolic factor, p40(phox), is associated to the complex and is reported to play regulatory roles. Initiation of the NADPH oxidase activation cascade has been reported as consecutive to phosphorylation on serines 359/370 and 379 of the p47(phox) C terminus. These serines surround a polyproline motif that can interact with the Src homology 3 (SH3) module of p40(phox) (SH3(p40)) or the C-terminal SH3 of p67(phox) (C-SH3(p67)). The latter one presents a higher affinity in the resting state for p47(phox). A change in SH3 binding preference following phosphorylation has been postulated earlier. Here we report the crystal structures of SH3(p40) alone or in complex with a 12-residue proline-rich region of p47(phox) at 1.46 angstrom resolution. Using intrinsic tryptophan fluorescence measurements, we compared the affinity of the strict polyproline motif and the whole C terminus peptide with both SH3(p40) and C-SH3(p67). These data reveal that SH3(p40) can interact with a consensus polyproline motif but also with a noncanonical motif of the p47(phox) C terminus. The electrostatic surfaces of both SH3 are very different, and therefore the binding preference for C-SH3p67 can be attributed to the polyproline motif recognition and particularly to the Arg-368(p47) binding mode. The noncanonical motif contributes equally to interaction with both SH3. The influence of serine phosphorylation on residues 359/370 and 379 on the affinity for both SH3 domains has been checked. We conclude that contrarily to previous suggestions, phosphorylation of Ser-359/370 does not modify the SH3 binding affinity for both SH3, whereas phosphorylation of Ser-379 has a destabilizing effect on both interactions. Other mechanisms than a phosphorylation induced switch between the two SH3 must therefore take place for NADPH oxidase activation cascade to start.	Univ Grenoble 1, Inst Biol Struct, CEA, Lab Prot Membranaires,CNRS,UMR 5075, F-38027 Grenoble, France; UJF, Dept Reponse & Dynam Cellulaire, BBSI, CEA,CNRS,UMR 5092, F-38054 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Fieschi, F (corresponding author), Univ Grenoble 1, Inst Biol Struct, CEA, Lab Prot Membranaires,CNRS,UMR 5075, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	fieschi@ibs.fr	Fieschi, Franck/W-2748-2019	DAGHER, Marie-Claire/0000-0001-6878-3169; FIESCHI, Franck/0000-0003-1194-8107				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bouin AP, 1998, J BIOL CHEM, V273, P30097, DOI 10.1074/jbc.273.46.30097; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cross AR, 2000, BIOCHEM J, V349, P113, DOI 10.1042/0264-6021:3490113; Dang PMC, 2003, BIOCHEMISTRY-US, V42, P4520, DOI 10.1021/bi0205754; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; Fuchs A, 1996, BBA-MOL CELL RES, V1312, P39, DOI 10.1016/0167-4889(96)00020-1; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; Grandvaux N, 1999, J CELL SCI, V112, P503; Grizot S, 2001, J BIOL CHEM, V276, P21627, DOI 10.1074/jbc.M100893200; Grizot S, 2001, BIOCHEMISTRY-US, V40, P3127, DOI 10.1021/bi0028439; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; Liang J, 1996, J MOL BIOL, V257, P632, DOI 10.1006/jmbi.1996.0190; Lopes LR, 2004, BIOCHEMISTRY-US, V43, P3723, DOI 10.1021/bi035636s; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NETWORK EDV, 1998, J MOL BIOL, V276, P417; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wientjes FB, 1996, BIOCHEM J, V317, P919, DOI 10.1042/bj3170919; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4	66	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13752	13761		10.1074/jbc.M412897200	http://dx.doi.org/10.1074/jbc.M412897200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15657040	hybrid			2022-12-25	WOS:000228095500071
J	Wan, HJ; Dingle, S; Xu, Y; Besnard, V; Kaestner, KH; Ang, SL; Wert, S; Stahlman, MT; Whitsett, JA				Wan, HJ; Dingle, S; Xu, Y; Besnard, V; Kaestner, KH; Ang, SL; Wert, S; Stahlman, MT; Whitsett, JA			Compensatory roles of Foxa1 and Foxa2 during lung morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-3-BETA; CELL SECRETORY PROTEIN; TRANSCRIPTION FACTOR-I; GENE-EXPRESSION; SONIC-HEDGEHOG; FLOOR PLATE; MOUSE LUNG; BRANCHING MORPHOGENESIS; GLUCOSE-HOMEOSTASIS; DEFINITIVE ENDODERM	Foxa1 and Foxa2 are closely related family members of the Foxa group of transcription factors that are co-expressed in subsets of respiratory epithelial cells throughout lung morphogenesis. Shared patterns of expression, conservation of DNA binding, and transcriptional activation domains indicate that they may serve complementary functions in the regulation of gene expression during lung morphogenesis. Whereas branching morphogenesis of the fetal lung occurs normally in the Foxa2(Delta/Delta) and Foxa1(-/-) mice, deletion of both Foxa1 and Foxa2 (in Foxa2(Delta/Delta), Foxa1(-/-) mice) inhibited cell proliferation, epithelial cell differentiation, and branching. Dilation of terminal lung tubules and decreased branching were observed as early as embryonic day 12.5. Foxa1 and Foxa2 regulated Shh (sonic hedgehog) and Shh-dependent genes in the respiratory epithelial cells that influenced the expression of genes in the pulmonary mesenchyme that are required for branching morphogenesis. Epithelial cell differentiation, as indicated by lack of expression of surfactant protein B, surfactant protein C, the Clara cell secretory protein, and Foxj1, was inhibited. Foxa family members regulate signaling and transcriptional programs required for morphogenesis and cell differentiation during formation of the lung.	Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England; Vanderbilt Univ, Dept Pediat, Sch Med, Nashville, TN 37232 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Pennsylvania; MRC National Institute for Medical Research; Vanderbilt University	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Neonatol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org		Besnard, Valerie/0000-0002-2614-629X; , Yan/0000-0003-2025-027X	Medical Research Council [MC_U117570533] Funding Source: Medline; NHLBI NIH HHS [HL38859, HL75770, HL56387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075770, P50HL056387, R37HL038859, P01HL056387, R01HL038859] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Besnard V, 2004, GENE EXPR PATTERNS, V5, P193, DOI 10.1016/j.modgep.2004.08.006; BINGLE CD, 1995, BIOCHEM J, V308, P197, DOI 10.1042/bj3080197; BINGLE CD, 1993, BIOCHEM J, V295, P227, DOI 10.1042/bj2950227; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; Cardoso WV, 2001, ANNU REV PHYSIOL, V63, P471, DOI 10.1146/annurev.physiol.63.1.471; CARDOSO WV, 1995, AM J PHYSIOL-LUNG C, V269, pL429, DOI 10.1152/ajplung.1995.269.4.L429; Christoffels VM, 1998, MOL CELL BIOL, V18, P6305, DOI 10.1128/MCB.18.11.6305; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Epstein DJ, 1999, DEVELOPMENT, V126, P281; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Hogan BLM, 1997, COLD SPRING HARB SYM, V62, P249; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Ikeda K, 1996, MOL CELL BIOL, V16, P3626; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LevinsonDushnik M, 1997, MOL CELL BIOL, V17, P3817, DOI 10.1128/MCB.17.7.3817; Lin L, 2002, CANCER RES, V62, P5273; Liu J, 2000, DEV DYNAM, V217, P343, DOI 10.1002/(SICI)1097-0177(200004)217:4<343::AID-DVDY2>3.0.CO;2-F; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Miller LAD, 2004, DEV DYNAM, V231, P57, DOI 10.1002/dvdy.20105; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Perl AKT, 1999, CLIN GENET, V56, P14, DOI 10.1034/j.1399-0004.1999.560103.x; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Shih DQ, 1999, P NATL ACAD SCI USA, V96, P10152, DOI 10.1073/pnas.96.18.10152; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; Shu WG, 2002, DEVELOPMENT, V129, P4831; Stahlman MT, 1998, J HISTOCHEM CYTOCHEM, V46, P955, DOI 10.1177/002215549804600809; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Wan HJ, 2004, P NATL ACAD SCI USA, V101, P14449, DOI 10.1073/pnas.0404424101; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Weaver M, 2003, DEV BIOL, V258, P169, DOI 10.1016/S0012-1606(03)00117-9; Weaver M, 2000, DEVELOPMENT, V127, P2695; Weidenfeld J, 2002, J BIOL CHEM, V277, P21061, DOI 10.1074/jbc.M111702200; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Zhou L, 1997, DEV DYNAM, V210, P305, DOI 10.1002/(SICI)1097-0177(199711)210:3<305::AID-AJA10>3.0.CO;2-9; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	60	187	194	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13809	13816		10.1074/jbc.M414122200	http://dx.doi.org/10.1074/jbc.M414122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15668254	hybrid			2022-12-25	WOS:000228095500078
J	Huang, YL; Hsu, YH; Han, YT; Meng, M				Huang, YL; Hsu, YH; Han, YT; Meng, M			mRNA guanylation catalyzed by the S-adenosylmethionine-dependent guanylyltransferase of bamboo mosaic virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; SEMLIKI-FOREST-VIRUS; CAPPING ENZYME; CRITICAL RESIDUES; COVALENT COMPLEX; GENOMIC RNA; POTEXVIRUS; METHYLATION; PROTEIN; INTERMEDIATE	The S-adenosylmethionine-dependent guanylyltransferase of bamboo mosaic virus belongs to a novel class of mRNA capping enzymes distantly conserved in Alphavirus-like superfamily. The reaction sequence of the viral enzyme has been proposed comprising steps of 1) binding of GTP and S-adenosylmethionine, 2) formation of m(7)GTP and S-adenosylhomocysteine, 3) formation of the covalent (Enzyme-m(7)GMP) intermediate, and 4) transfer of m(7)GMP from the intermediate to the RNA acceptor. In this study the acceptor specificity of the viral enzyme was characterized. The results show that adenylate or guanylate with 5'-diphosphate group is an essential feature for acceptors, which can be RNA or mononucleotide, to receive m7GMP. The transfer rate of m7GMP to guanylate is greater than to adenylate by a factor of similar to 3, and the K-m value for mononucleotide acceptor is similar to 10(3)-fold higher than that for RNA. The capping efficiency of the viral genomic RNA transcript depends on the length of the transcript and the formation of a putative stemloop structure, suggesting that mRNA capping process may participate in regulating the viral gene expression.	Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 40227, Taiwan	National Chung Hsing University	Meng, M (corresponding author), Natl Chung Hsing Univ, Grad Inst Biotechnol, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.	mhmeng@dragon.nchu.edu.tw						Ahola T, 1997, J VIROL, V71, P392, DOI 10.1128/JVI.71.1.392-397.1997; Ahola T, 1999, J VIROL, V73, P10061, DOI 10.1128/JVI.73.12.10061-10069.1999; AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; Cheng JH, 2002, J VIROL, V76, P6114, DOI 10.1128/JVI.76.12.6114-6120.2002; Chiu YL, 2002, MOL CELL, V10, P585, DOI 10.1016/S1097-2765(02)00630-5; Huang CY, 2001, J VIROL, V75, P2818, DOI 10.1128/JVI.75.6.2818-2824.2001; Huang FQ, 2000, BIOCHEMISTRY-US, V39, P15548, DOI 10.1021/bi002061f; Huang YL, 2004, J VIROL, V78, P1271, DOI 10.1128/JVI.78.3.1271-1280.2004; ITOH N, 1984, J BIOL CHEM, V259, P3930; Kong F, 1999, VIROLOGY, V259, P200, DOI 10.1006/viro.1999.9763; Lee YS, 1998, J GEN VIROL, V79, P1825, DOI 10.1099/0022-1317-79-7-1825; Li YI, 1998, J VIROL, V72, P10093, DOI 10.1128/JVI.72.12.10093-10099.1998; Li YI, 2001, J VIROL, V75, P12114, DOI 10.1128/JVI.75.24.12114-12120.2001; Li YI, 2001, J VIROL, V75, P782, DOI 10.1128/JVI.75.2.782-788.2001; LIN NS, 1994, J GEN VIROL, V75, P2513, DOI 10.1099/0022-1317-75-9-2513; Magden J, 2001, J VIROL, V75, P6249, DOI 10.1128/JVI.75.14.6249-6255.2001; Mao XD, 1996, BIOCHEMISTRY-US, V35, P6900, DOI 10.1021/bi960221a; Merits A, 1999, FEBS LETT, V455, P45, DOI 10.1016/S0014-5793(99)00856-X; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; STRAUSS EG, 1984, VIROLOGY, V133, P92, DOI 10.1016/0042-6822(84)90428-8; TAKKINEN K, 1986, NUCLEIC ACIDS RES, V14, P5667, DOI 10.1093/nar/14.14.5667; VENKATESAN S, 1980, J BIOL CHEM, V255, P2835; VENKATESAN S, 1982, P NATL ACAD SCI-BIOL, V79, P340, DOI 10.1073/pnas.79.2.340; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	26	38	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13153	13162		10.1074/jbc.M412619200	http://dx.doi.org/10.1074/jbc.M412619200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677480	hybrid			2022-12-25	WOS:000227922000127
J	Numata, A; Shimoda, K; Kamezaki, K; Haro, T; Kakumitsu, H; Shide, K; Kato, K; Miyamoto, T; Yamashita, Y; Oshima, Y; Nakajima, H; Iwama, A; Aoki, K; Takase, K; Gondo, H; Mano, H; Harada, M				Numata, A; Shimoda, K; Kamezaki, K; Haro, T; Kakumitsu, H; Shide, K; Kato, K; Miyamoto, T; Yamashita, Y; Oshima, Y; Nakajima, H; Iwama, A; Aoki, K; Takase, K; Gondo, H; Mano, H; Harada, M			Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/enhancer-binding protein alpha in granulocyte colony-stimulating factor signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE PROMOTER; DNA-BINDING; ADIPOCYTE DIFFERENTIATION; NEGATIVE REGULATOR; NUCLEAR-PROTEIN; FACTOR-RECEPTOR; DEFICIENT MICE; MYELOID CELLS; C/EBP; STAT3	The Janus kinase (Jak)-Stat pathway plays an essential role in cytokine signaling. Granulocyte colony-stimulating factor (G-CSF) promotes granulopoiesis and granulocytic differentiation, and Stat3 is the principle Stat protein activated by G-CSF. Upon treatment with G-CSF, the interleukin-3-dependent cell line 32D clone 3(32Dcl3) differentiates into neutrophils, and 32Dcl3 cells expressing dominant-negative Stat3 (32Dcl3/ DNStat3) proliferate in G-CSF without differentiation. Gene expression profile and quantitative PCR analysis of G-CSF-stimulated cell lines revealed that the expression of C/EBP alpha was up-regulated by the activation of Stat3. In addition, activated Stat3 bound to CCAAT/enhancer-binding protein (C/EBP)alpha, leading to the enhancement of the transcription activity of C/EBP alpha. Conditional expression of C/EBP alpha in 32Dcl3/ DNStat3 cells after G-CSF stimulation abolishes the G-CSF-dependent cell proliferation and induces granulocytic differentiation. Although granulocyte-specific genes, such as the G-CSF receptor, lysozyme M, and neutrophil gelatinase-associated lipocalin precursor (NGAL) are regulated by Stat3, only NGAL was induced by the restoration of C/EBP alpha after stimulation with G-CSF in 32Dcl3/ DNStat3 cells. These results show that one of the major roles of Stat3 in the G-CSF signaling pathway is to augment the function of C/EBP alpha, which is essential for myeloid differentiation. Additionally, cooperation of C/EBP alpha with other Stat3-activated proteins are required for the induction of some G-CSF responsive genes including lysozyme M and the G-CSF receptor.	Kyushu Univ, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan; Jichi Med Sch, Div Funct Genom, Tochigi 3290498, Japan; Jichi Med Sch, Dept Clin Pharmacol, Tochigi 3290498, Japan; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Ctr Expt Med, Lab Stem Cell Therapy,Minato Ku, Tokyo 1088639, Japan	Kyushu University; Jichi Medical University; Jichi Medical University; University of Tokyo; University of Tokyo	Shimoda, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kshimoda@intmed1.med.kyushu-u.ac.jp	Shide, Kotaro/AAG-7133-2020	Shide, Kotaro/0000-0002-0046-3254; Numata, Akihiko/0000-0001-6088-8302				Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; DEMETRI GD, 1991, BLOOD, V78, P2791; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1997, STEM CELLS S1, V15, P112; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Kamezaki K, 2005, STEM CELLS, V23, P252, DOI 10.1634/stemcells.2004-0173a; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; LIESCHKE GJ, 1994, BLOOD, V84, P1737; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; NATSUKA S, 1992, BLOOD, V79, P460; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; SCOTT LM, 1992, BLOOD, V80, P1725; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; SHIMODA K, 1994, BIOCHEM BIOPH RES CO, V203, P922, DOI 10.1006/bbrc.1994.2270; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TIAN SS, 1994, BLOOD, V84, P1760; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	42	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12621	12629		10.1074/jbc.M408442200	http://dx.doi.org/10.1074/jbc.M408442200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15664994	hybrid			2022-12-25	WOS:000227922000067
J	Li, J; Stern, DF				Li, J; Stern, DF			Regulation of CHK2 by DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-RESPONSE PATHWAYS; CELL-CYCLE ARREST; IONIZING-RADIATION; ATM PROTEIN; CATALYTIC SUBUNIT; DAMAGE CHECKPOINT; IN-VITRO; C-ABL; PHOSPHORYLATION EVENTS; RADIOSENSITIZING AGENT	Chk2 is a critical mediator of diverse cellular responses to DNA damage. Activation of Chk2 by DNA damage requires phosphorylation at sites including Thr(68). In earlier work, we found that an activity present in rabbit reticulocyte lysates phosphorylates and activates Chk2. We now find that hypophosphorylated Chk2 can be phosphorylated at Thr68 by various subcellular fractions of HEK293 cells. This activity is sensitive to the phosphatidylinositol 3'-kinase-like kinase inhibitor wortmannin, but not to caffeine. DNA enhances the Chk2 phosphorylation by cellular fractions in vitro. The wortmannin-sensitive Chk2 kinase activity is present in fractions from ATM-deficient cells. In contrast, Chk2 was not efficiently phosphorylated at Thr68 in vitro by fractions from cells with a defective DNA-dependent protein kinase (DNA-PK) catalytic subunit. Chk2 is phosphorylated by purified DNA-PK in vitro. Endogenous Chk2 coimmunoprecipitates Ku70 and Ku80. In a series of matched cell lines having and lacking functional DNA-PK, Chk2 activation by exposure of cells to ionizing radiation, or to camptothecin was consistently diminished in the absence of DNA-PK. Down-regulation of DNA-PKcs by either siRNA or a chemical inhibitor attenuated radiation-induced Chk2 phosphorylation. Ionizing radiation-induced Chk2 phosphorylation was wortmannin-sensitive in ATM-defective cells with depleted ATR. These results suggest that DNA-PK augments ATM and ATR in activation of Chk2 by DNA damage.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University; Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,BML342, New Haven, CT 06510 USA.	Df.stern@yale.edu			NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA82257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Anderson CW, 2001, RADIAT RES, V156, P2, DOI 10.1667/0033-7587(2001)156[0002:FMIPTG]2.0.CO;2; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; AUSUBEL FM, 2003, CURRENT PROTOCOLS MO, V2; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Durant S, 2003, NUCLEIC ACIDS RES, V31, P5501, DOI 10.1093/nar/gkg753; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Goudelock DM, 2003, J BIOL CHEM, V278, P29940, DOI 10.1074/jbc.M301765200; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; Jack MT, 2004, J BIOL CHEM, V279, P15269, DOI 10.1074/jbc.M309917200; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Kappes F, 2001, J BIOL CHEM, V276, P26317, DOI 10.1074/jbc.M100162200; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Lou ZK, 2004, J BIOL CHEM, V279, P46359, DOI 10.1074/jbc.C400375200; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McSherry TD, 2004, MOL CELL BIOL, V24, P9968, DOI 10.1128/MCB.24.22.9968-9985.2004; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Theard D, 2001, BIOCHEM BIOPH RES CO, V289, P1199, DOI 10.1006/bbrc.2001.6095; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Veuger SJ, 2003, CANCER RES, V63, P6008; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	79	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					12041	12050		10.1074/jbc.M412445200	http://dx.doi.org/10.1074/jbc.M412445200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15668230	hybrid			2022-12-25	WOS:000227761800138
J	Oakley, AJ; Loscha, KV; Schaeffer, PM; Liepinsh, E; Pintacuda, G; Wilce, MCJ; Otting, G; Dixon, NE				Oakley, AJ; Loscha, KV; Schaeffer, PM; Liepinsh, E; Pintacuda, G; Wilce, MCJ; Otting, G; Dixon, NE			Crystal and solution structures of the helicase-binding domain of Escherichia coli primase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; LAMBDA PROMOTER VECTORS; DNAB HEXAMERIC HELICASE; REPLICATION-FORK; BACILLUS-STEAROTHERMOPHILUS; FUNCTIONAL INTERACTION; SECONDARY-STRUCTURE; NMR-SPECTROSCOPY; RNA-POLYMERASE; PROTEIN	During bacterial DNA replication, the DnaG primase interacts with the hexameric DnaB helicase to synthesize RNA primers for extension by DNA polymerase. In Escherichia coli, this occurs by transient interaction of primase with the helicase. Here we demonstrate directly by surface plasmon resonance that the C-terminal domain of primase is responsible for interaction with DnaB(6). Determination of the 2.8-angstrom crystal structure of the C-terminal domain of primase revealed an asymmetric dimer. The monomers have an N-terminal helix bundle similar to the N-terminal domain of DnaB, followed by a long helix that connects to a C-terminal helix hairpin. The connecting helix is interrupted differently in the two monomers. Solution studies using NMR showed that an equilibrium exists between a monomeric species with an intact, extended but naked, connecting helix and a dimer in which this helix is interrupted in the same way as in one of the crystal conformers. The other conformer is not significantly populated in solution, and its presence in the crystal is due largely to crystal packing forces. It is proposed that the connecting helix contributes necessary structural flexibility in the primase-helicase complex at replication forks.	Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia; Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6907, Australia; Univ Western Australia, Sch Biomed & Chem Sci, Nedlands, WA 6907, Australia; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Australian National University; University of Western Australia; University of Western Australia; Karolinska Institutet	Dixon, NE (corresponding author), Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia.	dixon@rsc.anu.edu.au	Oakley, Aaron/A-9464-2013; Otting, Gottfried/H-8413-2014; Schaeffer, Patrick/C-3807-2012; Dixon, Nicholas E/A-1226-2008	Oakley, Aaron/0000-0002-4764-014X; Otting, Gottfried/0000-0002-0563-0146; Schaeffer, Patrick/0000-0002-0717-5984; Dixon, Nicholas E/0000-0002-5958-6945	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Barcena M, 2001, EMBO J, V20, P1462, DOI 10.1093/emboj/20.6.1462; Bird LE, 2000, BIOCHEMISTRY-US, V39, P171, DOI 10.1021/bi9918801; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; Chang P, 2000, J BIOL CHEM, V275, P26187, DOI 10.1074/jbc.M001800200; Donate LE, 2000, J MOL BIOL, V303, P383, DOI 10.1006/jmbi.2000.4132; ELVIN CM, 1990, GENE, V87, P123, DOI 10.1016/0378-1119(90)90503-J; Fallon JL, 2003, STRUCTURE, V11, P1303, DOI 10.1016/j.str.2003.09.004; Fass D, 1999, STRUCTURE, V7, P691, DOI 10.1016/S0969-2126(99)80090-2; Frick DN, 2001, ANNU REV BIOCHEM, V70, P39, DOI 10.1146/annurev.biochem.70.1.39; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hoffman DW, 1996, J MOL BIOL, V264, P1058, DOI 10.1006/jmbi.1996.0696; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jezewska MJ, 1996, J BIOL CHEM, V271, P4261; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORNBERG A, 1992, DNA REPLICATIO; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Loscha K, 2004, PROTEIN EXPRES PURIF, V33, P304, DOI 10.1016/j.pep.2003.10.001; Love CA, 1996, GENE, V176, P49, DOI 10.1016/0378-1119(96)00208-9; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Miles CS, 1997, BIOCHEM BIOPH RES CO, V231, P126, DOI 10.1006/bbrc.1997.6059; Mitkova AV, 2003, J BIOL CHEM, V278, P52253, DOI 10.1074/jbc.M308956200; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; OGAWA T, 1980, ANNU REV BIOCHEM, V49, P421, DOI 10.1146/annurev.bi.49.070180.002225; Otting G, 1997, PROG NUCL MAG RES SP, V31, P259, DOI 10.1016/S0079-6565(97)00012-5; Pan H, 2000, STRUCTURE, V8, P231, DOI 10.1016/S0969-2126(00)00101-5; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Podobnik M, 2000, J MOL BIOL, V300, P353, DOI 10.1006/jmbi.2000.3844; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; Stordal L, 1996, J BACTERIOL, V178, P4620, DOI 10.1128/jb.178.15.4620-4627.1996; Thirlway J, 2004, NUCLEIC ACIDS RES, V32, P2977, DOI 10.1093/nar/gkh628; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; Weigelt J, 1999, STRUCT FOLD DES, V7, P681, DOI 10.1016/S0969-2126(99)80089-6; Weigelt J, 1998, J BIOMOL NMR, V11, P233, DOI 10.1023/A:1008208020167; Williams NK, 2002, J BIOL CHEM, V277, P7790, DOI 10.1074/jbc.M110303200; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yang SX, 2002, J MOL BIOL, V321, P839, DOI 10.1016/S0022-2836(02)00711-8; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	54	59	61	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11495	11504		10.1074/jbc.M412645200	http://dx.doi.org/10.1074/jbc.M412645200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15649896	Green Accepted, hybrid			2022-12-25	WOS:000227761800074
J	Quintanilla, RA; Munoz, FJ; Metcalfe, MJ; Hitschfeld, M; Olivares, G; Godoy, JA; Inestrosa, NC				Quintanilla, RA; Munoz, FJ; Metcalfe, MJ; Hitschfeld, M; Olivares, G; Godoy, JA; Inestrosa, NC			Trolox and 17 beta-estradiol protect against amyloid beta-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GLYCOGEN-SYNTHASE KINASE-3-BETA; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; VITAMIN-E; KINASE-C; HIPPOCAMPAL-NEURONS; ESTROGEN-RECEPTORS; PC12 CELLS; TOXICITY; CATENIN	Oxidative stress is a key mechanism in amyloid beta-peptide (A beta)-mediated neurotoxicity; therefore, the protective roles of 17 beta-estradiol (E-2) and antioxidants ( Trolox and vitamin C) were assayed on hippocampal neurons. Our results show the following: 1) E-2 and Trolox attenuated the neurotoxicity mediated by A beta and H2O2 as measured by 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide reduction assays, quantification of apoptotic cells, and morphological studies of the integrity of the neurite network. 2) Vitamin C failed to protect neurons from A beta toxicity. 3) A beta-mediated endoperoxide production, reported to induce cell damage, was decreased in the presence of E-2 and Trolox. 4) Two key Wnt signaling components were affected by E-2 and Trolox; in fact, the enzyme glycogen synthase kinase 3 beta was inhibited by both E-2 and Trolox, and both compounds were able to stabilize cytoplasmic beta-catenin. 5) E-2 activated the expression of the Wnt-5a and Wnt-7a ligands, and at the same time, E-2, through the alpha estrogen receptor, was able to prevent the excitotoxic A beta-induced rise in bulk-free Ca2+ as an alternative pathway to increase cell viability. 6) Finally, the Wnt-7a ligand protected against cytoplasmic calcium disturbances induced by A beta treatment. Our results suggest that control of oxidative stress, regulation of cytoplasmic calcium, and activation of Wnt signaling may prevent A beta neurotoxicity.	Pontificia Univ Catolica Chile, Ctr Regulac Celular & Patol Joaquin V Luco, Fondo Areas Prioritarias Ctr,Fac Ciencias Biol, Millennium Inst Fundamental & Appl Biol, Santiago, Chile; Univ Pompeu Fabra, Unitat Senyalitzacio Cellular, Dept Ciencies Expt & Salut, Barcelona 08003, Spain	Pontificia Universidad Catolica de Chile; Pompeu Fabra University	Inestrosa, NC (corresponding author), Pontificia Univ Catolica Chile, Ctr Regulac Celular & Patol Joaquin V Luco, Fondo Areas Prioritarias Ctr,Fac Ciencias Biol, Millennium Inst Fundamental & Appl Biol, Alameda 340,Casilla 114-D, Santiago, Chile.	ninestr@genes.bio.puc.cl	Godoy, Juan A/F-5398-2018; QUINTANILLA, RODRIGO/ABG-8829-2021; Muñoz, F/E-6751-2014; Hitschfeld, Maureen/ABE-8602-2020	Godoy, Juan A/0000-0001-9920-6698; Muñoz, F/0000-0002-1343-3599; Hitschfeld, Maureen/0000-0001-7322-875X; Metcalfe, Mariajose/0000-0002-5016-8739; Olivares, Gonzalo/0000-0002-2784-0160				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alberi L, 2004, DEVELOPMENT, V131, P3229, DOI 10.1242/dev.01128; Alvarez A, 1998, J NEUROSCI, V18, P3213; Alvarez A, 1997, J MOL BIOL, V272, P348, DOI 10.1006/jmbi.1997.1245; Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Araya M, 2003, AM J CLIN NUTR, V77, P646, DOI 10.1093/ajcn/77.3.646; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Behl C, 1999, PROG NEUROBIOL, V57, P301, DOI 10.1016/S0301-0082(98)00055-0; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Bi RF, 2000, P NATL ACAD SCI USA, V97, P3602, DOI 10.1073/pnas.060034497; Bonnefort AB, 1998, FEBS LETT, V441, P220, DOI 10.1016/S0014-5793(98)01552-X; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; BUTTERFIELD DA, 1994, BIOCHEM BIOPH RES CO, V200, P710, DOI 10.1006/bbrc.1994.1508; Butterfield DA, 1999, REV NEUROSCIENCE, V10, P141; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Calderon FH, 1999, J NEUROSCI RES, V56, P620; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; Caricasole A, 2003, TRENDS PHARMACOL SCI, V24, P233, DOI 10.1016/S0165-6147(03)00100-7; Chaban VV, 2003, NEUROSCIENCE, V118, P941, DOI 10.1016/S0306-4522(02)00915-6; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; COLE G, 1988, BRAIN RES, V452, P165, DOI 10.1016/0006-8993(88)90021-2; Cordey M, 2003, J NEUROCHEM, V84, P1340, DOI 10.1046/j.1471-4159.2003.01631.x; Coyle-Rink J, 2002, CANCER BIOL THER, V1, P640, DOI 10.4161/cbt.313; Dale TC, 1998, BIOCHEM J, V329, P209; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; De Ferrari GV, 2000, BRAIN RES REV, V33, P1, DOI 10.1016/S0165-0173(00)00021-7; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; DONGMI S, 2004, NEUROREPORT, V15, P1959; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; English MA, 1999, J CLIN ENDOCR METAB, V84, P2080, DOI 10.1210/jc.84.6.2080; Farias GG, 2004, NEUROBIOL DIS, V17, P337, DOI 10.1016/j.nbd.2004.07.016; Ferreira A, 1997, MOL CELL NEUROSCI, V9, P220, DOI 10.1006/mcne.1997.0615; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fuentealba RA, 2004, BRAIN RES REV, V47, P275, DOI 10.1016/j.brainresrev.2004.07.018; Garrido JL, 2002, FASEB J, V16, P1982, DOI 10.1096/fj.02-0327fje; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gollapudi L, 1999, J NEUROSCI RES, V56, P99, DOI 10.1002/(SICI)1097-4547(19990401)56:1<99::AID-JNR13>3.0.CO;2-G; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Green PS, 1998, NEUROSCIENCE, V84, P7, DOI 10.1016/S0306-4522(97)00595-2; Hakimelahi S, 2000, J BIOL CHEM, V275, P10905, DOI 10.1074/jbc.275.15.10905; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Halliwell B, 1999, TRENDS BIOCHEM SCI, V24, P255, DOI 10.1016/S0968-0004(99)01418-8; HONJO H, 1992, J STEROID BIOCHEM, V41, P633, DOI 10.1016/0960-0760(92)90395-Y; Huang XD, 2004, J BIOL INORG CHEM, V9, P954, DOI 10.1007/s00775-004-0602-8; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Inestrosa NC, 1998, MOL NEUROBIOL, V17, P73, DOI 10.1007/BF02802025; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; Katsu T, 2003, NEUROSCI LETT, V353, P53, DOI 10.1016/j.neulet.2003.09.017; Kim H, 2001, NEUROSCI LETT, V302, P58, DOI 10.1016/S0304-3940(01)01659-7; Koppal T, 1998, BRAIN RES, V786, P270, DOI 10.1016/S0006-8993(97)01466-2; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Li R, 2000, J NEUROCHEM, V75, P1447, DOI 10.1046/j.1471-4159.2000.0751447.x; LOCKHART BP, 1994, J NEUROSCI RES, V39, P494, DOI 10.1002/jnr.490390416; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Lucas FR, 1997, DEV BIOL, V192, P31, DOI 10.1006/dbio.1997.8734; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Miranda S, 2000, PROG NEUROBIOL, V62, P633, DOI 10.1016/S0301-0082(00)00015-0; Miyaoka T, 1999, SCHIZOPHR RES, V38, P1, DOI 10.1016/S0920-9964(98)00179-0; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morris MC, 1998, ALZ DIS ASSOC DIS, V12, P121, DOI 10.1097/00002093-199809000-00001; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mulnard RA, 2000, JAMA-J AM MED ASSOC, V284, P308; Munoz FJ, 2002, J NEUROSCI, V22, P3081, DOI 10.1523/JNEUROSCI.22-08-03081.2002; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; Onorato M, 1989, Prog Clin Biol Res, V317, P781; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Owen R, 2003, MOL CELL NEUROSCI, V23, P626, DOI 10.1016/S1044-7431(03)00095-2; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Pereira C, 1999, NEUROBIOL DIS, V6, P209, DOI 10.1006/nbdi.1999.0241; Pike CJ, 1997, J NEUROCHEM, V69, P1601; Quintanilla RA, 2000, CELL CALCIUM, V28, P97, DOI 10.1054/ceca.2000.0135; SATOU T, 1995, BRAIN RES, V697, P35, DOI 10.1016/0006-8993(95)00748-F; Schafer M, 2004, BRAIN RES, V1005, P84, DOI 10.1016/j.brainres.2004.01.037; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shah RD, 2003, MOL CELL NEUROSCI, V24, P503, DOI 10.1016/S1044-7431(03)00166-0; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Shaywitz BA, 2000, JAMA-J AM MED ASSOC, V283, P1055, DOI 10.1001/jama.283.8.1055; Shea TB, 2003, J ALZHEIMERS DIS, V5, P323, DOI 10.3233/JAD-2003-5408; Shin SY, 2004, CANCER LETT, V212, P225, DOI 10.1016/j.canlet.2004.03.003; Smith JD, 2003, J MOL NEUROSCI, V20, P277, DOI 10.1385/JMN:20:3:277; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; Sribnick EA, 2004, J NEUROSCI RES, V76, P688, DOI 10.1002/jnr.20124; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; SUGIOKA K, 1987, FEBS LETT, V210, P37, DOI 10.1016/0014-5793(87)81293-0; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TAPPEL AL, 1968, GERIATRICS, V23, P97; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yallampalli S, 1998, NEUROSCI LETT, V251, P105, DOI 10.1016/S0304-3940(98)00515-1; Yao ZX, 1999, BRAIN RES, V847, P203, DOI 10.1016/S0006-8993(99)02047-8; Yoon WJ, 2003, J NEUROCHEM, V85, P525, DOI 10.1046/j.1471-4159.2003.01724.x; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhao LX, 2003, EXP BIOL MED, V228, P823, DOI 10.1177/15353702-0322807-08; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	103	108	115	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11615	11625		10.1074/jbc.M411936200	http://dx.doi.org/10.1074/jbc.M411936200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659394	hybrid			2022-12-25	WOS:000227761800089
J	Wang, Y; Jiang, HL				Wang, Y; Jiang, HL			Identification of a distal STAT5-binding DNA region that may mediate growth hormone regulation of insulin-like growth factor-I gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID PROTEIN INTERACTIONS; IGF-I; SIGNAL-TRANSDUCTION; RAPID ACTIVATION; BINDING-SITES; BODY GROWTH; TRANSCRIPTION; STAT5B; REVEALS; SPECIFICITY	Growth hormone (GH) regulates insulin-like growth factor-I (IGF-I) gene expression through signal transducer and activator of transcription 5b (STAT5b) and STAT5a. The objective of this study was to identify the cis-regulatory DNA region involved in this process. By cotransfection analyses of shotgun DNA fragments of a bacterial artificial chromosome sequence containing the entire human IGF-I gene and a large 5'-flanking region, a similar to 700- bp DNA region similar to 75 kb 5' to the IGF-I gene was found to have the ability to enhance gene expression from both heterologous and homologous promoters in the presence of constitutively active STAT5a or STAT5b. This 700-bp DNA region contains two closely located consensus STAT5-binding sites, and its sequence appears to be evolutionarily conserved. Electrophoretic mobility shift assays verified the ability of the two putative STAT5-binding sites to bind to STAT5a and STAT5b. Cotransfection analyses confirmed that both STAT5-binding sites were necessary for the similar to 700-bp DNA region to mediate STAT5a or STAT5b activation of gene transcription. Chromatin immunoprecipitation assays demonstrated that the chromosomal region containing these two STAT5-binding sites was bound by constitutively active STAT5b protein in HepG2 cells and that the binding was accompanied by increased expression of IGF-I mRNA. In reconstituted GH-responsive cells, this similar to 700-bp DNA region was able to mediate GH-induced STAT5a or STAT5b activation of gene expression. These results together suggest that this STAT5-binding site-containing distal 5'-flanking region of IGF-I gene may be an enhancer mediating GH- induced STAT5 activation of IGF- I gene transcription.	Virginia Polytech Inst & State Univ, Dept Anim & Poultry Sci, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	Jiang, HL (corresponding author), Virginia Polytech Inst & State Univ, Dept Anim & Poultry Sci, 3130 Litton Reaves Hall, Blacksburg, VA 24061 USA.	hojiang@vt.edu		, Honglin/0000-0001-9540-5788	NIDDK NIH HHS [R01 DK67961] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; Benbassat C, 1999, ENDOCRINOLOGY, V140, P3073, DOI 10.1210/en.140.7.3073; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bondarenko VA, 2003, BIOCHEM CELL BIOL, V81, P241, DOI 10.1139/o03-051; Bonifer C, 1999, GENE, V238, P277, DOI 10.1016/S0378-1119(99)00340-6; Calhoun VC, 2003, P NATL ACAD SCI USA, V100, P9878, DOI 10.1073/pnas.1233791100; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Carter-Su C, 2000, PEDIATR NEPHROL, V14, P550, DOI 10.1007/s004670000366; Cooper GM, 2003, CURR OPIN GENET DEV, V13, P604, DOI 10.1016/j.gde.2003.10.001; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Davey HW, 2001, ENDOCRINOLOGY, V142, P3836, DOI 10.1210/en.142.9.3836; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Frazer KA, 2004, GENOME RES, V14, P367, DOI 10.1101/gr.1961204; Gottgens B, 2000, NAT BIOTECHNOL, V18, P181, DOI 10.1038/72635; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P4741, DOI 10.1210/en.136.11.4741; Gronowski AM, 1996, ENDOCRINOLOGY, V137, P55, DOI 10.1210/en.137.1.55; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HUYNH HT, 1991, EXP CELL RES, V197, P191, DOI 10.1016/0014-4827(91)90422-Q; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; LESTUNFF C, 1995, ENDOCRINOLOGY, V136, P2230, DOI 10.1210/en.136.5.2230; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; Meton I, 1999, FEBS LETT, V444, P155, DOI 10.1016/S0014-5793(99)00064-2; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Santini S, 2003, GENOME RES, V13, P1111, DOI 10.1101/gr.700503; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; THOMAS MJ, 1994, ENDOCRINOLOGY, V135, P1584, DOI 10.1210/en.135.4.1584; THOMAS MJ, 1995, ENDOCRINOLOGY, V136, P562, DOI 10.1210/en.136.2.562; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Wood TJJ, 1997, MOL CELL ENDOCRINOL, V130, P69, DOI 10.1016/S0303-7207(97)00075-0; Ye P, 1997, ENDOCRINOLOGY, V138, P5466, DOI 10.1210/en.138.12.5466	43	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10955	10963		10.1074/jbc.M412808200	http://dx.doi.org/10.1074/jbc.M412808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15677453	hybrid			2022-12-25	WOS:000227761800011
J	Su, ZZ; Emdad, L; Sarkar, D; Randolph, A; Valerie, K; Yacoub, A; Dent, P; Fisher, PB				Su, ZZ; Emdad, L; Sarkar, D; Randolph, A; Valerie, K; Yacoub, A; Dent, P; Fisher, PB			Potential molecular mechanism for rodent tumorigenesis: mutational generation of Progression Elevated Gene-3 (PEG-3)	ONCOGENE			English	Article						dominant negative; GADD34; PEG-3; tumorigenesis	DAMAGE-INDUCIBLE GENE; RAT EMBRYO CELLS; GROWTH ARREST; PROTEIN GADD34; P38 KINASE; TRANSFORMATION PROGRESSION; UV-RADIATION; SERINE 15; HUMAN P53; APOPTOSIS	Progression Elevated Gene-3 (PEG-3) was cloned using subtraction hybridization as an upregulated transcript associated with transformation and tumor progression of rat embryo fibroblast cells. PEG-3 is a unique gene facilitating tumor progression by modulating multiple pathways in transformed cells, including genomic stability, angiogenesis and invasion. PEG-3 originates from mutation in the growth arrest and DNA damage inducible gene GADD34. A one base deletion in rat GADD34 results in a frame-shift and premature appearance of a stop-codon resulting in a C-terminally truncated molecule that is PEG3. We now document that mutation in the GADD34 gene is a frequent event during transformation and/or immortalization of rodent cells. Sequencing of the GADD34 gene in a number of independent rat tumor cell lines revealed that in a majority of these the GADD34 gene is mutated to either PEG-3 or a PEG-3-like gene with similar C-terminal truncations. An important function of GADD34 is to inhibit cell growth, predominantly by apoptosis, and we demonstrate that PEG-3 or C-terminal truncations of human GADD34 resembling PEG-3 prevent growth inhibition by both human and rat GADD34. Phosphorylation of p53 by GADD34 is one mechanism by which it inhibits growth and PEG-3 could prevent GADD34-induced p53 phosphorylation. In contrast, PEG-3 was unable to block other GADD34-induced changes, including eIF2 alpha dephosphorylation, indicating that its effects on GADD34 may be related more to its effect on cell growth rather than a global inhibitor of all GADD34 functions. We hypothesize that mutational generation of PEG-3 or a similar molecule is a critical event during rodent carcinogenesis. T he inherent property of PEG-3 to function as a dominant negative of the growth inhibitory property of GADD34 might rescue cells from DNA damage-induced apoptosis leading to growth independence and tumorigenesis.	Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Pathol, New York, NY 10032 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	Columbia University; Virginia Commonwealth University	Fisher, PB (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Valerie, Kristoffer/AAL-8299-2021					Adler HT, 1999, MOL CELL BIOL, V19, P7050; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Emdad L, 2005, J CELL PHYSIOL, V202, P135, DOI 10.1002/jcp.20097; FISCELLA M, 1993, ONCOGENE, V8, P1519; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Grishin AV, 2001, P NATL ACAD SCI USA, V98, P10172, DOI 10.1073/pnas.191130798; Hasegawa T, 1999, BBA-GEN SUBJECTS, V1428, P161, DOI 10.1016/S0304-4165(99)00060-4; Hasegawa T, 2000, BIOCHEM BIOPH RES CO, V267, P593, DOI 10.1006/bbrc.1999.1991; Hasegawa T, 2000, BIOCHEM J, V352, P795, DOI 10.1042/0264-6021:3520795; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097-0215(20010220)96:1<22::AID-IJC3>3.0.CO;2-K; Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Kojima E, 2003, FASEB J, V17, P1573, DOI 10.1096/fj.02-1184fje; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2001, CANCER RES, V61, P1604; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SU ZZ, 1993, ONCOGENE, V8, P1211; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2002, J CELL PHYSIOL, V192, P34, DOI 10.1002/jcp.10114; SU ZZ, 1994, CANCER RES, V54, P1865; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Valerie K, 1999, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, P69; Yagi A, 2003, J CELL BIOCHEM, V90, P1242, DOI 10.1002/jcb.10711; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	36	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2247	2255		10.1038/sj.onc.1208420	http://dx.doi.org/10.1038/sj.onc.1208420			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15674324				2022-12-25	WOS:000227857900012
J	Yu, M; Schreek, S; Cerni, C; Schamberger, C; Lesniewicz, K; Poreba, E; Vervoorts, J; Walsemann, G; Grotzinger, J; Kremmer, E; Mehraein, Y; Mertsching, J; Kraft, R; Austen, M; Luscher-Firzlaff, J; Luscher, B				Yu, M; Schreek, S; Cerni, C; Schamberger, C; Lesniewicz, K; Poreba, E; Vervoorts, J; Walsemann, G; Grotzinger, J; Kremmer, E; Mehraein, Y; Mertsching, J; Kraft, R; Austen, M; Luscher-Firzlaff, J; Luscher, B			PARP-10, a novel Myc-interacting protein with poly( ADP-ribose) polymerase activity, inhibits transformation	ONCOGENE			English	Article						Myc; PARP; transcription; transformation	RNA RECOGNITION MOTIFS; POLY(ADP-RIBOSE) POLYMERASE; C-MYC; MYC/MAX/MAD NETWORK; DNA-DAMAGE; HISTONE ACETYLATION; CATALYTIC DOMAIN; HUMAN TELOMERES; CELL-GROWTH; IN-VITRO	The proto-oncoprotein c-Myc functions as a transcriptional regulator that controls different aspects of cell behavior, including proliferation, differentiation, and apoptosis. In addition, Myc proteins have the potential to transform cells and are deregulated in the majority of human cancers. Several Myc-interacting factors have been described that mediate part of Myc's functions in the control of cell behavior. Here, we describe the isolation of a novel 150 kDa protein, designated PARP-10, that interacts with Myc. PARP-10 possesses domains with homology to RNA recognition motifs and to poly( ADPribose) polymerases ( PARP). Molecular modeling and biochemical analysis de. ne a PARP domain that is capable of ADP-ribosylating PARP-10 itself and core histones, but neither Myc nor Max. PARP-10 is localized to the nuclear and cytoplasmic compartments that is controlled at least in part by a Leu-rich nuclear export sequence (NES). Functionally, PARP-10 inhibits c-Myc-and E1A-mediated cotransformation of rat embryo fibroblasts, a function that is independent of PARP activity but that depends on a functional NES. Together, our findings de. ne a novel PARP enzyme involved in the control of cell proliferation.	Rhein Westfal TH Aachen, Abt Biochem & Mol Biol, Inst Biochem, Klinikum, D-52057 Aachen, Germany; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany; Univ Vienna, Inst Krebsforsch, A-1090 Vienna, Austria; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; GSF Munich, Inst Mol Immunol, D-81377 Munich, Germany; Univ Saarland, Inst Humangenet, D-66421 Homburg, Germany; Max Delbruck Ctr, D-13092 Berlin, Germany	RWTH Aachen University; Hannover Medical School; University of Vienna; University of Kiel; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Saarland University; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Luscher, B (corresponding author), Rhein Westfal TH Aachen, Abt Biochem & Mol Biol, Inst Biochem, Klinikum, Pauwelsstr 30, D-52057 Aachen, Germany.	luescher@rwth-aachen.de	; Luscher, Bernhard/A-7330-2011	Lesniewicz, Krzysztof/0000-0003-4399-858X; Luscher, Bernhard/0000-0002-9622-8709; Vervoorts, Jorg/0000-0002-3251-6496; Poreba, Elzbieta/0000-0003-2410-4974				Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CERNI C, 1995, ONCOGENE, V11, P587; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Conte MR, 2000, EMBO J, V19, P3132, DOI 10.1093/emboj/19.12.3132; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; Crowder SM, 1999, P NATL ACAD SCI USA, V96, P4892, DOI 10.1073/pnas.96.9.4892; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Domingues FS, 1999, PROTEINS, P112; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Ginisty H, 2001, J BIOL CHEM, V276, P14338, DOI 10.1074/jbc.M011120200; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kim H, 1997, BIOCHEM J, V322, P469, DOI 10.1042/bj3220469; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Michael WM, 2000, TRENDS CELL BIOL, V10, P46, DOI 10.1016/S0962-8924(99)01695-5; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; POLO S, 2003, SCI STKE, pRE17, DOI DOI 10.1126/STKE.2132003RE17; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Ruf A, 1996, P NATL ACAD SCI USA, V93, P7481, DOI 10.1073/pnas.93.15.7481; Sbodio JI, 2002, BIOCHEM J, V361, P451, DOI 10.1042/0264-6021:3610451; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; SIMONIN F, 1990, J BIOL CHEM, V265, P19249; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Tulin A, 2002, GENE DEV, V16, P2108, DOI 10.1101/gad.1003902; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198	73	118	124	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1982	1993		10.1038/sj.onc.1208410	http://dx.doi.org/10.1038/sj.onc.1208410			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15674325				2022-12-25	WOS:000227681900003
J	Knodler, LA; Finlay, BB; Steele-Mortimer, O				Knodler, LA; Finlay, BB; Steele-Mortimer, O			The Salmonella effector protein SopB protects epithelial cells from apoptosis by sustained activation of Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROTYPE TYPHIMURIUM; MONOCYTE-DERIVED MACROPHAGES; III SECRETION SYSTEM; PATHOGENICITY ISLAND; HOST-CELL; SEROVAR TYPHIMURIUM; CULTURED MACROPHAGES; INFECTED MACROPHAGES; POLYAMINE DEPLETION; ACTIN CYTOSKELETON	Invasion of epithelial cells by Salmonella enterica is mediated by bacterial "effector" proteins that are delivered into the host cell by a type III secretion system. Although primarily known for their roles in actin rearrangements and membrane ruffling, translocated effectors also affect host cell processes that are not directly associated with invasion. Here, we show that SopB/SigD, an effector with phosphoinositide phosphatase activity, has anti-apoptotic activity in Salmonella-infected epithelial cells. Salmonella induced the sustained activation of Akt/protein kinase B, a pro-survival kinase, in a SopB-dependent manner. Failure to activate Akt resulted in increased levels of apoptosis after infection with a sopB deletion mutant (DeltasopB). Furthermore, cells infected with wild type bacteria, but not the DeltasopB strain, were protected from camptothecin-induced cleavage of caspase-3 and subsequent apoptosis. The antiapoptotic activity of SopB was dependent on its phosphatase activity, because a catalytically inactive mutant was unable to protect cells from the effects of camptothecin. Finally, small interfering RNA was used to demonstrate the essential role of Akt in SopB-mediated protection against apoptosis. These results provide new insights into the mechanisms of apoptosis and highlight how bacterial effectors can intercept signaling pathways to manipulate host responses.	NIAID, Rocky Mt Labs, Intracellular Parasites Lab, NIH, Hamilton, MT 59840 USA; Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of British Columbia	Steele-Mortimer, O (corresponding author), NIAID, Rocky Mt Labs, Intracellular Parasites Lab, NIH, Hamilton, MT 59840 USA.	omortimer@niaid.nih.gov		Knodler, Leigh/0000-0002-3028-2198	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000909, Z01AI000909] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramovitch RB, 2003, EMBO J, V22, P60, DOI 10.1093/emboj/cdg006; Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x; Browne SH, 2002, INFECT IMMUN, V70, P7126, DOI 10.1128/IAI.70.12.7126-7135.2002; Chen LM, 1996, MOL MICROBIOL, V21, P1101, DOI 10.1046/j.1365-2958.1996.471410.x; Cirillo DM, 1998, MOL MICROBIOL, V30, P175, DOI 10.1046/j.1365-2958.1998.01048.x; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Collier-Hyams LS, 2002, J IMMUNOL, V169, P2846, DOI 10.4049/jimmunol.169.6.2846; Deng WL, 2003, AM J PHYSIOL-GASTR L, V284, pG821, DOI 10.1152/ajpgi.00406.2002; Deng WL, 2002, GASTROENTEROLOGY, V123, P206, DOI 10.1053/gast.2002.34209; FIERER J, 1993, INFECT IMMUN, V61, P5231, DOI 10.1128/IAI.61.12.5231-5236.1993; Galan JE, 2000, METHOD ENZYMOL, V325, P496; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Galyov EE, 1997, MOL MICROBIOL, V25, P903, DOI 10.1111/j.1365-2958.1997.mmi525.x; Gibson EM, 2002, CANCER RES, V62, P488; Grossmann J, 2002, AM J GASTROENTEROL, V97, P1421, DOI 10.1016/S0002-9270(02)04143-6; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Hernandez LD, 2004, SCIENCE, V304, P1805, DOI 10.1126/science.1098188; Hernandez LD, 2003, J CELL BIOL, V163, P1123, DOI 10.1083/jcb.200309161; Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396; Hueffer K, 2004, CELL MICROBIOL, V6, P1019, DOI 10.1111/j.1462-5822.2004.00451.x; Jamir Y, 2004, PLANT J, V37, P554, DOI 10.1046/j.1365-313X.2003.01982.x; Jarvelainen HA, 2003, TRENDS CELL BIOL, V13, P204, DOI 10.1016/S0962-8924(03)00032-1; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; Kim JM, 1998, J CLIN INVEST, V102, P1815, DOI 10.1172/JCI2466; Knodler LA, 2002, MOL MICROBIOL, V43, P1089, DOI 10.1046/j.1365-2958.2002.02820.x; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; Kurita A, 2003, MICROB PATHOGENESIS, V35, P43, DOI 10.1016/S0882-4010(03)00066-4; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; LUK GD, 1990, BIOCHEM SOC T, V18, P1090, DOI 10.1042/bst0181090; Marcus SL, 2002, CELL MICROBIOL, V4, P435, DOI 10.1046/j.1462-5822.2002.00202.x; Marcus SL, 2001, FEBS LETT, V494, P201, DOI 10.1016/S0014-5793(01)02356-0; Monack DM, 2000, J EXP MED, V192, P249, DOI 10.1084/jem.192.2.249; Monack DM, 2001, MICROBES INFECT, V3, P1201, DOI 10.1016/S1286-4579(01)01480-0; Monack DM, 2001, CELL MICROBIOL, V3, P825, DOI 10.1046/j.1462-5822.2001.00162.x; Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833; Muller A, 2001, INT J MED MICROBIOL, V291, P197, DOI 10.1078/1438-4221-00125; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Paesold G, 2002, CELL MICROBIOL, V4, P771, DOI 10.1046/j.1462-5822.2002.00233.x; Perfettini JL, 2003, BIOCHIMIE, V85, P763, DOI 10.1016/j.biochi.2003.08.006; Ray RM, 2000, AM J PHYSIOL-CELL PH, V278, pC480, DOI 10.1152/ajpcell.2000.278.3.C480; Reis BP, 2003, VET MICROBIOL, V97, P269, DOI 10.1016/j.vetmic.2003.09.019; Santos RL, 2001, INFECT IMMUN, V69, P2293, DOI 10.1128/IAI.69.4.2293-2301.2001; SCHAUSER K, 2004, IN PRESS HISTOCHEM C; Steele-Mortimer O, 2000, J BIOL CHEM, V275, P37718, DOI 10.1074/jbc.M008187200; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; Thomson BJ, 2001, INT J EXP PATHOL, V82, P65, DOI 10.1111/j.1365-2613.2001.iep195.x; Tsolis RM, 1999, INFECT IMMUN, V67, P4879, DOI 10.1128/IAI.67.9.4879-4885.1999; van der Velden AWM, 2003, J IMMUNOL, V171, P6742, DOI 10.4049/jimmunol.171.12.6742; van der Velden AWM, 2000, INFECT IMMUN, V68, P5702, DOI 10.1128/IAI.68.10.5702-5709.2000; Waterman SR, 2003, CELL MICROBIOL, V5, P501, DOI 10.1046/j.1462-5822.2003.00294.x; Watson PR, 2000, INFECT IMMUN, V68, P3744, DOI 10.1128/IAI.68.6.3744-3747.2000; Watson PR, 1998, INFECT IMMUN, V66, P1432, DOI 10.1128/IAI.66.4.1432-1438.1998; Zhang HFM, 2004, J BIOL CHEM, V279, P22539, DOI 10.1074/jbc.M314337200; Zhang SP, 2003, INFECT IMMUN, V71, P4795, DOI 10.1128/IAI.71.8.4795-4803.2003; Zhang SP, 2002, INFECT IMMUN, V70, P3843, DOI 10.1128/IAI.70.7.3843-3855.2002; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x; Zhou X, 2000, MICROBIOL IMMUNOL, V44, P987, DOI 10.1111/j.1348-0421.2000.tb02594.x; Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446	60	174	180	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9058	9064		10.1074/jbc.M412588200	http://dx.doi.org/10.1074/jbc.M412588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15642738	hybrid			2022-12-25	WOS:000227453100054
J	Shashidhar, S; Lorente, G; Nagavarapu, U; Nelson, A; Kuo, J; Cummins, J; Nikolich, K; Urfer, R; Foehr, ED				Shashidhar, S; Lorente, G; Nagavarapu, U; Nelson, A; Kuo, J; Cummins, J; Nikolich, K; Urfer, R; Foehr, ED			GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion	ONCOGENE			English	Article						CPR56; TM7XN1; glioma; adhesion; PAI-1; alpha-actinin	PROTEIN-COUPLED RECEPTORS; ALPHA-LATROTOXIN CIRL; PROTEOLYSIS; INHIBITION; DOMAINS	GPR56 ( also known as TM7XN1) is a newly discovered orphan G-protein-coupled receptor ( GPCR) of the secretin family that has a role in the development of neural progenitor cells and has been linked to developmental malformations of the human brain. GPR56 diverges from other secretin-like family members in that it has an extremely large N-terminal extracellular region (381 amino acids) and contains a novel feature among this new subclass, consisting of four cysteine residues that define a GPCR proteolytic site (GPS motif) located just before the first transmembrane spanning domain. The rest of the amino-terminal domain contains a large number of possible N- and O-linked glycosylation sites similar to mucin-like proteins. These features suggest a role in cell cell, or cell-matrix interactions. Here, we demonstrate upregulation of GPR56 in glioblastoma multiforme tumors using functional genomics. Immunohistochemistry studies confirmed the expression of GPR56 protein in a majority of glioblastoma/astrocytoma tumor samples with undetectable levels of expression in normal adult brain tissue. Immunofluorescence analysis of human glioma cells using anti-GPR56 antibodies demonstrate that GPR56 is expressed on the leading edge of membranefilopodia and colocalizes with alpha-actinin. Purified recombinant GPR56 extracellular domain protein inhibits glioma cell adhesion and causes abnormal cytoskeletal morphology and cell rounding. These results indicate that the extracellular domain may compete for unidentified ligand(s), and block the normal function of GPR56 in cell attachment. In reporter assays, overexpression of GPR56 activates the NF-kappaB, PAI-1 and TCF transcriptional response elements. These pathways have been implicated in cytoskeletal signaling, adhesion and tumor biology. The above results indicate that GPR56 serves as an adhesion GPCR and is involved in adhesion signaling.	AGY Therapeut Inc, San Francisco, CA 94080 USA		Foehr, ED (corresponding author), AGY Therapeut Inc, 270 E Grand Ave, San Francisco, CA 94080 USA.	efoehr@agyinc.com						Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Berger F, 2004, LANCET ONCOL, V5, P511, DOI 10.1016/S1470-2045(04)01531-1; BERGER M, 1999, GLIOMAS; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Fredriksson R, 2003, BIOCHEM BIOPH RES CO, V301, P725, DOI 10.1016/S0006-291X(03)00026-3; Fredriksson R, 2002, FEBS LETT, V531, P407, DOI 10.1016/S0014-5793(02)03574-3; Haier J, 2002, CLIN EXP METASTAS, V19, P665, DOI 10.1023/A:1021316531912; Hamann J, 2000, INT IMMUNOL, V12, P439, DOI 10.1093/intimm/12.4.439; Hayflick JS, 2000, J RECEPT SIGNAL TR R, V20, P119, DOI 10.3109/10799890009150640; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Kierszenbaum AL, 2003, MOL REPROD DEV, V64, P1, DOI 10.1002/mrd.10224; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Little KD, 2004, MOL BIOL CELL, V15, P2375, DOI 10.1091/mbc.E03-12-0886; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; Muller S, 2003, ONCOGENE, V22, P6661, DOI 10.1038/sj.onc.1206763; Obermann H, 2003, MOL REPROD DEV, V64, P13, DOI 10.1002/mrd.10220; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Singh SK, 2003, CANCER RES, V63, P5821; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Woods AJ, 2002, J BIOL CHEM, V277, P6428, DOI 10.1074/jbc.M109446200; Zendman AJW, 1999, FEBS LETT, V446, P292, DOI 10.1016/S0014-5793(99)00230-6	23	122	127	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1673	1682		10.1038/sj.onc.1208395	http://dx.doi.org/10.1038/sj.onc.1208395			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674329				2022-12-25	WOS:000227345100003
J	Tuna, M; Chavez-Reyes, A; Tari, AM				Tuna, M; Chavez-Reyes, A; Tari, AM			HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells	ONCOGENE			English	Article						Wilms' tumor 1; HER2/neu; Akt; cyclin D1; Bcl-2; breast cancer	TUMOR SUPPRESSOR GENE; WILMS-TUMOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; CYCLIN D1; BCL-2; AKT; SURVIVAL; PHOSPHORYLATION; OVEREXPRESSION	High levels of the Wilms' Tumor 1 (WT1) protein and mRNA had been associated with aggressive phenotypes of breast tumors. Here we report that the HER2/neu oncogene increases WT1 expression. Approximately threefold higher levels of WT1 protein were observed in MCF-7 breast cancer cells transfected with the HER2/neu oncogene than in parental MCF-7 cells. Conversely, inhibition of HER2/neu with the anti-HER2/neu trastuzumab (Herceptint) antibody decreased WT1 protein levels in HER2/neu-overexpressing BT-474 and SKBr3 cells. We also found that HER2/neu engages Akt to regulate WT1 levels since inhibition of Akt reduced WT1 levels. Decreased expression of WT1 protein led to cell cycle arrest at the G1 phase and increased apoptosis in HER2/neu-overexpressing cells, which is correlated with decreased cyclin D1 and Bcl-2 levels. Our data indicate that HER2/neu engages Akt to increase WT1 expression, and that WT1 protein plays a vital role in regulating cell cycle progression and apoptosis in HER2/neu-overexpressing breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 422, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 422, 1515 Holcombe Blvd, Houston, TX 77030 USA.	atari@mdanderson.org	Chavez-Reyes, Arturo/ABG-1231-2020	Chavez-Reyes, Arturo/0000-0002-6655-815X				ADNANE J, 1989, ONCOGENE, V4, P1389; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheema SK, 2003, J BIOL CHEM, V278, P19995, DOI 10.1074/jbc.M205865200; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Gold MR, 1999, J IMMUNOL, V163, P1894; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HEWITT SM, 1995, CANCER RES, V55, P5386; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; Karakas T, 2002, LEUKEMIA, V16, P846, DOI 10.1038/sj.leu.2402434; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lenferink AEG, 2001, CANCER RES, V61, P6583; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Oji Y, 2002, INT J CANCER, V100, P297, DOI 10.1002/ijc.10476; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Simeone AM, 2004, CANCER RES, V64, P1224, DOI 10.1158/0008-5472.CAN-03-2188; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	23	62	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1648	1652		10.1038/sj.onc.1208345	http://dx.doi.org/10.1038/sj.onc.1208345			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674342				2022-12-25	WOS:000227218200019
J	Li, J; Culman, J; Hortnagl, H; Zhao, Y; Gerova, N; Timm, M; Blume, A; Zimmermann, M; Seidel, K; Dirnagl, U; Unger, T				Li, J; Culman, J; Hortnagl, H; Zhao, Y; Gerova, N; Timm, M; Blume, A; Zimmermann, M; Seidel, K; Dirnagl, U; Unger, T			Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury	FASEB JOURNAL			English	Article						medial cerebral artery occlusion; AT1 receptor	II RECEPTOR SUBTYPES; AT(2) RECEPTOR; CARDIOVASCULAR MORBIDITY; CANDESARTAN CILEXETIL; CHRONIC PRETREATMENT; TRANSCRIPTION FACTOR; NEURITE OUTGROWTH; CONVERTING-ENZYME; ARTERY OCCLUSION; MORTALITY-RATE	Several lines of clinical and experimental evidence suggest an important role of the renin-angiotensin system in ischemic brain injury although the cellular regulation of the angiotensin AT1 and AT2 receptors and their potential relevance in this condition have not yet been clearly defined. We first assessed the regulation of brain AT1 and AT2 receptors in response to transient unilateral medial cerebral artery occlusion in rats by real-time RT-PCR, Western blot, and immunofluorescence labeling. AT2 receptors in the peri-infarct zone were significantly upregulated 2 days after transient focal cerebral ischemia. Increased AT2 receptors, which were abundantly distributed in a large number of brain regions adjacent to the infarct area including cerebral frontal cortex, piriform cortex, striatum, and hippocampus, were exclusively expressed in neurons. By contrast, AT1 receptors, which remained unaltered, were mainly expressed in astrocytes. In neurons of ischemic striatum, increased AT2 receptors were associated with intense neurite outgrowth. Blockade of central AT2 receptors with PD123177 abolished the neuroprotective effects of central AT1 receptor blockade with irbesartan on infarct size and neurological outcome. In primary cortical neurons, stimulation of AT2 receptors supported neuronal survival and neurite outgrowth. Our data indicate that cerebral AT2 receptors exert neuroprotective actions in response to ischemia-induced neuronal injury, possibly by supporting neuronal survival and neurite outgrowth in peri-ischemic brain areas.	Charite Univ Med Berlin, Inst Pharmacol & Toxicol, Cardiovasc Res Ctr, D-10115 Berlin, Germany; Charite Univ Med Berlin, Dept Expt Neurol, D-10115 Berlin, Germany; Univ Kiel, Univ Hosp Schleswig Holstein, Inst Pharmacol, D-24098 Kiel, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; Schleswig Holstein University Hospital	Unger, T (corresponding author), Charite Univ Med Berlin, Inst Pharmacol & Toxicol, Cardiovasc Res Ctr, Hess Str 3-4, D-10115 Berlin, Germany.	thomas.unger@charite.de	Li, Jun/C-4390-2011; Zhao, Yi/A-8806-2010	Dirnagl, Ulrich/0000-0003-0755-6119; SEIDEL, KERSTIN/0000-0002-9166-7032				ARENDT T, 1986, NEUROSCIENCE, V19, P1265, DOI 10.1016/0306-4522(86)90141-7; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Cote F, 1999, J BIOL CHEM, V274, P31686, DOI 10.1074/jbc.274.44.31686; Culman J, 2001, J RENIN-ANGIO-ALDO S, V2, P96, DOI 10.3317/jraas.2001.019; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dai WJ, 1999, STROKE, V30, P2391, DOI 10.1161/01.STR.30.11.2391; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Diep QN, 1999, HYPERTENSION, V34, P617, DOI 10.1161/01.HYP.34.4.617; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FERNANDEZ LA, 1986, STROKE, V17, P82, DOI 10.1161/01.STR.17.1.82; Fournier A, 2004, J AM COLL CARDIOL, V43, P1343, DOI 10.1016/j.jacc.2003.10.060; Gallinat S, 1998, MOL BRAIN RES, V57, P111, DOI 10.1016/S0169-328X(98)00079-5; GEHLERT DR, 1991, NEUROSCIENCE, V44, P501, DOI 10.1016/0306-4522(91)90073-W; Gohlke P, 2002, J HYPERTENS, V20, P909, DOI 10.1097/00004872-200205000-00026; Groth W, 2003, J HYPERTENS, V21, P2175, DOI 10.1097/00004872-200311000-00028; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Harms C, 2000, FASEB J, V14, P1814, DOI 10.1096/fj.99-0899com; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HOHLE S, 1995, EUR J PHARMACOL, V275, P277, DOI 10.1016/0014-2999(95)00005-6; Inada Y, 1997, CLIN EXP HYPERTENS, V19, P1079, DOI 10.3109/10641969709083206; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; Iwai M, 2004, CIRCULATION, V110, P843, DOI 10.1161/01.CIR.0000138848.58269.80; Kagiyama T, 2003, REGUL PEPTIDES, V110, P241, DOI 10.1016/S0167-0115(02)00223-9; KALISZEWSKI C, 1988, J CEREBR BLOOD F MET, V8, P149, DOI 10.1038/jcbfm.1988.43; Laflamme L, 1996, J BIOL CHEM, V271, P22729, DOI 10.1074/jbc.271.37.22729; Lenkei Z, 1997, FRONT NEUROENDOCRIN, V18, P383, DOI 10.1006/frne.1997.0155; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Li DY, 1999, CARDIOVASC RES, V41, P109, DOI 10.1016/S0008-6363(98)00196-5; Lucius R, 1998, J EXP MED, V188, P661, DOI 10.1084/jem.188.4.661; Makino I, 1996, NEUROPEPTIDES, V30, P596, DOI 10.1016/S0143-4179(96)90043-8; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; Reinecke K, 2003, FASEB J, V17, P2094, DOI 10.1096/fj.02-1193fje; STIER CT, 1993, J HYPERTENS, V11, pS37; Stroth U, 1998, MOL BRAIN RES, V53, P187, DOI 10.1016/S0169-328X(97)00298-2; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; TSUTSUMI K, 1993, BRAIN RES, V631, P212, DOI 10.1016/0006-8993(93)91537-3; Walther T, 2002, FASEB J, V16, P169, DOI 10.1096/fj.01-0601com; Zhao Y, 2003, J NEUROCHEM, V85, P759, DOI 10.1046/j.1471-4159.2003.01719.x	43	218	228	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					617	+		10.1096/fj.04-2960fje	http://dx.doi.org/10.1096/fj.04-2960fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665034				2022-12-25	WOS:000226576600013
J	Gabriel, FLP; Heidlberger, A; Rentsch, D; Giger, W; Guenther, K; Kohler, HPE				Gabriel, FLP; Heidlberger, A; Rentsch, D; Giger, W; Guenther, K; Kohler, HPE			A novel metabolic pathway for degradation of 4-nonylphenol environmental contaminants by Sphingomonas xenophaga Bayram - ipso-hydroxylation and intramolecular rearrangement*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAIN HBP1 PRP; ALKYLPHENOL POLYETHOXYLATES; NONYLPHENOL ISOMERS; P-NONYLPHENOL; PSEUDOMONAS; 4-HYDROXYACETOPHENONE; CYTOCHROME-P450; 4-ETHYLPHENOL; ELUCIDATION; OXIDATION	Several nonylphenol isomers with alpha-quaternary carbon atoms serve as growth substrates for Sphingomonas xenophaga Bayram, whereas isomers containing hydrogen atoms at the alpha-carbon do not (Gabriel, F. L. P., Giger, W., Guenther, K., and Kohler, H.- P. E. ( 2005) Appl. Environ. Microbiol. 71, 1123 - 1129). Three metabolites of 4-( 1- methyloctyl)phenol were isolated in mg quantities from cultures of strain Bayram supplemented with the growth substrate isomer 4-( 1- ethyl- 1,4- dimethyl- pentyl)- phenol. They were unequivocally identified as 4- hydroxy- 4-( 1- methyl- octyl)cyclohexa- 2,5- dienone, 4- hydroxy- 4-( 1- methyl- octyl)- cyclohex2- enone, and 2-( 1- methyl- octyl)- benzene- 1,4- diol by high pressure liquid chromatography- mass spectrometry and nuclear magnetic resonance spectroscopy. Furthermore, two metabolites originating from 4-n-nonylphenol were identified as 4- hydroxy- 4-nonyl-cyclohexa-2,5-dienone and 4- hydroxy- 4- nonyl-cyclohex-2-enone by high pressure liquid chromatography- mass spectrometry. We conclude that nonylphenols were initially hydroxylated at the ipsoposition forming 4-alkyl-4-hydroxy-cyclohexa-2,5-dienones. Dienones originating from growth substrate nonylphenol isomers underwent a rearrangement that involved a 1,2-C, O shift of the alkyl moiety as a cation to the oxygen atom of the geminal hydroxy group yielding 4-alkoxyphenols, from which the alkyl moieties can be easily detached as alcohols by known mechanisms. Dienones originating from nongrowth substrates did not undergo such a rearrangement because the missing alkyl substituents at the alpha-carbon atom prevented stabilization of the putative alpha-carbocation. Instead they accumulated and subsequently underwent side reactions, such as 1,2- C, C shifts and dihydrogenations. The ipso-hydroxylation and the proposed 1,2- C, O shift constitute key steps in a novel pathway that enables bacteria to detach alpha-branched alkyl moieties of alkylphenols for utilization of the aromatic part as a carbon and energy source.	Swiss Fed Inst Environm Sci & Technol EAWAG, CH-8600 Dubendorf, Switzerland; Mat Sci & Technol EMPA, CH-8600 Dubendorf, Switzerland; Duisburg Essen Univ, Inst Chem, D-47048 Duisburg, Germany	Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); Swiss Federal Institutes of Technology Domain; Swiss Federal Laboratories for Materials Science & Technology (EMPA); University of Duisburg Essen	Kohler, HPE (corresponding author), Swiss Fed Inst Environm Sci & Technol EAWAG, Mailbox 611,Uberlandstr 133, CH-8600 Dubendorf, Switzerland.	kohler@eawag.ch	Kohler, Hans-Peter/C-1456-2015; Rentsch, Daniel/D-9717-2018; Guenther, Klaus/B-3283-2010	Kohler, Hans-Peter/0000-0001-7667-0762; Rentsch, Daniel/0000-0002-9335-9527; Guenther, Klaus/0000-0003-0541-6980				Alexander P, 1943, BIOCHEM J, V37, P463, DOI 10.1042/bj0370463; Corvini PFX, 2004, APPL ENVIRON MICROB, V70, P6897, DOI 10.1128/AEM.70.11.6897-6900.2004; Corvini PFX, 2004, WATER SCI TECHNOL, V50, P189, DOI 10.2166/wst.2004.0327; Corvini PFX, 2004, BIODEGRADATION, V15, P9, DOI 10.1023/B:BIOD.0000009937.20251.d2; Dai MH, 2003, J BACTERIOL, V185, P302, DOI 10.1128/JB.185.1.302-310.2003; DARBY JM, 1987, J GEN MICROBIOL, V133, P2137; DENBESTEN C, 1993, CHEM RES TOXICOL, V6, P674, DOI 10.1021/tx00035a013; Fujii K, 2000, J BIOCHEM, V128, P909, DOI 10.1093/oxfordjournals.jbchem.a022841; Fujii K, 2001, INT J SYST EVOL MICR, V51, P603, DOI 10.1099/00207713-51-2-603; Gabriel FLP, 2005, APPL ENVIRON MICROB, V71, P1123, DOI 10.1128/AEM.71.3.1123-1129.2005; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Guenther K, 2002, ENVIRON SCI TECHNOL, V36, P1676, DOI 10.1021/es010199v; HARELAND WA, 1975, J BACTERIOL, V121, P272, DOI 10.1128/JB.121.1.272-285.1975; JONES KH, 1994, APPL ENVIRON MICROB, V60, P1978, DOI 10.1128/AEM.60.6.1978-1983.1994; Kamerbeek NM, 2001, EUR J BIOCHEM, V268, P2547, DOI 10.1046/j.1432-1327.2001.02137.x; KOHLER HPE, 1993, APPL ENVIRON MICROB, V59, P860, DOI 10.1128/AEM.59.3.860-866.1993; Laskin AI, 1999, J IND MICROBIOL BIOT, V23, P231, DOI 10.1038/sj.jim.2900748; Maarel M. J. E. C. van der, 1993, Biodegradation, V4, P81, DOI 10.1007/BF00702324; MCLEESE DW, 1981, CHEMOSPHERE, V10, P723, DOI 10.1016/0045-6535(81)90003-5; Montgomery-Brown J, 2003, ENVIRON ENG SCI, V20, P471, DOI 10.1089/109287503768335940; Ohe T, 1997, DRUG METAB DISPOS, V25, P116; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PRETSCH E, 1990, STRUKTURAUFKLAERUNG; REICHLIN F, 1994, APPL ENVIRON MICROB, V60, P4587, DOI 10.1128/AEM.60.12.4587-4591.1994; RIEGER PG, 1995, ENVIR SCI R, V49, P1; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Servos MR, 1999, WATER QUAL RES J CAN, V34, P123, DOI 10.2166/wqrj.1999.005; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; Tanghe T, 2000, BIODEGRADATION, V11, P11, DOI 10.1023/A:1026518727690; Tanghe T, 1999, APPL ENVIRON MICROB, V65, P746; Thiele B, 2004, ENVIRON SCI TECHNOL, V38, P3405, DOI 10.1021/es040026g; Thiele B, 1997, CHEM REV, V97, P3247, DOI 10.1021/cr970323m; Wheeler TF, 1997, J CHROMATOGR SCI, V35, P19, DOI 10.1093/chromsci/35.1.19; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; [No title captured]	36	80	87	5	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15526	15533		10.1074/jbc.M413446200	http://dx.doi.org/10.1074/jbc.M413446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15665329	Green Published, hybrid			2022-12-25	WOS:000228444800010
J	Cross, KJ; Huq, NL; Palamara, JE; Perich, JW; Reynolds, EC				Cross, KJ; Huq, NL; Palamara, JE; Perich, JW; Reynolds, EC			Physicochemical characterization of casein phosphopeptide-amorphous calcium phosphate nanocomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOSERYL-CONTAINING PEPTIDES; FREE CHEWING GUM; SYSTEM CA(OH)2-H3PO4-H2O; PHASE SYNTHESIS; BOVINE-MILK; REMINERALIZATION; ABSORPTION; COMPLEXES; MICELLE; ACID	Milk caseins stabilize calcium and phosphate ions and make them available to the neonate. Tryptic digestion of the caseins yields phosphopeptides from their polar N-terminal regions that contain clusters of phosphorylated seryl residues. These phosphoseryl clusters have been hypothesized to be responsible for the interaction between the caseins and calcium phosphate that lead to the formation of casein micelles. The casein phosphopeptides stabilize calcium and phosphate ions through the formation of complexes. The calcium phosphate in these complexes is biologically available for intestinal absorption and remineralization of subsurface lesions in tooth enamel. We have studied the structure of the complexes formed by the casein phosphopeptides with calcium phosphate using a range of physicochemical techniques including x-ray powder diffraction, scanning electron microscopy, transmission electron microscopy, and equilibrium binding analyses. The amorphous nature of the calcium phosphate phase was confirmed by two independent methods: x-ray powder diffraction and selected area diffraction. In solution, the ion activity product of a basic amorphous calcium phosphate phase was the only ion product that was a function of bound phosphate independent of pH, consistent with basic amorphous calcium phosphate being the phase stabilized by the casein phosphopeptides. Detailed investigations of calcium and calcium phosphate binding using a library of synthetic homologues and analogues of the casein phosphopeptides have revealed that although the fully phosphorylated seryl-cluster motif is pivotal for the interaction with calcium and phosphate, other factors are also important. In particular, calcium binding and calcium phosphate stabilization by the peptides was influenced by peptide net charge, length, and sequence.	Univ Melbourne, Sch Dent Sci, Ctr Oral Hlth Sci, Melbourne, Vic 3010, Australia	University of Melbourne	Reynolds, EC (corresponding author), Univ Melbourne, Sch Dent Sci, Ctr Oral Hlth Sci, Melbourne, Vic 3010, Australia.	e.reynolds@unimelb.edu.au	Huq, Laila/A-2861-2012; Cross, Keith/F-4566-2012; Cross, Keith J/N-4602-2013	Huq, Laila/0000-0001-7788-4797; Cross, Keith/0000-0002-4079-2132; Reynolds, Eric/0000-0002-6618-4856; Rahma, Indah/0000-0002-6855-1146				ADAMSON N, 1993, J CHROMATOGR, V646, P391, DOI 10.1016/0021-9673(93)83352-S; Bates RG, 1943, J RES NAT BUR STAND, V30, P129, DOI 10.6028/jres.030.012; Bienkiewicz EA, 1999, J BIOMOL NMR, V15, P203, DOI 10.1023/A:1008375029746; BJERRUM N, 1929, KGL DANSKE VIDENSK S, V9, P5; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CHUGHTAI A, 1968, J PHYS CHEM-US, V72, P208, DOI 10.1021/j100847a039; Cross KJ, 2001, BIOCHEM J, V356, P277, DOI 10.1042/0264-6021:3560277; Dalgleish DG, 2004, INT DAIRY J, V14, P1025, DOI 10.1016/j.idairyj.2004.04.008; de Kruif CG, 1999, INT DAIRY J, V9, P183, DOI 10.1016/S0958-6946(99)00058-8; Ferraretto A, 2001, J NUTR, V131, P1655, DOI 10.1093/jn/131.6.1655; GERBER HW, 1986, CALCIFIED TISSUE INT, V38, P350, DOI 10.1007/BF02555749; GREGORY TM, 1970, J RES NBS A PHYS CH, VA 74, P461, DOI 10.6028/jres.074A.036; Holt C, 1996, BIOCHEM J, V314, P1035, DOI 10.1042/bj3141035; HOLT C, 1988, PROTEIN ENG, V2, P251, DOI 10.1093/protein/2.4.251; Holt C, 1996, NETH MILK DAIRY J, V50, P85; Horne DS, 1998, INT DAIRY J, V8, P171, DOI 10.1016/S0958-6946(98)00040-5; HUQ NL, 1995, BBA-PROTEIN STRUCT M, V1247, P201; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; KITTS DD, 1992, BRIT J NUTR, V68, P765, DOI 10.1079/BJN19920132; LEE SL, 1980, INT J PEPT PROT RES, V16, P231; LEE YS, 1983, BRIT J NUTR, V49, P67, DOI 10.1079/BJN19830012; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P346, DOI 10.1021/bi00427a047; MCDOWELL H, 1977, J RES NBS A PHYS CH, V81, P273, DOI 10.6028/jres.081A.017; MCGANN TCA, 1983, CALCIFIED TISSUE INT, V35, P821, DOI 10.1007/BF02405131; MCGANN TCA, 1983, BIOCHIM BIOPHYS ACTA, V760, P415, DOI 10.1016/0304-4165(83)90383-5; MEISEL H, 1988, BIOL CHEM H-S, V369, P1275, DOI 10.1515/bchm3.1988.369.2.1275; MEYER JL, 1978, CALC TISS RES, V25, P59, DOI 10.1007/BF02010752; MYKKANEN HM, 1980, J NUTR, V110, P2141, DOI 10.1093/jn/110.11.2141; NANCOLLAS GH, 1989, ANAT RECORD, V224, P234, DOI 10.1002/ar.1092240213; PERICH JW, 1994, INT J PEPT PROT RES, V44, P305; PERICH JW, 1992, AUST J CHEM, V45, P385, DOI 10.1071/CH9920385; PERICH JW, 1992, INT J PEPT PROT RES, V40, P81; PERICH JW, 1991, METHOD ENZYMOL, V201, P225; REEVES RE, 1958, SCIENCE, V128, P472, DOI 10.1126/science.128.3322.472; REYNOLDS EC, 1994, ANAL BIOCHEM, V217, P277, DOI 10.1006/abio.1994.1119; Reynolds EC, 2003, J DENT RES, V82, P206, DOI 10.1177/154405910308200311; Reynolds EC, 1999, J CLIN DENT, V10, P86; REYNOLDS EC, 1995, J DENT RES, V74, P1272, DOI 10.1177/00220345950740060601; Reynolds EC, 1991, USPTO, Patent No. [US5015628, 5015628]; SATO R, 1986, J NUTR SCI VITAMINOL, V32, P67, DOI 10.3177/jnsv.32.67; Schmidt D. G., 1982, Developments in Dairy Chemistry, V1, P61; Shen P, 2001, J DENT RES, V80, P2066, DOI 10.1177/00220345010800120801; SHYU LJ, 1982, THESIS STATE U NEW Y; SMALES FC, 1972, CALC TISS RES, V8, P304; Stineman R. W., 1980, Creative Computing, V6, P54; VANHOOYDONK ACM, 1986, NETH MILK DAIRY J, V40, P297; Walstra P., 1984, DAIRY CHEM PHYS	47	178	198	3	72	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15362	15369		10.1074/jbc.M413504200	http://dx.doi.org/10.1074/jbc.M413504200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15657053	hybrid			2022-12-25	WOS:000228236800122
J	Kaneto, H; Matsuoka, T; Nakatani, Y; Miyatsuka, T; Matsuhisa, M; Hori, M; Yamasaki, Y				Kaneto, H; Matsuoka, T; Nakatani, Y; Miyatsuka, T; Matsuhisa, M; Hori, M; Yamasaki, Y			A crucial role of MafA as a novel therapeutic target for diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; ISLET BETA-CELLS; GLUCOSE TOXICITY; CONTROL ELEMENT; EXPRESSION; P300; DIFFERENTIATION; RIPE3B1; TRANSPLANTATION; ACTIVATION	MafA, a recently isolated pancreatic beta-cell-specific transcription factor, is a potent activator of insulin gene transcription. In this study, we show that MafA overexpression, together with PDX-1 ( pancreatic and duodenal homeobox factor-1) and NeuroD, markedly increases insulin gene expression in the liver. Consequently, substantial amounts of insulin protein were induced by such combination. Furthermore, in streptozotocin-induced diabetic mice, MafA overexpression in the liver, together with PDX-1 and NeuroD, dramatically ameliorated glucose tolerance, while combination of PDX-1 and NeuroD was much less effective. These results suggest a crucial role of MafA as a novel therapeutic target for diabetes.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan	Osaka University	Kaneto, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kaneto@medone.med.osaka-u.ac.jp; takaaki@medone.med.osaka-u.ac.jp						He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kajihara M, 2003, BIOCHEM BIOPH RES CO, V312, P831, DOI 10.1016/j.bbrc.2003.10.196; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; Kataoka K, 2004, J MOL ENDOCRINOL, V32, P9, DOI 10.1677/jme.0.0320009; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Matsuoka T, 2004, P NATL ACAD SCI USA, V101, P2930, DOI 10.1073/pnas.0306233101; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Moran A, 1997, J CLIN INVEST, V99, P534, DOI 10.1172/JCI119190; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Qiu Y, 2004, J BIOL CHEM, V279, P9796, DOI 10.1074/jbc.M307577200; Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200; Robertson RP, 2004, NEW ENGL J MED, V350, P694, DOI 10.1056/NEJMra032425; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; Sharma A, 1999, MOL CELL BIOL, V19, P704; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; Stanojevic V, 2004, ENDOCRINOLOGY, V145, P2918, DOI 10.1210/en.2003-1188; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Weir GC, 1997, DIABETES, V46, P1247, DOI 10.2337/diabetes.46.8.1247	28	112	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15047	15052		10.1074/jbc.M412013200	http://dx.doi.org/10.1074/jbc.M412013200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15664997	hybrid			2022-12-25	WOS:000228236800087
J	Richard, JP; Melikov, K; Brooks, H; Prevot, P; Lebleu, B; Chernomordik, LV				Richard, JP; Melikov, K; Brooks, H; Prevot, P; Lebleu, B; Chernomordik, LV			Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIVO PROTEIN TRANSDUCTION; HIV-1 TAT; FUSION PROTEINS; IN-VIVO; ANTENNAPEDIA HOMEODOMAIN; CAVEOLAR ENDOCYTOSIS; PENETRATING PEPTIDES; CRE RECOMBINASE; LIPID-BILAYERS; 3RD HELIX	Delivery of macromolecules mediated by protein transduction domains (PTDs) attracts a lot of interest due to its therapeutic and biotechnological potential. A major re-evaluation of the mechanism of PTD-mediated internalization and the role of endocytosis in this mechanism has been recently initiated. Here, we demonstrate that the entry of TAT peptide ( one of the most widely used PTDs) into different primary cells is ATP- and temperature-dependent, indicating the involvement of endocytosis. Specific inhibitors of clathrin-dependent endocytosis partially inhibit TAT peptide uptake, implicating this pathway in TAT peptide entry. In contrast, the caveolin-dependent pathway is not essential for the uptake of unconjugated TAT peptide as evidenced by the efficient internalization of TAT in the presence of the known inhibitors of raft/caveolin-dependent pathway and for cells lacking or deficient in caveolin-1 expression. Whereas a significant part of TAT peptide uptake involves heparan sulfate receptors, efficient internalization of peptide is observed even in their absence, indicating the involvement of other receptors. Our results suggest that unconjugated peptide might follow endocytic pathways different from those utilized by TAT peptide conjugated to different proteins.	NICHD, Sect Membrane Biol, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA; Univ Montpellier 2, CNRS, UMR 5124, F-34095 Montpellier, France	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Melikov, K (corresponding author), NICHD, Sect Membrane Biol, Lab Cellular & Mol Biophys, NIH, 10 Ctr Dr,Bldg 10,Rm 10D05, Bethesda, MD 20892 USA.	melikovk@mail.nih.gov	Melikov, Kamran/A-6604-2009	Richard, Jean-Philippe/0000-0003-2890-2316	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001501] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001501] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; Dardalhon V, 2001, P NATL ACAD SCI USA, V98, P9277, DOI 10.1073/pnas.161272698; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; Fujimoto T, 2000, J CELL SCI, V113, P3509; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Hariton-Gazal E, 2003, J CELL SCI, V116, P4577, DOI 10.1242/jcs.00757; Joshi SK, 2002, GENESIS, V33, P48, DOI 10.1002/gene.10089; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450; Matsui H, 2003, CURR PROTEIN PEPT SC, V4, P151, DOI 10.2174/1389203033487270; MONSIGNY M, 1984, BIOL CELL, V51, P187, DOI 10.1111/j.1768-322X.1984.tb00298.x; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Peitz M, 2002, P NATL ACAD SCI USA, V99, P4489, DOI 10.1073/pnas.032068699; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Sakai N, 2003, J AM CHEM SOC, V125, P14348, DOI 10.1021/ja037601l; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6	40	478	511	3	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15300	15306		10.1074/jbc.M401604200	http://dx.doi.org/10.1074/jbc.M401604200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15687490	hybrid			2022-12-25	WOS:000228236800115
J	Zeyda, M; Saemann, MD; Stuhlmeier, KM; Mascher, DG; Nowotny, PN; Zlabinger, GJ; Waldhausl, W; Stulnig, TM				Zeyda, M; Saemann, MD; Stuhlmeier, KM; Mascher, DG; Nowotny, PN; Zlabinger, GJ; Waldhausl, W; Stulnig, TM			Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; SIGNALING PATHWAYS; LIPID RAFTS; FISH-OIL; ADIPOCYTE DIFFERENTIATION; RHEUMATOID-ARTHRITIS; ANTIGEN PRESENTATION; IMMUNE-RESPONSES; PROTEIN-KINASE; TNF-ALPHA	Polyunsaturated fatty acids (PUFAs) modulate immune responses leading to clinically significant beneficial effects in a variety of inflammatory disorders. PUFA effects on T cells have been extensively studied, but their influence on human dendritic cells (DCs), which are the most potent antigen-presenting cells and play a key role in initiating immune responses, has not been elucidated so far. Here we show that PUFAs of the n-3 and n-6 series (arachidonic and eicosapentaenoic acid) affect human monocyte-derived DC differentiation and inhibit their activation by LPS, resulting in altered DC surface molecule expression and diminished cytokine secretion. Furthermore, the potency to stimulate T cells was markedly inhibited in PUFA-treated DCs. The PUFA-mediated block in LPS-induced DC activation is reflected by diminished TNF-alpha, IL-12p40, CD40, and COX-2 mRNA levels. Strikingly, typical LPS-induced signaling events such as degradation of I kappa B and activation of NF-kappa B were not affected by PUFAs, even though DC membrane lipid composition was markedly altered. Arachidonic and eicosapentaenoic acid both altered DC prostaglandin production, but inhibitors of cyclooxygenases and lipoxygenases did not abolish PUFA effects, indicating that the observed PUFA actions on DCs were independent of autoregulation via eicosanoids. These data demonstrate a unique interference with DC activation and function that could significantly contribute to the well known anti-inflammatory effects of PUFAs.	Med Univ Vienna, Dept Internal Med 3, Clin Div Endocrinol & Metab, A-1090 Vienna, Austria; Med Univ Vienna, Dept Internal Med 3, Div Nephrol & Dialysis, A-1090 Vienna, Austria; Ludwig Boltzmann Inst Rheumatol & Balneol, A-1107 Vienna, Austria; Pharmanalyt Lab GmbH, A-2500 Baden, Austria; Med Univ Vienna, Inst Immunol, A-1090 Vienna, Austria; Austrian Acad Sci, CeMM Ctr Mol Med, A-7780 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Ludwig Boltzmann Institute; Medical University of Vienna; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences	Stulnig, TM (corresponding author), Med Univ Vienna, Dept Internal Med 3, Clin Div Endocrinol & Metab, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	thomas.stulnig@meduniwien.ac.at		Zlabinger, Gerhard/0000-0002-7478-4173; Zeyda, Maximilian/0000-0001-5000-1974; Stulnig, Thomas/0000-0003-3300-6161				Albers R, 2002, BRIT J NUTR, V88, P291, DOI 10.1079/BJN2002614; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bell D, 1999, ADV IMMUNOL, V72, P255, DOI 10.1016/S0065-2776(08)60023-1; Belluzzi A, 2000, AM J CLIN NUTR, V71, p339S, DOI 10.1093/ajcn/71.1.339s; Blok WL, 1996, J NUTR, V126, P1515, DOI 10.1093/jn/126.6.1515; Calder PC, 1998, IMMUNOL TODAY, V19, P244, DOI 10.1016/S0167-5699(98)01264-X; Calder PC, 2001, CURR OPIN CLIN NUTR, V4, P115, DOI 10.1097/00075197-200103000-00006; Camp HS, 2001, ENDOCRINOLOGY, V142, P3207, DOI 10.1210/en.142.7.3207; Cleland LG, 2003, DRUGS, V63, P845, DOI 10.2165/00003495-200363090-00001; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Donadio JV, 2000, AM J CLIN NUTR, V71, p373S, DOI 10.1093/ajcn/71.1.373s; Duperrier K, 2000, J IMMUNOL METHODS, V238, P119, DOI 10.1016/S0022-1759(00)00147-2; Duperrier K, 2002, J LEUKOCYTE BIOL, V72, P953; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Fan YY, 2004, J IMMUNOL, V173, P6151, DOI 10.4049/jimmunol.173.10.6151; Fan YY, 2003, J NUTR, V133, P1913, DOI 10.1093/jn/133.6.1913; Flores-Romo L, 2001, IMMUNOLOGY, V102, P255, DOI 10.1046/j.1365-2567.2001.01204.x; FOWLER KH, 1993, J IMMUNOL, V151, P5186; GAVINO VC, 1981, J LIPID RES, V22, P763; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Harizi H, 2003, J IMMUNOL, V170, P139, DOI 10.4049/jimmunol.170.1.139; Harizi H, 2002, J IMMUNOL, V168, P2255, DOI 10.4049/jimmunol.168.5.2255; Harizi H, 2003, J LEUKOCYTE BIOL, V73, P756, DOI 10.1189/jlb.1002483; Hwang D, 2001, FASEB J, V15, P2556, DOI 10.1096/fj.01-0432com; Jaksits S, 2004, J IMMUNOL, V173, P1628, DOI 10.4049/jimmunol.173.3.1628; Jing H, 2003, J LEUKOCYTE BIOL, V74, P868, DOI 10.1189/jlb.0303116; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P190; Jozefowski S, 2003, INT IMMUNOPHARMACOL, V3, P865, DOI 10.1016/S1567-5769(03)00072-9; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Kaisho T, 2003, CURR MOL MED, V3, P759, DOI 10.2174/1566524033479366; Kew S, 2004, AM J CLIN NUTR, V79, P674; Laderach D, 2003, J IMMUNOL, V171, P1750, DOI 10.4049/jimmunol.171.4.1750; Lee JY, 2004, J BIOL CHEM, V279, P16971, DOI 10.1074/jbc.M312990200; Lee JY, 2003, J LIPID RES, V44, P479, DOI 10.1194/jlr.M200361-JLR200; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; Lyakh LA, 2000, J IMMUNOL, V165, P3647, DOI 10.4049/jimmunol.165.7.3647; Mayer K, 2003, J IMMUNOL, V171, P4837, DOI 10.4049/jimmunol.171.9.4837; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Sanaa N, 2004, J BIOL CHEM, V279, P25189, DOI 10.1074/jbc.M312431200; Sanderson P, 1997, J LEUKOCYTE BIOL, V62, P771, DOI 10.1002/jlb.62.6.771; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; SCOTT P, 1995, CURR OPIN IMMUNOL, V7, P34, DOI 10.1016/0952-7915(95)80026-3; Seder RA, 1996, J IMMUNOL, V157, P2745; SOYLAND E, 1993, EUR J CLIN INVEST, V23, P112, DOI 10.1111/j.1365-2362.1993.tb00750.x; Stallmach A, 2004, GUT, V53, P339, DOI 10.1136/gut.2003.020107; Stuhlmeier KM, 1996, EUR J IMMUNOL, V26, P1417, DOI 10.1002/eji.1830260703; Stulnig TM, 2003, INT ARCH ALLERGY IMM, V132, P310, DOI 10.1159/000074898; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; Triantafilou M, 2002, J CELL SCI, V115, P2603; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Wallace FA, 2001, J LEUKOCYTE BIOL, V69, P449; Whittaker DS, 2000, J IMMUNOL, V165, P4298, DOI 10.4049/jimmunol.165.8.4298; Woltman AM, 2003, J LEUKOCYTE BIOL, V73, P428, DOI 10.1189/jlb.0902431; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zelle-Rieser C, 2002, FEBS LETT, V511, P123, DOI 10.1016/S0014-5793(01)03326-9; Zeyda M, 2002, J BIOL CHEM, V277, P28418, DOI 10.1074/jbc.M203343200; Zeyda M, 2003, J IMMUNOL, V170, P6033, DOI 10.4049/jimmunol.170.12.6033; Zhou L, 2004, MOL CELL BIOL, V24, P2385, DOI 10.1128/MCB.24.6.2385-2396.2004	64	99	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14293	14301		10.1074/jbc.M410000200	http://dx.doi.org/10.1074/jbc.M410000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15684433	hybrid			2022-12-25	WOS:000228095500133
J	Cochran, JC; Gatial, JE; Kapoor, TM; Gilbert, SP				Cochran, JC; Gatial, JE; Kapoor, TM; Gilbert, SP			Monastrol inhibition of the mitotic kinesin Eg5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE INHIBITOR; ATP HYDROLYSIS; SPINDLE; MOTOR; ORGANIZATION; PROTEIN; MITOSIS; DYNAMICS; HISTORY; PATHWAY	Monastrol is a small, cell-permeable molecule that arrests cells in mitosis by specifically inhibiting Eg5, a member of the Kinesin-5 family. We have used steady-state and presteady-state kinetics as well as equilibrium binding approaches to define the mechanistic basis of S-monastrol inhibition of monomeric human Eg5/KSP. In the absence of microtubules(Mts), the basal ATPase activity is inhibited through slowed product release. In the presence of microtubules, the ATPase activity is also reduced with weakened binding of Eg5 to microtubules during steady-state ATP turnover. Monastrol-treated Eg5 also shows a decreased relative affinity for microtubules under equilibrium conditions. The Mt center dot Eg5 presteady-state kinetics of ATP binding and the subsequent ATP-dependent isomerization are unaffected during the first ATP turnover. However, monastrol appears to stabilize a conformation that allows for reversals at the ATP hydrolysis step. Monastrol promotes a dramatic decrease in the observed rate of Eg5 association with microtubules, and ADP release is slowed without trapping the Mt center dot Eg5 center dot ADP intermediate. We propose that S-monastrol binding to Eg5 induces a stable conformational change in the motor domain that favors ATP re-synthesis after ATP hydrolysis. The aberrant interactions with the microtubule and the reversals at the ATP hydrolysis step alter the ability of Eg5 to generate force, thereby yielding a nonproductive Mt center dot Eg5 complex that cannot establish or maintain the bipolar spindle.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10021 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Rockefeller University	Gilbert, SP (corresponding author), Univ Pittsburgh, Dept Biol Sci, 518 Langley Hall,4249 5th Ave, Pittsburgh, PA 15260 USA.	spg1@pitt.edu			NIAMS NIH HHS [K02-AR47841, K02 AR047841] Funding Source: Medline; NIGMS NIH HHS [GM54141, R01 GM054141, R37 GM054141] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR047841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054141, R01GM054141] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Brier S, 2004, BIOCHEMISTRY-US, V43, P13072, DOI 10.1021/bi049264e; Chakravarty A, 2004, MOL BIOL CELL, V15, P2116, DOI 10.1091/mbc.E03-08-0579; Cochran JC, 2004, J BIOL CHEM, V279, P38861, DOI 10.1074/jbc.M404203200; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; Crevel IMTC, 2004, CURR BIOL, V14, pR411, DOI 10.1016/j.cub.2004.05.030; Cytrynbaum EN, 2003, BIOPHYS J, V84, P757, DOI 10.1016/S0006-3495(03)74895-4; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; FINER JT, 2003, Patent No. 6545004; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Funk CJ, 2004, ANAL BIOCHEM, V329, P68, DOI 10.1016/j.ab.2004.02.032; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; Inoue S, 1997, J STRUCT BIOL, V118, P87, DOI 10.1006/jsbi.1996.3839; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kwon M, 2004, TRENDS CELL BIOL, V14, P194, DOI 10.1016/j.tcb.2004.03.003; Mailhes JB, 2004, MUTAT RES-GEN TOX EN, V559, P153, DOI 10.1016/j.mrgentox.2004.01.001; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Mitchison TJ, 2001, NAT CELL BIOL, V3, pE17, DOI 10.1038/35050656; Miyamoto David T, 2003, Prog Cell Cycle Res, V5, P349; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Nedelec F, 2003, CURR OPIN CELL BIOL, V15, P118, DOI 10.1016/S0955-0674(02)00014-5; Peterson JR, 2002, CHEM BIOL, V9, P1275, DOI 10.1016/S1074-5521(02)00284-3; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Saunders W, 1997, MOL BIOL CELL, V8, P1025, DOI 10.1091/mbc.8.6.1025; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Scholey JM, 2003, NATURE, V422, P746, DOI 10.1038/nature01599; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Yan YW, 2004, J MOL BIOL, V335, P547, DOI 10.1016/j.jmb.2003.10.074	40	126	129	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12658	12667		10.1074/jbc.M413140200	http://dx.doi.org/10.1074/jbc.M413140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15665380	Green Accepted, hybrid			2022-12-25	WOS:000227922000072
J	Ning, SB; Huye, LE; Pagano, JS				Ning, SB; Huye, LE; Pagano, JS			Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; NF-KAPPA-B; GENE-EXPRESSION REQUIRES; DOUBLE-STRANDED-RNA; LATENT MEMBRANE-PROTEIN-1; POSITIVE FEEDBACK; INDUCED APOPTOSIS; FACTOR COMPLEX; HOST-DEFENSE; CELL-GROWTH	Genes containing an interferon (IFN)-stimulated response element (ISRE) can be divided into two groups according to their inducibility by IFN and virus infection: one induced only by IFN and the other induced by both IFN and virus infection. Although it is now clear that IFN regulatory factor 7 (IRF7) is a multifunctional gene essential for induction of type I IFNs, regulation of the IRF7 promoter (IRF7p) is poorly understood. The IRF7 gene includes two IFN responsive elements, an IRF-binding element (IRFE) in the promoter region and an ISRE in the first intron, and is induced by the IFN-triggered Jak-STAT pathway by binding of the IFN-stimulated gene factor 3 (ISGF3) complex to the ISRE. In this study, we demonstrate that IRF3 and IRF7, which with the coactivators CREB-binding protein and P300 form the virus-activated factor (VAF) complex upon Sendai virus infection, bind to the IRF7 ISRE and IRFE and can directly activate IRF7 transcription. Promoter reporter assays show that both the ISRE and IRFE are responsive to activation by IRF7 and IRF3. In cells transiently expressing IRF7 or/and IRF3, the VAF level and binding of VAF are clearly increased after Sendai virus infection. Studies with Jak1 kinase inactive 293 cells that were stably transfected with a Jak1 kinase dead dominant negative construct, and the mutant cell lines SAN (IFN alpha(-)/beta(-)), U2A (IRF9(-)), U4A (Jak1(-)), and DKO (IRF1(-)/IRF2(-)) show that the IRF7 transcription activated directly by VAF is distinct from and independent of the IFN signaling pathway. Thus, IRF7 transcription is autoregulated by binding of the IRF7-containing VAF to its own ISRE and IRFE. The results show two distinct mechanisms for the activation of the IRF7 promoter, by IFN and by virus infection. A regulatory network between type I IFNs and IRF7 is proposed. The distinct pathways may reflect special roles for an efficient antiviral response at different stages of virus infection.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Pagano, JS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Campus Box 7295, Chapel Hill, NC 27599 USA.	joseph_pagano@med.unc.edu	Ning, Shunbin/I-3961-2019; Ning, Shunbin/AAC-6895-2021	Ning, Shunbin/0000-0001-5484-5779; 	NCI NIH HHS [CA 19014, T32-CA09156-27] Funding Source: Medline; NIAID NIH HHS [AI 42372-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA019014, T32CA009156] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Barnes BJ, 2003, CANCER RES, V63, P6424; Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Lu RQ, 2002, J BIOL CHEM, V277, P16592, DOI 10.1074/jbc.M111440200; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Matsumoto M, 1999, BIOL CHEM, V380, P699, DOI 10.1515/BC.1999.087; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAKOSHI J, 1990, CANCER RES, V50, P278; Morin P, 2002, J MOL BIOL, V316, P1009, DOI 10.1006/jmbi.2001.5401; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Ning S, 2003, J VIROL, V77, P9359, DOI 10.1128/JVI.77.17.9359-9368.2003; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; Qing J, 2004, MOL CELL BIOL, V24, P1411, DOI 10.1128/MCB.24.3.1411-1425.2004; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; Roberts RM, 1998, J INTERF CYTOK RES, V18, P805, DOI 10.1089/jir.1998.18.805; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suhara W, 2000, J BIOCHEM-TOKYO, V128, P301, DOI 10.1093/oxfordjournals.jbchem.a022753; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Yang HM, 2003, J BIOL CHEM, V278, P15495, DOI 10.1074/jbc.M212940200; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2001, J VIROL, V75, P12393, DOI 10.1128/JVI.75.24.12393-12401.2001; Zhang LW, 2001, J VIROL, V75, P341, DOI 10.1128/JVI.75.1.341-350.2001	57	70	73	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12262	12270		10.1074/jbc.M404260200	http://dx.doi.org/10.1074/jbc.M404260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15664995	Green Published, hybrid			2022-12-25	WOS:000227922000025
J	Sio, SO; Suehiro, T; Sugiura, R; Takeuchi, M; Mukai, H; Kuno, T				Sio, SO; Suehiro, T; Sugiura, R; Takeuchi, M; Mukai, H; Kuno, T			The role of the regulatory subunit of fission yeast calcineurin for in vivo activity and its relevance to FK506 sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; PHOSPHATASE-ACTIVITY; CATALYTIC SUBUNIT; BINDING PROTEIN; CYTOKINESIS; CALMODULIN; PATHWAY; HOMEOSTASIS; EXPRESSION	Calcineurin, a protein phosphatase required for Ca2+ signaling in many cell types, is a heterodimer composed of catalytic and regulatory subunits. The fission yeast genome encodes a single set of catalytic (Ppb1) and regulatory (Cnb1) subunits, providing an ideal model system to study the functions of these subunits in vivo. Here, we cloned the cnb1(+) gene and showed that the cnb1 knock-out (Delta cnb1) exhibits identical phenotypes with Delta ppb1 and that overexpression of Ppb1 failed to suppress the phenotypes of Delta cnb1. Interestingly, overexpression of the C-terminal-deleted Ppb1 (Ppb1 Delta C), the constitutively active form of Ppb1, also failed to suppress the phenotypes of Delta cnb1. FK506 caused MgCl2 sensitivity to the wild-type cells in an FKBP12-dependent manner. Co-overexpression of Ppb1 and Cnb1 suppressed the FK506-induced MgCl2 sensitivity, but the suppression was only partial, suggesting that an excess amount of the Ppb1-Cnb1 complex cannot compete out the FKBP12-FK506 complex. Although overexpression of Ppb1 Delta C alone had little effect on cell growth, co-overexpression of Ppb1 Delta C and Cnb1 caused a distinct growth defect. FK506 suppressed the growth defect when Cnb1 was co-expressed using the attenuated nmt1 promoter, but it failed to suppress the defect when Cnb1 was co-expressed using the wild-type nmt1 promoter. Knock-out of the prz1(+) gene, encoding a downstream target transcription factor of calcineurin, suppressed the growth defect irrespective of the promoter potency. These results suggest that Cnb1 is essential for the activation of calcineurin and that the activated calcineurin is the pharmacological target of the FKBP12-FK506 complex in vivo.	Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Mol Pharmacol & Pharmacogenom,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kinki Univ, Sch Pharmaceut Sci, Lab Mol Pharmacogenom, Higashiosaka, Osaka 5778502, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan; Kobe Univ, Grad Sch Sci & Technol, Kobe, Hyogo 6578501, Japan	Kobe University; Kindai University (Kinki University); Kobe University; Kobe University	Kuno, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Mol Pharmacol & Pharmacogenom,Chuo Ku, 7-5-1 Kusonoki Cho, Kobe, Hyogo 6500017, Japan.	tkuno@med.kobe-u.ac.jp		Mukai, Hideyuki/0000-0002-0167-8695				Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; ASAMI M, 1993, BIOCHEM BIOPH RES CO, V192, P1388, DOI 10.1006/bbrc.1993.1570; Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Cheng H, 2002, MOL BIOL CELL, V13, P2963, DOI 10.1091/mbc.01-09-0463; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; Cyert MS, 2001, ANNU REV GENET, V35, P647, DOI 10.1146/annurev.genet.35.102401.091302; Fujita M, 2002, GENETICS, V161, P971; HIGUCHI S, 1991, J BIOL CHEM, V266, P18104; Hirayama S, 2003, J BIOL CHEM, V278, P18078, DOI 10.1074/jbc.M212900200; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Kita A, 2004, MOL BIOL CELL, V15, P2920, DOI 10.1091/mbc.E03-09-0659; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; Lafuente MJ, 1997, FEBS LETT, V420, P39, DOI 10.1016/S0014-5793(97)01486-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; Lu YB, 2002, GENES CELLS, V7, P1009, DOI 10.1046/j.1365-2443.2002.00582.x; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Ogiso Y, 2004, MOL CELL BIOL, V24, P2324, DOI 10.1128/MCB.24.6.2324-2331.2004; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Sugiura R, 2004, CELL CYCLE, V3, P286; Sugiura R, 1999, NATURE, V399, P479, DOI 10.1038/20951; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; Sugiura R, 2003, NATURE, V424, P961, DOI 10.1038/nature01907; Toda T, 1996, MOL CELL BIOL, V16, P6752; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yada T, 2001, J BIOL CHEM, V276, P13579, DOI 10.1074/jbc.M009260200; YOSHIDA T, 1994, J CELL SCI, V107, P1725; Zhang YJ, 2000, J BIOL CHEM, V275, P35600, DOI 10.1074/jbc.M005575200	38	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12231	12238		10.1074/jbc.M414234200	http://dx.doi.org/10.1074/jbc.M414234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15657058	hybrid			2022-12-25	WOS:000227922000021
J	Zhu, H; Shuman, S				Zhu, H; Shuman, S			Structure-guided mutational analysis of the nucleotidyltransferase domain of Escherichia coli NAD(+)-dependent DNA ligase (LigA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING ENZYME; PHOSPHODIESTER BOND FORMATION; CRYSTAL-STRUCTURE; MECHANISM; VIRUS; ADENYLATION		Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org						Brotz-Oesterhelt H, 2003, J BIOL CHEM, V278, P39435, DOI 10.1074/jbc.M306479200; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Gajiwala KS, 2004, STRUCTURE, V12, P1449, DOI 10.1016/j.str.2004.05.017; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; GUMPORT RI, 1971, P NATL ACAD SCI USA, V68, P2559, DOI 10.1073/pnas.68.10.2559; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; Kaczmarek FS, 2001, J BACTERIOL, V183, P3016, DOI 10.1128/JB.183.10.3016-3024.2001; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; Lim JH, 2001, ARCH BIOCHEM BIOPHYS, V388, P253, DOI 10.1006/abbi.2001.2291; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; MODRICH P, 1971, P NATL ACAD SCI USA, V68, P1002, DOI 10.1073/pnas.68.5.1002; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Petit MA, 2000, NUCLEIC ACIDS RES, V28, P4642, DOI 10.1093/nar/28.23.4642; Sawaya R, 2003, BIOCHEMISTRY-US, V42, P8240, DOI 10.1021/bi034396d; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 2002, J BIOL CHEM, V277, P9661, DOI 10.1074/jbc.M110613200; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Sriskanda V, 2001, J BIOL CHEM, V276, P36100, DOI 10.1074/jbc.M105643200; SRISKANDA V, 2002, J BIOL CHEM, V277, P9685; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Timson DJ, 1999, J MOL BIOL, V285, P73, DOI 10.1006/jmbi.1998.2302; Wang LK, 2003, J BIOL CHEM, V278, P29454, DOI 10.1074/jbc.M304320200; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200	28	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12137	12144		10.1074/jbc.M413685200	http://dx.doi.org/10.1074/jbc.M413685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15671015	hybrid			2022-12-25	WOS:000227922000011
J	Eger, A; Aigner, K; Sonderegger, S; Dampier, B; Oehler, S; Schreiber, M; Berx, G; Cano, A; Beug, H; Foisner, R				Eger, A; Aigner, K; Sonderegger, S; Dampier, B; Oehler, S; Schreiber, M; Berx, G; Cano, A; Beug, H; Foisner, R			DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells	ONCOGENE			English	Article						epithelial-mesenchymal transition; cell adhesion; breast cancer; invasion; metastasis	ENHANCER-BINDING FACTOR; MESENCHYMAL TRANSITIONS; BETA-CATENIN; ZINC-FINGER; CARCINOMA-CELLS; UP-REGULATION; TUMOR-CELLS; SNAIL EXPRESSION; SUPPRESSOR GENE; E47 REPRESSORS	Downregulation of E-cadherin is a crucial event for epithelial to mesenchymal transition (EMT) in embryonic development and cancer progression. Using the EpFosER mammary tumour model we show that during EMT, upregulation of the transcriptional regulator deltaEF1 coincided with transcriptional repression of E-cadherin. Ectopic expression of deltaEF1 in epithelial cells was sufficient to downregulate E-cadherin and to induce EMT. Analysis of E-cadherin promoter activity and chromatin immunoprecipitation identified deltaEF1 as direct transcriptional repressor of E-cadherin. In human cancer cells, transcript levels of deltaEF1 correlated directly with the extent of E-cadherin repression and loss of the epithelial phenotype. The protein was enriched in nuclei of human cancer cells and physically associated with the E-cadherin promoter. RNA interference-mediated downregulation of deltaEF1 in cancer cells was sufficient to derepress E-cadherin expression and restore cell to cell adhesion, suggesting that deltaEF1 is a key player in late stage carcinogenesis.	Med Univ Vienna, Dept Biochem Med, Vienna Bioctr, Max F Perutz Labs, Vienna, Austria; Med Univ Vienna, Dept Obstet & Gynecol, Div Senol, Vienna, Austria; Ghent Univ VIB, Dept Molec Biomed Res, Ghent, Belgium; UAM, Dept Biochem, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; Res Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; Flanders Institute for Biotechnology (VIB); Ghent University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Eger, A (corresponding author), Med Univ Vienna, Dept Biochem Med, Vienna Bioctr, Max F Perutz Labs, Dr Bohrgasse 9, Vienna, Austria.	andreas.eger@univie.ac.at; roland.foisner@univie.ac.at	Foisner, Roland/AAD-1833-2019; Martin, Schreiber/F-2175-2013; Sonderegger, Stefan E/J-1567-2014	Martin, Schreiber/0000-0003-1102-7789; Sonderegger, Stefan E/0000-0001-9873-0885; Foisner, Roland/0000-0003-4734-4647; Berx, Geert/0000-0001-5770-2458				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Birchmeier C, 1996, ACTA ANAT, V156, P217; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Eger A, 2004, ONCOGENE, V23, P2672, DOI 10.1038/sj.onc.1207416; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; GRAFF JR, 1995, CANCER RES, V55, P5195; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hajra KM, 2002, CANCER RES, V62, P1613; Hay ED, 1995, ACTA ANAT, V154, P8; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; LAI ZC, 1993, P NATL ACAD SCI USA, V90, P4122, DOI 10.1073/pnas.90.9.4122; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Stemmler MP, 2003, DEV DYNAM, V227, P238, DOI 10.1002/dvdy.10301; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267; Tomita K, 2000, CANCER RES, V60, P3650; van Grunsven LA, 2001, J BONE JOINT SURG AM, V83A, pS40; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135	56	591	616	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 31	2005	24	14					2375	2385		10.1038/sj.onc.1208429	http://dx.doi.org/10.1038/sj.onc.1208429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15674322				2022-12-25	WOS:000227877400010
J	Hall, AM; Wiczer, BM; Herrmann, T; Stremmel, W; Bernlohr, DA				Hall, AM; Wiczer, BM; Herrmann, T; Stremmel, W; Bernlohr, DA			Enzymatic properties of purified murine fatty acid transport protein 4 and analysis of acyl-CoA synthetase activities in tissues from FATP4 null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INSULIN-RESISTANCE; EXPRESSION; DISRUPTION; ACTIVATION; COMPONENTS; CLONING; IMPORT; SYSTEM; GROWTH	Fatty acid transport protein 4 (FATP4) is an integral membrane protein expressed in the plasma and internal membranes of the small intestine and adipocyte as well as in the brain, kidney, liver, skin, and heart. FATP4 has been hypothesized to be bifunctional, exhibiting both fatty acid transport and acyl-CoA synthetase activities that work in concert to mediate fatty acid influx across biological membranes. To determine whether FATP4 is an acyl-CoA synthetase, the murine protein was engineered to contain a C-terminal FLAG epitope tag, expressed in COS1 cells via adenovirus-mediated infection and purified to near homogeneity using alpha-FLAG affinity chromatography. Kinetic analysis of the enzyme was carried out for long chain ( palmitic acid, C16: 0) and very long chain ( lignoceric acid, C24: 0) fatty acids as well as for ATP and CoA. FATP4 exhibited substrate specificity for C16: 0 and C24: 0 fatty acids with a V-max/K-m (C16: 0)/V-max/K-m ( C24: 0) of 1.5. Like purified FATP1, FATP4 was insensitive to inhibition by triacsin C but was sensitive to feedback inhibition by acyl-CoA. Although purified FATP4 exhibited high levels of palmitoyl-CoA and lignoceroyl-CoA synthetase activity, extracts from the skin and intestine of FATP4 null mice exhibited reduced esterification for C24: 0, but not C16: 0 or C18: 1, suggesting that in vivo, defects in very long chain fatty acid uptake may underlie the skin disorder phenotype of null mice.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Heidelberg Univ, Dept Internal Med 4, D-69120 Heidelberg, Germany	University of Minnesota System; University of Minnesota Twin Cities; Ruprecht Karls University Heidelberg	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 321 Church St SE,6-155 Jackson Hall, Minneapolis, MN 55455 USA.	bernl00@umn.edu		Hall, Angela Marie/0000-0003-0006-7910; Stremmel, Wolfgang/0000-0002-8545-1753	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053189] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK053189] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; Faergeman NJ, 2001, J BIOL CHEM, V276, P37051, DOI 10.1074/jbc.M100884200; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Frohnert BI, 2000, PROG LIPID RES, V39, P83, DOI 10.1016/S0163-7827(99)00018-1; Gertow K, 2004, DIABETOLOGIA, V47, P1118, DOI 10.1007/s00125-004-1417-4; Gertow K, 2004, J CLIN ENDOCR METAB, V89, P392, DOI 10.1210/jc.2003-030682; Gimeno RE, 2003, J BIOL CHEM, V278, P49512, DOI 10.1074/jbc.M309759200; Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200; Hatch GM, 2002, J LIPID RES, V43, P1380, DOI 10.1194/jlr.M200130-JLR200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herrmann T, 2003, J CELL BIOL, V161, P1105, DOI 10.1083/jcb.200207080; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Kim JK, 2004, J CLIN INVEST, V113, P756, DOI 10.1172/JCI200418917; Luiken JJFP, 1999, LIPIDS, V34, pS169, DOI 10.1007/BF02562278; Moulson CL, 2003, P NATL ACAD SCI USA, V100, P5274, DOI 10.1073/pnas.0431186100; NAGAMATSU K, 1985, BIOCHIM BIOPHYS ACTA, V836, P80, DOI 10.1016/0005-2760(85)90223-1; Pei ZT, 2004, J BIOL CHEM, V279, P54454, DOI 10.1074/jbc.M410091200; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Stuhlsatz-Krouper SM, 1999, PROSTAG LEUKOTR ESS, V60, P285, DOI 10.1016/S0952-3278(99)80001-5; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	25	111	115	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11948	11954		10.1074/jbc.M412629200	http://dx.doi.org/10.1074/jbc.M412629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653672	hybrid			2022-12-25	WOS:000227761800126
J	Imazawa, Y; Hisatake, K; Mitsuzawa, H; Matsumoto, M; Tsukui, T; Nakagawa, K; Nakadai, T; Shimada, M; Ishihama, A; Nogi, Y				Imazawa, Y; Hisatake, K; Mitsuzawa, H; Matsumoto, M; Tsukui, T; Nakagawa, K; Nakadai, T; Shimada, M; Ishihama, A; Nogi, Y			The fission yeast protein Ker1p is an ortholog of RNA polymerase I subunit A14 in Saccharomyces cerevisiae and is required for stable association of Rrn3p and RPA21 in RNA polymerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTION FACTOR; FUNCTIONAL HOMOLOG; A49 SUBUNIT; TIF-IA; GENE; RECRUITMENT; INITIATION; ENCODES	A heterodimer formed by the A14 and A43 subunits of RNA polymerase (pol) I in Saccharomyces cerevisiae is proposed to correspond to the Rpb4/Rpb7 and C17/C25 heterodimers in pol II and pol III, respectively, and to play a role(s) in the recruitment of pol I to the promoter. However, the question of whether the A14/A43 heterodimer is conserved in eukaryotes other than S. cerevisiae remains unanswered, although both Rpb4/Rpb7 and C17/C25 are conserved from yeast to human. To address this question, we have isolated a Schizosaccharomyces pombe gene named ker1(+) using a yeast two-hybrid system, including rpa21(+), which encodes an ortholog of A43, as bait. Although no homolog of A14 has previously been found in the S. pombe genome, functional characterization of Ker1p and alignment of Ker1p and A14 showed that Ker1p is an ortholog of A14. Disruption of ker1(+) resulted in temperature-sensitive growth, and the temperature-sensitive deficit of ker1 Delta was suppressed by overexpression of either rpa21(+) or rrn3(+), which encodes the rDNA transcription factor Rrn3p, suggesting that Ker1p is involved in stabilizing the association of RPA21 and Rrn3p in pol I. We also found that Ker1p dissociated from pol I in post-log-phase cells, suggesting that Ker1p is involved in growth-dependent regulation of rDNA transcription.	Saitama Med Sch, Dept Biol Mol, Moroyama, Saitama 3500495, Japan; Japan Sci & Technol Corp Ctr, Kawaguchi, Saitama 3320012, Japan; Saitama Med Sch, Res Ctr Genom Med, Hidaka, Saitama 3501241, Japan; Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan; Nippon Inst Biol Sci, Tokyo 1980024, Japan	Saitama Medical University; Japan Science & Technology Agency (JST); Saitama Medical University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Nogi, Y (corresponding author), Saitama Med Sch, Dept Biol Mol, 38 Morohongo, Moroyama, Saitama 3500495, Japan.	yasunogi@saitama-med.ac.jp		Hisatake, Koji/0000-0002-5795-3115				Alfa C., 1993, EXPT FISSION YEAST; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bischler N, 2002, EMBO J, V21, P4136, DOI 10.1093/emboj/cdf392; Bodem J, 2000, EMBO REP, V1, P171, DOI 10.1093/embo-reports/kvd032; BREANT B, 1983, EUR J BIOCHEM, V130, P247; BUHLER JM, 1976, FEBS LETT, V71, P37, DOI 10.1016/0014-5793(76)80893-9; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Cavanaugh AH, 2002, J BIOL CHEM, V277, P27423, DOI 10.1074/jbc.M201232200; Claypool JA, 2004, MOL BIOL CELL, V15, P946, DOI 10.1091/mbc.E03-08-0594; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; Ferri ML, 2000, MOL CELL BIOL, V20, P488, DOI 10.1128/MCB.20.2.488-495.2000; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; HARPER JW, 1993, CELL, V75, P805; HIRANO T, 1989, J CELL BIOL, V108, P243, DOI 10.1083/jcb.108.2.243; Hu P, 2002, MOL CELL BIOL, V22, P8044, DOI 10.1128/MCB.22.22.8044-8055.2002; Imai K, 1999, MOL GEN GENET, V261, P364, DOI 10.1007/s004380050977; Imazawa Y, 2002, GENES GENET SYST, V77, P147, DOI 10.1266/ggs.77.147; Imazawa Y, 2001, MOL GEN GENET, V264, P852, DOI 10.1007/s004380000375; Imazawa Y, 1999, MOL GEN GENET, V262, P749; Ishiguro A, 2000, MOL CELL BIOL, V20, P1263, DOI 10.1128/MCB.20.4.1263-1270.2000; JU QD, 1994, YEAST, V10, P151, DOI 10.1002/yea.320100203; Keener J, 1998, J BIOL CHEM, V273, P33795, DOI 10.1074/jbc.273.50.33795; Lanzendorfer M, 1997, GENE DEV, V11, P1037, DOI 10.1101/gad.11.8.1037; LILJELUND P, 1992, P NATL ACAD SCI USA, V89, P9302, DOI 10.1073/pnas.89.19.9302; Meka H, 2003, NUCLEIC ACIDS RES, V31, P4391, DOI 10.1093/nar/gkg652; Milkereit P, 1998, EMBO J, V17, P3692, DOI 10.1093/emboj/17.13.3692; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Mitsuzawa H, 2001, J BIOL CHEM, V276, P17117, DOI 10.1074/jbc.M100248200; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Nakagawa K, 2003, GENES GENET SYST, V78, P199, DOI 10.1266/ggs.78.199; OAKES M, 1993, MOL CELL BIOL, V13, P2441, DOI 10.1128/MCB.13.4.2441; Orlicky SM, 2001, J BIOL CHEM, V276, P10097, DOI 10.1074/jbc.M003165200; Peyroche E, 2002, P NATL ACAD SCI USA, V99, P14670, DOI 10.1073/pnas.232580799; Peyroche G, 2000, EMBO J, V19, P5473, DOI 10.1093/emboj/19.20.5473; Sakurai H, 1999, MOL CELL BIOL, V19, P7511; Sawin KE, 1996, P NATL ACAD SCI USA, V93, P15146, DOI 10.1073/pnas.93.26.15146; Seither P, 2001, BIOL CHEM, V382, P1163, DOI 10.1515/BC.2001.146; Sheffer A, 1999, MOL CELL BIOL, V19, P2672; SHERMAN F, 1986, LABORATORY COURSE MA, P163; Shpakovski GV, 2000, J MOL BIOL, V295, P1119, DOI 10.1006/jmbi.1999.3399; Siaut M, 2003, MOL CELL BIOL, V23, P195, DOI 10.1128/MCB.23.1.195-205.2003; SMID A, 1995, J BIOL CHEM, V270, P13534, DOI 10.1074/jbc.270.22.13534; THURIAUX P, 1995, J BIOL CHEM, V270, P24252, DOI 10.1074/jbc.270.41.24252; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; Todone F, 2001, MOL CELL, V8, P1137, DOI 10.1016/S1097-2765(01)00379-3; WADDELL S, 1995, NUCLEIC ACIDS RES, V23, P1836, DOI 10.1093/nar/23.10.1836; Woychik NA, 1998, COLD SPRING HARB SYM, V63, P311, DOI 10.1101/sqb.1998.63.311; YAMAGISHI M, 1988, GENE, V74, P503; Yamamoto K, 2004, MOL CELL BIOL, V24, P6338, DOI 10.1128/MCB.24.14.6338-6349.2004; Yamamoto RT, 1996, EMBO J, V15, P3964, DOI 10.1002/j.1460-2075.1996.tb00770.x; Yuan XJ, 2002, EMBO REP, V3, P1082, DOI 10.1093/embo-reports/kvf212; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4	55	7	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11467	11474		10.1074/jbc.M411150200	http://dx.doi.org/10.1074/jbc.M411150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647272	hybrid			2022-12-25	WOS:000227761800070
J	Liu, HT; Chang, DW; Yang, XL				Liu, HT; Chang, DW; Yang, XL			Interdimer processing and linearity of procaspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PROXIMITY MODEL; SIGNALING COMPLEX DISC; CASPASE-8 ACTIVATION; CELL-DEATH; APOPTOSIS; OLIGOMERIZATION; PROTEASE; MECHANISM; RECEPTOR; ASSOCIATION	Caspase activation during apoptosis occurs in a cascade from the initiator caspase(s) ( e. g. caspase-8) to the effector caspases ( e. g. caspase-3), which ensures the generation of large amounts of active caspases to dismantle cells. However, the mechanism that safeguards against inadvertent caspase activation is not well understood. Previous studies have suggested that the activation of procaspase-8 is mediated by cross-cleavage of precursor dimers, formed upon apoptosis induction, which are not only enzymatically competent but also highly susceptible to cleavage, and that procaspase-8 activation is a linear process without self-amplification. Effector procaspases constitutively exist as dimers and their activation is started by trans-cleavage by an initiator caspase followed by autocleavage of effector caspases. Here we show that the dimerization of caspase-3 molecules through their protease domains is required for their processing by initiator caspases. The subsequent autoprocessing takes place through cleavage between the dimeric intermediates. Moreover, mature caspase-3 fails to process its own precursor. Thus, despite a marked difference in the generation of active intermediates, the activation of initiator and effector caspases shares the features of interdimer cleavage and lack of self-amplification. These features may be important in preventing accidental cell death.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Yang, XL (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	xyang@mail.med.upenn.edu			NIGMS NIH HHS [1R01 GM60911] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060911] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chang DW, 2003, J BIOL CHEM, V278, P16466, DOI 10.1074/jbc.C300089200; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang XD, 2001, GENE DEV, V15, P2922; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	37	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11578	11582		10.1074/jbc.M414385200	http://dx.doi.org/10.1074/jbc.M414385200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15664982	hybrid			2022-12-25	WOS:000227761800084
J	Perry, SJ; Junger, S; Kohout, TA; Hoare, SRJ; Struthers, RS; Grigoriadis, DE; Maki, RA				Perry, SJ; Junger, S; Kohout, TA; Hoare, SRJ; Struthers, RS; Grigoriadis, DE; Maki, RA			Distinct conformations of the corticotropin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; OPIOID RECEPTORS; PLASMA-MEMBRANE; DOWN-REGULATION; I RECEPTOR; CRF; INTERNALIZATION; DESENSITIZATION; ENDOCYTOSIS; ACTIVATION	The corticotropin releasing factor (CRF) type 1 receptor (CRF1) is a class B family G protein-coupled receptor that regulates the hypothalamic-pituitary-adrenal stress axis. Astressin is an amino-terminal truncated analog of CRF that retains high affinity binding to the extracellular domain of the receptor and is believed to act as a neutral competitive antagonist of receptor activation. Here we show that despite being unable to activate the CRF1 receptor, astressin binding results in the internalization of the receptor. Furthermore, entirely different pathways of internalization of CRF1 receptors are utilized following CRF and astressin binding. CRF causes the receptor to be phosphorylated, recruit beta-arrestin2, and to be internalized rapidly, likely through clathrin-coated pits. Astressin, however, fails to induce receptor phosphorylation or beta-arrestin2 recruitment, and internalization is slow and occurs through a pathway that is insensitive to inhibitors of clathrin-coated pits and caveolae. The fate of the internalized receptors also differs because only CRF-induced internalization results in receptor down-regulation. Furthermore, we present evidence that for astressin to induce internalization it must interact with both the extracellular amino terminus and the juxtamembrane domain of the receptor. Astressin binds with 6-fold higher affinity to full-length CRF1 receptors than to a chimeric protein containing only the extracellular domain attached to the transmembrane domain of the activin IIB receptor, yet two 12-residue analogs of astressin have similar affinities for both proteins but are unable to induce receptor internalization. These data demonstrate that agonists and antagonists for CRF1 receptors promote distinct conformations, which are then differentially regulated.	Neurocrine Biosci Inc, Dept Biol Mol, San Diego, CA 92130 USA; Neurocrine Biosci Inc, Dept Endocrinol, San Diego, CA 92130 USA; Neurocrine Biosci Inc, Dept Pharmacol, San Diego, CA 92130 USA	Neurocrine Biosciences; Neurocrine Biosciences; Neurocrine Biosciences	Perry, SJ (corresponding author), Neurocrine Biosci Inc, Dept Biol Mol, 12790 El Camino Real, San Diego, CA 92130 USA.	sperry@neurocrine.com	Hoare, Sam/J-9018-2019					Assil-Kishawi I, 2002, J BIOL CHEM, V277, P32558, DOI 10.1074/jbc.M204964200; Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410; Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chatzaki E, 2004, J NEUROCHEM, V88, P1, DOI 10.1046/j.1471-4159.2003.02078.x; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Colvin RA, 2004, J BIOL CHEM, V279, P30219, DOI 10.1074/jbc.M403595200; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; Dautzenberg FM, 2002, BIOCHEM BIOPH RES CO, V298, P303, DOI 10.1016/S0006-291X(02)02463-4; Dautzenberg FM, 2002, MOL PHARMACOL, V61, P1132, DOI 10.1124/mol.61.5.1132; Dautzenberg FM, 2001, AM J PHYSIOL-REG I, V280, pR935, DOI 10.1152/ajpregu.2001.280.4.R935; Dautzenberg FM, 2002, TRENDS PHARMACOL SCI, V23, P71, DOI 10.1016/S0165-6147(02)01946-6; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gilligan PJ, 2000, J MED CHEM, V43, P1641, DOI 10.1021/jm990590f; Gray JA, 2001, BRAIN RES BULL, V56, P441, DOI 10.1016/S0361-9230(01)00623-2; Grigoriadis Dimitri E., 2001, Current Medicinal Chemistry - Central Nervous System Agents, V1, P63, DOI 10.2174/1568015013358734; GULYAS J, 1995, P NATL ACAD SCI USA, V92, P10575, DOI 10.1073/pnas.92.23.10575; Halmos G, 1996, P NATL ACAD SCI USA, V93, P2398, DOI 10.1073/pnas.93.6.2398; Harmar AJ, 2001, GENOME BIOL, V2; Hata Jonathan A, 2003, Mol Interv, V3, P264, DOI 10.1124/mi.3.5.264; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hoare SRJ, 2005, PEPTIDES, V26, P457, DOI 10.1016/j.peptides.2004.10.019; Hoare SRJ, 2004, BIOCHEMISTRY-US, V43, P3996, DOI 10.1021/bi036110a; Hoare SRJ, 2003, MOL PHARMACOL, V63, P751, DOI 10.1124/mol.63.3.751; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; Holsboer F, 1999, J PSYCHIATR RES, V33, P181, DOI 10.1016/S0022-3956(98)90056-5; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kohout TA, 2004, J BIOL CHEM, V279, P23214, DOI 10.1074/jbc.M402125200; KOOB GF, 1993, CIBA F SYMP, V172, P277; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Liaw CW, 1997, MOL ENDOCRINOL, V11, P980, DOI 10.1210/me.11.7.980; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; RICHARDSON UI, 1983, LIFE SCI, V33, P1981; Rivier C, 1996, BRAIN RES, V721, P83, DOI 10.1016/0006-8993(96)00164-3; RIVIER C, 1983, NATURE, V305, P325, DOI 10.1038/305325a0; Roth BL, 1998, CRIT REV NEUROBIOL, V12, P319, DOI 10.1615/CritRevNeurobiol.v12.i4.30; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Sneddon WB, 2004, ENDOCRINOLOGY, V145, P2815, DOI 10.1210/en.2003-1185; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Yamada Y, 2004, J MED CHEM, V47, P1075, DOI 10.1021/jm034180+	55	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11560	11568		10.1074/jbc.M412914200	http://dx.doi.org/10.1074/jbc.M412914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653688	hybrid			2022-12-25	WOS:000227761800082
J	Xiang, MH; Mohamalawari, D; Rao, R				Xiang, MH; Mohamalawari, D; Rao, R			A novel isoform of the secretory pathway Ca2+, Mn2+-ATPase, hSPCA2, has unusual properties and is expressed in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAILEY-HAILEY-DISEASE; YEAST GOLGI CA2+/MN2+-ATPASE; P-TYPE ATPASE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; FUNCTIONAL EXPRESSION; ION SELECTIVITY; CALCIUM-PUMP; COS-1 CELLS; PMR1	Unlike lower eukaryotes, mammalian genomes have a second gene, ATP2C2, encoding a putative member of ;the family of secretory pathway Ca2+, Mn2+-ATPases, SPCA2. Human SPCA2 shares 64% amino acid identity with the protein defective in Hailey Hailey disease, hSPCA1. We show that human SPCA2 (hSPCA2) has a more limited tissue distribution than hSPCA1, with prominent protein expression in brain and testis. In primary neuronal cells, endogenous SPCA2 has a highly punctate distribution that overlaps with vesicles derived from the trans-Golgi network and is thus different from the compact perinuclear distribution of hSPCA1 seen in keratinocytes and nonpolarized cells. Heterologous expression in a yeast strain lacking endogenous Ca2+ pumps reveals further functional differences from hSPCA1. Although the Mn2+-specific phenotype of hSPCA2 is similar to that of hSPCA1, Ca2+ ions are transported with much poorer affinity, resulting in only weak complementation of Ca2+-specific yeast phenotypes. These observations suggest that SPCA2 may have a more specialized role in mammalian cells, possibly in cellular detoxification of Mn2+ ions, similar to that in yeast. We point to the close links between manganese neurotoxicity and Parkinsonism that would predict an important physiological role for SPCA2 in the brain.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	rrao@jhmi.edu			NIGMS NIH HHS [GM62142] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062142] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Behne MJ, 2003, J INVEST DERMATOL, V121, P688, DOI 10.1046/j.1523-1747.2003.12528.x; Bolton EC, 2002, MOL CELL, V9, P879, DOI 10.1016/S1097-2765(02)00495-1; Burkhard PR, 2003, ARCH NEUROL-CHICAGO, V60, P521, DOI 10.1001/archneur.60.4.521; Callewaert G, 2003, CELL CALCIUM, V34, P157, DOI 10.1016/S0143-4160(03)00070-8; Dumont RA, 2001, J NEUROSCI, V21, P5066, DOI 10.1523/JNEUROSCI.21-14-05066.2001; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Fairclough RJ, 2003, J BIOL CHEM, V278, P24721, DOI 10.1074/jbc.M300509200; Greenough M, 2004, AM J PHYSIOL-CELL PH, V287, pC1463, DOI 10.1152/ajpcell.00179.2004; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Liang F, 1998, PLANT PHYSIOL, V118, P817, DOI 10.1104/pp.118.3.817; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Mandal D, 2003, J BIOL CHEM, V278, P35292, DOI 10.1074/jbc.M306166200; Mandal D, 2000, J BIOL CHEM, V275, P23933, DOI 10.1074/jbc.M002619200; Missiaen L, 2002, BIOCHEM BIOPH RES CO, V294, P249, DOI 10.1016/S0006-291X(02)00461-8; Olanow CW, 2004, ANN NY ACAD SCI, V1012, P209, DOI 10.1196/annals.1306.018; Reinhardt TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1595, DOI 10.1152/ajpcell.2000.279.5.C1595; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sen Gupta S, 2003, J BIOL CHEM, V278, P28831, DOI 10.1074/jbc.M303300200; Sorin A, 1997, J BIOL CHEM, V272, P9895; Sudbrak R, 2000, HUM MOL GENET, V9, P1131, DOI 10.1093/hmg/9.7.1131; Talla E, 1998, J BIOL CHEM, V273, P27831, DOI 10.1074/jbc.273.43.27831; Ton VK, 2004, J INVEST DERMATOL, V123, P1192, DOI 10.1111/j.0022-202X.2004.23437.x; Ton VK, 2004, AM J PHYSIOL-CELL PH, V287, pC580, DOI 10.1152/ajpcell.00135.2004; Ton VK, 2002, J BIOL CHEM, V277, P6422, DOI 10.1074/jbc.M110612200; Van Baelen K, 2003, BIOCHEM BIOPH RES CO, V306, P430, DOI 10.1016/S0006-291X(03)00977-X; Van Baelen K, 2001, J BIOL CHEM, V276, P10683, DOI 10.1074/jbc.M010553200; Wang P, 2004, J BIOL CHEM, V279, P20461, DOI 10.1074/jbc.M400264200; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wei Y, 2000, J BIOL CHEM, V275, P23927, DOI 10.1074/jbc.M002618200; Wuytack F, 2003, PFLUG ARCH EUR J PHY, V446, P148, DOI 10.1007/s00424-003-1011-5; Zhang SD, 2002, CHINESE CHEM LETT, V13, P17	37	94	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11608	11614		10.1074/jbc.M413116200	http://dx.doi.org/10.1074/jbc.M413116200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15677451	Green Published, hybrid			2022-12-25	WOS:000227761800088
J	Budde, A; Schneiderhan-Marra, N; Petersen, G; Brune, B				Budde, A; Schneiderhan-Marra, N; Petersen, G; Brune, B			Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1)	ONCOGENE			English	Article						HIF-1 alpha; pRB; transcriptional activation	FACTOR-ALPHA; S-PHASE; PROTEIN; HIF-1-ALPHA; INTERACTS; BINDING; STRESS; P53; FACTOR-1-ALPHA; RECRUITMENT	Hypoxia-inducible factor-1 alpha (HIF-1alpha) constitutes a regulatory subunit of HIF-1, a major transcriptional activator of genes that coordinate physiological and pathological responses towards hypoxia. In order to identify novel interaction partners of HIF-1alpha we have applied T7 phage display system and identified a domain inherent in the retinoblastoma protein ( pRB). The interaction between pRB and HIF-1alpha was confirmed by in vitro experiments and in transfected cells. Thereby, an HIF-1alpha domain spanning amino acids 530-694 was mapped to be required for pRB binding. Overexpression of pRB provoked transcriptional activation of HIF-1alpha under normoxia. Furthermore, the domain of pRB identified to bind HIF-1alpha in vitro is sufficient to cause HIF-1alpha transcriptional activation with the further notion that phosphorylation deficient pRB shows stronger HIF-1alpha transactivation. Using ChIP analysis, we show that HIF-1alpha responsive elements (HREs) are precipitated using alpha-pRB antibodies. Additionally, a functional interaction between pRB and HIF-1alpha is confirmed by showing that HIF-1alpha reverses the transcription repressor function of pRB.	Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany; Univ Erlangen Nurnberg, Fac Med, Dept Med, Expt Div 4, D-91054 Erlangen, Germany; Heidelberg Univ, Inst Zool, D-69120 Heidelberg, Germany	University of Kaiserslautern; University of Erlangen Nuremberg; Ruprecht Karls University Heidelberg	Brune, B (corresponding author), Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany.	bruene@rhrk.uni.kl.de						Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Danielsen T, 1998, BRIT J CANCER, V78, P1547, DOI 10.1038/bjc.1998.722; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Green SL, 2001, MOL CELL BIOL, V21, P1196, DOI 10.1128/MCB.21.4.1196-1206.2001; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Hui AM, 1999, INT J CANCER, V84, P604, DOI 10.1002/(SICI)1097-0215(19991222)84:6<604::AID-IJC11>3.0.CO;2-Y; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Krtolica A, 1996, CANCER RES, V56, P1168; LUDLOW JW, 1993, ONCOGENE, V8, P331; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marlowe JL, 2004, J BIOL CHEM, V279, P29013, DOI 10.1074/jbc.M404315200; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Rodi DJ, 1999, CURR OPIN BIOTECH, V10, P87, DOI 10.1016/S0958-1669(99)80016-0; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sche PP, 1999, CHEM BIOL, V6, P707, DOI 10.1016/S1074-5521(00)80018-6; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Wang F, 2004, J BIOL CHEM, V279, P46733, DOI 10.1074/jbc.M409002200; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	38	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1802	1808		10.1038/sj.onc.1208369	http://dx.doi.org/10.1038/sj.onc.1208369			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674338				2022-12-25	WOS:000227345100016
J	Hanson, S; Kim, E; Deppert, W				Hanson, S; Kim, E; Deppert, W			Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization	ONCOGENE			English	Article						redox factor 1; p53 DNA binding; p53 oligomerization	TUMOR-SUPPRESSOR P53; BASE EXCISION-REPAIR; WILD-TYPE P53; OLIGOMERIZATION DOMAIN; ACTIVATION; PROTEIN; CONFORMATION; TRANSACTIVATION; IDENTIFICATION; DIMERIZATION	Sequence-specific DNA binding is a major activity of the tumor suppressor p53 and a prerequisite for the transactivating potential of the protein. p53 interaction with target DNA is tightly regulated by various mechanisms, including binding of different components of the transcription machinery, post-translational modifications, and interactions with other factors that modulate p53 transactivation in a cell context-and promoter-specific manner. The bifunctional redox factor 1 (Ref-1/APE1) has been identified as one of the factors, which can stimulate p53 DNA binding by redox-dependent as well as redox-independent mechanisms. Whereas stimulation of p53 DNA binding by the redox activities of Ref-1 is understood quite well, little is known about mechanisms that underlie the redox-independent effects of Ref-1. We report in this study a previously unknown activity of Ref-1 as a factor promoting tetramerization of p53. We demonstrate that Ref-1 promotes association of dimers into tetramers, and de-stacking of higher oligomeric forms into the tetrameric form in vitro, thereby enhancing p53 binding to target DNA.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BERTHOLD H, 1992, PROTEIN EXPRES PURIF, V3, P50, DOI 10.1016/1046-5928(92)90055-2; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fritz G, 2003, TOXICOLOGY, V193, P67, DOI 10.1016/S0300-483X(03)00290-7; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; HAINAUT P, 1993, CANCER RES, V53, P4469; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Janus F, 1999, MOL CELL BIOL, V19, P2155; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; McCoy M, 1997, EMBO J, V16, P6230, DOI 10.1093/emboj/16.20.6230; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; Nourani A, 2003, J BIOL CHEM, V278, P19171, DOI 10.1074/jbc.C300036200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Tan ZQ, 2002, BRAIN RES, V929, P129, DOI 10.1016/S0006-8993(01)03360-1; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG Y, 1995, MOL CELL BIOL, V15, P2157; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Wolcke J, 2003, J BIOL CHEM, V278, P32587, DOI 10.1074/jbc.M303615200; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yakovleva T, 2002, TRENDS BIOCHEM SCI, V27, P612, DOI 10.1016/S0968-0004(02)02209-0; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	38	57	64	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1641	1647		10.1038/sj.onc.1208351	http://dx.doi.org/10.1038/sj.onc.1208351			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674341				2022-12-25	WOS:000227218200018
J	Vincent, AM; McLean, LL; Backus, C; Feldman, EL				Vincent, AM; McLean, LL; Backus, C; Feldman, EL			Short-term and hyperglycemia produces oxidative damage and apoptosis in neurons	FASEB JOURNAL			English	Article						reactive oxygen species; dorsal root ganglion; diabetic neuropathy	ALPHA-LIPOIC ACID; ANTIOXIDANT ENZYME-ACTIVITIES; DORSAL-ROOT GANGLION; LIPID-PEROXIDATION; ACTIVATED CASPASE-3; GENE-EXPRESSION; CELL-CULTURE; STRESS; SUPEROXIDE; NEUROPATHY	Dorsal root ganglia neurons in culture die through programmed cell death when exposed to elevated glucose, providing an in vitro model system for the investigation of the mechanisms leading to diabetic neuropathy. This study examines the time course of programmed cell death induction, regulation of cellular antioxidant capacity, and the protective effects of antioxidants in neurons exposed to hyperglycemia. We demonstrate that the first 2 h of hyperglycemia are sufficient to induce oxidative stress and programmed cell death. Using fluorimetric analysis of reactive oxygen species (ROS) production, in vitro assays of antioxidant enzymes, and immunocytochemical assays of cell death, we demonstrate superoxide formation, inhibition of aconitase, and lipid peroxidation within 1 h of hyperglycemia. These are followed by caspase-3 activation and DNA fragmentation. Antioxidant potential increases by 3-6 h but is insufficient to protect these neurons. Application of the antioxidant a-lipoic acid potently prevents glucose-induced oxidative stress and cell death. This study identifies cellular therapeutic targets to prevent diabetic neuropathy. Since oxidative stress is a common feature of the micro- and macrovascular complications of diabetes, the present findings have broad application to the treatment of diabetic patients.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Vincent, AM (corresponding author), Univ Michigan, Dept Neurol, 4414 Kresge III,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	andreav@umich.edu		Feldman, Eva/0000-0002-9162-2694	NINDS NIH HHS [R01 NS38849)] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038849] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alho H, 1998, RESTOR NEUROL NEUROS, V12, P159; Ametov AS, 2003, DIABETES CARE, V26, P770, DOI 10.2337/diacare.26.3.770; Apfel SC, 1999, DIABETES OBES METAB, V1, P3, DOI 10.1046/j.1463-1326.1999.00006.x; Bassi AM, 2002, TOXICOL IN VITRO, V16, P339, DOI 10.1016/S0887-2333(02)00016-4; Bhor VM, 2004, INT J BIOCHEM CELL B, V36, P89, DOI 10.1016/S1357-2725(03)00142-0; Bitar MS, 2004, HORM METAB RES, V36, P542, DOI 10.1055/s-2004-825760; BOQUIST L, 1985, FEBS LETT, V183, P173, DOI 10.1016/0014-5793(85)80979-0; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cheng C, 2003, DIABETES, V52, P2363, DOI 10.2337/diabetes.52.9.2363; Cotter MA, 2003, LIFE SCI, V73, P1813, DOI 10.1016/S0024-3205(03)00508-3; Dincer Y, 2002, CLIN EXP PHARMACOL P, V29, P281, DOI 10.1046/j.1440-1681.2002.03642.x; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Feldman EL, 2003, J CLIN INVEST, V111, P431, DOI 10.1172/JCI200317863; Feldman EL, 2002, Ellenberg and Rifkin's diabetes mellitus, P771; Grillo CA, 2003, NEUROSCIENCE, V121, P133, DOI 10.1016/S0306-4522(03)00343-9; Guegan C, 1999, NEUROBIOL DIS, V6, P180, DOI 10.1006/nbdi.1999.0240; Haak E, 2000, EXP CLIN ENDOCR DIAB, V108, P168, DOI 10.1055/s-2000-7739; Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7; Jones SC, 1999, DIABETOLOGIA, V42, P1113, DOI 10.1007/s001250051279; Kishi M, 2002, DIABETES, V51, P819, DOI 10.2337/diabetes.51.3.819; KISHI M, 2001, J PERIPHER NERV SYST, V6, P152; Kowluru RA, 2002, FREE RADICAL RES, V36, P993, DOI 10.1080/1071576021000006572; Kucukatay V, 2003, ARCH ENVIRON HEALTH, V58, P14, DOI 10.3200/AEOH.58.1.14-22; Li JM, 2003, J AM SOC NEPHROL, V14, pS221, DOI 10.1097/01.ASN.0000077406.67663.E7; Limaye PV, 2003, MOL CELL BIOCHEM, V243, P147, DOI 10.1023/A:1021620414979; Maritim AC, 2003, J NUTR BIOCHEM, V14, P288, DOI 10.1016/S0955-2863(03)00036-6; Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nickander KK, 1996, FREE RADICAL BIO MED, V21, P631, DOI 10.1016/0891-5849(96)00172-4; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Obrosova IG, 1999, INVEST OPHTH VIS SCI, V40, P680; Obrosova IG, 2003, DIABETES, V52, P864, DOI 10.2337/diabetes.52.3.864; Obrosova IG, 2000, FASEB J, V14, P1548, DOI 10.1096/fj.14.11.1548; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Polydefkis M, 2003, JAMA-J AM MED ASSOC, V290, P1371, DOI 10.1001/jama.290.10.1371; Pratico D, 2001, LIPIDS, V36, pS45, DOI 10.1007/s11745-001-0681-0; Quagliaro L, 2003, DIABETES, V52, P2795, DOI 10.2337/diabetes.52.11.2795; Russell JW, 1999, NEUROBIOL DIS, V6, P347, DOI 10.1006/nbdi.1999.0254; Russell JW, 2002, FASEB J, V16, P1738, DOI 10.1096/fj.01-1027com; Saengsirisuwan V, 2004, AM J PHYSIOL-ENDOC M, V287, pE529, DOI 10.1152/ajpendo.00013.2004; Schmeichel AM, 2003, DIABETES, V52, P165, DOI 10.2337/diabetes.52.1.165; Singleton JR, 2003, DIABETES, V52, P2867, DOI 10.2337/diabetes.52.12.2867; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Srinivasan P, 2002, INT J ONCOL, V20, P983; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; Sumner CJ, 2003, NEUROLOGY, V60, P108, DOI 10.1212/WNL.60.1.108; TAKEUCHI A, 1995, AM J PHYSIOL-RENAL, V268, pF13, DOI 10.1152/ajprenal.1995.268.1.F13; Turk HM, 2002, ACTA DIABETOL, V39, P117, DOI 10.1007/s005920200029; Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019; Vincent AM, 2004, DIABETES, V53, P726, DOI 10.2337/diabetes.53.3.726; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; Yildirim O, 2002, BIOL TRACE ELEM RES, V90, P143, DOI 10.1385/BTER:90:1-3:143; Zochodne DW, 1999, BRAIN PATHOL, V9, P369; Zochodne DW, 2001, BRAIN, V124, P2319, DOI 10.1093/brain/124.11.2319	54	212	236	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					638	+		10.1096/fj.04-2513fje	http://dx.doi.org/10.1096/fj.04-2513fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15677696	Green Published			2022-12-25	WOS:000226576600045
J	Uchiyama, S; Kobayashi, S; Takata, H; Ishihara, T; Hori, N; Higashi, T; Hayashihara, K; Sone, T; Higo, D; Nirasawa, T; Takao, T; Matsunaga, S; Fukui, K				Uchiyama, S; Kobayashi, S; Takata, H; Ishihara, T; Hori, N; Higashi, T; Hayashihara, K; Sone, T; Higo, D; Nirasawa, T; Takao, T; Matsunaga, S; Fukui, K			Proteome analysis of human metaphase chromosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-II-ALPHA; MITOTIC CHROMOSOMES; NUCLEAR-LOCALIZATION; RIBOSOMAL-PROTEINS; ESCHERICHIA-COLI; ACTIN ANTIBODIES; HUMAN CONDENSIN; CENP-A; CHROMATIN; MITOSIS	DNA is packaged as chromatin in the interphase nucleus. During mitosis, chromatin fibers are highly condensed to form metaphase chromosomes, which ensure equal segregation of replicated chromosomal DNA into the daughter cells. Despite > 1 century of research on metaphase chromosomes, information regarding the higher order structure of metaphase chromosomes is limited, and it is still not clear which proteins are involved in further folding of the chromatin fiber into metaphase chromosomes. To obtain a global view of the chromosomal proteins, we performed proteome analyses on three types of isolated human metaphase chromosomes. We first show the results from comparative proteome analyses of two types of isolated human metaphase chromosomes that have been frequently used in biochemical and morphological analyses. 209 proteins were quantitatively identified and classified into six groups on the basis of their known interphase localization. Furthermore, a list of 107 proteins was obtained from the proteome analyses of highly purified metaphase chromosomes, the majority of which are essential for chromosome structure and function. Based on the information obtained on these proteins and on their localizations during mitosis as assessed by immunostaining, we present a four-layer model of metaphase chromosomes. According to this model, the chromosomal proteins have been newly classified into each of four groups: chromosome coating proteins, chromosome peripheral proteins, chromosome structural proteins, and chromosome fibrous proteins. This analysis represents the first compositional view of human metaphase chromosomes and provides a protein framework for future research on this topic.	Osaka Univ, Grad Sch Engn, Dept Biotechnol, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Bruker Dalton KK, Yokohama, Kanagawa 2210022, Japan	Osaka University; Osaka University	Fukui, K (corresponding author), Osaka Univ, Grad Sch Engn, Dept Biotechnol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kfukui@bio.eng.osaka-u.ac.jp	UCHIYAMA, Susumu/F-9590-2017; Sone, Takefumi/L-1348-2013; Sone, Takefumi/AAB-9423-2020; Higashi, Tsunehito/G-1816-2012; Matsunaga, Sachihiro/F-8689-2010; Takata, Hideaki/L-6914-2018	UCHIYAMA, Susumu/0000-0002-5181-179X; Sone, Takefumi/0000-0003-3467-679X; Sone, Takefumi/0000-0003-3467-679X; Matsunaga, Sachihiro/0000-0003-3024-3559; Takata, Hideaki/0000-0001-9436-1517				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; ALBRIGHT SC, 1979, J BIOL CHEM, V254, P1065; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; Ausio J, 2000, BIOPHYS CHEM, V86, P141, DOI 10.1016/S0301-4622(00)00144-7; Chadwick BP, 2002, J CELL BIOL, V157, P1113, DOI 10.1083/jcb.200112074; CHIU ML, 1983, BIOCHIM BIOPHYS ACTA, V740, P342, DOI 10.1016/0167-4781(83)90144-6; CHIU ML, 1982, BIOCHIM BIOPHYS ACTA, V699, P110, DOI 10.1016/0167-4781(82)90144-0; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Christensen MO, 2002, J CELL BIOL, V157, P31, DOI 10.1083/jcb.200112023; Cole A., 1967, THEORETICAL BIOPHYSI, V1, P305; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; Dellaire G, 2003, NUCLEIC ACIDS RES, V31, P328, DOI 10.1093/nar/gkg018; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Earle E, 2000, HUM MOL GENET, V9, P187, DOI 10.1093/hmg/9.2.187; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Flemming W., 1882, ZELLSUBSTANZ KERN ZE; GASSER SM, 1987, EXP CELL RES, V173, P85, DOI 10.1016/0014-4827(87)90334-X; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Gassmann R, 2005, CHROMOSOMA, V113, P385, DOI 10.1007/s00412-004-0326-0; Haraguchi T, 2001, J CELL SCI, V114, P4575; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635; HERNANDEZVERDUN D, 1994, BIOESSAYS, V16, P179, DOI 10.1002/bies.950160308; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Kanoh J, 2003, CELL MOL LIFE SCI, V60, P2295, DOI 10.1007/s00018-003-3245-y; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; KUEHL L, 1984, J CELL BIOL, V99, P648, DOI 10.1083/jcb.99.2.648; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MANDEVILLE EC, 1990, CELL MOTIL CYTOSKEL, V15, P111, DOI 10.1002/cm.970150207; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; Martinez A, 1998, J AUTOIMMUN, V11, P611, DOI 10.1006/jaut.1998.0249; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; Moore SC, 2002, BIOCHEM CELL BIOL, V80, P311, DOI 10.1139/O02-081; Morrison C, 2002, NUCLEIC ACIDS RES, V30, P5318, DOI 10.1093/nar/gkf665; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; Pallier C, 2003, MOL BIOL CELL, V14, P3414, DOI 10.1091/mbc.E02-09-0581; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; Poirier M, 2000, MOL BIOL CELL, V11, P269, DOI 10.1091/mbc.11.1.269; Poirier MG, 2002, P NATL ACAD SCI USA, V99, P15393, DOI 10.1073/pnas.232442599; RUNGGER D, 1979, NATURE, V282, P320, DOI 10.1038/282320a0; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; SCHEER U, 1984, CELL, V39, P111, DOI 10.1016/0092-8674(84)90196-X; Scholey JM, 2003, NATURE, V422, P746, DOI 10.1038/nature01599; Sharp LW, 1929, BOT GAZ, V88, P349, DOI 10.1086/334009; Snee M, 2002, J CELL SCI, V115, P4661, DOI 10.1242/jcs.00137; Sone T, 2002, ARCH HISTOL CYTOL, V65, P445, DOI 10.1679/aohc.65.445; SPECTOR D, 1998, CELLS LAB MANUAL, V49, P11; Suckau D, 2003, ANAL BIOANAL CHEM, V376, P952, DOI 10.1007/s00216-003-2057-0; Sugata N, 2000, HUM MOL GENET, V9, P2919, DOI 10.1093/hmg/9.19.2919; Sumner AT, 1996, CHROMOSOME RES, V4, P5, DOI 10.1007/BF02254938; Sumner AT, 2003, CHROMOSOMES ORG FUNC, P5; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; Takemoto A, 2004, J BIOL CHEM, V279, P4551, DOI 10.1074/jbc.M310925200; Tavormina PA, 2002, J CELL BIOL, V158, P23, DOI 10.1083/jcb.200202053; TSANEV R, 1992, REPLICATION TRANSCRI; TURNER B, 2002, CHROMATIN GENE REGUL, P44; Uchiyama S, 2004, CYTOGENET GENOME RES, V107, P49, DOI 10.1159/000079571; VAMHOLDE KE, 1988, CHROMATIN, P69; WACHTLER F, 1993, MICRON, V24, P473, DOI 10.1016/0968-4328(93)90026-W; WADA A, 1986, J BIOCHEM, V100, P1583, DOI 10.1093/oxfordjournals.jbchem.a121866; YASUDA Y, 1990, CHROMOSOMA, V99, P152, DOI 10.1007/BF01735332; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	72	89	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16994	17004		10.1074/jbc.M412774200	http://dx.doi.org/10.1074/jbc.M412774200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15687487	Green Published, hybrid			2022-12-25	WOS:000228615500056
J	Samad, TA; Rebbapragada, A; Bell, E; Zhang, Y; Sidis, Y; Jeong, SJ; Campagna, JA; Perusini, S; Fabrizio, DA; Schneyer, AL; Lin, HY; Brivanlou, AH; Attisano, L; Woolf, CJ				Samad, TA; Rebbapragada, A; Bell, E; Zhang, Y; Sidis, Y; Jeong, SJ; Campagna, JA; Perusini, S; Fabrizio, DA; Schneyer, AL; Lin, HY; Brivanlou, AH; Attisano, L; Woolf, CJ			DRAGON, a bone morphogenetic protein co-receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPULSIVE GUIDANCE MOLECULE; GROWTH-FACTOR-BETA; NEURAL INDUCTION; RECEPTOR; SIGNALS; MEMBRANE; PATHWAY; REQUIREMENT; VERTEBRATES; MECHANISMS	Bone morphogenetic proteins (BMPs) are members of the transforming growth factor (TGF)beta superfamily of ligands that regulate many crucial aspects of embryonic development and organogenesis. Unlike other TGF beta ligands, co-receptors for BMP ligands have not been described. Here we show that DRAGON, a glycosylphosphatidylinositol-anchored member of the repulsive guidance molecule family, which is expressed early in the developing nervous system, enhances BMP but not TGF beta signaling. DRAGON binds directly to BMP2 and BMP4 but not to BMP7 or other TGF beta ligands. The enhancing action of DRAGON on BMP signaling is also reduced by administration of Noggin, a soluble BMP antagonist, indicating that the action of DRAGON is ligand-dependent. DRAGON associates directly with BMP type I (ALK2, ALK3, and ALK6) and type II (ActRII and ActRIIB) receptors, and its signaling is reduced by dominant negative Smad1 and ALK3 or -6 receptors. In the Xenopus embryo, DRAGON both reduces the threshold of the ability of Smad1 to induce mesodermal and endodermal markers and alters neuronal and neural crest patterning. The direct interaction of DRAGON with BMP ligands and receptors indicates that it is a BMP co-receptor that potentiates BMP signaling.	Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Rockefeller Univ, Lab Vertebrate Embryol, New York, NY 10021 USA; Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02129 USA; Massachusetts Gen Hosp, Renal Unit, Boston, MA 02129 USA; Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Toronto; Rockefeller University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Samad, TA (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Boston, MA 02129 USA.	samad@helix.mgh.harvard.edu	Bell, Esther/C-5329-2009; Woolf, Clifford/A-9784-2010					Altmann CR, 2001, INT REV CYTOL, V203, P447; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Benchabane H, 2003, MOL CELL BIOL, V23, P6646, DOI 10.1128/MCB.23.18.6646-6661.2003; Brinks H, 2004, J NEUROSCI, V24, P3862, DOI 10.1523/JNEUROSCI.5296-03.2004; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Caspary T, 2003, NAT REV NEUROSCI, V4, P289, DOI 10.1038/nrn1073; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Clarke TR, 2001, MOL ENDOCRINOL, V15, P946, DOI 10.1210/me.15.6.946; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097-4547(19980115)51:2<139::AID-JNR2>3.0.CO;2-E; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Kimelman D, 2000, CURR OPIN GENET DEV, V10, P350, DOI 10.1016/S0959-437X(00)00095-2; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Lee KJ, 1999, ANNU REV NEUROSCI, V22, P261, DOI 10.1146/annurev.neuro.22.1.261; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Lu CC, 2001, CURR OPIN GENET DEV, V11, P384, DOI 10.1016/S0959-437X(00)00208-2; Marchuk D A, 1998, Curr Opin Hematol, V5, P332, DOI 10.1097/00062752-199809000-00005; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Munoz-Sanjuan I, 2002, DEVELOPMENT, V129, P5529, DOI 10.1242/dev.00097; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Samad TA, 2004, J NEUROSCI, V24, P2027, DOI 10.1523/JNEUROSCI.4115-03.2004; Sharom FJ, 2002, BIOCHEM CELL BIOL, V80, P535, DOI 10.1139/O02-146; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Stemple DL, 2000, CURR BIOL, V10, pR843, DOI 10.1016/S0960-9822(00)00789-2; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Ying Y, 2001, DEV BIOL, V232, P484, DOI 10.1006/dbio.2001.0173; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	42	177	202	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14122	14129		10.1074/jbc.M410034200	http://dx.doi.org/10.1074/jbc.M410034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15671031	hybrid			2022-12-25	WOS:000228095500115
J	Luo, X; Shin, DM; Wang, XH; Konieczny, SF; Muallem, S				Luo, X; Shin, DM; Wang, XH; Konieczny, SF; Muallem, S			Aberrant localization of intracellular organelles, Ca2+ signaling, and exocytosis in Mist1 null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; TRANSCRIPTION FACTOR MIST1; SEROUS EXOCRINE CELLS; INOSITOL TRISPHOSPHATE; POLARIZED EXPRESSION; CALCIUM; MITOCHONDRIA; OSCILLATIONS; RECEPTORS; COMPLEXES	Ca2+ signaling and exocytosis are highly polarized functions of pancreatic acinar cells. The role of cellular architecture in these activities and the capacity of animals to tolerate aberrant acinar cell function are not known. A key regulator of acinar cell polarity is Mist1, a basic helix-loop-helix transcription factor. Ca2+ signaling and amylase release were examined in pancreatic acini of wild type and Mist1 null mice to gain insight into the importance of cellular architecture for Ca2+ signaling and regulated exocytosis. Mist1(-/-) acinar cells exhibited dramatically altered Ca2+ signaling with upregulation of the cholecystokinin receptor but minimal effect upon expression of the M3 receptor. However, stimulation of inositol 1,4,5- trisphosphate production by cholecystokinin and carbachol was inefficient in Mist1(-/-) cells. Although agonist stimulation of Mist1 (-/-) cells evoked a Ca2+ signal, often the Ca2+ increase was not in the form of typical Ca2+ oscillations but rather in the form of a peak/plateau-type response. Mist1(-/-) cells also displayed distorted apical-to-basal Ca2+ waves. The aberrant Ca2+ signaling was associated with mislocalization and reduced Ca2+ uptake by the mitochondria of stimulated Mist1(-/-) cells. Deletion of Mist1 also led to mislocalization of the Golgi apparatus and markedly reduced digestive enzyme content. The combination of aberrant Ca2+ signaling and reduced digestive enzyme content resulted in poor secretion of digestive enzymes. Yet, food consumption and growth of Mist1(-/-) mice were normal for at least 32 weeks. These findings reveal that Mist1 is critical to normal organelle localization in exocrine cells and highlight the critical importance of maintaining cellular architecture and polarized localization of cellular organelles in generating a propagating apical-to-basal Ca2+ wave. The studies also reveal the spare capacity of the exocrine pancreas that allows normal growth and development in the face of compromised exocrine pancreatic function.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Yonsei Univ, Coll Dent, Brain Korea Project Med Sci 21, Res Ctr Orofacial Hard Tissue Regenerat,Dept Oral, Seoul 120752, South Korea; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47901 USA; Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47901 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yonsei University; Yonsei University Health System; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	SHMUEL.MUALLEM@utsouthwestern.edu		Shin, Dong Min/0000-0001-6042-0435	NIDCR NIH HHS [DE13902] Funding Source: Medline; NIDDK NIH HHS [R01 DK055489, DK55489, DK38938] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK055489] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bruce JIE, 2004, J BIOL CHEM, V279, P12909, DOI 10.1074/jbc.M309070200; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; GILDBERG A, 1990, COMP BIOCHEM PHYS B, V97, P775, DOI 10.1016/0305-0491(90)90122-A; Gupta N, 2002, ANAL BIOCHEM, V311, P98, DOI 10.1016/S0003-2697(02)00379-2; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hankard R, 2002, HORM RES, V58, P16, DOI 10.1159/000064763; Hattori M, 2004, J BIOL CHEM, V279, P11967, DOI 10.1074/jbc.M311456200; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Johnson CL, 2004, MECH DEVELOP, V121, P261, DOI 10.1016/j.mod.2004.01.003; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Kim JY, 2002, GASTROENTEROLOGY, V122, P1941, DOI 10.1053/gast.2002.33617; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Li Q, 2004, J BIOL CHEM, V279, P27837, DOI 10.1074/jbc.C400184200; Luo X, 2001, MOL CELL, V7, P651, DOI 10.1016/S1097-2765(01)00211-8; Mooren FC, 2003, J BIOL CHEM, V278, P9361, DOI 10.1074/jbc.M207454200; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Pin CL, 2000, ANAT REC, V259, P157, DOI 10.1002/(SICI)1097-0185(20000601)259:2<157::AID-AR6>3.0.CO;2-0; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; Pozzan T, 2000, CELL CALCIUM, V28, P279, DOI 10.1054/ceca.2000.0166; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 2004, SCI STKE; Rukstalis JM, 2003, J CELL SCI, V116, P3315, DOI 10.1242/jcs.00631; Saluja AK, 1999, AM J PHYSIOL-GASTR L, V276, pG835, DOI 10.1152/ajpgi.1999.276.4.G835; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Shin DM, 2001, J BIOL CHEM, V276, P44146, DOI 10.1074/jbc.M105203200; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Voronina S, 2002, J PHYSIOL-LONDON, V540, P49, DOI 10.1113/jphysiol.2002.017525; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Yule DI, 1997, J BIOL CHEM, V272, P9093; Zhao XS, 2001, EMBO J, V20, P2680, DOI 10.1093/emboj/20.11.2680; Zhu LQ, 2004, MOL CELL BIOL, V24, P2673, DOI 10.1128/MCB.24.7.2673-2681.2004	40	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12668	12675		10.1074/jbc.M411973200	http://dx.doi.org/10.1074/jbc.M411973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15665001	hybrid			2022-12-25	WOS:000227922000073
J	Novotny-Diermayr, V; Lin, BH; Gu, L; Cao, XM				Novotny-Diermayr, V; Lin, BH; Gu, L; Cao, XM			Modulation of the interleukin-6 receptor subunit glycoprotein 130 complex and its signaling by LMO4 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE JAK1; LIM DOMAIN; PROTEIN LMO4; GENE; EXPRESSION; IDENTIFICATION; GP130; TRANSDUCTION; FAMILY; STAT3	The interleukin (IL)-6-type cytokines play major roles in a variety of biological processes by signaling through a common receptor subunit, glycoprotein (gp) 130. We performed yeast two-hybrid screening to identify new binding partners of the activated gp130 and the associated Janus kinases. LMO4, a LIM domain-containing protein that belongs to a family of oncogenes, was identified in this assay. Further studies show that LMO4 associates with gp130 and Janus kinase1 in several mammalian cell types. It also interacts with protein-tyrosine phosphatase 2 (SHP2) and suppressor of cytokine signaling 3 (SOCS3). The binding domains involved in these interactions were mapped, and the interactions were shown to be in a direct manner by in vitro binding assays. It is likely that LMO4 exists in the gp130 complex. The cellular localization of LMO4 was detected primarily in the nucleus with a substantial amount also detected in the cytoplasm in several cell types. The effect of LMO4 in IL-6 signaling was subsequently examined. Overexpression of LMO4 enhanced the transcriptional activity and target gene expression of Stat 3 (signal transducers and activators of transcription 3). Consistent with this, silencing LMO4 expression in stable cell lines expressing the small interfering RNA of LMO4 decreased Stat 3 activity. Furthermore, the half-life of gp130 was shortened, and the production of acute phase proteins induced by IL-6 was reduced. Together, our data reveal a positive regulatory role of LMO4 in IL-6 signaling, possibly by acting as a scaffold for stabilization of the gp130 complex. These studies may open up a link between the oncogenic effect of LMO proteins and their regulatory role in cytokine signaling in general.	Agcy Sci Technol & Res Singapore, Inst Mol & Cell Biol, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Cao, XM (corresponding author), Agcy Sci Technol & Res Singapore, Inst Mol & Cell Biol, Proteos Bldg,61 Biopolis Dr, Singapore 138673, Singapore.	mcbcaoxm@imcb.a-star.edu.sg						Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Fischer P, 2004, BIOCHEM J, V378, P449, DOI 10.1042/BJ20030893; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; Hirano T, 1998, Int Rev Immunol, V16, P249; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kudryavtseva EI, 2003, DEV DYNAM, V226, P604, DOI 10.1002/dvdy.10255; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Manetopoulos C, 2003, BIOCHEM BIOPH RES CO, V307, P891, DOI 10.1016/S0006-291X(03)01298-1; Nakashima K, 1999, J NEUROSCI, V19, P5429; NEALE GAM, 1995, CELL GROWTH DIFFER, V6, P587; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Novotny-Diermayr V, 2002, J BIOL CHEM, V277, P49134, DOI 10.1074/jbc.M206727200; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Saharinen P, 2003, MOL BIOL CELL, V14, P1448, DOI 10.1091/mbc.E02-06-0342; SANCHEZGARCIA I, 1995, ONCOGENE, V10, P1301; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Tse E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wittlin S, 2003, GENOMICS, V82, P280, DOI 10.1016/S0888-7543(03)00147-2; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	42	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12747	12757		10.1074/jbc.M500175200	http://dx.doi.org/10.1074/jbc.M500175200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677447	hybrid			2022-12-25	WOS:000227922000082
J	Zhu, GZ; Fujii, K; Belkina, N; Liu, Y; James, M; Herrero, J; Shaw, S				Zhu, GZ; Fujii, K; Belkina, N; Liu, Y; James, M; Herrero, J; Shaw, S			Exceptional disfavor for proline at the P+1 position among AGC and CAMK kinases establishes reciprocal specificity between them and the proline-directed kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRUCTURAL BASIS; SUBSTRATE RECOGNITION; PHOSPHORYLASE-KINASE; PEPTIDE SPECIFICITY; CRYSTAL-STRUCTURE; DETERMINANTS; ACTIVATION; COMPLEX; MOTIFS	To precisely regulate critical signaling pathways, two kinases that phosphorylate distinct sites on the same protein substrate must have mutually exclusive specificity. Evolution could assure this by designing families of kinase such as basophilic kinases and proline-directed kinase with distinct peptide specificity; their reciprocal peptide specificity would have to be very complete, since recruitment of substrate allows phosphorylation of even rather poor phosphorylation sites in a protein. Here we report a powerful evolutionary strategy that assures distinct substrates for basophilic kinases (PKA, PKG and PKC (AGC) and calmodulin-dependent protein kinase (CAMK)) and proline-directed kinase, namely by the presence or absence of proline at the P+1 position in substrates. Analysis of degenerate and non-degenerate peptides by in vitro kinase assays reveals that proline at the P+1 position in substrates functions as a "veto" residue in substrate recognition by AGC and CAMK kinases. Furthermore, analysis of reported substrates of two typical basophilic kinases, protein kinase C and protein kinase A, shows the lowest occurrence of proline at the P+1 position. Analysis of crystal structures and sequence conservation provides a molecular basis for this disfavor and illustrate its generality.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; AxCell Biosci, Newtown, PA 18940 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shaw, S (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.	sshaw@nih.gov			NATIONAL CANCER INSTITUTE [Z01BC009257, ZIABC009257] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bertrand JA, 2003, J MOL BIOL, V333, P393, DOI 10.1016/j.jmb.2003.08.031; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; Engh RA, 2001, ADV ENZYME REGUL, V41, P121, DOI 10.1016/S0065-2571(00)00010-8; Fujii K, 2004, P NATL ACAD SCI USA, V101, P13744, DOI 10.1073/pnas.0401881101; HALL FL, 1991, J BIOL CHEM, V266, P17430; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Huang JZ, 2001, PLANT CELL PHYSIOL, V42, P1079, DOI 10.1093/pcp/pce137; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaldis P, 2000, J BIOL CHEM, V275, P32578, DOI 10.1074/jbc.M003212200; Kannan N, 2004, PROTEIN SCI, V13, P2059, DOI 10.1110/ps.04637904; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kreegipuu A, 1998, FEBS LETT, V430, P45, DOI 10.1016/S0014-5793(98)00503-1; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Madhavan R, 1999, BBA-PROTEIN STRUCT M, V1434, P260, DOI 10.1016/S0167-4838(99)00193-4; Mann M, 2002, TRENDS BIOTECHNOL, V20, P261, DOI 10.1016/S0167-7799(02)01944-3; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhu GZ, 2005, CELL CYCLE, V4, P52, DOI 10.4161/cc.4.1.1353; Zolnierowicz Stanislaw, 2000, EMBO (European Molecular Biology Organization) Journal, V19, P483, DOI 10.1093/emboj/19.4.483	35	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10743	10748		10.1074/jbc.M413159200	http://dx.doi.org/10.1074/jbc.M413159200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647260	hybrid			2022-12-25	WOS:000227559600120
J	Ma, YX; Tomita, Y; Fan, SJ; Wu, KM; Tong, YZ; Zhao, ZG; Song, LN; Goldberg, ID; Rosen, EM				Ma, YX; Tomita, Y; Fan, SJ; Wu, KM; Tong, YZ; Zhao, ZG; Song, LN; Goldberg, ID; Rosen, EM			Structural determinants of the BRCA1: estrogen receptor interaction	ONCOGENE			English	Article						breast cancer susceptibility gene-1 ( BRCA1); estrogen receptor ( ER); ER-alpha; interaction; nuclear export sequence; nuclear receptor corepressor motif	BREAST-CANCER; INHIBITION; CELLS; PROTEINS; MUTATION; CARRIERS; GENE; IDENTIFICATION; RECOGNITION; BRCA1-BARD1	Previously, we showed that the BRCA1 protein interacts directly and functionally with estrogen receptor-alpha (ER-alpha), resulting in the inhibition of estradiol (E2)-stimulated ER-alpha transcriptional activity. The interaction sites were mapped to the N-terminus of BRCA1 ( within amino acids (aa) 1-302) and the ligand-binding domain/ activation function-2 (LBD/AF-2) region ( within aa 282-420) of ER-alpha. In this study, we have further characterized the structure/function relationship for the BRCA1 : ER-alpha interaction. We found that the N-terminal RING domain (aa 20-64) is not required for the BRCA1 : ER-alpha interaction. We identified two separate contact points for ER-alpha, one within aa 1-100 and the other within aa 100-200 of BRCA1; and we showed that each of these BRCA1 peptides interacts with BRCA1 in vitro and in vivo. By using different fragments of the BRCA1 N-terminus, we found that aa 67-100 and 101-133 are required for the interaction with ER-alpha, but that aa 1-67 and 134-302 are dispensible. Previously, we showed that BRCA1 aa 1-302 does not inhibit E2-stimulated ER-alpha transcriptional activity but does bind to ER-alpha and acts as a dominant negative inhibitor of the full-length BRCA1 protein. Somewhat surprisingly, we found that BRCA1 aa 1-100 and BRCA1 aa 101-200 (but not aa 201-300) each inhibited ER-alpha activity, although not as effciently as full-length BRCA1. Mutations within an HIV Rev-like nuclear export signal that resembles a nuclear receptor corepressor motif (aa 86-95) impaired the ability of both truncated (aa 1-100) and full-length (aa 1-1863) BRCA1 proteins to interact with and/or repress ER-alpha activity. Based on these findings, a partial BRCA1 : ER-alpha three-dimensional structure is proposed. The implications of these findings for understanding the BRCA1 : ER-alpha interaction are discussed.	Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20057 USA; Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, New York, NY 11040 USA	Georgetown University; Northwell Health; Yeshiva University	Rosen, EM (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, 3970 Reservoir Rd NW,Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu		Zhao, Zeguo/0000-0002-2901-5033	NCI NIH HHS [R01-CA80000, R01-CA82599] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082599, R01CA080000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morris JR, 2002, J BIOL CHEM, V277, P9382, DOI 10.1074/jbc.M109249200; Narod SA, 2001, ANN NY ACAD SCI, V952, P36, DOI 10.1111/j.1749-6632.2001.tb02726.x; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rodriguez JA, 2004, ONCOGENE, V23, P1809, DOI 10.1038/sj.onc.1207302; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vakser IA, 1999, P NATL ACAD SCI USA, V96, P8477, DOI 10.1073/pnas.96.15.8477; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	31	42	45	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 10	2005	24	11					1831	1846		10.1038/sj.onc.1208190	http://dx.doi.org/10.1038/sj.onc.1208190			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674350				2022-12-25	WOS:000227542000003
J	Iliopoulos, D; Guler, G; Han, SY; Johnston, D; Druck, T; McCorkell, KA; Palazzo, J; McCue, P; Baffa, R; Huebner, K				Iliopoulos, D; Guler, G; Han, SY; Johnston, D; Druck, T; McCorkell, KA; Palazzo, J; McCue, P; Baffa, R; Huebner, K			Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer	ONCOGENE			English	Article						CpG island methylation; WWOX; FHIT; methylation patterns; molecular markers	TUMOR-SUPPRESSOR GENE; ABERRANT PROMOTER METHYLATION; DNA METHYLATION; EXPRESSION; HYPERMETHYLATION; INACTIVATION; CARCINOMA; PROTEIN; SERUM; FRA16D	This study aimed to (a) determine if DNA methylation is a mechanism of WWOX (WW domain containing oxidoreductase) and FHIT ( fragile histidine triad) inactivation in lung, breast and bladder cancers; (b) examine distinct methylation patterns in neoplastic and adjacent tissues and (c) seek correlation of methylation patterns with disease status. Protein expression was detected by immunohistochemistry, and methylation status by methylation-specific PCR (MSP) and sequencing, in lung squamous cell carcinomas and adjacent tissues, invasive breast carcinomas, adjacent tissues and normal mammary tissues and bladder transitional cell carcinomas. Wwox and Fhit expression was reduced in cancers in association with hypermethylation. Differential patterns of WWOX and FHIT methylation were observed in neoplastic vs adjacent non-neoplastic tissues, suggesting that targeted MSP amplification could be useful in following treatment or prevention protocols. WWOX promoter MSP differentiates DNA of lung cancer from DNA of adjacent lung tissue. WWOX and FHIT promoter methylation is detected in tissue adjacent to breast cancer and WWOX exon 1 MSP distinguishes breast cancer DNA from DNA of adjacent and normal tissue. Differential methylation in cancerous vs adjacent tissues suggests that WWOX and FHIT hypermethylation analyses could enrich a panel of DNA methylation markers.	Dept Microbiol Immunol, Philadelphia, PA 19107 USA; Dept Pathol, Philadelphia, PA 19107 USA; Kimmel Canc Ctr, Dept Urol, Philadelphia, PA 19107 USA	Jefferson University	Huebner, K (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Wiseman Hall,Rm 455C,410 W 12th Ave, Columbus, OH 43210 USA.	K_Huebner@mail.jci.tju.edu	Iliopoulos, Dimitrios/AAE-9106-2019; GULER, GULNUR/I-9887-2013		NCI NIH HHS [CA77738, N01-CN-15128, N01-CN-15113, CA56036] Funding Source: Medline; NHLBI NIH HHS [T32-HLO7780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077738, P30CA056036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 1999, CANCER RES, V59, P793; Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.3.CO;2-9; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; Hennessy BT, 2003, EXPERT OPIN INV DRUG, V12, P1985, DOI 10.1517/eoid.12.12.1985.21990; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ingvarsson S, 1999, CANCER RES, V59, P2682; Ishii H, 2004, INT J HEMATOL, V79, P238, DOI 10.1532/IJH97.03145; Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077; Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096; Kuroki T, 2002, CANCER RES, V62, P2258; Maruyama R, 2001, CANCER RES, V61, P8659; McGregor F, 2002, CANCER RES, V62, P4757; Muller HM, 2003, CANCER RES, V63, P7641; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Palmisano WA, 2000, CANCER RES, V60, P5954; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Skopelitou AS, 2001, IN VIVO, V15, P169; SORIA JC, 2000, CANCER RES, V62, P351; Sozzi G, 1998, CANCER RES, V58, P5032; Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100; Tanaka H, 1998, CANCER RES, V58, P3429; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Yang QF, 2002, CLIN CANCER RES, V8, P2890; Yendamuri S, 2003, CANCER RES, V63, P878; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	33	160	192	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1625	1633		10.1038/sj.onc.1208398	http://dx.doi.org/10.1038/sj.onc.1208398			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674328				2022-12-25	WOS:000227218200016
J	Mutch, DM; Grigorov, M; Berger, A; Fay, LB; Roberts, MA; Watkins, SM; Williamson, G; German, JB				Mutch, DM; Grigorov, M; Berger, A; Fay, LB; Roberts, MA; Watkins, SM; Williamson, G; German, JB			An integrative metabolism approach identifies stearoyl-CoA desaturase as a target for an arachidonate-enriched diet	FASEB JOURNAL			English	Article						arachidonic acid; global error assessment (GEA) model; lipid metabolism; liver; metabolomics; microarray; mouse; nutrigenomics; singular value decomposition	POLYUNSATURATED FATTY-ACIDS; SINGULAR-VALUE DECOMPOSITION; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; GENE; N-3; EXPRESSION; PATHWAY; LIVER; MICE	Epidemiological studies have correlated diets containing higher intakes of PUFA with lower rates of chronic metabolic diseases. The molecular mechanisms regulated by the consumption of PUFA were examined by using an integrative metabolism approach assaying the liver transcriptome and lipid-metabolome of mice fed a control diet, an arachidonate (AA)-enriched fungal oil, an eicosapentaenoic ( EPA)/docosahexaenoic (DHA)-enriched fish oil, or a combination of the two oils. Hepatic gene transcription and fatty acid ( FA) metabolism were significantly altered by diets enriched with AA, as revealed by global error assessment and singular value decomposition (SVD) analysis, respectively. SVD analysis of the lipid data, reinforced with transcriptomics, suggests that the chronic feeding of AA modulates molecular endpoints similar to those previously reported in the obesity-resistant SCD1-/- mouse, namely, genes involved in lipid oxidation/synthesis and the significant changes in FA metabolism stemming from a repressed SCD1 activity. Specifically, the total levels and FA composition of several phospholipid (PL) species were significantly changed, with phosphatidylcholine ( PC) demonstrating the greatest alterations. Reduced PC levels were linked to decreased expression of enzymes in PC biosynthesis ( choline kinase, - 2.2-fold; glycerol-3-phosphate acyltransferase, 2.0- fold). Alterations in PL-FA composition were related to decreased expression of FA biosynthetic genes [ fatty acid synthetase, - 3.7-fold; stearoyl-CoA desaturase-1 (SCD1), - 1.8-fold]. Lower hepatic SCD1 gene expression levels were reflected in various aspects of FA metabolism through increased concentrations of palmitic ( fungal oil, + 45%; combination, + 106%) and stearic acids ( fungal oil, + 60%; combination, + 63%) in PC. Importantly, an integrated approach showed that these effects were not attenuated by the addition of an EPA/DHA-enriched fish oil, thereby identifying a previously unrecognized and distinct role for AA in the regulation of hepatic lipid metabolism.	Nestle Res Ctr, CH-1000 Lausanne, Switzerland; Univ Lausanne, Ctr integrat Genom, Lausanne, Switzerland; Lipom Technol Inc, Sacramento, CA USA; Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA	Nestle SA; University of Lausanne; University of California System; University of California Davis	Roberts, MA (corresponding author), Nestle Purina Pet Care Mail Zone 11T,1 Checkerboa, St Louis, MO 63164 USA.	mrsci68@yahoo.com	Williamson, Gary/AAE-9665-2019	Williamson, Gary/0000-0002-5624-6267; Mutch, David/0000-0002-0908-7259				Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Alter O, 2003, P NATL ACAD SCI USA, V100, P3351, DOI 10.1073/pnas.0530258100; Anderle P, 2004, NUTRITION, V20, P103, DOI 10.1016/j.nut.2003.09.018; Bellenger J, 2004, FASEB J, V18, P773, DOI 10.1096/fj.03-0950fje; Berger Alvin, 2002, Lipids Health Dis, V1, P2, DOI 10.1186/1476-511X-1-2; Bougnoux P, 1999, Curr Opin Clin Nutr Metab Care, V2, P121, DOI 10.1097/00075197-199903000-00005; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Cadroy Y, 1998, J IMMUNOL, V160, P6145; Calder PC, 2003, LIPIDS, V38, P343, DOI 10.1007/s11745-003-1068-y; Clarke SD, 2001, J NUTR, V131, P1129, DOI 10.1093/jn/131.4.1129; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; Collett ED, 2001, AM J PHYSIOL-CELL PH, V280, pC1066, DOI 10.1152/ajpcell.2001.280.5.C1066; Crawford MA, 2000, AM J CLIN NUTR, V71, p275S, DOI 10.1093/ajcn/71.1.275S; Das UN, 2000, PROSTAG LEUKOTR ESS, V63, P351, DOI 10.1054/plef.2000.0226; Duplus E, 2002, BIOCHEM PHARMACOL, V64, P893, DOI 10.1016/S0006-2952(02)01157-7; FOLCH J, 1957, J BIOL CHEM, V226, P497; German JB, 2002, J NUTR, V132, P2486, DOI 10.1093/jn/132.9.2486; Gerster H, 1998, INT J VITAM NUTR RES, V68, P159; Gonzalez B, 2000, PROSTAG LEUKOTR ESS, V62, P299, DOI 10.1054/plef.2000.0158; Green P, 1998, J NEUROSCI RES, V52, P129, DOI 10.1002/(SICI)1097-4547(19980415)52:2<129::AID-JNR1>3.0.CO;2-C; Griffin JL, 2004, PHYSIOL GENOMICS, V17, P140, DOI 10.1152/physiolgenomics.00158.2003; Ikeda I, 1996, J NUTR SCI VITAMINOL, V42, P541, DOI 10.3177/jnsv.42.541; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; Kramer JA, 2003, J NUTR, V133, P57, DOI 10.1093/jn/133.1.57; Lee DP, 2001, J LIPID RES, V42, P1979; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; Legrand P, 1997, J NUTR, V127, P249, DOI 10.1093/jn/127.2.249; MANSOURIAN R, 2004, IN PRESS BIOINFORMAT; Marmillot P, 2000, METABOLISM, V49, P508, DOI 10.1016/S0026-0495(00)80017-7; Miyazaki M, 2001, J LIPID RES, V42, P1018; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Moriguchi T, 2001, J LIPID RES, V42, P419; Murthy M, 2002, J LIPID RES, V43, P611; Mutch DM, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-17; Nordoy A, 2001, LIPIDS, V36, pS127, DOI 10.1007/s11745-001-0695-7; Ntambi JM, 1999, J LIPID RES, V40, P1549; Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; Petrik MBH, 2000, J NUTR, V130, P1153, DOI 10.1093/jn/130.5.1153; Phizicky E, 2003, NATURE, V422, P208, DOI 10.1038/nature01512; Pischon T, 2003, CIRCULATION, V108, P155, DOI 10.1161/01.CIR.0000079224.46084.C2; Rapoport SI, 2001, J LIPID RES, V42, P678; Ridgway ND, 2003, BIOCHEM J, V372, P811, DOI 10.1042/BJ20030252; Roche HM, 2000, AM J CLIN NUTR, V71, p232S, DOI 10.1093/ajcn/71.1.232s; Spector AA, 1999, LIPIDS, V34, pS1, DOI 10.1007/BF02562220; Uauy R, 2000, AM J CLIN NUTR, V71, p245S, DOI 10.1093/ajcn/71.1.245S; Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Watanabe S, 2001, PROSTAG OTH LIPID M, V66, P109, DOI 10.1016/S0090-6980(01)00152-6; Watkins SM, 2001, LIPIDS, V36, P247, DOI 10.1007/s11745-001-0714-8; Zeisel SH, 2001, J NUTR, V131, P1319, DOI 10.1093/jn/131.4.1319; Zhou L, 2001, J LIPID RES, V42, P1521	54	21	24	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1								10.1096/fj.04-2674fje	http://dx.doi.org/10.1096/fj.04-2674fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15670975				2022-12-25	WOS:000226576600012
J	Caristi, S; Piraino, G; Cucinotta, M; Valenti, A; Loddo, S; Teti, D				Caristi, S; Piraino, G; Cucinotta, M; Valenti, A; Loddo, S; Teti, D			Prostaglandin E-2 induces interleukin-8 gene transcription by activating C/EBP homologous protein in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; EPITHELIAL-CELLS; TYROSINE KINASE; E(2) RECEPTOR; EXPRESSION; IL-8; MACROPHAGES; INVOLVEMENT; MECHANISM	The effect of prostaglandin E-2 (PGE(2)) in regulating the synthesis of the pro-inflammatory chemokine interleukin-8 (IL-8) in T lymphocytes is not yet defined, even though it may reduce or enhance IL-8 synthesis in other cell types. Here, we demonstrate that, in human T cells, PGE(2) induced IL-8 mRNA transcription through prostaglandin E-2 receptors 1- and 4-dependent signal transduction pathways leading to the activation of the transcription factor C/EBP homologous protein ( CHOP), never before implicated in IL-8 transcription. Several kinases, including protein kinase C, Src family tyrosine kinases, phosphatidylinositol 3-kinase, and p38 MAPK, were involved in PGE(2)-induced CHOP activation and IL-8 production. The transactivation of the IL-8 promoter by CHOP was NF-kappa B-independent. Our data suggest that PGE(2) acts as a potent pro-inflammatory mediator by inducing IL-8 gene transcription in activated T cells through different signal transduction pathways leading to CHOP activation. These findings show the complexity with which PGE(2) regulates IL-8 synthesis by inhibiting or enhancing its production depending on the cell types and environmental conditions.	Univ Messina, Dept Expt Pathol & Microbiol, I-98125 Messina, Italy	University of Messina	Teti, D (corresponding author), Policlin Univ, Dept Expt Pathol & Microbiol, Via Consolare Valeria 1, I-98125 Messina, Italy.	dteti@unime.it	Loddo, Saverio/I-7397-2012	Loddo, Saverio/0000-0002-3338-9599; caristi, silvana/0000-0002-0016-7498				Agro A, 1996, J RHEUMATOL, V23, P862; Awasthi V, 2000, AM J PHYSIOL-LUNG C, V279, pL942, DOI 10.1152/ajplung.2000.279.5.L942; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BETZ M, 1991, J IMMUNOL, V146, P108; BRAIN SD, 1990, PHARMACOL THERAPEUT, V46, P57, DOI 10.1016/0163-7258(90)90035-Z; Breyer MD, 2000, AM J PHYSIOL-RENAL, V279, pF12, DOI 10.1152/ajprenal.2000.279.1.F12; Breyer RM, 2001, MOL PHARMACOL, V59, P1357, DOI 10.1124/mol.59.6.1357; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; GRIMM MC, 1995, J GASTROEN HEPATOL, V10, P387, DOI 10.1111/j.1440-1746.1995.tb01589.x; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Harris SG, 2002, J IMMUNOL, V168, P1372, DOI 10.4049/jimmunol.168.3.1372; Hattori T, 2003, FEBS LETT, V541, P33, DOI 10.1016/S0014-5793(03)00283-7; Hattori T, 2001, J INTERF CYTOK RES, V21, P323, DOI 10.1089/107999001300177510; Hwang D, 2000, ANNU REV NUTR, V20, P431, DOI 10.1146/annurev.nutr.20.1.431; Iwahashi N, 2002, BIOCHEM BIOPH RES CO, V294, P642, DOI 10.1016/S0006-291X(02)00528-4; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KELLER R, 1991, INT J CANCER, V49, P796, DOI 10.1002/ijc.2910490526; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; Mancuso G, 2002, J IMMUNOL, V169, P1401, DOI 10.4049/jimmunol.169.3.1401; Mastronarde JG, 1996, J INFECT DIS, V174, P262, DOI 10.1093/infdis/174.2.262; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; OGLE CK, 1994, INFLAMMATION, V18, P175, DOI 10.1007/BF01534558; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; Parhar K, 2003, IMMUNOLOGY, V108, P502, DOI 10.1046/j.1365-2567.2003.01603.x; Patrizio M, 2000, J NEUROCHEM, V74, P400, DOI 10.1046/j.1471-4159.2000.0740400.x; PLATZER C, 1995, INT IMMUNOL, V7, P517, DOI 10.1093/intimm/7.4.517; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; Roper R L, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P101; SCHREIBER S, 1990, CELL REGUL, V1, P403, DOI 10.1091/mbc.1.5.403; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; STANDIFORD TJ, 1992, AM J RESP CELL MOL, V6, P75, DOI 10.1165/ajrcmb/6.1.75; STRASSMANN G, 1994, J EXP MED, V180, P2365, DOI 10.1084/jem.180.6.2365; Sylvia VL, 2001, J STEROID BIOCHEM, V78, P261, DOI 10.1016/S0960-0760(01)00099-1; Takayama K, 2002, J BIOL CHEM, V277, P44147, DOI 10.1074/jbc.M204810200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Vang T, 2004, EUR J IMMUNOL, V34, P2191, DOI 10.1002/eji.200425036; Venza I, 2001, IMMUNOL CELL BIOL, V79, P482, DOI 10.1046/j.1440-1711.2001.01034.x; WERTHEIM WA, 1993, J IMMUNOL, V151, P2166; Wu GD, 1997, J BIOL CHEM, V272, P2396; Yu Y, 1998, J IMMUNOL, V161, P3746; Zeng L, 1996, BIOCHEMISTRY-US, V35, P7159, DOI 10.1021/bi960036x; Zeng L, 1996, J BIOL CHEM, V271, P27744, DOI 10.1074/jbc.271.44.27744	53	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14433	14442		10.1074/jbc.M410725200	http://dx.doi.org/10.1074/jbc.M410725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15659384	hybrid			2022-12-25	WOS:000228236800012
J	Perrino, FW; Harvey, S; McMillin, S; Hollis, T				Perrino, FW; Harvey, S; McMillin, S; Hollis, T			The human TREX2 3 '-> 5 '-exonuclease structure suggests a mechanism for efficient nonprocessive DNA catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; STRAND BREAK REPAIR; ESCHERICHIA-COLI; POLYMERASE-III; EXONUCLEASE ACTIVITY; PROOFREADING EXONUCLEASE; IDENTIFICATION; SITE; REPLICATION	The 3' --> 5'-exonucleases process DNA ends in many DNA repair pathways of human cells. Determination of the human TREX2 structure is the first of a dimeric 3'-deoxyribonuclease and indicates how this highly efficient nonprocessive enzyme removes nucleotides at DNA 3' termini. Symmetry in the TREX2 dimer positions the active sites at opposite outer edges providing open access for the DNA. Adjacent to each active site is a flexible region containing three arginines positioned appropriately to bind DNA and to control its entry into the active site. Mutation of these three arginines to alanines reduces the DNA binding capacity by similar to 100-fold with no effect on catalysis. The human TREX2 catalytic residues overlay with the bacterial DnaQ family of 3'-exonucleases confirming the structural conservation of the catalytic sites despite limited sequence identity, and mutations of these residues decrease the still measurable activity by similar to 10(5)-fold, confirming their catalytic role.	Wake Forest Univ, Ctr Struct Biol, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Hollis, T (corresponding author), Wake Forest Univ, Ctr Struct Biol, Dept Biochem, Winston Salem, NC 27157 USA.	thollis@wfubmc.edu			NIGMS NIH HHS [R01 GM069962] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069962] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARNES MH, 1995, GENE, V165, P45, DOI 10.1016/0378-1119(95)00530-J; Bebenek K, 2001, J BIOL CHEM, V276, P2317, DOI 10.1074/jbc.C000690200; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Brautigam CA, 1999, BIOCHEMISTRY-US, V38, P696, DOI 10.1021/bi981537g; Breyer WA, 2000, NAT STRUCT BIOL, V7, P1125; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; BRODY RS, 1986, J BIOL CHEM, V261, P7136; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chou KM, 2003, J BIOL CHEM, V278, P18289, DOI 10.1074/jbc.M212143200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; DeRose EF, 2002, BIOCHEMISTRY-US, V41, P94, DOI 10.1021/bi0114170; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldsby RE, 2002, P NATL ACAD SCI USA, V99, P15560, DOI 10.1073/pnas.232340999; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huang YP, 1997, FEBS LETT, V400, P94, DOI 10.1016/S0014-5793(96)01361-0; Ito J, 1998, MOL MICROBIOL, V27, P235, DOI 10.1046/j.1365-2958.1998.00673.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; Marti TM, 2004, CELL MOL LIFE SCI, V61, P336, DOI 10.1007/s00018-003-3223-4; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mazur DJ, 2001, J BIOL CHEM, V276, P17022, DOI 10.1074/jbc.M100623200; Miller H, 1996, BIOCHEMISTRY-US, V35, P12919, DOI 10.1021/bi960326d; Morita M, 2004, MOL CELL BIOL, V24, P6719, DOI 10.1128/MCB.24.15.6719-6727.2004; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Perrino Fred W., 1999, Cell Biochemistry and Biophysics, V30, P331, DOI 10.1007/BF02738118; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; Perrino FW, 2004, ADV ENZYME REGUL, V44, P37, DOI 10.1016/j.advenzreg.2003.11.010; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Strauss BS, 1997, NUCLEIC ACIDS RES, V25, P806, DOI 10.1093/nar/25.4.806; Taft-Benz SA, 1998, NUCLEIC ACIDS RES, V26, P4005, DOI 10.1093/nar/26.17.4005; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wong D, 2003, J BIOL CHEM, V278, P36242, DOI 10.1074/jbc.M306065200; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919	61	47	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15212	15218		10.1074/jbc.M500108200	http://dx.doi.org/10.1074/jbc.M500108200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15661738	hybrid			2022-12-25	WOS:000228236800106
J	Williams, JC; Sue, C; Banting, GS; Yang, H; Glerum, DM; Hendrickson, WA; Schon, EA				Williams, JC; Sue, C; Banting, GS; Yang, H; Glerum, DM; Hendrickson, WA; Schon, EA			Crystal structure of human SCO1 - Implications for redox signaling by a mitochondrial cytochrome c oxidase "assembly" protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; RHODOBACTER-SPHAEROIDES; HYDROGEN-PEROXIDE; MUTATIONS; THIOREDOXIN; DEFICIENCY; YEAST; GENE; METABOLISM	Human SCO1 and SCO2 are copper-binding proteins involved in the assembly of mitochondrial cytochrome c oxidase ( COX). We have determined the crystal structure of the conserved, intermembrane space core portion of apo-hSCO1 to 2.8 angstrom. It is similar to redox active proteins, including thioredoxins (Trx) and peroxiredoxins (Prx), with putative copper-binding ligands located at the same positions as the conserved catalytic residues in Trx and Prx. SCO1 does not have disulfide isomerization or peroxidase activity, but both hSCO1 and a sco1 null in yeast show extreme sensitivity to hydrogen peroxide. Of the six missense mutations in SCO1 and SCO2 associated with fatal mitochondrial disorders, one lies in a highly conserved exposed surface away from the copper-binding region, suggesting that this region is involved in protein-protein interactions. These data suggests that SCO functions not as a COX copper chaperone, but rather as a mitochondrial redox signaling molecule.	Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada	Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute; University of Alberta	Schon, EA (corresponding author), Columbia Univ, Dept Neurol, P&S 4-431,630 W 168th St, New York, NY 10032 USA.	eas3@columbia.edu	Glerum, Moira/AHD-3271-2022		NICHD NIH HHS [HD32062] Funding Source: Medline; NIGMS NIH HHS [GM34102] Funding Source: Medline; NINDS NIH HHS [NS39854, NS28828] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102, R37GM034102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039854, R01NS028828] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abajian C, 2004, J BIOL CHEM, V279, P53584, DOI 10.1074/jbc.M408099200; Balatri E, 2003, STRUCTURE, V11, P1431, DOI 10.1016/j.str.2003.10.004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Chinenov YV, 2000, J MOL MED, V78, P239, DOI 10.1007/s001090000110; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; D'Souza M, 2000, NUCLEIC ACIDS RES, V28, P335, DOI 10.1093/nar/28.1.335; Dickinson EK, 2000, J BIOL CHEM, V275, P26780; Eraso JM, 2000, BIOCHEMISTRY-US, V39, P2052, DOI 10.1021/bi9923858; Forsberg J, 2001, BIOCHEM SOC T, V29, P403, DOI 10.1042/BST0290403; Giles NM, 2003, CHEM BIOL, V10, P677, DOI 10.1016/S1074-5521(03)00174-1; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kang SW, 2004, J BIOL CHEM, V279, P2535, DOI 10.1074/jbc.M307698200; Katz AK, 2003, HELV CHIM ACTA, V86, P1320; Leary SC, 2004, HUM MOL GENET, V13, P1839, DOI 10.1093/hmg/ddh197; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; Lode A, 2002, YEAST, V19, P909, DOI 10.1002/yea.883; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Mattatall NR, 2000, J BIOL CHEM, V275, P28802, DOI 10.1074/jbc.M002741200; McEwan AG, 2002, FEBS LETT, V518, P10, DOI 10.1016/S0014-5793(02)02532-2; Musatov A, 2004, BIOCHEMISTRY-US, V43, P1003, DOI 10.1021/bi0358925; Nathaniel C, 2003, BIOCHEM J, V372, P241, DOI 10.1042/BJ20021765; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papadopoulou LC, 1999, NAT GENET, V23, P333; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; Richter OMH, 2003, REV PHYSIOL BIOCH P, V147, P47, DOI 10.1007/s10254-003-0006-0; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Sacconi S, 2003, PEDIATR RES, V53, P224, DOI 10.1203/01.PDR.0000048100.91730.6A; Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321; Seib KL, 2003, FEBS LETT, V546, P411, DOI 10.1016/S0014-5793(03)00632-X; Swem LR, 2003, EMBO J, V22, P4699, DOI 10.1093/emboj/cdg461; Tarnopolsky MA, 2004, AM J MED GENET A, V125A, P310, DOI 10.1002/ajmg.a.20466; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Thibodeau PA, 1999, FREE RADICAL BIO MED, V27, P1367, DOI 10.1016/S0891-5849(99)00183-5; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Valnot I, 2000, AM J HUM GENET, V67, P1104; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405	51	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15202	15211		10.1074/jbc.M410705200	http://dx.doi.org/10.1074/jbc.M410705200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15659396	hybrid			2022-12-25	WOS:000228236800105
J	Beland, M; Lohnes, D				Beland, M; Lohnes, D			Chicken ovalbumin upstream promoter-transcription factor members repress retinoic acid-induced Cdx1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; HOMEOBOX GENE CDX1; FACTOR COUP-TF; HISTONE DEACETYLASE; ORPHAN RECEPTORS; X-RECEPTOR; MECHANISMS; DOMAINS; CELLS; LIVER	It is well established that Hox genes are key players in specifying positional identity along the anterior-posterior axis and are targets of diverse transcription factors implicated in axial patterning. Members of the CDX family (CDX1, -2, and -4) are among such effectors of Hox expression as pertains to vertebral patterning in the mouse. Cdx members are themselves targets of signaling molecules that are also implicated in axial patterning, including retinoic acid (RA) and certain members of Wnt and fibroblast growth factor families. In this regard, we have previously shown that, in the mouse, Cdx1 is directly regulated by RA at the late primitive streak stage (embryonic day (E) 7.5) through a RA response element in the proximal Cdx1 promoter. At E8.5, Cdx1 expression remains essentially limited to the posterior embryo. RA, however, is excluded from the caudal embryo at this later stage, but is found in a more anterior domain encompassing the prospective trunk region. These observations suggest the existence of a repressor mechanism that prevents expression of Cdx1 in these anterior domains of retinoid signaling at E8.5. In the present study, we present evidence suggesting that chicken ovalbumin upstream promoter-transcription factor (COUP-TF) members antagonize RA-induced Cdx1 expression by competing with retinoid X receptor-retinoic acid receptor heterodimers for binding to the Cdx1 RA response element. Consistent with this, in situ hybridization analysis revealed that COUP-TFs are highly expressed in the anterior embryo in domains where Cdx1 transcripts are excluded. Together with other data, these findings suggest a model by which COUP-TF expression is induced by RA in the trunk region as a negative feedback mechanism to restrict Cdx1 expression to the caudal embryo.	Univ Montreal, Inst Rech Clin Montreal, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	Lohnes, D (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	dlohnes@uottawa.ca						Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Beland M, 2004, MOL CELL BIOL, V24, P5028, DOI 10.1128/MCB.24.11.5028-5038.2004; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; Brubaker K, 1996, DEV BRAIN RES, V93, P198, DOI 10.1016/0165-3806(96)00007-7; Charite J, 1998, DEVELOPMENT, V125, P4349; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; Houle M, 2000, MOL CELL BIOL, V20, P6579, DOI 10.1128/MCB.20.17.6579-6586.2000; Houle M, 2003, DEVELOPMENT, V130, P6555, DOI 10.1242/dev.00889; HU YL, 1993, J BIOL CHEM, V268, P27214; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JONK LJC, 1994, DEV BIOL, V161, P604, DOI 10.1006/dbio.1994.1056; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Leng X, 1996, MOL CELL BIOL, V16, P2332; Lickert H, 2000, DEVELOPMENT, V127, P3805; MEYER BI, 1993, DEVELOPMENT, V117, P191; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; PEREIRA FA, 1995, J STEROID BIOCHEM, V53, P503, DOI 10.1016/0960-0760(95)00097-J; Prinos P, 2001, DEV BIOL, V239, P257, DOI 10.1006/dbio.2001.0446; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; QIU YH, 1994, P NATL ACAD SCI USA, V91, P4451, DOI 10.1073/pnas.91.10.4451; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Smirnov DA, 2000, VIROLOGY, V268, P319, DOI 10.1006/viro.1999.0181; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; van den Akker E, 2002, DEVELOPMENT, V129, P2181; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Zhang P, 2002, MECH DEVELOP, V119, P109, DOI 10.1016/S0925-4773(02)00286-1	37	17	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13858	13862		10.1074/jbc.M412981200	http://dx.doi.org/10.1074/jbc.M412981200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677473	hybrid			2022-12-25	WOS:000228095500084
J	Borges, JC; Fischer, H; Craievich, AF; Ramos, CHI				Borges, JC; Fischer, H; Craievich, AF; Ramos, CHI			Low resolution structural study of two human HSP40 chaperones in solution - DjA1 from subfamily A and DjB4 from subfamily B have different quaternary structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER-LIKE DOMAIN; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; TERMINAL REGION; BINDING-SITES; CO-CHAPERONE; DNAJ; HSP70; SPECIFICITY; MECHANISM	Proteins that belong to the heat shock protein (Hsp) 40 family assist Hsp70 in many cellular functions and are important for maintaining cell viability. A knowledge of the structural and functional characteristics of the Hsp40 family is therefore essential for understanding the role of the Hsp70 chaperone system in cells. In this work, we used small angle x-ray scattering and analytical ultracentrifugation to study two representatives of human Hsp40, namely, DjA1 (Hdj2/dj2/HSDJ/Rdj1) from subfamily A and DjB4 (Hlj1/DnaJW) from subfamily B, and to determine their quaternary structure. We also constructed low resolution models for the structure of DjA1-(1-332), a C-terminal-deleted mutant of DjA1 in which dimer formation is prevented. Our results, together with the current structural information of the Hsp40 C-terminal and J-domains, were used to generate models of the internal structural organization of DjA1 and DjB4. The characteristics of these models indicated that DjA1 and DjB4 were both dimers, but with substantial differences in their quaternary structures: whereas DjA1 consisted of a compact dimer in which the N and C termini of the two monomers faced each other, DjB4 formed a dimer in which only the C termini of the two monomers were in contact. The two proteins also differed in their ability to bind unfolded luciferase. Overall, our results indicate that these representatives of subfamilies A and B of human Hsp40 have different quaternary structures and chaperone functions.	Lab Nacl Luz Sincrotron, Ctr Biol Mol Estrutural, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Inst Biol, Dept Bioquim, BR-13084971 Campinas, SP, Brazil; Univ Sao Paulo, Inst Fis, Dept Fis Aplicada, BR-05508900 Sao Paulo, Brazil	Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade de Sao Paulo	Ramos, CHI (corresponding author), Lab Nacl Luz Sincrotron, Ctr Biol Mol Estrutural, CP 6192, BR-13084971 Campinas, SP, Brazil.	cramos@lnls.br	Ramos, CH/C-1571-2012; Craievich, Aldo F/A-2852-2013; Borges, Julio C/C-6160-2008; Fischer, Hannes/C-2215-2012	Ramos, CH/0000-0002-7246-9081; Craievich, Aldo F/0000-0002-5103-0248; Borges, Julio C/0000-0003-4856-748X; Fischer, Hannes/0000-0003-2984-2028				Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Borges JC, 2005, PROTEIN PEPTIDE LETT, V12, P257, DOI 10.2174/0929866053587165; Borges JC, 2003, J BIOL CHEM, V278, P35337, DOI 10.1074/jbc.M305083200; Borges JC, 2001, GENET MOL BIOL, V24, P85, DOI 10.1590/S1415-47572001000100013; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; delaTorre JG, 1997, EUR BIOPHYS J BIOPHY, V25, P361, DOI 10.1007/s002490050049; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fan CY, 2005, J BIOL CHEM, V280, P695, DOI 10.1074/jbc.M410645200; Fan CY, 2004, MOL BIOL CELL, V15, P761, DOI 10.1091/mbc.E03-03-0146; Feigin L. A., 1987, STRUCTURE ANAL SMALL, P839; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Johnson JL, 2001, J CELL BIOL, V152, P851, DOI 10.1083/jcb.152.4.851; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kellermann G, 1997, J APPL CRYSTALLOGR, V30, P880, DOI 10.1107/S0021889897001829; Landry SJ, 2003, STRUCTURE, V11, P1465, DOI 10.1016/j.str.2003.11.012; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laue T, 2001, CURR OPIN STRUC BIOL, V11, P579, DOI 10.1016/S0959-440X(00)00250-5; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; Linke K, 2003, J BIOL CHEM, V278, P44457, DOI 10.1074/jbc.M307491200; Lopez N, 2003, MOL BIOL CELL, V14, P1172, DOI 10.1091/mbc.E02-09-0593; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Miernyk JA, 2001, CELL STRESS CHAPERON, V6, P209, DOI 10.1379/1466-1268(2001)006<0209:TJDPOA>2.0.CO;2; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Qian XG, 2002, BIOCHEM J, V361, P27, DOI 10.1042/0264-6021:3610027; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Terada K, 2000, J BIOL CHEM, V275, P24728, DOI 10.1074/jbc.M002021200; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Yan W, 1999, MOL CELL BIOL, V19, P7751; Zimm B H, 1974, Biophys Chem, V1, P279, DOI 10.1016/0301-4622(74)80014-1	59	48	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13671	13681		10.1074/jbc.M408349200	http://dx.doi.org/10.1074/jbc.M408349200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15661747	hybrid			2022-12-25	WOS:000228095500062
J	Gawenis, LR; Greeb, JM; Prasad, V; Grisham, C; Sanford, LP; Doetschman, T; Andringa, A; Miller, ML; Shull, GE				Gawenis, LR; Greeb, JM; Prasad, V; Grisham, C; Sanford, LP; Doetschman, T; Andringa, A; Miller, ML; Shull, GE			Impaired gastric acid secretion in mice with a targeted disruption of the NHE4 Na+/H+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H,K-ATPASE ALPHA-SUBUNIT; AE2 CL-/HCO3-EXCHANGER; RABBIT PARIETAL-CELLS; MOUSE STOMACH; EPITHELIAL-CELLS; TRANSGENIC MICE; DIFFERENTIAL EXPRESSION; GENE FAMILY; CORPUS; DYNAMICS	The NHE4 Na+/H+ exchanger is abundantly expressed on the basolateral membrane of gastric parietal cells. To test the hypothesis that it is required for normal acid secretion, NHE4-null mutant (NHE4(-/-)) mice were prepared by targeted disruption of the NHE4 (Slc9a4) gene. NHE4(-/-) mice survived and appeared outwardly normal. Analysis of stomach contents revealed that NHE4(-/-) mice were hypochlorhydric. The reduction in acid secretion was similar in 18-day-old, 9-week-old, and 6-month-old mice, indicating that the hypochlorhydria phenotype did not progress over time, as was observed in mice lacking the NHE2 Na+/H+ exchanger. Histological abnormalities were observed in the gastric mucosa of 9-week-old NHE4(-/-) mice, including sharply reduced numbers of parietal cells, a loss of mature chief cells, increased numbers of mucous and undifferentiated cells, and an increase in the number of necrotic and apoptotic cells. NHE4(-/-) parietal cells exhibited limited development of canalicular membranes and a virtual absence of tubulovesicles, and some of the microvilli had centrally bundled actin. We conclude that NHE4, which may normally be coupled with the AE2 Cl-/HCO3- exchanger, is important for normal levels of gastric acid secretion, gastric epithelial cell differentiation, and development of secretory canalicular and tubulovesicular membranes.	Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Biochem, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet, 231 Albert Sabin Way,ML524, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu			NHLBI NIH HHS [T32-HL7571] Funding Source: Medline; NIDDK NIH HHS [DK67749, DK50594] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594, F32DK067749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bachmann O, 1998, AM J PHYSIOL-GASTR L, V275, pG1085, DOI 10.1152/ajpgi.1998.275.5.G1085; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; BROOKSTEIN C, 1996, AM J PHYSIOL, V271, pC1629; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; Gawenis LR, 2004, J BIOL CHEM, V279, P30531, DOI 10.1074/jbc.M403779200; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; Karam SM, 2003, STEM CELLS, V21, P322, DOI 10.1634/stemcells.21-3-322; KARAM SM, 1993, ANAT REC, V236, P297, DOI 10.1002/ar.1092360204; KARAM SM, 1992, ANAT RECORD, V232, P231, DOI 10.1002/ar.1092320208; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; Lagadic-Gossmann D, 2004, CELL DEATH DIFFER, V11, P953, DOI 10.1038/sj.cdd.4401466; Lang F, 2004, J MOL RECOGNIT, V17, P473, DOI 10.1002/jmr.705; Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7; Li QT, 1996, J BIOL CHEM, V271, P3671, DOI 10.1074/jbc.271.7.3671; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LORENZ RG, 1993, J BIOL CHEM, V268, P26559; MAEDA M, 1995, J BIOCHEM-TOKYO, V117, P1305, DOI 10.1093/oxfordjournals.jbchem.a124859; MAKHLOUF GM, 1966, GASTROENTEROLOGY, V51, P149; Milller ML, 2002, CELL TISSUE RES, V309, P369, DOI 10.1007/s00441-002-0606-z; MUALLEM S, 1988, J BIOL CHEM, V263, P14703; MUALLEM S, 1985, J BIOL CHEM, V260, P6641; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; Park K, 1999, AM J PHYSIOL-GASTR L, V276, pG470, DOI 10.1152/ajpgi.1999.276.2.G470; PETROVIC S, 2003, AM J PHYSIOL, V284, pG1098; Pizzonia JH, 1998, AM J PHYSIOL-RENAL, V275, pF510, DOI 10.1152/ajprenal.1998.275.4.F510; REHM WS, 1975, ANN NY ACAD SCI, V264, P442, DOI 10.1111/j.1749-6632.1975.tb31502.x; Rossmann H, 2001, J PHYSIOL-LONDON, V534, P837, DOI 10.1111/j.1469-7793.2001.00837.x; Rossmann H, 2001, AM J PHYSIOL-GASTR L, V281, pG447, DOI 10.1152/ajpgi.2001.281.2.G447; Roussa E, 2001, J HISTOCHEM CYTOCHEM, V49, P463, DOI 10.1177/002215540104900406; Scarff KL, 1999, GASTROENTEROLOGY, V117, P605, DOI 10.1016/S0016-5085(99)70453-1; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Smolka AJ, 2000, BIOCHEM BIOPH RES CO, V273, P942, DOI 10.1006/bbrc.2000.3031; Sonnentag T, 2000, AM J PHYSIOL-GASTR L, V279, pG40, DOI 10.1152/ajpgi.2000.279.1.G40; Spicer Z, 2000, J BIOL CHEM, V275, P21555, DOI 10.1074/jbc.M001558200; STUARTTILLEY A, 1994, AM J PHYSIOL, V266, pC559, DOI 10.1152/ajpcell.1994.266.2.C559; Wang Z, 1996, J BIOL CHEM, V271, P7835, DOI 10.1074/jbc.271.13.7835; ZACHOS NC, 2004, ANNU REV PHYSIOL, V67, P18	38	62	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12781	12789		10.1074/jbc.M414118200	http://dx.doi.org/10.1074/jbc.M414118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15684419	hybrid			2022-12-25	WOS:000227922000086
J	Lee, KH; Lee, CT; Kim, YW; Han, SK; Shim, YS; Yoo, CG				Lee, KH; Lee, CT; Kim, YW; Han, SK; Shim, YS; Yoo, CG			Preheating accelerates mitogen-activated protein (MAP) kinase inactivation post-heat shock via a heat shock protein 70-mediated increase in phosphorylated MAP kinase phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; N-TERMINAL KINASE; KAPPA-B-ALPHA; TYROSINE-PHOSPHATASE; MAMMALIAN-CELLS; HSP27 GENE; IN-VIVO; PATHWAYS; HSP70; RESISTANCE	Heat shock (HS) activates mitogen-activated protein (MAP) kinases. Although prior exposure to nonlethal HS makes cells refractory to the lethal effect of a subsequent HS, it is unclear whether this also occurs in MAP kinase activation. This study was undertaken to evaluate the effect of a heat pretreatment on MAP kinase activation by a subsequent HS and to elucidate its possible mechanism. Preheating did not make BEAS-2B cells refractory to extracellular signal-regulated protein kinase (ERK) and c-Jun N-terminal kinase (JNK) activation by a second HS but accelerated their inactivation after HS. The rapid inactivation of ERK and JNK was dependent on de novo protein synthesis and associated with the up-regulation of heat shock protein 70 (HSP70). Moreover, the inhibition of phosphatase activity reversed this rapid inactivation. MAP kinase phosphatase-1 (MKP-1) expression was increased by HS, and the presence of its phosphorylated form (p-MKP-1) correlated with the observed rapid ERK and JNK inactivation. Blocking induction of p-MKP-1 with antisense MKP-1 oligonucleotides suppressed the rapid inactivation of ERK and JNK in preheated cells. HSP70 overexpression caused the early phosphorylation of MKP-1. Moreover, MKP-1 phosphorylation and the rapid inactivation of ERK were inhibited by blocking HSP70 induction in preheated cells. In addition, MKP-1 was insolubilized by HS, and HSP70 associated physically with MKP-1, suggesting that a chaperone effect of HSP70 might have caused the early phosphorylation of MKP-1. These results indicate that preheating accelerated MAP kinase inactivation after a second HS and that this is related to a HSP70-mediated increase in p-MKP-1.	Seoul Natl Univ Hosp, Clin Res Inst, Dept Internal Med, Div Pulm & Crit Care Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Div Pulm & Crit Care Med, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Lung Inst, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU)	Yoo, CG (corresponding author), Seoul Natl Univ Hosp, Clin Res Inst, Dept Internal Med, Div Pulm & Crit Care Med, 28 Yongon Dong, Seoul 110744, South Korea.	cgyoo@snu.ac.kr	Han, Sung Koo/J-5706-2012; Kim, Young Whan/J-5415-2012; Yoo, Chul Gyu/J-2771-2012; Lee, Choon-Taek/J-5611-2012					ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dorion S, 1999, J BIOL CHEM, V274, P37591, DOI 10.1074/jbc.274.53.37591; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GERNER EW, 1975, NATURE, V256, P500, DOI 10.1038/256500a0; Han J, 1999, NAT CELL BIOL, V1, pE39, DOI 10.1038/10032; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENLE KJ, 1976, RADIAT RES, V66, P505, DOI 10.2307/3574455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Kabakov AE, 2002, AM J PHYSIOL-CELL PH, V283, pC521, DOI 10.1152/ajpcell.00503.2001; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; Lee KH, 2004, EXP CELL RES, V299, P49, DOI 10.1016/j.yexcr.2004.05.013; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MORIMOTO R, 1993, SCIENCE, V269, P1409; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Woessmann W, 1999, J CELL BIOCHEM, V74, P648, DOI 10.1002/(SICI)1097-4644(19990915)74:4<648::AID-JCB14>3.0.CO;2-6; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yoo CG, 2000, J IMMUNOL, V164, P5416, DOI 10.4049/jimmunol.164.10.5416	47	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13179	13186		10.1074/jbc.M410059200	http://dx.doi.org/10.1074/jbc.M410059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677475	hybrid			2022-12-25	WOS:000227922000130
J	Li, L; Li, ZG; Sacks, DB				Li, L; Li, ZG; Sacks, DB			The transcriptional activity of estrogen receptor-alpha is dependent on Ca2+/calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET RECOGNITION; CALCIUM-CHANNELS; CELL-LINE; CALMODULIN; ACTIVATION; ESTRADIOL; MECHANISMS; EXPRESSION; BINDING; TRANSACTIVATION	Estrogen binds to estrogen receptors in cells, thereby activating the receptors and eliciting biological effects. One of the best characterized effects of estrogen receptor- (ER alpha) is transcriptional activation that regulates selected target genes in the nucleus. Work from several laboratories has documented a Ca2+- dependent interaction between ER alpha and calmodulin. In addition, we previously showed that antagonism of calmodulin function in cells prevented estradiol from inducing ER alpha transcriptional activity, suggesting that association of ER alpha with calmodulin participates in ER alpha function. In this study we adopted a multifaceted approach to directly address this hypothesis. The calmodulin binding domain on ER alpha was identified and several mutant ER alpha constructs unable to bind calmodulin were generated. Elimination of calmodulin binding prevented estradiol from stimulating ER alpha transcriptional activation. Essentially identical results were obtained when intracellular Ca2+ was chelated with the cell- permeable chelator 1,2- bis(o-aminophenoxy) ethane- N, N, N', N'- tetraacetic acid tetra( acetoxymethyl) ester ( BAPTA- AM). Moreover, CaM1234, a calmodulin mutant that is unable to bind Ca2+, functioned as a dominant negative construct. Transfection of cells with CaM1234 reduced estradiolstimulated ER alpha transcriptional activity. These data indicate that binding to calmodulin is required for normal transcriptional function of ER alpha.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735	NATIONAL CANCER INSTITUTE [R01CA093645] Funding Source: NIH RePORTER; NCI NIH HHS [CA93645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; BERTHOIS Y, 1990, MOL CELL ENDOCRINOL, V74, P11, DOI 10.1016/0303-7207(90)90201-I; Biswas DK, 1998, J BIOL CHEM, V273, P33817, DOI 10.1074/jbc.273.50.33817; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; BOUHOUTE A, 1994, BIOCHEM PHARMACOL, V47, P748, DOI 10.1016/0006-2952(94)90140-6; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CASTORIA G, 1988, MOL ENDOCRINOL, V2, P167, DOI 10.1210/mend-2-2-167; Cohen P, 1988, CALMODULIN; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Dickson R B, 2000, J Natl Cancer Inst Monogr, P135; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Lee WS, 2003, J BIOL CHEM, V278, P25940, DOI 10.1074/jbc.M302091200; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Li L, 2003, J BIOL CHEM, V278, P1195, DOI 10.1074/jbc.M210708200; Li ZG, 2003, J BIOL CHEM, V278, P4347, DOI 10.1074/jbc.M208579200; Li ZG, 2001, J BIOL CHEM, V276, P17354, DOI 10.1074/jbc.M010238200; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; METCALFE JC, 1991, CELLULAR CALCIUM, P123; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Pedrero JMG, 2002, MOL ENDOCRINOL, V16, P947; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004; Pusl T, 2002, J BIOL CHEM, V277, P27517, DOI 10.1074/jbc.M203002200; REESE JC, 1991, J BIOL CHEM, V266, P10880; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; Shao WL, 2004, P NATL ACAD SCI USA, V101, P11599, DOI 10.1073/pnas.0402997101; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Zhang WH, 2003, FEBS LETT, V546, P17, DOI 10.1016/S0014-5793(03)00436-8; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	43	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13097	13104		10.1074/jbc.M410642200	http://dx.doi.org/10.1074/jbc.M410642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15657064	hybrid			2022-12-25	WOS:000227922000120
J	Tachihara, K; Uemura, T; Kashiwagi, K; Igarashi, K				Tachihara, K; Uemura, T; Kashiwagi, K; Igarashi, K			Excretion of putrescine and spermidine by the protein encoded by YKL174c (TPO5) in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Q	POLYAMINE TRANSPORT PROTEIN; VACUOLAR MEMBRANE; AMINO-ACIDS; YEAST GOLGI; GENE; RESISTANCE; PERMEASE; GROWTH; IDENTIFICATION; TRAFFICKING	The properties of the protein encoded by YKL174c (TPO5) were studied. It was found that TPO5 excretes putrescine effectively and spermidine less effectively. gamma-Aminobutyric acid slightly inhibited the excretion of putrescine, but basic amino acids did not affect excretion, suggesting that TPO5 preferentially recognizes polyamines. Accordingly, yeast cells transformed with the plasmid encoding YKL174c (TPO5) were resistant to toxicity caused by 120 mM putrescine or by 3 mM spermidine, and a mutant with a disrupted YKL174c (TPO5) gene was sensitive to toxicity by 90 mM putrescine. The growth of this mutant was faster than that of the wildtype strain. In parallel, there was an increase in putrescine and spermidine content of the YKL174c (TPO5) mutant compared with wild-type. It is noted that TPO5 functions as a suppressor of cell growth by excreting polyamines. The level of YKL174c (TPO5) mRNA was increased by the addition of polyamines to the medium. The degree of induction of the mRNA was spermine > spermidine > putrescine. The subcellular localization of TPO5 was determined by immunostaining of hemagglutinin-tagged TPO5, and it was found on Golgi or post-Golgi secretory vesicles. Excretion of putrescine and spermidine by TPO5 was reduced in cells that have mutations in the secretory or endocytic pathways, indicating that both processes are involved in the excretion of polyamines.	Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan	Chiba University	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.	iga16077@p.chiba-u.ac.jp		Igarashi, Kazuei/0000-0003-3751-3187				ANDRE B, 1993, MOL GEN GENET, V237, P17; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P13869, DOI 10.1073/pnas.1835918100; Chen EJ, 2002, P NATL ACAD SCI USA, V99, P14837, DOI 10.1073/pnas.232591899; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; Desmoucelles C, 2002, J BIOL CHEM, V277, P27036, DOI 10.1074/jbc.M111433200; Dupre S, 2003, TRAFFIC, V4, P83, DOI 10.1034/j.1600-0854.2003.40204.x; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FUJII S, 1981, BIOCHIM BIOPHYS ACTA, V661, P342, DOI 10.1016/0005-2744(81)90023-1; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; KAISER C, 1994, METHODS YEAST GENETI, P141; KAKEGAWA T, 1988, ARCH BIOCHEM BIOPHYS, V261, P250, DOI 10.1016/0003-9861(88)90339-6; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; Kashiwagi K, 2002, J BIOL CHEM, V277, P24212, DOI 10.1074/jbc.M202849200; MARUYAMA T, 1994, BBA-BIOMEMBRANES, V1194, P289, DOI 10.1016/0005-2736(94)90311-5; Matta MAD, 2001, GENE, V272, P111, DOI 10.1016/S0378-1119(01)00558-3; OGASAWARA T, 1989, J BIOCHEM-TOKYO, V105, P164, DOI 10.1093/oxfordjournals.jbchem.a122633; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Raj VS, 2001, J BACTERIOL, V183, P4493, DOI 10.1128/JB.183.15.4493-4498.2001; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sorin A, 1997, J BIOL CHEM, V272, P9895; SUZUKI T, 1993, EUR J BIOCHEM, V215, P247, DOI 10.1111/j.1432-1033.1993.tb18029.x; Teixeira MC, 2002, BIOCHEM BIOPH RES CO, V292, P530, DOI 10.1006/bbrc.2002.6691; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; Uemura T, 2004, BIOCHEM BIOPH RES CO, V315, P1082, DOI 10.1016/j.bbrc.2004.01.162; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Vassylyev DG, 1998, J BIOL CHEM, V273, P17604, DOI 10.1074/jbc.273.28.17604	38	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12637	12642		10.1074/jbc.M410778200	http://dx.doi.org/10.1074/jbc.M410778200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668236	hybrid			2022-12-25	WOS:000227922000069
J	Humphries, AD; Streimann, IC; Stojanovski, D; Johnston, AJ; Yano, M; Hoogenraad, NJ; Ryan, MT				Humphries, AD; Streimann, IC; Stojanovski, D; Johnston, AJ; Yano, M; Hoogenraad, NJ; Ryan, MT			Dissection of the mitochondrial import and assembly pathway for human Tom40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; PROTEIN IMPORT; PREPROTEIN TRANSLOCASE; FUNCTIONAL-ANALYSIS; INTERMEMBRANE SPACE; RECEPTOR COMPLEX; ADP/ATP CARRIER; BIOGENESIS; CHANNEL; PORE	Tom40 is the channel-forming subunit of the translocase of the mitochondrial outer membrane ( TOM complex), essential for protein import into mitochondria. Tom40 is synthesized in the cytosol and contains information for its mitochondrial targeting and assembly. A number of stable import intermediates have been identified for Tom40 precursors in fungi, the first being an association with the sorting and assembly machinery (SAM) of the outer membrane. By examining the import pathway of human Tom40, we have been able to elucidate additional features in its import. We identify that Hsp90 is involved in delivery of the Tom40 precursor to mitochondria in an ATP-dependent manner. The precursor then forms its first stable intermediate with the outer face of the TOM complex before its membrane integration and assembly. Deletion of an evolutionary conserved region within Tom40 disrupts the TOM complex intermediate and causes it to stall at a new complex in the intermembrane space that we identify to be the mammalian SAM. Unlike its fungal counterparts, the human Tom40 precursor is not found stably arrested at a SAM intermediate. Nevertheless, we show that Tom40 assembly is reduced in mitochondria depleted of human Sam50. These findings are discussed in context with current models from fungal studies.	La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia; Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8600811, Japan	La Trobe University; Kumamoto University	Hoogenraad, NJ (corresponding author), La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia.	N.Hoogenraad@latrobe.edu.au; M.Ryan@latrobe.edu.au	Ryan, Michael/X-2152-2019; Hoogenraad, Nicholas J/C-7505-2011; Ryan, Michael T/C-6673-2011	Ryan, Michael/0000-0003-2586-8829; Ryan, Michael T/0000-0003-2586-8829; Stojanovski, Diana/0000-0002-0199-3222; Johnston, Amelia/0000-0003-4289-3516				Abdul KM, 2000, BIOCHEM BIOPH RES CO, V276, P1028, DOI 10.1006/bbrc.2000.3589; Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Armstrong LC, 1999, J CELL BIOCHEM, V74, P11, DOI 10.1002/(SICI)1097-4644(19990701)74:1<11::AID-JCB2>3.0.CO;2-V; Armstrong LC, 1997, J BIOL CHEM, V272, P6510, DOI 10.1074/jbc.272.10.6510; Bagos PG, 2004, NUCLEIC ACIDS RES, V32, pW400, DOI 10.1093/nar/gkh417; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Esaki M, 2003, NAT STRUCT BIOL, V10, P988, DOI 10.1038/nsb1008; Frohlich KU, 2000, FEBS LETT, V473, P6, DOI 10.1016/S0014-5793(00)01474-5; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; Harlow E., 1999, USING ANTIBODIES LAB; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; Johnston AJ, 2002, J BIOL CHEM, V277, P42197, DOI 10.1074/jbc.M205613200; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; KEIL P, 1993, J BIOL CHEM, V268, P19177; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; Matouschek A, 2001, NAT STRUCT BIOL, V8, P284, DOI 10.1038/86140; Meisinger C, 2004, DEV CELL, V7, P61, DOI 10.1016/j.devcel.2004.06.003; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Milenkovic D, 2004, J BIOL CHEM, V279, P22781, DOI 10.1074/jbc.C400120200; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; PERALTA D, 1993, EUR J BIOCHEM, V211, P881, DOI 10.1111/j.1432-1033.1993.tb17621.x; Pfanner N, 2004, NAT STRUCT MOL BIOL, V11, P1044, DOI 10.1038/nsmb852; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 2002, TRENDS BIOCHEM SCI, V27, P191, DOI 10.1016/S0968-0004(02)02065-0; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Ryan MT, 2004, CURR BIOL, V14, pR207, DOI 10.1016/j.cub.2004.02.024; Ryan MT, 2002, ADV PROTEIN CHEM, V59, P223; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Simpson RJ, 2003, PROTEINS PROTEOMICS; SMITH MG, 1995, MOL BIOL CELL, V6, P1381, DOI 10.1091/mbc.6.10.1381; Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; Suzuki H, 2004, J BIOL CHEM, V279, P50619, DOI 10.1074/jbc.M408604200; Taylor RD, 2003, J BIOL CHEM, V278, P765, DOI 10.1074/jbc.M208083200; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Waizenegger T, 2004, EMBO REP, V5, P704, DOI 10.1038/sj.embor.7400183; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200; Yano M, 2000, MOL CELL BIOL, V20, P7205, DOI 10.1128/MCB.20.19.7205-7213.2000; Yano M, 1998, J BIOL CHEM, V273, P26844, DOI 10.1074/jbc.273.41.26844; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445	62	142	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11535	11543		10.1074/jbc.M413816200	http://dx.doi.org/10.1074/jbc.M413816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644312	hybrid			2022-12-25	WOS:000227761800079
J	Johnson, LA; Guptaroy, B; Lund, D; Shamban, S; Gnegy, ME				Johnson, LA; Guptaroy, B; Lund, D; Shamban, S; Gnegy, ME			Regulation of amphetamine-stimulated dopamine efflux by protein kinase C beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOREPINEPHRINE TRANSPORTER; SYNAPSIN I; PKC-BETA; PHOSPHORYLATION; NA+,K+-ATPASE; NEUROMODULIN; TRAFFICKING; RECEPTOR; COCAINE; RECRUITMENT	Evidence suggests that protein kinase C (PKC) and intracellular calcium are important for amphetamine-stimulated outward transport of dopamine in rat striatum. In this study, we examined the effect of select PKC isoforms on amphetamine-stimulated dopamine efflux, focusing on Ca2+-dependent forms of PKC. Efflux of endogenous dopamine was measured in superfused rat striatal slices; dopamine was measured by high performance liquid chromatography. The non-selective classical PKC inhibitor Go6976 inhibited amphetamine-stimulated dopamine efflux, whereas rottlerin, a specific inhibitor of PKC delta, had no effect. A highly specific PKC beta inhibitor, LY379196, blocked dopamine efflux that was stimulated by either amphetamine or the PKC activator, 12-O-tetradecanoylphorbol-13-acetate. None of the PKC inhibitors significantly altered [H-3] dopamine uptake. PKC beta(I) and PKC beta(II), but not PKC alpha or PKC gamma, were co-immunoprecipitated from rat striatal membranes with the dopamine transporter (DAT). Conversely, antisera to PKC beta(I) and PKC beta(II) but not PKC alpha or PKC gamma were able to co-immunoprecipitate DAT. Amphetamine-stimulated dopamine efflux was significantly enhanced in hDAT-HEK 293 cells transfected with PKC beta(II) as compared with hDAT-HEK 293 cells alone, or hDAT-HEK 293 cells transfected with PKC alpha or PKC gamma. These results suggest that classical PKC beta(II) is physically associated with DAT and is important in maintaining the amphetamine-stimulated outward transport of dopamine in rat striatum.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Gnegy, ME (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 2220E MSRB III, Ann Arbor, MI 48109 USA.	pgnegy@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011697] Funding Source: NIH RePORTER; NIDA NIH HHS [DA11697] Funding Source: Medline; NIDDK NIH HHS [5P60DK-20572] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bauman AL, 2000, J NEUROSCI, V20, P7571; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Browman KE, 1998, BRAIN RES, V814, P112, DOI 10.1016/S0006-8993(98)01040-3; Budu CE, 2002, BRIT J PHARMACOL, V137, P1380, DOI 10.1038/sj.bjp.0704962; Cowell RM, 2000, EUR J PHARMACOL, V389, P59, DOI 10.1016/S0014-2999(99)00828-6; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Doolen S, 2002, FEBS LETT, V516, P187, DOI 10.1016/S0014-5793(02)02554-1; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; FREED C, 1995, J COMP NEUROL, V359, P340, DOI 10.1002/cne.903590211; Giambalvo CCT, 2004, SYNAPSE, V51, P128, DOI 10.1002/syn.10289; GIAMBALVO CT, 1992, NEUROPHARMACOLOGY, V31, P1211, DOI 10.1016/0028-3908(92)90049-U; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; Gnegy ME, 2004, MOL PHARMACOL, V66, P137, DOI 10.1124/mol.66.1.137; GNEGY ME, 1993, MOL BRAIN RES, V20, P289, DOI 10.1016/0169-328X(93)90055-T; Gonzalez MI, 2003, J NEUROSCI, V23, P5589; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Iwata SI, 1997, SYNAPSE, V26, P281, DOI 10.1002/(SICI)1098-2396(199707)26:3<281::AID-SYN9>3.0.CO;2-3; Iwata SI, 1996, J PHARMACOL EXP THER, V278, P1428; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; Kantor L, 1998, J PHARMACOL EXP THER, V284, P592; Kantor L, 2004, J PHARMACOL EXP THER, V311, P1044, DOI 10.1124/jpet.104.071068; Kantor L, 2001, J PHARMACOL EXP THER, V297, P1016; Khoshbouei H, 2004, PLOS BIOL, V2, P387, DOI 10.1371/journal.pbio.0020078; Lee KH, 2004, NEUROCHEM RES, V29, P1405, DOI 10.1023/B:NERE.0000026404.08779.43; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Melikian HE, 1999, J NEUROSCI, V19, P7699; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; SHEU FS, 1990, BIOCHEM BIOPH RES CO, V171, P1236, DOI 10.1016/0006-291X(90)90818-8; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Steketee JD, 1998, NEUROPHARMACOLOGY, V37, P339, DOI 10.1016/S0028-3908(98)00022-7; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; WANG T, 1990, J PHARMACOL EXP THER, V252, P689; WANG T, 1990, J MEMBRANE BIOL, V117, P131, DOI 10.1007/BF01868680; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zheng YN, 2003, J AM SOC NEPHROL, V14, P1116, DOI 10.1097/01.ASN.0000064700.58048.C1	41	109	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10914	10919		10.1074/jbc.M413887200	http://dx.doi.org/10.1074/jbc.M413887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647254	hybrid			2022-12-25	WOS:000227761800006
J	Vardouli, L; Moustakas, A; Stournaras, C				Vardouli, L; Moustakas, A; Stournaras, C			LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; LIM-KINASE; POLYMERIZATION DYNAMICS; SMAD PROTEINS; RHO-GTPASES; MESENCHYMAL TRANSDIFFERENTIATION; ACTIVATION; RECEPTOR; RAS; ROCK	Reorganization of the actin cytoskeleton in response to growth factor signaling, such as transforming growth factor beta (TGF-beta), controls cell adhesion, motility, and growth of diverse cell types. In Swiss3T3 fibroblasts, a widely used model for studies of actin reorganization, TGF-beta 1 induced rapid actin polymerization into stress fibers and concomitantly activated RhoA and RhoB small GTPases. Consequently, dominant-negative RhoA and RhoB mutants blocked TGF-beta 1-induced actin reorganization. Because Rho GTPases are known to regulate the activity of LIM-kinases (LIMK), we found that TGF-beta 1 induced LIMK2 phosphorylation with similar kinetics to Rho activation. Cofilin and LIMK2 co-precipitated and cofilin became phosphorylated in response to TGF-beta 1, whereas RNA interference against LIMK2 blocked formation of new stress fibers by TGF-beta 1. Because the kinase ROCK1 links Rho GTPases to LIMK2, we found that inhibiting ROCK1 activity blocked completely TGF-beta 1-induced LIMK2/cofilin phosphorylation and downstream stress fiber formation. We then tested whether the canonical TGF-beta receptor/Smad pathway mediates regulation of the above effectors and actin reorganization. Adenoviruses expressing constitutively activated TGF-beta type I receptor led to robust actin reorganization and Rho activation, whereas the constitutively activated TGF-beta type I receptor with mutated Smad docking sites (L45 loop) did not affect either actin organization or Rho activity. In line with this, ectopic expression of the inhibitory Smad7 inhibited TGF-beta 1-induced Rho activation and cytoskeletal reorganization. Our data define a novel pathway emanating from the TGF-beta type I receptor and leading to regulation of actin assembly, via the kinase LIMK2.	Ludwig Inst Canc Res, Ctr Biomed, SE-75124 Uppsala, Sweden; Univ Crete, Sch Med, Dept Biochem, GR-71110 Iraklion, Greece	Ludwig Institute for Cancer Research; University of Crete	Moustakas, A (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, SE-75124 Uppsala, Sweden.	aris.mousta-kas@licr.uu.se						Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Carpenter CL, 2000, CRIT CARE MED, V28, pN94, DOI 10.1097/00003246-200004001-00011; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; Dudas M, 2004, DEV BIOL, V266, P96, DOI 10.1016/j.ydbio.2003.10.007; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Foletta VC, 2004, EXP CELL RES, V294, P392, DOI 10.1016/j.yexcr.2003.11.024; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Koukouritaki SB, 1996, J CELL BIOCHEM, V62, P251, DOI 10.1002/(SICI)1097-4644(199608)62:2<251::AID-JCB13>3.0.CO;2-O; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lee-Hoeflich ST, 2004, EMBO J, V23, P4792, DOI 10.1038/sj.emboj.7600418; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Masszi A, 2003, AM J PHYSIOL-RENAL, V284, pF911, DOI 10.1152/ajprenal.00183.2002; Moustakas A, 1999, J CELL SCI, V112, P1169; Moustakas A, 2001, J CELL SCI, V114, P4359; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Papakonstanti EA, 1996, BIOCHEM J, V315, P241, DOI 10.1042/bj3150241; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Piek E, 1999, J CELL SCI, V112, P4557; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stournaras C, 1996, BIOCHEM PHARMACOL, V52, P1339, DOI 10.1016/S0006-2952(96)00389-9; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	51	145	152	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11448	11457		10.1074/jbc.M402651200	http://dx.doi.org/10.1074/jbc.M402651200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647284	hybrid			2022-12-25	WOS:000227761800068
J	Yook, JI; Li, XY; Ota, I; Fearon, ER; Weiss, SJ				Yook, JI; Li, XY; Ota, I; Fearon, ER; Weiss, SJ			Wnt-dependent regulation of the E-cadherin repressor snail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SNAIL; EPITHELIAL-MESENCHYMAL TRANSITIONS; BETA-CATENIN; NEURAL CREST; EXTRACELLULAR-MATRIX; CANCER-CELLS; COLON-CANCER; TUMOR-CELLS; EXPRESSION; PHOSPHORYLATION	Down-regulation of E-cadherin marks the initiation of the epithelial-mesenchymal transition, a process exploited by invasive cancer cells. The zinc finger transcription factor, Snail, functions as a potent repressor of E-cadherin expression that can, acting alone or in concert with the Wnt/beta-catenin/T cell factor axis, induce an epithelial-mesenchymal transition. Although mechanisms that coordinate signaling events initiated by Snail and Wnt remain undefined, we demonstrate that Snail displays beta-catenin-like canonical motifs that support its GSK3 beta-dependent phosphorylation, beta-TrCP-directed ubiquitination, and proteasomal degradation. Accordingly, Wnt signaling inhibits Snail phosphorylation and consequently increases Snail protein levels and activity while driving an in vivo epithelial-mesenchymal transition that is suppressed following Snail knockdown. These findings define a potential mechanism whereby Wnt signaling stabilizes Snail and beta-catenin proteins in tandem fashion so as to cooperatively engage transcriptional programs that control an epithelial-mesenchymal transition.	Univ Michigan, Life Sci Inst 5403, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Yonsei Univ, Coll Dent, Dept Oral Pathol, Project Med Sci BK21, Seoul 120742, South Korea; Univ Michigan, Div Med & Mol Genet, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Div Med & Mol Genet, Ctr Comprehens Canc, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Div Med & Mol Genet, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Yonsei University; Yonsei University Health System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Weiss, SJ (corresponding author), Univ Michigan, Life Sci Inst 5403, Ctr Comprehens Canc, 210 Washtenaw, Ann Arbor, MI 48109 USA.	SJWEISS@umich.edu	高, 雨莉/HGU-8187-2022	Yook, Jong In/0000-0002-7318-6112; Ota, Ichiro/0000-0003-3815-8877	NCI NIH HHS [R01 CA088308, R01 CA085463, R01 CA071699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085463, R01CA088308, R01CA071699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Aybar MJ, 2003, DEVELOPMENT, V130, P483, DOI 10.1242/dev.00238; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hajra KM, 2002, CANCER RES, V62, P1613; He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Howe LR, 1999, CANCER RES, V59, P1572; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; Nagahata T, 2003, CANCER SCI, V94, P515, DOI 10.1111/j.1349-7006.2003.tb01475.x; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Schlessinger K, 2004, NAT CELL BIOL, V6, P913, DOI 10.1038/ncb1004-913; SHIMAMURA K, 1994, DEVELOPMENT, V120, P2225; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wang ZH, 2003, CANCER RES, V63, P5234; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhurinsky J, 2000, J CELL SCI, V113, P3127	45	336	357	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11740	11748		10.1074/jbc.M413878200	http://dx.doi.org/10.1074/jbc.M413878200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647282	hybrid			2022-12-25	WOS:000227761800103
J	Arinze, IJ; Kawai, Y				Arinze, IJ; Kawai, Y			Transcriptional activation of the human G alpha(i2) gene promoter through nuclear factor-kappa B and antioxidant response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; EMBRYONAL CARCINOMA-CELLS; PROTEIN-KINASE; ALPHA-SUBUNIT; MEGAKARYOCYTIC DIFFERENTIATION; K562 CELLS; PROTOONCOGENE TRANSCRIPTION; LOCALIZATION SEQUENCE; OXIDATIVE STRESS; RETINOIC ACID	Very little is known regarding molecular mechanism(s) underlying transcriptional regulation of any G-protein gene despite the importance of G-protein expression in modulating cellular processes. Here we show that phorbol myristate acetate (PMA) and tert-butylhydroquinone (tBHQ), which induce oxidative stress in cells, up-regulate transcription of G alpha(i2) in K562 cells. Redox-sensing chemicals abrogated this transcriptional effect. A dominant negative I-kappa B double mutant (S32A/S36A) suppressed PMA-induced transcription by 54-62%, suggesting involvement of nuclear factor-kappa B (NF-kappa B). SN50, a cell-permeable peptide that inhibits nuclear import of stress-responsive transcription factors (such as NF-kappa B), inhibited PMA- and tBHQ-induced transcription. Deletion of an NF-kappa B-binding motif that maps at +10/+19 in the promoter resulted in 55-60% suppression of PMA- induced transcription, and 81% suppression of tBHQ-induced transcription. Mutation of an antioxidant response element ( ARE) that maps at -84/-76 in the promoter resulted in 51 and 86% decrease in PMA- and tBHQ-induced transcription, respectively. In electrophoretic mobility shift assays, this element formed complexes with the transcription factors NF-E2p45 and Nrf2 that are prototypic for binding to the ARE, as well as with c-Fos, which can also interact with the ARE. Chromatin immunoprecipitation analysis demonstrated recruitment of these transcription factors to the promoter. Exogenously transfected Nrf2 transactivated the G alpha(i2) gene promoter; the cytoskeleton-associated protein, Keap1, abrogated this effect. Taken together, the present studies reveal that transcription factors that bind NF-kappa B and/or antioxidant response elements play an activating role in the transcription of the human G alpha(i2) gene.	Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA	Meharry Medical College	Arinze, IJ (corresponding author), Meharry Med Coll, Dept Biochem, 1005 David B Todd Jr,Blvd, Nashville, TN 37208 USA.	iarinze@mmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008037] Funding Source: NIH RePORTER; NIGMS NIH HHS [S06-GM08037-32] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez-Maqueda M, 2004, J BIOL CHEM, V279, P21929, DOI 10.1074/jbc.M400492200; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 2004, HDB CELL SIGNALING, P99; Arinze IJ, 2003, J BIOL CHEM, V278, P17785, DOI 10.1074/jbc.M209430200; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BURGER SR, 1992, EXP CELL RES, V202, P28, DOI 10.1016/0014-4827(92)90400-3; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Datta R, 2000, J BIOL CHEM, V275, P41000, DOI 10.1074/jbc.M009322200; Davis MG, 2000, BIOCHEM J, V346, P455, DOI 10.1042/0264-6021:3460455; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Eschenhagen T, 1996, BASIC RES CARDIOL, V91, P41, DOI 10.1007/BF00795361; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 2002, SIGNAL TRANSDUCTION, P208; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; ITO K, 1997, BIOCHEM BIOPH RES CO, V236, P313; ITO K, 1995, MOL CELL BIOL, V15, P4184; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Kang CD, 1996, BIOCHEM BIOPH RES CO, V221, P95, DOI 10.1006/bbrc.1996.0551; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KINANE TB, 1993, J BIOL CHEM, V268, P24669; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Kinane TB, 1995, J BIOL CHEM, V270, P30760, DOI 10.1074/jbc.270.51.30760; LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304; Li JJ, 1997, CANCER RES, V57, P3569; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu DY, 2004, J BIOL CHEM, V279, P48434, DOI 10.1074/jbc.M407190200; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nishida M, 2002, J BIOL CHEM, V277, P9036, DOI 10.1074/jbc.M107392200; Papaiahgari S, 2004, J BIOL CHEM, V279, P42302, DOI 10.1074/jbc.M408275200; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SHETH B, 1991, BIOCHEM J, V275, P809, DOI 10.1042/bj2750809; Song XS, 2001, J BIOL CHEM, V276, P34651, DOI 10.1074/jbc.M105894200; SOZERI O, 1992, ONCOGENE, V7, P2259; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WEINSTEIN LS, 1990, MOL ENDOCRINOL, V4, P958, DOI 10.1210/mend-4-7-958; Werry TD, 2003, BIOCHEM J, V374, P281, DOI 10.1042/BJ20030312; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233	64	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9786	9795		10.1074/jbc.M414006200	http://dx.doi.org/10.1074/jbc.M414006200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640523	hybrid			2022-12-25	WOS:000227559600007
J	Dorval, KM; Bobechko, BP; Ahmad, KF; Bremner, R				Dorval, KM; Bobechko, BP; Ahmad, KF; Bremner, R			Transcriptional activity of the paired-like homeodomain proteins CHX10 and VSX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIPOLAR CELL-DIFFERENTIATION; DNA-SEQUENCE RECOGNITION; TATA-BINDING PROTEIN; HOMEOBOX GENE; HISTONE DEACETYLASE; REPRESSES TRANSCRIPTION; EXPRESSION; GROUCHO; DROSOPHILA; PHOTORECEPTOR	CHX10 and VSX1 are homeodomain (HD) proteins essential for normal retinal development. CHX10 is required first for retinal progenitor cell proliferation and later for bipolar cell differentiation, whereas VSX1 is important in the terminal differentiation of a subset of bipolar cells. Elucidating the transcriptional activity of CHX10 and VSX1 is required to understand how these factors control retinal development. We show that CHX10 and Vsx1 can function as transcriptional repressors. When tethered to a promoter by a heterologous LexA DNA-binding domain or its HD, CHX10 repressed multiple classes of activators in different immortalized cell lines. CHX10 blocked TATA-containing and TATA-less promoters, repressed at a distance, and inhibited a complex enhancer positioned upstream or downstream of the reporter gene, whereas retinoblastoma protein (RB) inhibited the downstream enhancer only. Interestingly, CHX10 mildly potentiated a subset of activators in chick neuronal cultures. Thus, CHX10 is both a versatile repressor and a context-specific weak activator. The CHX10 HD and CVC domains were sufficient for DNA binding and repression. VSX1 contains closely related homeo and CVC domains and, like CHX10, also repressed transcription. A VSX1 HD mutation, R166W, that impairs DNA binding and causes keratoconus in humans, hindered repressor function. Therefore, CHX10 and VSX1 may control retinal bipolar cell specification or differentiation by repressing genes required for the development of other cell types.	Univ Toronto, Cellular & Mol Div, Toronto Western Res Inst, Univ Hlth Network Program, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Ophthalmol & Visual Sci, Toronto, ON M5T 2S8, Canada; Univ Toronto, Vis Sci Res Program, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto	Bremner, R (corresponding author), Univ Toronto, Cellular & Mol Div, Toronto Western Res Inst, Univ Hlth Network Program, Mc6-424,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	rbremner@uhnres.utoronto.ca	Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212				ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ASO T, 1994, EMBO J, V13, P435, DOI 10.1002/j.1460-2075.1994.tb06278.x; Barabino SML, 1997, MECH DEVELOP, V63, P133, DOI 10.1016/S0925-4773(97)00036-1; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Bone-Larson C, 2000, J NEUROBIOL, V42, P232, DOI 10.1002/(SICI)1097-4695(20000205)42:2<232::AID-NEU7>3.0.CO;2-4; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Briata P, 1997, FEBS LETT, V402, P131, DOI 10.1016/S0014-5793(96)01512-8; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; Chen CMA, 2000, MECH DEVELOP, V90, P293; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Chow RL, 2004, P NATL ACAD SCI USA, V101, P1754, DOI 10.1073/pnas.0306520101; Chow RL, 2001, MECH DEVELOP, V109, P315, DOI 10.1016/S0925-4773(01)00585-8; DANIELS MP, 1974, J CELL BIOL, V63, P691, DOI 10.1083/jcb.63.2.691; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Green ES, 2003, DEVELOPMENT, V130, P539, DOI 10.1242/dev.00275; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hatakeyama J, 2001, DEVELOPMENT, V128, P1313; Hayashi T, 2000, GENOMICS, V67, P128, DOI 10.1006/geno.2000.6248; Heon E, 2002, HUM MOL GENET, V11, P1029, DOI 10.1093/hmg/11.9.1029; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; Hovde S, 2001, BIOCHEMISTRY-US, V40, P12013, DOI 10.1021/bi0108148; Hu YS, 1995, J CELL BIOCHEM, V59, P486, DOI 10.1002/jcb.240590409; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; Kageyama R, 1999, CELL RES, V9, P179, DOI 10.1038/sj.cr.7290016; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; Kobayashi M, 2001, DEVELOPMENT, V128, P1805; LEVINE EM, 1994, J COMP NEUROL, V348, P596, DOI 10.1002/cne.903480409; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Lopez-Rios J, 1999, MECH DEVELOP, V83, P155, DOI 10.1016/S0925-4773(99)00017-9; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mailhos C, 1998, DEVELOPMENT, V125, P937; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; Mintz-Hittner HA, 2004, OPHTHALMOLOGY, V111, P828, DOI 10.1016/j.ophtha.2003.07.006; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Ohtoshi A, 2004, CURR BIOL, V14, P530, DOI 10.1016/j.cub.2004.02.027; Ohtoshi A, 2001, BIOCHEM BIOPH RES CO, V286, P133, DOI 10.1006/bbrc.2001.5372; Passini MA, 1997, J COMP NEUROL, V388, P495, DOI 10.1002/(SICI)1096-9861(19971124)388:3<495::AID-CNE11>3.0.CO;2-L; Passini MA, 1998, DEV BRAIN RES, V109, P129, DOI 10.1016/S0165-3806(98)00069-8; Passini MA, 1998, DEV GENET, V23, P128, DOI 10.1002/(SICI)1520-6408(1998)23:2&lt;128::AID-DVG5&gt;3.0.CO;2-8; Percin EF, 2000, NAT GENET, V25, P397, DOI 10.1038/78071; POMERANTZ JL, 1994, BIOCHEMISTRY-US, V33, P10851, DOI 10.1021/bi00202a001; Rowan S, 2004, DEV BIOL, V271, P388, DOI 10.1016/j.ydbio.2004.03.039; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; SEMENZA GL, 1995, BIOCHEM BIOPH RES CO, V209, P257, DOI 10.1006/bbrc.1995.1497; Semina EV, 2000, GENOMICS, V63, P289, DOI 10.1006/geno.1999.6093; SVENDSEN PC, 1995, DEVELOPMENT, V121, P1253; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Toy J, 2002, INVEST OPHTH VIS SCI, V43, P3522; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TREISMAN J, 1989, CELL, V59, P553; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhu CQC, 2002, DEVELOPMENT, V129, P2835	81	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10100	10108		10.1074/jbc.M412676200	http://dx.doi.org/10.1074/jbc.M412676200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647262	hybrid			2022-12-25	WOS:000227559600045
J	Gorrell, A; Lawrence, SH; Ferry, JG				Gorrell, A; Lawrence, SH; Ferry, JG			Structural and kinetic analyses of arginine residues in the active site of the acetate kinase from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; BACTERIAL PHOSPHOTRANSFERASE SYSTEM; ESCHERICHIA-COLI; PHOSPHORYL TRANSFER; CRYSTAL-STRUCTURE; SUGAR-TRANSPORT; GUANIDINE DERIVATIVES; CHEMICAL RESCUE; GLYCEROL KINASE; ENZYME-I	Acetate kinase catalyzes transfer of the gamma-phosphate of ATP to acetate. The only crystal structure reported for acetate kinase is the homodimeric enzyme from Methanosarcina thermophila containing ADP and sulfate in the active site ( Buss, K. A., Cooper, D. C., Ingram-Smith, C., Ferry, J. G., Sanders, D. A., and Hasson, M. S. ( 2001) J. Bacteriol. 193, 680-686). Here we report two new crystal structure of the M. thermophila enzyme in the presence of substrate and transition state analogs. The enzyme co-crystallized with the ATP analog adenosine 5'-[gamma-thio]triphosphate contained AMP adjacent to thiopyrophosphate in the active site cleft of monomer B. The enzyme co-crystallized with ADP, acetate, Al3+, and F- contained a linear array of ADP-AlF3-acetate in the active site cleft of monomer B. Together, the structures clarify the substrate binding sites and support a direct in-line transfer mechanism in which AlF3 mimics the meta-phosphate transition state. Monomers A of both structures contained ADP and sulfate, and the active site clefts were closed less than in monomers B, suggesting that domain movement contributes to catalysis. The finding that His(180) was in close proximity to AlF3 is consistent with a role for stabilization of the meta-phosphate that is in agreement with a previous report indicating that this residue is essential for catalysis. Residue Arg(241) was also found adjacent to AlF3, consistent with a role for stabilization of the transition state. Kinetic analyses of Arg(241) and Arg(91) replacement variants indicated that these residues are essential for catalysis and also indicated a role in binding acetate.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ferry, JG (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	jgf3@psu.edu			NIGMS NIH HHS [GM44661] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044661] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ALLEN SHG, 1964, J BACTERIOL, V87, P171, DOI 10.1128/JB.87.1.171-187.1964; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; Boehlein SK, 1997, J BIOL CHEM, V272, P12384, DOI 10.1074/jbc.272.19.12384; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buss KA, 2001, J BACTERIOL, V183, P680, DOI 10.1128/JB.183.2.680-686.2001; Buss KA, 1997, PROTEIN SCI, V6, P2659; Bystrom CE, 1999, BIOCHEMISTRY-US, V38, P3508, DOI 10.1021/bi982460z; DAILEY FE, 1993, J BACTERIOL, V175, P3236, DOI 10.1128/JB.175.10.3236-3239.1993; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1506, DOI 10.1021/bi00548a038; FERRY JG, 1992, CRIT REV BIOCHEM MOL, V27, P473, DOI 10.3109/10409239209082570; FERRY JG, 1992, J BACTERIOL, V174, P5489, DOI 10.1128/JB.174.17.5489-5495.1992; FOX DK, 1986, J BIOL CHEM, V261, P3487; FOX DK, 1986, J BIOL CHEM, V261, P3498; GUNNARSSON LAH, 1982, FEMS MICROBIOL LETT, V14, P317; Hurley JH, 1996, ANNU REV BIOPH BIOM, V25, P137; Ingram-Smith C, 2000, J BIOL CHEM, V275, P33765, DOI 10.1074/jbc.M005303200; Iyer PP, 2001, J BACTERIOL, V183, P4244, DOI 10.1128/JB.183.14.4244-4250.2001; Iyer PP, 2004, STRUCTURE, V12, P559, DOI 10.1016/j.str.2004.03.007; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARL DM, 1980, MICROBIOL REV, V44, P739, DOI 10.1128/MMBR.44.4.739-796.1980; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATIMER MT, 1993, J BACTERIOL, V175, P6822, DOI 10.1128/jb.175.21.6822-6829.1993; Lehoux IE, 2000, BIOCHEMISTRY-US, V39, P10055, DOI 10.1021/bi000161f; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; Lipmann F, 1944, J BIOL CHEM, V155, P55; LIU F, 1990, J BIOL CHEM, V265, P7401; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; Miles RD, 2002, J BIOL CHEM, V277, P22547, DOI 10.1074/jbc.M105921200; Miles RD, 2001, J BIOL CHEM, V276, P45059, DOI 10.1074/jbc.M108355200; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; Pettigrew DW, 1998, ARCH BIOCHEM BIOPHYS, V349, P236, DOI 10.1006/abbi.1997.0444; PHILLIPS MA, 1992, PROTEIN SCI, V1, P517; PURICH DL, 1972, ARCH BIOCHEM BIOPHYS, V149, P307, DOI 10.1016/0003-9861(72)90326-8; ROMANIUK PJ, 1981, J BIOL CHEM, V256, P7322; ROSE IA, 1954, J BIOL CHEM, V211, P737; RUDIGER M, 1995, EMBO J, V14, P1599, DOI 10.1002/j.1460-2075.1995.tb07148.x; Rynkiewicz MJ, 1996, BIOCHEMISTRY-US, V35, P16174, DOI 10.1021/bi961311i; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; Singh-Wissmann K, 2000, BIOCHEMISTRY-US, V39, P3671, DOI 10.1021/bi991998h; Singh-Wissmann K, 1998, J BACTERIOL, V180, P1129, DOI 10.1128/JB.180.5.1129-1134.1998; SKARSTEDT MT, 1976, J BIOL CHEM, V251, P6775; TODHUNTER JA, 1974, BIOCHEM BIOPH RES CO, V60, P273, DOI 10.1016/0006-291X(74)90201-0; TODHUNTER JA, 1976, ARCH BIOCHEM BIOPHYS, V174, P120, DOI 10.1016/0003-9861(76)90330-1; Tripp BC, 2002, BIOCHEMISTRY-US, V41, P669, DOI 10.1021/bi010768b; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; ZINDER SH, 1985, J BACTERIOL, V163, P317, DOI 10.1128/JB.163.1.317-323.1985	55	42	45	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10731	10742		10.1074/jbc.M412118200	http://dx.doi.org/10.1074/jbc.M412118200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647264	hybrid			2022-12-25	WOS:000227559600119
J	Kambo, A; Sharma, VS; Casteel, DE; Woods, VL; Pilz, RB; Boss, GR				Kambo, A; Sharma, VS; Casteel, DE; Woods, VL; Pilz, RB; Boss, GR			Nitric oxide inhibits mammalian methylmalonyl-CoA mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND-DISSOCIATION ENERGY; METHIONINE SYNTHASE; PROPIONATE METABOLISM; COBALAMIN METABOLISM; HUMAN-LYMPHOBLASTS; REDUCED COBALAMIN; CRYSTAL-STRUCTURE; PURINE SYNTHESIS; NITROUS-OXIDE; COENZYME	Methylmalonyl-CoA mutase is a key enzyme in intermediary metabolism, and children deficient in enzyme activity have severe metabolic acidosis. We found that nitric oxide (NO) inhibits methylmalonyl-CoA mutase activity in rodent cell extracts. The inhibition of enzyme activity occurred within minutes and was not prevented by thiols, suggesting that enzyme inhibition was not occurring via NO reaction with cysteine residues to form nitrosothiol groups. Enzyme inhibition was dependent on the presence of substrate, implying that NO was reacting with cobalamin(II) (Cbl(II)) and/or the deoxyadenosyl radical ((CH2)-C-.-Ado), both of which are generated from the co-factor of the enzyme, 5 '-deoxyadenosylcobalamin (AdoCbl), on substrate binding. Consistent with this hypothesis was the finding that high micromolar concentrations (>= 600 mu M) of oxygen also inhibited enzyme activity. To study the mechanism of NO reaction with AdoCbl, we simulated the enzymatic reaction by photolyzing AdoCbl, and found that even at low NO concentrations, NO reacted with both the generated Cbl(II) and (CH2)-C-.-Ado indicating that NO could effectively compete with the back formation of AdoCbl. Thus, NO inhibition of methylmalonyl-CoA mutase appeared to be from the reaction of NO with both AdoCbl intermediates (Cbl(II) and (CH2)-C-.-Ado) generated during the enzymatic reaction. The inhibition of methylmalonyl-CoA mutase by NO was likely of physiological relevance because a NO donor inhibited enzyme activity in intact cells, and scavenging NO from cells or inhibiting cellular NO synthesis increased methylmalonyl-CoA mutase activity when measured subsequently in cell extracts.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gboss@ucsd.edu		Boss, Gerry/0000-0002-9758-8714	NCI NIH HHS [CA90932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BABIOR BM, 1969, BIOCHEMISTRY-US, V8, P2662, DOI 10.1021/bi00834a063; Banerjee R, 2003, CHEM REV, V103, P2083, DOI 10.1021/cr0204395; Banerjee R, 2002, BIOCHEM SOC T, V30, P621, DOI 10.1042/bst0300621; BAYSTON JH, 1969, J AM CHEM SOC, V91, P2775, DOI 10.1021/ja01038a060; BOSS GR, 1982, J BIOL CHEM, V257, P4242; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brouwer M, 1996, BLOOD, V88, P1857; CHEN EF, 1990, J BIOL CHEM, V265, P12987; Danishpajooh IO, 2001, J BIOL CHEM, V276, P27296, DOI 10.1074/jbc.M104043200; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; FINKE RG, 1984, INORG CHEM, V23, P3041, DOI 10.1021/ic00188a002; FIRTH RA, 1969, J CHEM SOC A, P381, DOI 10.1039/j19690000381; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; Foster MW, 2004, J BIOL CHEM, V279, P25891, DOI 10.1074/jbc.M313853200; GIBSON QH, 1970, J BIOL CHEM, V245, P3285; Glasstone S, 1955, TXB PHYS CHEM; HAY BP, 1986, J AM CHEM SOC, V108, P4820, DOI 10.1021/ja00276a020; HOGENKAMP HPC, 1963, J BIOL CHEM, V238, P477; Holscher C, 1997, TRENDS NEUROSCI, V20, P298, DOI 10.1016/S0166-2236(97)01065-5; IGNARRO L, 1995, ADV PHARMACOL, V34, P215; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KIKUCHI M, 1989, CLIN CHIM ACTA, V184, P307, DOI 10.1016/0009-8981(89)90064-8; KONDO H, 1981, J CLIN INVEST, V67, P1270, DOI 10.1172/JCI110155; Kruszyna H, 1998, J PHARMACOL EXP THER, V285, P665; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LloydJones DM, 1996, ANNU REV MED, V47, P365; LOTT WB, 1995, J AM CHEM SOC, V117, P12194, DOI 10.1021/ja00154a020; Ludwig ML, 1997, ANNU REV BIOCHEM, V66, P269, DOI 10.1146/annurev.biochem.66.1.269; Maiti N, 1999, J BIOL CHEM, V274, P32733, DOI 10.1074/jbc.274.46.32733; Mancia F, 1998, STRUCTURE, V6, P711, DOI 10.1016/S0969-2126(98)00073-2; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Mancia F, 1999, BIOCHEMISTRY-US, V38, P7999, DOI 10.1021/bi9903852; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; MORROW G, 1976, CLIN GENET, V10, P218; Nicolaou A, 1997, EUR J BIOCHEM, V244, P876, DOI 10.1111/j.1432-1033.1997.00876.x; Nicolaou A, 1996, EUR J CLIN INVEST, V26, P167, DOI 10.1046/j.1365-2362.1996.122254.x; PILZ RB, 1984, J BIOL CHEM, V259, P2927; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; RIEDEL B, 1995, CLIN CHEM, V41, P1164; Riedel B, 1999, BIOCHEM J, V341, P133, DOI 10.1042/0264-6021:3410133; ROCHELLE LG, 1995, J PHARMACOL EXP THER, V275, P48; Saavedra-Molina A, 2003, AMINO ACIDS, V24, P95, DOI 10.1007/s00726-002-0331-7; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SCRIVER CR, 1995, METABOLIC MOL BASES, P1423; Sharma VS, 2003, BIOCHEMISTRY-US, V42, P8900, DOI 10.1021/bi034469t; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Thoma NH, 2000, BIOCHEMISTRY-US, V39, P9213, DOI 10.1021/bi0004302; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Vlasie MD, 2004, BIOCHEMISTRY-US, V43, P8410, DOI 10.1021/bi036299q; WILKEMEYER M, 1992, SOMAT CELL MOLEC GEN, V18, P493, DOI 10.1007/BF01232646; WILKEMEYER MF, 1990, BIOCHEM J, V271, P449, DOI 10.1042/bj2710449; WILLARD HF, 1977, BIOCHEM BIOPH RES CO, V78, P927, DOI 10.1016/0006-291X(77)90511-3; WILLARD HF, 1976, HUM GENET, V34, P277, DOI 10.1007/BF00295291; Wolak M, 2001, J AM CHEM SOC, V123, P9780, DOI 10.1021/ja010530a	57	26	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10073	10082		10.1074/jbc.M411842200	http://dx.doi.org/10.1074/jbc.M411842200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647267	hybrid			2022-12-25	WOS:000227559600042
J	Abdel-Rahman, WM; Ollikainen, M; Kariola, R; Jarvinen, HJ; Mecklin, JP; Nystrom-Lahti, M; Knuutila, S; Peltomaki, P				Abdel-Rahman, WM; Ollikainen, M; Kariola, R; Jarvinen, HJ; Mecklin, JP; Nystrom-Lahti, M; Knuutila, S; Peltomaki, P			Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations	ONCOGENE			English	Article						HNPCC; colorectal cancer; mismatch repair; beta-catenin; CGH; p53; KRAS; CDX2; LOH	NONPOLYPOSIS COLON-CANCER; BETA-CATENIN; MICROSATELLITE INSTABILITY; INSTITUTE WORKSHOP; CDX2 EXPRESSION; APC MUTATIONS; ALLELIC LOSS; CARCINOMAS; TUMORS; DNA	A considerable fraction of families with HNPCC shows no germline mismatch repair (MMR) gene mutations. We previously detected 'hidden' MMR gene defects in 42% of such families, leaving the remaining 58% 'truly' mutation negative. Here, we characterized 50 colorectal carcinomas and five adenomas arising in HNPCC families; 24 truly MMR gene mutation negative and 31 MMR gene mutation positive. Among 31 tumors from MMR gene mutation positive families, 25 (81%) had active Wnt signaling as indicated by aberrant beta-catenin localization with or without CTNNB1 mutations, compared to only 7/18 tumors from MMR gene mutation negative families (39%; P = 0.005). CGH studies revealed stable profiles in 9/16 (56%) of MMR gene mutation negative tumors, which was significantly associated with membranous beta-catenin (P = 0.005). Tumors with membranous beta-catenin from the MMR gene mutation negative group also showed low frequency of TP53 mutations compared to those with nuclear beta-catenin. Thus, a majority of the MMR gene mutation negative cases exhibited a novel molecular pattern characterized by the paucity of changes in common pathways to colorectal carcinogenesis. This feature distinguishes the MMR gene mutation negative families from both HNPCC families linked to MMR defects and sporadic cases, suggesting the involvement of novel predisposition genes and pathways in such families.	Univ Helsinki, Dept Med Genet, Biomed Helsinki, Helsinki 00014, Finland; Zagazig Univ, Dept Pathol, Fac Med, Zagazig, Egypt; Univ Helsinki, Dept Biol & Environm Sci, Helsinki, Finland; Helsinki Univ Hosp, Dept Clin Genet, Helsinki, Finland; Helsinki Univ Hosp, Dept Surg 2, Helsinki, Finland; Jyvaskyla Cent Hosp, Dept Surg, Jyvaskyla, Finland; Haartman Inst, Dept Pathol, Lab Cytomol Genet, Helsinki, Finland; Univ Helsinki, HUSLAB, Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland	University of Helsinki; Egyptian Knowledge Bank (EKB); Zagazig University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Central Finland Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Abdel-Rahman, WM (corresponding author), Univ Helsinki, Dept Med Genet, Biomed Helsinki, POB 63 Haartmaninkatu 8, Helsinki 00014, Finland.	Wael.Abdel-Rahman@helsinki.fi	Mecklin, Jukka-Pekka/AAB-5378-2020; Mecklin, Jukka-Pekka/AAC-9650-2019; Ollikainen, Miina E/K-7464-2012	Mecklin, Jukka-Pekka/0000-0003-4895-2249; Ollikainen, Miina E/0000-0003-3661-7400; Abdel-Rahman, Wael/0000-0002-2149-1043; Peltomaki, Paivi/0000-0001-8819-2980; Nystrom, Minna/0000-0003-0827-0243				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Boland CR, 1998, CANCER RES, V58, P5248; Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653; COSTA A, 1995, J PATHOL, V176, P45, DOI 10.1002/path.1711760108; Curtis LJ, 2000, J PATHOL, V192, P440; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; El-Rifai W, 1997, LAB INVEST, V77, P699; Fujiwara T, 1998, AM J PATHOL, V153, P1063, DOI 10.1016/S0002-9440(10)65651-9; Hao XP, 2002, VIRCHOWS ARCH, V440, P362, DOI 10.1007/s00428-001-0570-0; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Holmberg M, 1998, Hum Mutat, V11, P482; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Huang JQ, 2001, CANCER RES, V61, P1619; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; KARIOLA R, IN PRESS FAM CANC; KIM HG, 1994, AM J PATHOL, V145, P148; Kitaeva MN, 1997, CANCER RES, V57, P4478; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2002, AM J PATHOL, V160, P1953, DOI 10.1016/S0002-9440(10)61144-3; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Leslie A, 2003, CANCER RES, V63, P4656; Liu T, 2001, CANCER RES, V61, P7798; Lovig T, 2002, SCAND J GASTROENTERO, V37, P1184, DOI 10.1080/003655202760373407; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Miyaki M, 1999, CANCER RES, V59, P4506; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P223, DOI 10.1002/gcc.2870140312; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Qualtrough D, 2002, GUT, V51, P184, DOI 10.1136/gut.51.2.184; Renkonen E, 2003, J CLIN ONCOL, V21, P3629, DOI 10.1200/JCO.2003.03.181; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Salahshor S, 1999, GENE CHROMOSOME CANC, V26, P247, DOI 10.1002/(SICI)1098-2264(199911)26:3<247::AID-GCC9>3.3.CO;2-8; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schweizer P, 2001, CANCER RES, V61, P2813; Sparks AB, 1998, CANCER RES, V58, P1130; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068	49	69	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1542	1551		10.1038/sj.onc.1208387	http://dx.doi.org/10.1038/sj.onc.1208387			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674332				2022-12-25	WOS:000227218200007
J	Curtin, JC; Spinella, MJ				Curtin, JC; Spinella, MJ			p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53	ONCOGENE			English	Article						p53; retinoic acid; embryonal carcinoma; repression	HISTONE-DEACETYLASE INHIBITORS; ACUTE PROMYELOCYTIC LEUKEMIA; TUMOR-CELL DIFFERENTIATION; RETINOIC ACID; TERATOCARCINOMA CELLS; TESTICULAR CANCER; NEURONAL DIFFERENTIATION; INDUCED APOPTOSIS; GENE-EXPRESSION; BINDING DOMAIN	Testicular germ cell tumors (TGCTs) arise despite possessing high levels of wild-type p53, suggesting p53 latency. We have previously shown that p53 repression in TGCT-derived human embryonal carcinoma (EC) is relieved upon treatment with all-trans retinoic acid (RA), resulting in enhanced p53 transactivation activity. To further investigate p53 repression in EC, a series of gal4-p53 truncation constructs were generated. Deletion of the core DNA-binding region, residues 117-274, had no effect on basal or RA-induced p53 activity. Progressively, larger truncations were made in the C- or N-terminal direction. Deletion of residues toward the C-terminus of p53 as far as residue 354 did not affect either the basal or RA-inducible activity of gal4-p53. When a small region in the N-terminus was deleted ( residues 105-116), relief of the basal repression of p53 activity characteristic of EC was observed. Fusion of this region to the VP16 activation domain (VPAD) resulted in a 10-20-fold repression of VPAD activity in NT2/D1 human EC cells, indicating that this region acts as a heterologous repressor. Owing to its location in the N-terminal half of p53, we have named this region the p53 N-terminal Repression Domain (p53-NRD). The p53-NRD mediated repression in a variety of cell lines, with the most prominent repression observed in human EC cells. While RA alone had no effect on p53-NRD activity, cotreatment with RA and the histone deacetylase inhibitor trichostatin-A (TSA) completely relieved p53-NRD-mediated repression. In contrast, NRD-mediated repression was not sensitive to RA and TSA in a derived RA-resistant cell line with a retinoic acid receptor gamma (RARgamma) defect, but sensitivity could be restored with transfection of RARgamma. These data indicate that a unique repressor domain resides in p53 at residues 90-116 whose activity can be modulated in the presence of 'differentiation therapy' and 'transcription therapy' agents.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [K01CA075154] Funding Source: NIH RePORTER; NCI NIH HHS [K01-CA75154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Andrews PW, 2002, PHILOS T R SOC B, V357, P405, DOI 10.1098/rstb.2002.1058; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; Chaganti RSK, 2000, CANCER RES, V60, P1475; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Chresta CM, 1996, CANCER RES, V56, P1834; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; Einhorn Lawrence H, 2002, Chest Surg Clin N Am, V12, P695, DOI 10.1016/S1052-3359(02)00029-7; Ferrara FF, 2001, CANCER RES, V61, P2; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Glass CK, 2000, GENE DEV, V14, P121; Gu JJ, 2001, ONCOGENE, V20, P3519, DOI 10.1038/sj.onc.1204454; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jones RH, 2003, EUR J CANCER, V39, P147, DOI 10.1016/S0959-8049(02)00612-3; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kouraklis G., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P477, DOI 10.2174/1568011023353921; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Lutzker SG, 2001, ONCOGENE, V20, P2982, DOI 10.1038/sj.onc.1204394; Mangelsdorf David J., 1994, P319; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; NASONBURCHENAL K, 1999, RETINOIDS HDB EXPT P, P301; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PENG HQ, 1993, CANCER RES, V53, P3574; Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368; Ronca F, 1999, J BIOL CHEM, V274, P18128, DOI 10.1074/jbc.274.25.18128; Shin DM, 1997, CLIN CANCER RES, V3, P875; Shin DM, 2000, J NATL CANCER I, V92, P69, DOI 10.1093/jnci/92.1.69; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Spinella MJ, 2003, J NUTR, V133, p273S, DOI 10.1093/jn/133.1.273S; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Varley Jenny, 2003, Methods Mol Biol, V222, P117; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zeng XY, 2000, CANCER RES, V60, P6184; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	58	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1481	1490		10.1038/sj.onc.1208130	http://dx.doi.org/10.1038/sj.onc.1208130			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674351				2022-12-25	WOS:000227218200001
J	Matarrese, P; Straface, E; Pietraforte, D; Gambardella, L; Vona, R; Maccaglia, A; Minetti, M; Malorni, W				Matarrese, P; Straface, E; Pietraforte, D; Gambardella, L; Vona, R; Maccaglia, A; Minetti, M; Malorni, W			Peroxynitrite induces senescence and apoptosis of red blood cells through the activation of aspartyl and cysteinyl proteases	FASEB JOURNAL			English	Article						erythrocyte; nitric oxide; cell death; aging; oxidative stress	OBSTRUCTIVE PULMONARY-DISEASE; HUMAN-ERYTHROCYTE-MEMBRANE; OXIDATIVE STRESS; NITRIC-OXIDE; PHOSPHATIDYLSERINE EXPOSURE; PHOSPHOLIPID ASYMMETRY; GLYCOPHORIN-A; CYTOPLASMIC DOMAIN; N-ACETYLCYSTEINE; BAND-3	Changes in the oxidative status of erythrocytes can reduce cell lifetime, oxygen transport, and delivery capacity to peripheral tissues and have been associated with a plethora of human diseases. Among reactive oxygen and nitrogen species of importance in red blood cell (RBC) homeostasis, superoxide and nitric oxide radicals play a key role. In the present work, we evaluated subcellular effects induced by peroxynitrite, the product of the fast reaction between superoxide and nitric oxide. Peroxynitrite induced 1) oxidation of oxyhemoglobin to methemoglobin, 2) cytoskeleton rearrangement, 3) ultrastructural alterations, and 4) altered expression of band-3 and decreased expression of glycophorin A. With respect to control cells, this occurred in a significantly higher percentage of human RBC (similar to 40%). The presence of antioxidants inhibited these modifications. Furthermore, besides these senescence-associated changes, other important modifications, absent in control RBC and usually associated with apoptotic cell death, were detected in a small but significant subset of peroxynitrite-exposed RBC (similar to 7%). Active protease cathepsin E and mu-calpain increased; activation of caspase 2 and caspase 3 was detected; and phosphatidylserine externalization, an early marker of apoptosis, was observed. Conversely, inhibition of cathepsin E, mu-calpain, as well as caspase 2 and 3 by specific inhibitors resulted in a significant impairment of erythrocyte "apoptosis." Altogether, these results indicate that peroxynitrite, a milestone of redox-mediated damage in human pathology, can hijack human RBC toward senescence and apoptosis by a mechanism involving both cysteinyl and aspartyl proteases.	Ist Super Sanita, Dept Drug Res & Evaluat, Sect Cell Aging & Degenerat, I-00161 Rome, Italy; Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Malorni, W (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Sect Cell Aging & Degenerat, Viale Regina Elena 299, I-00161 Rome, Italy.	Malorni@iss.it	Matarrese, Paola/A-4369-2014; Malorni, Walter/G-5874-2016; Pietraforte, Donatella/G-1816-2011; Vona, Rosa/AAL-4747-2021	Vona, Rosa/0000-0003-4501-8661; Pietraforte, Donatella/0000-0001-6370-912X; malorni, walter/0000-0002-1223-7000				Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; Bilto YY, 1998, CLIN HEMORHEOL MICRO, V18, P165; Boas FE, 1998, P NATL ACAD SCI USA, V95, P3077, DOI 10.1073/pnas.95.6.3077; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; Bratosin D, 2002, VOX SANG, V83, P307, DOI 10.1111/j.1423-0410.2002.tb05324.x; CAPRARI P, 1995, CHEM-BIOL INTERACT, V94, P243, DOI 10.1016/0009-2797(94)03339-A; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Comporti M, 2002, FREE RADICAL BIO MED, V32, P568, DOI 10.1016/S0891-5849(02)00759-1; CONNOR J, 1994, J BIOL CHEM, V269, P2399; Daugas E, 2001, CELL DEATH DIFFER, V8, P1131, DOI 10.1038/sj.cdd.4400953; de Jong K, 2001, BLOOD, V98, P1577, DOI 10.1182/blood.V98.5.1577; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; Fiorani M, 2002, FREE RADICAL BIO MED, V32, P64, DOI 10.1016/S0891-5849(01)00762-6; Galli F, 2002, NITRIC OXIDE-BIOL CH, V6, P186, DOI 10.1006/niox.2001.0397; GLASER T, 1994, P NATL ACAD SCI USA, V91, P7879, DOI 10.1073/pnas.91.17.7879; Grant SG, 1997, GENET TEST, V1, P261, DOI 10.1089/gte.1997.1.261; Groves JD, 1999, BIOCHEM SOC T, V27, P917, DOI 10.1042/bst0270917; Grzelak A, 2001, CELL BIOL INT, V25, P1163, DOI 10.1006/cbir.2001.0778; HUGHES HM, 1989, BIOCHEM J, V259, P537, DOI 10.1042/bj2590537; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P451; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kean LS, 2002, EXP HEMATOL, V30, P394, DOI 10.1016/S0301-472X(02)00780-4; Kiefer CR, 2000, CURR OPIN HEMATOL, V7, P113, DOI 10.1097/00062752-200003000-00007; Koppenol S, 1998, BBA-BIOMEMBRANES, V1369, P221, DOI 10.1016/S0005-2736(97)00224-1; Kuypers F A, 1998, Curr Opin Hematol, V5, P122; Kuypers FA, 1996, BLOOD, V87, P1179, DOI 10.1182/blood.V87.3.1179.bloodjournal8731179; Kyoizumi S, 1998, HUM GENET, V103, P405, DOI 10.1007/s004390050841; Lang F, 2003, PFLUG ARCH EUR J PHY, V447, P121, DOI 10.1007/s00424-003-1150-8; Lang KS, 2002, CELL PHYSIOL BIOCHEM, V12, P365, DOI 10.1159/000067907; Mallozzi C, 1997, FASEB J, V11, P1281, DOI 10.1096/fasebj.11.14.9409547; Malorni W, 2000, FEBS LETT, V468, P125, DOI 10.1016/S0014-5793(00)01187-X; Mandal D, 2003, J BIOL CHEM, V278, P52551, DOI 10.1074/jbc.M306914200; Mandal D, 2002, FEBS LETT, V513, P184, DOI 10.1016/S0014-5793(02)02294-9; Manno S, 2002, P NATL ACAD SCI USA, V99, P1943, DOI 10.1073/pnas.042688399; Manodori AB, 2002, J LAB CLIN MED, V140, P161, DOI 10.1067/mlc.2002.126504; Matarrese P, 2002, AM J PATHOL, V160, P1507, DOI 10.1016/S0002-9440(10)62577-1; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; Mesquita R, 2002, CLIN HEMORHEOL MICRO, V27, P137; MORROT G, 1986, P NATL ACAD SCI USA, V83, P6863, DOI 10.1073/pnas.83.18.6863; Neri M, 2000, ANAL CELL PATHOL, V21, P35, DOI 10.1155/2000/512786; Ohnishi S. T., 1994, MEMBRANE ABNORMALITI, P1; Pagano G, 1998, MED HYPOTHESES, V51, P253, DOI 10.1016/S0306-9877(98)90084-6; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Patel S, 1999, NAT CELL BIOL, V1, P467, DOI 10.1038/70249; Phumala N, 2003, FREE RADICAL RES, V37, P129, DOI 10.1080/1071576031000060607; Piacentini M, 2002, J NEUROCHEM, V81, P1061; Piagnerelli M, 2003, CRIT CARE MED, V31, P2156, DOI 10.1097/01.CCM.0000079608.00875.14; PICCININI G, 1995, MECH AGEING DEV, V78, P15, DOI 10.1016/0047-6374(94)01511-J; Poole J, 2000, BLOOD REV, V14, P31, DOI 10.1054/blre.1999.0124; PRYOR WA, 1995, AM J PHYSIOL, V268, P699; RADI R, 1991, J BIOL CHEM, V266, P4244; Reliene R, 2002, BLOOD, V100, P2208, DOI 10.1182/blood.V100.6.2208.h81802002208_2208_2215; Ristoff E, 2002, J INHERIT METAB DIS, V25, P223, DOI 10.1023/A:1015634032042; Romero N, 1999, ARCH BIOCHEM BIOPHYS, V368, P23, DOI 10.1006/abbi.1999.1272; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; Schrier SL, 2002, CURR OPIN HEMATOL, V9, P123, DOI 10.1097/00062752-200203000-00007; Steinberg MH, 2003, ANNU REV MED, V54, P89, DOI 10.1146/annurev.med.54.101601.152439; Straface E, 2002, BIOCHEM BIOPH RES CO, V290, P1393, DOI 10.1006/bbrc.2002.6340; Straface E, 2000, BIOCHEM BIOPH RES CO, V279, P552, DOI 10.1006/bbrc.2000.3981; TANAKA KI, 1976, BIOCHIM BIOPHYS ACTA, V426, P218, DOI 10.1016/0005-2736(76)90333-3; vonRuckmann B, 1997, BBA-BIOMEMBRANES, V1325, P226, DOI 10.1016/S0005-2736(96)00261-1; WALDER JA, 1984, J BIOL CHEM, V259, P238; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; Wood BL, 1996, BLOOD, V88, P1873; YAMAMOTO K, 1989, J BIOCHEM-TOKYO, V105, P114, DOI 10.1093/oxfordjournals.jbchem.a122604; Yasin Z, 2003, BLOOD, V102, P365, DOI 10.1182/blood-2002-11-3416	72	91	93	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					416	+		10.1096/fj.04-2450fje	http://dx.doi.org/10.1096/fj.04-2450fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15650007				2022-12-25	WOS:000226576600022
J	Alefantis, T; Mostoller, K; Jain, P; Harhaj, E; Grant, C; Wigdahl, B				Alefantis, T; Mostoller, K; Jain, P; Harhaj, E; Grant, C; Wigdahl, B			Secretion of the human T cell leukemia virus type I transactivator protein Tax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MYELOPATHY/TROPICAL SPASTIC PARAPARESIS; CENTRAL-NERVOUS-SYSTEM; CREB BINDING-PROTEIN; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATOR; ENDOPLASMIC-RETICULUM; 21-BASE-PAIR REPEATS; MOLECULAR MIMICRY; SIGNAL	Human T cell leukemia virus type I (HTLV-I) is the etiologic agent of adult T cell leukemia and HTLV-I-associated myelopathy/tropical spastic paraparesis. The HTLV-I protein Tax is well known as a transcriptional transactivator and inducer of cellular transformation. However, it is also known that extracellular Tax induces the production and release of cytokines, such as tumor necrosis factor-alpha and interleukin-6, which have adverse effects on cells of the central nervous system. The cellular process by which Tax exits the cell into the extracellular environment is currently unknown. In most cell types, Tax has been shown to localize primarily to the nucleus. However, Tax has also been found to accumulate in the cytoplasm. The results contained herein begin to characterize the process of Tax secretion from the cell. Specifically, cytoplasmic Tax was demonstrated to localize to organelles associated with the cellular secretory process including the endoplasmic reticulum and Golgi complex. Additionally, it was demonstrated that full-length Tax was secreted from both baby hamster kidney cells and a human kidney tumor cell line, suggesting that Tax enters the secretory pathway in a leaderless manner. Tax secretion was partially inhibited by brefeldin A, suggesting that Tax migrated from the endoplasmic reticulum to the Golgi complex. In addition, combined treatment of Tax-transfected BHK-21 cells with phorbol myristate acetate and ionomycin resulted in a small increase in the amount of Tax secreted, suggesting that a fraction of cytoplasmic Tax was present in the regulated secretory pathway. These studies begin to provide a link between Tax localization to the cytoplasm, the detection of Tax in the extracellular environment, its possible role as an extracellular effector molecule, and a potential role in neurodegenerative disease associated with HTLV-I infection.	Drexel Univ, Coll Med, Dept Microbiol & Immunol, Inst Mol Med & Infect Dis, Philadelphia, PA 19129 USA; Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA	Drexel University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Miami	Wigdahl, B (corresponding author), Drexel Univ, Coll Med, Dept Microbiol & Immunol, Inst Mol Med & Infect Dis, 2900 Queen Ln, Philadelphia, PA 19129 USA.	brian.wigdahl@drexelmed.edu			NCI NIH HHS [CA54559] Funding Source: Medline; NINDS NIH HHS [1 F31 NS 044801] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS044801] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Barmak K, 2003, VIROLOGY, V308, P1, DOI 10.1016/S0042-6822(02)00091-0; Barmak K, 2003, J NEUROVIROL, V9, P522, DOI 10.1080/13550280390218689; BONNEMA JD, 1994, J IMMUNOL, V152, P2098; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Calegari F, 1999, J BIOL CHEM, V274, P22539, DOI 10.1074/jbc.274.32.22539; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Cowan EP, 1997, J VIROL, V71, P6982, DOI 10.1128/JVI.71.9.6982-6989.1997; DHIBJALBUT S, 1994, ANN NEUROL, V36, P787, DOI 10.1002/ana.410360516; FIBI MR, 1995, BLOOD, V85, P1229, DOI 10.1182/blood.V85.5.1229.bloodjournal8551229; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; GRABENHORST E, 1995, EUR J BIOCHEM, V232, P718, DOI 10.1111/j.1432-1033.1995.718zz.x; Grant C, 2002, J CELL PHYSIOL, V190, P133, DOI 10.1002/JCP.10053; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kubota R, 2000, AIDS RES HUM RETROV, V16, P1705, DOI 10.1089/08892220050193182; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Levin MC, 2002, J INFECT DIS, V186, P1514, DOI 10.1086/344734; Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Liang XH, 1997, MOL IMMUNOL, V34, P907, DOI 10.1016/S0161-5890(97)00098-9; LINDHOLM P F, 1990, New Biologist, V2, P1034; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; Szymocha R, 2000, J NEUROVIROL, V6, P350, DOI 10.3109/13550280009030761; Szymocha R, 2000, J VIROL, V74, P6433, DOI 10.1128/JVI.74.14.6433-6441.2000; Szymocha R, 2000, AIDS RES HUM RETROV, V16, P1723, DOI 10.1089/08892220050193218; WESSNER R, 1995, J NEUROVIROL, V1, P62, DOI 10.3109/13550289509111011; Wessner Renee, 1997, Leukemia (Basingstoke), V11, P10; Yao J, 2000, FRONT BIOSCI-LANDMRK, V5, pD138, DOI 10.2741/Yao; Yao Y, 2000, LEUKEMIA, V14, P535; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	43	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17353	17362		10.1074/jbc.M409851200	http://dx.doi.org/10.1074/jbc.M409851200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15659397	hybrid			2022-12-25	WOS:000228615500100
J	Schlecker, T; Schmidt, A; Dirdjaja, N; Voncken, F; Clayton, C; Krauth-Siegel, RL				Schlecker, T; Schmidt, A; Dirdjaja, N; Voncken, F; Clayton, C; Krauth-Siegel, RL			Substrate specificity, localization, and essential role of the glutathione peroxidase-type tryparedoxin peroxidases in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM; TRYPANOTHIONE REDUCTASE; HYDROPEROXIDE; MITOCHONDRIAL; THIOREDOXIN; METABOLISM; EXPRESSION; GENE; INTERFERENCE; CLONING	Trypanosoma brucei, the causative agent of African sleeping sickness, encodes three nearly identical cysteine homologues of the classical selenocysteine-containing glutathione peroxidases. Although one of the sequences, peroxidase III, carries both putative mitochondrial and glycosomal targeting signals, the proteins are detectable only in the cytosol and mitochondrion of mammalian bloodstream and insect procyclic T. brucei. The enzyme is a trypanothione/tryparedoxin peroxidase as are the 2 Cys-peroxiredoxins of the parasite. Hydrogen peroxide, thymine hydroperoxide, and linoleic acid hydroperoxide are reduced with second order rate constants of 8.7 x 10(4), 7.6 x 10(4), and 4 x 10(4) M-1 s(-1), respectively, and represent probable physiological substrates. Phosphatidylcholine hydroperoxide is a very weak substrate and, in the absence of Triton X-100, even an inhibitor of the enzyme. The substrate preference clearly contrasts with that of the closely related T. cruzi enzyme, which reduces phosphatidylcholine hydroperoxides but not H2O2. RNA interference causes severe growth defects in bloodstream and procyclic cells in accordance with the peroxidases being essential in both developmental stages. Thus, the cellular functions of the glutathione peroxidase-type enzymes cannot be taken over by the 2 Cys-peroxiredoxins that also occur in the cytosol and mitochondrion of the parasite.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; Heidelberg Univ, Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Krauth-Siegel, RL (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 504, D-69120 Heidelberg, Germany.	krauth-siegel@urz.uni-heidelberg.de	Clayton, Christine/K-7700-2019	Clayton, Christine/0000-0002-6384-0731; Voncken, Frank/0000-0002-2929-276X				Bao YP, 1997, FEBS LETT, V410, P210, DOI 10.1016/S0014-5793(97)00591-7; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; Brigelius-Flohe R, 2003, BIOFACTORS, V17, P93, DOI 10.1002/biof.5520170110; Chang TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200; CUNNINGHAM M. P., 1962, TRANS ROY SOC TROP MED AND HYG, V56, P48, DOI 10.1016/0035-9203(62)90088-3; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; Drozdz M, 2002, EMBO J, V21, P1791, DOI 10.1093/emboj/21.7.1791; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Fang J, 2003, ARCH BIOCHEM BIOPHYS, V414, P294, DOI 10.1016/S0003-9861(03)00196-6; Flohe L, 2002, METHOD ENZYMOL, V347, P244; FORSTROM JW, 1979, ARCH BIOCHEM BIOPHYS, V193, P51, DOI 10.1016/0003-9861(79)90007-9; Furuya T, 2002, P NATL ACAD SCI USA, V99, P14177, DOI 10.1073/pnas.222454899; GIBIAN MJ, 1987, ANAL BIOCHEM, V163, P343, DOI 10.1016/0003-2697(87)90234-X; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; Grunfelder CG, 2002, TRAFFIC, V3, P547, DOI 10.1034/j.1600-0854.2002.30805.x; HAHN BS, 1976, J ORG CHEM, V41, P567, DOI 10.1021/jo00865a039; Hausler T, 1997, EUR J CELL BIOL, V73, P240; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Irsch T, 2004, J BIOL CHEM, V279, P22209, DOI 10.1074/jbc.M401240200; Kitahara J, 2003, GENE EXPRESSION, V11, P77, DOI 10.3727/000000003108748973; Lorenz P, 1998, EMBO J, V17, P3542, DOI 10.1093/emboj/17.13.3542; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; Muller S, 2003, TRENDS PARASITOL, V19, P320, DOI 10.1016/S1471-4922(03)00141-7; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Oatey PB, 1996, EUR J BIOCHEM, V241, P374, DOI 10.1111/j.1432-1033.1996.00374.x; Oda T, 2000, J BIOCHEM, V127, P665, DOI 10.1093/oxfordjournals.jbchem.a022655; Onn I, 2004, EUKARYOT CELL, V3, P277, DOI 10.1128/EC.3.2.277-287.2004; OPPERDOES FR, 1984, J CELL BIOL, V98, P1178, DOI 10.1083/jcb.98.4.1178; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Reckenfelderbaumer N, 2002, J BIOL CHEM, V277, P17548, DOI 10.1074/jbc.M112115200; Ridgley EL, 1999, BIOCHEM J, V340, P33, DOI 10.1042/0264-6021:3400033; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; Schmidt H, 2003, J BIOL CHEM, V278, P46329, DOI 10.1074/jbc.M305338200; Schoneck R, 1997, EUR J BIOCHEM, V243, P739, DOI 10.1111/j.1432-1033.1997.00739.x; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SMITH K, 1991, MOL BIOCHEM PARASIT, V48, P109, DOI 10.1016/0166-6851(91)90170-B; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; Sztajer H, 2001, J BIOL CHEM, V276, P7397, DOI 10.1074/jbc.M008631200; TABOR H, 1975, J BIOL CHEM, V250, P2648; TANG L, 1995, J BIOL CHEM, V270, P18313, DOI 10.1074/jbc.270.31.18367; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; Trujillo M, 2004, J BIOL CHEM, V279, P34175, DOI 10.1074/jbc.M404317200; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; URSINI F, 1995, METHOD ENZYMOL, V252, P38; URSINI F, 1986, INT J TISSUE REACT, V8, P99; Vickers TJ, 2004, J BIOL CHEM, V279, P49003, DOI 10.1074/jbc.M407958200; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wilkinson SM, 2002, J BIOL CHEM, V277, P17062, DOI 10.1074/jbc.M111126200; Wilkinson SR, 2003, J BIOL CHEM, V278, P31640, DOI 10.1074/jbc.M303035200; Wilkinson SR, 2002, P NATL ACAD SCI USA, V99, P13453, DOI 10.1073/pnas.202422899; Wilkinson SR, 2000, BIOCHEM J, V352, P755, DOI 10.1042/0264-6021:3520755; WILLIAMS DL, 1992, MOL BIOCHEM PARASIT, V52, P127, DOI 10.1016/0166-6851(92)90042-I; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	59	80	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14385	14394		10.1074/jbc.M413338200	http://dx.doi.org/10.1074/jbc.M413338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15664987	hybrid			2022-12-25	WOS:000228236800006
J	Abboud-Jarrous, G; Rangini-Guetta, Z; Aingorn, H; Atzmon, R; Elgavish, S; Peretz, T; Vlodavsky, I				Abboud-Jarrous, G; Rangini-Guetta, Z; Aingorn, H; Atzmon, R; Elgavish, S; Peretz, T; Vlodavsky, I			Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; LYSOSOMAL CYSTEINE PROTEASES; PROSTATE-SPECIFIC ANTIGEN; CATHEPSIN-L; CELL-SURFACE; SERINE PROTEASES; SUBSTRATE-SPECIFICITY; EXTRACELLULAR-MATRIX; MAMMALIAN HEPARANASE; SUBSITE SPECIFICITY	Heparanase is an endo-beta-D-glucuronidase that degrades heparan sulfate in the extracellular matrix and cell surfaces. Human proheparanase is produced as a latent 65-kDa polypeptide undergoing processing at two potential proteolytic cleavage sites, located at Glu(109)-Ser(110) (site 1) and Gln(157)-Lys(158) (site 2). Cleavage of proheparanase yields 8- and 50-kDa subunits that heterodimerize to form the active enzyme. The fate of the linker segment (Ser(110)-Gln(157)) residing between the two subunits, the mode of processing, and the protease(s) engaged in proheparanase processing are currently unknown. We applied multiple site-directed mutagenesis and deletions to study the nature of the potential cleavage sites and amino acids essential for processing of proheparanase in transfected human choriocarcinoma cells devoid of endogenous heparanase but possessing the enzymatic machinery for proper processing and activation of the proenzyme. Although mutagenesis at site 1 and its flanking sequences failed to identify critical residues for proteolytic cleavage, processing at site 2 required a bulky hydrophobic amino acid at position 156 (i.e. P2 of the cleavage site). Substitution of Tyr(156) by Ala or Glu, but not Val, resulted in cleavage at an upstream site in the linker segment, yielding an improperly processed inactive enzyme. Processing of the latent 65-kDa proheparanase in transfected Jar cells was inhibited by a cell-permeable inhibitor of cathepsin L. Moreover, recombinant 65-kDa proheparanase was processed and activated by cathepsin L in a cell-free system. Altogether, these results suggest that proheparanase processing at site 2 is brought about by cathepsin L-like proteases. The involvement of other members of the cathepsin family with specificity to bulky hydrophobic residues cannot be excluded. Our results and a three-dimensional model of the enzyme are expected to accelerate the design of inhibitory molecules capable of suppressing heparanase-mediated enhancement of tumor angiogenesis and metastasis.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Hadassah Hebrew Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Bioinformat Unit, IL-91120 Jerusalem, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il			NCI NIH HHS [R01-CA106456-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki H, 2004, J COMP PHYSIOL B, V174, P59, DOI 10.1007/s00360-003-0389-x; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P1; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Britton C, 2004, J CELL SCI, V117, P5133, DOI 10.1242/jcs.01387; Czapinska H, 1999, EUR J BIOCHEM, V260, P571, DOI 10.1046/j.1432-1327.1999.00160.x; David G, 1998, MATRIX BIOL, V17, P461, DOI 10.1016/S0945-053X(98)90092-0; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; ESSER RE, 1994, ARTHRITIS RHEUM, V37, P236, DOI 10.1002/art.1780370213; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Fischer D, 1999, PROTEINS, P209; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110; Hospital V, 2000, BIOCHEM J, V349, P587, DOI 10.1042/0264-6021:3490587; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koliopanos A, 2001, CANCER RES, V61, P4655; Lecaille F, 2002, BIOCHEMISTRY-US, V41, P8447, DOI 10.1021/bi025638x; Lecaille F, 2001, EUR J BIOCHEM, V268, P2733, DOI 10.1046/j.1432-1327.2001.02172.x; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Maxhimer JB, 2002, SURGERY, V132, P326, DOI 10.1067/msy.2002.125719; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Nardella C, 2004, BIOCHEMISTRY-US, V43, P1862, DOI 10.1021/bi030203a; Ohashi K, 2003, BBA-PROTEINS PROTEOM, V1649, P30, DOI 10.1016/S1570-9639(03)00152-3; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Pimenta DC, 2003, BIOCHEM J, V371, P1021, DOI 10.1042/BJ20021952; Pullikotil P, 2004, J BIOL CHEM, V279, P17338, DOI 10.1074/jbc.M313764200; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; Rehault S, 2002, BBA-PROTEIN STRUCT M, V1596, P55, DOI 10.1016/S0167-4838(02)00204-2; ROCHEFORT H, 1990, CANCER METAST REV, V9, P321, DOI 10.1007/BF00049522; Sambrook J, 2001, MOL CLONING LAB MANU; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Takaoka M, 2003, LAB INVEST, V83, P613, DOI 10.1097/01.LAB.0000067482.84946.BD; Toure BB, 2000, J BIOL CHEM, V275, P2349, DOI 10.1074/jbc.275.4.2349; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P327; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; Yasothornsrikul S, 2003, P NATL ACAD SCI USA, V100, P9590, DOI 10.1073/pnas.1531542100; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068	55	89	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13568	13575		10.1074/jbc.M413370200	http://dx.doi.org/10.1074/jbc.M413370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15659389	hybrid			2022-12-25	WOS:000228095500049
J	Aley, PK; Porter, KE; Boyle, JP; Kemp, PJ; Peers, C				Aley, PK; Porter, KE; Boyle, JP; Kemp, PJ; Peers, C			Hypoxic modulation of Ca2+ signaling in human venous endothelial cells - Multiple roles for reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; 2-AMINOETHOXYDIPHENYL BORATE 2-APB; INTRACELLULAR CALCIUM; NITRIC-OXIDE; CELLULAR MECHANISMS; NADPH OXIDASE; ION CHANNELS; ADP-RIBOSE; RELEASE; ACTIVATION	The effects of hypoxia (pO(2) similar to 25 mm Hg) on Ca2+ signaling stimulated by extracellular ATP in human saphenous vein endothelial cells were investigated using fluorimetric recordings from Fura-2 loaded cells. In the absence of extracellular Ca2+, ATP-evoked rises of cytosolic Ca2+ concentration ([Ca2+](i)) because of mobilization from the endoplasmic reticulum ( ER). These responses were reduced by prior exposure to hypoxia but potentiated during hypoxia. Hypoxia itself liberated Ca2+ from the ER, but unlike the effects of ATP this effect was not inhibited by blockade of the inositol trisphosphate receptor. By contrast, ryanodine blocked the effects of hypoxia but not those of ATP. Antioxidants abolished the effects of hypoxia but potentiated the effects of ATP. Inhibition of NADPH oxidase also augmented ATP-evoked responses but was without effect on hypoxia-evoked rises of [Ca2+](i). However, either uncoupling mitochondrial electron transport or inhibiting complex I markedly suppressed the actions of hypoxia yet exerted only small inhibitory effects on ATP-evoked rises of [Ca2+](i). Both hypoxia and ATP were able to activate capacitative Ca2+ entry. Our results indicate that hypoxia regulates intracellular Ca2+ signaling via two distinct pathways. First, it modulates agonist-evoked liberation of Ca2+ from the ER primarily through regulation of reactive oxygen species generation from NADPH oxidase. Second, it liberates Ca2+ from the ER via ryanodine receptors, an effect requiring mitochondrial reactive oxygen species generation. These findings suggest that local O-2 tension is a major determinant of Ca2+ signaling in the vascular endothelium, a finding that is likely to be of both physiological and pathophysiological importance.	Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England; Univ Cardiff, Sch Biosci, Cardiff CF10 3US, S Glam, Wales	University of Leeds; Cardiff University	Peers, C (corresponding author), Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England.	c.s.peers@leeds.ac.uk	Kemp, Paul/A-4634-2010; Boyle, John/N-4868-2016	Kemp, Paul/0000-0003-2773-973X; Peers, Chris/0000-0002-8354-346X; Aley, Parvinder/0000-0002-0749-8329				Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; Adams DJ, 2004, J CARDIOVASC ELECTR, V15, P598, DOI 10.1046/j.1540-8167.2004.03277.x; ARNOULD T, 1992, J CELL PHYSIOL, V152, P215, DOI 10.1002/jcp.1041520127; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; BUDD JS, 1991, BRIT J SURG, V78, P878, DOI 10.1002/bjs.1800780733; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 2000, J APPL PHYSIOL, V88, P1880, DOI 10.1152/jappl.2000.88.5.1880; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMPL V, 1995, EUR RESPIR J, V8, P515; Hu QH, 2000, CIRCULATION, V102, P2541, DOI 10.1161/01.CIR.102.20.2541; Hu QH, 2002, J BIOL CHEM, V277, P32546, DOI 10.1074/jbc.M201550200; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Kemp PJ, 2003, ANAT REC PART A, V270A, P41, DOI 10.1002/ar.a.10008; Kimura C, 2000, AM J PHYSIOL-HEART C, V279, pH2310, DOI 10.1152/ajpheart.2000.279.5.H2310; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; MARTIN TW, 1990, BIOCHIM BIOPHYS ACTA, V1054, P159, DOI 10.1016/0167-4889(90)90237-8; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MCCLAIN DE, 1995, FASEB J, V9, P1345, DOI 10.1096/fasebj.9.13.7557025; MICHIELS C, 1993, ANGIOLOGY, V44, P639, DOI 10.1177/000331979304400808; Michiels C, 1997, INT ANGIOL, V16, P134; Mojet MH, 1997, J PHYSIOL-LONDON, V504, P175, DOI 10.1111/j.1469-7793.1997.175bf.x; Nilius B, 2003, ENDOTHELIUM-J ENDOTH, V10, P5, DOI 10.1080/10623320303356; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Pearlstein DP, 2002, ARTERIOSCL THROM VAS, V22, P566, DOI 10.1161/01.ATV.0000012262.76205.6A; Pearson PJ, 1998, ANN THORAC SURG, V65, P1220, DOI 10.1016/S0003-4975(98)00096-4; Peers C, 1997, TRENDS PHARMACOL SCI, V18, P405; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Pirotton S, 1996, J AUTON PHARMACOL, V16, P353, DOI 10.1111/j.1474-8673.1996.tb00052.x; Putney J W Jr, 2001, Mol Interv, V1, P84; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Sethi JK, 1996, BIOCHEM J, V319, P613, DOI 10.1042/bj3190613; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358; Taniyama Y, 2003, HYPERTENSION, V42, P1075, DOI 10.1161/01.HYP.0000100443.09293.4F; Tran QK, 2000, CARDIOVASC RES, V48, P13, DOI 10.1016/S0008-6363(00)00172-3; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Yao XQ, 2003, TRENDS PHARMACOL SCI, V24, P263, DOI 10.1016/S0165-6147(03)00122-6	44	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13349	13354		10.1074/jbc.M413674200	http://dx.doi.org/10.1074/jbc.M413674200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15668229	hybrid			2022-12-25	WOS:000228095500021
J	Cai, Y; Jin, JJ; Florens, L; Swanson, SK; Kusch, T; Li, B; Workman, JL; Washburn, MP; Conaway, RC; Conaway, JW				Cai, Y; Jin, JJ; Florens, L; Swanson, SK; Kusch, T; Li, B; Workman, JL; Washburn, MP; Conaway, RC; Conaway, JW			The mammalian YL1 protein is a shared subunit of the TRRAP/TIP60 histone acetyltransferase and SRCAP complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; IDENTIFICATION TECHNOLOGY; MEDIATED TRANSCRIPTION; SHOTGUN PROTEOMICS; BINDING PROTEIN; YEAST; NUA4; EXCHANGE; DATABASE; MS/MS	The multiprotein mammalian TRRAP/TIP60-containing histone acetyltransferase (HAT) complex performs critical functions in a variety of cellular processes including transcriptional activation, double strand DNA break repair, and apoptosis. We previously isolated the TRRAP/TIP60 complex from HeLa cells (Cai, Y., Jin, J., Tomomori-Sato, C., Sato, S., Sorokina, I., Parmely, T. J., Conaway, R. C., and Conaway, J. W. (2003) J. Biol. Chem. 278, 42733-42736). Analysis of proteins present in preparations of the TRRAP/TIP60 complex led to the identification of several new subunits, as well as several potential subunits including the YL1 protein. Here we present evidence that the YL1 protein is a previously unrecognized subunit of the TRRAP/TIP60 HAT complex. In addition, we present evidence that YL1 is also a component of a novel mammalian multiprotein complex that includes the SNF2-related helicase SRCAP and resembles the recently described Saccharomyces cerevisiae SWR1 chromatin remodeling complex. Taken together, our findings identify the YL1 protein as a new subunit of the TRRAP/TIP60 HAT complex, and they suggest that YL1 plays multiple roles in chromatin modification and remodeling in cells.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Conaway, JW (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	jlc@stowers-institute.org		Conaway, Joan/0000-0002-2786-0663; Washburn, Michael/0000-0001-7568-2585; Florens, Laurence/0000-0002-9310-6650	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; HORIKAWA I, 1995, EXP CELL RES, V220, P11, DOI 10.1006/excr.1995.1286; HORIKAWA I, 1995, BIOCHEM BIOPH RES CO, V208, P999, DOI 10.1006/bbrc.1995.1433; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Johnston H, 1999, J BIOL CHEM, V274, P16370, DOI 10.1074/jbc.274.23.16370; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Krogan NJ, 2004, P NATL ACAD SCI USA, V101, P13513, DOI 10.1073/pnas.0405753101; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Monroy MA, 2003, MOL ENDOCRINOL, V17, P2519, DOI 10.1210/me.2003-0208; Monroy MA, 2001, J BIOL CHEM, V276, P40721, DOI 10.1074/jbc.M103615200; Owen-Hughes T, 1999, METH MOL B, V119, P319; Sadygov RG, 2002, J PROTEOME RES, V1, P211, DOI 10.1021/pr015514r; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e	23	157	166	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13665	13670		10.1074/jbc.M500001200	http://dx.doi.org/10.1074/jbc.M500001200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15647280	hybrid			2022-12-25	WOS:000228095500061
J	Race, PR; Lovering, AL; Green, RM; Ossor, A; White, SA; Searle, PF; Wrighton, CJ; Hyde, EI				Race, PR; Lovering, AL; Green, RM; Ossor, A; White, SA; Searle, PF; Wrighton, CJ; Hyde, EI			Structural and mechanistic studies of Escherichia coli nitroreductase with the antibiotic nitrofurazone - Reversed binding orientations in different redox states of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; VIBRIO-FISCHERI; FLAVOPROTEINS; PURIFICATION; DERIVATIVES; REFINEMENT; RESISTANCE; REDUCTASE; SYSTEM; NFSB	The antibiotics nitrofurazone and nitrofurantoin are used in the treatment of genitourinary infections and as topical antibacterial agents. Their action is dependent upon activation by bacterial nitroreductase flavoproteins, including the Escherichia coli nitroreductase (NTR). Here we show that the products of reduction of these antibiotics by NTR are the hydroxylamine derivatives. We show that the reduction of nitrosoaromatics is enzyme-catalyzed, with a specificity constant similar to 10,000-fold greater than that of the starting nitro compounds. This suggests that the reduction of nitro groups proceeds through two successive, enzyme-mediated reactions and explains why the nitroso intermediates are not observed. The global reaction rate for nitrofurazone determined in this study is over 10-fold higher than that previously reported, suggesting that the enzyme is much more active toward nitroaromatics than previously estimated. Surprisingly, in the crystal structure of the oxidized NTR-nitrofurazone complex, nitrofurazone is oriented with its amide group, rather than the nitro group to be reduced, positioned over the reactive N5 of the FMN cofactor. Free acetate, which acts as a competitive inhibitor with respect to NADH, binds in a similar orientation. We infer that the orientation of bound nitrofurazone depends upon the redox state of the enzyme. We propose that the charge distribution on the FMN rings, which alters upon reduction, is an important determinant of substrate binding and reactivity in flavoproteins with broad substrate specificity.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; ML Labs, Keele ST5 5SP, Staffs, England	University of Birmingham; Cancer Research UK; University of Birmingham	Hyde, EI (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	e.i.hyde@bham.ac.uk	Hyde, Eva/GPC-8431-2022	White, Scott/0000-0002-0202-6154; Lovering, Andrew/0000-0002-1856-7975; Hyde, Eva/0000-0003-3440-2799				ANLEZARK GM, 1992, BIOCHEM PHARMACOL, V44, P2289, DOI 10.1016/0006-2952(92)90671-5; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYANT DW, 1981, CAN J MICROBIOL, V27, P81, DOI 10.1139/m81-013; CELELAND WW, 1989, BIOCHIM BIOPHYS ACTA, V1000, P213; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Evans P. R., 1993, DATA COLLECTION PROC, P114; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Galante Y M, 1978, Methods Enzymol, V53, P15; GROENEWEGEN PEJ, 1992, J GEN MICROBIOL, V138, P1599, DOI 10.1099/00221287-138-8-1599; Guay DR, 2001, DRUGS, V61, P353, DOI 10.2165/00003495-200161030-00004; Haynes CA, 2002, J BIOL CHEM, V277, P11513, DOI 10.1074/jbc.M111334200; Johansson E, 2003, J MED CHEM, V46, P4009, DOI 10.1021/jm030843b; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; Leslie A. G. W., 1992, JOINT CCP4 ESF EACBM, V26; Lovering AL, 2001, J MOL BIOL, V309, P203, DOI 10.1006/jmbi.2001.4653; MATHISON BH, 1994, TOXICOL APPL PHARM, V127, P91, DOI 10.1006/taap.1994.1143; MCCALLA DR, 1970, J BACTERIOL, V104, P1126, DOI 10.1128/JB.104.3.1126-1134.1970; MCCALLA DR, 1974, MUTAT RES, V26, P3, DOI 10.1016/S0027-5107(74)80065-5; MCOSKER CC, 1994, J ANTIMICROB CHEMOTH, V33, P23, DOI 10.1093/jac/33.suppl_A.23; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Parkinson GN, 2000, J MED CHEM, V43, P3624, DOI 10.1021/jm000159m; PETERSON FJ, 1979, J BIOL CHEM, V254, P4009; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rodgers G. L., 1997, Journal of Burn Care and Rehabilitation, V18, P406, DOI 10.1097/00004630-199709000-00006; Roussel A., 1991, SILICON GRAPHICS GEO, V86; Sisson G, 2002, ANTIMICROB AGENTS CH, V46, P2116, DOI 10.1128/AAC.46.7.2116-2123.2002; TAYLOR JD, 1951, J BIOL CHEM, V191, P223; Whiteway J, 1998, J BACTERIOL, V180, P5529, DOI 10.1128/JB.180.21.5529-5539.1998; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wouters J, 1997, INT J QUANTUM CHEM, V64, P721, DOI 10.1002/(SICI)1097-461X(1997)64:6<721::AID-QUA9>3.0.CO;2-Y; Zenno S, 1996, J BIOCHEM-TOKYO, V120, P736	34	143	149	1	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13256	13264		10.1074/jbc.M409652200	http://dx.doi.org/10.1074/jbc.M409652200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15684426	hybrid			2022-12-25	WOS:000228095500009
J	Schneider, K; Kienow, L; Schmelzer, E; Colby, T; Bartsch, M; Miersch, O; Wasternack, C; Kombrink, E; Stuible, HP				Schneider, K; Kienow, L; Schmelzer, E; Colby, T; Bartsch, M; Miersch, O; Wasternack, C; Kombrink, E; Stuible, HP			A new type of peroxisomal acyl-coenzyme A synthetase from Arabidopsis thaliana has the catalytic capacity to activate biosynthetic precursors of jasmonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID; COA SYNTHETASE; SALICYLIC-ACID; MOLECULAR CHARACTERIZATION; MUTATIONAL ANALYSIS; FIREFLY LUCIFERASE; TARGETING SIGNAL; BETA-OXIDATION; GENE ENCODES; BENZOIC-ACID	Arabidopsis thaliana contains a large number of genes that encode carboxylic acid-activating enzymes, including nine long-chain fatty acyl-CoA synthetases, four 4-coumarate:CoA ligases (4CL), and 25 4CL-like-proteins of unknown biochemical function. Because of their high structural and sequence similarity with bona fide 4CLs and their highly hydrophobic putative substrate-binding pockets, the 4CL-like proteins At4g05160 and At5g63380 were selected for detailed analysis. Following heterologous expression, the purified proteins were subjected to a large scale screen to identify their preferred in vitro substrates. This study uncovered a significant activity of At4g05160 with medium-chain fatty acids, medium-chain fatty acids carrying a phenyl substitution, long-chain fatty acids, as well as the jasmonic acid precursors 12-oxo-phytodienoic acid and 3-oxo-2-(2'-pentenyl)-cyclopentane-1-hexanoic acid. The closest homolog of At4g05160, namely At5g63380, showed high activity with long-chain fatty acids and 12-oxo-phytodienoic acid, the latter representing the most efficiently converted substrate. By using fluorescent-tagged variants, we demonstrated that both 4CL-like proteins are targeted to leaf peroxisomes. Collectively, these data demonstrate that At4g05160 and At5g63380 have the capacity to contribute to jasmonic acid biosynthesis by initiating the beta-oxidative chain shortening of its precursors.	Max Planck Inst Plant Breeding Res, Dept Plant Microbe Interact, D-50829 Cologne, Germany; Leibniz Inst Plant Biochem, Dept Nat Prod Biotechnol, D-06120 Halle An Der Saale, Germany	Max Planck Society; Leibniz Institut fur Pflanzenbiochemie	Kombrink, E (corresponding author), Max Planck Inst Plant Breeding Res, Dept Plant Microbe Interact, Carl Von Linne Weg 10, D-50829 Cologne, Germany.	kombrink@mpiz-koeln.mpg.de						Ancillo G, 2003, PLANTA, V217, P566, DOI 10.1007/s00425-003-1029-0; Bartel B, 2001, J PLANT GROWTH REGUL, V20, P198, DOI 10.1007/s003440010025; Black PN, 2000, J BIOL CHEM, V275, P38547, DOI 10.1074/jbc.M006413200; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Corpas FJ, 2001, TRENDS PLANT SCI, V6, P145, DOI 10.1016/S1360-1385(01)01898-2; Dixon RA, 2001, PHYTOCHEMISTRY, V57, P1069, DOI 10.1016/S0031-9422(01)00092-9; Douglas CJ, 1996, TRENDS PLANT SCI, V1, P171, DOI 10.1016/1360-1385(96)10019-4; Ehlting J, 1999, PLANT J, V19, P9, DOI 10.1046/j.1365-313X.1999.00491.x; Fersht A., 1985, ENZYME STRUCTURE MEC; FULDA M, 1994, MOL GEN GENET, V242, P241, DOI 10.1007/BF00280412; Fulda M, 1997, PLANT MOL BIOL, V33, P911, DOI 10.1023/A:1005780529307; Fulda M, 2004, PLANT CELL, V16, P394, DOI 10.1105/tpc.019646; Fulda M, 2002, PLANT J, V32, P93, DOI 10.1046/j.1365-313X.2002.01405.x; Germain V, 2001, PLANT J, V28, P1, DOI 10.1046/j.1365-313X.2001.01095.x; Graham IA, 2002, PROG LIPID RES, V41, P156, DOI 10.1016/S0163-7827(01)00022-4; GROSS GG, 1966, Z NATURFORSCH PT B, VB 21, P683; Hamberger B, 2004, P NATL ACAD SCI USA, V101, P2209, DOI 10.1073/pnas.0307307101; Hartmann U, 1998, PLANT MOL BIOL, V36, P741, DOI 10.1023/A:1005921914384; Hayashi M, 1998, PLANT CELL, V10, P183, DOI 10.1105/tpc.10.2.183; Hayashi M, 2003, CURR OPIN PLANT BIOL, V6, P577, DOI 10.1016/j.pbi.2003.09.012; Hettema EH, 2000, BBA-MOL CELL BIOL L, V1486, P18, DOI 10.1016/S1388-1981(00)00045-7; Hiesinger M, 1997, FEBS LETT, V415, P16, DOI 10.1016/S0014-5793(97)01085-5; Hisanaga Y, 2004, J BIOL CHEM, V279, P31717, DOI 10.1074/jbc.M400100200; Howe GA, 2002, CURR OPIN PLANT BIOL, V5, P230, DOI 10.1016/S1369-5266(02)00250-9; Ishiguro S, 2001, PLANT CELL, V13, P2191, DOI 10.1105/tpc.13.10.2191; Ke J, 2000, PLANT PHYSIOL, V123, P497, DOI 10.1104/pp.123.2.497; Kragler F, 1998, P NATL ACAD SCI USA, V95, P13336, DOI 10.1073/pnas.95.22.13336; Lange PR, 2004, FEBS LETT, V571, P147, DOI 10.1016/j.febslet.2004.06.071; LEE HI, 1995, P NATL ACAD SCI USA, V92, P4076, DOI 10.1073/pnas.92.10.4076; LEON J, 1995, P NATL ACAD SCI USA, V92, P10413, DOI 10.1073/pnas.92.22.10413; Mano S, 2002, PLANT CELL PHYSIOL, V43, P331, DOI 10.1093/pcp/pcf037; MauchMani B, 1996, PLANT CELL, V8, P203, DOI 10.1105/tpc.8.2.203; Mauriala T, 2004, J CHROMATOGR B, V808, P263, DOI 10.1016/j.jchromb.2004.05.012; Miersch O, 2000, BIOL CHEM, V381, P715, DOI 10.1515/BC.2000.092; Mohan KVK, 2002, J VIROL, V76, P2543, DOI 10.1128/JVI.76.5.2543-2547.2002; Oba Y, 2003, FEBS LETT, V540, P251, DOI 10.1016/S0014-5793(03)00272-2; Pietrowska-Borek M, 2003, PLANT PHYSIOL, V131, P1401, DOI 10.1104/pp.011684; Reumann S, 2004, PLANT PHYSIOL, V136, P2587, DOI 10.1104/pp.104.043695; Reumann S, 2004, PLANT PHYSIOL, V135, P783, DOI 10.1104/pp.103.035584; Sanders PM, 2000, PLANT CELL, V12, P1041, DOI 10.1105/tpc.12.7.1041; Schaller F, 2001, J EXP BOT, V52, P11, DOI 10.1093/jexbot/52.354.11; Schneider K, 2003, P NATL ACAD SCI USA, V100, P8601, DOI 10.1073/pnas.1430550100; Schnurr J, 2004, PLANT CELL, V16, P629, DOI 10.1105/tpc.017608; Schnurr JA, 2002, PLANT PHYSIOL, V129, P1700, DOI 10.1104/pp.003251; Shockey JM, 2003, PLANT PHYSIOL, V132, P1065, DOI 10.1104/pp.103.020552; Shockey JM, 2002, PLANT PHYSIOL, V129, P1710, DOI 10.1104/pp.003269; Staswick PE, 2004, PLANT CELL, V16, P2117, DOI 10.1105/tpc.104.023549; Staswick PE, 2002, PLANT CELL, V14, P1405, DOI 10.1105/tpc.000885; Stelmach BA, 2001, J BIOL CHEM, V276, P12832, DOI 10.1074/jbc.M010743200; Stenzel I, 2003, PLANT MOL BIOL, V51, P895, DOI 10.1023/A:1023049319723; Stintzi A, 2000, P NATL ACAD SCI USA, V97, P10625, DOI 10.1073/pnas.190264497; Stintzi A, 2001, P NATL ACAD SCI USA, V98, P12837, DOI 10.1073/pnas.211311098; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; Stuible HP, 2000, FEBS LETT, V467, P117, DOI 10.1016/S0014-5793(00)01133-9; Stuible HP, 2001, J BIOL CHEM, V276, P26893, DOI 10.1074/jbc.M100355200; Tilton GB, 2004, J BIOL CHEM, V279, P7487, DOI 10.1074/jbc.M309532200; Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384; Turner JG, 2002, PLANT CELL, V14, pS153, DOI 10.1105/tpc.000679; Vessey DA, 2003, J BIOCHEM MOL TOXIC, V17, P1, DOI 10.1002/jbt.10056; Vessey DA, 2001, BIOCHEM J, V357, P283, DOI 10.1042/0264-6021:3570283; VICK BA, 1980, LIPIDS, V15, P468, DOI 10.1007/BF02534074; Weber H, 2002, TRENDS PLANT SCI, V7, P217, DOI 10.1016/S1360-1385(02)02250-1; Weisshaar B, 1998, CURR OPIN PLANT BIOL, V1, P251, DOI 10.1016/S1369-5266(98)80113-1; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; Winkel BSJ, 2004, ANNU REV PLANT BIOL, V55, P85, DOI 10.1146/annurev.arplant.55.031903.141714; ZIEGLER K, 1987, ARCH MICROBIOL, V149, P62, DOI 10.1007/BF00423138; Zolman BK, 2004, P NATL ACAD SCI USA, V101, P1786, DOI 10.1073/pnas.0304368101; Zolman BK, 2001, J BIOL CHEM, V276, P31037, DOI 10.1074/jbc.M104679200; Zolman BK, 2001, PLANT PHYSIOL, V127, P1266, DOI 10.1104/pp.010550; Zolman BK, 2000, GENETICS, V156, P1323	72	104	113	3	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13962	13972		10.1074/jbc.M413578200	http://dx.doi.org/10.1074/jbc.M413578200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677481	hybrid, Green Published			2022-12-25	WOS:000228095500098
J	Esteve, E; Mabrouk, K; Dupuis, A; Smida-Rezgui, S; Altafaj, X; Grunwald, D; Platel, JC; Andreotti, N; Marty, I; Sabatier, JM; Ronjat, M; De Waard, M				Esteve, E; Mabrouk, K; Dupuis, A; Smida-Rezgui, S; Altafaj, X; Grunwald, D; Platel, JC; Andreotti, N; Marty, I; Sabatier, JM; Ronjat, M; De Waard, M			Transduction of the scorpion toxin maurocalcine into cells - Evidence that the toxin crosses the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIVO PROTEIN TRANSDUCTION; TAT PROTEIN; DIHYDROPYRIDINE RECEPTOR; ANTENNAPEDIA HOMEODOMAIN; SARCOPLASMIC-RETICULUM; CELLULAR UPTAKE; 3RD HELIX; DELIVERY; RELEASE	Maurocalcine (MCa) is a 33-amino-acid residue peptide toxin isolated from the scorpion Scorpio maurus palmatus. External application of MCa to cultured myotubes is known to produce Ca2+ release from intracellular stores. MCa binds directly to the skeletal muscle isoform of the ryanodine receptor, an intracellular channel target of the endoplasmic reticulum, and induces long lasting channel openings in a mode of smaller conductance. Here we investigated the way MCa proceeds to cross biological membranes to reach its target. A biotinylated derivative of MCa was produced (MCab) and complexed with a fluorescent indicator (streptavidine-cyanine 3) to follow the cell penetration of the toxin. The toxin complex efficiently penetrated into various cell types without requiring metabolic energy (low temperature) or implicating an endocytosis mechanism. MCa appeared to share the same features as the so-called cell-penetrating peptides. Our results provide evidence that MCa has the ability to act as a molecular carrier and to cross cell membranes in a rapid manner (1-2 min), making this toxin the first demonstrated example of a scorpion toxin that translocates into cells.	CEA, DRDC, U607, INSERM, F-38054 Grenoble, France; CNRS, Format Rech Evolut 2738, Ingn Prot Lab, Fac Med Nord, F-13916 Marseille, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	De Waard, M (corresponding author), CEA, DRDC, U607, INSERM, 17 Rue Martyrs, F-38054 Grenoble, France.	mdewaard@cea.fr	ESTEVE, Eric/M-7490-2014; Marty, Isabelle/N-7114-2017; De Waard, Michel/G-7406-2014; Marty, Isabelle/ABF-5362-2020; Altafaj, Xavier/K-9257-2014	De Waard, Michel/0000-0002-2782-9615; Marty, Isabelle/0000-0003-3625-913X; Altafaj, Xavier/0000-0002-7595-0647; platel, jean-claude/0000-0001-5542-3076; ESTEVE, Eric/0000-0002-4548-9140; Ronjat, Michel/0000-0002-9728-6425; SABATIER, Jean-Marc/0000-0002-9040-5647				Altafaj X, 2005, J BIOL CHEM, V280, P4013, DOI 10.1074/jbc.C400433200; ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903; Chen L, 2003, J BIOL CHEM, V278, P16095, DOI 10.1074/jbc.M209501200; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; DORN A, 1994, PHARMACOL THERAPEUT, V61, P155, DOI 10.1016/0163-7258(94)90061-2; Dunican DJ, 2001, BIOPOLYMERS, V60, P45, DOI 10.1002/1097-0282(2001)60:1<45::AID-BIP1003>3.3.CO;2-0; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Esteve E, 2003, J BIOL CHEM, V278, P37822, DOI 10.1074/jbc.M305798200; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fajloun Z, 2000, FEBS LETT, V469, P179, DOI 10.1016/S0014-5793(00)01239-4; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; KIM DH, 1983, J BIOL CHEM, V258, P9662; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Marty I, 2000, J BIOL CHEM, V275, P8206, DOI 10.1074/jbc.275.11.8206; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; Mosbah A, 2000, PROTEINS, V40, P436, DOI 10.1002/1097-0134(20000815)40:3&lt;436::AID-PROT90&gt;3.0.CO;2-9; MOSBAH A, 1999, TOXICON, V37, P1233; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; PALADE P, 1987, J BIOL CHEM, V262, P6142; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; SeigneurinVenin S, 1996, EXP CELL RES, V223, P301, DOI 10.1006/excr.1996.0085; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010	33	58	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12833	12839		10.1074/jbc.M412521200	http://dx.doi.org/10.1074/jbc.M412521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15653689	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000227922000091
J	Guo, LW; Grant, JE; Hajipour, AR; Muradov, H; Arbabian, M; Artemyev, NO; Ruoho, AE				Guo, LW; Grant, JE; Hajipour, AR; Muradov, H; Arbabian, M; Artemyev, NO; Ruoho, AE			Asymmetric interaction between rod cyclic GMP phosphodiesterase gamma subunits and alpha beta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR CGMP PHOSPHODIESTERASE; GAF-A DOMAIN; BINDING-SITES; CATALYTIC SUBUNITS; NONCATALYTIC CGMP; OUTER SEGMENTS; HIGH-AFFINITY; RETINAL RODS; BOVINE; PDE6	Rod phosphodiesterase ( PDE6) is the central effector enzyme in vertebrate visual transduction. Holo-PDE6 consists of two similar catalytic subunits ( P alpha beta) and two identical inhibitory subunits ( P alpha). P alpha beta is the only heterodimer in the PDE superfamily, yet its significance for the function of PDE6 is poorly understood. An unequal interaction of P gamma with P beta as compared with P alpha in the PDE6 complex has not been reported. We investigated the interaction interface between full-length P gamma and P alpha beta, by differentiating P gamma interaction with each individual P alpha beta subunit through radiolabel transfer from various positions throughout the entire P gamma molecule. The efficiency of radiolabel transfer indicates that the close vicinity of serine 40 on P gamma makes a major contribution to the interaction with P alpha beta. In addition, a striking asymmetry of interaction between the P gamma polycationic region and the P alpha beta subunits was observed when the stoichiometry of P gamma versus the P alpha beta dimer was below 2. Preferential photolabeling on P beta from P gamma position 40 and on P alpha from position 30 increased while lowering the P gamma/P alpha beta ratio, but diminished when the P gamma/P alpha beta ratio was over 2. Our finding leads to the conclusion that two classes of P gamma binding sites exist on P alpha beta, each composed of GAF domains in both P alpha and P beta, differing from the conventional models suggesting that each P gamma binds only one of the P alpha beta catalytic subunits. This new model leads to insight into how the unique P alpha beta heterodimer contributes to the sophisticated regulation in visual transduction through interaction with P gamma.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Isfahan Univ Technol, Coll Chem, Pharmaceut Lab, Esfahan 84156, Iran	University of Wisconsin System; University of Wisconsin Madison; University of Iowa; Isfahan University of Technology	Ruoho, AE (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	aeruoho@facstaff.wisc.edu		Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033138] Funding Source: NIH RePORTER; NEI NIH HHS [EY10843] Funding Source: Medline; NIGMS NIH HHS [GM33138] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; Artemyev NO, 1996, J BIOL CHEM, V271, P25382, DOI 10.1074/jbc.271.41.25382; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; Berger AL, 1997, J BIOL CHEM, V272, P2714, DOI 10.1074/jbc.272.5.2714; Burns ME, 2002, NEURON, V36, P81, DOI 10.1016/S0896-6273(02)00911-X; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; D'Amours MR, 1999, BIOCHEM J, V340, P863, DOI 10.1042/0264-6021:3400863; DHANASEKARAN N, 1988, J BIOL CHEM, V263, P17942; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Granovsky AE, 2000, J BIOL CHEM, V275, P41258, DOI 10.1074/jbc.M008094200; Hurley James H, 2003, Sci STKE, V2003, pPE1; Kajimura N, 2002, J STRUCT BIOL, V139, P27, DOI 10.1016/S1047-8477(02)00502-6; Keresztes G, 2004, J BIOL CHEM, V279, P1581, DOI 10.1074/jbc.C300456200; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Muradov H, 2004, VISION RES, V44, P2437, DOI 10.1016/j.visres.2004.05.013; Muradov KG, 2002, BIOCHEMISTRY-US, V41, P3884, DOI 10.1021/bi015935m; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; OPPERT B, 1991, J BIOL CHEM, V266, P16607; OPPERT B, 1991, BIOCHEM BIOPH RES CO, V178, P474, DOI 10.1016/0006-291X(91)90131-P; Paglia MJ, 2002, J BIOL CHEM, V277, P5017, DOI 10.1074/jbc.M106328200; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki M, 2002, J BIOL CHEM, V277, P40675, DOI 10.1074/jbc.M203469200; Zoraghi R, 2004, MOL PHARMACOL, V65, P267, DOI 10.1124/mol.65.2.267	35	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12585	12592		10.1074/jbc.M410380200	http://dx.doi.org/10.1074/jbc.M410380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668239	hybrid			2022-12-25	WOS:000227922000063
J	Cobb, N; Conrads, T; Hille, R				Cobb, N; Conrads, T; Hille, R			Mechanistic studies of Rhodobacter sphaeroides Me2SO reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; OXYGEN-ATOM TRANSFER; RAY-ABSORPTION SPECTROSCOPY; DIMETHYLSULFOXIDE REDUCTASE; CRYSTAL-STRUCTURE; DMSO REDUCTASE; MOLYBDENUM; CAPSULATUS; SITE; SULFIDE	Studies of the molybdenum-containing dimethyl sulfoxide reductase from Rhodobacter sphaeroides have yielded new insight into its catalytic mechanism. A series of reductive titrations, performed over the pH range 6-10, reveal that the absorption spectrum of reduced enzyme is highly sensitive to pH. The reaction of reduced enzyme with dimethyl sulfoxide is found to be clearly biphasic throughout the pH range 6-8 with a fast, initial substrate-binding phase and substrate-concentration independent catalytic phase. The intermediate formed at the completion of the fast phase has the characteristic absorption spectrum of the established dimethyl sulfoxide-bound species. Quantitative reductive and oxidative titrations of the enzyme demonstrate that the molybdenum center takes up only two reducing equivalents, implying that the two pyranopterin equivalents of the molybdenum center are not formally redox active. Finally, the visible spectrum associated with the catalytically relevant "high-g split" Mo(V) species has been determined. Spectral deconvolution and EPR quantitation of enzyme-monitored turnover experiments with trimethylamine N-oxide as substrate reveal that no substrate-bound intermediate accumulates and that Mo(V) content remains near unity for the duration of the reaction. Similar experiments with dimethyl sulfoxide show that significant quantities of both the Mo(V) species and the dimethyl sulfoxide-bound complex accumulate during the course of reaction. Accumulation of the substrate-bound complex in the steady-state with dimethyl sulfoxide arises from partial reversal of the physiological reaction in which the accumulating product, dimethyl sulfide, reacts with oxidized enzyme to yield the substrate-bound intermediate, a process that significantly slows turnover.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Hille, R (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 333B Hamilton,1645 Neil Ave, Columbus, OH 43210 USA.	hille.1@osu.edu						Adams B, 1999, BIOCHEMISTRY-US, V38, P8501, DOI 10.1021/bi9902034; Aguey-Zinsou KF, 2002, J BIOL INORG CHEM, V7, P879, DOI 10.1007/s00775-002-0374-y; Bastian NR, 1995, BIOFACTORS, V5, P5; BASTIAN NR, 1991, J BIOL CHEM, V266, P45; Baugh PE, 1997, J BIOL INORG CHEM, V2, P634, DOI 10.1007/s007750050178; BENNETT B, 1994, EUR J BIOCHEM, V225, P321, DOI 10.1111/j.1432-1033.1994.00321.x; BENSON N, 1992, FEBS LETT, V307, P169, DOI 10.1016/0014-5793(92)80760-E; Bray RC, 2001, BIOCHEMISTRY-US, V40, P9810, DOI 10.1021/bi010559r; Bray RC, 2000, BIOCHEMISTRY-US, V39, P11258, DOI 10.1021/bi0000521; Burgmayer SJN, 2004, J BIOL INORG CHEM, V9, P59, DOI 10.1007/s00775-003-0496-x; CARADONNA JP, 1988, J AM CHEM SOC, V110, P2139, DOI 10.1021/ja00215a022; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; Eilers T, 2001, J BIOL CHEM, V276, P46989, DOI 10.1074/jbc.M108078200; FINNEGAN MG, 1993, INORG CHEM, V32, P2616, DOI 10.1021/ic00064a005; Garton SD, 1997, J AM CHEM SOC, V119, P12906, DOI 10.1021/ja972109l; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; George GN, 1999, J AM CHEM SOC, V121, P1256, DOI 10.1021/ja982843k; HOLM RH, 1990, COORDIN CHEM REV, V100, P183, DOI 10.1016/0010-8545(90)85010-P; HOLM RH, 1993, POLYHEDRON, V12, P571, DOI 10.1016/S0277-5387(00)84972-4; Johnson KE, 2001, J BIOL CHEM, V276, P13178, DOI 10.1074/jbc.M010965200; Li HK, 2000, J AM CHEM SOC, V122, P7673, DOI 10.1021/ja000643e; McAlpine AS, 1998, J MOL BIOL, V275, P613, DOI 10.1006/jmbi.1997.1513; Pilato R. S., 1999, BIOINORGANIC CATALYS, P81; Ridge JP, 2004, FEBS LETT, V563, P197, DOI 10.1016/S0014-5793(04)00301-1; Ridge JP, 2002, BIOCHEMISTRY-US, V41, P15762, DOI 10.1021/bi0266582; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; SCHULTZ BE, 1995, J AM CHEM SOC, V117, P827, DOI 10.1021/ja00107a031; Shaw AL, 1999, J BIOL CHEM, V274, P9911, DOI 10.1074/jbc.274.15.9911; Smith AT, 1998, BIOCHEM SOC T, V26, pS211, DOI 10.1042/bst026s211; TINOCO I, 1985, PHYSICAL CHEM PRICIP, P275; Turner SM, 1996, NATURE, V383, P513, DOI 10.1038/383513a0	32	37	37	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11007	11017		10.1074/jbc.M412050200	http://dx.doi.org/10.1074/jbc.M412050200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15649898	hybrid			2022-12-25	WOS:000227761800017
J	Edelstein, LC; Pan, A; Collins, T				Edelstein, LC; Pan, A; Collins, T			Chromatin modification and the endothelial-specific activation of the E-selectin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LEUKOCYTE ADHESION MOLECULE-1; HISTONE H3; TRANSCRIPTIONAL REPRESSION; PROMOTER REGION; LYSINE 9; IN-VIVO; ACETYLATION; EXPRESSION; METHYLATION	E- selectin plays a role in the binding and extravasation of leukocytes from the bloodstream. The E- selectin gene is rapidly and transiently expressed by endothelial cells activated by inflammatory stimuli. Despite the identification of factors critical for cytokine- induced activation of the E- selectin promoter, little is known about the mechanisms that restrict the gene expression to endothelial cells. We used in vivo approaches to characterize the E- selectin promoter in primary cultures of human umbilical vein endothelial cells and umbilical artery smooth muscle cells. In endothelial cells specifically, nucleosomes are remodeled after tumor necrosis factor ( TNF) alpha induction. Chromatin immunoprecipitation analysis demonstrated the binding of the p65 ( RelA) component of nuclear factor- kappa B ( NF- kappa B) to the endogenous E- selectin promoter after TNF alpha stimulation along with I kappa B kinase alpha. Multiple coactivators-1including p300, steroid receptor coactivator- 1, and p300/ cAMP- response element- binding protein ( CREB)- binding protein ( CBP)associated factor localize differentially to the E- selectin promoter. Additionally, TNF alpha induced localized histone hyperacetylation, phosphorylation, and methylation in the E- selectin gene specifically in endothelial cells. Postinduction repression of E- selectin expression is associated with recruitment of multiple deacetylases. Collectively, these studies suggest a model for the selective induction of the E- selectin gene in which the core promoter chromatin architecture is specifically modified in endothelial cells.	Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Collins, T (corresponding author), Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02115 USA.	tcollins@rics.bwh.harvard.edu		Edelstein, Leonard/0000-0002-8976-6410	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045462] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL045462, HL-45462, R01 HL045462-16] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adelman K, 2002, MOL CELL, V9, P451, DOI 10.1016/S1097-2765(02)00487-2; Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Caldarera C M, 1975, Recent Adv Stud Cardiac Struct Metab, V7, P91; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHU W, 1994, J IMMUNOL, V153, P4179; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; Edelstein LC, 2003, MOL CELL BIOL, V23, P2749, DOI 10.1128/MCB.23.8.2749-2761.2003; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Hwang KK, 2001, P NATL ACAD SCI USA, V98, P11423, DOI 10.1073/pnas.211303598; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kluger MS, 1997, J IMMUNOL, V158, P887; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Martens JHA, 2003, MOL CELL BIOL, V23, P1808, DOI 10.1128/MCB.23.5.1808-1816.2003; MARUSHIGE K, 1976, P NATL ACAD SCI USA, V73, P3937, DOI 10.1073/pnas.73.11.3937; MEACOCK S, 1994, J BIOL CHEM, V269, P31756; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Milstone DS, 2000, LAB INVEST, V80, P943, DOI 10.1038/labinvest.3780097; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pober JS, 2002, ARTHRITIS RES THER, V4, pS109, DOI 10.1186/ar576; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Read MA, 1996, J IMMUNOL, V157, P3472; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2002, GENE DEV, V16, P2219, DOI 10.1101/gad.232502; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576	56	57	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11192	11202		10.1074/jbc.M412997200	http://dx.doi.org/10.1074/jbc.M412997200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15671023	hybrid, Green Accepted			2022-12-25	WOS:000227761800040
J	Ghosh, A; Cheung, YY; Mansfield, BC; Chou, JY				Ghosh, A; Cheung, YY; Mansfield, BC; Chou, JY			Brain contains a functional glucose-6-phosphatase complex capable of endogenous glucose production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOHISTIDINE-ENZYME INTERMEDIATE; MICROSOMAL GLUCOSE-6-PHOSPHATASE; MURINE GLUCOSE-6-PHOSPHATASE; TRANSMEMBRANE TOPOLOGY; GLYCOGEN; GENE; IDENTIFICATION; ASTROCYTES; TRANSPORT; PHOSPHATE	Glucose is absolutely essential for the survival and function of the brain. In our current understanding, there is no endogenous glucose production in the brain, and it is totally dependent upon blood glucose. This glucose is generated between meals by the hydrolysis of glucose-6-phosphate (Glc-6-P) in the liver and the kidney. Recently, we reported a ubiquitously expressed Glc-6-P hydrolase, glucose-6-phosphatase-beta (Glc-6-Pase-beta), that can couple with the Glc-6-P transporter to hydrolyze Glc-6-P to glucose in the terminal stages of glycogenolysis and gluconeogenesis. Here we show that astrocytes, the main reservoir of brain glycogen, express both the Glc-6-Pase-beta and Glc-6-P transporter activities and that these activities can couple to form an active Glc-6-Pase complex, suggesting that astrocytes may provide an endogenous source of brain glucose.	NICHD, Sect Cellular Differentiat, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHD, Sect Cellular Differentiat, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241,9000 Rockville Pike, Bethesda, MD 20892 USA.	chouja@mail.nih.gov		Mansfield, Brian/0000-0002-8533-2789	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARION WJ, 1980, J BIOL CHEM, V255, P396; BAYNES J, 1999, MED BIOCH, P139; Boustead JN, 2004, J MOL ENDOCRINOL, V32, P33, DOI 10.1677/jme.0.0320033; Brown AM, 2004, J NEUROCHEM, V89, P537, DOI 10.1111/j.1471-4159.2004.02421.x; Brown AM, 2004, NEUROCHEM INT, V45, P529, DOI 10.1016/j.neuint.2003.11.005; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Cano N, 2002, CRIT CARE, V6, P317; Chen LY, 2003, HUM MOL GENET, V12, P2547, DOI 10.1093/hmg/ddg263; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; COLLINS JE, 1990, J INHERIT METAB DIS, V13, P195, DOI 10.1007/BF01799686; DRINGEN R, 1993, BRAIN RES, V623, P208, DOI 10.1016/0006-8993(93)91429-V; EYRE JA, 1994, BRAIN RES, V635, P349, DOI 10.1016/0006-8993(94)91461-3; Fillenz M, 1999, ACTA PHYSIOL SCAND, V167, P275; FORSYTH RJ, 1993, BIOCHEM J, V294, P145, DOI 10.1042/bj2940145; Gerich JE, 2001, DIABETES CARE, V24, P382, DOI 10.2337/diacare.24.2.382; Gerin I, 1999, GENE, V227, P189, DOI 10.1016/S0378-1119(98)00614-3; Ghosh A, 2002, J BIOL CHEM, V277, P32837, DOI 10.1074/jbc.M201853200; Ghosh A, 2004, J BIOL CHEM, V279, P12479, DOI 10.1074/jbc.M313271200; Gruetter R, 2003, J NEUROSCI RES, V74, P179, DOI 10.1002/jnr.10785; Guillam MT, 1998, P NATL ACAD SCI USA, V95, P12317, DOI 10.1073/pnas.95.21.12317; Guionie O, 2003, FEBS LETT, V551, P159, DOI 10.1016/S0014-5793(03)00903-7; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HERS H. G., 1964, ADVAN METAB DISORDERS, V1, P1; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 2000, HUM GENET, V107, P526, DOI 10.1007/s004390000404; Marcolongo P, 1998, FEBS LETT, V436, P247, DOI 10.1016/S0014-5793(98)01129-6; Martin CC, 2002, J MOL ENDOCRINOL, V29, P205, DOI 10.1677/jme.0.0290205; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; Pan CJ, 1999, J BIOL CHEM, V274, P13865, DOI 10.1074/jbc.274.20.13865; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Pan CJ, 1998, ARCH BIOCHEM BIOPHYS, V358, P17, DOI 10.1006/abbi.1998.0849; PARRY MJ, 1966, BIOCHEM J, V99, P266, DOI 10.1042/bj0990266; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; Pousset F, 1999, GLIA, V26, P12, DOI 10.1002/(SICI)1098-1136(199903)26:1<12::AID-GLIA2>3.0.CO;2-S; POWELL RC, 1981, METABOLISM, V30, P443, DOI 10.1016/0026-0495(81)90178-5; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Scriver C.R., 2001, METABOLIC MOL BASIS, VEighth; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shieh JJ, 2003, J BIOL CHEM, V278, P47098, DOI 10.1074/jbc.M309472200; Shieh JJ, 2004, J BIOL CHEM, V279, P26215, DOI 10.1074/jbc.M402036200; Stumpel F, 2001, P NATL ACAD SCI USA, V98, P11330, DOI 10.1073/pnas.211357698; TSALIKIAN E, 1984, AM J PHYSIOL, V247, pE513, DOI 10.1152/ajpendo.1984.247.4.E513; Wiesinger H, 1997, GLIA, V21, P22, DOI 10.1002/(SICI)1098-1136(199709)21:1<22::AID-GLIA3>3.0.CO;2-3	45	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11114	11119		10.1074/jbc.M410894200	http://dx.doi.org/10.1074/jbc.M410894200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15661744	hybrid			2022-12-25	WOS:000227761800030
J	Woods, A; Wang, GY; Beier, F				Woods, A; Wang, GY; Beier, F			RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; HYPERTROPHIC CHONDROCYTE DIFFERENTIATION; RHO-FAMILY GTPASES; CELL-SHAPE; GROWTH-FACTOR; MICROFILAMENT MODIFICATION; CYTOSKELETAL ARCHITECTURE; ARTICULAR CHONDROCYTES; EXTRACELLULAR-MATRIX; INDUCED REEXPRESSION	Endochondral ossification is initiated by the differentiation of mesenchymal precursor cells to chondrocytes (chondrogenesis). This process is characterized by a strong interdependence of cell shape, cytoskeletal organization, and the onset of chondrogenic gene expression, but the molecular mechanisms mediating these interactions are not known. Here we investigated the role of the RhoA/ROCK pathway, a well characterized regulator of cytoskeletal organization, in chondrogenesis. We show that pharmacological inhibition of ROCK signaling by Y27632 resulted in increased glycosaminoglycan synthesis and elevated expression of the chondrogenic transcription factor Sox9, whereas overexpression of RhoA in the chondrogenic cell line ATDC5 had the opposite effects. Suppression of Sox9 expression by ROCK signaling was achieved through repression of Sox9 promoter activity. These molecular changes were accompanied by reorganization of the actin cytoskeleton, where RhoA/ROCK signaling suppressed cortical actin organization, a hallmark of differentiated chondrocytes. This led us to analyze the regulation of Sox9 expression by drugs affecting cytoskeletal dynamics. Both inhibition of actin polymerization by cytochalasin D and stabilization of existing actin filaments by jasplakinolide resulted in increased Sox9 mRNA levels, whereas inhibition of microtubule polymerization by colchicine completely blocked Sox9 expression. In conclusion, our data suggest that RhoA/ROCK signaling suppresses chondrogenesis through the control of Sox9 expression and actin organization.	Univ Western Ontario, Canadian Inst Hlth, Res Grp Skeletal Dev & Remodeling, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Beier, F (corresponding author), Univ Western Ontario, Canadian Inst Hlth, Res Grp Skeletal Dev & Remodeling, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.	fbeier@uwo.ca	Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537				AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; Aigner T, 2002, CELL MOL LIFE SCI, V59, P5, DOI 10.1007/s00018-002-8400-3; Aigner T, 2002, CURR OPIN RHEUMATOL, V14, P578, DOI 10.1097/00002281-200209000-00018; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Ballock R. Tracy, 2003, Birth Defects Research, V69, P123, DOI 10.1002/bdrc.10014; Benitah SA, 2003, MOL BIOL CELL, V14, P40, DOI 10.1091/mbc.E02-08-0454; BENJAMIN M, 1994, MICROSC RES TECHNIQ, V28, P372, DOI 10.1002/jemt.1070280503; BENYA PD, 1988, J CELL BIOL, V106, P161, DOI 10.1083/jcb.106.1.161; BENYA PD, 1993, EXP CELL RES, V204, P268, DOI 10.1006/excr.1993.1033; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BENYA PD, 1988, PATHOL IMMUNOPATH R, V7, P51, DOI 10.1159/000157093; Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BROWN PD, 1988, J CELL BIOL, V106, P171, DOI 10.1083/jcb.106.1.171; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Cybulsky AV, 2004, AM J PHYSIOL-RENAL, V286, pF466, DOI 10.1152/ajprenal.00260.2003; DANIELS K, 1991, J CELL SCI, V100, P249; DESSAU W, 1981, J CELL BIOL, V90, P78, DOI 10.1083/jcb.90.1.78; Ghosh P, 2002, BIOGERONTOLOGY, V3, P85, DOI 10.1023/A:1015219716583; GLOWACKI J, 1983, P SOC EXP BIOL MED, V172, P93; Halawani D, 2004, ONCOGENE, V23, P3726, DOI 10.1038/sj.onc.1207422; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hollenbeck P, 2001, CURR BIOL, V11, pR820, DOI 10.1016/S0960-9822(01)00494-8; Idowu BD, 2000, HISTOCHEM J, V32, P165, DOI 10.1023/A:1004095207330; Iwamoto M, 2001, OSTEOARTHR CARTILAGE, V9, pS41, DOI 10.1053/joca.2001.0443; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kim SJ, 2003, J BIOL CHEM, V278, P42448, DOI 10.1074/jbc.M304887200; Kornak U, 2003, AM J HUM GENET, V73, P447, DOI 10.1086/377110; KUSTERMANS G, 2004, BIOCH J; Langelier E, 2000, J HISTOCHEM CYTOCHEM, V48, P1307, DOI 10.1177/002215540004801002; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LOTY S, 1995, BIOL CELL, V83, P149, DOI 10.1016/0248-4900(96)81303-7; MADSEN K, 1979, EXPERIENTIA, V35, P1572, DOI 10.1007/BF01953199; Malemud CJ, 2003, CELLS TISSUES ORGANS, V174, P34, DOI 10.1159/000070573; MALLEINGERIN F, 1991, EUR J CELL BIOL, V56, P364; MARCHISIO PC, 1984, EXP CELL RES, V151, P332, DOI 10.1016/0014-4827(84)90384-7; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Ott C, 2003, J BIOL CHEM, V278, P44305, DOI 10.1074/jbc.M309140200; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Reinhold MI, 2004, MOL ENDOCRINOL, V18, P241, DOI 10.1210/me.2003-0312; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sandell L., 1999, FRONT BIOSCI-LANDMRK, V4, P731; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Schnabel M, 2002, OSTEOARTHR CARTILAGE, V10, P62, DOI 10.1053/joca.2001.0482; Shum L, 2002, ARTHRITIS RES, V4, P94, DOI 10.1186/ar396; Sordella R, 2002, DEV CELL, V2, P553, DOI 10.1016/S1534-5807(02)00162-4; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; TAKIGAWA M, 1984, CELL DIFFER DEV, V14, P197, DOI 10.1016/0045-6039(84)90046-0; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; van der Eerden BCJ, 2003, ENDOCR REV, V24, P782, DOI 10.1210/er.2002-0033; VandenBerg E, 2004, J CELL BIOCHEM, V91, P926, DOI 10.1002/jcb.20011; VONDERMARK K, 1977, J CELL BIOL, V73, P736, DOI 10.1083/jcb.73.3.736; VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0; Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200; Weinhold B, 2000, EMBO J, V19, P5835, DOI 10.1093/emboj/19.21.5835; Witteck A, 2003, EXP CELL RES, V287, P106, DOI 10.1016/S0014-4827(03)00129-0; Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659	72	230	237	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11626	11634		10.1074/jbc.M409158200	http://dx.doi.org/10.1074/jbc.M409158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15665004	hybrid			2022-12-25	WOS:000227761800090
J	Cohen, P; Yang, GQ; Yu, XX; Soukas, AA; Wolfish, CS; Friedman, JM; Li, C				Cohen, P; Yang, GQ; Yu, XX; Soukas, AA; Wolfish, CS; Friedman, JM; Li, C			Induction of leptin receptor expression in the liver by leptin and food deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE-1; DB/DB MICE; IN-VITRO; DEFICIENCY; OBESITY; MODULATION; GENE; ACTIVATION; GENERATION; MUTATION	Leptin resistance is a common feature of obesity and the metabolic syndrome. However, the regulated expression of the leptin receptor (Ob-R) has not been studied in detail. Expression profiling of liver mRNA in leptin-treated wild-type mice revealed a marked increase in leptin receptor mRNA levels, which had not previously been described. This was confirmed by isoform-specific real-time PCR, which showed a > 25-fold increase in the mRNAs encoding the short forms (Ob-Ra, Ob-Rc) and a > 10-fold increase in the mRNA encoding the long (Ob-Rb) form of the leptin receptor in liver. In parallel, we also observed induction of plasma-soluble leptin receptor (SLR) protein by leptin administration, pair feeding, and short term food restriction. However, induction of SLR by leptin is abolished in mice with selective deletion of Ob-R from liver using Cre-LoxP technology. These data suggest that the liver is a major source of Ob-R mRNA expression under conditions of negative energy balance. Membrane-bound Ob-R is then shed into the circulation as SLR. Our study thus reveals an unexpected role of the liver in modulating total circulating leptin levels and possibly its biological activity.	Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, C (corresponding author), Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA.	Cai.Li@UTSouthwestern.edu	Abrams, William R/A-5782-2008		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060137] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60137] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chan JL, 2002, DIABETES, V51, P2105, DOI 10.2337/diabetes.51.7.2105; Chua SC, 1997, GENOMICS, V45, P264, DOI 10.1006/geno.1997.4962; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Cohen P, 2004, J NUTR, V134, p2455S, DOI 10.1093/jn/134.9.2455S; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Cohen Paul, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P271, DOI 10.2174/1568008033340117; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gavrilova O, 1997, J BIOL CHEM, V272, P30546, DOI 10.1074/jbc.272.48.30546; Ge HF, 2002, J BIOL CHEM, V277, P45898, DOI 10.1074/jbc.M205825200; Gibson WT, 2004, J CLIN ENDOCR METAB, V89, P4821, DOI 10.1210/jc.2004-0376; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Huang L, 2001, J BIOL CHEM, V276, P6343, DOI 10.1074/jbc.M009795200; Kowalski TJ, 2001, DIABETES, V50, P425, DOI 10.2337/diabetes.50.2.425; Landt M, 2000, CLIN CHEM, V46, P379; Lee GH, 1997, MAMM GENOME, V8, P445, DOI 10.1007/s003359900466; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Li C, 1998, J BIOL CHEM, V273, P10078, DOI 10.1074/jbc.273.16.10078; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; Maamra M, 2001, ENDOCRINOLOGY, V142, P4389, DOI 10.1210/en.142.10.4389; Mazerbourg S, 2004, GROWTH HORM IGF RES, V14, P71, DOI 10.1016/j.ghir.2003.10.002; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Ravussin E, 1997, NAT MED, V3, P238, DOI 10.1038/nm0297-238; Soukas A, 2000, GENE DEV, V14, P963; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; van Dielen FMH, 2002, J CLIN ENDOCR METAB, V87, P1708, DOI 10.1210/jc.87.4.1708; Yang GQ, 2004, MOL ENDOCRINOL, V18, P1354, DOI 10.1210/me.2004-0027; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	68	75	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10034	10039		10.1074/jbc.M413684200	http://dx.doi.org/10.1074/jbc.M413684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644325	hybrid			2022-12-25	WOS:000227559600037
J	Glerup, S; Boldt, HB; Overgaard, MT; Jensen, LS; Giudice, LC; Oxvig, C				Glerup, S; Boldt, HB; Overgaard, MT; Jensen, LS; Giudice, LC; Oxvig, C			Proteinase inhibition by proform of eosinophil major basic protein (pro-MBP) is a multistep process of intra- and intermolecular disulfide rearrangements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; PLASMA-PROTEIN; PAPP-A; PHYSIOLOGICAL INHIBITOR; THROMBIN-ANTITHROMBIN; INTEGRIN ACTIVATION; BINDING; COMPLEXES; IDENTIFICATION; EXPRESSION	The metzincin metalloproteinase pregnancy-associated plasma protein A (PAPP-A, pappalysin-1) promotes cell growth by the cleavage of insulin-like growth factor-binding proteins-4 and -5, causing the release of bound insulin-like growth factors. The proteolytic activity of PAPP-A is inhibited by the proform of eosinophil major basic protein (pro-MBP), which forms a covalent 2: 2 proteinase-inhibitor complex based on disulfide bonds. To understand the process of complex formation, we determined the status of cysteine residues in both of the uncomplexed molecules. A comparison of the disulfide structure of the reactants with the known disulfide structure of the PAPP-A center dot pro-MBP complex reveals that six cysteine residues of the pro-MBP subunit (Cys-51, Cys-89, Cys-104, Cys-107, Cys-128, and Cys-169) and two cysteine residues of the PAPP-A subunit (Cys-381 and Cys-652) change their status from the uncomplexed to the complexed states. Upon complex formation, three disulfide bonds of pro-MBP, which connect the acidic propiece with the basic, mature portion, are disrupted. In the PAPP-A center dot pro-MBP complex, two of these form the basis of both two interchain disulfide bonds between the PAPP-A and the pro-MBP subunits and two disulfide bonds responsible for pro-MBP dimerization, respectively. Based on the status of the reactants, we investigated the role of individual cysteine residues upon complex formation by mutagenesis of specific cysteine residues of both subunits. Our findings allow us to depict a hypothetical model of how the PAPP-A center dot pro-MBP complex is formed. In addition, we have demonstrated that complex formation is greatly enhanced by the addition of micromolar concentrations of reductants. It is therefore possible that the activity in vivo of PAPP-A is controlled by the redox potential, and it is further tempting to speculate that such mechanism operates under pathological conditions of altered redox potential.	Aarhus Univ, Dept Biol Mol, DK-8000 Aarhus, Denmark; Stanford Univ, Dept Gynecol & Obstet, Stanford, CA 94305 USA	Aarhus University; Stanford University	Oxvig, C (corresponding author), Aarhus Univ, Dept Biol Mol, Sci Pk,Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark.	co@mb.au.dk	Overgaard, Michael Toft/E-1354-2011	Overgaard, Michael Toft/0000-0002-1423-2481; Oxvig, Claus/0000-0002-4715-9719	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031579] Funding Source: NIH RePORTER; NICHD NIH HHS [HD31579-07] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON ME, 1980, J BIOL CHEM, V255, P9530; Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Boldt HB, 2001, BIOCHEM J, V358, P359, DOI 10.1042/0264-6021:3580359; BOLDT HB, 2004, J BIOL CHEM; BONNO M, 1994, LAB INVEST, V71, P560; CHANG AC, 1992, ARCH BIOCHEM BIOPHYS, V299, P100, DOI 10.1016/0003-9861(92)90249-V; Chen BK, 2003, J CLIN ENDOCR METAB, V88, P4465, DOI 10.1210/jc.2003-030193; Chen P, 2001, J BIOL CHEM, V276, P38628, DOI 10.1074/jbc.M105737200; Christiansen M, 2000, CLIN CHEM, V46, P1099; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Essex DW, 1999, BIOCHEMISTRY-US, V38, P10398, DOI 10.1021/bi990694s; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Giudice LC, 2002, J CLIN ENDOCR METAB, V87, P2359, DOI 10.1210/jc.87.5.2359; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; Kalli KR, 2004, INT J CANCER, V110, P633, DOI 10.1002/ijc.20185; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Lay AJ, 2000, NATURE, V408, P869, DOI 10.1038/35048596; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; O'Neill S, 2000, J BIOL CHEM, V275, P36984, DOI 10.1074/jbc.M003279200; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; Overgaard MT, 2004, FEBS LETT, V560, P147, DOI 10.1016/S0014-5793(04)00095-X; Overgaard MT, 2003, J BIOL CHEM, V278, P2106, DOI 10.1074/jbc.M208777200; OXVIG C, 1994, FEBS LETT, V341, P213, DOI 10.1016/0014-5793(94)80459-1; OXVIG C, 1995, J BIOL CHEM, V270, P13645, DOI 10.1074/jbc.270.23.13645; OXVIG C, 1993, J BIOL CHEM, V268, P12243; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pimanda JE, 2002, BLOOD, V100, P2832, DOI 10.1182/blood-2002-03-0770; Popken-Harris P, 1998, BLOOD, V92, P623, DOI 10.1182/blood.V92.2.623.414k32_623_631; Qin QP, 1997, CLIN CHEM, V43, P2323; Smith GCS, 2002, NATURE, V417, P916, DOI 10.1038/417916a; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Sun QH, 2002, BLOOD, V100, P2094, DOI 10.1182/blood-2002-02-0418; Swaminathan GJ, 2001, J BIOL CHEM, V276, P26197, DOI 10.1074/jbc.M100848200; Tu BP, 1999, P NATL ACAD SCI USA, V96, P4862, DOI 10.1073/pnas.96.9.4862; Wald NJ, 1999, NEW ENGL J MED, V341, P461, DOI 10.1056/NEJM199908123410701; Wallin M, 2004, EMBO J, V23, P54, DOI 10.1038/sj.emboj.7600012; Wilczynska M, 2003, EMBO J, V22, P1753, DOI 10.1093/emboj/cdg178; Xie LJ, 2001, J EXP MED, V193, P1341, DOI 10.1084/jem.193.12.1341; Yan BX, 2001, BIOCHEMISTRY-US, V40, P8861, DOI 10.1021/bi002902i; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200; Ye S, 2001, CURR OPIN STRUC BIOL, V11, P740, DOI 10.1016/S0959-440X(01)00275-5	49	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9823	9832		10.1074/jbc.M413228200	http://dx.doi.org/10.1074/jbc.M413228200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647258	hybrid			2022-12-25	WOS:000227559600011
J	Dallas, SL; Sivakumar, P; Jones, CJP; Chen, Q; Peters, DM; Mosher, DF; Humphries, MJ; Kielty, CM				Dallas, SL; Sivakumar, P; Jones, CJP; Chen, Q; Peters, DM; Mosher, DF; Humphries, MJ; Kielty, CM			Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICED IIICS REGION; EXTRACELLULAR-MATRIX; BINDING-PROTEIN; CELL-ADHESION; BONE; ACTIVATION; INTEGRINS; COMPLEX; POLYMERIZATION; IDENTIFICATION	Latent transforming growth factor-beta-binding proteins (LTBPs) are extracellular matrix (ECM) glycoproteins that play a major role in the storage of latent TGF beta in the ECM and regulate its availability. Here we show that fibronectin is critical for the incorporation of LTBP1 and transforming growth factor-beta (TGF beta) into the ECM of osteoblasts and fibroblasts. Immunolocalization studies suggested that fibronectin provides an initial scaffold that precedes and patterns LTBP1 deposition but that LTBP1 and fibronectin are later localized in separate fibrillar networks, suggesting that the initial template is lost. Treatment of fetal rat calvarial osteoblasts with a 70-kDa N-terminal fibronectin fragment that inhibits fibronectin assembly impaired incorporation of LTBP1 and TGF beta into the ECM. Consistent with this, LTBP1 failed to assemble in embryonic fibroblasts that lack the gene for fibronectin. LTBP1 assembly was rescued by full-length fibronectin and superfibronectin, which are capable of assembly into fibronectin fibrils, but not by other fibronectin fragments, including a 160-kDa RGD-containing fragment that activates alpha 5 beta 1 integrins. This suggests that the critical event for LTBP1 assembly is the formation of a fibronectin fibrillar network and that integrin ligation by fibronectin molecules alone is not sufficient. Not only was fibronectin essential for the initial incorporation of LTBP1 into the ECM, but the continued presence of fibronectin was required for the continued assembly of LTBP1. These studies highlight a nonredundant role for fibronectin in LTBP1 assembly into the ECM and suggest a novel role for fibronectin in regulation of TGF beta via LTBP1 interactions.	Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Univ Manchester, St Marys Hosp, Sch Med, Acad Unit Obstet & Gynaecol, Manchester M13 0JH, Lancs, England; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Missouri System; University of Missouri Kansas City; University of Manchester; University of Wisconsin System; University of Wisconsin Madison; University of Manchester	Dallas, SL (corresponding author), Univ Missouri, Sch Dent, Dept Oral Biol, 650 E 25th St, Kansas City, MO 64108 USA.	dallass@umkc.edu	Sivakumar, Pitchumani/AAA-8199-2022	Jones, Carolyn/0000-0002-0026-9494; Sivakumar, Pitchumani/0000-0002-1157-8831; Humphries, Martin/0000-0002-4331-6967	NCI NIH HHS [R29CA74262, KO1CA75387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075387, R29CA074262] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; Chen D, 1997, CALCIFIED TISSUE INT, V60, P283, DOI 10.1007/s002239900230; Chen Y, 2005, J MOL BIOL, V345, P175, DOI 10.1016/j.jmb.2004.10.039; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; Dallas SL, 2000, J BONE MINER RES, V15, P68, DOI 10.1359/jbmr.2000.15.1.68; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; Globus RK, 1998, J CELL SCI, V111, P1385; GODYNA S, 1995, MATRIX BIOL, V14, P467, DOI 10.1016/0945-053X(95)90004-7; Hyytiainen M, 2004, CRIT REV CL LAB SCI, V41, P233, DOI 10.1080/10408360490460933; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Koli K, 2001, MICROSC RES TECHNIQ, V52, P354, DOI 10.1002/1097-0029(20010215)52:4<354::AID-JEMT1020>3.0.CO;2-G; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MOSHER DF, 1983, ANN NY ACAD SCI, V408, P583, DOI 10.1111/j.1749-6632.1983.tb23275.x; Mostafavi-Pour Z, 2001, MATRIX BIOL, V20, P63, DOI 10.1016/S0945-053X(00)00131-1; MOULD AP, 1994, J BIOL CHEM, V269, P27224; Oklu R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601; Pereira M, 2002, J CELL SCI, V115, P609; PETERS DMP, 1987, SCANNING MICROSCOPY, V1, P757; Pfeilschifter J, 1999, CALCIFIED TISSUE INT, V64, P78, DOI 10.1007/s002239900582; Saharinen J, 2000, MOL BIOL CELL, V11, P2691, DOI 10.1091/mbc.11.8.2691; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sechler JL, 2001, J CELL BIOL, V154, P1081, DOI 10.1083/jcb.200102034; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; Sinha S, 1998, MATRIX BIOL, V17, P529, DOI 10.1016/S0945-053X(98)90106-8; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Unsold C, 2001, J CELL SCI, V114, P187; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200	38	231	239	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18871	18880		10.1074/jbc.M410762200	http://dx.doi.org/10.1074/jbc.M410762200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15677465	hybrid			2022-12-25	WOS:000228932300039
J	Fagerlund, R; Kinnunen, L; Kohler, M; Julkunen, I; Melen, K				Fagerlund, R; Kinnunen, L; Kohler, M; Julkunen, I; Melen, K			NF-kappa B is transported into the nucleus by importin alpha 3 and importin alpha 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; LOCALIZATION SEQUENCES; EXPORT SIGNAL; SUBCELLULAR-LOCALIZATION; FAMILY-MEMBERS; ANKYRIN REPEAT; REL PROTEINS; DNA-BINDING; P50; CLONING	NF-kappa B transcription factors are retained in the cytoplasm in an inactive form until they are activated and rapidly imported into the nucleus. We identified importin alpha 3 and importin alpha 4 as the main importin alpha isoforms mediating TNF-alpha-stimulated NF-kappa B p50/p65 heterodimer translocation into the nucleus. Importin alpha 3 and alpha 4 are close relatives in the human importin alpha family. We show that importin alpha 3 isoform also mediates nuclear import of NF-kappa B p50 homodimer in nonstimulated cells. Importin alpha 3 is shown to directly bind to previously characterized nuclear localization signals (NLSs) of NF-kappa B p50 and p65 proteins. Importin alpha molecules are known to have armadillo repeats that constitute the N-terminal and C-terminal NLS binding sites. We demonstrate by site-directed mutagenesis that NF-kappa B p50 binds to the N-terminal and p65 to the C-terminal NLS binding site of importin alpha 3. In vitro competition experiments and analysis of cellular NF-kappa B suggest that NF-kappa B binds to importin alpha only when it is free of I kappa B alpha. The present study demonstrates that the nuclear import of NF-kappa B is a highly regulated process mediated by a subset of importin alpha molecules.	Natl Inst Publ Hlth, Dept Viral Dis & Immmunol, Lab Infect Dis Immunol, FIN-00300 Helsinki, Finland; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Ostsee Clin Damp, Ctr Nephrol & Hypertens, D-24351 Damp, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Fagerlund, R (corresponding author), Natl Inst Publ Hlth, Dept Viral Dis & Immmunol, Lab Infect Dis Immunol, Mannerheimintie 166, FIN-00300 Helsinki, Finland.	riku.fagerlund@ktl.fi	Kinnunen, Leena/B-7059-2012	Kinnunen, Leena/0000-0001-8739-4812				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Berkowitz B, 2002, J BIOL CHEM, V277, P24694, DOI 10.1074/jbc.M200006200; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Cohen S, 2001, J BIOL CHEM, V276, P26769, DOI 10.1074/jbc.M102448200; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Malek S, 2003, J BIOL CHEM, V278, P23094, DOI 10.1074/jbc.M301022200; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Melen K, 1997, J BIOL CHEM, V272, P32353, DOI 10.1074/jbc.272.51.32353; Melen K, 1996, J BIOL CHEM, V271, P23478, DOI 10.1074/jbc.271.38.23478; Melen K, 2003, J BIOL CHEM, V278, P28193, DOI 10.1074/jbc.M303571200; Melen K, 2001, J BIOL CHEM, V276, P16447, DOI 10.1074/jbc.M008821200; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Moorthy AK, 2003, J BIOL CHEM, V278, P556, DOI 10.1074/jbc.M207515200; MORIN N, 1989, MOL CELL BIOL, V9, P4372, DOI 10.1128/MCB.9.10.4372; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Quensel C, 2004, MOL CELL BIOL, V24, P10246, DOI 10.1128/MCB.24.23.10246-10255.2004; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rosen RL, 1996, BLOOD, V88, P1206, DOI 10.1182/blood.V88.4.1206.bloodjournal8841206; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Seki T, 1997, BIOCHEM BIOPH RES CO, V234, P48, DOI 10.1006/bbrc.1997.6535; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Summers M., 1986, TEX AGR EXP STN B, V1555, P1; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	73	224	233	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15942	15951		10.1074/jbc.M500814200	http://dx.doi.org/10.1074/jbc.M500814200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15677444	hybrid			2022-12-25	WOS:000228444800060
J	De Silva, RS; Kovacikova, G; Lin, W; Taylor, RK; Skorupski, K; Kull, FJ				De Silva, RS; Kovacikova, G; Lin, W; Taylor, RK; Skorupski, K; Kull, FJ			Crystal structure of the virulence gene activator AphA from Vibrio cholerae reveals it is a novel member of the winged helix transcription factor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TCPPH PROMOTER; REGULATOR APHB; EXPRESSION; BINDING; OPERON; DNA; PROTEINS; CASCADE; TOXIN	AphA is a member of a new and largely uncharacterized family of transcriptional activators that is required for initiating virulence gene expression in Vibrio cholerae, the causative agent of the frequently fatal epidemic diarrheal disease cholera. AphA activates transcription by an unusual mechanism that appears to involve a direct interaction with the LysR-type regulator AphB at the tcpPH promoter. As a first step toward understanding the molecular basis for tcpPH activation by AphA and AphB, we have determined the crystal structure of AphA to 2.2 angstrom resolution. AphA is a dimer with an N-terminal winged helix DNA binding domain that is architecturally similar to that of the MarR family of transcriptional regulators. Unlike this family, however, AphA has a unique C-terminal antiparallel coiled coil domain that serves as its primary dimerization interface. AphA monomers are highly unstable by themselves and form a linked topology, requiring the protein to partially unfold to form the dimer. The structure of AphA also provides insights into how it cooperates with AphB to activate transcription, most likely by forming a heterotetrameric complex at the tcpPH promoter.	Dartmouth Coll, Dept Chem, Burke Lab 6128, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Microbiol & Immunol, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Kull, FJ (corresponding author), Dartmouth Coll, Dept Chem, Burke Lab 6128, Hanover, NH 03755 USA.	f.jon.kull@dartmouth.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI039654, R29AI041558, R21AI060031, R01AI072661, R01AI039654, R01AI041558] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI072661-01, R01 AI039654, R21 AI060031, AI39654, R01 AI041558, R01 AI072661, AI41558, R29 AI041558, R56 AI039654, AI060031] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Alekshun MN, 2000, MOL MICROBIOL, V35, P1394, DOI 10.1046/j.1365-2958.2000.01802.x; Barthelmebs L, 2000, J BACTERIOL, V182, P6724, DOI 10.1128/JB.182.23.6724-6731.2000; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; Karaolis DKR, 1998, P NATL ACAD SCI USA, V95, P3134, DOI 10.1073/pnas.95.6.3134; Kovacikova G, 2004, MOL MICROBIOL, V53, P129, DOI 10.1111/j.1365-2958.2004.04121.x; Kovacikova G, 1999, J BACTERIOL, V181, P4250, DOI 10.1128/JB.181.14.4250-4256.1999; Kovacikova G, 2003, J BACTERIOL, V185, P4825, DOI 10.1128/JB.185.16.4825-4836.2003; Kovacikova G, 2002, MOL MICROBIOL, V44, P533, DOI 10.1046/j.1365-2958.2002.02914.x; Kovacikova G, 2002, MOL MICROBIOL, V46, P1135, DOI 10.1046/j.1365-2958.2002.03229.x; Kovacikova G, 2001, MOL MICROBIOL, V41, P393, DOI 10.1046/j.1365-2958.2001.02518.x; Kwon HJ, 2000, NAT STRUCT BIOL, V7, P424; Li RG, 2003, J BACTERIOL, V185, P4219, DOI 10.1128/JB.185.14.4219-4225.2003; Lim D, 2002, J BIOL CHEM, V277, P29253, DOI 10.1074/jbc.M111381200; Miller MB, 2002, CELL, V110, P303, DOI 10.1016/S0092-8674(02)00829-2; Muraoka S, 2003, J MOL BIOL, V328, P555, DOI 10.1016/S0022-2836(03)00312-7; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Skorupski K, 1999, MOL MICROBIOL, V31, P763, DOI 10.1046/j.1365-2958.1999.01215.x; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Wu RY, 2003, J BIOL CHEM, V278, P20240, DOI 10.1074/jbc.M300292200	26	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13779	13783		10.1074/jbc.M413781200	http://dx.doi.org/10.1074/jbc.M413781200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15647287	Green Accepted, hybrid			2022-12-25	WOS:000228095500074
J	Lin, DB; Takemoto, DJ				Lin, DB; Takemoto, DJ			Oxidative activation of protein kinase C gamma through the C1 domain - Effects on gap junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PHORBOL-BINDING DOMAIN; LENS EPITHELIAL-CELLS; HYDROGEN-PEROXIDE; PKC-GAMMA; INTERCELLULAR COMMUNICATION; TYROSINE PHOSPHORYLATION; STRESS; IDENTIFICATION; MECHANISMS	The accumulation of reactive oxygen species (ROS, for example H2O2) is linked to several chronic pathologies, including cancer and cardiovascular and neurodegenerative diseases (Gate, L., Paul, J., Ba, G. N., Tew, K. D., and Tapiero, H. (1999) Biomed. Pharmacother. 53, 169 180). Protein kinase C (PKC) gamma is a unique isoform of PKC that is found in neuronal cells and eye tissues. This isoform is activated by ROS such as H2O2. Mutations (H101Y, G118D, S119P, and G128D) in the PKC gamma Cys-rich C1B domain caused a form of dominant non-episodic cerebellar ataxia in humans (Chen, D.-H., Brkanac, Z., Verlinde, C. L. M. J., Tan, X.-J., Bylenok, L., Nochli, D., Matsushita, M., Lipe, H., Wolff, J., Fernandez, M., Cimino, P. J., Bird, T. D., and Raskind, W. H. (2003) Am. J. Hum. Genet. 72, 839-849; van de Warrenburg, B. P. C., Verbeek, D. S., Piersma, S. J., Hennekam, F. A. M., Pearson, P. L., Knoers, N. V. A. M., Kremer, H. P. H., and Sinke, R. J. (2003) Neurology 61, 1760-1765). This could be due to a failure of the mutant PKC gamma proteins to be activated by ROS and to subsequently inhibit gap junctions. The purpose of this study was to demonstrate the cellular mechanism of activation of PKC gamma by H2O2 and the resultant effects on gap junction activity. H2O2 stimulated PKC gamma enzyme activity independently of elevations in cellular diacylglycerol, the natural PKC activator. Okadaic acid, a phosphatase inhibitor, did not affect H2O2-stimulated PKC gamma activity, indicating that dephosphorylation was not involved. The reductant, dithiothreitol, abolished the effects of H2O2, suggesting a direct oxidation of PKC gamma at the Cys-rich C1 domain. H2O2 induced the C1 domain of PKC gamma to translocate to plasma membranes, whereas the C2 domain did not. Direct effects of H2O2 on PKC gamma were demonstrated using two-dimensional SDS-PAGE. Results demonstrated that PKC gamma formed disulfide bonds in response to H2O2. H2O2-activated PKC gamma was targeted into caveolin-1- and connexin 43-containing lipid rafts, and the PKC gamma phosphorylated the connexin 43 gap junction proteins on Ser-368. This resulted in disassembly of connexin 43 gap junction plaques and decreased gap junction activity. Results suggested that H2O2 caused oxidation of the C1 domain, activation of the PKC gamma, and inhibition of gap junctions. This inhibition of gap junctions could provide a protection to cells against oxidative stress.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Takemoto, DJ (corresponding author), Kansas State Univ, Dept Biochem, 103 Willard Hall, Manhattan, KS 66506 USA.	dtak@ksu.edu		Lin, Dingbo/0000-0002-7441-8210	NATIONAL EYE INSTITUTE [R01EY013421] Funding Source: NIH RePORTER; NEI NIH HHS [EY13421] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Aronowski J, 2000, J CEREBR BLOOD F MET, V20, P343, DOI 10.1097/00004647-200002000-00016; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; CARDELL M, 1993, J NEUROCHEM, V61, P1308, DOI 10.1111/j.1471-4159.1993.tb13623.x; Chen DH, 2003, AM J HUM GENET, V72, P839, DOI 10.1086/373883; Chen KCW, 2004, EXP EYE RES, V78, P1057, DOI 10.1016/j.exer.2004.02.004; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Cho JH, 2002, CARCINOGENESIS, V23, P1163, DOI 10.1093/carcin/23.7.1163; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Fielding CJ, 2003, BBA-BIOMEMBRANES, V1610, P219, DOI 10.1016/S0005-2736(03)00020-8; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; Garcia L, 2002, FEBS LETT, V523, P90, DOI 10.1016/S0014-5793(02)02950-2; Gate L, 1999, BIOMED PHARMACOTHER, V53, P169, DOI 10.1016/S0753-3322(99)80086-9; Ha H, 2003, J BIOL CHEM, V278, P18573, DOI 10.1074/jbc.M212626200; Hering H, 2003, J NEUROSCI, V23, P3262; Hoffmann JH, 2004, EMBO J, V23, P160, DOI 10.1038/sj.emboj.7600016; Hossain MZ, 1999, J CELL PHYSIOL, V179, P87, DOI 10.1002/(SICI)1097-4652(199904)179:1<87::AID-JCP11>3.0.CO;2-K; Huang RP, 1999, CARCINOGENESIS, V20, P485, DOI 10.1093/carcin/20.3.485; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kennett SB, 2004, J BIOL CHEM, V279, P3300, DOI 10.1074/jbc.M305734200; KOLB H, 1993, VISUAL NEUROSCI, V10, P341, DOI 10.1017/S0952523800003734; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lewis S, 2001, MOL VIS, V7, P164; Lin D, 2004, MOL VIS, V10, P688; Lin DB, 2003, INVEST OPHTH VIS SCI, V44, P5259, DOI 10.1167/iovs.03-0296; Lin DB, 2003, INVEST OPHTH VIS SCI, V44, P1160, DOI 10.1167/iovs.02-0737; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; MAO JR, 1995, BRAIN RES, V677, P257, DOI 10.1016/0006-8993(95)00161-I; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Milton NGN, 2004, DRUG AGING, V21, P81, DOI 10.2165/00002512-200421020-00002; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Nguyen TA, 2003, EXP EYE RES, V76, P565, DOI 10.1016/S0014-4835(03)00049-6; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ohsawa M, 2001, EUR J PHARMACOL, V429, P157, DOI 10.1016/S0014-2999(01)01317-6; Pawelczyk T, 2000, MOL CELL BIOCHEM, V209, P69, DOI 10.1023/A:1007063331593; Rouach N, 2004, GLIA, V45, P28, DOI 10.1002/glia.10300; Saleh SM, 2000, EXP EYE RES, V71, P99, DOI 10.1006/exer.2000.0847; Saleh SM, 2001, MOL VIS, V7, P240; Shamloo M, 1999, NEUROREPORT, V10, P931, DOI 10.1097/00001756-199904060-00007; Shaw AR, 2003, CURR OPIN MOL THER, V5, P294; Shindo M, 2001, BIOORGAN MED CHEM, V9, P2073, DOI 10.1016/S0968-0896(01)00100-6; Stevanin G, 2004, ARCH NEUROL-CHICAGO, V61, P1242, DOI 10.1001/archneur.61.8.1242; Stone JR, 2004, ARCH BIOCHEM BIOPHYS, V422, P119, DOI 10.1016/j.abb.2003.12.029; Todt I, 2001, J MEMBRANE BIOL, V181, P107, DOI 10.1007/s00232001-0014-4; van de Warrenburg BPC, 2003, NEUROLOGY, V61, P1760, DOI 10.1212/01.WNL.0000098883.79421.73; VOET D, 2004, BIOCH BIOMOLECULES M, V1; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wagner LM, 2002, MOL VIS, V8, P59; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Wei CJ, 2004, ANNU REV CELL DEV BI, V20, P811, DOI 10.1146/annurev.cellbio.19.111301.144309; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; Yamamoto T, 2000, BIOCHEM BIOPH RES CO, V273, P960, DOI 10.1006/bbrc.2000.3048; Zhou JZ, 2003, J BIOL CHEM, V278, P5388, DOI 10.1074/jbc.M209695200	59	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13682	13693		10.1074/jbc.M407762200	http://dx.doi.org/10.1074/jbc.M407762200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15642736	hybrid, Green Submitted			2022-12-25	WOS:000228095500063
J	Hamburger, AE; Kim, S; Welch, BD; Kay, MS				Hamburger, AE; Kim, S; Welch, BD; Kay, MS			Steric accessibility of the HIV-1 gp41 N-trimer region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CORECEPTOR BINDING-SITE; ENVELOPE GLYCOPROTEIN; POTENT INHIBITORS; SYNTHETIC PEPTIDE; COILED-COIL; CRYSTAL-STRUCTURE; ATOMIC-STRUCTURE; ENTRY INHIBITOR; MEMBRANE-FUSION	During human immunodeficiency virus entry, gp41 undergoes a series of conformational changes that induce membrane fusion. Immediately prior to fusion, gp41 exists in a prehairpin intermediate in which the Nand C-peptide regions of gp41 are exposed. Rearrangement of this intermediate into a six-helix bundle composed of a trimeric coiled coil from the N-peptide region (N-trimer) surrounded by three peptides from the C-peptide region provides the driving force for membrane fusion, whereas prevention of six-helix bundle formation inhibits viral entry. Because of its central role in mediating viral entry, the N-trimer region of gp41 is a key vaccine target. Extensive efforts to discover potent and broadly neutralizing antibodies (Abs) against the N-trimer region have, thus far, been unsuccessful. In this study, we attached a potent C-peptide inhibitor that binds to the N-trimer region to cargo proteins of various sizes to examine the steric accessibility of the N-trimer during fusion. These inhibitors show a progressive loss of potency with increasing cargo size. Extension of the cargo/C-peptide linker partially restores inhibitory potency. These results demonstrate that the human immunodeficiency virus defends its critical hairpin-forming machinery by steric exclusion of large proteins and may explain the current dearth of neutralizing Abs against the N-trimer. In contrast, previous results suggest the C-peptide region is freely accessible during fusion, demonstrating that the N- and C- peptide regions are in structurally distinct environments. Based on these results, we also propose new strategies for the generation of neutralizing Abs that overcome this steric block.	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Utah System of Higher Education; University of Utah; Massachusetts Institute of Technology (MIT)	Kay, MS (corresponding author), Univ Utah, Dept Biochem, MREB 211,50 N Med Dr, Salt Lake City, UT 84132 USA.	kay@biochem.utah.edu		Kim, Sunghwan/0000-0002-1927-9617	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM066521] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01GM066521] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbato G, 2003, J MOL BIOL, V330, P1101, DOI 10.1016/S0022-2836(03)00611-9; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Canziani GA, 2004, ANAL BIOCHEM, V325, P301, DOI 10.1016/j.ab.2003.11.004; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7; COPLEN LJ, 1990, PROTEINS, V7, P16, DOI 10.1002/prot.340070103; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Golding H, 2002, J VIROL, V76, P6780, DOI 10.1128/JVI.76.13.6780-6790.2002; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; KOZARSKY K, 1989, J ACQ IMMUN DEF SYND, V2, P163; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Labrijn AF, 2003, J VIROL, V77, P10557, DOI 10.1128/JVI.77.19.10557-10565.2003; Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200; Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; McCaffrey RA, 2004, J VIROL, V78, P3279, DOI 10.1128/JVI.78.7.3279-3295.2004; McGaughey GB, 2004, CURR HIV RES, V2, P193, DOI 10.2174/1570162043484933; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; MILLER M, 2004, 13 INT HIV DRUG RES; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Opalka D, 2004, J IMMUNOL METHODS, V287, P49, DOI 10.1016/j.jim.2004.01.016; Reeves JD, 2004, J VIROL, V78, P5476, DOI 10.1128/JVI.78.10.5476-5485.2004; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Root MJ, 2003, P NATL ACAD SCI USA, V100, P5016, DOI 10.1073/pnas.0936926100; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Sia SK, 2003, P NATL ACAD SCI USA, V100, P9756, DOI 10.1073/pnas.1733910100; Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Weiss Carol D, 2003, AIDS Rev, V5, P214; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102; Zwick MB, 2004, J VIROL, V78, P3155, DOI 10.1128/JVI.78.6.3155-3161.2004; Zwick MB, 2003, J VIROL, V77, P5863, DOI 10.1128/JVI.77.10.5863-5876.2003	52	65	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12567	12572		10.1074/jbc.M412770200	http://dx.doi.org/10.1074/jbc.M412770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15657041	hybrid, Green Accepted			2022-12-25	WOS:000227922000061
J	Jin, ZG; Wong, C; Wu, J; Berk, BC				Jin, ZG; Wong, C; Wu, J; Berk, BC			Flow shear stress stimulates Gab1 tyrosine phosphorylation to mediate protein kinase B and endothelial nitric-oxide synthase activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; DOCKING PROTEIN; GRB2-ASSOCIATED BINDER-1; ADAPTER PROTEINS; FACTOR RECEPTORS; MECHANISMS; CYTOKINE; AKT	Fluid shear stress generated by blood flow modulates endothelial cell function via specific intracellular signaling events. We showed previously that flow activated the phosphatidylinositol 3-kinase (PI3K), Akt, and endothelial nitric-oxide synthase ( eNOS) via Src kinase-dependent transactivation of vascular endothelial growth factor receptor 2 ( VEGFR2). The scaffold protein Gab1 plays an important role in receptor tyrosine kinase-mediated signal transduction. We found here that laminar flow ( shear stress = 12 dynes/cm(2)) rapidly stimulated Gab1 tyrosine phosphorylation in both bovine aortic endothelial cells and human umbilical vein endothelial cells, which correlated with activation of Akt and eNOS. Gab1 phosphorylation as well as activation of Akt and eNOS by flow was inhibited by the Src kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[ 3,4-d] pyrimidine) and VEGFR2 kinase inhibitors SU1498 and VTI, suggesting that flow-mediated Gab1 phosphorylation is Src kinase-dependent and VEGFR2-dependent. Tyrosine phosphorylation of Gab1 by flow was functionally important, because flow stimulated the association of Gab1 with the PI3K subunit p85 in a time-dependent manner. Furthermore, transfection of a Gab1 mutant lacking p85 binding sites inhibited flow-induced activation of Akt and eNOS. Finally, knockdown of endogenous Gab1 by small interference RNA abrogated flow activation of Akt and eNOS. These data demonstrate a critical role of Gab1 in flow-stimulated PI3K/ Akt/eNOS signal pathway in endothelial cells.	Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Sch Med & Dent, Rochester, NY 14642 USA; Univ Rochester, Dept Med, Sch Med & Dent, Rochester, NY 14642 USA; H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	University of Rochester; University of Rochester	Jin, ZG (corresponding author), Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Sch Med & Dent, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.	zheng-gen_jin@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064839, R01HL080611] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64839, R01 HL080611-05, R01 HL064839, R01 HL080611] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Claesson-Welsh L, 2003, BIOCHEM SOC T, V31, P20, DOI 10.1042/bst0310020; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; Go YM, 2001, J APPL PHYSIOL, V91, P1574, DOI 10.1152/jappl.2001.91.4.1574; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; Jin ZG, 2004, ARTERIOSCL THROM VAS, V24, P1186, DOI 10.1161/01.ATV.0000130664.51010.28; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Lamothe B, 2004, MOL CELL BIOL, V24, P5657, DOI 10.1128/MCB.24.13.5657-5666.2004; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Nishida K, 2003, CANCER SCI, V94, P1029, DOI 10.1111/j.1349-7006.2003.tb01396.x; Osawa M, 2002, J CELL BIOL, V158, P773, DOI 10.1083/jcb.200205049; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; Tai LK, 2002, ARTERIOSCL THROM VAS, V22, P1790, DOI 10.1161/01.ATV.0000034475.40227.40; Tedgui A, 2001, CIRC RES, V88, P877, DOI 10.1161/hh0901.090440; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Tsao PS, 1996, CIRCULATION, V94, P1682, DOI 10.1161/01.CIR.94.7.1682; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; ZEIHER AM, 1996, LANCET S1, V348, P10; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002	42	82	86	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12305	12309		10.1074/jbc.M500294200	http://dx.doi.org/10.1074/jbc.M500294200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15665327	Green Accepted, hybrid			2022-12-25	WOS:000227922000030
J	Peng, XY; Guo, XX; Borkan, SC; Bharti, A; Kuramochi, Y; Calderwood, S; Sawyer, DB				Peng, XY; Guo, XX; Borkan, SC; Bharti, A; Kuramochi, Y; Calderwood, S; Sawyer, DB			Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALORIC RESTRICTION; C-CBL; GELDANAMYCIN; HSP90; BINDING; CANCER; TUMORIGENESIS; DEGRADATION; MODULATION; ANTIBODIES	Heat shock protein (Hsp) 90 is a ubiquitously expressed chaperone that stabilizes expression of multiple signaling kinases involved in growth regulation, including ErbB2, Raf-1, and Akt. The chaperone activity of Hsp90 requires ATP, which binds with similar to 10-fold lower affinity than ADP. This suggests that Hsp90 may be a physiological ATP sensor, regulating the stability of growth signaling cascades in relation to cellular energy charge. Here we show that lowering ATP concentration by inhibiting glycolysis or mitochondrial respiration in isolated myocytes triggers rapid dissociation of Hsp90 from ErbB2 and degradation of ErbB2 along with other client proteins. The effect of disrupting Hsp90 chaperone activity by ATP depletion was similar to the effect of the pharmacological Hsp90 inhibitor geldanamycin. ATP depletion-induced disruption of Hsp90 chaperone activity was associated with cellular resistance to growth factor activation of intracellular signaling. ErbB2 degradation was also induced by the physiological stress of beta-adrenergic receptor stimulation in electrically stimulated cells. These results support a role for Hsp90 as an ATP sensor that modulates tissue growth factor responsiveness under metabolically stressed conditions and provide a novel mechanism by which cellular responsiveness to growth factor stimulation is modulated by cellular energy charge.	Boston Univ, Med Ctr, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Med Ctr, Ctr Mol Stress Response, Boston, MA 02118 USA; Boston Univ, Med Ctr, Div Renal, Boston, MA 02118 USA; Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Div Mol & Cellular Biol, Boston, MA 02115 USA	Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center	Sawyer, DB (corresponding author), Boston Univ, Med Ctr, Whitaker Cardiovasc Inst, 650 Albany St, Boston, MA 02118 USA.	douglas.sawyer@bmc.org		Borkan, Steven/0000-0003-3062-9486; Bharti, Ajit/0000-0001-7972-6688	NHLBI NIH HHS [HL68144] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068144] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Burzynski SR, 2005, MED HYPOTHESES, V64, P201, DOI 10.1016/j.mehy.2004.06.010; Carreras CW, 2003, ANAL BIOCHEM, V317, P40, DOI 10.1016/S0003-2697(03)00060-5; Chiosis G, 2001, CHEM BIOL, V8, P289, DOI 10.1016/S1074-5521(01)00015-1; COHEN LA, 1988, CANCER RES, V48, P4276; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dikalov S, 2002, J BIOL CHEM, V277, P25480, DOI 10.1074/jbc.M203271200; GORMAN MW, 1992, CIRC RES, V70, P1146, DOI 10.1161/01.RES.70.6.1146; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Griffin TM, 2004, AM J PHYSIOL-HEART C, V287, pH1081, DOI 10.1152/ajpheart.00921.2003; Hu YZ, 2003, J BIOL CHEM, V278, P17299, DOI 10.1074/jbc.M300788200; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; Jayakumar J, 2001, CIRCULATION, V104, pI303; KANGAS L, 1984, MED BIOL, V62, P338; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Klapper LN, 2000, CANCER RES, V60, P3384; Kritchevsky D, 2002, HYBRIDOMA HYBRIDOM, V21, P147, DOI 10.1089/153685902317401753; KRITCHEVSKY D, 1990, P SOC EXP BIOL MED, V193, P35, DOI 10.3181/00379727-193-42986; Kuramochi Y, 2004, AM J PHYSIOL-CELL PH, V286, pC222, DOI 10.1152/ajpcell.00312.2003; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lim CC, 2004, J BIOL CHEM, V279, P8290, DOI 10.1074/jbc.M308033200; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Neckers L, 2002, CLIN CANCER RES, V8, P962; Nishiyama N, 2003, CANCER RES, V63, P7876; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Ruchalski K, 2003, AM J PHYSIOL-CELL PH, V285, pC1483, DOI 10.1152/ajpcell.00049.2003; Sano M, 2001, NEUROPHARMACOLOGY, V40, P947, DOI 10.1016/S0028-3908(01)00018-1; Sawyer DB, 2002, CIRCULATION, V105, P1551, DOI 10.1161/01.CIR.0000013839.41224.1C; Schneider JW, 2001, SEMIN ONCOL, V28, P18, DOI 10.1053/sonc.2001.28546; Wiggers H, 2001, J AM COLL CARDIOL, V37, P100, DOI 10.1016/S0735-1097(00)01059-7; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yu XD, 2002, J NATL CANCER I, V94, P504; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	37	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13148	13152		10.1074/jbc.M410838200	http://dx.doi.org/10.1074/jbc.M410838200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15671027	hybrid			2022-12-25	WOS:000227922000126
J	Pfister, TD; Ohki, T; Ueno, T; Hara, I; Adachi, S; Makino, Y; Ueyama, N; Lu, Y; Watanabe, Y				Pfister, TD; Ohki, T; Ueno, T; Hara, I; Adachi, S; Makino, Y; Ueyama, N; Lu, Y; Watanabe, Y			Monooxygenation of an aromatic ring by F43W/H64D/V68I myoglobin mutant and hydrogen peroxide - Myoglobin mutants as a model for P450 hydroxylaation chemistry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; CYTOCHROME-C PEROXIDASE; HEME THIOLATE LIGAND; CRYSTAL-STRUCTURE; PROTEIN RADICALS; COMPOUND-I; MULTIPLE MECHANISMS; OXYGEN-EXCHANGE; TRYPTOPHAN	Myoglobin (Mb) is used as a model system for other heme proteins and the reactions they catalyze. The latest novel function to be proposed for myoglobin is a P450 type hydroxylation activity of aromatic carbons (Watanabe, Y., and Ueno, T. (2003) Bull. Chem. Soc. Jpn. 76, 1309-1322). Because Mb does not contain a specific substrate binding site for aromatic compounds near the heme, an engineered tryptophan in the heme pocket was used to model P450 hydroxylation of aromatic compounds. The monooxygenation product was not previously isolated because of rapid subsequent oxidation steps (Hara, I., Ueno, T., Ozaki, S., Itoh, S., Lee, K., Ueyama, N., and Watanabe, Y. (2001) J. Biol. Chem. 276, 36067-36070). In this work, a Mb variant (F43W/H64D/V68I) is used to characterize the monooxygenated intermediate. A modified (+16 Da) species forms upon the addition of 1 eq of H2O2. This product was digested with chymotrypsin, and the modified peptide fragments were isolated and characterized as 6-hydroxytryptophan using matrix-assisted laser desorption ionization time-of-flight tandem mass spectroscopy and H-1 NMR. This engineered Mb variant represents the first enzyme to preferentially hydroxylate the indole side chain of Trp at the C6 position. Finally, heme extraction was used to demonstrate that both the formation of the 6-hydroxytryptophan intermediate (+16 Da) and subsequent oxidation to form the +30 Da final product are catalyzed by the heme cofactor, most probably via the compound I intermediate. These results provide insight into the mechanism of hydroxylation of aromatic carbons by heme proteins, demonstrating that non-thiolate-ligated heme enzymes can perform this function. This establishes Mb compound I as a model for P450 type aromatic hydroxylation chemistry.	Nagoya Univ, Dept Chem, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Univ Illinois, Dept Biochem, Champaign, IL 61820 USA; Univ Illinois, Dept Chem, Champaign, IL 61820 USA; Nagoya Univ, Res Ctr Mat Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Grad Univ Adv Studies, Okazaki, Aichi 448585, Japan; Osaka Univ, Grad Sch Sci, Dept Macromol Sci, Osaka 5600043, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan	Nagoya University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Nagoya University; Graduate University for Advanced Studies - Japan; Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Watanabe, Y (corresponding author), Nagoya Univ, Dept Chem, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	yoshi@nucc.cc.nagoya-u.ac.jp	Lu, Yi/GQQ-1069-2022; Lu, Yi/B-5461-2010; liu, yi/GXE-9662-2022	Lu, Yi/0000-0003-1221-6709; Lu, Yi/0000-0003-1221-6709; 				Auclair K, 2001, J AM CHEM SOC, V123, P4877, DOI 10.1021/ja0040262; Bhaskar B, 2003, J MOL BIOL, V328, P157, DOI 10.1016/S0022-2836(03)00179-7; Choinowski T, 1999, J MOL BIOL, V286, P809, DOI 10.1006/jmbi.1998.2507; COON MJ, 1987, J BIOSCIENCE, V11, P35, DOI 10.1007/BF02704655; Coon MJ, 2003, BIOCHEM BIOPH RES CO, V312, P163, DOI 10.1016/j.bbrc.2003.10.084; COPLEY DB, 1964, P CHEM SOC LONDON, P300; DeGray JA, 1997, J BIOL CHEM, V272, P2359; DEMONTELLANO PR, 1995, CYTOCHROME P450 STRU, pD245; Dorovska-Taran V, 1998, EUR J BIOCHEM, V253, P659, DOI 10.1046/j.1432-1327.1998.2530659.x; EATON RW, 1995, J BACTERIOL, V177, P6983, DOI 10.1128/jb.177.23.6983-6988.1995; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; Giulivi C, 1998, FREE RADICAL BIO MED, V24, P269, DOI 10.1016/S0891-5849(97)00226-8; Gunther MR, 1998, BIOCHEM J, V330, P1293; Gunther MR, 2003, CHEM RES TOXICOL, V16, P652, DOI 10.1021/tx0256580; Hara I, 2001, J BIOL CHEM, V276, P36067, DOI 10.1074/jbc.C100371200; Kato S, 2002, J AM CHEM SOC, V124, P8506, DOI 10.1021/ja0256414; Lardinois OM, 2003, J BIOL CHEM, V278, P36214, DOI 10.1074/jbc.M304726200; LEVINGER DC, 1995, J CHEM SOC CHEM COMM, P2305, DOI 10.1039/c39950002305; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; LI HY, 1995, J AM CHEM SOC, V117, P6297, DOI 10.1021/ja00128a019; LI HY, 1995, ACTA CRYSTALLOGR D, V51, P21, DOI 10.1107/S0907444994009194; Li QS, 2000, CHEM-EUR J, V6, P1531, DOI 10.1002/(SICI)1521-3765(20000502)6:9<1531::AID-CHEM1531>3.3.CO;2-4; Lu Y, 2001, CHEM REV, V101, P3047, DOI 10.1021/cr0000574; Makris TM, 2002, DRUG METAB REV, V34, P691, DOI 10.1081/DMR-120015691; Matsui T, 1999, J AM CHEM SOC, V121, P9952, DOI 10.1021/ja9914846; Matsui T, 1997, J BIOL CHEM, V272, P32735, DOI 10.1074/jbc.272.52.32735; Moran GR, 2000, J AM CHEM SOC, V122, P4535, DOI 10.1021/ja994479a; Musatov A, 2004, BIOCHEMISTRY-US, V43, P1003, DOI 10.1021/bi0358925; Newcomb M, 2003, ARCH BIOCHEM BIOPHYS, V409, P72, DOI 10.1016/S0003-9861(02)00445-9; OConnor KE, 1997, APPL ENVIRON MICROB, V63, P4287, DOI 10.1128/AEM.63.11.4287-4291.1997; Ohno T, 2000, J INORG BIOCHEM, V82, P123, DOI 10.1016/S0162-0134(00)00141-0; Ozaki S, 1997, J AM CHEM SOC, V119, P6666, DOI 10.1021/ja970453c; Ozaki S, 2001, BIOCHEMISTRY-US, V40, P1044, DOI 10.1021/bi001579g; Ozaki S, 2000, COORDIN CHEM REV, V198, P39, DOI 10.1016/S0010-8545(00)00234-4; Ozaki SI, 2001, ACCOUNTS CHEM RES, V34, P818, DOI 10.1021/ar9502590; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; Poulos TL, 2003, BIOCHEM BIOPH RES CO, V312, P35, DOI 10.1016/j.bbrc.2003.09.239; Primus JL, 2000, BIOCHEM BIOPH RES CO, V272, P551, DOI 10.1006/bbrc.2000.2809; RAO SI, 1993, J BIOL CHEM, V268, P803; SAWAKI Y, 1979, J AM CHEM SOC, V101, P6292, DOI 10.1021/ja00515a023; Schlichting I, 1997, FEBS LETT, V415, P253, DOI 10.1016/S0014-5793(97)01135-6; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Terentis AC, 2002, J BIOL CHEM, V277, P15788, DOI 10.1074/jbc.M200457200; TschirretGuth RA, 1996, ARCH BIOCHEM BIOPHYS, V335, P93, DOI 10.1006/abbi.1996.0485; van Haandel MJH, 1998, INORG CHIM ACTA, V276, P98; vanWickern B, 1997, J CHROMATOGR A, V786, P57; Watanabe Y, 2003, B CHEM SOC JPN, V76, P1309, DOI 10.1246/bcsj.76.1309; WILKS A, 1992, J BIOL CHEM, V267, P8827; Witting PK, 2002, BIOCHEMISTRY-US, V41, P11495, DOI 10.1021/bi025835w; Yang HJ, 2003, BIOCHEMISTRY-US, V42, P10174, DOI 10.1021/bi034605u; Yi XW, 1999, P NATL ACAD SCI USA, V96, P12412, DOI 10.1073/pnas.96.22.12412; YONETANI T, 1967, J BIOL CHEM, V242, P5008; Yoshioka S, 2001, EUR J BIOCHEM, V268, P252, DOI 10.1046/j.1432-1033.2001.01872.x	55	24	25	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12858	12866		10.1074/jbc.M410853200	http://dx.doi.org/10.1074/jbc.M410853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15664991	hybrid			2022-12-25	WOS:000227922000094
J	Wen, J; Huang, SM; Pack, SD; Yu, XB; Brandt, SJ; Noguchi, CT				Wen, J; Huang, SM; Pack, SD; Yu, XB; Brandt, SJ; Noguchi, CT			Tal1/SCL binding to pericentromeric DNA represses transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 METHYLATION; LOCUS-CONTROL REGION; LOOP-HELIX PROTEINS; BETA-GLOBIN LOCUS; HEMATOPOIETIC-CELLS; GENE-EXPRESSION; NUCLEAR-MATRIX; TARGET GENE; CHROMATIN; HETEROCHROMATIN	Tal1/SCL is a basic helix-loop-helix transcription factor critical for normal hematopoiesis. To understand the mechanisms underlying transcriptional regulation by Tal1/SCL, we combined an in vitro DNA binding strategy and an in vivo chromatin immunoprecipitation analysis to search for Tal1/SCL target regions in K562 erythroleukemia cells. A 0.4-kb genomic DNA clone containing two Tal1/SCL binding E-boxes and GATA- and SATB1-binding motifs (EEGS) was identified that localized to the pericentromeric region with high homology to satellite 2 DNA. Pericentric DNA is related to heterochromatin and gene inactivation. We found that Tal1/SCL could complex with the histone H3 lysine 9 (H3K9)-specific methyltransferase Suv39H1. Binding of Tal1/SCL to EEGS chromatin correlated with hypermethylation of H3K9 and the association of heterochromatin protein HP1 to this region. In Rep4 reporter gene assays, EEGS affected repression in a manner dependent on the expression level of Tal1/SCL that was accompanied by increased H3K9 methylation in chromatin associated with EEGS and a linked promoter. A specific histone deacetylase inhibitor, trichostatin A, relieved Tal1/SCL-mediated repression by EEGS. In addition, SATB1 bound EEGS chromatin and promoted Tal1/SCL EEGS-dependent repression. We expand the list of potential interacting partners for Tal1/SCL by demonstrating direct associations of Tal1/SCL with SATB1 and with Suv39H1. These results reveal a novel mechanism of action for Tal1/SCL and implicate heterochromatin-like silencing via a cis-acting binding motif for transcriptional repression.	NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NINDS, NIH, Surg Neurol Branch, Bethesda, MD 20892 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Tennessee Valley Vet Affairs Healthcare Syst, Nashville, TN 37232 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Vanderbilt University; Vanderbilt University; Vanderbilt University	Noguchi, CT (corresponding author), NIDDK, Mol Med Branch, NIH, Bldg 10,Rm 9N307,10 Ctr,MSC 1822, Bethesda, MD 20892 USA.	cnoguchi@helix.nih.gov	Pack, Svetlana/C-2020-2014	Pack, Svetlana/0000-0003-3256-6626	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025021, ZIADK025021] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alcobia I, 2000, BLOOD, V95, P1608, DOI 10.1182/blood.V95.5.1608.005k32_1608_1615; Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Brown KE, 2001, NAT CELL BIOL, V3, P602, DOI 10.1038/35078577; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Case SS, 1999, DNA CELL BIOL, V18, P805, DOI 10.1089/104454999314809; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Cohen-Kaminsky S, 1998, EMBO J, V17, P5151, DOI 10.1093/emboj/17.17.5151; Conley CA, 2001, GENOMICS, V73, P127, DOI 10.1006/geno.2000.6501; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; CUNNINGHAM JM, 1994, BLOOD, V84, P1298; Cuvier O, 1998, MOL CELL BIOL, V18, P7478, DOI 10.1128/MCB.18.12.7478; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Elnitski L, 1997, J BIOL CHEM, V272, P369; FANCASTEL C, 1999, CELL, V99, P259; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischer RS, 2003, FEBS LETT, V547, P228, DOI 10.1016/S0014-5793(03)00711-7; Gasser SM, 2001, CELL, V104, P639, DOI 10.1016/S0092-8674(01)00259-8; Gubin AN, 1999, GENOMICS, V59, P168, DOI 10.1006/geno.1999.5855; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; KohwiShigematsu T, 1997, BIOCHEMISTRY-US, V36, P12005, DOI 10.1021/bi971444j; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lahlil R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004; Lecuyer E, 2002, BLOOD, V100, P2430, DOI 10.1182/blood-2002-02-0568; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Pack SD, 1999, CANCER RES, V59, P5560; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Ravet E, 2004, BLOOD, V103, P3326, DOI 10.1182/blood-2003-05-1689; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Saveliev A, 2003, NATURE, V422, P909, DOI 10.1038/nature01596; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Subramanian T, 2003, FEBS LETT, V540, P255, DOI 10.1016/S0014-5793(03)00275-8; Tolstonog GV, 2001, DNA CELL BIOL, V20, P509, DOI 10.1089/104454901317094945; van der Vlag J, 2000, J BIOL CHEM, V275, P697, DOI 10.1074/jbc.275.1.697; VISSEL B, 1989, GENOMICS, V5, P407, DOI 10.1016/0888-7543(89)90003-7; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Xu ZX, 2003, MOL CELL BIOL, V23, P7585, DOI 10.1128/MCB.23.21.7585-7599.2003; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Yoon HG, 2005, MOL CELL BIOL, V25, P324, DOI 10.1128/MCB.25.1.324-335.2005; Yu XB, 2002, DEVELOPMENT, V129, P505	63	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12956	12966		10.1074/jbc.M412721200	http://dx.doi.org/10.1074/jbc.M412721200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677454	hybrid			2022-12-25	WOS:000227922000105
J	Wu, Q; Ding, W; Mirza, A; Van Arsdale, T; Wei, I; Bishop, WR; Basso, A; McClanahan, T; Luo, L; Kirschmeier, P; Gustafson, E; Hernandez, M; Liu, SX				Wu, Q; Ding, W; Mirza, A; Van Arsdale, T; Wei, I; Bishop, WR; Basso, A; McClanahan, T; Luo, L; Kirschmeier, P; Gustafson, E; Hernandez, M; Liu, SX			Integrative Genomics revealed RAI3 is a cell growth-promoting gene and a novel p53 transcriptional target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; APOPTOSIS; INHIBITION; ANTIBODIES; INDUCTION; PROTEIN; CANCER; DOMAIN; GADD45	In this study, differential gene expression between normal human mammary epithelial cells and their malignant counterparts (eight well established breast cancer cell lines) was studied using Incyte GeneAlbum 1-6, which contains 65,873 cDNA clones representing 33,515 individual genes. 3,152 cDNAs showed a >= 3.0- fold expression level change in at least one of the human breast cancer cell lines as compared with normal human mammary epithelial cells. Integration of breast tumor gene expression data with the genes in the tumor suppressor p53 signaling pathway yielded 128 genes whose expression is altered in breast tumor cell lines and in response to p53 expression. A hierarchical cluster analysis of the 128 genes revealed that a significant portion of genes demonstrate an opposing expression pattern, i.e. p53-activated genes are down-regulated in the breast tumor lines, whereas p53-repressed genes are up-regulated. Most of these genes are involved in cell cycle regulation and/or apoptosis, consistent with the tumor suppressor function of p53. Follow-up studies on one gene, RAI3, suggested that p53 interacts with the promoter of RAI3 and repressed its expression at the onset of apoptosis. The expression of RAI3 is elevated in most tumor cell lines expressing mutant p53, whereas RAI3 mRNA is relatively repressed in the tumor cell lines expressing wild-type p53. Furthermore, ectopic expression of RAI3 in 293 cells promotes anchorage-independent growth and small interfering RNA-mediated depletion of RAI3 in AsPc-1 pancreatic tumor cells induces cell morphological change. Taken together, these data suggest a role for RAI3 in tumor growth and demonstrate the predictive power of integrative genomics.	Schering Plough Res Inst, Kenilworth, NJ 07033 USA; DNAX Res Inst Molec & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Schering-Plough Research Institute; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Liu, SX (corresponding author), Schering Plough Res Inst, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	suxing.liu@spcorp.com	McClanahan, Tim/K-4998-2019					Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; CHEN IT, 1995, ONCOGENE, V11, P1931; Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fei PW, 2002, CANCER RES, V62, P7316; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Gruvberger S, 2001, CANCER RES, V61, P5979; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; LIU S, 2004, METHODS MOL BIOL CHE, V2, P33; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SALORAFAS GH, 2000, BRIT J SURG, V87, P149; SHAWVER LK, 1994, CANCER RES, V54, P1367; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WINER EP, 2001, PRINCIPLES PRACTICE, V2, P1651; Wu Q, 2002, J BIOL CHEM, V277, P36329, DOI 10.1074/jbc.M204962200; ZAJCHOWSKI D, 1988, CANCER RES, V48, P7041	31	36	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12935	12943		10.1074/jbc.M409901200	http://dx.doi.org/10.1074/jbc.M409901200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15659406	hybrid			2022-12-25	WOS:000227922000103
J	Chen, K; Ou, XM; Chen, G; Choi, SH; Shih, JC				Chen, K; Ou, XM; Chen, G; Choi, SH; Shih, JC			R1, a novel repressor of the human monoamine oxidase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; 5-HT1A RECEPTOR GENE; B-GENES; PROMOTER ORGANIZATION; MOLECULAR-BASIS; DEFICIENT MICE; MAO-A; TRANSCRIPTION; BEHAVIOR; BRAIN	Monoamine oxidase catalyzes the oxidative deamination of a number of neurotransmitters. A deficiency in monoamine oxidase A results in aggressive behavior in both humans and mice. Studies on the regulation of monoamine oxidase A gene expression have shown that the Sp1 family is important for monoamine oxidase A expression. To search for novel transcription factors, the sequences of three Sp1 sites in the monoamine oxidase A core promoter were used in the yeast one- hybrid system to screen a human cDNA library. A novel repressor, R1 ( RAM2), has been cloned. The R1 cDNA encodes a protein with 454 amino acids and an open reading frame at the 5'- end. The transfection of R1 in a human neuroblastoma cell line, SK-N-BE (2)-C, inhibited the monoamine oxidase A promoter and enzymatic activity. The degree of inhibition of monoamine oxidase A by R1 correlated with the level of R1 protein expression. R1 was also found to repress monoamine oxidase A promoter activity within a natural chromatin environment. A gel-shift assay indicated that the endogenous R1 protein in SK-N-BE (2)-C cells interacted with the R1 binding sequence. R1 also bound directly to the natural monoamine oxidase A promoter in vivo as shown by chromatin immunoprecipitation assay. Immunocytochemical analysis showed that R1 was expressed in both cytosol and nucleus, which suggested a role for R1 in transcriptional regulation. Northern blot analysis revealed the presence of endogenous R1 mRNA in human brain and peripheral tissues. Taken together, this study shows that R1 is a novel repressor that inhibits monoamine oxidase A gene expression.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave,PSC 528, Los Angeles, CA 90033 USA.	jcshih@usc.edu			NIMH NIH HHS [R01 MH067968, R01 MH67968, R37 MH39085, R37 MH039085, R01 MH067968-05] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039085, R01MH067968] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; CHEN K, 2004, J BIOL CHEM, V22, P22; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Geha RM, 2001, J BIOL CHEM, V276, P9877, DOI 10.1074/jbc.M006972200; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Grimsby J, 1997, NAT GENET, V17, P206, DOI 10.1038/ng1097-206; Holschneider DP, 2002, AM J PHYSIOL-HEART C, V282, pH964, DOI 10.1152/ajpheart.00309.2001; Holschneider DP, 2002, AM J PHYSIOL-HEART C, V282, pH1751, DOI 10.1152/ajpheart.00600.2001; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; Ou XM, 2000, J BIOL CHEM, V275, P8161, DOI 10.1074/jbc.275.11.8161; Ou XM, 2004, J BIOL CHEM, V279, P21021, DOI 10.1074/jbc.M312638200; Ou XM, 2001, J BIOL CHEM, V276, P14299, DOI 10.1074/jbc.M005363200; Prescott JE, 2001, J BIOL CHEM, V276, P48276, DOI 10.1074/jbc.M107357200; Sagin FG, 2004, NEUROTOXICOLOGY, V25, P91, DOI 10.1016/S0161-813X(03)00089-5; Saura J, 1996, NEUROSCIENCE, V70, P755, DOI 10.1016/S0306-4522(96)83013-2; Shih J. C., 1999, Neurobiology (Budapest), V7, P235; SHIH JC, 1991, NEUROPSYCHOPHARMACOL, V4, P1; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; SHIH JC, 1993, J PSYCHIATR NEUROSCI, V18, P25; Thorpe LW, 1987, J HISTOCHEM CYTOCHEM, V35, P23, DOI 10.1177/35.1.3025289; Wong WK, 2002, J BIOL CHEM, V277, P22222, DOI 10.1074/jbc.M202844200; Wong WK, 2001, MOL PHARMACOL, V59, P852, DOI 10.1124/mol.59.4.852; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; ZHU QS, 1994, J NEUROSCI, V14, P7393; ZHU QS, 1992, J NEUROSCI, V12, P4437	29	50	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11552	11559		10.1074/jbc.M410033200	http://dx.doi.org/10.1074/jbc.M410033200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15654081	Green Accepted, hybrid			2022-12-25	WOS:000227761800081
J	Neelon, K; Wang, Y; Stec, B; Roberts, MF				Neelon, K; Wang, Y; Stec, B; Roberts, MF			Probing the mechanism of the Archaeoglobus fulgidus inositol-1-phosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-PHOSPHATE SYNTHASE; INOSITOL-PHOSPHATE; COMPATIBLE SOLUTE; CRYSTAL-STRUCTURE; DI-MYO-INOSITOL-1,1-PHOSPHATE; ACCUMULATION; SALINITY; ENZYME	myo-Inositol-1-phosphate synthase (mIPS) catalyzes the conversion of glucose-6-phosphate (G-6-P) to inositol-1-phosphate. In the sulfate-reducing archaeon Archaeoglobus fulgidus it is a metal-dependent thermozyme that catalyzes the first step in the biosynthetic pathway of the unusual osmolyte di-myo-inositol-1,1'-phosphate. Several site-specific mutants of the archaeal mIPS were prepared and characterized to probe the details of the catalytic mechanism that was suggested by the recently solved crystal structure and by the comparison to the yeast mIPS. Six charged residues in the active site (Asp(225), Lys(274), Lys(278), Lys(306), Asp(332), and Lys(367)) and two noncharged residues (Asn(255) and Leu(257)) have been changed to alanine. The charged residues are located at the active site and were proposed to play binding and/or direct catalytic roles, whereas noncharged residues are likely to be involved in proper binding of the substrate. Kinetic studies showed that only N255A retains any measurable activity, whereas two other mutants, K306A and D332A, can carry out the initial oxidation of G-6-P and reduction of NAD(+) to NADH. The rest of the mutant enzymes show major changes in binding of G-6-P ( monitored by the P-31 line width of inorganic phosphate when G-6-P is added in the presence of EDTA) or NAD(+) (detected via changes in the protein intrinsic fluorescence). Characterization of these mutants provides new twists on the catalytic mechanism previously proposed for this enzyme.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA; Univ Texas, Dept Chem, El Paso, TX 79968 USA	Boston College; University of Texas System; University of Texas El Paso	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, 2609 Beacon St, Chestnut Hill, MA 02467 USA.	mary.roberts@bc.edu		Stec, Boguslaw/0000-0002-8696-0349	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064481] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM64481] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen LJ, 2000, BIOCHEMISTRY-US, V39, P12415, DOI 10.1021/bi001517q; Chen LJ, 1998, J BACTERIOL, V180, P3785, DOI 10.1128/JB.180.15.3785-3792.1998; CIULLA RA, 1994, APPL ENVIRON MICROB, V60, P3660, DOI 10.1128/AEM.60.10.3660-3664.1994; Jin XS, 2004, J BIOL CHEM, V279, P13889, DOI 10.1074/jbc.M308986200; Jin XS, 2003, ACTA CRYSTALLOGR D, V59, P1154, DOI 10.1107/S0907444903008205; Lamosa P, 1998, APPL ENVIRON MICROB, V64, P3591; Lamosa P, 2000, APPL ENVIRON MICROB, V66, P1974, DOI 10.1128/AEM.66.5.1974-1979.2000; MARTINS LO, 1995, APPL ENVIRON MICROB, V61, P3299, DOI 10.1128/AEM.61.9.3299-3303.1995; Movahedzadeh F, 2004, MOL MICROBIOL, V51, P1003, DOI 10.1046/j.1365-2958.2003.03900.x; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; Norman RA, 2002, STRUCTURE, V10, P393, DOI 10.1016/S0969-2126(02)00718-9; Overduin M, 2001, Mol Interv, V1, P150; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Roberts MF, 2004, FRONT BIOSCI-LANDMRK, V9, P1999, DOI 10.2741/1366; Ruiz JM, 2001, TRENDS PLANT SCI, V6, P403, DOI 10.1016/S1360-1385(01)02054-4; SCHOLZ S, 1992, FEBS LETT, V306, P239, DOI 10.1016/0014-5793(92)81008-A; Stein AJ, 2002, J BIOL CHEM, V277, P9484, DOI 10.1074/jbc.M109371200; Stieglitz KA, 2005, BIOCHEMISTRY-US, V44, P213, DOI 10.1021/bi048267o; Tian F, 1999, J AM CHEM SOC, V121, P5795, DOI 10.1021/ja9900196	19	14	15	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11475	11482		10.1074/jbc.M500469200	http://dx.doi.org/10.1074/jbc.M500469200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653679	hybrid			2022-12-25	WOS:000227761800071
J	Marszalek, JR; Kitidis, C; DiRusso, CC; Lodish, HF				Marszalek, JR; Kitidis, C; DiRusso, CC; Lodish, HF			Long-chain acyl-CoA synthetase 6 preferentially promotes DHA metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; NEURITE OUTGROWTH; PC12 CELLS; RAT-LIVER; DIACYLGLYCEROL LEVELS; HIPPOCAMPAL-NEURONS; MOLECULAR-CLONING; TRANSPORT PROTEIN; ARACHIDONIC-ACID; MEMBRANE	Previously we demonstrated that supplementation with the polyunsaturated fatty acids (PUFA) arachidonic acid (AA) or docosahexaenoic acid (DHA) increased neurite outgrowth of PC12 cells during differentiation, and that overexpression of rat acyl-CoA synthetase long-chain family member 6 (Acsl6, formerly ACS2) further increased PUFA-enhanced neurite outgrowth. However, whether Acsl6 overexpression enhanced the amount of PUFA accumulated in the cells or altered the partitioning of any fatty acids into phospholipids (PLs) or triacylglycerides (TAGs) was unknown. Here we show that Acsl6 overexpression specifically promotes DHA internalization, activation to DHA-CoA, and accumulation in differentiating PC12 cells. In contrast, oleic acid (OA) and AA internalization and activation to OA-CoA and AA-CoA were increased only marginally by Acsl6 overexpression. Additionally, the level of total cellular PLs was increased in Acsl6 overexpressing cells when the medium was supplemented with AA and DHA, but not with OA. Acsl6 overexpression increased the incorporation of [C-14]-labeled OA, AA, or DHA into PLs and TAGs. These results do not support a role for Acsl6 in the specific targeting of fatty acids into PLs or TAGs. Rather, our data support the hypothesis that Acsl6 functions primarily in DHA metabolism, and that its overexpression increases DHA and AA internalization primarily during the first 24 h of neuronal differentiation to stimulate PL synthesis and enhance neurite outgrowth.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Ordway Res Inst Inc, Albany, NY 12208 USA; Albany Med Coll, Albany, NY 12208 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Ordway Research Institute; Albany Medical College	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu	DiRusso, Concetta C/M-1884-2014	DiRusso, Concetta/0000-0001-7388-9152	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066105] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL66105] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Araki W, 1997, P NATL ACAD SCI USA, V94, P11946, DOI 10.1073/pnas.94.22.11946; Basu-Modak S, 1999, J BIOL CHEM, V274, P35881, DOI 10.1074/jbc.274.50.35881; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; BLACK PN, 1988, J BACTERIOL, V170, P2850, DOI 10.1128/jb.170.6.2850-2854.1988; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; DEHAUT F, 1993, NEUROSCI LETT, V161, P133, DOI 10.1016/0304-3940(93)90277-R; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; Furuya Hiroyuki, 2002, Nihon Arukoru Yakubutsu Igakkai Zasshi, V37, P513; Gargiulo CE, 1999, J LIPID RES, V40, P881; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; HOLUB BJ, 1978, J BIOL CHEM, V253, P691; Iijima H, 1996, EUR J BIOCHEM, V242, P186, DOI 10.1111/j.1432-1033.1996.0186r.x; Ikemoto A, 1997, NEUROCHEM RES, V22, P671, DOI 10.1023/A:1027393724676; INNIS SM, 1991, PROG LIPID RES, V30, P39, DOI 10.1016/0163-7827(91)90006-Q; Jensen CL, 2002, CLIN PERINATOL, V29, P261, DOI 10.1016/S0095-5108(02)00010-6; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; Knapp S, 1999, BRAIN RES, V822, P52, DOI 10.1016/S0006-8993(99)01072-0; KohyamaKoganeya A, 1997, FEBS LETT, V409, P258, DOI 10.1016/S0014-5793(97)00526-7; Lewin TM, 2002, ARCH BIOCHEM BIOPHYS, V404, P263, DOI 10.1016/S0003-9861(02)00247-3; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Li JX, 1998, BRAIN RES, V803, P44, DOI 10.1016/S0006-8993(98)00595-2; Li JX, 1999, BRAIN RES, V818, P252, DOI 10.1016/S0006-8993(98)01280-3; Marszalek JR, 2004, J BIOL CHEM, V279, P23882, DOI 10.1074/jbc.M313460200; NARIAI T, 1994, CLIN EXP METASTAS, V12, P213, DOI 10.1007/BF01753889; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; OKUDA S, 1994, NEUROSCIENCE, V63, P691, DOI 10.1016/0306-4522(94)90515-0; Pownall HJ, 2003, ACTA PHYSIOL SCAND, V178, P357, DOI 10.1046/j.1365-201X.2003.01154.x; Rapoport SI, 2001, J MOL NEUROSCI, V16, P243, DOI 10.1385/JMN:16:2-3:243; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Sessler AM, 1996, J BIOL CHEM, V271, P29854, DOI 10.1074/jbc.271.47.29854; SOTO AM, 1985, J STEROID BIOCHEM, V23, P87, DOI 10.1016/0022-4731(85)90265-1; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1994, J NEUROCHEM, V62, P1231; WILSON DB, 1982, J BIOL CHEM, V257, P3510; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200	39	88	96	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10817	10826		10.1074/jbc.M411750200	http://dx.doi.org/10.1074/jbc.M411750200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15655248	hybrid			2022-12-25	WOS:000227559600129
J	Rayner, BS; Wu, BJ; Raftery, M; Stocker, R; Witting, PK				Rayner, BS; Wu, BJ; Raftery, M; Stocker, R; Witting, PK			Human S-nitroso oxymyoglobin is a store of vasoactive nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NO-CENTER-DOT; HUMAN MYOGLOBIN; ALPHA-TOCOPHEROL; HUMAN PLASMA; HEME IRON; OXYGEN; TRANSNITROSATION; IDENTIFICATION; HEMOGLOBIN; CYSTEINE	Nitric oxide ((NO)-N-center dot) regulates vascular function, and myoglobin (Mb) is a heme protein present in skeletal, cardiac, and smooth muscle, where it facilitates O-2 transfer. Human ferric Mb binds (NO)-N-center dot to yield nitrosylheme and S-nitroso (S-NO) Mb (Witting, P. K., Douglas, D. J., and Mauk, A. G. (2001) J. Biol. Chem. 276, 3991 3998). Here we show that human ferrous oxy-myoglobin (oxyMb) oxidizes (NO)-N-center dot, with a second order rate constant k = 2.8 +/- 0.1 x 10(7) M-1 (.)s(-1) as determined by stopped-flow spectroscopy. Mixtures containing oxyMb and S-nitrosoglutathione or S-nitrosocysteine added at 1.5- 2 moles of S-nitrosothiol/mol oxyMb yielded S-NO oxyMb through trans-nitrosation equilibria as confirmed with mass spectrometry. Rate constants for the equilibrium reactions were k(forward) = 110 +/- 3 and k(reverse) = 16 +/- 3 M(-1.)s(-1) for S- nitrosoglutathione and k(forward) = 293 +/- 5 and k(reverse) = 20 +/- 2 M(-1.)s(-1) for S- nitrosocysteine. Incubation of S- NO oxyMb with Cu2+ ions stimulated (NO)-N-center dot release as measured with a (NO)-N-center dot electrode. Similarly, Cu2+ released (NO)-N-center dot from Mb immunoprecipitated from cultured human vascular smooth muscle cells (VSMCs) that were pre-treated with diethylaminenonoate. No (NO)-N-center dot release was observed from VSMCs treated with vehicle alone or immunoprecipitates obtained from porcine aortic endothelial cells with and without diethylaminenonoate treatment. Importantly, pre-constricted aortic rings relaxed in the presence of S- NO oxyMb in a cyclic GMP-dependent process. These data indicate that human oxyMb rapidly oxidizes (NO)-N-center dot and that biologically relevant S- nitrosothiols can trans-(S)nitrosate human oxyMb. Furthermore, S-NO oxyMb can be isolated from cultured human VSMCs exposed to an exogenous (NO)-N-center dot donor at physiologic concentration. The potential biologic implications of S-NO oxyMb acting as a source of (NO)-N-center dot are discussed.	Concord Repatriat Gen Hosp, ANZAC Res Inst, Vasc Biol Grp, Concord, NSW 2139, Australia; Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; Univ New S Wales, Biomed Mass Spectrometry Unit, Sydney, NSW 2052, Australia	Concord Repatriation General Hospital; University of Sydney; ANZAC Research Institute; University of New South Wales Sydney; University of New South Wales Sydney	Witting, PK (corresponding author), Concord Repatriat Gen Hosp, ANZAC Res Inst, Vasc Biol Grp, Hosp Rd, Concord, NSW 2139, Australia.	pwitting@anzac.edu.au	Stocker, Roland/AAV-4489-2021; Witting, Paul/ABD-2053-2020; Ekanayake, Kanchana/P-8817-2016; Research Institute, ANZAC/CAE-9030-2022; Witting, Paul/L-9786-2019	Witting, Paul/0000-0003-2237-7004; Wu, Ben/0000-0003-2826-4190				AlSadoni HH, 1997, BRIT J PHARMACOL, V121, P1047, DOI 10.1038/sj.bjp.0701218; Andriambeloson E, 2002, REDOX REP, V7, P131, DOI 10.1179/135100002125000361; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Brookes PS, 2003, J BIOL CHEM, V278, P31603, DOI 10.1074/jbc.M211784200; Brovkovych V, 1999, J PHARMACEUT BIOMED, V19, P135, DOI 10.1016/S0731-7085(98)00090-9; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; BRUNORI M, 2001, TRENDS BIOCHEM SCI, V26, P290; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; COLONNA G, 1982, BIOCHEMISTRY-US, V21, P212, DOI 10.1021/bi00531a002; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Enoki Y, 1998, COMP BIOCHEM PHYS B, V120, P183, DOI 10.1016/S0305-0491(98)10007-X; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Fujita S, 1998, CARDIOVASC RES, V38, P655, DOI 10.1016/S0008-6363(98)00051-0; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038/nm0503-496; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HAGLER L, 1979, J BIOL CHEM, V254, P6505; He GW, 2001, CIRCULATION, V104, pI344; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Hogg N, 1999, ANAL BIOCHEM, V272, P257, DOI 10.1006/abio.1999.4199; Hogg N, 2000, FREE RADICAL BIO MED, V28, P1478, DOI 10.1016/S0891-5849(00)00248-3; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; Hunter CL, 1997, BIOCHEMISTRY-US, V36, P1018, DOI 10.1021/bi961993+; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; Janero DR, 2004, P NATL ACAD SCI USA, V101, P16958, DOI 10.1073/pnas.0406075101; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Joshi MS, 2001, NITRIC OXIDE-BIOL CH, V5, P561, DOI 10.1006/niox.2001.0369; Jourd'heuil D, 2000, FREE RADICAL BIO MED, V28, P409, DOI 10.1016/S0891-5849(99)00257-9; JURGENS KD, 1994, P NATL ACAD SCI USA, V91, P3829, DOI 10.1073/pnas.91.9.3829; Kalyanaraman B, 1996, METHODS ENZYMOL, V268, P168; KATZ IR, 1984, J BIOL CHEM, V259, P7504; KEANEY JF, 1994, J CLIN INVEST, V93, P844, DOI 10.1172/JCI117039; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LUI X, 2004, AM J PHYSIOL-HEART C, V2874, pH2421; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; Muller B, 1996, BRIT J PHARMACOL, V119, P1281, DOI 10.1111/j.1476-5381.1996.tb16034.x; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; Papadopoulos S, 2001, P NATL ACAD SCI USA, V98, P5904, DOI 10.1073/pnas.101109798; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Qiu Y, 1998, J BIOL CHEM, V273, P23426, DOI 10.1074/jbc.273.36.23426; Rossi R, 1997, ANAL BIOCHEM, V254, P215, DOI 10.1006/abio.1997.2424; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Spencer NY, 2000, J BIOL CHEM, V275, P36562, DOI 10.1074/jbc.M005347200; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Tsikas D, 2002, J CHROMATOGR B, V772, P335, DOI 10.1016/S1570-0232(02)00121-6; Vanin AF, 2004, NITRIC OXIDE-BIOL CH, V10, P60, DOI 10.1016/j.niox.2004.02.005; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; Witting PK, 2002, BIOCHEMISTRY-US, V41, P11495, DOI 10.1021/bi025835w; Witting PK, 2001, J BIOL CHEM, V276, P3991, DOI 10.1074/jbc.M005758200; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890; Zhang H, 1996, ANAL BIOCHEM, V237, P141, DOI 10.1006/abio.1996.0212; Zhang J, 2001, AM J PHYSIOL-HEART C, V280, pH1318; Zhang Y, 2002, FREE RADICAL BIO MED, V32, P1212, DOI 10.1016/S0891-5849(02)00829-8; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	66	33	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9985	9993		10.1074/jbc.M410564200	http://dx.doi.org/10.1074/jbc.M410564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644316	hybrid			2022-12-25	WOS:000227559600031
J	Carlin, SM; Resink, TJ; Tamm, M; Roth, M				Carlin, SM; Resink, TJ; Tamm, M; Roth, M			Urokinase signal transduction and its role in cell migration	FASEB JOURNAL			English	Article						uPAR; signaling; FAK; SHP2; cell migration	FOCAL-ADHESION-KINASE; RENAL EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; PLASMINOGEN-ACTIVATOR; INTEGRIN FUNCTION; RECEPTOR; APOPTOSIS; SRC; PHOSPHATASE; CASPASES	Urokinase and its receptor uPAR play a role in cell migration that is being actively characterized. We previously reported that urokinase potentiates cell migration in human airway smooth muscle cells only where there is some primary migratory stimulus such as PDGF or recent exposure to growth medium. In this study, we examined the signaling of urokinase through its receptor, which lacks an intracellular domain and is presumed to act through associations with other membrane proteins. Whereas PDGF ( 30 min) and PDGF with urokinase increased the amount of the tyrosine dephosphorylase SHP2 in the membrane fraction, urokinase alone ( 30 min) decreased membrane SHP2. Analysis of the time course of urokinase stimulation showed that SHP2 was brought into association with the urokinase receptor uPAR between 2.5 and 20 min of urokinase, and later dissociated from it. Focal adhesion kinase was steadily lost from association with uPAR during urokinase stimulation, but its phosphorylation state increased and it became cleaved to smaller molecules. Association of uPAR with caveolin also decreased during urokinase stimulation. In contrast, the tyrosine kinase Src increased in the membrane fraction in response to urokinase stimulation. Disruption of raft structures by cyclodextrin treatment led to potentiation of PDGF chemotaxis, similar to urokinase action. Blocking of dephosphorylase activity with vanadate reduced basal cell migration and blocked the action of urokinase on PDGF chemotaxis. These observations support a role for urokinase in altering the phosphorylation state of focal adhesions, leading to breakdown of their structure and facilitation of cell motility.	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Woolcock Inst Med Res, Camperdown, NSW, Australia	University of Basel; University of Sydney; Woolcock Institute of Medical Research	Roth, M (corresponding author), Univ Basel Hosp, Dept Res, Hebelstr 20, CH-4031 Basel, Switzerland.	michelr@med.usyd.edu.au	Roth, Michael/H-8657-2019	Roth, Michael/0000-0002-8139-2821				AGUIRREGHISO JA, 2002, ONCOGENE, V21, P2513; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Carlin SM, 2003, AM J PHYSIOL-LUNG C, V284, pL1020, DOI 10.1152/ajplung.00092.2002; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EL L, 1980, J BIOCHEM BIOPH METH, V3, P207; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Freyer AM, 2001, AM J RESP CELL MOL, V25, P569, DOI 10.1165/ajrcmb.25.5.4605; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879; JOHNSON PRA, 1995, AM J PHYSIOL-LUNG C, V269, pL514, DOI 10.1152/ajplung.1995.269.4.L514; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; Kohyama T, 2001, AM J PHYSIOL-LUNG C, V281, pL1257, DOI 10.1152/ajplung.2001.281.5.L1257; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mao HP, 2003, J BIOL CHEM, V278, P18214, DOI 10.1074/jbc.M300126200; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Ossowski L, 1999, MEDICINA-BUENOS AIRE, V59, P547; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285	33	33	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					195	202		10.1096/fj.04-1644com	http://dx.doi.org/10.1096/fj.04-1644com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15677342				2022-12-25	WOS:000227591900023
J	Kolossov, E; Lu, ZJ; Drobinskaya, I; Gassanov, N; Duan, YQ; Sauer, H; Manzke, O; Bloch, W; Bohlen, H; Hescheler, J; Fleischmann, BK				Kolossov, E; Lu, ZJ; Drobinskaya, I; Gassanov, N; Duan, YQ; Sauer, H; Manzke, O; Bloch, W; Bohlen, H; Hescheler, J; Fleischmann, BK			Identification and characterization of embryonic stem cell-derived pacemaker and atrial cardiomyocytes	FASEB JOURNAL			English	Article						ES cells; cardiac differentiation; alpha-myosin heavy chain promoter; atrial-like cells; pacemaker-like cells	GREEN FLUORESCENT PROTEIN; MYOSIN GENE-EXPRESSION; HEAVY-CHAIN GENE; CARDIAC-MUSCLE; CA2+ CHANNEL; IN-VITRO; HEART; TISSUE; CARDIOMYOGENESIS; MORPHOGENESIS	The aim of this study was to identify and functionally characterize cardiac subtypes during early stages of development. For this purpose, transgenic embryonic stem cells were generated using the alpha-myosin heavy chain promoter driving the expression of the enhanced green fluorescent protein (EGFP). EGFP-positive clusters of cells were first observed as early as 7 days of development, thus, even before the initiation of the contractile activity. Flow cytometry and single-cell fluorescence measurements evidenced large diversities of EGFP intensity. Patch-clamp experiments showed EGFP expression exclusively in pacemaker and atrial but not ventricular cells. The highest fluorescence intensities were detected in pacemaker-like cardiomyocytes. In accordance, multielectrode-array recordings of whole embryoid bodies confirmed that the pacemaker center coincided with strongly EGFP-positive areas. The cardiac subtypes displayed already at this early stage differential characteristics of electrical activity and ion channel expression. Thus, quantitation of the alpha-myosin heavy chain driven reporter gene expression allows identification and functional characterization of early cardiac subtypes.	Axiogenesis AG, Cologne, Germany; Univ Cologne, Inst Nuerophysiol, Cologne, Germany; Univ Cologne, Inst Internal Med 1, Cologne, Germany; German Sports Univ, Dept Mol & Cellular Sport Med, Cologne, Germany; Univ Bonn, Inst Physiol 1, D-53115 Bonn, Germany	University of Cologne; University of Cologne; German Sport University Cologne; University of Bonn	Kolossov, E (corresponding author), Univ Bonn, Inst Physiol 1, Argelanderstr 2A, D-53115 Bonn, Germany.	eugen.kolossov@axiogenesis.com; bernd.fleischmann@uni-bonn.de						Abi-Gerges N, 2000, J PHYSIOL-LONDON, V523, P377, DOI 10.1111/j.1469-7793.2000.t01-2-00377.x; Accili EA, 2002, NEWS PHYSIOL SCI, V17, P32, DOI 10.1152/physiologyonline.2002.17.1.32; ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; Christoffels VM, 2000, DEV BIOL, V223, P266, DOI 10.1006/dbio.2000.9753; Davies MP, 1996, CIRC RES, V78, P15, DOI 10.1161/01.RES.78.1.15; DEGROOT IJM, 1989, ANAT REC, V224, P365, DOI 10.1002/ar.1092240305; DIFRANCESCO D, 1995, CARDIOVASC RES, V29, P449, DOI 10.1016/S0008-6363(96)88518-X; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Fijnvandraat AC, 2003, CARDIOVASC RES, V58, P399, DOI 10.1016/S0008-6363(03)00282-7; Fleischmann M, 1998, FEBS LETT, V440, P370, DOI 10.1016/S0014-5793(98)01476-8; GORZA L, 1986, J CELL BIOL, V102, P1758, DOI 10.1083/jcb.102.5.1758; Gryshchenko O, 2000, PFLUG ARCH EUR J PHY, V439, P798, DOI 10.1007/s004240051007; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Igelmund P, 1999, PFLUG ARCH EUR J PHY, V437, P669, DOI 10.1007/s004240050831; Ji GJ, 1999, FASEB J, V13, P313, DOI 10.1096/fasebj.13.2.313; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; KAMINO K, 1991, PHYSIOL REV, V71, P53, DOI 10.1152/physrev.1991.71.1.53; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; KUROO M, 1986, J CLIN INVEST, V77, P340, DOI 10.1172/JCI112310; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; NANOT J, 1977, J EMBRYOL EXP MORPH, V37, P133; RINDT H, 1993, J BIOL CHEM, V268, P5332; Robbins J, 1997, TRENDS CARDIOVAS MED, V7, P185, DOI 10.1016/S1050-1738(97)00048-0; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; TAYLOR JJ, 1978, AM J PHYSIOL, V235, pH407, DOI 10.1152/ajpheart.1978.235.4.H407; VANMIEROP LH, 1967, AM J PHYSIOL, V212, P407, DOI 10.1152/ajplegacy.1967.212.2.407; Viatchenko-Karpinski S, 1999, P NATL ACAD SCI USA, V96, P8259, DOI 10.1073/pnas.96.14.8259; WESSELS A, 1991, ANAT REC, V229, P355, DOI 10.1002/ar.1092290309; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; Xie LH, 1997, AM J PHYSIOL-HEART C, V272, pH1741, DOI 10.1152/ajpheart.1997.272.4.H1741; YUTZEY KE, 1995, DEV BIOL, V170, P531, DOI 10.1006/dbio.1995.1234; Zammit PS, 2000, DEV DYNAM, V217, P75, DOI 10.1002/(SICI)1097-0177(200001)217:1<75::AID-DVDY7>3.0.CO;2-L	34	85	101	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					577	+		10.1096/fj.03-1451fje	http://dx.doi.org/10.1096/fj.03-1451fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15659535				2022-12-25	WOS:000226576600021
J	McDaid, J; Yamashita, K; Chora, A; Ollinger, R; Strom, TB; Li, XC; Bach, FH; Soares, MP				McDaid, J; Yamashita, K; Chora, A; Ollinger, R; Strom, TB; Li, XC; Bach, FH; Soares, MP			Heme oxygenase-1 modulates the allo-immune response by promoting activation-induced cell death of T cells	FASEB JOURNAL			English	Article						T lymphocytes; apoptosis; cellular activation	ISCHEMIA/REPERFUSION INJURY; OVEREXPRESSION; INDUCTION; APOPTOSIS; ALLOGRAFT; GENE; INHIBITION; SUPPRESSES; PROTECTS; STRESS	Heme oxygenase-1 (HO-1), which degrades heme into three products (carbon monoxide, free iron, and biliverdin), plays a protective role in many models of disease via its anti-inflammatory, anti-apoptotic, and anti-proliferative actions. Overexpression of HO-1 has been shown to suppress immune responses and prolong the survival of allografts; however, the underlying mechanism is not clear. We demonstrate two "new" properties of HO-1 that mediate activation induced cell death (AICD) of allo-antigen-responsive murine CD4(+) T cells, resulting in immunomodulation. First, it functions in vivo and in vitro to "boost" the proliferative response of CD4(+) T cells to allo-antigens in the early phase of allo-antigen-driven immune responses. This "boosting" effect is accompanied with a significant increase of activation markers and IL-2 production. Second, it exerts a pro-apoptotic effect in those activated T cells after the initial burst of proliferation. We further show that the AICD effect is mediated through the Fas/CD95- FasL signal transduction pathway. Correlating with the above-mentioned findings is the observed prolongation of mouse heart graft survival when HO-1 is expressed in vivo in both donor and recipient. In conclusion, induction of HO-1 expression accelerates clonal deletion of peripheral alloreactive CD4(+) T cells by promoting AICD, which is presumably a key mechanism for its immunomodulatory effects such as in prolonging the survival of transplanted organs.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Immunobiol Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Immunol, Boston, MA 02215 USA; Inst Gulbenkian Ciencias, P-2781901 Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Instituto Gulbenkian de Ciencia	Soares, MP (corresponding author), Gulbenkian Inst Sci, Inflammat Lab, Rua Quinta Grande 6, P-2780 Oeiras, Portugal.	mpsoares@igc.gulbenkian.pt	Ferreira Chora, Angelo/AAZ-6503-2021; Soares, Miguel P/G-4188-2011; Strom, Terry B./E-9268-2010; Öllinger, Robert/D-1538-2009	Ferreira Chora, Angelo/0000-0002-7941-7196; Strom, Terry B./0000-0002-7570-0736; Ollinger, Robert/0000-0002-4499-1673; Soares, Miguel/0000-0002-9314-4833; Li, Xian Chang/0000-0002-5981-2762	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058688, R01HL067040] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-58688, R01 HL-67040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; Araujo JA, 2003, J IMMUNOL, V171, P1572, DOI 10.4049/jimmunol.171.3.1572; Berberat PO, 2003, FASEB J, V17, P1724, DOI 10.1096/fj.03-0229fje; Bouchet D, 2002, TRANSPL IMMUNOL, V9, P235, DOI 10.1016/S0966-3274(02)00037-0; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chauveau C, 2002, AM J TRANSPLANT, V2, P581, DOI 10.1034/j.1600-6143.2002.20702.x; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Ducoroy P, 2003, BLOOD, V101, P194, DOI 10.1182/blood-2002-02-0603; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Genestier L, 1998, J CLIN INVEST, V102, P322, DOI 10.1172/JCI2676; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Katori M, 2002, TRANSPLANTATION, V73, P287, DOI 10.1097/00007890-200201270-00023; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Leung DTM, 2000, J IMMUNOL, V164, P3527, DOI 10.4049/jimmunol.164.7.3527; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RASHID A, 1992, J IMMUNOL, V148, P1382; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sykes M, 1997, NAT MED, V3, P783, DOI 10.1038/nm0797-783; Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4; Tsui TY, 2003, CIRCULATION, V107, P2623, DOI 10.1161/01.CIR.0000066911.03770.8D; Tullius SG, 2002, TRANSPLANTATION, V74, P591, DOI 10.1097/00007890-200209150-00001; Van Parijs L, 1998, J IMMUNOL, V160, P2065; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; Visner GA, 2003, CIRCULATION, V107, P911, DOI 10.1161/01.CIR.0000048191.75585.60; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; WATERFIELD JD, 1987, IMMUNOLOGY, V61, P173; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Woo J, 1998, TRANSPL IMMUNOL, V6, P84, DOI 10.1016/S0966-3274(98)80022-1	41	85	92	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					458	+		10.1096/fj.04-2217fje	http://dx.doi.org/10.1096/fj.04-2217fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15640283				2022-12-25	WOS:000226576600027
J	Stewart, RS; Harris, DA				Stewart, RS; Harris, DA			A transmembrane form of the prion protein is localized in the Golgi apparatus of neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE TOPOLOGY; SIGNAL SEQUENCE; PRP; APOPTOSIS; PEPTIDE; DISEASE; CELLS; NEURODEGENERATION; NEUROTOXICITY	(PrP)-Pr-Ctm is a transmembrane version of the prion protein that has been proposed to be a neurotoxic intermediate underlying prion-induced pathogenesis. In previous studies, we found that PrP molecules carrying mutations in the N-terminal signal peptide (L9R) and the transmembrane domain (3AV) were synthesized exclusively in the CtmPrP form in transfected cell lines. To characterize the properties of (PrP)-Pr-Ctm in a neuronal setting, we have utilized cerebellar granule neurons cultured from Tg(L9R- 3AV) mice that developed a fatal neurodegenerative illness. We found that about half of the L9R- 3AV PrP synthesized in these neurons represents (PrP)-Pr-Ctm, with the rest being (PrP)-Pr-Sec, the glycolipid anchored form that does not span the membrane. Both forms contained an uncleaved signal peptide, and they are differentially glycosylated. (PrP)-Pr-Sec was localized on the surface of neuronal processes. Most surprisingly, CtmPrP was concentrated in the Golgi apparatus, rather in the endoplasmic reticulum as it is in transfected cell lines. Our study is the first to analyze the properties of (PrP)-Pr-Ctm in a neuronal context, and our results suggest new hypotheses about how this form may exert its neurotoxic effects.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	dharris@cellbiology.wustl.edu		Harris, David/0000-0002-6985-5790	NINDS NIH HHS [NS35496] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Holscher C, 2001, J BIOL CHEM, V276, P13388, DOI 10.1074/jbc.M007331200; Kim SJ, 2002, MOL BIOL CELL, V13, P3775, DOI 10.1091/mbc.E02-05-0293; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; Kuroda R, 1996, J BIOCHEM-TOKYO, V120, P828; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Maag RS, 2003, CURR OPIN CELL BIOL, V15, P456, DOI 10.1016/S0955-0674(03)00075-9; Machamer CE, 2003, TRENDS CELL BIOL, V13, P279, DOI 10.1016/S0962-8924(03)00101-6; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Miller TM, 1996, J NEUROSCI, V16, P7487; Mishra RS, 2002, J BIOL CHEM, V277, P24554, DOI 10.1074/jbc.M200213200; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Prusiner SB, 2004, PRION BIOL DIS; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; Stewart RS, 2003, J BIOL CHEM, V278, P45960, DOI 10.1074/jbc.M307833200; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; Tremblay P, 2004, J VIROL, V78, P2088, DOI 10.1128/JVI.78.4.2088-2099.2004; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	41	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15855	15864		10.1074/jbc.M412298200	http://dx.doi.org/10.1074/jbc.M412298200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15671025	hybrid			2022-12-25	WOS:000228444800050
J	Harris, MB; Mostecki, J; Rothman, PB				Harris, MB; Mostecki, J; Rothman, PB			Repression of an interleukin-4-responsive promoter requires cooperative BCL-6 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; GERMLINE EPSILON-PROMOTER; GERMINAL-CENTER FORMATION; APOPTOTIC CELL-DEATH; PLZF-RAR-ALPHA; NF-KAPPA-B; BTB/POZ DOMAIN; DNA-BINDING; SYNERGISTIC ACTIVATION; HISTONE DEACETYLASE	BCL-6 functions as a potent transcriptional repressor that binds with specificity to DNA elements bearing marked similarity to STAT recognition sequences. Previous studies have demonstrated that BCL-6 and Stat6 can both bind and regulate the I is an element of promoter that controls immunoglobulin heavy chain class switching to IgE. Examination of BCL-6(-/-) and BCL-6(-/-) Stat6(-/-) mice has demonstrated that BCL-6 is a repressor of IgE and that Stat6 is still required for the interleukin-4 (IL-4) induction of class switching to IgE in B cells lacking BCL-6. To define the mechanisms by which BCL-6 represses IL-4 function, we analyzed the role of BCL-6 in repressing the I is an element of promoter. There are three BCL-6-binding sites within this IL-4-responsive promoter. Analysis of I is an element of promoters that have mutated BCL-6-binding sites demonstrates that at least two of these sites are required for maximal BCL-6 repression of this locus. Footprinting analysis demonstrates that BCL-6 binds cooperatively to the two upstream binding sites in the I is an element of promoter. This cooperative binding requires the POZ domain of BCL-6. Furthermore, activated Stat6 molecules can displace BCL-6 from one of these binding sites. These data demonstrate that cooperative interaction between BCL-6 molecules is required for repression of the I is an element of promoter.	Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med & Microbiol, New York, NY 10032 USA	Columbia University; Columbia University	Rothman, PB (corresponding author), Roy J & Lucille A Carver Col Med, Dept Internal Med, SE308 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	paul-rothman@uiowa.edu			NATIONAL CANCER INSTITUTE [P01CA072699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054821] Funding Source: NIH RePORTER; NCI NIH HHS [CA72699] Funding Source: Medline; NIAID NIH HHS [AI54821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1994, BLOOD, V83, P2423; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; Burz DS, 1998, EMBO J, V17, P5998, DOI 10.1093/emboj/17.20.5998; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN W, 1995, MOL CELL BIOL, V15, P3424; COTRAN RS, 1989, ROBBINS PATHOLOGIC B, P708; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Dent AL, 1998, P NATL ACAD SCI USA, V95, P13823, DOI 10.1073/pnas.95.23.13823; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; FUJITA K, 1995, INT IMMUNOL, V7, P1529, DOI 10.1093/intimm/7.9.1529; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huynh KD, 2000, GENE DEV, V14, P1810; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Li XM, 1999, CANCER RES, V59, P5275; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LO CF, 1994, BLOOD, V83, P1757; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Messner B, 1997, J IMMUNOL, V159, P3330; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mikita T, 1998, J IMMUNOL, V161, P1822; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Numoto M, 1999, BIOCHEM BIOPH RES CO, V256, P573, DOI 10.1006/bbrc.1999.0375; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Ptashne M, 1992, GENETIC SWITCH PHAGE; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; ROTHMAN P, 1994, IMMUNITY, V1, P456; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; TENHARMSEL A, 1993, MOL CELL BIOL, V13, P2742, DOI 10.1128/MCB.13.5.2742; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BHH, 1993, CANCER RES, V53, P2732; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	60	36	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13114	13121		10.1074/jbc.M412649200	http://dx.doi.org/10.1074/jbc.M412649200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15659391	hybrid			2022-12-25	WOS:000227922000122
J	van Weelden, SWH; van Hellemond, JJ; Opperdoes, FR; Tielens, AGM				van Weelden, SWH; van Hellemond, JJ; Opperdoes, FR; Tielens, AGM			New functions for parts of the Krebs cycle in procyclic Trypanosoma brucei, a cycle not operating as a cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORM; MALATE-DEHYDROGENASE; GLUCOSE REPRESSION; ENZYME-ACTIVITIES; FATTY-ACIDS; EXPRESSION; METABOLISM; THREONINE; CULTURE; KINASE	We investigated whether substrate availability influences the type of energy metabolism in procyclic Trypanosoma brucei. We show that absence of glycolytic substrates ( glucose and glycerol) does not induce a shift from a fermentative metabolism to complete oxidation of substrates. We also show that glucose ( and even glycolysis) is not essential for normal functioning and proliferation of pleomorphic procyclic T. brucei cells. Furthermore, absence of glucose did not result in increased degradation of amino acids. Variations in availability of glucose and glycerol did result, however, in adaptations in metabolism in such a way that the glycosome was always in redox balance. We argue that it is likely that, in procyclic cells, phosphoglycerate kinase is located not only in the cytosol, but also inside glycosomes, as otherwise an ATP deficit would occur in this organelle. We demonstrate that procyclic T. brucei uses parts of the Krebs cycle for purposes other than complete degradation of mitochondrial substrates. We suggest that citrate synthase plus pyruvate dehydrogenase and malate dehydrogenase are used to transport acetyl-CoA units from the mitochondrion to the cytosol for the biosynthesis of fatty acids, a process we show to occur in proliferating procyclic cells. The part of the Krebs cycle consisting of alpha-ketoglutarate dehydrogenase and succinylCoA synthetase was used for the degradation of proline and glutamate to succinate. We also demonstrate that the subsequent enzymes of the Krebs cycle, succinate dehydrogenase and fumarase, are most likely used for conversion of succinate into malate, which can then be used in gluconeogenesis.	Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3584 CM Utrecht, Netherlands; Catholic Univ Louvain, Trop Dis Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, Biochem Lab, Christian Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	Utrecht University; Universite Catholique Louvain; Universite Catholique Louvain	Tielens, AGM (corresponding author), Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, POB 80176, NL-3508 TD Utrecht, Netherlands.	tielens@vet.uu.nl	Opperdoes, Fred/N-9922-2019; Opperdoes, Frederik R/C-8897-2018; van Hellemond, Jaap/T-7555-2019	Opperdoes, Fred/0000-0003-1984-3764; Opperdoes, Frederik R/0000-0003-1984-3764; van Hellemond, Jaap/0000-0003-4862-7796; Tielens, Aloysius/0000-0002-5485-1105				ALEXANDER K, 1991, MOL BIOCHEM PARASIT, V46, P1, DOI 10.1016/0166-6851(91)90193-A; Anderson SA, 1998, EXP PARASITOL, V89, P63, DOI 10.1006/expr.1998.4260; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; BLIGH EG, 1959, CAN J MED SCI, V37, P911, DOI DOI 10.1139/O59-099; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; Brouwers JFHM, 1997, MOL BIOCHEM PARASIT, V88, P175, DOI 10.1016/S0166-6851(97)00091-1; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Chaudhuri M, 1998, MOL BIOCHEM PARASIT, V95, P53, DOI 10.1016/S0166-6851(98)00091-7; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; Concepcion JL, 2001, MOL BIOCHEM PARASIT, V118, P111, DOI 10.1016/S0166-6851(01)00381-4; Coustou V, 2003, J BIOL CHEM, V278, P49625, DOI 10.1074/jbc.M307872200; CROSS GAM, 1975, PARASITOLOGY, V71, P311, DOI 10.1017/S0031182000046758; DURIEUX PO, 1991, MOL BIOCHEM PARASIT, V45, P19, DOI 10.1016/0166-6851(91)90023-Y; Estevez AM, 1999, MOL BIOCHEM PARASIT, V100, P5, DOI 10.1016/S0166-6851(99)00024-9; EVANS DA, 1972, J PROTOZOOL, V19, P686, DOI 10.1111/j.1550-7408.1972.tb03561.x; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; Furuya T, 2002, P NATL ACAD SCI USA, V99, P14177, DOI 10.1073/pnas.222454899; Gombert AK, 2001, J BACTERIOL, V183, P1441, DOI 10.1128/JB.183.4.1441-1451.2001; Hannaert V, 2003, P NATL ACAD SCI USA, V100, P1067, DOI 10.1073/pnas.0335769100; Hannaert Veronique, 2003, Kinetoplastid Biology and Disease, V2, pUnpaginated; HART DT, 1984, MOL BIOCHEM PARASIT, V12, P25, DOI 10.1016/0166-6851(84)90041-0; Hunger-Glaser I, 1999, MOL BIOCHEM PARASIT, V100, P43, DOI 10.1016/S0166-6851(99)00025-0; HUNT M, 1995, BBA-PROTEIN STRUCT M, V1249, P15, DOI 10.1016/0167-4838(95)00061-X; LINSTEAD DJ, 1977, J GEN MICROBIOL, V101, P243, DOI 10.1099/00221287-101-2-243; MISSET O, 1987, EUR J BIOCHEM, V162, P493, DOI 10.1111/j.1432-1033.1987.tb10667.x; Morita YS, 2000, SCIENCE, V288, P140, DOI 10.1126/science.288.5463.140; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; MUTURINJOGU R, 1980, MOL BIOCHEM PARASIT, V1, P13, DOI 10.1016/0166-6851(80)90038-9; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P291, DOI 10.1016/0166-6851(81)90062-1; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P21, DOI 10.1111/j.1432-1033.1977.tb11566.x; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; OPPERDOES FR, 1982, FEBS LETT, V143, P60, DOI 10.1016/0014-5793(82)80270-6; RILEY JF, 1962, BIOCHEM J, V85, P211; Riviere L, 2004, J BIOL CHEM, V279, P45337, DOI 10.1074/jbc.M407513200; Saas J, 2000, J BIOL CHEM, V275, P2745, DOI 10.1074/jbc.275.4.2745; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; terKuile BH, 1997, J BACTERIOL, V179, P4699, DOI 10.1128/jb.179.15.4699-4705.1997; TIELENS AGM, 1992, MOL BIOCHEM PARASIT, V56, P49, DOI 10.1016/0166-6851(92)90153-B; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; Tyler KM, 2000, CELL MOTIL CYTOSKEL, V46, P269, DOI 10.1002/1097-0169(200008)46:4&lt;269::AID-CM4&gt;3.0.CO;2-V; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; Vassella E, 2000, GENE DEV, V14, P615; Vassella E, 2004, MOL BIOL CELL, V15, P3986, DOI 10.1091/mbc.E04-04-0341; Vernal J, 2001, MOL BIOCHEM PARASIT, V117, P217, DOI 10.1016/S0166-6851(01)00343-7; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; WOOD R, 1983, J CHROMATOGR, V254, P237, DOI 10.1016/S0021-9673(01)88338-2	47	86	90	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12451	12460		10.1074/jbc.M412447200	http://dx.doi.org/10.1074/jbc.M412447200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15647263	hybrid			2022-12-25	WOS:000227922000048
J	Youn, BY; Moinuddin, SGA; Davin, LB; Lewis, NG; Kang, CH				Youn, BY; Moinuddin, SGA; Davin, LB; Lewis, NG; Kang, CH			Crystal structures of apo-form and binary/ternary complexes of Podophyllum secoisolariciresinol dehydrogenase, an enzyme involved in formation of health-protecting and plant defense lignans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WESTERN RED CEDAR; THUJA-PLICATA-DONN; BENZYLIC ETHER REDUCTASES; CELL-FREE-EXTRACTS; PINORESINOL-LARICIRESINOL; ALCOHOL-DEHYDROGENASE; FORSYTHIA-INTERMEDIA; TELLIMAGRANDIN-II; DIRIGENT PROTEINS; CONIFERYL ALCOHOL	(-)-Matairesinol is a central biosynthetic intermediate to numerous 8-8 '-lignans, including the antiviral agent podophyllotoxin in Podophyllum species and its semi-synthetic anticancer derivatives teniposide, etoposide, and Etopophos (R). It is formed by action of an enantiospecific secoisolariciresinol dehydrogenase, an NAD(H)-dependent oxidoreductase that catalyzes the conversion of (-)-secoisolariciresinol. Matairesinol is also a plant-derived precursor of the cancer-preventative "mammalian" lignan or "phytoestrogen" enterolactone, formed in the gut following ingestion of high fiber dietary foodstuffs, for example. Additionally, secoisolariciresinol dehydrogenase is involved in pathways to important plant defense molecules, such as plicatic acid in the western red cedar (Thuja plicata) heartwood. To understand the molecular and enantiospecific basis of Podophyllum secoisolariciresinol dehydrogenase, crystal structures of the apo-form and binary/ternary complexes were determined at 1.6, 2.8, and 2.0 angstrom resolution, respectively. The enzyme is a homotetramer, consisting of an alpha/beta single domain monomer containing seven parallel beta-strands flanked by eight alpha-helices on both sides. Its overall monomeric structure is similar to that of NAD(H)-dependent shortchain dehydrogenases/reductases, with a conserved Asp(47) forming a hydrogen bond with both hydroxyl groups of the adenine ribose of NAD(H), and thus specificity toward NAD(H) instead of NADP(H). The highly conserved catalytic triad (Ser153, Tyr167, and Lys171) is adjacent to both NAD(+) and substrate molecules, where Tyr167 functions as a general base. Following analysis of high resolution structures of the apo-form and two complex forms, the molecular basis for both the enantio-specificity and the reaction mechanism of secoisolariciresinol dehydrogenase is discussed and compared with that of pinoresinol-lariciresinol reductase.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University; Washington State University	Kang, CH (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	chkang@wsunix.wsu.edu		Kang, ChulHee/0000-0002-0693-7860; Davin, Laurence/0000-0002-3248-6485				ADLERCREUTZ H, 1992, J STEROID BIOCHEM, V41, P331, DOI 10.1016/0960-0760(92)90359-Q; ADLERCREUTZ H, 1988, PROGR CANC RES THERA, V35, P409; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anterola AM, 2002, PHYTOCHEMISTRY, V61, P221, DOI 10.1016/S0031-9422(02)00211-X; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; BRUNGER AT, 1992, X PLOR SYST CRYSTALL; Burlat V, 2001, PHYTOCHEMISTRY, V57, P883, DOI 10.1016/S0031-9422(01)00117-0; Canel C, 2000, PHYTOCHEMISTRY, V54, P115, DOI 10.1016/S0031-9422(00)00094-7; Cho MH, 2003, P NATL ACAD SCI USA, V100, P10641, DOI 10.1073/pnas.1934562100; CHU A, 1993, J BIOL CHEM, V268, P27026; Davin Laurence B., 2003, Phytochemistry Reviews, V2, P257, DOI 10.1023/B:PHYT.0000046175.83729.b5; Davin LB, 2003, PHYTOCHEMISTRY, V62, P501, DOI 10.1016/S0031-9422(02)00540-X; Davin LB, 2000, PLANT PHYSIOL, V123, P453, DOI 10.1104/pp.123.2.453; Davin LB, 1997, SCIENCE, V275, P362, DOI 10.1126/science.275.5298.362; DinkovaKostova AT, 1996, J BIOL CHEM, V271, P29473, DOI 10.1074/jbc.271.46.29473; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; Ford J. D., 2001, THESIS WASHINGTON ST; Ford JD, 2000, PROCEEDINGS OF THE 58TH FLAX INSTITUTE OF THE UNITED STATES, P39; Ford JD, 2001, J NAT PROD, V64, P1388, DOI 10.1021/np010367x; Ford JD, 2000, BASIC LIFE SCI, V66, P675; Fujita M, 1999, J BIOL CHEM, V274, P618, DOI 10.1074/jbc.274.2.618; Gang DR, 1999, CHEM BIOL, V6, P143, DOI 10.1016/S1074-5521(99)89006-1; Gang DR, 1999, J BIOL CHEM, V274, P7516, DOI 10.1074/jbc.274.11.7516; Gang DR, 1998, ACS SYM SER, V697, P389, DOI DOI 10.1021/BK-1998-0697.CH025; GARDNER JAF, 1960, CAN J CHEM, V38, P2387, DOI 10.1139/v60-324; GARDNER JAF, 1966, CAN J CHEMISTRY, V44, P52, DOI 10.1139/v66-009; GARDNER JAF, 1959, CAN J CHEM, V37, P1703, DOI 10.1139/v59-246; Halls SC, 2002, BIOCHEMISTRY-US, V41, P9455, DOI 10.1021/bi0259709; Halls SC, 2004, BIOCHEMISTRY-US, V43, P2587, DOI 10.1021/bi035959o; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Katayama T, 1998, J WOOD SCI, V44, P244, DOI 10.1007/BF00521971; Kim MK, 2002, PLANT MOL BIOL, V49, P199, DOI 10.1023/A:1014940930703; Kim MK, 2002, PHYTOCHEMISTRY, V61, P311, DOI 10.1016/S0031-9422(02)00261-3; Lewis N. G., 1999, COMPREHENSIVE NATURA, V1, P639, DOI DOI 10.1016/B978-0-08-091283-7.00027-8; LEWIS NG, 1995, ACS SYM SER, V588, P135; LEWIS NG, 1994, ACS SYM SER, V562, P202; Min TP, 2003, J BIOL CHEM, V278, P50714, DOI 10.1074/jbc.M308493200; Moinuddin SGA, 2003, ORG BIOMOL CHEM, V1, P2307, DOI 10.1039/b302632a; Morreel K, 2004, PLANT PHYSIOL, V136, P4023, DOI 10.1104/pp.104.049312; Morreel K, 2004, PLANT PHYSIOL, V136, P3537, DOI 10.1104/pp.104.049304; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niemetz R, 2003, PHYTOCHEMISTRY, V64, P1197, DOI 10.1016/j.phytochem.2003.08.013; Niemetz R, 2003, PHYTOCHEMISTRY, V62, P301, DOI 10.1016/S0031-9422(02)00557-5; Pereira PJB, 2001, NAT STRUCT BIOL, V8, P215, DOI 10.1038/84948; Powell AJ, 2000, J MOL BIOL, V303, P311, DOI 10.1006/jmbi.2000.4139; Ralph J, 1997, SCIENCE, V277, P235, DOI 10.1126/science.277.5323.235; Ralph J, 1998, P NATL ACAD SCI USA, V95, P12803, DOI 10.1073/pnas.95.22.12803; Suzuki S, 1998, BIOSCI BIOTECH BIOCH, V62, P1468, DOI 10.1271/bbb.62.1468; Teoh K. H., 2003, Flaxseed in human nutrition, P41; UMEZAWA T, 1991, J BIOL CHEM, V266, P10210; Umezawa Toshiaki, 2003, Phytochemistry Reviews, V2, P371, DOI 10.1023/B:PHYT.0000045487.02836.32; Wang CZ, 2001, CHEM COMMUN, P113, DOI 10.1039/b008174o; Xia ZQ, 2000, PHYTOCHEMISTRY, V55, P537, DOI 10.1016/S0031-9422(00)00242-9; Xia ZQ, 2001, J BIOL CHEM, V276, P12614, DOI 10.1074/jbc.M008622200; Yang JK, 2003, P NATL ACAD SCI USA, V100, P455, DOI 10.1073/pnas.0137017100	55	45	48	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12917	12926		10.1074/jbc.M413266200	http://dx.doi.org/10.1074/jbc.M413266200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15653677	hybrid			2022-12-25	WOS:000227922000101
J	Swarts, HGP; Koenderink, JB; Willems, PHGM; Krieger, E; De Pont, JJHHM				Swarts, HGP; Koenderink, JB; Willems, PHGM; Krieger, E; De Pont, JJHHM			Asn(792) participates in the hydrogen bond network around the K+-binding pocket of gastric H,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-BINDING; SARCOPLASMIC-RETICULUM; COMPETITIVE INHIBITOR; STRUCTURAL-CHANGES; CALCIUM-PUMP; H+,K+-ATPASE; NA+,K+-ATPASE; CONFORMATION; MUTATION; ATPASE	Asn(792) present in M5 of gastric H, K-ATPase is highly conserved within the P-type ATPase family. A direct role in K+ binding was postulated for Na, K-ATPase but was not found in a recent model for gastric H, K-ATPase (Koenderink, J. B., Swarts, H. G. P., Willems, P. H. G. M., Krieger, E., and De Pont, J. J. H. H. M. (2004) J. Biol. Chem. 279, 16417-16424). Therefore, its role in K+ binding and E-1/E-2 conformational equilibrium in gastric H, K-ATPase was studied by site-directed mutagenesis and expression in Sf9 cells. N792Q and N792A, but not N792D and N792E, had a markedly reduced K+ affinity in both the ATPase and dephosphorylation reactions. In addition, N792A shifted the conformational equilibrium to the E-1 form. In double mutants, the effect of N792A on K+ sensitivity was overruled by either E820Q (K+-independent activity) or E343D ( no dephosphorylation activity). Models were made for the mutants based on the E-2 structure of Ca2+-ATPase. In the wild-type model the acid amide group of Asn(792) has hydrogen bridges to Lys(791), Ala(339), and Val(341). Comparison of the effects of the various mutants suggests that the hydrogen bridge between the carbonyl oxygen of Asn792 and the amino group of Lys(791) is essential for the K+ sensitivity and the E-2 preference of wild-type enzyme. Moreover, there was a high positive correlation (r = 0.98) between the in silico calculated energy difference of the E-2 form ( mutants versus wild type) and the experimentally measured IC50 values for vanadate, which reflects the direction of the E-2<-> E-1 conformational equilibrium. These data strongly support the validity of the model in which Asn(792) participates in the hydrogen bond network around the K+-binding pocket.	Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Bioinformat, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	De Pont, JJHHM (corresponding author), Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.dePont@ncmls.ru.nl	Willems, P.H.G.M./L-4759-2015; Koenderink, Jan/N-3578-2014	Willems, P.H.G.M./0000-0002-0915-1599; 				Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; Hermsen HPH, 1998, BIOCHEM J, V331, P465, DOI 10.1042/bj3310465; Jorgensen PL, 2003, ANN NY ACAD SCI, V986, P22, DOI 10.1111/j.1749-6632.2003.tb07135.x; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; Koenderink JB, 2004, J BIOL CHEM, V279, P16417, DOI 10.1074/jbc.M400020200; Krieger E, 2004, PROTEINS, V57, P678, DOI 10.1002/prot.20251; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MENDLEIN J, 1990, J BIOL CHEM, V265, P5030; Nayal M, 1996, J MOL BIOL, V256, P228, DOI 10.1006/jmbi.1996.0081; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; Swarts HGP, 1998, EMBO J, V17, P3029, DOI 10.1093/emboj/17.11.3029; Swarts HGP, 1999, MOL PHARMACOL, V55, P541; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Swarts HGP, 2001, J BIOL CHEM, V276, P36909, DOI 10.1074/jbc.M103945200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vagin O, 2002, BIOCHEMISTRY-US, V41, P12755, DOI 10.1021/bi025921w; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; Wang GL, 2003, BIOINFORMATICS, V19, P1589, DOI 10.1093/bioinformatics/btg224	25	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11488	11494		10.1074/jbc.M412321200	http://dx.doi.org/10.1074/jbc.M412321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644331	hybrid, Green Published			2022-12-25	WOS:000227761800073
J	Barrera, NP; Ormond, SJ; Henderson, RM; Murrell-Lagnado, RD; Edwardson, JM				Barrera, NP; Ormond, SJ; Henderson, RM; Murrell-Lagnado, RD; Edwardson, JM			Atomic force microscopy imaging demonstrates that P2X(2) receptors are trimers but that P2X(6) receptor subunits do not oligomerize	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION-CHANNEL; MOLECULAR PHYSIOLOGY; IDENTIFICATION; TRANSLOCATION; ARCHITECTURE; TRAFFICKING; SUBTYPES; VOLUMES; NEURONS; MOTIF	P2X receptors are cation-selective channels activated by extracellular ATP. The architecture of these receptors is still not completely clear. Here we have addressed this issue by both chemical cross-linking and direct imaging of individual receptors by atomic force microscopy (AFM). Cross-linking of the P2X(2) receptor produced higher order adducts, consistent with the presence of trimers. The mean molecular volume of the receptor determined by AFM (409 nm(3)) also points to a trimeric structure. P2X(2) receptors bearing His(6) epitope tags were incubated with anti-His(6) antibodies, and the resultant complexes were imaged by AFM. For receptors with two bound antibodies, the mean angle between the antibodies was 123 degrees, again indicating that the receptor is a trimer. In contrast, cross-linking of the P2X(6) receptor did not produce higher order adducts, and the mean molecular volume of the receptor was 145 nm(3). We conclude that P2X(2) receptors are trimers, whereas the P2X(6) receptor subunits do not form stable oligomers.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Edwardson, JM (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	jme1000@cam.ac.uk		Murrell-Lagnado, Ruth/0000-0003-2743-7977; Barrera, Nelson/0000-0001-7825-1406	Biotechnology and Biological Sciences Research Council [B19797] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aschrafi A, 2004, J MOL BIOL, V342, P333, DOI 10.1016/j.jmb.2004.06.092; BEAN BP, 1990, J NEUROSCI, V10, P1; Berge T, 2000, BIOPHYS J, V79, P479, DOI 10.1016/S0006-3495(00)76309-0; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Ding SH, 1999, J GEN PHYSIOL, V113, P695, DOI 10.1085/jgp.113.5.695; Durchschlag H, 1997, J APPL CRYSTALLOGR, V30, P803, DOI 10.1107/S0021889897003348; Ellis DJ, 1999, NAT STRUCT BIOL, V6, P15; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; GRANT EH, 1957, PHYS MED BIOL, V2, P17, DOI 10.1088/0031-9155/2/1/303; Jiang LH, 2003, J NEUROSCI, V23, P8903; Jones CA, 2004, MOL PHARMACOL, V65, P979, DOI 10.1124/mol.65.4.979; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Kim M, 1997, BIOCHEM BIOPH RES CO, V240, P618, DOI 10.1006/bbrc.1997.7713; Larmer J, 1997, PFLUG ARCH EUR J PHY, V434, P254, DOI 10.1007/s004240050393; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Neish CS, 2003, NANOTECHNOLOGY, V14, P864, DOI 10.1088/0957-4484/14/8/305; Neish CS, 2002, BRIT J PHARMACOL, V135, P1943, DOI 10.1038/sj.bjp.0704660; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Saslowsky DE, 2002, J BIOL CHEM, V277, P26966, DOI 10.1074/jbc.M204669200; Schneider SW, 1998, PFLUG ARCH EUR J PHY, V435, P362, DOI 10.1007/s004240050524; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653	25	156	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10759	10765		10.1074/jbc.M412265200	http://dx.doi.org/10.1074/jbc.M412265200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15657042	hybrid			2022-12-25	WOS:000227559600122
J	Guan, HC; Hou, SH; Ricciardi, RP				Guan, HC; Hou, SH; Ricciardi, RP			DNA binding of repressor nuclear factor-kappa B p50/p50 depends on phosphorylation of Ser(337) by the protein kinase A catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CLASS-I ENHANCER; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-MECHANISMS; P65 SUBUNIT; RHEUMATOID-ARTHRITIS; 12-TRANSFORMED CELLS; P50; TRANSACTIVATION; EXPRESSION	The NF-kappa B p50/p50 homodimer is mainly associated with transcriptional repression. Previously, we demonstrated that phosphorylation of NF-kappa B p50 Ser(337) is critical for DNA binding. Here, we report that p50 Ser(337) is constitutively phosphorylated by the protein kinase A catalytic subunit (PKAc) in three different cell types, which may account for the constant binding of p50/p50 to DNA in unstimulated cells. This was demonstrated first by showing that treatment of cells with PKAc-specific inhibitors blocked p50/p50 DNA binding. Second, phosphorylation of p50 by PKAc was prevented by substitution of Ser337 to alanine. Third, both p50 and PKAc proteins as well as kinase activity that phosphorylates p50 were found to co-fractionate following gel filtration chromatography. Finally, PKAc and p50 were shown to be able to reciprocally co-immunoprecipitate one another, and their physical association was blocked by a PKA catalytic site inhibitory peptide. This indicates that phosphorylation of p50 Ser337 involves direct contact with the PKAc catalytic center. In contrast to the dramatic elevation of nuclear p50/p65 heterodimers induced by tumor necrosis factor alpha, DNA binding of p50/p50 homodimers was not greatly altered. Taken together, these findings reveal for the first time that there is a direct interaction between PKAc and p50 that accounts for constitutive phosphorylation of p50 Ser(337) and the existence of DNA bound p50/p50 in the nuclei of most resting cells. This mechanism of DNA binding by p50/p50 following phosphorylation of Ser337 by PKAc may represent an important means for maintaining stable negative regulation of NF-kappa B gene expression in the absence of extracellular stimulation.	Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ricciardi, RP (corresponding author), Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA.	ricciardi@biochem.dental.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER; NCI NIH HHS [CA29797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Driessler F, 2004, CLIN EXP IMMUNOL, V135, P64, DOI 10.1111/j.1365-2249.2004.02342.x; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Griffioen G, 2002, CURR GENET, V41, P199, DOI 10.1007/s00294-002-0308-9; Grundstrom S, 2004, J BIOL CHEM, V279, P8460, DOI 10.1074/jbc.M312398200; Guan HC, 2003, VIROLOGY, V309, P114, DOI 10.1016/S0042-6822(02)00135-6; He B, 2003, EUR J BIOCHEM, V270, P2174, DOI 10.1046/j.1432-1033.2003.03574.x; Hou SH, 2003, J BIOL CHEM, V278, P45994, DOI 10.1074/jbc.M307971200; Hou SH, 2002, J VIROL, V76, P3212, DOI 10.1128/JVI.76.7.3212-3220.2002; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; LI CCH, 1994, J BIOL CHEM, V269, P30089; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liu XH, 1996, MOL CELL BIOL, V16, P398; Makarov SS, 2001, ARTHRITIS RES, V3, P200, DOI 10.1186/ar300; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Thornburg NJ, 2003, CANCER RES, V63, P8293; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	41	79	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9957	9962		10.1074/jbc.M412180200	http://dx.doi.org/10.1074/jbc.M412180200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642694	hybrid			2022-12-25	WOS:000227559600027
J	Hong, M; Lin, MY; Huang, JM; Baumeister, P; Hakre, S; Roy, AL; Lee, AS				Hong, M; Lin, MY; Huang, JM; Baumeister, P; Hakre, S; Roy, AL; Lee, AS			Transcriptional regulation of the Grp78 promoter by endoplasmic reticulum stress - Role of TFII-I and its tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; ER STRESS; CA2+ DEPLETION; C-FOS; NF-Y; ACTIVATION; GLUCOSE; ELEMENT; INDUCTION; ATF6	TFII-I is a signal-induced multi-functional transcription factor that has recently been implicated as a regulatory component of the endoplasmic reticulum ( ER) stress response. TFII-I acts through ER stress-induced binding to the ER stress element, which is highly conserved in promoters of ER stress-inducible genes such as Grp78/BiP. Interestingly, its tyrosine phosphorylation sites are required for its activation of the Grp78 promoter. Toward understanding the link between TFII-I, the tyrosine kinase signaling pathway, and Grp78 activation, we discovered that Tg stress induces a dramatic increase of TFII-I phosphorylation at Tyr(248) and localization of this form of TFII-I to the nucleus. Chromatin immunoprecipitation analysis further reveals enhanced TFII-I binding to the Grp78 promoter in vivo upon ER stress. Previously, we reported that genistein, a general inhibitor of tyrosine kinase, could suppress ER stress induction of Grp78 by inhibiting complex formation on the ER stress element; however, the mechanism is not known. Consistent with TFII-I being a target of genistein suppression, we observed that genistein could suppress Tg stress-induced phosphorylation of TFII-I. We further demonstrate that c-Src, which is one of kinases identified to mediate phosphorylation of TFII-I at Tyr(248), is activated by Tg stress and is able to stimulate the Grp78 promoter activity. Lastly, using stable cell lines with suppressed TFII-I levels, we show that TFII-I is required for optimal induction of Grp78 by ER stress. Our studies provide a molecular link that connects the c-Src tyrosine kinase transduction pathway to ER stress-induced transcriptional activation of Grp78 mediated by TFII- I.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, USC, Los Angeles, CA 90089 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Program Immunol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA	University of Southern California; University of Southern California; Tufts University; Tufts University; Tufts University	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, 1441 Eastlake Ave,Rm 5308, Los Angeles, CA 90089 USA.	amylee@hsc.usc.edu		Lee, Amy/0000-0002-0378-5443	NATIONAL CANCER INSTITUTE [R01CA027607, R37CA027607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045150, R56AI045150] Funding Source: NIH RePORTER; NCI NIH HHS [CA27607] Funding Source: Medline; NIAID NIH HHS [AI45150] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; CAO XJ, 1995, J BIOL CHEM, V270, P494, DOI 10.1074/jbc.270.1.494; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; Cheriyath V, 2002, J BIOL CHEM, V277, P22798, DOI 10.1074/jbc.M202956200; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; He HL, 2000, ONCOGENE, V19, P5936, DOI 10.1038/sj.onc.1203994; Hong M, 2004, J BIOL CHEM, V279, P11354, DOI 10.1074/jbc.M309804200; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim DW, 2000, MOL CELL BIOL, V20, P1140, DOI 10.1128/MCB.20.4.1140-1148.2000; KIM YK, 1989, GENE, V77, P123, DOI 10.1016/0378-1119(89)90366-1; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; LI WWF, 1993, J BIOL CHEM, V268, P12003; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	34	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16821	16828		10.1074/jbc.M413753200	http://dx.doi.org/10.1074/jbc.M413753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15664986	hybrid			2022-12-25	WOS:000228615500035
J	Toth, KF; Mazurkiewicz, J; Rippe, K				Toth, KF; Mazurkiewicz, J; Rippe, K			Association states of nucleosome assembly protein 1 and its complexes with histones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; TRANSCRIPTION FACTOR-BINDING; ANALYTICAL ULTRACENTRIFUGATION; CORE PARTICLE; ANGSTROM RESOLUTION; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SELF-ASSOCIATION; HUMAN-CELLS; CHAPERONE	The histone chaperone NAP1 is a carrier of histones during nuclear import, nucleosome assembly, and chromatin remodeling. Analytical ultracentrifugation was used to determine the association states of NAP1 alone and in complexes with core histones. In addition, the concentration dependence of the association was quantified by determining the equilibrium dissociation constant between different NAP1 species. At physiological protein and salt concentrations the prevalent species were the NAP1 dimer and octamer. These were also the association states found to interact with histones in a stoichiometry of one NAP1 monomer per histone. Based on these results a model for a cell cycle- dependent shift of the NAP1 dimer- octamer equilibrium is proposed that reflects different biological functions of NAP1.	Heidelberg Univ, AG Mol Biophys, Kirchhoff Inst Phys, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Abt Mol Genet B060, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Rippe, K (corresponding author), Heidelberg Univ, AG Mol Biophys, Kirchhoff Inst Phys, Neuenheimer Feld 227, D-69120 Heidelberg, Germany.	Karsten.Rippe@kip.uni-heidelberg.de	Rippe, Karsten/A-3562-2012	Rippe, Karsten/0000-0001-9951-9395				Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Asahara H, 2002, MOL CELL BIOL, V22, P2974, DOI 10.1128/MCB.22.9.2974-2983.2002; BAXEVANIS AD, 1991, BIOCHEMISTRY-US, V30, P8817, DOI 10.1021/bi00100a013; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dong AW, 2003, PLANTA, V216, P561, DOI 10.1007/s00425-002-0910-6; Dutta S, 2001, MOL CELL, V8, P841, DOI 10.1016/S1097-2765(01)00354-9; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Harp JM, 2000, ACTA CRYSTALLOGR D, V56, P1513, DOI 10.1107/S0907444900011847; HAUGLAND RP, 2004, HDB FLUORESCENT PROB, P20; Haushalter KA, 2003, NAT REV MOL CELL BIO, V4, P613, DOI 10.1038/nrm1177; ISHIMI Y, 1985, CELL STRUCT FUNCT, V10, P373, DOI 10.1247/csf.10.373; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1996, MOL CELL BIOL, V16, P3112; JOHNSTON GC, 1979, J BACTERIOL, V137, P1; Kepert JF, 2003, BIOPHYS J, V85, P4012, DOI 10.1016/S0006-3495(03)74815-2; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lee KM, 1997, P NATL ACAD SCI USA, V94, P8959, DOI 10.1073/pnas.94.17.8959; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Li MF, 1999, J MOL BIOL, V293, P1067, DOI 10.1006/jmbi.1999.3207; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Luger K, 1999, METHOD ENZYMOL, V304, P3; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McBryant SJ, 2004, BIOCHEMISTRY-US, V43, P10592, DOI 10.1021/bi035881b; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; Miyaji-Yamaguchi M, 2003, MOL CELL BIOL, V23, P6672, DOI 10.1128/MCB.23.18.6672-6684.2003; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Mortensen EM, 2002, MOL BIOL CELL, V13, P2091, DOI 10.1091/mbc.01-10-0500; Nakagawa T, 2001, J BIOL CHEM, V276, P27384, DOI 10.1074/jbc.M101331200; Ohkuni K, 2003, BIOCHEM BIOPH RES CO, V306, P5, DOI 10.1016/S0006-291X(03)00907-0; Ostashevsky J, 2002, MOL BIOL CELL, V13, P2157, DOI 10.1091/mbc.02-01-0608; Prado A, 2004, BIOCHEM CELL BIOL, V82, P437, DOI 10.1139/O04-042; Regnard C, 2000, J BIOL CHEM, V275, P15969, DOI 10.1074/jbc.M000045200; Rippe K, 1998, J MOL BIOL, V278, P915, DOI 10.1006/jmbi.1998.1746; Rodriguez P, 1997, GENOMICS, V44, P253, DOI 10.1006/geno.1997.4868; Rodriguez P, 2000, J MOL BIOL, V298, P225, DOI 10.1006/jmbi.2000.3674; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Studitsky VM, 2004, TRENDS BIOCHEM SCI, V29, P127, DOI 10.1016/j.tibs.2004.01.003; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; VANHOLDE KE, 1989, CHROMATIN, P416; Wachsmuth M, 2000, J MOL BIOL, V298, P677, DOI 10.1006/jmbi.2000.3692; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Weidemann T, 2003, J MOL BIOL, V334, P229, DOI 10.1016/j.jmb.2003.08.063; Zimmerman ZA, 2001, MOL BIOL CELL, V12, P201, DOI 10.1091/mbc.12.1.201	60	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15690	15699		10.1074/jbc.M413329200	http://dx.doi.org/10.1074/jbc.M413329200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15687486	Green Accepted, hybrid			2022-12-25	WOS:000228444800030
J	Cappai, R; Cheng, F; Ciccotosto, GD; Needham, BE; Masters, CL; Multhaup, G; Fransson, LA; Mani, K				Cappai, R; Cheng, F; Ciccotosto, GD; Needham, BE; Masters, CL; Multhaup, G; Fransson, LA; Mani, K			The amyloid precursor protein (APP) of Alzheimer disease and its paralog, APLP2, modulate the Cu/Zn-nitric oxide-catalyzed degradation of glypican-1 heparan sulfate in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE OUTGROWTH; BETA-PROTEIN; DEPENDENT AUTOCLEAVAGE; BINDING DOMAIN; ASCORBIC-ACID; GROWTH-FACTOR; COPPER LEVELS; MICE; SECRETASE; CELLS	Processing of the recycling proteoglycan glypican-1 involves the release of its heparan sulfate chains by copper ion- and nitric oxide-catalyzed ascorbate-triggered autodegradation. The Alzheimer disease amyloid precursor protein (APP) and its paralogue, the amyloid precursor-like protein 2 (APLP2), contain copper ion-, zinc ion-, and heparan sulfate-binding domains. We have investigated the possibility that APP and APLP2 regulate glypican-1 processing during endocytosis and recycling. By using cell-free biochemical experiments, confocal laser immunofluorescence microscopy, and flow cytometry of tissues and cells from wild-type and knock-out mice, we find that (a) APP and glypican-1 colocalize in perinuclear compartments of neuroblastoma cells, (b) ascorbate-triggered nitric oxide-catalyzed glypican-1 autodegradation is zinc ion- dependent in the same cells, (c) in cell-free experiments, APP but not APLP2 stimulates glypican-1 autodegradation in the presence of both Cu(II) and Zn(II) ions, whereas the Cu(I) form of APP and the Cu( II) and Cu(I) forms of APLP2 inhibit autodegradation, (d) in primary cortical neurons from APP or APLP2 knock-out mice, there is an increased nitric oxide-catalyzed degradation of heparan sulfate compared with brain tissue and neurons from wild-type mice, and ( e) in growth-quiescent fibroblasts from APLP2 knock-out mice, but not from APP knock-out mice, there is also an increased heparan sulfate degradation. We propose that the rate of autoprocessing of glypican-1 is modulated by APP and APLP2 in neurons and by APLP2 in fibroblasts. These observation identify a functional relationship between the heparan sulfate and copper ion binding activities of APP/APLP2 in their modulation of the nitroxyl anion-catalyzed heparan sulfate degradation in glypican-1.	Lund Univ, Dept Cell & Mol Biol, Saect Cell & Matrix Biol, SE-22184 Lund, Sweden; Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; Univ Melbourne, Ctr Neurosci, Parkville, Vic 3010, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany	Lund University; University of Melbourne; University of Melbourne; Free University of Berlin	Fransson, LA (corresponding author), Lund Univ, Dept Cell & Mol Biol, Saect Cell & Matrix Biol, BMC C13, SE-22184 Lund, Sweden.	lars-ake.fransson@medkem.lu.se	Cappai, Roberto/B-3347-2010	Cappai, Roberto/0000-0002-9505-8496; Mani, Katrin/0000-0002-1821-0634				Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Bellingham SA, 2004, J NEUROCHEM, V91, P423, DOI 10.1111/j.1471-4159.2004.02731.x; BUSH AI, 1993, J BIOL CHEM, V268, P16109; Cheng F, 2002, J BIOL CHEM, V277, P44431, DOI 10.1074/jbc.M205241200; CLARRIS HJ, 1994, J NEUROSCI RES, V38, P248, DOI 10.1002/jnr.490380303; Dawson GR, 1999, NEUROSCIENCE, V90, P1, DOI 10.1016/S0306-4522(98)00410-2; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fransson LA, 2004, CELL MOL LIFE SCI, V61, P1016, DOI 10.1007/s00018-004-3445-0; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heber S, 2000, J NEUROSCI, V20, P7951; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Huang XP, 2004, J BIOL CHEM, V279, P37886, DOI 10.1074/jbc.M402130200; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Ling Y, 2003, INT J BIOCHEM CELL B, V35, P1505, DOI 10.1016/S1357-2725(03)00133-X; Maeda N, 2000, P NATL ACAD SCI USA, V97, P841, DOI 10.1073/pnas.97.2.841; Mani K, 2004, J BIOL CHEM, V279, P12918, DOI 10.1074/jbc.M313678200; Mani K, 2003, J BIOL CHEM, V278, P38956, DOI 10.1074/jbc.M300394200; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; MULTHAUP G, 1994, FEBS LETT, V355, P151, DOI 10.1016/0014-5793(94)01176-1; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; Scholefield Z, 2003, J CELL BIOL, V163, P97, DOI 10.1083/jcb.200303059; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SMALL DH, 1994, J NEUROSCI, V14, P2117; Smith MA, 1997, J NEUROSCI, V17, P2653; Sotiriou S, 2002, NAT MED, V8, P514, DOI 10.1038/nm0502-514; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VANHORSSENS J, 2002, LANCET, V2, P482; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; Watanabe N, 2004, FASEB J, V18, P1013, DOI 10.1096/fj.03-1040fje; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; White AR, 1998, J NEUROSCI, V18, P6207; White AR, 2002, J NEUROSCI, V22, P365, DOI 10.1523/JNEUROSCI.22-02-00365.2002; Williamson TG, 1996, J BIOL CHEM, V271, P31215, DOI 10.1074/jbc.271.49.31215; WILLIAMSON TG, 1995, J NEUROCHEM, V65, P2201; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	44	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13913	13920		10.1074/jbc.M409179200	http://dx.doi.org/10.1074/jbc.M409179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677459	hybrid			2022-12-25	WOS:000228095500092
J	Tickler, AK; Smith, DG; Ciccotosto, GD; Tew, DJ; Curtain, CC; Carrington, D; Masters, CL; Bush, AI; Cherny, RA; Cappai, R; Wade, JD; Barnham, KJ				Tickler, AK; Smith, DG; Ciccotosto, GD; Tew, DJ; Curtain, CC; Carrington, D; Masters, CL; Bush, AI; Cherny, RA; Cappai, R; Wade, JD; Barnham, KJ			Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutaselike structures and inhibition of neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; PROTEIN STRUCTURES; TRANSGENIC MICE; COPPER-BINDING; METAL-IONS; ZINC; MEMBRANES; TOXICITY; COMPLEXES; HISTIDINE	The toxicity of the amyloid-beta peptide (A beta) is thought to be responsible for the neurodegeneration associated with Alzheimer disease. Generation of hydrogen peroxide has been implicated as a key step in the toxic pathway. A beta coordinates the redox active metal ion Cu2+ to catalytically generate H2O2. Structural studies on the interaction of A beta with Cu have suggested that the coordination sphere about the Cu2+ resembles the active site of superoxide dismutase 1. To investigate the potential role for such structures in the toxicity of A beta, two novel A beta 40 peptides, A beta 40(His tau Me) and A beta 40(His pi Me), have been prepared, in which the histidine residues 6, 13, and 14 have been substituted with modified histidines where either the pi- or tau-nitrogen of the imidazole side chain is methylated to prevent the formation of bridging histidine moieties. These modifications did not inhibit the ability of these peptides to form fibrils. However, the modified peptides were four times more effective at generating H2O2 than the native sequence. Despite the ability to generate more H2O2, these peptides were not neurotoxic. Whereas the modifications to the peptide altered the metal binding properties, they also inhibited the interaction between the peptides and cell surface membranes. This is consistent with the notion that A beta-membrane interactions are important for neurotoxicity and that inhibiting these interactions has therapeutic potential.	Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; Howard Florey Inst Med Res, Melbourne, Vic 3010, Australia; Univ Melbourne, Sch Chem, Parkville, Vic 3010, Australia; Univ Melbourne, Ctr Neurosci, Parkville, Vic 3010, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3168, Australia; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Genet & Aging Res Unit,Lab Oxidat Biol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Psychiat, Charlestown, MA 02129 USA	University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Monash University; Harvard University; Harvard University	Barnham, KJ (corresponding author), Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia.	kbarnham@unimelb.edu.au	Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007; Cappai, Roberto/B-3347-2010	Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069; Wade, John/0000-0002-1352-6568; Curtain, Cyril/0000-0001-6955-320X; Cappai, Roberto/0000-0002-9505-8496				Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Barnham KJ, 2004, FASEB J, V18, P1427, DOI 10.1096/fj.04-1890fje; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Carneiro FA, 2003, J BIOL CHEM, V278, P13789, DOI 10.1074/jbc.M210615200; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Ciccotosto GD, 2004, J BIOL CHEM, V279, P42528, DOI 10.1074/jbc.M406465200; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Curtain CC, 2003, J BIOL CHEM, V278, P2977, DOI 10.1074/jbc.M205455200; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GORDON LM, 1988, ELECT SPIN RESONANCE; Hertel C, 1997, P NATL ACAD SCI USA, V94, P9412, DOI 10.1073/pnas.94.17.9412; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14225, DOI 10.1073/pnas.94.26.14225; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14231, DOI 10.1073/pnas.94.26.14231; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; LI G, 1989, BIOCHEMISTRY-US, V28, P7446, DOI 10.1021/bi00444a044; Liu ST, 1999, BIOCHEMISTRY-US, V38, P9373, DOI 10.1021/bi990205o; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McLaurin J, 1997, EUR J BIOCHEM, V245, P355, DOI 10.1111/j.1432-1033.1997.t01-2-00355.x; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; Ohtsu H, 2000, J AM CHEM SOC, V122, P5733, DOI 10.1021/ja994050j; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; REMELLI M, 1994, J CHEM SOC DALTON, P2049, DOI 10.1039/dt9940002049; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; SUNDBERG RJ, 1974, CHEM REV, V74, P471, DOI 10.1021/cr60290a003; Syme CD, 2004, J BIOL CHEM, V279, P18169, DOI 10.1074/jbc.M313572200; Tickler AK, 2001, J PEPT SCI, V7, P488, DOI 10.1002/psc.342	40	102	106	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13355	13363		10.1074/jbc.M414178200	http://dx.doi.org/10.1074/jbc.M414178200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15668252	hybrid			2022-12-25	WOS:000228095500022
J	Kobrinsky, E; Tiwari, S; Maltsev, VA; Harry, JB; Lakatta, E; Abernethy, DR; Soldatov, NM				Kobrinsky, E; Tiwari, S; Maltsev, VA; Harry, JB; Lakatta, E; Abernethy, DR; Soldatov, NM			Differential role of the alpha(1C) subunit tails in regulation of the Ca(v)1.2 channels by membrane potential ss subunits, and Ca2+ ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CALCIUM-CHANNELS; PROTEIN-KINASE-C; BETA-SUBUNIT; SPLICE VARIANTS; MOLECULAR DETERMINANTS; ENDOPLASMIC-RETICULUM; ALPHA(2)DELTA SUBUNIT; VENTRICULAR MYOCYTES; CALMODULIN-BINDING; MODULATION	Voltage-gated Ca(v)1.2 channels are composed of the pore-forming alpha(1C) and auxiliary beta and alpha(2)delta subunits. Voltage-dependent conformational rearrangements of the alpha(1C) subunit C-tail have been implicated in Ca2+ signal transduction. In contrast, the alpha(1C) N-tail demonstrates limited voltage-gated mobility. We have asked whether these properties are critical for the channel function. Here we report that transient anchoring of the alpha(1C) subunit C-tail in the plasma membrane inhibits Ca2+-dependent and slow voltage-dependent inactivation. Both alpha(2)delta and beta subunits remain essential for the functional channel. In contrast, if alpha(1C) subunits are expressed with alpha(2)delta but in the absence of a beta subunit, plasma membrane anchoring of the alpha(1C) N terminus or its deletion inhibit both voltage- and Ca2+-dependent inactivation of the current. The following findings all corroborate the importance of the alpha(1C) N-tail/beta interaction: (i) coexpression of beta restores inactivation properties, (ii) release of the alpha(1C) N terminus inhibits the beta-deficient channel, and (iii) voltage-gated mobility of the alpha(1C) N-tail vis a vis the plasma membrane is increased in the beta-deficient ( silent) channel. Together, these data argue that both the alpha(1C) N- and C-tails have important but different roles in the voltage- and Ca2+-dependent inactivation, as well as beta subunit modulation of the channel. The alpha(1C) N-tail may have a role in the channel trafficking and is a target of the beta subunit modulation. The beta subunit facilitates voltage gating by competing with the N- tail and constraining its voltage- dependent rearrangements. Thus, cross-talk between the alpha(1C) C and N termini, beta subunit, and the cytoplasmic pore region confers the multifactorial regulation of Cav1.2 channels.	NIA, Clin Invest Lab, Baltimore, MD 21224 USA; NIA, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Soldatov, NM (corresponding author), NIA, Clin Invest Lab, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	soldatovN@grc.nia.nih.gov	Lakatta, Edward G/AAL-1447-2020; Maltsev, Victor/AAY-9460-2020	Maltsev, Victor/0000-0002-3832-791X; Lakatta, Edward/0000-0002-4772-0035	NATIONAL INSTITUTE ON AGING [Z01AG000294, ZIAAG000294] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abernethy DR, 2002, J PHARMACOL EXP THER, V300, P724, DOI 10.1124/jpet.300.3.724; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BOURINET E, 1992, FEBS LETT, V299, P5, DOI 10.1016/0014-5793(92)80087-W; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; Cornet V, 2002, EUR J NEUROSCI, V16, P883, DOI 10.1046/j.1460-9568.2002.02168.x; Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dzhura I, 2003, J PHYSIOL-LONDON, V550, P731, DOI 10.1113/jphysiol.2003.043778; Felix R, 1997, J NEUROSCI, V17, P6884; Harms GS, 2001, BIOPHYS J, V81, P2639, DOI 10.1016/S0006-3495(01)75907-3; Harry JB, 2004, J BIOL CHEM, V279, P46367, DOI 10.1074/jbc.M409523200; Howes AL, 2003, J BIOL CHEM, V278, P40343, DOI 10.1074/jbc.M305964200; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; JAY SD, 1991, J BIOL CHEM, V266, P3287; Kobrinsky E, 2004, BIOPHYS J, V87, P844, DOI 10.1529/biophysj.104.041152; Kobrinsky E, 2003, J BIOL CHEM, V278, P5021, DOI 10.1074/jbc.M211254200; LIPSCOMBE D, 2004, CALCIUM CHANNEL PHAR, P365; Meir A, 2000, BIOPHYS J, V79, P731, DOI 10.1016/S0006-3495(00)76331-4; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Romanin C, 2000, FEBS LETT, V487, P301, DOI 10.1016/S0014-5793(00)02361-9; Shi CZ, 2002, J BIOL CHEM, V277, P6813, DOI 10.1074/jbc.M110524200; Shirokov R, 1998, J GEN PHYSIOL, V111, P807, DOI 10.1085/jgp.111.6.807; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SINGERLAHAT D, 1992, BIOCHIM BIOPHYS ACTA, V1137, P39, DOI 10.1016/0167-4889(92)90097-U; Soldatov MM, 2003, TRENDS PHARMACOL SCI, V24, P167, DOI 10.1016/S0165-6147(03)00065-8; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Soldatov NM, 2000, J MEMBRANE BIOL, V177, P129, DOI 10.1007/s002320001106; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Viard P, 2004, NAT NEUROSCI, V7, P939, DOI 10.1038/nn1300; Woo SH, 2003, J PHYSIOL-LONDON, V552, P437, DOI 10.1113/jphysiol.2003.048330; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zhou Z, 2000, J PHYSIOL-LONDON, V523, P57, DOI 10.1111/j.1469-7793.2000.t01-2-00057.x; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	43	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12474	12485		10.1074/jbc.M412140200	http://dx.doi.org/10.1074/jbc.M412140200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15671035	hybrid			2022-12-25	WOS:000227922000051
J	Li, T; Lu, L				Li, T; Lu, L			Epidermal growth factor-induced proliferation requires down-regulation of Pax6 in corneal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE C-GAMMA-1; FACTOR STIMULATION; WOUND CLOSURE; UP-REGULATION; EGF RECEPTOR; GENE; EYE; EXPRESSION; KINASE	Growth factors play important roles in regulating corneal epithelial cell proliferation/ differentiation during wound healing. It is suggested that PAX6 involves corneal epithelium lineage-specific differentiation ( Liu, J. J., Kao, W. W., and Wilson, S. E. ( 1999) Exp. Eye Res. 68, 295 - 301); however, the regulatory mechanism and function of Pax6 in growth factor- induced corneal epithelial responses is still unknown. In the present study, we found that the mitogenic effect of epidermal growth factor ( EGF) in corneal epithelial cells required suppression of PAX6 activity through cellular mechanisms involving Erk-signaling pathway- mediated increase in CTCF expression. EGF- induced CCCTC binding factor ( CTCF) activation subsequently inhibited Pax6 expression by interacting with a CTCF- specific region upstream of the pax6 P0 promoter. Suppression of EGF-induced Erk activation by specific inhibitor or by the dominant expression of a silent Erk mutant effectively abolished the effects of EGF stimulation on regulations of CTCF and pax6. Apparently, down-regulation of Pax6 expression induced by EGF is required for corneal epithelial proliferation, because overexpression of pax6 in these cells attenuated EGF- induced proliferation. In contrast, knockdown of mRNA expression with pax6- or CTCF- specific small interfering RNA in corneal epithelial cells significantly promoted or attenuated EGF- induced proliferation, respectively. Thus, our results revealed a new regulatory mechanism that involves cellular signaling events and pax6 transcription regulation in growth factor- mediated proliferation. In corneal epithelial cells, this suggests that inhibition of pax6 expression is a prerequisite for EGF to elicit controls of cell growth and fate.	Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, David Geffen Sch Med, Div Mol Med, Torrance, CA 90502 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lu, L (corresponding author), Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, David Geffen Sch Med, Div Mol Med, 1124 W Carson St,C-2, Torrance, CA 90502 USA.	lluou@ucla.edu			NEI NIH HHS [EY15282, EY12953, R01 EY015281] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015281, R01EY012953] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; Bildin VN, 2000, J MEMBRANE BIOL, V177, P41, DOI 10.1007/s002320001098; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Davis JA, 1996, J NEUROSCI, V16, P5082; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Gehring WJ, 1996, GENES CELLS, V1, P11, DOI 10.1046/j.1365-2443.1996.11011.x; Gehring WJ, 1999, TRENDS GENET, V15, P371, DOI 10.1016/S0168-9525(99)01776-X; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Islam M, 2000, EXP EYE RES, V70, P261, DOI 10.1006/exer.1999.0783; Islam M, 2001, INVEST OPHTH VIS SCI, V42, P1472; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Kammandel B, 1999, DEV BIOL, V205, P79, DOI 10.1006/dbio.1998.9128; Kang SJ, 1999, OPHTHALMOLOGICA, V213, P20, DOI 10.1159/000027388; Kang SS, 2000, INVEST OPHTH VIS SCI, V41, P2164; Kang SS, 2001, CURR EYE RES, V23, P397, DOI 10.1076/ceyr.23.6.397.6965; Koroma BM, 1997, INVEST OPHTH VIS SCI, V38, P108; Kumar JP, 2001, CELL, V104, P687, DOI 10.1016/S0092-8674(01)00265-3; Li T, 2004, J BIOL CHEM, V279, P27575, DOI 10.1074/jbc.M313942200; Liu JJ, 1999, EXP EYE RES, V68, P295, DOI 10.1006/exer.1998.0593; Lu L, 2001, EXP BIOL MED, V226, P653, DOI 10.1177/153537020222600711; Macdonald R, 1997, DEVELOPMENT, V124, P2397; MARTIN P, 1992, ONCOGENE, V7, P1721; OLIW EH, 1987, PROSTAGLANDINS, V34, P3, DOI 10.1016/0090-6980(87)90258-9; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Roderick C, 2003, J MEMBRANE BIOL, V196, P41, DOI 10.1007/s00232-003-0623-1; Shiraishi A, 1998, INVEST OPHTH VIS SCI, V39, P2554; TAO WH, 1995, INVEST OPHTH VIS SCI, V36, P2614; Underhill DA, 2000, BIOCHEM CELL BIOL, V78, P629, DOI 10.1139/bcb-78-5-629; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; Wang YL, 1998, GENE, V216, P293, DOI 10.1016/S0378-1119(98)00345-X; Williams SC, 1998, MECH DEVELOP, V73, P225, DOI 10.1016/S0925-4773(98)00057-4; Yang H, 2001, J MEMBRANE BIOL, V183, P93, DOI 10.1007/s00232-001-0057-6; YU FSX, 1995, INVEST OPHTH VIS SCI, V36, P1997; Zhang Y, 1999, INVEST OPHTH VIS SCI, V40, P2819; Zhang Y, 1998, CURR EYE RES, V17, P294, DOI 10.1076/ceyr.17.3.294.5223; Zhang Y, 1997, INVEST OPHTH VIS SCI, V38, P1139	37	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12988	12995		10.1074/jbc.M412458200	http://dx.doi.org/10.1074/jbc.M412458200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15659382	hybrid			2022-12-25	WOS:000227922000108
J	van Bloois, E; Nagamori, S; Koningstein, G; Ullers, RS; Preuss, M; Oudega, B; Harms, N; Kaback, HR; Herrmann, JM; Luirink, J				van Bloois, E; Nagamori, S; Koningstein, G; Ullers, RS; Preuss, M; Oudega, B; Harms, N; Kaback, HR; Herrmann, JM; Luirink, J			The Sec-independent function of Escherichia coli YidC is evolutionary-conserved and essential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; MEMBRANE-PROTEIN INSERTION; SYNTHASE SUBUNIT-C; INNER MEMBRANE; TRANSLOCATION; OXA1; ATP; INTEGRATION; BIOGENESIS; FAMILY	YidC plays a role in the integration and assembly of many ( if not all) Escherichia coli inner membrane proteins. Strikingly, YidC operates in two distinct pathways: one associated with the Sec translocon that also mediates protein translocation across the inner membrane and one independent from the Sec translocon. YidC is homologous to Alb3 and Oxa1 that function in the integration of proteins into the thylakoid membrane of chloroplasts and inner membrane of mitochondria, respectively. Here, we have expressed the conserved region of yeast Oxa1 in a conditional E. coli yidC mutant. We find that Oxa1 restores growth upon depletion of YidC. Data obtained from in vivo protease protection assays and in vitro cross-linking and folding assays suggest that Oxa1 complements the insertion of Sec-independent proteins but is unable to take over the Secassociated function of YidC. Together, our data indicate that the Sec- independent function of YidC is conserved and essential for cell growth.	Free Univ Amsterdam, Inst Mol Cell Biol, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands; Univ Calif Los Angeles, Inst Mol Biol, Dept Physiol & Microbiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	Vrije Universiteit Amsterdam; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Munich	Luirink, J (corresponding author), Free Univ Amsterdam, Inst Mol Cell Biol, Dept Mol Microbiol, De Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	joen.luirink@falw.vu.nl	Nagamori, Shushi/P-4530-2018; Luirink, Joen/AAB-8658-2021	Nagamori, Shushi/0000-0003-0203-2754; Luirink, J./0000-0001-8431-0804	NIDDK NIH HHS [DK5113109] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051131, R56DK051131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Chen MY, 2002, BIOL CHEM, V383, P1565, DOI 10.1515/BC.2002.176; Dalbey RE, 2004, J CELL BIOL, V166, P769, DOI 10.1083/jcb.200405161; de Gier JWL, 2003, EMBO REP, V4, P939, DOI 10.1038/sj.embor.embor921; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; Froderberg L, 2004, J BIOL CHEM, V279, P31026, DOI 10.1074/jbc.M403229200; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; Funes S, 2004, FEBS LETT, V569, P89, DOI 10.1016/j.febslet.2004.05.055; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; Hashemzadeh-Bonehi L, 1998, MOL MICROBIOL, V30, P676, DOI 10.1046/j.1365-2958.1998.01116.x; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Houben ENG, 2002, J BIOL CHEM, V277, P35880, DOI 10.1074/jbc.M205556200; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Jia LX, 2003, EMBO J, V22, P6438, DOI 10.1093/emboj/cdg624; Jiang FL, 2003, J BIOL CHEM, V278, P48965, DOI 10.1074/jbc.M307362200; Jiang FL, 2002, J BIOL CHEM, V277, P19281, DOI 10.1074/jbc.M110857200; Klostermann E, 2002, BIOCHEM J, V368, P777, DOI 10.1042/BJ20021291; Koch HG, 2002, J BIOL CHEM, V277, P5715, DOI 10.1074/jbc.C100683200; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005; Lemaire C, 2000, J BIOL CHEM, V275, P23471, DOI 10.1074/jbc.M002045200; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Nagamori S, 2004, J CELL BIOL, V165, P53, DOI 10.1083/jcb.200402067; Nagamori S, 2003, J BIOL CHEM, V278, P14820, DOI 10.1074/jbc.M300332200; Nargang FE, 2002, J BIOL CHEM, V277, P12846, DOI 10.1074/jbc.M112099200; Rapoport TA, 2004, TRENDS CELL BIOL, V14, P568, DOI 10.1016/j.tcb.2004.09.002; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Stuart RA, 2002, BBA-MOL CELL RES, V1592, P79, DOI 10.1016/S0167-4889(02)00266-5; Szyrach G, 2003, EMBO J, V22, P6448, DOI 10.1093/emboj/cdg623; Urbanus ML, 2002, J BIOL CHEM, V277, P12718, DOI 10.1074/jbc.M200311200; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; van Bloois E, 2004, FEBS LETT, V576, P97, DOI 10.1016/j.febslet.2004.08.069; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; Yi L, 2004, J BIOL CHEM, V279, P39260, DOI 10.1074/jbc.M405490200	42	50	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12996	13003		10.1074/jbc.M414094200	http://dx.doi.org/10.1074/jbc.M414094200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15671040	hybrid, Green Published			2022-12-25	WOS:000227922000109
J	Bastow, ER; Lamb, KJ; Lewthwaite, JC; Osborne, AC; Kavanagh, E; Wheeler-Jones, CPD; Pitsillides, AA				Bastow, ER; Lamb, KJ; Lewthwaite, JC; Osborne, AC; Kavanagh, E; Wheeler-Jones, CPD; Pitsillides, AA			Selective activation of the MEK-ERK pathway is regulated by mechanical stimuli in forming joints and promotes pericellular matrix formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE LIMB DEVELOPMENT; CD44 CYTOPLASMIC DOMAIN; PROGRAMMED CELL-DEATH; MAP KINASE; HYALURONAN-BINDING; KNEE-JOINT; IN-VITRO; ENDOTHELIAL-CELLS; GENE-EXPRESSION; POSSIBLE ROLES	It is well established that local modification of extracellular matrix (ECM) hyaluronan composition is vital in the regulation of cell behavior. Indeed, the formation of articulating chick joint cavities, which requires mechanical stimuli derived from skeletal movement, is dependent upon the accumulation of an ECM rich in hyaluronan ( HA). However, the mechanisms responsible for such precise mechano-dependent regulation of cell behavior and the formation of a HA-rich ECM remain undefined. Here we show that extracellular-regulated kinase 1/2 (ERK1/2) is selectively activated in cells at sites of cavity formation and activity diminished by in ovo immobilization that induces cartilaginous fusion across presumptive joint interzones. In vitro analyses offer mechanistic support for the role of mechanical stimuli in promoting a MEK-dependent activation of ERK1/2. In addition, our direct regulation of ERK1/2 phosphorylation status via modulation of its up-stream "classical cascade" activator either pharmacologically or by transfection with dominant negative or constitutively active Mek confirms the essential role for ERK1/2 activation in the elaboration of HA-rich pericellular matrices. Together, our findings demonstrate that the MEK-ERK pathway, regulated by mechanical stimuli, controls HA-rich matrix assembly. The precision of ERK1/2 activation selectively distinguishing cells at the joint line suggests that it directly contributes to the loss of tissue cohesion essential for generating HA-rich cavities between joint elements during their development.	Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0TU, England	University of London; University of London Royal Veterinary College	Pitsillides, AA (corresponding author), Univ London Royal Vet Coll, Dept Vet Basic Sci, Royal Coll St, London NW1 0TU, England.	apitsill@rvc.ac.uk						AbuHijleh G, 1997, CLIN ANAT, V10, P183, DOI 10.1002/(SICI)1098-2353(1997)10:3<183::AID-CA4>3.0.CO;2-V; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSEN H, 1961, AM J ANAT, V108, P111, DOI 10.1002/aja.1001080108; Black EJ, 2000, CURR BIOL, V10, P1119, DOI 10.1016/S0960-9822(00)00699-0; Bobick BE, 2004, J BIOL CHEM, V279, P4588, DOI 10.1074/jbc.M309805200; Bullard KM, 2003, INT J CANCER, V107, P739, DOI 10.1002/ijc.11475; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; CLARRIS BJ, 1968, EXP CELL RES, V49, P181, DOI 10.1016/0014-4827(68)90530-2; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAIG FM, 1990, J ANAT, V171, P17; Cummins AB, 2003, AM J PATHOL, V162, P713, DOI 10.1016/S0002-9440(10)63867-9; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dowthwaite GP, 2003, MATRIX BIOL, V22, P311, DOI 10.1016/S0945-053X(03)00037-4; Dowthwaite GP, 1999, MATRIX BIOL, V18, P523, DOI 10.1016/S0945-053X(99)00044-X; Dowthwaite GP, 1998, J HISTOCHEM CYTOCHEM, V46, P641, DOI 10.1177/002215549804600509; DRACHMAN DB, 1962, LANCET, V2, P523; Dudley AT, 2002, NATURE, V418, P539, DOI 10.1038/nature00945; EDWARDS JCW, 1994, J ANAT, V185, P355; Fell HB, 1934, PROC R SOC SER B-BIO, V116, P316, DOI 10.1098/rspb.1934.0076; GUTHRIE S, 1992, RES VET SCI, V52, P67, DOI 10.1016/0034-5288(92)90060-F; Hacker U, 1997, DEVELOPMENT, V124, P3565; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hardingham T, 1999, BIOCHEM SOC T, V27, P124, DOI 10.1042/bst0270124; Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092-8674(01)00222-7; HELDIN P, 1993, EXP CELL RES, V208, P422, DOI 10.1006/excr.1993.1264; Houliston RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1266, DOI 10.1152/ajpcell.2001.281.4.C1266; Ito MM, 2000, J ANAT, V197, P659, DOI 10.1046/j.1469-7580.2000.19740659.x; Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756-3282(02)00797-4; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; Kavanagh E, 2002, J HISTOCHEM CYTOCHEM, V50, P1039, DOI 10.1177/002215540205000806; Kavanagh E, 2002, CELL BIOL INT, V26, P679, DOI 10.1006/cbir.2002.0918; Kawakami Y, 2003, NAT CELL BIOL, V5, P513, DOI 10.1038/ncb989; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; Kimura S, 1996, J MORPHOL, V229, P337, DOI 10.1002/(SICI)1097-4687(199609)229:3<337::AID-JMOR8>3.0.CO;2-V; KNUDSON W, 1991, J CELL SCI, V99, P227; Lamb KJ, 2003, INT J EXP PATHOL, V84, P55, DOI 10.1046/j.1365-2613.2003.00338.x; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE GM, 1993, J CELL BIOL, V123, P1899, DOI 10.1083/jcb.123.6.1899; Lizarraga G, 2002, DEV BIOL, V243, P44, DOI 10.1006/dbio.2001.0559; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mikic B, 2000, J REHABIL RES DEV, V37, P127; MITROVIC DR, 1977, AM J ANAT, V150, P333, DOI 10.1002/aja.1001500207; MORI C, 1995, ANAT REC, V242, P103, DOI 10.1002/ar.1092420114; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nishida Y, 1999, J BIOL CHEM, V274, P21893, DOI 10.1074/jbc.274.31.21893; Nofal GA, 2002, J HISTOCHEM CYTOCHEM, V50, P1313, DOI 10.1177/002215540205001004; Osborne A. C., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P448; Pearce MJ, 1996, BIOCHEM BIOPH RES CO, V218, P500, DOI 10.1006/bbrc.1996.0089; Peck D, 1998, J CELL SCI, V111, P1595; PITSILLIDES AA, 1995, J HISTOCHEM CYTOCHEM, V43, P263, DOI 10.1177/43.3.7868856; Pitsillides AA, 2003, METH MOLEC MED, V80, P399; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; PITSILLIDES AA, 1998, NITRIC OXIDE BONE JO, P151; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; Rilla K, 2002, J CELL SCI, V115, P3633, DOI 10.1242/jcs.00042; SCOTT JE, 1965, HISTOCHEMISTRY, V5, P221, DOI 10.1007/BF00306130; Slevin M, 1998, LAB INVEST, V78, P987; SOLURSH M, 1980, DEV BIOL, V75, P121, DOI 10.1016/0012-1606(80)90148-7; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Spitz F, 2001, SCIENCE, V291, P1713, DOI 10.1126/science.1059665; Stasko SE, 2001, J ENDOCRINOL, V171, P237, DOI 10.1677/joe.0.1710237; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; Takahashi I, 2003, EUR J CELL BIOL, V82, P182, DOI 10.1078/0171-9335-00307; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Trentani A, 2002, EUR J NEUROSCI, V15, P1681, DOI 10.1046/j.1460-9568.2002.02000.x; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; UFF CR, 1995, EUR J IMMUNOL, V25, P1883, DOI 10.1002/eji.1830250714; Volmat V, 2001, J CELL SCI, V114, P3433; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; WEISS RH, 1998, AM J PHYSIOL, V274, P1521; Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769; Zaman G, 2000, BONE, V27, P233, DOI 10.1016/S8756-3282(00)00324-0	75	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11749	11758		10.1074/jbc.M414495200	http://dx.doi.org/10.1074/jbc.M414495200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647286	hybrid			2022-12-25	WOS:000227761800104
J	Hancock, CN; Dangi, S; Shapiro, P				Hancock, CN; Dangi, S; Shapiro, P			Protein phosphatase 2A activity associated with golgi membranes during the G(2)/M phase may regulate phosphorylation of ERK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATIC-CELL MITOSIS; MAP KINASE; MITOTIC PHOSPHORYLATION; SIGNALING PATHWAYS; IN-VIVO; C-FOS; ACTIVATION; CYCLE; COMPLEX; FRAGMENTATION	The extracellular signal-regulated kinase (ERK) 1 and 2 proteins are mitogen-activated protein kinase (MAPK) members that regulate cell proliferation and differentiation. ERK proteins are activated exclusively by MAPK kinase 1 and 2 phosphorylation of threonine and tyrosine residues located within the conserved TXY MAPK activation motif. Although dual phosphorylation of Thr and Tyr residues confers full activation of ERK, in vitro studies suggest that a single phosphorylation on either Thr or Tyr may yield partial ERK activity. Previously, we have demonstrated that phosphorylation of the tyrosine residue (Tyr(P) ERK) may be involved in regulating the Golgi complex structure during the G(2) and M phases of the cell cycle (Cha, H., and Shapiro, P. (2001) J. Cell Biol. 153, 1355-1368). In the present study, we examined mechanisms for generating Tyr(P) ERK by determining cell cycle-dependent changes in localized phosphatase activity. Using fractionated nuclei-free cell lysates, we find increased serine/threonine phosphatase activity associated with Golgi-enriched membranes in cells synchronized in the late G(2)/early M phase as compared with G(1) phase cells. The addition of phosphatase inhibitors in combination with immunodepletion assays identified this activity to be related to protein phosphatase 2A (PP2A). The increased activity was accounted for by elevated PP2A association with mitotic Golgi membranes as well as increased catalytic activity after normalization of PP2A protein levels in the phosphatase assays. These data indicate that localized changes in PP2A activity may be involved in regulating proteins involved in Golgi disassembly as cells enter mitosis.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Shapiro, P (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St, Baltimore, MD 21201 USA.	pshapiro@rx.umaryland.edu			NATIONAL CANCER INSTITUTE [R21CA105299] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA105299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cha H, 2004, BIOCHEM J, V378, P857, DOI 10.1042/BJ20031173; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Colanzi A, 2003, J CELL BIOL, V161, P27, DOI 10.1083/jcb.200208099; Dangi S, 2003, CELL SIGNAL, V15, P667, DOI 10.1016/S0898-6568(03)00002-0; Dirac-Svejstrup AB, 2000, J CELL BIOL, V150, P475, DOI 10.1083/jcb.150.3.475; Ghosh P, 2003, J CELL BIOL, V160, P699, DOI 10.1083/jcb.200211080; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Hastie CJ, 1998, FEBS LETT, V431, P357, DOI 10.1016/S0014-5793(98)00775-3; Helps NR, 1998, J CELL SCI, V111, P1331; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; Ito A, 2003, AM J PATHOL, V162, P479, DOI 10.1016/S0002-9440(10)63842-4; Jesch SA, 1998, MOL BIOL CELL, V9, P623, DOI 10.1091/mbc.9.3.623; Jesch SA, 2001, MOL BIOL CELL, V12, P1811, DOI 10.1091/mbc.12.6.1811; Kins S, 2003, AM J PATHOL, V163, P833, DOI 10.1016/S0002-9440(10)63444-X; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Misumi Y, 2001, J BIOL CHEM, V276, P6867, DOI 10.1074/jbc.M010121200; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Okuwaki M, 2002, MOL BIOL CELL, V13, P2016, DOI 10.1091/mbc.02-03-0036; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Sumiyoshi E, 2002, J CELL SCI, V115, P1403; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Wang PY, 2003, EMBO J, V22, P2658, DOI 10.1093/emboj/cdg255; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yao Z, 2000, FEBS LETT, V468, P37, DOI 10.1016/S0014-5793(00)01191-1; Yeh PY, 2004, J BIOL CHEM, V279, P26143, DOI 10.1074/jbc.M402362200; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200; Zhou GS, 2002, J BIOL CHEM, V277, P6391, DOI 10.1074/jbc.M107014200	53	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11590	11598		10.1074/jbc.M408273200	http://dx.doi.org/10.1074/jbc.M408273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15654082	hybrid			2022-12-25	WOS:000227761800086
J	Janowiak, BE; Griffith, OW				Janowiak, BE; Griffith, OW			Glutathione synthesis in Streptococcus agalactiae - One protein accounts for gamma-glutamylcysteine synthetase and glutathione synthetase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE-CYSTEINE LIGASE; STATE ANALOG INHIBITORS; ESCHERICHIA-COLI-B; D-ALANINE LIGASE; RAT-KIDNEY; BUTHIONINE SULFOXIMINE; KINETIC MECHANISM; S-TRANSFERASE; DDLA GENE; PURIFICATION	gamma-Glutamylcysteine synthetase (gamma-GCS) and glutathione synthetase (GS), distinct enzymes that together account for glutathione (GSH) synthesis, have been isolated and characterized from several Gram-negative prokaryotes and from numerous eukaryotes including mammals, amphibians, plants, yeast, and protozoa. Glutathione synthesis is relatively uncommon among the Gram-positive bacteria, and, to date, neither the genes nor the proteins involved have been identified. In the present report, we show that crude extracts of Streptococcus agalactiae catalyze the gamma-GCS and GS reactions and can synthesize GSH from its constituent amino acids. The putative gene for S. agalactiae gamma-GCS was identified and cloned, and the corresponding protein was expressed and purified. Surprisingly, it was found that the isolated enzyme catalyzes both the ATP-dependent synthesis of L-gamma-glutamyl-L-cysteine from L-glutamate and L-cysteine and the ATP-dependent synthesis of GSH from L-gamma-glutamyl-L-cysteine and glycine. This novel bifunctional enzyme, referred to as gamma-GCS-GS, has been characterized in terms of catalytic activity, substrate specificity, and inhibition by GSH, cystamine, and transition state analog sulfoximines. The N-terminal 518 amino acids of gamma-GCS-GS (total M-r 85,000) show 32% identity and 43% similarity with E. coli gamma-GCS (M-r 58,000), but the C-terminal putative GS domain (remaining 202 amino acids) of gamma-GCS-GS shows no significant homology with known GS sequences. The C terminus (360 amino acids) is, however, homologous to D-Ala, D-Ala ligase (24% identity; 38% similarity), an enzyme having the same protein fold as known GS proteins. These results are discussed in terms of the evolution of GSH synthesis and the possible occurrence of a similar bifunctional GSH synthesis enzyme in other bacterial species.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Griffith, OW (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	griffith@mcw.edu		Janowiak, Blythe/0000-0001-8103-2474				Abbott JJ, 2001, J BIOL CHEM, V276, P42099, DOI 10.1074/jbc.M104672200; ARCA P, 1990, FEBS LETT, V263, P77, DOI 10.1016/0014-5793(90)80709-R; BOUTER S, 1988, BIOCHEM PHARMACOL, V37, P577, DOI 10.1016/0006-2952(88)90128-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; Brenot A, 2004, INFECT IMMUN, V72, P408, DOI 10.1128/IAI.72.1.408-413.2004; BROWN CM, 1972, J APPL CHEM BIOTECHN, V22, P363, DOI 10.1002/jctb.5020220307; Bubert A, 1997, J CLIN MICROBIOL, V35, P179, DOI 10.1128/JCM.35.1.179-183.1997; CAMPBELL EB, 1991, ANAL BIOCHEM, V194, P268, DOI 10.1016/0003-2697(91)90229-M; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Copley SD, 2002, GENOME BIOL, V3; DAUB E, 1988, BIOCHEMISTRY-US, V27, P3701, DOI 10.1021/bi00410a027; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; Frankenberg L, 2002, J BACTERIOL, V184, P6351, DOI 10.1128/JB.184.22.6351-6356.2002; Glaser P, 2002, MOL MICROBIOL, V45, P1499, DOI 10.1046/j.1365-2958.2002.03126.x; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; GRIFFITH OW, 1977, BIOCHEM BIOPH RES CO, V79, P919, DOI 10.1016/0006-291X(77)91198-6; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P268, DOI 10.1073/pnas.76.1.268; GRIFFITH OW, 1981, J BIOL CHEM, V256, P4900; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Gushima H, 1983, J Appl Biochem, V5, P210; Hibi T, 2004, P NATL ACAD SCI USA, V101, P15052, DOI 10.1073/pnas.0403277101; Hiratake J, 2002, BIOSCI BIOTECH BIOCH, V66, P1500, DOI 10.1271/bbb.66.1500; HUANG CS, 1993, J BIOL CHEM, V268, P20578; IIZUKA M, 1989, J BACTERIOL, V171, P6039, DOI 10.1128/jb.171.11.6039-6042.1989; Inoue Y, 1998, BBA-GENE STRUCT EXPR, V1395, P315, DOI 10.1016/S0167-4781(97)00199-1; INOUE Y, 1993, APPL MICROBIOL BIOT, V38, P473; Jez JM, 2004, J BIOL CHEM, V279, P33463, DOI 10.1074/jbc.M405127200; Kelly BS, 2002, J BIOL CHEM, V277, P50, DOI 10.1074/jbc.M107961200; King KY, 2000, J BACTERIOL, V182, P5290, DOI 10.1128/JB.182.19.5290-5299.2000; LEBO RV, 1978, J BIOL CHEM, V253, P2615; MEISTER A, 1976, ANNU REV BIOCHEM, V45, P559, DOI 10.1146/annurev.bi.45.070176.003015; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1985, METHOD ENZYMOL, V113, P445; Misra I, 1998, PROTEIN EXPRES PURIF, V13, P268, DOI 10.1006/prep.1998.0897; MOOZ ED, 1967, BIOCHEMISTRY-US, V6, P1722, DOI 10.1021/bi00858a022; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Njalsson R, 2001, BIOCHEM BIOPH RES CO, V289, P80, DOI 10.1006/bbrc.2001.5961; OPPENHEIMER L, 1979, J BIOL CHEM, V254, P5184; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Phlippen N, 2003, J BIOL CHEM, V278, P40152, DOI 10.1074/jbc.M303102200; RUOFF KL, 1990, EUR J CLIN MICROBIOL, V9, P75, DOI 10.1007/BF01963630; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; Sherrill C, 1998, J BACTERIOL, V180, P1454, DOI 10.1128/JB.180.6.1454-1459.1998; STRUMEYER D, 1962, BIOCHEM PREP, V9, P52; TELLELIN H, 2002, P NATL ACAD SCI USA, V99, P12391; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tokutake N, 1998, BIOORGAN MED CHEM, V6, P1935, DOI 10.1016/S0968-0896(98)00142-4; Tu ZH, 1998, BIOCHEM J, V336, P675, DOI 10.1042/bj3360675; Vuilleumier S, 1997, J BACTERIOL, V179, P1431, DOI 10.1128/jb.179.5.1431-1441.1997; WILLETT NP, 1966, J BACTERIOL, V91, P2245, DOI 10.1128/JB.91.6.2245-2250.1966; ZAWADZKE LE, 1991, BIOCHEMISTRY-US, V30, P1673, DOI 10.1021/bi00220a033	58	87	103	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11829	11839		10.1074/jbc.M414326200	http://dx.doi.org/10.1074/jbc.M414326200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15642737	hybrid			2022-12-25	WOS:000227761800112
J	Kamradt, MC; Lu, ML; Werner, ME; Kwan, T; Chen, F; Strohecker, A; Oshita, S; Wilkinson, JC; Yu, CJ; Oliver, PG; Duckett, CS; Buchsbaum, DJ; LoBuglio, AF; Jordan, VC; Cryns, VL				Kamradt, MC; Lu, ML; Werner, ME; Kwan, T; Chen, F; Strohecker, A; Oshita, S; Wilkinson, JC; Yu, CJ; Oliver, PG; Duckett, CS; Buchsbaum, DJ; LoBuglio, AF; Jordan, VC; Cryns, VL			The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESMIN-RELATED MYOPATHY; CYTOTOXIC LIGAND TRAIL; CYTOCHROME-C; MYOGENIC DIFFERENTIATION; TUMORICIDAL ACTIVITY; PROMOTES APOPTOSIS; APAF-1 APOPTOSOME; DEATH DOMAIN; RECEPTOR; CHAPERONE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor alpha family of cytokines that preferentially induces apoptosis in transformed cells, making it a promising cancer therapy. However, many neoplasms are resistant to TRAIL-induced apoptosis by mechanisms that are poorly understood. We demonstrate that the expression of the small heat shock protein alpha B-crystallin (but not other heat shock proteins or apoptosis-regulating proteins) correlates with TRAIL resistance in a panel of human cancer cell lines. Stable expression of wild-type alpha B-crystallin, but not a pseudophosphorylation mutant impaired in its assembly and chaperone function, protects cancer cells from TRAIL-induced caspase-3 activation and apoptosis in vitro. Furthermore, selective inhibition of alpha B-crystallin expression by RNA interference sensitizes cancer cells to TRAIL. In addition, wild-type alpha B-crystallin promotes xenograft tumor growth and inhibits TRAIL-induced apoptosis in vivo in nude mice, whereas a pseudophosphorylation alpha B-crystallin mutant impaired in its anti-apoptotic function inhibits xenograft tumor growth. Collectively, these findings indicate that alpha B-crystallin is a novel regulator of TRAIL-induced apoptosis and tumor growth. Moreover, these results demonstrate that targeted inhibition of alpha B-crystallin promotes TRAIL-induced apoptosis, thereby suggesting a novel strategy to overcome TRAIL resistance in cancer.	Northwestern Univ, Feinberg Sch Med, Dept Med, Cell Death Regulat Lab, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Michigan System; University of Michigan; University of Chicago; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Cryns, VL (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Cell Death Regulat Lab, 303 E Chicago Ave, Chicago, IL 60611 USA.	v-cryns@northwestern.edu	JORDAN, V.Craig/AAX-3562-2020; Yu, Chunjiang/E-9419-2012; Jordan, V. Craig/H-4491-2011	Duckett, Colin/0000-0001-9413-2263; Buchsbaum, Donald/0000-0003-2797-5847	NCI NIH HHS [P50CA89018, T32CA70085] Funding Source: Medline; NIDDK NIH HHS [T32DK07169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089018, T32CA070085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burns TF, 2001, J BIOL CHEM, V276, P37879; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Chelouche-Lev D, 2004, CANCER-AM CANCER SOC, V100, P2543, DOI 10.1002/cncr.20304; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Keane MM, 1999, CANCER RES, V59, P734; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531; PINDER SE, 1994, J PATHOL, V174, P209, DOI 10.1002/path.1711740310; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Takashi M, 1998, UROL RES, V26, P395, DOI 10.1007/s002400050075; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	50	180	193	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11059	11066		10.1074/jbc.M413382200	http://dx.doi.org/10.1074/jbc.M413382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653686	hybrid			2022-12-25	WOS:000227761800023
J	Mandell, KJ; Babbin, BA; Nusrat, A; Parkos, CA				Mandell, KJ; Babbin, BA; Nusrat, A; Parkos, CA			Junctional adhesion molecule 1 regulates epithelial cell morphology through effects on beta 1 Integrins and Rap1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; GTP-BINDING PROTEIN; IMMUNOGLOBULIN SUPERFAMILY; ENDOTHELIAL-CELLS; TIGHT JUNCTIONS; F11 RECEPTOR; ACTIVATION; INTEGRIN; AF-6; KINASE	Epithelial tight junctions form a selectively permeable barrier to ions and small molecules. Junctional adhesion molecule 1 (JAM1/JAM-A/F11R) is a tight junction-associated transmembrane protein that has been shown to participate in the regulation of epithelial barrier function. In a recent study, we presented evidence suggesting that JAM1 homodimer formation is critical for epithelial barrier function (Mandell, K. J., McCall, I. C., and Parkos, C. A. ( 2004) J. Biol. Chem. 279, 16254 16262). Here we have used small interfering RNA to investigate the effect of the loss of JAM1 expression on epithelial cell function. Consistent with our previous study, knockdown of JAM1 was observed to increase paracellular permeability in epithelial monolayers. Interestingly, knockdown of JAM1 also produced dramatic changes in cell morphology, and a similar effect was observed with expression of a JAM1 mutant lacking the putative homodimer interface. Further studies revealed that JAM1 knockdown decreased cell-matrix adhesion and spreading on matrix proteins that are ligands of beta 1 integrins. These changes were characterized by a decrease in beta 1 integrin protein levels and loss of beta 1 integrin staining at the cell surface. Immunolabeling of cells for the small GTPase Rap1, a known activator of beta 1 integrins, revealed colocalization of Rap1 with JAM1 at intercellular junctions, and knockdown of JAM1 resulted in decreased Rap1 activity. Lastly, knockdown of Rap1b resulted in diminished beta 1 integrin expression and altered cell morphology analogous to that observed with knockdown of JAM1. Together, these results suggest that JAM1 regulates epithelial cell morphology and beta 1 integrin expression by modulating activity of the small GTPase Rap1.	Emory Univ, Sch Med, Epithelial Pathobiol Res Unit, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Mandell, KJ (corresponding author), Emory Univ, Sch Med, Epithelial Pathobiol Res Unit, Dept Pathol & Lab Med, 615 Michael St,Rm 125, Atlanta, GA 30322 USA.	kjmande@emory.edu	Parkos, Charles a/B-3896-2009; Nusrat, Asma/B-3887-2009		NIDDK NIH HHS [DK64399, R01 DK61379, R01 DK59888, R01 DK72564] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059888, R01DK072564, R01DK061379, R24DK064399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babinska A, 2002, THROMB HAEMOSTASIS, V88, P843, DOI 10.1055/s-0037-1613312; Babinska A, 2002, THROMB HAEMOSTASIS, V87, P712, DOI 10.1055/s-0037-1613070; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; Blanco D, 2004, LAB INVEST, V84, P999, DOI 10.1038/labinvest.3700129; Boettner B, 2003, GENETICS, V165, P159; Boettner B, 2001, METHOD ENZYMOL, V332, P151; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Cera MR, 2004, J CLIN INVEST, V114, P729, DOI 10.1172/JCI200421231; Cramer LP, 2002, CELL MOTIL CYTOSKEL, V51, P27, DOI 10.1002/cm.10013; D'Silva NJ, 2003, J CELL PHYSIOL, V196, P532, DOI 10.1002/jcp.10331; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Enserink JM, 2004, J BIOL CHEM, V279, P44889, DOI 10.1074/jbc.M404599200; Fasano A, 2000, ANN NY ACAD SCI, V915, P214; Forrest JC, 2003, J BIOL CHEM, V278, P48434, DOI 10.1074/jbc.M305649200; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Godfrey RWA, 1997, MICROSC RES TECHNIQ, V38, P488, DOI 10.1002/(SICI)1097-0029(19970901)38:5<488::AID-JEMT5>3.0.CO;2-E; Gupta SK, 2000, IUBMB LIFE, V50, P51; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kinashi T, 2004, IMMUNOL LETT, V93, P1, DOI 10.1016/j.imlet.2004.02.008; Kinashi T, 2004, BLOOD, V103, P1033, DOI 10.1182/blood-2003-07-2499; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; KORNECKI E, 1990, J BIOL CHEM, V265, P10042; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; Kuiperij HB, 2003, BBA-MOL CELL RES, V1593, P141, DOI 10.1016/S0167-4889(02)00365-8; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; Larson MK, 2003, BLOOD, V101, P1409, DOI 10.1182/blood-2002-05-1533; Lee JH, 2002, MOL CELL BIOL, V22, P7658, DOI 10.1128/MCB.22.21.7658-7666.2002; Liang TW, 2000, AM J PHYSIOL-CELL PH, V279, pC1733, DOI 10.1152/ajpcell.2000.279.6.C1733; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Liu Y, 2000, J CELL SCI, V113, P2363; MADARA JL, 1992, ANN NY ACAD SCI, V664, P47, DOI 10.1111/j.1749-6632.1992.tb39748.x; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Mandell KJ, 2004, J BIOL CHEM, V279, P16254, DOI 10.1074/jbc.M309483200; Martin TA, 2001, HISTOL HISTOPATHOL, V16, P1183, DOI 10.14670/HH-16.1183; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; Naik MU, 2003, BLOOD, V102, P2108, DOI 10.1182/blood-2003-04-1114; Naik MU, 2003, ARTERIOSCL THROM VAS, V23, P2165, DOI 10.1161/01.ATV.0000093982.84451.87; NAIK UP, 1995, BIOCHEM J, V310, P155, DOI 10.1042/bj3100155; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Ozaki H, 2000, BIOCHEM BIOPH RES CO, V276, P873, DOI 10.1006/bbrc.2000.3574; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Prota AE, 2003, P NATL ACAD SCI USA, V100, P5366, DOI 10.1073/pnas.0937718100; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Sanders SE, 1995, EPITHELIAL CELL BIOL, V4, P25; Sobocka MB, 2000, BLOOD, V95, P2600; Stutzmann J, 2000, MICROSC RES TECHNIQ, V51, P179, DOI 10.1002/1097-0029(20001015)51:2<179::AID-JEMT9>3.0.CO;2-4; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691	67	159	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11665	11674		10.1074/jbc.M412650200	http://dx.doi.org/10.1074/jbc.M412650200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15677455	hybrid			2022-12-25	WOS:000227761800095
J	Tsuboi, K; Sun, YX; Okamoto, Y; Araki, N; Tonai, T; Ueda, N				Tsuboi, K; Sun, YX; Okamoto, Y; Araki, N; Tonai, T; Ueda, N			Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANNABINOID RECEPTOR; PROCATHEPSIN-L; ANANDAMIDE; CLONING; AMIDES; PALMITOYLETHANOLAMIDE; ENZYME; BRAIN; MICE; 2-ARACHIDONOYLGLYCEROL	Bioactive N-acylethanolamines, including anandamide (an endocannabinoid) and N-palmitoylethanolamine (an anti-inflammatory and neuroprotective substance), are hydrolyzed to fatty acids and ethanolamine by fatty acid amide hydrolase. Moreover, we found another amidohydrolase catalyzing the same reaction only at acidic pH, and we purified it from rat lung (Ueda, N., Yamanaka, K., and Yamamoto, S. (2001) J. Biol. Chem. 276, 35552-35557). Here we report complementary DNA cloning and functional expression of the enzyme termed "N-acylethanolamine-hydrolyzing acid amidase (NAAA)" from human, rat, and mouse. The deduced primary structures revealed that NAAA had no homology to fatty acid amide hydrolase but belonged to the choloylglycine hydrolase family. Human NAAA was essentially identical to a gene product that had been noted to resemble acid ceramidase but lacked ceramide hydrolyzing activity. The recombinant human NAAA overexpressed in HEK293 cells hydrolyzed various N-acylethanolamines with N-palmitoylethanolamine as the most reactive substrate. Most interestingly, a very low ceramide hydrolyzing activity was also detected with NAAA, and N-lauroylethanolamine hydrolyzing activity was observed with acid ceramidase. By the use of tunicamycin and endoglycosidase, NAAA was found to be a glycoprotein. Furthermore, the enzyme was proteolytically processed to a shorter form at pH 4.5 but not at pH 7.4. Expression analysis of a green fluorescent protein-NAAA fusion protein showed a lysosome-like distribution in HEK293 cells. The organ distribution of the messenger RNA in rats revealed its wide distribution with the highest expression in lung. These results demonstrated that NAAA is a novel N-acylethanolamine-hydrolyzing enzyme that shows structural and functional similarity to acid ceramidase.	Kagawa Univ, Sch Med, Dept Biochem, Miki, Kagawa 7610793, Japan; Kagawa Univ, Sch Med, Dept Cell Biol & Histol, Miki, Kagawa 7610793, Japan; Natl Zentsuji Hosp, Dept Orthoped Surg, Zentsuji, Kagawa 7650001, Japan; Natl Zentsuji Hosp, Clin Res Inst, Zentsuji, Kagawa 7650001, Japan	Kagawa University; Kagawa University	Ueda, N (corresponding author), Kagawa Univ, Sch Med, Dept Biochem, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	nueda@med.kagawa-u.ac.jp	OKAMOTO, Yasuo/J-8438-2015	Araki, Nobukazu/0000-0001-6160-210X				Araki N, 2003, J CELL SCI, V116, P247, DOI 10.1242/jcs.00235; BACHUR NR, 1965, J BIOL CHEM, V240, P1019; Bar J, 2001, HUM MUTAT, V17, P199, DOI 10.1002/humu.5; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Bisogno T, 2002, CURR PHARM DESIGN, V8, P533, DOI 10.2174/1381612023395655; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calignano A, 2001, EUR J PHARMACOL, V419, P191, DOI 10.1016/S0014-2999(01)00988-8; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; CHRISTIAENS H, 1992, APPL ENVIRON MICROB, V58, P3792, DOI 10.1128/AEM.58.12.3792-3798.1992; Clement AB, 2003, J NEUROSCI, V23, P3916; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cravatt BF, 2003, CURR OPIN CHEM BIOL, V7, P469, DOI 10.1016/S1367-5931(03)00079-6; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349; DIMARZO V, BIOCH BIOPHYS ACTA, V1392, P153; EPPS DE, 1979, BIOCHEM BIOPH RES CO, V90, P628, DOI 10.1016/0006-291X(79)91281-6; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Goparaju SK, 1998, FEBS LETT, V422, P69, DOI 10.1016/S0014-5793(97)01603-7; Gulaya NM, 1998, CHEM PHYS LIPIDS, V97, P49, DOI 10.1016/S0009-3084(98)00093-0; HANSEN HS, 1995, BBA-LIPID LIPID MET, V1258, P303, DOI 10.1016/0005-2760(95)00134-X; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; HANUS L, 1993, J MED CHEM, V36, P3032, DOI 10.1021/jm00072a026; Hong SB, 1999, GENOMICS, V62, P232, DOI 10.1006/geno.1999.5953; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kondo S, 1998, ARCH BIOCHEM BIOPHYS, V354, P303, DOI 10.1006/abbi.1998.0688; Kurahashi Y, 1997, BIOCHEM BIOPH RES CO, V237, P512, DOI 10.1006/bbrc.1997.7180; Lambert DM, 1999, CURR MED CHEM, V6, P757; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Lichtman AH, 2002, J PHARMACOL EXP THER, V302, P73, DOI 10.1124/jpet.302.1.73; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Maccarrone M, 2002, BIOCHEM J, V366, P137, DOI 10.1042/BJ20020438; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Schmid HHO, 2002, PROSTAG LEUKOTR ESS, V66, P363, DOI 10.1054/plef.2001.0348; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Suresh CG, 1999, NAT STRUCT BIOL, V6, P414, DOI 10.1038/8213; Terrazzino S, 2004, FASEB J, V18, P1580, DOI 10.1096/fj.03-1080fje; Tsuboi K, 2004, BIOCHEM J, V379, P99, DOI 10.1042/BJ20031695; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; Ueda N, 2000, CHEM PHYS LIPIDS, V108, P107, DOI 10.1016/S0009-3084(00)00190-0; Ueda N, 1999, FEBS LETT, V454, P267, DOI 10.1016/S0014-5793(99)00820-0; Ueda N, 2001, J BIOL CHEM, V276, P35552, DOI 10.1074/jbc.M106261200; Ueda N, 2002, PROSTAG OTH LIPID M, V68-9, P521, DOI 10.1016/S0090-6980(02)00053-9; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Vandevoorde S, 2003, J MED CHEM, V46, P4373, DOI 10.1021/jm0340795	62	264	277	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11082	11092		10.1074/jbc.M413473200	http://dx.doi.org/10.1074/jbc.M413473200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15655246	hybrid			2022-12-25	WOS:000227761800026
J	Riazi, AM; Lee, HY; Hsu, C; Van Arsdell, G				Riazi, AM; Lee, HY; Hsu, C; Van Arsdell, G			CSX/Nkx2.5 modulates differentiation of skeletal myoblasts and promotes differentiation into neuronal cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DIFFERENTIATION; CARDIOMYOCYTE DIFFERENTIATION; CONDUCTION SYSTEM; EXPRESSION; HEART; NKX2-5; GENE; PROTEIN; TRANSCRIPTION; MYOCYTES	CSX/Nkx2.5 transcription factor plays a pivotal role in cardiac development; however, its role in development and differentiation of other organs has not been investigated. In this study, we used C2C12 myoblasts and human fetal primary myoblasts to investigate the function of Nkx2.5 in skeletal myogenesis. The expression levels of Nkx2.5 decreased as C2C12 myoblasts elongated and fused to form myotubes. The expression of human NKX2.5 in C2C12 myoblasts inhibited myocyte differentiation and myotube formation, and up-regulated Gata4 and Tbx5 expression. The expression of NKX2.5 in terminally differentiated C2C12 myotubes resulted in a change in morphology and breakdown into smaller myotubes. Furthermore, overexpression of NKX2.5 in C2C12 cells and primary cultures of human fetal myoblasts led to differentiation of myoblasts into neuron-like cells and expression of neuronal markers. This study sheds light on the previously unknown non-cardiac functions of Nkx2.5 transcription factor.	Hosp Sick Children, Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Riazi, AM (corresponding author), Hosp Sick Children, Div Cardiovasc Res, Rm 7017 McMaster Bldg,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	ali.riazi@sickkids.ca						Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Bruneau BG, 2002, CIRC RES, V90, P509, DOI 10.1161/01.RES.0000013072.51957.B7; CHIN LS, 1995, P NATL ACAD SCI USA, V92, P9230, DOI 10.1073/pnas.92.20.9230; Evans SM, 1999, SEMIN CELL DEV BIOL, V10, P73, DOI 10.1006/scdb.1999.0282; Frith-Terhune A, 1998, MOL CELLS, V8, P637; GUO K, 1995, MOL CELL BIOL, V15, P3823; Hiltunen JO, 1996, CIRC RES, V79, P930, DOI 10.1161/01.RES.79.5.930; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Ichaso N, 1998, ONCOGENE, V17, P1871, DOI 10.1038/sj.onc.1202100; Jay PY, 2004, J CLIN INVEST, V113, P1130, DOI 10.1172/JCI200419846; Kasahara H, 2003, J MOL CELL CARDIOL, V35, P243, DOI 10.1016/S0022-2828(03)00002-6; Kasahara H, 1998, CIRC RES, V82, P936, DOI 10.1161/01.RES.82.9.936; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LINTS TJ, 1993, DEVELOPMENT, V119, P419; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2; Rosania GR, 2000, NAT BIOTECHNOL, V18, P304, DOI 10.1038/73753; Schwartz RJ, 1999, DEVELOPMENT, V126, P4187; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Springer ML, 1997, SOMAT CELL MOLEC GEN, V23, P203, DOI 10.1007/BF02721371; Sun GF, 2004, J CELL BIOCHEM, V92, P189, DOI 10.1002/jcb.20039; Syagailo YV, 2002, GENE, V294, P259, DOI 10.1016/S0378-1119(02)00798-9; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Vitadello M, 1996, J MOL CELL CARDIOL, V28, P1833, DOI 10.1006/jmcc.1996.0176; WANG J, 1995, BIOCHEM BIOPH RES CO, V206, P82, DOI 10.1006/bbrc.1995.1012	28	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10716	10720		10.1074/jbc.M500028200	http://dx.doi.org/10.1074/jbc.M500028200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15653675	hybrid			2022-12-25	WOS:000227559600117
J	Rutherford, JC; Ojeda, L; Balk, J; Muhlenhoff, U; Lill, R; Winge, DR				Rutherford, JC; Ojeda, L; Balk, J; Muhlenhoff, U; Lill, R; Winge, DR			Activation of the iron regulon by the yeast Aft1/Aft2 transcription factors depends on mitochondrial but not cytosolic iron-sulfur protein biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CLUSTER BIOSYNTHESIS; OXIDATIVE STRESS; GENE-EXPRESSION; FE/S PROTEINS; AFT1; MATURATION; BINDING; HOMEOSTASIS; RESISTANCE	Two transcriptional activators, Aft1 and Aft2, regulate iron homeostasis in Saccharomyces cerevisiae. These factors induce the expression of iron regulon genes in iron-deficient yeast but are inactivated in iron-replete cells. Iron inhibition of Aft1/Aft2 is abrogated in cells defective for Fe-S cluster biogenesis within the mitochondrial matrix (Chen, O. S., Crisp, R. J., Valachovic, M., Bard, M., Winge, D. R., and Kaplan, J. (2004) J. Biol. Chem. 279, 29513-29518). To determine whether iron sensing by Aft1/Aft2 requires the function of the mitochondrial Fe-S export and cytosolic Fe-S protein assembly systems, we evaluated the expression of the iron regulon in cells depleted of glutathione and in cells depleted of Atm1, Nar1, Cfd1, and Nbp35. The iron regulon is induced in cells depleted of Atm1 with Aft1 largely responsible for the induced gene expression. Aft2 is activated at a later time in Atm1-depleted cells. Likewise, the iron regulon is induced in cells depleted of glutathione. In contrast, repression of NAR1, CFD1, or NBP35 fails to induce the iron regulon despite strong inhibition of cytosolic/nuclear Fe-S protein assembly. Thus, iron sensing by Aft1/Aft2 is not linked to the maturation of cytosolic/nuclear Fe-S proteins, but the mitochondrial inner membrane transporter Atm1 is important to transport the inhibitory signal. Although Aft1 and Aft2 sense a signal emanating from the Fe-S cluster biogenesis pathway, there is no indication that the proteins are inhibited by direct binding of an Fe-S cluster.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Philipps University Marburg	Lill, R (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	Lill@mailer.uni-marburg.de; dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010	Lill, Roland/0000-0002-8345-6518	NCI NIH HHS [CA61286] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061286] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balk J, 2004, CHEMBIOCHEM, V5, P1044, DOI 10.1002/cbic.200400061; Balk J, 2004, EMBO J, V23, P2105, DOI 10.1038/sj.emboj.7600216; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Chen OS, 2004, J BIOL CHEM, V279, P29513, DOI 10.1074/jbc.M403209200; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Chloupkova M, 2003, J MOL BIOL, V331, P155, DOI 10.1016/S0022-2836(03)00666-1; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; LILL R, 2005, IN PRESS TRENDS BIOC, V30; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Roy A, 2003, EMBO J, V22, P4826, DOI 10.1093/emboj/cdg455; Rutherford JC, 2004, EUKARYOT CELL, V3, P1, DOI 10.1128/EC.3.1.1-13.2004; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Taura T, 1998, P NATL ACAD SCI USA, V95, P7427, DOI 10.1073/pnas.95.13.7427; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200	32	192	200	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10135	10140		10.1074/jbc.M413731200	http://dx.doi.org/10.1074/jbc.M413731200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15649888	hybrid			2022-12-25	WOS:000227559600049
J	Yamano, K; Ishikawa, D; Esaki, M; Endo, T				Yamano, K; Ishikawa, D; Esaki, M; Endo, T			The phosphate carrier has an ability to be sorted to either the TIM22 pathway or the TIM23 pathway for its import into yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TWIN-PORE TRANSLOCASE; INTERMEMBRANE SPACE; PROTEIN TRANSLOCATION; ADP/ATP CARRIER; OUTER-MEMBRANE; COMPLEX	Most mitochondrial proteins are synthesized in the cytosol, imported into mitochondria via the TOM40 ( translocase of the mitochondrial outer membrane 40) complex, and follow several distinct sorting pathways to reach their destination submitochondrial compartments. Phosphate carrier (PiC) is an inner membrane protein with 6 transmembrane segments (TM1-TM6) and requires, after translocation across the outer membrane, the Tim9-Tim10 complex and the TIM22 complex to be inserted into the inner membrane. Here we analyzed an in vitro import of fusion proteins between various PiC segments and mouse dihydrofolate reductase. The fusion protein without TM1 and TM2 was translocated across the outer membrane but was not inserted into the inner membrane. The fusion proteins without TM1-TM4 were not inserted into the inner membrane but instead translocated across the inner membrane. Functional defects of Tim50 of the TIM23 complex caused either by depletion of the protein or the addition of anti-Tim50 antibodies blocked translocation of the fusion proteins without TM1-TM4 across the inner membrane, suggesting that lack of TM1-TM4 led to switch of its sorting pathway from the TIM22 pathway to the TIM23 pathway. PiC thus appears to have a latent signal for sorting to the TIM23 pathway, which is exposed by reduced interactions with the Tim9-Tim10 complex and maintenance of the import competence.	Nagoya Univ, Dept Chem, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Inst Adv Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, JST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Nagoya University; Japan Science & Technology Agency (JST); Nagoya University; Japan Science & Technology Agency (JST); Nagoya University	Endo, T (corresponding author), Nagoya Univ, Dept Chem, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	endo@biochem.chem.nagoya-u.ac.jp	Esaki, Masatoshi/ABS-6645-2022; Esaki, Masatoshi/L-6591-2017					Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Chacinska A, 2004, EMBO J, V23, P3735, DOI 10.1038/sj.emboj.7600389; Curran SP, 2004, J BIOL CHEM, V279, P43744, DOI 10.1074/jbc.M404878200; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; DAUM G, 1982, J BIOL CHEM, V257, P3028; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Esaki M, 1999, P NATL ACAD SCI USA, V96, P11770, DOI 10.1073/pnas.96.21.11770; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; KITADA K, 1995, GENE, V165, P203, DOI 10.1016/0378-1119(95)00552-H; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; Naoe M, 2004, J BIOL CHEM, V279, P47815, DOI 10.1074/jbc.M410272200; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Pfanner N, 2004, NAT STRUCT MOL BIOL, V11, P1044, DOI 10.1038/nsmb852; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; SIRRENBERG C, 1997, J BIOL CHEM, V272, P29663; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	20	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10011	10017		10.1074/jbc.M413264200	http://dx.doi.org/10.1074/jbc.M413264200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644337	hybrid			2022-12-25	WOS:000227559600034
J	Cornelis, S; Bruynooghe, Y; Van Loo, G; Saelens, X; Vandenabeele, P; Beyaert, R				Cornelis, S; Bruynooghe, Y; Van Loo, G; Saelens, X; Vandenabeele, P; Beyaert, R			Apoptosis of hematopoietic cells induced by growth factor withdrawal is associated with caspase-9 mediated cleavage of Raf-1	ONCOGENE			English	Article						apoptosis; caspase; IL-3; mitochondria; Raf-1	PROTEIN-KINASE; SIGNALING PATHWAYS; CYTOCHROME-C; MITOCHONDRIA; ACTIVATION; DEATH; PHOSPHORYLATION; RECEPTOR; SURVIVAL; RELEASE	The Raf-1 serine/threonine kinase is a key protein that is implicated in the transmission of many growth and cell survival signals. In the present study we demonstrate that apoptosis of hematopoietic cells induced by IL-3-deprivation is associated with the cleavage of Raf-1, resulting in the separation of the N-terminal regulatory domain and the C-terminal kinase domain. Raf-1 cleavage specifically occurs upon triggering of the mitochondrial death pathway, and coincides with the activation of specific caspases. Moreover, Bcl-2 overexpression or treatment with the caspase inhibitor z-VAD.fmk completely prevented Raf-1 cleavage, whereas caspase inhibition by treatment of cells with Ac-DEVD.fmk or z-IETD.fmk, or CrmA overexpression had no effect. Furthermore, in vitro cleavage studies indicate that caspase-9, which is the apical protease in the mitochondrial death pathway, is able to cleave Raf-1 at position D279. Cell fractionation studies showed that the Raf-1 C-terminal fragment that is generated upon IL-3 withdrawal is localized predominantly to the mitochondria. In addition, constitutive expression of this C-terminal Raf-1 fragment fused to a mitochondrial targeting sequence in Ba/F3 pre-B cells significantly delays apoptosis induced by IL-3 withdrawal. These results suggest an important role for caspase-9 mediated cleavage of Raf-1 in the negative feedback regulation of hematopoietic cell apoptosis induced by growth factor withdrawal.	State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium; State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signaling & Cell Death, B-9052 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Beyaert, R (corresponding author), State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Belgium.	rudi.beyaert@dmbr.ugent.be	Saelens, Xavier/N-5728-2015; Vandenabeele, Peter/C-8597-2009; , van Loo Geert/AAD-1220-2019; Vandenabeele, Peter/AAD-5793-2022; Beyaert, Rudi/B-2589-2009; van Loo, Geert/C-1505-2009	, van Loo Geert/0000-0002-8427-4775; Vandenabeele, Peter/0000-0002-6669-8822; , Xavier/0000-0002-3861-6965; Beyaert, Rudi/0000-0002-5704-582X				Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bojes HK, 1999, CELL DEATH DIFFER, V6, P61, DOI 10.1038/sj.cdd.4400452; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; HAPEL AJ, 1984, BLOOD, V64, P786; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Le Mellay V, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-14; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Majewski M, 1999, CANCER RES, V59, P2815; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Potokar M, 2003, FEBS LETT, V544, P153, DOI 10.1016/S0014-5793(03)00494-0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Troppmair J, 2003, BIOCHEM PHARMACOL, V66, P1341, DOI 10.1016/S0006-2952(03)00483-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P1207, DOI 10.1038/sj.cdd.4401101; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	52	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2005	24	9					1552	1562		10.1038/sj.onc.1208401	http://dx.doi.org/10.1038/sj.onc.1208401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674327				2022-12-25	WOS:000227218200008
J	Zagha, E; Ozaita, A; Chang, SY; Nadal, MS; Lin, U; Saganich, MJ; McCormack, T; Akinsanya, KO; Qi, SY; Rudy, B				Zagha, E; Ozaita, A; Chang, SY; Nadal, MS; Lin, U; Saganich, MJ; McCormack, T; Akinsanya, KO; Qi, SY; Rudy, B			DPP10 modulates Kv4-mediated A-type potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; DIPEPTIDYL PEPTIDASE IV; K+ CHANNELS; PROTEIN DPPX; AIRWAY HYPERRESPONSIVENESS; DIFFERENTIAL EXPRESSION; BRAIN; SUBUNITS; CURRENTS; CLONING	A new member of a family of proteins characterized by structural similarity to dipeptidyl peptidase (DPP) IV known as DPP10 was recently identified and linked to asthma susceptibility; however, the cellular functions of DPP10 are thus far unknown. DPP10 is highly homologous to subfamily member DPPX, which we previously reported as a modulator of Kv4-mediated A-type potassium channels (Nadal, M. S., Ozaita, A., Amarillo, Y., Vega-Saenz de Miera, E., Ma, Y., Mo, W., Goldberg, E. M., Misumi, Y., Ikehara, Y., Neubert, T. A., and Rudy, B. ( 2003) Neuron. 37, 449-461). We studied the ability of DPP10 protein to modulate the properties of Kv4.2 channels in heterologous expression systems. We found DPP10 activity to be nearly identical to DPPX activity and significantly different from DPPIV activity. DPPX and DPP10 facilitated Kv4.2 protein trafficking to the cell membrane, increased A-type current magnitude, and modified the voltage dependence and kinetic properties of the current such that they resembled the properties of A-type currents recorded in neurons in the central nervous system. Using in situ hybridization, we found DPP10 to be prominently expressed in brain neuronal populations that also express Kv4 subunits. Furthermore, DPP10 was detected in immunoprecipitated Kv4.2 channel complexes from rat brain membranes, confirming the association of DPP10 proteins with native Kv4.2 channels. These experiments suggest that DPP10 contributes to the molecular composition of A-type currents in the central nervous system. To dissect the structural determinants of these integral accessory proteins, we constructed chimeras of DPPX, DPP10, and DPPIV lacking the extracellular domain. Chimeras of DPPX and DPP10, but not DPPIV, were able to modulate the properties of Kv4.2 channels, highlighting the importance of the intracellular and transmembrane domains in this activity.	NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Ferring Res Inst, Dept Cellular & Mol Biol, San Diego, CA 92121 USA	New York University; New York University; Salk Institute; State University System of Florida; University of Florida	Chang, SY (corresponding author), NYU, Sch Med, Dept Physiol & Neurosci, 442 MSB,550 1st Ave, New York, NY 10016 USA.		Ozaita, Andres/H-3411-2015	Ozaita, Andres/0000-0002-2239-7403; Rudy, Bernardo/0000-0001-5748-6900; Nadal, Marcela/0000-0002-1679-4760	NINDS NIH HHS [NS30989, NS045217] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045217, R01NS030989] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Amberg GC, 2003, AM J PHYSIOL-CELL PH, V284, pC583, DOI 10.1152/ajpcell.00301.2002; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Baxter D A, 1991, Curr Opin Neurobiol, V1, P105, DOI 10.1016/0959-4388(91)90017-2; Boonacker E, 2003, EUR J CELL BIOL, V82, P53, DOI 10.1078/0171-9335-00302; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P31, DOI 10.1113/jphysiol.1971.sp009366; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537, DOI 10.1165/ajrcmb.23.4.4199; Hildebrandt M, 2000, CLIN SCI, V99, P93, DOI 10.1042/CS19990368; HILLE B, 2001, IONIC CHANNELS EXCIT, P136; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Johnston D, 2000, J PHYSIOL-LONDON, V525, P75, DOI 10.1111/j.1469-7793.2000.00075.x; Kin Y, 2001, J BIOCHEM-TOKYO, V129, P289, DOI 10.1093/oxfordjournals.jbchem.a002856; Lambeir AM, 2003, CRIT REV CL LAB SCI, V40, P209, DOI 10.1080/713609354; Liss B, 2001, EMBO J, V20, P5715, DOI 10.1093/emboj/20.20.5715; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nadal MS, 2001, J PHYSIOL-LONDON, V537, P801; Ozaita A, 2002, J NEUROPHYSIOL, V88, P394, DOI 10.1152/jn.2002.88.1.394; Qi SY, 2003, BIOCHEM J, V373, P179, DOI 10.1042/BJ20021914; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Rhodes KJ, 2004, J NEUROSCI, V24, P7903, DOI 10.1523/JNEUROSCI.0776-04.2004; Rocha CA, 2004, BIOPHYS J, V86, p536A; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Saganich MJ, 2001, J NEUROSCI, V21, P4609, DOI 10.1523/JNEUROSCI.21-13-04609.2001; Schoppa NE, 1999, NAT NEUROSCI, V2, P1106, DOI 10.1038/16033; Serodio P, 1998, J NEUROPHYSIOL, V79, P1081, DOI 10.1152/jn.1998.79.2.1081; Watanabe S, 2002, P NATL ACAD SCI USA, V99, P8366, DOI 10.1073/pnas.122210599	31	106	113	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18853	18861		10.1074/jbc.M410613200	http://dx.doi.org/10.1074/jbc.M410613200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15671030	hybrid			2022-12-25	WOS:000228932300037
J	Li, ZK; Niu, JG; Uwagawa, T; Peng, BL; Chiao, PJ				Li, ZK; Niu, JG; Uwagawa, T; Peng, BL; Chiao, PJ			Function of polo-like kinase 3 in NF-kappa B-mediated proapoptotic response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PROTEIN-SYNTHESIS; CELL-CYCLE ARREST; INDUCED APOPTOSIS; FAS-LIGAND; SERINE/THREONINE KINASE; T-LYMPHOCYTES; DNA-DAMAGE; ACTIVATION; P53; DEATH	RelA, the p65 subunit of NF-kappa B transcription factors, plays a key role in regulation of antiapoptotic and proapoptotic responses. However, the downstream target genes regulated by RelA-NF-kappa B in the initiation of proapoptotic signaling were not identified. We previously showed that RelA-NF-kappa B functioned as a proapoptotic factor by activating the p53-signaling pathway in response to doxycycline-induced superoxide. In the present study, we demonstrate that the ability of doxycycline/ superoxide to induce expression of polo-like kinase 3 (Plk3) depends on NF-kappa B activity. We identified a kappa B binding site in the promoter of Plk3, and this kappa B site is directly involved in its induction by the RelA-NF-kappa B complex. Plk3 formed a complex with p53 and was involved in the phosphorylation of p53 on Ser-20 in response to superoxide. Inhibition of Plk3 expression by Plk3 small interfering RNA suppressed the doxycycline/ superoxide-mediated apoptosis. Overexpression of wildtype Plk3 in HCT116 p53(+/+) cells induced rapid apoptosis, whereas overexpression of wild-type Plk3 in HCT116 p53(-/-) cells and the kinase-defective mutant Plk3(K91R) in p53(-/-) cells induced delayed onset of apoptosis. Furthermore, mutagenesis of Plk3 showed that the N-terminal domain ( amino acids 1 - 26) is essential for the induction of delay onset of apoptosis. These data show that Plk3 is a RelA-NF-kappa B-regulated gene that induces apoptosis in both p53-dependent and - independent signaling pathways, suggesting a possible mechanism for RelA-NF-kappa B-regulated proapoptotic responses.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.	pjchiao@mdanderson.org			NATIONAL CANCER INSTITUTE [P01CA078778, R01CA097159] Funding Source: NIH RePORTER; NCI NIH HHS [CA 097159, CA 78778] Funding Source: Medline; PHS HHS [PA-98-029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bahassi El Mustapha, 2002, Oncogene, V21, P6633; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Conn CW, 2000, CANCER RES, V60, P6826; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Fife RS, 1997, J LAB CLIN MED, V130, P530, DOI 10.1016/S0022-2143(97)90130-X; Fujioka S, 2004, J BIOL CHEM, V279, P27549, DOI 10.1074/jbc.M313435200; Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GILBERTSONBEADLING S, 1995, CANCER CHEMOTH PHARM, V36, P418, DOI 10.1007/BF00686191; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KROON AM, 1985, BIOCHEM BIOPH RES CO, V128, P1190, DOI 10.1016/0006-291X(85)91066-6; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; Matsui K, 1998, J IMMUNOL, V161, P3469; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Putnam JB, 1999, CANCER, V86, P1992, DOI 10.1002/(SICI)1097-0142(19991115)86:10<1992::AID-CNCR16>3.0.CO;2-M; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; VAN AD, 1996, SCIENCE, V274, P787; VANDENBOGERT C, 1981, CANCER RES, V41, P1943; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271	42	42	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16843	16850		10.1074/jbc.M410119200	http://dx.doi.org/10.1074/jbc.M410119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15671037	hybrid			2022-12-25	WOS:000228615500038
J	Turkish, AR; Henneberry, AL; Cromley, D; Padamsee, M; Oelkers, P; Bazzi, H; Christiano, AM; Billheimer, JT; Sturley, SL				Turkish, AR; Henneberry, AL; Cromley, D; Padamsee, M; Oelkers, P; Bazzi, H; Christiano, AM; Billheimer, JT; Sturley, SL			Identification of two novel human Acyl-CoA wax alcohol acyltransferases - Members of the diacylglycerol acyltransferase 2 (DGAT2) gene superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOACYLGLYCEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE; SUBSTRATE-SPECIFICITY; LEPTIN SENSITIVITY; COENZYME; OBESITY; YEAST; TRIACYLGLYCEROL; BIOSYNTHESIS; CLONING	The esterification of alcohols such as sterols, diacylglycerols, and monoacylglycerols with fatty acids represents the formation of both storage and cytoprotective molecules. Conversely, the overproduction of these molecules is associated with several disease pathologies, including atherosclerosis and obesity. The human acyl-CoA:diacylglycerol acyltransferase (DGAT) 2 gene superfamily comprises seven members, four of which have been previously implicated in the synthesis of di- or triacylglycerol. The remaining 3 members comprise an X-linked locus and have not been characterized. We describe here the expression of DGAT2 and the three X-linked genes in Saccharomyces cerevisiae strains virtually devoid of neutral lipids. All four gene products mediate the synthesis of triacylglycerol; however, two of the X-linked genes act as acyl-CoA wax alcohol acyltransferases (AWAT 1 and 2) that predominantly esterify long chain (wax) alcohols with acyl-CoA-derived fatty acids to produce wax esters. AWAT1 and AWAT2 have very distinct substrate preferences in terms of alcohol chain length and fatty acyl saturation. The enzymes are expressed in many human tissues but predominate in skin. In situ hybridizations demonstrate a differentiation-specific expression pattern within the human sebaceous gland for the two AWAT genes, consistent with a significant role in the composition of sebum.	Columbia Univ, Med Ctr, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Dermatol Genet & Dev, New York, NY 10032 USA; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	Columbia University; Columbia University; Columbia University; University of Pennsylvania	Sturley, SL (corresponding author), Columbia Univ, Med Ctr, Inst Human Nutr, 650 W 168th St, New York, NY 10032 USA.	sls37@columbia.edu	Bazzi, Hisham/AAA-6584-2021	Bazzi, Hisham/0000-0001-8388-4005; Oelkers, Peter/0000-0002-2421-472X; Padamsee, Mahajabeen/0000-0002-0741-3014	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054320] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07343] Funding Source: Medline; NIDDK NIH HHS [DK54320] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Cao JS, 2003, J BIOL CHEM, V278, P25657, DOI 10.1074/jbc.M302835200; Cao JS, 2003, J BIOL CHEM, V278, P13860, DOI 10.1074/jbc.M300139200; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2002, J CLIN INVEST, V109, P175, DOI 10.1172/JCI0213880; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Chen HC, 2002, ENDOCRINOLOGY, V143, P2893, DOI 10.1210/en.143.8.2893; Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200; Cheng JB, 2004, J BIOL CHEM, V279, P37798, DOI 10.1074/jbc.M406226200; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; DOWNING DT, 1987, J INVEST DERMATOL S, V88, P2; FREEMAN CP, 1966, J LIPID RES, V7, P324; GREEN SC, 1984, J INVEST DERMATOL, V83, P114, DOI 10.1111/1523-1747.ep12263287; GunayAygun M, 1997, BEHAV GENET, V27, P307, DOI 10.1023/A:1025683829856; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jiang Y, 2004, AM J HUM GENET, V75, P220, DOI 10.1086/422699; Kalscheuer R, 2003, J BIOL CHEM, V278, P8075, DOI 10.1074/jbc.M210533200; Katsanis N, 1999, AM J HUM GENET, V65, P1672, DOI 10.1086/302684; Krauss Ronald M., 1998, American Journal of Medicine, V105, p58S, DOI 10.1016/S0002-9343(98)00213-7; Kunst L, 2003, PROG LIPID RES, V42, P51, DOI 10.1016/S0163-7827(02)00045-0; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; LARDIZABEL KD, 2000, Patent No. 15243; Lee DP, 2001, J LIPID RES, V42, P1979; LEHNER R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P171, DOI 10.1016/0005-2760(92)90042-T; Lentes KU, 1999, J RECEPT SIGNAL TR R, V19, P229, DOI 10.3109/10799899909036648; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Li WD, 2003, DIABETES, V52, P1557, DOI 10.2337/diabetes.52.6.1557; Lockwood JF, 2003, AM J PHYSIOL-ENDOC M, V285, pE927, DOI 10.1152/ajpendo.00179.2003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1987, MOL CLONING LAB MANU; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; Miyazaki M, 2001, J NUTR, V131, P2260, DOI 10.1093/jn/131.9.2260; Mulhall BP, 2002, J GASTROEN HEPATOL, V17, P1136, DOI 10.1046/j.1440-1746.2002.02881.x; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; Oelkers PM, 2004, TOP CURR GENET, V6, P289; ROSS R, 1995, MOL CARDIOVASCULAR M, P11; RUSTAN AC, 1988, J LIPID RES, V29, P1417; Saar K, 2003, PEDIATRICS, V111, P321, DOI 10.1542/peds.111.2.321; Sandager L, 2000, BIOCHEM SOC T, V28, P700; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; STEWART ME, 1992, SEMIN DERMATOL, V11, P100; STEWART ME, 1986, J INVEST DERMATOL, V86, P706, DOI 10.1111/1523-1747.ep12276326; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Subauste Angela, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P263, DOI 10.2174/1568008033340081; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; TAVANI DM, 1982, J LIPID RES, V23, P774; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tinkelenberg AH, 2000, J BIOL CHEM, V275, P40667, DOI 10.1074/jbc.C000710200; Vincent MC, 2001, EUR J HUM GENET, V9, P355, DOI 10.1038/sj.ejhg.5200635; Yang HY, 1997, J BIOL CHEM, V272, P3980, DOI 10.1074/jbc.272.7.3980; Yen CLE, 2003, J BIOL CHEM, V278, P18532, DOI 10.1074/jbc.M301633200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899; Yu YH, 2004, ANN MED, V36, P252, DOI 10.1080/07853890410028429; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	64	75	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14755	14764		10.1074/jbc.M500025200	http://dx.doi.org/10.1074/jbc.M500025200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15671038	hybrid			2022-12-25	WOS:000228236800052
J	Wolkowicz, R; Jager, GC; Nolan, GP				Wolkowicz, R; Jager, GC; Nolan, GP			A random peptide library fused to CCR5 for selection of mimetopes expressed on the mammalian cell surface via retroviral vectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; DISPLAY; IDENTIFICATION; INHIBITORS; APTAMERS	A random peptide library was expressed on the surface of a mammalian cell by applying retroviral vectors. The random sequence was fused to the CCR5 chemokine receptor, which served as a scaffold to present the library at the cell surface. We used this library to isolate an epitope mimetope in a proof of principle system. This approach can become a tool for rapid creation of peptidic expression domains in a eukaryotic environment. Applications include the creation of decoys for receptors in cell-cell interactions, screening for molecules that drive ligand expression on target cells in two-cell interaction screens, among other utilities.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA	Stanford University	Nolan, GP (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Baxter Lab Genet Pharmacol, CCSR Bldg,Rm 3205,269 Campus Dr, Stanford, CA 94305 USA.	gnolan@stanford.edu	Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043	NHLBI NIH HHS [N01-HV-28183] Funding Source: Medline; NIAID NIH HHS [AI 35304 R01] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035304] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blum JH, 2000, P NATL ACAD SCI USA, V97, P2241, DOI 10.1073/pnas.040573397; Boder ET, 2000, METHOD ENZYMOL, V328, P430, DOI 10.1016/S0076-6879(00)28410-3; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Eyckerman S, 2001, NAT CELL BIOL, V3, P1114, DOI 10.1038/ncb1201-1114; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gallagher WM, 1997, ONCOGENE, V14, P185; Grabherr R, 2001, TRENDS BIOTECHNOL, V19, P231, DOI 10.1016/S0167-7799(01)01610-9; Green LS, 2001, BIOTECHNIQUES, V30, P1094, DOI 10.2144/01305dd02; Kieke MC, 1999, P NATL ACAD SCI USA, V96, P5651, DOI 10.1073/pnas.96.10.5651; Kinsella TM, 2002, J BIOL CHEM, V277, P37512, DOI 10.1074/jbc.M206162200; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Luo B, 2004, P NATL ACAD SCI USA, V101, P5494, DOI 10.1073/pnas.0400551101; Maur AAD, 2002, J BIOL CHEM, V277, P45075, DOI 10.1074/jbc.M205264200; McBride JD, 1996, J MOL BIOL, V259, P819, DOI 10.1006/jmbi.1996.0360; Miyagishi M, 2004, VIRUS RES, V102, P117, DOI 10.1016/j.virusres.2004.01.022; Peelle B, 2001, CHEM BIOL, V8, P521, DOI 10.1016/S1074-5521(01)00031-X; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; RING CS, 1993, FASEB J, V7, P783, DOI 10.1096/fasebj.7.9.8330685; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Sen G, 2004, NAT GENET, V36, P183, DOI 10.1038/ng1288; SWIFT S, 1999, CURRENT PROTOCOLS  S, V31, P14; Tolstrup AB, 2001, GENE, V263, P77; Wallach D, 1998, CURR OPIN IMMUNOL, V10, P131, DOI 10.1016/S0952-7915(98)80240-9; Wiesner C, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf079; Wolkowicz R, 2003, FRONT BIOSCI-LANDMRK, V8, pD603, DOI 10.2741/952; Wolkowicz Roland, 2004, Methods Mol Biol, V246, P391; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717	27	19	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15195	15201		10.1074/jbc.M500254200	http://dx.doi.org/10.1074/jbc.M500254200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15657029	hybrid			2022-12-25	WOS:000228236800104
J	Summers, MK; Bothos, J; Halazonetis, TD				Summers, MK; Bothos, J; Halazonetis, TD			The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleus	ONCOGENE			English	Article						CHFR; cyclin B1; checkpoint; prophase; mitosis	HISTONE H3 PHOSPHORYLATION; CHROMOSOME MISSEGREGATION; EPIGENETIC INACTIVATION; ENVELOPE BREAKDOWN; STRESS CHECKPOINT; MAMMALIAN-CELLS; CPG ISLAND; FHA DOMAIN; AURORA-B; SPINDLE	CHFR, a novel checkpoint gene inactivated in human cancer, delays chromosome condensation in cells treated with microtubule poisons. To understand the molecular mechanism for this delay, we characterized cells with inactivated CHFR and stably transfected derivatives expressing the wild-type gene. After exposure to microtubule poisons, the CHFR-expressing cells arrested transiently in early prophase with a characteristic ruffled morphology of the nuclear envelope and no signs of chromosome condensation. Several markers suggested that Cyclin A/Cdc2 had been activated, whereas Aur-ora-A and -B and Cyclin B1/Cdc2 were inactive. Further, Cyclin B1 was excluded from the nucleus. Ectopic expression of Cyclin B1 with a mutant nuclear export sequence induced chromosome condensation, and thus overcame the CHFR checkpoint. We conclude that the mechanism by which CHFR delays chromosome condensation involves inhibition of accumulation of Cyclin B1 in the nucleus.	Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; Univ Penn, Cell & Mol Biol Program, Biomed Grad Studies, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Halazonetis, TD (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	halazonetis@wistar.upenn.edu	Halazonetis, Thanos/D-7923-2011		NATIONAL CANCER INSTITUTE [T32CA009677, R01CA089630, T32CA009171] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171, CA09677, CA89630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bertholon J, 2003, ONCOGENE, V22, P8956, DOI 10.1038/sj.onc.1207078; Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831; BULLOUGH WS, 1951, PROC R SOC SER B-BIO, V138, P562, DOI 10.1098/rspb.1951.0041; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chaturvedi P, 2002, CANCER RES, V62, P1797; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Erson AE, 2004, MOL CARCINOGEN, V39, P26, DOI 10.1002/mc.10161; Georgatos SD, 1997, J CELL SCI, V110, P2129; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; JHA MN, 1994, CANCER RES, V54, P5011; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mariatos G, 2003, CANCER RES, V63, P7185; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; MCINTOSH JR, 1989, SCIENCE, V246, P622; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Salina D, 2002, CELL, V108, P97, DOI 10.1016/S0092-8674(01)00628-6; Satoh A, 2003, CANCER RES, V63, P8606; Schneider U, 1999, BIOCHEMISTRY-US, V38, P4620, DOI 10.1021/bi9827060; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695; Stavridi ES, 2002, STRUCTURE, V10, P891, DOI 10.1016/S0969-2126(02)00776-1; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200	55	49	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2589	2598		10.1038/sj.onc.1208428	http://dx.doi.org/10.1038/sj.onc.1208428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15674323				2022-12-25	WOS:000228356700001
J	Inoue, M; Nakamura, Y; Yasuda, K; Yasaka, N; Hara, T; Schnaufer, A; Stuart, K; Fukuma, T				Inoue, M; Nakamura, Y; Yasuda, K; Yasaka, N; Hara, T; Schnaufer, A; Stuart, K; Fukuma, T			The 14-3-3 proteins of Trypanosoma brucei function in motility, cytokinesis, and cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-3-3 PROTEINS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; DNA-REPLICATION; IN-VIVO; PHOSPHORYLATION; INHIBITION; NUCLEAR; YEAST; PHOSPHATASES	The cDNAs for two isoforms (I and II) of the 14-3-3 proteins have been cloned and functionally characterized in Trypanosoma brucei. The amino acid sequences of isoforms I and II have 47 and 50% identity to the human tau isoform, respectively, with important conserved features including a potential amphipathic groove for the binding of phosphoserine/phosphothreonine-containing motifs and a nuclear export signal-like domain. Both isoforms are abundantly expressed at approximately equal levels (1-2 x 10(6) molecules/cell) and localized mainly in the cytoplasm. Knockdown by induction of double-stranded RNA of isoform I and/or II in both bloodstream and procyclic forms resulted first in a reduction of cell motility and then significant reduction in cell growth rates and morphological changes; the changes include aberrant numbers of organelles and abnormal shapes and sizes that mimic phenotypes produced by various cytokinesis inhibitors. Morphological and fluorescence-activated cell sorting analysis of the cell cycle suggested that isoforms I and II might play important roles in nuclear (G(2)-M transition) and cell (M-G(1) transition) division. These findings indicate that the 14-3-3 proteins play important roles in cell motility, cytokinesis, and the cell cycle.	Kurume Univ, Sch Med, Dept Parasitol, Fukuoka 8300011, Japan; Excel Japan Grp, Shinjuku Ku, Tokyo, Japan; Seattle Biomed Res Inst, Seattle, WA 98109 USA	Kurume University; Center for Infectious Disease Research	Inoue, M (corresponding author), Kurume Univ, Sch Med, Dept Parasitol, 67 Asahi Machi, Fukuoka 8300011, Japan.	inouedna@med.kurume-u.ac.jp		Schnaufer, Achim/0000-0003-2132-5560				Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Bunney TD, 2001, P NATL ACAD SCI USA, V98, P4249, DOI 10.1073/pnas.061437498; Callejo M, 2002, J BIOL CHEM, V277, P38416, DOI 10.1074/jbc.M202050200; CARRINGTON M, 1993, PROTOCOLS MOL PARASI, P1; Chaudhri M, 2003, BIOCHEM BIOPH RES CO, V300, P679, DOI 10.1016/S0006-291X(02)02902-9; Cheng AY, 2000, J BIOL CHEM, V275, P1846, DOI 10.1074/jbc.275.3.1846; DAS A, 1994, J CELL SCI, V107, P3477; Dean DA, 1999, EXP CELL RES, V253, P713, DOI 10.1006/excr.1999.4716; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Grellier P, 1999, CELL MOTIL CYTOSKEL, V42, P36, DOI 10.1002/(SICI)1097-0169(1999)42:1&lt;36::AID-CM4&gt;3.0.CO;2-G; Huang ZH, 2004, BIOL REPROD, V71, P177, DOI 10.1095/biolreprod.104.027284; LI SY, 1995, BIOCHEM BIOPH RES CO, V212, P793, DOI 10.1006/bbrc.1995.2038; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Moorhead G, 1999, PLANT J, V18, P1, DOI 10.1046/j.1365-313X.1999.00417.x; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Orr GA, 2000, INFECT IMMUN, V68, P1350, DOI 10.1128/IAI.68.3.1350-1358.2000; Ploubidou A, 1999, J CELL SCI, V112, P4641; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Roberts MR, 2000, CURR OPIN PLANT BIOL, V3, P400, DOI 10.1016/S1369-5266(00)00103-5; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; van Hemert MJ, 2001, YEAST, V18, P889, DOI 10.1002/yea.739; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WERA S, 1995, J BIOL CHEM, V270, P21374, DOI 10.1074/jbc.270.36.21374; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4	35	40	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14085	14096		10.1074/jbc.M412336200	http://dx.doi.org/10.1074/jbc.M412336200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15653691	hybrid			2022-12-25	WOS:000228095500111
J	Valentinis, B; Bianchi, A; Zhou, D; Cipponi, A; Catalanotti, F; Russo, V; Traversari, C				Valentinis, B; Bianchi, A; Zhou, D; Cipponi, A; Catalanotti, F; Russo, V; Traversari, C			Direct effects of polymyxin B on human dendritic cells maturation - The role of I kappa B-alpha/NF-kappa B and ERK1/2 pathways and adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TNF-ALPHA; CHEMOKINE SECRETION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; EXPRESSION; LIPOPOLYSACCHARIDE; ANTIGEN; RECEPTOR; SURVIVAL	Polymyxin B is a lipopolysaccharide binding antibiotic used to inactivate potential lipopolysaccharide contaminations when evaluating the activity of different agents on innate immune cells. We report that polymyxin B is able to induce directly in monocyte- derived human dendritic cells ( DCs) several functional and molecular modifications characteristic of DCs undergoing a maturation process. DCs incubated with polymyxin B up- regulate the expression of HLA class I and II, the co- stimulatory CD86 molecule, and show an increase in the fraction of adherent cells at short time, which persist at 48 h of incubation. Adhesion to the plate was required for the polymyxin B- induced DCs maturation. A transient activation of I kappa B- alpha/ NF- kappa B and ERK1/ 2 pathways at short time and a further ERK1/ 2 activation at long term were also detected. Neither up- regulation of the maturation marker CD83 nor activation of p38 nor induction of cytokines secretion was observed in DCs treated with polymyxin B. We demonstrated that inhibition of I kappa B- alpha/ NF- kappa B pathway abolishes polymyxin B effects. ERK1/ 2 inhibition instead allowed DCs treated with polymyxin B to progress in their maturation process as revealed by the increased up- regulation of the CD83 co- stimulatory molecules, the activation of p38, and the reduced adhesion to culture plates at 48 h of incubation. Our results indicate that polymyxin B induces a partial maturation of human DCs through increased adhesion to a substrate and activation of the I kappa B- alpha/NF-kappa B pathway. The increased ERK1/ 2 activation observed, even though correlating with the initial phases of the maturation process, actually inhibits the occurrence of full maturation.	Molmed, I-20132 Milan, Italy; H San Raffaele Sci Inst, Canc Immunotherapy & Gene Therapy Program, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Valentinis, B (corresponding author), Molmed, Via Olgettina 58, I-20132 Milan, Italy.	barbara.valentinis@molmed.com	Russo, Vincenzo/K-5650-2016	Russo, Vincenzo/0000-0003-1592-5041; Bianchi, Alessandro/0000-0003-3107-1621				Ardeshna KM, 2000, BRIT J HAEMATOL, V108, P817; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Bhattacharyya A, 2002, BIOCHEM J, V368, P121, DOI 10.1042/BJ20020555; Bouchon A, 2001, J EXP MED, V194, P1111, DOI 10.1084/jem.194.8.1111; Brand U, 1998, EUR J IMMUNOL, V28, P1673, DOI 10.1002/(SICI)1521-4141(199805)28:05<1673::AID-IMMU1673>3.0.CO;2-J; Breithaupt TB, 1996, CELL IMMUNOL, V173, P124, DOI 10.1006/cimm.1996.0258; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Davidson L, 2004, J BIOL CHEM, V279, P1980, DOI 10.1074/jbc.M309827200; de Assis MC, 2002, NITRIC OXIDE-BIOL CH, V7, P254, DOI 10.1016/S1089-8603(02)00123-4; Emmanuel C, 2002, CYTOKINE, V18, P237, DOI 10.1006/cyto.2002.1042; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; JACOBS DM, 1977, J IMMUNOL, V118, P21; Kaiser E, 2003, BIOCHEM BIOPH RES CO, V305, P573, DOI 10.1016/S0006-291X(03)00820-9; Kikuchi K, 2003, IMMUNOL LETT, V89, P149, DOI 10.1016/S0165-2478(03)00134-2; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Lee JH, 2004, J IMMUNOL, V172, P608, DOI 10.4049/jimmunol.172.1.608; Lundqvist A, 2002, CANCER IMMUNOL IMMUN, V51, P139, DOI 10.1007/s00262-002-0265-7; Mahnke K, 1996, J LEUKOCYTE BIOL, V60, P465, DOI 10.1002/jlb.60.4.465; McGilvray ID, 1997, J BIOL CHEM, V272, P10287; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mizutani C, 2002, BIOCHEM BIOPH RES CO, V297, P664, DOI 10.1016/S0006-291X(02)02235-0; Neumann M, 2000, BLOOD, V95, P277; Nikulina M, 2004, J IMMUNOL, V173, P1925, DOI 10.4049/jimmunol.173.3.1925; OISHI K, 1988, J BIOL CHEM, V263, P6865; Puig-Kroger A, 2001, BLOOD, V98, P2175, DOI 10.1182/blood.V98.7.2175; Puig-Kroger A, 2000, J IMMUNOL, V165, P4338, DOI 10.4049/jimmunol.165.8.4338; Randolph GJ, 2001, SEMIN IMMUNOL, V13, P267, DOI 10.1006/smim.2001.0322; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Rosengart MR, 2000, SHOCK, V13, P183, DOI 10.1097/00024382-200003000-00003; Roy A, 2003, LIPIDS, V38, P965, DOI 10.1007/s11745-003-1150-5; Russo V, 2000, P NATL ACAD SCI USA, V97, P2185, DOI 10.1073/pnas.040540197; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; STUTCHFIELD J, 1986, BIOCHEM BIOPH RES CO, V136, P1001, DOI 10.1016/0006-291X(86)90432-8; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; Tsubery H, 2000, BIOCHEMISTRY-US, V39, P11837, DOI 10.1021/bi000386q; Tsuzuki H, 2001, J SURG RES, V100, P127, DOI 10.1006/jsre.2001.6227; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; VARECKA L, 1987, FEBS LETT, V225, P173, DOI 10.1016/0014-5793(87)81152-3; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Xia CQ, 2003, SCAND J IMMUNOL, V58, P23, DOI 10.1046/j.1365-3083.2003.01268.x; Yanagawa Y, 2002, J LEUKOCYTE BIOL, V71, P125	51	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14264	14271		10.1074/jbc.M410791200	http://dx.doi.org/10.1074/jbc.M410791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15671028	hybrid			2022-12-25	WOS:000228095500129
J	Browning, H; Hackney, DD				Browning, H; Hackney, DD			The EB1 homolog Mal3 stimulates the ATPase of the kinesin Tea2 by recruiting it to the microtubule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DOMAIN; PURIFICATION; TIP1P; MAINTENANCE; DYNAMICS; POLARITY; GROWTH	Tea2 is a kinesin family member from Schizosaccharomyces pombe that is targeted to microtubule tips and cell ends in a process that depends on Mal3. Constructs of Tea2 containing the motor domain only or the motor domain plus the N-terminal extension are monomeric, whereas a construct including the first predicted coiled coil region is dimeric. These constructs have a low basal rate of ATP hydrolysis of < 0.1 s(-1), but microtubules stimulate the rate of ATP hydrolysis to a maximum of similar to 15 s(-1). Hydrodynamic analysis of Mal3 indicates that it is dimeric. Mal3 is known to associate with Tea2, and analysis with the above Tea2 constructs indicates that the principal site of interaction of Mal3 with Tea2 is the N-terminal extension, although a weaker interaction is also observed with the motor domain alone. In parallel to the binding studies, Mal3 strongly stimulates the ATPase of constructs containing the N-terminal extension by decreasing the K-0.5(MT) for stimulation by microtubules but only weakly stimulates motor domains without the N-terminal extension. Mal3 reduces the K0.5( MT) values without affecting the k(cat) value at saturating microtubule level. Binding of Mal3 to microtubules induces an increase in the binding of Tea2 and a reciprocal stimulation of Mal3 binding by Tea2 is also observed. Tea2 is a plus end directed motor that drives sliding of axonemes when adsorbed to a glass surface. The sliding rate is initially unaffected by Mal3, but axonemes stop moving on continued exposure to Mal3.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University	Hackney, DD (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.	ddh@andrew.cmu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Behrens R, 2002, J CELL BIOL, V157, P783, DOI 10.1083/jcb.200112027; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Browning H, 2000, J CELL BIOL, V151, P15, DOI 10.1083/jcb.151.1.15; Browning H, 2003, NAT CELL BIOL, V5, P812, DOI 10.1038/ncb1034; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Busch KE, 2004, CURR BIOL, V14, P548, DOI 10.1016/j.cub.2004.03.029; Busch KE, 2004, DEV CELL, V6, P831, DOI 10.1016/j.devcel.2004.05.008; Carvalho P, 2004, DEV CELL, V6, P815, DOI 10.1016/j.devcel.2004.05.001; Chang F, 2003, NAT CELL BIOL, V5, P294, DOI 10.1038/ncb0403-294; Hayashi I, 2003, J BIOL CHEM, V278, P36430, DOI 10.1074/jbc.M305773200; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Kimple ME, 2002, BIOTECHNIQUES, V33, P578, DOI 10.2144/02333rr01_11842a; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Lucast LJ, 2001, BIOTECHNIQUES, V30, P544, DOI 10.2144/01303st06; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Newman JRS, 2000, P NATL ACAD SCI USA, V97, P13203, DOI 10.1073/pnas.97.24.13203; Niccoli T, 2002, J CELL SCI, V115, P1651; Rehberg M, 2002, MOL BIOL CELL, V13, P2301, DOI 10.1091/mbc.E02-01-0054; Sawin KE, 2004, J CELL SCI, V117, P689, DOI 10.1242/jcs.00925; Stock MF, 2001, METH MOL B, V164, P43; Stock MF, 1999, J BIOL CHEM, V274, P14617, DOI 10.1074/jbc.274.21.14617; Stock MF, 2003, J BIOL CHEM, V278, P52315, DOI 10.1074/jbc.M309419200; STOCK MF, 2001, METHODS MOL BIOL KIN, P65; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tirnauer JS, 2002, MOL BIOL CELL, V13, P4308, DOI 10.1091/mbc.e02-04-0236; VERDE F, 1995, J CELL BIOL, V131, P1529, DOI 10.1083/jcb.131.6.1529	28	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12299	12304		10.1074/jbc.M413620200	http://dx.doi.org/10.1074/jbc.M413620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15665379	hybrid			2022-12-25	WOS:000227922000029
J	Castanheira, P; Samyn, B; Sergeant, K; Clemente, JC; Dunn, BM; Pires, E; Van Beeumen, J; Faro, C				Castanheira, P; Samyn, B; Sergeant, K; Clemente, JC; Dunn, BM; Pires, E; Van Beeumen, J; Faro, C			Activation, proteolytic processing, and peptide specificity of recombinant cardosin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC PROTEINASE; SUBSITE SPECIFICITY; PROTEASE; BARLEY; EXPRESSION; PURIFICATION; PROPHYTEPSIN; METHIONINE; PEPSINOGEN; PHYTEPSIN	Cardosins are model plant aspartic proteases, a group of proteases that are involved in cell death events associated with plant senescence and stress responses. They are synthesized as single- chain zymogens, and subsequent conversion into two-chain mature enzymes is a crucial step in the regulation of their activity. Here we describe the activation and proteolytic processing of recombinant procardosin A. The cleavage sites involved in this multi-step autocatalytic process were determined, some of them using a novel method for C- terminal sequence analysis. Even though the two- chain recombinant enzyme displayed similar properties as natural cardosin A, a single- chain mutant form was engineered based on the processing results and produced in Escherichia coli. Determination of its primary specificity using two combinatorial peptide libraries revealed that this mutant form behaved like the natural enzyme. The primary specificity of the enzyme closely resembles those of cathepsin D and plasmepsins, suggesting that cardosin A shares the same peptide scissile bond preferences of its vacuolar/ lysosomal mammalian and protozoan homologues.	Univ Coimbra, Fac Ciencias & Tecnol, Dept Bioquim, P-3000 Coimbra, Portugal; Univ Coimbra, Ctr Neurociencias & Biol Celular, P-3004517 Coimbra, Portugal; Univ Ghent, Dept Biochem Physiol & Microbiol, Lab Prot Biochem & Protein Engn, B-9000 Ghent, Belgium; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	Universidade de Coimbra; Universidade de Coimbra; Ghent University; State University System of Florida; University of Florida	Faro, C (corresponding author), Univ Coimbra, Fac Ciencias & Tecnol, Dept Bioquim, Apt 3126, P-3000 Coimbra, Portugal.	cfaro@imagem.ibili.uc.pt	sergeant, kjell/M-9789-2015; Sergeant, Kjell/E-5419-2012; Samyn, Bart/F-4149-2014; Castanheira, Pedro/A-1273-2011	sergeant, kjell/0000-0003-2071-3510; Sergeant, Kjell/0000-0003-2071-3510; Castanheira, Pedro/0000-0001-6764-1783; Pires, Euclides/0000-0002-5853-0165; Faro, Carlos/0000-0002-0480-8379				Alves MFM, 2003, BIOCHEM J, V373, P981, DOI 10.1042/BJ20030438; Beers EP, 2004, PHYTOCHEMISTRY, V65, P43, DOI 10.1016/j.phytochem.2003.09.005; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; Bernstein NK, 1999, CURR OPIN STRUC BIOL, V9, P684; Beyer BB, 2005, BIOCHEMISTRY-US, V44, P1768, DOI 10.1021/bi047886u; Bhatt D, 2000, BIOORG CHEM, V28, P374, DOI 10.1006/bioo.2001.1197; BOYD VL, 1992, ANAL BIOCHEM, V206, P344, DOI 10.1016/0003-2697(92)90376-I; Chen FQ, 1997, PLANT MOL BIOL, V35, P821, DOI 10.1023/A:1005833207707; CHEN Z, 1991, J BIOL CHEM, V266, P11718; Egas C, 2000, J BIOL CHEM, V275, P38190, DOI 10.1074/jbc.M006093200; Faro C, 1999, J BIOL CHEM, V274, P28724, DOI 10.1074/jbc.274.40.28724; FARO C, 2005, IN PRESS CURR PROTEI; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Kato Y, 2004, PLANTA, V220, P97, DOI 10.1007/s00425-004-1328-0; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; KOELSCH G, 1994, FEBS LETT, V343, P6, DOI 10.1016/0014-5793(94)80596-2; Koelsch G, 2000, BBA-PROTEIN STRUCT M, V1480, P117, DOI 10.1016/S0167-4838(00)00068-6; Lindholm P, 2000, MECH DEVELOP, V93, P169, DOI 10.1016/S0925-4773(00)00254-9; MUNFORD RS, 1995, J LIPID RES, V36, P1653; Murakami S, 2000, FEBS LETT, V468, P15, DOI 10.1016/S0014-5793(00)01186-8; Mutlu A, 1999, PHYSIOL PLANTARUM, V105, P569, DOI 10.1034/j.1399-3054.1999.105324.x; Nakano T, 1997, PLANT CELL, V9, P1673, DOI 10.1105/tpc.9.9.1673; Park H, 2001, BIOSCI BIOTECH BIOCH, V65, P702, DOI 10.1271/bbb.65.702; RamalhoSantos M, 1997, PLANTA, V203, P204, DOI 10.1007/s004250050183; Richter C, 1998, BIOCHEM J, V335, P481, DOI 10.1042/bj3350481; Runeberg-Roos P, 1998, PLANT J, V15, P139, DOI 10.1046/j.1365-313X.1998.00187.x; Samyn B, 2005, NAT METHODS, V2, P193, DOI 10.1038/NMETH738; Samyn B, 2000, ANAL CHEM, V72, P1389, DOI 10.1021/ac991049u; SANNY CG, 1975, J BIOL CHEM, V250, P2635; Simoes I, 2004, EUR J BIOCHEM, V271, P2067, DOI 10.1111/j.1432-1033.2004.04136.x; Tormakangas K, 2001, PLANT CELL, V13, P2021, DOI 10.1105/tpc.13.9.2021; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Verissimo P, 1996, EUR J BIOCHEM, V235, P762, DOI 10.1111/j.1432-1033.1996.00762.x; White PC, 1999, J BIOL CHEM, V274, P16685, DOI 10.1074/jbc.274.24.16685; Xia YJ, 2004, EMBO J, V23, P980, DOI 10.1038/sj.emboj.7600086	36	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13047	13054		10.1074/jbc.M412076200	http://dx.doi.org/10.1074/jbc.M412076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677463	hybrid			2022-12-25	WOS:000227922000115
J	LIn, XN; Varnai, P; Csordas, G; Balla, A; Nagai, T; Miyawaki, A; Balla, T; Hajnoczky, G				LIn, XN; Varnai, P; Csordas, G; Balla, A; Nagai, T; Miyawaki, A; Balla, T; Hajnoczky, G			Control of calcium signal propagation to the mitochondria by inositol 1,4,5-trisphosphate-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTICALLY INACTIVE PROTEIN; PLECKSTRIN HOMOLOGY DOMAIN; ENDOPLASMIC-RETICULUM; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MEMBRANE LOCALIZATION; RYANODINE RECEPTORS; CA2+; OSCILLATIONS; ACTIVATION; BINDING	Cytosolic Ca2+ ([Ca2+](c)) signals triggered by many agonists are established through the inositol 1,4,5-trisphosphate (IP3) messenger pathway. This pathway is believed to use Ca2+-dependent local interactions among IP3 receptors (IP3R) and other Ca2+ channels leading to coordinated Ca2+ release from the endoplasmic reticulum throughout the cell and coupling Ca2+ entry and mitochondrial Ca2+ uptake to Ca2+ release. To evaluate the role of IP3 in the local control mechanisms that support the propagation of [Ca2+](c) waves, storeoperated Ca2+ entry, and mitochondrial Ca2+ uptake, we used two IP3-binding proteins (IP3BP): 1) the PH domain of the phospholipase C-like protein, p130 (p130PH); and 2) the ligand-binding domain of the human type-IIP3R (IP3R224-605). As expected, p130PH-GFP and GFP-IP3R224-605 behave as effective mobile cytosolic IP3 buffers. In COS-7 cells, the expression of IP3BPs had no effect on store-operated Ca2+ entry. However, the IP3-linked [Ca2+] c signal appeared as a regenerative wave and IP3BPs slowed down the wave propagation. Most importantly, IP3BPs largely inhibited the mitochondrial [Ca2+] signal and decreased the relationship between the [Ca2+](c) and mitochondrial [Ca2+] signals, indicating disconnection of the mitochondria from the [Ca2+](c) signal. These data suggest that IP3 elevations are important to regulate the local interactions among IP3Rs during propagation of [Ca2+](c) waves and that the IP3-dependent synchronization of Ca2+ release events is crucial for the coupling between Ca2+ release and mitochondrial Ca2+ uptake.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Semmelweis Univ, Fac Med, Dept Physiol, H-1444 Budapest, Hungary; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; RIKEN, Brain Sci Inst, Adv Technol Dev Ctr, Lab Cell Funct & Dynam, Wako, Saitama 3510198, Japan	Jefferson University; Semmelweis University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); RIKEN	Hajnoczky, G (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 253 JAH, Philadelphia, PA 19107 USA.	Gyorgy.Hajnoczky@jefferson.edu	Miyawaki, Atsushi/K-3569-2014	Miyawaki, Atsushi/0000-0002-2329-3235; Balla, Andras/0000-0002-6450-2793; Csordas, Gyorgy/0000-0003-3156-1460; Balla, Tamas/0000-0002-9077-3335; Nagai, Takeharu/0000-0003-2650-9895	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bolsover S, 2001, BIOCHEM J, V356, P345, DOI 10.1042/0264-6021:3560345; Callamaras N, 1998, J PHYSIOL-LONDON, V509, P81, DOI 10.1111/j.1469-7793.1998.081bo.x; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Csordas G, 2001, CELL CALCIUM, V29, P249, DOI 10.1054/ceca.2000.0191; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 2000, J PHYSIOL-LONDON, V529, P69, DOI 10.1111/j.1469-7793.2000.00069.x; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; Kanematsu T, 2002, EMBO J, V21, P1004, DOI 10.1093/emboj/21.5.1004; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; Lee SB, 2004, J BIOL CHEM, V279, P24362, DOI 10.1074/jbc.M312772200; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; Ma HT, 2003, BIOCHEM J, V376, P667, DOI 10.1042/BJ20031345; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Putney JW, 2001, J CELL SCI, V114, P2223; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 2004, SCIENCE STKE; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Takeuchi H, 2000, BIOCHEM J, V349, P357, DOI 10.1042/0264-6021:3490357; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Varnai P, 2002, J BIOL CHEM, V277, P27412, DOI 10.1074/jbc.M109672200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Wagner J, 2004, CELL CALCIUM, V35, P433, DOI 10.1016/j.ceca.2003.10.009; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; Young KW, 2003, J BIOL CHEM, V278, P20753, DOI 10.1074/jbc.M211555200	49	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12820	12832		10.1074/jbc.M411591200	http://dx.doi.org/10.1074/jbc.M411591200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15644334	hybrid			2022-12-25	WOS:000227922000090
J	Thomae, TL; Stevens, EA; Bradfield, CA				Thomae, TL; Stevens, EA; Bradfield, CA			Transforming growth factor-beta 3 restores fusion in palatal shelves exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; EQUIVALENCY FACTORS TEFS; EDGE EPITHELIAL-CELLS; SPRAGUE-DAWLEY RATS; FOLLOW-UP; AH-RECEPTOR; POLYCHLORINATED-BIPHENYLS; YUCHENG CHILDREN; KNOCKOUT MICE; TCDD EXPOSURE	The pollutant, 2,3,7,8-tetrachlorodibenzo-p-dioxin ("dioxin"), has been implicated in the etiology of a wide variety of human birth defects. In an effort to identify pharmacological blockers of dioxin-induced terata, we performed a histological and microscopic analysis of the developing murine palate that had been exposed to dioxin. In both in vivo and in vitro model systems, we observed that dioxin exposure leads to a reduction in the number of filopodial extensions at the medial epithelial edge of the developing palate. Given that this filopodial aberration is similar to the phenotype observed in Tgf beta 3 null mice, a mutant known to display a 100% incidence of cleft palate, we examined the interaction between TGF beta 3 and dioxin in palatal fusion. We found that that the addition of TGF beta 3 to an in vitro palate culture model prevented the dioxin-induced reduction in filopodial density. Moreover, TGF beta 3 exposure completely prevented the dioxin-induced block of palatal fusion in this system. Although these data do not point to a direct cellular or molecular mechanism for TGF beta 3 dioxin antagonism, these results do suggest that TGF beta 3 or stimulators of this signaling pathway hold potential as antidotes for dioxin-induced terata and that this opposing pharmacology may extend to additional toxicological endpoints.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bradfield, CA (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	Bradfield@oncology.wisc.edu			NCI NIH HHS [P30-CA014520, T32-CA009135] Funding Source: Medline; NIEHS NIH HHS [R01 ES006883, R01-ES006883] Funding Source: Medline; NIGMS NIH HHS [T32 GM008692] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014520, T32CA009135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT BD, 1987, TERATOLOGY, V35, P329, DOI 10.1002/tera.1420350307; ABBOTT BD, 1989, TOXICOL APPL PHARM, V100, P119, DOI 10.1016/0041-008X(89)90096-3; ABBOTT BD, 1991, TERATOLOGY, V43, P119, DOI 10.1002/tera.1420430205; ARVIDSON K, 1988, SCANNING MICROSCOPY, V2, P385; ASSENNATO G, 1989, AM J IND MED, V16, P119, DOI 10.1002/ajim.4700160203; BERTAZZI PA, 1994, DIOXINS HLTH, P449; BIRNBAUM LS, 1995, ENVIRON HEALTH PERSP, V103, P89, DOI 10.2307/3432515; BJERKE DL, 1994, TOXICOL APPL PHARM, V127, P241, DOI 10.1006/taap.1994.1158; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; CARAMASCHI F, 1981, INT J EPIDEMIOL, V10, P135, DOI 10.1093/ije/10.2.135; Chen Yung-Cheng Joseph, 1992, Journal of the Formosan Medical Association, V91, P704; COURTNEY KD, 1971, TOXICOL APPL PHARM, V20, P396, DOI 10.1016/0041-008X(71)90282-1; COUTURE LA, 1990, TERATOLOGY, V42, P619, DOI 10.1002/tera.1420420606; DILIBERTO JJ, 1993, TOXICOL APPL PHARM, V120, P315, DOI 10.1006/taap.1993.1117; FERGUSON MWJ, 1987, IRISH J MED SCI, V156, P309, DOI 10.1007/BF02951261; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; Gato A, 2002, DEV BIOL, V250, P393, DOI 10.1006/dbio.2002.0792; Gonzalez FJ, 1995, TOXICOL LETT, V82-3, P117, DOI 10.1016/0378-4274(95)03548-6; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; GRANT WF, 1979, MUTAT RES, V65, P83, DOI 10.1016/0165-1110(79)90001-0; GUO YL, 1994, J TOXICOL ENV HEALTH, V41, P83, DOI 10.1080/15287399409531828; HSU ST, 1985, ENVIRON HEALTH PERSP, V59, P5, DOI 10.2307/3429867; Kaartinen V, 1997, DEV DYNAM, V209, P255, DOI 10.1002/(SICI)1097-0177(199707)209:3<255::AID-AJA1>3.0.CO;2-H; KLAASSEN CD, 1985, FUND APPL TOXICOL, V5, P806, DOI 10.1016/0272-0590(85)90164-2; KNUTSON JC, 1980, CELL, V22, P27, DOI 10.1016/0092-8674(80)90151-8; KURATSUN.M, 1971, HEALTH SERV REP, V86, P1083, DOI 10.2307/4594392; Kuratsune M, 1972, Environ Health Perspect, V1, P119, DOI 10.2307/3428163; Kuratsune M., 1989, HALOGENATED BIPHENYL, P381; LAI TJ, 1994, CHEMOSPHERE, V29, P2405, DOI 10.1016/0045-6535(94)90409-X; LAURIAULT VVM, 1991, MOL PHARMACOL, V40, P125; Loertscher JA, 2002, TOXICOL SCI, V68, P465, DOI 10.1093/toxsci/68.2.465; Loertscher JA, 2001, TOXICOL APPL PHARM, V175, P121, DOI 10.1006/taap.2001.9202; MACKAY D, 1992, ILLUSTRATED HDB PHYS, P195; Martinez-Alvarez C, 2000, INT J DEV BIOL, V44, P331; Martinez-Alvarez C, 2004, DEV BIOL, V265, P207, DOI 10.1016/j.ydbio.2003.09.022; Nawshad A, 2004, ARCH ORAL BIOL, V49, P675, DOI 10.1016/j.archoralbio.2004.05.007; Needham LL, 1999, ENVIRON RES, V80, pS200, DOI 10.1006/enrs.1998.3928; Paajarvi G, 2005, CARCINOGENESIS, V26, P201, DOI 10.1093/carcin/bgh289; Pisano MM, 2000, METH MOL B, V137, P267; PLUIM HJ, 1994, ACTA PAEDIATR, V83, P583; PLUIM HJ, 1993, ENVIRON HEALTH PERSP, V101, P504, DOI 10.2307/3431587; POLAND A, 1990, MOL PHARMACOL, V38, P306; POLAND A, 1980, MOL PHARMACOL, V17, P86; POLAND A, 1994, MOL PHARMACOL, V46, P915; PRATT RM, 1984, TERATOGEN CARCIN MUT, V4, P427, DOI 10.1002/tcm.1770040505; Rogan W.J., 1989, HALOGENATED BIPHENYL, P401; SAFE S, 1990, CRIT REV TOXICOL, V21, P51, DOI 10.3109/10408449009089873; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; SEILER JP, 1978, MUTAT RES, V55, P197, DOI 10.1016/0165-1110(78)90004-0; Signorini S, 2000, ANDROLOGIA, V32, P263, DOI 10.1046/j.1439-0272.2000.00394.x; Stellman JM, 2003, NATURE, V422, P681, DOI 10.1038/nature01537; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; Taya Y, 1999, DEVELOPMENT, V126, P3869; Tudela C, 2002, INT J DEV BIOL, V46, P333; Van den Berg M, 1998, ENVIRON HEALTH PERSP, V106, P775, DOI 10.1289/ehp.98106775; van Leeuven F. X. R., 1997, ORGANOHALOGEN COMPOU, V34, P237; van Leeuwen FXR, 2000, CHEMOSPHERE, V40, P1095, DOI 10.1016/S0045-6535(99)00358-6; Walker MK, 1996, FUND APPL TOXICOL, V30, P178, DOI 10.1006/faat.1996.0054; Wang XF, 1997, TOXICOL APPL PHARM, V147, P151, DOI 10.1006/taap.1997.8242; WASSOM J S, 1977, Mutation Research, V47, P141; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716; YAMASHITA F, 1985, ENVIRON HEALTH PERSP, V59, P41, DOI 10.2307/3429872; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019; Yoshizawa K, 2005, TOXICOL SCI, V83, P64, DOI 10.1093/toxsci/kfi016; Yu ML, 2000, INT J EPIDEMIOL, V29, P672, DOI 10.1093/ije/29.4.672; YU ML, 1991, NEUROTOXICOL TERATOL, V13, P195, DOI 10.1016/0892-0362(91)90011-K; YU MLM, 1994, CHEMOSPHERE, V29, P2413, DOI 10.1016/0045-6535(94)90410-3; Ziegler J, 1997, J NATL CANCER I, V89, P1184; ZOBER A, 1990, INT ARCH OCC ENV HEA, V62, P139, DOI 10.1007/BF00383591	72	35	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12742	12746		10.1074/jbc.M410780200	http://dx.doi.org/10.1074/jbc.M410780200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668235	hybrid			2022-12-25	WOS:000227922000081
J	Berkmen, M; Boyd, D; Beckwith, J				Berkmen, M; Boyd, D; Beckwith, J			The nonconsecutive disulfide bond of Escherichia coli phytase (AppA) renders it dependent on the protein-disulfide isomerase, DsbC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; ACID-PHOSPHATASE; ENDOPLASMIC-RETICULUM; PERIPLASMIC PROTEIN; CHAPERONE ACTIVITY; CRYSTAL-STRUCTURES; LIGHT-CHAINS; GENE; OXIDOREDUCTASES; IDENTIFICATION	The formation of protein disulfide bonds in the Escherichia coli periplasm by the enzyme DsbA is an inaccurate process. Many eukaryotic proteins with nonconsecutive disulfide bonds expressed in E. coli require an additional protein for proper folding, the disulfide bond isomerase DsbC. Here we report studies on a native E. coli periplasmic acid phosphatase, phytase ( AppA), which contains three consecutive and one nonconsecutive disulfide bonds. We show that AppA requires DsbC for its folding. However, the activity of an AppA mutant lacking its nonconsecutive disulfide bond is DsbC-independent. An AppA homolog, Agp, a periplasmic acid phosphatase with similar structure, lacks the nonconsecutive disulfide bond but has the three consecutive disulfide bonds found in AppA. The consecutively disulfide-bonded Agp is not dependent on DsbC but is rendered dependent by engineering into it the conserved nonconsecutive disulfide bond of AppA. Taken together, these results provide support for the proposal that proteins with nonconsecutive disulfide bonds require DsbC for full activity and that disulfide bonds are formed predominantly during translocation across the cytoplasmic membrane.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Beckwith, J (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	jbeckwith@hms.harvard.edu		Berkmen, Mehmet/0000-0002-9579-9745	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055090] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-55090] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BERGMAN LW, 1979, J SUPRAMOL STR CELL, V11, P9, DOI 10.1002/jss.400110103; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; BOQUET PL, 1987, J BACTERIOL, V169, P1663, DOI 10.1128/jb.169.4.1663-1669.1987; Braun P, 2001, J BIOL CHEM, V276, P26030, DOI 10.1074/jbc.M007122200; Chang JY, 2004, BIOCHEMISTRY-US, V43, P4522, DOI 10.1021/bi0360354; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Cottrill MA, 2002, CAN J MICROBIOL, V48, P801, DOI 10.1139/W02-076; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; DASSA E, 1982, J BIOL CHEM, V257, P6669; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DELORENZ.F, 1966, J BIOL CHEM, V241, P1562; Elksne L E, 1996, J Bacteriol, V178, P4306; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Garrett JB, 2004, APPL ENVIRON MICROB, V70, P3041, DOI 10.1128/AEM.70.5.3041-3046.2004; Golovan S, 2000, CAN J MICROBIOL, V46, P59, DOI 10.1139/cjm-46-1-59; GREINER R, 1993, ARCH BIOCHEM BIOPHYS, V303, P107, DOI 10.1006/abbi.1993.1261; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hiniker A, 2004, J BIOL CHEM, V279, P12967, DOI 10.1074/jbc.M311391200; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee DC, 2003, J BIOL CHEM, V278, P31412, DOI 10.1074/jbc.M213154200; Lim D, 2000, NAT STRUCT BIOL, V7, P108; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Miksch G, 2002, APPL MICROBIOL BIOT, V59, P685, DOI 10.1007/s00253-002-1071-z; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Rodriguez E, 2000, ARCH BIOCHEM BIOPHYS, V382, P105, DOI 10.1006/abbi.2000.2021; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; Sone M, 1997, J BIOL CHEM, V272, P10349; TOUATI E, 1986, MOL GEN GENET, V202, P257, DOI 10.1007/BF00331647	42	101	107	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11387	11394		10.1074/jbc.M411774200	http://dx.doi.org/10.1074/jbc.M411774200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15642731	hybrid			2022-12-25	WOS:000227761800061
J	Ismaili, N; Blind, R; Garabedian, MJ				Ismaili, N; Blind, R; Garabedian, MJ			Stabilization of the unliganded glucocorticoid receptor by TSG101	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DEPENDENT PHOSPHORYLATION; STEROID-RECEPTOR; GENE-EXPRESSION; BREAST-CANCER; PROTEIN; UBIQUITIN; ANDROGEN; TRANSACTIVATION; TRANSCRIPTION	The glucocorticoid receptor ( GR) has been shown to undergo hormone- dependent down- regulation via transcriptional, post- transcriptional, and posttranslational mechanisms. However, the mechanisms involved in modulating GR levels in the absence of hormone remain enigmatic. Here we demonstrate that TSG101, a previously identified GR- interacting protein, stabilizes the hypophosphorylated form of GR in the absence of ligand. We found that a non- phosphorylated version of GR ( S203A/ S211A) showed enhanced interaction with TSG101 as compared with the wild type GR, suggesting that TSG101 interacts more favorably with GR when it is not phosphorylated. A significant accumulation of GR S203A/ S211A protein is detected in the absence of ligand when TSG101 is overexpressed, whereas no increase in the wild type phosphorylated GR or phosphomimetic GR S203E/ S211E was observed in mammalian cells. In contrast, down- regulation of TSG101 expression by siRNA renders the hypophosphorylated form of GR unstable. We further show that TSG101 stabilizes GR by impeding its degradation by the proteasome and extending receptor half- life. Thus, in absence of a ligand, TSG101 binds GR and protects the non- phosphorylated receptor from degradation.	NYU, Sch Med, Dept Microbiol, Inst Canc, New York, NY 10016 USA; NYU, Sch Med, Dept Urol, Inst Canc, New York, NY 10016 USA	New York University; New York University	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol, Inst Canc, 550 1St Ave, New York, NY 10016 USA.	garabm01@med.nyu.edu		Blind, Raymond/0000-0002-1358-6309; ISMAILI, NAIMA/0000-0001-6662-8499				Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; BODWELL JE, 1995, J STEROID BIOCHEM, V52, P135, DOI 10.1016/0960-0760(94)00157-H; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; Burgdorf S, 2004, J BIOL CHEM, V279, P17524, DOI 10.1074/jbc.M313703200; CIDLOWSKI JA, 1982, ENDOCRINOLOGY, V110, P1653, DOI 10.1210/endo-110-5-1653; CIDLOWSKI JA, 1981, ENDOCRINOLOGY, V109, P1975; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hermoso MA, 2004, MOL CELL BIOL, V24, P4743, DOI 10.1128/MCB.24.11.4743-4756.2004; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOECK W, 1990, J BIOL CHEM, V265, P5403; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; Ismaili N, 2004, ANN NY ACAD SCI, V1024, P86, DOI 10.1196/annals.1321.007; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kawa SK, 1996, J STEROID BIOCHEM, V57, P259, DOI 10.1016/0960-0760(96)00001-5; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; Lee MP, 1997, CANCER RES, V57, P3131; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lu NZ, 2004, ANN NY ACAD SCI, V1024, P102, DOI 10.1196/annals.1321.008; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mohler JL, 1996, CLIN CANCER RES, V2, P889; Myers EL, 2002, J VIROL, V76, P11226, DOI 10.1128/JVI.76.22.11226-11235.2002; Oh H, 2002, P NATL ACAD SCI USA, V99, P5430, DOI 10.1073/pnas.082123999; ORTI E, 1989, J BIOL CHEM, V264, P9728; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pocuca N, 1998, J STEROID BIOCHEM, V66, P303, DOI 10.1016/S0960-0760(98)00057-0; Ponting CP, 1997, J MOL MED-JMM, V75, P467; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; SILVA CM, 1994, STEROIDS, V59, P436, DOI 10.1016/0039-128X(94)90013-2; SMITH JS, 1993, ENDOCRINOLOGY, V133, P1085, DOI 10.1210/en.133.3.1085; Stavreva DA, 2004, MOL CELL BIOL, V24, P2682, DOI 10.1128/MCB.24.7.2682-2697.2004; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Sundquist WI, 2004, MOL CELL, V13, P783, DOI 10.1016/S1097-2765(04)00129-7; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200; WANG Z, 2003, J BIOL CHEM; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Webster JC, 1997, J BIOL CHEM, V272, P9287; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Yamamoto K R, 1995, Harvey Lect, V91, P1	55	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11120	11126		10.1074/jbc.M500059200	http://dx.doi.org/10.1074/jbc.M500059200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657031	hybrid			2022-12-25	WOS:000227761800031
J	Jordan, JD; He, JC; Eungdamrong, NJ; Gomes, I; Ali, W; Nguyen, T; Bivona, TG; Philips, MR; Devi, LA; Iyengar, R				Jordan, JD; He, JC; Eungdamrong, NJ; Gomes, I; Ali, W; Nguyen, T; Bivona, TG; Philips, MR; Devi, LA; Iyengar, R			Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G alpha(o/i)-triggered proteasomal degradation of Rap1GAPII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; GROWTH CONE; PROTEIN; INHIBITION; NEURONS	The G alpha(o/i)-coupled CB1 cannabionoid receptor induces neurite outgrowth in Neuro-2A cells. The mechanisms of signaling through G alpha(o/i) to induce neurite outgrowth were studied. The expression of G alpha(o/i) reduces the stability of its direct interactor protein, Rap1GAPII, by targeting it for ubiquitination and proteasomal degradation. This results in the activation of Rap1. G alpha(o/i)-induced activation of endogenous Rap1 in Neuro-2A cells is blocked by the proteasomal inhibitor lactacystin. G alpha(o/i) stimulates neurite outgrowth that is blocked by the expression of dominant negative Rap1. Expression of Rap1GAPII also blocks the G alpha(o/i)-induced neurite outgrowth and treatment with proteasomal inhibitors potentiates this inhibition. The endogenous G alpha(o/i)-coupled cannabinoid ( CB1) receptor in Neuro-2A cells stimulates the degradation of Rap1GAPII; activation of Rap1 and treatment with pertussis toxin or lactacystin blocks these effects. The CB1 receptor-stimulated neurite outgrowth is blocked by treatment with pertussis toxin, small interfering RNA for Rap, lactacystin, and expression of Rap1GAPII. Thus, the G alpha(o/i)-coupled cannabinoid receptor, by regulating the proteasomal degradation of Rap1GAPII, activates Rap1 to induce neurite outgrowth.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; NYU Med Ctr, Dept Med, New York, NY 10029 USA; NYU Med Ctr, Dept Cell Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York University; New York University	Iyengar, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1215,1 Gustave Levy Pl, New York, NY 10029 USA.	ravi.iyengar@mssm.edu	Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776; Mark, Philips/0000-0002-1179-8156; Hwangpo, Tracy Anh/0000-0002-4851-599X; Jordan, Dedrick/0000-0002-0706-9583	NHLBI NIH HHS [HL-007824] Funding Source: Medline; NIDA NIH HHS [DA-00458, DA-05798, DA-08863] Funding Source: Medline; NIGMS NIH HHS [GM-54508, GM-55279] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F30DA005798, R56DA008863, R37DA008863, R01DA008863] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Carey KD, 2002, METHOD ENZYMOL, V345, P383; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Lotto B, 1999, NEUROSCI LETT, V269, P87, DOI 10.1016/S0304-3940(99)00422-X; Meng JW, 2002, J BIOL CHEM, V277, P43417, DOI 10.1074/jbc.M204074200; MINANA MD, 1990, P NATL ACAD SCI USA, V87, P4335, DOI 10.1073/pnas.87.11.4335; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Reinoso BS, 1996, J NEUROSCI RES, V43, P439, DOI 10.1002/(SICI)1097-4547(19960215)43:4<439::AID-JNR5>3.0.CO;2-G; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; Tsygankova OM, 2004, J BIOL CHEM, V279, P5501, DOI 10.1074/jbc.M305824200; Wu G, 1998, J NEUROCYTOL, V27, P1, DOI 10.1023/A:1006910001869; Xiang Y, 2002, NAT NEUROSCI, V5, P843, DOI 10.1038/nn899	23	90	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11413	11421		10.1074/jbc.M411521200	http://dx.doi.org/10.1074/jbc.M411521200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657046	hybrid			2022-12-25	WOS:000227761800064
J	Leonard, JL; Simpson, G; Leonard, DM				Leonard, JL; Simpson, G; Leonard, DM			Characterization of the protein dimerization domain responsible for assembly of functional selenodeiodinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II IODOTHYRONINE 5-DEIODINASE; RAT-KIDNEY; 5'-DEIODINASE ACTIVITY; SDS-PAGE; DEIODINASE; ENZYME; LIVER; SOLUBILIZATION; LOCALIZATION; ASTROCYTES	Thyroid hormone metabolism is catalyzed by a small family of selenoenzymes. Type I deiodinase (D1) is the best characterized family member and is an integral membrane protein composed of two 27-kDa subunits that assemble to a functional holoenzyme after translation. To characterize the protein domain(s) responsible for this post-translational assembly event, we used deletion/truncation analysis coupled with immune depletion assays to map the dimerization domain of D1. The results of our studies show that a highly conserved sequence of 16 amino acids in the C-terminal half of the D1 subunit, -(DFL)-F-148-YI-EAH-DGW(163), serves as the dimerization domain. Based on the high conservation of this domain, we synthesized a novel bait peptide-green fluorescent protein fusion probe (DDDGFP) to examine holoenzyme assembly of other family members. Overexpression of either the DDDGFP or an inert D1 subunit (M4) into SeD2 (accession number U53505)-expressing C6 cells specifically led to the loss of > 90% of the catalytic activity. Catalytically inactive D2 heterodimers composed of SeD2: DDDGFP subunits were rescued by specific immune precipitation with anti-SeD2 IgG, suggesting that SeD2 requires two functional subunits to assemble a catalytically active holoenzyme. These findings identify and characterize the essential dimerization domain responsible for post-translational assembly of selenodeiodinases and show that family members can intermingle through this highly conserved protein domain.	Univ Massachusetts, Sch Med, Dept Cell & Mol Physiol, Mol Endocrinol Lab, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Leonard, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Cell & Mol Physiol, Mol Endocrinol Lab, 55 Lake Ave N, Worcester, MA 01655 USA.	jack.leonard@umassmed.edu						BECKER KB, 1995, ENDOCRINOLOGY, V136, P4424, DOI 10.1210/en.136.10.4424; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; BRINKE DAD, 1979, BIOCHEM J, V180, P273; Callebaut I, 2003, J BIOL CHEM, V278, P36887, DOI 10.1074/jbc.M305725200; CAREY MC, 1972, ARCH INTERN MED, V130, P506, DOI 10.1001/archinte.130.4.506; CROTEAU W, 1995, J BIOL CHEM, V270, P16569, DOI 10.1074/jbc.270.28.16569; Crow MK, 2001, BIOTECHNIQUES, V30, P311, DOI 10.2144/01302st04; Curcio-Morelli C, 2003, ENDOCRINOLOGY, V144, P937, DOI 10.1210/en.2002-220960; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; Farwell AP, 1996, J BIOL CHEM, V271, P16369, DOI 10.1074/jbc.271.27.16369; FEKKES D, 1983, BIOCHIM BIOPHYS ACTA, V742, P324, DOI 10.1016/0167-4838(83)90318-7; FEKKES D, 1980, BIOCHIM BIOPHYS ACTA, V613, P41, DOI 10.1016/0005-2744(80)90190-4; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; Kohrle J, 2002, METHOD ENZYMOL, V347, P125; Kohrle Josef, 2004, Z Arztl Fortbild Qualitatssich, V98 Suppl 5, P17; KUMAR MA, 1992, BIOTECHNIQUES, V12, P198; LEONARD JL, 1991, J BIOL CHEM, V266, P11262; LEONARD JL, 1981, BIOCHIM BIOPHYS ACTA, V659, P205, DOI 10.1016/0005-2744(81)90285-0; Leonard JL, 1999, ENDOCRINOLOGY, V140, P2206, DOI 10.1210/en.140.5.2206; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; LEONARD JL, 1980, ENDOCRINOLOGY, V107, P1376, DOI 10.1210/endo-107-5-1376; Leonard JL, 2001, J BIOL CHEM, V276, P2600, DOI 10.1074/jbc.M006973200; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P2137, DOI 10.1210/endo-103-6-2137; Leonard JL, 1986, THYROID HORMONE META, P189; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; VISSER TJ, 1976, BIOCHEM J, V157, P479, DOI 10.1042/bj1570479; Zhang XC, 1996, J BIOCHEM BIOPH METH, V31, P145, DOI 10.1016/0165-022X(95)00032-M	30	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11093	11100		10.1074/jbc.M500011200	http://dx.doi.org/10.1074/jbc.M500011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659403	hybrid			2022-12-25	WOS:000227761800027
J	Marshall, S; Nadeau, O; Yamasaki, K				Marshall, S; Nadeau, O; Yamasaki, K			Glucosamine-induced activation of glycogen biosynthesis in isolated adipocytes - Evidence for a rapid allosteric control mechanism within the hexosamine biosynthesis pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; UDP-N-ACETYLGLUCOSAMINE; DEPENDENT DIABETES-MELLITUS; SKELETAL-MUSCLE; IN-VIVO; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; INDUCED DESENSITIZATION; TRANSPORT SYSTEM; AMINO-ACIDS; SYNTHASE	Enhanced flux through the hexosamine biosynthesis pathway (HBP) induces insulin resistance and facilitates lipid storage through the up-regulation of enzyme mRNA levels. Both actions occur over several hours and require gene expression. We now identify a regulatory arm of the HBP that involves rapid allosteric activation of glycogen synthase (GS) and stimulation of glycogen biosynthesis (GBS). When insulin-pretreated adipocytes were exposed to 2 mM GlcN, incorporation of [C-14] glucose into glycogen doubled by 10 min (t(1/2) of < 5 min), whereas UDP-glucose levels were concomitantly decreased during this time (t(1/2) of 1.4 min; > 90% depletion). Stimulation of GBS and depletion of UDP-glucose both correlated with an early and rapid rise in the levels of glucosamine-6-phosphate (GlcN-6-P), a known activator of GS. The lowering of GlcN-6-P levels by removing extracellular GlcN (> 80% reduction by 45 min) was accompanied by the restoration of UDP-glucose levels. Prolonged GlcN treatment (20 min to 2 h) inhibited GBS, which corresponded to a massive intracellular accumulation of GlcN-6-P (t(1/2) of similar to 32 min; > 1,400 nmol/g). From these data, we conclude the following. 1) GlcN treatment elevated intracellular GlcN-6-P levels within minutes, resulting in allosteric activation of GS, stimulation of GBS, and a reduction in steady-state levels of UDP-glucose due to increased precursor utilization. 2) Prolonged treatment with high concentrations of GlcN caused massive accumulation of GlcN-6-P that adversely affected cellular metabolism and reduced GBS. 3) The biphasic actions of GlcN on GBS may explain many of the discrepant reports on the role of the HBP in glycogen metabolism.	Hexos Inc, Woodinville, WA 98072 USA		Marshall, S (corresponding author), Hexos Inc, 18304 NE 153rd St, Woodinville, WA 98072 USA.	Hexos@comcast.net		Yamasaki, Kazumitsu/0000-0002-8414-2393				Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Bouche C, 2004, ENDOCR REV, V25, P807, DOI 10.1210/er.2003-0026; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Broschat KO, 2002, J BIOL CHEM, V277, P14764, DOI 10.1074/jbc.M201056200; Bulik DA, 2000, J BIOL CHEM, V275, P14722, DOI 10.1074/jbc.275.19.14722; Ciaraldi TP, 1999, ENDOCRINOLOGY, V140, P3971, DOI 10.1210/en.140.9.3971; CROOK ED, 1995, DIABETES, V44, P314, DOI 10.2337/diabetes.44.3.314; Crook ED, 1996, DIABETES, V45, P322, DOI 10.2337/diabetes.45.3.322; GIACCARI A, 1995, DIABETOLOGIA, V38, P518, DOI 10.1007/BF00400719; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; KANJI MI, 1976, J BIOL CHEM, V251, P2258; Karam JH, 1996, HORM METAB RES, V28, P440, DOI 10.1055/s-2007-979834; Kruszynska YT, 1996, J INVEST MED, V44, P413; LARALEMUS R, 1992, ARCH BIOCHEM BIOPHYS, V297, P213, DOI 10.1016/0003-9861(92)90664-I; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; Marshall S, 2004, J BIOL CHEM, V279, P35313, DOI 10.1074/jbc.M404133200; Marshall S, 2000, DIABETES ANNUAL/13, P97; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MARSHALL S, 1991, FASEB J, V5, P3031, DOI 10.1096/fasebj.5.15.1743436; MARSHALL S, 2002, CURR OPIN ENDOCRINOL, V9, P160; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MCCLAIN DA, 2001, CURR OPIN ENDOCRINOL, V9, P186; Obici S, 2003, ENDOCRINOLOGY, V144, P5172, DOI 10.1210/en.2003-0999; Parker G, 2004, J BIOL CHEM, V279, P20636, DOI 10.1074/jbc.M312139200; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROPSON IJ, 1988, J BIOL CHEM, V263, P11697; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Rossetti Luciano, 1996, P544; Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SIMONSON DC, 1997, INT TXB DIABETES MEL, P713; SMITH RL, 1985, J BIOL CHEM, V260, P273; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; Virkamaki A, 1999, DIABETES, V48, P1101, DOI 10.2337/diabetes.48.5.1101; Virkamaki A, 1997, ENDOCRINOLOGY, V138, P2501, DOI 10.1210/en.138.6.2501; VUORINENMARKKOLA H, 1992, DIABETES, V41, P571, DOI 10.2337/diabetes.41.5.571; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415	41	20	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11018	11024		10.1074/jbc.M413499200	http://dx.doi.org/10.1074/jbc.M413499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647256	hybrid			2022-12-25	WOS:000227761800018
J	Wittchen, ES; Worthylake, RA; Kelly, P; Casey, PJ; Quilliam, LA; Burridge, K				Wittchen, ES; Worthylake, RA; Kelly, P; Casey, PJ; Quilliam, LA; Burridge, K			Rap1 GTPase inhibits leukocyte transmigration by promoting endothelial barrier function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; EPITHELIAL-CELLS; VASCULAR ENDOTHELIUM; ADHERENS JUNCTIONS; TIGHT JUNCTIONS; EXCHANGE FACTOR; RHO-GTPASES; ADHESION; ACTIVATION; PROTEIN	The passage of leukocytes out of the blood circulation and into tissues is necessary for the normal inflammatory response, but it also occurs inappropriately in many pathological situations. This process is limited by the barrier presented by the junctions between adjacent endothelial cells that line blood vessels. Here we show that activation of the Rap1 GTPase in endothelial cells accelerated de novo assembly of endothelial cell-cell junctions and increased the barrier function of endothelial monolayers. In contrast, depressing Rap1 activity by expressing Rap1GAP led to disassembly of these junctions and increased their permeability. We also demonstrate that endogenous Rap1 was rapidly activated at early stages of junctional assembly, confirming the involvement of Rap1 during junctional assembly. Intriguingly, elevating Rap1 activity selectively within endothelial cells decreased leukocyte transendothelial migration, whereas inhibiting Rap1 activity by expression of Rap1GAP increased leukocyte transendothelial migration, providing physiological relevance to our hypothesis that Rap1 augments barrier function of interendothelial cell junctions. Furthermore, these results suggest that Rap1 may be a novel therapeutic target for clinical conditions in which an inappropriate inflammatory response leads to disease.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Chapel Hill, NC 27599 USA; Louisiana State Univ, Dept Pharmacol, Shreveport, LA 71130 USA; Duke Univ, Ctr Med, Dept Pharmacol, Durham, NC 27710 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46208 USA; Indiana Univ, Walther Canc Inst, Dept Biochem & Mol Biol, Indianapolis, IN 46208 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Duke University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Wittchen, ES (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, 12-026 Lineberger Canc Ctr, Chapel Hill, NC 27599 USA.	erika_wittchen@med.unc.edu		Casey, Patrick/0000-0002-7366-9309	NCI NIH HHS [CA100869] Funding Source: Medline; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIDCR NIH HHS [DE13079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100869] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Balduini A, 2004, EXP CELL RES, V300, P84, DOI 10.1016/j.yexcr.2004.07.011; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CRONE C, 1982, BRAIN RES, V241, P49, DOI 10.1016/0006-8993(82)91227-6; Cullere X, 2005, BLOOD, V105, P1950, DOI 10.1182/blood-2004-05-1987; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Edens HA, 2000, ADV DRUG DELIVER REV, V41, P315, DOI 10.1016/S0169-409X(00)00049-1; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Hauert AB, 2002, INT J BIOCHEM CELL B, V34, P838, DOI 10.1016/S1357-2725(02)00010-9; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kinashi T, 2004, BLOOD, V103, P1033, DOI 10.1182/blood-2003-07-2499; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; Mitra RS, 2003, ONCOGENE, V22, P6243, DOI 10.1038/sj.onc.1206534; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; MOY AB, 1993, J CLIN INVEST, V92, P1198, DOI 10.1172/JCI116690; Moy AB, 1998, AM J PHYSIOL-LUNG C, V274, pL1024, DOI 10.1152/ajplung.1998.274.6.L1024; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; STEVENSON BR, 1988, J CELL BIOL, V107, P2401, DOI 10.1083/jcb.107.6.2401; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Vestweber D, 2002, CURR OPIN CELL BIOL, V14, P587, DOI 10.1016/S0955-0674(02)00372-1; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; Wittchen ES, 2003, MOL BIOL CELL, V14, P1757, DOI 10.1091/mbc.E02-08-0486; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Yamamoto T, 1999, BIOCHEM BIOPH RES CO, V259, P103, DOI 10.1006/bbrc.1999.0731; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	43	140	142	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11675	11682		10.1074/jbc.M412595200	http://dx.doi.org/10.1074/jbc.M412595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15661741	Green Published, hybrid			2022-12-25	WOS:000227761800096
J	Yu, HJ; Liu, JQ; Bock, A; Li, J; Luo, GM; Shen, JC				Yu, HJ; Liu, JQ; Bock, A; Li, J; Luo, GM; Shen, JC			Engineering glutathione transferase to a novel glutathione peroxidase mimic with high catalytic efficiency - Incorporation of selenocysteine into a glutathione-binding scaffold using an auxotrophic expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASES; ACTIVE-SITE; SUBSTITUTING SELENOCYSTEINE; ESCHERICHIA-COLI; LUCILIA-CUPRINA; SELENOSUBTILISIN; HYDROPEROXIDE; PURIFICATION; GENERATION; MECHANISM	Glutathione peroxidase (GPx, EC 1.11.1.9) protects cells against oxidative damage by catalyzing the reduction of hydroperoxides with glutathione (GSH). Several attempts have been made to imitate its function for mechanical study and for its pharmacological development as an antioxidant. By replacing the active site serine 9 with a cysteine and then substituting it with selenocysteine in a cysteine auxotrophic system, catalytically essential residue selenocysteine was bioincorporated into GSH-specific binding scaffold, and thus, glutathione S-transferase (GST, EC 2.5.1.18) from Lucilia cuprina was converted into a selenium-containing enzyme, seleno-LuGST1-1, by genetic engineering. Taking advantage of the important structure similarities between seleno-LuGST1-1 and naturally occurring GPx in the specific GSH binding sites and the geometric conformation for the active selenocysteine in their common GSH binding domain-adopted thioredoxin fold, the as-generated selenoenzyme displayed a significantly high efficiency for catalyzing the reduction of hydrogen peroxide by glutathione, being comparable with those of natural GPxs. The catalytic behaviors of this engineered selenoenzyme were found to be similar to those of naturally occurring GPx. It exhibited pH and temperature-dependent catalytic activity and a typical ping-pong kinetic mechanism. Engineering GST into an efficient GPx-like biocatalyst provided new proof for the previous assumption that both GPx and GST were evolved from a common thioredoxin-like ancestor to accommodate different functions throughout evolution.	Jilin Univ, Minist Educ, Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China; Univ Munich, Lehrstuhl Mikrobiol, D-80638 Munich, Germany; Jilin Univ, Minist Educ, Key Lab Mol Enzymol & Engn, Changchun 130023, Peoples R China	Jilin University; University of Munich; Jilin University	Liu, JQ (corresponding author), Jilin Univ, Minist Educ, Key Lab Supramol Struct & Mat, 10 Qianwei Rd, Changchun 130012, Peoples R China.	jqliu2000@yahoo.com						*AM PHARM BIOT, 1992, HOEF SCI INSTR MAN, P5; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; BELL IM, 1993, BIOCHEMISTRY-US, V32, P3754, DOI 10.1021/bi00065a030; BOARD P, 1994, BIOCHEM J, V299, P425, DOI 10.1042/bj2990425; BOARD PG, 1995, BIOCHEM J, V311, P247, DOI 10.1042/bj3110247; BOARD PG, 1987, BIOCHEM J, V248, P937, DOI 10.1042/bj2480937; Boschi-Muller S, 1998, FEBS LETT, V439, P241, DOI 10.1016/S0014-5793(98)01377-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caccuri AM, 1997, J BIOL CHEM, V272, P29681, DOI 10.1074/jbc.272.47.29681; CHU FF, 1993, J BIOL CHEM, V268, P2571; COTGREAVE IA, 1992, BIOCHEM PHARMACOL, V43, P793, DOI 10.1016/0006-2952(92)90245-E; DeSantis G, 1999, CURR OPIN BIOTECH, V10, P324, DOI 10.1016/S0958-1669(99)80059-7; Ding L, 1998, BIOCHEM J, V332, P251, DOI 10.1042/bj3320251; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; Flohe L, 1989, COENZYMES COFACTORS, P644; FLOHE L, 1971, HOPPESEYLERS Z PHYSL, V353, P151; FORSTROM JW, 1978, BIOCHEMISTRY-US, V17, P2639, DOI 10.1021/bi00606a028; Habig W H, 1981, Methods Enzymol, V77, P398; Hazebrouck S, 2000, J BIOL CHEM, V275, P28715, DOI 10.1074/jbc.M004985200; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; Liu JQ, 1999, CHEM COMMUN, P199, DOI 10.1039/a808347i; LUO GM, 1994, BIOCHEM BIOPH RES CO, V198, P1240, DOI 10.1006/bbrc.1994.1175; MA WC, 1993, CHIN BIOCH J, V9, P234; MANNERVIK B, 1985, METHOD ENZYMOL, V113, P490; Mannervik B, 1998, CHEM-BIOL INTERACT, V112, P15, DOI 10.1016/S0009-2797(97)00147-6; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Mugesh G, 2000, CHEM SOC REV, V29, P347, DOI 10.1039/a908114c; MULLER S, 1994, BIOCHEMISTRY-US, V33, P3404, DOI 10.1021/bi00177a034; Qi DF, 2001, CHEM REV, V101, P3081, DOI 10.1021/cr000059o; Ren XJ, 2002, CHEM BIOL, V9, P789, DOI 10.1016/S1074-5521(02)00167-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Takebe G, 2002, J BIOL CHEM, V277, P41254, DOI 10.1074/jbc.M202773200; URSINI F, 1995, METHOD ENZYMOL, V252, P38; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; WILSON SR, 1989, J AM CHEM SOC, V111, P5936, DOI 10.1021/ja00197a065; WU ZP, 1990, J AM CHEM SOC, V112, P5647, DOI 10.1021/ja00170a043; YAMAMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P541, DOI 10.1006/abbi.1993.1458	40	83	86	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11930	11935		10.1074/jbc.M408574200	http://dx.doi.org/10.1074/jbc.M408574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15649895	hybrid			2022-12-25	WOS:000227761800123
J	Jia, YZ; Qi, C; Zhang, ZY; Zhu, YT; Rao, SM; Zhu, YJ				Jia, YZ; Qi, C; Zhang, ZY; Zhu, YT; Rao, SM; Zhu, YJ			Peroxisome proliferator-activated receptor-binding protein null mutation results in defective mammary gland development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PROGESTERONE-RECEPTOR; NUCLEAR RECEPTORS; COACTIVATOR; BREAST; ESTROGEN; PBP; DIFFERENTIATION; IDENTIFICATION; TUMORIGENESIS	A conditional null mutation of peroxisome proliferator-activated receptor-binding protein (PBP) gene was generated to understand its role in mammary gland development. PBP-deficient mammary glands exhibited retarded ductal elongation during puberty, and decreased alveolar density during pregnancy and lactation. PBP- deficient mammary glands could not produce milk to nurse pups during lactation. Both the mammary ductal elongation in response to estrogen treatment and the mammary lobuloalveolar proliferation stimulated by estrogen plus progesterone were attenuated in PBP-deficient mammary glands. The proliferation index was decreased in PBP-deficient mammary glands. PBP- deficient mammary epithelial cells expressed abundant beta-casein, whey acidic protein, and WDNM1 mRNA, indicating a relatively intact differentiated function. PBP-deficient epithelial cells were unable to form mammospheres, which were considered to be derived from mammary progenitor/stem cells. We conclude that PBP plays a pivotal role in the normal mammary gland development.	Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Zhu, YJ (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Av, Chicago, IL 60611 USA.	y-zhu2@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA088898, R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84472, CA 88898] Funding Source: Medline; NIEHS NIH HHS [K08 ES 00356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baum M, 1998, BRIT J CANCER, V78, P1, DOI 10.1038/bjc.1998.753; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2002, J MAMMARY GLAND BIOL, V7, P39, DOI 10.1023/A:1015718406329; Brisken C, 2000, GENE DEV, V14, P650; Charpentier AH, 2000, CANCER RES, V60, P5977; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gallahan D, 1996, CANCER RES, V56, P1775; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Jain S, 1998, AM J PATHOL, V153, P349, DOI 10.1016/S0002-9440(10)65577-0; Jia YZ, 2004, J BIOL CHEM, V279, P24427, DOI 10.1074/jbc.M402391200; JORDAN VC, 1988, CRC CR REV CL LAB SC, V26, P97, DOI 10.3109/10408368809106860; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Maden M, 2000, P NUTR SOC, V59, P65, DOI 10.1017/S0029665100000082; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Medina D, 2001, CANCER LETT, V169, P1, DOI 10.1016/S0304-3835(01)00507-9; Morriss-Kay GM, 1999, INT REV CYTOL, V188, P73; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Murphy LC, 2002, BIOMED PHARMACOTHER, V56, P65, DOI 10.1016/S0753-3322(01)00157-3; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nass SJ, 1999, HEMATOL ONCOL CLIN N, V13, P311, DOI 10.1016/S0889-8588(05)70058-7; Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Qi C, 2004, J BIOL CHEM, V279, P33696, DOI 10.1074/jbc.M401266200; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YANG J, 1980, P NATL ACAD SCI-BIOL, V77, P2088, DOI 10.1073/pnas.77.4.2088; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	41	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10766	10773		10.1074/jbc.M413331200	http://dx.doi.org/10.1074/jbc.M413331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647257	hybrid			2022-12-25	WOS:000227559600123
J	Morrison, MD; Reiley, W; Zhang, MY; Sun, SC				Morrison, MD; Reiley, W; Zhang, MY; Sun, SC			An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-kappa B signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B2 P100; CD40; SURVIVAL; KINASE; EXPRESSION; GENE; PROTEINS; SYSTEM; LIGAND; IKK	BAFF receptor (BAFFR) is a member of the TNF receptor ( TNFR) superfamily that regulates the survival and maturation of B cells. BAFFR exerts its signaling function by inducing activation of NF-kappa B, although the underlying mechanism has not been well defined. By using a chimeric BAFFR, we show that BAFFR preferentially induces the noncanonical NF-kappa B signaling pathway. This specific function of BAFFR is mediated by a sequence motif, PVPAT, which is homologous to the TRAF-binding site (PVQET) present in CD40, a TNFR known to induce both the canonical and noncanonical NF-kappa B pathways. Mutation of this putative TRAF-binding motif within BAFFR abolishes its interaction with TRAF3 as well as its ability to induce noncanonical NF-kappa B. Interestingly, modification of the PVPAT sequence to the typical TRAF-binding sequence, PVQET, is sufficient to render the BAFFR capable of inducing strong canonical NF-kappa B signaling. Further, this functional acquisition of the modified BAFFR is associated with its stronger and more rapid association with TRAF3. These findings suggest that the PVPAT sequence of BAFFR not only functions as a key signaling motif of BAFFR but also determines its signaling specificity in the induction of the noncanonical NF-kappa B pathway.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NATIONAL CANCER INSTITUTE [R01CA094922, T32CA060395] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA60395-09, CA94922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; D'Souza BN, 2004, J VIROL, V78, P1800, DOI 10.1128/JVI.78.4.1800-1816.2004; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HAMANO T, 1982, J IMMUNOL, V129, P1403; Hatada EN, 2003, J IMMUNOL, V171, P761, DOI 10.4049/jimmunol.171.2.761; Haxhinasto SA, 2002, J IMMUNOL, V169, P1145, DOI 10.4049/jimmunol.169.3.1145; Hostager BS, 2002, J IMMUNOL, V168, P3318, DOI 10.4049/jimmunol.168.7.3318; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Mackay F, 2004, CURR OPIN PHARMACOL, V4, P347, DOI 10.1016/j.coph.2004.02.009; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Manning E, 2002, EUR J IMMUNOL, V32, P39, DOI 10.1002/1521-4141(200201)32:1<39::AID-IMMU39>3.0.CO;2-Y; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Patke A, 2004, CURR OPIN IMMUNOL, V16, P251, DOI 10.1016/j.coi.2004.01.007; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Sasaki Y, 2004, J IMMUNOL, V173, P2245, DOI 10.4049/jimmunol.173.4.2245; Shulga-Morskaya S, 2004, J IMMUNOL, V173, P2331, DOI 10.4049/jimmunol.173.4.2331; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Trescol-Biemont MC, 2004, BIOCHIMIE, V86, P287, DOI 10.1016/j.biochi.2004.04.001; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xu LG, 2002, J IMMUNOL, V169, P6883, DOI 10.4049/jimmunol.169.12.6883; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101	42	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10018	10024		10.1074/jbc.M413634200	http://dx.doi.org/10.1074/jbc.M413634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644327	hybrid			2022-12-25	WOS:000227559600035
J	Xin, MG; Deng, XM				Xin, MG; Deng, XM			Nicotine inactivation of the proapoptotic function of Bax through phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG-CANCER; BCL-2 FAMILY-MEMBERS; INDUCED APOPTOSIS; MITOCHONDRIA; PROTEIN; UBIQUITINATION; TRANSLOCATION; DEGRADATION; SURVIVAL; SMOKING	Nicotine-induced cell survival is associated with chemoresistance of human lung cancer cells, but our understanding of the intracellular mechanism(s) is fragmentary. Bax is a major proapoptotic member of the Bcl2 family and a molecule required for apoptotic cell death. Growth factor (i.e. granulocyte-macrophage colony-stimulating factor)-induced phosphorylation of Bax has been reported to negatively regulate its proapoptotic function. Because Bax is ubiquitously expressed in both small cell lung cancer and non-small cell lung cancer cells, nicotine may mimic growth factor( s) to regulate the activity of Bax. We found that nicotine potently induces Bax phosphorylation at Ser-184, which results in abrogation of the proapoptotic activity of Bax and increased cell survival. AKT, a known physiological Bax kinase, is activated by nicotine, co-localizes with Bax in the cytoplasm, and can directly phosphorylate Bax in vitro. Treatment of cells with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 or specific depletion of AKT expression by RNA interference can block both nicotine-induced Bax phosphorylation and cell survival. Importantly, nicotine-induced Bax phosphorylation potently blocks stress-induced translocation of Bax from cytosol to mitochondria, impairs Bax insertion into mitochondrial membranes, and reduces the half-life of Bax protein (i.e. from 9-12 h to < 6 h). Because knockdown of Bax expression by gene silencing results in prolonged cell survival following treatment with cisplatin in the absence or presence of nicotine, Bax may be an essential component in the nicotine survival signaling pathway. Thus, nicotine-induced survival and chemoresistance of human lung cancer cells may occur in a novel mechanism involving activation of PI3K/AKT that directly phosphorylates and inactivates the proapoptotic function of Bax.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu	高, 雨莉/HGU-8187-2022					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; *AM CANC SOC, 2003, CANC FACTS FIG, P13; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Dresler CM, 2003, LUNG CANCER-J IASLC, V39, P119, DOI 10.1016/S0169-5002(02)00455-5; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Eldering E, 2004, EUR J IMMUNOL, V34, P1950, DOI 10.1002/eji.200324817; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Groeger AM, 2001, ANTICANCER RES, V21, P3627; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Heusch WL, 1998, CARCINOGENESIS, V19, P551, DOI 10.1093/carcin/19.4.551; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; Maki CG, 1996, CANCER RES, V56, P2649; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; OLTVAI ZN, 1993, CELL, V74, P619; PARK PG, 1995, CANCER RES, V55, P3504; Perissin L, 1996, ANTICANCER RES, V16, P3409; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schuller HM, 2002, NAT REV CANCER, V2, P455, DOI 10.1038/nrc824; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	47	182	210	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10781	10789		10.1074/jbc.M500084200	http://dx.doi.org/10.1074/jbc.M500084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642728	hybrid			2022-12-25	WOS:000227559600125
J	Dey, S; Grant, GA; Sacchettini, JC				Dey, S; Grant, GA; Sacchettini, JC			Crystal structure of Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOGLYCERATE DEHYDROGENASE; PHOSPHOGLYCERATE DEHYDROGENASE; SERINE BIOSYNTHESIS; BACILLUS-SUBTILIS; ELECTRON-DENSITY; PURIFICATION; INHIBITION; RESOLUTION; PATHWAYS; PRODUCT	Phosphoglycerate dehydrogenases exist in at least three different structural motifs. The first D-3-phosphoglycerate dehydrogenase structure to be determined was from Escherichia coli and is a tetramer composed of identical subunits that contain three discernable structural domains. The crystal structure of D-3-phosphoglycerate dehydrogenase from Mycobacterium tuberculosis has been determined at 2.3 angstrom. This enzyme represents a second structural motif of the D-3-phosphoglycerate dehydrogenase family, one that contains an extended C-terminal region. This structure is also a tetramer of identical subunits, and the extended motif of 135 amino acids exists as a fourth structural domain. This intervening domain exerts quite a surprising characteristic to the structure by introducing significant asymmetry in the tetramer. The asymmetric unit is composed of two identical subunits that exist in two different conformations characterized by rotation of -180 degrees around a hinge connecting two of the four domains. This asymmetric arrangement results in the formation of two different and distinct domain interfaces between identical domains in the asymmetric unit. As a result, the surface of the intervening domain that is exposed to solvent in one subunit is turned inward in the other subunit toward the center of the structure where it makes contact with other structural elements. Significant asymmetry is also seen at the subunit level where different conformations exist at the NAD-binding site and the putative serine-binding site in the two unique subunits.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Texas A&M University System; Texas A&M University College Station; Washington University (WUSTL); Washington University (WUSTL)	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	sacchett@tamu.edu	Dey, Sanghamitra/AAV-7921-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achouri Y, 1997, BIOCHEM J, V323, P365, DOI 10.1042/bj3230365; Ali V, 2004, EUR J BIOCHEM, V271, P2670, DOI 10.1111/j.1432-1033.2004.04195.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chipman DM, 2001, CURR OPIN STRUC BIOL, V11, P694, DOI 10.1016/S0959-440X(01)00272-X; Cho Y, 2003, J BIOL CHEM, V278, P8333, DOI 10.1074/jbc.M212124200; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; CHRISTOPHER J, 1999, SPOCK; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Devedjiev Y, 2004, J MOL BIOL, V343, P395, DOI 10.1016/j.jmb.2004.08.037; Dey S, 2005, J BIOL CHEM, V280, P14884, DOI 10.1074/jbc.M414488200; GOLDBERG JD, 1994, J MOL BIOL, V236, P1123, DOI 10.1016/0022-2836(94)90016-7; GRANT GA, 1989, BIOCHEM BIOPH RES CO, V165, P1371, DOI 10.1016/0006-291X(89)92755-1; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; ICHIHARA A, 1957, J BIOL CHEM, V224, P331; Ioerger TR, 2002, ACTA CRYSTALLOGR D, V58, P2043, DOI 10.1107/S0907444902016724; Kantardjieff KA, 2002, ACTA CRYSTALLOGR D, V58, P735, DOI 10.1107/S0O907444901019588; Kessler D, 2004, J MOL BIOL, V342, P183, DOI 10.1016/j.jmb.2004.07.028; LAMZIN VS, 1994, J MOL BIOL, V236, P759, DOI 10.1006/jmbi.1994.1188; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peters-Wendisch P, 2002, APPL MICROBIOL BIOT, V60, P437, DOI 10.1007/s00253-002-1161-y; SASKI R, 1975, EUR J BIOCHEM, V51, P415, DOI 10.1111/j.1432-1033.1975.tb03941.x; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schreiter ER, 2003, NAT STRUCT BIOL, V10, P794, DOI 10.1038/nsb985; SCHUDSON M, 1995, FORBES MEDIA CRITIC, V2, P76; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P423, DOI 10.1107/S0108768195003661; Slaughter J C, 1975, Methods Enzymol, V41, P278; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; WALSH DA, 1966, J BIOL CHEM, V241, P4068; WALSH DA, 1965, BIOCHEMISTRY-US, V4, P1076, DOI 10.1021/bi00882a015	34	53	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14892	14899		10.1074/jbc.M414489200	http://dx.doi.org/10.1074/jbc.M414489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15668249	hybrid			2022-12-25	WOS:000228236800068
J	Gloyn, AL; Odili, S; Zelent, D; Buettger, C; Castleden, HAJ; Steele, AM; Stride, A; Shiota, C; Magnuson, MA; Lorini, R; d'Annunzio, G; Stanley, CA; Kwagh, J; van Schaftingen, E; Veiga-da-Cunha, M; Barbetti, F; Dunten, P; Hah, Y; Grimsby, J; Taub, R; Ellard, S; Hattersley, AT; Matschinsky, FM				Gloyn, AL; Odili, S; Zelent, D; Buettger, C; Castleden, HAJ; Steele, AM; Stride, A; Shiota, C; Magnuson, MA; Lorini, R; d'Annunzio, G; Stanley, CA; Kwagh, J; van Schaftingen, E; Veiga-da-Cunha, M; Barbetti, F; Dunten, P; Hah, Y; Grimsby, J; Taub, R; Ellard, S; Hattersley, AT; Matschinsky, FM			Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL GLUCOKINASE; GLUCOSE-HOMEOSTASIS; INSULIN-RELEASE; TYPE-2 MODY-2; PROTEIN; GENE; HYPOGLYCEMIA; IDENTIFICATION; HYPERGLYCEMIA; LIVER	Glucokinase (GCK) serves as the pancreatic glucose sensor. Heterozygous inactivating GCK mutations cause hyperglycemia, whereas activating mutations cause hypoglycemia. We studied the GCK V62M mutation identified in two families and co-segregating with hyperglycemia to understand how this mutation resulted in reduced function. Structural modeling locates the mutation close to five naturally occurring activating mutations in the allosteric activator site of the enzyme. Recombinant glutathionyl S-transferase-V62M GCK is paradoxically activated rather than inactivated due to a decreased S-0.5 for glucose compared with wild type (4.88 versus 7.55 mM). The recently described pharmacological activator (RO0281675) interacts with GCK at this site. V62M GCK does not respond to RO0281675, nor does it respond to the hepatic glucokinase regulatory protein (GKRP). The enzyme is also thermally unstable, but this lability is apparently less pronounced than in the proven instability mutant E300K. Functional and structural analysis of seven amino acid substitutions at residue Val(62) has identified a non-linear relationship between activation by the pharmacological activator and the van der Waals interactions energies. Smaller energies allow a hydrophobic interaction between the activator and glucokinase, whereas larger energies prohibit the ligand from fitting into the binding pocket. We conclude that V62M may cause hyperglycemia instability in combination with loss of control by a putative endogenous activator and/or GKRP. This study illustrates that mutations that cause hyperglycemia are not necessarily kinetically inactivating but may exert their effects by other complex mechanisms. Elucidating such mechanisms leads to a deeper understanding of the GCK glucose sensor and the biochemistry of beta-cells and hepatocytes.	Univ Penn, Sch Med, Diabet Res Ctr, Philadelphia, PA 19104 USA; Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Diabet Res Labs, Oxford OX3 7LJ, England; Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX2 5DW, Devon, England; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Univ Genoa, G Gaslini Inst, Dept Pediat, I-16147 Genoa, Italy; Childrens Hosp Philadelphia, Div Endocrinol, Philadelphia, PA 19104 USA; Christan de Duve Inst Cellular Pathol, Chim Physiol Lab, BE-1200 Brussels, Belgium; Catholic Univ Louvain, BE-1200 Brussels, Belgium; Osped Pediat Bambino Gesu, Ist Ricovero & Cura Carattere Sci, I-81001323 Rome, Italy; Hoffmann La Roche Inc, Dept Metab Dis, Nutley, NJ 07110 USA	University of Pennsylvania; Pennsylvania Medicine; University of Oxford; University of Exeter; University of Pennsylvania; Vanderbilt University; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Universite Catholique Louvain; IRCCS Bambino Gesu; Roche Holding	Matschinsky, FM (corresponding author), Univ Penn, Sch Med, Diabet Res Ctr, Rm 510,Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	matsch@mail.med.upenn.edu	Barbetti, Fabrizio/AAK-9106-2021; Magnuson, Mark/AAY-7172-2021; Barbetti, Fabrizio/I-7351-2018; Van+Schaftingen, Emile/AAF-5532-2020; Magnuson, Mark A/B-1335-2009	Barbetti, Fabrizio/0000-0003-4687-980X; Magnuson, Mark/0000-0002-8824-6499; Barbetti, Fabrizio/0000-0003-4687-980X; Magnuson, Mark A/0000-0002-8824-6499; Ellard, Sian/0000-0002-7620-5526; Hattersley, Andrew/0000-0001-5620-473X; STANLEY, CHARLES/0000-0003-4881-9392; d'Annunzio, Giuseppe/0000-0002-1856-2277; Van Schaftingen, Emile/0000-0002-6199-7647; Gloyn, Anna/0000-0003-1205-1844	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK022122, R37DK022122, R01DK053013] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 22122, R01-DK53013] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez E, 2002, J NEUROCHEM, V80, P45, DOI 10.1046/j.0022-3042.2001.00677.x; Arden C, 2004, DIABETES, V53, P2346, DOI 10.2337/diabetes.53.9.2346; Baltrusch S, 2001, J BIOL CHEM, V276, P43915, DOI 10.1074/jbc.M105470200; Brocklehurst KJ, 2004, DIABETES, V53, P535, DOI 10.2337/diabetes.53.3.535; Burke CV, 1999, BIOCHEM J, V342, P345, DOI 10.1042/0264-6021:3420345; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; Christesen HBT, 2002, DIABETES, V51, P1240, DOI 10.2337/diabetes.51.4.1240; CORBETT WL, 2003, Patent No. 2385328; Cuesta-Munoz AL, 2004, DIABETES, V53, P2164, DOI 10.2337/diabetes.53.8.2164; Davis EA, 1999, DIABETOLOGIA, V42, P1175, DOI 10.1007/s001250051289; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; Gloyn AL, 2003, HUM MUTAT, V22, P353, DOI 10.1002/humu.10277; Gloyn AL, 2004, FRONT DIABETES, V16, P92; Gloyn AL, 2003, DIABETES, V52, P2433, DOI 10.2337/diabetes.52.9.2433; Grimsby J, 2000, J BIOL CHEM, V275, P7826, DOI 10.1074/jbc.275.11.7826; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; JETTON TL, 1994, J BIOL CHEM, V269, P3641; Kamata K, 2004, STRUCTURE, V12, P429, DOI 10.1016/j.str.2004.02.005; Kesavan P, 1997, BIOCHEM J, V322, P57, DOI 10.1042/bj3220057; LIANG Y, 1995, BIOCHEM J, V309, P167, DOI 10.1042/bj3090167; Mahalingam B, 1999, DIABETES, V48, P1698, DOI 10.2337/diabetes.48.9.1698; Matschinsky FM, 2002, DIABETES, V51, pS394, DOI 10.2337/diabetes.51.2007.S394; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; Miller SP, 1999, DIABETES, V48, P1645, DOI 10.2337/diabetes.48.8.1645; Moukil MA, 2000, DIABETES, V49, P195, DOI 10.2337/diabetes.49.2.195; Munoz-Alonso MJ, 2000, J BIOL CHEM, V275, P32406, DOI 10.1074/jbc.M000841200; Njolstad PR, 1998, ACTA PAEDIATR, V87, P853, DOI 10.1080/080352598750013626; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Rizzo MA, 2002, J BIOL CHEM, V277, P34168, DOI 10.1074/jbc.M112478200; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; Stride A, 2002, DIABETOLOGIA, V45, P427, DOI 10.1007/s00125-001-0770-9; Toyoda Y, 2001, HORM METAB RES, V33, P329, DOI 10.1055/s-2001-15418; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; Veiga-da-Cunha M, 2003, DIABETOLOGIA, V46, P704, DOI 10.1007/s00125-003-1083-y; VeigadaCunha M, 1996, DIABETOLOGIA, V39, P1173, DOI 10.1007/BF02658503; VeigadaCunha M, 1996, J BIOL CHEM, V271, P6292, DOI 10.1074/jbc.271.11.6292; ZAWALICH WS, 1977, J BIOL CHEM, V252, P8519	42	77	87	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14105	14113		10.1074/jbc.M413146200	http://dx.doi.org/10.1074/jbc.M413146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677479	hybrid			2022-12-25	WOS:000228095500113
J	Jones, LS; Peek, LJ; Power, J; Markham, A; Yazzie, B; Middaugh, CR				Jones, LS; Peek, LJ; Power, J; Markham, A; Yazzie, B; Middaugh, CR			Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXIDE ADJUVANT; THERMAL-STABILITY; VACCINE ADJUVANTS; SURFACE; SUBSTITUTION	The effect of adsorption onto aluminum salt adjuvants on the structure and stability of three model protein antigens was studied using fluorescence and Fourier transform infrared spectroscopies, as well as isothermal titration and differential scanning calorimetric techniques. Lysozyme was preferentially adsorbed to aluminum phosphate (Adju-Phos(R)), whereas ovalbumin and bovine serum albumin were better adsorbed to aluminum hydroxide (Alhydrogel(R)). A linearized Langmuir adsorption isotherm was used to obtain information regarding the binding interactions between proteins and adjuvants. Binding energetics and stoichiometry data obtained from isothermal titration calorimetry measurements were complex. Based on the spectroscopic and differential scanning calorimetry studies, the structure of all three proteins, when adsorbed to the surface of an aluminum salt, was altered in such a way as to render the proteins less thermally stable. Besides the pharmaceutical significance of this destabilization, we consider the possibility that this phenomenon may facilitate the presentation of antigens and thus contribute to the adjuvant activity of the aluminum salts.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA	University of Kansas	Jones, LS (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2095 Constant Ave, Lawrence, KS 66047 USA.	LaToya.Jones@UCHSC.edu; middaugh@ku.edu	Braun, LaToya/I-9506-2019	Braun, LaToya/0000-0002-6886-808X; Power, Jonathan/0000-0002-6922-100X				Ametani A, 2003, BIOSCI BIOTECH BIOCH, V67, P1507, DOI 10.1271/bbb.67.1507; BRANDAU DT, 1991, MOL IMMUNOL, V28, P1019, DOI 10.1016/0161-5890(91)90188-P; Brandau DT, 2003, J PHARM SCI-US, V92, P218, DOI 10.1002/jps.10296; Bulone D, 2001, BIOPHYS CHEM, V91, P61, DOI 10.1016/S0301-4622(01)00155-7; Burrell LS, 2000, VACCINE, V19, P275, DOI 10.1016/S0264-410X(00)00160-2; Fauci AS, 2001, CLIN INFECT DIS, V32, P675, DOI 10.1086/319235; Gupta R.K., 1995, VACCINE DESIGN SUBUN, P229; Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8; Iyer S, 2004, VACCINE, V22, P1475, DOI 10.1016/j.vaccine.2003.10.023; Iyer S, 2003, PHARM DEV TECHNOL, V8, P81, DOI 10.1081/PDT-120017526; Jendrek S, 2003, VACCINE, V21, P3011, DOI 10.1016/S0264-410X(03)00109-9; Johnston CT, 2002, J PHARM SCI, V91, P1702, DOI 10.1002/jps.10166; KATZENSTEIN GE, 1986, P NATL ACAD SCI USA, V83, P4268, DOI 10.1073/pnas.83.12.4268; Lindblad EB, 2004, IMMUNOL CELL BIOL, V82, P497, DOI 10.1111/j.0818-9641.2004.01286.x; MATSUNO K, 1991, ARCH BIOCHEM BIOPHYS, V291, P349, DOI 10.1016/0003-9861(91)90145-9; SEEBER SJ, 1991, VACCINE, V9, P201, DOI 10.1016/0264-410X(91)90154-X; SHIRODKAR S, 1990, PHARMACEUT RES, V7, P1282, DOI 10.1023/A:1015994006859; So T, 1997, J BIOL CHEM, V272, P32136, DOI 10.1074/jbc.272.51.32136; STEADMAN BL, 1992, BIOTECHNOL BIOENG, V40, P8, DOI 10.1002/bit.260400103; Thai R, 2004, J BIOL CHEM, V279, P50257, DOI 10.1074/jbc.M405738200; VOGEL FR, 1995, PHARM BIOT, V6, P141, DOI DOI 10.1007/978-1-4615-1823-5_	21	147	155	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13406	13414		10.1074/jbc.M500687200	http://dx.doi.org/10.1074/jbc.M500687200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15684430	hybrid			2022-12-25	WOS:000228095500028
J	Trabold, PA; Weinberger, M; Feng, L; Burhans, WC				Trabold, PA; Weinberger, M; Feng, L; Burhans, WC			Activation of budding yeast replication origins and suppression of lethal DNA damage effects on origin function by ectopic expression of the co-chaperone protein Mge1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION COMPLEX; CELL-DEATH; LARGE T; CDC6; BINDING; CYCLE; CHECKPOINT; APOPTOSIS; PHASE; GRPE	Initiation of DNA replication in eukaryotes requires the origin recognition complex (ORC) and other proteins that interact with DNA at origins of replication. In budding yeast, the temperature-sensitive orc2-1 mutation alters these interactions in parallel with defects in initiation of DNA replication and in checkpoints that depend on DNA replication forks. Here we show that DNA-damaging drugs modify protein-DNA interactions at budding yeast replication origins in association with lethal effects that are enhanced by the orc2-1 mutation or suppressed by a different mutation in ORC. A dosage suppressor screen identified the budding yeast co-chaperone protein Mge1p as a high copy suppressor of the orc2-1-specific lethal effects of adozelesin, a DNA-alkylating drug. Ectopic expression of Mge1p also suppressed the temperature sensitivity and initiation defect conferred by the orc2-1 mutation. In wild type cells, ectopic expression of Mge1p also suppressed the lethal effects of adozelesin in parallel with the suppression of adozelesin-induced alterations in protein-DNA interactions at origins, stimulation of initiation of DNA replication, and binding of the precursor form of Mge1p to nuclear chromatin. Mge1p is the budding yeast homologue of the Escherichia coli co-chaperone protein GrpE, which stimulates initiation at bacterial origins of replication by promoting interactions of initiator proteins with origin sequences. Our results reveal a novel, proliferation-dependent cytotoxic mechanism for DNA-damaging drugs that involves alterations in the function of initiation proteins and their interactions with DNA.	Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Burhans, WC (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA.	wburhans@acsu.buffalo.edu			NCI NIH HHS [P30 CA16056, CA81326, CA84086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084086, P30CA016056, R01CA081326] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056; Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; Blanchard F, 2002, MOL BIOL CELL, V13, P1536, DOI 10.1091/mbc.02-02-0010; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; Burhans W, 2002, CELL DEATH DIFFER, V9, P870, DOI 10.1038/sj.cdd.4401086; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; Dekker PJT, 1997, J MOL BIOL, V270, P321, DOI 10.1006/jmbi.1997.1131; Deloche O, 1996, J BIOL CHEM, V271, P23960, DOI 10.1074/jbc.271.39.23960; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; Frei C, 2000, GENE DEV, V14, P81; Giraldo R, 2001, P NATL ACAD SCI USA, V98, P4938, DOI 10.1073/pnas.081079298; Herman PK, 2002, CURR OPIN MICROBIOL, V5, P602, DOI 10.1016/S1369-5274(02)00377-6; Illenye S, 2004, GENOMICS, V83, P66, DOI 10.1016/S0888-7543(03)00205-2; Kaguni JM, 1997, MOL CELLS, V7, P145; Konieczny I, 1999, GENET ENG P, V21, P95; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; Le Gac NT, 2002, J BIOL CHEM, V277, P5660, DOI 10.1074/jbc.M108316200; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; Madeo F, 2002, CURR GENET, V41, P208, DOI 10.1007/s00294-002-0310-2; MAIO B, 1997, J MOL BIOL, V265, P541; Mizushima T, 2000, GENE DEV, V14, P1631; Pelizon C, 2002, EMBO REP, V3, P780, DOI 10.1093/embo-reports/kvf161; POLISSI A, 1995, FEMS MICROBIOL REV, V17, P159; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Santocanale C, 1997, METHOD ENZYMOL, V283, P377; Schories B, 2004, CELL DEATH DIFFER, V11, P940, DOI 10.1038/sj.cdd.4401411; Shimada K, 2002, GENE DEV, V16, P3236, DOI 10.1101/gad.239802; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; SIKORSKI RS, 1989, GENETICS, V122, P19; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stevenson LF, 2001, P NATL ACAD SCI USA, V98, P3946, DOI 10.1073/pnas.051013498; Tannock I, 1998, BASIC SCI ONCOLOGY; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; WEILAND KL, 1991, BIOCHEMISTRY-US, V30, P7559, DOI 10.1021/bi00244a027; Weinberger M, 1999, J BIOL CHEM, V274, P35975, DOI 10.1074/jbc.274.50.35975; Weinberger M, 2003, IUBMB LIFE, V55, P467, DOI 10.1080/15216540310001612336; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; Yim H, 2003, MOL BIOL CELL, V14, P4250, DOI 10.1091/mbc.E03-01-0029; Yin MB, 2004, MOL PHARMACOL, V66, P153, DOI 10.1124/mol.66.1.153	47	2	2	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12413	12421		10.1074/jbc.M411327200	http://dx.doi.org/10.1074/jbc.M411327200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15647270	hybrid			2022-12-25	WOS:000227922000043
J	Yoshizawa-Sugata, N; Ishii, A; Taniyama, C; Matsui, E; Arai, K; Masai, H				Yoshizawa-Sugata, N; Ishii, A; Taniyama, C; Matsui, E; Arai, K; Masai, H			A second human Dbf4/ASK-related protein, Drf1/ASKL1, is required for efficient progression of S and M phases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC7; HUMAN CDC7-RELATED KINASE; IN-VITRO PHOSPHORYLATION; CELL-CYCLE; CHROMOSOMAL LOCALIZATION; REGULATORY SUBUNIT; G(1)/S TRANSITION; HSK1 KINASE; INITIATION; CHECKPOINT	Cdc7- Dbf4 kinase is conserved through evolution and regulates initiation and progression of DNA replication. In human, ASK/ hsDbf4 binds and activates huCdc7 during S phase and this kinase complex is essential for DNA replication and cell proliferation. Drf1/ASKL1, a second human Dbf4/ASK-related protein, shares three conserved Dbf4 motifs previously identified on all of the Dbf4-related molecules. Drf1/ASKL1 can bind and activate huCdc7, and Cdc7-ASKL1 complex phosphorylates MCM2. ASKL1 transcription and protein levels oscillate during cell cycle and increase at late S to G2/ M phases. The protein is detected predominantly in the nuclearsoluble fraction but not in the chromatin- bound fraction. Inhibition of Drf1/ ASKL1 expression by siRNA results in attenuation of cell growth and in the increase of late S and G2/ M phase population. siRNA treatment on synchronized cell population revealed that S phase progression is delayed when ASKL1 protein level is decreased. S phase delay may be linked to replication fork block, because increased levels of gamma H2AX and activated form of Chk2 are detected with ASKL1 siRNA in the absence of any additional DNA damages. Furthermore, mitotic progression is retarded in ASKL1 or Cdc7 siRNA- treated cells. Our results suggest that ASKL1 in a complex with Cdc7 may play a role in normal progression of both S and M phases.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Integrat Life Sci, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Tokyo 1138613, Japan.	hmasai@rinshoken.or.jp		Yoshizawa-Sugata, Naoko/0000-0001-8792-8669				Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Fujii-Yamamoto H, 2005, J BIOL CHEM, V280, P12976, DOI 10.1074/jbc.M412224200; Hunt T, 1991, Semin Cell Biol, V2, P213; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; Kim JM, 2003, MUTAT RES-FUND MOL M, V532, P29, DOI 10.1016/j.mrfmmm.2003.08.008; Kim JM, 1998, J BIOL CHEM, V273, P23248, DOI 10.1074/jbc.273.36.23248; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; Lepke M, 1999, MOL GEN GENET, V262, P220, DOI 10.1007/s004380051078; Masai H, 2000, BIOCHEM BIOPH RES CO, V275, P228, DOI 10.1006/bbrc.2000.3281; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H., 1999, FRONT BIOSCI, V4, pD834; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakamura T, 2000, GENES CELLS, V5, P463, DOI 10.1046/j.1365-2443.2000.00343.x; Nakamura T, 2002, MOL CELL BIOL, V22, P309, DOI 10.1128/MCB.22.1.309-320.2002; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Ogino K, 2001, J BIOL CHEM, V276, P31376, DOI 10.1074/jbc.M102197200; RADZIOANDZELM E, 1995, STRUCTURE, V3, P1135; Sato N, 2003, GENES CELLS, V8, P451, DOI 10.1046/j.1365-2443.2003.00647.x; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCLAFANI RA, 1994, MOL MICROBIOL, V11, P805, DOI 10.1111/j.1365-2958.1994.tb00358.x; Sclafani RA, 2000, J CELL SCI, V113, P2111; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; Wohlschlegel JA, 2001, MOL CELL BIOL, V21, P4868, DOI 10.1128/MCB.21.15.4868-4874.2001; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200	37	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13062	13070		10.1074/jbc.M411653200	http://dx.doi.org/10.1074/jbc.M411653200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668232	hybrid			2022-12-25	WOS:000227922000117
J	Bezy, O; Elabd, C; Cochet, O; Petersen, RK; Kristiansen, K; Dani, C; Ailhaud, R; Amri, EZ				Bezy, O; Elabd, C; Cochet, O; Petersen, RK; Kristiansen, K; Dani, C; Ailhaud, R; Amri, EZ			Delta-interacting protein A, a new inhibitory partner of CCAAT/enhancer-binding protein beta, implicated in adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CLONAL EXPANSION; GENE-EXPRESSION; C/EBP-BETA; LEUCINE-ZIPPER; ACTIVATION; PHOSPHORYLATION; TRANSCRIPTION; ORGANIZATION; GENERATION; ISOFORMS	CCAAT/enhancer-binding protein beta (C/EBP beta) is expressed early during the adipocyte differentiation program and plays an important role in this process. In an attempt to identify novel proteins that interact with C/EBP beta, we performed a yeast two-hybrid screen with a preadipocyte cDNA library and identified a new co-regulator, delta-interacting protein A (DIPA). DIPA mRNA is expressed during adipocyte differentiation of clonal cell lines. DIPA interacts with C/EBP beta and -delta proteins in intact cells and inhibits their transcriptional activity but not that of C/EBP alpha. Stable overexpression of DIPA in preadipocytes partially inhibits adipocyte differentiation, whereas its gene silencing enhances this process. DIPA and C/EBP beta co-localize in the nucleus, and overexpression of DIPA in preadipocytes results in a partial inhibition of the mitotic clonal expansion which is critical for differentiation. Thus, DIPA is a novel partner of C/EBP beta that down-regulates early events of adipogenesis.	Fac Sci, Inst Signaling Dev Biol & Canc Res, Ctr Biochim, UMR 6543 CNRS, F-06108 Nice, France; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	University of Southern Denmark	Amri, EZ (corresponding author), Fac Sci, Inst Signaling Dev Biol & Canc Res, Ctr Biochim, UMR 6543 CNRS, Parc Valrose, F-06108 Nice, France.	amri@unice.fr	Kristiansen, Karsten/J-5148-2014; DANI, Christian/G-3639-2014	Kristiansen, Karsten/0000-0002-6024-0917; DANI, Christian/0000-0003-3228-0230; amri, Ez-Zoubir/0000-0001-8426-5396; Bezy, Olivier/0000-0003-4367-5043				Abderrahim-Ferkoune A, 2003, J LIPID RES, V44, P994, DOI 10.1194/jlr.M200382-JLR200; Abderrahim-Ferkoune A, 2004, EXP CELL RES, V293, P219, DOI 10.1016/j.yexcr.2003.10.020; AMRI EZ, 1991, J LIPID RES, V32, P1449; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; Belmonte N, 2001, MOL ENDOCRINOL, V15, P2037, DOI 10.1210/me.15.11.2037; Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Elberg G, 2000, J BIOL CHEM, V275, P27815; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kubo Y, 2000, IN VITRO CELL DEV-AN, V36, P38; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Massiera F, 2003, J LIPID RES, V44, P271, DOI 10.1194/jlr.M200346-JLR200; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tong Q, 2001, Rev Endocr Metab Disord, V2, P349, DOI 10.1023/A:1011863414321; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; Welm AL, 1999, MOL CELL BIOL, V19, P1695; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	42	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11432	11438		10.1074/jbc.M411741200	http://dx.doi.org/10.1074/jbc.M411741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644333	hybrid			2022-12-25	WOS:000227761800066
J	Chang, FJ; Lemme, S; Sun, Q; Sunahara, RK; Beuve, A				Chang, FJ; Lemme, S; Sun, Q; Sunahara, RK; Beuve, A			Nitric oxide-dependent allosteric inhibitory role of a second nucleotide binding site in soluble guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; CATALYTIC MECHANISM; PROXIMAL BINDING; CEREBELLAR CELLS; HEME; ACTIVATION; KINETICS; RECEPTOR; MODEL; DISSOCIATION	The mechanism of desensitization of the nitric oxide (NO) receptor (alpha(1)center dot beta(1) isoform of soluble guanylyl cyclase, sGC) is not known. Models of the structure of alpha(1)center dot beta(1), based on the x-ray crystal structure of adenylyl cyclase (AC) suggest the existence of a nucleotide-like binding site, in addition to the putative catalytic site. We have previously reported that mutating residues that coordinate Mg2+ GTP (substrate) binding in alpha(1)center dot beta(1) into those present in AC fully reverts GC activity to AC activity. The wild-type form of alpha(1)center dot beta(1) (GC-wt) and the mutant form (AC-mut, alpha(1)R592Q center dot beta(1)E473K, C541D) were purified, and their sensitivities to various nucleotides were assessed. In using the AC-mut as well as other mutants that coordinate purine binding, we were able to distinguish allosteric inhibitory effects of guanine nucleotides from competitively inhibitory effects on catalytic activity. Here we report that several nucleotide analogs drastically alter sGC and AC-mut activity by acting at a second nucleotide site, likely pseudosymmetric to the catalytic site. In particular, Mg(2+)GTP gamma S and Mg(2+)ATP gamma S inhibited cyclase activity through a mixed, non-competitive mechanism that was only observable under NO stimulation and not under basal conditions. The non-competitive pattern of inhibition was not present in mutants carrying the substitution beta(1)D477A, the pseudosymmetric equivalent to alpha(1)D529 (located in the substrate-binding site and involved in substrate binding and catalysis), or with the double mutations alpha(1)E525K, C594D, the pseudosymmetric equivalent to beta(1)E473K, C541D. Taken together these data suggest that occupation of the second site by nucleotides may underlie part of the mechanism of desensitization of sGC.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, Newark, NJ 07103 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Texas, Sch Med, Houston, TX 77030 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Michigan System; University of Michigan; University of Texas System	Beuve, A (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, Newark, NJ 07103 USA.	annie.beuve@umdnj.edu	Sunahara, Roger/AAJ-8667-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068603, R01GM067640] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM068603, R01-GM067640, R01-GM068603] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrew CR, 2002, BIOCHEMISTRY-US, V41, P2353, DOI 10.1021/bi011419k; Ballou DP, 2002, P NATL ACAD SCI USA, V99, P12097, DOI 10.1073/pnas.192209799; Bellamy TC, 2002, P NATL ACAD SCI USA, V99, P507, DOI 10.1073/pnas.012368499; Bellamy TC, 2002, BRIT J PHARMACOL, V136, P95, DOI 10.1038/sj.bjp.0704687; Bellamy TC, 2001, J BIOL CHEM, V276, P4287, DOI 10.1074/jbc.M006677200; Bellamy TC, 2002, MOL CELL BIOCHEM, V230, P165, DOI 10.1023/A:1014204426331; BRANDWEIN HJ, 1982, J BIOL CHEM, V257, P1309; CHRISMAN TD, 1975, J BIOL CHEM, V250, P374; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; Ferrero R, 2000, J NEUROCHEM, V75, P2029, DOI 10.1046/j.1471-4159.2000.0752029.x; Friebe A, 1999, BIOCHEMISTRY-US, V38, P15253, DOI 10.1021/bi9908944; Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; Gille A, 2004, J BIOL CHEM, V279, P19955, DOI 10.1074/jbc.M312560200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hurley JH, 1998, CURR OPIN STRUC BIOL, V8, P770, DOI 10.1016/S0959-440X(98)80097-3; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; KIMURA H, 1974, J BIOL CHEM, V249, P6910; Lamothe M, 2004, BIOCHEMISTRY-US, V43, P3039, DOI 10.1021/bi0360051; Lawson DM, 2000, EMBO J, V19, P5661, DOI 10.1093/emboj/19.21.5661; Lawson DM, 2003, BIOCHEM SOC T, V31, P553, DOI 10.1042/BST0310553; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Murthy KS, 2004, NEUROCHEM INT, V45, P845, DOI 10.1016/j.neuint.2004.03.014; Negrerie M, 2001, J BIOL CHEM, V276, P46815, DOI 10.1074/jbc.M102224200; PARKINSON SJ, 1994, J BIOL CHEM, V269, P22683; Pellicena P, 2004, P NATL ACAD SCI USA, V101, P12854, DOI 10.1073/pnas.0405188101; Ruiz-Stewart I, 2004, P NATL ACAD SCI USA, V101, P37, DOI 10.1073/pnas.0305080101; Ruiz-Stewart I, 2002, EUR J BIOCHEM, V269, P2186, DOI 10.1046/j.1432-1033.2002.02874.x; RUSSWURM M, 2002, J BIOL CHEM, V26, P26; Sharma VS, 1999, METHODS, V19, P494, DOI 10.1006/meth.1999.0892; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Zhao YD, 1998, BIOCHEMISTRY-US, V37, P12458, DOI 10.1021/bi9811563; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	40	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11513	11519		10.1074/jbc.M412203200	http://dx.doi.org/10.1074/jbc.M412203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15649897	hybrid			2022-12-25	WOS:000227761800076
J	Ginger, ML; Ngazoa, ES; Pereira, CA; Pullen, TJ; Kabiri, M; Becker, K; Gull, K; Steverding, D				Ginger, ML; Ngazoa, ES; Pereira, CA; Pullen, TJ; Kabiri, M; Becker, K; Gull, K; Steverding, D			Intracellular positioning of isoforms explains an unusually large adenylate kinase gene family in the parasite Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE LEVEL PHOSPHORYLATION; ESCHERICHIA-COLI; RIBONUCLEOTIDE REDUCTASE; CRYSTAL-STRUCTURE; CMP KINASE; MITOCHONDRIAL; PROTEIN; GLYCOSOMES; EXPRESSION; DEHYDROGENASE	Adenylate kinases occur classically as cytoplasmic and mitochondrial enzymes, but the expression of seven adenylate kinases in the flagellated protozoan parasite Trypanosoma brucei (order, Kinetoplastida; family, Trypanosomatidae) easily exceeds the number of isoforms previously observed within a single cell and raises questions as to their location and function. We show that a requirement to target adenylate kinase into glycosomes, which are unique kinetoplastid-specific microbodies of the peroxisome class in which many reactions of carbohydrate metabolism are compartmentalized, and two different flagellar structures as well as cytoplasm and mitochondrion explains the expansion of this gene family in trypanosomes. The three isoforms that are selectively built into either the flagellar axoneme or the extra-axonemal paraflagellar rod, which is essential for motility, all contain long N-terminal extensions. Biochemical analysis of the only short form trypanosome adenylate kinase revealed that this enzyme catalyzes phosphotransfer of gamma-phosphate from ATP to AMP, CMP, and UMP acceptors; its high activity and specificity toward CMP is likely to reflect an adaptation to very low intracellular cytidine nucleotide pools. Analysis of some of the phosphotransfer network using RNA interference suggests considerable complexity within the homeostasis of cellular energetics. The anchoring of specific adenylate kinases within two distinct flagellar structures provides a paradigm for metabolic organization and efficiency in other flagellates.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Giessen, Interdisziplinares Forschungszentrum, D-35392 Giessen, Germany; Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Invest Med Alfredo Lanari, RA-1427 Buenos Aires, DF, Argentina; Heidelberg Univ, Inst Hyg, D-69120 Heidelberg, Germany; Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England	University of Oxford; Justus Liebig University Giessen; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Ruprecht Karls University Heidelberg; University of East Anglia	Gull, K (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	keith.gull@pathology.oxford.ac.uk; dsteverding@hotmail.com	Pereira, Claudio A/F-5382-2012; Pullen, Timothy J/H-2143-2011; Steverding, Dietmar/A-6947-2010; Steverding, Dietmar/ABD-9452-2021	Pereira, Claudio A/0000-0001-7874-1894; Pullen, Timothy J/0000-0002-6853-5701; Steverding, Dietmar/0000-0002-0050-7771; Ginger, Michael/0000-0002-9643-8482				BANDLOW W, 1988, EUR J BIOCHEM, V178, P451, DOI 10.1111/j.1432-1033.1988.tb14469.x; Bastin P, 1999, J CELL SCI, V112, P3769; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; BERGHAUSER J, 1975, BIOCHIM BIOPHYS ACTA, V397, P370, DOI 10.1016/0005-2744(75)90126-6; BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; Breidbach T, 2000, FEBS LETT, V473, P212, DOI 10.1016/S0014-5793(00)01533-7; BRUN R, 1979, ACTA TROP, V36, P289; Bucurenci N, 1996, J BIOL CHEM, V271, P2856, DOI 10.1074/jbc.271.5.2856; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Conway C, 2002, MOL MICROBIOL, V45, P1687, DOI 10.1046/j.1365-2958.2002.03122.x; Coustou V, 2003, J BIOL CHEM, V278, P49625, DOI 10.1074/jbc.M307872200; Dzeja PP, 2003, J EXP BIOL, V206, P2039, DOI 10.1242/jeb.00426; FELDHAUS P, 1975, EUR J BIOCHEM, V57, P197, DOI 10.1111/j.1432-1033.1975.tb02291.x; FukamiKobayashi K, 1996, FEBS LETT, V385, P214, DOI 10.1016/0014-5793(96)00367-5; GLASER M, 1975, J BACTERIOL, V123, P128, DOI 10.1128/JB.123.1.128-136.1975; Hannaert Veronique, 2003, Kinetoplastid Biology and Disease, V2, pUnpaginated; HART DT, 1984, MOL BIOCHEM PARASIT, V12, P25, DOI 10.1016/0166-6851(84)90041-0; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Hofer A, 2001, P NATL ACAD SCI USA, V98, P6412, DOI 10.1073/pnas.111139498; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Janssen E, 2003, J BIOL CHEM, V278, P12937, DOI 10.1074/jbc.M211465200; Kaldis P, 1996, J CELL SCI, V109, P2079; KONRAD M, 1992, J BIOL CHEM, V267, P25652; KONRAD M, 1993, J BIOL CHEM, V268, P11326; KONRAD M, 1988, J BIOL CHEM, V263, P19468; LILJELUND P, 1986, Molecular and General Genetics, V205, P74, DOI 10.1007/BF02428034; Lorenz P, 1998, EMBO J, V17, P3542, DOI 10.1093/emboj/17.13.3542; MCLAUGHLIN J, 1985, MOL BIOCHEM PARASIT, V14, P219, DOI 10.1016/0166-6851(85)90040-4; Miki K, 2004, P NATL ACAD SCI USA, V101, P16501, DOI 10.1073/pnas.0407708101; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Moyersoen J, 2004, FEMS MICROBIOL REV, V28, P603, DOI 10.1016/j.femsre.2004.06.004; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; MULLERDIECKMANN HJ, 1994, J MOL BIOL, V236, P361, DOI 10.1006/jmbi.1994.1140; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P291, DOI 10.1016/0166-6851(81)90062-1; Pereira CA, 2002, J EUKARYOT MICROBIOL, V49, P82, DOI 10.1111/j.1550-7408.2002.tb00346.x; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; Pullen TJ, 2004, MOL BIOL CELL, V15, P3257, DOI 10.1091/mbc.E04-03-0217; Ren H, 2005, P NATL ACAD SCI USA, V102, P303, DOI 10.1073/pnas.0407459102; Riviere L, 2004, J BIOL CHEM, V279, P45337, DOI 10.1074/jbc.M407513200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scheffzek K, 1996, BIOCHEMISTRY-US, V35, P9716, DOI 10.1021/bi960642s; SCHOFF PK, 1989, J BIOL CHEM, V264, P6086; SCHRICKER R, 1992, GENE, V122, P111, DOI 10.1016/0378-1119(92)90038-Q; Schultz CP, 1997, ARCH BIOCHEM BIOPHYS, V340, P144, DOI 10.1006/abbi.1997.9888; SERINA L, 1995, BIOCHEMISTRY-US, V34, P5066, DOI 10.1021/bi00015a018; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Strobel G, 2002, MOL BIOL CELL, V13, P1439, DOI 10.1091/mbc.01-08-0396; SU JY, 1991, NUCLEIC ACIDS RES, V19, P823, DOI 10.1093/nar/19.4.823; Szewczyk E, 2001, J BIOL CHEM, V276, P37722, DOI 10.1074/jbc.M105645200; terKuile BH, 1997, J BACTERIOL, V179, P4699, DOI 10.1128/jb.179.15.4699-4705.1997; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; van Weelden SWH, 2005, J BIOL CHEM, V280, P12451, DOI 10.1074/jbc.M412447200; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WATANABE T, 1976, J BIOL CHEM, V251, P182; Wickstead B, 2003, NUCLEIC ACIDS RES, V31, P3993, DOI 10.1093/nar/gkg445; Wirschell M, 2004, MOL BIOL CELL, V15, P2729, DOI 10.1091/mbc.E03-11-0820; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODS A, 1989, J CELL SCI, V93, P491; Zhang H, 2004, J CELL SCI, V117, P4179, DOI 10.1242/jcs.01297	63	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11781	11789		10.1074/jbc.M413821200	http://dx.doi.org/10.1074/jbc.M413821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657034	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000227761800107
J	Jensen, PH; Weilguny, D; Matthiesen, F; McGuire, KA; Shi, L; Hojrup, P				Jensen, PH; Weilguny, D; Matthiesen, F; McGuire, KA; Shi, L; Hojrup, P			Characterization of the oligomer structure of recombinant human mannan-binding lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; PULMONARY SURFACTANT APOPROTEIN; COLLAGEN-LIKE DOMAIN; ACTIVATES COMPLEMENT; CLASSICAL PATHWAY; SERINE-PROTEASE; SERUM LECTIN; PROTEINS; LIVER; GENE	Mannan-binding lectin (MBL) belongs to a family of proteins called the collectins, which show large differences in their ultrastructures. These differences are believed to be determined by different N-terminal disulfide-bonding patterns. So far only the bonding pattern of two of the simple forms (recombinant rat MBL-C and bovine CL-43) have been determined. Recombinant MBL expressed in human cells was purified, and the structure of the N-terminal region was determined. Preliminary results on human plasma-derived MBL revealed high similarity to the recombinant protein. Here we report the structure of the N-terminal part of recombinant human MBL and present a model to explain the oligomerization pattern. Using a strategy of consecutive enzymatic digestions and matrix-assisted laser desorption ionization mass spectrometry, we succeeded in identifying a number of disulfide-linked peptides from the N-terminal cysteine-rich region. Based on these building blocks, we propose a model that can explain the various oligomeric forms found in purified MBL preparations. Furthermore, the model was challenged by the production of cysteine to serine mutants of the three N-terminally situated cysteines. The oligomerization patterns of these mutants support the proposed model. The model indicates that the polypeptide dimer is the basic unit in the oligomerization.	Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; NatImmune AS, DK-2100 Copenhagen, Denmark; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Dev Immunol, Boston, MA 02144 USA	University of Southern Denmark; Harvard University; Harvard Medical School; Massachusetts General Hospital	Hojrup, P (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense, Denmark.	php@bmb.sdu.dk	Højrup, Peter/ABG-8477-2020	Hojrup, Peter/0000-0002-7838-6180	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM062580] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62580] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHILDS RA, 1990, J BIOL CHEM, V265, P20770; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; DAVIS AE, 1984, BIOCHEMISTRY-US, V23, P2139, DOI 10.1021/bi00305a006; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; GARRED P, 1992, CLIN EXP IMMUNOL, V90, P517; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Hansen S, 1998, IMMUNOBIOLOGY, V199, P165, DOI 10.1016/S0171-2985(98)80025-9; Hansen S, 2002, J IMMUNOL, V169, P5726, DOI 10.4049/jimmunol.169.10.5726; HOLMSKOV U, 1995, BIOCHEM J, V305, P889, DOI 10.1042/bj3050889; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JENSEN UG, 1996, PURIFICATION CHARACT; Jensenius JC, 2003, BIOCHEM SOC T, V31, P763, DOI 10.1042/BST0310763; Krogh TN, 1999, ANAL BIOCHEM, V274, P153, DOI 10.1006/abio.1999.4254; KURATA H, 1993, BIOCHEM BIOPH RES CO, V191, P1204, DOI 10.1006/bbrc.1993.1345; Larsen F, 2004, J BIOL CHEM, V279, P21302, DOI 10.1074/jbc.M400520200; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; Liu H, 2001, SCAND J IMMUNOL, V53, P489, DOI 10.1046/j.1365-3083.2001.00908.x; LU J, 1990, J IMMUNOL, V144, P2287; Ma Y, 1997, J BIOCHEM-TOKYO, V122, P810; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; NIELSEN PH, 2001, THESIS U SO DENMARK; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; REID KBM, 1976, BIOCHEM J, V155, P19, DOI 10.1042/bj1550019; Rothmann AB, 1997, EUR J BIOCHEM, V243, P630, DOI 10.1111/j.1432-1033.1997.t01-1-00630.x; SASTRY R, 1995, MAMM GENOME, V6, P103, DOI 10.1007/BF00303252; SUPER M, 1992, NAT GENET, V2, P50, DOI 10.1038/ng0992-50; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Vorup-Jensen T, 2001, INT IMMUNOPHARMACOL, V1, P677, DOI 10.1016/S1567-5769(00)00052-7; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1999, J IMMUNOL, V163, P4953; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0	40	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11043	11051		10.1074/jbc.M412472200	http://dx.doi.org/10.1074/jbc.M412472200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653690	hybrid			2022-12-25	WOS:000227761800021
J	Kihara, M; Chatani, E; Sakai, M; Hasegawa, K; Naiki, H; Goto, Y				Kihara, M; Chatani, E; Sakai, M; Hasegawa, K; Naiki, H; Goto, Y			Seeding-dependent maturation of ss(2)-microglobulin amyloid fibrils at neutral pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; BETA(2)-MICROGLOBULIN; BETA-2-MICROGLOBULIN; AGGREGATION; PEPTIDE; SULFATE; FORM; FIBRILLOGENESIS; PRECURSORS; EXTENSION	beta 2-Microglobulin (beta 2-m) is a major component of amyloid fibrils deposited in patients with dialysis-related amyloidosis. Recent studies have focused on the mechanism by which amyloid fibrils are formed under physiological conditions, which had been difficult to reproduce quantitatively. Yamamoto et al. (Yamamoto, S., Hasegawa, K., Yamaguchi, I., Tsutsumi, S., Kardos, J., Goto, Y., Gejyo, F. & Naiki, H. (2004) Biochemistry 43, 11075-11082) showed that a combination of seed fibrils prepared under acidic conditions and a low concentration of sodium dodecyl sulfate below its critical micelle concentration enabled extensive fibril formation at pH 7.0. Here, we found that repeated self-seeding at pH 7.0 with fibrils formed at the same pH causes a marked acceleration of growth, indicating the maturation of fibrils. The observed maturation can be simulated by assuming the existence of two types of fibrils with different growth rates. Importantly, some mutations of beta 2-m or the addition of a low concentration of urea, both destabilizing the native conformation, were not enough to extend the fibrils at pH 7.0, and a low concentration of sodium dodecyl sulfate (i.e. 0.5 mM) was essential. Thus, even though the first stage fibrils in patients are unstable and require stabilizing factors to remain at neutral pH, they can adapt to a neutral pH with repeated self-seeding, implying a mechanism of development of amyloid deposition after a long latent period in patients.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, CREST, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, CREST, Matsuoka, Fukui 9101193, Japan; Univ Fukui, Fac Med Sci, Matsuoka, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); University of Fukui	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014					Andreola A, 2003, J BIOL CHEM, V278, P2444, DOI 10.1074/jbc.M204801200; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Corazza A, 2004, J BIOL CHEM, V279, P9176, DOI 10.1074/jbc.M310779200; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Eakin CM, 2004, BIOCHEMISTRY-US, V43, P7808, DOI 10.1021/bi049792q; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Floege J, 2001, KIDNEY INT, V59, pS164, DOI 10.1046/j.1523-1755.2001.59780164.x; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Hagihara Y, 2002, BIOCHEMISTRY-US, V41, P1020, DOI 10.1021/bi015693q; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Ivanova MI, 2004, P NATL ACAD SCI USA, V101, P10584, DOI 10.1073/pnas.0403756101; Ji SR, 2002, J BIOL CHEM, V277, P6273, DOI 10.1074/jbc.M104146200; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; Pertinhez TA, 2002, FEBS LETT, V529, P193, DOI 10.1016/S0014-5793(02)03333-1; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ramirez-Alvarado M, 2002, J MOL BIOL, V323, P17, DOI 10.1016/S0022-2836(02)00840-9; REYNOLDS JA, 1970, J BIOL CHEM, V245, P5161; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; Yamaguchi I, 2001, BIOCHEMISTRY-US, V40, P8499, DOI 10.1021/bi0027128; Yamamoto S, 2004, BIOCHEMISTRY-US, V43, P11075, DOI 10.1021/bi049262u; Yamamoto S, 2004, J AM SOC NEPHROL, V15, P126, DOI 10.1097/01.ASN.0000103228.81623.C7; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462	42	63	65	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					12012	12018		10.1074/jbc.M411949200	http://dx.doi.org/10.1074/jbc.M411949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659393	Green Published, hybrid			2022-12-25	WOS:000227761800134
J	Marcus, AI; Peters, U; Thomas, SL; Garrett, S; Zelnak, A; Kapoor, TM; Giannakakou, P				Marcus, AI; Peters, U; Thomas, SL; Garrett, S; Zelnak, A; Kapoor, TM; Giannakakou, P			Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE INHIBITOR; MICROTUBULE DYNAMICS; MULTIDRUG-RESISTANCE; SPINDLE; EG5; PACLITAXEL; POLYMERIZATION; CYTOTOXICITY; CHEMOTHERAPY; COMBINATION	Taxanes are powerful chemotherapy agents that target the microtubule cytoskeleton, leading to mitotic arrest and cell death; however, their clinical efficacy has been hampered due to the development of drug resistance. Therefore, other proteins involved in spindle assembly are being examined as potential targets for anticancer therapy. The mitotic kinesin, Eg5 is critical for proper spindle assembly; as such, inhibition of Eg5 leads to mitotic arrest making it a potential anticancer target. We wanted to validate Eg5 as a therapeutic target and determine if Eg5 inhibitors retain activity in Taxol-resistant cells. Using affinity chromatography we first show that the compound HR22C16 is an Eg5 inhibitor and does not interact with other microtubule motor proteins tested. Furthermore, HR22C16 along with its analogs, inhibit cell survival in both Taxol-sensitive and -resistant ovarian cancer cells with at least 15-fold greater efficacy than monastrol, the first generation Eg5 inhibitor. Further analysis with HR22C16-A1, the most potent HR22C16 analog, showed that it retains efficacy in PgP-overexpressing cells, suggesting that it is not a PgP substrate. We further show that HR22C16-A1 induces cell death following mitotic arrest via the intrinsic apoptotic pathway. Interestingly, the combination of HR22C16-A1 with Taxol results in an antagonistic antiproliferative and antimitotic effect, possibly due to the abrogation of Taxol-induced mitotic spindles by HR22C16-A1. Taken together, our results show that Eg5 inhibitors have promising anticancer activity and can be potentially used to overcome Taxol resistance in the clinical setting.	Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10021 USA	Emory University; Rockefeller University	Giannakakou, P (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA.	pgianna@emory.edu		Peters, Ulf/0000-0003-4664-8198; Injac, Sarah/0000-0002-6389-369X	NCI NIH HHS [R01 CA100202, 1R01 CA100202-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM65933] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065933] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cassimeris Lynne, 2003, Current Issues in Molecular Biology, V5, P99; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; Desai A, 1999, METHOD CELL BIOL, V61, P385; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Garrett S, 2003, CURR BIOL, V13, pR810, DOI 10.1016/j.cub.2003.09.052; Geney R, 2002, CLIN CHEM LAB MED, V40, P918, DOI 10.1515/CCLM.2002.161; Giannakakou P, 1998, INT J CANCER, V75, P57, DOI 10.1002/(SICI)1097-0215(19980105)75:1<57::AID-IJC10>3.3.CO;2-V; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HEGDE PS, 2004, P AN M AM SOC CLIN, V22, P134; Hotha S, 2003, ANGEW CHEM INT EDIT, V42, P2379, DOI 10.1002/anie.200351173; HOULISTON E, 1994, DEV BIOL, V164, P147, DOI 10.1006/dbio.1994.1187; Jordan M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P1, DOI 10.2174/1568011023354290; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kapoor TM, 2001, J CELL BIOL, V154, P1125, DOI 10.1083/jcb.200106011; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Martello LA, 2000, CLIN CANCER RES, V6, P1978; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Rowinsky EK, 1997, ANNU REV MED, V48, P353; SAFRIT JT, 1993, GYNECOL ONCOL, V48, P214, DOI 10.1006/gyno.1993.1036; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Uzbekov R, 1999, MICROSC RES TECHNIQ, V45, P31, DOI 10.1002/(SICI)1097-0029(19990401)45:1<31::AID-JEMT3>3.0.CO;2-K; Whitehead CM, 1998, J CELL SCI, V111, P2551; Wilson L, 1999, CELL STRUCT FUNCT, V24, P329, DOI 10.1247/csf.24.329; Yuan SY, 2002, UROL RES, V30, P282, DOI 10.1007/s00240-002-0263-4; Zhou J, 2002, J BIOL CHEM, V277, P39777, DOI 10.1074/jbc.M203927200	31	151	159	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11569	11577		10.1074/jbc.M413471200	http://dx.doi.org/10.1074/jbc.M413471200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653676	hybrid, Green Accepted			2022-12-25	WOS:000227761800083
J	Morty, RE; Pelle, R; Vadasz, I; Uzcanga, GL; Seeger, W; Bubis, J				Morty, RE; Pelle, R; Vadasz, I; Uzcanga, GL; Seeger, W; Bubis, J			Oligopeptidase B from Trypanosoma evansi - A parasite peptidase that inactivates atrial natriuretic factor in the bloodstream of infected hosts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUCEI-BRUCEI; SERINE OLIGOPEPTIDASES; PROLYL OLIGOPEPTIDASE; AFRICAN TRYPANOSOMES; RAT; CRUZI; PURIFICATION; PROTEINASE; SPECIFICITY; CONGOLENSE	Serine oligopeptidases of trypanosomatids are emerging as important virulence factors and therapeutic targets in trypanosome infections. We report here the isolation and characterization of oligopeptidase B ( OpdB) and its corresponding gene from Trypanosoma evansi, a pathogen of significant veterinary importance. The T. evansi opdB gene was present as a single copy per haploid genome containing an open reading frame of 2148 bp encoding a protein of 80.664 kDa. Purified OpdB hydrolyzed substrates with basic residues in P-1 ( k(cat)/ Km for carbobenzyloxy-(L)-arginyl-(L)-arginyl-7-amido-4-methylcoumarin, 337s(-1.)mu M-1) and exhibited potent arginyl carboxypeptidase activity ( kcat/ Km for Val-Lys-Arg down arrow Arg-OH, 231 s(-1.)mM(-1)). While not secreted, T. evansi released OpdB into the plasma of infected hosts where it retained catalytic activity. Plasma OpdB levels correlated with blood parasitemia. In vitro, OpdB cleaved the peptide hormone atrial natriuretic factor (ANF) at four sites: Arg(3)down arrow Arg(4), Arg(4)down arrow Ser(5), Arg(11)down arrow Ile(12), and Arg(27)down arrow Tyr(28), thereby abrogating smooth muscle relaxant and prohypotensive properties of ANF. Circulating plasma ANF levels in T. evansi-infected rats were depressed from 130 to 8 pg(.)ml(-1), and plasma ANF levels inversely correlated with plasma OpdB activity. The in vitro half-life of ANF in rat plasma was reduced 300-fold in plasma from T. evansi-infected rodents, which contains high levels of OpdB activity. Addition of OpdB inhibitors to cell-free plasma from infected rodents significantly abrogated this ANF hydrolysis. Furthermore the in vivo ANF half-life was reduced 5-fold in T. evansi-infected rats. Thus, we propose a role for OpdB in peptide hormone dysregulation in trypanosomiasis, specifically in generating the depressed plasma levels of ANF in mammals infected with T. evansi.	Univ Giessen, Ctr Med, Dept Internal Med, D-35392 Giessen, Germany; Int Livestock Res Inst, Nairobi, Kenya; Univ Simon Bolivar, Dept Biol Celular, Caracas 1081A, Venezuela	Justus Liebig University Giessen; CGIAR; International Livestock Research Institute (ILRI); Simon Bolivar University	Morty, RE (corresponding author), Univ Giessen, Ctr Med, Dept Internal Med, Aulweg 123,Raum 6-11, D-35392 Giessen, Germany.	rory.morty@innere.med.uni-giessen.giessen.de	Vadasz, Istvan/AAO-8288-2021	Uzcanga, Graciela Lucia/0000-0003-1680-2086; Vadasz, Istvan/0000-0003-1370-9783; Bubis, Jose/0000-0002-8839-6745; Seeger, Werner/0000-0003-1946-0894				ABEBE G, 1993, ACTA ENDOCRINOL-COP, V129, P75, DOI 10.1530/acta.0.1290075; Aiyar A, 2000, Methods Mol Biol, V132, P221; ANOSA V O, 1976, Tropical Animal Health and Production, V8, P14, DOI 10.1007/BF02383360; Biswas D, 2001, EXP PARASITOL, V99, P148, DOI 10.1006/expr.2001.4664; BOREHAM PFL, 1976, BRIT J PHARMACOL, V58, P137, DOI 10.1111/j.1476-5381.1976.tb07702.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brun R, 1998, VET PARASITOL, V79, P95, DOI 10.1016/S0304-4017(98)00146-0; Burleigh BA, 1997, J CELL BIOL, V136, P609, DOI 10.1083/jcb.136.3.609; CONDRA CL, 1988, J CLIN INVEST, V81, P1348, DOI 10.1172/JCI113462; DEBOLD AJ, 1982, P SOC EXP BIOL MED, V170, P133; DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713; Desquesnes M, 1996, Rev Elev Med Vet Pays Trop, V49, P322; Fulop V, 2000, EMBO REP, V1, P277, DOI 10.1093/embo-reports/kvd048; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Goossens B, 1998, VET PARASITOL, V79, P283, DOI 10.1016/S0304-4017(98)00171-X; GRAB DJ, 1987, J CELL BIOL, V105, P737, DOI 10.1083/jcb.105.2.737; Grellier P, 2001, J BIOL CHEM, V276, P47078, DOI 10.1074/jbc.M106017200; GROS C, 1990, EUR J PHARMACOL, V179, P45, DOI 10.1016/0014-2999(90)90400-Z; HARRIS P, 1987, BRIT HEART J, V58, P190; Hemerly JP, 2003, BIOCHEM J, V373, P933, DOI 10.1042/BJ20030342; Hermanson G.T., 1992, IMMOBILIZED AFFINITY; HEUMANN D, 1989, MOL BIOCHEM PARASIT, V33, P67, DOI 10.1016/0166-6851(89)90043-1; Hoare C, 1972, TRYPANOSOMES MAMMALS; HUBLART M, 1990, ACTA TROP, V47, P177, DOI 10.1016/0001-706X(90)90024-T; Jaffe CL, 2003, PARASITOL RES, V91, P229, DOI 10.1007/s00436-003-0960-0; LONSDALEECCLES JD, 1995, BIOCHEM J, V305, P549, DOI 10.1042/bj3050549; LUBBESMEYER HJ, 1988, AM J PHYSIOL, V254, pR567, DOI 10.1152/ajpregu.1988.254.4.R567; Maack T, 1996, KIDNEY INT, V49, P1732, DOI 10.1038/ki.1996.257; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Mackey ZB, 2004, J BIOL CHEM, V279, P48426, DOI 10.1074/jbc.M402470200; Maugeri DA, 2004, FEMS MICROBIOL LETT, V234, P117, DOI 10.1016/j.femsle.2004.03.018; MISONO KS, 1984, BIOCHEM BIOPH RES CO, V123, P444, DOI 10.1016/0006-291X(84)90250-X; MORRISON WI, 1981, AM J PATHOL, V102, P168; Morty RE, 1999, J BIOL CHEM, V274, P26149, DOI 10.1074/jbc.274.37.26149; Morty RE, 1999, MOL BIOCHEM PARASIT, V102, P145, DOI 10.1016/S0166-6851(99)00097-3; Morty RE, 2002, J BACTERIOL, V184, P3329, DOI 10.1128/JB.184.12.3329-3337.2002; Morty RE, 2001, INFECT IMMUN, V69, P2757, DOI 10.1128/IAI.69.4.2757-2761.2001; MURTHY KK, 1988, BIOCHEM J, V250, P665, DOI 10.1042/bj2500665; NDUNGU JM, 1991, J SMALL ANIM PRACT, V32, P579, DOI 10.1111/j.1748-5827.1991.tb00891.x; NDUNGU JM, 1992, PARASITOL RES, V78, P553, DOI 10.1007/BF00936451; Okenu DMN, 1999, PARASITOL RES, V85, P424, DOI 10.1007/s004360050571; OLINS GM, 1987, BIOCHIM BIOPHYS ACTA, V901, P97, DOI 10.1016/0005-2736(87)90260-4; PELLE R, 1993, MOL BIOCHEM PARASIT, V59, P277, DOI 10.1016/0166-6851(93)90225-M; Rao MR, 1998, DRUG CHEM TOXICOL, V21, P27, DOI 10.3109/01480549809017848; SANTANA JM, 1992, BIOCHEM BIOPH RES CO, V187, P1466, DOI 10.1016/0006-291X(92)90467-Y; Santana JM, 1997, BIOCHEM J, V325, P129, DOI 10.1042/bj3250129; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Simonsen U, 1999, J PHYSIOL-LONDON, V516, P271, DOI 10.1111/j.1469-7793.1999.271aa.x; SOUDAN B, 1993, EXP CLIN ENDOCRINOL, V101, P166, DOI 10.1055/s-0029-1211225; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; SUGIMOTO K, 1992, AGENT ACTION SUPPL, V38, P376; SUGIYAMA M, 1984, BIOCHEM BIOPH RES CO, V123, P338, DOI 10.1016/0006-291X(84)90418-2; TETAERT D, 1993, INT J PEPT PROT RES, V41, P147; THIBAULT G, 1985, BIOCHEM BIOPH RES CO, V130, P981, DOI 10.1016/0006-291X(85)91711-5; THIBAULT G, 1984, BIOCHEM BIOPH RES CO, V125, P938, DOI 10.1016/0006-291X(84)91374-3; TIZARD I, 1978, MICROBIOL REV, V42, P661, DOI 10.1128/MMBR.42.4.664-681.1978; Troeberg L, 1999, EXP PARASITOL, V91, P349, DOI 10.1006/expr.1998.4386; Troeberg L, 1996, EUR J BIOCHEM, V238, P728, DOI 10.1111/j.1432-1033.1996.0728w.x; Wise W C, 1989, Prog Clin Biol Res, V299, P243; Yamaguchi K, 2000, SHOCK, V14, P535, DOI 10.1097/00024382-200014050-00007	61	55	63	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10925	10937		10.1074/jbc.M410066200	http://dx.doi.org/10.1074/jbc.M410066200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644339	hybrid			2022-12-25	WOS:000227761800008
J	Sanggaard, KW; Karring, H; Valnickova, Z; Thogersen, IB; Enghild, JJ				Sanggaard, KW; Karring, H; Valnickova, Z; Thogersen, IB; Enghild, JJ			The TSG-6 and I alpha I interaction promotes a transesterification cleaving the protein-glycosaminoglycan-protein (PGP) cross-link	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL-ELECTROPHORESIS; TRYPSIN-INHIBITOR; EXTRACELLULAR-MATRIX; HEAVY-CHAINS; HYALURONAN; BIKUNIN; BINDING; SEQUENCE; COMPLEX; FAMILY	During co-incubation of human inter-alpha-inhibitor (I alpha I) and human tumor necrosis factor-stimulated gene 6 protein (TSG-6) SDS-stable interactions are formed between the two proteins. We have analyzed the products of this reaction and characterized the mechanism of complex formation. Following the incubation seven new bands not previously identified were apparent in SDS-PAGE. Three of these bands did not contain TSG-6, including heavy chain (HC)1 center dot bikunin, HC2 center dot bikunin, and free bikunin. In addition high molecular weight complexes composed of the same components as I alpha I, including HC1, HC2, and bikunin, were formed. The formation of these complexes was prevented by the addition of hyaluronan. The cross-links stabilizing these complexes displaying properties similar to the protein-glycosaminoglycan-protein (PGP) cross-link. The TSG-6-containing SDS-stable complexes were composed of HC1 center dot TSG-6 or HC2 center dot TSG-6 exclusively. Both glycosylated and non-glycosylated TSG-6 participated in the complex formation. The HC center dot TSG-6 cross-links were different from the PGP cross-link and were determined to be ester bonds between the alpha-carbonyl of the C-terminal Asp of the heavy chain and most likely a hydroxyl group containing the TSG-6 residue. The mechanism involved cleaving the PGP cross-link of I alpha I during a transesterification reaction. A TSG-6 hydroxyl group reacts with the ester bond between the alpha-carbonyl of the C-terminal Asp residues of HC1 or HC2 and carbon-6 of an internal N-acetylgalactosamine of the chondroitin-4-sulfate chain. An intermediate is formed resulting in a partitioning of the reaction between HC(1 or 2)center dot TSG-6 complexes and transfer of HC(1 or 2) to the chondroitin via competing pathways.	Aarhus Univ, Dept Mol Biol, Ctr Insoluble Prot Struct, DK-8000 Aarhus, Denmark	Aarhus University	Enghild, JJ (corresponding author), Aarhus Univ, Dept Mol Biol, Ctr Insoluble Prot Struct, Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark.	jje@mb.au.dk		Enghild, Jan Johannes/0000-0001-9292-9172; Karring, Henrik/0000-0002-4672-1503				BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; Enghild JJ, 1999, BIOCHEMISTRY-US, V38, P11804, DOI 10.1021/bi9908540; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; POTEMPA J, 1989, J BIOL CHEM, V264, P15109; POWERS RW, 1995, AM J PHYSIOL, V269, P290; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; SCHAGGER H, 1988, ANAL BIOCHEM, V173, P201, DOI 10.1016/0003-2697(88)90179-0; Steinbuch M, 1976, Methods Enzymol, V45, P760; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URIEL J, 1968, NATURE, V218, P578, DOI 10.1038/218578b0; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	32	44	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11936	11942		10.1074/jbc.M409016200	http://dx.doi.org/10.1074/jbc.M409016200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653696	hybrid			2022-12-25	WOS:000227761800124
J	Schnepp, A; Lindgren, PK; Hulsmann, H; Kroger, S; Paulsson, M; Hartmann, U				Schnepp, A; Lindgren, PK; Hulsmann, H; Kroger, S; Paulsson, M; Hartmann, U			Mouse testican-2 - Expression, glycosylation, and effects on neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; STRUCTURAL CHARACTERIZATION; PROTEOGLYCAN; BINDING; BRAIN; PROTEIN; ATTACHMENT; LAMININ; MODULE; MATRIX	Mouse testican-2 was cloned, sequenced, and shown to be a proteoglycan with a multidomain structure closely similar to that of the human ortholog, previously described as a calcium binding extracellular matrix molecule of the BM-40/SPARC/osteonectin family (Vannahme, C., Schubel, S., Herud, M., Gosling, S., Hulsmann, H., Paulsson, M., Hartmann, U., and Maurer, P. (1999). J. Neurochem. 73, 12 - 20). Recombinant mouse testican-2 was used to prepare specific antibodies that allowed the detection of testican-2 in various brain structures but also in lung, testis, and in several endocrine glands. Although the testican-2 expressed in EBNA-293 cells carried both heparan sulfate and chondroitin/dermatan sulfate glycosaminoglycan chains, the tissue form always contained only heparan sulfate. Both tissue-derived and recombinant testican-2 carried N-linked glycans. Tissue-derived forms of testican-2 were detected as proteoglycans of varying size, whereas a portion of the molecules produced by EBNA-293 cells were core proteins, lacking glycosaminoglycans. Both the proteoglycan and core protein forms of testican-2 inhibited neurite extension from cultured primary cerebellar neurons and may play regulatory roles in the development of the central nervous system.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany	University of Cologne; University of Cologne; Johannes Gutenberg University of Mainz	Hartmann, U (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzman Str 52, D-50931 Cologne, Germany.	ursula.hartmann@uni-koeln.de		Kroger, Stephan/0000-0002-4626-1690				ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; BaSalamah MAM, 2001, BIOCHEM BIOPH RES CO, V283, P1083, DOI 10.1006/bbrc.2001.4900; Bocock JP, 2003, EUR J BIOCHEM, V270, P4008, DOI 10.1046/j.1432-1033.2003.03789.x; Bonnet F, 1996, J BIOL CHEM, V271, P4373; BONNET F, 1992, BIOCHEM J, V288, P565, DOI 10.1042/bj2880565; Charbonnier F, 2000, MECH DEVELOP, V90, P317, DOI 10.1016/S0925-4773(99)00255-5; Charbonnier F, 1998, GENOMICS, V48, P377, DOI 10.1006/geno.1997.5199; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; EDGAR D, 1984, EMBO J, V3, P1463, DOI 10.1002/j.1460-2075.1984.tb01997.x; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Hartmann U, 2001, MATRIX BIOL, V20, P23, DOI 10.1016/S0945-053X(00)00137-2; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; Marr HS, 2003, MATRIX BIOL, V22, P259, DOI 10.1016/S0945-053X(03)00036-2; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Nakada M, 2003, CANCER RES, V63, P3364; Nakada M, 2001, CANCER RES, V61, P8896; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OOHIRA A, 1994, NEUROSCI RES, V20, P195, DOI 10.1016/0168-0102(94)90088-4; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; TRENKNER E, 1977, J CELL BIOL, V75, P915, DOI 10.1083/jcb.75.3.915; Vannahme C, 2002, J BIOL CHEM, V277, P37977, DOI 10.1074/jbc.M203830200; Vannahme C, 1999, J NEUROCHEM, V73, P12, DOI 10.1046/j.1471-4159.1999.0730012.x; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200	27	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11274	11280		10.1074/jbc.M414276200	http://dx.doi.org/10.1074/jbc.M414276200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657052	hybrid			2022-12-25	WOS:000227761800047
J	Sumpio, BE; Yun, S; Cordova, AC; Haga, M; Zhang, J; Koh, Y; Madri, JA				Sumpio, BE; Yun, S; Cordova, AC; Haga, M; Zhang, J; Koh, Y; Madri, JA			MAPKs (ERK1/2, p38) and AKT can be phosphorylated by shear stress independently of platelet endothelial cell adhesion molecule-1 (CD31) in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC STRAIN; TYROSINE PHOSPHORYLATION; FLUID-FLOW; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CYTOSOLIC CA2+; G-PROTEINS; PECAM-1; ACTIVATION; PATHWAYS	PECAM- 1 ( CD31) is a member of the Ig superfamily of cell adhesion molecules and is expressed on endothelial cells ( EC) as several circulating blood elements including platelets, polymorphonuclear leukocytes, monocytes, and lymphocytes. PECAM- 1 tyrosine phosphorylation has been observed following mechanical stimulation of EC but its role in mechanosensing is still incompletely understood. The aim of this study was to investigate the involvement of PECAM- 1 in signaling cascades in response to fluid shear stress ( SS) in vascular ECs. PECAM- 1- deficient ( KO) and PECAM- reconstituted murine microvascular ECs, 50 and 100% confluent bovine aortic EC ( BAEC), and human umbilical vein EC ( HUVEC) transfected with antisense PECAM- 1 oligonucleotides were exposed to oscillatory SS ( 14 dynes/ cm(2)) for 0, 5, 10, 30 or 60 min. The tyrosine phosphorylation level of PECAM- 1 immunoprecipitated from SS- stimulated PECAM- reconstituted, but not PECAM- 1- KO, murine ECs increased. Although PECAM- 1 was phosphorylated in 100% confluent BAEC and HUVEC, its phosphorylation level in 50% confluent BAECs or HUVEC was not detected by SS. Likewise PECAM- 1 phosphorylation was robust in the wild type and scrambled-transfected HUVEC but not in the PECAM- 1 antisense-HUVEC. ERK1/ 2, p38 MAPK, and AKT were activated by SS in all cell types tested, including the PECAM- 1- KO murine ECs, 50% confluent BAECs, and HUVEC transfected with antisense PECAM- 1. This suggests that PECAM-1 may not function as a major mechanoreceptor for activation of MAPK and AKT in ECs and that there are likely to be other mechanoreceptors in ECs functioning to detect shear stress and trigger intercellular signals.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Catholic Univ, Sch Med, Dept Surg, Seoul, South Korea	Yale University; Yale University; Catholic University of Korea	Sumpio, BE (corresponding author), Yale Univ, Sch Med, Dept Vasc Surg, 333 Cedar St,FMB 137, New Haven, CT 06510 USA.	bauer.sumpio@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054732, R37HL028373] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0I HL-54732, R37 HL-28373] Funding Source: Medline; PHS HHS [P01-KD55389] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; ANDO J, 1988, IN VITRO CELL DEV B, V24, P871; AWOLESI MA, 1995, J CLIN INVEST, V96, P1449, DOI 10.1172/JCI118181; Azuma N, 2000, J VASC SURG, V32, P789, DOI 10.1067/mva.2000.107989; Azuma N, 2001, AM J PHYSIOL-HEART C, V280, pH189, DOI 10.1152/ajpheart.2001.280.1.H189; Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011; Cohen CR, 1997, EXP CELL RES, V231, P184, DOI 10.1006/excr.1996.3450; DARDIK A, 2005, IN PRESS J VASC SURG; Davies PF, 2002, ARTERIOSCL THROM VAS, V22, P1755, DOI 10.1161/01.ATV.0000034391.00347.71; Duncan GS, 1999, J IMMUNOL, V162, P3022; Fujiwara K, 2001, CELL STRUCT FUNCT, V26, P11, DOI 10.1247/csf.26.11; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Gratzinger D, 2003, BIOCHEM BIOPH RES CO, V301, P243, DOI 10.1016/S0006-291X(02)02982-0; Gudi SRP, 1996, CIRC RES, V79, P834, DOI 10.1161/01.RES.79.4.834; Haga M, 2003, ENDOTHELIUM-J ENDOTH, V10, P149, DOI 10.1080/713715223; HARADA N, 1995, BIOCHEM BIOPH RES CO, V214, P69, DOI 10.1006/bbrc.1995.2257; Ikeda M, 1999, AM J PHYSIOL-HEART C, V276, pH614; Ilan N, 2000, J BIOL CHEM, V275, P21435, DOI 10.1074/jbc.M001857200; Ilan N, 2003, CURR OPIN CELL BIOL, V15, P515, DOI 10.1016/S0955-0674(03)00100-5; Ilan N, 1999, J CELL SCI, V112, P3005; Kaufman DA, 2004, BIOCHEM BIOPH RES CO, V320, P1076, DOI 10.1016/j.bbrc.2004.06.055; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; Kito H, 2000, J APPL PHYSIOL, V89, P2391, DOI 10.1152/jappl.2000.89.6.2391; Kraiss LW, 2000, AM J PHYSIOL-HEART C, V278, pH1537, DOI 10.1152/ajpheart.2000.278.5.H1537; KUCHAN MJ, 1994, AM J PHYSIOL, V267, pC753, DOI 10.1152/ajpcell.1994.267.3.C753; LI W, 2005, IN PRESS AM J PHYSL; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Lu TT, 1996, P NATL ACAD SCI USA, V93, P11808, DOI 10.1073/pnas.93.21.11808; Maas M, 2003, AM J PHYSIOL-HEART C, V285, pH2336, DOI 10.1152/ajpheart.00509.2003; MO M, 1991, AM J PHYSIOL, V260, pH1698, DOI 10.1152/ajpheart.1991.260.5.H1698; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Newman PJ, 2003, ARTERIOSCL THROM VAS, V23, P953, DOI 10.1161/01.ATV.0000071347.69358.D9; OHNO M, 1993, CIRCULATION, V88, P193, DOI 10.1161/01.CIR.88.1.193; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; Osawa M, 1997, EUR J CELL BIOL, V72, P229; Rosales OR, 1997, BIOCHEM J, V326, P385, DOI 10.1042/bj3260385; SCHILLING WP, 1992, EXP CELL RES, V198, P31, DOI 10.1016/0014-4827(92)90145-X; SHEN J, 1992, AM J PHYSIOL, V262, P384; Solowiej A, 2003, AM J PATHOL, V162, P953, DOI 10.1016/S0002-9440(10)63890-4; SUMPIO BE, 1993, HEMODYNAMIC FORCES V; Wong CWY, 2000, MOL BIOL CELL, V11, P3109, DOI 10.1091/mbc.11.9.3109; XIE Y, 1993, P NATL ACAD SCI USA, V90, P5569, DOI 10.1073/pnas.90.12.5569; YANO Y, 1996, AM J PHYSIOL, V271, P635; Yun SS, 2002, J BIOL CHEM, V277, P34808, DOI 10.1074/jbc.M205417200	45	58	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11185	11191		10.1074/jbc.M414631200	http://dx.doi.org/10.1074/jbc.M414631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15668248	hybrid			2022-12-25	WOS:000227761800039
J	Panchal, RG; Halverson, KM; Ribot, W; Lane, D; Kenny, T; Abshire, TG; Ezzell, JW; Hoover, TA; Powell, B; Little, S; Kasianowicz, JJ; Bavari, S				Panchal, RG; Halverson, KM; Ribot, W; Lane, D; Kenny, T; Abshire, TG; Ezzell, JW; Hoover, TA; Powell, B; Little, S; Kasianowicz, JJ; Bavari, S			Purified Bacillus anthracis lethal toxin complex formed in Vitro and during infection exhibits functional and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTECTIVE ANTIGEN COMPONENT; PROTEIN-KINASE KINASE; PLANAR LIPID-BILAYERS; PROTEOLYTIC INACTIVATION; MAMMALIAN-CELLS; FACTOR CLEAVES; EDEMA FACTOR; N-TERMINUS; MEMBRANE; CHANNEL	Anthrax protective antigen (PA, 83 kDa), a pore-forming protein, upon protease activation to 63 kDa (PA(63)), translocates lethal factor (LF) and edema factor (EF) from endosomes into the cytosol of the cell. The relatively small size of the heptameric PA(63) pore (similar to 12 angstrom) raises questions as to how large molecules such as LF and EF can move through the pore. In addition, the reported high binding affinity between PA and EF/LF suggests that EF/LF may not dissociate but remain complexed with activated PA(63). In this study, we found that purified (PA(63))(7)-LF complex exhibited biological and functional activities similar to the free LF. Purified LF complexed with PA(63) heptamer was able to cleave both a synthetic peptide substrate and endogenous mitogen-activated protein kinase kinase substrates and kill susceptible macrophage cells. Electrophysiological studies of the complex showed strong rectification of the ionic current at positive voltages, an effect similar to that observed if LF is added to the channels formed by heptameric PA(63) pore. Complexes of (PA(63))(7)-LF found in the plasma of infected animals showed functional activity. Identifying active complex in the blood of infected animals has important implications for therapeutic design, especially those directed against PA and LF. Our studies suggest that the individual toxin components and the complex must be considered as critical targets for anthrax therapeutics.	USAMRIID, Frederick, MD 21702 USA; NCI SAIC Frederick, NIH, Dev Therapeut Program, Target Struct Based Drug Discovery Grp, Frederick, MD 21702 USA; NIST, Gaithersburg, MD 20899 USA	United States Army Medical Research Institute of Infectious Diseases; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institute of Standards & Technology (NIST) - USA	Panchal, RG (corresponding author), USAMRIID, 1425 Porter St, Frederick, MD 21702 USA.	rekha.panchal@amedd.army.mil; sina.bavari@amedd.army.mil	Bavari, Sina/L-3642-2019; Panchal, Rekha/None	Bavari, Sina/0000-0001-8424-5635; Ribot, Wilson/0000-0002-9691-4004; Panchal, Rekha/0000-0001-8621-9078				Abrami L, 2004, J CELL BIOL, V166, P645, DOI 10.1083/jcb.200312072; Agrawal A, 2003, NATURE, V424, P329, DOI 10.1038/nature01794; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P905, DOI 10.1085/jgp.96.5.905; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Di Marzio EA, 2003, J CHEM PHYS, V119, P6378, DOI 10.1063/1.1603725; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Duesbery NS, 1999, CELL MOL LIFE SCI, V55, P1599, DOI 10.1007/s000180050399; Duesbery NS, 1999, J APPL MICROBIOL, V87, P289, DOI 10.1046/j.1365-2672.1999.00892.x; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; Erwin JL, 2001, INFECT IMMUN, V69, P1175, DOI 10.1128/IAI.69.2.1175-1177.2001; EZZELL JW, 1992, J GEN MICROBIOL, V138, P543, DOI 10.1099/00221287-138-3-543; FINKELSTEIN A, 1994, TOXICOLOGY, V87, P29, DOI 10.1016/0300-483X(94)90153-8; KASIANOWICZ JJ, 1995, BIOPHYS J, V69, P94, DOI 10.1016/S0006-3495(95)79879-4; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LITTLE SF, 1988, INFECT IMMUN, V56, P1807, DOI 10.1128/IAI.56.7.1807-1813.1988; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Nguyen TL, 2004, J BIOMOL STRUCT DYN, V22, P253, DOI 10.1080/07391102.2004.10531226; Panchal RG, 2004, NAT STRUCT MOL BIOL, V11, P67, DOI 10.1038/nsmb711; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Pellizzari R, 2000, INT J MED MICROBIOL, V290, P421; Popov SG, 2002, FEBS LETT, V527, P211, DOI 10.1016/S0014-5793(02)03228-3; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Singh Y, 1999, INFECT IMMUN, V67, P1853; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Zhang S, 2004, BIOPHYS J, V87, P3842, DOI 10.1529/biophysj.104.050864; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	37	47	49	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10834	10839		10.1074/jbc.M412210200	http://dx.doi.org/10.1074/jbc.M412210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644338	hybrid			2022-12-25	WOS:000227559600131
J	Yang, CS; Yu, CC; Chuang, HC; Chang, CW; Chang, GD; Yao, TP; Chen, HW				Yang, CS; Yu, CC; Chuang, HC; Chang, CW; Chang, GD; Yao, TP; Chen, HW			FBW2 targets GCMa to the ubiquitin-proteasome degradation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; DNA-BINDING; C-MYC; PROTEIN STABILITY; BETA-CATENIN; CELLS; DROSOPHILA; LIGASE; SKP2; EXPRESSION	The GCM proteins GCMa/1 and GCMb/2 are novel zinc-containing transcription factors critical for glial cell differentiation in fly and for placental as well as parathyroid gland development in mouse. Previous pulse-chase experiments have demonstrated differential protein stabilities of GCM proteins with half-lives from similar to 30 min to 2 h (Tuerk, E. E., Schreiber, J., and Wegner, M. (2000) J. Biol. Chem. 275, 4774-4782). However, little is known about the machinery that controls GCM protein degradation. Here, we report the identification of an SCF complex as the GCM ubiquitin-protein isopeptide ligase (E3) that regulates human GCMa (hGCMa) degradation. We found that SKP1 and CUL1, two key components of the SCF complex, associate with hGCMa in vivo. We further identify the human F-box protein FBW2 (hFBW2) as the substrate recognition subunit in the SCF E3 complex for hGCMa. We show that hFBW2 interacts with hGCMa in a phosphorylation-dependent manner and promotes hGCMa ubiquitination. Supporting a critical role for hFBW2 in hGCMa degradation, knockdown of hFBW2 expression by RNA interference leads to a reduction in hGCMa ubiquitination and a concomitant increase in hGCMa protein stability. Our study identifies the SCFhFBW2 E3 complex as the key machinery that targets hGCMa to the ubiquitin-proteasome degradation system.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Grad Inst Biochem Sci, Taipei 106, Taiwan; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Academia Sinica - Taiwan; National Taiwan University; Duke University	Chen, HW (corresponding author), Acad Sinica, Inst Biol Chem, Rm 609,128 Acad Rd,Sect 2, Taipei 115, Taiwan.	hwchen@gate.sinica.edu.tw	Chang, Ching-Wen/N-7867-2018	Chang, Ching-Wen/0000-0002-5693-3809				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Alfonso TB, 2002, DEV BIOL, V248, P369, DOI 10.1006/dbio.2002.0740; Anson-Cartwright L, 2000, NAT GENET, V25, P311, DOI 10.1038/77076; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Basyuk E, 1999, DEV DYNAM, V214, P303, DOI 10.1002/(SICI)1097-0177(199904)214:4<303::AID-AJA3>3.3.CO;2-2; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen CP, 2004, PLACENTA, V25, P413, DOI 10.1016/j.placenta.2003.10.014; Cohen SX, 2003, EMBO J, V22, P1835, DOI 10.1093/emboj/cdg182; Gunther T, 2000, NATURE, V406, P199, DOI 10.1038/35018111; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kammerer M, 2001, EMBO J, V20, P4664, DOI 10.1093/emboj/20.17.4664; Kanemura Y, 1999, FEBS LETT, V442, P151, DOI 10.1016/S0014-5793(98)01650-0; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Schreiber J, 2000, MOL CELL BIOL, V20, P2466, DOI 10.1128/MCB.20.7.2466-2474.2000; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Schreiber J, 1998, NUCLEIC ACIDS RES, V26, P2337, DOI 10.1093/nar/26.10.2337; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tuerk EE, 2000, J BIOL CHEM, V275, P4774, DOI 10.1074/jbc.275.7.4774; Van de Bor V, 2002, CURR OPIN GENET DEV, V12, P465, DOI 10.1016/S0959-437X(02)00327-1; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yamada K, 1999, J BIOL CHEM, V274, P32279, DOI 10.1074/jbc.274.45.32279; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; Yu CC, 2002, J BIOL CHEM, V277, P50062, DOI 10.1074/jbc.M209316200	40	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10083	10090		10.1074/jbc.M413986200	http://dx.doi.org/10.1074/jbc.M413986200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15640526	hybrid, Green Published			2022-12-25	WOS:000227559600043
J	Phillips, T; Leeuwenburgh, C				Phillips, T; Leeuwenburgh, C			Muscle fiber-specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction	FASEB JOURNAL			English	Article						aging; muscle fiber type; life-extension; exercise	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; MITOCHONDRIAL ABNORMALITIES; IKK-GAMMA; AGE; COMPLEX; MEN; ACTIVATION	Increased tumor necrosis factor-alpha (TNF-alpha) levels have been found with age and are connected to muscle atrophy and cell loss, yet the signaling events that occur in vivo are unknown. Calorie restriction (CR), a robust intervention shown to repeatedly evade the physiological declines associated with aging, has been reported to reduce TNF-alpha and may assist in understanding the mechanisms of muscle sarcopenia. The effects of age and CR on muscle mass, myocyte area, fiber number, myocyte TNF-alpha expression, plasma TNF-alpha levels, and specific elements linked with the TNF-alpha signaling cascade (TNF-R1, IKKgamma, IkappaBalpha, p65, NF-kappaB binding activity, FADD, caspase-8, and DNA fragmentation) were investigated in soleus ( predominately Type I fiber), and superficial vastus lateralis (SVL, predominately Type II fiber), of 6-month-old ad libitum fed (6AL), 26-month-old ad libitum fed (26AL), and 26-month-old calorie-restricted (26CR) male Fischer 344 rats ( CR = 40% restriction compared with ad libitum). Plasma TNF-alpha was increased with age, and the age-associated rise was attenuated with life-long CR. In soleus muscle, we reported a greater capacity to cultivate inflammatory signaling through the transcription factor NF-kappaB compared with that detected in SVL with age. In contrast, in the SVL TNF-alpha stimulated apoptotic signaling with age to a much higher extent than was observed in the soleus. Moreover, a reduction in muscle mass, cross-sectional area, and fiber number in the SVL coincided with this age-linked elevation in apoptosis. In agreement with CR's ability, TNF-alpha stimulation of both inflammatory and apoptotic pathways were abrogated. Our results suggest that TNF-alpha signals transmitted to specific fiber types determine the decision of selecting life or death signaling pathways and are linked to the extent of fiber loss experienced in the aging muscle. Such a specific potential may constitute a major proponent in the pathogenesis of sarcopenia.	Univ Florida, Biochem Aging Lab, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Leeuwenburgh, C (corresponding author), Univ Florida, Biochem Aging Lab, 25 FLG,POB 118206, Gainesville, FL 32611 USA.	cleeuwen@ufl.edu		Leeuwenburgh, Christiaan/0000-0003-0826-4257	NIA NIH HHS [AG21042, R01-AG17994] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG021042, R01AG017994] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALNAQEEB MA, 1987, J ANAT, V153, P31; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Bartke A, 2001, J GERONTOL A-BIOL, V56, pB340, DOI 10.1093/gerona/56.8.B340; Baumgartner RN, 1999, MECH AGEING DEV, V107, P123, DOI 10.1016/S0047-6374(98)00130-4; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; Blough E, 1999, BIOTECHNIQUES, V26, P202, DOI 10.2144/99262bm05; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001; BUA EA, 2004, FASEB J; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chung HY, 2002, MICROSC RES TECHNIQ, V59, P264, DOI 10.1002/jemt.10203; Dalla Libera L, 1999, AM J PHYSIOL-CELL PH, V277, pC982, DOI 10.1152/ajpcell.1999.277.5.C982; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dirks A, 2002, AM J PHYSIOL-REG I, V282, pR519, DOI 10.1152/ajpregu.00458.2001; Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003; Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003; DOHERTY TJ, 1993, J APPL PHYSIOL, V74, P868, DOI 10.1152/jappl.1993.74.2.868; Dutta C, 1997, J NUTR, V127, pS992, DOI 10.1093/jn/127.5.992S; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Greiwe JS, 2001, FASEB J, V15, P475, DOI 10.1096/fj.00-0274com; Gupta S, 2002, J CLIN IMMUNOL, V22, P185, DOI 10.1023/A:1016089607548; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; Kim HJ, 2002, FREE RADICAL BIO MED, V32, P991, DOI 10.1016/S0891-5849(02)00798-0; Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304-3940(97)00190-0; LARSSON L, 1995, PROG NEUROBIOL, V45, P397, DOI 10.1016/0301-0082(95)98601-Z; LARSSON L, 1978, ACTA PHYSIOL SCAND, V103, P31, DOI 10.1111/j.1748-1716.1978.tb06187.x; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LEXELL J, 1995, J GERONTOL A-BIOL, V50, P11; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luff AR, 1998, ANN NY ACAD SCI, V854, P92, DOI 10.1111/j.1749-6632.1998.tb09895.x; MCKIERNAN S, 2004, FASEB J; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morin CL, 1997, J GERONTOL A-BIOL, V52, pB190, DOI 10.1093/gerona/52A.4.B190; Morley JE, 2001, J LAB CLIN MED, V137, P231, DOI 10.1067/mlc.2001.113504; Nair K S, 2000, Mayo Clin Proc, V75 Suppl, pS14; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Paolisso G, 1998, AM J PHYSIOL-ENDOC M, V275, pE294, DOI 10.1152/ajpendo.1998.275.2.E294; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Reid MB, 2001, RESP RES, V2, P269, DOI 10.1186/rr67; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Roubenoff R, 2003, AM J MED, V115, P429, DOI 10.1016/j.amjmed.2003.05.001; Roubenoff R, 1998, J GERONTOL A-BIOL, V53, pM20, DOI 10.1093/gerona/53A.1.M20; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Spaulding CC, 1997, MECH AGEING DEV, V93, P87, DOI 10.1016/S0047-6374(96)01824-6; SPOONER CE, 1992, CLIN IMMUNOL IMMUNOP, V62, pS11, DOI 10.1016/0090-1229(92)90036-N; Suh Y, 2002, MECH AGEING DEV, V123, P881, DOI 10.1016/S0047-6374(02)00025-8; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Vescovo G, 1998, J MOL CELL CARDIOL, V30, P2449, DOI 10.1006/jmcc.1998.0807; World Medical Association, 2002, AM J PHYSIOL-REG I, V283, pR281, DOI DOI 10.1152/AJPREGU.00279.2002; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	60	212	223	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					668	+		10.1096/fj.04-2870fje	http://dx.doi.org/10.1096/fj.04-2870fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665035				2022-12-25	WOS:000226576600014
J	Dedmon, MM; Christodoulou, J; Wilson, MR; Dobson, CM				Dedmon, MM; Christodoulou, J; Wilson, MR; Dobson, CM			Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISFOLDING DISEASES; PARKINSONS-DISEASE; COMMON MECHANISM; PROTEIN; CHAPERONE; HSP70; DNAK; NMR; NEURODEGENERATION; TOXICITY	Parkinson's disease (PD) is a neurodegenerative disorder affecting an estimated 4 million people worldwide. Intracellular proteinaceous inclusions called Lewy bodies are the histological hallmarks of PD and are primarily composed of aggregated alpha-synuclein (alpha Syn). Although the detailed mechanisms remain unclear, mounting evidence suggests that the misfolding of alpha Syn into prefibrillar and fibrillar species is the driving force responsible for cellular toxicity. We show here that the molecular chaperone heat shock protein (Hsp) 70 strongly inhibits alpha Syn fibril formation via preferential binding to prefibrillar species. Moreover, our studies reveal that Hsp70 alters the characteristics of toxic alpha Syn aggregates and indicate that cellular toxicity arises from the prefibrillar forms of alpha Syn. This work therefore elucidates a specific role of Hsp70 in the pathogenesis of PD and supports the general concept that chaperone action is a crucial aspect in protecting against the otherwise damaging consequences of protein misfolding.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia	University of Cambridge; University of Wollongong	Dedmon, MM (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cmd44@cam.ac.uk	Wilson, Mark R/B-3254-2018	Wilson, Mark R/0000-0002-9551-7445; Christodoulou, John/0000-0002-6710-3843				ANTONY T, 1998, P NATL ACAD SCI USA, V95, P9861; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Ben-Zvi AP, 1998, P NATL ACAD SCI USA, V95, P15275, DOI 10.1073/pnas.95.26.15275; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Burkholder WF, 1996, P NATL ACAD SCI USA, V93, P10632, DOI 10.1073/pnas.93.20.10632; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dedmon MM, 2005, J AM CHEM SOC, V127, P476, DOI 10.1021/ja044834j; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dobson CM, 2003, NAT REV DRUG DISCOV, V2, P154, DOI 10.1038/nrd1013; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Fernandez CO, 2004, EMBO J, V23, P2039, DOI 10.1038/sj.emboj.7600211; GETHING MJ, 1997, GUIDEBOOK SERIES, P3; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lee JC, 2004, P NATL ACAD SCI USA, V101, P16466, DOI 10.1073/pnas.0407307101; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Muchowskil PJ, 2002, NEURON, V35, P9, DOI 10.1016/S0896-6273(02)00761-4; Nardai G, 2002, EXP GERONTOL, V37, P1257, DOI 10.1016/S0531-5565(02)00134-1; NORDSTEDT C, 1994, J BIOL CHEM, V269, P30773; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Poon S, 2002, FEBS LETT, V513, P259, DOI 10.1016/S0014-5793(02)02326-8; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Tanaka N, 2002, P NATL ACAD SCI USA, V99, P15398, DOI 10.1073/pnas.242317099; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024; Zerovnik E, 2002, EUR J BIOCHEM, V269, P3362, DOI 10.1046/j.1432-1033.2002.03024.x; Zhang JD, 1998, ARCH BIOCHEM BIOPHYS, V356, P177, DOI 10.1006/abbi.1998.0784	56	199	210	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14733	14740		10.1074/jbc.m413024200	http://dx.doi.org/10.1074/jbc.m413024200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15671022	hybrid			2022-12-25	WOS:000228236800050
J	Kubatzky, KF; Liu, W; Goldgraben, K; Simmerling, C; Smith, SO; Constantinescu, SN				Kubatzky, KF; Liu, W; Goldgraben, K; Simmerling, C; Smith, SO; Constantinescu, SN			Structural requirements of the extracellular to transmembrane domain junction for erythropoietin receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPO RECEPTOR; CROSS-LINKING; JUXTAMEMBRANE DOMAIN; SIGNAL-TRANSDUCTION; PROTEIN HORMONE; HELPER-FREE; HIGH-TITER; ACTIVATION; DIMERIZATION; COMPLEX	The erythropoietin receptor (EpoR) is crucial for erythrocyte formation. The x-ray crystal structures of the EpoR extracellular domain lack the juxtamembrane (JM) region and the junction to the transmembrane (TM) domain. Yet the JM-TM regions are important for transmitting the conformational change imposed on the receptor dimer by Epo binding. Cysteine-scanning mutagenesis of the JM-TM regions identified three novel constitutively active mutants, demonstrating close disulfide-bonded juxtapositioning of these residues in the JM (L223C) and N-terminal TM domain (L226C, I227C). Chemical cross-linking defined the interface of the active helical TM dimer and revealed that the JM-TM segment encompassing Leu(226)-Leu(230) is non-helical. Molecular dynamics and NMR studies indicated that the TM-JM junction forms an N-terminal helix cap. This structure is important for EpoR function because replacement of this motif by consecutive leucines rendered the receptor constitutively active.	Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Catholic Univ Louvain, MEXP Unit, Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium; SUNY Stony Brook, Dept Biochem & Cell Biol, Ctr Struct Biol, Stony Brook, NY 11794 USA	Ludwig Institute for Cancer Research; Universite Catholique Louvain; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Constantinescu, SN (corresponding author), Ludwig Inst Canc Res, B-1200 Brussels, Belgium.	stefan.constantinescu@bru.licr.org	Constantinescu, Stefan N/E-5277-2012	Kubatzky, Katharina F./0000-0003-3739-9329; Constantinescu, Stefan N./0000-0002-8599-2699	NIGMS NIH HHS [GM-46732, R01 GM061678-05, R01 GM061678] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061678, R01GM046732, R55GM046732] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; BENNETT AE, 1995, J CHEM PHYS, V103, P6951, DOI 10.1063/1.470372; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CASE D, 2002, AMBER 7 USERS MANUAL; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Elliott S, 1996, J BIOL CHEM, V271, P24691, DOI 10.1074/jbc.271.40.24691; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Greiser JS, 2002, J BIOL CHEM, V277, P26959, DOI 10.1074/jbc.M204113200; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; LEE GF, 1994, J BIOL CHEM, V269, P29920; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; METZ G, 1994, J MAGN RESON SER A, V110, P219, DOI 10.1006/jmra.1994.1208; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ROST B, 1995, PROTEIN SCI, V4, P521; Ruan WM, 2004, J BIOL CHEM, V279, P3273, DOI 10.1074/jbc.M309311200; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; SAITO H, 1986, MAGN RESON CHEM, V24, P835, DOI 10.1002/mrc.1260241002; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Simmerling C, 2002, J AM CHEM SOC, V124, P11258, DOI 10.1021/ja0273851; SOTIROPOULOS A, 1995, FEBS LETT, V369, P169, DOI 10.1016/0014-5793(95)00734-Q; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Tjandra N, 1997, J AM CHEM SOC, V119, P9576, DOI 10.1021/ja9721374; Tsui V, 2001, BIOPOLYMERS, V56, P275, DOI 10.1002/1097-0282(2000)56:4<275::AID-BIP10024>3.0.CO;2-E; Walters KJ, 1997, NAT STRUCT BIOL, V4, P744, DOI 10.1038/nsb0997-744; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156	52	37	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14844	14854		10.1074/jbc.M411251200	http://dx.doi.org/10.1074/jbc.M411251200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15657048	hybrid			2022-12-25	WOS:000228236800063
J	Li, XJ; Grunwald, D; Mathieu, J; Morel, F; Stasia, MJ				Li, XJ; Grunwald, D; Mathieu, J; Morel, F; Stasia, MJ			Crucial role of two potential cytosolic regions of Nox2, (TSSTKTIRRS200)-T-191 and (484)DESQANHFAVHHDEEKD(500), on NADPH oxidase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; BIOLOGICAL DEFENSE-MECHANISMS; SUPEROXIDE-GENERATING SYSTEM; ELECTRON-TRANSPORT CHAIN; LEUKEMIA CELL-LINE; CYTOCHROME B(558); MICROBICIDAL OXIDASE; FUNCTIONAL-ANALYSIS; FLAVOCYTOCHROME-B	Assembly of cytosolic factors p67(phox) and p47(phox) with cytochrome b(558) is one of the crucial keys for NADPH oxidase activation. Certain sequences of Nox2 appear to be involved in cytosolic factor interaction. The role of the D-loop (TSSTKTIRRS200)-T-191 and the C-terminal (484)DESQANHFAVHHDEEKD(500) of Nox2 on oxidase activity and assembly was investigated. Charged amino acids were mutated to neutral or reverse charge by directed mutagenesis to generate 21 mutants. Recombinant wild-type or mutant Nox2 were expressed in the X-CGD PLB-985 cell model. K195A/E, R198E, R199E, and RR198199QQ/AA mutations in the D-loop of Nox2 totally abolished oxidase activity. However, these D-loop mutants demonstrated normal p47(phox) translocation and iodonitrotetrazolium (INT) reductase activity, suggesting that charged amino acids of this region are essential for electron transfer from FAD to oxygen. Replacement of Nox2 D-loop with its homolog of Nox1, Nox3, or Nox4 was fully functional. In addition, fMLP (formylmethionylleucylphenylalanine)activated R199Q-Nox2 and D-loop(Nox4)-Nox2 mutants exhibited four to eight times the NADPH oxidase activity of control cells, suggesting that these mutations lead to a more efficient oxidase activation process. In contrast, the D484T and D500A/R/G mutants of the alpha-helical loop of Nox2 exhibited no NADPH oxidase and INT reductase activities associated with a defective p47(phox) membrane translocation. This suggests that the alpha-helical loop of the C-terminal of Nox2 is probably involved in the correct assembly of the NADPH oxidase complex occurring during activation, permitting cytosolic factor translocation and electron transfer from NADPH to FAD.	Univ Grenoble 1, Ctr Hosp Univ, Enzymol Lab, Grp Rech & Etud Proc Inflammatoire EA 2938, F-38043 Grenoble, France; Commissariat Energie Atom, Dept Reponse & Dynam Cellulaire, F-38054 Grenoble, France; Serv Sante Armees, Ctr Rech, Dept Radiobiol, F-38702 La Tronche, France	CHU Grenoble Alpes; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Stasia, MJ (corresponding author), Univ Grenoble 1, Ctr Hosp Univ, Enzymol Lab, Grp Rech & Etud Proc Inflammatoire EA 2938, F-38043 Grenoble, France.	MJStasia@chu-grenoble.fr						Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; AZUMA H, 1995, BLOOD, V85, P3274, DOI 10.1182/blood.V85.11.3274.bloodjournal85113274; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BABIOR BM, 1975, J LAB CLIN MED, V85, P235; Baldridge CW, 1933, AM J PHYSIOL, V103, P235, DOI 10.1152/ajplegacy.1932.103.1.235; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; BATO G, 1998, BIOCHIM BIOPHYS ACTA, V406, P188; BELLAVITE P, 1982, INFLAMMATION, V6, P21, DOI 10.1007/BF00910716; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; Biberstine-Kinkade KJ, 1999, J BIOL CHEM, V274, P10451, DOI 10.1074/jbc.274.15.10451; Bionda C, 2004, HUM GENET, V115, P418, DOI 10.1007/s00439-004-1173-z; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; COHENTANUGI L, 1991, EUR J BIOCHEM, V202, P649, DOI 10.1111/j.1432-1033.1991.tb16419.x; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; CROSS AR, 1994, J BIOL CHEM, V269, P21448; Dang PMC, 2002, P NATL ACAD SCI USA, V99, P4262, DOI 10.1073/pnas.072345299; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; Dusi S, 1998, J IMMUNOL, V161, P4968; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Goldblatt D, 2000, CLIN EXP IMMUNOL, V122, P1, DOI 10.1046/j.1365-2249.2000.01314.x; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; Leusen JHW, 2000, BLOOD, V95, P666; MANDELL GL, 1974, INFECT IMMUN, V9, P337, DOI 10.1128/IAI.9.2.337-341.1974; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Paclet MH, 2000, BIOCHEMISTRY-US, V39, P9302, DOI 10.1021/bi000483j; Park MY, 1997, BIOCHEM BIOPH RES CO, V234, P531, DOI 10.1006/bbrc.1997.6672; Pedruzzi E, 2002, BRIT J HAEMATOL, V117, P719, DOI 10.1046/j.1365-2141.2002.03521.x; Rae J, 1998, AM J HUM GENET, V62, P1320, DOI 10.1086/301874; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Roesler J, 1999, EXP HEMATOL, V27, P505, DOI 10.1016/S0301-472X(98)00024-1; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SBARRA AJ, 1959, J BIOL CHEM, V234, P1355; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stasia MJ, 2005, HUM GENET, V116, P72, DOI 10.1007/s00439-004-1208-5; Stasia MJ, 2003, J INFECT DIS, V188, P1593, DOI 10.1086/379035; Stasia MJ, 2002, BBA-MOL BASIS DIS, V1586, P316, DOI 10.1016/S0925-4439(01)00110-7; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TUCKER KA, 1987, BLOOD, V70, P372; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; Yu LX, 1999, BLOOD, V94, P2497, DOI 10.1182/blood.V94.7.2497.419k11_2497_2504; Zhen L, 1998, J BIOL CHEM, V273, P6575, DOI 10.1074/jbc.273.11.6575; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	63	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14962	14973		10.1074/jbc.M500226200	http://dx.doi.org/10.1074/jbc.M500226200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15684431	hybrid			2022-12-25	WOS:000228236800077
J	Robbins, JB; McKinney, MC; Guzman, CE; Sriratana, B; Fitz-Gibbon, S; Ha, T; Cann, IKO				Robbins, JB; McKinney, MC; Guzman, CE; Sriratana, B; Fitz-Gibbon, S; Ha, T; Cann, IKO			The euryarchaeota, nature's medium for engineering of single-stranded DNA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MYCOBACTERIUM-TUBERCULOSIS; DEINOCOCCUS-RADIODURANS; SULFOLOBUS-SOLFATARICUS; REPLICATION; SSB; POLYMERASE; IDENTIFICATION; RECOMBINATION	The architecture of single-stranded DNA-binding proteins, which play key roles in DNA metabolism, is based on different combinations of the oligonucleotide/oligosaccharide binding ( OB) fold. Whereas the polypeptide serving this function in bacteria contains one OB fold, the eukaryotic functional homolog comprises a complex of three proteins, each harboring at least one OB fold. Here we show that unlike these groups of organisms, the Euryarchaeota has exploited the potential in the OB fold to re-invent single-stranded DNA-binding proteins many times. However, the most common form is a protein with two OB folds and one zinc finger domain. We created several deletion mutants of this protein based on its conserved motifs, and from these structures functional chimeras were synthesized, supporting the hypothesis that gene duplication and recombination could lead to novel functional forms of single-stranded DNA-binding proteins. Biophysical studies showed that the orthologs of the two OB fold/one zinc finger replication protein A in Methanosarcina acetivorans and Methanopyrus kandleri exhibit two binding modes, wrapping and stretching of DNA. However, the ortholog in Ferroplasma acidarmanus possessed only the stretching mode. Most interestingly, a second single-stranded DNA-binding protein, FacRPA2, in this archaeon exhibited the wrapping mode. Domain analysis of this protein, which contains a single OB fold, showed that its architecture is similar to the functional homologs thought to be unique to the Crenarchaeotes. Most unexpectedly, genes coding for similar proteins were found in the genomes of eukaryotes, including humans. Although the diversity shown by archaeal single-stranded DNA-binding proteins is unparalleled, the presence of their simplest form in many organisms across all domains of life is of greater evolutionary consequence.	Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Ctr Astrobiol, Los Angeles, CA 90095 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of California System; University of California Los Angeles	Cann, IKO (corresponding author), Univ Illinois, Dept Anim Sci, 1207 W Gregory Dr, Urbana, IL 61801 USA.	icann@uiuc.edu	Ha, Taekjip/B-9506-2009	Ha, Taekjip/0000-0003-2195-6258	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065367, T32GM008276] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM065367, 5T32GM08276, GM65367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALEXEI I, 2002, P NATL ACAD SCI USA, V99, P4644; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bar-Ziv R, 2001, P NATL ACAD SCI USA, V98, P9068, DOI 10.1073/pnas.151242898; Bernstein DA, 2004, P NATL ACAD SCI USA, V101, P8575, DOI 10.1073/pnas.0401331101; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; Chedin F, 1998, TRENDS BIOCHEM SCI, V23, P273, DOI 10.1016/S0968-0004(98)01243-2; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; Dabrowski S, 2002, MICROBIOL-SGM, V148, P3307, DOI 10.1099/00221287-148-10-3307; DEVRIES J, 1994, EUR J BIOCHEM, V224, P613; Eggington JM, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-2; FAY PJ, 1981, J BIOL CHEM, V256, P976; Genschel J, 1996, GENE, V182, P137, DOI 10.1016/S0378-1119(96)00535-5; Handa P, 2001, J BIOL CHEM, V276, P16992, DOI 10.1074/jbc.M100393200; Haseltine CA, 2002, MOL MICROBIOL, V43, P1505, DOI 10.1046/j.1365-2958.2002.02807.x; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kelly TJ, 1998, P NATL ACAD SCI USA, V95, P14634, DOI 10.1073/pnas.95.25.14634; Kelman Z, 1999, J BIOL CHEM, V274, P28751, DOI 10.1074/jbc.274.40.28751; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Kerr ID, 2003, EMBO J, V22, P2561, DOI 10.1093/emboj/cdg272; Komori K, 2001, J BIOL CHEM, V276, P25654, DOI 10.1074/jbc.M102423200; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P11611, DOI 10.1021/bi020361m; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Murphy MC, 2004, BIOPHYS J, V86, P2530, DOI 10.1016/S0006-3495(04)74308-8; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Purnapatre K, 1999, EUR J BIOCHEM, V264, P591, DOI 10.1046/j.1432-1327.1999.00684.x; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Rambaut A, 1995, SE AL SEQUENCE ALIGN; Robbins JB, 2004, J BIOL CHEM, V279, P6315, DOI 10.1074/jbc.M304491200; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P310; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VALUER B, 2002, MOL FLUORESCENCE, P125; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P5088; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	46	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15325	15339		10.1074/jbc.M412870200	http://dx.doi.org/10.1074/jbc.M412870200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15671019	hybrid			2022-12-25	WOS:000228236800118
J	Shin, I; Kim, S; Song, H; Kim, HRC; Moon, A				Shin, I; Kim, S; Song, H; Kim, HRC; Moon, A			H-ras-specific activation of Rac-MKK3/6-p38 pathway - Its critical role in invasion and migration of breast epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; MAP KINASE KINASE; PROTEIN-KINASE; N-RAS; SIGNAL-TRANSDUCTION; DOWN-REGULATION; TRANSFORMATION; EXPRESSION; CANCER; PROMOTES	Human tumors frequently exhibit constitutively activated Ras signaling, which contributes to the malignant phenotype. Mounting evidence suggests unique roles of the Ras family members, H-Ras, N-Ras and K-Ras, in normal and pathological conditions. In an effort to dissect distinct Ras isoform-specific functions in malignant phenotypic changes, we previously established H-Ras- and N-Ras-activated MCF10A human breast epithelial cell lines. Using these, we showed that p38 kinase is a key signaling molecule differentially regulated between H-Ras and N-Ras, leading to H-Ras-specific induction of invasive and migrative phenotypes. The present study is to further investigate H-Ras- and N-Ras-mediated signaling pathways and to unveil how these pathways are integrated for regulation of invasive/migrative phenotypic conversion of human breast epithelial cells. Here we report that the Rac-MAPK kinase (MKK)3/6-p38 pathway is a unique signaling pathway activated by H-Ras, leading to the invasive/migrative phenotype. In contrast, Raf-MEK-ERK and phosphatidylinositol 3-kinase-Akt pathways, which are fundamental to proliferation and differentiation, are activated by both H-Ras and N-Ras. A significant role for p38 in cell invasion is further supported by the observation that p38 activation by MKK6 transfection is sufficient to induce invasive and migrative phenotypes in MCF10A cells. Activation of the MKK6-p38 pathway results in a marked induction of matrix metalloproteinase (MMP)-2, whereas it had little effect on MMP-9, suggesting MMP-2 up-regulation by MKK6-p38 pathway as a key step for H-Ras- induced invasion and migration. We also provide evidence for cross-talk among the Rac, Raf, and phosphatidylinositol 3-kinase pathways critical for regulation of MMP-2 and MMP-9 expression and invasive phenotype. Taken together, the present study elucidated the role of the Rac-MKK3/6-p38 pathway leading to H-Ras- specific induction of malignant progression in breast epithelial cells, providing implications for developing therapeutic strategies for mammary carcinoma to target Ras downstream signaling molecules required for malignant cancer cell behavior but less critical for normal cell functions.	Duksung Womens Univ, Coll Pharm, Seoul 132714, South Korea; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Duksung Women's University; Wayne State University	Moon, A (corresponding author), Duksung Womens Univ, Coll Pharm, Seoul 132714, South Korea.	armoon@duksung.ac.kr						ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Booden MA, 2000, J BIOL CHEM, V275, P23559, DOI 10.1074/jbc.M001368200; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CARBONE A, 1991, ONCOGENE, V6, P731; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Huang C, 2004, J CELL BIOL, V164, P593, DOI 10.1083/jcb.200307081; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim MS, 2003, CANCER RES, V63, P5454; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lee ZH, 2000, MOL PHARMACOL, V58, P1536, DOI 10.1124/mol.58.6.1536; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHER J, 1995, ONCOGENE, V11, P1639; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Parker CG, 1998, BIOCHEM BIOPH RES CO, V249, P791, DOI 10.1006/bbrc.1998.9250; Pola S, 2003, J BIOL CHEM, V278, P40601, DOI 10.1074/jbc.M306510200; Price JT, 1999, CANCER RES, V59, P5475; Prior IA, 2001, J CELL SCI, V114, P1603; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Tanno S, 2001, CANCER RES, V61, P589; URA H, 1989, CANCER RES, V49, P4615; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002; Xu QY, 2003, ONCOGENE, V22, P5537, DOI 10.1038/sj.onc.1206796; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	72	157	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14675	14683		10.1074/jbc.M411625200	http://dx.doi.org/10.1074/jbc.M411625200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15677464	hybrid			2022-12-25	WOS:000228236800043
J	Canaff, L; Hendy, GN				Canaff, L; Hendy, GN			Calcium-sensing receptor gene transcription is up-regulated by the proinflammatory cytokine, interleukin-1 beta - Role of the NF-kappa B pathway and kappa B elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; CRITICALLY-ILL PATIENTS; NEONATAL SEVERE HYPERPARATHYROIDISM; PARATHYROID-HORMONE; CA2+-SENSING RECEPTOR; CALCITONIN PRECURSORS; IONIZED CALCIUM; MESSENGER-RNA; PTH SECRETION; CELL-LINE	The calcium- sensing receptor ( CASR) in parathyroid, thyroid, and kidney is essential for calcium homeostasis. Hypocalcemia is common in critically ill patients having increased circulating proinflammatory cytokines, although the causes are unknown. We hypothesized that the cytokines increase CASR expression and reduce the set point for parathyroid hormone suppression by extracellular calcium, leading to hypocalcemia and hypoparathyroidism. Here, we show in vivo in the rat that parathyroid, thyroid, and kidney CASR mRNA and protein increased after injection of interleukin- 1 beta. This was associated with decreased circulating parathyroid hormone, calcium, and 1,25- dihydroxyvitamin D levels. Interleukin- 1 beta stimulated endogenous CASR gene transcripts and transfected promoter reporter activity in human thyroid C- cells ( TT cells) and kidney proximal tubule ( HKC) cells. Cotransfection of NF- kappa B proteins enhanced activity of the reporter constructs, whereas cotransfection with inhibitor- kappa B or application of an NF- kappa B nuclear localization sequence peptide abrogated responsiveness to cytokine or NF- kappa B proteins. Mutagenesis of some, but not all, of the potential kappa B elements in the 5 ' part of the CASR gene led to loss of responsiveness to cytokine. These elements conferred cytokine responsiveness to a heterologous promoter, and in electrophoretic mobility shift assays, NF- kappa B complexes formed on the same three kappa B elements. In summary, the CASR gene has several functional kappa B elements that mediate its upregulation by proinflammatory cytokines and probably contribute to altered extracellular calcium homeostasis in the critically ill.	Royal Victoria Hosp, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University	Hendy, GN (corresponding author), Royal Victoria Hosp, Calcium Res Lab, Rm H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	geoffrey.hendy@mcgill.ca						Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bland R, 1999, ENDOCRINOLOGY, V140, P2027, DOI 10.1210/en.140.5.2027; BOYCE BF, 1989, ENDOCRINOLOGY, V125, P2780, DOI 10.1210/endo-125-5-2780; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Canaff L, 2002, J BIOL CHEM, V277, P30337, DOI 10.1074/jbc.M201804200; Canaff L, 2001, J BIOL CHEM, V276, P4070, DOI 10.1074/jbc.M009317200; Carlstedt F, 1999, SCAND J CLIN LAB INV, V59, P47, DOI 10.1080/00365519950185995; Chikatsu N, 2000, J BIOL CHEM, V275, P7553, DOI 10.1074/jbc.275.11.7553; D'Souza-Li L, 2001, HUM MUTAT, V18, P411, DOI 10.1002/humu.1212; DANDONA P, 1994, J CLIN ENDOCR METAB, V79, P1605, DOI 10.1210/jc.79.6.1605; DESAI TK, 1987, CRIT CARE CLIN, V3, P927; Farmer PK, 2000, AM J PHYSIOL-ENDOC M, V279, pE213, DOI 10.1152/ajpendo.2000.279.1.E213; Freichel M, 1996, ENDOCRINOLOGY, V137, P3842, DOI 10.1210/en.137.9.3842; FUDGE NJ, 2004, BMC PHYSL; GARRETT JE, 1995, ENDOCRINOLOGY, V136, P5202, DOI 10.1210/en.136.11.5202; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hastbacka J, 2003, ACTA ANAESTH SCAND, V47, P1264, DOI 10.1046/j.1399-6576.2003.00236.x; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JANICIC N, 1995, MAMM GENOME, V6, P798, DOI 10.1007/BF00539007; KLEIN GL, 1995, BONE, V17, P455, DOI 10.1016/8756-3282(95)00279-1; Klein GL, 2000, PEDIATR NEPHROL, V14, P301, DOI 10.1007/s004670050763; Lavigne JR, 1998, ENDOCRINE, V9, P293, DOI 10.1385/ENDO:9:3:293; Lepage R, 1999, J CLIN ENDOCR METAB, V84, P2654, DOI 10.1210/jc.84.8.2654; Lind L, 2000, CRIT CARE MED, V28, P93, DOI 10.1097/00003246-200001000-00015; LIND L, 1999, FRONT HORM RES, V24, P67; MATSUMOTO T, 1987, AM J PHYSIOL, V253, pE503, DOI 10.1152/ajpendo.1987.253.5.E503; MOULAND AJ, 1991, ENDOCRINOLOGY, V128, P441, DOI 10.1210/endo-128-1-441; Muller B, 2000, EUR J CLIN INVEST, V30, P823; Murphey ED, 2000, CRIT CARE MED, V28, P3885, DOI 10.1097/00003246-200012000-00024; Nielsen PK, 1997, BIOCHEM BIOPH RES CO, V238, P880, DOI 10.1006/bbrc.1997.7207; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RASMUSSEN AK, 1993, AUTOIMMUNITY, V16, P141, DOI 10.3109/08916939308993319; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Toribio RE, 2003, J MOL ENDOCRINOL, V31, P609, DOI 10.1677/jme.0.0310609; Toribio RE, 2001, AM J VET RES, V62, P938, DOI 10.2460/ajvr.2001.62.938; TRECHSEL V, 1980, AM J PHYSIOL, V239, pE119; WEISINGER JR, 1989, J BONE MINER RES, V4, P929; Whang KT, 1998, J CLIN ENDOCR METAB, V83, P3296, DOI 10.1210/jc.83.9.3296; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; ZALOGA GP, 1992, CRIT CARE MED, V20, P251, DOI 10.1097/00003246-199202000-00014; ZALOGA GP, 1987, ANN INTERN MED, V107, P36, DOI 10.7326/0003-4819-107-1-36; ZALOGA GP, 1988, CIRC SHOCK, V24, P143; Zivin JR, 2001, AM J KIDNEY DIS, V37, P689, DOI 10.1016/S0272-6386(01)80116-5	49	81	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14177	14188		10.1074/jbc.M408587200	http://dx.doi.org/10.1074/jbc.M408587200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15684428	hybrid			2022-12-25	WOS:000228095500121
J	Pandey, AV; Miller, WL				Pandey, AV; Miller, WL			Regulation of 17,20 lyase activity by cytochrome b(5) and by serine phosphorylation of P450c17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; STEROID 17-ALPHA-HYDROXYLASE/17,20 LYASE; TESTICULAR MICROSOMAL CYTOCHROME-P-450; 17,20-LYASE ACTIVITY; ESCHERICHIA-COLI; ADRENOCORTICAL ADENOMAS; ANDROGEN SYNTHESIS; CUSHINGS-SYNDROME; LIVER MICROSOMES; HUMAN-GENE	Cytochrome P450c17 catalyzes the 17 alpha-hydroxylase activity required for glucocorticoid synthesis and the 17,20 lyase activity required for sex steroid synthesis. Most P450 enzymes have fixed ratios of their various activities, but the ratio of these two activities of P450c17 is regulated post-translationally. We have shown that serine phosphorylation of P450c17 and the allosteric action of cytochrome b(5) increase 17,20 lyase activity, but it has not been apparent whether these two post-translational mechanisms interact. Using purified enzyme systems, we now show that the actions of cytochrome b(5) are independent of the state of P450c17 phosphorylation. Suppressing cytochrome b(5) expression in human adrenal NCI-H295A cells by >85% with RNA interference had no effect on 17 alpha-hydroxylase activity but reduced 17,20 lyase activity by 30%. Increasing P450c17 phosphorylation could compensate for this reduced activity. When expressed in bacteria, human P450c17 required either cytochrome b(5) or phosphorylation for 17,20 lyase activity. The combination of cytochrome b(5) and phosphorylation was not additive. Cytochrome b(5) and phosphorylation enhance 17,20 lyase activity independently of each other, probably by increasing the interaction between P450c17 and NADPH-cytochrome P450 oxidoreductase.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, Bldg MR4 Rm 209, San Francisco, CA 94143 USA.	wlmlab@itsa.ucsf.edu	Pandey, Amit V/A-7223-2008; Miller, Walter L/J-3696-2012; Pandey, Amit V/AAO-6442-2020	Pandey, Amit V/0000-0001-8331-5902; Pandey, Amit V/0000-0001-8331-5902	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041958] Funding Source: NIH RePORTER; NICHD NIH HHS [HD41958] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altuve A, 2001, BIOCHEMISTRY-US, V40, P9469, DOI 10.1021/bi010636i; APTER D, 1979, ACTA PAEDIATR SCAND, V68, P599, DOI 10.1111/j.1651-2227.1979.tb05062.x; Arlt W, 2002, ENDOCRINOLOGY, V143, P4665, DOI 10.1210/en.2002-220456; Auchus RJ, 1999, MOL ENDOCRINOL, V13, P1169, DOI 10.1210/me.13.7.1169; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Brock BJ, 1999, BIOCHEMISTRY-US, V38, P1598, DOI 10.1021/bi9821059; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHUNG BC, 1987, P NATL ACAD SCI USA, V84, P407, DOI 10.1073/pnas.84.2.407; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; Dharia S, 2004, BIOL REPROD, V71, P83, DOI 10.1095/biolreprod.103.026732; Fluck CE, 2004, NAT GENET, V36, P228, DOI 10.1038/ng1300; GAZDAR AF, 1990, CANCER RES, V50, P5488; Geller DH, 1999, MOL ENDOCRINOL, V13, P167, DOI 10.1210/me.13.1.167; Geller DH, 1997, NAT GENET, V17, P201, DOI 10.1038/ng1097-201; GIORDANO SJ, 1993, HUM GENET, V92, P615, DOI 10.1007/BF00420948; GIORDANO SJ, 1991, BIOCHEM BIOPH RES CO, V178, P38, DOI 10.1016/0006-291X(91)91776-9; Guryev OL, 2001, BIOCHEMISTRY-US, V40, P5018, DOI 10.1021/bi002305w; IMAI T, 1993, J BIOL CHEM, V268, P19681; ISHIIOHBA H, 1984, J BIOCHEM-TOKYO, V95, P335, DOI 10.1093/oxfordjournals.jbchem.a134613; KATAGIRI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P343, DOI 10.1006/abbi.1995.1173; KOMINAMI S, 1992, J STEROID BIOCHEM, V42, P57, DOI 10.1016/0960-0760(92)90011-7; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; LeeRobichaud P, 1997, BIOCHEM J, V321, P857, DOI 10.1042/bj3210857; LEEROBICHAUD P, 1995, BIOCHEM J, V308, P901, DOI 10.1042/bj3080901; LIN D, 1991, J BIOL CHEM, V266, P15992; LIN D, 1993, ENDOCRINOLOGY, V132, P2498, DOI 10.1210/en.132.6.2498; Louis N, 1997, VIROLOGY, V233, P423, DOI 10.1006/viro.1997.8597; LU AYH, 1969, J BIOL CHEM, V244, P3714; Lutz LB, 2001, P NATL ACAD SCI USA, V98, P13728, DOI 10.1073/pnas.241471598; Mapes S, 2002, ENDOCRINOLOGY, V143, P1451, DOI 10.1210/en.143.4.1451; Mapes S, 1999, J CLIN ENDOCR METAB, V84, P3382, DOI 10.1210/jc.84.9.3382; Miller WL, 1997, STEROIDS, V62, P133, DOI 10.1016/S0039-128X(96)00172-9; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Miller WL, 1999, ACTA PAEDIATR, V88, P60, DOI 10.1111/j.1651-2227.1999.tb14405.x; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Mulrooney SB, 2000, PROTEIN EXPRES PURIF, V19, P173, DOI 10.1006/prep.2000.1228; NAKAJIN S, 1981, J BIOL CHEM, V256, P6134; NAKAJIN S, 1984, J BIOL CHEM, V259, P3971; NITTA H, 1991, ENDOCRINOLOGY, V129, P2033, DOI 10.1210/endo-129-4-2033; Ogishima T, 2003, J BIOL CHEM, V278, P21204, DOI 10.1074/jbc.M301698200; OMURA T, 1964, J BIOL CHEM, V239, P2370; ONODA M, 1982, BIOCHEM BIOPH RES CO, V108, P454, DOI 10.1016/0006-291X(82)90850-6; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; PICADOLEONARD J, 1987, DNA-J MOLEC CELL BIO, V6, P439, DOI 10.1089/dna.1987.6.439; RIVERA M, 1992, BIOCHEMISTRY-US, V31, P12233, DOI 10.1021/bi00163a037; Rodriguez H, 1997, J CLIN ENDOCR METAB, V82, P365, DOI 10.1210/jc.82.2.365; SAKAI N, 1992, FEBS LETT, V301, P60, DOI 10.1016/0014-5793(92)80210-8; SAKAI Y, 1993, J CLIN ENDOCR METAB, V76, P1286, DOI 10.1210/jc.76.5.1286; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; SKLAR CA, 1980, J CLIN ENDOCR METAB, V51, P548, DOI 10.1210/jcem-51-3-548; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; Soucy P, 2002, J STEROID BIOCHEM, V80, P71, DOI 10.1016/S0960-0760(01)00171-6; SPARKES RS, 1991, DNA CELL BIOL, V10, P359, DOI 10.1089/dna.1991.10.359; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; Suzuki T, 2000, CLIN ENDOCRINOL, V53, P739, DOI 10.1046/j.1365-2265.2000.01144.x; Wijesuriya SD, 1999, J BIOL CHEM, V274, P38097, DOI 10.1074/jbc.274.53.38097; Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V342, P329, DOI 10.1006/abbi.1997.0125; Yamazaki H, 2001, J BIOL CHEM, V276, P30885, DOI 10.1074/jbc.M105011200; YANAGIBASHI K, 1986, J BIOL CHEM, V261, P8429; Yanase T, 1998, ENDOCR J, V45, P89, DOI 10.1507/endocrj.45.89; ZHANG LH, 1995, P NATL ACAD SCI USA, V92, P10619, DOI 10.1073/pnas.92.23.10619; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074	65	111	122	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13265	13271		10.1074/jbc.M414673200	http://dx.doi.org/10.1074/jbc.M414673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15687493	hybrid			2022-12-25	WOS:000228095500010
J	Tormay, P; Coates, ARM; Henderson, B				Tormay, P; Coates, ARM; Henderson, B			The intercellular signaling activity of the Mycobacterium tuberculosis chaperonin 60.1 protein resides in the equatorial domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES BONE-RESORPTION; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; SWISS-MODEL; HEAT-SHOCK-PROTEIN-60; RECEPTOR; EXPRESSION; CYTOKINES; RELEASE; BINDING	The major heat shock protein, chaperonin 60, has been established to have intercellular signaling activity in addition to its established protein-folding function. Mycobacterium tuberculosis is one of a small proportion of bacteria to encode two chaperonin 60 proteins. We have demonstrated that chaperonin 60.1 from this bacterium is a very active stimulator of human monocytes. To determine structure/function relationships of chaperonin 60.1 we have cloned and expressed the apical, equatorial, and intermediate domains of this protein. We have found that the signaling activity of M. tuberculosis chaperonin 60.1 resides in the equatorial domain. This activity of the recombinant equatorial domain was completely blocked by treating the protein with proteinase K, ruling out lipopolysaccharide contamination as the cause of the cell activation. Blockade of the activity of the equatorial domain by anti-CD14 monoclonal antibodies reveals that this domain activates monocytes by binding to CD14. Looking at the oligomeric state of the active proteins, using native gel electrophoresis and protein cross-linking we found that recombinant M. tuberculosis chaperonin 60.1 fails to form the prototypic tetradecameric structure of chaperonin 60 proteins under the conditions tested and only forms dimers. It is therefore concluded that the monocyte-stimulating activity of M. tuberculosis Cpn60.1 resides in the monomeric subunit and within this subunit the biological activity is due to the equatorial domain.	St George Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England; UCL, Eastman Dent Inst, Div Microbial Dis, London WC1X 8LD, England	St Georges University London; University of London; University College London	Tormay, P (corresponding author), St George Hosp, Sch Med, Dept Cellular & Mol Med, Cranmer Terrace, London SW17 0RE, England.	p.tormay@sghms.ac.uk		Coates, Anthony/0000-0001-8052-3175				Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; COATES ARM, 1993, MOL MICROBIOL, V8, P787, DOI 10.1111/j.1365-2958.1993.tb01624.x; Coates ARM, 1999, BIOTECHNOL GENET ENG, V16, P393, DOI 10.1080/02648725.1999.10647985; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; FRIEDLAND JS, 1993, CLIN EXP IMMUNOL, V91, P58; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Habich C, 2004, FEBS LETT, V568, P65, DOI 10.1016/j.febslet.2004.05.010; Habich C, 2003, FEBS LETT, V533, P105, DOI 10.1016/S0014-5793(02)03772-9; HANEWAY CA, 2002, ANNU REV IMMUNOL, V20, P197; Henderson B, 2003, PROG INFLAM RES, P175; KIRBY AC, 1995, J CLIN INVEST, V96, P1185, DOI 10.1172/JCI118150; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; KONG TH, 1993, P NATL ACAD SCI USA, V90, P2608, DOI 10.1073/pnas.90.7.2608; Lewthwaite J, 1998, TRENDS MICROBIOL, V6, P426, DOI 10.1016/S0966-842X(98)01362-6; Lewthwaite JC, 2001, INFECT IMMUN, V69, P7349, DOI 10.1128/IAI.69.12.7349-7355.2001; Maguire M, 2003, J CHROMATOGR B, V786, P117, DOI 10.1016/S1570-0232(02)00732-8; Maguire M, 2002, CELL STRESS CHAPERON, V7, P317, DOI 10.1379/1466-1268(2002)007<0317:CUISOC>2.0.CO;2; Meghji S, 1997, J EXP MED, V186, P1241, DOI 10.1084/jem.186.8.1241; Meghji S, 2003, BONE, V33, P419, DOI 10.1016/S8756-3282(03)00117-0; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Panayi GS, 2004, CURR OPIN IMMUNOL, V16, P531, DOI 10.1016/j.coi.2004.05.017; Qamra R, 2004, J MOL BIOL, V342, P605, DOI 10.1016/j.jmb.2004.07.066; Saibil H, 2000, CURR OPIN STRUC BIOL, V10, P251, DOI 10.1016/S0959-440X(00)00074-9; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Tabona P, 1998, J IMMUNOL, V161, P1414; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; van Eden W, 1998, IMMUNOL TODAY, V19, P303, DOI 10.1016/S0167-5699(98)01283-3; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8	30	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14272	14277		10.1074/jbc.M414158200	http://dx.doi.org/10.1074/jbc.M414158200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677470	hybrid			2022-12-25	WOS:000228095500130
J	Naggi, A; Casu, B; Perez, M; Torri, G; Cassinelli, G; Penco, S; Pisano, C; Giannini, G; Ishai-Michaeli, R; Vlodavsky, I				Naggi, A; Casu, B; Perez, M; Torri, G; Cassinelli, G; Penco, S; Pisano, C; Giannini, G; Ishai-Michaeli, R; Vlodavsky, I			Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; TUMOR-METASTASIS; EXTRACELLULAR-MATRIX; HEPATOCELLULAR-CARCINOMA; MAMMALIAN HEPARANASE; MEDIATED DEGRADATION; SULFATE; EXPRESSION; ANGIOGENESIS; ANTICOAGULANT	Heparanase is an endo-beta-glucuronidase that cleaves heparan sulfate (HS) chains of heparan sulfate proteoglycans on cell surfaces and in the extracellular matrix (ECM). Heparanase, overexpressed by most cancer cells, facilitates extravasation of blood-borne tumor cells and causes release of growth factors sequestered by HS chains, thus accelerating tumor growth and metastasis. Inhibition of heparanase with HS mimics is a promising target for a novel strategy in cancer therapy. In this study, in vitro inhibition of recombinant heparanase was determined for heparin derivatives differing in degrees of 2-O- and 6-O- sulfation, N-acetylation, and glycol splitting of nonsulfated uronic acid residues. The contemporaneous presence of sulfate groups at O-2 of IdoA and at O-6 of GlcN was found to be non-essential for effective inhibition of heparanase activity provided that one of the two positions retains a high degree of sulfation. N-Desulfation/N-acetylation involved a marked decrease in the inhibitory activity for degrees of N-acetylation higher than 50%, suggesting that at least one NSO3 group per disaccharide unit is involved in interaction with the enzyme. On the other hand, glycol splitting of preexisting or of both preexisting and chemically generated nonsulfated uronic acids dramatically increased the heparanase-inhibiting activity irrespective of the degree of N-acetylation. Indeed N-acetylated heparins in their glycol-split forms inhibited heparanase as effectively as the corresponding N-sulfated derivatives. Whereas heparin and N-acetylheparins containing unmodified D-glucuronic acid residues inhibited heparanase by acting, at least in part, as substrates, their glycol-split derivatives were no more susceptible to cleavage by heparanase. Glycol-split N-acetylheparins did not release basic fibroblast growth factor from ECM and failed to stimulate its mitogenic activity. The combination of high inhibition of heparanase and low release/potentiation of ECM-bound growth factor indicates that N-acetylated, glycol-split heparins are potential antiangiogenic and antimetastatic agents that are more effective than their counterparts with unmodified backbones.	G Ronzoni Inst Chem & Biochem Res, I-20133 Milan, Italy; Sigma Tau Res Dept, I-00040 Pomezia, Rome, Italy; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel; Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Casu, B (corresponding author), G Ronzoni Inst Chem & Biochem Res, Via G Colombo 81, I-20133 Milan, Italy.	casu@ronzoni.it		Torri, Giangiacomo/0000-0002-2077-1203; pisano, claudio/0000-0001-8624-2980				Altinbas M, 2004, J THROMB HAEMOST, V2, P1266, DOI 10.1111/j.1538-7836.2004.00871.x; BARNER M, 1987, BLOOD, V70, P551; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bertini S, 2005, BIOMACROMOLECULES, V6, P168, DOI 10.1021/bm049693s; Casu B, 1996, ARZNEIMITTEL-FORSCH, V46, P472; Casu B, 2004, J MED CHEM, V47, P838, DOI 10.1021/jm030893g; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Casu B, 2002, BIOCHEMISTRY-US, V41, P10519, DOI 10.1021/bi020118n; CASU B, 1986, ARZNEIMITTEL-FORSCH, V36-1, P637; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; CASU B, 1990, NEW TRENDS HAEMOSTAS, P2; CIFONELL.JA, 1968, CARBOHYD RES, V8, P233, DOI 10.1016/S0008-6215(00)80159-7; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; HRICOVINI M, 2003, 12 EUR CARB S GREN F; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; Katz A, 2002, ISRAEL MED ASSOC J, V4, P996; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koliopanos A, 2001, CANCER RES, V61, P4655; KORRAMIAN BA, 1987, IND POLYSACCHARIDES, P339; Kwan CP, 2001, J BIOL CHEM, V276, P23421, DOI 10.1074/jbc.M010786200; Lapierre F, 1996, GLYCOBIOLOGY, V6, P355, DOI 10.1093/glycob/6.3.355; Lever R, 2002, NAT REV DRUG DISCOV, V1, P140, DOI 10.1038/nrd724; Levidiotis V, 2001, KIDNEY INT, V60, P1287, DOI 10.1046/j.1523-1755.2001.00934.x; LEVVY GA, 1959, BIOCHEM J, V73, P127, DOI 10.1042/bj0730127; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Lindahl U, 2000, GLYCOCONJUGATE J, V17, P597, DOI 10.1023/A:1011030711317; Linhardt RJ, 2003, J MED CHEM, V46, P2551, DOI 10.1021/jm030176m; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; MATSUO M, 1993, CARBOHYD RES, V241, P209, DOI 10.1016/0008-6215(93)80107-P; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Miao HQ, 1997, J CLIN INVEST, V99, P1565, DOI 10.1172/JCI119319; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; MULLOY B, 1993, BIOCHEM J, V293, P840; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Parish CR, 1999, CANCER RES, V59, P3433; PARISH CR, 1987, INT J CANCER, V40, P511, DOI 10.1002/ijc.2910400414; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; PIANI S, 1993, J CARBOHYD CHEM, V12, P507, DOI 10.1080/07328309308019404; Pisano C, 2005, GLYCOBIOLOGY, V15, p1C, DOI 10.1093/glycob/cwi007; REJ RN, 1990, CARBOHYD RES, V200, P437, DOI 10.1016/0008-6215(90)84209-D; Sandback-Pikas D., 1998, J BIOL CHEM, V273, P18770; Sato T, 2004, J SURG ONCOL, V87, P174, DOI 10.1002/jso.20097; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 2003, PATHOPHYSIOL HAEMO T, V33, P59, DOI 10.1159/000073296; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; Xiao Y, 2003, HEPATOL RES, V26, P192, DOI 10.1016/S1386-6346(03)00107-4; Zcharia E, 2005, FASEB J, V19, P211, DOI 10.1096/fj.04-1970com	66	191	210	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12103	12113		10.1074/jbc.M414217200	http://dx.doi.org/10.1074/jbc.M414217200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15647251	hybrid			2022-12-25	WOS:000227922000007
J	Jana, NR; Dikshit, P; Goswami, A; Kotliarova, S; Murata, S; Tanaka, K; Nukina, N				Jana, NR; Dikshit, P; Goswami, A; Kotliarova, S; Murata, S; Tanaka, K; Nukina, N			Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; N-TERMINAL HUNTINGTIN; E3 UBIQUITIN LIGASE; CASPASE ACTIVATION; AGGREGATION; SUPPRESSION; NEURODEGENERATION; HSP70; IDENTIFICATION; UBIQUITYLATION	A major hallmark of the polyglutamine diseases is the formation of neuronal intranuclear inclusions of the disease proteins that are ubiquitinated and often associated with various chaperones and proteasome components. But, how the polyglutamine proteins are ubiquitinated and degraded by the proteasomes are not known. Here, we demonstrate that CHIP (C terminus of Hsp70-interacting protein) co-immunoprecipitates with the polyglutamine-expanded huntingtin or ataxin-3 and associates with their aggregates. Transient overexpression of CHIP increases the ubiquitination and the rate of degradation of polyglutamine-expanded huntingtin or ataxin-3. Finally, we show that overexpression of CHIP suppresses the aggregation and cell death mediated by expanded polyglutamine proteins and the suppressive effect is more prominent when CHIP is overexpressed along with Hsc70.	Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India; RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Wako, Saitama 3510198, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bankyo Ku, Tokyo 1138613, Japan	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); RIKEN; Tokyo Metropolitan Institute of Medical Science	Jana, NR (corresponding author), Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India.	nihar@nbrc.ac.in; nukina@riken.brain.go.jp	Murata, Shigeo/A-1426-2010; Nukina, Nobuyuki/GPP-6265-2022	Murata, Shigeo/0000-0002-3177-3503; Jana, Nihar/0000-0002-6549-4211				Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chai YH, 1999, J NEUROSCI, V19, P10338; Choi JS, 2004, BIOCHEM BIOPH RES CO, V321, P574, DOI 10.1016/j.bbrc.2004.07.010; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 2004, J NEUROCHEM, V91, P299, DOI 10.1111/j.1471-4159.2004.02713.x; Holmberg CI, 2004, EMBO J, V23, P4307, DOI 10.1038/sj.emboj.7600426; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Lin X, 1999, NEURON, V24, P499, DOI 10.1016/S0896-6273(00)81104-6; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Wang GH, 2000, HUM MOL GENET, V9, P1795, DOI 10.1093/hmg/9.12.1795; Wang GH, 1999, NEUROREPORT, V10, P2435, DOI 10.1097/00001756-199908200-00001; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	26	245	257	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11635	11640		10.1074/jbc.M412042200	http://dx.doi.org/10.1074/jbc.M412042200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15664989	hybrid			2022-12-25	WOS:000227761800091
J	Muntener, K; Willimann, A; Zwicky, R; Svoboda, B; Mach, L; Baici, A				Muntener, K; Willimann, A; Zwicky, R; Svoboda, B; Mach, L; Baici, A			Folding competence of N-terminally truncated forms of human procathepsin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-B; CYSTEINE PROTEASES; CRYSTAL-STRUCTURE; ACTIVE-SITE; PROPEPTIDE; PROREGION; INHIBITION; ENZYME; DOMAIN; CELLS	Besides acting as an inhibitor, the propeptide of human cathepsin B exerts an important auxiliary function as a chaperone in promoting correct protein folding. To explore the ability of N-terminally truncated forms of procathepsin B to fold into enzymatically active proteins, we produced procathepsin B variants progressively lacking N-terminal structural elements in baculovirus-infected insect cells. N-terminal truncation of the propeptide by up to 22 amino acids did not impair the production of activable procathepsin B. Secreted forms lacking the first 20, 21, or 22 amino acids spontaneously generated mature cathepsin B through autocatalytic processing, demonstrating that the first alpha-helix (Asp(11)-Arg(20)) is necessary for efficient inhibition of the enzyme by its propeptide. In contrast, proenzymes lacking the N-terminal part including the first beta-sheet (Trp(24)-Ala(26)) of the propeptide or containing an amino acid mutation directly preceding this beta-sheet were no longer properly folded. This shows that interactions between Trp(24) of the propeptide and Tyr(183), Tyr(188), and Phe(180) of the mature enzyme are important for stabilization and essential for procathepsin B folding. Thus, proenzyme forms missing more than the N-terminal 22 amino acids of the propeptide (notably truncated cathepsin B produced by the mRNA splice variant lacking exons 2 and 3, resulting in a propeptide shortened by 34 amino acids) are devoid of proteolytic activity because they cannot fold correctly. Thus, any pathophysiological involvement of truncated cathepsin B must be ascribed to properties other than proteolysis.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Agr Univ Vienna, Inst Angew Genet & Zellbiol, A-1190 Vienna, Austria	University of Zurich; University of Natural Resources & Life Sciences, Vienna	Baici, A (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	abaici@bioc.unizh.ch		Mach, Lukas/0000-0001-9013-5408; Baici, Antonio/0000-0002-2980-0541				Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; Baici A, 1996, BIOCHEM J, V317, P901, DOI 10.1042/bj3170901; BAICI A, 2002, WILEY ENCY MOL MED, V3, P2181; Cappetta M, 2002, BIOL CHEM, V383, P1215, DOI 10.1515/BC.2002.134; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Chacinska A, 2002, TRENDS CELL BIOL, V12, P299, DOI 10.1016/S0962-8924(02)02310-3; Chagas JR, 1996, FEBS LETT, V392, P233, DOI 10.1016/0014-5793(96)00822-8; Chen YM, 1996, FEBS LETT, V393, P24, DOI 10.1016/0014-5793(96)00847-2; Cygler M, 1997, BIOCHIMIE, V79, P645, DOI 10.1016/S0300-9084(97)83497-9; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; GRAF M, 1981, LAB INVEST, V45, P587; Mehtani S, 1998, J BIOL CHEM, V273, P13236, DOI 10.1074/jbc.273.21.13236; MORT JS, 1986, BIOCHEM J, V233, P57, DOI 10.1042/bj2330057; Mucha J, 2001, GLYCOBIOLOGY, V11, P769, DOI 10.1093/glycob/11.9.769; Muntener K, 2003, HISTOCHEM CELL BIOL, V119, P93, DOI 10.1007/s00418-002-0487-y; Muntener K, 2004, J BIOL CHEM, V279, P41012, DOI 10.1074/jbc.M405333200; ODEBERG H, 1976, INFECT IMMUN, V14, P1276; Pietschmann S, 2002, BIOL CHEM, V383, P1453, DOI 10.1515/BC.2002.165; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Sarkar M, 1998, GLYCOCONJUGATE J, V15, P193, DOI 10.1023/A:1006928624913; Schilling K, 2001, BIOL CHEM, V382, P859, DOI 10.1515/BC.2001.105; Sivaraman J, 2000, J MOL BIOL, V295, P939, DOI 10.1006/jmbi.1999.3410; SMITH SM, 1989, J BIOL CHEM, V264, P20487; STRASSER R, 2004, BIOCH J; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; Wiederanders B, 2000, ADV EXP MED BIOL, V477, P261	29	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11973	11980		10.1074/jbc.M413052200	http://dx.doi.org/10.1074/jbc.M413052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657038	hybrid			2022-12-25	WOS:000227761800129
J	Zoraghi, R; Bessay, EP; Corbin, JD; Francis, SH				Zoraghi, R; Bessay, EP; Corbin, JD; Francis, SH			Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CATALYTIC DOMAIN; SMOOTH-MUSCLE; GAF-DOMAIN; PHOTORECEPTOR PHOSPHODIESTERASE; MOLECULAR DETERMINANTS; AMINO-ACIDS; GMP; PHOSPHORYLATION	The cGMP-binding cGMP-specific phosphodiesterase (PDE5) contains a catalytic domain that hydrolyzes cGMP and a regulatory (R) domain that contains two GAFs (a and b; GAF is derived from the proteins mammalian cGMP-binding PDEs, Anabaena adenylyl cyclases, and Escherichia coli (FhlA)). The R domain binds cGMP allosterically, provides for dimerization, and is phosphorylated at a site regulated by allosteric cGMP binding. Quaternary structures and cGMP-binding properties of 10 human PDE5A1 constructs containing one or both GAFs were characterized. Results reveal that: 1) high affinity homo-dimerization occurs between GAF a modules (K-D < 30 nM) and between GAF b modules (KD = 1-20 pM), and the sequence between the GAFs ( Thr(322)-Asp(403)) contributes to dimer stability; 2) 176 amino acids (Val(156)-Gln(331)) in GAF a are adequate for cGMP binding; 3) GAF a has higher affinity for cGMP (K-D < 40 nM) than does the isolated R domain (KD = 110 nM) or holoenzyme (K-D = 200 nM), suggesting that the sequence containing GAF b and its flanking amino acids autoinhibits GAF a cGMP-binding affinity in intact R domain; 4) a mutant (Met(1)-Glu(321)) containing only GAF a has high affinity, biphasic cGMP-binding kinetics consistent with structural heterogeneity of GAF a, suggesting that the presence of GAF b is not required for biphasic cGMP-dissociation kinetics observed in holoenzyme or isolated R domain; 5) significant cGMP binding by GAF b was not detected; and 6) the sequence containing GAF b and its flanking amino acids is critical for cGMP stimulation of Ser(102) phosphorylation by cyclic nucleotide-dependent protein kinases. Results yield new insights into PDE5 functions, further define boundaries that provide for allosteric cGMP binding, and identify regions that contribute to dimerization.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Francis, SH (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 702 Light Hall, Nashville, TN 37232 USA.	Sharron.Francis@vanderbilt.edu			NIDDK NIH HHS [DK40299, DK58277] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040299, R01DK058277] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlstrom M, 1999, BIOCHEM PHARMACOL, V58, P1335, DOI 10.1016/S0006-2952(99)00199-9; Anantharaman V, 2001, J MOL BIOL, V307, P1271, DOI 10.1006/jmbi.2001.4508; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3; BARBER R, 1981, MOL PHARMACOL, V19, P38; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Blount MA, 2004, MOL PHARMACOL, V66, P144, DOI 10.1124/mol.66.1.144; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; Chuang AT, 1998, LIFE SCI, V63, P185, DOI 10.1016/S0024-3205(98)00259-8; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; Corbin JD, 2003, MOL PHARMACOL, V63, P1364, DOI 10.1124/mol.63.6.1364; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; FLOCKHART DA, 1984, BRAIN RECEPTOR MET A, P209; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; Francis SH, 2002, J BIOL CHEM, V277, P47581, DOI 10.1074/jbc.M206088200; Francis SH, 1998, METHODS, V14, P81, DOI 10.1006/meth.1997.0567; Francis Sharron H, 2003, Curr Urol Rep, V4, P457, DOI 10.1007/s11934-003-0027-x; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; Gopal VK, 2001, EUR J BIOCHEM, V268, P3304, DOI 10.1046/j.1432-1327.2001.02233.x; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; Hempel CM, 1996, NATURE, V384, P166, DOI 10.1038/384166a0; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; Huai Q, 2004, P NATL ACAD SCI USA, V101, P9624, DOI 10.1073/pnas.0401120101; Huai Q, 2004, J BIOL CHEM, V279, P13095, DOI 10.1074/jbc.M311556200; Huai Q, 2003, STRUCTURE, V11, P865, DOI 10.1016/S0969-2126(03)00123-0; Huang DM, 2004, J BIOL CHEM, V279, P48143, DOI 10.1074/jbc.M404338200; Jeremy JY, 1997, BRIT J UROL, V79, P958, DOI 10.1046/j.1464-410X.1997.00206.x; Kanacher T, 2002, EMBO J, V21, P3672, DOI 10.1093/emboj/cdf375; Kendirci M, 2004, EXPERT OPIN PHARMACO, V5, P923, DOI 10.1517/14656566.5.4.923; Laxman S, 2005, J BIOL CHEM, V280, P3771, DOI 10.1074/jbc.M408111200; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Little R, 2003, J BIOL CHEM, V278, P28711, DOI 10.1074/jbc.M301992200; Liu L, 2002, CELL SIGNAL, V14, P45, DOI 10.1016/S0898-6568(01)00216-9; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Martinez Sergio E, 2002, Mol Interv, V2, P317, DOI 10.1124/mi.2.5.317; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; Mercapide J, 1999, BIOCHEM PHARMACOL, V58, P1675, DOI 10.1016/S0006-2952(99)00252-X; Mullershausen F, 2003, J CELL BIOL, V160, P719, DOI 10.1083/jcb.200211041; Muradov KG, 2003, J BIOL CHEM, V278, P10594, DOI 10.1074/jbc.M208456200; Okada D, 2002, BIOCHEMISTRY-US, V41, P9672, DOI 10.1021/bi025727+; Richter W, 2002, J BIOL CHEM, V277, P40212, DOI 10.1074/jbc.M203585200; Rotella David P, 2003, Curr Opin Investig Drugs, V4, P60; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Rybalkin SD, 2002, J BIOL CHEM, V277, P3310, DOI 10.1074/jbc.M106562200; Schlossmann J, 2003, ANN MED, V35, P21, DOI 10.1080/07853890310004093; Sebkhi A, 2003, CIRCULATION, V107, P3230, DOI 10.1161/01.CIR.0000074226.20466.B1; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; Shimizu-Albergine M, 2003, J NEUROSCI, V23, P6452; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STROOP SD, 1991, J BIOL CHEM, V266, P23802; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; Turko IV, 1999, MOL PHARMACOL, V56, P124, DOI 10.1124/mol.56.1.124; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Turko IV, 1998, BIOCHEM J, V329, P505; Turko IV, 1998, BIOCHEMISTRY-US, V37, P4200, DOI 10.1021/bi972448r; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; Vaandrager AB, 2000, GASTROENTEROLOGY, V118, P108, DOI 10.1016/S0016-5085(00)70419-7; Walter U, 2004, BLOOD, V104, P2609, DOI 10.1182/blood-2004-06-2389; Wu AY, 2004, J BIOL CHEM, V279, P37928, DOI 10.1074/jbc.M404287200; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zoraghi R, 2004, MOL PHARMACOL, V65, P267, DOI 10.1124/mol.65.2.267	70	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					12051	12063		10.1074/jbc.M413611200	http://dx.doi.org/10.1074/jbc.M413611200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15677448	hybrid			2022-12-25	WOS:000227761800139
J	Kil, IS; Park, JW				Kil, IS; Park, JW			Regulation of mitochondrial NADP(+)-dependent isocitrate dehydrogenase activity by glutathionylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN DNA-BINDING; OXIDATIVE STRESS; REVERSIBLE INACTIVATION; PARKINSONS-DISEASE; RESPIRATORY BURST; N-ETHYLMALEIMIDE; S-THIOLATION; NITRIC-OXIDE; PROTEIN; IDENTIFICATION	Recently, we demonstrated that the control of mitochondrial redox balance and oxidative damage is one of the primary functions of mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDPm). Because cysteine residue(s) in IDPm are susceptible to inactivation by a number of thiol-modifying reagents, we hypothesized that IDPm is likely a target for regulation by an oxidative mechanism, specifically glutathionylation. Oxidized glutathione led to enzyme inactivation with simultaneous formation of a mixed disulfide between glutathione and the cysteine residue(s) in IDPm, which was detected by immunoblotting with anti-GSH IgG. The inactivated IDPm was reactivated enzymatically by glutaredoxin2 in the presence of GSH, indicating that the inactivated form of IDPm is a glutathionyl mixed disulfide. Mass spectrometry and site-directed mutagenesis further confirmed that glutathionylation occurs to a Cys(269) of IDPm. The glutathionylated IDPm appeared to be significantly less susceptible than native protein to peptide fragmentation by reactive oxygen species and proteolytic digestion, suggesting that glutathionylation plays a protective role presumably through the structural alterations. HEK293 cells and intact respiring mitochondria treated with oxidants inducing GSH oxidation such as H2O2 or diamide showed a decrease in IDPm activity and the accumulation of glutathionylated enzyme. Using immunoprecipitation with anti-IDPm IgG and immunoblotting with anti-GSH IgG, we were also able to purify and positively identify glutathionylated IDPm from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model for Parkinson's disease. The results of the current study indicate that IDPm activity appears to be modulated through enzymatic glutathionylation and deglutathionylation during oxidative stress.	Kyungpook Natl Univ, Dept Biochem, Coll Nat Sci, Taegu 702701, South Korea	Kyungpook National University	Park, JW (corresponding author), Kyungpook Natl Univ, Dept Biochem, Coll Nat Sci, Taegu 702701, South Korea.	parkjw@knu.ac.kr						Albers DS, 2000, J NEURAL TRANSM-SUPP, P133; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Benderdour M, 2003, J BIOL CHEM, V278, P45154, DOI 10.1074/jbc.M306285200; Bharath S, 2002, BIOCHEM PHARMACOL, V64, P1037, DOI 10.1016/S0006-2952(02)01174-7; BRANDWEIN HJ, 1981, J BIOL CHEM, V256, P2958; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Cock HR, 2002, EPILEPSY RES, V48, P157, DOI 10.1016/S0920-1211(01)00334-5; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; FATANIA HR, 1993, FEBS LETT, V322, P245, DOI 10.1016/0014-5793(93)81579-O; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; Hornykiewicz O, 1987, Adv Neurol, V45, P19; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; JOHANSON RA, 1981, ARCH BIOCHEM BIOPHYS, V207, P21, DOI 10.1016/0003-9861(81)90003-5; KAJIYAMA K, 1987, CIRC RES, V61, P301, DOI 10.1161/01.RES.61.2.301; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; KOSHLAND DE, 1985, CURR TOP CELL REGUL, V27, P13; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Lee JH, 2003, J BIOL CHEM, V278, P51360, DOI 10.1074/jbc.M302332200; Lee SM, 2001, BIOCHIMIE, V83, P1057, DOI 10.1016/S0300-9084(01)01351-7; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; NISHINAKA Y, 1993, J CARDIOVASC PHARM, V21, P448, DOI 10.1097/00005344-199303000-00015; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SILVA CM, 1989, J BIOL CHEM, V264, P6638; Slama P, 2001, FEBS LETT, V491, P55, DOI 10.1016/S0014-5793(01)02147-0; SMYTH GE, 1991, J BIOL CHEM, V266, P14918; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; SZWEDA LL, 1993, ARCH BIOCHEM BIOPHYS, V301, P381; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; Ward NE, 1998, J BIOL CHEM, V273, P12558, DOI 10.1074/jbc.273.20.12558; WATABE S, 1995, BIOCHEM BIOPH RES CO, V213, P1010, DOI 10.1006/bbrc.1995.2229; Yang ES, 2002, FREE RADICAL BIO MED, V33, P927, DOI 10.1016/S0891-5849(02)00981-4	48	112	114	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10846	10854		10.1074/jbc.M411306200	http://dx.doi.org/10.1074/jbc.M411306200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15653693	hybrid			2022-12-25	WOS:000227559600133
J	Kerkhoff, C; Nacken, W; Benedyk, M; Dagher, MC; Sopalla, C; Doussiere, J				Kerkhoff, C; Nacken, W; Benedyk, M; Dagher, MC; Sopalla, C; Doussiere, J			The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67(phox) and Rac-2	FASEB JOURNAL			English	Article						neutrophils; cytosolic phox proteins; MRP8/14; superoxide O2(.-); gene silencing	CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; HUMAN NEUTROPHIL ACTIVATION; PHENYLARSINE OXIDE; PLASMA-MEMBRANE; INTERMEDIATE-FILAMENTS; FLAVOCYTOCHROME-B; CYTOCHROME B(558); CYTOSOLIC FACTORS; REACTIVE OXYGEN	The Ca2+- and arachidonic acid-binding S100A8/A9 protein complex was recently identified by in vitro studies as a novel partner of the phagocyte NADPH oxidase. The present study demonstrated its functional relevance by the impaired oxidase activity in neutrophil-like NB4 cells, after specific blockage of S100A9 expression, and bone marrow polymorphonuclear neutrophils from S100A9(-/-) mice. The impaired oxidase activation could also be mimicked in a cell-free system by pretreatment of neutrophil cytosol with an S100A9-specific antibody. Further analyses gave insights into the molecular mechanisms by which S100A8/A9 promoted NADPH oxidase activation. In vitro analysis of oxidase activation as well as protein-protein interaction studies revealed that S100A8 is the privileged interaction partner for the NADPH oxidase complex since it bound to p67(phox) and Rac, whereas S100A9 did interact with neither p67phox nor p47(phox). Moreover, S100A8/A9 transferred the cofactor arachidonic acid to NADPH oxidase as shown by the impotence of a mutant S100A8/A9 complex unable to bind arachidonic acid to enhance NADPH oxidase activity. It is concluded that S100A8/A9 plays an important role in phagocyte NADPH oxidase activation.	Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; UJF, Dept Reponse & Dynam Cellulaires, Lab Biochim & Biophys Syst Integres, UMR CEA CNRS 5092, Grenoble, France; IZKF, Munster, Germany	University of Munster; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Kerkhoff, C (corresponding author), Univ Munster, Inst Expt Dermatol, Rontgenstr 21, D-48149 Munster, Germany.	kerkhoc@uni-muenster.de		DAGHER, Marie-Claire/0000-0001-6878-3169				ABO A, 1992, J BIOL CHEM, V267, P16767; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BURKHARDT K, 1995, TRANSPLANT P, V27, P890; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Doussiere J, 1996, BIOCHEMISTRY-US, V35, P13400, DOI 10.1021/bi960916b; Doussiere J, 2001, BIOCHEM BIOPH RES CO, V285, P1317, DOI 10.1006/bbrc.2001.5324; Doussiere J, 1999, BIOCHEMISTRY-US, V38, P16394, DOI 10.1021/bi991502w; Doussiere J, 1998, EUR J BIOCHEM, V251, P649, DOI 10.1046/j.1432-1327.1998.2510649.x; Doussiere J, 2002, EUR J BIOCHEM, V269, P3246, DOI 10.1046/j.1432-1033.2002.03002.x; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; Faure J, 2001, BIOCHIMIE, V83, P409, DOI 10.1016/S0300-9084(01)01263-9; Foubert TR, 2002, BBA-BIOMEMBRANES, V1567, P221, DOI 10.1016/S0005-2736(02)00619-3; Frosch M, 2004, J LEUKOCYTE BIOL, V75, P198, DOI 10.1189/jlb.0203076; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; Geiszt M, 2001, J LEUKOCYTE BIOL, V69, P191; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; GREEN TR, 1990, J BIOL CHEM, V265, P19324; Grogan A, 1997, J CELL SCI, V110, P3071; Guignard F, 1996, EUR J BIOCHEM, V241, P265, DOI 10.1111/j.1432-1033.1996.0265t.x; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; HOWARD TH, 1987, J CLIN INVEST, V79, P1359, DOI 10.1172/JCI112962; JOUAN A, 1993, ANAL BIOCHEM, V214, P252, DOI 10.1006/abio.1993.1485; Kato M, 2002, J IMMUNOL, V169, P5252, DOI 10.4049/jimmunol.169.9.5252; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Kerkhoff C, 1999, FEBS LETT, V460, P134, DOI 10.1016/S0014-5793(99)01322-8; Kerkhoff C, 2002, J BIOL CHEM, V277, P41879, DOI 10.1074/jbc.M207990200; Kerkhoff C, 2001, BIOCHEMISTRY-US, V40, P241, DOI 10.1021/bi001791k; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; LEMARCHAND P, 1992, J BIOL CHEM, V267, P19379; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; Liu L, 1996, J IMMUNOL METHODS, V192, P173, DOI 10.1016/0022-1759(96)00049-X; Manitz MP, 2003, MOL CELL BIOL, V23, P1034, DOI 10.1128/MCB.23.3.1034-1043.2003; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MULLER G, 1993, ARTERIOSCLER THROMB, V13, P1317, DOI 10.1161/01.ATV.13.9.1317; N'Diaye EN, 1997, LEUKEMIA, V11, P2131, DOI 10.1038/sj.leu.2400855; Nacken W, 2004, FEBS LETT, V572, P289, DOI 10.1016/j.febslet.2004.07.024; Nacken W, 2003, MICROSC RES TECHNIQ, V60, P569, DOI 10.1002/jemt.10299; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTH J, 1993, BLOOD, V82, P1875; Roulin K, 1999, EXP CELL RES, V247, P410, DOI 10.1006/excr.1998.4382; SAKATA A, 1987, J IMMUNOL, V138, P4353; SAWAI T, 1993, BIOCHEM BIOPH RES CO, V195, P264, DOI 10.1006/bbrc.1993.2039; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; Sopalla C, 2002, BIOL CHEM, V383, P1895, DOI 10.1515/BC.2002.213; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Vaissiere C, 1999, J LEUKOCYTE BIOL, V65, P629, DOI 10.1002/jlb.65.5.629; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; van den Bos C, 1998, PROTEIN EXPRES PURIF, V13, P313, DOI 10.1006/prep.1998.0917; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Vilhardt F, 2004, EMBO J, V23, P739, DOI 10.1038/sj.emboj.7600066; WAN CP, 1993, J IMMUNOL METHODS, V159, P131, DOI 10.1016/0022-1759(93)90150-6; Wientjes FB, 2001, BIOCHEM BIOPH RES CO, V289, P382, DOI 10.1006/bbrc.2001.5982; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x	68	120	135	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					467	+		10.1096/fj.04-2377fje	http://dx.doi.org/10.1096/fj.04-2377fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15642721				2022-12-25	WOS:000226576600024
J	Dickmanns, A; Schmidt, B; Rudolph, MG; Mariappan, M; Dierks, T; von Figura, K; Ficner, R				Dickmanns, A; Schmidt, B; Rudolph, MG; Mariappan, M; Dierks, T; von Figura, K; Ficner, R			Crystal structure of human pFGE, the paralog of the C alpha-formylglycine-generating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SULFATASE DEFICIENCY; PROTEIN MODIFICATION; ELECTRON-DENSITY; GENE; CONVERSION; CYSTEINE; SECONDARY; PROGRAM; ERRORS	In eukaryotes, sulfate esters are degraded by sulfatases, which possess a unique C alpha-formylglycine residue in their active site. The defect in post-translational formation of the C alpha-formylglycine residue causes a severe lysosomal storage disorder in humans. Recently, FGE (formylglycine-generating enzyme) has been identified as the protein required for this specific modification. Using sequence comparisons, a protein homologous to FGE was found and denoted pFGE (paralog of FGE). pFGE binds a sulfatase-derived peptide bearing the FGE recognition motif, but it lacks formylglycine-generating activity. Both proteins belong to a large family of pro- and eukaryotic proteins containing the DUF323 domain, a formylglycine-generating enzyme domain of unknown three-dimensional structure. We have crystallized the glycosylated human pFGE and determined its crystal structure at a resolution of 1.86 angstrom. The structure reveals a novel fold, which we denote the FGE fold and which therefore serves as a paradigm for the DUF323 domain. It is characterized by an asymmetric partitioning of secondary structure elements and is stabilized by two calcium cations. A deep cleft on the surface of pFGE most likely represents the sulfatase polypeptide binding site. The asymmetric unit of the pFGE crystal contains a homodimer. The putative peptide binding site is buried between the monomers, indicating a biological significance of the dimer. The structure suggests the capability of pFGE to form a heterodimer with FGE.	Univ Gottingen, Inst Mikrobiol & Genet, Abt Mol Strukturbiol, D-37077 Gottingen, Germany; Univ Gottingen, Biochem Abt 2, D-37073 Gottingen, Germany	University of Gottingen; University of Gottingen	Ficner, R (corresponding author), Univ Gottingen, Inst Mikrobiol & Genet, Abt Mol Strukturbiol, Justus von Liebig Weg 9, D-37077 Gottingen, Germany.	rficner@gwdg.de	mariappan, malaiyalam/K-9024-2012; Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339; Rudolph, Markus/0000-0003-0447-1101				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; DIERKS T, IN PRESS CELL; EISENHABER F, 1995, CRIT REV BIOCHEM MOL, V30, P1, DOI 10.3109/10409239509085139; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fey J, 2001, J BIOL CHEM, V276, P47021, DOI 10.1074/jbc.M108943200; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, J MOL BIOL, V100, P283, DOI 10.1016/S0022-2836(76)80064-2; Kertesz MA, 2000, FEMS MICROBIOL REV, V24, P135, DOI 10.1016/S0168-6445(99)00033-9; Khaleeli N, 2000, BIOCHEMISTRY-US, V39, P8666, DOI 10.1021/bi000534c; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Landgrebe J, 2003, GENE, V316, P47, DOI 10.1016/S0378-1119(03)00746-7; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Mariappan M, 2005, J BIOL CHEM, V280, P15173, DOI 10.1074/jbc.M413698200; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McGowan SJ, 1996, MOL MICROBIOL, V22, P415, DOI 10.1046/j.1365-2958.1996.00125.x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Preusser-Kunze A, 2005, J BIOL CHEM, V280, P14900, DOI 10.1074/jbc.M413383200; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1992, ACTA CRYSTALLOGR A, V48, P104, DOI 10.1107/S0108767391008024; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	40	21	23	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15180	15187		10.1074/jbc.M414317200	http://dx.doi.org/10.1074/jbc.M414317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15687489	hybrid			2022-12-25	WOS:000228236800102
J	Benians, A; Nobles, M; Hosny, S; Tinker, A				Benians, A; Nobles, M; Hosny, S; Tinker, A			Regulators of G-protein signaling form a quaternary complex with the agonist, receptor, and G-protein - A novel explanation for the acceleration of signaling activation kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CHANNEL; HETEROTRIMERIC G-PROTEINS; RGS PROTEINS; PLASMA-MEMBRANE; MEDIATED MODULATION; POTASSIUM CHANNELS; PHOSPHOLIPASE-C; BINDING; INHIBITION; SUBUNIT	Regulators of G-protein signaling (RGS) proteins modulate signaling through heterotrimeric G-proteins. They act to enhance the intrinsic GTPase activity of the G alpha subunit but paradoxically have also been shown to enhance receptor-stimulated activation. To study this paradox, we used a G-protein gated K+ channel to report the dynamics of the G-protein cycle and fluorescence resonance energy transfer techniques with cyan and yellow fluorescent protein-tagged proteins to report physical interaction. Our data show that the acceleration of the activation kinetics is dissociated from deactivation kinetics and dependent on receptor and RGS type, G-protein isoform, and RGS expression levels. By using fluorescently tagged proteins, fluorescence resonance energy transfer microscopy showed a stable physical interaction between the G-protein alpha subunit and RGS (RGS8 and RGS7) that is independent of the functional state of the G-protein. RGS8 does not directly interact with G-protein-coupled receptors. Our data show participation of the RGS in the ternary complex between agonist-receptor and G-protein to form a "quaternary complex." Thus we propose a novel model for the action of RGS proteins in the G-protein cycle in which the RGS protein appears to enhance the "kinetic efficacy" of the ternary complex, by direct association with the G-protein alpha subunit.	UCL, BHF Labs, London WC1E 6JJ, England; UCL, Dept Med, London WC1E 6JJ, England	University of London; University College London; University of London; University College London	Tinker, A (corresponding author), UCL, BHF Labs, Room 420,4th Floor,5 Univ St, London WC1E 6JJ, England.	a.tinker@ucl.ac.uk						Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Benians A, 2003, J BIOL CHEM, V278, P10851, DOI 10.1074/jbc.M212299200; Benians A, 2003, P NATL ACAD SCI USA, V100, P6239, DOI 10.1073/pnas.1037595100; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bhattacharyya R, 2003, BIOCHEM J, V371, P709, DOI 10.1042/BJ20021897; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Derrien A, 2003, J BIOL CHEM, V278, P16107, DOI 10.1074/jbc.M210371200; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Drici MD, 2000, BRIT J PHARMACOL, V131, P569, DOI 10.1038/sj.bjp.0703611; Erickson MG, 2003, BIOPHYS J, V85, P599, DOI 10.1016/S0006-3495(03)74504-4; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; FREISSMUTH M, 1991, BIOCHEM J, V275, P651, DOI 10.1042/bj2750651; Giblin JP, 1999, J BIOL CHEM, V274, P22652, DOI 10.1074/jbc.274.32.22652; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; HUNT TW, 1994, J BIOL CHEM, V269, P29565; Inanobe A, 2001, J PHYSIOL-LONDON, V535, P133, DOI 10.1111/j.1469-7793.2001.t01-1-00133.x; Ivanina T, 2004, J BIOL CHEM, V279, P17260, DOI 10.1074/jbc.M313425200; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; Jeong SW, 2001, J PHYSIOL-LONDON, V535, P335, DOI 10.1111/j.1469-7793.2001.00335.x; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Leaney JL, 2000, P NATL ACAD SCI USA, V97, P5651, DOI 10.1073/pnas.080572297; Leaney JL, 2002, J BIOL CHEM, V277, P28803, DOI 10.1074/jbc.M204683200; Leaney JL, 2000, J BIOL CHEM, V275, P921, DOI 10.1074/jbc.275.2.921; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Masuho I, 2004, J NEUROCHEM, V88, P161, DOI 10.1046/j.1471-4159.2003.02139.x; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; Neubig RR, 2002, J PEPT RES, V60, P312, DOI 10.1034/j.1399-3011.2002.21064.x; NEUBIG RR, 1988, BIOCHEMISTRY-US, V27, P2374, DOI 10.1021/bi00407a019; NOMA A, 1978, PFLUG ARCH EUR J PHY, V377, P193, DOI 10.1007/BF00584272; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Pentcheva T, 2001, J IMMUNOL, V166, P6625, DOI 10.4049/jimmunol.166.11.6625; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; Takida S, 2005, MOL PHARMACOL, V67, P132, DOI 10.1124/mol.104.003418; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TIAN WN, 1994, MOL PHARMACOL, V45, P524; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; Wise A, 1997, BIOCHEM J, V321, P721, DOI 10.1042/bj3210721; Witherow DS, 2003, RECEPTOR CHANNEL, V9, P205, DOI 10.1080/10606820390203848; Witherow DS, 2003, J BIOL CHEM, V278, P21307, DOI 10.1074/jbc.M212884200; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yamada M, 1998, PHARMACOL REV, V50, P723; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zerangue N, 1998, CURR BIOL, V8, pR313, DOI 10.1016/S0960-9822(98)70196-4; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151; Zhong HL, 2003, J BIOL CHEM, V278, P7278, DOI 10.1074/jbc.M208819200	61	63	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13383	13394		10.1074/jbc.M410163200	http://dx.doi.org/10.1074/jbc.M410163200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677457	hybrid			2022-12-25	WOS:000228095500025
J	Ma, XY; Koepke, J; Panjikar, S; Fritzsch, G; Stockigt, J				Ma, XY; Koepke, J; Panjikar, S; Fritzsch, G; Stockigt, J			Crystal structure of vinorine synthase, the first representative of the BAHD superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-ANTHOCYANIN 5-O-GLUCOSIDE-6'''-O-MALONYLTRANSFERASE; SALVIA-SPLENDENS FLOWERS; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CARNITINE ACETYLTRANSFERASE; TRANSFERASE CDNA; ENZYME; BIOSYNTHESIS; CRYSTALLIZATION; PURIFICATION	Vinorine synthase is an acetyltransferase that occupies a central role in the biosynthesis of the antiarrhythmic monoterpenoid indole alkaloid ajmaline in the plant Rauvolfia. Vinorine synthase belongs to the benzylalcohol acetyl-, anthocyanin-O-hydroxy-cinnamoyl-, anthranilate-N-hydroxy-cinnamoyl/benzoyl-, deacetylvindoline acetyltransferase (BAHD) enzyme superfamily, members of which are involved in the biosynthesis of several important drugs, such as morphine, Taxol, or vindoline, a precursor of the anti-cancer drugs vincaleucoblastine and vincristine. The x-ray structure of vinorine synthase is described at 2.6-angstrom resolution. Despite low sequence identity, the two-domain structure of vinorine synthase shows surprising similarity with structures of several CoA-dependent acyltransferases such as dihydrolipoyl transacetylase, polyketide-associated protein A5, and carnitine acetyltransferase. All conserved residues typical for the BAHD family are found in domain 1. His(160) of the HXXXD motif functions as a general base during catalysis. It is located in the center of the reaction channel at the interface of both domains and is accessible from both sides. The channel runs through the entire molecule, allowing the substrate and co-substrate to bind independently. Asp(164) points away from the catalytic site and seems to be of structural rather than catalytic importance. Surprisingly, the DFGWG motif, which is indispensable for the catalyzed reaction and unique to the BAHD family, is located far away from the active site and seems to play only a structural role. Vinorine synthase represents the first solved protein structure of the BAHD superfamily.	Johannes Gutenberg Univ Mainz, Inst Pharm, Dept Pharmaceut Biol, D-55099 Mainz, Germany; Max Planck Inst Biophys, Dept Mol Membrane Biol, D-60439 Frankfurt, Germany; DESY, Hamburg Outstn, European Mol Biol Lab, D-22603 Hamburg, Germany	Johannes Gutenberg University of Mainz; Max Planck Society; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Stockigt, J (corresponding author), Johannes Gutenberg Univ Mainz, Inst Pharm, Dept Pharmaceut Biol, Staudinger Weg 5, D-55099 Mainz, Germany.	stoeckig@mail.uni-mainz.de	Panjikar, Santosh/D-2709-2012	Panjikar, Santosh/0000-0001-7429-3879				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barleben L, 2005, BBA-PROTEINS PROTEOM, V1747, P89, DOI 10.1016/j.bbapap.2004.09.026; Bayer A, 2004, BIOORGAN MED CHEM, V12, P2787, DOI 10.1016/j.bmc.2004.02.029; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buglino J, 2004, J BIOL CHEM, V279, P30634, DOI 10.1074/jbc.M404011200; Cordell G.a, 1995, ALAKLOIDS, P115; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dudareva N, 2000, PLANT PHYSIOL, V122, P627, DOI 10.1104/pp.122.3.627; Gerasimenko I, 2004, BIOORGAN MED CHEM, V12, P2781, DOI 10.1016/j.bmc.2004.02.028; GIBBS MR, 1990, BIOCHEMISTRY-US, V29, P11261, DOI 10.1021/bi00503a015; Grothe T, 2001, J BIOL CHEM, V276, P30717, DOI 10.1074/jbc.M102688200; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; Keating TA, 2002, NAT STRUCT BIOL, V9, P522, DOI 10.1038/nsb810; Kleywegt GJ, 1997, ACTA CRYSTALLOGR D, V53, P179, DOI 10.1107/S0907444996012279; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Ma XY, 2004, BBA-PROTEINS PROTEOM, V1702, P121, DOI 10.1016/j.bbapap.2004.06.013; Ma XY, 2004, BBA-PROTEINS PROTEOM, V1701, P129, DOI 10.1016/j.bbapap.2004.06.011; MA XY, 2005, IN PRESS ACTA CRYS D; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PANJIKAR S, 2005, IN PRESS ACTA CRYS D; PFITZNER A, 1986, Z NATURFORSCH C, V41, P103; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; St-Pierre B, 1998, PLANT J, V14, P703, DOI 10.1046/j.1365-313x.1998.00174.x; St-Pierre B, 2000, RECENT ADV PHYTOCHEM, V34, P285, DOI 10.1016/S0079-9920(00)80010-6; Suzuki H, 2004, PLANT J, V38, P994, DOI 10.1111/j.1365-313X.2004.02101.x; Suzuki H, 2003, BIOCHEMISTRY-US, V42, P1764, DOI 10.1021/bi020618g; Suzuki H, 2001, J BIOL CHEM, V276, P49013, DOI 10.1074/jbc.M108444200; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Walker K, 2000, P NATL ACAD SCI USA, V97, P583, DOI 10.1073/pnas.97.2.583; Walker K, 2000, ARCH BIOCHEM BIOPHYS, V374, P371, DOI 10.1006/abbi.1999.1609; Walker K, 2000, P NATL ACAD SCI USA, V97, P13591, DOI 10.1073/pnas.250491997; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	43	130	140	4	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13576	13583		10.1074/jbc.M414508200	http://dx.doi.org/10.1074/jbc.M414508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15665331	hybrid			2022-12-25	WOS:000228095500050
J	Chen, YX; Mant, CT; Farmer, SW; Hancock, REW; Vasil, ML; Hodges, RS				Chen, YX; Mant, CT; Farmer, SW; Hancock, REW; Vasil, ML; Hodges, RS			Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE LIQUID-CHROMATOGRAPHY; ACID SIDE-CHAINS; DIFFERENT AQUEOUS ENVIRONMENTS; LIGAND-RECEPTOR INTERFACE; TRANSMEMBRANE PEPTIDE; CATIONIC PEPTIDES; GRAMICIDIN-S; AMPHIPATHIC PEPTIDES; HEMOLYTIC ACTIVITIES; HYDROPHOBIC MOMENT	In the present study, the 26-residue peptide sequence Ac-KWKSFLKTFKSAVKTVLHTALKAISS-amide (V-681) was utilized as the framework to study the effects of peptide hydrophobicity/hydrophilicity, amphipathicity, and helicity ( induced by single amino acid substitutions in the center of the polar and nonpolar faces of the amphipathic helix) on biological activities. The peptide analogs were also studied by temperature profiling in reversed-phase high performance liquid chromatography, from 5 to 80 degrees C, to evaluate the self-associating ability of the molecules in solution, another important parameter in understanding peptide antimicrobial and hemolytic activities. A higher ability to self-associate in solution was correlated with weaker antimicrobial activity and stronger hemolytic activity of the peptides. Biological studies showed that strong hemolytic activity of the peptides generally correlated with high hydrophobicity, high amphipathicity, and high helicity. In most cases, the D-amino acid substituted peptides possessed an enhanced average antimicrobial activity compared with L-diastereomers. The therapeutic index of V-681 was improved 90- and 23-fold against Gram-negative and Gram-positive bacteria, respectively. By simply replacing the central hydrophobic or hydrophilic amino acid residue on the nonpolar or the polar face of these amphipathic derivatives of V-681 with a series of selected D-/L-amino acids, we demonstrated that this method has excellent potential for the rational design of antimicrobial peptides with enhanced activities.	Univ Colorado, Dept Biochem & Mol Genet, Hlth Sci Ctr Fitzsimons, Aurora, CO 80045 USA; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z3, Canada; Univ Colorado, Dept Microbiol, Hlth Sci Ctr Fitzsimons, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of British Columbia; University of Colorado System; University of Colorado Anschutz Medical Campus	Hodges, RS (corresponding author), Univ Colorado, Dept Biochem & Mol Genet, Hlth Sci Ctr Fitzsimons, Biomol Struct MS 8101,POB 6511, Aurora, CO 80045 USA.	robert.hodges@uchsc.edu	Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503; Farmer, Susan/0000-0002-6712-7810	NIAID NIH HHS [R01 AI015940, R37 AI015940, R01AI48717, AI15940] Funding Source: Medline; NIGMS NIH HHS [R01 GM061855, R01GM61855] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048717, R01AI015940, R37AI015940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061855] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREU D, 1992, FEBS LETT, V296, P190, DOI 10.1016/0014-5793(92)80377-S; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Blondelle SE, 1999, BBA-BIOMEMBRANES, V1462, P89, DOI 10.1016/S0005-2736(99)00202-3; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BLONDELLE SE, 1995, BIOPHYS J, V68, P351, DOI 10.1016/S0006-3495(95)80194-3; Calza L, 2004, EXPERT OPIN PHARMACO, V5, P1899, DOI 10.1517/14656566.5.9.1899; Carver T, 2003, BIOINFORMATICS, V19, P1837, DOI 10.1093/bioinformatics/btg251; Chen Y, 2002, J PEPT RES, V59, P18, DOI 10.1046/j.1397-002x.2001.10994.x; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DEVAUX PF, 1985, BIOCHIM BIOPHYS ACTA, V822, P63, DOI 10.1016/0304-4157(85)90004-8; Devine DA, 2002, CURR PHARM DESIGN, V8, P703, DOI 10.2174/1381612023395501; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; EHRENSTEIN G, 1977, Q REV BIOPHYS, V10, P1, DOI 10.1017/S0033583500000123; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 2002, FEMS MICROBIOL LETT, V206, P143, DOI 10.1016/S0378-1097(01)00480-3; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HODGES RS, HPLC PEPTIDES PROTEI; Jacqueline C, 2004, INT J ANTIMICROB AG, V24, P393, DOI 10.1016/j.ijantimicag.2004.03.013; KHALED MA, 1978, BIOCHEMISTRY-US, V17, P2490; Kondejewski LH, 1999, J BIOL CHEM, V274, P13181, DOI 10.1074/jbc.274.19.13181; Kondejewski LH, 2002, J BIOL CHEM, V277, P67, DOI 10.1074/jbc.M107825200; Lee DL, 2004, J PEPT RES, V63, P69, DOI 10.1046/j.1399-3011.2003.00106.x; Lee DL, 2003, J BIOL CHEM, V278, P22918, DOI 10.1074/jbc.M301777200; Lee DL, 2003, BIOPOLYMERS, V71, P28, DOI 10.1002/bip.10374; Liu F, 2004, BIOPHYS J, V87, P2470, DOI 10.1529/biophysj.104.046342; Liu F, 2004, BIOCHEMISTRY-US, V43, P3679, DOI 10.1021/bi036214l; Liu F, 2002, BIOCHEMISTRY-US, V41, P9197, DOI 10.1021/bi025661i; Mant CT, 2003, J CHROMATOGR A, V1009, P29, DOI 10.1016/S0021-9673(03)00621-6; Mant CT, 2003, J CHROMATOGR A, V1009, P45, DOI 10.1016/S0021-9673(03)00919-1; Mant CT, 2002, J CHROMATOGR A, V972, P61, DOI 10.1016/S0021-9673(02)00356-4; Mant CT, 2002, J CHROMATOGR A, V972, P45, DOI 10.1016/S0021-9673(02)00354-0; MANT CT, 1993, AMPHIPATHIC HELIX, P39; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; McInnes C, 2000, J BIOL CHEM, V275, P14287, DOI 10.1074/jbc.275.19.14287; Monera OD, 1995, J PEPT SCI, V1, P319, DOI 10.1002/psc.310010507; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Oren Z, 1997, J BIOL CHEM, V272, P14643, DOI 10.1074/jbc.272.23.14643; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; PURCELL AW, 1995, PEPTIDE RES, V8, P160; Salgado J, 2001, J BIOMOL NMR, V21, P191, DOI 10.1023/A:1012946026231; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 1996, J BIOL CHEM, V271, P7305, DOI 10.1074/jbc.271.13.7305; Sitaram N, 2002, CURR PHARM DESIGN, V8, P727, DOI 10.2174/1381612023395358; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; Steinberg DA, 1997, ANTIMICROB AGENTS CH, V41, P1738, DOI 10.1128/AAC.41.8.1738; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; van 't Hof W, 2001, BIOL CHEM, V382, P597, DOI 10.1515/BC.2001.072; Wagenlehner FME, 2004, INT J ANTIMICROB AG, V24, pS39, DOI 10.1016/j.ijantimicag.2004.02.002; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zhang L, 1998, BIOCHEM BIOPH RES CO, V247, P674, DOI 10.1006/bbrc.1998.8848; Zhang LJ, 2001, J BIOL CHEM, V276, P35714, DOI 10.1074/jbc.M104925200; Zhang LJ, 1999, BIOCHEMISTRY-US, V38, P8102, DOI 10.1021/bi9904104; ZHOU N E, 1990, Peptide Research, V3, P8; ZHOU NE, 1994, PROTEIN PEPTIDE LETT, V1, P114	60	488	520	6	96	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12316	12329		10.1074/jbc.M413406200	http://dx.doi.org/10.1074/jbc.M413406200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677462	hybrid, Green Accepted			2022-12-25	WOS:000227922000032
J	Das, A; Xi, L; Kukreja, RC				Das, A; Xi, L; Kukreja, RC			Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; K-ATP CHANNELS; INDUCED CARDIOPROTECTION; POTASSIUM CHANNELS; ORAL SILDENAFIL; PROTEIN; CGMP; ACTIVATION; HEART; ZAPRINAST	We investigated the effect of sildenafil in protection against necrosis or apoptosis in cardiomyocytes. Adult mouse ventricular myocytes were treated with sildenafil (1 or 10 mu M) for 1 h before 40 min of simulated ischemia (SI). Necrosis was determined by trypan blue exclusion and lactate dehydrogenase release following SI alone or plus 1 or 18 h of reoxygenation (RO). Apoptosis was assessed by terminal deoxynucleotidyl transferase-mediated nick end labeling assay and mitochondrial membrane potential measured using a fluorescent probe 5,5 ', 6,6 '-tetrachloro-1,1 ',3,3 '-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1). Sildenafil reduced necrosis as indicated by decrease in trypan blue-positive myocytes and leakage of lactate dehydrogenase compared with untreated cells after either SI or SI-RO. The number of terminal deoxynucleotidyl transferase-mediated nick end labeling-positive myocytes or loss of JC-1 fluorescence following SI and 18 h of RO was attenuated in the sildenafil-treated group with concomitant inhibition of caspase 3 activity. An early increase in Bcl-2 to Bax ratio with sildenafil treatment was also observed in myocytes after SI-RO. The increase of Bcl-2 expression by sildenafil was inhibited by nitric-oxide synthase (NOS) inhibitor, L-nitro-amino-methyl-ester. The drug also enhanced mRNA and protein content of inducible NOS (iNOS) and endothelial NOS ( eNOS) in the myocytes. Sildenafil-induced protection against necrosis and apoptosis was absent in the myocytes derived from iNOS knock-out mice and was attenuated in eNOS knock-out myocytes. The up-regulation of Bcl-2 expression by sildenafil was also absent in iNOS-deficient myocytes. Reverse transcription-PCR, Western blots, and immunohistochemical assay confirmed the expression of phosphodiesterase-5 in mouse cardiomyocytes. These data provide strong evidence for a direct protective effect of sildenafil against necrosis and apoptosis through NO signaling pathway. The results may have possible therapeutic potential in preventing myocyte cell death following ischemia/reperfusion.	Virginia Commonwealth Univ, Med Ctr, Div Cardiol, Dept Internal Med, Richmond, VA 23298 USA	Virginia Commonwealth University	Kukreja, RC (corresponding author), Virginia Commonwealth Univ, Med Ctr, Div Cardiol, Dept Internal Med, Box 980281, Richmond, VA 23298 USA.	rakesh@hsc.vcu.edu	Xi, Lei/A-3078-2008; Das, Anindita/K-8003-2013	Xi, Lei/0000-0002-7569-3329; Das, Anindita/0000-0003-4422-7277	NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051045, R37HL051045, R01HL059469, R01HL079424] Funding Source: NIH RePORTER; NCI NIH HHS [CA16059] Funding Source: Medline; NHLBI NIH HHS [HL59469, HL51045, HL79424] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrams D, 2000, Heart, V84, pE4, DOI 10.1136/heart.84.2.e4; Akao M, 2001, CIRC RES, V88, P1267, DOI 10.1161/hh1201.092094; Andoh T, 2002, ANN NY ACAD SCI, V962, P1, DOI 10.1111/j.1749-6632.2002.tb04051.x; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; Boolell M, 1996, Int J Impot Res, V8, P47; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Das A, 2004, AM J PHYSIOL-HEART C, V286, pH1455, DOI 10.1152/ajpheart.01040.2003; Das A, 2001, J BIOL CHEM, V276, P3279, DOI 10.1074/jbc.M008454200; Das S, 2002, DRUG EXP CLIN RES, V28, P213; Fagan KA, 2001, RESP RES, V2, P90, DOI 10.1186/rr44; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Freude B, 2000, J MOL CELL CARDIOL, V32, P197, DOI 10.1006/jmcc.1999.1066; Gibson A, 2001, EUR J PHARMACOL, V411, P1, DOI 10.1016/S0014-2999(00)00824-4; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gross GJ, 2000, BASIC RES CARDIOL, V95, P280, DOI 10.1007/s003950050004; Guo Y, 1999, P NATL ACAD SCI USA, V96, P11507, DOI 10.1073/pnas.96.20.11507; Han J, 2002, AM J PHYSIOL-HEART C, V283, pH1545, DOI 10.1152/ajpheart.01052.2001; Ito M, 1996, CELL SIGNAL, V8, P575, DOI 10.1016/S0898-6568(96)00112-X; Kajstura J, 1997, J MOL CELL CARDIOL, V29, P859, DOI 10.1006/jmcc.1996.0333; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Katz SD, 2000, J AM COLL CARDIOL, V36, P845, DOI 10.1016/S0735-1097(00)00790-7; Kukreja RC, 2004, J MOL CELL CARDIOL, V36, P165, DOI 10.1016/j.yjmcc.2003.11.001; Loughney K, 1998, GENE, V216, P139, DOI 10.1016/S0378-1119(98)00303-5; Mathur A, 2000, CARDIOVASC RES, V46, P126, DOI 10.1016/S0008-6363(00)00002-X; Michelakis E, 2002, CIRCULATION, V105, P2398, DOI 10.1161/01.CIR.0000016641.12984.DC; Ockaili R, 2002, AM J PHYSIOL-HEART C, V283, pH1263, DOI 10.1152/ajpheart.00324.2002; Prasad S, 2000, NEW ENGL J MED, V343, P1342, DOI 10.1056/NEJM200011023431814; Rakhit RD, 2000, AM J PHYSIOL-HEART C, V278, pH1211, DOI 10.1152/ajpheart.2000.278.4.H1211; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Reffelmann T, 2003, CIRCULATION, V108, P239, DOI 10.1161/01.CIR.0000081166.87607.E2; Ruiz-Meana M, 2003, AM J PHYSIOL-HEART C, V285, pH999, DOI 10.1152/ajpheart.00035.2003; Salloum F, 2003, CIRC RES, V92, P595, DOI 10.1161/01.RES.0000066853.09821.98; Salvioli S, 2000, CYTOMETRY, V40, P189, DOI 10.1002/1097-0320(20000701)40:3<189::AID-CYTO3>3.0.CO;2-6; Sarfati M, 2003, BLOOD, V101, P265, DOI 10.1182/blood-2002-01-0075; Sasaki N, 2000, CIRCULATION, V101, P439, DOI 10.1161/01.CIR.101.4.439; Sebkhi A, 2003, CIRCULATION, V107, P3230, DOI 10.1161/01.CIR.0000074226.20466.B1; Senzaki H, 2001, FASEB J, V15, P1718, DOI 10.1096/fj.00-0538com; Shakir SAW, 2001, BRIT MED J, V322, P651, DOI 10.1136/bmj.322.7287.651; Tejero-Taldo MI, 2002, J MOL CELL CARDIOL, V34, P185, DOI 10.1006/jmcc.2001.1500; Wallis RM, 1999, AM J CARDIOL, V83, p3C; Wilkens H, 2001, CIRCULATION, V104, P1218, DOI 10.1161/hc3601.096826; Xi L, 1999, CIRCULATION, V99, P2157, DOI 10.1161/01.CIR.99.16.2157; Xi L, 1998, MOL CELL BIOCHEM, V186, P69, DOI 10.1023/A:1006811128561; Xiao RP, 1999, CIRC RES, V84, P43; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhao TC, 2000, CIRCULATION, V102, P902; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429; Ziolo MT, 2003, BRIT J PHARMACOL, V138, P986, DOI 10.1038/sj.bjp.0705112	49	286	305	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12944	12955		10.1074/jbc.M404706200	http://dx.doi.org/10.1074/jbc.M404706200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668244	hybrid			2022-12-25	WOS:000227922000104
J	Gao, J; Wei, YS; Huang, Y; Liu, DP; Liu, G; Wu, M; Wu, L; Zhang, QJ; Zhang, ZQ; Zhang, R; Liang, CC				Gao, J; Wei, YS; Huang, Y; Liu, DP; Liu, G; Wu, M; Wu, L; Zhang, QJ; Zhang, ZQ; Zhang, R; Liang, CC			The expression of intact and mutant human apoAI/CIII/AIV/AV gene cluster in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-C-III; INTESTINAL EXPRESSION; DENSITY-LIPOPROTEIN; APOCIII ENHANCER; APO-CIII; A-IV; HYPERTRIGLYCERIDEMIA; ATHEROGENESIS; ASSOCIATION; ELEMENT	The apoAI/CIII/AIV gene cluster is involved in lipid metabolism and has a complex pattern of gene expression modulated by a common regulatory element, the apoCIII enhancer. A new member of this cluster, apolipoprotein (apo) AV, has recently been discovered as a novel modifier in triglyceride metabolism. To determine the expression of all four apo genes in combination and, most importantly, whether the transcription of apoAV is coregulated by the apoCIII enhancer in the cluster, we generated an intact transgenic line carrying the 116-kb human apoAI/CIII/AIV/AV gene cluster and a mutant transgenic line in which the apoCIII enhancer was deleted from the 116-kb structure. We demonstrated that the apoCIII enhancer regulated hepatic and intestinal apoAI, apoCIII, and apoAIV expression; however, it did not direct the newly identified apoAV in the cluster. Furthermore, human apo genes displayed integrated position-independent expression and a closer approximation of copy number-dependent expression in the intact transgenic mice. Because apoCIII and apoAV play opposite roles in triglyceride homeostasis, we analyzed the lipid profiles in our transgenic mice to assess the effects of human apoAI gene cluster expression on lipid metabolism. The triglyceride level was elevated in intact transgenic mice but decreased in mutant ones compared with nontransgenic mice. In addition, the expression of human apoAI and apoAIV elevated high density lipoprotein cholesterol in transgenic mice fed an atherogenic diet. In conclusion, our studies with human apoAI/CIII/AIV/AV gene cluster transgenic models showed that the apoCIII enhancer regulated expression of apoAI, apoCIII, and apoAIV but not apoAV in vivo and showed the influences of expression of the entire cluster on lipid metabolism.	Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Peking Union Med Coll, Beijing 100005, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Liu, DP (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.	liudp@pumc.edu.cn		Huang, Yue/0000-0003-1800-1282				AALTOSETALA K, 1994, J CLIN INVEST, V93, P1776, DOI 10.1172/JCI117163; AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Baralle M, 1999, FEBS LETT, V445, P45, DOI 10.1016/S0014-5793(99)00096-4; Baroukh N, 2004, ARTERIOSCL THROM VAS, V24, P1297, DOI 10.1161/01.ATV.0000130463.68272.1d; BEYEC JL, 1999, J BIOL CHEM, V274, P4954; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; Dillon N, 2000, BIOESSAYS, V22, P657, DOI 10.1002/1521-1878(200007)22:7<657::AID-BIES8>3.3.CO;2-U; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; ECKARDSTEIN AV, 2000, CURR OPIN CARDIOL, V15, P348; Eichenbaum-Voline S, 2004, ARTERIOSCL THROM VAS, V24, P167, DOI 10.1161/01.ATV.0000099881.83261.D4; Feng DX, 2001, P NATL ACAD SCI USA, V98, P15073, DOI 10.1073/pnas.251550598; Georgopoulos S, 2000, NUCLEIC ACIDS RES, V28, P4919, DOI 10.1093/nar/28.24.4919; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Groenendijk M, 2001, ATHEROSCLEROSIS, V157, P1, DOI 10.1016/S0021-9150(01)00539-1; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Kan HY, 2000, J BIOL CHEM, V275, P30423, DOI 10.1074/jbc.M005641200; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; Mar R, 2004, CIRC RES, V94, P993, DOI 10.1161/01.RES.0000124922.61830.F0; Olivier M, 2004, GENOMICS, V83, P912, DOI 10.1016/j.ygeno.2003.11.016; Ostos MA, 2001, ARTERIOSCL THROM VAS, V21, P1023, DOI 10.1161/01.ATV.21.6.1023; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUNIN EM, 1991, P NATL ACAD SCI USA, V88, P434; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; Vergnes L, 2000, ARTERIOSCL THROM VAS, V20, P2267, DOI 10.1161/01.ATV.20.10.2267; Vu-Dac N, 2003, J BIOL CHEM, V278, P17982, DOI 10.1074/jbc.M212191200; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; Zannis VI, 2001, CURR OPIN LIPIDOL, V12, P181, DOI 10.1097/00041433-200104000-00012	33	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12559	12566		10.1074/jbc.M409883200	http://dx.doi.org/10.1074/jbc.M409883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15649902	hybrid			2022-12-25	WOS:000227922000060
J	Guo, SD; Ilasaca, ML; Dzau, VJ				Guo, SD; Ilasaca, ML; Dzau, VJ			Identification of calcium-modulating cyclophilin ligand (CAML) as transducer of angiotensin II-mediated nuclear factor of activated T cells (NFAT) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PROTEIN-TYROSINE PHOSPHORYLATION; RECEPTOR-ASSOCIATED PROTEIN; CARDIAC-HYPERTROPHY; TYPE-1 RECEPTOR; CLONING; ATRAP; FIBROBLASTS; ANTAGONISTS; EXPRESSION	Angiotensin II (Ang II) plays a central role in cardiovascular physiology and disease. Ang II type I receptor (AT1) is thought to mediate most actions of Ang II. A novel AT1 receptor intracellular partner called AT1 receptor-associated protein (ATRAP) was identified, but its exact function has not been elucidated. A yeast two-hybrid screen using ATRAP as bait identified calcium-modulating cyclophilin ligand (CAML) as an ATRAP partner. Yeast two-hybrid and coimmunoprecipitation analysis demonstrated that the N-terminal hydrophilic domain of CAML (amino acids (aa) 1-189) mediates a specific interaction between ATRAP and CAML. Our analysis also showed that aa 40-82 of ATRAP contribute to this interaction. Bioluminescence resonance energy transfer and intracellular colocalization analysis by immunofluorescence in HEK293 cells verified this association within endoplasmic reticulum vesicular structures. Functionally, transcriptional reporter assays and RNA interference ATRAP experiments demonstrated that ATRAP knockdown increased nuclear factor of activated T cells (NFAT) activity. Overexpression of ATRAP decreased Ang II- or CAML- induced NFAT transcriptional activation, whereas an ATRAP-interacting domain of CAML (aa 1-189) sensitized NFAT activation in response to Ang II. These results indicate that CAML is an important signal transducer for the actions of Ang II in regulating the calcineurin-NFAT pathway and suggest that the interaction of CAML with ATRAP may mediate the Ang II actions in vascular physiology.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Res Labs, Boston, MA 02115 USA; Duke Univ, Ctr Med, Dept Med, Durham, NC 27708 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Duke University	Dzau, VJ (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Res Labs, Boston, MA 02115 USA.	victor.dzau@duke.edu			NHLBI NIH HHS [HL058516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058516] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; Cui TX, 2000, BIOCHEM BIOPH RES CO, V279, P938, DOI 10.1006/bbrc.2000.4055; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Holloway MP, 1998, J BIOL CHEM, V273, P16346, DOI 10.1074/jbc.273.26.16346; Holloway MP, 1996, J BIOL CHEM, V271, P8549, DOI 10.1074/jbc.271.15.8549; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; Lopez-Ilasaca M, 2003, MOL BIOL CELL, V14, P5038, DOI 10.1091/mbc.E03-06-0383; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Sayeski PP, 2001, J BIOL CHEM, V276, P10556, DOI 10.1074/jbc.M008856200; SCHORB W, 1994, J BIOL CHEM, V269, P19626; Suzuki E, 2002, CIRC RES, V90, P1004, DOI 10.1161/01.RES.0000017629.70769.CC; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Tran DD, 2003, DEV CELL, V5, P245, DOI 10.1016/S1534-5807(03)00207-7; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	28	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12536	12541		10.1074/jbc.M500296200	http://dx.doi.org/10.1074/jbc.M500296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668245	hybrid			2022-12-25	WOS:000227922000057
J	Hoodbhoy, T; Joshi, S; Boja, ES; Williams, SA; Stanley, P; Dean, J				Hoodbhoy, T; Joshi, S; Boja, ES; Williams, SA; Stanley, P; Dean, J			Human sperm do not bind to rat zonae pellucidae despite the presence of four homologous glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-I; MOLECULAR-CLONING; CORE 2; STRUCTURAL-CHARACTERIZATION; MASS-SPECTROMETRY; GENOME SEQUENCE; EGG RECOGNITION; KNOCKOUT MICE; MOUSE OOCYTES; O-GLYCANS	The specificity of sperm-egg recognition in mammals is mediated primarily by the zona pellucida surrounding ovulated eggs. Mouse sperm are quite promiscuous and bind to human eggs, but human spermatozoa will not bind to mouse eggs. The mouse zona pellucida contains three glycoproteins, ZP1, ZP2, and ZP3, which are conserved in rat and human. The recent observation that human zonae pellucidae contain a fourth protein raises the possibility that the presence of four zona proteins will support human sperm binding. Using mass spectrometry, four proteins that are similar in size and share 62-70% amino acid identity with human ZP1, ZP2, ZP3, and ZP4/ZPB were detected in rat zonae pellucidae. However, although mouse and rat spermatozoa bind to eggs from each rodent, human sperm bind to neither, and the presence of human follicular fluid did not alter the specificity of sperm binding. In addition, mutant mouse eggs lacking hybrid/complex N-glycans or deficient in Core 2 O-glycans were no more able to support human sperm binding than normal mouse eggs. These data suggest that the presence of four zona proteins are not sufficient to support human sperm binding to rodent eggs and that additional determinants must be responsible for taxon-specific fertilization among mammals.	NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Yeshiva University; Albert Einstein College of Medicine	Hoodbhoy, T (corresponding author), NIDDK, Cellular & Dev Biol Lab, NIH, Bldg 50,Rm 3128, Bethesda, MD 20892 USA.	tanyah@intra.niddk.nih.gov		Stanley, Pamela/0000-0001-5704-3747	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015506] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akatsuka K, 1998, MOL REPROD DEV, V51, P454, DOI 10.1002/(SICI)1098-2795(199812)51:4&lt;454::AID-MRD13&gt;3.0.CO;2-G; ARAKI Y, 1992, BIOL REPROD, V46, P912, DOI 10.1095/biolreprod46.5.912; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; Bauskin AR, 1999, MOL HUM REPROD, V5, P534, DOI 10.1093/molehr/5.6.534; BEDFORD JM, 1977, ANAT RECORD, V188, P477, DOI 10.1002/ar.1091880407; Bedford JM, 1998, BIOL REPROD, V59, P1275, DOI 10.1095/biolreprod59.6.1275; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; Boja ES, 2003, J BIOL CHEM, V278, P34189, DOI 10.1074/jbc.M304026200; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; CHAMBERLIN ME, 1990, P NATL ACAD SCI USA, V87, P6014, DOI 10.1073/pnas.87.16.6014; Chiu PCN, 2003, BIOL REPROD, V69, P365, DOI 10.1095/biolreprod.102.012658; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Dean J, 2004, BIOESSAYS, V26, P29, DOI 10.1002/bies.10412; Dell A, 2003, P NATL ACAD SCI USA, V100, P15631, DOI 10.1073/pnas.2635507100; Easton RL, 2000, J BIOL CHEM, V275, P7731, DOI 10.1074/jbc.275.11.7731; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; EPIFANO O, 1995, DEVELOPMENT, V121, P1947; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; HARRIS JD, 1994, DNA SEQUENCE, V4, P361, DOI 10.3109/10425179409010186; Hoodbhoy T, 2004, REPRODUCTION, V127, P417, DOI 10.1530/rep.1.00181; Hughes DC, 1999, BBA-GENE STRUCT EXPR, V1447, P303, DOI 10.1016/S0167-4781(99)00181-5; Huyser C, 1997, HUM REPROD, V12, P792, DOI 10.1093/humrep/12.4.792; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; Jovine L, 2002, NAT CELL BIOL, V4, P457, DOI 10.1038/ncb802; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; Lefievre L, 2004, HUM REPROD, V19, P1580, DOI 10.1093/humrep/deh301; LIANG LF, 1990, MOL CELL BIOL, V10, P1507, DOI 10.1128/MCB.10.4.1507; LIANG LF, 1993, DEV BIOL, V156, P399, DOI 10.1006/dbio.1993.1087; Liu CY, 1996, P NATL ACAD SCI USA, V93, P5431, DOI 10.1073/pnas.93.11.5431; LIU CY, 1995, MOL BIOL CELL, V6, P577, DOI 10.1091/mbc.6.5.577; Liu DY, 1997, MOL HUM REPROD, V3, P1015, DOI 10.1093/molehr/3.11.1015; Lu QX, 1997, DEVELOPMENT, V124, P4121; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; Mullins LJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-221; NAGDAS SK, 1994, BIOL REPROD, V51, P262, DOI 10.1095/biolreprod51.2.262; NOGUCHI S, 1993, BIOCHIM BIOPHYS ACTA, V1158, P217, DOI 10.1016/0304-4165(93)90018-4; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Rankin T, 1999, DEVELOPMENT, V126, P3847; Rankin TL, 2001, DEVELOPMENT, V128, P1119; Rankin TL, 2003, DEV CELL, V5, P33, DOI 10.1016/S1534-5807(03)00195-3; Rankin TL, 1998, DEVELOPMENT, V125, P2415; RINGUETTE MJ, 1988, DEV BIOL, V127, P287, DOI 10.1016/0012-1606(88)90315-6; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; SHABANOWITZ RB, 1988, J REPROD FERTIL, V82, P151; Shi SL, 2004, MOL CELL BIOL, V24, P9920, DOI 10.1128/MCB.24.22.9920-9929.2004; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; TULSIANI DRP, 1992, BIOL REPROD, V46, P93, DOI 10.1095/biolreprod46.1.93; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Yanagimachi R., 1994, P189; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Zhao M, 2004, BIOCHEMISTRY-US, V43, P12090, DOI 10.1021/bi048958k	54	69	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12721	12731		10.1074/jbc.M413569200	http://dx.doi.org/10.1074/jbc.M413569200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677449	hybrid			2022-12-25	WOS:000227922000079
J	Kasper, MR; Roeth, JF; Williams, M; Filzen, TM; Fleis, RI; Collins, KL				Kasper, MR; Roeth, JF; Williams, M; Filzen, TM; Fleis, RI; Collins, KL			HIV-1 Nef disrupts antigen presentation early in the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX CLASS-I; IMMUNODEFICIENCY-VIRUS TYPE-1; CD4 DOWN-MODULATION; MHC CLASS-I; PROTEIN-KINASE; T-CELLS; PHOSPHORYLATION; TRAFFICKING; MOLECULES; INFECTION	Human immunodeficiency virus, type 1 Nef disrupts viral antigen presentation and promotes viral immune evasion from cytotoxic T lymphocytes. There is evidence that Nef acts early in the secretory pathway to redirect major histocompatibility complex class I (MHC-I) from the trans-Golgi network to the endolysosomal pathway. However, a competing model suggests that Nef acts much later by accelerating MHC-I turnover at the cell surface. Here we demonstrate that Nef targets early forms of MHC-I molecules in the endoplasmic reticulum by preferentially binding hypophosphorylated cytoplasmic tails. The Nef-MHC-I complex migrates normally into the Golgi apparatus but subsequently fails to arrive at the cell surface and become phosphorylated. Cell type-specific differences in the rate of MHC-I transport through the secretory pathway correlate with responsiveness to Nef and co-precipitation of adaptor protein 1 with the Nef(.)MHC-I complex. We propose that the assembly of a Nef(.)MHC-I(.)adaptor protein 1 complex early in the secretory pathway is important for Nef activity.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Cell & Mol Biol Grad Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Collins, KL (corresponding author), Univ Michigan, Dept Internal Med, 4301 MSRB 3,Box 0638,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	klcollin@umich.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051192, R01AI046998] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI46998, R01 AI051192] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Capps GG, 2000, MOL IMMUNOL, V37, P59, DOI 10.1016/S0161-5890(00)00019-5; Chang AH, 1998, FEBS LETT, V441, P307, DOI 10.1016/S0014-5793(98)01569-5; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; De Silva AD, 1999, J IMMUNOL, V163, P4413; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; EICHHOLTZ T, 1992, J BIOL CHEM, V267, P22490; Glushakova S, 2001, J VIROL, V75, P10113, DOI 10.1128/JVI.75.21.10113-10117.2001; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; GUILD BC, 1984, J BIOL CHEM, V259, P3504; HAWLEY RG, 1994, GENE THER, V1, P136; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; Kasper MR, 2003, J VIROL, V77, P3041, DOI 10.1128/JVI.77.5.3041-3049.2003; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Lewinsohn DA, 2002, VIROLOGY, V294, P13, DOI 10.1006/viro.2001.1294; LIPPE R, 1991, J EXP MED, V174, P1159, DOI 10.1084/jem.174.5.1159; Maini MK, 1999, GASTROENTEROLOGY, V117, P1386, DOI 10.1016/S0016-5085(99)70289-1; Mangasarian A, 1999, J VIROL, V73, P1964, DOI 10.1128/JVI.73.3.1964-1973.1999; Munch J, 2001, J VIROL, V75, P10532, DOI 10.1128/JVI.75.21.10532-10536.2001; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; Paulson E, 2001, VIROLOGY, V288, P369, DOI 10.1006/viro.2001.1086; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Rickinson AB, 1997, ANNU REV IMMUNOL, V15, P405, DOI 10.1146/annurev.immunol.15.1.405; RIDDELL SR, 1992, SCIENCE, V257, P238; Roeth JF, 2004, J CELL BIOL, V167, P903, DOI 10.1083/jcb.200407031; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; Tomiyama H, 2002, J VIROL, V76, P7535, DOI 10.1128/JVI.76.15.7535-7543.2002; Williams M, 2005, J VIROL, V79, P632, DOI 10.1128/JVI.79.1.632-636.2005; Williams M, 2002, J VIROL, V76, P12173, DOI 10.1128/JVI.76.23.12173-12184.2002; Yang OO, 2002, J VIROL, V76, P1626, DOI 10.1128/JVI.76.4.1626-1631.2002; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	44	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12840	12848		10.1074/jbc.M413538200	http://dx.doi.org/10.1074/jbc.M413538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15653685	hybrid			2022-12-25	WOS:000227922000092
J	Rahmani, M; Read, JT; Carthy, JM; McDonald, PC; Wong, BW; Esfandiarei, M; Si, XN; Luo, ZS; Luo, HL; Rennie, PS; McManus, BM				Rahmani, M; Read, JT; Carthy, JM; McDonald, PC; Wong, BW; Esfandiarei, M; Si, XN; Luo, ZS; Luo, HL; Rennie, PS; McManus, BM			Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PROTEIN EXPRESSION PATTERNS; MESSENGER-RNA LEVELS; CORONARY-ARTERIES; GROWTH-FACTOR; PROTEOGLYCAN SYNTHESIS; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; RESTENOTIC LESIONS	The proteoglycan versican is pro- atherogenic and central to vascular injury and repair events. We identified the signaling pathways and promoter elements involved in regulation of versican expression in vascular smooth muscle cells. Phosphatidylinositol 3- kinase inhibitor, LY294002, significantly decreased versican-luciferase ( Luc) promoter activity and endogenous mRNA levels. We further examined the roles of protein kinase B and glycogen synthase kinase (GSK)- 3 beta, downstream effectors of phosphatidylinositol 3- kinase, in the regulation of versican transcription. Co- transfection of dominant negative and constitutively active protein kinase B constructs with a versican- Luc construct decreased and increased promoter activity, respectively. Inhibition of GSK-3 beta activity by LiCl augmented accumulation of beta-catenin and caused induction of versican- Luc activity as well as versican mRNA levels. beta- Catenin has no DNA binding domain, therefore it cannot directly induce transcription of the versican promoter. Software analysis of the versican promoter revealed two potential binding sites for T- cell factors ( TCFs), proteins that confer transcriptional activation of beta- catenin. Electrophoretic mobility shift andsupershift assays revealed specific binding of human TCF- 4 and beta- catenin to oligonucleotides corresponding to a potential TCF binding site in the versican promoter. In addition to binding assays, we directly assessed the dependence of versican promoter activity on TCF binding sites. Site- directed mutagenesis of the TCF site located - 492 bp relative to the transcription start site markedly diminished versican-Luc activity. Co- transfection of TCF- 4 with versican-Luc did not increase promoter activity, but addition of beta- catenin and TCF- 4 significantly stimulated basal versican promoter activity. Our findings suggest that versican transcription is predominantly mediated by the GSK- 3 beta pathway via the beta- catenin- TCF transcription factor complex in smooth muscle cells, wherein such regulation contributes to the normal or aberrant formation of provisional matrix in vascular injury and repair events.	St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V6T 2B5, Canada; Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC V6T 2B5, Canada	St. Paul's Hospital; University of Saskatchewan; University of British Columbia	McManus, BM (corresponding author), St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, 1081 Burrard St, Vancouver, BC V6T 2B5, Canada.	bmcmanus@mrl.ubc.ca	Wong, Brian/B-6168-2009; Esfandiarei, Mitra/V-1258-2019; Esfandiarei, Mitra/R-9903-2019	Wong, Brian/0000-0001-8447-3064; Esfandiarei, Mitra/0000-0003-3218-7781				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Blankesteijn WM, 2000, AM J PATHOL, V157, P877, DOI 10.1016/S0002-9440(10)64601-9; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; CAMPBELL JH, 1993, CLIN SCI, V85, P501, DOI 10.1042/cs0850501; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Esfandiarei M, 2004, J VIROL, V78, P4289, DOI 10.1128/JVI.78.8.4289-4298.2004; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Farb A, 2004, CIRCULATION, V110, P940, DOI 10.1161/01.CIR.0000139337.56084.30; GARRATT KN, 1991, J AM COLL CARDIOL, V17, P442, DOI 10.1016/S0735-1097(10)80113-5; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; Goodwin A. M., 2002, Angiogenesis, V5, P1, DOI 10.1023/A:1021563510866; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Haase HR, 1998, J CELL PHYSIOL, V174, P353, DOI 10.1002/(SICI)1097-4652(199803)174:3<353::AID-JCP9>3.0.CO;2-N; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Hecht A, 2003, J BIOL CHEM, V278, P3776, DOI 10.1074/jbc.M210081200; IOZZO RV, 1992, GENOMICS, V14, P845, DOI 10.1016/S0888-7543(05)80103-X; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; Kishimoto J, 2000, GENE DEV, V14, P1181; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korswagen HC, 1999, COLD SPRING HARB SYM, V64, P141, DOI 10.1101/sqb.1999.64.141; Lee RT, 2001, J BIOL CHEM, V276, P13847, DOI 10.1074/jbc.M010556200; Lin H, 1996, J HEART LUNG TRANSPL, V15, P1233; Lin H, 1996, J HEART LUNG TRANSPL, V15, P1223; Lin H, 1998, CARDIOVASC PATHOL, V7, P31, DOI 10.1016/S1054-8807(97)00057-4; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Mao C, 2000, ARTERIOSCL THROM VAS, V20, P43, DOI 10.1161/01.ATV.20.1.43; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; NASO MF, 1994, J BIOL CHEM, V269, P32999; NASO MF, 1995, GENOMICS, V29, P297, DOI 10.1006/geno.1995.1251; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Polakis P, 2000, GENE DEV, V14, P1837; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; QWARNSTROM EE, 1993, BIOCHEM J, V294, P613, DOI 10.1042/bj2940613; Rahmani M, 2004, CAN J CARDIOL, V20, p58B; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; Schonherr E, 1997, ARCH BIOCHEM BIOPHYS, V339, P353, DOI 10.1006/abbi.1996.9854; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Shimizu-Hirota R, 2001, J AM SOC NEPHROL, V12, P2609, DOI 10.1681/ASN.V12122609; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074-7696(08)61987-7; Wang XH, 2004, AM J PHYSIOL-HEART C, V287, pH2376, DOI 10.1152/ajpheart.01173.2003; Wang XH, 2002, CIRC RES, V90, P340, DOI 10.1161/hh0302.104466; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Williams KJ, 2001, CURR OPIN LIPIDOL, V12, P477, DOI 10.1097/00041433-200110000-00002; Yeung LHY, 2003, BIOCHEM J, V371, P843, DOI 10.1042/BJ20021816	61	74	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13019	13028		10.1074/jbc.M411766200	http://dx.doi.org/10.1074/jbc.M411766200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668231	hybrid			2022-12-25	WOS:000227922000112
J	Kobayashi, Y; Mizoguchi, T; Take, I; Kurihara, S; Udagawa, N; Takahashi, N				Kobayashi, Y; Mizoguchi, T; Take, I; Kurihara, S; Udagawa, N; Takahashi, N			Prostaglandin E-2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; BONE-RESORPTION; SIGNALING PATHWAY; HEMATOPOIETIC PRECURSORS; DEFECTIVE INTERLEUKIN-1; OSTEOPROTEGERIN LIGAND; IN-VITRO; ACTIVATION; RANK	Prostaglandin E-2 (PGE(2)) synergistically enhances the receptor activator for NF-kappa B ligand (RANKL)-induced osteoclastic differentiation of the precursor cells. Here we investigated the mechanisms of the stimulatory effect of PGE2 on osteoclast differentiation. PGE2 enhanced osteoclastic differentiation of RAW264.7 cells in the presence of RANKL through EP2 and EP4 prostanoid receptors. RANKL-induced degradation of I kappa B alpha and phosphorylation of p38 MAPK and c-Jun N-terminal kinase in RAW264.7 cells were up-regulated by PGE2 in a cAMP-dependent protein kinase A (PKA)-dependent manner, suggesting that EP2 and EP4 signals cross-talk with RANK signals. Transforming growth factor beta-activated kinase 1 (TAK1), an important MAPK kinase kinase in several cytokine signals, possesses a PKA recognition site at amino acids 409 - 412. PKA directly phosphorylated TAK1 in RAW264.7 cells transfected with wild-type TAK1 but not with the Ser(412) -> Ala mutant TAK1. Ser(412) -> Ala TAK1 served as a dominant-negative mutant in PKA-enhanced degradation of I kappa B alpha, phosphorylation of p38 MAPK, and PGE(2)-enhanced osteoclastic differentiation in RAW264.7 cells. Furthermore, forskolin enhanced tumor necrosis factor alpha-induced I kappa B alpha degradation, p38 MAPK phosphorylation, and osteoclastic differentiation in RAW264.7 cells. Ser412 3 Ala TAK1 abolished the stimulatory effects of forskolin on those cellular events induced by tumor necrosis factor alpha. Ser412 3 Ala TAK1 also inhibited the forskolin-induced up-regulation of interleukin 6 production in RAW264.7 cells treated with lipopolysaccharide. These results suggest that the phosphorylation of the Ser(412) residue in TAK1 by PKA is essential for cAMP/PKA-induced up-regulation of osteoclastic differentiation and cytokine production in the precursor cells.	Matsumoto Dent Univ, Inst Oral Sci, Nagano 39990781, Japan; Matsumoto Dent Univ, Dept Orthodont, Nagano 39990781, Japan; Matsumoto Dent Univ, Dept Biochem, Nagano 39990781, Japan	Matsumoto Dental University; Matsumoto Dental University; Matsumoto Dental University	Takahashi, N (corresponding author), Matsumoto Dent Univ, Inst Oral Sci, 1780 Hirooka Gobara Shiojiri, Nagano 39990781, Japan.	takahashinao@po.mdu.ac.jp	KOBAYASHI, YASUHIRO/AAU-4931-2021	Kobayashi, Yasuhiro/0000-0002-0903-3226				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; BARON R, 1986, AM J PATHOL, V122, P363; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Chambers TJ, 2000, J PATHOL, V192, P4; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; IBBOTSON KJ, 1984, J CELL BIOL, V99, P471, DOI 10.1083/jcb.99.2.471; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Isumi Y, 1998, BIOCHEM BIOPH RES CO, V244, P325, DOI 10.1006/bbrc.1998.8261; Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656; Iwahashi H, 2000, J IMMUNOL, V164, P5403, DOI 10.4049/jimmunol.164.10.5403; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; LI X, 2000, ENDOCRINOLOGY, V143, P3105; Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Moreno JL, 2003, BLOOD, V102, P1078, DOI 10.1182/blood-2002-11-3437; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195; OSDOBY P, 1982, J EXP ZOOL, V224, P331, DOI 10.1002/jez.1402240306; Rosenberg D, 2002, ANN NY ACAD SCI, V968, P65, DOI 10.1111/j.1749-6632.2002.tb04327.x; Sakuma Y, 2000, INFECT IMMUN, V68, P6819, DOI 10.1128/IAI.68.12.6819-6825.2000; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Tang YM, 1998, J NEUROIMMUNOL, V84, P207, DOI 10.1016/S0165-5728(97)00257-9; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Tintut Y, 2002, J BIOL CHEM, V277, P14221, DOI 10.1074/jbc.M111551200; Tomita M, 2002, BONE, V30, P159, DOI 10.1016/S8756-3282(01)00688-3; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	55	102	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11395	11403		10.1074/jbc.M411189200	http://dx.doi.org/10.1074/jbc.M411189200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647289	hybrid			2022-12-25	WOS:000227761800062
J	Ma, L; Tsatsos, NG; Towle, HC				Ma, L; Tsatsos, NG; Towle, HC			Direct role of ChREBP center dot Mlx in regulating hepatic glucose-responsive genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; LIPOGENIC ENZYME GENES; PYRUVATE-KINASE GENE; WILLIAMS-BEUREN-SYNDROME; FATTY-ACID BIOSYNTHESIS; HIGH-CARBOHYDRATE DIET; TRANSCRIPTION FACTORS; RAT-LIVER; THYROID-HORMONE; MESSENGER-RNA	Enzymes required for de novo lipogenesis are induced in mammalian liver after a meal high in carbohydrates. In addition to insulin, increased glucose metabolism initiates an intracellular signaling pathway that transcriptionally regulates genes encoding lipogenic enzymes. A cis-acting sequence, the carbohydrate response element (ChoRE), has been found in the promoter region of several of these genes. ChREBP (carbohydrate response element-binding protein) was recently identified as a candidate transcription factor in the glucose-signaling pathway. We reported that ChREBP requires the heterodimeric partner Max-like factor X (Mlx) to bind to ChoRE sequences. In this study we provide further evidence to support a direct role of Mlx in glucose signaling in the liver. We constructed two different dominant negative forms of Mlx that could dimerize with ChREBP but block its binding to DNA. When introduced into hepatocytes, both dominant negative forms of Mlx inhibited the glucose response of a transfected ChoRE-containing promoter. The glucose response was rescued by adding exogenous wild type Mlx or ChREBP, but not MondoA, a paralog of ChREBP that can also form a heterodimer with Mlx. Furthermore, dominant negative Mlx blocked the induction of glucose-responsive genes from their natural chromosomal context under high glucose conditions. In contrast, genes induced by the insulin and thyroid hormone-signaling pathways were unaffected by dominant negative Mlx. Mlx was present in the glucose-responsive complex of liver nuclear extract from which ChREBP was purified. In conclusion, Mlx is an obligatory partner of ChREBP in regulating lipogenic enzyme genes in liver.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Towle, HC (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	towle@mail.ahc.umn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050456, R01DK026919] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK50456, DK26919] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BERRY MJ, 1990, MOL ENDOCRINOL, V4, P743, DOI 10.1210/mend-4-5-743; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; Billin AN, 2000, MOL CELL BIOL, V20, P8845, DOI 10.1128/MCB.20.23.8845-8854.2000; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cairo S, 2001, HUM MOL GENET, V10, P617, DOI 10.1093/hmg/10.6.617; de Luis O, 2000, EUR J HUM GENET, V8, P215, DOI 10.1038/sj.ejhg.5200435; Dentin R, 2004, J BIOL CHEM, V279, P20314, DOI 10.1074/jbc.M312475200; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim TS, 1996, J NUTR, V126, P611, DOI 10.1093/jn/126.3.611; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIASH CN, 1980, J CLIN INVEST, V65, P1126, DOI 10.1172/JCI109766; MENJO M, 1993, ENDOCRINOLOGY, V133, P2984, DOI 10.1210/en.133.6.2984; Meroni G, 2000, ONCOGENE, V19, P3266, DOI 10.1038/sj.onc.1203634; O'Callaghan BL, 2001, J BIOL CHEM, V276, P16033, DOI 10.1074/jbc.M101557200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Rufo C, 2001, J BIOL CHEM, V276, P21969, DOI 10.1074/jbc.M100461200; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1994, J BIOL CHEM, V269, P9380; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SPENCE JT, 1983, J BIOL CHEM, V258, P9143; Stoeckman AK, 2004, J BIOL CHEM, V279, P15662, DOI 10.1074/jbc.M311301200; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; TAKEDA Y, 1967, BIOCHIM BIOPHYS ACTA, V136, P214, DOI 10.1016/0304-4165(67)90066-9; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; TOWLE HC, 1986, FASEB J, V45, P2406; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298	48	129	139	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					12019	12027		10.1074/jbc.M413063200	http://dx.doi.org/10.1074/jbc.M413063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15664996	hybrid			2022-12-25	WOS:000227761800135
J	Wang, XL; Ye, D; Peterson, TE; Cao, S; Shah, VH; Katusic, ZS; Sieck, GC; Lee, HC				Wang, XL; Ye, D; Peterson, TE; Cao, S; Shah, VH; Katusic, ZS; Sieck, GC; Lee, HC			Caveolae targeting and regulation of large conductance Ca2+-activated K+ channels in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PIG CORONARY-ARTERY; P42/44 MAP KINASE; ACTIVATED POTASSIUM CHANNELS; CARDIAC SODIUM-CHANNELS; AIRWAY SMOOTH-MUSCLE; DOWN-REGULATION; EPOXYEICOSATRIENOIC ACIDS; NONSELECTIVE CATION; SCAFFOLDING DOMAIN	The vascular endothelium is richly endowed with caveolae, which are specialized membrane microdomains that facilitate the integration of specific cellular signal transduction processes. We found that the large conductance Ca2+- activated K+ ( BK) channels are associated with caveolin-1 in bovine aortic endothelial cells (BAECs). OptiPrep gradient cell fractionation demonstrated that BK channels were concentrated in the caveolae-rich fraction in BAECs. Immunofluorescence imaging showed co-localization of caveolin-1 and BK channels in the BAEC membrane. Immunoprecipitation and glutathione S-transferase pull-down assay results indicated that caveolin-1 and BK channels are physically associated. However, whole cell patch clamp recordings could not detect BK (iberiotoxin-sensitive) currents in cultured BAECs under baseline conditions, even though the presence of BK mRNA and protein expression was confirmed by reverse transcription-PCR and Western blots. Cholesterol depletion redistributed the BK channels to non-caveolar fractions of BAECs, resulting in BK channel activation (7.3 +/- 1.6 pA/picofarad (pF), n = 5). BK currents were also activated by isoproterenol (ISO, 1 mu M, 6.9 +/- 2.4 pA/ pF, n = 6). Inclusion of a caveolin-1 scaffolding domain peptide (10 mu M) in the pipette solution completely abrogated the effects of ISO on BK channel activation, whereas inclusion of the scrambled control peptide ( 10 mu M) did not inhibit the ISO effects. We have also found that caveolin-1 knockdown by small interference RNA activated BK currents (5.3 +/- 1.4 pA/pF, n = 6). We conclude that: 1) BK channels are targeted to caveolae microdomains in vascular endothelial cells; 2) caveolin-1 interacts with BK channels and exerts a negative regulatory effect on channel functions; and 3) BK channels are inactive under control conditions but can be activated by cholesterol depletion, knockdown of caveolin-1 expression, or ISO stimulation. These novel findings may have important implications for the role of BK channels in the regulation of endothelial function.	Mayo Clin, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Dept Anesthesiol, Rochester, MN 55905 USA; Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Lee, HC (corresponding author), Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	lee.honchi@mayo.edu	Peterson, Timothy E/J-9793-2012	sieck, gary/0000-0003-3040-9424	NHLBI NIH HHS [HL-74180, HL-63754] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL074180, R01HL074180, R01HL063754] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Baron A, 1996, J PHYSIOL-LONDON, V493, P691, DOI 10.1113/jphysiol.1996.sp021415; Baron A, 1997, J PHYSIOL-LONDON, V504, P537, DOI 10.1111/j.1469-7793.1997.537bd.x; BENY JL, 1994, AM J PHYSIOL, V266, pH1465, DOI 10.1152/ajpheart.1994.266.4.H1465; Cao S, 2001, J BIOL CHEM, V276, P14249, DOI 10.1074/jbc.M006258200; Chiang HT, 2001, J MEMBRANE BIOL, V182, P203, DOI 10.1007/s00232-001-0044-y; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Darby PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1226, DOI 10.1152/ajplung.2000.279.6.L1226; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Droogmans G, 2001, POTASSIUM CHANNELS IN CARDIOVASCULAR BIOLOGY, P639; DULL RO, 1997, LUNG, P653; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Ferraro JT, 2004, AM J PHYSIOL-CELL PH, V286, pC831, DOI 10.1152/ajpcell.00224.2003; FICHTNER H, 1987, J MEMBRANE BIOL, V98, P125, DOI 10.1007/BF01872125; Frieden M, 2000, J PHYSIOL-LONDON, V524, P715, DOI 10.1111/j.1469-7793.2000.00715.x; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gauthier KM, 2002, J PHYSIOL-LONDON, V545, P829, DOI 10.1113/jphysiol.2002.029843; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Gratton JP, 2003, CANCER CELL, V4, P31, DOI 10.1016/S1535-6108(03)00168-5; Hailstones D, 1998, J LIPID RES, V39, P369; Kamouchi M, 1997, CELL CALCIUM, V22, P497, DOI 10.1016/S0143-4160(97)90077-4; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; Lasley RD, 2001, TRENDS CARDIOVAS MED, V11, P259, DOI 10.1016/S1050-1738(01)00120-7; Lee HC, 1999, J PHYSIOL-LONDON, V519, P153, DOI 10.1111/j.1469-7793.1999.0153o.x; LING BN, 1992, AM J PHYSIOL, V263, pH1827, DOI 10.1152/ajpheart.1992.263.6.H1827; Liu GX, 2004, EMBO J, V23, P2196, DOI 10.1038/sj.emboj.7600228; Liu J, 1999, J BIOL CHEM, V274, P15781, DOI 10.1074/jbc.274.22.15781; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; MINSHALL RD, 2003, AM J PHYSIOL, V285, pL119; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NELSON MT, 1995, AM J PHYSIOL, V268, P799; Nilius B, 1997, ANNU REV PHYSIOL, V59, P145, DOI 10.1146/annurev.physiol.59.1.145; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Peterson TE, 1999, CIRC RES, V85, P29; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Razani B, 2001, J BIOL CHEM, V276, P38121; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; RUSKO J, 1992, J PHYSIOL-LONDON, V455, P601, DOI 10.1113/jphysiol.1992.sp019318; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sage SO, 2001, POTASSIUM CHANNELS IN CARDIOVASCULAR BIOLOGY, P651; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCORNIK FS, 1993, AM J PHYSIOL, V265, pH1460, DOI 10.1152/ajpheart.1993.265.4.H1460; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Yarbrough TL, 2002, CIRC RES, V90, P443, DOI 10.1161/hh0402.105177; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	58	110	112	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11656	11664		10.1074/jbc.M410987200	http://dx.doi.org/10.1074/jbc.M410987200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15665381	hybrid			2022-12-25	WOS:000227761800094
J	Hiesberger, T; Shao, XL; Gourley, E; Reimann, A; Pontoglio, M; Igarashi, P				Hiesberger, T; Shao, XL; Gourley, E; Reimann, A; Pontoglio, M; Igarashi, P			Role of the hepatocyte nuclear factor-1 beta (HNF-1 beta) C-terminal domain in Pkhd1 (ARPKD) gene transcription and renal cystogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; HNF1 HOMEOPROTEIN FAMILY; EPITHELIAL-CELLS; DNA-BINDING; FACTOR-I; PROTEIN; EXPRESSION; MUTATION; DIMERIZATION; PROMOTER	Hepatocyte nuclear factor-1 beta (HNF-1 beta) is a homeodomain-containing transcription factor that regulates tissue-specific gene expression in the kidney and other epithelial organs. Mutations of HNF-1 beta produce congenital cystic abnormalities of the kidney, and previous studies showed that HNF-1 beta regulates the expression of the autosomal recessive polycystic kidney disease (ARPKD) gene, Pkhd1. Here we show that the C-terminal region of HNF-1 beta contains an activation domain that is functional when fused to a heterologous DNA-binding domain. An HNF-1 beta deletion mutant lacking the C-terminal domain interacts with wild-type HNF-1 beta, binds DNA, and functions as a dominant-negative inhibitor of a chromosomally integrated Pkhd1 promoter. The activation of the Pkhd1 promoter by wild-type HNF-1 beta is stimulated by sodium butyrate or coactivators CREB (cAMP-response element)-binding protein (CBP) and P/CAF. The interaction with CBP and P/CAF requires the C-terminal domain. Expression of an HNF-1 beta C-terminal deletion mutant in transgenic mice produces renal cysts, increased cell proliferation, and dilatation of the ureter similar to mice with kidney-specific inactivation of HNF-1 beta. Pkhd1 expression is inhibited in cystic collecting ducts but not in non-cystic proximal tubules, despite transgene expression in this nephron segment. We conclude that the C-terminal domain of HNF-1 beta is required for the activation of the Pkhd1 promoter. Deletion mutants lacking the C-terminal domain function as dominant-negative mutants, possibly by preventing the recruitment of histone acetylases to the promoter. Cyst formation correlates with inhibition of Pkhd1 expression, which argues that mutations of HNF-1 beta produce kidney cysts by down-regulating the ARPKD gene, Pkhd1. Expression of HNF-1 beta in proximal tubules may protect against cystogenesis.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Nephrol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Basic Sci, Dallas, TX 75390 USA; Inst Pasteur, CNRS URA 1644, Unit Gene Express & Dis, F-75014 Paris, France	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Hiesberger, T (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Thomas.Hiesberger@UTSouthwestern.edu		Igarashi, Peter/0000-0001-8698-1185	NIDDK NIH HHS [P50 DK-57328, R01-DK-42921, R01 DK042921] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057328, R01DK042921] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH I, 1991, NUCLEIC ACIDS RES, V19, P3553, DOI 10.1093/nar/19.13.3553; BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; Bai Y, 2002, AM J PHYSIOL-RENAL, V283, pF839, DOI 10.1152/ajprenal.00128.2002; Barbacci E, 1999, DEVELOPMENT, V126, P4795; Barbacci E, 2004, HUM MOL GENET, V13, P3139, DOI 10.1093/hmg/ddh338; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; Bingham C, 2003, KIDNEY INT, V63, P1645, DOI 10.1046/j.1523-1755.2003.00903.x; Bingham C, 2000, KIDNEY INT, V57, P898, DOI 10.1046/j.1523-1755.2000.057003898.x; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; Cheret C, 2002, J MOL BIOL, V322, P929, DOI 10.1016/S0022-2836(02)00816-1; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; Coffinier C, 1999, DEVELOPMENT, V126, P4785; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Gresh L, 2004, EMBO J, V23, P1657, DOI 10.1038/sj.emboj.7600160; Hiesberger T, 2004, J CLIN INVEST, V113, P814, DOI 10.1172/JCI200420083; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; LAZZARO D, 1992, DEVELOPMENT, V114, P469; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; Onuchic LF, 2002, AM J HUM GENET, V70, P1305, DOI 10.1086/340448; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; Pontoglio M, 2000, J AM SOC NEPHROL, V11, pS140; Pontoglio M, 2000, EMBO REP, V1, P359, DOI 10.1093/embo-reports/kvd071; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Quaggin SE, 1998, MECH DEVELOP, V71, P37, DOI 10.1016/S0925-4773(97)00201-3; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; RINGEISEN F, 1993, J BIOL CHEM, V268, P25706; Shao XL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016443.50138.CD; Shelton JM, 2000, J LIPID RES, V41, P532; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833; Wild W, 2000, P NATL ACAD SCI USA, V97, P4695, DOI 10.1073/pnas.080010897; WOODS AE, 1996, LAB HISTOPATHOLOGY C, V1; WOODS AE, 1996, LAB HISTOPATHOLOGY C, V2; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388	36	63	67	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10578	10586		10.1074/jbc.M414121200	http://dx.doi.org/10.1074/jbc.M414121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647252	hybrid			2022-12-25	WOS:000227559600103
J	Scholz, C; Wieder, T; Starck, L; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Scholz, C; Wieder, T; Starck, L; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway	ONCOGENE			English	Article						arsenic trioxide; caspase-independence; ATP; mitochondria; necrosis	ACUTE PROMYELOCYTIC LEUKEMIA; DRUG-INDUCED APOPTOSIS; DAMAGE-INDUCED APOPTOSIS; HUMAN CARCINOMA-CELLS; CYTOCHROME-C; IDENTIFIES PATIENTS; AMPLIFICATION LOOP; GROWTH-INHIBITION; DEPENDENT PATHWAY; MALIGNANT-CELLS	Cell death is generally believed to occur either by accidental, lytic necrosis or by programmed cell death, that is, apoptosis. The initiation and execution of cell death, however, is far more complex and includes pathways like caspase-independent apoptosis or actively triggered necrosis. In this study, we investigated the mechanisms of cell death induced by arsenic trioxide ( arsenite, As2O3), a clinically efficient agent in anticancer therapy. As2O3-induced cell death coincides with cytochrome c release, facilitates mitochondrial permeability transition and is sensitive to inhibition by Bcl-x(L), indicating that cell demise is regulated through the mitochondrial apoptosis pathway. Nevertheless, only little caspase-3 activation was observed and As2O3-induced cell death was only weakly obstructed by the broad spectrum caspase inhibitor z-VAD-fmk. Moreover, disruption of caspase-9 or -2 failed to decrease the amount of As2O3-mediated cell death. Interestingly, As2O3-induced cell death had a predominantly necrosis-like phenotype as assessed by Annexin-V/propidium iodide staining and LDH release. Finally, blocking glutathione synthetase by buthionine sulfoximine enhanced the As2O3-mediated necrosis-like cell death without increasing caspase-3 cleavage. As2O3 does, however, not directly inhibit caspases, but appears to interfere with caspase activation. Altogether, our data clearly delineate a mode of As2O3-triggered cell death that differs considerably from that induced by conventional anticancer drugs. These findings may explain the capability of As2O3 to efficiently kill even chemoresistant tumor cells with disturbed apoptosis signaling and caspase activation, a frequent finding in malignancy.	Humboldt Univ, Charite, Dept Hematol Oncol & Tumor Immunol, Robert Rossle Klin, D-13353 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Charite, Dept Hematol Oncol & Tumor Immunol, Robert Rossle Klin, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	pdaniel@mdc-berlin.de	Essmann, Frank/ABG-7409-2020; Schulze-Osthoff, Klaus/N-9025-2013; Scholz, Christian W/Q-2778-2017	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Scholz, Christian W/0000-0001-6260-4086				Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1998, BLOOD, V92, P4750, DOI 10.1182/blood.V92.12.4750.424k34_4750_4757; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LANOTTE M, 1991, BLOOD, V77, P1080; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rudner J, 2001, J CELL SCI, V114, P4161; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Schmelz K, 2004, ONCOGENE, V23, P6743, DOI 10.1038/sj.onc.1207848; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang TS, 1996, J CELL PHYSIOL, V169, P256, DOI 10.1002/(SICI)1097-4652(199611)169:2<256::AID-JCP5>3.0.CO;2-N; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang CH, 1999, BRIT J CANCER, V81, P796, DOI 10.1038/sj.bjc.6690766; Zhang W, 1998, LEUKEMIA, V12, P1383, DOI 10.1038/sj.leu.2401112; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	62	69	73	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1904	1913		10.1038/sj.onc.1208233	http://dx.doi.org/10.1038/sj.onc.1208233			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674346				2022-12-25	WOS:000227542000009
J	Hermsen, M; Snijders, A; Guervos, MA; Taenzer, S; Koerner, U; Baak, J; Pinkel, D; Albertson, D; van Diest, P; Meijer, G; Schrock, E				Hermsen, M; Snijders, A; Guervos, MA; Taenzer, S; Koerner, U; Baak, J; Pinkel, D; Albertson, D; van Diest, P; Meijer, G; Schrock, E			Centromeric chromosomal translocations show tissue-specific differences between squamous cell carcinomas and adenocarcinomas	ONCOGENE			English	Article						SKY; array CGH centromeres; whole arm translocation; squamous cell carcinoma; adenocarcinoma	IN-SITU HYBRIDIZATION; TOPOISOMERASE-II; CYTOGENETIC ABNORMALITIES; COLORECTAL ADENOMA; DNA; PROGRESSION; LEVEL; INSTABILITY; RESPECT; CANCER	Structural chromosomal aberrations are common in epithelial tumors. Here, we compared the location of centromeric breaks associated with whole arm translocations in seven adenocarcinoma cell lines and nine squamous cell carcinoma cell lines using SKY, micro-array-based comparative genomic hybridization (array CGH) and fluorescence in situ hybridization (FISH). Whole arm translocations were more frequent in squamous cell carcinomas (112 in nine cell lines and nine in one short-term culture) than in adenocarcinomas (13 in seven cases) and most often resulted in copy number alterations. Array CGH analysis demonstrated that in all squamous cell carcinomas and in most adenocarcinomas, the breakpoints of unbalanced whole arm translocations occurred between the two clones on the array flanking the centromeres. However, FISH with centromeric probes revealed that in squamous cell carcinomas, the marker chromosomes with whole arm translocations contained centromeres comprised of material from both participating chromosomes, while in adenocarcinomas centromeric material from only one of the chromosomes was present. These observations suggest that different mechanisms of centromeric instability underlie the formation of chromosomal aberrations in adenocarcinomas and squamous cell carcinomas.	Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Jena, Inst Mol Biotechnol, D-6900 Jena, Germany; SiR Hosp, Dept Pathol, Stavanger, Norway; Humboldt Univ, Inst Med Genet, Berlin, Germany	Vrije Universiteit Amsterdam; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Friedrich Schiller University of Jena; Humboldt University of Berlin	Hermsen, M (corresponding author), Univ Principado Asturias, Dept Otolaryngol, Inst Oncol, Hosp Cent Asturias, Edificio Polivalente A,1 Planta,Calle Dr Emilio V, Oviedo 33006, Asturias, Spain.	mhermsen@hca.es	Guervós, Marta A./H-7446-2015		NCI NIH HHS [CA94407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA094407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Bakshi RP, 2001, CRIT REV BIOCHEM MOL, V36, P1, DOI 10.1080/20014091074165; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Floridia G, 2000, EMBO REP, V1, P489; HERMIEU JF, 2001, CORRESPONDANCES PELV, V1, P43; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hermsen M, 2001, J PATHOL, V194, P177; Hermsen MAJA, 1998, J PATHOL, V186, P356; Hermsen MAJA, 1996, GENE CHROMOSOME CANC, V15, P1; Israeli O, 2003, GYNECOL ONCOL, V90, P629, DOI 10.1016/S0090-8258(03)00375-5; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Jin C, 2000, GENE CHROMOSOME CANC, V28, P66, DOI 10.1002/(SICI)1098-2264(200005)28:1<66::AID-GCC8>3.0.CO;2-4; Jin YS, 2000, CHROMOSOMA, V109, P476, DOI 10.1007/s004120000107; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; Martins C, 1999, EUR J CANCER, V35, P498, DOI 10.1016/S0959-8049(98)00368-2; Meijer GA, 1998, J CLIN PATHOL, V51, P901, DOI 10.1136/jcp.51.12.901; NAKAO K, 2004, CARCINOGENESIS  0304; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schrock E, 1999, DIAGNOSTIC CYTOGENET, P416; SCHROCK E, 2001, CURRENT PROTOCOLS CY; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Soulie P, 1999, CANCER GENET CYTOGEN, V115, P118, DOI 10.1016/S0165-4608(99)00073-4; Sumner AT, 1998, J MED GENET, V35, P833, DOI 10.1136/jmg.35.10.833; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; Tirkkonen M, 1997, CANCER RES, V57, P1222; van Grieken NCT, 2000, J PATHOL, V192, P301, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH697&gt;3.0.CO;2-F; van Triest B, 1999, CLIN CANCER RES, V5, P643; Varis A, 2001, CANCER GENET CYTOGEN, V127, P53, DOI 10.1016/S0165-4608(00)00423-4; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Weiss MM, 2003, J PATHOL, V199, P157, DOI 10.1002/path.1260; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; 2001, NCI NCBIS SKY M FISH	39	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1571	1579		10.1038/sj.onc.1208294	http://dx.doi.org/10.1038/sj.onc.1208294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674345				2022-12-25	WOS:000227218200010
J	Zcharia, E; Zilka, R; Yaar, A; Yacoby-Zeevi, O; Zetser, A; Metzger, S; Sarid, R; Naggi, A; Casu, B; Ilan, N; Vlodavsky, I; Abramovitch, R				Zcharia, E; Zilka, R; Yaar, A; Yacoby-Zeevi, O; Zetser, A; Metzger, S; Sarid, R; Naggi, A; Casu, B; Ilan, N; Vlodavsky, I; Abramovitch, R			Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models	FASEB JOURNAL			English	Article						heparan sulfate; keratinocytes; blood vessel maturation; extracellular matrix; MRI; tissue repair; wound fluid	GROWTH-FACTORS; EXTRACELLULAR-MATRIX; LAMINARIN SULFATE; TUMOR-METASTASIS; MAMMALIAN HEPARANASE; ENZYMATIC-ACTIVITY; NITRIC-OXIDE; KEY ENZYME; EXPRESSION; INHIBITION	Orchestration of the rapid formation and reorganization of new tissue observed in wound healing involves not only cells and polypeptides but also the extracellular matrix (ECM) microenvironment. The ability of heparan sulfate (HS) to interact with major components of the ECM suggests a key role for HS in maintaining the structural integrity of the ECM. Heparanase, an endoglycosidase- degrading HS in the ECM and cell surface, is involved in the enzymatic machinery that enables cellular invasion and release of HS-bound polypeptides residing in the ECM. Bioavailabilty and activation of multitude mediators capable of promoting cell migration, proliferation, and neovascularization are of particular importance in the complex setting of wound healing. We provide evidence that heparanase is normally expressed in skin and in the wound granulation tissue. Heparanase stimulated keratinocyte cell migration and wound closure in vitro. Topical application of recombinant heparanase significantly accelerated wound healing in a flap/punch model and markedly improved flap survival. These heparanase effects were associated with enhanced wound epithelialization and blood vessel maturation. Similarly, a marked elevation in wound angiogenesis, evaluated by MRI analysis and histological analyses, was observed in heparanase-overexpressing transgenic mice. This effect was blocked by a novel, newly developed, heparanase-inhibiting glycol-split fragment of heparin. These results clearly indicate that elevation of heparanase levels in healing wounds markedly accelerates tissue repair and skin survival that are mediated primarily by an enhanced angiogenic response.	Hadassah Hebrew Univ Med Ctr, Dept Oncol, Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, Dept Med, Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, Dept Gene Therapy, Jerusalem, Israel; InSight Biopharmaceut, Rehovot, Israel; Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; G Ronzoni Inst Chem & Biochem Res, Milan, Italy	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Bar Ilan University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Ilan, N (corresponding author), Technion Israel Inst Technol, Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	netailan@tx.technion.ac.il; vlodavsk@cc.huji.ac.il			NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER; NCI NIH HHS [CA106456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramovitch R, 1998, BRIT J CANCER, V77, P440, DOI 10.1038/bjc.1998.70; Abramovitch R, 1999, CANCER RES, V59, P5012; Andriessen MP, 1997, J PATHOL, V183, P264; Bennett SP, 2003, BRIT J SURG, V90, P133, DOI 10.1002/bjs.4019; Bernard D, 2001, J INVEST DERMATOL, V117, P1266, DOI 10.1046/j.1523-1747.2001.15401.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bosman FT, 2003, J PATHOL, V200, P423, DOI 10.1002/path.1437; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Casu B, 2004, J MED CHEM, V47, P838, DOI 10.1021/jm030893g; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; CUNNINGHAM LD, 1992, J CLIN INVEST, V89, P878, DOI 10.1172/JCI115667; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2004, J PATHOL, V203, P594, DOI 10.1002/path.1554; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Gong F, 2003, J BIOL CHEM, V278, P35152, DOI 10.1074/jbc.M300925200; HOFFMAN R, 1995, J CELL SCI, V108, P3591; Hoffman R, 1996, BRIT J CANCER, V73, P1183, DOI 10.1038/bjc.1996.228; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; MAGRATH JA, 1997, J PATHOL, V183, P251; Marchetti D, 2003, INT J CANCER, V104, P167, DOI 10.1002/ijc.10930; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Mustoe Thomas A., 1994, Wound Repair and Regeneration, V2, P277, DOI 10.1046/j.1524-475X.1994.20408.x; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Norfleet AM, 2000, WOUND REPAIR REGEN, V8, P517, DOI 10.1046/j.1524-475x.2000.00517.x; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rolny C, 2002, J BIOL CHEM, V277, P19315, DOI 10.1074/jbc.M111805200; Saijo M, 2003, HISTOCHEM CELL BIOL, V120, P493, DOI 10.1007/s00418-003-0589-1; Schonherr E, 2000, Dev Immunol, V7, P89, DOI 10.1155/2000/31748; Schubert SY, 2004, LAB INVEST, V84, P535, DOI 10.1038/labinvest.3700084; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Takase H, 1999, J CARDIOVASC PHARM, V33, P223, DOI 10.1097/00005344-199902000-00007; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Varki NM, 2002, SEMIN THROMB HEMOST, V28, P53, DOI 10.1055/s-2002-20564; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 2003, PATHOPHYSIOL HAEMO T, V33, P59, DOI 10.1159/000073296; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WU LC, 1995, GROWTH FACTORS, V12, P29, DOI 10.3109/08977199509003211; Xu Y, 2001, J BIOL CHEM, V276, P34990, DOI 10.1074/jbc.M103661200; Yamawaki H, 2000, BRIT J PHARMACOL, V131, P1546, DOI 10.1038/sj.bjp.0703771; Zetser A, 2003, CANCER RES, V63, P7733; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	60	130	140	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					211	221		10.1096/fj.04-1970com	http://dx.doi.org/10.1096/fj.04-1970com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15677344				2022-12-25	WOS:000227591900025
J	Brickley, K; Smith, MJ; Beck, M; Stephenson, FA				Brickley, K; Smith, MJ; Beck, M; Stephenson, FA			GRIF-1 and OIP106, members of a novel gene family of coiled-coil domain proteins - Association in vivo and in vitro with kinesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-GLCNAC TRANSFERASE; HUNTINGTIN; MITOCHONDRIA; TRANSPORT; RECEPTOR; NEURONS; CLONING; IDENTIFICATION; TRAFFICKING; P150(GLUED)	gamma-Aminobutyric acidA receptor-interacting factor (GRIF-1) is a 913-amino acid protein proposed to function as a GABA(A) receptor beta(2) subunit-interacting, trafficking protein. GRIF-1 shares similar to 44% amino acid sequence identity with O-linked N-acetylglucosamine transferase interacting protein 106, OIP106. Both proteins contain predicted coiled-coil domains and probably constitute a novel gene family. The Drosophila orthologue of this family of proteins may be Milton. Milton shares similar to 44% amino acid homology with GRIF-1. Milton is proposed to function in kinesin-mediated transport of mitochondria to nerve terminals. We report here that GRIF-1 and OIP106 also associate with kinesin and mitochondria. Following expression in human embryonic kidney 293 cells, both GRIF-1 and OIP106 were shown by co-immunoprecipitation to be specifically associated with an endogenous kinesin heavy chain species of 115 kDa and exogenous KIF5C. Association of GRIF-1 with kinesin was also evident in native brain and heart tissue. In the brain, anti-GRIF-1-(8-633) antibodies specifically co-immunoprecipitated two kinesin-immunoreactive species with molecular masses of 118 and 115 kDa, and in the heart, one kinesin-immunoreactive species, 115 kDa, was immunoprecipitated. Further studies revealed that GRIF-1 was predominantly associated with KIF5A in the brain and with KIF5B in both the heart and in HEK 293 cells. Yeast two-hybrid interaction assays and immunoprecipitations showed that GRIF-1 associated directly with KIF5C with the GRIF-1/KIF5C interaction domain localized to GRIF-1-(124-283). These results further support a role for GRIF-1 and OIP106 in protein and/or organelle transport in excitable cells in a manner analogous to glutamate receptor-interacting-protein 1, in the motor-dependent transport of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate glutamate excitatory neurotransmitter receptors to dendrites.	Univ London, Dept Pharmaceut & Biol Chem, Sch Pharm, London WC1N 1AX, England	University of London; University College London; University of London School of Pharmacy	Stephenson, FA (corresponding author), Univ London, Dept Pharmaceut & Biol Chem, Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.	anne.stephenson@ulsop.ac.uk	Smith, Miriam/J-4001-2015	Smith, Miriam/0000-0002-3184-0817				Akhtar S, 2002, J BIOL CHEM, V277, P16376, DOI 10.1074/jbc.M109698200; Beck M, 2002, J BIOL CHEM, V277, P30079, DOI 10.1074/jbc.M200438200; Cole RN, 2001, J NEUROCHEM, V79, P1080, DOI 10.1046/j.1471-4159.2001.00655.x; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gorska-Andrzejak J, 2003, J COMP NEUROL, V463, P372, DOI 10.1002/cne.10750; Guillaud L, 2003, J NEUROSCI, V23, P131; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; Hanover JA, 2003, ARCH BIOCHEM BIOPHYS, V409, P287, DOI 10.1016/S0003-9861(02)00578-7; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; Iyer SPN, 2003, J BIOL CHEM, V278, P24608, DOI 10.1074/jbc.M300036200; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; Kanai Y, 2000, J NEUROSCI, V20, P6374, DOI 10.1523/JNEUROSCI.20-17-06374.2000; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; Li YK, 2002, J BIOL CHEM, V277, P28212, DOI 10.1074/jbc.M111612200; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Marcora E, 2003, P NATL ACAD SCI USA, V100, P9578, DOI 10.1073/pnas.1133382100; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; SMITH M, 2003, 5693 SOC NEUR; STEPHENSON FA, 1991, MOL NEUROBIOL, P183; Stowers RS, 2002, NEURON, V36, P1063, DOI 10.1016/S0896-6273(02)01094-2; Tang R, 2003, ELECTRON LETT, V39, P195, DOI 10.1049/el:20030141; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8	27	132	148	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14723	14732		10.1074/jbc.M409095200	http://dx.doi.org/10.1074/jbc.M409095200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15644324	hybrid			2022-12-25	WOS:000228236800049
J	Liu, ZM; Zhang, CX; Dronadula, N; Li, QY; Rao, GN				Liu, ZM; Zhang, CX; Dronadula, N; Li, QY; Rao, GN			Blockade of nuclear factor of activated T cells activation signaling suppresses balloon injury-induced neointima formation in a rat carotid artery model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; RECEPTOR TYROSINE KINASE; TRANSCRIPTION FACTOR; CYCLOOXYGENASE-2 EXPRESSION; COX-2 INHIBITION; NF-ATC; GROWTH; TRANSACTIVATION; PROLIFERATION; HYPERPLASIA	We have previously reported that nuclear factor of activated T cells (NFATs) play an important role in the regulation of vascular smooth muscle cell migration and proliferation by receptor tyrosine kinase and G protein-coupled receptor agonists, platelet-derived growth factor-BB and thrombin, respectively. To understand the role of NFATs in vascular disease, we have now studied the involvement of these transcription factors in neointima formation in a rat carotid artery balloon injury model. The levels of NFATc1 in injured right common carotid arteries were increased at 72 h, 1 week, and 2 weeks after balloon injury compared with its levels in uninjured left common carotid arteries. Intraperitoneal injection of cyclosporine A (CsA), a pharmacological inhibitor of the calcineurin-NFAT activation pathway, suppressed balloon injury-induced neointima formation by 40%. Similarly, adenoviral-mediated expression of GFPVIVIT, a competent peptide inhibitor of the calcineurin-NFAT activation pathway, in injured arteries also reduced neointima formation by about 40%. Furthermore, CsA and GFPVIVIT attenuated balloon injury-induced neointimal smooth muscle cell proliferation as determined by bromodeoxyuridine staining. Platelet-derived growth factor-BB induced the expression of COX-2 in cultured VSMC in a time- and NFAT-dependent manner. COX-2 expression was also increased in the right common carotid artery in a time- dependent manner after balloon injury as compared with its levels in uninjured left common carotid artery and both CsA and GFPVIVIT negated this response. Together these results for the first time demonstrate that NFATs play a critical role in neointima formation via induction of expression of COX-2.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physio1.utmem.edu	zhang, xiang chun/HCH-7063-2022	zhang, xiang chun/0000-0001-8303-6495	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064165, R01HL069908] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69908, HL64165] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; Bushdid PB, 2003, CIRC RES, V92, P1305, DOI 10.1161/01.RES.0000077045.84609.9F; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Decker EL, 2003, NUCLEIC ACIDS RES, V31, P911, DOI 10.1093/nar/gkg186; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Goetze S, 1999, HYPERTENSION, V33, P183, DOI 10.1161/01.HYP.33.1.183; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Granja AG, 2004, J BIOL CHEM, V279, P53736, DOI 10.1074/jbc.M406620200; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Hedin KE, 1997, J IMMUNOL, V159, P5431; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kegley KM, 2001, DEV BIOL, V232, P115, DOI 10.1006/dbio.2001.0179; Koehne CH, 2004, SEMIN ONCOL, V31, P12, DOI 10.1053/j.seminoncol.2004.03.041; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Liu ZM, 2004, J BIOL CHEM, V279, P41218, DOI 10.1074/jbc.M406917200; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; RODRIGUEZ C, 1999, P NATL ACAD SCI USA, V96, P7214; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sandler AB, 2004, SEMIN ONCOL, V31, P45, DOI 10.1053/j.seminoncol.2004.03.045; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Sugimoto T, 2001, J AM SOC NEPHROL, V12, P1359, DOI 10.1681/ASN.V1271359; Tanaka K, 2003, CIRC RES, V93, P783, DOI 10.1161/01.RES.0000096651.13001.B4; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; van Rooij E, 2002, J BIOL CHEM, V277, P48617, DOI 10.1074/jbc.M206532200; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Yang HM, 2004, CIRCULATION, V110, P301, DOI 10.1161/01.CIR.0000135467.43430.16; Yellaturu CR, 2002, BIOCHEM J, V368, P183, DOI 10.1042/BJ20020347; Zhang CX, 2004, AM J PHYSIOL-HEART C, V287, pH659, DOI 10.1152/ajpheart.00162.2004	48	82	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14700	14708		10.1074/jbc.M500322200	http://dx.doi.org/10.1074/jbc.M500322200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15681847	hybrid			2022-12-25	WOS:000228236800046
J	Loewen, CJR; Levine, TP				Loewen, CJR; Levine, TP			A highly conserved binding site in vesicle-associated membrane protein-associated protein (VAP) for the FFAT motif of lipid-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CAENORHABDITIS-ELEGANS; SCS2 GENE; GENOME; VAMP; MSP; HOMOLOG; IDENTIFICATION	A variety of lipid-binding proteins contain a recently described motif, designated FFAT (two phenylalanines in an acidic tract), which binds to vesicle-associated-membrane protein-associated protein (VAP). VAP is a conserved integral membrane protein of the endoplasmic reticulum that contains at its amino terminus a domain related to the major sperm protein of nematode worms. Here we have studied the FFAT-VAP interaction in Saccharomyces cerevisiae, where the VAP homologue Scs2 regulates phospholipid metabolism via an interaction with the FFAT motif of Opi1. By introducing mutations at random into Scs2, we found that mutations that abrogated binding to FFAT were clustered in the most highly conserved region. Using site-directed mutagenesis, we identified several critical residues, including two lysines widely separated in the primary sequence. By examining all other conserved basic residues, we identified a third residue that was moderately important for binding FFAT. Modeling VAP on the known structure of major sperm protein showed that the critical residues form a patch on a positively charged face of the protein. In vivo functional studies of SCS22, a second SCS2-like gene in S. cerevisiae, showed that SCS2 was the dominant gene in the regulation of Opi1, with a minor contribution from SCS22. We then established that reduction in the affinity of Scs2 mutants for FFAT correlated well with loss of function, indicating the importance of these residues for binding FFAT motifs. Finally, we found that human VAP-A could substitute for Scs2 but that it functioned poorly, suggesting that other factors modulate the binding of Scs2 to proteins with FFAT motifs.	UCL, Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England	University of London; University College London	Levine, TP (corresponding author), UCL, Inst Ophthalmol, Div Cell Biol, Bath St, London EC1V 9EL, England.	tim.levine@ucl.ac.uk		Levine, Timothy/0000-0002-7231-0775				Amarilio R, 2005, J BIOL CHEM, V280, P5934, DOI 10.1074/jbc.M409566200; Baker AME, 2002, J MOL BIOL, V319, P491, DOI 10.1016/S0022-2836(02)00294-2; Blandin G, 2000, FEBS LETT, V487, P31, DOI 10.1016/S0014-5793(00)02275-4; Brachmann CB, 1998, YEAST, V14, P115; Brickner JH, 2004, PLOS BIOL, V2, P1843, DOI 10.1371/journal.pbio.0020342; Bullock TL, 1996, J MOL BIOL, V263, P284, DOI 10.1006/jmbi.1996.0575; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Craven RJ, 2001, GENETICS, V158, P145; Cuperus G, 2002, GENETICS, V162, P633; Dietrich FS, 2004, SCIENCE, V304, P304, DOI 10.1126/science.1095781; Ettayebi K, 2003, J VIROL, V77, P11790, DOI 10.1128/JVI.77.21.11790-11797.2003; Foster LJ, 2000, TRAFFIC, V1, P512, DOI 10.1034/j.1600-0854.2000.010609.x; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Kagiwada S, 1998, J BACTERIOL, V180, P1700, DOI 10.1128/JB.180.7.1700-1708.1998; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; Lapierre LA, 1999, J CELL SCI, V112, P3723; Levine TP, 2001, MOL BIOL CELL, V12, P1633, DOI 10.1091/mbc.12.6.1633; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; NIKAWA J, 1995, J BIOCHEM, V118, P39, DOI 10.1093/oxfordjournals.jbchem.a124889; Nishimura AL, 2004, AM J HUM GENET, V75, P822, DOI 10.1086/425287; Nishimura Y, 1999, BIOCHEM BIOPH RES CO, V254, P21, DOI 10.1006/bbrc.1998.9876; Pall GS, 2004, GENOMICS, V84, P1051, DOI 10.1016/j.ygeno.2004.08.017; Pennetta G, 2002, NEURON, V35, P291, DOI 10.1016/S0896-6273(02)00769-9; Reggiori F, 2000, MOL BIOL CELL, V11, P3737, DOI 10.1091/mbc.11.11.3737; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SIKORSKI RS, 1989, GENETICS, V122, P19; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; Skehel PA, 2000, P NATL ACAD SCI USA, V97, P1101, DOI 10.1073/pnas.97.3.1101; Smith HE, 1998, J MOL BIOL, V279, P605, DOI 10.1006/jmbi.1998.1793; Soussan L, 1999, J CELL BIOL, V146, P301, DOI 10.1083/jcb.146.2.301; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Weir ML, 1998, BIOCHEM J, V333, P247, DOI 10.1042/bj3330247; Weir ML, 2001, BIOCHEM BIOPH RES CO, V286, P616, DOI 10.1006/bbrc.2001.5437; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; Wyles JP, 2002, J BIOL CHEM, V277, P29908, DOI 10.1074/jbc.M201191200; Wyles JP, 2004, EXP CELL RES, V297, P533, DOI 10.1016/j.yexcr.2004.03.052	39	159	165	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14097	14104		10.1074/jbc.M500147200	http://dx.doi.org/10.1074/jbc.M500147200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15668246	hybrid			2022-12-25	WOS:000228095500112
J	Nazabal, A; Maddelein, ML; Bonneu, M; Saupe, SJ; Schmitter, JM				Nazabal, A; Maddelein, ML; Bonneu, M; Saupe, SJ; Schmitter, JM			Probing the structure of the infectious amyloid form of the prion-forming domain of HET-s using high resolution hydrogen/deuterium exchange monitored by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS PODOSPORA-ANSERINA; AMIDE HYDROGEN-EXCHANGE; ELECTROSPRAY-IONIZATION; CORE STRUCTURE; IN-VITRO; SACCHAROMYCES-CEREVISIAE; PROTEIN-STRUCTURE; H/D-EXCHANGE; FIBRILS; FIBERS	The HET-s prion protein of Podospora anserina represents a valuable model system to study the structural basis of prion propagation. In this system, prion infectivity can be generated in vitro from a recombinant protein. We have previously identified the region of the HET-s protein involved in amyloid formation and prion propagation. Herein, we show that a recombinant peptide corresponding to the C-terminal prion-forming domain of HET-s (residues 218-289) displays infectivity. We used high resolution hydrogen/deuterium exchange analyzed by mass spectrometry to gain insight into the structural organization of this infectious amyloid form of the HET-s-(218-289) protein. Deuterium incorporation was analyzed by ion trap mass spectrometry for 76 peptides generated by pepsin proteolysis of HET-s-(218-289). By taking into account sequence overlaps in these peptides, a resolution ranging from 4-amino acids stretches to a single residue could be achieved. This approach allowed us to define highly protected regions alternating with more accessible segments along the HET-s-(218-289) sequence. The HET-s-(218-289) fibrils are thus likely to be organized as a succession of beta-sheet segments interrupted by short turns or short loops.	Univ Bordeaux 2, Inst Biochim & Genet Cellulaires, Lab Genet Mol Champignons, CNRS,UMR 5095, F-33077 Bordeaux, France; Inst Europeen Chim & Biol, CNRS, UMR 5144, F-33600 Pessac, France; Univ Bordeaux 2, Plate Forme Genom Fonct, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Saupe, SJ (corresponding author), Univ Bordeaux 2, Inst Biochim & Genet Cellulaires, Lab Genet Mol Champignons, CNRS,UMR 5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	nazabal@org.chem.ethz.ch; sven.saupe@ibgc.u-bordeaux2.fr	MADDELEIN, Marie-Lise/G-5395-2010	saupe, sven/0000-0002-5589-721X				Balguerie A, 2004, J CELL SCI, V117, P2599, DOI 10.1242/jcs.01116; Balguerie A, 2003, EMBO J, V22, P2071, DOI 10.1093/emboj/cdg213; Coustou V, 1997, P NATL ACAD SCI USA, V94, P9773, DOI 10.1073/pnas.94.18.9773; Coustou-Linares V, 2001, MOL MICROBIOL, V42, P1325, DOI 10.1046/j.1365-2958.2001.02707.x; Dos Reis S, 2002, J BIOL CHEM, V277, P5703, DOI 10.1074/jbc.M110183200; Engen JR, 2001, ANAL CHEM, V73, p256A, DOI 10.1021/ac012452f; Englander SW, 1997, PROTEIN SCI, V6, P1101, DOI 10.1002/pro.5560060517; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Ippel JH, 2002, P NATL ACAD SCI USA, V99, P8648, DOI 10.1073/pnas.132098999; Kajava AV, 2004, P NATL ACAD SCI USA, V101, P7885, DOI 10.1073/pnas.0402427101; Kheterpal I, 2001, BIOCHEMISTRY-US, V40, P11757, DOI 10.1021/bi010805z; Kheterpal I, 2003, BIOCHEMISTRY-US, V42, P14092, DOI 10.1021/bi0357816; Kheterpal I, 2003, PROTEIN SCI, V12, P635, DOI 10.1110/ps.0225703; Kheterpal I, 2000, P NATL ACAD SCI USA, V97, P13597, DOI 10.1073/pnas.250288897; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Kishimoto A, 2004, BIOCHEM BIOPH RES CO, V315, P739, DOI 10.1016/j.bbrc.2004.01.117; Kraus M, 2003, RAPID COMMUN MASS SP, V17, P222, DOI 10.1002/rcm.901; Kuwata K, 2003, P NATL ACAD SCI USA, V100, P14790, DOI 10.1073/pnas.2433563100; LIU YQ, 1994, J AM SOC MASS SPECTR, V5, P19, DOI 10.1016/1044-0305(94)85080-1; Maddelein ML, 2002, P NATL ACAD SCI USA, V99, P7402, DOI 10.1073/pnas.072199199; Maier CS, 1999, BIOCHEMISTRY-US, V38, P1136, DOI 10.1021/bi981938w; Nazabal A, 2003, BIOCHEMISTRY-US, V42, P8852, DOI 10.1021/bi0344275; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raschke TM, 1998, CURR OPIN BIOTECH, V9, P80, DOI 10.1016/S0958-1669(98)80088-8; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Smith DL, 1997, J MASS SPECTROM, V32, P135, DOI 10.1002/(SICI)1096-9888(199702)32:2<135::AID-JMS486>3.0.CO;2-M; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Tito P, 2000, J MOL BIOL, V303, P267, DOI 10.1006/jmbi.2000.4142; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Tuite MF, 2004, MOL CELL, V14, P541, DOI 10.1016/j.molcel.2004.05.012; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; WAGNER DS, 1994, PROTEIN SCI, V3, P1305, DOI 10.1002/pro.5560030817; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 2004, GENE DEV, V18, P470, DOI 10.1101/gad.1177104; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Yamaguchi KI, 2004, J MOL BIOL, V338, P559, DOI 10.1016/j.jmb.2004.02.067; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522	45	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13220	13228		10.1074/jbc.M413185200	http://dx.doi.org/10.1074/jbc.M413185200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15647259	hybrid			2022-12-25	WOS:000228095500005
J	Xie, J; Guo, Q				Xie, J; Guo, Q			PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANS-GOLGI NETWORK; GAMMA-SECRETASE; ALPHA-SECRETASE; CLEAVING ENZYME; A-BETA; TRANSMEMBRANE ASPARTATES; INTRACELLULAR GENERATION; TRANSCRIPTION FACTOR; MUTANT PRESENILIN-1; CYTOSOLIC DOMAIN	Mounting evidence indicates that aberrant production and aggregation of amyloid beta-peptide (A beta)-(1-42) play a central role in the pathogenesis of Alzheimer disease (AD). A beta is produced when amyloid precursor protein (APP) is cleaved by beta- and gamma-secretases at the N and C termini of the A beta domain, respectively. The beta-secretase is membrane-bound aspartyl protease, most commonly known as BACE1. Because BACE1 cleaves APP at the N terminus of the A beta domain, it catalyzes the first step in A beta generation. PAR-4 (prostate apoptosis response-4) is a leucine zipper protein that was initially identified to be associated with neuronal degeneration and aberrant A beta production in models of AD. We now report that the C-terminal domain of PAR-4 is necessary for forming a complex with the cytosolic tail of BACE1 in co-immunoprecipitation assays and in vitro pull-down experiments. Overexpression of PAR-4 significantly increased, whereas silencing of PAR-4 expression by RNA interference significantly decreased, beta-secretase cleavage of APP. These results suggest that PAR-4 may be directly involved in regulating the APP cleavage activity of BACE1. Because the increased BACE1 activity observed in AD patients does not seem to arise from genetic mutations or polymorphisms in BACE1, the identification of PAR-4 as an endogenous regulator of BACE1 activity may have significant implications for developing novel therapeutic strategies for AD.	Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Guo, Q (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, BMSB 607,940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	qing-guo@ouhsc.edu						Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Cruts M, 2001, NEUROSCI LETT, V313, P105, DOI 10.1016/S0304-3940(01)02234-0; DE SB, 1999, NATURE, V398, P518; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Dewji NN, 1996, P NATL ACAD SCI USA, V93, P12575, DOI 10.1073/pnas.93.22.12575; Dingwall C, 2001, J CLIN INVEST, V108, P1243, DOI 10.1172/JCI200114402; Dominguez DI, 2001, AMYLOID, V8, P124, DOI 10.3109/13506120109007356; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Ghosh AK, 2001, J MED CHEM, V44, P2865, DOI 10.1021/jm0101803; Guo Q, 2004, J BIOL CHEM, V279, P4596, DOI 10.1074/jbc.M309811200; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Guo Q, 2001, J BIOL CHEM, V276, P16040, DOI 10.1074/jbc.M010996200; Guo Q, 1997, J NEUROSCI, V17, P4212; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hardy J, 1999, NATURE, V398, P466, DOI 10.1038/18979; He XY, 2003, BIOCHEMISTRY-US, V42, P12174, DOI 10.1021/bi035199h; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hong L, 2002, BIOCHEM SOC T, V30, P530, DOI 10.1042/bst0300530; Hooper NM, 2002, CURR MED CHEM, V9, P1107, DOI 10.2174/0929867023370121; HOOPER NM, 1995, TRENDS BIOCHEM SCI, V20, P15, DOI 10.1016/S0968-0004(00)88942-2; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Huse JT, 2000, MOL NEUROBIOL, V22, P81; Ikeuchi T, 2003, J BIOL CHEM, V278, P7010, DOI 10.1074/jbc.M209252200; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kim YT, 2002, EUR J BIOCHEM, V269, P5668, DOI 10.1046/j.1432-1033.2002.03277.x; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Koelsch G, 2003, BIOCHEM SOC SYMP, V70, P213, DOI 10.1042/bss0700213; Kopan R, 2002, NEURON, V33, P321, DOI 10.1016/S0896-6273(02)00585-8; Lahiri DK, 2003, CURR DRUG TARGETS, V4, P97, DOI 10.2174/1389450033346957; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; Lee EB, 2003, J BIOL CHEM, V278, P4458, DOI 10.1074/jbc.M210105200; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Li T, 2003, J NEUROSCI, V23, P3272; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Lindfors K, 2000, BIOCHEM BIOPH RES CO, V276, P660, DOI 10.1006/bbrc.2000.3480; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; McPhie DL, 2001, MOL BRAIN RES, V97, P103, DOI 10.1016/S0169-328X(01)00294-7; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Nicolaou M, 2001, NEUROGENETICS, V3, P203; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Page G, 1999, FEBS LETT, V462, P187, DOI 10.1016/S0014-5793(99)01529-X; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Roggo Silvio, 2002, Current Topics in Medicinal Chemistry, V2, P359, DOI 10.2174/1568026024607490; Rossner S, 2001, J NEUROSCI RES, V64, P437; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Sisodia SS, 2000, SCIENCE, V289, P2296, DOI 10.1126/science.289.5488.2296; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Sun AY, 2002, EXP NEUROL, V175, P10, DOI 10.1006/exnr.2002.7875; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tang J, 2003, J MOL NEUROSCI, V20, P299, DOI 10.1385/JMN:20:3:299; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Tsai JY, 2002, CURR MED CHEM, V9, P1087, DOI 10.2174/0929867023370185; Turner RT, 2002, BIOCHEMISTRY-US, V41, P8742, DOI 10.1021/bi025926t; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Tyler SJ, 2002, BIOCHEM BIOPH RES CO, V299, P373, DOI 10.1016/S0006-291X(02)02635-9; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xie J, 2005, J NEUROCHEM, V92, P59, DOI 10.1111/j.1471-4159.2004.02834.x; Xie J, 2004, J BIOL CHEM, V279, P28266, DOI 10.1074/jbc.M401495200; Xie J, 2004, NEUROBIOL DIS, V16, P150, DOI 10.1016/j.nbd.2004.02.003; Xu M, 2002, NEUROBIOL AGING, V23, P1023, DOI 10.1016/S0197-4580(02)00126-4; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	108	50	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13824	13832		10.1074/jbc.M411933200	http://dx.doi.org/10.1074/jbc.M411933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15671026	hybrid			2022-12-25	WOS:000228095500080
J	Lisenbee, CS; Dong, MQ; Miller, LJ				Lisenbee, CS; Dong, MQ; Miller, LJ			Paired cysteine mutagenesis to establish the pattern of disulfide bonds in the functional intact secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AMINO-TERMINAL TAIL; EXTRACELLULAR DOMAINS; SPATIAL APPROXIMATION; 3-DIMENSIONAL MODEL; MUTATIONAL ANALYSIS; PEPTIDE AGONIST; HORMONE-BINDING; LIGAND-BINDING; SOLUBLE FORM	The amino-terminal domain of class B G protein-coupled receptors contains six conserved cysteine residues involved in structurally and functionally critical disulfide bonds. The mapping of these bonds has been unclear, with one pattern based on biochemical and NMR structural characterizations of refolded, nonglycosylated amino-terminal fragments, and another pattern derived from functional characterizations of intact receptors having paired cysteine mutations. In the present study, we determined the disulfide bonding pattern of the prototypic class B secretin receptor by applying the same paired cysteine mutagenesis approach and confirming the predicted bonding pattern with proteolytic cleavage of intact functional receptor. As expected, systematic mutation to serine of the six conserved cysteine residues within this region of the secretin receptor singly and in pairs resulted in loss of function of most constructs. Notable exceptions were single mutations of the 4th and 6th cysteine residues and paired mutations involving the 1st and 3rd, 2nd and 5th, and 4th and 6th conserved cysteines, with secretin eliciting statistically significant cAMP responses above basal levels of activation for each of these constructs. Immunofluorescence microscopy confirmed similar levels of plasma membrane expression for each of the mutated receptors. Furthermore, cyanogen bromide cleaved a series of wild type and mutant secretin receptors, yielding patterns that agreed with our paired cysteine mutagenesis results. In conclusion, these data suggest the same pattern of disulfide bonding as that predicted previously by NMR and thus support a consistent pattern of amino-terminal disulfide bonds in class B G protein-coupled receptors.	Mayo Clin, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Miller, LJ (corresponding author), Mayo Clin, Ctr Canc, 13400 E Sheva Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu			NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; Chey WY, 2003, J GASTROENTEROL, V38, P1025, DOI 10.1007/s00535-003-1235-3; Ding WQ, 2002, GASTROENTEROLOGY, V122, P500, DOI 10.1053/gast.2002.31039; Ding WQ, 2002, CANCER RES, V62, P5223; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Dong MQ, 2004, J BIOL CHEM, V279, P2894, DOI 10.1074/jbc.M310407200; Dong MQ, 2003, J BIOL CHEM, V278, P48300, DOI 10.1074/jbc.M309166200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Dong MQ, 2002, RECEPTOR CHANNEL, V8, P189, DOI 10.1080/10606820213686; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Lins L, 2001, J BIOL CHEM, V276, P10153, DOI 10.1074/jbc.M009730200; Liu Y, 1997, BIOCHEMISTRY-US, V36, P5323, DOI 10.1021/bi962423c; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OHYAMA K, 1995, REGUL PEPTIDES, V57, P141, DOI 10.1016/0167-0115(95)00030-F; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; Perrin MH, 2003, J BIOL CHEM, V278, P15595, DOI 10.1074/jbc.M210476200; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Qi LJ, 1997, BIOCHEMISTRY-US, V36, P12442, DOI 10.1021/bi970997r; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; SPECTOR DL, 1998, CELLS LAB MANUAL, P1053; Taylor WR, 2003, COMPUT BIOL CHEM, V27, P103, DOI 10.1016/S1476-9271(03)00020-3; Vilardaga JP, 1997, EUR J BIOCHEM, V246, P173, DOI 10.1111/j.1432-1033.1997.00173.x; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; Zang MW, 2003, MOL PHARMACOL, V63, P993, DOI 10.1124/mol.63.5.993	37	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12330	12338		10.1074/jbc.M414016200	http://dx.doi.org/10.1074/jbc.M414016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15664984	hybrid			2022-12-25	WOS:000227922000033
J	Mao, LM; Yang, L; Arora, A; Choe, ES; Zhang, GC; Liu, ZG; Fibuch, EE; Wang, JQ				Mao, LM; Yang, L; Arora, A; Choe, ES; Zhang, GC; Liu, ZG; Fibuch, EE; Wang, JQ			Role of protein phosphatase 2A in mGluR5-regulated MEK/ERK phosphorylation in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; SIGNAL-REGULATED KINASE; SKELETAL-MUSCLE CELLS; STRIATAL NEURONS; TYROSINE PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; ACTIVATION; PATHWAY; GROWTH	The regulation of protein phosphorylation requires coordinated interaction between protein kinases and protein phosphatases (PPs). Recent evidence has shown that the G alpha q-protein-coupled metabotropic glutamate receptor (mGluR) 5 up-regulates phosphorylation of MAPK/ERK1/2. However, signaling mechanisms linking mGluR5 to ERK are poorly understood. In this study, roles of a major serine/threonine PP, PP2A, in this event were evaluated in cultured neurons. We found that the PP1/2A inhibitors okadaic acid and calyculin A mimicked the effect of the mGluR5 agonists (RS)-3,5-dihydroxyphenylglycine and (RS)-2-chloro-5-hydroxyphenylglycine in facilitating phosphorylation of ERK1/2 and its upstream kinase, MEK1/2, in a PP2A-dependent but not PP1-dependent manner. Co-administration of either inhibitor with an mGluR5 agonist produced additive phosphorylation of ERK1/2. Enzymatic assays showed a basal level of phosphatase activity of PP2A under normal conditions, and activation of mGluR5 selectively inhibited PP2A, but not PP1, activity. In addition, a physical association of the cytoplasmic C terminus of mGluR5 with PP2A was observed, and ligand activation of mGluR5 reduced mGluR5-PP2A binding. Additional mechanistic studies revealed that mGluR5 activation increased tyrosine (Tyr(307)) phosphorylation of PP2A, which was dependent on activation of a p60c-Src family tyrosine kinase, but not the epidermal growth factor receptor tyrosine kinase and resulted in dissociation of PP2A from mGluR5 and reduced PP2A activity. Together, we have identified a novel, mGluR5-triggered signaling mechanism involving use- and Src-dependent inactivation of PP2A, which contributes to mGluR5 activation of MEK1/2 and ERK1/2.	Univ Missouri, Sch Med, Dept Basic Med Sci, Kansas City, MO 64108 USA; Univ Missouri, Sch Med, Dept Anesthesiol, Kansas City, MO 64108 USA; Pusan Natl Univ, Div Biol Sci, Pusan 609735, South Korea	University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; Pusan National University	Wang, JQ (corresponding author), Univ Missouri, Sch Med, Dept Basic Med Sci, 5411 Holmes St, Kansas City, MO 64108 USA.	wangjq@umkc.edu			NIDA NIH HHS [R01DA010355] Funding Source: Medline; NIMH NIH HHS [R01MH061469] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010355] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ango F, 2000, J NEUROSCI, V20, P8710; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Begum N, 1999, BIOCHEM J, V344, P895, DOI 10.1042/0264-6021:3440895; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BRAUTIGAN DL, 1994, RECENT PROG HORM RES, V49, P197; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; de la Torre P, 2005, CELL SIGNAL, V17, P427, DOI 10.1016/j.cellsig.2004.09.002; Dingledine R, 1999, PHARMACOL REV, V51, P7; Enz R, 2003, BIOCHEM J, V372, P183, DOI 10.1042/BJ20021750; Enz R, 2002, J NEUROCHEM, V81, P1130, DOI 10.1046/j.1471-4159.2002.00922.x; Ferraguti F, 1999, EUR J NEUROSCI, V11, P2073, DOI 10.1046/j.1460-9568.1999.00626.x; Flajolet M, 2003, P NATL ACAD SCI USA, V100, P16006, DOI 10.1073/pnas.2136600100; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kerner JA, 1997, MOL BRAIN RES, V48, P259, DOI 10.1016/S0169-328X(97)00102-2; Kim M, 2004, MOL CELL BIOL, V24, P573, DOI 10.1128/MCB.24.2.573-583.2004; Li SP, 2003, CANCER RES, V63, P3473; Mao LM, 2005, J NEUROSCI, V25, P2741, DOI 10.1523/JNEUROSCI.4360-04.2005; Mao LM, 2002, MOL PHARMACOL, V62, P473, DOI 10.1124/mol.62.3.473; Mitsuhashi S, 2003, J BIOL CHEM, V278, P82, DOI 10.1074/jbc.M208888200; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nozaki K, 2001, MOL NEUROBIOL, V23, P1, DOI 10.1385/MN:23:1:01; Ogris E, 1999, J VIROL, V73, P7390, DOI 10.1128/JVI.73.9.7390-7398.1999; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Peavy RD, 2001, J NEUROSCI, V21, P9619, DOI 10.1523/JNEUROSCI.21-24-09619.2001; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Schinkmann KA, 2000, J NEUROCHEM, V74, P1931, DOI 10.1046/j.1471-4159.2000.0741931.x; SHIGEMOTO R, 1993, NEUROSCI LETT, V163, P53, DOI 10.1016/0304-3940(93)90227-C; Shiraishi Y, 2004, J COMP NEUROL, V473, P582, DOI 10.1002/cne.20116; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; Strack S, 1998, J COMP NEUROL, V392, P515; Takai A, 2000, BIOCHEM J, V350, P81, DOI 10.1042/0264-6021:3500081; Tallaksen-Greene SJ, 1998, BRAIN RES, V780, P210, DOI 10.1016/S0006-8993(97)01141-4; TESTA CM, 1995, J COMP NEUROL, V354, P241, DOI 10.1002/cne.903540207; Thandi S, 2002, J NEUROCHEM, V83, P1139, DOI 10.1046/j.1471-4159.2002.01217.x; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wang John Q., 2003, Current Neuropharmacology, V1, P1, DOI 10.2174/1570159033360548; Wang JQ, 2004, MOL NEUROBIOL, V29, P1, DOI 10.1385/MN:29:1:01; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Yang L, 2004, J NEUROSCI, V24, P10846, DOI 10.1523/JNEUROSCI.2496-04.2004; Yokoyama N, 2001, FEBS LETT, V505, P460, DOI 10.1016/S0014-5793(01)02874-5; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200	54	70	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12602	12610		10.1074/jbc.M411709200	http://dx.doi.org/10.1074/jbc.M411709200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15661743	hybrid			2022-12-25	WOS:000227922000065
J	Sell, DR; Biemel, KM; Reihl, O; Lederer, MO; Strauch, CM; Monnier, VM				Sell, DR; Biemel, KM; Reihl, O; Lederer, MO; Strauch, CM; Monnier, VM			Glucosepane is a major protein cross-link of the senescent human extracellular matrix - Relationship with diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; CORONARY-HEART-DISEASE; ADVANCED GLYCATION; SKIN COLLAGEN; OXIDATIVE STRESS; STRUCTURE ELUCIDATION; TAIL TENDON; MORTALITY; AGE; GLYCOXIDATION	The extracellular matrix in most tissues is characterized by progressive age-related stiffening and loss of proteolytic digestibility that are accelerated in diabetes and can be duplicated by the nonenzymatic reaction of reducing sugars and extracellular matrix proteins. However, most cross-links of the Maillard reaction described so far are present in quantities too low to account for these changes. Here we have determined in human skin and glomerular basement membrane (GBM) collagen the levels of the recently discovered lysine-arginine cross-links derived from glucose, methylglyoxal, glyoxal, and 3-deoxyglucosone, i.e. glucosepane, MODIC, GODIC, and DOGDIC, respectively. Insoluble preparations of skin collagen (n = 110) and glomerular basement membrane (GBM, n = 28) were enzymatically digested, and levels were measured by isotope dilution technique using liquid chromatography/mass spectrometry. In skin, all cross-links increased with age (p < 0.0001) except DOGDIC (p = 0.34). In nondiabetic controls, levels at 90 years were 2000, 30, and 15 pmol/mg for glucosepane, MODIC, and GODIC, respectively. Diabetes, but not renal failure, increased glucosepane to 5000 pmol/mg (p < 0.0001), and for all others, increased it to < 60 pmol/ mg (p < 0.01). In GBMs, glucosepane reached up to 500 pmol/ mg of collagen and was increased in diabetes ( p < 0.0001) but not old age. In conclusion, glucosepane is the single major cross-link of the senescent extracellular matrix discovered so far, accounting for up to > 120 mole% of triple helical collagen modification in diabetes. Its presence in high quantities may contribute to a number of structural and cell matrix dysfunctions observed in aging and diabetes.	Case Western Reserve Univ, Inst Pathol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Hohenheim, Inst Lebensmittelchem 170, D-70593 Stuttgart, Germany	Case Western Reserve University; Case Western Reserve University; University Hohenheim	Sell, DR (corresponding author), Case Western Reserve Univ, Inst Pathol, Sch Med, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	drs7@cwru.edu	Monnier, Vincent M/B-1371-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK057733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018629] Funding Source: NIH RePORTER; NIA NIH HHS [AG18629] Funding Source: Medline; NIDDK NIH HHS [DK-57733] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed N, 2002, BIOCHEM J, V364, P1; Ahmed N, 2003, INVEST OPHTH VIS SCI, V44, P5287, DOI 10.1167/iovs.03-0573; Bailey AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047-6374(98)00119-5; Baynes J. W., 1989, MAILLARD REACTION AG, P43; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Biemel KM, 2002, J BIOL CHEM, V277, P24907, DOI 10.1074/jbc.M202681200; BROWNLEE M, 1979, DIABETES, V28, P121, DOI 10.2337/diabetes.28.2.121; Brownlee M, 1979, Adv Exp Med Biol, V124, P141; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BUCKINGHAM B, 1990, J CLIN INVEST, V86, P1046, DOI 10.1172/JCI114807; Cheng RZ, 2004, J BIOL CHEM, V279, P45441, DOI 10.1074/jbc.M405664200; COHEN MP, 1980, J BIOL CHEM, V255, P1767; DEVIT AP, 2000, J GERONTOL BIOL SCI, V55, pB593; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; EBLE AS, 1983, J BIOL CHEM, V258, P9406; Erbersdobler H. F., 1986, Amino-carbonyl reactions in food and biological systems. Proceedings of the 3rd International Symposium on the Maillard Reaction, Susono, Shizuoka, Japan, 1-5 July, 1985., P481; EVERITT AV, 1983, MECH AGEING DEV, V22, P233, DOI 10.1016/0047-6374(83)90079-9; EVERITT AV, 1972, EXP GERONTOL, V7, P45, DOI 10.1016/0531-5565(72)90034-4; FAZIO MJ, 1989, CUTIS, V43, P437; Forbes JM, 2004, DIABETES, V53, P1813, DOI 10.2337/diabetes.53.7.1813; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GARLICK RL, 1988, DIABETES, V37, P1144, DOI 10.2337/diabetes.37.8.1144; HEYDEN S, 1980, J CHRON DIS, V33, P265, DOI 10.1016/0021-9681(80)90021-1; KESSLER II, 1971, AM J MED, V51, P715, DOI 10.1016/0002-9343(71)90299-3; Kochakian M, 1996, DIABETES, V45, P1694, DOI 10.2337/diabetes.45.12.1694; KOHN RR, 1982, DIABETES S3, V31, P47; Lai-Fook SJ, 2000, J APPL PHYSIOL, V89, P163, DOI 10.1152/jappl.2000.89.1.163; Lee DH, 2004, AM J CLIN NUTR, V80, P1194, DOI 10.1093/ajcn/80.5.1194; Monnier VM, 2003, ARCH BIOCHEM BIOPHYS, V419, P1, DOI 10.1016/j.abb.2003.08.014; MOORE S, 1954, J BIOL CHEM, V211, P907; Mullick AE, 2001, AM J PHYSIOL-HEART C, V281, pH2204, DOI 10.1152/ajpheart.2001.281.5.H2204; Mustata GT, 2005, DIABETES, V54, P517, DOI 10.2337/diabetes.54.2.517; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; Peppa Melpomeni, 2004, Curr Diab Rep, V4, P31, DOI 10.1007/s11892-004-0008-6; Phillips P, 1998, Aust Fam Physician, V27, P59; PRICE RG, 1977, J BIOL CHEM, V252, P8597; Qvist J, 1996, SCAND J SOC MED, V24, P67, DOI 10.1177/140349489602400111; Reihl O, 2004, CARBOHYD RES, V339, P705, DOI 10.1016/j.carres.2003.12.009; Schalkwijk CG, 2004, DIABETES-METAB RES, V20, P369, DOI 10.1002/dmrr.488; SCHLEICHER E, 1986, BIOCHIM BIOPHYS ACTA, V884, P199, DOI 10.1016/0304-4165(86)90244-8; Sell David R., 1995, P235; SELL DR, 1989, J BIOL CHEM, V264, P21597; SELL DR, 1993, DIABETOLOGIA, V36, P936, DOI 10.1007/BF02374476; Sell DR, 2004, J BIOL CHEM, V279, P54173, DOI 10.1074/jbc.M408946200; Sell DR, 2003, J GERONTOL A-BIOL, V58, P508; Sell DR, 1997, MECH AGEING DEV, V95, P81, DOI 10.1016/S0047-6374(97)01863-0; Sell DR, 2000, FASEB J, V14, P145, DOI 10.1096/fasebj.14.1.145; Sumino H, 2004, J AM GERIATR SOC, V52, P945, DOI 10.1111/j.1532-5415.2004.52262.x; TAKEKOSHI H, 1983, Tohoku Journal of Experimental Medicine, V141, P523; VATER CA, 1979, BIOCHEM J, V181, P639, DOI 10.1042/bj1810639; Verzijl N, 2000, BIOCHEM J, V350, P381, DOI 10.1042/0264-6021:3500381; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; WellsKnecht MC, 1997, J CLIN INVEST, V100, P839, DOI 10.1172/JCI119599	54	148	159	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12310	12315		10.1074/jbc.M500733200	http://dx.doi.org/10.1074/jbc.M500733200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677467	hybrid			2022-12-25	WOS:000227922000031
J	Kohler, GA; Gong, X; Bentink, S; Theiss, S; Pagani, GM; Agabian, N; Hedstrom, L				Kohler, GA; Gong, X; Bentink, S; Theiss, S; Pagani, GM; Agabian, N; Hedstrom, L			The functional basis of mycophenolic acid resistance in Candida albicans IMP dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE MONOPHOSPHATE DEHYDROGENASE; ANTIFUNGAL DRUG-RESISTANCE; GENE DISRUPTION; INHIBITION; MECHANISM; YEAST; INFECTIONS; PRODUCTS; STRAINS; COMPLEX	Candida albicans is an important fungal pathogen of immunocompromised patients. In cell culture, C. albicans is sensitive to mycophenolic acid (MPA) and mizoribine, both natural product inhibitors of IMP dehydrogenase (IMPDH). These drugs have opposing interactions with the enzyme. MPA prevents formation of the closed enzyme conformation by binding to the same site as a mobile flap. In contrast, mizoribine monophosphate, the active metabolite of mizoribine, induces the closed conformation. Here, we report the characterization of IMPDH from wild-type and MPA-resistant strains of C. albicans. The wild-type enzyme displays significant differences from human IMPDHs, suggesting that selective inhibitors that could be novel antifungal agents may be developed. IMPDH from the MPA-resistant strain contains a single substitution (A251T) that is far from the MPA-binding site. The A251T variant was 4-fold less sensitive to MPA as expected. This substitution did not affect the k(cat) value, but did decrease the Km values for both substrates, so the mutant enzyme is more catalytically efficient as measured by the value of k(cat)/K-m. These simple criteria suggest that the A251T variant would be the evolutionarily superior enzyme. However, the A251T substitution caused the enzyme to be 40-fold more sensitive to mizoribine monophosphate. This result suggests that A251T stabilizes the closed conformation, and this hypothesis is supported by further inhibitor analysis. Likewise, the MPA-resistant strain was more sensitive to mizoribine in cell culture. These observations illustrate the evolutionary challenge posed by the gauntlet of chemical warfare at the microbial level.	Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Brandeis Univ, Grad Program Biophys & Struct Biol, Waltham, MA 02454 USA; Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA	Brandeis University; Brandeis University; University of Wurzburg; University of California System; University of California San Francisco	Hedstrom, L (corresponding author), Brandeis Univ, Dept Biochem, MS 009,415 South St, Waltham, MA 02454 USA.	hedstrom@brandeis.edu	Koehler, Gerwald/L-3624-2019	Koehler, Gerwald/0000-0002-0087-8206	NIAID NIH HHS [R01 AI33317] Funding Source: Medline; NIGMS NIH HHS [GM54403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033317] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beckerman J, 2001, INFECT IMMUN, V69, P108, DOI 10.1128/IAI.69.1.108-114.2001; Boysen M, 1996, MICROBIOL-SGM, V142, P541, DOI 10.1099/13500872-142-3-541; CARR SF, 1993, J BIOL CHEM, V268, P27286; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; Digits JA, 2000, BIOCHEMISTRY-US, V39, P1771, DOI 10.1021/bi992288e; Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192; Farazi T, 1997, J BIOL CHEM, V272, P961, DOI 10.1074/jbc.272.2.961; FASOLI MOF, 1990, J GEN MICROBIOL, V136, P1475, DOI 10.1099/00221287-136-8-1475; FONZI WA, 1993, GENETICS, V134, P717; Gan L, 2003, BIOCHEMISTRY-US, V42, P857, DOI 10.1021/bi0271401; Geisen R, 2001, INT J FOOD MICROBIOL, V65, P183, DOI 10.1016/S0168-1605(00)00514-6; GILLUM AM, 1984, MOL GEN GENET, V198, P179, DOI 10.1007/BF00328721; Goodwin TJD, 2000, GENOME RES, V10, P174, DOI 10.1101/gr.10.2.174; GOSHORN AK, 1989, GENETICS, V123, P667; HAGER PW, 1995, BIOCHEM PHARMACOL, V49, P1323, DOI 10.1016/0006-2952(95)00026-V; Hedstrom L, 1999, CURR MED CHEM, V6, P545; Hyle JW, 2003, J BIOL CHEM, V278, P28470, DOI 10.1074/jbc.M303736200; Ishikawa H, 1999, CURR MED CHEM, V6, P575; Jarvis SM, 1998, BRIT J PHARMACOL, V123, P1587, DOI 10.1038/sj.bjp.0701775; Kohler GA, 1997, J BACTERIOL, V179, P2331; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Link JO, 1996, J AM CHEM SOC, V118, P2091, DOI 10.1021/ja9534056; McLoughlin SY, 2004, CHEM BIOL, V11, P735, DOI 10.1016/j.chembiol.2004.03.031; McPhillips CC, 2004, P NATL ACAD SCI USA, V101, P12171, DOI 10.1073/pnas.0403341101; MIZUNO K, 1974, J ANTIBIOT, V27, P775, DOI 10.7164/antibiotics.27.775; Morschhauser J, 1999, MOL MICROBIOL, V32, P547, DOI 10.1046/j.1365-2958.1999.01393.x; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P74; Odds FC, 2000, TRENDS MICROBIOL, V8, P200, DOI 10.1016/S0966-842X(00)01752-2; QUINN CM, 1990, MYCOPATHOLOGIA, V111, P165, DOI 10.1007/BF02282799; Rundberget T, 2002, J CHROMATOGR A, V964, P189, DOI 10.1016/S0021-9673(02)00698-2; Sanglard D, 2002, ENFERM INFEC MICR CL, V20, P462, DOI 10.1016/S0213-005X(02)72842-5; Schlippe YVG, 2004, BIOCHEMISTRY-US, V43, P4511, DOI 10.1021/bi035823q; Schneweis I, 2000, APPL ENVIRON MICROB, V66, P3639, DOI 10.1128/AEM.66.8.3639-3641.2000; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; Slugoski MD, 2004, YEAST, V21, P1269, DOI 10.1002/yea.1178; Staib P, 2000, GENE, V242, P393, DOI 10.1016/S0378-1119(99)00512-0; Staib P, 1999, MOL MICROBIOL, V32, P533, DOI 10.1046/j.1365-2958.1999.01367.x; Theiss S, 2002, MYCOSES, V45, P345, DOI 10.1046/j.1439-0507.2002.00792.x; Wang W, 1997, BIOCHEMISTRY-US, V36, P8479, DOI 10.1021/bi970226n; White TC, 1998, CLIN MICROBIOL REV, V11, P382, DOI 10.1128/CMR.11.2.382; Wirsching S, 2000, MOL MICROBIOL, V36, P856, DOI 10.1046/j.1365-2958.2000.01899.x; Wu John C., 1994, Perspectives in Drug Discovery and Design, V2, P185, DOI 10.1007/BF02171743	42	45	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11295	11302		10.1074/jbc.M409847200	http://dx.doi.org/10.1074/jbc.M409847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15665003	hybrid			2022-12-25	WOS:000227761800050
J	Pao, CS; Benovic, JL				Pao, CS; Benovic, JL			Structure/function analysis of alpha(2A)-adrenergic receptor interaction with G protein-coupled receptor kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; G-BETA-GAMMA; ALPHA(2)-ADRENERGIC RECEPTORS; ALPHA-2-ADRENERGIC RECEPTOR; RHODOPSIN KINASE; ACTIVATION; PHOSPHORYLATION; DESENSITIZATION; ARRESTINS; SPECIFICITY	G protein-coupled receptors (GPCRs) mediate the ability of a diverse array of extracellular stimuli to control intracellular signaling. Many GPCRs are phosphorylated by G protein-coupled receptor kinases (GRKs), a process that mediates agonist-specific desensitization in many cells. Although GRK binding to activated GPCRs results in kinase activation and receptor phosphorylation, relatively little is known about the mechanism of GRK/GPCR interaction or how this interaction results in kinase activation. Here, we used the alpha(2A)-adrenergic receptor (alpha(2A)AR) as a model to study GRK/receptor interaction because GRK2 phosphorylation of four adjacent serines within the large third intracellular loop of this receptor is known to mediate desensitization. Various domains of the alpha(2A)AR were expressed as glutathione S-transferase fusion proteins and tested for the ability to bind purified GRK2. The second and third intracellular loops of the alpha(2A)AR directly interacted with GRK2, whereas the first intracellular loop and C-terminal domain did not. Truncation mutagenesis identified three discrete regions within the third loop that contributed to GRK2 binding, the membrane proximal N- and C-terminal regions as well as a central region adjacent to the phosphorylation sites. Site-directed mutagenesis revealed a critical role for specific basic residues within these regions in mediating GRK2 interaction with the alpha(2A)AR. Mutation of these residues within the holo-alpha(2A)AR diminished GRK2-promoted phosphorylation of the receptor as well as the ability of the kinase to be activated by receptor binding. These studies provide new insight into the mechanism of interaction and activation of GRK2 by GPCRs and suggest that GRK2 binding is critical not only for receptor phosphorylation but also for full activity of the kinase.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.	benovic@mail.jci.tju.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHEN CY, 1993, J BIOL CHEM, V268, P7825; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gan XQ, 2004, J BIOL CHEM, V279, P49741, DOI 10.1074/jbc.M407570200; HAGA K, 1994, J BIOL CHEM, V269, P12594; Jala VR, 2005, J BIOL CHEM, V280, P4880, DOI 10.1074/jbc.M409821200; Jinsi A, 1996, EUR J PHARMACOL, V302, P183, DOI 10.1016/0014-2999(96)00049-0; KIM CM, 1993, RECEPTOR, V3, P39; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PAO CS, 2002, SCI STKE; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; WADE SM, 1994, MOL PHARMACOL, V45, P1191; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026	47	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11052	11058		10.1074/jbc.M412996200	http://dx.doi.org/10.1074/jbc.M412996200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653687	hybrid			2022-12-25	WOS:000227761800022
J	Li, ZY; Kitchen, JL; Boeneman, K; Anand, P; Crooke, E				Li, ZY; Kitchen, JL; Boeneman, K; Anand, P; Crooke, E			Restoration of growth to acidic phospholipid-deficient cells by DnaA(L366K) is independent of its capacity for nucleotide binding and exchange and requires DnaA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI CHROMOSOMAL ORIGIN; IN-VITRO REPLICATION; ESCHERICHIA-COLI; INITIATOR PROTEIN; COMPLEX; DOMAIN; CYCLE; OLIGOMERIZATION; HDA	In the absence of adequate levels of cellular acidic phospholipids, Escherichia coli remain viable but are arrested for growth. Expression of a DnaA protein that contains a single amino acid substitution in the membrane-binding domain, DnaA(L366K), in concert with expression of wild-type DnaA protein, restores growth. DnaA protein has high affinity for ATP and ADP, and in vitro lipid bilayers that are fluid and contain acidic phospholipids reactivate inert ADP-DnaA by promoting an exchange of ATP for ADP. Here, nucleotide and lipid interactions and replication activity of purified DnaA(L366K) were examined to gain insight into the mechanism of how it restores growth to cells lacking acidic phospholipids. DnaA(L366K) behaved like wildtype DnaA with respect to nucleotide binding affinities and hydrolysis properties, specificity of acidic phospholipids for nucleotide release, and origin binding. Yet, DnaA(L366K) was feeble at initiating replication from oriC unless augmented with a limiting quantity of wildtype DnaA, reflecting the in vivo requirement that both wild-type and a mutant form of DnaA must be expressed and act together to restore growth to acidic phospholipid deficient cells.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Program Tumor Biol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Crooke, E (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	crooke@georgetown.edu	Gemmill, Kelly/G-2167-2012		NCI NIH HHS [T32CA009686] Funding Source: Medline; NIGMS NIH HHS [R01GM49700, R01 GM049700] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049700] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; Blaesing F, 2000, MOL MICROBIOL, V36, P557, DOI 10.1046/j.1365-2958.2000.01881.x; Camara JE, 2003, J BACTERIOL, V185, P3244, DOI 10.1128/JB.185.10.3244-3248.2003; Carr KM, 2001, J BIOL CHEM, V276, P44919, DOI 10.1074/jbc.M107463200; CASSLER MR, 1995, EMBO J, V14, P5833, DOI 10.1002/j.1460-2075.1995.tb00271.x; Cassler MR, 1999, NUCLEIC ACIDS RES, V27, P4570, DOI 10.1093/nar/27.23.4570; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; Crooke E, 1995, METHOD ENZYMOL, V262, P500; CROOKE E, 1992, J BIOL CHEM, V267, P16779; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Hase M, 1998, J BIOL CHEM, V273, P28651, DOI 10.1074/jbc.273.44.28651; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; HWANG DS, 1990, J BIOL CHEM, V265, P19244; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Ichihashi N, 2003, J BIOL CHEM, V278, P28778, DOI 10.1074/jbc.M212202200; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Kato J, 2001, EMBO J, V20, P4253, DOI 10.1093/emboj/20.15.4253; Kim PD, 2003, J BACTERIOL, V185, P1817, DOI 10.1128/JB.185.6.1817-1824.2003; Kitchen JL, 1999, BIOCHEMISTRY-US, V38, P6213, DOI 10.1021/bi982733q; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; Li ZY, 1999, PROTEIN EXPRES PURIF, V17, P41, DOI 10.1006/prep.1999.1094; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; Ryan VT, 2004, MOL MICROBIOL, V51, P1347, DOI 10.1046/j.1365-2958.2003.03906.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Simmons LA, 2003, MOL MICROBIOL, V49, P849, DOI 10.1046/j.1365-2958.2003.03603.x; SLATER S, 1993, J BACTERIOL, V175, P4260, DOI 10.1128/JB.175.13.4260-4262.1993; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; Weigel C, 1999, MOL MICROBIOL, V34, P53, DOI 10.1046/j.1365-2958.1999.01568.x; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; YUNG BYM, 1989, J BIOL CHEM, V264, P6146; Zheng WD, 2001, EMBO J, V20, P1164, DOI 10.1093/emboj/20.5.1164	41	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9796	9801		10.1074/jbc.M413923200	http://dx.doi.org/10.1074/jbc.M413923200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642730	hybrid			2022-12-25	WOS:000227559600008
J	Oesterreicher, S; Blum, WF; Schmidt, B; Braulke, T; Kubler, B				Oesterreicher, S; Blum, WF; Schmidt, B; Braulke, T; Kubler, B			Interaction of insulin-like growth factor II (IGF-II) with multiple plasma proteins - High affinity binding of plasminogen to IGF-II and IGF-binding protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYSIS; PREGNANCY; RECEPTOR; IGFBP-3; SERUM; IDENTIFICATION; TRANSFERRIN; INHIBITOR; FRAGMENTS; COMPLEX	In the circulation, most of the insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases are bound in high molecular mass complexes of >= 150 kDa. To investigate molecular interactions between proteins involved in IGF(.)IGFBP complexes, Cohn fraction IV of human plasma was subjected to IGF-II affinity chromatography followed by reversed-phase high pressure liquid chromatography and analysis of bound proteins. Mass spectrometry and Western blotting revealed the presence of IGFBP-3, IGFBP-5, transferrin, plasminogen, prekallikrein, antithrombin III, and the soluble IGF-II/mannose 6-phosphate receptor in the eluate. Furthermore, an IGFBP-3 protease cleaving also IGFBP-2 but not IGFBP-4 was co-purified from the IGF-II column. Inhibitor studies and IGFBP-3 zymography have demonstrated that the 92-kDa IGFBP-3 protease belongs to the class of serine-dependent proteases. IGF-II ligand blotting and surface plasmon resonance spectrometry have been used to identify plasminogen as a novel high affinity IGF-II-binding protein capable of binding to IGFBP-3 with 50-fold higher affinity than transferrin. In combination with transferrin, the overall binding constant of plasminogen/transferrin for IGF-II was reduced 7-fold. Size exclusion chromatography of the IGF-II matrix eluate revealed that transferrin, plasminogen, and the IGFBP-3 protease are present in different high molecular mass complexes of >= 440 kDa. The present data indicate that IGFs, low and high affinity IGFBPs, several IGFBP-associated proteins, and IGFBP proteases can interact, which may result in the formation of binary, ternary, and higher molecular weight complexes capable of modulating IGF binding properties and the stability of IGFBPs.	Univ Hamburg, Childrens Hosp, Dept Biochem, Hosp Eppendorf, D-20246 Hamburg, Germany; Eli Lilly & Co, D-61350 Bad Homburg, Germany; Univ Childrens Hosp, D-35392 Giessen, Germany; Univ Gottingen, Dept Biochem 2, D-37073 Gottingen, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Eli Lilly; Lilly Deutschland GmbH; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen	Braulke, T (corresponding author), Univ Hamburg, Childrens Hosp, Dept Biochem, Hosp Eppendorf, Martinistr 52, D-20246 Hamburg, Germany.	braulke@uke.uni-hamburg.de	Braulke, Thomas/AAV-9121-2020; Kuebler, Bernd/K-2823-2017	Braulke, Thomas/0000-0002-2336-8532; Kuebler, Bernd/0000-0002-4472-871X				BAXTER RC, 1989, J BIOL CHEM, V264, P11843; Baxter RC, 2002, J CLIN ENDOCR METAB, V87, P271, DOI 10.1210/jc.87.1.271; BLUM WF, 1990, J CLIN ENDOCR METAB, V70, P1292, DOI 10.1210/jcem-70-5-1292; Booth BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE465, DOI 10.1152/ajpendo.1996.271.3.E465; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Byun DW, 2001, J CLIN ENDOCR METAB, V86, P847, DOI 10.1210/jc.86.2.847; Campbell PG, 1999, J BIOL CHEM, V274, P30215, DOI 10.1074/jbc.274.42.30215; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; Campbell PG, 1998, AM J PHYSIOL-ENDOC M, V275, pE321, DOI 10.1152/ajpendo.1998.275.2.E321; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE996, DOI 10.1152/ajpendo.1997.273.5.E996; Collen D, 2001, Hematology Am Soc Hematol Educ Program, P1; Durham SK, 1999, HORM METAB RES, V31, P216, DOI 10.1055/s-2007-978722; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KIESS W, 1987, P NATL ACAD SCI USA, V84, P7720, DOI 10.1073/pnas.84.21.7720; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; Kricker JA, 2003, ENDOCRINOLOGY, V144, P2807, DOI 10.1210/en.2002-221086; Kubler B, 2002, FEBS LETT, V518, P124, DOI 10.1016/S0014-5793(02)02673-X; Kubler B, 1998, ENDOCRINOLOGY, V139, P1556, DOI 10.1210/en.139.4.1556; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Maile LA, 1999, GROWTH HORM IGF RES, V9, P85, DOI 10.1054/ghir.1999.0096; Maile LA, 1998, ENDOCRINOLOGY, V139, P4772, DOI 10.1210/en.139.12.4772; Maile LA, 2000, GROWTH HORM IGF RES, V10, P71, DOI 10.1054/ghir.2000.0142; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Nam TJ, 1997, ENDOCRINOLOGY, V138, P2972, DOI 10.1210/en.138.7.2972; PARKER KC, 1983, BIOCHEMISTRY-US, V22, P1145, DOI 10.1021/bi00274a024; Renne T, 2002, J BIOL CHEM, V277, P4892, DOI 10.1074/jbc.M105221200; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; Standker L, 2000, BIOCHEMISTRY-US, V39, P5082, DOI 10.1021/bi992513s; Storch S, 2001, FEBS LETT, V509, P395, DOI 10.1016/S0014-5793(01)03204-5; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; Upton Z, 1999, ENDOCRINOLOGY, V140, P2928, DOI 10.1210/en.140.6.2928; Weinzimer SA, 2001, J CLIN ENDOCR METAB, V86, P1806, DOI 10.1210/jc.86.4.1806; Xu Y, 1998, J CLIN ENDOCR METAB, V83, P437, DOI 10.1210/jc.83.2.437; ZAPF J, 1981, J CLIN INVEST, V68, P1321, DOI 10.1172/JCI110379; Zwad O, 2002, FEBS LETT, V510, P211, DOI 10.1016/S0014-5793(01)03267-7	40	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9994	10000		10.1074/jbc.M411754200	http://dx.doi.org/10.1074/jbc.M411754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642732	hybrid			2022-12-25	WOS:000227559600032
J	Dirmeier, U; Hoffmann, R; Kilger, E; Schultheiss, U; Briseno, C; Gires, O; Kieser, A; Eick, D; Sugden, B; Hammerschmidt, W				Dirmeier, U; Hoffmann, R; Kilger, E; Schultheiss, U; Briseno, C; Gires, O; Kieser, A; Eick, D; Sugden, B; Hammerschmidt, W			Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis	ONCOGENE			English	Article						Epstein-Barr virus; B cell proliferation; latent membrane protein; target genes; c-myc; p53	MEMBRANE-PROTEIN 1; NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; DOMAIN PROTEIN; CELL-LINE; LMP1; PATHWAY	Latent membrane protein 1 (LMP1), an oncoprotein encoded by Epstein-Barr virus (EBV), is an integral membrane protein, which acts like a constitutively active receptor. LMP1 is critical for some facet of EBV's induction and maintenance of proliferation of infected B cells. It, in part, mimics signaling by the CD40 receptor and has been implicated in regulating proliferation, survival, or both properties of EBV-infected cells. We established a conditional LMP1 allele in the context of the intact EBV genome to de. ne the immediate-early cellular target genes regulated by LMP1 in order to assess its contributions to infected human B cells. The functional analysis of this conditional system indicated that LMP1 specifically induces mitogenic B-cell activation through c-myc and Jun/AP1 family members and confirms its direct role in upregulating expression of multiple genes with opposing activities involved in cell survival. LMP1's signals were found to be essential for the G(1)/S transition in human B cells; cells lacking LMP1's signals are cell cycle arrested and survive quiescently. LMP1's activities are therefore not required to maintain survival in nonproliferating cells. LMP1 does induce both pro- and antiapoptotic genes whose balance seems to permit survival during LMP1's induction and maintenance of proliferation.	GSF Munich, Natl Res Ctr Environm & Hlth, Dept Gene Vectors, D-81377 Munich, Germany; Max Von Pettenkofer Inst, Dept Bacteriol, D-80336 Munich, Germany; Univ Munich, Dept Otorhinolaryngol, D-81377 Munich, Germany; Inst Clin Mol Biol & Tumour Genet, D-81377 Munich, Germany; Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; University of Munich; University of Wisconsin System; University of Wisconsin Madison	Hammerschmidt, W (corresponding author), GSF Munich, Natl Res Ctr Environm & Hlth, Dept Gene Vectors, Marchioninstr 25, D-81377 Munich, Germany.	hammerschmidt@gsf.de	Kieser, Arnd/M-4616-2014; Hoffmann, Reinhard/I-8748-2018; Hammerschmidt, Wolfgang/ABG-3921-2021; Gires, Olivier/V-2689-2017	Kieser, Arnd/0000-0003-0783-1950; Hoffmann, Reinhard/0000-0003-1514-1183; Hammerschmidt, Wolfgang/0000-0002-4659-0427; Gires, Olivier/0000-0002-2292-7064	NCI NIH HHS [CA22443, CA70723, P30CA14529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; [Anonymous], 1997, EPSTEIN BARR VIRUS K; Ardila-Osorio H, 1999, INT J CANCER, V81, P645, DOI 10.1002/(SICI)1097-0215(19990517)81:4<645::AID-IJC22>3.0.CO;2-0; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Brennan P, 2001, J BIOL CHEM, V276, P1195, DOI 10.1074/jbc.M005461200; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen HL, 2003, J VIROL, V77, P4139, DOI 10.1128/JVI.77.7.4139-4148.2003; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Dadgostar H, 2002, P NATL ACAD SCI USA, V99, P1497, DOI 10.1073/pnas.032665099; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Dirmeier U, 2003, CANCER RES, V63, P2982; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Hammerschmidt W, 2004, TRENDS MOL MED, V10, P331, DOI 10.1016/j.molmed.2004.05.006; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi M, 2002, J VIROL, V76, P455, DOI 10.1128/JVI.76.1.455-459.2002; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2002, J VIROL, V76, P11551, DOI 10.1128/JVI.76.22.11551-11560.2002; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lam N, 2003, CELL SIGNAL, V15, P9, DOI 10.1016/S0898-6568(02)00083-9; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; QU LR, 1992, J VIROL, V66, P3715, DOI 10.1128/JVI.66.6.3715-3724.1992; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Wan J, 2004, MOL CELL BIOL, V24, P192, DOI 10.1128/MCB.24.1.192-199.2004; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Yasui T, 2004, P NATL ACAD SCI USA, V101, P278, DOI 10.1073/pnas.2237224100; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Zhao RB, 2000, GENE DEV, V14, P981	52	111	117	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1711	1717		10.1038/sj.onc.1208367	http://dx.doi.org/10.1038/sj.onc.1208367			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674340				2022-12-25	WOS:000227345100007
J	Lechpammer, M; Xu, XJ; Ellis, FH; Bhattacharaya, N; Shapiro, GI; Loda, M				Lechpammer, M; Xu, XJ; Ellis, FH; Bhattacharaya, N; Shapiro, GI; Loda, M			Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice	ONCOGENE			English	Article						Barrett's esophagus; Barrett's associated adenocarcinoma; p27; flavopiridol; mouse model	DEPENDENT KINASE INHIBITOR; BARRETTS-ESOPHAGUS; CYCLIN D1; ADENOCARCINOMA; CANCER; APOPTOSIS; CELLS; TRIAL; CHEMOPREVENTION; NEOPLASMS	The cyclin-dependent kinase (cdk) inhibitor p27 preferentially inactivates cdk complexes required for progression through the G1/S transition. Loss of p27 is associated with aggressive behavior in a variety of tumors, including Barrett's associated adenocarcinoma (BAA). We have previously shown that gastroduodenal-esophageal reflux (GDER) together with N-methyl-N-benzylnitrosamine (MBN) induces Barrett's esophagus (BE) and malignant transformation of the esophageal mucosa in mice. This process is enhanced in a p27 null background. Here, we show that chronic flavopiridol administration sharply reduced the prevalence of BE in GDER/MBN-treated p27 knockout mice when compared to animals treated with diluent only (7 vs 26%, P = 0.0079). Similarly, flavopiridol reduced the prevalence of BAA (11 vs 32%, P = 0.0098) and overall cancer prevalence (15 vs 60%, P < 0.0001). In addition, appropriate molecular targeting by flavopiridol in tumor cells was confirmed by downregulation of cyclin D1, a known target of this pan-cdk inhibitor. The results of this study represent the experimental basis for chemoprevention with cdk inhibitors in human BE and BAA.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiothorac Surg, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Loda, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, D740 44 Binney St, Boston, MA 02115 USA.	massimo_loda@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [P20CA090578, P50CA090381, R01CA090687, P01CA089021] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90381, P01 CA89021, R01 CA90687, P20 CA90578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson M, 2003, BIOORG MED CHEM LETT, V13, P3021, DOI 10.1016/S0960-894X(03)00638-3; Arguello F, 1998, BLOOD, V91, P2482; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Bytzer P, 1999, AM J GASTROENTEROL, V94, P86; Carlson B, 1999, CANCER RES, V59, P4634; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Ellis F H Jr, 1997, Dis Esophagus, V10, P165; Ellis FH, 2001, J THORAC CARDIOV SUR, V122, P809, DOI 10.1067/mtc.2001.116471; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Heath EI, 2003, DIS ESOPHAGUS, V16, P177, DOI 10.1046/j.1442-2050.2003.00325.x; Jenkins GJS, 2002, BRIT J SURG, V89, P824, DOI 10.1046/j.1365-2168.2002.02107.x; Lam LT, 2001, GENOME BIOL, V2; MCCORMICK J, 2003, P AN M AM SOC CLIN, V22, pA835; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Phillips RW, 2003, AM J SURG PATHOL, V27, P1442, DOI 10.1097/00000478-200311000-00006; PIERGA JY, 2003, P AN M AM SOC CLIN, V22, pA840; Schrump DS, 1998, CLIN CANCER RES, V4, P2885; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Singh SP, 1998, CANCER RES, V58, P1730; Tan AR, 2002, J CLIN ONCOL, V20, P4074, DOI 10.1200/JCO.2002.01.043; Xu XJ, 2000, J SURG RES, V88, P120, DOI 10.1006/jsre.1999.5774; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	26	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1683	1688		10.1038/sj.onc.1208375	http://dx.doi.org/10.1038/sj.onc.1208375			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674336				2022-12-25	WOS:000227345100004
J	Duan, WM; Gabril, MY; Moussa, M; Chan, FL; Sakai, H; Fong, GH; Xuan, JW				Duan, WM; Gabril, MY; Moussa, M; Chan, FL; Sakai, H; Fong, GH; Xuan, JW			Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model	ONCOGENE			English	Article						prostate cancer; SV40 Tag oncogene; mouse cancer modeling; knockin mouse; tumorigenesis and progression; PSP94( beta microseminoprotein)	TISSUE-SPECIFIC EXPRESSION; ETS TRANSCRIPTION FACTOR; BETA-MICROSEMINOPROTEIN; GENE-EXPRESSION; SECRETORY PROTEIN; ORGAN SYSTEMS; ANTIGEN GENE; TUMOR-GROWTH; CANCER; MICE	Prostate cancer (CaP) is the most common cancer in adult men in North America. Since there is no naturally occurring prostate cancer in the mouse, preclinical studies stipulate for the establishment of a genetically manipulated mouse CaP model with features close to the human situation. In view of the limitations of transgenic technique-derived CaP models, herein we report the first application of knockin technology to establish a new mouse adenocarcinoma prostate model (PSP-KIMAP) by targeting of SV40 Tag to a prostate tissue-specific gene, PSP94 (prostate secretory protein of 94 amino acids). In order to demonstrate its novelty, we compared KIMAP to a PSP94 gene-directed transgenic mouse adenocarcinoma of the prostate (PSP-TGMAP) model. The CaP development of the PSP-KIMAP mice started almost immediately after puberty at 10 weeks of age from mouse prostatic intraepithelial neoplasia (mPIN) with micro-invasion to well-differentiated CaP, and demonstrated a close-to-human kinetics of prolonged tumor growth and a predominance of well and moderately differentiated tumors. The invasive nature of KIMAP model was demonstrated by multitissue metastases (lymph node, lung and liver etc) and also by immunohistochemical study of multiple invasive prostate tumor markers. PSP-KIMAP model is responsive to androgen deprivation (castration). The knockin technology in our KIMAP model demonstrates highly predictive CaP development procedures and many advantageous features, which the traditional transgenic technique-derived CaP models could not reach for both basic and clinical studies. These features include the high stability of both phenotype and genotype, highly synchronous prostate cancer development, high and precise prostate tissue targeting and with no founder line variation. The differences between the two CaP models were attributed to the introduction of a single endogenous knockin mutation, resulting in a CaP model self-regulated and controlled by a prostate gene promoter/enhancer of PSP94.	Univ Western Ontario, Dept Surg, London, ON, Canada; Univ Western Ontario, Dept Pathol, London, ON, Canada; Chinese Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Nagasaki Univ, Sch Med, Dept Urol, Nagasaki 852, Japan; Univ Connecticut, Dept Physiol, Farmington, CT USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Chinese University of Hong Kong; Nagasaki University; University of Connecticut	Xuan, JW (corresponding author), London Hlth Sci Ctr, Urol Res Lab, 375 S St, London, ON N6A 4G5, Canada.	jim.xuan@lhsc.on.ca	Chan, Franky L./M-1043-2018	Chan, Franky L./0000-0003-0567-2052				Abate-Shen Cory, 2002, Trends Genet, V18, pS1, DOI 10.1016/S0168-9525(02)02683-5; ABRAHAMSSON PA, 1988, PROSTATE, V12, P39, DOI 10.1002/pros.2990120106; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; Deshmukh N, 1998, PATHOLOGY PROSTATE; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; DUBE JY, 1987, J ANDROL, V8, P182; Fernlund P, 1996, ARCH BIOCHEM BIOPHYS, V334, P73, DOI 10.1006/abbi.1996.0431; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gabril MY, 2002, GENE THER, V9, P1589, DOI 10.1038/sj.gt.3301895; GARABEDIAN EM, 1998, P NATL ACAD SCI USA, V62, P227; Gingrich JR, 1996, CANCER RES, V56, P4096; Green JE, 1998, PROSTATE, V36, P59, DOI 10.1002/(SICI)1097-0045(19980615)36:1<59::AID-PROS11>3.0.CO;2-H; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; HARA M, 1989, J LAB CLIN MED, V113, P541; Huss WJ, 2001, SEMIN CANCER BIOL, V11, P245, DOI 10.1006/scbi.2001.0373; HYAKUTAKE H, 1993, PROSTATE, V22, P347, DOI 10.1002/pros.2990220409; Imasato Y, 2000, J UROLOGY, V164, P1819, DOI 10.1016/S0022-5347(05)67113-3; Imasato Y, 2001, ENDOCRINOLOGY, V142, P2138, DOI 10.1210/en.142.5.2138; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kim MJ, 2002, CANCER RES, V62, P2999; Lazure C, 2001, PROTEIN SCI, V10, P2207, DOI 10.1110/ps.06501; LOKESHWAR BL, 1993, CANCER RES, V53, P4855; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Masumori N, 2001, CANCER RES, V61, P2239; Matsubara S, 2001, CANCER RES, V61, P6012; Matusik RJ, 2001, CONT ENDOCRINOL, P401; Miyamoto N, 1997, DEVELOPMENT, V124, P1653; Mostofi FK, 2002, HISTOLOGICAL TYPING; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; PerezStable C, 1997, CANCER RES, V57, P900; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Shibata MA, 1996, CANCER RES, V56, P4894; Shukeir N, 2003, CANCER RES, V63, P2072; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P7843, DOI 10.1073/pnas.86.20.7843; Stege R, 2000, CLIN CANCER RES, V6, P160; THOMPSON TC, 1996, UROL ONCOL, V2, P99; Watabe T, 2002, P NATL ACAD SCI USA, V99, P401, DOI 10.1073/pnas.012574899; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; Xuan JW, 1999, DNA CELL BIOL, V18, P11, DOI 10.1089/104454999315583	43	30	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1510	1524		10.1038/sj.onc.1208229	http://dx.doi.org/10.1038/sj.onc.1208229			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674347				2022-12-25	WOS:000227218200004
J	Yurchenko, V; Pushkarsky, T; Li, JH; Dai, WW; Sherry, B; Bukrinsky, M				Yurchenko, V; Pushkarsky, T; Li, JH; Dai, WW; Sherry, B; Bukrinsky, M			Regulation of CD147 cell surface expression - Involvement of the proline residue in the CD147 transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPHILIN HOMOLOG NINAA; CYCLOSPORINE-A; RECEPTOR; PREDICTION; CHAPERONE; TOPOLOGY; PROTEINS; ENCODES	CD147, also known as extracellular matrix metalloproteinase inducer, is a regulator of matrix metalloproteinase production and serves as a signaling receptor for extracellular cyclophilins. Here we demonstrate that the cell surface expression of CD147 is regulated by cyclophilins via the transmembrane domain of CD147. Solution binding experiments demonstrated that the transmembrane domain was both necessary and sufficient for CD147 binding to cyclophilin A ( CypA). Treatment with cyclosporin A significantly reduced surface expression of CD147 and of CD8-CD147 fusion protein carrying the extracellular domain of CD8 fused to the transmembrane and cytoplasmic domains of CD147, but did not affect expression of CD8. Peptide binding studies demonstrated specific interaction between CypA and the proline-containing peptide from the CD147 transmembrane domain. Mutation of this proline residue reduced binding of CD147-derived peptides to CypA and also diminished transport of CD147 to the plasma membrane without reducing the total level of CD147 expression. These results suggest involvement of a cyclophilin-related protein in CD147 cell surface expression and provide molecular details for regulation of CD147 trafficking by cyclophilins.	George Washington Univ, Med Ctr, Washington, DC 20037 USA; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA; N Shore Long Isl Jewish Res Inst, Manhasset, NY 11030 USA	George Washington University; Yeshiva University; Albert Einstein College of Medicine; Northwell Health	Bukrinsky, M (corresponding author), George Washington Univ, Med Ctr, Ross Hall,Rm 734,2300 Eye St NW, Washington, DC 20037 USA.	mtmmib@gwumc.edu	Sherry, Barbara/GSD-7179-2022; Yurchenko, Vyacheslav/E-4532-2013	Sherry, Barbara/0000-0003-3119-1463; Yurchenko, Vyacheslav/0000-0003-4765-3263	NIAID NIH HHS [R01 AI29110, R01 AI38245] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029110, R01AI038245] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ansari H, 2002, MOL CELL BIOL, V22, P6993, DOI 10.1128/MCB.22.20.6993-7003.2002; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bernhagen J, 1998, J MOL MED-JMM, V76, P151, DOI 10.1007/s001090050204; BISWAS C, 1995, CANCER RES, V55, P434; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Brown CR, 2001, J BIOL CHEM, V276, P48017, DOI 10.1074/jbc.M109222200; Bukrinsky MI, 2002, TRENDS IMMUNOL, V23, P323, DOI 10.1016/S1471-4906(02)02237-8; Chklovskaia E, 2001, BLOOD, V97, P1027, DOI 10.1182/blood.V97.4.1027; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Colgan J, 2004, IMMUNITY, V21, P189, DOI 10.1016/j.immuni.2004.07.005; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; ELLIS SM, 1989, CANCER RES, V49, P3385; FERREIRA PA, 1995, J BIOL CHEM, V270, P23179, DOI 10.1074/jbc.270.39.23179; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Huang TM, 2002, J BIOL CHEM, V277, P37798, DOI 10.1074/jbc.M204786200; Ikeda Masami, 2002, In Silico Biology, V2, P19; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; Kasinrerk W, 1999, IMMUNOLOGY, V96, P184; Klein CA, 2002, NAT BIOTECHNOL, V20, P387, DOI 10.1038/nbt0402-387; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; ONDEK B, 1992, J BIOL CHEM, V267, P16460; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; Sherry B, 1998, P NATL ACAD SCI USA, V95, P1758, DOI 10.1073/pnas.95.4.1758; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; Shiraishi S, 2000, NEUROSCI LETT, V293, P211, DOI 10.1016/S0304-3940(00)01513-5; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; Yurchenko V, 2002, J BIOL CHEM, V277, P22959, DOI 10.1074/jbc.M201593200; Yurchenko V, 2001, BIOCHEM BIOPH RES CO, V288, P786, DOI 10.1006/bbrc.2001.5847; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	33	56	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17013	17019		10.1074/jbc.M412851200	http://dx.doi.org/10.1074/jbc.M412851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15671024	hybrid			2022-12-25	WOS:000228615500058
J	Zhai, DY; Luciano, F; Zhu, XW; Guo, B; Satterthwait, AC; Reed, JC				Zhai, DY; Luciano, F; Zhu, XW; Guo, B; Satterthwait, AC; Reed, JC			Humanin binds and nullifies bid activity by blocking its activation of Bax and Bak	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBER; CELL-DEATH; MOLECULAR TRANSPORTERS; MITOCHONDRIAL PROTEIN; OLIGOMERIZES BAK; A-BETA; APOPTOSIS; SURVIVAL; CLEAVAGE	Recently, we discovered that Humanin (HN), a small endogenous peptide of 24 amino acids, binds to and inhibits the proapoptotic protein Bax. We show here that HN also interacts with the BH3-only Bcl-2/Bax family protein, Bid, as well as a truncated form of Bid (tBid) associated with protease-mediated activation of this proapoptotic protein. Synthetic HN peptide binds purified Bid and tBid in vitro and blocks tBid-induced release of cytochrome c and SMAC from isolated mitochondria, whereas mutant peptides that fail to bind Bid or tBid lack this activity. Moreover, HN peptide also retained protective activity on bax-/- mitochondria, indicating that HN can block tBid-induced release of apoptogenic proteins from these organelles in a Bax-independent manner. HN peptide inhibits tBid-induced oligomerization of Bax and Bak in mitochondrial membranes, as shown by experiments with chemical crosslinkers or gel filtration. Gene transfection experiments showed that HN ( but not an inactive mutant of HN) also protects intact cells from apoptosis induced by overexpression of tBid. We conclude that Bid represents an additional cellular target of HN, and we propose that HN-mediated suppression of Bid contributes to the antiapoptotic activity of this endogenous peptide.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org	luciano, frederic/P-6264-2016	luciano, frederic/0000-0001-9253-4998	NIGMS NIH HHS [GM60554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Hashimoto Y, 2001, BIOCHEM BIOPH RES CO, V283, P460, DOI 10.1006/bbrc.2001.4765; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Jan YW, 2004, CELL, V116, P751, DOI 10.1016/S0092-8674(04)00204-1; Jung SS, 2003, J NEUROCHEM, V84, P266, DOI 10.1046/j.1471-4159.2003.01524.x; Kariya S, 2003, MOL CELL BIOCHEM, V254, P83, DOI 10.1023/A:1027372519726; Kariya S, 2002, NEUROREPORT, V13, P903, DOI 10.1097/00001756-200205070-00034; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krajewska M, 2002, CELL DEATH DIFFER, V9, P145, DOI 10.1038/sj/cdd/4400934; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luciano F, 2005, J BIOL CHEM, V280, P15825, DOI 10.1074/jbc.M413062200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Niikura T, 2002, J NEUROSCI RES, V70, P380, DOI 10.1002/jnr.10354; Plesnila N, 2002, EUR SURG RES, V34, P37, DOI 10.1159/000048885; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhai DY, 2003, BIOCHEM J, V376, P229, DOI 10.1042/BJ20030374; Zhai DY, 2001, EUR J BIOCHEM, V268, P48, DOI 10.1046/j.1432-1327.2001.01841.x; Zhai DY, 2000, FEBS LETT, V472, P293, DOI 10.1016/S0014-5793(00)01471-X; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	48	108	113	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15815	15824		10.1074/jbc.M411902200	http://dx.doi.org/10.1074/jbc.M411902200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15661737	hybrid			2022-12-25	WOS:000228444800045
J	Bonsager, BC; Nielsen, PK; Abou Hachem, M; Fukuda, K; Praetorius-Ibba, M; Svensson, B				Bonsager, BC; Nielsen, PK; Abou Hachem, M; Fukuda, K; Praetorius-Ibba, M; Svensson, B			Mutational analysis of target enzyme recognition of the beta-trefoil fold barley alpha-amylase/subtilisin inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; SITE-DIRECTED MUTAGENESIS; AMYLASE-SUBTILISIN INHIBITOR; PROTEIN INHIBITOR; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; BINDING-KINETICS; HOT-SPOTS; COMPLEX; EQUILIBRIUM	The barley alpha-amylase/subtilisin inhibitor ( BASI) inhibits alpha-amylase 2 (AMY2) with subnanomolar affinity. The contribution of selected side chains of BASI to this high affinity is discerned in this study, and binding to other targets is investigated. Seven BASI residues along the AMY2-BASI interface and four residues in the putative protease-binding loop on the opposite side of the inhibitor were mutated. A total of 15 variants were compared with the wild type by monitoring the alpha-amylase and protease inhibitory activities using Blue Starch and azoalbumin, respectively, and the kinetics of binding to target enzymes by surface plasmon resonance. Generally, the mutations had little effect on k(on), whereas the k(off) values were increased up to 67-fold. The effects on the inhibitory activity, however, were far more pronounced, and the K-i values of some mutants on the AMY2-binding side increased 2-3 orders of magnitude, whereas mutations on the other side of the inhibitor had virtually no effect. The mutants K140L, D150N, and E168T lost inhibitory activity, revealing the pivotal role of charge interactions for BASI activity on AMY2. A fully hydrated Ca2+ at the AMY2-BASI interface mediates contacts to the catalytic residues of AMY2. Mutations involving residues contacting the solvent ligands of this Ca2+ had weaker affinity for AMY2 and reduced sensitivity to the Ca2+ modulation of the affinity. These results suggest that the Ca2+ and its solvation sphere are integral components of the AMY2-BASI complex, thus illuminating a novel mode of inhibition and a novel role for calcium in relation to glycoside hydrolases.	Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark; Tech Univ Denmark, BioCtr DTU, Biochem & Nutr Grp, DK-2800 Kgs Lyngby, Denmark	Technical University of Denmark	Svensson, B (corresponding author), Carlsberg Lab, Dept Chem, Gamle Carlsberg Vej 10, DK-2500 Copenhagen, Denmark.	bis@biocentrum.dtu.dk	Abou Hachem, Maher/M-4772-2019	Abou Hachem, Maher/0000-0001-8250-1842; Svensson, Birte/0000-0002-2993-8196				ABE J, 1993, BIOCHEM J, V293, P151, DOI 10.1042/bj2930151; AJANDOUZ EH, 1992, BIOCHIM BIOPHYS ACTA, V1159, P193, DOI 10.1016/0167-4838(92)90025-9; Alam N, 2001, BIOCHEMISTRY-US, V40, P4229, DOI 10.1021/bi002537v; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bieth J., 1974, BAYER S, P463; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; Bonsager BC, 2003, PROTEIN EXPRES PURIF, V30, P185, DOI 10.1016/S1046-5928(03)00103-7; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; CHONG S, 1997, GENE, V192, P277; Coutinho PM, 1999, ROY SOC CH, P3; D'Ovidio R, 2004, BBA-PROTEINS PROTEOM, V1696, P237, DOI 10.1016/j.bbapap.2003.08.012; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Desmyter A, 2002, J BIOL CHEM, V277, P23645, DOI 10.1074/jbc.M202327200; Drake AW, 2004, ANAL BIOCHEM, V328, P35, DOI 10.1016/j.ab.2003.12.025; Fong CC, 2002, ANAL CHIM ACTA, V456, P201, DOI 10.1016/S0003-2670(02)00033-8; Franco OL, 2002, EUR J BIOCHEM, V269, P397, DOI 10.1046/j.0014-2956.2001.02656.x; Garcia-Olmedo F., 1987, OXFORD SURVEYS PLANT, P275; Gelinas AD, 2004, J MOL BIOL, V339, P447, DOI 10.1016/j.jmb.2004.03.074; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Janecek S, 1997, J MOL EVOL, V45, P322, DOI 10.1007/PL00006236; Kadziola A, 1998, J MOL BIOL, V278, P205, DOI 10.1006/jmbi.1998.1683; Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195; LEAH R, 1989, PLANT MOL BIOL, V12, P673, DOI 10.1007/BF00044158; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; MacGregor EA, 2001, BBA-PROTEIN STRUCT M, V1546, P1, DOI 10.1016/S0167-4838(00)00302-2; MIRKOV TE, 1995, GLYCOBIOLOGY, V5, P45, DOI 10.1093/glycob/5.1.45; Mori H, 2002, EUR J BIOCHEM, V269, P5377, DOI 10.1046/j.1432-1033.2002.03185.x; MUNDY J, 1983, CARLSBERG RES COMMUN, V48, P81, DOI 10.1007/BF02906171; MUNDY J, 1984, FEBS LETT, V167, P210, DOI 10.1016/0014-5793(84)80128-3; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; NEIBA L, 1996, ANAL BIOCHEM, V324, P155; Nielsen PK, 2004, BBA-PROTEINS PROTEOM, V1696, P157, DOI 10.1016/j.bbapap.2003.09.019; Nielsen PK, 2003, BIOCHEMISTRY-US, V42, P1478, DOI 10.1021/bi020508+; OHTSUBO KI, 1992, FEBS LETT, V309, P68, DOI 10.1016/0014-5793(92)80741-X; ONESTI S, 1991, J MOL BIOL, V217, P153, DOI 10.1016/0022-2836(91)90618-G; PAL GP, 1994, FEBS LETT, V341, P167, DOI 10.1016/0014-5793(94)80450-8; Payan F, 2004, J BIOL CHEM, V279, P36029, DOI 10.1074/jbc.M404225200; Pekkarinen AI, 2003, J AGR FOOD CHEM, V51, P1710, DOI 10.1021/jf026035v; Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3; Robert X, 2003, STRUCTURE, V11, P973, DOI 10.1016/S0969-2126(03)00151-5; Rodenburg KW, 2000, EUR J BIOCHEM, V267, P1019, DOI 10.1046/j.1432-1327.2000.01094.x; Santimone M, 2004, BBA-PROTEINS PROTEOM, V1696, P181, DOI 10.1016/j.bbapap.2003.11.001; Schuck P, 1996, ANAL BIOCHEM, V240, P262, DOI 10.1006/abio.1996.0356; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SIDENIUS U, 1995, FEBS LETT, V361, P250, DOI 10.1016/0014-5793(95)00187-E; Strobl S, 1998, STRUCTURE, V6, P911, DOI 10.1016/S0969-2126(98)00092-6; Svensson B, 2004, BBA-PROTEINS PROTEOM, V1696, P145, DOI 10.1016/j.bbapap.2003.07.004; SVENSSON B, 1985, CARLSBERG RES COMMUN, V50, P15, DOI 10.1007/BF02910534; TAKASE K, 1994, BIOCHEMISTRY-US, V33, P7925, DOI 10.1021/bi00191a020; Vallee F, 1998, STRUCTURE, V6, P649, DOI 10.1016/S0969-2126(98)00066-5; VOGL T, 1995, J MOL BIOL, V254, P481, DOI 10.1006/jmbi.1995.0632; WESELAKE RJ, 1985, J CEREAL SCI, V3, P249, DOI 10.1016/S0733-5210(85)80018-7; WHITAKER JR, 1989, P PROT CO PROD S PHO, P354; WIEGAND G, 1995, J MOL BIOL, V247, P99, DOI 10.1006/jmbi.1994.0125; WILCOX ER, 1984, BIOCHEMISTRY-US, V23, P1783, DOI 10.1021/bi00303a031; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007	57	15	16	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14855	14864		10.1074/jbc.M412222200	http://dx.doi.org/10.1074/jbc.M412222200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15657043	hybrid			2022-12-25	WOS:000228236800064
J	Ohashi, A; Zdzienicka, MZ; Chen, JJ; Couch, FJ				Ohashi, A; Zdzienicka, MZ; Chen, JJ; Couch, FJ			Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; BRCA2; PROTEIN; REPAIR; RAD51; GENE; CELLS; PATHWAY; INACTIVATION; BRCA2/FANCD1	The BRCA2 breast cancer tumor suppressor is involved in the repair of double strand breaks and broken replication forks by homologous recombination through its interaction with DNA repair protein Rad51. Cells defective in BRCA2.FANCD1 are extremely sensitive to mitomycin C (MMC) similarly to cells deficient in any of the Fanconi anemia (FA) complementation group proteins (FANC). These observations suggest that the FA pathway and the BRCA2 and Rad51 repair pathway may be linked, although a functional connection between these pathways in DNA damage signaling remains to be determined. Here, we systematically investigated the interaction between these pathways. We show that in response to DNA damage, BRCA2-dependent Rad51 nuclear focus formation was normal in the absence of FANCD2 and that FANCD2 nuclear focus formation and mono-ubiquitination appeared normal in BRCA2-deficient cells. We report that the absence of BRCA2 substantially reduced homologous recombination repair of DNA breaks, whereas the absence of FANCD2 had little effect. Furthermore, we established that depletion of BRCA2 or Rad51 had a greater effect on cell survival in response to MMC than depletion of FANCD2 and that depletion of BRCA2 in FANCD2 mutant cells further sensitized these cells to MMC. Our results suggest that FANCD2 mediates double strand DNA break repair independently of Rad51-associated homologous recombination.	Mayo Clin, Coll Med, Dept Oncol, Rochester, MN 55905 USA; Coll Med, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis Human & Clin, NL-2333 AL Leiden, Netherlands	Mayo Clinic; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Chen, JJ (corresponding author), Mayo Clin, Coll Med, Dept Oncol, 200 1st St SW, Rochester, MN 55905 USA.	Chen.Junjie@mayo.edu			NATIONAL CANCER INSTITUTE [P50CA102701, R01CA089239, P20CA102701, R01CA087898, R01CA092312] Funding Source: NIH RePORTER; NCI NIH HHS [CA102701, CA87898, P50 CA102701, CA89239, CA92312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Bruun D, 2003, DNA REPAIR, V2, P1007, DOI 10.1016/S1568-7864(03)00112-5; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; Digweed M, 2002, CARCINOGENESIS, V23, P1121, DOI 10.1093/carcin/23.7.1121; Folias A, 2002, HUM MOL GENET, V11, P2591, DOI 10.1093/hmg/11.21.2591; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Godthelp BC, 2002, ONCOGENE, V21, P5002, DOI 10.1038/sj.onc.1205656; Grompe M, 2001, HUM MOL GENET, V10, P2253, DOI 10.1093/hmg/10.20.2253; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hussain S, 2004, HUM MOL GENET, V13, P1241, DOI 10.1093/hmg/ddh135; Hussain S, 2003, HUM MOL GENET, V12, P2503, DOI 10.1093/hmg/ddg266; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; LEVITUS M, 2003, BLOOD; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Tarsounas M, 2004, PHILOS T R SOC B, V359, P87, DOI 10.1098/rstb.2003.1368; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Warren M, 2002, HUM MOL GENET, V11, P841, DOI 10.1093/hmg/11.7.841; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yamamoto K, 2005, MOL CELL BIOL, V25, P34, DOI 10.1128/MCB.25.1.34-43.2005; Yu VPCC, 2000, GENE DEV, V14, P1400; Zdzienicka MZ, 2002, TRENDS MOL MED, V8, P458, DOI 10.1016/S1471-4914(02)02411-5; Zhang M, 2004, ACTA PHARMACOL SIN, V25, P61	40	66	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14877	14883		10.1074/jbc.M414669200	http://dx.doi.org/10.1074/jbc.M414669200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15671039	hybrid, Green Published			2022-12-25	WOS:000228236800066
J	Cao, XW; Ding, X; Guo, Z; Zhou, RH; Wang, RS; Long, F; Wu, F; Bi, F; Wang, QC; Fan, DM; Forte, JG; Teng, MK; Yao, XB				Cao, XW; Ding, X; Guo, Z; Zhou, RH; Wang, RS; Long, F; Wu, F; Bi, F; Wang, QC; Fan, DM; Forte, JG; Teng, MK; Yao, XB			PALS1 specifies the localization of ezrin to the apical membrane of gastric parietal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED DISTRIBUTION; RECYCLING HYPOTHESIS; CYTOSKELETAL LINKER; DROSOPHILA STARDUST; ACID-SECRETION; HCL SECRETION; OXYNTIC CELLS; DISCS LOST; PROTEIN; FAMILY	The ERM (ezrin/radixin/moesin) proteins provide a regulated linkage between membrane proteins and the cortical cytoskeleton and also participate in signal transduction pathways. Ezrin is localized to the apical membrane of parietal cells and couples the protein kinase A activation cascade to regulated HCl secretion in gastric parietal cells. Here, we show that the integrity of ezrin is essential for parietal cell activation and provide the first evidence that ezrin interacts with PALS1, an evolutionarily conserved PDZ and SH3 domain-containing protein. Our biochemical study verifies that ezrin binds to PALS1 via its N terminus and is co-localized with PALS1 to the apical membrane of gastric parietal cells. Furthermore, our study shows that PALS1 is essential for the apical localization of ezrin, as either suppression of PALS1 protein accumulation or deletion of the PALS1-binding domain of ezrin eliminated the apical localization of ezrin. Finally, our study demonstrates the essential role of ezrin-PALS1 interaction in the apical membrane remodeling associated with parietal cell secretion. Taken together, these results define a novel molecular mechanism linking ezrin to the conserved apical polarity complexes and their roles in polarized epithelial secretion of gastric parietal cells.	Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Peoples R China; Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Shanxi, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine; University of California System; University of California Berkeley; Air Force Military Medical University	Yao, XB (corresponding author), Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Peoples R China.	yaoxb@ustc.edu.cn	Yao, Xuebiao/P-5771-2014; Wang, Qichen/B-4198-2015; Cao, Xinwang/W-2883-2019	cao, xinwang/0000-0002-8052-7333	NIDDK NIH HHS [DK-56292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Ammar DA, 2002, AM J PHYSIOL-GASTR L, V282, pG23, DOI 10.1152/ajpgi.00277.2002; Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; BLACK JA, 1982, GASTROENTEROLOGY, V83, P595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chae TH, 2004, NAT GENET, V36, P264, DOI 10.1038/ng1302; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Forte JG, 1996, TRENDS CELL BIOL, V6, P45, DOI 10.1016/0962-8924(96)81009-9; FORTE TM, 1977, GASTROENTEROLOGY, V73, P941; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HANZEL DK, 1989, AM J PHYSL, V256; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; YAO X, 1993, AM J PHYSIOL, V265, P36; Yao XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI 10.1146/annurev.physiol.65.072302.114200; Yao XB, 1996, J BIOL CHEM, V271, P7224, DOI 10.1074/jbc.271.12.7224; YAO XB, 1995, MOL BIOL CELL, V6, P541, DOI 10.1091/mbc.6.5.541; Yeaman C, 1999, CURR BIOL, V9, pR515, DOI 10.1016/S0960-9822(99)80324-8; Zhou RH, 2003, J BIOL CHEM, V278, P35651, DOI 10.1074/jbc.M303416200; Zhou RH, 2003, MOL BIOL CELL, V14, P1097, DOI 10.1091/mbc.E02-07-0425	34	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13584	13592		10.1074/jbc.M411941200	http://dx.doi.org/10.1074/jbc.M411941200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677456	hybrid			2022-12-25	WOS:000228095500051
J	Gabele, E; Reif, S; Tsukada, S; Bataller, R; Yata, Y; Morris, T; Schrum, LW; Brenner, DA; Rippe, RA				Gabele, E; Reif, S; Tsukada, S; Bataller, R; Yata, Y; Morris, T; Schrum, LW; Brenner, DA; Rippe, RA			The role of p70(S6K) in hepatic stellate cell collagen gene expression and cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; NECROSIS-FACTOR-ALPHA; GROWTH-FACTORS ACTIONS; SMOOTH-MUSCLE-CELLS; FAT-STORING CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; MESSENGER-RNA; DNA-SYNTHESIS; S6 KINASE	During fibrosis the hepatic stellate cell (HSC) undergoes a complex activation process characterized by increased proliferation and extracellular matrix deposition. The 70-kDa ribosomal S6 kinase (p70(S6K)) is activated by mitogens, growth factors, and hormones in a phosphatidylinositol 3-kinase-dependent manner. p70(S6K) regulates protein synthesis, proliferation, and cell cycle control. Because these processes are involved in HSC activation, we investigated the role of p70(S6K) in HSC proliferation, cell cycle control, and type I collagen expression. Platelet-derived growth factor ( PDGF) stimulated p70(S6K) phosphorylation, which was blocked by LY294002, an inhibitor of phosphatidylinositol 3-kinase. Rapamycin blocked phosphorylation of p70(S6K) but had no affect on PDGF-induced Akt phosphorylation, positioning p70(S6K) downstream of Akt. Transforming growth factor-beta, which inhibits HSC proliferation, did not affect PDGF-induced p70(S6K) phosphorylation. Rapamycin treatment did not affect alpha 1(I) collagen mRNA but reduced type I collagen protein secretion. Expression of smooth muscle alpha-actin was not affected by rapamycin treatment, indicating that HSC activation was not altered. Rapamycin inhibited serum-induced DNA synthesis similar to 2-fold. Moreover, rapamycin decreased expression of cyclins D1, D3, and E but not cyclin D2, Rb-Ser(780), and Rb-Ser(795). Together, p70(S6K) plays a crucial role in HSC proliferation, collagen expression, and cell cycle control, thus representing a potential therapeutic target for liver fibrosis.	Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Charlotte	Rippe, RA (corresponding author), Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, CB 7032,Med Biomol Res Bldg,Rm 7340B, Chapel Hill, NC 27599 USA.	rarippe@med.unc.edu		Bataller, Ramon/0000-0002-1119-7799; Brenner, David/0000-0003-2573-525X	NIAAA NIH HHS [AA10459, AA11605] Funding Source: Medline; NIDDK NIH HHS [DK34987, DK065972] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987, R01DK065972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010459, R29AA010459, P60AA011605, P50AA011605] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARMENDARIZBORUNDA J, 1992, J BIOL CHEM, V267, P14316; BACHEM MG, 1989, BIOCHEM BIOPH RES CO, V162, P708, DOI 10.1016/0006-291X(89)92368-1; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Coffer PJ, 1998, BIOCHEM J, V335, P1; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; FRIEDMAN SL, 1998, DIS LIVER, P371; Gabele E, 2003, FRONT BIOSCI, V8, P69, DOI DOI 10.2741/887; Ganesan LP, 2004, J BIOL CHEM, V279, P54416, DOI 10.1074/jbc.M408188200; Garnovskaya MN, 2004, J BIOL CHEM, V279, P24899, DOI 10.1074/jbc.M311622200; GEERTS A, 1991, HEPATOLOGY, V13, P1193, DOI 10.1002/hep.1840130628; Gentilini A, 2000, J HEPATOL, V32, P227, DOI 10.1016/S0168-8278(00)80067-7; Gerasimovskaya EV, 2005, J BIOL CHEM, V280, P1838, DOI 10.1074/jbc.M409466200; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hanna AN, 1999, J BIOL CHEM, V274, P12722, DOI 10.1074/jbc.274.18.12722; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JIANG W, 1993, ONCOGENE, V8, P3447; Kawada N, 1999, J HEPATOL, V30, P1057, DOI 10.1016/S0168-8278(99)80260-8; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lee Y, 2003, EXP MOL MED, V35, P222, DOI 10.1038/emm.2003.30; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MAK KM, 1984, GASTROENTEROLOGY, V87, P188; Marra F, 1999, HEPATOLOGY, V30, P951, DOI 10.1002/hep.510300406; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; Marra F, 1997, GASTROENTEROLOGY, V112, P1297, DOI 10.1016/S0016-5085(97)70144-6; MATSUOKA M, 1989, LIVER, V9, P71; Miyakoda M, 1999, BIOCHEM BIOPH RES CO, V266, P377, DOI 10.1006/bbrc.1999.1829; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; Pinzani M, 2001, SEMIN LIVER DIS, V21, P397, DOI 10.1055/s-2001-17554; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAMADORI G, 1990, VIRCHOWS ARCH B, V59, P349, DOI 10.1007/BF02899424; Reed SI, 1997, CANCER SURV, V29, P7; Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Rivera CA, 2001, AM J PHYSIOL-GASTR L, V281, pG200, DOI 10.1152/ajpgi.2001.281.1.G200; Saile B, 1999, HEPATOLOGY, V30, P196, DOI 10.1002/hep.510300144; Schnabl B, 2001, HEPATOLOGY, V34, P953, DOI 10.1053/jhep.2001.28790; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Skrtic S, 1999, ENDOCRINOLOGY, V140, P5729, DOI 10.1210/en.140.12.5729; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Svegliati-Baroni G, 2001, HEPATOLOGY, V33, P1130, DOI 10.1053/jhep.2001.23788; TAKAHARA T, 1988, LAB INVEST, V59, P509; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Zhu JL, 1999, GASTROENTEROLOGY, V117, P1198, DOI 10.1016/S0016-5085(99)70406-3	66	77	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13374	13382		10.1074/jbc.M409444200	http://dx.doi.org/10.1074/jbc.M409444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677443	Green Published, hybrid			2022-12-25	WOS:000228095500024
J	Martens, N; Uzan, G; Wery, M; Hooghe, R; Hooghe-Peters, EL; Gertler, A				Martens, N; Uzan, G; Wery, M; Hooghe, R; Hooghe-Peters, EL; Gertler, A			Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and leptin signaling by interacting with STAT5 or STAT3 and attenuating their nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CYTOSKELETON; MICE LACKING; RECEPTOR; TRANSDUCER; ACTIVATOR; PROTEINS; OVINE; SOCS; PHOSPHORYLATION; EXPRESSION	We report here the role of one of the less studied members of the family of suppressors of cytokine signaling ( SOCS), namely SOCS-7, in cytokine signaling. We demonstrate that SOCS-7 inhibits prolactin (PRL), growth hormone (GH), or leptin (LEP) signaling mediated through STAT3 and STAT5 in a dose-dependent manner. SOCS-7 also attenuated STAT3 and STAT5 signaling induced by overexpression of JH1, the catalytic subdomain of JAK2. Since SOCS-7 interacted with phosphorylated STAT3 or STAT5, we assumed that SOCS-7 acts at the level of STAT proteins. Indeed, we showed that SOCS-7 inhibits PRL- and leptin-induced STAT5 and STAT3 phosphorylation and prevented the nuclear translocation of activated STAT3. Taken together, our results indicate that SOCS-7 is a physiological dysregulator of PRL, leptin, and probably also GH signaling and that its mode of action is a novel variation of SOCS protein inhibition of cytokine-inducible STAT-mediated signal transduction.	Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; Univ Libre Brussels, Sch Med, Neuroendocrine Immunol & Pharmacol Dept, B-1090 Brussels, Belgium; Fac Univ Notre Dame Paix, Mol Genet Lab, B-5000 Namur, Belgium	Hebrew University of Jerusalem; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Namur	Gertler, A (corresponding author), Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel.	gertler@agri.huji.ac.il	Wery, Maxime/AAR-2426-2020	Wery, Maxime/0000-0003-3004-471X				Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; Bayle J, 2004, J BIOL CHEM, V279, P12249, DOI 10.1074/jbc.M313381200; Ben-Yair L, 2002, PROTEIN EXPRES PURIF, V25, P456, DOI 10.1016/S1046-5928(02)00044-X; Biener E, 2003, ENDOCRINOLOGY, V144, P3532, DOI 10.1210/en.2003-0096; Caprio M, 2003, BIOL REPROD, V68, P1199, DOI 10.1095/biolreprod.102.007831; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Dogusan Z, 2000, J NEUROIMMUNOL, V109, P34, DOI 10.1016/S0165-5728(00)00300-3; Duan CJ, 2004, J BIOL CHEM, V279, P43684, DOI 10.1074/jbc.M408495200; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Giordanetto F, 2003, PROTEIN ENG, V16, P115, DOI 10.1093/proeng/gzg015; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Inagaki-Ohara K, 2003, CURR OPIN PHARMACOL, V3, P435, DOI 10.1016/S1471-4892(03)00070-5; Krebs DL, 2004, P NATL ACAD SCI USA, V101, P15446, DOI 10.1073/pnas.0406870101; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; KREBS DL, 2003, SCI STKE, V169, pPE6; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Leibovich H, 2000, ANIM REPROD SCI, V64, P33, DOI 10.1016/S0378-4320(00)00198-6; Martens N, 2004, EXP CELL RES, V298, P239, DOI 10.1016/j.yexcr.2004.04.002; MARTENS N, 2002, ARCH PHYSIOL BIOCHEM, V110, pB25; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matuoka K, 1997, BIOCHEM BIOPH RES CO, V239, P488, DOI 10.1006/bbrc.1997.7492; Raver N, 2002, GEN COMP ENDOCR, V126, P52, DOI 10.1006/gcen.2001.7766; Rico-Bautista E, 2004, EXP CELL RES, V294, P269, DOI 10.1016/j.yexcr.2003.11.017; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; SCARABELLI L, 2003, J ENDOCRINOL INVEST, V36, P718; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; UZAN G, 2003, P ISR END SOC ANN M; Wiederkehr-Adam M, 2003, J BIOL CHEM, V278, P16117, DOI 10.1074/jbc.M300261200; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Yoshimura A, 2004, J LEUKOCYTE BIOL, V75, P422, DOI 10.1189/jlb.0403194	30	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13817	13823		10.1074/jbc.M411596200	http://dx.doi.org/10.1074/jbc.M411596200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677474	hybrid			2022-12-25	WOS:000228095500079
J	Patel, NA; Kaneko, S; Apostolatos, HS; Bae, SS; Watson, JE; Davidowitz, K; Chappell, DS; Birnbaum, MJ; Cheng, JQ; Cooper, DR				Patel, NA; Kaneko, S; Apostolatos, HS; Bae, SS; Watson, JE; Davidowitz, K; Chappell, DS; Birnbaum, MJ; Cheng, JQ; Cooper, DR			Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase C beta II alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; INSULIN-RESISTANCE; IN-VIVO; EXPRESSION; EXON; PATHWAY; ACTIVATION; INHIBITION	Insulin regulates alternative splicing of PKC beta II mRNA by phosphorylation of SRp40 via a phosphatidylinositol 3-kinase pathway (Patel, N. A., Chalfant, C. E., Watson, J. E., Wyatt, J. R., Dean, N. M., Eichler, D. C., and Cooper, D. C. ( 2001) J. Biol. Chem. 276, 22648-22654). Transient transfection of constitutively active Akt2 kinase promotes PKC beta II exon inclusion. Serine/arginine-rich (SR) RNA-binding proteins regulating the selection of alternatively spliced exons are potential substrates of Akt kinase because many of them contain RXRXX(S/T) motifs. Here we show that Akt2 kinase phosphorylated SRp40 in vivo and in vitro. Mutation of Ser(86) on SRp(40) blocked in vitro phosphorylation. In control Akt2(+/+) fibroblasts, insulin treatment increased the phosphorylation of endogenous SR proteins, but their phosphorylation state remained unaltered by insulin in fibroblasts from Akt2(-/-) mice. Levels of PKC beta II protein were up-regulated by insulin in Akt2(+/+) cells; however, only very low levels of PKC beta II were detected in Akt2(-/-) cells and did not change following insulin treatment. Endogenous PKC beta I and -beta II mRNA levels in Akt2(+/+) and Akt2(-/-) gastrocnemius muscle tissues were compared using quantitative real time PCR. The results indicated a 54% decrease in the expression of PKC beta II levels in Akt(-/-), whereas PKC beta I levels remained unchanged in both samples. Further, transfection of Akt2(-/-) cells with a PKC beta II splicing minigene revealed defective beta II exon inclusion. Co-transfection of the mutated SRp40 attenuated beta II exon inclusion. This study provides in vitro and in vivo evidence showing Akt2 kinase directly phosphorylated SRp40, thereby connecting the insulin, PI 3-kinase/Akt pathway with phosphorylation of a site on a nuclear splicing protein promoting exon inclusion. This model is upheld in Akt2-deficient mice with insulin resistance leading to diabetes mellitus.	James A Haley Vet Hosp, Res Serv 151, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ Penn, Sch Med, Dept Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Howard Hughes Medical Institute; University of Pennsylvania	Cooper, DR (corresponding author), James A Haley Vet Hosp, Res Serv 151, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	dcooper@hsc.usf.edu	Cooper, Denise R./A-4740-2012; Patel, Niketa/A-1392-2012	Patel, Niketa A./0000-0003-4811-8596; Birnbaum, Morris/0000-0001-9972-8680; Corbin, Karen/0000-0003-2065-0003	NATIONAL CANCER INSTITUTE [R29CA077935, R01CA077935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039615, R01DK054393] Funding Source: NIH RePORTER; NCI NIH HHS [CA077935] Funding Source: Medline; NIDDK NIH HHS [DK39615, DK54393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Cazalla D, 2002, MOL CELL BIOL, V22, P6871, DOI 10.1128/MCB.22.19.6871-6882.2002; Chalfant CE, 1996, MOL ENDOCRINOL, V10, P1273, DOI 10.1210/me.10.10.1273; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; Chalfant CE, 1998, J BIOL CHEM, V273, P910, DOI 10.1074/jbc.273.2.910; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHEW SL, 1995, ENDOCRINOLOGY, V136, P1939, DOI 10.1210/en.136.5.1939; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Collins FS, 2003, SCIENCE, V300, P286, DOI 10.1126/science.1084564; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; COOPER DR, 1987, J BIOL CHEM, V262, P3633; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; Du KY, 1998, J BIOL CHEM, V273, P35208, DOI 10.1074/jbc.273.52.35208; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Koizumi J, 1999, J BIOL CHEM, V274, P11125, DOI 10.1074/jbc.274.16.11125; Kosaki A, 1998, J BIOL CHEM, V273, P10331, DOI 10.1074/jbc.273.17.10331; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Moeslein FM, 1999, J BIOL CHEM, V274, P26697, DOI 10.1074/jbc.274.38.26697; Muro AF, 1998, FEBS LETT, V437, P137, DOI 10.1016/S0014-5793(98)01201-0; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Okamoto Y, 1998, BIOCHEM BIOPH RES CO, V249, P872, DOI 10.1006/bbrc.1998.9247; Ozes ON, 1999, NATURE, V401, P82; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Patel NA, 2004, MOL ENDOCRINOL, V18, P899, DOI 10.1210/me.2003-0391; Patel NA, 2003, J BIOL CHEM, V278, P1149, DOI 10.1074/jbc.M206797200; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; Patti ME, 2004, CURR OPIN CLIN NUTR, V7, P383, DOI 10.1097/01.mco.0000134359.23288.72; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; Schmittgen TD, 2001, METHODS, V25, P383, DOI 10.1006/meth.2001.1260; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Stamm S, 1999, MOL BRAIN RES, V64, P108, DOI 10.1016/S0169-328X(98)00313-1; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447	62	99	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14302	14309		10.1074/jbc.M411485200	http://dx.doi.org/10.1074/jbc.M411485200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15684423	hybrid			2022-12-25	WOS:000228095500134
J	Picone, D; Di Fiore, A; Ercole, C; Franzese, M; Sica, F; Tomaselli, S; Mazzarella, L				Picone, D; Di Fiore, A; Ercole, C; Franzese, M; Sica, F; Tomaselli, S; Mazzarella, L			The role of the hinge loop in domain swapping - The special case of bovine seminal ribonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; THERMODYNAMIC ANALYSIS; PROTEIN STRUCTURES; RNASE; DIMER; RESOLUTION; MOLSCRIPT; PROGRAM; ENZYME; ERRORS	Bovine seminal ribonuclease (BS-RNase) is a covalent homodimeric enzyme homologous to pancreatic ribonuclease (RNase A), endowed with a number of special biological functions. It is isolated as an equilibrium mixture of swapped (MxM) and unswapped (M=M) dimers. The interchanged N termini are hinged on the main bodies through the peptide 16-22, which changes conformation in the two isomers. At variance with other proteins, domain swapping in BS-RNase involves two dimers having a similar and highly constrained quaternary association, mainly dictated by two interchain disulfide bonds. This provides the opportunity to study the intrinsic ability to swap as a function of the hinge sequence, without additional effects arising from dissociation or quaternary structure modifications. Two variants, having Pro(19) or the whole sequence of the hinge replaced by the corresponding residues of RNase A, show equilibrium and kinetic parameters of the swapping similar to those of the parent protein. In comparison, the x-ray structures of MxM indicate, within a substantial constancy of the quaternary association, a greater mobility of the hinge residues. The relative insensitivity of the swapping tendency to the substitutions in the hinge region, and in particular to the replacement of Pro19 by Ala, contrasts with the results obtained for other swapped proteins and can be rationalized in terms of the unique features of the seminal enzyme. Moreover, the results indirectly lend credit to the hypothesis that the major role of Pro19 resides in directing the assembly of the non-covalent dimer, the species produced by selective reduction of the interchain disulfides and considered responsible for the special biological functions of BS-RNase.	Univ Naples Federico II, Dipartimento Chim, Complesso Univ Monte SantAngelo, I-80126 Naples, Italy; CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR)	Mazzarella, L (corresponding author), Univ Naples Federico II, Dipartimento Chim, Complesso Univ Monte SantAngelo, Via Cynthia, I-80126 Naples, Italy.	lelio.mazzarella@unina.it	Picone, Delia/I-5605-2012; Picone, Delia/L-2480-2015; Di Fiore, Anna/AAW-3780-2020; tomaselli, simona/A-6075-2012; Di Fiore, Anna/AAX-5655-2020	Picone, Delia/0000-0002-7582-2581; Picone, Delia/0000-0002-7582-2581; Di Fiore, Anna/0000-0003-2924-5194; tomaselli, simona/0000-0002-8627-6838; 				Avitabile F, 2003, BIOCHEMISTRY-US, V42, P8704, DOI 10.1021/bi0342517; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; Berisio R, 2003, FEBS LETT, V554, P105, DOI 10.1016/S0014-5793(03)01114-1; Berisio R, 2002, ACTA CRYSTALLOGR D, V58, P441, DOI 10.1107/S0907444901021758; BRUNGER AT, 1996, DEP MOL BIOPHYSICS B; Catanzano F, 1997, BIOCHEMISTRY-US, V36, P14403, DOI 10.1021/bi971358j; Catanzano F, 1997, PROTEIN SCI, V6, P1682, DOI 10.1002/pro.5560060808; Ciglic MI, 1998, BIOCHEMISTRY-US, V37, P4008, DOI 10.1021/bi972203e; Crescenzi O, 2001, J BIOMOL NMR, V20, P289, DOI 10.1023/A:1011294812364; CRESTFIELD A M, 1962, Arch Biochem Biophys, VSuppl 1, P217; D'Alessio G., 1997, RIBONUCLEASES STRUCT, P383; DALESSIO G, 1975, BIOCHEMISTRY-US, V14, P1116, DOI 10.1021/bi00677a004; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DIDONATO A, 1981, BIOCHEMISTRY-US, V20, P7232, DOI 10.1021/bi00528a028; Ercole C, 2003, EUR J BIOCHEM, V270, P4729, DOI 10.1046/j.1432-1033.2003.03872.x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gotte G, 1999, EUR J BIOCHEM, V265, P680, DOI 10.1046/j.1432-1327.1999.00761.x; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNITZ M, 1946, J BIOL CHEM, V164, P563; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; MAZZARELLA L, 1993, ACTA CRYSTALLOGR D, V49, P389, DOI 10.1107/S0907444993003403; Merlino A, 2004, BIOPOLYMERS, V73, P689, DOI 10.1002/bip.20016; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Sica F, 2004, J BIOL CHEM, V279, P36753, DOI 10.1074/jbc.M405655200; Sica F, 2003, PROTEINS, V52, P263, DOI 10.1002/prot.10407; Vitagliano L, 1999, J MOL BIOL, V293, P569, DOI 10.1006/jmbi.1999.3158	34	30	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13771	13778		10.1074/jbc.M413157200	http://dx.doi.org/10.1074/jbc.M413157200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15647261	hybrid			2022-12-25	WOS:000228095500073
J	Wagner, EJ; Baraniak, AP; Sessions, OM; Mauger, D; Moskowitz, E; Garcia-Blanco, MA				Wagner, EJ; Baraniak, AP; Sessions, OM; Mauger, D; Moskowitz, E; Garcia-Blanco, MA			Characterization of the intronic splicing silencers flanking FGFR2 exon IIIb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-2; TRACT BINDING-PROTEIN; POLYPYRIMIDINE TRACT; SEX-LETHAL; RNA-BINDING; HNRNP A1; ELEMENT; AUTOREGULATION; REPRESSION; SPECIFICITY	The cell type-specific alternative splicing of FGFR2 pre-mRNA results in the mutually exclusive use of exons IIIb and IIIc, which leads to critically important differences in receptor function. The choice of exon IIIc in mesenchymal cells involves activation of this exon and repression of exon IIIb. This repression is mediated by the function of upstream and downstream intronic splicing silencers (UISS and DISS). Here we present a detailed characterization of the determinants of silencing function within UISS and DISS. We used a systematic mutational analysis, introducing deletions and substitutions to define discrete elements within these two silencers of exon IIIb. We show that UISS requires polypyrimidine tract-binding protein (PTB)-binding sites, which define the UISS1 sub-element, and an eight nucleotide sequence 5'-GCAGCACC-3' (UISS2) that is also required. Even though UISS2 does not bind PTB, the full UISS can be replaced with a synthetic silencer designed to provide optimal PTB binding. DISS is composed of a 5'-conserved sub-element (5'-CE) and two regions that contain multiple PTB sites and are functionally redundant (DISS1 and DISS2). DISS1 and DISS2 are separated by the activator sequence IAS2, and together these opposing elements form the intronic control element. Deletion of DISS in the FGFR2 exon IIIb context resulted in the near full inclusion of exon IIIb, and insertion of this silencer downstream of a heterologous exon with a weak 5' splice site was capable of repressing exon inclusion. Extensive deletion analysis demonstrated that the majority of silencing activity could be mapped to the conserved octamer CUCGGUGC within the 5'CE. Replacement of 5'CE and DISS1 with PTB-binding elements failed to restore repression of exon IIIb. We tested the importance of the relative position of the silencers and of the sub-elements within each silencer. Whereas UISS1, UISS2, DISS1, and DISS2 appear somewhat malleable, the 5'CE is rigid in terms of relative position and redundancy. Our data defined elements of function within the ISSs flanking exon IIIb and suggested that silencing of this exon is mediated by multiple trans-acting factors.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Program Mol Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	garci001@mc.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063090] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63090] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baraniak AP, 2003, MOL CELL BIOL, V23, P9327, DOI 10.1128/MCB.23.24.9327-9337.2003; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; Black D L, 2003, Prog Mol Subcell Biol, V31, P187; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Burns RC, 2004, DEV BIOL, V265, P61, DOI 10.1016/j.ydbio.2003.09.021; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DELL KR, 1992, J BIOL CHEM, V267, P21225; Deshpande G, 1999, DEVELOPMENT, V126, P2841; Deshpande G, 1996, MOL CELL BIOL, V16, P5036; Eis PS, 2001, NAT BIOTECHNOL, V19, P673, DOI 10.1038/90290; Fairbrother WG, 2000, MOL CELL BIOL, V20, P6816, DOI 10.1128/MCB.20.18.6816-6825.2000; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; Gooding C, 1998, RNA, V4, P85; Grabowski PJ, 2004, BIOCHEM SOC T, V32, P924, DOI 10.1042/BST0320924; Gromak N, 2003, EMBO J, V22, P6356, DOI 10.1093/emboj/cdg609; Gromak N, 2003, RNA, V9, P443, DOI 10.1261/rna.2191903; Hajihosseini MK, 2001, P NATL ACAD SCI USA, V98, P3855, DOI 10.1073/pnas.071586898; Hatton AR, 1998, MOL CELL, V2, P787, DOI 10.1016/S1097-2765(00)80293-2; HIGGINS DG, 1986, METHOD ENZYMOL, V266, P383; Ho TH, 2004, EMBO J, V23, P3103, DOI 10.1038/sj.emboj.7600300; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; Jones RB, 2001, NUCLEIC ACIDS RES, V29, P3557, DOI 10.1093/nar/29.17.3557; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Mistry N, 2003, RNA, V9, P209, DOI 10.1261/rna.2470903; Muh SJ, 2002, J BIOL CHEM, V277, P50143, DOI 10.1074/jbc.M207409200; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; Nasim FUH, 2002, RNA, V8, P1078, DOI 10.1017/S1355838202024056; Oldridge M, 1999, AM J HUM GENET, V64, P446, DOI 10.1086/302245; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Robson-Dixon ND, 2004, J BIOL CHEM, V279, P29075, DOI 10.1074/jbc.M312747200; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; Sironi M, 2004, NUCLEIC ACIDS RES, V32, P1783, DOI 10.1093/nar/gkh341; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Wagner EJ, 2003, RNA, V9, P1552, DOI 10.1261/rna.5840803; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wagner Eric J, 2004, Methods Mol Biol, V257, P29, DOI 10.1385/1-59259-750-5:029; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yanowitz JL, 1999, MOL CELL BIOL, V19, P3018; Yasumoto H, 2004, PROSTATE, V61, P236, DOI 10.1002/pros.20093; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; Yeakley JM, 2002, NAT BIOTECHNOL, V20, P353, DOI 10.1038/nbt0402-353; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536; Zhang L, 1999, RNA, V5, P117, DOI 10.1017/S1355838299981530; Zhang L, 1996, RNA, V2, P682; Zhang XHF, 2004, GENE DEV, V18, P1241, DOI 10.1101/gad.1195304; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	60	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14017	14027		10.1074/jbc.M414492200	http://dx.doi.org/10.1074/jbc.M414492200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15684416	hybrid			2022-12-25	WOS:000228095500104
J	Wang, X; Huang, QQ; Breckenridge, MT; Chen, AH; Crawford, TO; Morton, DH; Jin, JP				Wang, X; Huang, QQ; Breckenridge, MT; Chen, AH; Crawford, TO; Morton, DH; Jin, JP			Cellular fate of truncated slow skeletal muscle troponin T produced by Glu(180) nonsense mutation in amish nemaline myopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; CARDIAC TROPONIN; STRUCTURAL ORGANIZATION; REGULATED EXPRESSION; TROPOMYOSIN ISOFORMS; F-ACTIN; BINDING; GENE; MODULATION; PROTEINS	A nonsense mutation at codon Glu(180) in exon 11 of slow skeletal muscle troponin T (TnT) gene (TNNT1) causes an autosomal-recessive inherited nemaline myopathy. We previously reported the absence of intact or prematurely terminated slow TnT polypeptide in Amish nemaline myopathy (ANM) patient muscle. The present study further investigates the expression and fate of mutant slow TnT in muscle cells. Intact slow TnT mRNA was readily detected in patient muscle, indicating unaffected transcription and RNA splicing. Sequence of the cloned cDNAs revealed the single nucleotide mutation in two alternatively spliced isoforms of slow TnT mRNA. Mutant TNNT1 cDNA is translationally active in Escherichia coli and non-muscle eukaryotic cells, producing the expected truncated slow TnT protein. The mutant mRNA was expressed at significant levels in differentiated C2C12 myotubes, but unlike intact exogenous TnT, truncated slow TnT protein was not detected. Transfective expression in undifferentiated myoblasts produced slow TnT mRNA but not a detectable amount of truncated or intact slow TnT proteins, indicating a muscle cell-specific proteolysis of TnT when it is not integrated into myofilaments. The slow TnT-(1-179) fragment has substantially lower affinity for binding to tropomyosin, in keeping with the loss of one of two tropomyosin-binding sites. Our findings suggest that inefficient incorporation into myofilament is responsible for the instability of mutant slow TnT in ANM muscle. Rapid degradation of the truncated slow TnT protein, rather than instability of the nonsense mRNA, provides the protective mechanism against the potential dominant negative effect of the mutant TnT fragment.	Evanston NW Healthcare, Sect Mol Cardiol, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Evanston, IL 60201 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21287 USA; Clin Special Children, Strasburg, PA 17579 USA	NorthShore University Health System; Northwestern University; Feinberg School of Medicine; Case Western Reserve University; Johns Hopkins University; Johns Hopkins University	Jin, JP (corresponding author), Evanston NW Healthcare, Sect Mol Cardiol, Evanston, IL 60201 USA.	jpjin@northwestern.edu	Jin, Jian-Ping/AAD-1149-2020; Crawford, Thomas/E-6307-2012	Jin, JP/0000-0001-9932-1063	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD044824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048816] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-048816] Funding Source: Medline; NICHD NIH HHS [HD-044824] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baldwin KM, 2001, J APPL PHYSIOL, V90, P345, DOI 10.1152/jappl.2001.90.1.345; Barton PJR, 1999, GENOMICS, V57, P102, DOI 10.1006/geno.1998.5702; Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; Biesiadecki BJ, 2002, J BIOL CHEM, V277, P18459, DOI 10.1074/jbc.M200788200; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; CabralLilly D, 1997, BIOPHYS J, V73, P1763, DOI 10.1016/S0006-3495(97)78206-7; GAHLMANN R, 1987, J BIOL CHEM, V262, P16122; GARROW JS, 1982, P NUTR SOC, V41, P373, DOI 10.1079/PNS19820052; Gomes A, 2003, BIOPHYS J, V84, p319A; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HEELEY DH, 1988, BIOCHEMISTRY-US, V27, P8227, DOI 10.1021/bi00421a036; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; Hossain MM, 2003, AM J PHYSIOL-CELL PH, V284, pC156, DOI 10.1152/ajpcell.00233.2002; Huang QQ, 1999, GENE, V229, P1, DOI 10.1016/S0378-1119(99)00051-7; Huang QQ, 1999, J MOL EVOL, V49, P780, DOI 10.1007/PL00006600; ISHII Y, 1991, J BIOL CHEM, V266, P6894; Jin JP, 2000, AM J PHYSIOL-CELL PH, V279, pC1067, DOI 10.1152/ajpcell.2000.279.4.C1067; Jin JP, 2000, BIOCHEMISTRY-US, V39, P11702, DOI 10.1021/bi9927437; Jin JP, 1998, GENE, V214, P121, DOI 10.1016/S0378-1119(98)00214-5; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; JIN JP, 1995, J BIOL CHEM, V270, P6908; Jin JP, 2003, J BIOL CHEM, V278, P26159, DOI 10.1074/jbc.M303469200; Jin JP, 2001, BIOCHEMISTRY-US, V40, P2623, DOI 10.1021/bi002423j; Jin JP, 1996, BIOCHEM BIOPH RES CO, V225, P883, DOI 10.1006/bbrc.1996.1267; Johnston JJ, 2000, AM J HUM GENET, V67, P814, DOI 10.1086/303089; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; LIN JJC, 1985, HYBRIDOMA, V4, P223, DOI 10.1089/hyb.1985.4.223; Lin JJC, 1984, MONOCLONAL ANTIBODIE, P119; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MAQUAT LE, 1995, RNA, V1, P453; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; Ogut O, 2000, J BIOL CHEM, V275, P26089, DOI 10.1074/jbc.M910360199; Ogut O, 1998, J BIOL CHEM, V273, P27858, DOI 10.1074/jbc.273.43.27858; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; RINDT H, 1993, J BIOL CHEM, V268, P5332; SAMSON F, 1994, BIOCHEM BIOPH RES CO, V199, P841, DOI 10.1006/bbrc.1994.1305; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; Wang J, 1997, GENE, V193, P105, DOI 10.1016/S0378-1119(97)00100-5; Wendt T, 1997, J STRUCT BIOL, V118, P1, DOI 10.1006/jsbi.1996.3834; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	47	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13241	13249		10.1074/jbc.M413696200	http://dx.doi.org/10.1074/jbc.M413696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15665378	hybrid			2022-12-25	WOS:000228095500007
J	Wilson, DK; Cerna, D; Chew, E				Wilson, DK; Cerna, D; Chew, E			The 1.1-angstrom structure of the spindle checkpoint protein Bub3p reveals functional regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WD-REPEAT PROTEIN; CRYSTAL-STRUCTURE; ASSEMBLY CHECKPOINT; GENES; PHOSPHORYLATION; ASSOCIATION; COMPONENT; RESIDUES; INSIGHTS; ENCODES	Bub3p is a protein that mediates the spindle checkpoint, a signaling pathway that ensures correct chromosome segregation in organisms ranging from yeast to mammals. It is known to function by co-localizing at least two other proteins, Mad3p and the protein kinase Bub1p, to the kinetochore of chromosomes that are not properly attached to mitotic spindles, ultimately resulting in cell cycle arrest. Prior sequence analysis suggested that Bub3p was composed of three or four WD repeats (also known as WD40 and beta-transducin repeats), short sequence motifs appearing in clusters of 4-16 found in many hundreds of eukaryotic proteins that fold into four-stranded blade-like sheets. We have determined the crystal structure of Bub3p from Saccharomyces cerevisiae at 1.1 angstrom and a crystallographic R-factor of 15.3%, revealing seven authentic repeats. In light of this, it appears that many of these repeats therefore remain hidden in sequences of other proteins. Analysis of random and site-directed mutants identifies the surface of Bub3p involved in checkpoint function through binding of Bub1p and Mad3p. Sequence alignments indicate that these surfaces are mostly conserved across Bub3 proteins from diverse species. A structural comparison with other proteins containing WD repeats suggests that these folds may bind partner proteins using similar surface areas on the top and sides of the propeller. The sequences composing these regions are the most divergent within the repeat across all WD repeat proteins and could potentially be modulated to provide specificity in partner protein binding without perturbation of the core structure.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Wilson, DK (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	dave@alanine.ucdavis.edu			NIGMS NIH HHS [GM59810, GM66135, GM17891] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066135, F31GM017891, R01GM059810] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Colosimo A, 1999, BIOTECHNIQUES, V26, P870, DOI 10.2144/99265bm15; Fraschini R, 2001, EMBO J, V20, P6648, DOI 10.1093/emboj/20.23.6648; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Grabsch H, 2003, J PATHOL, V200, P16, DOI 10.1002/path.1324; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; Harlow E., 1988, LAB MANUAL; Harper JW, 2002, TRENDS CELL BIOL, V12, P104, DOI 10.1016/S0962-8924(01)02238-3; Hisbergues M, 2001, PROTEIN SCI, V10, P293, DOI 10.1110/ps.22701; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Larsen NA, 2004, J MOL BIOL, V344, P885, DOI 10.1016/j.jmb.2004.09.094; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Madrona AY, 2004, PROTEIN SCI, V13, P1557, DOI 10.1110/ps.04704704; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mohri K, 2004, J BIOL CHEM, V279, P31697, DOI 10.1074/jbc.M403351200; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 2000, P NATL ACAD SCI USA, V97, P960, DOI 10.1073/pnas.97.3.960; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pickles LM, 2002, STRUCTURE, V10, P751, DOI 10.1016/S0969-2126(02)00768-2; Puig O, 1998, YEAST, V14, P1139; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Seeley TW, 1999, BIOCHEM BIOPH RES CO, V257, P589, DOI 10.1006/bbrc.1999.0514; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; van Nocker S, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-50; Voegtli WC, 2003, J BIOL CHEM, V278, P34373, DOI 10.1074/jbc.M302773200; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	46	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13944	13951		10.1074/jbc.M412919200	http://dx.doi.org/10.1074/jbc.M412919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15644329	hybrid			2022-12-25	WOS:000228095500096
J	Brierley, MM; Fish, EN				Brierley, MM; Fish, EN			Functional relevance of the conserved DNA-binding domain of STAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA; TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; NUCLEAR ACCUMULATION; PROTEIN-KINASE; ACTIVATION; CELLS; PROMOTERS; PATHWAY; SEQUENCES	Several distinct type I interferon ( IFN)-inducible STAT2- containing complexes have been identified. For the IFN-stimulated gene factor 3 ( ISGF3), STAT1 and IRF- 9 mediate IFN-stimulated response element ( ISRE) binding, whereas STAT2 provides a potent transactivational domain. ISGF3- independent STAT2- containing complexes, specifically STAT2: 1 and STAT2: 3, bind a gamma- activated sequence ( GAS)- like element, yet the contribution of each STAT to DNA binding is unknown. Moreover, the contribution of these ISGF3- independent STAT2- containing complexes to IFN-inducible responses is not defined. Accordingly, we generated mutant cDNAs, targeting the DNA-binding domain in STAT2. These cDNAs were introduced by transfection into U6A cells lacking STAT2, resulting in a panel of cell lines expressing mutant STAT2 proteins. Studies assessed the sensitivity of U6A cells reconstituted with intact STAT2 ( U6A- 2) and cells expressing mutant STAT2s ( U6A-2E426A, E427A ( EE- AA), U6A- 2V453I, U6A-2V454I, U6A-2V454A, U6A- 2V453I, V454I(VV-II), U6A2N458A) to IFN-inducible responses. Our data reveal that none of the mutations in the STAT2 DNA- binding domain affected IFN- inducible ISGF3 activation, and only the VV- II mutation restricted antiviral and growth inhibitory responses to IFN. Indeed, U6A-2VV-II cells are refractory to these IFN- inducible biological activities and also exhibit impaired IFN- inducible GAS-driven transcriptional activation and subsequent gene expression. Chromatin immunoprecipitation assays revealed that the VV-II mutation in STAT2 does not abrogate, but reduces the DNA binding activity of STAT2: 1 heterodimers. Taken together, these data suggest a role for the conserved DNA- binding domain of STAT2 specific to the activity of ISGF3- independent STAT2- containing complexes.	Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Fish, EN (corresponding author), Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Div Cell & Mol Biol, Canadian Blood Serv Bldg,Rm 424, Toronto, ON M5G 2M1, Canada.	en.fish@utoronto.ca						Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Brierley MM, 2002, J INTERF CYTOK RES, V22, P835, DOI 10.1089/107999002760274845; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; Ghislain JJ, 2001, J INTERF CYTOK RES, V21, P379, DOI 10.1089/107999001750277853; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Li YZ, 2004, J BIOL CHEM, V279, P970, DOI 10.1074/jbc.M309927200; Lillemeier BF, 2001, EMBO J, V20, P2508, DOI 10.1093/emboj/20.10.2508; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Masters J, 2001, J BIOL CHEM, V276, P48371, DOI 10.1074/jbc.M108019200; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Uddin S, 1997, BLOOD, V90, P2574; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Yang E, 2002, J BIOL CHEM, V277, P13455, DOI 10.1074/jbc.M112038200	40	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13029	13036		10.1074/jbc.M500426200	http://dx.doi.org/10.1074/jbc.M500426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668228	hybrid			2022-12-25	WOS:000227922000113
J	Duggin, IG; Matthews, JM; Dixon, NE; Wake, RG; Mackay, JP				Duggin, IG; Matthews, JM; Dixon, NE; Wake, RG; Mackay, JP			A complex mechanism determines polarity of DNA replication fork arrest by the replication terminator complex of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; BINDING; EQUILIBRIUM; CHROMOSOME; IDENTIFICATION; CONSTANTS; HELICASE; MUTANTS; BARRIER; REGION	Two dimers of the replication terminator protein (RTP) of Bacillus subtilis bind to a chromosomal DNA terminator site to effect polar replication fork arrest. Cooperative binding of the dimers to overlapping half-sites within the terminator is essential for arrest. It was suggested previously that polarity of fork arrest is the result of the RTP dimer at the blocking (proximal) side within the complex binding very tightly and the permissive-side RTP dimer binding relatively weakly. In order to investigate this "differential binding affinity" model, we have constructed a series of mutant terminators that contain half-sites of widely different RTP binding affinities in various combinations. Although there appeared to be a correlation between binding affinity at the proximal half-site and fork arrest efficiency in vivo for some terminators, several deviated significantly from this correlation. Some terminators exhibited greatly reduced binding cooperativity (and therefore have reduced affinity at each half-site) but were highly efficient in fork arrest, whereas one terminator had normal affinity over the proximal half-site, yet had low fork arrest efficiency. The results show clearly that there is no direct correlation between the RTP binding affinity (either within the full complex or at the proximal half-site within the full complex) and the efficiency of replication fork arrest in vivo. Thus, the differential binding affinity over the proximal and distal half-sites cannot be solely responsible for functional polarity of fork arrest. Furthermore, efficient fork arrest relies on features in addition to the tight binding of RTP to terminator DNA.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia	University of Sydney; Australian National University	Duggin, IG (corresponding author), Hutchinson MRC Res Ctr, Hills Rd, Cambridge CB2 2XZ, England.	iduggin@gmail.com	Dixon, Nicholas E/A-1226-2008; Matthews, Jacqueline/A-7322-2013; Duggin, Iain/B-3904-2011; Mackay, Joel/D-6834-2011	Dixon, Nicholas E/0000-0002-5958-6945; Duggin, Iain/0000-0003-4868-7350; Matthews, Jacqueline/0000-0001-8518-3472; Mackay, Joel/0000-0001-7508-8033				BUSSIERE DE, 1995, CELL, V80, P651; Codlin S, 2003, EMBO J, V22, P3431, DOI 10.1093/emboj/cdg330; Dalgaard JZ, 2001, GENE DEV, V15, P2060, DOI 10.1101/gad.200801; Duggin I.G., 2002, BACILLUS SUBTILIS IT, P87; Duggin IG, 1999, J MOL BIOL, V286, P1325, DOI 10.1006/jmbi.1999.2553; Gautam A, 2001, J BIOL CHEM, V276, P23471, DOI 10.1074/jbc.M009537200; GOLDSTEIN RF, 1990, ANAL BIOCHEM, V190, P220, DOI 10.1016/0003-2697(90)90184-B; Hayes D., 1995, SEDNTERP SEDIMENTATI; HILL TM, 1996, ESCHERICHIA COLI SAL, P1602; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Johzuka K, 2002, GENES CELLS, V7, P99, DOI 10.1046/j.1356-9597.2001.00508.x; KIRK L, 1994, EXPT METHODS INTRO A, P69; Kobayashi T, 2003, MOL CELL BIOL, V23, P9178, DOI 10.1128/MCB.23.24.9178-9188.2003; Kralicek AV, 1997, NUCLEIC ACIDS RES, V25, P590, DOI 10.1093/nar/25.3.590; KRALICEK AV, 1993, BIOCHEMISTRY-US, V32, P10216, DOI 10.1021/bi00089a043; LANGLEY DB, 1993, MOL MICROBIOL, V10, P771, DOI 10.1111/j.1365-2958.1993.tb00947.x; Lemon KP, 2001, P NATL ACAD SCI USA, V98, P212, DOI 10.1073/pnas.011506098; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; Manna AC, 1996, CELL, V87, P881, DOI 10.1016/S0092-8674(00)81995-9; Manna AC, 1996, P NATL ACAD SCI USA, V93, P3253, DOI 10.1073/pnas.93.8.3253; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; Mohanty BK, 2004, J BIOL CHEM, V279, P1932, DOI 10.1074/jbc.M309078200; Mohanty BK, 2001, J BIOL CHEM, V276, P13160, DOI 10.1074/jbc.M010940200; Pai KS, 1996, EMBO J, V15, P3164, DOI 10.1002/j.1460-2075.1996.tb00679.x; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; SENEAR DF, 1993, ELECTROPHORESIS, V14, P704, DOI 10.1002/elps.11501401112; Senear DF, 1998, METHODS, V16, P3, DOI 10.1006/meth.1998.0641; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; SMITH MT, 1994, J MOL BIOL, V241, P335, DOI 10.1006/jmbi.1994.1510; Smith MT, 1996, J MOL BIOL, V260, P54, DOI 10.1006/jmbi.1996.0381; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; Wake RG, 1997, FEMS MICROBIOL LETT, V153, P247, DOI 10.1016/S0378-1097(97)00245-0; Ward TR, 2000, MOL CELL BIOL, V20, P4948, DOI 10.1128/MCB.20.13.4948-4957.2000; WEISS AS, 1986, J MOL BIOL, V188, P199, DOI 10.1016/0022-2836(86)90304-9; Wilce JA, 2001, NAT STRUCT BIOL, V8, P206, DOI 10.1038/84934	35	11	12	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13105	13113		10.1074/jbc.M414187200	http://dx.doi.org/10.1074/jbc.M414187200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15657033	hybrid			2022-12-25	WOS:000227922000121
J	Gangisetty, O; Jones, CE; Bhagwat, M; Nossal, NG				Gangisetty, O; Jones, CE; Bhagwat, M; Nossal, NG			Maturation of bacteriophage T4 lagging strand fragments depends on interaction of T4 RNase H with T4 32 protein rather than the T4 gene 45 clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; PROTEIN-PROTEIN INTERACTIONS; FLAP ENDONUCLEASE-1; OKAZAKI FRAGMENT; ESCHERICHIA-COLI; SLIDING-CLAMP; SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; PROCESSIVITY-CLAMP; REPLICATION FORK	In the bacteriophage T4 DNA replication system, T4 RNase H removes the RNA primers and some adjacent DNA before the lagging strand fragments are ligated. This 5 '-nuclease has strong structural and functional similarity to the FEN1 nuclease family. We have shown previously that T4 32 protein binds DNA behind the nuclease and increases its processivity. Here we show that T4 RNase H with a C-terminal deletion (residues 278-305) retains its exonuclease activity but is no longer affected by 32 protein. T4 gene 45 replication clamp stimulates T4 RNase H on nicked or gapped substrates, where it can be loaded behind the nuclease, but does not increase its processivity. An N-terminal deletion (residues 2-10) of a conserved clamp interaction motif eliminates stimulation by the clamp. In the crystal structure of T4 RNase H, the binding sites for the clamp at the N terminus and for 32 protein at the C terminus are located close together, away from the catalytic site of the enzyme. By using mutant T4 RNase H with deletions in the binding site for either the clamp or 32 protein, we show that it is the interaction of T4 RNase H with 32 protein, rather than the clamp, that most affects the maturation of lagging strand fragments in the T4 replication system in vitro and T4 phage production in vivo.	NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Nossal, NG (corresponding author), NIDDK, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm 2A19, Bethesda, MD 20892 USA.	ngn@helix.nih.gov	Jones, Charles/GVS-9497-2022	Gangisetty, Omkaram/0000-0001-6280-0642	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alley SC, 1999, J BIOL CHEM, V274, P24485, DOI 10.1074/jbc.274.35.24485; Alley SC, 2001, J BIOL CHEM, V276, P39340, DOI 10.1074/jbc.M104956200; Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Belanger KG, 1998, MOL CELL, V2, P693, DOI 10.1016/S1097-2765(00)80167-7; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; Bhagwat M, 2001, J BIOL CHEM, V276, P28516, DOI 10.1074/jbc.M103914200; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; Carver TE, 1997, BIOCHEMISTRY-US, V36, P14409, DOI 10.1021/bi971423p; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; De Saro FJL, 2003, P NATL ACAD SCI USA, V100, P14689, DOI 10.1073/pnas.2435454100; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; Dionne I, 2003, MOL CELL, V11, P275, DOI 10.1016/S1097-2765(02)00824-9; Fu TJ, 1996, EMBO J, V15, P4414, DOI 10.1002/j.1460-2075.1996.tb00814.x; Garg P, 2004, GENE DEV, V18, P2764, DOI 10.1101/gad.1252304; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henneke G, 2003, TRENDS BIOCHEM SCI, V28, P384, DOI 10.1016/S0968-0004(03)00138-5; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; Huang YJ, 1999, GENETICS, V153, P1501; Hubscher U, 2001, MOL CELLS, V12, P149; ITAYA M, 1991, MOL GEN GENET, V227, P424, DOI 10.1007/BF00273933; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; JIANG H, 1993, J BIOL CHEM, V268, P7904; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; Jones CE, 2004, J BIOL CHEM, V279, P25721, DOI 10.1074/jbc.M402128200; Jones CE, 2004, J BIOL CHEM, V279, P12067, DOI 10.1074/jbc.M313840200; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Leu FP, 2003, MOL CELL, V11, P315, DOI 10.1016/S1097-2765(03)00042-X; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Ma YJ, 2004, J BIOL CHEM, V279, P19035, DOI 10.1074/jbc.M311738200; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; Pickering TJ, 1999, NUCLEIC ACIDS RES, V27, P730, DOI 10.1093/nar/27.3.730; Qiu JZ, 2004, J BIOL CHEM, V279, P24394, DOI 10.1074/jbc.M401464200; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; Sanders GM, 1997, EMBO J, V16, P3124, DOI 10.1093/emboj/16.11.3124; SANDERS GM, 1995, EMBO J, V14, P3966, DOI 10.1002/j.1460-2075.1995.tb00068.x; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran PT, 2002, DNA REPAIR, V1, P895, DOI 10.1016/S1568-7864(02)00114-3; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WILLIAMS KR, 1994, MOL BIOL BACTERIOP T, V4, P301; Woodworth DL, 1996, GENETICS, V143, P1081; Xu Y, 2000, J BIOL CHEM, V275, P20949, DOI 10.1074/jbc.M909135199	62	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12876	12887		10.1074/jbc.M414025200	http://dx.doi.org/10.1074/jbc.M414025200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15659404	hybrid			2022-12-25	WOS:000227922000096
J	Ichimura, T; Yamamura, H; Sasamoto, K; Tominaga, Y; Taoka, M; Kakiuchi, K; Shinkawa, T; Takahashi, N; Shimada, S; Isobe, T				Ichimura, T; Yamamura, H; Sasamoto, K; Tominaga, Y; Taoka, M; Kakiuchi, K; Shinkawa, T; Takahashi, N; Shimada, S; Isobe, T			14-3-3 proteins modulate the expression of epithelial Na+ channels by phosphorylation-dependent interaction with Nedd4-2 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE KINASE SGK; MEMBRANE-PROTEIN 2A; SODIUM-CHANNEL; LIDDLES SYNDROME; ENAC REGULATION; DELTA-SUBUNIT; PY MOTIF; SERUM; IDENTIFICATION; ACTIVATION	The ubiquitin E3 protein ligase Nedd4-2 is a physiological regulator of the epithelial sodium channel ENaC, which is essential for transepithelial Na+ transport and is linked to Liddle's syndrome, an autosomal dominant disorder of human salt-sensitive hypertension. Nedd4-2 function is negatively regulated by phosphorylation via a serum- and glucocorticoid-inducible protein kinase (Sgk1), which serves as a mechanism to inhibit the ubiquitination-dependent degradation of ENaC. We report here that 14-3-3 proteins participate in this regulatory process through a direct interaction with a phosphorylated form of human Nedd4-2 (a human gene product of KIAA0439, termed hNedd4-2). The interaction is dependent on Sgk1-catalyzed phosphorylation of hNedd4-2 at Ser-468. We found that this interaction preserved the activity of the Sgk1-stimulated ENaC-dependent Na+ current while disrupting the interaction decreased ENaC density on the Xenopus laevis oocytes surface possibly by enhancing Nedd4-2-mediated ubiquitination that leads to ENaC degradation. Our findings suggest that 14-3-3 proteins modulate the cell surface density of ENaC cooperatively with Sgk1 kinase by maintaining hNedd4-2 in an inactive phosphorylated state.	Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Tokyo 1920397, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol Morphol, Nagoya, Aichi 4678601, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Prote Syst Project,Pioneer Res Genome Frontier,ME, Hachioji, Tokyo 1920397, Japan; Daiichi Pharmaceut Co Ltd, Res Technol Ctr, Edogawa Ku, Tokyo 1348630, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Hachioji, Tokyo 1920397, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol Morphol, Nagoya, Aichi 4678601, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Prote Syst Project,Pioneer Res Genome Frontier,ME, Hachioji, Tokyo 1920397, Japan; Tokyo Univ Agr & Technol, Fac Agr, Dept Appl Biosyst Sci, Tokyo 1838509, Japan	Tokyo Metropolitan University; Nagoya City University; Tokyo Metropolitan University; Daiichi Sankyo Company Limited; Tokyo Metropolitan University; Nagoya City University; Tokyo Metropolitan University; Tokyo University of Agriculture & Technology	Ichimura, T (corresponding author), Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Minami Osawa 1-1,Hachioji Shi, Tokyo 1920397, Japan.	ichimura@mial.comp.metro-u.ac.jp	TAKAHASHI, Nobuhiro/G-1129-2013; Isobe, Toshiaki/Q-9279-2017	Taoka, Masato/0000-0001-5554-4951				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Boehmer C, 2003, J NEUROCHEM, V86, P1181, DOI 10.1046/j.1471-4159.2003.01937.x; Boehmer C, 2003, BIOCHEM BIOPH RES CO, V306, P156, DOI 10.1016/S0006-291X(03)00921-5; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; Debonneville C, 2004, MOL CELL BIOL, V24, P2397, DOI 10.1128/MCB.24.6.2397-2409.2004; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200; Dieter M, 2004, OBES RES, V12, P862, DOI 10.1038/oby.2004.104; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fotia AB, 2004, J BIOL CHEM, V279, P28930, DOI 10.1074/jbc.M402820200; Fouladkou F, 2004, AM J PHYSIOL-RENAL, V287, pF550, DOI 10.1152/ajprenal.00353.2003; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Henke G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430; Honey S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e24; Ichimura T, 2002, BIOCHEMISTRY-US, V41, P5566, DOI 10.1021/bi015946f; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; ILELEY JL, 2002, CELL SIGNAL, V14, P183; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; KAMYNINA E, 2002, AM J PHYSIOL, V283, pE377; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Lu PJ, 1999, NATURE, V399, P784; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; McDonald FJ, 2002, AM J PHYSIOL-RENAL, V283, pF431, DOI 10.1152/ajprenal.00080.2002; Meek SEM, 2004, J BIOL CHEM, V279, P32046, DOI 10.1074/jbc.M403044200; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Palmada M, 2004, BIOCHEM BIOPH RES CO, V321, P1001, DOI 10.1016/j.bbrc.2004.07.064; Palmada M, 2004, AM J PHYSIOL-GASTR L, V287, pG143, DOI 10.1152/ajpgi.00121.2003; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pham N, 2001, J BIOL CHEM, V276, P46995, DOI 10.1074/jbc.M108373200; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Stokes JB, 1999, KIDNEY INT, V56, P2318, DOI 10.1046/j.1523-1755.1999.00803.x; Toyo-oka K, 2003, NAT GENET, V34, P274, DOI 10.1038/ng1169; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; VERDECIA MA, 2000, NAT STRUCT BIOL, V7, P611; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yamamura H, 2004, J BIOL CHEM, V279, P44483, DOI 10.1074/jbc.M408929200; Yamamura H, 2004, J BIOL CHEM, V279, P12529, DOI 10.1074/jbc.M400274200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	68	154	155	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13187	13194		10.1074/jbc.M412884200	http://dx.doi.org/10.1074/jbc.M412884200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677482	hybrid			2022-12-25	WOS:000227922000131
J	Sakuragi, Y; Zybailov, B; Shen, GZ; Bryant, DA; Golbeck, JH; Diner, BA; Karygina, I; Pushkar, Y; Stehlik, D				Sakuragi, Y; Zybailov, B; Shen, GZ; Bryant, DA; Golbeck, JH; Diner, BA; Karygina, I; Pushkar, Y; Stehlik, D			Recruitment of a foreign quinone into the A(1) site of photosystem I - Characterization of a menB rubA double deletion mutant in Synechococcus sp PCC 7002 devoid of F-X, F-A, and F-B and containing plastquinone or exchanged 9,10-anthraquinone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYLLOQUINONE BIOSYNTHETIC-PATHWAY; ELECTRON-PARAMAGNETIC-RESONANCE; TRIPLET-STATE; ACCEPTOR; SYNECHOCYSTIS; EPR; PLASTOQUINONE; CHLOROPHYLLS; INACTIVATION; CAROTENOIDS	A photosystem I ( PS I) complex containing plastoquinone-9 (PQ-9) but devoid of F-X, F-B, and F-A was isolated and characterized from a mutant strain of Synechococcus sp. PCC 7002 in which the menB and rubA genes were insertionally inactivated. In isolated PS I trimers, the decay of P700(+) measured in the near-IR and the decay of A(1)(-) measured in the near-UV were found to be biphasic, with (averaged) room temperature lifetimes of 12 and 350 mu s. The decay-associated spectra of both kinetic phases are characteristic of the oxidized minus reduced difference spectrum of a semiquinone, consistent with charge recombination between P700(+) and PQ-9(-). The amplitude of the flash- induced absorbance changes in both the near- IR and the near- UV show that approximately one- half of the A(1) binding sites are either empty or nonfunctional. A spin- polarized chlorophyll triplet is observed by time- resolved EPR, and it is attributed to the 3P700 product of P700(+) A(0)(-) charge recombination via the T-0 spin level in those PS I complexes that do not contain a functional quinone. In those A(1) sites that are occupied, the P700(+) Q(-) polarization pattern indicates that PQ-9 is oriented in a similar manner to that in the menB mutant. When excess 9,10-anthraquinone is added in vitro, it displaces PQ-9 and occupies the A(1) binding site more readily than in the menB mutant. This can be explained by a greater accessibility to the A(1) site in the menB rubA mutant due to the absence of FX and the stromal ridge polypeptides. The relatively low binding affinity of 9,10-anthraquinone allows it to be readily removed from the A(1) site by washing. However, all A(1) sites are shown to bind napthoquinones with high affinity and thus are proven to be functionally competent in quinone binding. The ability to readily displace PQ-9 from the A(1) site makes the menB rubA mutant ideal for introducing novel quinones, particularly anthraquinones, into PS I.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; DuPont Co Inc, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA; Free Univ Berlin, Inst Expt Phys, D-14195 Berlin, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; DuPont; Free University of Berlin	Golbeck, JH (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	jhg5@psu.edu	Sakuragi, Yumiko/E-9707-2012	Sakuragi, Yumiko/0000-0002-9405-5197; Zybailov, Boris/0000-0003-2432-9145				BENSASSON R, 1973, BIOCHIM BIOPHYS ACTA, V325, P175, DOI 10.1016/0005-2728(73)90163-1; Bittl R, 2001, J PHYS CHEM B, V105, P5525, DOI 10.1021/jp0033014; BUDIL DE, 1991, BIOCHIM BIOPHYS ACTA, V1057, P1, DOI 10.1016/S0005-2728(05)80081-7; Cohen RO, 2004, BIOCHEMISTRY-US, V43, P4741, DOI 10.1021/bi035633f; DILLEY R. A., 1963, ANALYT BIOCHEM, V5, P531, DOI 10.1016/0003-2697(63)90073-3; Diner BA, 1998, METHOD ENZYMOL, V297, P337; Dunphy P.J., 1971, METHODS ENZYMOLOGY, VVolume 18, P407, DOI [10.1016/S0076-6879(71)18035-4, DOI 10.1016/S0076-6879(71)18035-4]; Frank HA, 1996, PHOTOCHEM PHOTOBIOL, V63, P257, DOI 10.1111/j.1751-1097.1996.tb03022.x; FRANK HA, 1979, P NATL ACAD SCI USA, V76, P5124, DOI 10.1073/pnas.76.10.5124; Frigaard NU, 2004, METH MOL B, V274, P325; GOLBECK JH, 1979, BIOCHIM BIOPHYS ACTA, V547, P347, DOI 10.1016/0005-2728(79)90016-1; Itoh S, 2001, BBA-BIOENERGETICS, V1507, P115, DOI 10.1016/S0005-2728(01)00199-2; Johnson TW, 2001, J BIOL CHEM, V276, P39512, DOI 10.1074/jbc.M104040200; Johnson TW, 2000, J BIOL CHEM, V275, P8523, DOI 10.1074/jbc.275.12.8523; Johnson TW, 2003, BBA-BIOENERGETICS, V1557, P67, DOI 10.1016/S0005-2728(02)00396-1; JOHNSON TW, 2003, CRC HDB ORGANIC PHOT, P119; KAMLOWSKI A, 1996, BER BUNSEN PHYS CHEM, V100, P2081; KRIEGER A, 1995, BBA-BIOENERGETICS, V1229, P193, DOI 10.1016/0005-2728(95)00002-Z; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MacKinney G, 1941, J BIOL CHEM, V140, P315; Pushkar YN, 2005, J BIOL CHEM, V280, P12382, DOI 10.1074/jbc.M412940200; Pushkar YN, 2004, J MOL STRUCT, V700, P233, DOI 10.1016/j.molstruc.2004.02.015; Pushkar YN, 2004, J PHYS CHEM B, V108, P9439, DOI 10.1021/jp0361879; Sakuragi Y, 2004, THESIS PENNSYLVANIA; SCHLODDER E, 2001, P 12 INT C PHOT, V6015; Semenov AY, 2000, J BIOL CHEM, V275, P23429, DOI 10.1074/jbc.M000508200; Shen GZ, 2002, J BIOL CHEM, V277, P20355, DOI 10.1074/jbc.M201104200; Shen GZ, 2002, J BIOL CHEM, V277, P20343, DOI 10.1074/jbc.M201103200; Shinkarev VP, 2002, BIOPHYS J, V83, P2885, DOI 10.1016/S0006-3495(02)75298-3; SIECKMANN I, 1993, BIOCHEMISTRY-US, V32, P4842, DOI 10.1021/bi00069a020; van der Est A, 1998, BBA-BIOENERGETICS, V1409, P87, DOI 10.1016/S0005-2728(98)00152-2; van der Est A, 2001, BBA-BIOENERGETICS, V1507, P212, DOI 10.1016/S0005-2728(01)00204-3; Vassiliev IR, 1997, BIOPHYS J, V72, P301, DOI 10.1016/S0006-3495(97)78669-7; Vassiliev IR, 2001, BBA-BIOENERGETICS, V1507, P139, DOI 10.1016/S0005-2728(01)00197-9; Yoshida E, 2003, ANAL SCI, V19, P1001, DOI 10.2116/analsci.19.1001; ZIEGLER K, 1989, Z NATURFORSCH C, V44, P468; Zybailov B, 2000, J BIOL CHEM, V275, P8531, DOI 10.1074/jbc.275.12.8531	37	27	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12371	12381		10.1074/jbc.M412943200	http://dx.doi.org/10.1074/jbc.M412943200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15681848	hybrid			2022-12-25	WOS:000227922000038
J	Wang, T; Hu, YC; Dong, SZ; Fan, M; Tamae, D; Ozeki, M; Gao, Q; Gius, D; Li, JJ				Wang, T; Hu, YC; Dong, SZ; Fan, M; Tamae, D; Ozeki, M; Gao, Q; Gius, D; Li, JJ			Co-activation of ERK, NF-kappa B, and GADD45 beta in response to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; SUPEROXIDE-DISMUTASE GENE; FREE-RADICAL SCAVENGERS; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTORS; STRESS RESPONSES; INHIBITOR PD98059; INDUCED APOPTOSIS; GENOTOXIC STRESS; FAMILY PROTEINS	NF-kappa B has been well documented to play a critical role in signaling cell stress reactions. The extracellular signal-regulated kinase (ERK) regulates cell proliferation and survival. GADD45 beta is a primary cell cycle element responsive to NF-kappa B activation in anti-apoptotic responses. The present study provides evidence demonstrating that NK-kappa B, ERK and GADD45 beta are co-activated by ionizing radiation (IR) in a pattern of mutually dependence to increase cell survival. Stress conditions generated in human breast cancer MCF-7 cells by the administration of a single exposure of 5 Gy IR resulted in the activation of ERK but not p38 or JNK, along with an enhancement of the NF-kappa B transactivation and GADD45 beta expression. Overexpression of dominant negative Erk (DN-Erk) or pre-exposure to ERK inhibitor PD98059 inhibited NF-kappa B. Transfection of dominant negative mutant I kappa B that blocks NF-kappa B nuclear translocation, inhibited ERK activity and GADD45 beta expression and increased cell radiosensitivity. Interaction of p65 and ERK was visualized in living MCF-7 cells by bimolecular fluorescence complementation analysis. Antisense inhibition of GADD45 beta strikingly blocked IR-induced NF-kappa B and ERK but not p38 and JNK. Overall, these results demonstrate a possibility that NF-kappa B, ERK, and GADD45 beta are able to coordinate in a loop-like signaling network to defend cells against the cytotoxicity induced by ionizing radiation.	Purdue Univ, Sch Hlth Sci, Div Mol Radiobiol, W Lafayette, IN 47907 USA; Beckman Res Inst, Div Radiat Oncol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Duarte, CA 91010 USA; Bio Rad Labs Inc, Life Sci Grp, San Ramon, CA 94583 USA; NCI, Ctr Canc Res, Radiat Oncol Sci Program, Mol Radiat Oncol,NIH, Bethesda, MD 20892 USA; Purdue Univ, Sch Hlth Sci, Div Mol Radiobiol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; City of Hope; Beckman Research Institute of City of Hope; City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Purdue University System; Purdue University; Purdue University West Lafayette Campus	Li, JJ (corresponding author), Purdue Univ, Sch Hlth Sci, Div Mol Radiobiol, 1279 Civil Engn Blvd,550 Stadium Mall Dr, W Lafayette, IN 47907 USA.	jjli@purdue.edu		Li, Jian Jian/0000-0003-3694-9675	NCI NIH HHS [R01 CA101990] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010544, R01CA101990] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; Ajenjo N, 2004, J BIOL CHEM, V279, P32813, DOI 10.1074/jbc.M313656200; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Amundson SA, 2001, RADIAT RES, V156, P657, DOI 10.1667/0033-7587(2001)156[0657:IOGEAA]2.0.CO;2; Anders M, 2003, CANCER RES, V63, P2088; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Bebien M, 2003, ONCOGENE, V22, P1836, DOI 10.1038/sj.onc.1206334; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bradbury CM, 2001, CANCER RES, V61, P7689; Chen XF, 2002, CANCER RES, V62, P1213; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; Chung HK, 2003, J BIOL CHEM, V278, P28079, DOI 10.1074/jbc.M212835200; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Duffey DC, 1999, CANCER RES, V59, P3468; Fornace AJ, 1999, GENE EXPRESSION, V7, P387; Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7; Granville DJ, 2000, BLOOD, V95, P256; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Hara T, 1998, BIOCHEM BIOPH RES CO, V244, P41, DOI 10.1006/bbrc.1998.8210; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hassan KA, 2002, CANCER RES, V62, P6414; He HC, 1999, CELL GROWTH DIFFER, V10, P307; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kataoka Y, 2002, INT J RADIAT ONCOL, V53, P180, DOI 10.1016/S0360-3016(01)02820-6; Kiningham KK, 1997, CANCER RES, V57, P5265; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li ZK, 2001, RADIAT RES, V155, P543, DOI 10.1667/0033-7587(2001)155[0543:EGAIMH]2.0.CO;2; Li ZK, 2001, FREE RADICAL BIO MED, V30, P260, DOI 10.1016/S0891-5849(00)00468-8; Liang K, 2003, MOL CANCER THER, V2, P1113; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Meier KE, 1998, CELL SIGNAL, V10, P415, DOI 10.1016/S0898-6568(97)00140-X; MOODIE SA, 1995, ONCOGENE, V11, P447; Murley JS, 2001, FREE RADICAL BIO MED, V30, P1426, DOI 10.1016/S0891-5849(01)00554-8; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Shonai T, 2002, CELL DEATH DIFFER, V9, P963, DOI 10.1038/sj.cdd.4401050; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Spitz DR, 2004, CANCER METAST REV, V23, P311, DOI 10.1023/B:CANC.0000031769.14728.bc; Sreekumar A, 2001, CANCER RES, V61, P7585; Suzuki K, 2001, CANCER RES, V61, P5396; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang TL, 2002, INT IMMUNOPHARMACOL, V2, P1509, DOI 10.1016/S1567-5769(02)00058-9; Xia LQ, 2004, CANCER RES, V64, P221, DOI 10.1158/0008-5472.CAN-03-0969; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Zelivianski S, 2003, INT J CANCER, V107, P478, DOI 10.1002/ijc.11413; ZHAN QM, 1994, CANCER RES, V54, P2755; Zhao WL, 2001, CANCER RES, V61, P5537	72	62	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12593	12601		10.1074/jbc.M410982200	http://dx.doi.org/10.1074/jbc.M410982200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15642734	hybrid, Green Accepted			2022-12-25	WOS:000227922000064
J	Wang, Y; Shibasaki, F; Mizuno, K				Wang, Y; Shibasaki, F; Mizuno, K			Calcium signal-induced cofilin dephosphorylation is mediated by slingshot via calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN DEPOLYMERIZING FACTOR; LIM-KINASE 1; PHOSPHATASE SLINGSHOT; BINDING PROTEIN; IN-VIVO; PHOSPHORYLATION; ACTIVATION; DYNAMICS; CELLS; REORGANIZATION	Cofilin, an essential regulator of actin filament dynamics, is inactivated by phosphorylation at Ser-3 and reactivated by dephosphorylation. Although cofilin undergoes dephosphorylation in response to extracellular stimuli that elevate intracellular Ca2+ concentrations, signaling mechanisms mediating Ca2+-induced cofilin dephosphorylation have remained unknown. We investigated the role of Slingshot (SSH) 1L, a member of a SSH family of protein phosphatases, in mediating Ca2+-induced cofilin dephosphorylation. The Ca2+ ionophore A23187 and Ca2+-mobilizing agonists, ATP and histamine, induced SSH1L activation and cofilin dephosphorylation in cultured cells. A23187- or histamine-induced SSH1L activation and cofilin dephosphorylation were blocked by calcineurin inhibitors or a dominant-negative form of calcineurin, indicating that calcineurin mediates Ca2+-induced SSH1L activation and cofilin dephosphorylation. Importantly, knockdown of SSH1L expression by RNA interference abolished A23187- or calcineurin-induced cofilin dephosphorylation. Furthermore, calcineurin dephosphorylated SSH1L and increased the cofilin-phosphatase activity of SSH1L in cell-free assays. Based on these findings, we suggest that Ca2+-induced cofilin dephosphorylation is mediated by calcineurin-dependent activation of SSH1L.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Cell Physiol, Tokyo 1138613, Japan	Tohoku University; Tokyo Metropolitan Institute of Medical Science	Mizuno, K (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan.	kmizuno@biology.tohoku.ac.jp	Mizuno, Kensaku/G-8631-2015					AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Aguiari G, 2003, BIOCHEM BIOPH RES CO, V301, P657, DOI 10.1016/S0006-291X(02)03011-5; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Birkenfeld J, 2001, BIOCHEM BIOPH RES CO, V286, P493, DOI 10.1006/bbrc.2001.5435; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Endo M, 2003, J NEUROSCI, V23, P2527; Fukazawa' Y, 2003, NEURON, V38, P447, DOI 10.1016/S0896-6273(03)00206-X; Groth RD, 2003, BIOCHEM BIOPH RES CO, V311, P1159, DOI 10.1016/j.bbrc.2003.09.002; Henley J, 2004, TRENDS CELL BIOL, V14, P320, DOI 10.1016/j.tcb.2004.04.006; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Kaji N, 2003, J BIOL CHEM, V278, P33450, DOI 10.1074/jbc.M305802200; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lee KH, 2000, EUR J IMMUNOL, V30, P892, DOI 10.1002/1521-4141(200003)30:3<892::AID-IMMU892>3.0.CO;2-U; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Meberg PJ, 2000, J NEUROSCI, V20, P2459; Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896-6273(02)00758-4; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Nagata-Ohashi K, 2004, J CELL BIOL, V165, P465, DOI 10.1083/jcb.200401136; Nishita M, 2004, J BIOL CHEM, V279, P7193, DOI 10.1074/jbc.M312591200; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Ohta Y, 2003, GENES CELLS, V8, P811, DOI 10.1046/j.1365-2443.2003.00678.x; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SUZUKI K, 1995, J BIOL CHEM, V270, P19551, DOI 10.1074/jbc.270.33.19551; Takuma T, 1996, J BIOCHEM, V120, P35; Toshima J, 2001, J BIOL CHEM, V276, P31449, DOI 10.1074/jbc.M102988200; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zhan Q, 2003, CELL MOTIL CYTOSKEL, V54, P1, DOI 10.1002/cm.10079	41	172	181	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12683	12689		10.1074/jbc.M411494200	http://dx.doi.org/10.1074/jbc.M411494200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15671020	hybrid			2022-12-25	WOS:000227922000075
J	Shi, QL; Chen, HL; Xu, H; Gibson, GE				Shi, QL; Chen, HL; Xu, H; Gibson, GE			Reduction in the E2k subunit of the alpha-ketoglutarate dehydrogenase complex has effects independent of complex activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE SUPRANUCLEAR PALSY; ELEMENT-BINDING-PROTEIN; IN-SITU MITOCHONDRIA; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; ESCHERICHIA-COLI; PARKINSONS-DISEASE; ISOCITRATE DEHYDROGENASE; THIOREDOXIN REDUCTASE; RESPIRATORY-FAILURE	The activity of the alpha-ketoglutarate dehydrogenase complex (KGDHC) declines in brains of patients with several neurodegenerative diseases. KGDHC consists of multiple copies of E1k, E2k, and E3. E1k and E2k are unique to KGDHC and may have functions independent of the complex. The present study tested the consequences of different levels of diminished E2k mRNA on protein levels of the subunits, KGDHC activity, and physiological responses. Human embryonic kidney cells were stably transfected with an E2k sense or antisense expression vector. Sense control (E2k-mRNA-100) was compared with two clones in which the mRNA was reduced to 67% of control (E2k-mRNA-67) or to 30% of control (E2k-mRNA-30). The levels of the E2k protein in clones paralleled the reduction in mRNA, and E3 proteins were unaltered. Unexpectedly, the clone with the greatest reduction in E2k protein (E2k-mRNA-30) had a 40% increase in E1k protein. The activity of the complex was only 52% of normal in E2k-mRNA-67 clone, but was near normal (90%) in E2k-mRNA-30 clone. Subsequent experiments tested whether the physiological consequences of a reduction in E2k mRNA correlated more closely to E2k protein or to KGDHC activity. Growth rate, increased DCF-detectable reactive oxygen species, and cell death in response to added oxidant were proportional to E2k proteins, but not complex activity. These results were not predicted because subunits unique to KGDHC have never been manipulated in mammalian cells. These results suggest that in addition to its essential role in metabolism, the E2k component of KGDHC may have other novel roles.	Cornell Univ, Weill Med Coll, Burke Med Res Inst, Dept Neurol & Neurosci, White Plains, NY 10605 USA	Cornell University	Gibson, GE (corresponding author), Cornell Univ, Weill Med Coll, Burke Med Res Inst, Dept Neurol & Neurosci, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	ggibson@med.cornell.edu			NIA NIH HHS [AG11921, AG14930, AG14600] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011921, R01AG014600, P01AG014930] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albers DS, 2000, J NEUROCHEM, V74, P878, DOI 10.1046/j.1471-4159.2000.740878.x; Albers DS, 1999, J NEUROCHEM, V73, P881, DOI 10.1046/j.1471-4159.1999.0730881.x; ASAHINA T, 1995, DIABETES, V44, P520, DOI 10.2337/diabetes.44.5.520; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; Berg A, 1998, EUR J BIOCHEM, V252, P45, DOI 10.1046/j.1432-1327.1998.2520045.x; Borlongan C V, 1996, J Fla Med Assoc, V83, P335; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Bunik V, 1997, BIOL CHEM, V378, P1125, DOI 10.1515/bchm.1997.378.10.1125; Bunik V, 2000, J MOL CATAL B-ENZYM, V8, P165, DOI 10.1016/S1381-1177(99)00054-5; Bunik VI, 2003, EUR J BIOCHEM, V270, P1036, DOI 10.1046/j.1432-1033.2003.03470.x; Bunik VI, 2002, EUR J BIOCHEM, V269, P5004, DOI 10.1046/j.1432-1033.2002.03204.x; BUTTERWORTH RF, 1993, ALCOHOL CLIN EXP RES, V17, P1084, DOI 10.1111/j.1530-0277.1993.tb05668.x; CATE RL, 1980, J BIOL CHEM, V255, P7556; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; Chinopoulos C, 2000, NEUROCHEM INT, V36, P483, DOI 10.1016/S0197-0186(99)00161-8; DANSON MJ, 1978, P NATL ACAD SCI USA, V75, P5386, DOI 10.1073/pnas.75.11.5386; de Jong L, 2000, FEBS LETT, V483, P62, DOI 10.1016/S0014-5793(00)02086-X; ELZINGA SDJ, 1993, NUCLEIC ACIDS RES, V21, P5328, DOI 10.1093/nar/21.23.5328; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; Gibson GE, 1999, ANN NY ACAD SCI, V893, P79, DOI 10.1111/j.1749-6632.1999.tb07819.x; GIBSON GE, 1988, ARCH NEUROL-CHICAGO, V45, P836, DOI 10.1001/archneur.1988.00520320022009; Gibson GE, 2003, NEUROCHEM INT, V43, P129, DOI 10.1016/S0197-0186(02)00225-5; Gibson GE, 1998, ANN NEUROL, V44, P676, DOI 10.1002/ana.410440414; Gibson GE, 2000, BBA-MOL BASIS DIS, V1502, P319, DOI 10.1016/S0925-4439(00)00057-0; Gibson GE, 2000, ANN NEUROL, V48, P297, DOI 10.1002/1531-8249(200009)48:3<297::AID-ANA3>3.0.CO;2-Z; Gourlay LJ, 2003, J BIOL CHEM, V278, P32631, DOI 10.1074/jbc.M303862200; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jimenez-Jimenez FJ, 1999, NEUROSCI LETT, V271, P33, DOI 10.1016/S0304-3940(99)00515-7; Johnson MT, 1997, P NATL ACAD SCI USA, V94, P14512, DOI 10.1073/pnas.94.26.14512; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; Khayat M, 2001, J IMMUNOL, V166, P2937, DOI 10.4049/jimmunol.166.5.2937; Kim MR, 2003, BIOCHEM BIOPH RES CO, V304, P119, DOI 10.1016/S0006-291X(03)00547-3; Klivenyi P, 2004, J NEUROCHEM, V88, P1352, DOI 10.1046/j.1471-4159.2003.02263.x; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Mastrogiacomo F, 1996, NEURODEGENERATION, V5, P27, DOI 10.1006/neur.1996.0004; Mastrogiacomo F, 1996, ANN NEUROL, V39, P592, DOI 10.1002/ana.410390508; MASTROGIACOMO F, 1993, J NEUROCHEM, V61, P2007, DOI 10.1111/j.1471-4159.1993.tb07436.x; McCammon MT, 2003, MOL BIOL CELL, V14, P958, DOI 10.1091/mbc.E02-07-0422; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; MIZUNO Y, 1994, ANN NEUROL, V35, P204, DOI 10.1002/ana.410350212; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; Park LCH, 1999, J NEUROCHEM, V72, P1948, DOI 10.1046/j.1471-4159.1999.0721948.x; Park LCH, 2000, ANAL BIOCHEM, V277, P86, DOI 10.1006/abio.1999.4359; Park LCH, 2001, J NEUROSCI RES, V66, P1028, DOI 10.1002/jnr.10062; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; PETTIT FH, 1973, J BIOL CHEM, V248, P5282; Reed LJ, 2001, J BIOL CHEM, V276, P38329, DOI 10.1074/jbc.R100026200; REPETTO B, 1991, MOL CELL BIOL, V11, P3931, DOI 10.1128/MCB.11.8.3931; REPETTO B, 1990, MOL CELL BIOL, V10, P4221, DOI 10.1128/MCB.10.8.4221; SCHOONEN WGEJ, 1990, J BIOL CHEM, V265, P11118; SCHOONEN WGEJ, 1990, MUTAT RES, V237, P173; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; TANAKA N, 1972, J BIOL CHEM, V247, P4043; Terwel D, 1998, J NEUROL SCI, V161, P47, DOI 10.1016/S0022-510X(98)00240-8; WAGENKNECHT T, 1983, J MOL BIOL, V165, P523, DOI 10.1016/S0022-2836(83)80217-4; WAGENKNECHT T, 1987, J BIOL CHEM, V262, P877; WAGENKNECHT T, 1986, BIOCHEM BIOPH RES CO, V135, P802, DOI 10.1016/0006-291X(86)90999-X; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WASKIEWICZ DE, 1984, BIOCHEMISTRY-US, V23, P3136, DOI 10.1021/bi00309a005; Xu H, 2001, J NEUROCHEM, V78, P132	67	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10888	10896		10.1074/jbc.M409064200	http://dx.doi.org/10.1074/jbc.M409064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15649899	hybrid			2022-12-25	WOS:000227761800004
J	Takahashi-Terada, A; Kotera, M; Ohshima, K; Furumoto, T; Matsumura, H; Kai, Y; Izui, K				Takahashi-Terada, A; Kotera, M; Ohshima, K; Furumoto, T; Matsumura, H; Kai, Y; Izui, K			Maize phosphoenolpyruvate carboxylase - Mutations at the putative binding site for glucose 6-phosphate caused desensitization and abolished responsiveness to regulatory phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALLOSTERIC SITE; 3-DIMENSIONAL STRUCTURE; DIRECTED MUTAGENESIS; C-4 PHOTOSYNTHESIS; ACID-METABOLISM; PYRUVATE-KINASE; PLANTS; FRUCTOSE-1,6-BISPHOSPHATE; EXPRESSION	Phosphoenolpyruvate carboxylases ( PEPC, EC 4.1.1.31) from higher plants are regulated by both allosteric effects and reversible phosphorylation. Previous x-ray crystallographic analysis of Zea mays PEPC has revealed a binding site for sulfate ion, speculated to be the site for an allosteric activator, glucose 6-phosphate (Glc-6-P) (Matsumura, H., Xie, Y., Shirakata, S., Inoue, T., Yoshinaga, T., Ueno, Y., Izui, K., and Kai, Y. ( 2002) Structure (Lond.) 10, 1721-1730). Because kinetic experiments have also supported this notion, each of the four basic residues (Arg-183, -184, -231, and -372' on the adjacent subunit) located at or near the binding site was replaced by Gln, and the kinetic properties of recombinant mutant enzymes were investigated. Complete desensitization to Glc-6-P was observed for R183Q, R184Q, R183Q/R184Q ( double mutant), and R372Q, as was a marked decrease in the sensitivity for R231Q. The heterotropic effect of Glc-6-P on an allosteric inhibitor, L-malate, was also abolished, but sensitivity to Gly, another allosteric activator of monocot PEPC, was essentially not affected, suggesting the distinctness of their binding sites. Considering the kinetic and structural data, Arg-183 and Arg-231 were suggested to be involved directly in the binding with phosphate group of Glc-6-P, and the residues Arg-184 and Arg-372 were thought to be involved in making up the site for Glc-6-P and/ or in the transmission of an allosteric regulatory signal. Most unexpectedly, the mutant enzymes had almost lost responsiveness to regulatory phosphorylation at Ser-15. An apparent lack of kinetic competition between the phosphate groups of Glc-6-P and of phospho-Ser at 15 suggested the distinctness of their binding sites. The possible roles of these Arg residues are discussed.	Kyoto Univ, Grad Sch Biostudies, Lab Plant Physiol, Sakyo Ku, Kyoto 6068502, Japan; Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan	Kyoto University; Osaka University	Izui, K (corresponding author), Kyoto Univ, Grad Sch Biostudies, Lab Plant Physiol, Sakyo Ku, Kyoto 6068502, Japan.	izui@kais.kyoto-u.ac.jp	Kotera, Masaaki/AAJ-9938-2020	Matsumura, Hiroyoshi/0000-0003-0361-3796				BANDARIAN V, 1992, PLANT PHYSIOL, V100, P1411, DOI 10.1104/pp.100.3.1411; Blasing OE, 2000, J BIOL CHEM, V275, P27917; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHANAN BB, 2000, BIOCH MOL BIOL PLANT, P812; BUCHANAN BB, 2000, BIOCH MOL BIOL PLANT, P619; Buchbinder JL, 2001, ANNU REV BIOPH BIOM, V30, P191, DOI 10.1146/annurev.biophys.30.1.191; Chen LM, 2004, PLANTA, V219, P440, DOI 10.1007/s00425-004-1244-3; Chollet R, 1996, ANNU REV PLANT PHYS, V47, P273, DOI 10.1146/annurev.arplant.47.1.273; CUNIN R, 1975, MOL GEN GENET, V140, P51, DOI 10.1007/BF00268988; Dong LY, 1998, PLANT CELL PHYSIOL, V39, P865, DOI 10.1093/oxfordjournals.pcp.a029446; Dong LY, 1997, PLANT CELL PHYSIOL, V38, P1340, DOI 10.1093/oxfordjournals.pcp.a029127; Dong LY, 1997, BIOSCI BIOTECH BIOCH, V61, P545, DOI 10.1271/bbb.61.545; Fenton AW, 2002, ARCH BIOCHEM BIOPHYS, V397, P28, DOI 10.1006/abbi.2001.2634; Frank J, 2001, BIOPHYS CHEM, V92, P53, DOI 10.1016/S0301-4622(01)00185-5; GERHART JC, 1963, COLD SPRING HARB SYM, V28, P491, DOI 10.1101/SQB.1963.028.01.065; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IZUI K, 1982, J BIOCHEM, V92, P423, DOI 10.1093/oxfordjournals.jbchem.a133949; Izui K, 2004, ANNU REV PLANT BIOL, V55, P69, DOI 10.1146/annurev.arplant.55.031903.141619; IZUI K, 1970, J BIOCHEM-TOKYO, V68, P227, DOI 10.1093/oxfordjournals.jbchem.a129350; IZUI K, 1986, NUCLEIC ACIDS RES, V14, P1615, DOI 10.1093/nar/14.4.1615; IZUI K, 2002, ENZYMES LYASE, V4, P37; JENKINS CLD, 1987, BIOCHEM INT, V14, P219; JOHNSON LN, 1990, J BIOL CHEM, V265, P2409; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; Kai Y, 1999, P NATL ACAD SCI USA, V96, P823, DOI 10.1073/pnas.96.3.823; Kai Y, 2003, ARCH BIOCHEM BIOPHYS, V414, P170, DOI 10.1016/S0003-9861(03)00170-X; KODAKI T, 1984, J BIOCHEM-TOKYO, V95, P637, DOI 10.1093/oxfordjournals.jbchem.a134652; Lardy H, 1972, ENZYMES, P117; LATZKO E, 1983, PHYSIOL VEG, V21, P805; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; Matsumura H, 2002, STRUCTURE, V10, P1721, DOI 10.1016/S0969-2126(02)00913-9; Miyao M, 2003, ARCH BIOCHEM BIOPHYS, V414, P197, DOI 10.1016/S0003-9861(03)00117-6; Mujica-Jimenez C, 1998, BBA-PROTEIN STRUCT M, V1386, P132, DOI 10.1016/S0167-4838(98)00093-4; Nimmo HG, 2003, ARCH BIOCHEM BIOPHYS, V414, P189, DOI 10.1016/S0003-9861(03)00115-2; Ogawa N, 1997, PLANT CELL PHYSIOL, V38, P76, DOI 10.1093/oxfordjournals.pcp.a029088; OLEARY MH, 1982, ANNU REV PLANT PHYS, V33, P297, DOI 10.1146/annurev.pp.33.060182.001501; Patel HM, 2004, J BACTERIOL, V186, P5129, DOI 10.1128/jb.186.15.5129-5137.2004; PODESTA FE, 1987, PLANT CELL PHYSIOL, V28, P375; Rath VL, 1996, STRUCTURE, V4, P463, DOI 10.1016/S0969-2126(96)00051-2; Sako Y, 1997, FEMS MICROBIOL LETT, V153, P159, DOI 10.1016/S0378-1097(97)00253-X; SUTTON F, 1986, J BIOL CHEM, V261, P6078; Svensson P, 2003, ARCH BIOCHEM BIOPHYS, V414, P180, DOI 10.1016/S0003-9861(03)00165-6; Tovar-Mendez A, 2000, PLANT PHYSIOL, V123, P149, DOI 10.1104/pp.123.1.149; Trapani S, 2001, J MOL BIOL, V313, P1059, DOI 10.1006/jmbi.2001.5093; Tsuchida Y, 2001, FEBS LETT, V507, P318, DOI 10.1016/S0014-5793(01)02994-5; Ueno Y, 1997, FEBS LETT, V417, P57, DOI 10.1016/S0014-5793(97)01254-4; Ueno Y, 2000, PLANT J, V21, P17, DOI 10.1046/j.1365-313x.2000.00649.x; VIDAL J, 1997, TRENDS PLANT SCI, V2, P1360; YANAGISAWA S, 1988, FEBS LETT, V229, P107, DOI 10.1016/0014-5793(88)80807-X; Yano M, 1997, EUR J BIOCHEM, V247, P74, DOI 10.1111/j.1432-1033.1997.t01-1-00074.x	50	37	39	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11798	11806		10.1074/jbc.M408768200	http://dx.doi.org/10.1074/jbc.M408768200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15665330	hybrid			2022-12-25	WOS:000227761800109
J	Vaughn, J; Huang, SL; Wessel, I; Sorensen, TK; Hsieh, T; Jensen, LH; Jensen, PB; Sehested, M; Nitiss, JL				Vaughn, J; Huang, SL; Wessel, I; Sorensen, TK; Hsieh, T; Jensen, LH; Jensen, PB; Sehested, M; Nitiss, JL			Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE ANALYSIS; N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; SACCHAROMYCES-CEREVISIAE; DOUBLE HELIX; CORE-DOMAIN; ALPHA; MECHANISM; BISDIOXOPIPERAZINE; INHIBITION	Type II DNA topoisomerases catalyze changes in DNA topology and use nucleotide binding and hydrolysis to control conformational changes required for the enzyme reaction. We examined the ATP hydrolysis activity of a bisdioxopiperazine-resistant mutant of human topoisomerase II alpha with phenylalanine substituted for tyrosine at residue 50 in the ATP hydrolysis domain of the enzyme. This substitution reduced the DNA-dependent ATP hydrolysis activity of the mutant protein without affecting the relaxation activity of the enzyme. A similar but stronger effect was seen when the homologous mutation (Tyr(28) -> Phe) was introduced in yeast Top2. The ATPase activities of human TOP2 alpha(Tyr(50) -> Phe) and yeast Top2(Tyr28 3 Phe) were resistant to both bisdioxopiperazines and the ATPase inhibitor sodium orthovanadate. Like bisdioxopiperazines, vanadate traps the enzyme in a salt-stable closed conformation termed the closed clamp, which can be detected in the presence of circular DNA substrates. Consistent with the vanadate-resistant ATPase activity, salt-stable closed clamps were not detected in reactions containing the yeast or human mutant protein, vanadate, and ATP. Similarly, ADP trapped wild-type topoisomerase II as a closed clamp, but could not trap either the human or yeast mutant enzymes. Our results demonstrate that bisdioxopiperazine-resistant mutants exhibit a difference in the stability of the closed clamp formed by the enzyme and that this difference in stability may lead to a loss of DNA-stimulated ATPase. We suggest that the DNA-stimulated ATPase of topoisomerase II is intimately connected with steps that occur while the N-terminal domain of the enzyme is dimerized.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Rigshosp 5444, Lab Ctr, Dept Pathol, DK-2100 Copenhagen, Denmark; Rigshosp 5074, Finsen Ctr, Lab Expt Med Oncol, DK-2100 Copenhagen, Denmark; Duke Univ, Dept Biochem, Durham, NC 27710 USA	St Jude Children's Research Hospital; Rigshospitalet; Rigshospitalet; Duke University	Nitiss, JL (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.nitiss@stjude.org	Wu, Wan-lin/G-8937-2012; Hsieh, Tao-shih/G-9305-2012; Nitiss, John/E-9974-2010; Wessel, Irene/AAG-3259-2021	Wessel, Irene/0000-0001-9986-5001; Nitiss, John/0000-0002-1013-4972	NCI NIH HHS [CA23099, CA52814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023099, R01CA052814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Baird CL, 2001, J BIOL CHEM, V276, P27893, DOI 10.1074/jbc.M102544200; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chang S, 1998, J BIOL CHEM, V273, P19822, DOI 10.1074/jbc.273.31.19822; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Corbett KD, 2003, EMBO J, V22, P151, DOI 10.1093/emboj/cdg008; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; Hu T, 2002, J BIOL CHEM, V277, P5944, DOI 10.1074/jbc.M111394200; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1991, CANCER RES, V51, P4909; JANNATIPOUR M, 1993, J BIOL CHEM, V268, P18586; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Jensen LH, 2000, FEBS LETT, V480, P201, DOI 10.1016/S0014-5793(00)01934-7; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; Morris SK, 2000, J BIOL CHEM, V275, P2613, DOI 10.1074/jbc.275.4.2613; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Nitiss JL, 1998, BIOCHEMISTRY-US, V37, P3078, DOI 10.1021/bi9723257; Noble CG, 2002, J MOL BIOL, V318, P361, DOI 10.1016/S0022-2836(02)00049-9; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; Renodon-Corniere A, 2002, BIOCHEMISTRY-US, V41, P13395, DOI 10.1021/bi0263614; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; ROCA J, 1995, TRENDS BIOCHEM SCI, V20, P156, DOI 10.1016/S0968-0004(00)88993-8; Sehested M, 1998, CANCER RES, V58, P1460; Skouboe C, 2003, J BIOL CHEM, V278, P5768, DOI 10.1074/jbc.M210332200; Snapka RM, 1996, BIOCHEM PHARMACOL, V52, P543, DOI 10.1016/0006-2952(96)00305-X; Walker JV, 2004, J BIOL CHEM, V279, P25947, DOI 10.1074/jbc.M312314200; Walker JV, 2002, CANCER INVEST, V20, P570, DOI 10.1081/CNV-120002156; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wessel I, 1999, CANCER RES, V59, P3442; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	43	22	22	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11920	11929		10.1074/jbc.M411841200	http://dx.doi.org/10.1074/jbc.M411841200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647268	hybrid			2022-12-25	WOS:000227761800122
J	Connelly, L; Madhani, M; Hobbs, AJ				Connelly, L; Madhani, M; Hobbs, AJ			Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice - A pro-inflammatory role for eNOS-derived no in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; AKT-DEPENDENT PHOSPHORYLATION; NECROSIS-FACTOR-ALPHA; SEPTIC SHOCK; L-ARGININE; UP-REGULATION; PATHWAY; ACTIVATION; CELLS; EXPRESSION	The expression of inducible nitric-oxide synthase (iNOS) and subsequent "high-output" nitric oxide (NO) production underlies the systemic hypotension, inadequate tissue perfusion, and organ failure associated with septic shock. Therefore, modulators of iNOS expression and activity, both endogenous and exogenous, are important in determining the magnitude and time course of this condition. We have shown previously that NO from the constitutive endothelial NOS (eNOS) is necessary to obtain maximal iNOS expression and activity following exposure of murine macrophages to lipopolysaccharide (LPS). Thus, eNOS represents an important regulator of iNOS expression in vitro. Herein, we validate this hypothesis in vivo using a murine model of sepsis. A temporal reduction in iNOS expression and activity was observed in LPS-treated eNOS knock-out (KO) mice as compared with wild-type animals; this was reflected in a more stable hemodynamic profile in eNOS KO mice during endotoxaemia. Furthermore, in human umbilical vein endothelial cells, LPS leads to the activation of eNOS through phosphoinositide 3-kinase- and Akt/protein kinase B-dependent enzyme phosphorylation. These data indicate that the pathogenesis of sepsis is characterized by an initial eNOS activation, with the resultant NO acting as a co-stimulus for the expression of iNOS, and therefore highlight a novel pro-inflammatory role for eNOS.	UCL, Wolfson Inst Biomed Res, London WC1E 6AE, England	University of London; University College London	Hobbs, AJ (corresponding author), UCL, Wolfson Inst Biomed Res, Cruciform Bldg,Gower St, London WC1E 6AE, England.	a.hobbs@ucl.ac.uk	Madhani, Melanie/I-4342-2014; Connelly, Linda/GVS-4612-2022	Madhani, Melanie/0000-0001-8596-763X; Hobbs, Adrian/0000-0002-3589-7108				Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557; Barsacchi R, 2003, MOL PHARMACOL, V63, P886, DOI 10.1124/mol.63.4.886; Braulio VB, 2004, AM J PHYSIOL-ENDOC M, V287, pE912, DOI 10.1152/ajpendo.00540.2003; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; Cardaropoli S, 2003, J HYPERTENS, V21, P2103, DOI 10.1097/00004872-200311000-00020; Chauhan SD, 2003, FASEB J, V17, P773, DOI 10.1096/fj.02-0668fje; Chun KH, 2003, JNCI-J NATL CANCER I, V95, P291, DOI 10.1093/jnci/95.4.291; Connelly L, 2003, J BIOL CHEM, V278, P26480, DOI 10.1074/jbc.M302238200; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; EVANS T, 1993, CIRC SHOCK, V41, P77; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GOMEZJIMENEZ J, 1995, CRIT CARE MED, V23, P253, DOI 10.1097/00003246-199502000-00009; Hattori Y, 2003, EUR J PHARMACOL, V481, P153, DOI 10.1016/j.ejphar.2003.09.034; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; Kang WS, 2004, J PHARMACOL EXP THER, V310, P452, DOI 10.1124/jpet.104.066506; Kauser K, 1997, J VASC RES, V34, P229, DOI 10.1159/000159227; Kawanaka H, 2002, HEPATOLOGY, V35, P393, DOI 10.1053/jhep.2002.30958; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Peng TQ, 2003, J BIOL CHEM, V278, P8099, DOI 10.1074/jbc.M207288200; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; Rees DD, 1998, BRIT J PHARMACOL, V124, P540, DOI 10.1038/sj.bjp.0701815; SALVEMINI D, 1989, EUR J PHARMACOL, V171, P135, DOI 10.1016/0014-2999(89)90437-8; SALVEMINI D, 1990, P NATL ACAD SCI USA, V87, P2593, DOI 10.1073/pnas.87.7.2593; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Thoenes M, 1996, J MOL CELL CARDIOL, V28, P165, DOI 10.1006/jmcc.1996.0016; Tunctan B, 1998, PHARMACOL RES, V38, P405, DOI 10.1006/phrs.1998.0381; Wray GM, 1998, SHOCK, V9, P329, DOI 10.1097/00024382-199805000-00003; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576	41	127	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10040	10046		10.1074/jbc.M411991200	http://dx.doi.org/10.1074/jbc.M411991200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647265	hybrid			2022-12-25	WOS:000227559600038
J	Gumpricht, E; Dahl, R; Devereaux, MW; Sokol, RJ				Gumpricht, E; Dahl, R; Devereaux, MW; Sokol, RJ			Licorice compounds glycyrrhizin and 18 beta-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION; INDUCED APOPTOSIS; HEPATIC MITOCHONDRIA; CELL-DEATH; IN-VITRO; URSODEOXYCHOLIC ACID; DEPENDENT MANNER; LIVER-INJURY; GROWTH	The accumulation of hydrophobic bile acids results in cholestatic liver injury by increasing oxidative stress, mitochondrial dysfunction, and activation of cell signaling pathways. Licorice root and its constituents have been utilized as antihepatotoxic agents. The purpose of this study was to evaluate the potential modulation by a primary component of licorice root, glycyrrhizin (GL), and its metabolite, 18 beta-glycyrrhetinic acid (GA), in a hepatocyte model of cholestatic liver injury. Preincubation of fresh rat hepatocyte suspensions with GL or GA reduced glycochenodeoxycholic acid (GCDC)-dependent reactive oxygen species generation, with GA more potent than GL. Interestingly, GL and GA had opposing effects toward GCDC-induced cytotoxicity; GA prevented both necrosis and apoptosis, whereas GL enhanced apoptosis. GCDC promoted activation of caspase 10, caspase 3, and PARP; all were inhibited by GA but not GL. Induction of apoptosis by GCDC was also associated with activation of JNK, which was prevented by GA. Activation of caspase 9 and dissipation of mitochondrial membrane potential were prevented by GA but not GL. In liver mitochondrial studies, GL and GA were both potent inhibitors of the mitochondrial permeability transition, reactive oxygen species generation, and cytochrome c release at submicromolar concentrations. Results from this study suggest that GL exhibits proapoptotic properties, whereas GA is a potent inhibitor of bile acid-induced apoptosis and necrosis in a manner consistent with its antioxidative effect.	Childrens Hosp, Pediat Liver Ctr, Denver, CO 80218 USA; Univ Colorado, Sch Med, Sect Pediat Gastroenterol Hepatol & Nutr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Sch Med, Pediat Gen Clin Res Ctr, Denver, CO 80262 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sokol, RJ (corresponding author), Childrens Hosp, Pediat Liver Ctr, Box B290,1056 E 19th Ave, Denver, CO 80218 USA.	Sokol.Ronald@tchden.org		Gumpricht, Eric/0000-0001-6034-3484	NIDDK NIH HHS [R01 DK-38446] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038446] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAO T, 1991, BIOCHEM PHARMACOL, V41, P1025; Armanini D, 2002, EXP CLIN ENDOCR DIAB, V110, P257, DOI 10.1055/s-2002-34587; Aso Y., 1977, IGAKUNO AYUMI, V102, P562; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Chan HT, 2003, TOXICOLOGY, V188, P211, DOI 10.1016/S0300-483X(03)00087-8; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chieco P, 1997, HISTOCHEM J, V29, P875, DOI 10.1023/A:1026446008712; DEGROOT G, 1988, J CHROMATOGR, V456, P71, DOI 10.1016/0021-9673(86)80007-3; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; Graf D, 2002, GASTROENTEROLOGY, V122, P1411, DOI 10.1053/gast.2002.32976; GREIM H, 1973, BIOCHEM MED METAB B, V8, P280, DOI 10.1016/0006-2944(73)90032-X; Gumpricht E, 2004, PEDIATR RES, V55, P814, DOI 10.1203/01.PDR.0000117845.23762.6B; Gumpricht E, 2002, J BIOL CHEM, V277, P25823, DOI 10.1074/jbc.M112305200; Gumpricht E, 2000, TOXICOL APPL PHARM, V164, P102, DOI 10.1006/taap.2000.8894; HATTORI M, 1988, CHEM PHARM BULL, V33, P210; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; ISHIDA S, 1993, BIOL PHARM BULL, V16, P293; Jeong HG, 2002, PHARMACOL RES, V46, P221, DOI 10.1016/S1043-6618(02)00121-4; Jones SA, 2004, EXP CELL RES, V292, P29, DOI 10.1016/j.yexcr.2003.08.005; Kinjo J, 2003, BIOL PHARM BULL, V26, P1357, DOI 10.1248/bpb.26.1357; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Krutovskikh VA, 2002, ONCOGENE, V21, P1989, DOI 10.1038/sj.onc.1205187; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Kyriakis John M, 2004, Methods Mol Biol, V250, P61; Li MK, 2004, SEMIN LIVER DIS, V24, P21; NAGAI T, 1991, ARCH ENVIRON CON TOX, V20, P432, DOI 10.1007/BF01064416; NOSE M, 1994, PLANTA MED, V60, P136, DOI 10.1055/s-2006-959435; PATEL T, 1994, J CLIN INVEST, V94, P2183, DOI 10.1172/JCI117579; Powell AA, 2001, BIOCHEM J, V356, P481, DOI 10.1042/0264-6021:3560481; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Rodrigues CMP, 1998, MOL MED, V4, P165, DOI 10.1007/BF03401914; Rodrigues CMP, 1999, CELL DEATH DIFFER, V6, P842, DOI 10.1038/sj.cdd.4400560; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Schoemaker MH, 2004, HEPATOLOGY, V39, P1563, DOI 10.1002/hep.20246; Schwabe RF, 2004, FASEB J, V18, P720, DOI 10.1096/fj.03-0771fje; Shah GM, 1995, ANAL BIOCHEM, V232, P251, DOI 10.1006/abio.1995.0016; Shivaram KN, 1998, FREE RADICAL BIO MED, V25, P480, DOI 10.1016/S0891-5849(98)00077-X; Sokol RJ, 1998, GASTROENTEROLOGY, V114, P164, DOI 10.1016/S0016-5085(98)70644-4; Sokol RJ, 2003, J PEDIATR GASTR NUTR, V37, P4, DOI 10.1097/00005176-200307000-00003; SOKOL RJ, 1995, GASTROENTEROLOGY, V109, P1249, DOI 10.1016/0016-5085(95)90585-5; Sokol RJ, 2001, PEDIATR RES, V49, P519, DOI 10.1203/00006450-200104000-00014; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Takeda S, 1996, J PHARM PHARMACOL, V48, P902, DOI 10.1111/j.2042-7158.1996.tb05998.x; Tanahashi T, 2002, J STEROID BIOCHEM, V80, P441, DOI 10.1016/S0960-0760(02)00033-X; van Rossum TGJ, 1999, CLIN THER, V21, P2080, DOI 10.1016/S0149-2918(00)87239-2; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Webster CRL, 2001, HEPATOLOGY, V33, P608, DOI 10.1053/jhep.2001.22756; YAMAMURA Y, 1992, J PHARM SCI, V81, P1042, DOI 10.1002/jps.2600811018; Yerushalmi B, 2001, HEPATOLOGY, V33, P616, DOI 10.1053/jhep.2001.22702; Yoshikawa M, 1999, BIOL PHARM BULL, V22, P951, DOI 10.1248/bpb.22.951	54	112	122	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10556	10563		10.1074/jbc.M411673200	http://dx.doi.org/10.1074/jbc.M411673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642733	hybrid			2022-12-25	WOS:000227559600100
J	Liu, XF; Yuan, H; Fu, BJ; Disbrow, GL; Apolinario, T; Tomaic, V; Kelley, ML; Baker, CC; Huibregtse, J; Schlegel, R				Liu, XF; Yuan, H; Fu, BJ; Disbrow, GL; Apolinario, T; Tomaic, V; Kelley, ML; Baker, CC; Huibregtse, J; Schlegel, R			The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERASE REVERSE-TRANSCRIPTASE; CALCIUM-INDUCED DIFFERENTIATION; TUMOR-SUPPRESSOR PROTEIN; HUMAN EPITHELIAL-CELLS; TYPE-16 E6; C-MYC; CATALYTIC SUBUNIT; HUMAN KERATINOCYTES; MUTATIONAL ANALYSIS; ANGELMAN-SYNDROME	Most human cancer cells display increased telomerase activity that appears to be critical for continued cell proliferation and tumor formation. The E6 protein of malignancy-associated human papillomaviruses increases cellular telomerase in primary human keratinocytes at least partly via transcriptional activation of the telomerase catalytic subunit, hTERT. In the present study, we investigated whether E6AP, a ubiquitin ligase well known for binding and mediating some of the activities of the E6 oncoprotein, participated in the transactivation of the hTERT promoter. Our results demonstrate that E6 mutants that fail to bind E6AP are also defective for increasing telomerase activity and transactivating the hTERT promoter. More importantly, E6AP knock-out mouse cells and small interfering RNA techniques demonstrated that E6AP was required for hTERT promoter transactivation in both mouse and human cells. Neither E6 nor E6AP bound to the hTERT promoter or activated the promoter in the absence of the partner protein. With all transactivation-competent E6 proteins, induction of the hTERT promoter was dependent upon E box elements in the core promoter. It appears, therefore, that E6-mediated activation of the hTERT promoter requires a complex of E6-E6AP to engage the hTERT promoter and that activation is dependent upon Myc binding sites in the promoter. The recruitment of a cellular ubiquitin ligase to the hTERT promoter during E6-mediated transcriptional activation suggests a role for the local ubiquitination (and potential degradation) of promoter-associated regulatory proteins, including the Myc protein.	Georgetown Univ, Dept Pathol & Oncol, Sch Med, Washington, DC 20057 USA; NCI, Cellular Oncol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; Univ Texas, Inst Cellular & Mol Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Austin	Schlegel, R (corresponding author), Georgetown Univ, Med Ctr, Dept Pathol, 3900 Reservoir Rd,NW, Washington, DC 20057 USA.	schleger@georgetown.edu	Yuan, Hang/E-8670-2010		NCI NIH HHS [R01CA53371, R01CA106440] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010312] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA053371] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; Avilion AA, 1996, CANCER RES, V56, P645; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; Be XB, 2001, BIOCHEMISTRY-US, V40, P1293, DOI 10.1021/bi0019592; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chen JJ, 1997, VIROLOGY, V236, P30, DOI 10.1006/viro.1997.8725; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Chen JJ, 1998, J BIOL CHEM, V273, P13537, DOI 10.1074/jbc.273.22.13537; Cooper B, 2003, VIROLOGY, V306, P87, DOI 10.1016/S0042-6822(02)00012-0; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Degenhardt YY, 2001, J VIROL, V75, P151, DOI 10.1128/JVI.75.1.151-160.2001; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu BJ, 2003, CANCER RES, V63, P7815; Gao QS, 2000, J BIOL CHEM, V275, P14824, DOI 10.1074/jbc.275.20.14824; Gao QS, 2002, CANCER RES, V62, P3315; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Li SY, 1999, ONCOGENE, V18, P5727, DOI 10.1038/sj.onc.1202960; Lu ZM, 2004, J BIOL CHEM, V279, P35664, DOI 10.1074/jbc.M403385200; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; McMurray HR, 2003, J VIROL, V77, P9852, DOI 10.1128/JVI.77.18.9852-9861.2003; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; MUNGER K, 1989, J VIROL, V63, P4417; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Ned R, 1997, J VIROL, V71, P4866, DOI 10.1128/JVI.71.6.4866-4870.1997; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Ramakrishnan S, 1998, CANCER RES, V58, P622; RAPP L, 1998, BIOCHIM BIOPHYS ACTA, V1378, P1; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; Sherman L, 1997, VIROLOGY, V237, P296, DOI 10.1006/viro.1997.8778; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Suprynowicz FA, 2000, J BIOL CHEM, V275, P5111, DOI 10.1074/jbc.275.7.5111; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 1998, CANCER RES, V58, P1558; Thomas M, 1999, J GEN VIROL, V80, P1513, DOI 10.1099/0022-1317-80-6-1513; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yuan H, 2002, J VIROL, V76, P10685, DOI 10.1128/JVI.76.21.10685-10691.2002; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zur Hausen H, 2001, JNCI-J NATL CANCER I, V93, P252	87	86	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10807	10816		10.1074/jbc.M410343200	http://dx.doi.org/10.1074/jbc.M410343200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15655249	hybrid			2022-12-25	WOS:000227559600128
J	Liu, JW; Chandra, D; Rudd, MD; Butler, AP; Pallotta, V; Brown, D; Coffer, PJ; Tang, DG				Liu, JW; Chandra, D; Rudd, MD; Butler, AP; Pallotta, V; Brown, D; Coffer, PJ; Tang, DG			Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS	ONCOGENE			English	Article						apoptosis; Bim; Bcl-2; ROS; FOXO3a; MnSOD; cancer therapy	BCL-2 FAMILY-MEMBER; REACTIVE OXYGEN; TRANSCRIPTION FACTORS; CELL-SURVIVAL; CYTOCHROME-C; KAPPA-B; ACTIVATION; EXPRESSION; BIM; DEATH	Most cancer therapeutics fails to eradicate cancer because cancer cells rapidly develop resistance to its proapoptotic effects. The underlying mechanisms remain incompletely understood. Here we show that three representative apoptotic stimuli, that is, serum starvation, a mitochondrial toxin, and a DNA-damaging agent (etoposide), rapidly induce several distinct classes of prosurvival molecules, in particular, Bcl-2/Bcl-X-L and superoxide dismutase (SOD; including both MnSOD and Cu/ZnSOD). At the population level, the induction of these prosurvival molecules occurs prior to or concomitant with the induction of proapoptotic molecules such as Bim and Bak. Blocking the induction using siRNAs of the prosurvival or proapoptotic molecules facilitates or inhibits apoptosis, respectively. One master transcription factor, FOXO3a, is involved in the transcriptional activation of some of these prosurvival (e. g., MnSOD) and proapoptotic (e. g., Bim) molecules. Interestingly, in all three apoptotic systems, FOXO3a itself is also upregulated at the transcriptional level. Mechanistic studies indicate that reactive oxygen species (ROS) are rapidly induced upon apoptotic stimulation and that ROS inhibitors/scavengers block the induction of FOXO3a, MnSOD, and Bim. Finally, we show that apoptotic stimuli also upregulate prosurvival molecules in normal diploid human fibroblasts and at subapoptotic concentrations. Taken together, these results suggest that various apoptotic inducers may rapidly mobilize prosurvival mechanisms through ROS-activated master transcription factors such as FOXO3a. The results imply that effective anticancer therapeutics may need to combine both apoptosis-inducing and survival-suppressing strategies.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div 1C, Smithville, TX 78957 USA; Ambion Inc, Austin, TX 78744 USA; Univ Utrecht, Med Ctr, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands	University of Texas System; UTMD Anderson Cancer Center; Utrecht University	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020; Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Chandra D, 2003, J BIOL CHEM, V278, P17408, DOI 10.1074/jbc.M300750200; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Joshi B, 1999, CANCER RES, V59, P4343; Kinnula VL, 2003, AM J RESP CRIT CARE, V167, P1600, DOI 10.1164/rccm.200212-1479SO; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Liu JW, 2002, CANCER RES, V62, P2976; Martin AG, 2002, J BIOL CHEM, V277, P50834, DOI 10.1074/jbc.M209369200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nair VD, 2004, J BIOL CHEM, V279, P27494, DOI 10.1074/jbc.M312135200; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; Sade H, 2004, CELL DEATH DIFFER, V11, P416, DOI 10.1038/sj.cdd.4401347; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tang DG, 1998, CANCER RES, V58, P3466; Tang DG, 1997, J CELL PHYSIOL, V172, P155, DOI 10.1002/(SICI)1097-4652(199708)172:2<155::AID-JCP3>3.0.CO;2-N; Valks DM, 2003, J BIOL CHEM, V278, P25542, DOI 10.1074/jbc.M303760200; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200	45	79	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2020	2031		10.1038/sj.onc.1208385	http://dx.doi.org/10.1038/sj.onc.1208385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15674333				2022-12-25	WOS:000227681900006
J	Syed, V; Mukherjee, K; Lyons-Weiler, J; Lau, KM; Mashima, T; Tsuruo, T; Ho, SM				Syed, V; Mukherjee, K; Lyons-Weiler, J; Lau, KM; Mashima, T; Tsuruo, T; Ho, SM			Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling	ONCOGENE			English	Article						cDNA microarray; hormonal carcinogenesis; ovarian surface epithelial cells; apoptosis; cancer cell invasion; metastasis	SURFACE EPITHELIAL-CELLS; TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; ORAL-CONTRACEPTIVES; INDUCED APOPTOSIS; B ISOFORMS; LONG ARM; PR-A; EXPRESSION; RECEPTOR	Although progesterone (P4) has been implicated to offer protection against ovarian cancer (OCa), little is known of its mechanism of action. The goal of this study was to identify P4-regulated genes that have anti-OCa action. Three immortalized nontumorigenic human ovarian surface epithelial ( HOSE) cell lines and three OCa (OVCA) cell lines were subjected to 5 days of P4 treatment. Transcriptional pro. ling with a cDNA microarray containing approximate to2400 known genes was used to identify genes (1) whose expression was consistently downregulated in OVCA cell lines compared to HOSE cell lines, and ( 2) whose expression was restored in OCa cell lines by P4 treatment. From the candidates selected, activating transcription factor-3 (ATF-3), caveolin-1, deleted in liver cancer-1 (DLC-1), and nonmetastatic clone 23 ( NM23-H2) were chosen for post hoc functional studies based on their previously reported action as tumor suppressors or apoptosis inducers. Semiquantitative RT-PCR analyses confirmed loss of or reduced transcription of these genes in OVCA cells when compared to HOSE cells and their upregulation following P4 treatment. Hormonal specificity was demonstrated by blockade experiments with a progestin antagonist RU 38486. Ectopic expression of caveolin-1, DLC-1, and NM23-H2 caused growth inhibition in OVCA cell cultures, but not in HOSE cell cultures, while forced expression of ATF-3 suppressed growth in both. Overexpression of AFT-3 also enhanced caspase-3 activity in both HOSE and OVCA cells, whereas ectopic expression of caveolin-1 and DLC-1 only activated this enzyme in OCa cells. In contrast, NM23-H2 overexpression was ineffective in activating caspase-3. Overexpression of any of the four genes in OCa cells reduced soft-agar colony formation and cell invasiveness. Taken together, we have identified four new P4-regulated, antitumor genes forOCa. However, their modes of action differ significantly; ATF-3 primarily functions as an apoptosis inducer, NM23-H2 as a suppressor of cell motility, and caveolin-1 and DLC-1 exhibiting features of classical tumor suppressors. To the best of our knowledge, except for NM23-H2, this is the first report linking P4 to the regulation of these tumor suppressor/proapoptotic genes, which could serve as future therapeutic targets.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Pittsburgh, Inst Canc, Benedum Ctr Oncol Informat, Ctr Pathol Informat,Dept Pathol, Pittsburgh, PA 15232 USA; Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Japanese Fdn Canc Res, Tokyo 170, Japan; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese University of Hong Kong; Prince of Wales Hospital; Japanese Foundation for Cancer Research; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Rm 504,Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	Shuk-mei.Ho@umassmed.edu	Lyons-Weiler, James/Q-4948-2019	Lyons-Weiler, James/0000-0001-9343-7508; Lau, Kin-Mang/0000-0001-5888-1937	NATIONAL CANCER INSTITUTE [R01CA094221, R03CA091250] Funding Source: NIH RePORTER; NCI NIH HHS [CA091250, CA94221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1994, LANCET, V344, P1250, DOI 10.1016/S0140-6736(94)90749-8; Athanassiadou P, 1998, EUR J CANCER PREV, V7, P225, DOI 10.1097/00008469-199806000-00007; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bender FC, 2000, CANCER RES, V60, P5870; Bu SZ, 1997, CANCER, V79, P1944, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V; Callow ME, 2000, APPL ENVIRON MICROB, V66, P3249, DOI 10.1128/AEM.66.8.3249-3254.2000; Cheng KW, 2001, MOL ENDOCRINOL, V15, P2078, DOI 10.1210/me.15.12.2078; CRAMER DW, 1982, NEW ENGL J MED, V307, P1047, DOI 10.1056/NEJM198210213071703; Das H, 2000, BRIT J CANCER, V82, P1682; Davis M, 1996, CANCER RES, V56, P741; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fournier HN, 2003, J BIOENERG BIOMEMBR, V35, P81, DOI 10.1023/A:1023450008347; Freshney RI, 1994, MANUAL BASIC TECHNIQ; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Ho SM, 2003, ONCOGENE, V22, P4243, DOI 10.1038/sj.onc.1206437; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; Hu Z, 2000, Zhonghua Fu Chan Ke Za Zhi, V35, P423; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; KEITH BM, 2001, GYNECOL ONCOL, V82, P127, DOI DOI 10.1006/GYN0.2001.6221); Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Koike M, 1999, ONCOLOGY-BASEL, V56, P160, DOI 10.1159/000011958; La Vecchia C, 2001, EUR J CANCER PREV, V10, P125, DOI 10.1097/00008469-200104000-00002; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Lau KM, 2003, LAB INVEST, V83, P743, DOI 10.1097/01.LAB.0000069519.06988.24; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lyons-Weiler J, 2003, GENOME RES, V13, P503, DOI 10.1101/gr.104003; Makrigiannakis A, 2000, ANN NY ACAD SCI, V900, P16; MANDAI M, 1995, BRIT J CANCER, V72, P691, DOI 10.1038/bjc.1995.395; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Modan B, 1998, AM J EPIDEMIOL, V147, P1038; Murdoch WJ, 2002, REPRODUCTION, V123, P743, DOI 10.1530/rep.0.1230743; Ng IOL, 2000, CANCER RES, V60, P6581; Nishizuka S, 1997, BRIT J CANCER, V76, P1567, DOI 10.1038/bjc.1997.598; Ouatas T, 2003, CLIN CANCER RES, V9, P3763; Patel Satish, 2004, Appl Bioinformatics, V3, P49; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; RAJA RLT, 1981, PROGR CLIN BIOL RES, P149; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Salazar-Martinez E, 1999, CANCER RES, V59, P3658; Sartorius CA, 2003, BREAST CANCER RES TR, V79, P287, DOI 10.1023/A:1024031731269; Schildkraut JM, 2002, JNCI-J NATL CANCER I, V94, P32; SCHNEIDER HP, 1995, INT J FERTIL MENOP S, V1, P40; Shao R, 2003, BIOL REPROD, V68, P914, DOI 10.1095/biolreprod.102.009035; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Syed V, 2003, ONCOGENE, V22, P6883, DOI 10.1038/sj.onc.1206828; Tas F, 2002, AM J CLIN ONCOL-CANC, V25, P164, DOI 10.1097/00000421-200204000-00012; Thomas HV, 1998, ANN HUM BIOL, V25, P69, DOI 10.1080/03014469800005432; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Xu XJ, 2004, GENE, V328, P143, DOI 10.1016/j.gene.2003.12.003; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yen SS, 1994, MATERNAL FETAL MED P, P382; Yu S, 2001, J CELL BIOCHEM, V82, P445, DOI 10.1002/jcb.1171; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	67	91	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1774	1787		10.1038/sj.onc.1207991	http://dx.doi.org/10.1038/sj.onc.1207991			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674352				2022-12-25	WOS:000227345100013
J	Garg, A; Bhasin, M; Raghava, GPS				Garg, A; Bhasin, M; Raghava, GPS			Support vector machine-based method for subcellular localization of human proteins using amino acid compositions, their order, and similarity search	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTION; LOCATION; SITES	Here we report a systematic approach for predicting subcellular localization ( cytoplasm, mitochondrial, nuclear, and plasma membrane) of human proteins. First, support vector machine (SVM)-based modules for predicting subcellular localization using traditional amino acid and dipeptide (i + 1) composition achieved overall accuracy of 76.6 and 77.8%, respectively. PSI-BLAST, when carried out using a similarity-based search against a nonredundant data base of experimentally annotated proteins, yielded 73.3% accuracy. To gain further insight, a hybrid module (hybrid1) was developed based on amino acid composition, dipeptide composition, and similarity information and attained better accuracy of 84.9%. In addition, SVM modules based on a different higher order dipeptide i. e. i + 2, i + 3, and i + 4 were also constructed for the prediction of subcellular localization of human proteins, and overall accuracy of 79.7, 77.5, and 77.1% was accomplished, respectively. Furthermore, another SVM module hybrid2 was developed using traditional dipeptide ( i + 1) and higher order dipeptide ( i + 2, i + 3, and i + 4) compositions, which gave an overall accuracy of 81.3%. We also developed SVM module hybrid3 based on amino acid composition, traditional and higher order dipeptide compositions, and PSI-BLAST output and achieved an overall accuracy of 84.4%. A Web server HSLPred (www.imtech. res. in/raghava/hslpred/ or bioinformatics. uams. edu/ raghava/hslpred/) has been designed to predict subcellular localization of human proteins using the above approaches.	Inst Microbial Technol, Bioinformat Ctr, Chandigarh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Raghava, GPS (corresponding author), Inst Microbial Technol, Bioinformat Ctr, Sector 39A, Chandigarh, India.	raghava@imtech.res.in	Raghava, Gajendra P.S./AAA-2413-2022; Bhasin, Manoj/B-3018-2009; Raghava, Gajendra/B-1717-2009	Raghava, Gajendra P.S./0000-0002-8902-2876; Bhasin, Manoj/0000-0001-5172-420X				Alberts B, 1994, MOL BIOL CELL, P1255; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; Bhasin M, 2004, NUCLEIC ACIDS RES, V32, pW414, DOI 10.1093/nar/gkh350; BRENDEL V, 1992, MATH COMPUT MODEL, V16, P37, DOI 10.1016/0895-7177(92)90150-J; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; Chou KC, 2002, J BIOL CHEM, V277, P45765, DOI 10.1074/jbc.M204161200; Chou KC, 1999, PROTEIN ENG, V12, P107, DOI 10.1093/protein/12.2.107; CHOU KC, 1995, PROTEINS, V21, P319, DOI 10.1002/prot.340210406; Donnes P, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-25; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FRIEDMAN JH, 1974, IEEE T COMPUT, VC 23, P881, DOI 10.1109/T-C.1974.224051; FRIEDMAN JH, 1991, ANN STAT, V19, P1, DOI 10.1214/aos/1176347963; Fujiwara Y, 2001, Genome Inform, V12, P103; Gardy JL, 2003, NUCLEIC ACIDS RES, V31, P3613, DOI 10.1093/nar/gkg602; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Hua SJ, 2001, BIOINFORMATICS, V17, P721, DOI 10.1093/bioinformatics/17.8.721; LODISH H, 1995, MOL CELL BIOL, P739; Nair R, 2003, NUCLEIC ACIDS RES, V31, P3337, DOI 10.1093/nar/gkg514; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Ward JJ, 2003, BIOINFORMATICS, V19, P1650, DOI 10.1093/bioinformatics/btg223; Yuan Z, 1999, FEBS LETT, V451, P23, DOI 10.1016/S0014-5793(99)00506-2	25	179	193	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14427	14432		10.1074/jbc.M411789200	http://dx.doi.org/10.1074/jbc.M411789200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15647269	hybrid			2022-12-25	WOS:000228236800011
J	Choi, HS; Choi, BY; Cho, YY; Zhu, F; Bode, AM; Dong, ZG				Choi, HS; Choi, BY; Cho, YY; Zhu, F; Bode, AM; Dong, ZG			Phosphorylation of Ser(28) in histone H3 mediated by mixed lineage kinase-like mitogen-activated protein triple kinase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHROMOSOME CONDENSATION; CHROMATIN REMODELING ENZYMES; B-INDUCED PHOSPHORYLATION; EARLY GENE INDUCTION; MAP KINASE; H3 PHOSPHORYLATION; TRANSCRIPTION; MSK1; IDENTIFICATION; EXPRESSION	The mitogen-activated protein kinase cascades elicit modification of chromatin proteins such as histone H3 by phosphorylation concomitant with gene activation. Here, we demonstrate for the first time that the mixed lineage kinase-like mitogen-activated protein triple kinase (MLTK)-alpha phosphorylates histone H3 at Ser(28). MLTK-alpha but neither a kinase-negative mutant of MLTK-alpha nor MLTK-beta interacted with and phosphorylated histone H3 in vivo and in vitro. When overexpressed in 293T or JB6 Cl41 cells, MLTK-alpha phosphorylated histone H3 at Ser(28) but not at Ser(10). The interaction between MLTK-alpha and histone H3 was enhanced by stimulation with ultraviolet B light (UVB) or epidermal growth factor (EGF), which resulted in the accumulation of MLTK-beta in the nucleus. UVB- or EGF-induced phosphorylation of histone H3 at Ser(28) was not affected by PD 98059, a MEK inhibitor, or SB 202190, a p38 kinase inhibitor, in MLTK-alpha-overexpressing JB6 Cl41 cells. Significantly, UVB- or EGF-induced phosphorylation of histone H3 at Ser(28) was blocked by small interfering RNA of MLTK-alpha. The inhibition of histone H3 phosphorylation at Ser(28) in the MLTK-alpha knock-down JB6 Cl41 cells was not due to a defect in mitogen- and stress-activated protein kinase 1 or 90-kDa ribosomal S6 kinase (p90(RSK)) activity. In summary, these results illustrate that MLTK-alpha plays a key role in the UVB- and EGF-induced phosphorylation of histone H3 at Ser(28), suggesting that MLTK-alpha might be a new histone H3 kinase at the level of mitogen- activated protein kinase kinase kinases.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	ZHU, Feng/G-3567-2010; ZHU, Feng/C-1303-2010; Cho, Yong-Yeon/AAD-4263-2020	Zhu, Feng/0000-0003-1172-0102	NATIONAL CANCER INSTITUTE [R37CA081064, R01CA077646, R01CA081064, P01CA088961] Funding Source: NIH RePORTER; NCI NIH HHS [CA81064, CA77646, CA88961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; CANO E, 1995, J CELL SCI, V108, P3599; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cho YY, 2004, CANCER RES, V64, P3855, DOI 10.1158/0008-5472.CAN-04-0201; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; EARNSHAW WC, 1991, CHROMOSOMA, V100, P139, DOI 10.1007/BF00337241; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Kirschmann DA, 2000, CANCER RES, V60, P3359; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Lee KM, 1999, BIOCHEMISTRY-US, V38, P8423, DOI 10.1021/bi990090o; Liu TC, 2000, BIOCHEM BIOPH RES CO, V274, P811, DOI 10.1006/bbrc.2000.3236; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; Ota T, 2002, CANCER RES, V62, P5168; Peterson CL, 2002, EMBO REP, V3, P319, DOI 10.1093/embo-reports/kvf075; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Schlesinger TK, 1998, FRONT BIOSCI, V3, P1181; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Svejstrup JQ, 2003, SCIENCE, V301, P1053, DOI 10.1126/science.1088901; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Van Hooser A, 1998, J CELL SCI, V111, P3497; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Wu JH, 2004, CANCER RES, V64, P6461, DOI 10.1158/0008-5472.CAN-04-0866; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200	54	20	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13545	13553		10.1074/jbc.M410521200	http://dx.doi.org/10.1074/jbc.M410521200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15684425	hybrid			2022-12-25	WOS:000228095500046
J	Leo, E; Gould, KA; Pan, XS; Capranico, G; Sanderson, MR; Palumbo, M; Fisher, LM				Leo, E; Gould, KA; Pan, XS; Capranico, G; Sanderson, MR; Palumbo, M; Fisher, LM			Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE-DETERMINING REGION; ESCHERICHIA-COLI; QUINOLONE ANTIBACTERIALS; BINDING-SITE; COMPLEX-FORMATION; BACTERIOPHAGE-MU; WILD-TYPE; II-ALPHA; MECHANISM; INHIBITION	Topoisomerase ( topo) IV and gyrase are bacterial type IIA DNA topoisomerases essential for DNA replication and chromosome segregation that act via a transient double- stranded DNA break involving a covalent enzyme-DNA " cleavage complex." Despite their mechanistic importance, the DNA breakage determinants are not understood for any bacterial type II enzyme. We investigated DNA cleavage by Streptococcus pneumoniae topo IV and gyrase stabilized by gemifloxacin and other antipneumococcal fluoroquinolones. Topo IV and gyrase induce distinct but overlapping repertoires of double- strand DNA breakage sites that were essentially identical for seven different quinolones and were augmented ( in intensity) by positive or negative supercoiling. Sequence analysis of 180 topo IV and 126 gyrase sites promoted by gemifloxacin on pneumococcal DNA revealed the respective consensus sequences: G( G/ C)( A/ T) A* GNNCT( T/ A) N( C/ A) and GN(4)G( G/ C)( A/ C) G* GNNCTTN( C/ A) ( preferred bases are underlined; disfavored bases are in small capitals; N indicates no preference; and asterisk indicatesDNAscission between - 1 and + 1 positions). Both enzymes show strong preferences for bases clustered symmetrically around the DNA scission site, i. e. + 1G/ + 4C, - 4G/ + 8C, and particularly the novel - 2A/ + 6T, but with no preference at + 2/ + 3 within the staggered 4- bp overhang. Asymmetric elements include - 3G and several unfavored bases. These cleavage preferences, the first for Gram- positive type IIA topoisomerases, differ markedly from those reported for Escherichia coli topo IV ( consensus ( A/ G)* T/ A) and gyrase, which are based on fewer sites. However, both pneumococcal enzymes cleaved an E. coli gyrase site suggesting overlap in gyrase determinants. We propose a model for the cleavage complex of topo IV/ gyrase that accommodates the unique - 2A/ + 6T and other preferences.	Univ London, St Georges Hosp, Sch Med,Dept Basic Med Sci Biochem & Immunol, Mol Genet Grp, London SW17 0RE, England; Univ Bologna, G Moruzzi Dept Biochem, I-40126 Bologna, Italy; Kings Coll London, Randall Ctr Cell & Mol Biophys, London SE1 1UL, England; Univ Padua, Dept Pharmaceut Sci, I-35131 Padua, Italy	St Georges University London; University of London; University of Bologna; University of London; King's College London; University of Padua	Fisher, LM (corresponding author), Univ London, St Georges Hosp, Sch Med,Dept Basic Med Sci Biochem & Immunol, Mol Genet Grp, London SW17 0RE, England.	lfisher@sghms.ac.uk	Capranico, Giovanni/K-1678-2014	Capranico, Giovanni/0000-0002-8708-6454; Palumbo, Manlio/0000-0002-3163-1564; Gould, Katherine/0000-0002-2528-9512; Fisher, Larry Mark/0000-0002-2172-3369				BIGIONI M, 1994, NUCLEIC ACIDS RES, V22, P2274, DOI 10.1093/nar/22.12.2274; Bromberg KD, 2003, J BIOL CHEM, V278, P7406, DOI 10.1074/jbc.M212056200; Bromberg KD, 2003, BIOCHEMISTRY-US, V42, P3393, DOI 10.1021/bi027383t; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Capranico G, 1998, J BIOL CHEM, V273, P12732, DOI 10.1074/jbc.273.21.12732; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Crisona NJ, 2000, GENE DEV, V14, P2881, DOI 10.1101/gad.838900; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; CULLEN ME, 1989, ANTIMICROB AGENTS CH, V33, P886, DOI 10.1128/AAC.33.6.886; De la Tour CB, 1998, J BACTERIOL, V180, P274, DOI 10.1128/JB.180.2.274-281.1998; Drlica K, 1997, MICROBIOL MOL BIOL R, V61, P377, DOI 10.1128/.61.3.377-392.1997; Espeli O, 2004, MOL MICROBIOL, V52, P925, DOI 10.1111/j.1365-2958.2004.04047.x; FISHER LM, 1986, EMBO J, V5, P1411, DOI 10.1002/j.1460-2075.1986.tb04375.x; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Huang WM, 1996, ANNU REV GENET, V30, P79; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; Khodursky AB, 1998, J BIOL CHEM, V273, P27668, DOI 10.1074/jbc.273.42.27668; KHODURSKY AB, 2000, P NATL ACAD SCI USA, V97, P11801; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; Kwok Y, 1999, J BIOL CHEM, V274, P17226, DOI 10.1074/jbc.274.24.17226; LECOMTE S, 1994, ANTIMICROB AGENTS CH, V38, P2810, DOI 10.1128/AAC.38.12.2810; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; LOCKSHON D, 1985, J MOL BIOL, V181, P63, DOI 10.1016/0022-2836(85)90324-9; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MIZUUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P1847, DOI 10.1073/pnas.77.4.1847; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; Noble CG, 2003, ANTIMICROB AGENTS CH, V47, P854, DOI 10.1128/AAC.47.3.854-862.2003; Oram M, 2003, MOL MICROBIOL, V50, P333, DOI 10.1046/j.1365-2958.2003.03690.x; ORAM M, 1991, ANTIMICROB AGENTS CH, V35, P387, DOI 10.1128/AAC.35.2.387; PALU G, 1992, P NATL ACAD SCI USA, V89, P9671, DOI 10.1073/pnas.89.20.9671; Pan XS, 1999, ANTIMICROB AGENTS CH, V43, P1129, DOI 10.1128/AAC.43.5.1129; Pan XS, 1997, ANTIMICROB AGENTS CH, V41, P471, DOI 10.1128/AAC.41.2.471; Pan XS, 1996, J BACTERIOL, V178, P4060, DOI 10.1128/jb.178.14.4060-4069.1996; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321, DOI 10.1128/AAC.40.10.2321; Pan XS, 2001, ANTIMICROB AGENTS CH, V45, P3140, DOI 10.1128/AAC.45.11.3140-3147.2001; PAN XS, 1998, THESIS U LONDON; PATO ML, 1990, P NATL ACAD SCI USA, V87, P8716, DOI 10.1073/pnas.87.22.8716; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3879, DOI 10.1021/bi00435a038; WAHLE E, 1988, EMBO J, V7, P1889, DOI 10.1002/j.1460-2075.1988.tb03022.x; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yague G, 2002, ANTIMICROB AGENTS CH, V46, P413, DOI 10.1128/AAC.46.2.413-419.2002; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1271, DOI 10.1128/AAC.34.6.1271; YOSHIDA H, 1991, ANTIMICROB AGENTS CH, V35, P1647, DOI 10.1128/AAC.35.8.1647; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	52	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14252	14263		10.1074/jbc.M500156200	http://dx.doi.org/10.1074/jbc.M500156200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15659402	hybrid			2022-12-25	WOS:000228095500128
J	Wahl-Schott, C; Baumann, L; Zong, XG; Biel, M				Wahl-Schott, C; Baumann, L; Zong, XG; Biel, M			An arginine residue in the pore region is a key determinant of chloride dependence in cardiac pacemaker channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CATION CURRENT; RABBIT SINOATRIAL NODE; DOMINANT-NEGATIVE SUPPRESSION; THALAMIC RELAY NEURONS; CURRENT I-F; HCN CHANNELS; TYROSINE KINASE; MOLECULAR-BASIS; CELLS; INHIBITION	The modulation of ion channel activity by extracellular ions plays a central role in the control of heart function. Here, we show that the sinoatrial pacemaker current I-f is strongly affected by the extracellular Cl- concentration. We investigated the molecular basis of the Cl- dependence in heterologously expressed hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that represent the molecular correlate of I-f. Currents carried by the two cardiac HCN channel isoforms (HCN2 and HCN4) showed the same strong Cl- dependence as the sinoatrial I-f and decreased to about 10% in the absence of external Cl-. In contrast, the neuronal HCN1 current was reduced to only 50% under the same conditions. Depletion of Cl- did not affect the voltage dependence of activation or the ion selectivity of the channels, indicating that the reduction of I-f was caused by a decrease of channel conductance. A series of chimeras between HCN1 and HCN2 was constructed to identify the structural determinants underlying the different Cl- dependence of HCN1 and HCN2. Exchange of the ion-conducting pore region was sufficient to switch the Cl- dependence from HCN1- to HCN2-type and vice versa. Replacement of a single alanine residue in the pore of HCN1 (Ala-352) by an arginine residue present in HCN2 at equivalent position (Arg-405) induced HCN2-type chloride sensitivity in HCN1. Our data indicate that Arg-405 is a key component of a domain that allosterically couples Cl- binding with channel activation.	Univ Munich, Dept Pharm Pharmakol Nat Wissensch, D-81377 Munich, Germany	University of Munich	Biel, M (corresponding author), Univ Munich, Dept Pharm, Zentrum Pharmaforsch, Butenandtstr 7-13, D-81377 Munich, Germany.	mbiel@cup.uni-muenchen.de	Wahl-Schott, Christian A/J-2623-2015; Biel, Martin/G-1175-2014	Biel, Martin/0000-0002-9974-3052				Accili EA, 1997, J PHYSIOL-LONDON, V500, P643, DOI 10.1113/jphysiol.1997.sp022049; Adrogue HJ, 1998, NEW ENGL J MED, V338, P107, DOI 10.1056/NEJM199801083380207; Altomare C, 2003, J PHYSIOL-LONDON, V549, P347, DOI 10.1113/jphysiol.2002.027698; Azene EM, 2003, J PHYSIOL-LONDON, V547, P349, DOI 10.1113/jphysiol.2003.039768; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Baruscotti M, 2004, ANN NY ACAD SCI, V1015, P111, DOI 10.1196/annals.1302.009; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; CHANG F, 1991, J PHYSIOL-LONDON, V440, P367, DOI 10.1113/jphysiol.1991.sp018713; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Decher N, 2003, PFLUG ARCH EUR J PHY, V446, P633, DOI 10.1007/s00424-003-1127-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Er F, 2003, CIRCULATION, V107, P485, DOI 10.1161/01.CIR.0000045672.32920.CB; FRACE AM, 1992, J PHYSIOL-LONDON, V453, P307, DOI 10.1113/jphysiol.1992.sp019230; Galla JH, 2000, J AM SOC NEPHROL, V11, P369, DOI 10.1681/ASN.V112369; Gravante B, 2004, J BIOL CHEM, V279, P43847, DOI 10.1074/jbc.M401598200; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Kimura K, 2004, GENES CELLS, V9, P631, DOI 10.1111/j.1356-9597.2004.00752.x; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Mangoni ME, 2001, CARDIOVASC RES, V52, P51, DOI 10.1016/S0008-6363(01)00370-4; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; Mingin GC, 1999, J UROLOGY, V162, P1122, DOI 10.1016/S0022-5347(01)68092-3; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Munsch T, 1999, J PHYSIOL-LONDON, V519, P493, DOI 10.1111/j.1469-7793.1999.0493m.x; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Nolan MF, 2003, CELL, V115, P551, DOI 10.1016/S0092-8674(03)00884-5; Notomi T, 2004, J COMP NEUROL, V471, P241, DOI 10.1002/cne.11039; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Peco-Antic A, 2000, PEDIATR NEPHROL, V15, P286, DOI 10.1007/s004670000419; Qu JH, 2004, J BIOL CHEM, V279, P43497, DOI 10.1074/jbc.M405018200; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Roncaglia P, 2002, BIOPHYS J, V83, P1953, DOI 10.1016/S0006-3495(02)73957-X; Santonastaso P, 1998, INT J EAT DISORDER, V24, P439, DOI 10.1002/(SICI)1098-108X(199812)24:4<439::AID-EAT12>3.0.CO;2-4; Schram G, 2002, CIRC RES, V90, P939, DOI 10.1161/01.RES.0000018627.89528.6F; Schulze-Bahr E, 2003, J CLIN INVEST, V111, P1537, DOI 10.1172/JCI200316387; Shibata S, 1999, BRIT J PHARMACOL, V128, P1284, DOI 10.1038/sj.bjp.0702903; Stieber J, 2004, TRENDS CARDIOVAS MED, V14, P23, DOI 10.1016/j.tcm.2003.09.006; Stieber J, 2003, P NATL ACAD SCI USA, V100, P15235, DOI 10.1073/pnas.2434235100; Ueda K, 2004, J BIOL CHEM, V279, P27194, DOI 10.1074/jbc.M311953200; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Vargas G, 2002, J MEMBRANE BIOL, V188, P115, DOI 10.1007/s00232-001-0178-y; Wu JY, 1997, PFLUG ARCH EUR J PHY, V434, P509, DOI 10.1007/s004240050430; Wu JY, 2000, BBA-BIOMEMBRANES, V1463, P15, DOI 10.1016/S0005-2736(99)00233-3; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Yu HG, 2004, PFLUG ARCH EUR J PHY, V447, P392, DOI 10.1007/s00424-003-1204-y; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009; Zong XG, 2001, J BIOL CHEM, V276, P6313, DOI 10.1074/jbc.M010326200	49	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13694	13700		10.1074/jbc.M413197200	http://dx.doi.org/10.1074/jbc.M413197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15644313	hybrid			2022-12-25	WOS:000228095500064
J	Ezoe, S; Matsumura, I; Gale, K; Satoh, Y; Ishikawa, J; Mizuki, M; Takahashi, S; Minegishi, N; Nakajima, K; Yamamoto, M; Enver, T; Kanakura, Y				Ezoe, S; Matsumura, I; Gale, K; Satoh, Y; Ishikawa, J; Mizuki, M; Takahashi, S; Minegishi, N; Nakajima, K; Yamamoto, M; Enver, T; Kanakura, Y			GATA transcription factors inhibit cytokine-dependent growth and survival of a hematopoietic cell line through the inhibition of STAT3 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; MEGAKARYOCYTIC DIFFERENTIATION; STEM-CELLS; IN-VITRO; ACTIVATION; PROLIFERATION; APOPTOSIS; PROTEINS; MICE; INVOLVEMENT	Although GATA-1 and GATA-2 were shown to be essential for the development of hematopoietic cells by gene targeting experiments, they were also reported to inhibit the growth of hematopoietic cells. Therefore, in this study, we examined the effects of GATA-1 and GATA-2 on cytokine signals. A tamoxifen-inducible form of GATA-1 (GATA-1/ERT) showed a minor inhibitory effect on interleukin-3 (IL-3)-dependent growth of an IL3-dependent cell line Ba/F3. On the other hand, it drastically inhibited TPO-dependent growth and gp130-mediated growth/survival of Ba/F3. Similarly, an estradiol-inducible form of GATA-2 (GATA-2/ER) disrupted thrombopoietin (TPO)-dependent growth and gp130-mediated growth/survival of Ba/F3. As for this mechanism, we found that both GATA-1 and GATA-2 directly bound to STAT3 both in vitro and in vivo and inhibited its DNA-binding activity in gel shift assays and chromatin immunoprecipitation assays, whereas they hardly affected STAT5 activity. In addition, endogenous GATA-1 was found to interact with STAT3 in normal megakaryocytes, suggesting that GATA-1 may inhibit STAT3 activity in normal hematopoietic cells. Furthermore, we found that GATA-1 suppressed STAT3 activity through its N-zinc finger domain. Together, these results suggest that, besides the roles as transcription factors, GATA family proteins modulate cytokine signals through protein-protein interactions, thereby regulating the growth and survival of hematopoietic cells.	Osaka Univ, Grad Sch Med, Dept Hematol Oncol, Suita, Osaka 5650871, Japan; Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England; Univ Tsukuba, Inst Basic Med Sci, Div Anat & Embryol, Tsukuba, Ibaraki 3058575, Japan; Tohoku Univ, Sch Med, Dept Mol Diagnost, Sendai, Miyagi 9808575, Japan; Osaka City Univ, Grad Sch Med, Dept Immunol, Osaka 5458585, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3050006, Japan; Univ Tsukuba, Inst Basic Med Inst, Tsukuba, Ibaraki 3050006, Japan; John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England	Osaka University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Tsukuba; Tohoku University; Osaka Metropolitan University; University of Tsukuba; University of Tsukuba; University of Oxford	Matsumura, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	matumura@bldon.med.osaka-u.ac.jp	Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436				Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Ezoe S, 2002, BLOOD, V100, P3512, DOI 10.1182/blood-2002-04-1177; Farrar JD, 2001, J EXP MED, V193, P643, DOI 10.1084/jem.193.5.643; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Freson K, 2001, BLOOD, V98, P85, DOI 10.1182/blood.V98.1.85; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kawasaki A, 2003, BLOOD, V101, P3668, DOI 10.1182/blood-2002-08-2474; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kirito K, 2002, BLOOD, V99, P3220, DOI 10.1182/blood.V99.9.3220; Kirito K, 2002, BLOOD, V99, P102, DOI 10.1182/blood.V99.1.102; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Mascareno E, 1998, P NATL ACAD SCI USA, V95, P5590, DOI 10.1073/pnas.95.10.5590; Matsumura I, 2000, BLOOD, V96, P2440; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI DOI 10.1073/PNAS.92.10.4601; PENVY L, 1991, NATURE, V349, P257; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; SCHIVDASANI RA, 1997, EMBO J, V16, P3965; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Vyas P, 1999, BLOOD, V93, P2867; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	49	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13163	13170		10.1074/jbc.M413461200	http://dx.doi.org/10.1074/jbc.M413461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15673499	hybrid			2022-12-25	WOS:000227922000128
J	Komonyi, O; Papai, G; Enunlu, I; Muratoglu, S; Pankotai, T; Kopitova, D; Maroy, P; Udvardy, A; Boros, I				Komonyi, O; Papai, G; Enunlu, I; Muratoglu, S; Pankotai, T; Kopitova, D; Maroy, P; Udvardy, A; Boros, I			DTL, the Drosophila homolog of PIMT/Tgs1 nuclear receptor coactivator-interacting protein/RNA methyltransferase, has an essential role in development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION; RNA; INITIATION; TGS1; PIMT	We describe a novel Drosophila gene, dtl ( Drosophila Tat-like), which encodes a 60-kDa protein with RNA binding activity and a methyltransferase ( MTase) domain. Dtl has an essential role in Drosophila development. The homologs of DTL recently described include PIMT ( peroxisome proliferator-activated receptor-interacting protein with a methyltransferase domain), an RNA-binding protein that interacts with and enhances the nuclear receptor coactivator function, and TGS1, the methyltransferase involved in the formation of the 2,2,7-trimethylguanosine (m(3)G) cap of non-coding small RNAs. DTL is expressed throughout all of the developmental stages of Drosophila. The dtl mRNA has two ORFs (uORF and dORF). The product of dORF is the 60-kDa PIMT/TGS1 homolog protein that is translated from an internal AUG located 538 bp downstream from the 5' end of the message. This product of dtl is responsible for the formation of the m3G cap of small RNAs of Drosophila. Trimethylguanosine synthase activity is essential in Drosophila. The deletion in the dORF or point mutation in the putative MTase active site results in a reduced pool of m3G cap-containing RNAs and lethality in the early pupa stage. The 5' region of the dtl message also has the coding capacity ( uORF) for a 178 amino acid protein. For complete rescue of the lethal phenotype of dtl mutants, the presence of the entire dtl transcription unit is required. Transgenes that carry mutations within the uORF restore the MTase activity but result in only partial rescue of the lethal phenotype. Interestingly, two transgenes bearing a mutation in uORF or dORF in trans can result in complete rescue.	Univ Szeged, Dept Genet & Mol Biol, H-6726 Szeged, Hungary; Biol Res Ctr, Inst Biochem, H-6726 Szeged, Hungary; Russian Acad Sci, Inst Gene Biol, Moscow 117334, Russia	Szeged University; Hungarian Academy of Sciences; Hungarian Biological Research Center; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Boros, I (corresponding author), Univ Szeged, Dept Genet & Mol Biol, Kozep Fasor 52, H-6726 Szeged, Hungary.	borosi@bio.u-szeged.hu	Pankotai, Tibor/A-5942-2015	Pankotai, Tibor/0000-0001-9810-5465; Boros, Imre/0000-0001-8504-9687; Muratoglu Catania, Selen/0000-0002-1804-4875; Papai, Gabor/0000-0002-2779-8679				Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; Gatignol A, 2000, Adv Pharmacol, V48, P209; HAMADA K, 1996, NATURE, V380, P175; Hausmann S, 2005, J BIOL CHEM, V280, P4021, DOI 10.1074/jbc.C400554200; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; Kozak M, 2003, GENE, V318, P1, DOI 10.1016/S0378-1119(03)00774-1; Misra P, 2002, J BIOL CHEM, V277, P20011, DOI 10.1074/jbc.M201739200; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Mouaikel J, 2003, NUCLEIC ACIDS RES, V31, P4899, DOI 10.1093/nar/gkg656; Mouaikel J, 2002, MOL CELL, V9, P891, DOI 10.1016/S1097-2765(02)00484-7; PAPAI G, 2005, IN PRESS GENE AMST; Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206; SPRADLING AC, 1975, DROSOPHILA PRACTICAL, P175; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Ye X, 1997, MOL CELL BIOL, V17, P1714, DOI 10.1128/MCB.17.3.1714; YELVERTON E, 1994, MOL MICROBIOL, V11, P303, DOI 10.1111/j.1365-2958.1994.tb00310.x; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	22	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12397	12404		10.1074/jbc.M409251200	http://dx.doi.org/10.1074/jbc.M409251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15684427	hybrid, Green Accepted			2022-12-25	WOS:000227922000041
J	Pung, YF; Wong, PTH; Kumar, PP; Hodgson, WC; Kini, RM				Pung, YF; Wong, PTH; Kumar, PP; Hodgson, WC; Kini, RM			Ohanin, a novel protein from king cobra venom, induces hypolocomotion and hyperalgesia in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B30.2-LIKE DOMAIN PROTEINS; MAMMARY EPITHELIAL-CELLS; SNAKE-VENOMS; IN-VITRO; MEMBRANE; FAMILY; BUTYROPHILIN; STONUSTOXIN; DATABASE; DESIGN	We have identified, purified, and determined the complete amino acid sequence of a novel protein, ohanin from Ophiophagus hannah ( king cobra) venom. It is a small protein containing 107 amino acid residues with a molecular mass of 11951.47 +/- 0.67 Da as assessed by electrospray ionization-mass spectrometry. It does not show similarity to any known families of snake venom proteins and hence is the first member of a new family of snake venom proteins. It shows similarity to PRY and SPRY domain proteins. It is nontoxic up to 10 mg/kg when injected intraperitoneally in mice. Ohanin produced statistically significant and dose-dependent hypolocomotion in mice. In a pain threshold assay, it showed dose-dependent hyperalgesic effect. The ability of the protein to elicit a response at greatly reduced doses when injected intracerebroventricularly as compared with intraperitoneal administration in both the locomotion and hot plate experiments strongly suggests that ohanin acts on the central nervous system. Since the natural abundance of the protein in the venom is low (similar to 1 mg/g), a synthetic gene was constructed and expressed. The recombinant protein, which was obtained in the insoluble fraction in Escherichia coli, was purified under denaturing condition and was refolded. Recombinant ohanin is structurally and functionally similar to native protein as determined by circular dichroism and hot plate assay, suggesting that it will be useful in future structure-function relationship studies.	Natl Univ Singapore, Fac Sci, Dept Biol Sci, Protein Sci Lab, Singapore 117543, Singapore; Natl Univ Singapore, Fac Med, Dept Pharmacol, Singapore 117597, Singapore; Monash Univ, Dept Pharmacol, Monash Venom Grp, Clayton, Vic 3800, Australia; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	National University of Singapore; National University of Singapore; Monash University; Virginia Commonwealth University	Kini, RM (corresponding author), Natl Univ Singapore, Fac Sci, Dept Biol Sci, Protein Sci Lab, Sci Dr 4, Singapore 117543, Singapore.	dbskinim@nus.edu.sg	Pung, Yuh Fen/E-8959-2016; Kumar, Prakash P/A-6236-2009; Kini, Manjunatha/H-8029-2012	Pung, Yuh Fen/0000-0001-6195-3970; Kumar, Prakash P/0000-0002-0963-1664; Kini, Manjunatha/0000-0002-6100-3251; Hodgson, Wayne/0000-0002-9919-0144				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Banghart LR, 1998, J BIOL CHEM, V273, P4171, DOI 10.1074/jbc.273.7.4171; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DUFTON MJ, 1993, ENDEAVOUR, V17, P138, DOI 10.1016/0160-9327(93)90104-B; Harvey AL., 1991, SNAKE TOXINS, P1; Henry J, 1997, BIOCHEM BIOPH RES CO, V235, P162, DOI 10.1006/bbrc.1997.6751; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; Hodgson WC, 2002, CLIN EXP PHARMACOL P, V29, P807, DOI 10.1046/j.1440-1681.2002.03740.x; HOWARDJONES N, 1985, WHO CHRON, V39, P51; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; Ishii T, 1995, BBA-GEN SUBJECTS, V1245, P285, DOI 10.1016/0304-4165(95)00102-6; Jones HM, 2000, GENE, V258, P173, DOI 10.1016/S0378-1119(00)00367-X; Joseph JS, 1999, BLOOD, V94, P621, DOI 10.1182/blood.V94.2.621.414k25_621_631; Kini RM, 2002, CLIN EXP PHARMACOL P, V29, P815, DOI 10.1046/j.1440-1681.2002.03725.x; Kordis D, 2000, GENE, V261, P43, DOI 10.1016/S0378-1119(00)00490-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1979, SNAKE VENOMS, P159; LOW KSY, 1993, TOXICON, V31, P1471, DOI 10.1016/0041-0101(93)90212-2; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; MOCHCAMORALES J, 1990, TOXICON, V28, P299, DOI 10.1016/0041-0101(90)90065-F; Paxinos G, 2004, MOUSE BRAIN STEREOTA; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; Seto MH, 1999, PROTEINS, V35, P235, DOI 10.1002/(SICI)1097-0134(19990501)35:2<235::AID-PROT9>3.3.CO;2-O; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Sung JML, 2002, BIOCHEM PHARMACOL, V63, P1113, DOI 10.1016/S0006-2952(02)00857-2; Torres AM, 2003, J BIOL CHEM, V278, P40097, DOI 10.1074/jbc.M305322200; VERNET C, 1993, J MOL EVOL, V37, P600; Woolfe G, 1944, J PHARMACOL EXP THER, V80, P300	30	75	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13137	13147		10.1074/jbc.M414137200	http://dx.doi.org/10.1074/jbc.M414137200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668253	hybrid			2022-12-25	WOS:000227922000125
J	Lamour, N; Riviere, L; Coustou, V; Coombs, GH; Barrett, MP; Bringaud, F				Lamour, N; Riviere, L; Coustou, V; Coombs, GH; Barrett, MP; Bringaud, F			Proline metabolism in procyclic Trypanosoma brucei is down-regulated in the presence of glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE LEVEL PHOSPHORYLATION; CULTURE FORMS; GENE-PRODUCT; AMINO-ACIDS; SEQUENCE; PROTEIN; ENZYME; LOCALIZATION; GLYCOPROTEIN; RHODESIENSE	Proline metabolism has been studied in procyclic form Trypanosoma brucei. These parasites consume six times more proline from the medium when glucose is in limiting supply than when this carbohydrate is present as an abundant energy source. The sensitivity of procyclic T. brucei to oligomycin increases by three orders of magnitude when the parasites are obliged to catabolize proline in medium depleted in glucose. This indicates that oxidative phosphorylation is far more important to energy metabolism in this latter case than when glucose is available and the energy needs of the parasite can be fulfilled by substrate level phosphorylation alone. A gene encoding proline dehydrogenase, the first enzyme of the proline catabolic pathway, was cloned. RNA interference studies revealed the loss of this activity to be conditionally lethal. Proline dehydrogenase defective parasites grew as wild-type when glucose was available, but, unlike wild-type cells, they failed to proliferate using proline. In parasites grown in the presence of glucose, proline dehydrogenase activity was markedly lower than when glucose was absent from the medium. Proline uptake too was shown to be diminished when glucose was abundant in the growth medium. Wild-type cells were sensitive to 2-deoxy-D-glucose if grown using proline as the principal carbon source, but not in glucose-rich medium, indicating that this non-catabolizable glucose analogue might also stimulate repression of proline utilization. These results indicate that the ability of trypanosomes to use proline as an energy source can be regulated depending upon the availability of glucose.	Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Univ Bordeaux 2, UMR 5162 CNRS, Lab Genom Fonctionnelle Trypanosomatides, F-33076 Bordeaux, France	University of Glasgow; UDICE-French Research Universities; Universite de Bordeaux	Barrett, MP (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland.	m.barrett@bio.gla.ac.uk; bringaud@u-bordeaux2.fr		Barrett, Mike/0000-0001-9447-3519				BALOGUN RA, 1974, COMP BIOCHEM PHYSIOL, V49, P215, DOI 10.1016/0300-9629(74)90110-8; Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6; BATES LS, 1973, PLANT SOIL, V39, P205, DOI 10.1007/BF00018060; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; BESTEIRO S, 2005, IN PRESS TRENDS PARA; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; BROWN ED, 1993, J BIOL CHEM, V268, P8972; BRUN R, 1979, ACTA TROP, V36, P289; BURSELL E, 1973, T ROY SOC TROP MED H, V67, P296, DOI 10.1016/0035-9203(73)90222-8; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Coustou V, 2003, J BIOL CHEM, V278, P49625, DOI 10.1074/jbc.M307872200; CROSS GAM, 1975, PARASITOLOGY, V71, P311, DOI 10.1017/S0031182000046758; CZOK R, 1974, METHOD ENZYMAT AN, V3, P1585; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; EVANS DA, 1972, J PROTOZOOL, V19, P686, DOI 10.1111/j.1550-7408.1972.tb03561.x; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; FORD WCL, 1973, T ROY SOC TROP MED H, V67, P257, DOI 10.1016/0035-9203(73)90157-0; GILBERT RJ, 1983, COMP BIOCHEM PHYS B, V74, P277, DOI 10.1016/0305-0491(83)90012-3; Hannaert Veronique, 2003, Kinetoplastid Biology and Disease, V2, pUnpaginated; Hasne MP, 2000, MOL BIOCHEM PARASIT, V111, P299, DOI 10.1016/S0166-6851(00)00321-2; HAYWARD DC, 1993, P NATL ACAD SCI USA, V90, P2979, DOI 10.1073/pnas.90.7.2979; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JOHNSON AB, 1962, J BIOL CHEM, V237, P1876; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; MENZEL R, 1981, J MOL BIOL, V148, P21, DOI 10.1016/0022-2836(81)90233-3; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Nielsen H, 1996, PROTEINS, V24, P165, DOI 10.1002/(SICI)1097-0134(199602)24:2<165::AID-PROT4>3.0.CO;2-I; NOLAN DP, 1992, EUR J BIOCHEM, V209, P207, DOI 10.1111/j.1432-1033.1992.tb17278.x; Obungu VH, 1999, COMP BIOCHEM PHYS B, V123, P59, DOI 10.1016/S0305-0491(99)00040-1; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P21, DOI 10.1111/j.1432-1033.1977.tb11566.x; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Raz B, 1997, ACTA TROP, V68, P139, DOI 10.1016/S0001-706X(97)00079-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TERKUILE BH, 1992, J BACTERIOL, V174, P2929, DOI 10.1128/JB.174.9.2929-2934.1992; terKuile BH, 1997, J BACTERIOL, V179, P4699, DOI 10.1128/jb.179.15.4699-4705.1997; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; Vassella E, 2000, GENE DEV, V14, P615; Vassella E, 2004, MOL BIOL CELL, V15, P3986, DOI 10.1091/mbc.E04-04-0341; Verlinde CLM, 2001, DRUG RESIST UPDATE, V4, P50, DOI 10.1054/drup.2000.0177; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; WANG SS, 1987, MOL CELL BIOL, V7, P4431, DOI 10.1128/MCB.7.12.4431; WILLIAMS N, 1994, J BIOENERG BIOMEMBR, V26, P173, DOI 10.1007/BF00763066	47	156	159	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11902	11910		10.1074/jbc.M414274200	http://dx.doi.org/10.1074/jbc.M414274200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15665328	hybrid			2022-12-25	WOS:000227761800120
J	Zhao, L; Guo, M; Matsuoka, TA; Hagman, DK; Parazzoli, SD; Poitout, V; Stein, R				Zhao, L; Guo, M; Matsuoka, TA; Hagman, DK; Parazzoli, SD; Poitout, V; Stein, R			The islet beta cell-enriched MafA activator is a key regulator of insulin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLATION; HOMEODOMAIN PROTEIN; CHROMATIN-STRUCTURE; DIABETES-MELLITUS; ADENOVIRUS E1A; II GENE; IN-VIVO; EXPRESSION; PDX-1; PANCREAS	The islet-enriched MafA, PDX-1, and BETA2 activators contribute to both beta cell-specific and glucose-responsive insulin gene transcription. To investigate how these factors impart activation, their combined impact upon insulin enhancer-driven expression was first examined in non-beta cell line transfection assays. Individual expression of PDX-1 and BETA2 led to little or no activation, whereas MafA alone did so modestly. MafA together with PDX-1 or BETA2 produced synergistic activation, with even higher insulin promoter activity found when all three proteins were present. Stimulation was attenuated upon compromising either MafA transactivation or DNA-binding activity. MafA interacted with endogenous PDX-1 and BETA2 in coimmunoprecipitation and in vitro GST pull-down assays, suggesting that regulation involved direct binding. Dominant-negative acting and small interfering RNAs of MafA also profoundly reduced insulin promoter activity in beta cell lines. In addition, MafA was induced in parallel with insulin mRNA expression in glucose-stimulated rat islets. Insulin mRNA levels were also elevated in rat islets by adenoviral-mediated expression of MafA. Collectively, these results suggest that MafA plays a key role in coordinating and controlling the level of insulin gene expression in islet beta cells.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Vanderbilt University; University of Washington; University of Washington Seattle	Stein, R (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 723 Light Hall, Nashville, TN 37232 USA.	roland.stein@vanderbilt.edu		Poitout, Vincent/0000-0002-6555-5053	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058096, P01DK042502, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK42502, P60 DK20593, R01-DK58096, R01 DK058096] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; Blanchi B, 2003, NAT NEUROSCI, V6, P1091, DOI 10.1038/nn1129; Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Cissell MA, 2003, J BIOL CHEM, V278, P751, DOI 10.1074/jbc.M205905200; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUZ Y, 1995, DEVELOPMENT, V121, P11; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; Kelpe CL, 2003, J BIOL CHEM, V278, P30015, DOI 10.1074/jbc.M302548200; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MacLean HE, 2003, DEV BIOL, V262, P51, DOI 10.1016/S0012-1606(03)00324-5; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Matsuoka T, 2004, P NATL ACAD SCI USA, V101, P2930, DOI 10.1073/pnas.0306233101; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Moates JM, 2003, DIABETES, V52, P403, DOI 10.2337/diabetes.52.2.403; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Nishizawa M, 2003, ONCOGENE, V22, P7882, DOI 10.1038/sj.onc.1206526; Offield MF, 1996, DEVELOPMENT, V122, P983; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Oster A, 1998, J HISTOCHEM CYTOCHEM, V46, P707, DOI 10.1177/002215549804600602; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; Pictet R., 1972, HDB PHYSL, P25; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Qiu Y, 2004, J BIOL CHEM, V279, P9796, DOI 10.1074/jbc.M307577200; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; Samaras SE, 2003, J BIOL CHEM, V278, P12263, DOI 10.1074/jbc.M210801200; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sander M, 2000, DEVELOPMENT, V127, P5533; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; Wicksteed B, 2001, J BIOL CHEM, V276, P22553, DOI 10.1074/jbc.M011214200; Yasuda T, 2002, DIABETES, V51, P224, DOI 10.2337/diabetes.51.1.224; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532	57	149	200	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11887	11894		10.1074/jbc.M409475200	http://dx.doi.org/10.1074/jbc.M409475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15665000	hybrid			2022-12-25	WOS:000227761800118
J	Saeki, N; Tokuo, H; Ikebe, M				Saeki, N; Tokuo, H; Ikebe, M			BIG1 is a binding partner of myosin IXb and regulates its Rho-GTPase activating protein activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE PROTEIN; ADP-RIBOSYLATION FACTOR-1; ARF; CLONING; DOMAIN; FAMILY	Myosin IXb, a member of the myosin superfamily, is a molecular motor that possesses a GTPase activating protein ( GAP) for Rho. Through the yeast two-hybrid screening using the tail domain of myosin IXb as bait we found BIG1, a guanine nucleotide exchange factor for ADP-ribosylation factor (Arf1), as a potential binding partner for myosin IXb. The interaction between myosin IXb and BIG1 was demonstrated by co-immunoprecipitation of endogenous myosin IXb and BIG1 with anti-BIG1 antibodies in normal rat kidney cells. Using the isolated proteins, it was demonstrated that myosin IXb and BIG1 directly bind to each other. Various truncation mutants of the myosin IXb tail domain were produced, and it was revealed that the binding region of myosin IXb to BIG1 is the zinc finger/GAP domain. Interestingly, the GAP activity of myosin IXb was significantly inhibited by the addition of BIG1 with IC50 of 0.06 mu M. The RhoA binding to myosin IXb was inhibited by the addition of BIG1 with the concentration similar to the inhibition of the GAP activity. Likewise, RhoA inhibited the BIG1 binding of myosin IXb. These results suggest that BIG1 and RhoA compete with each other for the binding to myosin IXb, thus resulting in the inhibition of the GAP activity by BIG1. The present study identified BIG1, the Arf guanine nucleotide exchange factor, as a new binding partner for myosin IXb, which inhibited the GAP activity of myosin IXb. The findings raise a concept that the myosin transports the signaling molecule as a cargo that functions as a regulator for the myosin molecule.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu		Tokuo, Hiroshi/0000-0002-7614-7805	NCI NIH HHS [SC006103] Funding Source: Medline; NIAMS NIH HHS [AR41653, AR048898] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR048898] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Camera P, 2003, NAT CELL BIOL, V5, P1071, DOI 10.1038/ncb1064; Chieregatti E, 1998, J CELL SCI, V111, P3597; Gorman SW, 1999, GENOMICS, V59, P150, DOI 10.1006/geno.1999.5867; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Li HW, 2003, P NATL ACAD SCI USA, V100, P1627, DOI 10.1073/pnas.0337678100; Mansour SJ, 1999, P NATL ACAD SCI USA, V96, P7968, DOI 10.1073/pnas.96.14.7968; Martin ME, 2000, J BIOL CHEM, V275, P19050, DOI 10.1074/jbc.275.25.19050; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Post PL, 2002, J BIOL CHEM, V277, P11679, DOI 10.1074/jbc.M111173200; Randazzo PA, 1997, BIOCHEM J, V324, P413, DOI 10.1042/bj3240413; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567	24	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10128	10134		10.1074/jbc.M413415200	http://dx.doi.org/10.1074/jbc.M413415200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644318	hybrid			2022-12-25	WOS:000227559600048
J	Spangenburg, EE				Spangenburg, EE			SOCS-3 induces myoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; SERUM RESPONSE FACTOR; GROWTH-FACTOR-II; MUSCLE-CELLS; MYOGENIC DIFFERENTIATION; CYTOKINE SIGNALING-3; SKELETAL MYOBLASTS; TIME-COURSE; IGF-I; EXPRESSION	Myoblast differentiation is characterized by a sequence of events that includes an increase in insulin-like growth factor ( IGF)-I and contractile gene expression. The increase in IGF-I expression activates cell signaling mechanisms that participate in the differentiation process. One potential contributor is the SOCS-3 ( suppressor of cytokine signaling-3) gene, which regulates signaling mechanisms and may be sensitive to changes in IGF-I concentrations. For the first time, the role of SOCS-3 is investigated in myoblast differentiation. SOCS-3 mRNA levels and SOCS-3 transcriptional activity increase during myoblast differentiation. SOCS-3 gene expression is induced, at least in part, by activation of the IGF-I receptor during myoblast differentiation. Overexpression of SOCS-3 cDNA significantly increased transcriptional activation of the 2.0-kb skeletal alpha-actin promoter in differentiating C2C12 myoblasts. In addition, overexpression of SOCS-3 specifically increased serum response factor-driven transcriptional activity but had no effect on nuclear-factor of activated T cell-driven transcriptional activity. SOCS-3 overexpression induced skeletal alpha-actin transcription in a myoblast cell line that cannot respond to endogenous IGF-I, indicating that SOCS-3 can contribute to the myoblast differentiation process in the absence of IGF-I. These data suggest that IGF-I induces myoblast differentiation, in part, by increasing SOCS-3 expression.	Univ Calif Davis, Sch Med, Div Biol Sci, Exercise Biol Program, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Physiol & Membrane Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Spangenburg, EE (corresponding author), Univ Calif Davis, Sch Med, Div Biol Sci, Exercise Biol Program, 1 Shields Ave, Davis, CA 95616 USA.	eespangenburg@ucdavis.edu						Adams GR, 1999, J APPL PHYSIOL, V87, P1705, DOI 10.1152/jappl.1999.87.5.1705; Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Auernhammer CJ, 2000, ANN NY ACAD SCI, V917, P658; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Carson JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1624, DOI 10.1152/ajpcell.1996.270.6.C1624; Carson JA, 1998, AM J PHYSIOL-CELL PH, V275, pC1438, DOI 10.1152/ajpcell.1998.275.6.C1438; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Childs TE, 2003, AM J PHYSIOL-CELL PH, V285, pC391, DOI 10.1152/ajpcell.00478.2002; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Dey BR, 2000, BIOCHEM BIOPH RES CO, V278, P38, DOI 10.1006/bbrc.2000.3762; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; Galvin CD, 2003, MOL CELL ENDOCRINOL, V200, P19, DOI 10.1016/S0303-7207(02)00420-3; Goldshmit Y, 2004, J BIOL CHEM, V279, P16349, DOI 10.1074/jbc.M312873200; Greenhalgh CJ, 2002, J BIOL CHEM, V277, P40181, DOI 10.1074/jbc.C200450200; Haddad F, 2005, J APPL PHYSIOL, V98, P911, DOI 10.1152/japplphysiol.01026.2004; Hill M, 2003, J PHYSIOL-LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832; Horsley V, 2004, CELLS TISSUES ORGANS, V176, P67, DOI 10.1159/000075028; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Huang KC, 2003, FEBS LETT, V555, P385, DOI 10.1016/S0014-5793(03)01297-3; James PL, 1996, J CELL BIOL, V133, P683, DOI 10.1083/jcb.133.3.683; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Kataoka Y, 2003, J BIOL CHEM, V278, P44178, DOI 10.1074/jbc.M304884200; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; Li L, 2004, J BIOL CHEM, V279, P34107, DOI 10.1074/jbc.M312672200; Lim W, 2004, PHYSIOL GENOMICS, V18, P79, DOI 10.1152/physiolgenomics.00148.2003; Metcalf D, 2003, STEM CELLS, V21, P5, DOI 10.1634/stemcells.21-1-5; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; Paoni NF, 2002, PHYSIOL GENOMICS, V11, P263, DOI 10.1152/physiolgenomics.00110.2002; Pattison JS, 2003, J PHYSIOL-LONDON, V553, P357, DOI 10.1113/jphysiol.2003.047233; Pedranzini L, 2004, J CLIN INVEST, V114, P619, DOI 10.1172/JCI200422800; SCHWARTZ RJ, 1981, J HISTOCHEM CYTOCHEM, V29, P1014, DOI 10.1177/29.9.7288159; Shi H, 2004, J BIOL CHEM, V279, P34733, DOI 10.1074/jbc.M403886200; Soulez M, 1996, MOL CELL BIOL, V16, P6065; Spangenburg EE, 2004, ENDOCRINOLOGY, V145, P2054, DOI 10.1210/en.2003-1476; Spangenburg EE, 2002, AM J PHYSIOL-CELL PH, V283, pC204, DOI 10.1152/ajpcell.00574.2001; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Szepeshazi K, 2001, ENDOCRINOLOGY, V142, P4371, DOI 10.1210/en.142.10.4371; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tonozuka Y, 2004, BLOOD, V104, P3550, DOI 10.1182/blood-2004-03-1066; Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004; Vyas DR, 2002, AM J PHYSIOL-CELL PH, V283, pC545, DOI 10.1152/ajpcell.00049.2002; Wei L, 2000, AM J PHYSIOL-HEART C, V278, pH1736, DOI 10.1152/ajpheart.2000.278.6.H1736; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351	56	38	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10749	10758		10.1074/jbc.M410604200	http://dx.doi.org/10.1074/jbc.M410604200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15653674	hybrid			2022-12-25	WOS:000227559600121
J	Vallejo, J; Hardin, CD				Vallejo, J; Hardin, CD			Expression of caveolin-1 in lymphocytes induces caveolae formation and recruitment of phosphofructokinase to the plasma membrane	FASEB JOURNAL			English	Article						glycolytic enzymes; carbohydrate metabolism; PFK	VASCULAR SMOOTH-MUSCLE; GLYCOLYTIC-ENZYMES; GLUCOSE 1,6-BISPHOSPHATE; MELANOMA-CELLS; F-ACTIN; ASSOCIATION; COMPLEX; BINDING; PROTEIN; ATP	Compartmentation of carbohydrate metabolism has been shown in a wide range of tissues including reports of one compartment of glycolysis associated with the plasma membrane of cells. However, only in the erythrocyte has the physical basis for plasma membrane-associated glycolytic pathway been established. We have previously found that phosphofructokinase (PFK) appeared to colocalize with the fairly ubiquitous plasma membrane protein caveolin-1 (CAV-1), consistent with a role for CAV-1 as an anchor for glycolysis to the plasma membrane. To test the hypothesis that CAV-1 functions as a scaffolding protein for PFK, we transfected human lymphocytes ( a cell without CAV-1 expression) with human CAV-1 cDNA. We demonstrate that expression of CAV-1 in lymphocytes results in the formation of caveolae at the plasma membrane and affects the subcellular localization of PFK by recruiting PFK to the plasma membrane. Targeting of PFK by CAV-1 also was validated by the significant colocalization between the proteins after transfection, which resulted in a correlation of 0.97 +/- 0.004 between the two fluorophores. This finding is significant in as much as it illustrates the CAV-1 feasibility of generating binding sites for glycolytic enzymes on the plasma membrane. We therefore conclude that CAV-1 functions as a scaffolding protein for PFK and that this may contribute to the elucidation of the basis for carbohydrate compartmentation to the plasma membrane in a wide variety of cell types.	Univ Missouri, Dept Med Pharmacol & Physiol, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Hardin, CD (corresponding author), Univ Missouri, Dept Med Pharmacol & Physiol, MA 415 Med Sci Bldg, Columbia, MO 65212 USA.	HardinC@missouri.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL007094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060668] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL F32-07094] Funding Source: Medline; NIDDK NIH HHS [DK60668] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Ashkenazy-Shahar M, 1999, MOL GENET METAB, V67, P334, DOI 10.1006/mgme.1999.2877; BENTAL M, 1993, MAGN RESON MED, V29, P317, DOI 10.1002/mrm.1910290307; BRONSTEIN WW, 1981, CAN J BIOCHEM CELL B, V59, P494, DOI 10.1139/o81-069; Cameron PL, 1997, J NEUROSCI, V17, P9520; CHENZION M, 1992, INT J BIOCHEM, V24, P1661, DOI 10.1016/0020-711X(92)90185-4; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Damico LA, 1996, J MOL CELL CARDIOL, V28, P989, DOI 10.1006/jmcc.1996.0092; DAUM G, 1988, BIOCHIM BIOPHYS ACTA, V939, P277, DOI 10.1016/0005-2736(88)90071-5; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Firestein BL, 1999, J BIOL CHEM, V274, P10545, DOI 10.1074/jbc.274.15.10545; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; Glass-Marmor L, 1999, EUR J PHARMACOL, V370, P195, DOI 10.1016/S0014-2999(99)00155-7; GREEN DE, 1965, ARCH BIOCHEM BIOPHYS, V112, P635, DOI 10.1016/0003-9861(65)90107-4; HARDIN CD, 1992, J GEN PHYSIOL, V99, P21, DOI 10.1085/jgp.99.1.21; HARRIS SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P306, DOI 10.1016/0167-4838(90)90242-8; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; Hoffman J F, 1997, Curr Opin Hematol, V4, P112; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; JENKINS JD, 1985, J BIOL CHEM, V260, P426; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; KARKHOFFSCHWEIZER R, 1987, BIOCHEM BIOPH RES CO, V146, P827, DOI 10.1016/0006-291X(87)90605-X; Karlsson M, 2001, FASEB J, V15, P249, DOI 10.1096/fj.01-0646fje; Karniel M, 2000, MOL GENET METAB, V69, P40, DOI 10.1006/mgme.1999.2954; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; Kimura A, 2002, J BIOL CHEM, V277, P40167; KNULL HR, 1980, J NEUROCHEM, V34, P222, DOI 10.1111/j.1471-4159.1980.tb04646.x; Lahtinen U, 2003, FEBS LETT, V538, P85, DOI 10.1016/S0014-5793(03)00135-2; LEHOTZKY A, 1994, BIOCHEM BIOPH RES CO, V204, P585, DOI 10.1006/bbrc.1994.2499; LEHOTZKY A, 1993, J BIOL CHEM, V268, P10888; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Lloyd PG, 2001, J CELL BIOCHEM, V82, P399, DOI 10.1002/jcb.1170; LOW PS, 1993, J BIOL CHEM, V268, P14627; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; PROVERBIO F, 1977, J GEN PHYSIOL, V69, P605, DOI 10.1085/jgp.69.5.605; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Samstag Y, 2003, J LEUKOCYTE BIOL, V73, P30, DOI 10.1189/jlb.0602272; Scherer PE, 1997, J BIOL CHEM, V272, P20698, DOI 10.1074/jbc.272.33.20698; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schlegel A, 2001, J CELL PHYSIOL, V186, P329, DOI 10.1002/1097-4652(2001)9999:9999<000::AID-JCP1045>3.0.CO;2-0; Schwartz D, 2000, MOL GENET METAB, V69, P159, DOI 10.1006/mgme.2000.2960; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sotgia F, 2003, AM J PATHOL, V163, P2619, DOI 10.1016/S0002-9440(10)63616-4; Sowa G, 2003, P NATL ACAD SCI USA, V100, P6511, DOI 10.1073/pnas.1031672100; Taggart MJ, 2001, NEWS PHYSIOL SCI, V16, P61; Thyberg J, 2000, LAB INVEST, V80, P915, DOI 10.1038/labinvest.3780095; Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200; Vallejo J, 2004, AM J PHYSIOL-CELL PH, V286, pC43, DOI 10.1152/ajpcell.00483.2002; Vertessy BG, 1997, J BIOL CHEM, V272, P25542, DOI 10.1074/jbc.272.41.25542; Vertessy BG, 1997, BIOCHEMISTRY-US, V36, P2051, DOI 10.1021/bi9623441; Vertessy BG, 1996, FEBS LETT, V379, P191, DOI 10.1016/0014-5793(95)01510-8; von Ruckmann B, 2002, BBA-BIOMEMBRANES, V1559, P43, DOI 10.1016/S0005-2736(01)00435-7; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Zwingmann C, 2001, GLIA, V34, P200, DOI 10.1002/glia.1054	63	20	20	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					586	+		10.1096/fj.04-2380fje	http://dx.doi.org/10.1096/fj.04-2380fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665033				2022-12-25	WOS:000226576600017
J	Wang, J; Ho, L; Qin, WP; Rocher, AB; Seror, I; Humala, N; Maniar, K; Dolios, G; Wang, R; Hof, PR; Pasinetti, GM				Wang, J; Ho, L; Qin, WP; Rocher, AB; Seror, I; Humala, N; Maniar, K; Dolios, G; Wang, R; Hof, PR; Pasinetti, GM			Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						AD; A beta neuropathology; neuritic plaque deposition	ALPHA-SECRETASE CLEAVAGE; LOW-FAT DIET; PRECURSOR PROTEIN; LOW-CARBOHYDRATE; TRANSGENIC MICE; IN-VIVO; CONVERTING-ENZYME; RISK-FACTORS; WEIGHT-LOSS; FOLLOW-UP	This study was designed to explore the possibility that caloric restriction (CR) may benefit Alzheimer's disease (AD) by preventing beta-amyloid (Abeta) neuropathology pivotal to the initiation and progression of the disease. We report that a CR dietary regimen prevents Abeta peptides generation and neuritic plaque deposition in the brain of a mouse model of AD neuropathology through mechanisms associated with promotion of anti-amyloidogenic alpha-secretase activity. Study findings support existing epidemiological evidence indicating that caloric intake may influence risk for AD and raises the possibility that CR may be used in preventative measures aimed at delaying the onset of AD amyloid neuropathology.	CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Adv Imaging Program, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pasinetti, GM (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu	Wang, Rong/A-8721-2009	Pasinetti, Giulio/0000-0002-1524-5196	NATIONAL INSTITUTE ON AGING [P01AG002219] Funding Source: NIH RePORTER; NIA NIH HHS [AG02219] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allinson TMJ, 2004, EUR J BIOCHEM, V271, P2539, DOI 10.1111/j.1432-1033.2004.04184.x; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Burns M, 2003, J NEUROSCI, V23, P5645; Bussiere T, 2002, NEUROSCIENCE, V112, P75, DOI 10.1016/S0306-4522(02)00056-8; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Gustafson D, 2003, ARCH INTERN MED, V163, P1524, DOI 10.1001/archinte.163.13.1524; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Ho L, 2004, FASEB J, V18, P902, DOI 10.1096/fj.03-0978fje; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Kuusisto J, 1997, BRIT MED J, V315, P1045, DOI 10.1136/bmj.315.7115.1045; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Ledesma MD, 2003, EMBO REP, V4, P1190, DOI 10.1038/sj.embor.7400021; Lichtenthaler SF, 2004, J CLIN INVEST, V113, P1384, DOI 10.1172/JCI200421746; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; MAKIMURA H, 2003, BMC PHYSL, V3; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Meckling KA, 2004, J CLIN ENDOCR METAB, V89, P2717, DOI 10.1210/jc.2003-031606; Meyer JS, 2000, ANN NY ACAD SCI, V903, P411, DOI 10.1111/j.1749-6632.2000.tb06393.x; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Mohajeri MH, 2004, FEBS LETT, V562, P16, DOI 10.1016/S0014-5793(04)00169-3; Nimchinsky EA, 2000, J COMP NEUROL, V416, P112, DOI 10.1002/(SICI)1096-9861(20000103)416:1<112::AID-CNE9>3.0.CO;2-K; Pedersen WA, 2004, NEUROBIOL DIS, V17, P500, DOI 10.1016/j.nbd.2004.08.003; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Ristow M, 2004, J MOL MED, V82, P510, DOI 10.1007/s00109-004-0552-1; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Takeda K, 2003, J ENDOCRINOL, V176, P237, DOI 10.1677/joe.0.1760237; VALLET PG, 1992, ACTA NEUROPATHOL, V83, P170, DOI 10.1007/BF00308476; Vanhanen M, 1998, CURR OPIN NEUROL, V11, P673, DOI 10.1097/00019052-199812000-00011; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WANG R, 1991, J BIOL CHEM, V266, P16960; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	38	205	223	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					659	+		10.1096/fj.04-3182fje	http://dx.doi.org/10.1096/fj.04-3182fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15650008				2022-12-25	WOS:000226576600023
J	Preusser-Kunze, A; Mariappan, M; Schmidt, B; Gande, SL; Mutenda, K; Wenzel, K; von Figura, K; Dierks, T				Preusser-Kunze, A; Mariappan, M; Schmidt, B; Gande, SL; Mutenda, K; Wenzel, K; von Figura, K; Dierks, T			Molecular characterization of the human C alpha-formylglycine-generating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SULFATASE DEFICIENCY; ENDOPLASMIC-RETICULUM; PROTEIN MODIFICATION; EUKARYOTIC SULFATASES; HUMAN ARYLSULFATASE; CRYSTAL-STRUCTURE; CYSTEINE; CONVERSION; MECHANISM; GENE	alpha-formylglycine (FGly) is the catalytic residue in the active site of sulfatases. In eukaryotes, it is generated in the endoplasmic reticulum by post-translational modification of a conserved cysteine residue. The FGly-generating enzyme (FGE), performing this modification, is an endoplasmic reticulum-resident enzyme that upon overexpression is secreted. Recombinant FGE was purified from cells and secretions to homogeneity. Intracellular FGE contains a high mannose type N-glycan, which is processed to the complex type in secreted FGE. Secreted FGE shows partial N-terminal trimming up to residue 73 without loosing catalytic activity. FGE is a calcium-binding protein containing an N-terminal (residues 86 168) and a C-terminal (residues 178-374) protease-resistant domain. The latter is stabilized by three disulfide bridges arranged in a clamp-like manner, which links the third to the eighth, the fourth to the seventh, and the fifth to the sixth cysteine residue. The innermost cysteine pair is partially reduced. The first two cysteine residues are located in the sequence preceding the N-terminal protease-resistant domain. They can form intramolecular or intermolecular disulfide bonds, the latter stabilizing homodimers. The C-terminal domain comprises the substrate binding site, as evidenced by yeast two-hybrid interaction assays and photocross-linking of a substrate peptide to proline 182. Peptides derived from all known human sulfatases served as substrates for purified FGE indicating that FGE is sufficient to modify all sulfatases of the same species.	Univ Gottingen, Inst Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Max Planck Inst Biophys Chem, Abt Neurobiol, D-37077 Gottingen, Germany	University of Gottingen; Max Planck Society	Dierks, T (corresponding author), Univ Bielefeld, Univ Str 25, D-33615 Bielefeld, Germany.	tdierks@gwdg.de	mariappan, malaiyalam/K-9024-2012; Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				BASNER R, 1979, PEDIATR RES, V13, P1316, DOI 10.1203/00006450-197912000-00002; Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Cosma MP, 2004, HUM MUTAT, V23, P576, DOI 10.1002/humu.20040; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; Dorman G, 2000, TRENDS BIOTECHNOL, V18, P64, DOI 10.1016/S0167-7799(99)01402-X; Fey J, 2001, J BIOL CHEM, V276, P47021, DOI 10.1074/jbc.M108943200; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; Hansske B, 2002, J CLIN INVEST, V109, P725, DOI 10.1172/JCI200214010; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; Jahn O, 2004, ANAL BIOANAL CHEM, V378, P1031, DOI 10.1007/s00216-003-2353-8; Jahn O, 2002, P NATL ACAD SCI USA, V99, P12055, DOI 10.1073/pnas.192449299; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; Kreykenbohm V, 2002, EUR J CELL BIOL, V81, P273, DOI 10.1078/0171-9335-00247; Landgrebe J, 2003, GENE, V316, P47, DOI 10.1016/S0378-1119(03)00746-7; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Mariappan M, 2005, J BIOL CHEM, V280, P15173, DOI 10.1074/jbc.M413698200; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; Prestwich GD, 1997, PHOTOCHEM PHOTOBIOL, V65, P222, DOI 10.1111/j.1751-1097.1997.tb08548.x; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; von Bulow R, 2001, J MOL BIOL, V305, P269, DOI 10.1006/jmbi.2000.4297; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K; VONFIGURA K, 2004, LYSOSOMAL DISORDERS, P131	32	63	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14900	14910		10.1074/jbc.M413383200	http://dx.doi.org/10.1074/jbc.M413383200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15657036	hybrid			2022-12-25	WOS:000228236800069
J	Casper, JM; Kemp, MG; Ghosh, M; Randall, GM; Vaillant, A; Leffak, M				Casper, JM; Kemp, MG; Ghosh, M; Randall, GM; Vaillant, A; Leffak, M			The c-myc DNA-unwinding element-binding protein modulates the assembly of DNA replication complexes in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; CHROMOSOMAL DNA; HELA-CELLS; INITIATION ZONE; SACCHAROMYCES-CEREVISIAE; SEQUENCE ELEMENTS; RE-REPLICATION; LATENT ORIGIN; S-PHASE; GENE	The presence of DNA- unwinding elements ( DUEs) at eukaryotic replicators has raised the question of whether these elements contribute to origin activity by their intrinsic helical instability, as protein-binding sites, or both. We used the human c-myc DUE as bait in a yeast one-hybrid screen and identified a DUE- binding protein, designated DUE- B, with a predicted mass of 23.4 kDa. Based on homology to yeast proteins, DUE- B was previously classified as an aminoacyl- tRNA synthetase; however, the human protein is similar to 60 amino acids longer than its orthologs in yeast and worms and is primarily nuclear. In vivo, chromatin-bound DUE- B localized to the c-myc DUE region. DUE- B levels were constant during the cell cycle, although the protein was preferentially phosphorylated in cells arrested early in S phase. Inhibition of DUE- B protein expression slowed HeLa cell cycle progression from G(1) to S phase and induced cell death. DUE- B extracted from HeLa cells or expressed from baculovirus migrated as a dimer during gel filtration and co-purified with ATPase activity. In contrast to endogenous DUE- B, baculovirus- expressed DUE- B efficiently formed high molecular mass complexes in Xenopus egg and HeLa extracts. In Xenopus extracts, baculovirus- expressed DUE- B inhibited chromatin replication and replication protein A loading in the presence of endogenous DUE- B, suggesting that differential covalent modification of these proteins can alter their effect on replication. Recombinant DUE- B expressed in HeLa cells restored replication activity to egg extracts immunodepleted with anti- DUE-B antibody, suggesting that DUE-B plays an important role in replication in vivo.	Wright State Univ, Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45435 USA; REPLICor Inc, Laval, PQ H7V 4A9, Canada	University System of Ohio; Wright State University Dayton	Leffak, M (corresponding author), Wright State Univ, Sch Med, Dept Biochem & Mol Biol, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.	michael.leffak@wright.edu	Kemp, Michael G./AAT-1545-2021	Kemp, Michael G./0000-0001-8203-0745; VAILLANT, Andrew/0000-0002-1433-0700	NIGMS NIH HHS [GM53819] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053819] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; Altman AL, 2004, MOL CELL BIOL, V24, P4138, DOI 10.1128/MCB.24.10.4138-4150.2004; Altman AL, 2001, MOL CELL BIOL, V21, P1098, DOI 10.1128/MCB.21.4.1098-1110.2001; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BERBERICH S, 1995, J MOL BIOL, V245, P92, DOI 10.1006/jmbi.1994.0010; Chou DM, 2002, J BIOL CHEM, V277, P40520, DOI 10.1074/jbc.M207226200; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DOBBS DL, 1994, NUCLEIC ACIDS RES, V22, P2479, DOI 10.1093/nar/22.13.2479; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Huang RY, 1996, NUCLEIC ACIDS RES, V24, P816, DOI 10.1093/nar/24.5.816; HUNG DT, 1992, BIOCHEM BIOPH RES CO, V184, P733, DOI 10.1016/0006-291X(92)90651-Z; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Keller C, 2002, J BIOL CHEM, V277, P31430, DOI 10.1074/jbc.M202165200; KELLY T, 1988, CANC CELLS, V6, P467; Kinoshita Y, 2004, J BIOL CHEM, V279, P35879, DOI 10.1074/jbc.M401640200; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Knockaert M, 2002, ONCOGENE, V21, P6413, DOI 10.1038/sj.onc.1205908; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; LEFFAK M, 1989, MOL CELL BIOL, V9, P586, DOI 10.1128/MCB.9.2.586; Liu GQ, 2003, MOL CELL BIOL, V23, P1832, DOI 10.1128/MCB.23.5.1832-1842.2003; Lopez-Girona A, 1998, MOL BIOL CELL, V9, P63, DOI 10.1091/mbc.9.1.63; Malott M, 1999, MOL CELL BIOL, V19, P5685; Masuda T, 2003, GENES CELLS, V8, P145, DOI 10.1046/j.1365-2443.2003.00621.x; MCWHINNEY C, 1995, DNA CELL BIOL, V14, P565, DOI 10.1089/dna.1995.14.565; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; Meng XF, 2002, BIOCHEM GENET, V40, P303, DOI 10.1023/A:1020256718720; Mesner LD, 2003, MOL CELL BIOL, V23, P804, DOI 10.1128/MCB.23.3.804-814.2003; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; NATALE DA, 1993, NUCLEIC ACIDS RES, V21, P555, DOI 10.1093/nar/21.3.555; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; Nenguke T, 2003, HUM MOL GENET, V12, P1021, DOI 10.1093/hmg/ddg111; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Paixao S, 2004, MOL CELL BIOL, V24, P2958, DOI 10.1128/MCB.24.7.2958-2967.2004; Patrick SM, 1997, BBA-GENE STRUCT EXPR, V1354, P279, DOI 10.1016/S0167-4781(97)00136-X; Phi-van L, 1998, J BIOL CHEM, V273, P18300, DOI 10.1074/jbc.273.29.18300; Rein T, 1999, J BIOL CHEM, V274, P25792, DOI 10.1074/jbc.274.36.25792; Ritzi M, 2003, J CELL SCI, V116, P3971, DOI 10.1242/jcs.00708; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Schaarschmidt D, 2002, NUCLEIC ACIDS RES, V30, P4176, DOI 10.1093/nar/gkf532; Schepers A, 2001, EMBO J, V20, P4588, DOI 10.1093/emboj/20.16.4588; Shi L, 1998, FEMS MICROBIOL REV, V22, P229, DOI 10.1016/S0168-6445(98)00015-1; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; Tao L, 1997, J MOL BIOL, V273, P509, DOI 10.1006/jmbi.1997.1352; Tao L, 2001, J CELL BIOCHEM, V82, P522, DOI 10.1002/jcb.1173; Tao L, 2000, J CELL BIOCHEM, V78, P442, DOI 10.1002/1097-4644(20000901)78:3<442::AID-JCB9>3.0.CO;2-1; Trivedi A, 1998, DNA CELL BIOL, V17, P885, DOI 10.1089/dna.1998.17.885; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; Vas A, 2001, MOL CELL BIOL, V21, P5767, DOI 10.1128/MCB.21.17.5767-5777.2001; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Waltz SE, 1996, NUCLEIC ACIDS RES, V24, P1887, DOI 10.1093/nar/24.10.1887; Wang LX, 2004, MOL CELL BIOL, V24, P3373, DOI 10.1128/MCB.24.8.3373-3386.2004; Wilmes GM, 2002, P NATL ACAD SCI USA, V99, P101, DOI 10.1073/pnas.012578499; Yamaguchi R, 2003, CELL, V113, P115, DOI 10.1016/S0092-8674(03)00200-9	62	17	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13071	13083		10.1074/jbc.M404754200	http://dx.doi.org/10.1074/jbc.M404754200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15653697	hybrid			2022-12-25	WOS:000227922000118
J	Koyanagi, M; Hijikata, M; Watashi, K; Masui, O; Shimotohno, K				Koyanagi, M; Hijikata, M; Watashi, K; Masui, O; Shimotohno, K			Centrosomal P4.1-associated protein is a new member of transcriptional coactivators for nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS CORE PROTEIN; HISTONE ACETYLTRANSFERASE; ACTIVATION; ACETYLATION; PHOSPHORYLATION; P65; CBP/P300; RECEPTOR; SUBUNIT; COMPLEX	Nuclear factor-kappa B ( NF-kappa B) is a transcription factor important for various cellular events such as inflammation, immune response, proliferation, and apoptosis. In this study, we performed a yeast two-hybrid screening using the N-terminal domain of the p65 subunit ( RelA) of NF-kappa B as bait and isolated centrosomal P4.1-associated protein ( CPAP) as a candidate for a RelA-associating partner. Glutathione S-transferase pull-down assays and co-immunoprecipitation experiments followed by Western blotting also showed association of CPAP with RelA. When overexpressed, CPAP enhanced NF-kappa B- dependent transcription induced by tumor necrosis factor-alpha (TNF alpha). Reduction of the protein level of endogenous CPAP by RNA interference resulted in decreased activation of NF-kappa B by TNF alpha. After treatment with TNF alpha, a portion of CPAP was observed to accumulate in the nucleus, although CPAP was found primarily in the cytoplasm without any stimulation. Moreover, CPAP was observed in a complex recruited to the transcriptional promoter region containing the NF-kappa B-binding motif. One hybrid assay showed that CPAP has the potential to activate gene expression when tethered to the transcriptional promoter. These data suggest that CPAP functions as a coactivator of NF-kappa B-mediated transcription. Since a physiological interaction between CPAP and the coactivator p300/CREB-binding protein was also observed and synergistic activation of NF-kappa B- mediated transcription was achieved by these proteins, CPAP-dependent transcriptional activation is likely to include p300/CREB-binding protein.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp	Masui, Osamu/AAH-4111-2019					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Masui O, 2002, INT J MOL MED, V9, P489; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Peng B, 2002, MOL ENDOCRINOL, V16, P2019, DOI 10.1210/me.2002-0108; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Watashi K, 2003, MOL CELL BIOL, V23, P7498, DOI 10.1128/MCB.23.21.7498-7509.2003; Watashi K, 2001, VIROLOGY, V286, P391, DOI 10.1006/viro.2001.0990; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	40	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12430	12437		10.1074/jbc.M410420200	http://dx.doi.org/10.1074/jbc.M410420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15687488	hybrid			2022-12-25	WOS:000227922000045
J	Ludeman, MJ; Kataoka, H; Srinivasan, Y; Esmon, NL; Esmon, CT; Coughlin, SR				Ludeman, MJ; Kataoka, H; Srinivasan, Y; Esmon, NL; Esmon, CT; Coughlin, SR			PAR1 cleavage and signaling in response to activated protein C and thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PROSTACYCLIN PRODUCTION; CATALYZED ACTIVATION; ENDOTHELIAL-CELLS; FACTOR-XA; RECEPTOR; COAGULATION; IDENTIFICATION; INHIBITION; MECHANISMS	Activated protein C (APC), a natural anticoagulant protease, can trigger cellular responses via protease-activated receptor-1 (PAR1), a G protein-coupled receptor for thrombin. Whether this phenomenon contributes to the physiological effects of APC is unknown. Toward answering this question, we compared the kinetics of PAR1 cleavage on endothelial cells by APC versus thrombin. APC did cleave PAR1 on the endothelial surface, and antibodies to the endothelial protein C receptor inhibited such cleavage. Importantly, however, APC was similar to 10(4)-fold less potent than thrombin in this setting. APC and thrombin both triggered PAR1-mediated responses in endothelial cells including expression of antiapoptotic ( tumor necrosis factor-alpha-induced a20 and iap-1) and chemokine (interleukin-8 (il-8) and cxcl3) genes, but again, APC was similar to 10(4)-fold less potent than thrombin. The addition of zymogen protein C to endothelial cultures did not alter the rate of PAR1 cleavage at low or high concentrations of thrombin, and PAR1 cleavage was substantial at thrombin concentrations too low to trigger detectable conversion of protein C to APC. Thus, locally generated APC did not contribute to PAR1 cleavage beyond that effected by thrombin in this system. Although consistent with reports that sufficiently high concentrations of APC can cleave and activate PAR1 in culture, our data suggest that a significant physiological role for PAR1 activation by APC is unlikely.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, 513 Parnassus Ave,HSE-1307, San Francisco, CA 94143 USA.	coughlin@cvrimail.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907, R01HL059202] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59202, HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altrogge LM, 2000, ANAL BIOCHEM, V277, P33, DOI 10.1006/abio.1999.4356; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BRASS LF, 1994, J BIOL CHEM, V269, P2943; BRASS LF, 1992, J BIOL CHEM, V267, P13795; Camerer E, 2004, BLOOD, V103, P152, DOI 10.1182/blood-2003-08-2707; Camerer E, 2002, J BIOL CHEM, V277, P16081, DOI 10.1074/jbc.M108555200; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Esmon CT, 2002, ANN MED, V34, P598, DOI 10.1080/078538902321117823; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON NL, 1982, J BIOL CHEM, V257, P859; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; HEEB MJ, 1991, J BIOL CHEM, V266, P17606; ISHII K, 1993, J BIOL CHEM, V268, P9780; Johnson K, 1998, J IMMUNOL, V160, P5130; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Joyce DE, 2002, CRIT CARE MED, V30, pS288, DOI 10.1097/00003246-200205001-00019; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Kurosawa S, 2000, J IMMUNOL, V165, P4697, DOI 10.4049/jimmunol.165.8.4697; Laszik Z, 1997, CIRCULATION, V96, P3633; Levi M, 2003, BLOOD, V101, P4823, DOI 10.1182/blood-2002-10-3254; Ludeman MJ, 2004, J BIOL CHEM, V279, P18592, DOI 10.1074/jbc.M310836200; Macias WL, 2002, CLIN PHARMACOL THER, V72, P391, DOI 10.1067/mcp.2002.128148; Mann KG, 2003, J THROMB HAEMOST, V1, P1504, DOI 10.1046/j.1538-7836.2003.00298.x; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; MOSNIER LO, 2004, BLOOD; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; NICK JA, 2004, BLOOD; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; OWEN WG, 1981, J BIOL CHEM, V256, P5532; Parry MAA, 1996, BIOCHEM J, V320, P335, DOI 10.1042/bj3200335; Pawlinski R, 2004, BLOOD, V103, P1342, DOI 10.1182/blood-2003-09-3051; Pendurthi UR, 2002, ARTERIOSCL THROM VAS, V22, P1421, DOI 10.1161/01.ATV.0000030200.59331.3F; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; Riewald M, 2003, J ENDOTOXIN RES, V9, P317, DOI 10.1179/096805103225002584; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Ruf W, 2003, J THROMB HAEMOST, V1, P1495, DOI 10.1046/j.1538-7836.2003.00300.x; Shibata M, 2001, CIRCULATION, V103, P1799, DOI 10.1161/01.CIR.103.13.1799; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; Taylor FB, 2000, BLOOD, V95, P1680, DOI 10.1182/blood.V95.5.1680.005k33_1680_1686; Taylor FB, 2004, J THROMB HAEMOST, V2, P708, DOI 10.1111/j.1538-7836.2004.00751.x; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; Zimmerman GA, 1996, ADV EXP MED BIOL, V416, P297	52	143	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13122	13128		10.1074/jbc.M410381200	http://dx.doi.org/10.1074/jbc.M410381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15665002	hybrid			2022-12-25	WOS:000227922000123
J	Prasad, NK; Decker, SJ				Prasad, NK; Decker, SJ			SH2-containing 5 '-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent downregulation of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; 3T3-L1 ADIPOCYTES; ADAPTER PROTEIN; HOMOLOGY DOMAIN; RHO-GTPASES; SYNAPTOJANIN; ACTIVATION; ADHESION	Phosphoinositide lipid second messengers are integral components of signaling pathways mediated by insulin, growth factors, and integrins. SHIP2 dephosphorylates phosphatidylinositol 3,4,5-trisphosphate generated by the activated phosphatidylinositol 3'-kinase. SHIP2 down-regulates insulin signaling and is present at higher levels in diabetes and obesity. SHIP2 associates with p130Cas and filamin, regulators of cell adhesion/migration and cytoskeleton, influencing cell adhesion/spreading. Type I collagen specifically induces Src-mediated tyrosine phosphorylation of SHIP2. To better understand SHIP2 function, we employed RNA interference (RNAi) approach to silence the expression of the endogenous SHIP2 in HeLa cells. Suppression of SHIP2 levels caused severe F-actin deformities characterized by weak cortical actin and peripheral actin spikes. SHIP2 RNAi cells displayed cell-spreading defects involving a notable absence of focal contact structures and the formation of multiple slender membrane protrusions capped by actin spikes. Furthermore, decreased SHIP2 levels altered distribution of early endocytic antigen 1 (EEA1)-positive endocytic vesicles and of vesicles containing internalized epidermal growth factor (EGF) and transferrin. EGF treatment of SHIP2 RNAi cells led to the following: enhanced EGF receptor ( EGFR) degradation; increased EGFR ubiquitination; and increased association of EGFR with c-Cbl ubiquitin ligase. Taken together, these experiments demonstrate that SHIP2 functions in the maintenance and dynamic remodeling of actin structures as well as in endocytosis, having a major impact on ligand-induced EGFR internalization and degradation. Accordingly, we suggest that, in HeLa cells, SHIP2 plays a distinct role in signaling pathways mediated by integrins and growth factor receptors.	Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48105 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Michigan System; University of Michigan	Prasad, NK (corresponding author), Purdue Univ, Sch Vet Med, LYNN Hall,625 Harrison St, W Lafayette, IN 47907 USA.	nprasad@purdue.edu						Baumgartener James W., 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P291, DOI 10.2174/1568008033340144; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chi YL, 2004, J BIOL CHEM, V279, P44987, DOI 10.1074/jbc.M406416200; Choi Y, 2002, ONCOGENE, V21, P5289, DOI 10.1038/sj.onc.1205650; Clement S, 2004, NATURE, V431, P878, DOI 10.1038/nature03003; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DECKER SJ, 1989, J BIOL CHEM, V264, P17641; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Hori H, 2002, DIABETES, V51, P2387, DOI 10.2337/diabetes.51.8.2387; Kaisaki PJ, 2004, DIABETES, V53, P1900, DOI 10.2337/diabetes.53.7.1900; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; Marion E, 2002, DIABETES, V51, P2012, DOI 10.2337/diabetes.51.7.2012; Mitchell CA, 2002, IUBMB LIFE, V53, P25, DOI 10.1080/15216540210815; Murakami S, 2004, ENDOCRINOLOGY, V145, P3215, DOI 10.1210/en.2003-1574; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; Prasad N, 2002, J CELL SCI, V115, P3807, DOI 10.1242/jcs.00070; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sasaoka T, 2003, ENDOCRINOLOGY, V144, P4204, DOI 10.1210/en.2003-0190; Sasaoka T, 2001, DIABETOLOGIA, V44, P1258, DOI 10.1007/s001250100645; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Vandenbroere I, 2003, BIOCHEM BIOPH RES CO, V300, P494, DOI 10.1016/S0006-291X(02)02894-2; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Woscholski R, 1997, TRENDS BIOCHEM SCI, V22, P427, DOI 10.1016/S0968-0004(97)01120-1; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	42	76	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13129	13136		10.1074/jbc.M410289200	http://dx.doi.org/10.1074/jbc.M410289200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668240	hybrid			2022-12-25	WOS:000227922000124
J	Sarker, KP; Wilson, SM; Bonni, S				Sarker, KP; Wilson, SM; Bonni, S			SnoN is a cell type-specific mediator of transforming growth factor-beta responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; SMAD INTERACTION MOTIF; MAMMALIAN-CELLS; SIGNAL-TRANSDUCTION; RECEPTOR COMPLEX; RNA INTERFERENCE; GENE-EXPRESSION; C-MYC; FAMILY; SKI	The transforming growth factor-beta ( TGF-beta) family of secreted proteins have pleiotropic functions that are critical to normal development and homeostasis. However, the intracellular mechanisms by which the TGF-beta proteins elicit cellular responses remain incompletely understood. The Smad proteins provide a major means for the propagation of the TGF-beta signal from the cell surface to the nucleus, where the Smad proteins regulate gene expression leading to TGF-beta- dependent cellular responses including the inhibition of cell proliferation. Recent studies have suggested that a nuclear Smad- interacting protein termed SnoN, when overexpressed in cells, suppresses TGF-beta- induced Smad signaling and TGF-beta inhibition of cell proliferation. However, the physiologic function of endogenous SnoN in TGF-beta-mediated biological responses remained to be elucidated. Here, we determined the effect of genetic knockdown of SnoN by RNA interference on TGF- beta responses in mammalian cells. Unexpectedly, we found that SnoN knock- down specifically inhibited TGF- beta- induced transcription in the lung epithelial cell line Mv1Lu but not in HeLa or HaCaT cells. SnoN knock- down was also found to block TGF-beta- dependent cell cycle arrest in Mv1Lu cells. Collectively, these data indicate that rather than suppressing TGF-beta- induced responses, endogenous SnoN acts as a positive mediator of TGF-beta- induced transcription and cell cycle arrest in lung epithelial cells. Our study also shows that SnoN couples the TGF-beta signal to gene expression in a cell-specific manner.	Univ Calgary, Fac Med, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Bonni, S (corresponding author), Univ Calgary, Fac Med, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	sbonni@ucalgary.ca						Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657-685.2003; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOYER PL, 1993, ONCOGENE, V8, P457; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Germain S, 2000, GENE DEV, V14, P435; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 2004, CURR OPIN GENET DEV, V14, P65, DOI 10.1016/j.gde.2003.11.003; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Miyagishi Makoto, 2004, Methods Mol Biol, V252, P483; Miyazono K, 2000, BIOL PHARM BULL, V23, P1125; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; Moustakas A, 2001, J CELL SCI, V114, P4359; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Pearson-White S, 2003, MOL CELL BIOL, V23, P5446, DOI 10.1128/MCB.23.15.5446-5459.2003; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Randall RA, 2004, MOL CELL BIOL, V24, P1106, DOI 10.1128/MCB.24.3.1106-1121.2004; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Suzuki H, 2004, ONCOGENE, V23, P5068, DOI 10.1038/sj.onc.1207690; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wotton D, 2001, CURR TOP MICROBIOL, V254, P145; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu WL, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh010; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200	56	54	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13037	13046		10.1074/jbc.M409367200	http://dx.doi.org/10.1074/jbc.M409367200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677458	hybrid			2022-12-25	WOS:000227922000114
J	Xia, H				Xia, H			Regulation of gamma-fibrinogen chain expression by heterogeneous nuclear ribonucleoprotein A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; BETA-FIBRINOGEN; 5-FLANKING REGION; ALPHA-FIBRINOGEN; BINDING PROTEINS; HNRNP A1; IN-VITRO; PROMOTER; GENE; DEGRADATION	Earlier studies showed that HepG2 cells stably transfected with any one fibrinogen chain cDNA enhanced the expression of the other two fibrinogen chains. In this report, a regulatory element "TGCTCTC" in the gamma-fibrinogen promoter region, -322 to -316, is identified, which is involved in increased expression of gamma chain in HepG2 cells that are transfected with B beta fibrinogen cDNA. By electrophoretic mobility shift assay, three DNA-protein complexes were found to form with the regulatory element. The amount of the protein complexes that bind with the regulatory element was much reduced in HepG2 cells transfected with B beta cDNA. By DNA-affinity chromatography, mass spectrometry, and supershift assay, human heterogeneous nuclear ribonucleoprotein A1 ( hnRNP A1) was identified as a component of the complexes. Overexpression of hnRNP A1 suppressed basal gamma-fibrinogen transcription. These results indicate that the basal expression of gamma-fibrinogen is regulated by a constitutive transcriptional repressor protein, hnRNP A1, and the decreased binding activity of hnRNP A1 leads to the overexpression of gamma chain in HepG2 cells that overexpress the B beta chain.	New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA	New York Blood Center	Xia, H (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, 310 E 67th St, New York, NY 10021 USA.	hxia@nybloodcenter.org						ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; Blomback B, 1996, THROMB RES, V83, P1, DOI 10.1016/0049-3848(96)00111-9; Brown ET, 1998, BLOOD, V92, P3286, DOI 10.1182/blood.V92.9.3286.421k20_3286_3293; Campillos M, 2003, NUCLEIC ACIDS RES, V31, P3063, DOI 10.1093/nar/gkg435; Chen H, 2003, P NATL ACAD SCI USA, V100, P6109, DOI 10.1073/pnas.1031395100; Chen H, 2000, J BIOL CHEM, V275, P35557, DOI 10.1074/jbc.M007117200; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; Donev RM, 2002, MOL CELL BIOCHEM, V233, P181, DOI 10.1023/A:1015504318726; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P89; EVANS E, 1987, J BIOL CHEM, V262, P10850; GREEN F, 1993, THROMB HAEMOSTASIS, V70, P915; GRIENINGER G, 1989, ANN NY ACAD SCI, V557, P257; HENSCHEN AH, 1993, THROMB HAEMOSTASIS, V70, P42; HU CH, 1995, J BIOL CHEM, V270, P28342; Huang SM, 1996, J BIOL CHEM, V271, P27942, DOI 10.1074/jbc.271.44.27942; HUMPHRIES SE, 1987, LANCET, V1, P1452, DOI 10.1016/S0140-6736(87)92205-7; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097-4644(20001201)79:3<395::AID-JCB50>3.0.CO;2-M; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MIZUGUCHI J, 1995, J BIOL CHEM, V270, P28350; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; NICKERSON JM, 1981, BIOCHEMISTRY-US, V20, P2818, DOI 10.1021/bi00513a017; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROY S, 1994, J BIOL CHEM, V269, P691; ROY S, 1992, J BIOL CHEM, V267, P23151; ROY SN, 1990, J BIOL CHEM, V265, P6389; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; THOMAS A, 1994, HUM MUTAT, V3, P79, DOI 10.1002/humu.1380030117; THOOFT FM, 1999, ARTERIOSCLER THROMB, V19, P3063; WILKISON G, 1988, CELL, V54, P841; Xia H, 1999, BIOCHEM BIOPH RES CO, V261, P590, DOI 10.1006/bbrc.1999.1081; Xia H, 2000, BIOCHEM BIOPH RES CO, V273, P377, DOI 10.1006/bbrc.2000.2914; Xia H, 2001, ARCH BIOCHEM BIOPHYS, V390, P137, DOI 10.1006/abbi.2001.2374; Xu WF, 1996, J BIOL CHEM, V271, P27948, DOI 10.1074/jbc.271.44.27948; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287	48	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13171	13178		10.1074/jbc.M414120200	http://dx.doi.org/10.1074/jbc.M414120200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15671034	hybrid			2022-12-25	WOS:000227922000129
J	Roscoe, W; Veitch, GIL; Gong, XQ; Pellegrino, E; Bai, D; McLachlan, E; Shao, Q; Kidder, GM; Laird, DW				Roscoe, W; Veitch, GIL; Gong, XQ; Pellegrino, E; Bai, D; McLachlan, E; Shao, Q; Kidder, GM; Laird, DW			Oculodentodigital dysplasia-causing connexin43 mutants are non-functional and exhibit dominant effects on wild-type connexin43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; MARIE-TOOTH-DISEASE; LIVE MAMMALIAN-CELLS; X-LINKED FORM; MEMBRANE CHANNELS; INTERCELLULAR COMMUNICATION; HEARING-LOSS; TUMOR CELLS; RAT-HEART; MUTATIONS	Oculodentodigital dysplasia, a rare condition displaying congenital craniofacial deformities and limb abnormalities, has been associated with over 20 known human connexin43 (Cx43) mutations. The localization of two of these mutants, G21R and G138R, was examined in Cx43-positive normal rat kidney cells (NRK) and Cx43-negative gap junctional intercellular communication-deficient HeLa cells. Green fluorescent protein-tagged and untagged Cx43 G21R and G138R mutants were transported to the plasma membrane and formed punctate structures reminiscent of gap junction plaques in both NRK and HeLa cells. Further localization studies revealed no significant trafficking defects as subpopulations of Cx43 mutants were found in both the Golgi apparatus and lysosomes, not unlike wild-type Cx43. Dual patch clamp functional analysis of the mutants expressed in gap junctional intercellular communication-deficient N2A cells revealed that neither G21R nor G138R formed functional gap junction channels, although they successfully reached cell-cell interfaces between cell pairs. Importantly, when either mutant was expressed in NRK cells, dye coupling experiments revealed that both mutants inhibited endogenous Cx43 function. These studies suggest that, although patients suffering from oculodentodigital dysplasia possess one wild-type Cx43 allele, it is likely that Cx43-mediated gap junctional intercellular communication is reduced below 50% because of a dominant-negative effect of mutant Cx43 on wild-type Cx43.	Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Laird, DW (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, Dent Sci Bldg,Rm 00077, London, ON N6A 5C1, Canada.	dale.laird@fmd.uwo.ca	Bai, Donglin/ABB-9924-2021; Laird, Dale W/AAL-2407-2020; Laird, Dale w/E-4176-2015; Bai, Donglin/A-5799-2008	Bai, Donglin/0000-0003-1112-6947; Laird, Dale W/0000-0002-4568-3285; Bai, Donglin/0000-0003-1112-6947				Abrams CK, 2001, BRAIN RES, V900, P9, DOI 10.1016/S0006-8993(00)03327-8; Alexander DB, 2003, CURR MED CHEM, V10, P2045, DOI 10.2174/0929867033456927; Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Boyadjiev SA, 1999, GENOMICS, V58, P34, DOI 10.1006/geno.1999.5814; Bukauskas FF, 2000, P NATL ACAD SCI USA, V97, P2556, DOI 10.1073/pnas.050588497; Castro CHM, 2003, CELL COMMUN ADHES, V10, P445, DOI 10.1080/15419060390267700; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Falk MM, 2000, EUR J CELL BIOL, V79, P564, DOI 10.1078/0171-9335-00080; Falk MM, 1998, J BIOL CHEM, V273, P7856, DOI 10.1074/jbc.273.14.7856; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; FALK MM, 1994, J CELL BIOL, V127, P343, DOI 10.1083/jcb.127.2.343; Feldman PA, 1997, J MEMBRANE BIOL, V155, P275, DOI 10.1007/s002329900180; Gladwin A, 1997, HUM MOL GENET, V6, P123, DOI 10.1093/hmg/6.1.123; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Jorgensen NR, 2003, J BIOL CHEM, V278, P4082, DOI 10.1074/jbc.M205880200; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Laird DW, 2001, METH MOL B, V154, P135; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LAIRD DW, 1990, J CELL SCI, V97, P109; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Lecanda F, 2000, J CELL BIOL, V151, P931, DOI 10.1083/jcb.151.4.931; Li WEI, 2002, DEVELOPMENT, V129, P2031; Loddenkemper T, 2002, J NEUROL, V249, P584, DOI 10.1007/s004150200068; Martin PEM, 2000, J NEUROCHEM, V74, P711, DOI 10.1046/j.1471-4159.2000.740711.x; Marziano NK, 2003, HUM MOL GENET, V12, P805, DOI 10.1093/hmg/ddg076; Morley GE, 1997, J CARDIOVASC ELECTR, V8, P939, DOI 10.1111/j.1540-8167.1997.tb00856.x; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; NAUS CCG, 1993, EXP CELL RES, V206, P72, DOI 10.1006/excr.1993.1122; Nelis E, 1999, HUM MUTAT, V13, P11, DOI 10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.0.CO;2-A; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; Pal JD, 2000, AM J PHYSIOL-CELL PH, V279, pC596, DOI 10.1152/ajpcell.2000.279.3.C596; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; Qin H, 2003, J BIOL CHEM, V278, P30005, DOI 10.1074/jbc.M300614200; Rabionet R, 2000, HUM MUTAT, V16, P190, DOI 10.1002/1098-1004(200009)16:3<190::AID-HUMU2>3.3.CO;2-9; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Ressot C, 2000, BRAIN RES REV, V32, P192, DOI 10.1016/S0165-0173(99)00081-8; Richardson RR, 2004, J MED GENET, V41, P60, DOI 10.1136/jmg.2003.012005; Rouan F, 2001, J CELL SCI, V114, P2105; Rouan F, 2003, EXP DERMATOL, V12, P191, DOI 10.1034/j.1600-0625.2003.120210.x; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Seki A, 2004, CIRC RES, V95, P22, DOI 10.1161/01.RES.0000140737.62245.c5; SEKI AC, 2004, HEART RHYTHM, V1, P1; Sohl G, 2003, CELL COMMUN ADHES, V10, P173, DOI 10.1080/15419060390262877; Srinivas M, 1999, J PHYSIOL-LONDON, V517, P673, DOI 10.1111/j.1469-7793.1999.0673s.x; Steel KP, 1998, NAT GENET, V20, P319, DOI 10.1038/3781; Thomas T, 2004, J BIOL CHEM, V279, P19157, DOI 10.1074/jbc.M314117200; Thonnissen E, 2002, HUM GENET, V111, P190, DOI 10.1007/s00439-002-0750-2; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Waldo KL, 1999, DEV BIOL, V208, P307, DOI 10.1006/dbio.1999.9219; Wang HL, 2003, J NEUROCHEM, V84, P735, DOI 10.1046/j.1471-4159.2003.01555.x; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076	54	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11458	11466		10.1074/jbc.M409564200	http://dx.doi.org/10.1074/jbc.M409564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644317	hybrid			2022-12-25	WOS:000227761800069
J	Shia, WJ; Osada, S; Florens, L; Swanson, SK; Washburn, MP; Workman, JL				Shia, WJ; Osada, S; Florens, L; Swanson, SK; Washburn, MP; Workman, JL			Characterization of the yeast trimeric-SAS acetyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IDENTIFICATION TECHNOLOGY; HISTONE VARIANT H2A.Z; SACCHAROMYCES-CEREVISIAE; SILENCING PROTEIN; SWI/SNF COMPLEX; DNA-REPLICATION; HAT COMPLEX; CHROMATIN; HETEROCHROMATIN; TRANSCRIPTION	The yeast SAS2 (Something About Silencing 2) gene encodes a member of the MYST protein family of histone acetyltransferases (HATs) and is involved in transcriptional silencing at all silent loci (HML, HMR, telomeres, and rDNA) in Saccharomyces cerevisiae. Sas2 is the catalytic subunit of a yeast histone acetyltransferase complex termed SAS complex. The enzymatic activity of SAS complex on free histones has been reported, but nucleosomal HAT activity has not yet been documented. Here we show that the native yeast SAS complex is a small trimeric protein complex composed solely of Sas2, Sas4, and Sas5 with a molecular mass of about 125 kDa. It is capable of acetylating both free histones and nucleosomes, although the nucleosomal HAT activity of SAS complex is very weak when compared with that of NuA4, the other member of MYST HAT complex. We also demonstrate that the putative acetyl CoA binding motif in Sas2 is essential for both the in vivo silencing function and the enzymatic activity of SAS complex. Unlike NuA4, which acetylates all four available lysines at the N-terminal tail of histone H4, SAS complex exclusively acetylates lysine 16 of histone H4 in vitro and is required for the bulk of H4 lysine 16 acetylation in vivo. This specific lysine preference corresponds to the role of SAS complex in antagonizing the spreading of Sir proteins at silent loci in S. cerevisiae.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Osaka Univ, Grad Sch Pharmaceut, Lab Environm Biochem, Suita, Osaka 5650871, Japan	Stowers Institute for Medical Research; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Osaka University	Workman, JL (corresponding author), Stowers Inst Med Res, 1000 E 50th, Kansas City, MO 64110 USA.	jlw@stowers-institute.org		Washburn, Michael/0000-0001-7568-2585; Florens, Laurence/0000-0002-9310-6650	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047867] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM-047867] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; Ehrenhofer-Murray AE, 2004, EUR J BIOCHEM, V271, P2335, DOI 10.1111/j.1432-1033.2004.04162.x; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; John S, 2000, GENE DEV, V14, P1196; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Le Masson I, 2003, MOL CELL BIOL, V23, P6086, DOI 10.1128/MCB.23.17.6086-6102.2003; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Lee KK, 2004, BIOCHEM SOC T, V32, P899, DOI 10.1042/BST0320899; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Moshkin YM, 2002, GENE DEV, V16, P2621, DOI 10.1101/gad.231202; Oki M, 2004, MOL CELL BIOL, V24, P1956, DOI 10.1128/MCB.24.5.1956-1967.2004; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Sherman JM, 1997, TRENDS GENET, V13, P308, DOI 10.1016/S0168-9525(97)01198-0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Sutton A, 2003, J BIOL CHEM, V278, P16887, DOI 10.1074/jbc.M210709200; Sutton A, 2001, GENETICS, V158, P587; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Tyler JK, 2001, MOL CELL BIOL, V21, P6574, DOI 10.1128/MCB.21.19.6574-6584.2001; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Xu EY, 1999, GENETICS, V153, P25; Xu EY, 1999, GENETICS, V153, P13; Zhang HY, 2004, MOL CELL BIOL, V24, P9424, DOI 10.1128/MCB.24.21.9424-9436.2004	48	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11987	11994		10.1074/jbc.M500276200	http://dx.doi.org/10.1074/jbc.M500276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659401	hybrid			2022-12-25	WOS:000227761800131
J	Tang, C; Williams, DC; Ghirlando, R; Clore, GM				Tang, C; Williams, DC; Ghirlando, R; Clore, GM			Solution structure of enzyme IIA(Chitobiose) from the N,N '-diacetylchitobiose branch of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYL TRANSFER COMPLEX; PHOSPHOCARRIER PROTEIN HPR; MANNITOL TRANSPORTER IIMANNITOL; SIGNAL-TRANSDUCING PROTEIN; N-TERMINAL DOMAIN; DIPOLAR COUPLINGS; CRYSTAL-STRUCTURE; NMR STRUCTURE; CARBOHYDRATE TRANSPORTERS; STAPHYLOCOCCUS-AUREUS	The solution structure of trimeric Escherichia coli enzyme IIA(Chb) (34 kDa), a component of the N,N'-diacetylchitobiose/lactose branch of the phosphotransferase signal transduction system, has been determined by NMR spectroscopy. Backbone residual dipolar couplings were used to provide long range orientational restraints, and long range (vertical bar i - j vertical bar >= 5 residues) nuclear Overhauser enhancement restraints were derived exclusively from samples in which at least one subunit was N-15/C-13/H-2/(Val-Leu-Ile)-methyl-protonated. Each subunit consists of a three-helix bundle. Hydrophobic residues lining helix 3 of each subunit are largely responsible for the formation of a parallel coiled-coil trimer. The active site histidines (His-89 from each subunit) are located in three symmetrically placed deep crevices located at the interface of two adjacent subunits (A and C, C and B, and B and A). Partially shielded from bulk solvent, structural modeling suggests that phosphorylated His-89 is stabilized by electrostatic interactions with the side chains of His-93 from the same subunit and Gln-91 from the adjacent subunit. Comparison with the x-ray structure of Lactobacillus lactis IIA(Lac) reveals some substantial structural differences, particularly in regard to helix 3, which exhibits a 40 degrees kink in IIA(Lac) versus a 7 degrees bend in IIAChb. This is associated with the presence of an unusually large (230-angstrom(3)) buried hydrophobic cavity at the trimer interface in IIALac that is reduced to only 45 angstrom(3) in IIA(Chb).	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.	mariusc@intra.niddk.nih.gov	Ghirlando, Rodolfo/A-8880-2009; Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Tang, Chun/0000-0001-6477-6500	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK029023, ZIADK033007, Z01DK029023, Z01DK033007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AB E, 1997, PROTEIN SCI, V6, P304; AB E, 2001, J MOL BIOL, V308, P993, DOI 10.1006/jmbi.2001.4623; Al-Hashimi HM, 2000, J MAGN RESON, V142, P153, DOI 10.1006/jmre.1999.1937; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; BAX A, 1994, METHOD ENZYMOL, V239, P79; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Cornilescu G, 2002, J BIOL CHEM, V277, P42289, DOI 10.1074/jbc.M207314200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEVOS WM, 1990, J BIOL CHEM, V265, P22554; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P2517, DOI 10.1021/bi962924y; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; Goto NK, 1999, J BIOMOL NMR, V13, P369, DOI 10.1023/A:1008393201236; Grishaev A, 2004, J AM CHEM SOC, V126, P7281, DOI 10.1021/ja0319994; Hansen MR, 2000, METHOD ENZYMOL, V317, P220; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; HAYS JB, 1973, J BIOL CHEM, V248, P941; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; Jaroniec CP, 2004, J BIOMOL NMR, V30, P181, DOI 10.1023/B:JNMR.0000048946.71249.2f; JIA ZC, 1993, J BIOL CHEM, V268, P22490; KALBITZER HR, 1993, EUR J BIOCHEM, V216, P205, DOI 10.1111/j.1432-1033.1993.tb18134.x; Keyhani N, 2000, J BIOL CHEM, V275, P33110, DOI 10.1074/jbc.M001717200; Keyhani NO, 2000, J BIOL CHEM, V275, P33091, DOI 10.1074/jbc.M001044200; Keyhani NO, 1997, P NATL ACAD SCI USA, V94, P14367, DOI 10.1073/pnas.94.26.14367; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Legler PM, 2004, J BIOL CHEM, V279, P39115, DOI 10.1074/jbc.M406764200; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; McClain DL, 2001, J MOL BIOL, V313, P371, DOI 10.1006/jmbi.2001.5044; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; PELTON JG, 1993, PROTEIN SCI, V2, P543; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; Sliz P, 1997, STRUCTURE, V5, P775, DOI 10.1016/S0969-2126(97)00232-3; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Tugarinov V, 2004, J AM CHEM SOC, V126, P9827, DOI 10.1021/ja048738u; van Montfort RLM, 1998, STRUCTURE, V6, P377, DOI 10.1016/S0969-2126(98)00039-2; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; VANNULAND NAJ, 1994, J MOL BIOL, V237, P544, DOI 10.1006/jmbi.1994.1254; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; WITTEKIND M, 1992, PROTEIN SCI, V1, P1363, DOI 10.1002/pro.5560011016; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; Yang DW, 1999, J BIOMOL NMR, V14, P333, DOI 10.1023/A:1008314803561; Yang DW, 1999, J BIOMOL NMR, V14, P273, DOI 10.1023/A:1008381929212; Zeng XG, 1997, PROTEIN SCI, V6, P2218; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006	75	11	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11770	11780		10.1074/jbc.M414300200	http://dx.doi.org/10.1074/jbc.M414300200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15654077	hybrid			2022-12-25	WOS:000227761800106
J	Ray, R; Choi, M; Zhang, ZJ; Silverman, GA; Askew, D; Mukherjee, AB				Ray, R; Choi, M; Zhang, ZJ; Silverman, GA; Askew, D; Mukherjee, AB			Uteroglobin suppresses SCCA gene expression associated with allergic asthma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERPIN; CONTAINS; DISEASE; LOCUS	Uteroglobin (UG), the founding member of the Secreto-globin superfamily, is a potent anti-inflammatory protein constitutively expressed at a high level in the airway epithelia of all mammals. We previously reported that the lungs of UG-knock-out (UG-KO) mice express elevated levels of Th2 cytokines (e. g. interleukin (IL)- 4 and IL-13), which are augmented by allergen sensitization and challenge leading to exaggerated airway inflammation. Notably, these responses are suppressed by recombinant UG treatment (Mandal, A. K., Zhang, Z., Ray, R., Choi, M. S., Chowdhury, B., Pattabiraman, N., and Mukherjee, A. B. (2004) J. Exp. Med. 199, 1317-1330). Recent reports indicate that human orthologs of murine squamous cell carcinoma antigen-2 (SCCA-2/serpinb3a), a serine protease-inhibitor, are overexpressed in the airways of asthmatic patients. We report here that compared with wild type littermates, UG-KO mouse lungs express markedly elevated levels of SCCA- 2 mRNA and protein, which are augmented by allergen-challenge. Most importantly, these effects are abrogated by recombinant UG treatment. We further demonstrate that treatment of cultured human bronchial epithelial cells with IL-4 or IL-13 stimulates phosphorylation of STAT-1 and STAT-6 leading to SCCA- 1 (SERPINB3) and SCCA- 2 (SERPINB4) gene expression. We propose that: (i) IL-4- and IL-13- stimulated SCCA gene expression is mediated via STAT-1 and STAT-6 activation, and (ii) by suppressing the production, and most likely by interfering with the signaling of these cytokines, UG inhibits SCCA gene expression associated with airway inflammation in asthma.	NICHD, Sect Dev Genet, Heritable Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Mukherjee, AB (corresponding author), NICHD, Sect Dev Genet, Heritable Dis Branch, NIH, Bethesda, MD 20892 USA.	mukherja@exchange.nih.gov	Silverman, Gary/AAJ-1269-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000910] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000910] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Askew DJ, 2004, GENOMICS, V84, P166, DOI 10.1016/j.ygeno.2004.01.014; Bartuski AJ, 1998, GENOMICS, V54, P297, DOI 10.1006/geno.1998.5586; Chen LC, 2001, J IMMUNOL, V167, P3025, DOI 10.4049/jimmunol.167.6.3025; Izuhara K, 2003, CLIN CHEM LAB MED, V41, P860, DOI 10.1515/CCLM.2003.130; Izuhara K., 2002, Current Drug Targets - Inflammation and Allergy, V1, P263, DOI 10.2174/1568010023344661; Kim HS, 2001, MAT SCI ENG A-STRUCT, V299, P305, DOI 10.1016/S0921-5093(00)01416-7; KLUG J, 2000, ANN NY ACAD SCI, V923, P349; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; Sakata Y, 2004, J BIOL CHEM, V279, P5081, DOI 10.1074/jbc.M311585200; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Shijubo N, 1999, AM J RESP CRIT CARE, V160, P930, DOI 10.1164/ajrccm.160.3.9803113; Silverman GA, 1998, TUMOR BIOL, V19, P480, DOI 10.1159/000030041; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972; Zhang ZJ, 1997, DNA CELL BIOL, V16, P73, DOI 10.1089/dna.1997.16.73; Zhang ZJ, 1997, SCIENCE, V276, P1408, DOI 10.1126/science.276.5317.1408	18	28	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9761	9764		10.1074/jbc.C400581200	http://dx.doi.org/10.1074/jbc.C400581200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15677460	hybrid			2022-12-25	WOS:000227559600002
J	Ego, T; Tanaka, Y; Shimotohno, K				Ego, T; Tanaka, Y; Shimotohno, K			Interaction of HTLV-1 Tax and methyl-CpG-binding domain 2 positively regulates the gene expression from the hypermethylated LTR	ONCOGENE			English	Article						Tax; methyl-CpG-binding domain 2; epigenetic regulation	T-CELL LEUKEMIA; VIRUS TYPE-I; MONOCLONAL-ANTIBODIES; DEMETHYLASE ACTIVITY; LENTIVIRUS VECTOR; DNA METHYLATION; TERMINAL REPEAT; C-MYB; PROTEIN; TRANSCRIPTION	Epigenetic regulation of gene expression is critical in the maintenance of cellular homeostasis. Dysregulation of normal epigenetic transcription occurs in abnormal physiological conditions, such as those seen in cancer cells and cells infected with parasites, making the mechanism underlying abnormal epigenetic transcription of great interest. Gene expression of human T-cell leukemia virus type 1 (HTLV-1) is regulated by a viral transcriptional stimulator, Tax. We herein report a novel mechanism of transcription from the HTLV-1 long terminal repeat (LTR) that is regulated by Tax. In this study, we determined that Tax is able to activate transcription from the LTR, even when it was heavily methylated. In addition, the methyl-CpG-binding domain 2 (MBD2) protein played an important role in Tax-mediated transcriptional activation. We demonstrated the importance of a physical interaction between Tax and MBD2 in enhancing the transcriptional activity of Tax against the methylated LTR. Furthermore, we identified the formation of a protein complex composed of MBD2 and Tax bound to the methylated LTR. We propose a new model of epigenetic regulation by MBD2 acting in concert with a virally encoded transactivator, Tax. Our observation provides insight into the epigenetic regulation of gene expression and the diverse mechanisms of transcriptional regulation using methylated promoters.	Kyoto Univ, Dept Viral Oncol, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Univ Ryukyus, Fac Med, Nishihara, Okinawa 9030215, Japan	Kyoto University; University of the Ryukyus	Shimotohno, K (corresponding author), Kyoto Univ, Dept Viral Oncol, Inst Virus Res, Sakyo Ku, 53 Kawara Cho, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp						Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Ariumi Y, 2001, BIOCHEM BIOPH RES CO, V287, P556, DOI 10.1006/bbrc.2001.5626; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Fujita H, 2003, MOL CELL BIOL, V23, P2645, DOI 10.1128/MCB.23.8.2645-2657.2003; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nicot C, 2000, MOL CELL BIOL, V20, P8580, DOI 10.1128/MCB.20.22.8580-8589.2000; Nicot C, 2001, MOL CELL BIOL, V21, P7391, DOI 10.1128/MCB.21.21.7391-7402.2001; NOSAKA T, 1993, NUCLEIC ACIDS RES, V21, P5124, DOI 10.1093/nar/21.22.5124; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; TANAKA Y, 1991, INT J CANCER, V48, P623, DOI 10.1002/ijc.2910480423; TANAKA Y, 1986, INT J CANCER, V37, P35, DOI 10.1002/ijc.2910370107; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshida M, 2004, BLOOD, V103, P2753, DOI 10.1182/blood-2003-07-2482	42	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1914	1923		10.1038/sj.onc.1208394	http://dx.doi.org/10.1038/sj.onc.1208394			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674330				2022-12-25	WOS:000227542000010
J	Liu, LH; Bosmans, F; Maeterns, C; Zhu, RH; Wang, DC; Tytgat, J				Liu, LH; Bosmans, F; Maeterns, C; Zhu, RH; Wang, DC; Tytgat, J			Molecular basis of the mammalian potency of the scorpion alpha-like toxin, BmK M1	FASEB JOURNAL			English	Article						voltage-gated Na+ channels	SODIUM-CHANNEL; FUNCTIONAL EXPRESSION; MEMBRANE-PROTEIN; NEUROTOXIN; SITE; SELECTIVITY; SUBUNIT; BINDING; LQH-2; TIPE	In-depth structure-function studies of voltage-gated Na+ channels and peptide toxins are continuously increasing our understanding of their interaction. In this study, an effective yeast expression system was used to study the role of 14 N- and C-terminal residues from the a-like toxin BmK M1 from the Chinese scorpion Buthus martensii Karsch. With the use of site-directed mutagenesis, all of these residues were individually substituted by one or more amino acids, resulting in a total of 19 mutants. These were then subjected to a bioassay on mice, an elaborate electrophysiological characterization on three cloned voltage-gated Na+ channels (Na(v)1.2, Na(v)1.5, and para), and a circular dichroism analysis. Our results reveal large mutant-dependent differences that emphasize important and specific roles for the studied residues. By mutating single amino acids, we were able to redirect the a-like characteristics of BmK M1 (active on both mammals and insects) to either much higher mammal specificity or, in a few cases, total insect specificity. This study therefore represents a thorough mapping and elucidation of three epitopes that underlie the molecular basis of the mammalian and insecticidal potency of the scorpion a-like toxin, BmK M1 on voltage-gated Na+ channels.	Chinese Acad Sci, Inst Biophys, Ctr Molec Biol, Beijing 100101, Peoples R China; Univ Leuven, Lab Toxicol, B-3000 Leuven, Belgium	Chinese Academy of Sciences; Institute of Biophysics, CAS; KU Leuven	Wang, DC (corresponding author), Chinese Acad Sci, Inst Biophys, Ctr Molec Biol, 15 Datun Rd, Beijing 100101, Peoples R China.	dcwang@ibp.ac.cn; Jan.Tytgat@pharm.kuleuven.ac.be	Bosmans, Frank/T-5589-2017; Bosmans, Frank/A-9660-2013; Tytgat, Jan/F-1560-2010	Bosmans, Frank/0000-0002-6476-235X; Bosmans, Frank/0000-0002-6476-235X; Tytgat, Jan/0000-0003-1778-6022; Bosmans, Frank/0000-0002-0451-6050				Bosmans F, 2002, FEBS LETT, V532, P131, DOI 10.1016/S0014-5793(02)03653-0; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen HJ, 2002, EUR J NEUROSCI, V16, P767, DOI 10.1046/j.1460-9568.2002.02142.x; Denac H, 2000, N-S ARCH PHARMACOL, V362, P453, DOI 10.1007/s002100000319; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Gordon D, 2003, TOXICON, V41, P125, DOI 10.1016/S0041-0101(02)00294-5; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; Grolleau F, 2001, J EXP BIOL, V204, P711; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; He XL, 1999, J MOL BIOL, V292, P125, DOI 10.1006/jmbi.1999.3036; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Karbat I, 2004, J BIOL CHEM, V279, P31679, DOI 10.1074/jbc.M402048200; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; Leipold E, 2004, MOL PHARMACOL, V65, P685, DOI 10.1124/mol.65.3.685; Li HM, 1996, J MOL BIOL, V261, P415, DOI 10.1006/jmbi.1996.0473; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MEIER J, 1986, TOXICON, V24, P395, DOI 10.1016/0041-0101(86)90199-6; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Seibert AL, 2004, BIOCHEMISTRY-US, V43, P7082, DOI 10.1021/bi0496135; Shao F, 1999, PROTEIN EXPRES PURIF, V17, P358, DOI 10.1006/prep.1999.1127; Sun YM, 2003, J BIOL CHEM, V278, P24125, DOI 10.1074/jbc.M211931200; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; Wang CG, 2003, BIOCHEMISTRY-US, V42, P4699, DOI 10.1021/bi0270438; Wang SY, 2003, CELL SIGNAL, V15, P151, DOI 10.1016/S0898-6568(02)00085-2; Warmke JW, 1997, J GEN PHYSIOL, V110, P119, DOI 10.1085/jgp.110.2.119; Xiong YM, 1997, TOXICON, V35, P1025, DOI 10.1016/S0041-0101(96)00224-3; Yu FH, 2003, J NEUROSCI, V23, P7577; Zhu SY, 2004, J MOL EVOL, V58, P145, DOI 10.1007/s00239-003-2534-2; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810; Zlotkin E, 1999, ANNU REV ENTOMOL, V44, P429, DOI 10.1146/annurev.ento.44.1.429	37	38	39	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					594	+		10.1096/fj.04-2485fje	http://dx.doi.org/10.1096/fj.04-2485fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15677695				2022-12-25	WOS:000226576600044
J	Untersmayr, E; Bakos, N; Scholl, I; Kundi, M; Roth-Walter, F; Szalai, K; Riemer, AB; Ankersmit, HJ; Scheiner, O; Boltz-Nitulescu, G; Jensen-Jarolim, E				Untersmayr, E; Bakos, N; Scholl, I; Kundi, M; Roth-Walter, F; Szalai, K; Riemer, AB; Ankersmit, HJ; Scheiner, O; Boltz-Nitulescu, G; Jensen-Jarolim, E			Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients	FASEB JOURNAL			English	Article						food allergy; digestion; epidemiology; skin prick test; oral sensitization; ST2; simulated gastric fluid	FOOD ALLERGENS; ST2 PROTEIN; DIGESTIBILITY; PREVALENCE; EXPRESSION; OMEPRAZOLE; DYSPEPSIA; DIGESTION; BIOLOGY; ULCER	Recently, we have demonstrated that anti-ulcer drugs, such as H2-receptor blockers and proton pump inhibitors, promote the development of immediate type food allergy toward digestion-labile proteins in mice. The aim of this study was to examine the allergological relevance of these findings in humans. In an observational cohort study, we screened 152 adult patients from a gastroenterological outpatient clinic with negative case histories for atopy or allergy, who were medicated with H2-receptor blockers or proton pump inhibitors for 3 months. IgE reactivities to food allergens before and after 3 months of anti-acid treatment were compared serologically. Ten percent of the patients showed a boost of preexisting IgE antibodies and 15% de novo IgE formation toward numerous digestion-labile dietary compounds, like milk, potato, celery, carrots, apple, orange, wheat, and rye flour. Thus, the relative risk to develop food-specific IgE after anti-acid therapy was 10.5 (95% confidence interval: 1.44 - 76.48). The long-term effect was evaluated 5 months after therapy. Food-specific IgE could still be measured in 6% of the patients, as well as significantly elevated serum concentrations of ST2, a Th2-specific marker. An unspecific boost during the pollen season could be excluded, as 50 untreated control patients revealed no changes in their IgE pattern. In line with our previous animal experiments, our data strongly suggest that anti-ulcer treatment primes the development of IgE toward dietary compounds in long-term acid-suppressed patients.	Med Univ Vienna, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Hetenyi Geza Hosp, Dept Dermatol, H-5000 Szolnok, Hungary; Med Univ Vienna, Dept Occupat & Social Hlth, A-1090 Vienna, Austria; Med Univ Vienna, Dept CT Surg, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Jensen-Jarolim, E (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	erika.jensen-jarolim@meduniwien.ac.at	Jensen-Jarolim, Erika/C-5120-2018; Untersmayr, Eva/GRY-4470-2022; Roth-Walter, Franziska/V-4651-2017	Jensen-Jarolim, Erika/0000-0003-4019-5765; Roth-Walter, Franziska/0000-0001-5005-9228; Riemer, Angelika/0000-0002-5865-0714; Ankersmit, Hendrik Jan/0000-0002-8761-3517; Untersmayr, Eva/0000-0002-1963-499X				Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Bjornsson E, 1996, ANN ALLERG ASTHMA IM, V77, P327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGET DW, 1990, GASTROENTEROLOGY, V99, P345, DOI 10.1016/0016-5085(90)91015-X; CHIVERTON SG, 1989, GUT, V30, P594, DOI 10.1136/gut.30.5.594; COOK GC, 1985, SCAND J GASTROENTERO, V20, P17, DOI 10.3109/00365528509093751; Corder AP, 1996, BRIT J CLIN PRACT, V50, P245; Fu TT, 2002, J AGR FOOD CHEM, V50, P7154, DOI 10.1021/jf020599h; Hefle SL, 1996, FOOD TECHNOL-CHICAGO, V50, P86; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; HUNT RH, 1988, SCAND J GASTROENTERO, V23, P34, DOI 10.3109/00365528809099128; ISOLAURI J, 1995, ANN MED, V27, P67, DOI 10.3109/07853899509031939; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; JONES RH, 1990, GUT, V31, P401, DOI 10.1136/gut.31.4.401; Kelso JM, 2000, CLIN EXP ALLERGY, V30, P905, DOI 10.1046/j.1365-2222.2000.00872.x; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALLING HJ, 1993, ALLERGY, V48, P9; MCCARTHY DM, 1991, NEW ENGL J MED, V325, P1017; McDonnell JM, 2001, NAT STRUCT BIOL, V8, P437, DOI 10.1038/87603; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120; PEDEN NR, 1979, LANCET, V2, P199; Penston JG, 1996, ALIMENT PHARM THERAP, V10, P83; PRICHARD PJ, 1985, GASTROENTEROLOGY, V88, P64, DOI 10.1016/S0016-5085(85)80133-5; Richardson P, 1998, DRUGS, V56, P307, DOI 10.2165/00003495-199856030-00002; SAMLOFF IM, 1989, GASTROENTEROLOGY, V96, P586, DOI 10.1016/S0016-5085(89)80054-X; SHARMA BK, 1984, GUT, V25, P957, DOI 10.1136/gut.25.9.957; Taylor SL, 2001, J ALLERGY CLIN IMMUN, V107, P765, DOI 10.1067/mai.2001.114241; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; Yagami T, 2000, J ALLERGY CLIN IMMUN, V106, P752, DOI 10.1067/mai.2000.109171; Yagami T, 2002, INT ARCH ALLERGY IMM, V128, P271, DOI 10.1159/000063859; Yanagisawa K, 1997, J BIOCHEM-TOKYO, V121, P95; 2003, MED LETT DRUGS THER, V45, P61	35	157	161	2	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					656	+		10.1096/fj.04-3170fje	http://dx.doi.org/10.1096/fj.04-3170fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15671152				2022-12-25	WOS:000226576600005
J	Hildesheim, J; Salvador, JM; Hollander, MC; Fornace, AJ				Hildesheim, J; Salvador, JM; Hollander, MC; Fornace, AJ			Casein kinase 2-and protein kinase A-regulated adenomatous polyposis coli and beta-catenin cellular localization is dependent on p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT; SUBCELLULAR-LOCALIZATION; CYCLIN D1; PHOSPHORYLATION; APC; COMPLEX; TARGET; IRRADIATION; EXPRESSION; APOPTOSIS	Skin cancer is the most common form of malignancy in the world with epidemic proportions. Identifying the biochemical and molecular mechanisms underlying the events leading to tumors is paramount to designing new and effective treatments that may aid in treating and/or preventing skin cancers. Herein we identify p38 MAPK, along with its positive modulator, Gadd45a, as important regulators of nucleocytoplasmic shuttling of the adenomatous polyposis coli (APC) tumor suppressor. APC normally functions to block beta-catenin from promoting cell proliferation and migration/invasion. Keratinocytes lacking proper p38 MAPK activation, either due to lack of Gadd45a or through the use of p38 MAPK-specific inhibitors, are unable to effectively transport APC into the nucleus. We also show that p38 MAPK is able to directly associate with and modulate both casein kinase 2 (CK2) and protein kinase A (PKA), which promote and block APC nuclear import, respectively. We demonstrate that p38 MAPK is able to not only enhance CK2 kinase activity but also suppress PKA kinase activity. Moreover, lack of normal p38 MAPK activity in either Gadd45a-null keratinocytes or in p38 MAPK inhibitor treated keratinocytes leads to decreased CK2 activity and increased PKA activity. In either case, disruption of APC nuclear import results in elevated levels of free cellular, and potentially oncogenic, beta-catenin. Numerous tumors, including skin cancers, are associated with high levels of beta-catenin, and our data indicate that p38 MAPK signaling, along with Gadd45a, may provide tumor suppressor-like functions in part by promoting APC nuclear localization and effective beta-catenin regulation.	NCI, Gene Response Sect, CCR, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hildesheim, J (corresponding author), NCI, Gene Response Sect, CCR, NIH, Bldg 37,Rm 6144,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	jh30h@nih.gov	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Salvador, Jesus Maria/0000-0002-1087-9675				Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; BUTZ S, 1994, FEBS LETT, V355, P195, DOI 10.1016/0014-5793(94)01205-9; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Furukawa F, 2003, HEPATOLOGY, V38, P879, DOI 10.1053/jhep.2003.50384; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Granet C, 2002, CELL SIGNAL, V14, P679, DOI 10.1016/S0898-6568(02)00008-6; Hagen T, 2002, BIOCHEM BIOPH RES CO, V294, P324, DOI 10.1016/S0006-291X(02)00485-0; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Hildesheim J, 2004, ONCOGENE, V23, P1829, DOI 10.1038/sj.onc.1207301; Hildesheim J, 2004, J INVEST DERMATOL, V122, P497, DOI 10.1111/j.1523-1747.2004.22229.x; Hildesheim J, 2002, CANCER RES, V62, P7305; HOOD JK, 2000, BIOCHIM BIOPHYS ACTA, V1471, P31; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Neufeld KL, 2000, EMBO REP, V1, P519; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; URBACH F, 1991, DERMATOL CLIN, V9, P751; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	43	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17221	17226		10.1074/jbc.M410440200	http://dx.doi.org/10.1074/jbc.M410440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15649893	hybrid			2022-12-25	WOS:000228615500084
J	Popescu, CI; Paduraru, C; Dwek, RA; Petrescu, SM				Popescu, CI; Paduraru, C; Dwek, RA; Petrescu, SM			Soluble tyrosinase is an endoplasmic reticulum (ER)-associated degradation substrate retained in the ER by calreticulin and BiP/GRP78 and not calnexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULOCUTANEOUS ALBINISM TYPE-1; QUALITY-CONTROL; MISFOLDED GLYCOPROTEINS; RECYCLING PATHWAY; PROTEIN ERGIC-53; MOLECULAR-BASIS; GENE; RETENTION; MUTATIONS; BINDING	Tyrosinase is a type I membrane protein regulating the pigmentation process in humans. Mutations of the human tyrosinase gene cause the tyrosinase negative type I oculocutaneous albinism (OCAI). Some OCAI mutations were shown to delete the transmembrane domain or to affect its hydrophobic properties, resulting in soluble tyrosinase mutants that are retained in the endoplasmic reticulum (ER). To understand the specific mechanisms involved in the ER retention of soluble tyrosinase, we have constructed a tyrosinase mutant truncated at its C-terminal end and investigated its maturation process. The mutant is retained in the ER, and it is degraded through the proteasomal pathway. We determined that the mannose trimming is required for an efficient degradation process. Moreover, this soluble ER-associated degradation substrate is stopped at the ER quality control checkpoint with no requirements for an ER-Golgi recycling pathway. Co-immmunoprecipitation experiments showed that soluble tyrosinase interacts with calreticulin and BiP/GRP78 (and not calnexin) during its ER transit. Expression of soluble tyrosinase in calreticulin-deficient cells resulted in the export of soluble tyrosinase of the ER, indicating the calreticulin role in ER retention. Taken together, these data show that OCAI soluble tyrosinase is an ER-associated degradation substrate that, unlike other albino tyrosinases, associates with calreticulin and BiP/GRP78. The lack of specificity for calnexin interaction reveals a novel role for calreticulin in OCAI albinism.	Romanian Acad, Inst Biochem, Bucharest 060031 17, Romania; Oxford Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England	Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; University of Oxford	Petrescu, SM (corresponding author), Romanian Acad, Inst Biochem, Splaiul Independentei 296, Bucharest 060031 17, Romania.	stefana.petrescu@biochim.ro	Popescu, Costin-Ioan/C-3033-2012; Petrescu, Stefana/AAJ-9505-2021; Petrescu, Stefana M/I-9240-2012	Petrescu, Stefana/0000-0002-4047-0811; Petrescu, Stefana M/0000-0002-4047-0811				Ahner A, 2004, TRENDS CELL BIOL, V14, P474, DOI 10.1016/j.tcb.2004.07.013; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; Breimer LH, 1995, CLIN CHIM ACTA, V243, P35, DOI 10.1016/0009-8981(95)06152-5; Chen K, 2002, MOL BIOL CELL, V13, P1953, DOI 10.1091/mbc.02-02-0022; CHINTAMANENI CD, 1991, P NATL ACAD SCI USA, V88, P5272, DOI 10.1073/pnas.88.12.5272; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; Furumura M, 1998, BIOCHEM BIOPH RES CO, V242, P579, DOI 10.1006/bbrc.1997.8007; GIEBEL LB, 1991, GENOMICS, V9, P435, DOI 10.1016/0888-7543(91)90409-8; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; King RA, 2003, HUM GENET, V113, P502, DOI 10.1007/s00439-003-0998-1; Klumperman J, 1998, J CELL SCI, V111, P3411; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Oetting WS, 2003, PIGM CELL RES, V16, P307, DOI 10.1034/j.1600-0749.2003.00045.x; Oetting WS, 1999, HUM MUTAT, V13, P99, DOI 10.1002/(SICI)1098-1004(1999)13:2<99::AID-HUMU2>3.3.CO;2-3; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Petrescu SM, 2000, BIOCHEMISTRY-US, V39, P5229, DOI 10.1021/bi000107z; Rosemblat S, 1998, EXP CELL RES, V239, P344, DOI 10.1006/excr.1997.3901; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; Toyofuku K, 2001, BIOCHEM J, V355, P259, DOI 10.1042/0264-6021:3550259; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	36	34	36	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13833	13840		10.1074/jbc.M413087200	http://dx.doi.org/10.1074/jbc.M413087200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677452	hybrid			2022-12-25	WOS:000228095500081
J	Bari, M; Battista, N; Fezza, F; Finazzi-Agro, A; Maccarrone, M				Bari, M; Battista, N; Fezza, F; Finazzi-Agro, A; Maccarrone, M			Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells - Implications for anandamide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID AMIDE HYDROLASE; HUMAN ENDOTHELIAL-CELLS; ENDOCANNABINOID SYSTEM; VANILLOID RECEPTORS; THERAPEUTIC IMPLICATIONS; MEMBRANE CHOLESTEROL; AGONIST; CB1; TRANSDUCTION; INVOLVEMENT	Several G protein-coupled receptors function within lipid rafts plasma membrane microdomains, which may be important in limiting signal transduction. Here we show that treatment of rat C6 glioma cells with the raft disruptor methyl-beta-cyclodextrin (MCD) doubles the binding efficiency (i.e. the ratio between maximum binding and dissociation constant) of type-1 cannabinoid receptors (CB1R), which belong to the rhodopsin family of G protein-coupled receptors. In parallel, activation of CB1R by the endogenous agonist anandamide (AEA) leads to similar to 3-fold higher [S-35]GTP gamma S binding in MCD-treated cells than in controls, and CB1R-dependent signaling via adenylate cyclase, and p42/p44 MAPK is almost doubled by MCD. Unlike CB1R, the other AEA-binding receptor TRPV1, the AEA synthetase NAPE-PLD, and the AEA hydrolase FAAH are not modulated by MCD, whereas the activity of the AEA membrane transporter (AMT) is reduced to similar to 50% of the controls. We also show that MCD reduces dose-dependently AEA-induced apoptosis in C6 cells but not in human CHP100 neuroblastoma cells, which mirror the endocannabinoid system of C6 cells but are devoid of CB1R. MCD reduces also cytochrome c release from mitochondria of C6 cells, and this effect is CB1R-dependent and partly mediated by activation of p42/p44 MAPK. Altogether, the present data suggest that lipid rafts control CB1R binding and signaling, and that CB1R activation underlies the protective effect of MCD against apoptosis.	Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Santa Lucia Ctr Expt Neurobiol, Ist Ricovero & Cura & Carattere Sci C Mondino, I-00133 Rome, Italy	University of Teramo; University of Rome Tor Vergata; IRCCS Fondazione Casimiro Mondino; IRCCS Santa Lucia	Maccarrone, M (corresponding author), Univ Teramo, Dept Biomed Sci, Piazza A Moro 45, I-64100 Teramo, Italy.	mmaccarrone@unite.it	Battista, Natalia/AAC-2529-2019	Battista, Natalia/0000-0002-1936-6710				Annabi B, 2004, J BIOL CHEM, V279, P21888, DOI 10.1074/jbc.M313694200; BAYEWITCH M, 1995, FEBS LETT, V375, P143, DOI 10.1016/0014-5793(95)01207-U; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Bisogno T, 2002, CURR PHARM DESIGN, V8, P533, DOI 10.2174/1381612023395655; Biswas KK, 2003, HEPATOLOGY, V38, P1167, DOI 10.1053/jhep.2003.50459; Bouaboula M, 1999, FEBS LETT, V449, P61, DOI 10.1016/S0014-5793(99)00395-6; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Breivogel CS, 1998, J BIOL CHEM, V273, P16865, DOI 10.1074/jbc.273.27.16865; Contassot E, 2004, GYNECOL ONCOL, V93, P182, DOI 10.1016/j.ygyno.2003.12.040; Coutts AA, 2001, J NEUROSCI, V21, P2425; Cravatt BF, 2003, CURR OPIN CHEM BIOL, V7, P469, DOI 10.1016/S1367-5931(03)00079-6; De Petrocellis L, 2001, J BIOL CHEM, V276, P12856, DOI 10.1074/jbc.M008555200; De Petrocellis L, 2004, BRIT J PHARMACOL, V141, P765, DOI 10.1038/sj.bjp.0705666; del Pulgar TG, 2002, J BIOL CHEM, V277, P36527, DOI 10.1074/jbc.M205797200; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Do Y, 2004, J IMMUNOL, V173, P2373, DOI 10.4049/jimmunol.173.4.2373; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Fride E, 2002, PROSTAG LEUKOTR ESS, V66, P221, DOI 10.1054/plef.2001.0360; Gaetani S, 2003, TRENDS MOL MED, V9, P474, DOI 10.1016/j.molmed.2003.09.005; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; GOMEZ DP, 2000, BIOCHEM J, V347, P369; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hillard CJ, 2003, BRIT J PHARMACOL, V140, P802, DOI 10.1038/sj.bjp.0705468; Howlett AC, 2000, CHEM PHYS LIPIDS, V108, P53, DOI 10.1016/S0009-3084(00)00187-0; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; Jacobsson SOP, 2001, J PHARMACOL EXP THER, V299, P951; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kunzelmann-Marche C, 2002, J BIOL CHEM, V277, P19876, DOI 10.1074/jbc.M200324200; Liu BY, 2003, BIOPHYS J, V85, P2988, DOI 10.1016/S0006-3495(03)74719-5; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2000, J BIOL CHEM, V275, P13484, DOI 10.1074/jbc.275.18.13484; Maccarrone M, 2003, CELL DEATH DIFFER, V10, P946, DOI 10.1038/sj.cdd.4401284; Maccarrone M, 2003, J BIOL CHEM, V278, P32726, DOI 10.1074/jbc.M302123200; Maccarrone M, 2002, J NEUROCHEM, V82, P1444, DOI 10.1046/j.1471-4159.2002.01072.x; Macho A, 1999, CELL DEATH DIFFER, V6, P155, DOI 10.1038/sj.cdd.4400465; McFarland MJ, 2004, J BIOL CHEM, V279, P41991, DOI 10.1074/jbc.M407250200; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Mechoulam R, 2002, PROSTAG LEUKOTR ESS, V66, P93, DOI 10.1054/plef.2001.0340; Mitter D, 2003, J NEUROCHEM, V84, P35, DOI 10.1046/j.1471-4159.2003.01258.x; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Parasassi T, 1997, BIOPHYS J, V72, P2413, DOI 10.1016/S0006-3495(97)78887-8; Parolaro D, 2002, PROSTAG LEUKOTR ESS, V66, P319, DOI 10.1054/plef.2001.0355; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; REGGIO PH, 2004, 14 ANN S CANN JUN 22; Ross RA, 2001, BRIT J PHARMACOL, V132, P631, DOI 10.1038/sj.bjp.0703850; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sarker KP, 2003, J NEUROCHEM, V85, P50, DOI 10.1046/j.1471-4159.2003.01663.x; Sarker KP, 2003, CELL MOL LIFE SCI, V60, P1200, DOI 10.1007/s00018-003-3055-2; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Szallasi A, 1999, PHARMACOL REV, V51, P159; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Yamaji K, 2003, THROMB HAEMOSTASIS, V89, P875, DOI 10.1055/s-0037-1613475; Yang N, 2004, J BIOL CHEM, V279, P20898, DOI 10.1074/jbc.M400625200	65	166	171	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12212	12220		10.1074/jbc.M411642200	http://dx.doi.org/10.1074/jbc.M411642200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15657045	hybrid			2022-12-25	WOS:000227922000019
J	Bodoy, S; Martin, L; Zorzano, A; Palacin, M; Estevez, R				Bodoy, S; Martin, L; Zorzano, A; Palacin, M; Estevez, R			Identification of LAT4, a novel amino acid transporter with system L activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; HEAVY-CHAIN; DISTINCT; KIDNEY; GENE; PHENYLKETONURIA; REABSORPTION; EXCHANGERS; EXPRESSION; PLACENTA	System L amino acid transporters mediate the movement of bulky neutral amino acids across cell membranes. Until now three proteins that induce system L activity have been identified: LAT1, LAT2, and LAT3. The former two proteins belong to the solute carrier family 7 (SLC7), whereas the latter belongs to SLC43. In the present study we present a new cDNA, designated LAT4, which also mediates system L activity when expressed in Xenopus laevis oocytes. Human LAT4 exhibits 57% identity to human LAT3. Like LAT3, the amino acid transport activity induced by LAT4 is sodium-, chloride- and pH-independent, is not trans-stimulated, and shows two kinetic components. The low affinity component of LAT4 induced activity is sensitive to the sulfhydryl-specific reagent N-ethylmaleimide but not that with high affinity. Mutation in LAT4 of the SLC43 conserved serine 297 to alanine abolishes sensitivity to N-ethylmaleimide. LAT4 activity is detected at the basolateral membrane of PCT kidney cells. In situ hybridization experiments show that LAT4 mRNA is restricted to the epithelial cells of the distal tubule and the collecting duct in the kidney. In the intestine, LAT4 is mainly present in the cells of the crypt.	Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain	University of Barcelona	Estevez, R (corresponding author), Univ Barcelona, Dept Biochem & Mol Biol, Avda Diagonal 645, E-08028 Barcelona, Spain.	restevez@pcb.ub.es	Palacín, Manuel/G-9786-2015; Martin Jaular, Lorena/ABI-7121-2020; Estevez, Raul/D-8610-2015; Bodoy, Susanna/H-6883-2015; Zorzano, Antonio/R-5479-2018; Bertran, Joan/AAT-3145-2021	Martin Jaular, Lorena/0000-0002-1511-8576; Estevez, Raul/0000-0003-1579-650X; Bodoy, Susanna/0000-0001-9261-4373; Bertran, Joan/0000-0002-4276-336X; Palacin, Manuel/0000-0002-8670-293X				Babu E, 2003, J BIOL CHEM, V278, P43838, DOI 10.1074/jbc.M305221200; Beck FX, 1998, PFLUG ARCH EUR J PHY, V436, P814, DOI 10.1007/s004240050710; BELL GI, 1993, J BIOL CHEM, V268, P19161; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BLONDEAU JP, 1993, J NEUROCHEM, V60, P1407, DOI 10.1111/j.1471-4159.1993.tb03302.x; CARTIER N, 1993, J CELL SCI, V104, P695; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1510; Cole KA, 1998, GENOMICS, V51, P282, DOI 10.1006/geno.1998.5359; DANTZLER WH, 1988, AM J PHYSIOL, V255, pF397, DOI 10.1152/ajprenal.1988.255.3.F397; DEVES R, 1993, J PHYSIOL-LONDON, V468, P753, DOI 10.1113/jphysiol.1993.sp019799; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; GANDOLFI SA, 1987, BIOCHIM BIOPHYS ACTA, V904, P29, DOI 10.1016/0005-2736(87)90083-6; GARCIASANCHO FJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P538, DOI 10.1016/0005-2736(75)90031-0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Koch R, 2003, PEDIATRICS, V112, P1523; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUDO Y, 1990, J INHERIT METAB DIS, V13, P617, DOI 10.1007/BF01799516; KUDO Y, 1987, BIOCHIM BIOPHYS ACTA, V904, P309, DOI 10.1016/0005-2736(87)90380-4; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; NOVAK DA, 1994, BIOCHEM J, V301, P671, DOI 10.1042/bj3010671; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; OXENDER DL, 1963, NATURE, V197, P765, DOI 10.1038/197765a0; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; SALTER M, 1986, BIOCHEM J, V233, P499, DOI 10.1042/bj2330499; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Sekine T, 2000, PFLUG ARCH EUR J PHY, V440, P337, DOI 10.1007/s004240000297; Shikano N, 2003, NUCL MED BIOL, V30, P31, DOI 10.1016/S0969-8051(02)00350-5; Soler M, 2002, BIOCHEM J, V366, P757, DOI 10.1042/BJ20011807; Stuart RO, 2001, AM J PHYSIOL-RENAL, V281, pF1148, DOI 10.1152/ajprenal.2001.281.6.F1148; THOMPSON GN, 1991, ARCH DIS CHILD, V66, P1346, DOI 10.1136/adc.66.11.1346; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Verrey F, 2003, PFLUG ARCH EUR J PHY, V445, P529, DOI 10.1007/S00424-002-0973-Z; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; YUDILEVICH DL, 1980, BIOCHIM BIOPHYS ACTA, V596, P315, DOI 10.1016/0005-2736(80)90364-8	40	193	205	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					12002	12011		10.1074/jbc.M408638200	http://dx.doi.org/10.1074/jbc.M408638200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659399	hybrid, Green Published			2022-12-25	WOS:000227761800133
J	Harmon, JS; Stein, R; Robertson, RP				Harmon, JS; Stein, R; Robertson, RP			Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH GLUCOSE-CONCENTRATIONS; CHRONIC EXPOSURE; HIT CELLS; TRANSCRIPTION FACTORS; BINDING-PROTEINS; HIT-T15 CELLS; II GENE; TOXICITY; PROMOTER; FAMILY	Glucose toxicity in pancreatic islet beta cells causes loss of insulin gene expression, content, and secretion due to loss of binding of transcription factors, most notably PDX- 1 and RIPE- 3b1 activator, to the promoter region of the insulin gene. Recently, RIPE- 3b1 activator was cloned and identified as the mammalian homologue of avian MafA/ Maf- L ( MafA). This enabled us to carry out more extensive studies of the role of MafA in glucotoxicity than were hitherto possible. Northern analysis of glucotoxic HIT- T15 cells revealed normal amounts of MafA mRNA, but Western analysis demonstrated a 97 +/- 1% reduction in MafA protein ( p < 0.0001). The proteasome is a likely site for MafA degradation as lactacystin, an irreversible proteasome inhibitor, caused an accumulation of MafA protein. Antioxidants have previously been shown to prevent the adverse effects of glucose toxicity on beta cell function both in vivo and in vitro. In the current study, chronic culturing of HIT- T15 cells with the antioxidant N- acetylcysteine ( NAC) prevented loss of MafA protein ( late passage = 18.9 +/- 10.4% of early passage, p < 0.001; late passage with NAC = 68.7 +/- 19.7% of early passage, p = not significant) and loss of DNA binding ( late passage = 63.7 +/- 9% of early passage, p < 0.02; late passage with NAC = 116 +/- 10% of early passage, p = not significant). Additionally, transient transfection of PDX- 1 or MafA cDNA into glucotoxic cells increased PDX- 1 and MafA protein levels and individually increased insulin promoter activity ( untreated = 34%, PDX- 1 = 70%, MafA = 78%; percentage of activity of early passage cells), whereas the combined transfection of MafA and PDX- 1 completely restored insulin promoter activity. This recovery of promoter activity following transient transfection had no effect on endogenous insulin mRNA. However, adenoviral infection of MafA and PDX- 1 significantly increased endogenous insulin mRNA levels by 93% ( 121 +/- 9 versus 233 +/- 18 density light units; n = 5, p < 0.001). We conclude that the absence of MafA protein from beta cells via chronic oxidative stress contributes importantly to the loss of endogenous insulin gene expression as glucose toxicity develops.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Vanderbilt University	Robertson, RP (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	rpr@pnri.org	Roberston, R Paul/AAX-5613-2021		NIDDK NIH HHS [R01 DK 38325] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038325] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1984, DIABETES, V33, P297, DOI 10.2337/diabetes.33.3.297; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; Crawford DR, 1996, FREE RADICAL BIO MED, V21, P521, DOI 10.1016/0891-5849(96)00160-8; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Harmon JS, 1998, DIABETES, V47, P900, DOI 10.2337/diabetes.47.6.900; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; Kajihara M, 2003, BIOCHEM BIOPH RES CO, V312, P831, DOI 10.1016/j.bbrc.2003.10.196; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; Kataoka K, 2004, J MOL ENDOCRINOL, V32, P9, DOI 10.1677/jme.0.0320009; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Matsuoka T, 2004, P NATL ACAD SCI USA, V101, P2930, DOI 10.1073/pnas.0306233101; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; Read ML, 1997, FEBS LETT, V418, P68, DOI 10.1016/S0014-5793(97)01352-5; Robertson RP, 2003, DIABETES, V52, P581, DOI 10.2337/diabetes.52.3.581; ROBERTSON RP, 1992, J CLIN INVEST, V90, P320, DOI 10.1172/JCI115865; Samaras SE, 2003, J BIOL CHEM, V278, P12263, DOI 10.1074/jbc.M210801200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seufert J, 1998, J CLIN INVEST, V101, P2528, DOI 10.1172/JCI2401; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Wice BM, 2001, DIABETOLOGIA, V44, P453, DOI 10.1007/s001250051643; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	32	175	185	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11107	11113		10.1074/jbc.M410345200	http://dx.doi.org/10.1074/jbc.M410345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15664999	hybrid			2022-12-25	WOS:000227761800029
J	Kasbohm, EA; Guo, R; Yowell, CW; Bagchi, G; Kelly, P; Arora, P; Casey, PJ; Daaka, Y				Kasbohm, EA; Guo, R; Yowell, CW; Bagchi, G; Kelly, P; Arora, P; Casey, PJ; Daaka, Y			Androgen receptor activation by G(s) signaling in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; HORMONE; PHOSPHORYLATION; IDENTIFICATION; INTERLEUKIN-6; INHIBITION; PATHWAY; TARGET; GROWTH; GENES	The androgen receptor (AR) is activated in prostate cancer patients undergoing androgen ablative therapy and mediates growth of androgen-insensitive prostate cancer cells, suggesting it is activated by nonandrogenic factors. We demonstrate that activated alpha subunit of heterotrimeric guanine nucleotide-binding G(S) protein activates the AR in prostate cancer cells and also synergizes with low concentration of androgen to more fully activate the AR. The G alpha(S) activates protein kinase A, which is required for the nuclear partition and activation of AR. These data suggest a role for G alpha(S) and PKA in the transactivation of AR in prostate cancer cells under the environment of reduced androgen levels.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Daaka, Y (corresponding author), Duke Univ, Med Ctr, Dept Surg, DUMC 2607, Durham, NC 27710 USA.	daaka001@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309	NIA NIH HHS [AG17952] Funding Source: Medline; NIDDK NIH HHS [DK60917] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017952] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anscher MS, 2004, JAMA-J AM MED ASSOC, V291, P1380, DOI 10.1001/jama.291.11.1380; Benovic Jeffrey L., 2002, Journal of Allergy and Clinical Immunology, V110, pS229, DOI 10.1067/mai.2002.129370; Blok LJ, 1996, ENDOCR RES, V22, P197, DOI 10.3109/07435809609030508; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1997, PROSTATE, V32, P106, DOI 10.1002/(SICI)1097-0045(19970701)32:2<106::AID-PROS5>3.0.CO;2-K; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y., 2004, SCI STKE, V216, pr; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Feldman DS, 2002, J BIOL CHEM, V277, P28631, DOI 10.1074/jbc.M204753200; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; GELLER J, 1995, J CLIN ENDOCR METAB, V80, P1074, DOI 10.1210/jcem.80.4.7714070; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Huang HC, 2002, J PROTEIN CHEM, V21, P111, DOI 10.1023/A:1014528328673; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Ko L, 2002, MOL CELL BIOL, V22, P357, DOI 10.1128/MCB.22.1.357-369.2002; Kokontis JM, 1999, VITAM HORM, V55, P219; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Kue PF, 2002, INT J CANCER, V102, P572, DOI 10.1002/ijc.10734; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; MEIER UT, 1992, CELL, V70, P127; Nambi P, 2003, ASSAY DRUG DEV TECHN, V1, P305, DOI 10.1089/15406580360545116; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Porter AT, 2001, UROL ONCOL, V6, P131, DOI 10.1016/S1078-1439(00)00124-1; Scanlan TS, 2004, NAT MED, V10, P638, DOI 10.1038/nm1051; Sivashanmugam P, 2004, J BIOL CHEM, V279, P21154, DOI 10.1074/jbc.M313776200; So Alan, 2003, Can J Urol, V10, P2040; Solit DB, 2003, SEMIN ONCOL, V30, P709, DOI 10.1016/S0093-7754(03)00346-4; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; Taub JS, 2003, CANCER RES, V63, P2037; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	43	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11583	11589		10.1074/jbc.M414423200	http://dx.doi.org/10.1074/jbc.M414423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653681	hybrid			2022-12-25	WOS:000227761800085
J	Kim, JI; Lee, CJ; Jin, MS; Lee, CH; Paik, SG; Lee, H; Lee, JO				Kim, JI; Lee, CJ; Jin, MS; Lee, CH; Paik, SG; Lee, H; Lee, JO			Crystal structure of CD14 and its implications for lipopolysaccharide signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PEPTIDOGLYCAN; RECEPTOR; RECOGNITION; BINDING; ENDOTOXIN; LPS; IDENTIFICATION; ACTIVATION; PROTEIN; MICE	Lipopolysaccharide, the endotoxin of Gram-negative bacteria, induces extensive immune responses that can lead to fatal septic shock syndrome. The core receptors recognizing lipopolysaccharide are CD14, TLR4, and MD-2. CD14 binds to lipopolysaccharide and presents it to the TLR4/MD-2 complex, which initiates intracellular signaling. In addition to lipopolysaccharide, CD14 is capable of recognizing a few other microbial and cellular products. Here, we present the first crystal structure of CD14 to 2.5 angstrom resolution. A large hydrophobic pocket was found on the NH2-terminal side of the horseshoe-like structure. Previously identified regions involved in lipopolysaccharide binding map to the rim and bottom of the pocket indicating that the pocket is the main component of the lipopolysaccharide-binding site. Mutations that interfere with lipopolysaccharide signaling but not with lipopolysaccharide binding are also clustered in a separate area near the pocket. Ligand diversity of CD14 could be explained by the generous size of the pocket, the considerable flexibility of the rim of the pocket, and the multiplicity of grooves available for ligand binding.	Chungnam Natl Univ, Inst Biotechnol, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Chungnam Natl Univ, Dept Biol, Sch Biosci & Biotechnol, Taejon 305701, South Korea	Chungnam National University; Korea Advanced Institute of Science & Technology (KAIST); Korea University; Chungnam National University	Lee, H (corresponding author), Chungnam Natl Univ, Inst Biotechnol, Taejon 305701, South Korea.	hlee@cnu.ac.kr; jieoh.lee@kaist.ac.kr	Lee, Jie-Oh/C-1581-2011; Lee, Jie-Oh/AAG-4302-2020	Lee, Jie-Oh/0000-0001-6519-6049				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Cunningham MD, 2000, J IMMUNOL, V164, P3255, DOI 10.4049/jimmunol.164.6.3255; Dziarski R, 2000, INFECT IMMUN, V68, P5254, DOI 10.1128/IAI.68.9.5254-5260.2000; Dziarski R, 2003, CELL MOL LIFE SCI, V60, P1793, DOI 10.1007/s00018-003-3019-6; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Fujihara M, 2003, PHARMACOL THERAPEUT, V100, P171, DOI 10.1016/j.pharmthera.2003.08.003; Gregory CD, 1999, APOPTOSIS, V4, P11, DOI 10.1023/A:1009673914340; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hoshino K, 1999, J IMMUNOL, V162, P3749; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; JUAN TSC, 1995, J BIOL CHEM, V270, P17237, DOI 10.1074/jbc.270.29.17237; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leturcq DJ, 1996, J CLIN INVEST, V98, P1533, DOI 10.1172/JCI118945; MCGINLEY MD, 1995, J BIOL CHEM, V270, P5213, DOI 10.1074/jbc.270.10.5213; Miyake K, 2003, INT IMMUNOPHARMACOL, V3, P119, DOI 10.1016/S1567-5769(02)00258-8; Muroi M, 2002, J BIOL CHEM, V277, P42372, DOI 10.1074/jbc.M205966200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Schimke J, 1998, P NATL ACAD SCI USA, V95, P13875, DOI 10.1073/pnas.95.23.13875; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shapiro RA, 1997, INFECT IMMUN, V65, P293, DOI 10.1128/IAI.65.1.293-297.1997; Stelter F, 1997, EUR J BIOCHEM, V243, P100, DOI 10.1111/j.1432-1033.1997.00100.x; Stelter F, 1998, PROG CLIN BIOL RES, V397, P301; Stelter F, 1999, J IMMUNOL, V163, P6035; Sugiyama T, 2001, J IMMUNOL, V166, P826, DOI 10.4049/jimmunol.166.2.826; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361	39	183	196	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11347	11351		10.1074/jbc.M414607200	http://dx.doi.org/10.1074/jbc.M414607200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15644310	hybrid			2022-12-25	WOS:000227761800056
J	Luo, Y; Haltiwanger, RS				Luo, Y; Haltiwanger, RS			O-fucosylation of notch occurs in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION DEFICIENCY; HAMSTER OVARY CELLS; FACTOR-LIKE MODULES; FACTOR-LIKE REPEATS; GDP-FUCOSE; LINKED FUCOSE; PROTEIN O-FUCOSYL-TRANSFERASE-1; LIGAND-BINDING; GOLGI; GLYCOSYLATION	LADII (leukocyte adhesion deficiency type II)/CDGIIc (congenital disorder of glycosylation type IIc) is a rare autosomal recessive disease characterized by leukocyte adhesion deficiency as well as severe neurological and developmental abnormalities. It is caused by mutations in the Golgi GDP-fucose transporter, resulting in a reduction of fucosylated antigens on the cell surface. A recent study using fibroblasts from LADII/CDGIIc patients suggested that although terminal fucosylation of N-glycans is reduced severely, protein O-fucosylation is generally unaffected (Sturla, L., Rampal, R., Haltiwanger, R. S., Fruscione, F., Etzioni, A., and Tonetti, M. (2003) J. Biol. Chem. 278, 26727-26733). A potential explanation for this phenomenon is that enzymes adding O-fucose to proteins localize to cell organelles other than the Golgi apparatus. In this study, we investigated the subcellular localization of protein O-fucosyltransferase 1 (O-FucT-1), which is responsible for adding O-fucose to epidermal growth factor-like repeats. Our analysis reveals that, unlike all other known fucosyltransferases, O-FucT-1 is a soluble protein that localizes to the endoplasmic reticulum (ER). In addition, it appears that O-FucT-1 is retained in the ER by a KDEL-like sequence at its C terminus. Our results also suggest that enzymatic addition of O-fucose to proteins occurs in the ER, suggesting that a novel, ER-localized GDP-fucose transporter may exist. The fact that O-FucT-1 recognizes properly folded epidermal growth factor-like repeats, together with this unique localization, suggests that it may play a role in quality control.	SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.	Robert.Haltiwanger@stonybrook.edu			NIGMS NIH HHS [GM61126, R01 GM061126] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2000, DEV DYNAM, V218, P280; Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Etzioni A, 2002, AM J MED GENET, V110, P131, DOI 10.1002/ajmg.10423; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Haltiwanger RS, 2002, CURR OPIN STRUC BIOL, V12, P593, DOI 10.1016/S0959-440X(02)00371-8; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; LOWE JB, 1993, BAILLIERE CLIN HAEM, V6, P465, DOI 10.1016/S0950-3536(05)80155-6; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Martinez-Duncker I, 2003, GLYCOBIOLOGY, V13, p1C, DOI 10.1093/glycob/cwg113; Milland J, 2001, J BIOL CHEM, V276, P12012, DOI 10.1074/jbc.M010018200; Moloney DJ, 1999, GLYCOBIOLOGY, V9, P679, DOI 10.1093/glycob/9.7.679; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Murshid A, 2004, CELL MOL LIFE SCI, V61, P133, DOI 10.1007/s00018-003-3352-9; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Sasamura T, 2003, DEVELOPMENT, V130, P4785, DOI 10.1242/dev.00679; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Sousa VL, 2004, BBA-GEN SUBJECTS, V1675, P95, DOI 10.1016/j.bbagen.2004.08.015; Sturla L, 2003, J BIOL CHEM, V278, P26727, DOI 10.1074/jbc.M304068200; Sturla L, 2001, PEDIATR RES, V49, P537, DOI 10.1203/00006450-200104000-00016; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Wang Y, 1996, GLYCOBIOLOGY, V6, P837, DOI 10.1093/glycob/6.8.837	34	121	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11289	11294		10.1074/jbc.M414574200	http://dx.doi.org/10.1074/jbc.M414574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653671	hybrid			2022-12-25	WOS:000227761800049
J	Rangwala, R; Banine, F; Borg, JP; Sherman, LS				Rangwala, R; Banine, F; Borg, JP; Sherman, LS			Erbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between Merlin and Adherens junction protein complexes in Schwann cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF2 TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-2 GENE; E-CADHERIN; NERVE INJURY; PRODUCT; ERBB2; GROWTH; RAS; LOCALIZATION; ADHESION	Biallelic mutations in the neurofibromatosis 2 (NF2) gene are linked to schwannoma and meningioma tumorigenesis. Cells with NF2 mutations exhibit elevated levels of phosphorylated extracellular signal-regulated kinase (ERK) and aberrant cell-cell and cell-matrix contacts. The NF2 gene product, merlin, associates with adherens junction protein complexes, suggesting that part of its function as a tumor suppressor involves regulating cell junctions. Here, we find that a novel PDZ protein, called erbin, binds directly to the merlin-binding partner, EBP0, and regulates adherens junction dissociation through a MAP kinase-dependent mechanism. Reducing erbin expression using a targeted siRNA in primary cultures of Schwann cells results in altered cell-cell interactions, disruption of E- cadherin adherens junctions, increased cell proliferation, and elevated levels of phosphorylated ERK, all phenotypes observed in cells that lack merlin. Reduction of erbin expression also results in the dissociation of merlin from adherens junction proteins and an increase in the levels of phosphorylated merlin. These phenotypes can be rescued if cells with reduced levels of erbin are treated with a pharmacological inhibitor of ERK kinase. Collectively, these data indicate that erbin regulates MAP kinase activation in Schwann cells and suggest that erbin links merlin to both adherens junction protein complexes and the MAP kinase signaling pathway.	Oregon Hlth & Sci Univ, Oregon Natl Primage Res Ctr, Div Neurosci, Beaverton, OR 97006 USA; INSERM, UM599, Inst Cancerol Marseille, F-13009 Marseille, France; Inst J Paoli I Calmettes, F-13009 Marseille, France	Oregon Health & Science University; Oregon National Primate Research Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Sherman, LS (corresponding author), Oregon Hlth & Sci Univ, Oregon Natl Primage Res Ctr, Div Neurosci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	shermanl@ohsu.edu	Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382	NCRR NIH HHS [RR00163] Funding Source: Medline; NINDS NIH HHS [NS39550] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039550] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Balice-Gordon RJ, 1998, J CELL BIOL, V142, P1095, DOI 10.1083/jcb.142.4.1095; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Erickson SL, 1997, DEVELOPMENT, V124, P4999; FANNON AM, 1995, J CELL BIOL, V129, P189, DOI 10.1083/jcb.129.1.189; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Fraenzer JT, 2003, INT J ONCOL, V23, P1493; Garratt AN, 2000, J CELL BIOL, V148, P1035, DOI 10.1083/jcb.148.5.1035; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Hasegawa M, 1996, J NEUROPATH EXP NEUR, V55, P424, DOI 10.1097/00005072-199604000-00005; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200; Izawa I, 2002, GENES CELLS, V7, P475, DOI 10.1046/j.1365-2443.2002.00533.x; Jacoby LB, 1996, GENE CHROMOSOME CANC, V17, P45, DOI 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; KOLCH W, 2003, SCI STKE; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nam JS, 2002, JPN J CANCER RES, V93, P1020, DOI 10.1111/j.1349-7006.2002.tb02479.x; Ohno H, 2002, ONCOGENE, V21, P7042, DOI 10.1038/sj.onc.1205852; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Stemmer-Rachamimov AO, 1998, J NEUROPATH EXP NEUR, V57, P1164, DOI 10.1097/00005072-199812000-00008; Stoll G, 1999, BRAIN PATHOL, V9, P313; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; Wanner IB, 2002, J NEUROSCI, V22, P4066, DOI 10.1523/JNEUROSCI.22-10-04066.2002; Wiederhold T, 2004, ONCOGENE, V23, P8815, DOI 10.1038/sj.onc.1208110; Woldeyesus MT, 1999, GENE DEV, V13, P2538, DOI 10.1101/gad.13.19.2538; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Young P, 2002, MOL CELL NEUROSCI, V21, P341, DOI 10.1006/mcne.2002.1177	52	60	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11790	11797		10.1074/jbc.M414154200	http://dx.doi.org/10.1074/jbc.M414154200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659388	hybrid			2022-12-25	WOS:000227761800108
J	Singh, R; Haque, I; Ahmad, F				Singh, R; Haque, I; Ahmad, F			Counteracting osmolyte trimethylamine N-oxide destabilizes proteins at pH below its pK(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CHAPERONES; LACTATE-DEHYDROGENASE; THERMAL-STABILITY; UREA; STABILIZATION; EQUILIBRIUM; MECHANISM; FISHES; HYDRATION	Earlier studies have reported that trimethylamine N-oxide (TMAO), a naturally occurring osmolyte, is a universal stabilizer of proteins because it folds unstructured proteins and counteracts the deleterious effects of urea and salts on the structure and function of proteins. This conclusion has been reached from the studies of the effect of TMAO on proteins in the pH range 6.0-8.0. In this pH range TMAO is almost neutral (zwitterionic form), for it has a pK(a) of 4.66 +/- 0.10. We have asked the question of whether the effect of TMAO on protein stability is pH-dependent. To answer this question we have carried out thermal denaturation studies of lysozyme, ribonuclease-A, and apo-alpha-lactalbumin in the presence of various TMAO concentrations at different pH values above and below the pKa of TMAO. The main conclusion of this study is that near room temperature TMAO destabilizes proteins at pH values below its pK(a), whereas it stabilizes proteins at pH values above its pK(a). This conclusion was reached by determining the T-m (midpoint of denaturation), Delta H-m (denaturational enthalpy change at T-m), Delta C-p (constant pressure heat capacity change), and Delta G(D)degrees (denaturational Gibbs energy change at 25 degrees C) of proteins in the presence of different TMAO concentrations. Other conclusions of this study are that Tm and Delta G(D)degrees depend on TMAO concentration at each pH value and that Delta H-m and Delta C-p are not significantly changed in the presence of TMAO.	Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India	Jamia Millia Islamia	Ahmad, F (corresponding author), Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India.	faizan_ahmad@yahoo.com	Haque, Inamul/I-2482-2019; Ahmad, Faizan/AGH-4493-2022	Ahmad, Faizan/0000-0001-7021-7502; Haque, Inamul/0000-0002-1307-9446				ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Baskakov I, 1998, BIOPHYS J, V74, P2658, DOI 10.1016/S0006-3495(98)77971-8; Baskakov IV, 1999, J BIOL CHEM, V274, P10693, DOI 10.1074/jbc.274.16.10693; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BIGELOW C C, 1960, C R Trav Lab Carlsberg, V31, P305; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; Chilson OP, 2003, EUR J BIOCHEM, V270, P4823, DOI 10.1046/j.1432-1033.2003.03881.x; Claiborne JB, 2002, J EXP ZOOL, V293, P302, DOI 10.1002/jez.10125; DELPINO IMP, 1995, BIOCHEMISTRY-US, V34, P8621, DOI 10.1021/bi00027a011; Devlin GL, 2001, AM J RESP CELL MOL, V24, P727, DOI 10.1165/ajrcmb.24.6.4407; FORSTER RP, 1976, AM J PHYSIOL, V230, P925, DOI 10.1152/ajplegacy.1976.230.4.925; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; HAMAGUCHI K, 1963, J BIOCHEM-TOKYO, V54, P111; Kaushik JK, 2003, J BIOL CHEM, V278, P26458, DOI 10.1074/jbc.M300815200; Kelly RH, 1999, BIOL BULL, V196, P18, DOI 10.2307/1543162; Kumar R, 2001, J BIOL CHEM, V276, P18146, DOI 10.1074/jbc.M100825200; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; Mello CC, 2003, PROTEIN SCI, V12, P1522, DOI 10.1110/ps.0372903; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; NATALIA AC, 2001, EUR J BIOCHEM, V268, P506; Pace C N, 1986, Methods Enzymol, V131, P266; PFEIL W, 1985, STUD BIOPHYS, V109, P163; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Qu YX, 2003, BIOCHEMISTRY-US, V42, P5837, DOI 10.1021/bi0206457; Qu YX, 1998, P NATL ACAD SCI USA, V95, P9268, DOI 10.1073/pnas.95.16.9268; Ratnaparkhi GS, 2001, J BIOL CHEM, V276, P28789, DOI 10.1074/jbc.M101906200; Rivas G, 1999, BIOCHEMISTRY-US, V38, P9379, DOI 10.1021/bi990355z; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P5278, DOI 10.1021/bi00138a006; Seibel BA, 2002, J EXP BIOL, V205, P297; Sinha A, 2000, BIOCHEM J, V345, P711, DOI 10.1042/0264-6021:3450711; SOMERO GN, 1986, AM J PHYSIOL, V251, pR197, DOI 10.1152/ajpregu.1986.251.2.R197; SUGAI S, 1973, BIOCHIM BIOPHYS ACTA, V328, P35, DOI 10.1016/0005-2795(73)90327-9; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Timasheff SN, 2002, P NATL ACAD SCI USA, V99, P9721, DOI 10.1073/pnas.122225399; Treberg JR, 2002, J EXP ZOOL, V293, P39, DOI 10.1002/jez.10109; Waldegger S, 1998, J MEMBRANE BIOL, V162, P95, DOI 10.1007/s002329900346; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Xie GF, 1997, PROTEIN SCI, V6, P211; YANCEY PH, 1980, J EXP ZOOL, V212, P205, DOI 10.1002/jez.1402120207; YANCEY PH, 1979, BIOCHEM J, V183, P317, DOI 10.1042/bj1830317; Yancey PH, 2001, J EXP ZOOL, V289, P172, DOI 10.1002/1097-010X(20010215)289:3<172::AID-JEZ3>3.0.CO;2-J; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Zou Q, 2002, J AM CHEM SOC, V124, P1192, DOI 10.1021/ja004206b	48	94	95	6	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11035	11042		10.1074/jbc.M410716200	http://dx.doi.org/10.1074/jbc.M410716200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653673	hybrid			2022-12-25	WOS:000227761800020
J	Wang, Y; Castoreno, AB; Stockinger, W; Nohturfft, A				Wang, Y; Castoreno, AB; Stockinger, W; Nohturfft, A			Modulation of endosomal cholesteryl ester metabolism by membrane cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ACYL-COENZYME; O-ACYLTRANSFERASE; VASCULAR-LESIONS; INTRACELLULAR-TRANSPORT; ATHEROSCLEROTIC LESIONS; ENDOPLASMIC-RETICULUM; LIPID-ACCUMULATION; MACROPHAGES; ARTERIOSCLEROSIS	Cells acquire cholesterol in part by endocytosis of cholesteryl ester containing lipoproteins. In endosomes and lysosomes cholesteryl ester is hydrolyzed by acidic cholesteryl ester hydrolase producing cholesterol and fatty acids. Under certain pathological conditions, however, such as in atherosclerosis, excessive levels of cholesteryl ester accumulate in lysosomes for reasons that are poorly understood. Here, we have studied endosomal and lysosomal cholesteryl ester metabolism in cultured mouse macrophages and with cell-free extracts. We show that net hydrolysis of cholesteryl ester is coupled to the transfer of cholesterol to membranes. When membrane cholesterol levels are low, absorption of cholesterol effectively drives cholesteryl ester hydrolysis. When cholesterol levels in acceptor membranes approach saturation or when cholesterol export is blocked, cholesterol is re-esterified in endosomes. These results reveal a new facet of cellular cholesterol homeostasis and provide a potential explanation for cholesteryl ester accumulation in lysosomes of atherosclerotic cells.	Harvard Univ, Dept Mol & Cellular Biol, Biol Labs, Cambridge, MA 02138 USA	Harvard University	Nohturfft, A (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Biol Labs, 16 Divin Ave, Cambridge, MA 02138 USA.	axno@mcb.harvard.edu		Nohturfft, Axel/0000-0001-9484-3209	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059934] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK059934-01, R01 DK059934, R01 DK059934-04, R01 DK059934-03, R01 DK59934, R01 DK059934-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKAWA K, 1994, BBA-LIPID LIPID MET, V1213, P127; ASSMANN G, 1995, METABOLIC MOL BASES, P2563; BALASUBRAMANIAM S, 1978, BIOCHEM J, V174, P863, DOI 10.1042/bj1740863; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BOCAN TMA, 1991, ARTERIOSCLER THROMB, V11, P1830, DOI 10.1161/01.ATV.11.6.1830; BROWN MS, 1976, CELL, V9, P663, DOI 10.1016/0092-8674(76)90130-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Budavari S, 2001, ENCY CHEM DRUGS BIOL; Buhman KK, 2001, J BIOL CHEM, V276, P40369, DOI 10.1074/jbc.R100050200; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; de Duve C, 1974, Acta Cardiol, VSuppl 20, P9; ERICKSON SK, 1980, J LIPID RES, V21, P930; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; GOLDFISCHER S, 1975, AM J PATHOL, V78, P497; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Jerome WG, 1998, J LIPID RES, V39, P1362; Jerome WG, 2003, MICROSC MICROANAL, V9, P54, DOI 10.1017/S1431927603030010; Johnson W J, 1996, Subcell Biochem, V27, P239; Jonas A., 2002, BIOCH LIPIDS LIPOPRO, P483; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; Khelef N, 2000, ARTERIOSCL THROM VAS, V20, P1769; KINNUNEN PM, 1988, BIOCHEMISTRY-US, V27, P7344, DOI 10.1021/bi00419a025; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; Le Chatelier H. L., 1888, ANN MINES, V13, P157; LICHTENSTEIN AH, 1980, J BIOL CHEM, V255, P9098; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; METHERALL JE, 1991, J BIOL CHEM, V266, P12734; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; NILSSON A, 1973, BIOCHIM BIOPHYS ACTA, V296, P593, DOI 10.1016/0005-2760(73)90120-3; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; Roussel A, 1999, J BIOL CHEM, V274, P16995, DOI 10.1074/jbc.274.24.16995; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; SILLENCE DJ, 1993, BIOCHEM J, V290, P381, DOI 10.1042/bj2900381; SLOTTE JP, 1987, BIOCHIM BIOPHYS ACTA, V917, P231, DOI 10.1016/0005-2760(87)90127-5; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; STARY HC, 1992, CIRCULATION, V85, P391, DOI 10.1161/01.CIR.85.1.391; STARY HC, 1994, ARTERIOSCLER THROMB, V14, P840, DOI 10.1161/01.ATV.14.5.840; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Tall AR, 1998, EUR HEART J, V19, pA31; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; Yang L, 2004, J BIOL CHEM, V279, P46253, DOI 10.1074/jbc.M408155200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; ZHOU X, 1992, J LIPID RES, V33, P1233	56	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11876	11886		10.1074/jbc.M414676200	http://dx.doi.org/10.1074/jbc.M414676200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657032	Green Accepted, hybrid			2022-12-25	WOS:000227761800117
J	Yamamoto, A; Mizukami, Y; Sakurai, H				Yamamoto, A; Mizukami, Y; Sakurai, H			Identification of a novel class of target genes and a novel type of binding sequence of heat shock transcription factor in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST METALLOTHIONEIN GENE; GENOME-WIDE ANALYSIS; DNA-BINDING; FACTOR CONTAINS; MOLECULAR CHAPERONES; COOPERATIVE BINDING; GLUCOSE STARVATION; STRESS-RESPONSE; PROTEIN-KINASE; IN-VITRO	In response to hyperthermia, heat shock transcription factor (HSF) activates transcription of a set of genes encoding heat shock proteins (HSPs). The promoter regions of HSP genes contain the HSF binding sequence called the heat shock element (HSE), which consists of contiguous inverted repeats of the sequence 5 '-nGAAn-3 ' (where n is any nucleotide). We have constructed an hsf1 mutant of Saccharomyces cerevisiae and analyzed genome-wide changes in heat shock response in the mutant cells. The results have revealed that Hsf1 is necessary for heat-induced transcription of not only HSP but also genes encoding proteins involved in diverse cellular processes such as protein degradation, detoxification, energy generation, carbohydrate metabolism, and maintenance of cell wall integrity. Approximately half of the Hsf1-regulated genes lacked the typical HSE in their promoter regions. Instead, several of these genes have a novel Hsf1 binding sequence that contains three direct repeats of nTTCn (or nGAAn) interrupted by 5 bp. The number and spacing of the repeating units are critical determinants for heat-induced transcription as well as for recognition by Hsf1. In the yeast genome, the presence of the sequence is enriched in Hsf1-regulated genes, suggesting that it is generally used as an HSE in the Hsf1 regulon.	Kanazawa Univ, Fac Med, Sch Hlth Sci, Kanazawa, Ishikawa 9200942, Japan	Kanazawa University	Sakurai, H (corresponding author), Kanazawa Univ, Fac Med, Sch Hlth Sci, 5-11-80 Kodatsuno, Kanazawa, Ishikawa 9200942, Japan.	sakurai@kenroku.kanazawa-u.ac.jp		Sakurai, Hiroshi/0000-0002-0336-2301				Ahn SG, 2001, GENE DEV, V15, P2134, DOI 10.1101/gad.894801; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; Amoros M, 2001, MOL MICROBIOL, V39, P1523, DOI 10.1046/j.1365-2958.2001.02339.x; Boy-Marcotte E, 1999, MOL MICROBIOL, V33, P274, DOI 10.1046/j.1365-2958.1999.01467.x; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; Drees BL, 1997, J MOL BIOL, V273, P61, DOI 10.1006/jmbi.1997.1283; ERKINE AM, 1995, NUCLEIC ACIDS RES, V23, P1822, DOI 10.1093/nar/23.10.1822; Erkine AM, 1999, MOL CELL BIOL, V19, P1627; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; FLICK KE, 1994, J BIOL CHEM, V269, P12475; Fukasawa T, 2001, DNA RES, V8, P23, DOI 10.1093/dnares/8.1.23; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; Hahn JS, 2004, J BIOL CHEM, V279, P5169, DOI 10.1074/jbc.M311005200; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Hashikawa N, 2004, MOL CELL BIOL, V24, P3648, DOI 10.1128/MCB.24.9.3648-3659.2004; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MCDANIEL D, 1989, MOL CELL BIOL, V9, P4789, DOI 10.1128/MCB.9.11.4789; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; Sakurai H, 2003, GENES CELLS, V8, P951, DOI 10.1046/j.1356-9597.2003.00689.x; Sakurai H, 2001, BIOCHEM BIOPH RES CO, V285, P696, DOI 10.1006/bbrc.2001.5234; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; Santoro N, 1998, MOL CELL BIOL, V18, P6340, DOI 10.1128/MCB.18.11.6340; Sato T, 1999, FEBS LETT, V463, P307, DOI 10.1016/S0014-5793(99)01654-3; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; SILAR P, 1991, MOL CELL BIOL, V11, P1232, DOI 10.1128/MCB.11.3.1232; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Tachibana T, 2002, J BIOL CHEM, V277, P22140, DOI 10.1074/jbc.M201267200; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; Treger JM, 1998, J BIOL CHEM, V273, P26875, DOI 10.1074/jbc.273.41.26875; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; VUISTER GW, 1994, NAT STRUCT BIOL, V1, P605, DOI 10.1038/nsb0994-605; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Yan LJ, 2002, EMBO J, V21, P5164, DOI 10.1093/emboj/cdf528; YANG WM, 1991, MOL CELL BIOL, V11, P3676, DOI 10.1128/MCB.11.7.3676; YOUNG MR, 1993, MOL CELL BIOL, V13, P5637, DOI 10.1128/MCB.13.9.5637	61	124	130	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11911	11919		10.1074/jbc.M411256200	http://dx.doi.org/10.1074/jbc.M411256200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647283	hybrid			2022-12-25	WOS:000227761800121
J	Zhang, ML; Breitwieser, GE				Zhang, ML; Breitwieser, GE			High affinity interaction with filamin a protects against calcium-sensing receptor degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; GROWTH-FACTOR RECEPTOR; KINASE-C; EXTRACELLULAR DOMAIN; ACTIN CYTOSKELETON; TERMINAL TAIL; ACTIVATION; BINDING; CA2+; CAR	Calcium- sensing receptors ( CaR) regulate cell proliferation, differentiation, and apoptosis through the MAPK pathway. MAPK pathway activation requires the cytoskeletal scaffold protein filamin A. Here we examine the interactions of CaR with filamin A in HEK- 293 and M2 or A7 melanoma cells to determine how interactions with filamin A facilitate signaling. Filamin A interacts with CaR through two predicted beta- strands from residues 962 to 981; interactions between filamin A and CaR are greatly enhanced by exposure to 5 mM Ca2+. Truncations or deletions ( from 972 to 997 or 962 to 981) of the CaR carboxyl terminus eliminate high affinity interactions with filamin A, but CaR- mediated MAPK pathway activation still occurs. CaR- mediated ERK phosphorylation can be localized to a predicted alpha- helix proximal to the membrane, which has been shown to be important for G protein- mediated signaling ( residues 868 - 879). In M2 cells ( - filamin A), CaR expression levels are very low; cotransfection of CaR with filamin A increases total cellular CaR and increases plasma membrane localization of CaR, facilitating CaR signaling to the MAPK pathway; similar results were obtained in HEK- 293 cells. Interaction with filamin A increases cellular CaR by preventing CaR degradation, thereby facilitating CaR signaling. In addition, filamin A facilitates signaling to the MAPK pathway even by CaR truncations or deletion mutants that cannot engage in high affinity interactions with filamin A, suggesting the targeting of critical signaling proteins to CaR.	Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA	Syracuse University	Breitwieser, GE (corresponding author), Syracuse Univ, Dept Biol, 108 Coll Pl,122 Lyman Hall, Syracuse, NY 13244 USA.	gebreitw@syr.edu		Breitwieser, Gerda/0000-0001-9081-0362	NIGMS NIH HHS [GM58578, R01 GM077563, R01 GM077563-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058578, R01GM077563] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Bai M, 2004, CELL CALCIUM, V35, P197, DOI 10.1016/j.ceca.2003.10.018; Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Chang W, 1999, MOL CELL ENDOCRINOL, V158, P13, DOI 10.1016/S0303-7207(99)00189-6; Chang WH, 2001, J BIOL CHEM, V276, P44129, DOI 10.1074/jbc.M104834200; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; D'Addario M, 2001, J BIOL CHEM, V276, P31969, DOI 10.1074/jbc.M102715200; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Enz R, 2003, BIOCHEM J, V372, P183, DOI 10.1042/BJ20021750; Enz R, 2002, FEBS LETT, V514, P184, DOI 10.1016/S0014-5793(02)02361-X; Gama L, 1999, BIOTECHNIQUES, V26, P814, DOI 10.2144/99265bm03; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; Gama L, 2001, J BIOL CHEM, V276, P39053, DOI 10.1074/jbc.M105662200; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; He HJ, 2003, J BIOL CHEM, V278, P27096, DOI 10.1074/jbc.M301003200; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Holstein DM, 2004, J BIOL CHEM, V279, P10060, DOI 10.1074/jbc.M312039200; Jiang YF, 2002, J BIOL CHEM, V277, P50543, DOI 10.1074/jbc.M205798200; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; MacLeod RJ, 2004, BIOCHEM BIOPH RES CO, V320, P455, DOI 10.1016/j.bbrc.2004.05.198; Maldonado-Perez D, 2003, BIOCHEM BIOPH RES CO, V311, P610, DOI 10.1016/j.bbrc.2003.10.041; Miedlich S, 2002, J BIOL CHEM, V277, P49691, DOI 10.1074/jbc.M205578200; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Pi M, 2002, ENDOCRINOLOGY, V143, P3830, DOI 10.1210/en.2002-220240; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Sampson LJ, 2003, J BIOL CHEM, V278, P41988, DOI 10.1074/jbc.M307479200; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Yano S, 2004, BONE, V35, P664, DOI 10.1016/j.bone.2004.04.014; Young SH, 2002, J BIOL CHEM, V277, P46871, DOI 10.1074/jbc.M207083200	41	84	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11140	11146		10.1074/jbc.M412242200	http://dx.doi.org/10.1074/jbc.M412242200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657061	hybrid			2022-12-25	WOS:000227761800034
J	Huang, WQ; Zhao, SJ; Ammanamanchi, S; Brattain, M; Venkatasubbarao, K; Freeman, JW				Huang, WQ; Zhao, SJ; Ammanamanchi, S; Brattain, M; Venkatasubbarao, K; Freeman, JW			Trichostatin a induces transforming growth factor ss type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1 center dot NF-Y complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTOR; PANCREATIC-CANCER; NF-Y; BETA RECEPTOR; FUNCTIONAL INTERACTION; GENETIC ALTERATIONS; ACTIVATION; EXPRESSION	Transforming growth factor beta type II receptor (T beta RII) is a tumor suppressor gene that can be transcriptionally silenced by histone deacetylases (HDACs) in cancer cells. In this report, we demonstrated the mechanism by which trichostatin A (TSA), an inhibitor of HDAC, induces the expression of T beta RII in human pancreatic cancer cell lines by modulating the transcriptional components that bind a specific DNA region of the T beta RII promoter. This region of the T beta RII promoter possesses Sp1 and NF-Y binding sites in close proximity ( located at -102 and -83, respectively). Treatment of cells with TSA activates the T beta RII promoter in a time-dependent manner through the recruitment of p300 and PCAF into a Sp1(.)NF-Y(.)HDAC complex that binds this DNA element. The recruitment of p300 and PCAF into the complex is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. Transient overexpression of p300 or PCAF potentiated TSA-induced T beta RII promoter activity. The effect of PCAF was dependent on its histone acetyltransferase activity, whereas that of p300 was independent. Stable transfection of PCAF caused an increase in T beta RII mRNA expression, the association of PCAF with T beta RII promoter, and the acetylation of Sp1. Taken together, these results showed that TSA treatment of pancreatic cancer cells leads to transcriptional activation of the T beta RII promoter through modulation of the components of a Sp1(.)NF-Y(.)p300(.)PCAF(.)HDAC-1 multiprotein complex. Moreover, the interaction of NF-Y with the Sp1-associated complex may further explain why this specific Sp1 site mediates transcriptional responsiveness to TSA.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Roswell Park Cancer Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Freeman, JW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	freemanjw@uthscsa.edu	Huang, Weiqi/E-4341-2010		NCI NIH HHS [CA96122] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed MM, 2002, J BIOL CHEM, V277, P2234, DOI 10.1074/jbc.M110168200; Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Blasco F, 2004, ONCOLOGY-BASEL, V67, P277, DOI 10.1159/000081329; Borestrom C, 2003, J VIROL, V77, P821, DOI 10.1128/JVI.77.2.821-829.2003; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Chan HM, 2001, J CELL SCI, V114, P2363; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dempsey NJ, 2003, BLOOD, V102, P4214, DOI 10.1182/blood-2002-12-3766; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Fralix KD, 2000, CANCER, V88, P2010, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2010::AID-CNCR5>3.0.CO;2-5; Freeman JW, 2004, FRONT BIOSCI-LANDMRK, V9, P1889, DOI 10.2741/1388; Goggins M, 1998, CANCER RES, V58, P5329; Goodman RH, 2000, GENE DEV, V14, P1553; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Jennings R, 2001, ONCOGENE, V20, P6899, DOI 10.1038/sj.onc.1204808; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Li CG, 2002, J BIOL CHEM, V277, P38399, DOI 10.1074/jbc.M203188200; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Schwarte-Waldhoff I, 2002, J GASTROINTEST CANC, V31, P47, DOI 10.1385/IJGC:31:1-3:47; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Song CZ, 2003, J MOL BIOL, V329, P207, DOI 10.1016/S0022-2836(03)00429-7; Venkatasubbarao K, 1998, GENE CHROMOSOME CANC, V22, P138, DOI 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y; Venkatasubbarao K, 2000, ANTICANCER RES, V20, P43; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhao LY, 2003, ONCOGENE, V22, P8316, DOI 10.1038/sj.onc.1206916; Zhao SJ, 2003, CANCER RES, V63, P2624	41	108	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10047	10054		10.1074/jbc.M408680200	http://dx.doi.org/10.1074/jbc.M408680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647279	hybrid			2022-12-25	WOS:000227559600039
J	Borlak, J; Meier, T; Halter, R; Spanel, R; Spanel-Borowski, K				Borlak, J; Meier, T; Halter, R; Spanel, R; Spanel-Borowski, K			Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours	ONCOGENE			English	Article						HCC; EGF; transgenic mice; tumour stages; gene expression profiling	FACTOR-ALPHA; C-FOS; ACTIVATION; RECEPTOR; CELLS; MICE; OVEREXPRESSION; CARCINOGENESIS; CYTOKINESIS; PROGRESSION	Epidermal growth factor is an important mitogen for hepatocytes. Its overexpression promotes hepatocellular carcinogenesis. To identify the network of genes regulated through EGF, we investigated the liver transcriptome during various stages of hepatocarcinogenesis in EGF2B transgenic mice. Targeted overexpression of IgEGF induced distinct hepatocellular lesions and eventually solid tumours at the age of 6-8 months, as evidenced by histopathology. We used the murine MG U74Av2 oligonucleotide microarrays to identify transcript signatures in 12 tumours of small ( n = 5, pooled), medium ( n = 4) and large sizes ( n = 3), and compared the findings with three nontumorous transgenic livers and four control livers. Global gene expression analysis at successive stages of carcinogenesis revealed hallmarks linked to tumour size. A comparison of gene expression profiles of nontumorous transgenic liver versus control liver provided insight into the initial events predisposing liver cells to malignant transformation, and we found overexpression of c-fos, eps-15, TGIF, IGFBP1, Alcam, ets-2 and repression of Gas-1 as distinct events. Further, when gene expression profiles of small manifested tumours were compared with nontumorous transgenic liver, additional changes were obvious and included overexpression of junB, Id-1, minopontin, villin, claudin-7, RR M2, p34cdc2, cyclinD1 and cyclinB1 among others. These genes are therefore strongly associated with tumour formation. Our study provided new information on the tumour stage-dependent network of EGF-regulated genes, and we identified candidate genes linked to tumorigenes and progression of disease.	Fraunhofer Inst Toxicol & Expt Med, Dept Pharmacol & Mol Med, D-30625 Hannover, Germany; Inst Pathol, Viersen, Germany; Univ Leipzig, Inst Anat, D-7010 Leipzig, Germany	Fraunhofer Gesellschaft; Leipzig University	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Dept Pharmacol & Mol Med, Nikolai Fuchsstr 1, D-30625 Hannover, Germany.	Borlak@item.fraunhofer.de						ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; Chen SY, 2000, ANTISENSE NUCLEIC A, V10, P111, DOI 10.1089/oli.1.2000.10.111; Choi S, 2000, CLIN EXP METASTAS, V18, P45, DOI 10.1023/A:1026507713080; Chung YH, 2000, CANCER, V89, P977, DOI 10.1002/1097-0142(20000901)89:5<977::AID-CNCR6>3.0.CO;2-I; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; Evdokiou A, 1998, EXP CELL RES, V240, P359, DOI 10.1006/excr.1998.4011; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Gotoh M, 2002, PATHOL INT, V52, P19, DOI 10.1046/j.1440-1827.2002.01316.x; Hogan B, 1994, MANIPULATING MOUSE E; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kubicka S, 2000, LIVER, V20, P312, DOI 10.1034/j.1600-0676.2000.020004312.x; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; Melhuish TA, 2001, J BIOL CHEM, V276, P32109, DOI 10.1074/jbc.M103377200; Okabe H, 2001, CANCER RES, V61, P2129; Ostrowski J, 2000, BRIT J CANCER, V82, P1041; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Ramljak D, 1998, CANCER RES, V58, P3590; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; TONJES RR, 1995, ONCOGENE, V10, P765; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Witz IP, 2000, J CELL BIOCHEM, P61; WU JC, 1994, CANCER RES, V54, P5964; YAMAGUCHI K, 1995, J SURG ONCOL, V58, P240	32	98	107	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1809	1819		10.1038/sj.onc.1208196	http://dx.doi.org/10.1038/sj.onc.1208196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674348				2022-12-25	WOS:000227542000001
J	Di Vizio, D; Cito, L; Boccia, A; Chieffi, P; Insabato, L; Pettinato, G; Motti, ML; Schepis, F; D'Amico, W; Fabiani, F; Tavernise, B; Venuta, S; Fusco, A; Viglietto, A				Di Vizio, D; Cito, L; Boccia, A; Chieffi, P; Insabato, L; Pettinato, G; Motti, ML; Schepis, F; D'Amico, W; Fabiani, F; Tavernise, B; Venuta, S; Fusco, A; Viglietto, A			Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors	ONCOGENE			English	Article						PTEN; germ cell tumors; ITGCN; p27(kip1)	KINASE INHIBITOR P27(KIP1); PRIMARY PROSTATE-CANCER; MOUSE SERTOLI CELLS; GROWTH-FACTOR; NEURONAL DIFFERENTIATION; EMBRYONIC-DEVELOPMENT; COWDEN DISEASE; BREAST-CANCER; EXPRESSION; MUTATIONS	PTEN/MMAC1/TEP1 ( hereafter PTEN) is a tumor suppressor gene (located at 10q23) that is frequently mutated or deleted in sporadic human tumors. PTEN encodes a multifunctional phosphatase, which negatively regulates cell growth, migration and survival via the phosphatidylinositol 3'-kinase/AKT signalling pathway. Accordingly, Pten(+/-) mice develop various types of tumors including teratocarcinomas and teratomas. We have investigated PTEN expression in 60 bioptic specimens of germ cell tumors (32 seminomas, 22 embryonal carcinomas and six teratomas) and 22 intratubular germ cell neoplasias (ITGCN) adjacent to the tumors for PTEN protein and mRNA expression. In total, 10 testicular biopsies were used as controls. In the testis, PTEN was abundantly expressed in germ cells whereas it was virtually absent from 56% of seminomas as well as from 86% of embryonal carcinomas and virtually all teratomas. On the contrary, ITGCN intensely expressed PTEN, indicating that loss of PTEN expression is not an early event in testicular tumor development. The loss of PTEN expression occurs mainly at the RNA level as determined by in situ hybridization of cellular mRNA (17/22) but also it may involve some kind of post-transcriptional mechanisms in the remaining 25% of cases. Analysis of microsatellites D10S551, D10S541 and D10S1765 in GCTs (n = 22) showed LOH at the PTEN locus at 10q23 in at least 36% of GCTs (three embryonal carcinoma, three seminoma, two teratoma); one seminoma and one embryonal (9%) carcinoma presented an inactivating mutation in the PTEN gene (2/22). Finally, we demonstrated that the phosphatidylinositol 3'-kinase/AKT pathway, which is regulated by the PTEN phosphatase, is crucial in regulating the proliferation of the NT2/D1 embryonal carcinoma cells, and that the cyclin-dependent kinase inhibitor p27(kip1) is a key downstream target of this pathway.	Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Lab Oncol Mol 3, I-88100 Catanzaro, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Sci Biomorol & Funz, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples 2, Dipartimento Med Sperimentale, I-80138 Naples, Italy	Magna Graecia University of Catanzaro; University of Naples Federico II; University of Naples Federico II; Universita della Campania Vanvitelli	Viglietto, A (corresponding author), Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Lab Oncol Mol 3, Campus Univ Germaneto Viale Europa, I-88100 Catanzaro, Italy.	viglietto@sun.ceos.na.cnr.it	Schepis, Filippo/H-9417-2014; Chieffi, Paolo/ABA-7892-2020	Schepis, Filippo/0000-0001-6549-5102; chieffi, paolo/0000-0001-8483-5635; PETTINATO, Guido/0000-0003-2599-0357; Fusco, Alfredo/0000-0003-3332-5197				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Cairns P, 1997, CANCER RES, V57, P4997; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; DAMING L, 1998, P NATL ACAD SCI USA, V95, P15406; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; IQBAL UA, 2000, J NATL CANCER I, V92, P861; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Luukko K, 1999, MECH DEVELOP, V83, P187, DOI 10.1016/S0925-4773(99)00050-7; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matsui Y, 1998, APMIS, V106, P142, DOI 10.1111/j.1699-0463.1998.tb01329.x; McMenamin ME, 1999, CANCER RES, V59, P4291; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; Mertens F, 1997, CANCER RES, V57, P2765; Moe-Behrens GHG, 2003, MOL ENDOCRINOL, V17, P2630, DOI 10.1210/me.2003-0006; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Risinger JI, 1997, CANCER RES, V57, P4736; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Scala S, 1998, INT J ONCOL, V13, P665; Sette C, 1997, DEVELOPMENT, V124, P2267; Skotheim RI, 2003, APMIS, V111, P136, DOI 10.1034/j.1600-0463.2003.11101181.x; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Viglietto G, 1996, ONCOGENE, V13, P577; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; Wang SI, 1997, CANCER RES, V57, P4183; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200; Wu Y, 2001, J BIOL CHEM, V276, P21745, DOI 10.1074/jbc.M101480200; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	59	91	95	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1882	1894		10.1038/sj.onc.1208368	http://dx.doi.org/10.1038/sj.onc.1208368			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674339				2022-12-25	WOS:000227542000007
J	Ghittoni, R; Patrussi, L; Pirozzi, K; Pellegrini, M; Lazzerini, PE; Capecchi, PL; Pasini, FL; Baldari, CT				Ghittoni, R; Patrussi, L; Pirozzi, K; Pellegrini, M; Lazzerini, PE; Capecchi, PL; Pasini, FL; Baldari, CT			Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases	FASEB JOURNAL			English	Article						statins; lipid rafts; MAP kinase pathways; TCR internalization	COA REDUCTASE INHIBITORS; SMALL G-PROTEINS; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; TCR; STATINS; EXPRESSION; KINASE; GERANYLGERANYLATION; INTERNALIZATION	Statins are widely used hypocholesterolemic drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of the mevalonate pathway whose biosynthetic end product is cholesterol. In addition to lowering circulating cholesterol, statins perturb the composition of cell membranes, resulting in disruption of lipid rafts, which function as signaling platforms in immunoreceptor signaling. Furthermore, by inhibiting protein prenylation, a process also dependent on mevalonate, statins block membrane targeting and hence activity of small GTPases, which control multiple pathways triggered by these receptors. T-cell activation is crucially dependent on Ras, Rho and Rab GTPases. Furthermore TCR signaling is orchestrated at lipid rafts, identifying T-cells as potential cellular targets of statins. Here we report that simvastatin suppresses T-cell activation and proliferation as the result of its capacity to inhibit HMG-CoA reductase. T-cell treatment with simvastatin does not affect intracellular cholesterol levels or raft integrity nor, accordingly, the initial tyrosine phosphorylation-dependent cascade. Conversely, inhibition of protein prenylation by simvastatin results in a dramatic impairment in the pathways regulated by small GTPases, including the Ras/MAP kinase pathway, the Rac/stress kinase pathway, and the Rab-dependent pathway of receptor endocytosis. The results identify Ras superfamily GTPases as strategic molecular targets in T-cell immunosuppression by statins.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; Univ Siena, Policlin Le Scotte, Dept Clin Med & Immunol Sci, I-53100 Siena, Italy	University of Siena; University of Siena	Baldari, CT (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Aldo Moro 2, I-53100 Siena, Italy.	baldari@unisi.it	Patrussi, Laura/AAD-4332-2020; Laghi Pasini, Franco/P-8994-2016	Laghi Pasini, Franco/0000-0003-0146-4416; Patrussi, Laura/0000-0003-1542-6955; Baldari, Cosima/0000-0002-4414-6744				Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; Andre P, 1997, J IMMUNOL, V159, P5253; Bini L, 2003, BIOCHEM J, V369, P301, DOI 10.1042/BJ20020503; Blanco-Colio LM, 2003, KIDNEY INT, V63, P12, DOI 10.1046/j.1523-1755.2003.00744.x; Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; D'Oro U, 2002, J IMMUNOL, V169, P6269, DOI 10.4049/jimmunol.169.11.6269; Danesh FR, 2002, P NATL ACAD SCI USA, V99, P8301, DOI 10.1073/pnas.122228799; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Essig M, 1998, CIRC RES, V83, P683, DOI 10.1161/01.RES.83.7.683; Eto M, 2002, CIRCULATION, V105, P1756, DOI 10.1161/01.CIR.0000015465.73933.3B; Goldman F, 1996, BLOOD, V88, P4611, DOI 10.1182/blood.V88.12.4611.bloodjournal88124611; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Graham TE, 1998, J IMMUNOL, V161, P6733; Hausding M, 2000, BRIT J PHARMACOL, V131, P553, DOI 10.1038/sj.bjp.0703607; HE HT, 2005, IN PRESS SEMIN IMMUN, V17; Ichimaru N, 2001, ATHEROSCLEROSIS, V158, P417, DOI 10.1016/S0021-9150(01)00438-5; Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9; Johnson BA, 2003, AM J RESP CRIT CARE, V167, P1271, DOI 10.1164/rccm.200205-410OC; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kirsch C, 2003, BIOCHEM PHARMACOL, V65, P843, DOI 10.1016/S0006-2952(02)01654-4; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Libby P, 2003, AM J CARDIOL, V91, p4B, DOI 10.1016/S0002-9149(02)03267-8; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Masamura K, 2003, ARTERIOSCL THROM VAS, V23, P512, DOI 10.1161/01.ATV.0000060461.64771.F0; Massy ZA, 1999, KIDNEY INT, V56, pS80, DOI 10.1038/sj.ki.4495407; Mehra MR, 2002, J AM COLL CARDIOL, V40, P1609, DOI 10.1016/S0735-1097(02)02340-9; Ortego M, 1999, ATHEROSCLEROSIS, V147, P253, DOI 10.1016/S0021-9150(99)00193-8; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Rodman JS, 2000, J CELL SCI, V113, P183; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; van Seventer GA, 1998, TRANSPLANT P, V30, P4270, DOI 10.1016/S0041-1345(98)01410-9; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Weitz-Schmidt G, 2002, TRENDS PHARMACOL SCI, V23, P482, DOI 10.1016/S0165-6147(02)02077-1; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	49	115	126	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					605	+		10.1096/fj.04-2702fje	http://dx.doi.org/10.1096/fj.04-2702fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15677697				2022-12-25	WOS:000226576600001
J	Kaigler, D; Krebsbach, PH; West, ER; Horger, K; Huang, YC; Mooney, DJ				Kaigler, D; Krebsbach, PH; West, ER; Horger, K; Huang, YC; Mooney, DJ			Endothelial cell modulation of bone marrow stromal cell osteogenic potential	FASEB JOURNAL			English	Article						bone development; bone regeneration; osteoprogenitor cells; BMP-2; osteogenic differentiation	POROUS HYDROXYAPATITE; GROWTH-FACTOR; GENE-THERAPY; PROTEIN; MICROVESSELS; EXPRESSION; DEFECTS; MEMBERS; HYPOXIA; COMPLEX	In the context of bone development and regeneration, the intimate association of the vascular endothelium with osteogenic cells suggests that endothelial cells (ECs) may directly regulate the differentiation of osteoprogenitor cells. To investigate this question, bone marrow stromal cells (BMSCs) were cultured: in the presence of EC-conditioned medium, on EC extracellular matrix, and in EC cocultures with and without cell contact. RNA and protein were isolated from ECs and analyzed by reverse transcriptase-polymerase chain reaction and Western blotting, respectively, for expression of bone morphogenetic protein 2 (BMP-2). In animal studies, BMSCs and ECs were cotransplanted into severe combined immunodeficient mice on biodegradable polymer matrices, and histomorphometric analysis was performed to determine the extent of new bone and blood vessel formation. ECs significantly increased BMSC osteogenic differentiation in vitro only when cultured in direct contact. ECs expressed BMP-2, and experiments employing interfering RNA inhibition confirmed its production as contributing to the increased BMSC osteogenic differentiation. In vivo, cotransplantation of ECs with BMSCs resulted in greater bone formation than did transplantation of BMSCs alone. These data suggest that ECs function not only to form the microvasculature that delivers nutrients to developing bone but also to modulate the differentiation of osteoprogenitor cells in vitro and in vivo.	Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Oral Med Pathol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem & Biomed Engn, Ann Arbor, MI 48109 USA	Harvard University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mooney, DJ (corresponding author), Harvard Univ, Div Engn & Appl Sci, 29 Oxford St,325 Pierce Hall, Cambridge, MA 02138 USA.	mooneyd@deas.harvard.edu	Krebsbach, Paul H./AAC-4765-2021	Mooney, David/0000-0001-6299-1194	NIDCR NIH HHS [F30 DE05747, R01-DE013835] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F30DE005747, R01DE013835] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534-200206000-00033; BRONCKERS ALJJ, 1987, J HISTOCHEM CYTOCHEM, V35, P825, DOI 10.1177/35.8.3298423; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115; Dong J, 2001, J BIOMED MATER RES, V57, P208, DOI 10.1002/1097-4636(200111)57:2<208::AID-JBM1160>3.0.CO;2-N; FRIEDENSTEIN AJ, 1978, EXP HEMATOL, V6, P440; Fuchs S, 2001, J AM COLL CARDIOL, V37, P1726, DOI 10.1016/S0735-1097(01)01200-1; Gao JZ, 2001, TISSUE ENG, V7, P363, DOI 10.1089/10763270152436427; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; Gysin R, 2002, GENE THER, V9, P991, DOI 10.1038/sj.gt.3301772; JONES AR, 1995, J ORTHOP RES, V13, P553, DOI 10.1002/jor.1100130410; Kaigler D, 2003, TISSUE ENG, V9, P95, DOI 10.1089/107632703762687573; Kon E, 2000, J BIOMED MATER RES, V49, P328; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Krebsbach PH, 2000, HUM GENE THER, V11, P1201, DOI 10.1089/10430340050015248; Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401; LATSINIK N V, 1986, Ontogenez, V17, P27; Li WM, 2000, CYTOKINE, V12, P1017, DOI 10.1006/cyto.1999.0678; MANOLAGAS SC, 1981, J BIOL CHEM, V256, P7115; Mendes SC, 2002, TISSUE ENG, V8, P911, DOI 10.1089/107632702320934010; MICHIELS C, 1994, EXP CELL RES, V213, P43, DOI 10.1006/excr.1994.1171; Mohan RR, 1998, INVEST OPHTH VIS SCI, V39, P2626; Mooney DJ, 1996, BIOMATERIALS, V17, P1417, DOI 10.1016/0142-9612(96)87284-X; Murphy WL, 2004, J DENT RES, V83, P204, DOI 10.1177/154405910408300304; Nor JE, 2001, LAB INVEST, V81, P453, DOI 10.1038/labinvest.3780253; OHGUSHI H, 1990, J BIOMED MATER RES, V24, P1563, DOI 10.1002/jbm.820241202; OKUMURA M, 1991, BIOMATERIALS, V12, P411, DOI 10.1016/0142-9612(91)90010-8; OWEN M, 1988, J CELL SCI, P63; PATT HM, 1982, EXP HEMATOL, V10, P738; Pelissier P, 2003, PLAST RECONSTR SURG, V111, P1932, DOI 10.1097/01.PRS.0000055044.14093.EA; ROMANA MC, 1990, PLAST RECONSTR SURG, V85, P587, DOI 10.1097/00006534-199004000-00014; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Shang QX, 2001, J CRANIOFAC SURG, V12, P586, DOI 10.1097/00001665-200111000-00017; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; STREETEN EA, 1990, BONE MINER, V10, P85, DOI 10.1016/0169-6009(90)90084-S; URIST MR, 1982, CLIN ORTHOP RELAT R, P219; VILLANUEVA JE, 1990, J BONE MINER RES, V5, P733; Villars F, 2002, AM J PHYSIOL-CELL PH, V282, pC775, DOI 10.1152/ajpcell.00310.2001; Vogelin E, 2002, PLAST RECONSTR SURG, V109, P190; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; YAJIMA H, 1995, J RECONSTR MICROSURG, V11, P201, DOI 10.1055/s-2007-1006533; ZAIDI M, 1993, BONE, V14, P97, DOI 10.1016/8756-3282(93)90234-2	46	196	209	5	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					665	+		10.1096/fj.04-2529fje	http://dx.doi.org/10.1096/fj.04-2529fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15677693	Green Published			2022-12-25	WOS:000226576600002
J	Mizuno, S; Matsumoto, K; Li, MY; Nakamura, T				Mizuno, S; Matsumoto, K; Li, MY; Nakamura, T			HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis	FASEB JOURNAL			English	Article						c-Met; HGF supplement therapy; resolution of fibrosis; chronic respiratory failure; myofibroblast cell death	HEPATOCYTE GROWTH-FACTOR; PULMONARY-FIBROSIS; FACTOR SUPPRESSES; EPITHELIAL-CELLS; GENE-EXPRESSION; RENAL FIBROSIS; BLEOMYCIN; ACTIVATION; PROLIFERATION; LOCALIZATION	Pulmonary fibrosis is characterized by a loss of lung epithelial cells, replaced by interstitial myofibroblasts to deposit extracellular matrix (ECM) proteins. Previous studies demonstrated that hepatocyte growth factor (HGF) improved lung fibrosis in murine models, whereas molecular mechanisms whereby HGF improved lung fibrosis have yet to be fully understood. When MRC-5 human lung fibroblasts were treated with transforming growth factor-beta1, the cells underwent phenotypic change similar to myofibroblasts and this was associated with upregulation of c-Met/HGF receptor expression. For the myofibroblast-like cells, HGF increased activities of MMP-2/-9, predominant enzymes for breakdown of fibronectin (FN). Under such conditions, HGF induced caspase-dependent apoptosis, linked with a decrease in a FN central cell binding (CCB) domain involved in FAK phosphorylation. When MMI270 ( a broad-spectrum MMP inhibitor) was added together with HGF, decreases in FN-CCB domain expression and FAK phosphorylation by HGF were restored, and these events were associated with an inhibition of HGF-induced apoptosis, suggesting that increased activities of MMPs underlie the major mechanism of HGF-mediated apoptosis in myofibroblasts. In bleomycin-treated mice, c-Met expression was found on interstitial myofibroblasts and HGF increased apoptosis in culture of myofibroblasts isolated from bleomycin-treated murine lungs. Furthermore, administration of recombinant HGF to bleomycin-treated mice increased lung MMP activities and enhanced myofibroblast apoptosis, while in vivo MMI270 injections together with HGF inhibited such MMP activation, leading to suppressed myofibroblast apoptosis. In conclusion, we identified HGF as a key ligand to elicit myofibroblast apoptosis and ECM degradation, whereas activation of the HGF/c-Met system in fibrotic lungs may be considered a target to attenuate progression of chronic lung disorders.	Osaka Univ, Grad Sch Med, Dept Mol Regenerat Med, Div Mol regenerat Med, Suita, Osaka 5650871, Japan	Osaka University	Nakamura, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Regenerat Med, Div Mol regenerat Med, Yamadaoka 2-2-B7, Suita, Osaka 5650871, Japan.	nakamura@onbich.med.osaka-u.ac.jp	LI, Ming-Yue/I-2727-2016; Matsumoto, Kunio/D-8441-2015	Matsumoto, Kunio/0000-0002-6532-4482				Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; Bessho K, 2003, AM J PHYSIOL-RENAL, V284, pF1171, DOI 10.1152/ajprenal.00326.2002; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Conner EA, 1997, BIOCHEM BIOPH RES CO, V236, P396, DOI 10.1006/bbrc.1997.6938; Fukuda Y, 1998, LAB INVEST, V78, P687; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; HAGIMOTO N, AM J RESP CELL MOL B, V17, P272; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; Hattori N, 2004, AM J PATHOL, V164, P1091, DOI 10.1016/S0002-9440(10)63196-3; Hayashi T, 1996, AM J PATHOL, V149, P1241; Hess S, 1999, ENDOCRINOLOGY, V140, P2908, DOI 10.1210/en.140.6.2908; Inoue T, 2002, FASEB J, V16, P268, DOI 10.1096/fj.02-0442fje; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; KATAYAMA M, 1989, EXP CELL RES, V185, P229, DOI 10.1016/0014-4827(89)90051-7; Kosai K, 1999, HEPATOLOGY, V30, P151, DOI 10.1002/hep.510300102; Lane WJ, 2000, BLOOD, V96, P4152; Marchand-Adam S, 2003, AM J RESP CRIT CARE, V168, P1156, DOI 10.1164/rccm.200212-1514OC; Mason RJ, 2002, AM J RESP CELL MOL, V26, P517, DOI 10.1165/ajrcmb.26.5.f239; MATSUDA Y, 1995, J BIOCHEM-TOKYO, V118, P643, DOI 10.1093/oxfordjournals.jbchem.a124958; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; Mizuno S, 2004, AM J PHYSIOL-RENAL, V286, pF134, DOI 10.1152/ajprenal.00199.2003; Mizuno S, 2000, KIDNEY INT, V57, P937; Mizuno S, 1998, J CLIN INVEST, V101, P1827, DOI 10.1172/JCI1709; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Ohmichi H, 1996, AM J PHYSIOL-LUNG C, V270, pL1031, DOI 10.1152/ajplung.1996.270.6.L1031; Ohmichi H, 1998, DEVELOPMENT, V125, P1315; OHTA K, 1995, AM J RESP CRIT CARE, V152, P1659, DOI 10.1164/ajrccm.152.5.7582311; Ozaki I, 2002, J HEPATOL, V36, P169, DOI 10.1016/S0168-8278(01)00245-8; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; PHAN SH, 1991, J CLIN INVEST, V87, P148, DOI 10.1172/JCI114964; Phan SH, 2002, CHEST, V122, p286S, DOI 10.1378/chest.122.6_suppl.286S; Sakamaki Y, 2002, AM J RESP CELL MOL, V26, P525, DOI 10.1165/ajrcmb.26.5.4714; Taniyama Y, 2000, CIRCULATION, V102, P246, DOI 10.1161/01.CIR.102.2.246; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Umeda Y, 2004, LAB INVEST, V84, P836, DOI 10.1038/labinvest.3700098; Yaekashiwa M, 1997, AM J RESP CRIT CARE, V156, P1937, DOI 10.1164/ajrccm.156.6.9611057; Yang JW, 2003, AM J PATHOL, V163, P621, DOI 10.1016/S0002-9440(10)63689-9; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; Zhang HY, 1997, J IMMUNOL, V158, P1392; Zhang HY, 1999, AM J RESP CELL MOL, V21, P658, DOI 10.1165/ajrcmb.21.6.3720; ZHANG K, 1994, AM J PATHOL, V145, P114; ZHANG K, 1995, AM J PATHOL, V147, P352	47	139	151	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					580	+		10.1096/fj.04-1535fje	http://dx.doi.org/10.1096/fj.04-1535fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665032				2022-12-25	WOS:000226576600016
J	Bass, R; Werner, F; Odintsova, E; Sugiura, T; Berditchevski, F; Ellis, V				Bass, R; Werner, F; Odintsova, E; Sugiura, T; Berditchevski, F; Ellis, V			Regulation of urokinase receptor proteolytic function by the tetraspanin CD82	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; METASTASIS SUPPRESSOR GENE; LIGAND-BINDING; CELL-ADHESION; KAI1 EXPRESSION; BOUND UROKINASE; IN-VITRO; INTEGRIN; CANCER; ASSOCIATION	The high affinity interaction between the urokinase-type plasminogen activator (uPA) and its glycolipid-anchored cellular receptor (uPAR) promotes plasminogen activation and the efficient generation of pericellular proteolytic activity. We demonstrate here that expression of the tetraspanin CD82/KAI1 (a tumor metastasis suppressor) leads to a profound effect on uPAR function. Pericellular plasminogen activation was reduced by similar to 50-fold in the presence of CD82, although levels of components of the plasminogen activation system were unchanged. uPAR was present on the cell surface and molecularly intact, but radioligand binding analysis with uPA and anti-uPAR antibodies revealed that it was in a previously undetected cryptic form unable to bind uPA. This was not due to direct interactions between uPAR and CD82, as they neither co-localized on the cell surface nor could be co-immunoprecipitated. However, expression of CD82 led to a redistribution of uPAR to focal adhesions, where it was shown by double immunofluorescence labeling to co-localize with the integrin alpha(5)beta(1), which was also redistributed in the presence of CD82. Co-immunoprecipitation experiments showed that, in the presence of CD82, uPAR preferentially formed stable associations with alpha(5)beta(1), but not with a variety of other integrins, including alpha(3)beta(1). These data suggest that CD82 inhibits the proteolytic function of uPAR indirectly, directing uPAR and alpha(5)beta(1) to focal adhesions and promoting their association with a resultant loss of uPA binding. This represents a novel mechanism whereby tetraspanins, integrins, and uPAR, systems involved in cell adhesion and migration, cooperate to regulate pericellular proteolytic activity and may suggest a mechanism for the tumor-suppressive effects of CD82/KAI1.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of East Anglia; Cancer Research UK; University of Birmingham	Ellis, V (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	v.ellis@uea.ac.uk	Bass, Rosemary A/A-5328-2009; Ellis, Vincent/D-1860-2009	Bass, Rosemary A/0000-0003-4997-5207; Ellis, Vincent/0000-0003-1956-073X; Werner, Finn/0000-0002-3930-3821				Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Bass R, 2002, BIOCHEM SOC T, V30, P189, DOI 10.1042/BST0300189; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 2001, J CELL SCI, V114, P4143; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Chapman HA, 2001, THROMB HAEMOSTASIS, V86, P124; Cunningham O, 2003, EMBO J, V22, P5994, DOI 10.1093/emboj/cdg588; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Ellis V, 1996, J BIOL CHEM, V271, P14779, DOI 10.1074/jbc.271.25.14779; ELLIS V, 1990, J BIOL CHEM, V265, P9904; Ellis V, 2003, CURR TOP DEV BIOL, V54, P263, DOI 10.1016/S0070-2153(03)54012-1; ELLIS V, 1989, J BIOL CHEM, V264, P2185; Ellis V, 2001, FEBS LETT, V506, P1, DOI 10.1016/S0014-5793(01)02845-9; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Guo XZ, 1996, CANCER RES, V56, P4876; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; List K, 1999, J IMMUNOL METHODS, V222, P125, DOI 10.1016/S0022-1759(98)00189-6; Liu FS, 2001, AM J PATHOL, V159, P1629, DOI 10.1016/S0002-9440(10)63009-X; Lombardi DP, 1999, CANCER RES, V59, P5724; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; MYOHANEN HT, 1993, J HISTOCHEM CYTOCHEM, V41, P1291; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; Ploug M, 1998, BIOCHEMISTRY-US, V37, P3612, DOI 10.1021/bi972787k; Pluskota E, 2003, BLOOD, V101, P1582, DOI 10.1182/blood-2002-06-1842; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Reuning U, 2003, CURR PHARM DESIGN, V9, P1529, DOI 10.2174/1381612033454612; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; Sawada S, 2003, J BIOL CHEM, V278, P26323, DOI 10.1074/jbc.C300210200; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Shibagaki N, 1999, EUR J IMMUNOL, V29, P4081, DOI 10.1002/(SICI)1521-4141(199912)29:12<4081::AID-IMMU4081>3.3.CO;2-9; Shliom O, 2000, J BIOL CHEM, V275, P24304, DOI 10.1074/jbc.M002024200; Sidenius N, 2002, J BIOL CHEM, V277, P27982, DOI 10.1074/jbc.M111736200; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Tarui T, 2003, J BIOL CHEM, V278, P29863, DOI 10.1074/jbc.M304694200; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; XUE W, 1994, J IMMUNOL, V152, P4630; Yang XH, 2001, CANCER RES, V61, P5284	73	45	52	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14811	14818		10.1074/jbc.M414189200	http://dx.doi.org/10.1074/jbc.M414189200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15677461	hybrid			2022-12-25	WOS:000228236800059
J	Eastman, RT; White, J; Hucke, O; Bauer, K; Yokoyama, K; Nallan, L; Chakrabarti, D; Verlinde, CLMJ; Gelb, MH; Rathod, PK; Van Voorhis, WC				Eastman, RT; White, J; Hucke, O; Bauer, K; Yokoyama, K; Nallan, L; Chakrabarti, D; Verlinde, CLMJ; Gelb, MH; Rathod, PK; Van Voorhis, WC			Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITES; CRYSTAL-STRUCTURE; BETA-SUBUNIT; TRANSFERASE; EXPRESSION; CLONING; POTENT	The post-translational farnesylation of proteins serves to anchor a subset of intracellular proteins to membranes in eukaryotic organisms and also promotes protein-protein interactions. Inhibition of protein farnesyltransferase (PFT) is lethal to the pathogenic protozoa Plasmodium falciparum. Parasites were isolated that were resistant to BMS-388891, a tetrahydroquinoline (THQ) PFT inhibitor. Resistance was associated with a 12-fold decrease in drug susceptibility. Genotypic analysis revealed a single point mutation in the beta subunit in resistant parasites. The resultant tyrosine 837 to cysteine alteration in the beta subunit corresponded to the binding site for the THQ and peptide substrate. Biochemical analysis of Y837C-PFT demonstrated a 13-fold increase in BMS-388891 concentration necessary for inhibiting 50% of the enzyme activity. These data are consistent with PFT as the target of BMS-388891 in P. falciparum and suggest that PFT inhibitors should be combined with other antimalarial agents for effective therapy.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; State University System of Florida; University of Central Florida	Van Voorhis, WC (corresponding author), Univ Washington, Dept Med, 1959 NE Pacific, Seattle, WA 98195 USA.	wesley@u.washington.edu	VERLINDE, CHRISTOPHE LMJ/J-5796-2013	VERLINDE, CHRISTOPHE LMJ/0000-0002-7790-3203; gelb, michael/0000-0001-7000-5219	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI060360, R01AI026912, R29AI026912, R01AI054384] Funding Source: NIH RePORTER; NIAID NIH HHS [AI054384, AI26912, AI60360] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Bell IM, 2004, J MED CHEM, V47, P1869, DOI 10.1021/jm0305467; Buckner FS, 2002, MOL BIOCHEM PARASIT, V122, P181, DOI 10.1016/S0166-6851(02)00099-3; Chakrabarti D, 1998, MOL BIOCHEM PARASIT, V94, P175, DOI 10.1016/S0166-6851(98)00065-6; Chakrabarti D, 2002, J BIOL CHEM, V277, P42066, DOI 10.1074/jbc.M202860200; Del Villar K, 1999, J BIOL CHEM, V274, P27010, DOI 10.1074/jbc.274.38.27010; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Dunten P, 1998, BIOCHEMISTRY-US, V37, P7907, DOI 10.1021/bi980531o; Feller SE, 2002, J AM CHEM SOC, V124, P318, DOI 10.1021/ja0118340; Haluska P, 2002, EUR J CANCER, V38, P1685, DOI 10.1016/S0959-8049(02)00166-1; Jiang L, 2000, ANTIMICROB AGENTS CH, V44, P1047, DOI 10.1128/AAC.44.4.1047-1050.2000; JORGENSEN WL, 1990, J AM CHEM SOC, V112, P4768, DOI 10.1021/ja00168a022; Kral AM, 1997, J BIOL CHEM, V272, P27319, DOI 10.1074/jbc.272.43.27319; Long SB, 2001, P NATL ACAD SCI USA, V98, P12948, DOI 10.1073/pnas.241407898; May J, 2003, TRENDS PARASITOL, V19, P432, DOI 10.1016/j.pt.2003.08.001; McMartin C, 1997, J COMPUT AID MOL DES, V11, P333, DOI 10.1023/A:1007907728892; MITSUZAWA H, 1995, P NATL ACAD SCI USA, V92, P1704, DOI 10.1073/pnas.92.5.1704; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Ohkanda J, 2004, J MED CHEM, V47, P432, DOI 10.1021/jm030236o; Ohkanda J, 2001, BIOORG MED CHEM LETT, V11, P761, DOI 10.1016/S0960-894X(01)00055-5; Ohwada T, 1998, TETRAHEDRON LETT, V39, P7877, DOI 10.1016/S0040-4039(98)01746-8; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; RATHOD PK, 1994, ANTIMICROB AGENTS CH, V38, P2871, DOI 10.1128/AAC.38.12.2871; Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389; Rathod PK, 2001, INFEC DIS S, P287; Reid TS, 2004, BIOCHEMISTRY-US, V43, P6877, DOI 10.1021/bi049723b; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sebti SM, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2003.12.012; Taylor JS, 2003, EMBO J, V22, P5963, DOI 10.1093/emboj/cdg571; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; White NJ, 2004, J CLIN INVEST, V113, P1084, DOI [10.1172/JCI21682, 10.1172/JCI200421682]; Wiesner J, 2004, ANGEW CHEM INT EDIT, V43, P251, DOI 10.1002/anie.200351169; YOKOYAMA K, 1992, BIOCHEM SOC T, V20, P489, DOI 10.1042/bst0200489	34	55	58	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13554	13559		10.1074/jbc.M413556200	http://dx.doi.org/10.1074/jbc.M413556200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15661734	Green Published, hybrid			2022-12-25	WOS:000228095500047
J	Pannu, R; Singh, AK; Singh, I				Pannu, R; Singh, AK; Singh, I			A novel role of lactosylceramide in the regulation of tumor necrosis factor alpha-mediated proliferation of rat primary astrocytes - Implications for astrogliosis following neurotrauma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; LIPID RAFTS; REACTIVE ASTROCYTES; ERK/MAP KINASE; MESSENGER-RNA; CELL-LINE; TNF-ALPHA; EXPRESSION	The present study describes the role of glycosphingolipids in neuroinflammatory disease and investigates tumor necrosis factor alpha (TNF alpha)-induced astrogliosis following spinal cord injury. Astrogliosis is the hallmark of neuroinflammation and is characterized by proliferation of astrocytes and increased glial fibrillary acidic protein (GFAP) gene expression. In primary astrocytes, TNF alpha stimulation increased the intracellular levels of lactosylceramide (LacCer) and induced GFAP expression and astrocyte proliferation. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol.HCl (PDMP), a glucosylceramide synthase and LacCer synthase (GalT-2) inhibitor, inhibited astrocyte proliferation and GFAP expression, which were reversed by exogenous supplementation of LacCer but not by other glycosphingolipids. TNF alpha caused a rapid increase in the activity of GalT-2 and synthesis of LacCer. Silencing of GalT-2 gene using antisense oligonucleotides also attenuated the proliferation of astrocytes and GFAP expression. The PDMP and antisense-mediated inhibition of proliferation and GFAP expression was well correlated with decreased Ras/ERK1/2 pathway activation. Furthermore, TNF alpha-mediated astrocyte proliferation and GFAP expression was also inhibited by LY294002, a phosphatidylinositol 3-kinase inhibitor, which was reversed by exogenous LacCer. LY294002 also inhibited TNF alpha-induced GalT-2 activation and LacCer synthesis, suggesting a phosphatidylinositol 3-kinase-mediated regulation of GalT-2. In vivo, PDMP treatment attenuated chronic ERK1/2 activation and spinal cord injury (SCI)-induced astrocyte proliferation with improved functional recovery post-SCI. Therefore, the in vivo studies support the conclusions drawn from cell culture studies and provide evidence for the role of LacCer in TNF alpha-induced astrogliosis in a rat model of SCI. To our knowledge, this is the first report demonstrating the role of LacCer in the regulation of TNF alpha-induced proliferation and reactivity of primary astrocytes.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Dept Pediat, Charleston, SC USA; Ralph H Johnson Vet Affairs Med Ctr, Dept Pathol, Charleston, SC USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 316 Clin Sci Bldg,96 Jonathan Lucas St, Charleston, SC 29425 USA.	singhi@musc.edu	Singh, Ashok/HGF-2506-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022576, R01NS034741, R01NS040144, R37NS022576, R01NS037766] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-22576, NS-40144, NS-34741, NS-37766] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BARNA BP, 1990, J NEUROIMMUNOL, V30, P239, DOI 10.1016/0165-5728(90)90108-Y; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BETHEA JR, 1990, J NEUROIMMUNOL, V30, P1, DOI 10.1016/0165-5728(90)90047-Q; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; ENG LF, 1992, PROG BRAIN RES, V94, P353; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fern R, 2001, Prog Brain Res, V132, P405; FICHARD A, 1991, DEV BIOL, V148, P1, DOI 10.1016/0012-1606(91)90312-Q; Giri S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0798com; Gong NL, 2004, P NATL ACAD SCI USA, V101, P6490, DOI 10.1073/pnas.0308684101; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Houle JD, 2003, EXP NEUROL, V182, P247, DOI 10.1016/S0014-4886(03)00029-3; Iwabuchi K, 2002, BLOOD, V100, P1454, DOI 10.1182/blood.V100.4.1454.h81602001454_1454_1464; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LACHMAN LB, 1987, J IMMUNOL, V138, P2913; Mandell JW, 1999, NEUROREPORT, V10, P3567, DOI 10.1097/00001756-199911260-00019; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Moon LDF, 2000, EXP NEUROL, V161, P49, DOI 10.1006/exnr.1999.7230; MUCKE L, 1993, FASEB J, V7, P1226, DOI 10.1096/fasebj.7.13.8405808; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pannu R, 2004, J NEUROSCI, V24, P5942, DOI 10.1523/JNEUROSCI.1271-04.2004; Parkin ET, 2001, BIOCHEM J, V358, P209, DOI 10.1042/0264-6021:3580209; Pebay A, 2001, EUR J NEUROSCI, V13, P2067, DOI 10.1046/j.0953-816x.2001.01585.x; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Rabchevsky AG, 2001, ARCH NEUROL-CHICAGO, V58, P721, DOI 10.1001/archneur.58.5.721; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Steeves JD, 1998, ANN NY ACAD SCI, V860, P412, DOI 10.1111/j.1749-6632.1998.tb09065.x; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tatagiba M, 1997, NEUROSURGERY, V40, P541, DOI 10.1097/00006123-199703000-00023; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Won JS, 2004, J NEUROCHEM, V88, P583, DOI 10.1046/j.1471-4159.2003.02165.x; Won JS, 2001, BRAIN RES, V903, P207, DOI 10.1016/S0006-8993(01)02452-0; YAJIMA K, 1979, LAB INVEST, V41, P385; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yanase H, 2001, PIGM CELL RES, V14, P103, DOI 10.1034/j.1600-0749.2001.140205.x; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang L, 2000, NEUROREPORT, V11, P409, DOI 10.1097/00001756-200002070-00037	50	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13742	13751		10.1074/jbc.M411959200	http://dx.doi.org/10.1074/jbc.M411959200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15668227	hybrid			2022-12-25	WOS:000228095500070
J	Paruchuri, S; Broom, O; Dib, K; Sjolander, A				Paruchuri, S; Broom, O; Dib, K; Sjolander, A			The pro-inflammatory mediator leukotriene D-4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GTPASES; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; COLORECTAL-CANCER; HUMAN NEUTROPHILS; ACTIVATION; ADHESION; RECEPTORS; CDC42; CHEMOTAXIS	Inflammatory bowel diseases are associated with increased risk of developing colon cancer. A possible role of the pro-inflammatory leukotriene D-4 (LTD4) in this process has been implicated by the findings that LTD4 can signal increased proliferation and survival, both hallmarks of a cancer cell, in non-transformed intestinal epithelial cells. Here we make the novel finding that LTD4 can also signal increased motility in these cells. In parallel, we found that LTD4 induced a simultaneous transient 10-fold increase in Rac but not Cdc42 activity. These data were also supported by the ability of LTD4 to activate the Rac GDP/GTP exchange factor Vav2. Further, LTD4 triggered a 3-fold transient increase in phosphatidylinositol 3-kinase (PI3K) phosphorylation, a possible upstream activator of the Vav2/Rac signaling pathway. The activation of Rac was blocked by the PI3K inhibitors LY294002 and wortmannin and by transfection of a kinase-negative mutant of PI3K or a dominant-negative form of Vav2. Furthermore, Rac was found to co-localize with actin in LTD4-generated membrane ruffles that were formed by a PI3K-dependent mechanism. In accordance, the inhibition of the PI3K and Rac signaling pathway also blocked the LTD4-induced migration of the intestinal cells. The present data reveal that an inflammatory mediator such as LTD4 cannot only increase proliferation and survival of non-transformed intestinal epithelial cells but also, via a PI3K/Rac signaling pathway, trigger a motile response in such cells. These data demonstrate the capacity of inflammatory mediators to participate in the process by which inflammatory bowel conditions increase the risk for colon cancer development.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Sjolander, A (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Entrance 78, SE-20502 Malmo, Sweden.	anita.sjolander@exppat.mas.lu.se						Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Cantrell DA, 2001, J CELL SCI, V114, P1439; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN CC, 1990, EUR J PHARMACOL, V191, P273; Claesson HE, 1999, J INTERN MED, V245, P205, DOI 10.1046/j.1365-2796.1999.00418.x; Dib K, 2003, J BIOL CHEM, V278, P24181, DOI 10.1074/jbc.M302300200; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; Fenteany G, 2000, CURR BIOL, V10, P831, DOI 10.1016/S0960-9822(00)00579-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HENLE G, 1957, J IMMUNOL, V79, P54; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Marcoux N, 2003, ONCOGENE, V22, P6100, DOI 10.1038/sj.onc.1206712; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Massoumi R, 2003, EXP CELL RES, V289, P342, DOI 10.1016/S0014-4827(03)00285-4; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mohri T, 1999, EXP CELL RES, V253, P533, DOI 10.1006/excr.1999.4720; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ohd JF, 2000, GASTROENTEROLOGY, V119, P1007, DOI 10.1053/gast.2000.18141; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Paruchuri S, 2003, J BIOL CHEM, V278, P45577, DOI 10.1074/jbc.M302881200; Paruchuri S, 2002, J CELL SCI, V115, P1883; Pelletier S, 2003, MOL CELL BIOL, V23, P1316, DOI 10.1128/MCB.23.4.1316-1333.2003; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thodeti CK, 2000, J BIOL CHEM, V275, P9849, DOI 10.1074/jbc.275.13.9849; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	41	58	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13538	13544		10.1074/jbc.M409811200	http://dx.doi.org/10.1074/jbc.M409811200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15657050	hybrid			2022-12-25	WOS:000228095500045
J	Robison, JG; Lu, L; Dixon, K; Bissler, JJ				Robison, JG; Lu, L; Dixon, K; Bissler, JJ			DNA lesion-specific Co-localization of the Mre11/Rad50/Nbs1 (MRN) complex and replication protein A (RPA) to repair foci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; DEPENDENT NUCLEAR-DYNAMICS; ATAXIA-TELANGIECTASIA; CELLULAR-RESPONSE; INDUCED APOPTOSIS; CHROMOSOMAL DNA; BINDING-PROTEIN; DAMAGE RESPONSE; PHOSPHORYLATION; MRE11	The DNA damage response, triggered by DNA replication stress or DNA damage, involves the activation of DNA repair and cell cycle regulatory proteins including the MRN (Mre11, Rad50, and Nbs1) complex and replication protein A (RPA). The induction of replication stress by hydroxyurea (HU) or DNA damage by camptothecin (CAMPT), etoposide (ETOP), or mitomycin C (MMC) led to the formation of nuclear foci containing phosphorylated Nbs1. HU and CAMPT treatment also led to the formation of RPA foci that co-localized with phospho-Nbs1 foci. After ETOP treatment, phospho-Nbs1 and RPA foci were detected but not within the same cell. MMC treatment resulted in phospho-Nbs1 foci formation in the absence of RPA foci. Consistent with the presence or absence of RPA foci, RPA hyperphosphorylation was present following HU, CAMPT, and ETOP treatment but absent following MMC treatment. The lack of co-localization of phospho-Nbs1 and RPA foci may be due to relatively shorter stretches of single-stranded DNA generated following ETOP and MMC treatment. These data suggest that, even though the MRN complex and RPA can interact, their interaction may be limited to responses to specific types of lesions, particularly those that have longer stretches of single-stranded DNA. In addition, the consistent formation of phospho-Nbs1 foci in all of the treatment groups suggests that the MRN complex may play a more universal role in the recognition and response to DNA lesions of all types, whereas the role of RPA may be limited to certain subsets of lesions.	Childrens Hosp, Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Bissler, JJ (corresponding author), Childrens Hosp, Med Ctr, Div Nephrol & Hypertens, MLC 7022,3333 Burnet Ave, Cincinnati, OH 45229 USA.	john.bissler@cchmc.org		Bissler, John/0000-0001-9685-9183	NIDDK NIH HHS [R01-DK061458] Funding Source: Medline; NINDS NIH HHS [R01-NS34782] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034782] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; Binz SK, 2003, J BIOL CHEM, V278, P35584, DOI 10.1074/jbc.M305388200; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Block WD, 2004, NUCLEIC ACIDS RES, V32, P997, DOI 10.1093/nar/gkh265; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CHEN GL, 1984, J BIOL CHEM, V259, P3560; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; De Silva IU, 2002, NUCLEIC ACIDS RES, V30, P3848, DOI 10.1093/nar/gkf479; FALK SJ, 1992, INT J RADIAT BIOL, V61, P749, DOI 10.1080/09553009214551601; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P10558, DOI 10.1021/bi9607517; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hande Kenneth R, 2003, Cancer Chemother Biol Response Modif, V21, P103; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; KENNY MK, 1990, J BIOL CHEM, V265, P769; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kobayashi J, 2004, DNA REPAIR, V3, P855, DOI 10.1016/j.dnarep.2004.03.023; Lee JH, 2003, MOL CANCER RES, V1, P674; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Lobachev K, 2004, CURR BIOL, V14, P2107, DOI 10.1016/j.cub.2004.11.051; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; McHugh PJ, 2001, LANCET ONCOL, V2, P483, DOI 10.1016/S1470-2045(01)00454-5; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; O'Neill KL, 1998, APOPTOSIS, V3, P369, DOI 10.1023/A:1009689407261; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Ritchie KB, 2000, GENETICS, V155, P475; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Robison JG, 2002, BIOELECTROMAGNETICS, V23, P106, DOI 10.1002/bem.103; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SESTILI P, 1995, CARCINOGENESIS, V16, P703, DOI 10.1093/carcin/16.4.703; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; TOMASZ M, 1995, CHEM BIOL, V2, P575, DOI 10.1016/1074-5521(95)90120-5; Tomasz M, 1997, PHARMACOL THERAPEUT, V76, P73, DOI 10.1016/S0163-7258(97)00088-0; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Wang Y, 2000, GENE DEV, V14, P927; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	69	33	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12927	12934		10.1074/jbc.M414391200	http://dx.doi.org/10.1074/jbc.M414391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15653682	hybrid			2022-12-25	WOS:000227922000102
J	Bottomley, MJ; Stier, G; Pennacchini, D; Legube, G; Simon, B; Akhtar, A; Sattler, M; Musco, G				Bottomley, MJ; Stier, G; Pennacchini, D; Legube, G; Simon, B; Akhtar, A; Sattler, M; Musco, G			NMR structure of the first PHD finger of autoimmune regulator protein (AIRE1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASES; SAND DOMAIN; FUNCTIONAL DOMAINS; BINDING; MUTATIONS; RING; DEGRADATION; MUTAGENESIS; REFINEMENT; REVEALS	Mutations in the autoimmune regulator protein AIRE1 cause a monogenic autosomal recessively inherited disease: autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). AIRE1 is a multidomain protein that harbors two plant homeodomain (PHD)-type zinc fingers. The first PHD finger of AIRE1 is a mutational hot spot, to which several pathological point mutations have been mapped. Using heteronuclear NMR spectroscopy, we determined the solution structure of the first PHD finger of AIRE1 (AIRE1-PHD1), and characterized the peptide backbone mobility of the domain. We performed a conformational analysis of pathological AIRE1-PHD1 mutants that allowed us to rationalize the structural impact of APECED-causing mutations and to identify an interaction site with putative protein ligands of the AIRE1-PHD1 domain. The structure unequivocally exhibits the canonical PHD finger fold, with a highly conserved tryptophan buried inside the structure. The PHD finger is stabilized by two zinc ions coordinated in an interleaved (cross-brace) scheme. This zinc coordination resembles RING finger domains, which can function as E3 ligases in the ubiquitination pathway. Based on this fold similarity, it has been suggested that PHD fingers might also function as E3 ligases, although this hypothesis is controversial. At variance to a previous report, we could not find any evidence that AIRE1-PHD1 has an intrinsic E3 ubiquitin ligase activity, nor detect any direct interaction between AIRE1-PHD1 and its putative cognate E2. Consistently, we show that the AIRE1-PHD1 structure is clearly distinct from the RING finger fold. Our results point to a function of the AIRE1-PHD1 domain in protein-protein interactions, which is impaired in some APECED mutations.	Ist Ric Biol Mol P Angeletti, I-00040 Pomezia, RM, Italy; European Mol Biol Lab, D-69117 Heidelberg, Germany	Merck & Company; European Molecular Biology Laboratory (EMBL)	Musco, G (corresponding author), Ist Sci San Raffaele, Dulbecco Telethon Inst, Biomol NMR Lab, Via Olgettina 58, I-20132 Milan, Italy.	musco.giovanna@hsr.it	LEGUBE, Gaelle/AAX-9772-2021; Sattler, Michael/A-2407-2012; musco, giovanna/I-7122-2012; Sattler, Michael/C-1169-2010; Musco, Giovanna/Q-2756-2019	Sattler, Michael/0000-0002-1594-0527; musco, giovanna/0000-0002-0469-2994; Simon, Bernd/0000-0003-0164-5516	Telethon [TCP99035] Funding Source: Medline	Telethon(Fondazione Telethon)		Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Akiyoshi H, 2004, J BIOL CHEM, V279, P33984, DOI 10.1074/jbc.M400702200; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Belz T, 2002, METHODS, V26, P233, DOI 10.1016/S1046-2023(02)00027-0; Bjorses P, 2000, AM J HUM GENET, V66, P378, DOI 10.1086/302765; Bottomley MJ, 2001, NAT STRUCT BIOL, V8, P626, DOI 10.1038/89675; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dodd RB, 2004, J BIOL CHEM, V279, P53840, DOI 10.1074/jbc.M409662200; Dominguez C, 2004, STRUCTURE, V12, P633, DOI 10.1016/j.str.2004.03.004; Eberharter A, 2004, EMBO J, V23, P4029, DOI 10.1038/sj.emboj.7600382; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Gibson TJ, 1998, TRENDS BIOCHEM SCI, V23, P242, DOI 10.1016/S0968-0004(98)01231-6; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Halonen M, 2004, HUM MUTAT, V23, P245, DOI 10.1002/humu.20003; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Heino M, 2001, HUM MUTAT, V18, P205, DOI 10.1002/humu.1176; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Kwan AHY, 2003, STRUCTURE, V11, P803, DOI 10.1016/S0969-2126(03)00122-9; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Lo Surdo P, 2003, MOL ENDOCRINOL, V17, P1283, DOI 10.1210/me.2002-0409; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Pascual J, 2000, J MOL BIOL, V304, P723, DOI 10.1006/jmbi.2000.4308; PELTON JG, 1993, PROTEIN SCI, V2, P543; Peterson P, 2004, CLIN EXP IMMUNOL, V135, P348, DOI 10.1111/j.1365-2249.2004.02384.x; Pitkanen J, 2003, GENES IMMUN, V4, P12, DOI 10.1038/sj.gene.6363929; Pitkanen J, 2001, J BIOL CHEM, V276, P19597, DOI 10.1074/jbc.M008322200; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051; Ramsey C, 2002, HUM MOL GENET, V11, P3299, DOI 10.1093/hmg/11.26.3299; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Rinderle C, 1999, HUM MOL GENET, V8, P277, DOI 10.1093/hmg/8.2.277; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Scheel H, 2003, TRENDS CELL BIOL, V13, P285, DOI 10.1016/S0962-8924(03)00102-8; Uchida D, 2004, J EXP MED, V199, P167, DOI 10.1084/jem.20031291; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	54	75	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11505	11512		10.1074/jbc.M413959200	http://dx.doi.org/10.1074/jbc.M413959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15649886	hybrid			2022-12-25	WOS:000227761800075
J	Hache, G; Liddament, MT; Harris, RS				Hache, G; Liddament, MT; Harris, RS			The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EDITING ENZYME APOBEC3G; VIRUS-LIKE PARTICLES; ANTIVIRAL ACTIVITY; HIV-1 VIRIONS; VIF PROTEIN; IN-VIVO; DEGRADATION; GAG; EVOLUTION; IMMUNITY	The human proteins APOBEC3F and APOBEC3G restrict retroviral infection by deaminating cytosine residues in the first cDNA strand of a replicating virus. These proteins have two putative deaminase domains, and it is unclear whether one or both catalyze deamination, unlike their homologs, AID and APOBEC1, which are well characterized single domain deaminases. Here, we show that only the C-terminal cytosine deaminase domain of APOBEC3F and -3G governs retroviral hypermutation. A chimeric protein with the N-terminal cytosine deaminase domain from APOBEC3G and the C-terminal cytosine deaminase domain from APOBEC3F elicited a dinucleotide hypermutation preference nearly indistinguishable from that of APOBEC3F. This 5'-T (C) under bar -> T (T) under bar mutational specificity was confirmed in a heterologous Escherichia coli-based mutation assay, in which the 5'-C (C) under bar -> C (T) under bar dinucleotide hypermutation preference of APOBEC3G also mapped to the C-terminal deaminase domain. An N-terminal APOBEC3G deletion mutant displayed a preference indistinguishable from that of the full-length protein, and replacing the C-terminal deaminase domain of APOBEC3F with AID resulted in an AID-like mutational signature. Together, these data indicate that only the C-terminal domain of APOBEC3F and -3G dictates the retroviral minus strand 5'-T (C) under bar and 5'-C (C) under bar dinucleotide hypermutation preferences, respectively, leaving the N-terminal domain to perform other aspects of retroviral restriction.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Harris, RS (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.	rsh@umn.edu		Liddament, Mark/0000-0002-8130-3972				Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Douaisi M, 2004, BIOCHEM BIOPH RES CO, V321, P566, DOI 10.1016/j.bbrc.2004.07.005; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Honjo T, 2004, IMMUNITY, V20, P659, DOI 10.1016/j.immuni.2004.05.011; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Li JL, 2004, J CELL BIOCHEM, V92, P560, DOI 10.1002/jcb.20082; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Sawyer SL, 2004, PLOS BIOL, V2, P1278, DOI 10.1371/journal.pbio.0020275; Schafer A, 2004, VIROLOGY, V328, P163, DOI 10.1016/j.virol.2004.08.006; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang JZ, 2004, HUM MOL GENET, V13, P1785, DOI 10.1093/hmg/ddh183; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	33	148	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10920	10924		10.1074/jbc.M500382200	http://dx.doi.org/10.1074/jbc.M500382200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647250	hybrid			2022-12-25	WOS:000227761800007
J	Kaldis, P				Kaldis, P			The N-terminal peptide of the Kaposi's sarcoma-associated herpesvirus (KSHV)-cyclin determines substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT-KINASE; CDK-ACTIVATING KINASE; VIRUS-ENCODED CYCLIN; STRUCTURAL BASIS; POTENTIAL MEDIATOR; CRYSTAL-STRUCTURE; IN-VIVO; INHIBITOR; PHOSPHORYLATION; P27(KIP1)	Cyclin- dependent kinases ( Cdks) are activated by cyclin binding and phosphorylation by the Cdk- activating kinase ( CAK). Activation of Cdk6 by the D- type cyclins requires phosphorylation of Cdk6 by CAK on threonine 177. In contrast, Cdk6 is activated by the Kaposi's sarcomaassociated herpesvirus ( KSHV)- cyclin in the absence and presence of CAK phosphorylation. The activity of Cdk6 (.) KSHV- cyclin complexes was investigated here by analyzing mutants of the KSHV- cyclin and Cdk6 in vitro as well as in U2OS cells. Deletion of the N terminus of the KSHV- cyclin affects the substrate specificity indicating that the N terminus is required for phosphorylation of histone H1 but not for other substrates. Mutation of residues in the region 180 - 200 of the KSHVcyclin decreases the binding affinity to Cdk6 in U2OS cells but increases the activity of Cdk6 (.) KSHV- cyclin complexes in vitro indicating that low affinity binding of cyclins to the Cdk subunit might favor increased on- or off- rates of Cdk substrates. Expression of high levels of p16(INK4a) in cells leads to the formation of a heterotrimeric complex composed of Cdk6 (.) KSHV- cyclin, and p16(INK4a). Some of the Cdk6 (.) KSHV- cyclin (.) p16 complexes were found to be active indicating that there might be different modes of p16 binding to Cdk6 (.) cyclin complexes.	NCI, NCI, Mouse Canc Genet Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaldis, P (corresponding author), NCI, NCI, Mouse Canc Genet Program, Frederick, MD 21702 USA.	kaldis@ncifcrf.gov	Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591	NATIONAL CANCER INSTITUTE [Z01SC010367] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; Brooks LA, 1997, J PATHOL, V182, P262, DOI 10.1002/(SICI)1096-9896(199707)182:3<262::AID-PATH836>3.0.CO;2-Q; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Child ES, 2001, ONCOGENE, V20, P3311, DOI 10.1038/sj.onc.1204447; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; Kaldis P, 2000, J BIOL CHEM, V275, P32578, DOI 10.1074/jbc.M003212200; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Laman H, 2001, MOL CELL BIOL, V21, P624, DOI 10.1128/MCB.21.2.624-635.2001; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Moore PS, 1998, TRENDS GENET, V14, P144, DOI 10.1016/S0168-9525(98)01408-5; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Ojala PM, 1999, CANCER RES, V59, P4984; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Russo AA, 1997, METHOD ENZYMOL, V283, P3; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Schulze-Gahmen U, 2002, NAT STRUCT BIOL, V9, P177, DOI 10.1038/nsb756; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; Sugaya M, 2005, BLOOD, V105, P2356, DOI 10.1182/blood-2004-08-3364; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verschuren EW, 2004, CANCER RES, V64, P581, DOI 10.1158/0008-5472.CAN-03-1863; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	72	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11165	11174		10.1074/jbc.M408887200	http://dx.doi.org/10.1074/jbc.M408887200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15664993	hybrid			2022-12-25	WOS:000227761800037
J	Kilpatrick, ZE; Cakouros, D; Kumar, S				Kilpatrick, ZE; Cakouros, D; Kumar, S			Ecdysone-mediated up-regulation of the effector caspase DRICE is required for hormone-dependent apoptosis in Drosophila cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID REGULATION; BROAD-COMPLEX; CYTOCHROME-C; DEATH; DRONC; METAMORPHOSIS; EXPRESSION; ACTIVATION; PATHWAYS; PROMOTER	The Drosophila steroid hormone ecdysone mediates cell death during metamorphosis by regulating the transcription of a number of cell death genes. The apical caspase DRONC is known to be transcriptionally regulated by ecdysone during development. Here we demonstrate that ecdysone also regulates the transcription of DRICE, a major effector caspase and a downstream target for DRONC in the fly. Using RNA interference in an ecdysone-responsive Drosophila cell line, we show that drice up-regulation is essential for apoptosis induced by ecdysone. We also show that drice expression is specifically controlled by the ecdysone-regulated transcription factor BR-C. Combined with previous observations, our results indicate that transcriptional regulation of the components of the core apoptotic machinery plays a key role in hormone-regulated programmed cell death during Drosophila development.	Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Inst, POB 14,Rundle Mall, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Baehrecke EH, 2000, CELL DEATH DIFFER, V7, P1057, DOI 10.1038/sj.cdd.4400753; Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Broadus J, 1999, MOL CELL, V3, P143, DOI 10.1016/S1097-2765(00)80305-6; Cakouros D, 2004, J CELL BIOL, V165, P631, DOI 10.1083/jcb.200311057; Cakouros D, 2002, J CELL BIOL, V157, P985, DOI 10.1083/jcb.200201034; Chew SK, 2004, DEV CELL, V7, P897, DOI 10.1016/j.devcel.2004.09.016; Daish TJ, 2004, DEV CELL, V7, P909, DOI 10.1016/j.devcel.2004.09.018; Daish TJ, 2003, CELL DEATH DIFFER, V10, P1348, DOI 10.1038/sj.cdd.4401312; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DIBELLO PR, 1991, GENETICS, V129, P385; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 2004, J CELL BIOL, V167, P405, DOI 10.1083/jcb.200408054; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Jiang CA, 2000, MOL CELL, V5, P445, DOI 10.1016/S1097-2765(00)80439-6; Jiang CG, 1997, DEVELOPMENT, V124, P4673; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; Kumar S, 2004, TRENDS BIOCHEM SCI, V29, P193, DOI 10.1016/j.tibs.2004.02.001; Lee CY, 2000, CELL RES, V10, P193, DOI 10.1038/sj.cr.7290048; Lee CY, 2000, MOL CELL, V6, P433, DOI 10.1016/S1097-2765(00)00042-3; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Lee CY, 2002, DEV BIOL, V252, P138, DOI 10.1006/dbio.2002.0838; Lee CY, 2002, DEV BIOL, V250, P101, DOI 10.1006/dbio.2002.0784; Lee CY, 2001, DEVELOPMENT, V128, P1443; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Ress C, 2000, TISSUE CELL, V32, P464, DOI 10.1016/S0040-8166(00)80003-8; Richardson H, 2002, J IMMUNOL METHODS, V265, P21, DOI 10.1016/S0022-1759(02)00068-6; Thummel CS, 1996, TRENDS GENET, V12, P306, DOI 10.1016/0168-9525(96)10032-9; Truman JW, 2002, ANNU REV ENTOMOL, V47, P467, DOI 10.1146/annurev.ento.47.091201.145230; Zakeri Z, 2002, J IMMUNOL METHODS, V265, P3, DOI 10.1016/S0022-1759(02)00067-4	33	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11981	11986		10.1074/jbc.M413971200	http://dx.doi.org/10.1074/jbc.M413971200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657059	hybrid			2022-12-25	WOS:000227761800130
J	Gardner, OS; Shiau, CW; Chen, CS; Graves, LM				Gardner, OS; Shiau, CW; Chen, CS; Graves, LM			Peroxisome proliferator-activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R - Correlation with endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; GROWTH-FACTOR RECEPTOR; HUMAN BREAST-CANCER; TYROSINE KINASE; TRANSLATIONAL CONTROL; PPAR-GAMMA; INDUCED PHOSPHORYLATION; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; REGULATED PROTEIN	The thiazolidinediones (TZDs) are synthetic peroxisome proliferator-activated receptor gamma (PPAR gamma) ligands that promote increased insulin sensitivity in type II diabetic patients. In addition to their ability to improve glucose homeostasis, TZDs also exert anti-proliferative effects by a mechanism that is unclear. Our laboratory has shown that two TZDs, ciglitazone and troglitazone, rapidly induce calcium-dependent p38 mitogen-activated protein kinase ( MAPK) phosphorylation in liver epithelial cells. Here, we further characterize the mechanism responsible for p38 MAPK activation by PPAR gamma ligands and correlate this with the induction of endoplasmic reticulum ( ER) stress. Specifically, we show that TZDs rapidly activate the ER stress-responsive pancreatic eukaryotic initiation factor 2 alpha (eIF2 alpha) kinase or PKR (double-stranded RNA-activated protein kinase)like endoplasmic reticulum kinase/pancreatic eIF2 alpha kinase, and that activation of these kinases is correlated with subsequent eIF2 alpha phosphorylation. Interestingly, PPAR gamma ligands not only activated calcium/calmodulin-dependent kinase II (CaMKII) 2-fold over control, but the selective CaMKII inhibitor, KN-93, attenuated MKK3/6 and p38 as well as PKR and eIF2 alpha phosphorylation. Although CaMKII was not affected by inhibition of PKR with 2-aminopurine, phosphorylation of MKK3/6 and p38 as well as eIF2 alpha were significantly reduced. Collectively, these data provide evidence that CaMKII is a regulator of PKR-dependent p38 and eIF2 alpha phosphorylation in response to ER calcium depletion by TZDs. Furthermore, using structural derivatives of TZDs that lack PPAR alpha ligand-binding activity as well as a PPAR gamma antagonist, we show that activation of these kinase signaling pathways is PPAR gamma-independent.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curr Toxicol, Chapel Hill, NC 27599 USA; Ohio State Univ, Coll Pharm, Div Med Chem, Columbus, OH 43210 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; Ohio State University	Graves, LM (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	lmg@med.unc.edu	Graves, Lee/AAG-5470-2021					Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Bennett RL, 2004, J BIOL CHEM, V279, P42687, DOI 10.1074/jbc.M403321200; Berlanga JJ, 1998, J BIOL CHEM, V273, P32340, DOI 10.1074/jbc.273.48.32340; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Chen KD, 1998, J BIOL CHEM, V273, P749, DOI 10.1074/jbc.273.2.749; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; EARP HS, 1995, J BIOL CHEM, V270, P28440; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fan YH, 2004, BIOORG MED CHEM LETT, V14, P2547, DOI 10.1016/j.bmcl.2004.02.087; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gardner OS, 2003, J BIOL CHEM, V278, P46261, DOI 10.1074/jbc.M307827200; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Kubota T, 1998, CANCER RES, V58, P3344; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lennon AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LODISH HF, 1990, J BIOL CHEM, V265, P10893; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Palakurthi SS, 2001, CANCER RES, V61, P6213; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; SOHDA T, 1982, CHEM PHARM BULL, V30, P3580; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Teruel T, 2003, J BIOL CHEM, V278, P263, DOI 10.1074/jbc.M207200200; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	50	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10109	10118		10.1074/jbc.M410445200	http://dx.doi.org/10.1074/jbc.M410445200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15649892	hybrid			2022-12-25	WOS:000227559600046
J	Huang, H; Rastegar, M; Bodner, C; Goh, SL; Rambaldi, I; Featherstone, M				Huang, H; Rastegar, M; Bodner, C; Goh, SL; Rambaldi, I; Featherstone, M			MEIS C termini harbor transcriptional activation domains that respond to cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 PHOSPHORYLATION; RETINOIC ACID; HOMEOBOX GENE; HOX PROTEINS; DNA-BINDING; COOPERATIVE INTERACTIONS; SEGMENTAL EXPRESSION; HOMEODOMAIN PROTEINS; EARLY HINDBRAIN; NUCLEAR IMPORT	MEIS proteins form heteromeric DNA-binding complexes with PBX monomers and (PBXHOX)-H-. heterodimers. We have shown previously that transcriptional activation by (PBXHOX)-H-. is augmented by either protein kinase A (PKA) or the histone deacetylase inhibitor trichostatin A (TSA). To examine the contribution of MEIS proteins to this response, we used the chromatin immuno-precipitation assay to show that MEIS1 in addition to PBX1, HOXA1, and HOXB1 was recruited to a known (PBXHOX)-H-. target, the Hoxb1 autoregulatory element following Hoxb1 transcriptional activation in P19 cells. Subsequent to TSA treatment, MEIS1 recruitment lagged behind that of HOX and PBX partners. MEIS1A also enhanced the transcriptional activation of a reporter construct bearing the Hoxb1 autoregulatory element after treatment with TSA. The MEIS1 homeodomain and protein-protein interaction with PBX contributed to this activity. We further mapped TSA-responsive and CREB-binding protein-dependent PKA-responsive transactivation domains to the MEIS1A and MEIS1B C termini. Fine mutation of the 56-residue MEIS1A C terminus revealed four discrete regions required for transcriptional activation function. All of the mutations impairing the response to TSA likewise reduced activation by PKA, implying a common mechanistic basis. C-terminal deletion of MEIS1 impaired transactivation without disrupting DNA binding or complex formation with HOX and PBX. Despite sequence similarity to MEIS and a shared ability to form heteromeric complexes with PBX and HOX partners, the PREP1 C terminus does not respond to TSA or PKA. Thus, MEIS C termini possess transcriptional regulatory domains that respond to cell signaling and confer functional differences between MEIS and PREP proteins.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	McGill University	Featherstone, M (corresponding author), McGill Univ, Ctr Canc, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	mark.featherstone@mcgill.ca	Featherstone, Mark/E-8057-2010; Rastegar, Mojgan/T-9394-2019	Featherstone, Mark/0000-0003-1576-046X; Rastegar, Mojgan/0000-0003-3619-6116				Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Alexandre C, 2003, DEVELOPMENT, V130, P729, DOI 10.1242/dev.00286; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Azpiazu N, 1998, GENE DEV, V12, P261, DOI 10.1101/gad.12.2.261; Barrow JR, 2000, DEVELOPMENT, V127, P933; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; Bischof LJ, 1998, ENDOCR RES, V24, P489, DOI 10.3109/07435809809032637; Burglin TR, 1998, DEV GENES EVOL, V208, P113, DOI 10.1007/s004270050161; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Calvo KR, 1999, ONCOGENE, V18, P8033, DOI 10.1038/sj.onc.1203377; Cecconi F, 1997, DEV DYNAM, V210, P184, DOI 10.1002/(SICI)1097-0177(199710)210:2<184::AID-AJA10>3.0.CO;2-E; Chariot A, 1999, ONCOGENE, V18, P4007, DOI 10.1038/sj.onc.1202776; Choe SK, 2002, DEVELOPMENT, V129, P585; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DeManno DA, 1999, MOL ENDOCRINOL, V13, P91, DOI 10.1210/me.13.1.91; Di Rocco G, 2001, J BIOL CHEM, V276, P20506, DOI 10.1074/jbc.M011175200; Dibner C, 2001, DEVELOPMENT, V128, P3415; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Featherstone M, 2003, AD DEV BIOL, V13, P1; Ferretti E, 2000, DEVELOPMENT, V127, P155; Fognani C, 2002, NUCLEIC ACIDS RES, V30, P2043, DOI 10.1093/nar/30.9.2043; Gebelein B, 2002, DEV CELL, V3, P487, DOI 10.1016/S1534-5807(02)00257-5; Grieder NC, 1997, EMBO J, V16, P7402, DOI 10.1093/emboj/16.24.7402; Haller K, 2002, DEV DYNAM, V225, P358, DOI 10.1002/dvdy.10167; Huang H, 2003, DEV DYNAM, V227, P608, DOI 10.1002/dvdy.10344; Huang H, 2003, MOL CELL BIOL, V23, P3636, DOI 10.1128/MCB.23.10.3636-3645.2003; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Inbal A, 2001, DEVELOPMENT, V128, P3405; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; Kilstrup-Nielsen C, 2003, EMBO J, V22, P89, DOI 10.1093/emboj/cdg010; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, MECH DEVELOP, V63, P5, DOI 10.1016/S0925-4773(97)00669-2; Kobayashi M, 2003, DEVELOPMENT, V130, P741, DOI 10.1242/dev.00289; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Li XL, 1999, EMBO J, V18, P198, DOI 10.1093/emboj/18.1.198; Maeda R, 2001, ONCOGENE, V20, P1329, DOI 10.1038/sj.onc.1204250; MANAK JR, 1994, DEVELOPMENT, V120, P3605; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Marty T, 2001, DEVELOPMENT, V128, P2833; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; OGO A, 1995, J BIOL CHEM, V270, P25340, DOI 10.1074/jbc.270.43.25340; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAMBALDI I, 1994, NUCLEIC ACIDS RES, V22, P376, DOI 10.1093/nar/22.3.376; Rastegar M, 2004, MOL CELL BIOL, V24, P8090, DOI 10.1128/MCB.24.18.8090-8103.2004; Ryoo HD, 1999, GENE DEV, V13, P1704, DOI 10.1101/gad.13.13.1704; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; Saleh M, 2000, EXP CELL RES, V260, P105, DOI 10.1006/excr.2000.5010; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Salzberg A, 1999, MECH DEVELOP, V80, P3, DOI 10.1016/S0925-4773(98)00187-7; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Steeman S, 1997, GENOME RES, V7, P142, DOI 10.1101/gr.7.2.142; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; Studer M, 1998, DEVELOPMENT, V125, P1025; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Vlachakis N, 2001, DEVELOPMENT, V128, P1299; Waskiewicz AJ, 2001, DEVELOPMENT, V128, P4139; White RAH, 2000, MECH DEVELOP, V91, P217, DOI 10.1016/S0925-4773(99)00306-8	74	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10119	10127		10.1074/jbc.M413963200	http://dx.doi.org/10.1074/jbc.M413963200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15654074	hybrid			2022-12-25	WOS:000227559600047
J	Nosek, J; Rycovska, A; Makhov, AM; Griffith, JD; Tomaska, L				Nosek, J; Rycovska, A; Makhov, AM; Griffith, JD; Tomaska, L			Amplification of telomeric arrays via rolling-circle mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR MITOCHONDRIAL GENOMES; BINDING PROTEIN; T-LOOPS; DNA; YEAST; REPLICATION; IDENTIFICATION; ARCHITECTURE; MAINTENANCE; CELLS	Alternative (telomerase-independent) lengthening of telomeres mediated through homologous recombination is often accompanied by a generation of extrachromosomal telomeric circles (t-circles), whose role in direct promotion of recombinational telomere elongation has been recently demonstrated. Here we present evidence that t-circles in a natural telomerase-deficient system of mitochondria of the yeast Candida parapsilosis replicate independently of the linear chromosome via a rolling-circle mechanism. This is supported by an observation of (i) single-stranded DNA consisting of concatameric arrays of telomeric sequence, (ii) lasso-shaped molecules representing rolling-circle intermediates, and (iii) preferential incorporation of deoxyribonucleotides into telomeric fragments and t-circles. Analysis of naturally occurring variant t-circles revealed conserved motifs with potential function in driving the rolling-circle replication. These data indicate that extrachromosomal t-circles observed in a wide variety of organisms, including yeasts, plants, Xenopus laevis, and certain human cell lines, may represent independent replicons generating telomeric sequences and, thus, actively participating in telomere dynamics. Moreover, because of the promiscuous occurrence of t-circles across phyla, the results from yeast mitochondria have implications related to the primordial system of telomere maintenance, providing a paradigm for evolution of telomeres in nuclei of early eukaryotes.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Comenius Univ, Dept Genet, Fac Nat Sci, Bratislava 84215, Slovakia; Comenius Univ, Dept Biochem, Bratislava 84215, Slovakia	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Comenius University Bratislava; Comenius University Bratislava	Tomaska, L (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	tomaska@fns.uniba.sk	Nosek, Jozef/A-7581-2008; Tomaska, Lubomir/I-3071-2014	Nosek, Jozef/0000-0002-1020-5451; Tomaska, Lubomir/0000-0003-4886-1910	FOGARTY INTERNATIONAL CENTER [R03TW005654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; FIC NIH HHS [1-R03-TW05654-01] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; Cohen S, 2002, EMBO REP, V3, P1168, DOI 10.1093/embo-reports/kvf240; de Lange T, 2004, NAT REV MOL CELL BIO, V5, P323, DOI 10.1038/nrm1359; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; FUKUDA A, 1976, J BIOCHEM-TOKYO, V80, P253, DOI 10.1093/oxfordjournals.jbchem.a131271; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; KORNBERG A, 1992, DNA REPLICATION, P298; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; Lindstrom UM, 2002, P NATL ACAD SCI USA, V99, P15953, DOI 10.1073/pnas.252396199; Lundblad V, 2002, ONCOGENE, V21, P522, DOI 10.1038/sj.onc.1205079; Lustig AJ, 2003, NAT REV GENET, V4, P916, DOI 10.1038/nrg1207; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Martin W, 2003, PHILOS T R SOC B, V358, P59, DOI 10.1098/rstb.2002.1183; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Natarajan S, 2003, EUKARYOT CELL, V2, P1115, DOI 10.1128/EC.2.5.1115-1127.2003; Natarajan S, 2002, MOL CELL BIOL, V22, P4512, DOI 10.1128/MCB.22.13.4512-4521.2002; Nosek J, 1999, J BIOL CHEM, V274, P8850, DOI 10.1074/jbc.274.13.8850; NOSEK J, 1995, MOL GEN GENET, V247, P61, DOI 10.1007/BF00425822; Nosek J, 2004, MOL GENET GENOMICS, V272, P173, DOI 10.1007/s00438-004-1046-0; Nosek J, 2003, CURR GENET, V44, P73, DOI 10.1007/s00294-003-0426-z; Nosek J, 1998, TRENDS GENET, V14, P184, DOI 10.1016/S0168-9525(98)01443-7; NOSEK J, 2002, MOL B INT U, V22, P396; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Reddel RR, 2003, LANCET, V361, P1840, DOI 10.1016/S0140-6736(03)13538-6; Reddel RR, 2003, CANCER LETT, V194, P155, DOI 10.1016/S0304-3835(02)00702-4; Regev A, 1998, ONCOGENE, V17, P3455, DOI 10.1038/sj.onc.1202250; Rycovska A, 2004, MICROBIOL-SGM, V150, P1571, DOI 10.1099/mic.0.26988-0; Sambrook J, 2001, MOL CLONING LAB MANU; Tomaska L, 1997, J BIOL CHEM, V272, P3049, DOI 10.1074/jbc.272.5.3049; Tomaska L, 2000, NUCLEIC ACIDS RES, V28, P4479, DOI 10.1093/nar/28.22.4479; Tomaska L, 2004, FEBS LETT, V567, P142, DOI 10.1016/j.febslet.2004.04.058; Tomaska L, 2002, MITOCHONDRION, V1, P455, DOI 10.1016/S1567-7249(02)00009-0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011	38	61	66	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10840	10845		10.1074/jbc.M409295200	http://dx.doi.org/10.1074/jbc.M409295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15657051	Green Published, hybrid			2022-12-25	WOS:000227559600132
J	Nieddu, E; Melchiori, A; Pescarolo, MP; Bagnasco, L; Biasotti, B; Licheri, B; Malacarne, D; Tortolina, L; Castagnino, N; Pasa, S; Cimoli, G; Avignolo, C; Ponassi, R; Balbi, C; Patrone, E; D'Arrigo, C; Barboro, P; Vasile, F; Orecchia, P; Carnemolla, B; Damonte, G; Millo, E; Palomba, D; Fassina, G; Mazzei, M; Parodi, S				Nieddu, E; Melchiori, A; Pescarolo, MP; Bagnasco, L; Biasotti, B; Licheri, B; Malacarne, D; Tortolina, L; Castagnino, N; Pasa, S; Cimoli, G; Avignolo, C; Ponassi, R; Balbi, C; Patrone, E; D'Arrigo, C; Barboro, P; Vasile, F; Orecchia, P; Carnemolla, B; Damonte, G; Millo, E; Palomba, D; Fassina, G; Mazzei, M; Parodi, S			Sequence specific peptidomimetic molecules inhibitors of a protein-protein interaction at the helix 1 level of c-Myc	FASEB JOURNAL			English	Article						D-peptides; protein-protein contacts; growth inhibition; structural studies	SECONDARY STRUCTURE; CELL-GROWTH; DNA; INTERNALIZATION; RECOGNITION; COMPLEX; DOMAIN	Our work is focused in the broad area of strategies and efforts to inhibit protein - protein interactions. The possible strategies in this field are definitely much more varied than in the case of ATP-pocket inhibitors. In our previous work ( 10), we reported that a retro-inverso ( RI) form of Helix1 (H1) of c-Myc, linked to an RI-internalization sequence arising from the third alpha-helix of Antennapedia (Int) was endowed with an antiproliferative and proapoptotic activity toward the cancer cell lines MCF-7 and HCT-116. The activity apparently was dependent upon the presence of the Myc motif. In this work, by ala-scan mapping of the H1 portion of our molecules with Daa, we found two amino acids necessary for antiproliferative activity: D-Lys in 4 and D-Arg in 5 ( numbers refer to L-forms). In the natural hetero-dimer, these two side chains project to the outside of the four alpha-helix bundle. Moreover, we were able to obtain three peptides more active than the original lead. They strongly reduced cell proliferation and survival (RI-Int-VV-H1-E2A, S6A, F8A; RI-Int-VV-H1-S6A, F8A, R11A; RI-Int-VV-H1-S6A, F8A, Q13A): after 8 days at 10 muM total cell number was similar to 1% of the number of cells initially seeded. In these more potent molecules, the ablated side chains project to the inside in the corresponding natural four alpha-helix bundle. In the present work, we also investigated the behavior of our molecules at the biochemical level. Using both a circular dichroism (CD) and a fluorescence anisotropy approach, we noted that side chains projecting at the interior of the four alpha-helix bundle are needed for inducing the partial unfolding of Myc-H2, without an opening of the leucine zipper. Side chains projecting at the outside are not required for this biochemical effect. However, antiproliferative activity had the opposite requirements: side chains projecting at the outside of the bundle were essential, and, on the contrary, ablation of one side chain at a time projecting at the inside increased rather than decreased biological activity. We conclude that our active molecules probably interfere at the level of a protein - protein interaction between Myc-Max and a third protein of the transcription complex. Finally, CD and nuclear magnetic resonance (NMR) data, plus dynamic simulations, suggest a prevalent random coil conformation of the H1 portion of our molecules, at least in diluted solutions. The introduction of a kink ( substitution with proline in positions 5 or 7) led to an important reduction of biological activity. We have also synthesized a longer peptido-mimetic molecule (RI-Int-H1-S6A, F8A-loop-H2) with the intent of obtaining a wider zone of interaction and a stronger interference at the level of the higher-order structure (enhanceosome). RI-Int-H1-S6A, F8A-loop-H2 was less active rather than more active in respect to RI-Int-VV-H1-S6A, F8A, apparently because it has a clear bent to form a - sheet ( CD and NMR data).	Univ Genoa, Dept Pharmaceut Sci, I-16132 Genoa, Italy; Natl Canc Inst, Expt Oncol Lab, Genoa, Italy; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy; Inst Study Macromol, Genoa Sect, Genoa, Italy; Univ Genoa, Dept Biophys Sci & Technol, Genoa, Italy; Natl Canc Inst, Cell Biol Lab, Genoa, Italy; Inst Giannina Gaslini, Genoa, Italy; Ctr Excellence Biomed Res, Dept Expt Med, Biochem Sect, Genoa, Italy; Xeptagen SpA, Naples, Italy	University of Genoa; University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa	Nieddu, E (corresponding author), Univ Genoa, Dept Pharmaceut Sci, I-16132 Genoa, Italy.	erika.nieddu@unige.it	Millo, Enrico/K-3218-2018; orecchia, paola/AAH-3509-2019; Fassina, Giorgio/I-7127-2012; Barboro, Paola/AAE-7144-2019	Millo, Enrico/0000-0002-4019-0051; Fassina, Giorgio/0000-0003-1845-2657; Barboro, Paola/0000-0001-9074-9290; D'Arrigo, Cristina/0000-0002-5352-5287; orecchia, paola/0000-0003-0556-9784; VASILE, FRANCESCA/0000-0002-3926-8261				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BHATIA K, 1994, BLOOD, V84, P883; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cimoli G, 2001, TUMORI J, V87, pS20; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Fieber W, 2001, J MOL BIOL, V307, P1395, DOI 10.1006/jmbi.2001.4537; Giorello L, 1998, CANCER RES, V58, P3654; GREENFIELD N, 1967, BIOCHEMISTRY-US, V6, P1630, DOI 10.1021/bi00858a009; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Jean-Francois N, 2003, J MOL BIOL, V326, P1577, DOI 10.1016/S0022-2836(03)00029-9; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; KURT W, 2003, ENCY HUMAN GENOME, P457; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pescarolo MP, 2001, FASEB J, V15, P31; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rudolph C, 1999, ANAL BIOCHEM, V269, P66, DOI 10.1006/abio.1999.3095	24	20	22	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					632	+		10.1096/fj.04-2369fje	http://dx.doi.org/10.1096/fj.04-2369fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15671156				2022-12-25	WOS:000226576600006
J	Sellers, KW; Sun, CW; Diez-Freire, C; Waki, H; Morisseau, C; Falck, JR; Hammock, BD; Paton, JF; Raizada, MK				Sellers, KW; Sun, CW; Diez-Freire, C; Waki, H; Morisseau, C; Falck, JR; Hammock, BD; Paton, JF; Raizada, MK			Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat	FASEB JOURNAL			English	Article						brain stem; baroreceptor reflex; central nervous system	ANGIOTENSIN-II; EPOXYEICOSATRIENOIC ACIDS; BARORECEPTOR REFLEX; CORONARY-ARTERIES; ARACHIDONIC-ACID; IN-VIVO; INHIBITION; ACTIVATION; EXPRESSION	The role of soluble epoxide hydrolase (sEH) in the central control of blood pressure ( BP) has not been elucidated in spite of peripheral sEH overexpression being linked to hypertension. Thus, our objective was to investigate the involvement of brain sEH in BP control. sEH expression in the hypothalamus and brain stem, two cardioregulatory brain areas, was increased in the spontaneously hypertensive rat (SHR) compared to the Wistar Kyoto (WKY) rat. Inhibition of the enzyme by intracerebroventricular (icv) delivery of AUDA further increased both BP and heart rate (HR) by 32 +/- 6 mmHg and 54 +/- 10 bpm, respectively, ( P< 0.05) in the SHR. Analysis of waveform telemetry data revealed a decrease in spontaneous baroreceptor reflex gain following sEH inhibition, indicating the sustained increase in BP may be due to a decrease in baroreceptor reflex function. The hypertensive effect of sEH inhibition is likely a result of an increase in epoxyeicosatrienoic acid (EET)-mediated generation of ROS. This view is supported by the following: 1) Inhibition of EET formation attenuates AUDA-induced increase in BP; 2) delivery of an EET agonist increases BP and HR in the WKY rat, and 3) inhibition of NAD(P)H oxidase by gp91ds-tat prevents AUDA-induced increases in BP and HR. Finally, electrophysiological studies demonstrate that AUDA increased neuronal firing rate exclusively in the SHR, an effect completely abolished by gp91ds-tat. These observations suggest that EETs and sEH inhibition are involved in increasing BP in the SHR. We suggest that an increased expression of sEH is a futile central nervous system response in protection against hypertension.	Univ Florida, Coll Med, McKnight Brain Inst, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA; Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Calif Davis, Ctr Canc, Davis, CA 95616 USA; Dept Entomol, Davis, CA USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	State University System of Florida; University of Florida; University of Bristol; University of California System; University of California Davis; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Raizada, MK (corresponding author), Univ Florida, Coll Med, McKnight Brain Inst, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA.	mraizada@phys.med.ufl.edu	Paton, Julian/AAM-2121-2020; Sun, Chengwen/AAC-4522-2019	Sun, Chengwen/0000-0001-5889-8448; Falck, John/0000-0002-9219-7845; Paton, Julian/0000-0001-7410-2913; Waki, Hidefumi/0000-0002-4278-2077	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033610, R01HL056921, R37HL033610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, P30ES005707, R37ES002710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56921, HL33610] Funding Source: Medline; NIEHS NIH HHS [P30 ES05707, R37 ES02710, P42 ES04699] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brand-Schieber E, 2000, J PHYSIOL PHARMACOL, V51, P655; Campbell WB, 2002, AM J PHYSIOL-HEART C, V282, pH1656, DOI 10.1152/ajpheart.00597.2001; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Coleman JE, 2003, PHYSIOL GENOMICS, V12, P221, DOI 10.1152/physiolgenomics.00135.2002; Falck JR, 2003, AM J PHYSIOL-HEART C, V284, pH337, DOI 10.1152/ajpheart.00831.2001; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Fornage M, 2002, HYPERTENSION, V40, P485, DOI 10.1161/01.HYP.0000032278.75806.68; FROHLICH ED, 1988, J HYPERTENS, V6, pS2, DOI 10.1097/00004872-198812040-00002; GOLDSTEIN DS, 1983, HYPERTENSION, V5, P86, DOI 10.1161/01.HYP.5.1.86; GRANT DF, 1993, J BIOL CHEM, V268, P17628; Imig JD, 2002, HYPERTENSION, V39, P690, DOI 10.1161/hy0202.103788; Lindpaintner K, 1994, Curr Opin Nephrol Hypertens, V3, P30, DOI 10.1097/00041552-199401000-00004; Lohmeier TE, 2004, HYPERTENSION, V43, P306, DOI 10.1161/01.HYP.0000111837.73693.9b; LOUIS WJ, 1990, J CARDIOVASC PHARM, V16, pS1, DOI 10.1097/00005344-199006167-00002; Okuda T, 2002, BIOCHEM BIOPH RES CO, V296, P537, DOI 10.1016/S0006-291X(02)00902-6; Oosting J, 1997, J HYPERTENS, V15, P391, DOI 10.1097/00004872-199715040-00010; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; RAIZADA MK, 1995, ADV EXP MED BIOL, V377, P331; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Sinal CJ, 2000, J BIOL CHEM, V275, P40504, DOI 10.1074/jbc.M008106200; Sun CW, 2003, J NEUROPHYSIOL, V90, P3155, DOI 10.1152/jn.00222.2003; Thrasher TN, 2002, AM J PHYSIOL-REG I, V282, pR1044, DOI 10.1152/ajpregu.00431.2001; TRIPPODO NC, 1981, CIRC RES, V48, P309, DOI 10.1161/01.RES.48.3.309; Waki H, 2003, J PHYSIOL-LONDON, V546, P233, DOI 10.1113/jphysiol.2002.030270; Yang H, 2004, HYPERTENSION, V43, P324, DOI 10.1161/01.HYP.0000113045.12850.cd; Yu ZG, 2000, CIRC RES, V87, P992, DOI 10.1161/01.RES.87.11.992; Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA	28	51	56	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					626	+		10.1096/fj.04-3128fje	http://dx.doi.org/10.1096/fj.04-3128fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15659536				2022-12-25	WOS:000226576600019
J	Barrett, DM; Black, SM; Todor, H; Schmidt-Ullrich, RK; Dawson, KS; Mikkelsen, RB				Barrett, DM; Black, SM; Todor, H; Schmidt-Ullrich, RK; Dawson, KS; Mikkelsen, RB			Inhibition of protein-tyrosine phosphatases by mild oxidative stresses is dependent on S-nitrosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HYDROGEN-PEROXIDE; REVERSIBLE INACTIVATION; KINASE ACTIVITY; A431 CELLS; RECEPTOR; ACTIVATION; SIGNAL; 1B; PHOSPHORYLATION	Previous studies have shown that a Ca2+-dependent nitric-oxide synthase (NOS) is activated as part of a cellular response to low doses of ionizing radiation. Genetic and pharmacological inhibitor studies linked this NO signaling to the radiation-induced activation of ERK1/2. Herein, a mechanism for the radiation-induced activation of Tyr phosphorylation-dependent pathways (e.g. ERK1/2) involving the inhibition of protein-Tyr phosphatases (PTPs) by S-nitrosylation is tested. The basis for this mechanism resides in the redox-sensitive active site Cys in PTPs. These studies also examined oxidative stress induced by low concentrations of H2O2. S-Nitrosylation of total cellular PTP and immunopurified SHP-1 and SHP-2 was detected as protection of PTP enzymatic activity from alkylation by N-ethylmaleimide and reversal by ascorbate. Both radiation and H2O2 protected PTP activity from alkylation by a mechanism reversible by ascorbate and inhibited by NOS inhibitors or expression of a dominant negative mutant of NOS-1. Radiation and H2O2 stimulated a transient increase in cytoplasmic free [Ca2+]. Radiation, H2O2, and the Ca2+ ionophore, ionomycin, also stimulated NOS activity, and this was associated with an enhanced S-nitrosylation of the active site Cys(453) determined by isolation of S-nitrosylated wild type but not active site Cys(453) --> Ser SHP-1 mutant by the "biotin-switch" method. Thus, one consequence of oxidative stimulation of NO generation is S-nitrosylation and inhibition of PTPs critical in cellular signal transduction pathways. These results support the conclusion that a mild oxidative signal is converted to a nitrosative one due to the better redox signaling properties of NO.	Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; Univ Montana, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA; Univ Montana, Int Heart Inst, Missoula, MT 59812 USA	Virginia Commonwealth University; Virginia Commonwealth University; University of Montana System; University of Montana; International Heart Institute of Montana Foundation; University of Montana System; University of Montana	Mikkelsen, RB (corresponding author), Massey Canc Ctr, 401 Coll St, Richmond, VA 23298 USA.	rmikkels@vcu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039110] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA065896, P01CA072955, R25CA089055] Funding Source: NIH RePORTER; NCI NIH HHS [CA65896, CA72955, CA89055] Funding Source: Medline; NHLBI NIH HHS [HL070061] Funding Source: Medline; NICHD NIH HHS [HD39110] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Bleyle LA, 1999, CELL SIGNAL, V11, P719, DOI 10.1016/S0898-6568(99)00043-1; Brookes PS, 2004, MITOCHONDRION, V3, P187, DOI 10.1016/j.mito.2003.10.001; Callsen D, 1999, FREE RADICAL BIO MED, V26, P1544, DOI 10.1016/S0891-5849(99)00015-5; Carballal S, 2003, BIOCHEMISTRY-US, V42, P9906, DOI 10.1021/bi027434m; Colston JT, 2002, J BIOL CHEM, V277, P23477, DOI 10.1074/jbc.M108676200; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Foster MW, 2004, J BIOL CHEM, V279, P25891, DOI 10.1074/jbc.M313853200; FREEMAN BA, 1982, LAB INVEST, V47, P412; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; Giulivi C, 2003, FREE RADICAL BIO MED, V34, P397, DOI 10.1016/S0891-5849(02)01298-4; Gow AJ, 2001, J CELL PHYSIOL, V187, P277, DOI 10.1002/jcp.1085; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; HECKER M, 1994, J NEUROCHEM, V62, P1524; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Jackson MD, 2001, CHEM REV, V101, P2313, DOI 10.1021/cr000247e; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Kim JE, 2004, J BIOL CHEM, V279, P9758, DOI 10.1074/jbc.M312722200; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kone BC, 2003, AM J PHYSIOL-RENAL, V285, pF178, DOI 10.1152/ajprenal.00048.2003; Kroncke KD, 2002, J BIOL CHEM, V277, P13294, DOI 10.1074/jbc.M111216200; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Leach JK, 2002, J BIOL CHEM, V277, P15400, DOI 10.1074/jbc.M110309200; Leach JK, 2001, CANCER RES, V61, P3894; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li S, 2003, ARCH BIOCHEM BIOPHYS, V410, P269, DOI 10.1016/S0003-9861(02)00696-3; Li S, 2002, ANAL BIOCHEM, V303, P217, DOI 10.1006/abio.2002.5592; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Lucas KA, 2000, PHARMACOL REV, V52, P375; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Mallis RJ, 2000, ARCH BIOCHEM BIOPHYS, V383, P60, DOI 10.1006/abbi.2000.2048; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; MANSBRIDGE JN, 1992, J CELL PHYSIOL, V151, P433, DOI 10.1002/jcp.1041510302; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Phung YT, 1999, IUBMB LIFE, V48, P333, DOI 10.1080/152165499307062; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schmidt-Ullrich RK, 2003, ONCOGENE, V22, P5855, DOI 10.1038/sj.onc.1206698; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STEVENSON MA, 1994, CANCER RES, V54, P12; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; TODD DG, 1994, CANCER RES, V54, P5224; Tuttle S, 1998, INT J RADIAT ONCOL, V42, P833, DOI 10.1016/S0360-3016(98)00331-9; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yeh DC, 1999, J BIOL CHEM, V274, P33148, DOI 10.1074/jbc.274.46.33148; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	68	101	105	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14453	14461		10.1074/jbc.M411523200	http://dx.doi.org/10.1074/jbc.M411523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15684422	hybrid			2022-12-25	WOS:000228236800014
J	Qiu, JZ; Yoon, JH; Shen, BH				Qiu, JZ; Yoon, JH; Shen, BH			Search for apoptotic nucleases in yeast - Role of Tat-D nuclease in apoptotic DNA degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HUMAN FLAP ENDONUCLEASE-1; C-ELEGANS; REQUIREMENT; HOMOLOG; MUTATION; DELETION; MARKERS; PROTEIN; STRESS	DNA fragmentation/degradation is an important step for apoptosis. However, in unicellular organisms such as yeast, this process has rarely been investigated. In the current study, we revealed eight apoptotic nuclease candidates in Saccharyomyces cerevisiae, analogous to the Caenorhabditis elegans apoptotic nucleases. One of them is Tat-D. Sequence comparison indicates that Tat-D is conserved across kingdoms, implicating that it is evolutionarily and functionally indispensable. In order to better understand the biochemical and biological functions of Tat-D, we have overexpressed, purified, and characterized the S. cerevisiae Tat-D (scTat-D). Our biochemical assays revealed that scTat-D is an endo-/exonuclease. It incises the double-stranded DNA without obvious specificity via its endonuclease activity and excises the DNA from the 3'- to 5'-end by its exonuclease activity. The enzyme activities are metal-dependent with Mg2+ as an optimal metal ion and an optimal pH around 5. We have also identified three amino acid residues, His(185), Asp(325), and Glu(327), important for its catalysis. In addition, our study demonstrated that knock-out of TAT-D in S. cerevisiae increases the TUNEL-positive cells and cell survival in response to hydrogen hyperoxide treatment, whereas overexpression of Tat-D facilitates cell death. These results suggest a role of Tat-D in yeast apoptosis.	City Hope Natl Med Ctr, Dept Radiat Biol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Grad Program Biol Sci, Duarte, CA 91010 USA; Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Qiu, JZ (corresponding author), City Hope Natl Med Ctr, Dept Radiat Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	jqiu@coh.org		Shen, Binghui/0000-0002-4408-407X	NATIONAL CANCER INSTITUTE [R01CA085344, R01CA073764] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA085344, R01CA073764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Burhans WC, 2003, MUTAT RES-FUND MOL M, V532, P227, DOI 10.1016/j.mrfmmm.2003.08.019; Del Carratore R, 2002, MUTAT RES-GEN TOX EN, V513, P183, DOI 10.1016/S1383-5718(01)00310-2; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evans CJ, 2002, GENE, V295, P61, DOI 10.1016/S0378-1119(02)00819-3; Frohlich KU, 2001, EXP GERONTOL, V37, P27, DOI 10.1016/S0531-5565(01)00177-2; Huh GH, 2002, PLANT J, V29, P649, DOI 10.1046/j.0960-7412.2001.01247.x; Jin C, 2002, NAT REV MOL CELL BIO, V3, P453, DOI 10.1038/nrm832; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; Kawane K, 2001, SCIENCE, V292, P1546, DOI 10.1126/science.292.5521.1546; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Ludovico P, 2001, MICROBIOL-SGM, V147, P3335, DOI 10.1099/00221287-147-12-3335; Ludovico P, 2002, MOL BIOL CELL, V13, P2598, DOI 10.1091/mbc.E01-12-0161; Lyon CJ, 2000, GENE, V252, P147, DOI 10.1016/S0378-1119(00)00213-4; Madeo F, 2004, CURR OPIN MICROBIOL, V7, P655, DOI 10.1016/j.mib.2004.10.012; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Manon S, 2004, ANTIOXID REDOX SIGN, V6, P259, DOI 10.1089/152308604322899323; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Parrish JZ, 2003, EMBO J, V22, P3451, DOI 10.1093/emboj/cdg320; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Priault M, 2003, FEMS YEAST RES, V4, P15, DOI 10.1016/S1567-1356(03)00143-0; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; Qiu JZ, 2001, J BIOL CHEM, V276, P4901, DOI 10.1074/jbc.M007825200; Qiu JZ, 2004, J BIOL CHEM, V279, P24394, DOI 10.1074/jbc.M401464200; Qiu JZ, 2002, J BIOL CHEM, V277, P24659, DOI 10.1074/jbc.M111941200; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Scovassi AI, 2003, EUR J HISTOCHEM, V47, P185; Severin FF, 2002, CURR BIOL, V12, pR233, DOI 10.1016/S0960-9822(02)00776-5; Wadskog I, 2004, MOL BIOL CELL, V15, P1436, DOI 10.1091/mbc.E03-02-0114; Walport MJ, 2000, NAT GENET, V25, P135, DOI 10.1038/75963; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamaki M, 2001, GENES CELLS, V6, P1043, DOI 10.1046/j.1365-2443.2001.00487.x; Yasutomo K, 2001, NAT GENET, V28, P313, DOI 10.1038/91070; [No title captured]	48	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15370	15379		10.1074/jbc.M413547200	http://dx.doi.org/10.1074/jbc.M413547200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15657035	hybrid			2022-12-25	WOS:000228236800123
J	Alberts, AS; Qin, HJ; Carr, HS; Frost, JA				Alberts, AS; Qin, HJ; Carr, HS; Frost, JA			PAK1 negatively regulates the activity of the Rho exchange factor NET1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL ONCOGENE PRODUCT; NUCLEOTIDE EXCHANGE; FAMILY PROTEINS; CYTOPLASMIC DIVISION; DEPENDENT ACTIVATION; GDP/GTP EXCHANGE; CELL-CYCLE; KINASE; PHOSPHORYLATION; GTPASES	Rho family small G-protein activity is controlled by guanine nucleotide exchange factors that stimulate the release of GDP, thus allowing GTP binding. Once activated, Rho proteins control cell signaling through interactions with downstream effector proteins, leading to changes in cytoskeletal organization and gene expression. The ability of Rho family members to modulate the activity of other Rho proteins is also intrinsic to these processes. In this work we show that the Rac/Cdc42hs-regulated protein kinase PAK1 down-regulates the activity of the RhoA-specific guanine nucleotide exchange factor NET1. Specifically, PAK1 phosphorylates NET1 on three sites in vitro: serines 152, 153, and 538. Replacement of serines 152 and 153 with glutamate residues down-regulates the activity of NET1 as an exchange factor in vitro and its ability to stimulate actin stress fiber formation in cells. Using a phospho-specific antibody that recognizes NET1 phosphorylated on serine 152, we show that PAK1 phosphorylates NET1 on this site in cells and that Rac1 stimulates serine 152 phosphorylation in a PAK1-dependent manner. Furthermore, coexpression of constitutively active PAK1 inhibits the ability of NET1 to stimulate actin polymerization only when serines 152 and 153 are present. These data provide a novel mechanism for the control of RhoA activity by Rac1 through the PAK-dependent phosphorylation of NET1 to reduce its activity as a guanine nucleotide exchange factor.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Van Andel Res Inst, Lab Cell Struct & Signal Integrat, Grand Rapids, MI USA	University of Texas System; University of Texas Health Science Center Houston; Van Andel Institute	Frost, JA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.	jeffrey.a.frost@uth.tmc.edu		Frost, Jeffrey/0000-0001-9722-1536	NATIONAL CANCER INSTITUTE [R21CA107529] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA107529] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEPFELBACHER M, 1995, BIOCHEM J, V308, P853, DOI 10.1042/bj3080853; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chan AML, 1996, ONCOGENE, V12, P1259; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kristelly R, 2004, J BIOL CHEM, V279, P47352, DOI 10.1074/jbc.M406056200; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schmidt A, 2002, J BIOL CHEM, V277, P14581, DOI 10.1074/jbc.M111108200; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Toksoz D, 2002, HISTOL HISTOPATHOL, V17, P915, DOI 10.14670/HH-17.915; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wherlock M, 2002, J CELL SCI, V115, P239; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	49	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12152	12161		10.1074/jbc.M405073200	http://dx.doi.org/10.1074/jbc.M405073200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15684429	hybrid			2022-12-25	WOS:000227922000013
J	Bei, L; Lu, YF; Eklund, EA				Bei, L; Lu, YF; Eklund, EA			HOXA9 activates transcription of the gene encoding gp91(Phox) during myeloid differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING PROTEIN; BONE-MARROW-CELLS; DNA-BINDING; FUSION GENE; IN-VITRO; EXPRESSION; LEUKEMIA; REPRESSION; P67(PHOX); COMPLEXES	The CYBB gene encodes gp91(Phox); a component of the phagocyte respiratory burst oxidase. CYBB transcription is restricted to myeloid cells differentiated beyond the promyelocyte stage. In undifferentiated myeloid cells, the homeodomain (HD) transcription factor HoxA10 represses CYBB transcription via a cis element in the proximal promoter. During myelopoiesis, phosphorylation of conserved tyrosine residues in the HD decreases HoxA10 binding to this CYBB cis element. In the current studies, we found HoxA9 activates CYBB transcription in differentiated myeloid cells via the same cis element. We find HoxA9-mediated CYBB-transcription requires Pbx1 but is inhibited by Meis1. Additionally, phosphorylation of the conserved HD tyrosines increases HoxA9 binding to the CYBB promoter. The HOXA9 gene is involved in leukemia-associated translocations with the gene encoding Nup98, a nucleopore protein. We find expression of a Nup98-hoxA9 fusion protein blocks HoxA9-induced CYBB transcription in differentiating myeloid cells. In comparison to HoxA9, Nup98-hoxA9 has greater binding affinity for the CYBB cis element, but binding is not altered by HD tyrosine phosphorylation. Therefore, these studies identify CYBB as a common target gene repressed by HoxA10 and activated by HoxA9. These studies also suggest overexpression of Meis1 or Nup98-hoxA9 represses myeloid-specific gene transcription, thereby contributing to differentiation block in leukemogenesis.	Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Jesse Brown Vet Affairs Med Ctr, Lakeside Div, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Eklund, EA (corresponding author), Northwestern Univ, Feinberg Sch Med, 710 N Fairbanks Ct,Olson Pavil,Rm 8524, Chicago, IL 60611 USA.	e-eklund@northwestern.edu						ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Calvo KR, 2001, P NATL ACAD SCI USA, V98, P13120, DOI 10.1073/pnas.231115398; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 2002, J BIOL CHEM, V277, P36878, DOI 10.1074/jbc.M203917200; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Ghannam G, 2004, J BIOL CHEM, V279, P866, DOI 10.1074/jbc.M307280200; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Kautz B, 2001, J BIOL CHEM, V276, P37868; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kumar AR, 2004, BLOOD, V103, P1823, DOI 10.1182/blood-2003-07-2582; LaRonde-LeBlanc NA, 2003, GENE DEV, V17, P2060, DOI 10.1101/gad.1103303; LARRICK JW, 1980, J IMMUNOL, V125, P6; Lu YF, 2003, J BIOL CHEM, V278, P47792, DOI 10.1074/jbc.M305885200; NEWBURGER PE, 1991, J BIOL CHEM, V266, P16171; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; SAMBROOK H, MOL CLONING LAB MANU; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shen WF, 1999, MOL CELL BIOL, V19, P3051; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5	34	55	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12359	12370		10.1074/jbc.M408138200	http://dx.doi.org/10.1074/jbc.M408138200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15681849	hybrid			2022-12-25	WOS:000227922000037
J	Garcia-Vallejo, JJ; van Dijk, W; van Die, I; Gringhuis, SI				Garcia-Vallejo, JJ; van Dijk, W; van Die, I; Gringhuis, SI			Tumor necrosis factor-alpha up-regulates the expression of beta 1,4-galactosyltransferase I in primary human endothelial cells by mRNA stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; L-SELECTIN; TRANSLATIONAL CONTROL; RHEUMATOID-ARTHRITIS; ADHESION MOLECULE-1; LEUKOCYTE ADHESION; SOMATIC-CELLS; GALACTOSYLTRANSFERASE; ELEMENT	During the course of an inflammatory response, the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF alpha) triggers endothelial cells to increase the expression levels of adhesion molecules that are pivotal for the rolling, adhesion, and transmigration of leukocytes over the endothelial cell wall. Here we show that TNF alpha, in addition, has a regulatory function in the biosynthesis of proper carbohydrate molecules on endothelial cells that constitute ligands for adhesion molecules on leukocytes. Our data show that TNF alpha induced an increase in the expression of beta 1,4-galactosyltransferase-1 (beta 4GalT-1) in primary human umbilical vein endothelial cells in a time- and concentration-dependent manner. The beta 4GalT-1 mRNA up-regulation correlated with an increase in the Golgi expression and catalytic activity of the enzyme. Furthermore, an enhanced incorporation of galactose was observed in newly synthesized glycoproteins. Analysis of the molecular mechanism behind the up-regulation of beta 4GalT-1 showed that the increase in mRNA levels is due to an enhanced stability of the transcripts. These data strongly demonstrate that TNF alpha modulates the glycosylation of endothelial cells by a mechanism that directly enhances the stability of beta 4GalT-1 mRNA transcripts.	Vrije Univ Amsterdam, Ctr Med, Dept Mol Cell Biol & Immunol, Glycoimmunol Grp, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Garcia-Vallejo, JJ (corresponding author), Vrije Univ Amsterdam, Ctr Med, Dept Mol Cell Biol & Immunol, Glycoimmunol Grp, POB 7057, NL-1007 MB Amsterdam, Netherlands.	jj.garciavallejo@vumc.nl	Garcia-Vallejo, Juan/H-4162-2012; Vallejo, Juan Garcia/AAA-3765-2020	Garcia-Vallejo, Juan/0000-0001-6238-7069; Gringhuis, Sonja/0000-0003-0383-4978				Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6; Asano M, 2003, BLOOD, V102, P1678, DOI 10.1182/blood-2003-03-0836; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BELL JE, 1976, J BIOL CHEM, V251, P3003; Berger EG, 2003, BIOCHIMIE, V85, P261, DOI 10.1016/S0300-9084(03)00008-7; BERGER EG, 1986, CARBOHYD RES, V149, P23, DOI 10.1016/S0008-6215(00)90366-5; Berger EG, 2002, GLYCOBIOLOGY, V12, p29R, DOI 10.1093/glycob/12.2.29R; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Charron M, 1998, P NATL ACAD SCI USA, V95, P14805, DOI 10.1073/pnas.95.25.14805; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Garcia-Vallejo JJ, 2004, ANAL BIOCHEM, V329, P293, DOI 10.1016/j.ab.2004.02.037; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; Hirata T, 2002, J IMMUNOL, V169, P4307, DOI 10.4049/jimmunol.169.8.4307; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kaburagi Y, 2002, J IMMUNOL, V168, P2970, DOI 10.4049/jimmunol.168.6.2970; Kotani N, 2001, BIOCHEM J, V357, P827, DOI 10.1042/0264-6021:3570827; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemaire S, 1998, GLYCOCONJUGATE J, V15, P161, DOI 10.1023/A:1006968206257; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Mantovani A, 1998, TRANSPLANT P, V30, P4239, DOI 10.1016/S0041-1345(98)01402-X; Meisner NC, 2004, CHEMBIOCHEM, V5, P1432, DOI 10.1002/cbic.200400219; Mikulowska-Mennis A, 2001, AM J PATHOL, V159, P671, DOI 10.1016/S0002-9440(10)61738-5; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Nakayama F, 2000, J INVEST DERMATOL, V115, P299, DOI 10.1046/j.1523-1747.2000.00032.x; Pasqualetto V, 2000, CARBOHYD RES, V328, P301, DOI 10.1016/S0008-6215(00)00116-6; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Renkonen J, 2002, AM J PATHOL, V161, P543, DOI 10.1016/S0002-9440(10)64210-1; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; Schnyder-Candrian S, 2000, P NATL ACAD SCI USA, V97, P8369, DOI 10.1073/pnas.97.15.8369; Scocca JR, 2003, BIOCHIMIE, V85, P403, DOI 10.1016/S0300-9084(03)00055-5; SHAPER JH, 2001, HDB GLYCOSYLTRANSFER, P11; SHAPER JH, 2000, CARBOHYDRATES CHEM B, P175; Shur BD, 1998, GLYCOCONJUGATE J, V15, P537, DOI 10.1023/A:1006951407168; Smeets TJM, 2003, ANN RHEUM DIS, V62, P635, DOI 10.1136/ard.62.7.635; SPERTINI O, 1992, J EXP MED, V175, P1789, DOI 10.1084/jem.175.6.1789; Takizawa M, 1999, BBA-MOL CELL BIOL L, V1438, P301, DOI 10.1016/S1388-1981(99)00051-7; Taylor PC, 2000, ARTHRITIS RHEUM-US, V43, P38, DOI 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L; van Die I, 1999, FEBS LETT, V450, P52, DOI 10.1016/S0014-5793(99)00462-7; Wingender E, 2000, TRENDS GLYCOSCI GLYC, V12, P255, DOI 10.4052/tigg.12.255; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499	52	30	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12676	12682		10.1074/jbc.M410093200	http://dx.doi.org/10.1074/jbc.M410093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668241	hybrid, Green Published			2022-12-25	WOS:000227922000074
J	MacRae, JI; Serrano, AA; Morrice, NA; Mehlert, A; Ferguson, MAJ				MacRae, JI; Serrano, AA; Morrice, NA; Mehlert, A; Ferguson, MAJ			Structural characterization of NETNES, a novel glycoconjugate in Trypanosoma cruzi epimastigotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM; TRANS-SIALIDASE; SURFACE GLYCOPROTEIN; LEISHMANIA-MEXICANA; SIGNAL PEPTIDES; O-GLYCOSYLATION; OLIGOSACCHARIDES; BIOSYNTHESIS; LIPOPEPTIDOPHOSPHOGLYCAN; PROTEOPHOSPHOGLYCANS	The unicellular stercorarian protozoan parasite Trypanosoma cruzi is the etiological agent of Chagas' disease. The epimastigote form of the parasite is covered in a dense coat of glycoinositol phospholipids and short glycosylphosphatidylinositol (GPI)-anchored mucin-like molecules. Here, we describe the purification and structural characterization of NETNES, a relatively minor but unusually complex glycoprotein that coexists with these major surface components. The mature glycoprotein is only 13 amino acids in length, with the sequence AQENETNESGSID, and exists in two forms with either four or five post-translational modifications. These are either one or two asparagine-linked oligo-mannose glycans, two linear alpha-mannose glycans linked to serine residues via phosphodiester linkages, and a GPI membrane anchor attached to the C-terminal aspartic acid residue. The variety and density of post-translational modifications on an unusually small peptide core make NETNES a unique type of glycoprotein. The N-glycans are predominantly Man alpha 1-6(Man alpha 1-3) Man alpha 1-6(Man alpha 1-3)Man beta 1-4GlcNAc beta 1-4GlcNAc beta 1-Asn; the phosphate-linked glycans are a mixture of (Man alpha 1-2) (0-3)Man1-P-Ser; and the GPI anchor has the structure Man alpha 1-2(ethanolamine phosphate)Man alpha 1-2Man alpha 1-6Man alpha 1-4(2-aminoethylphosphonate-6)GlcN alpha 1-6-myo-inositol-1-P-3(sn-1-O-(C-16:0)alkyl-2-O-(C-16:0) acylglycerol). Four putative NETNES genes were found in the T. cruzi genome data base. These genes are predicted to encode 65-amino acid proteins with cleavable 26-amino acid N-terminal signal peptides and 26-amino acid C-terminal GPI addition signal peptides.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dow St, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Ferguson, Michael A. J./F-7829-2010; Acosta-Serrano, Alvaro/L-5503-2015	Ferguson, Michael A. J./0000-0003-1321-8714; Acosta-Serrano, Alvaro/0000-0002-2576-7959; MacRae, James/0000-0002-1464-8583				Acosta-Serrano A, 2001, MOL BIOCHEM PARASIT, V114, P143, DOI 10.1016/S0166-6851(01)00245-6; Acosta-Serrano A., 1995, J BIOL CHEM, V270, P27244; Agrellos OA, 2003, MOL BIOCHEM PARASIT, V126, P93, DOI 10.1016/S0166-6851(02)00245-1; Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; Basombrio MA, 2002, J PARASITOL, V88, P489, DOI 10.1645/0022-3395(2002)088[0489:TDOTGG]2.0.CO;2; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BIERMANN CJ, 1989, ANAL CARBOHYDRATES G, P27; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; Campo V, 2004, MOL BIOCHEM PARASIT, V133, P81, DOI 10.1016/j.molbiopara.2003.09.006; Carreira JC, 1996, GLYCOCONJUGATE J, V13, P955, DOI 10.1007/BF01053191; CARVER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309, DOI 10.1016/0003-9861(92)90523-Y; de Lederkremer RM, 2001, CURR PHARM DESIGN, V7, P1165, DOI 10.2174/1381612013397519; DELEDERKREMER RM, 1976, BIOCHIM BIOPHYS ACTA, V444, P85, DOI 10.1016/0304-4165(76)90226-9; DELEDERKREMER RM, 1993, EUR J BIOCHEM, V218, P929, DOI 10.1111/j.1432-1033.1993.tb18449.x; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; Di Noia JM, 1998, J BIOL CHEM, V273, P10843, DOI 10.1074/jbc.273.18.10843; Di Noia JM, 2002, J EXP MED, V195, P401, DOI 10.1084/jem.20011433; Eisenhaber B, 2000, TRENDS BIOCHEM SCI, V25, P340, DOI 10.1016/S0968-0004(00)01601-7; Ferguson M. A. J., 1993, GLYCOBIOLOGY, P349; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1983, BIOCHEM J, V213, P313, DOI 10.1042/bj2130313; Frasch ACC, 2000, PARASITOL TODAY, V16, P282, DOI 10.1016/S0169-4758(00)01698-7; GUSTAFSON GL, 1980, J BIOL CHEM, V255, P7208; Haynes PA, 1996, GLYCOBIOLOGY, V6, P869, DOI 10.1093/glycob/6.8.869; Ilg T, 2000, PARASITOL TODAY, V16, P489, DOI 10.1016/S0169-4758(00)01791-9; ILG T, 1994, J BIOL CHEM, V269, P24073; Jones C, 2004, BIOCHEMISTRY-US, V43, P11889, DOI 10.1021/bi048942u; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Klein C, 1999, BIOCHEM J, V344, P775, DOI 10.1042/0264-6021:3440775; LEDERKREMER RM, 1985, BIOCH INT, V10, P89; MacRae JI, 2005, GLYCOBIOLOGY, V15, P131, DOI 10.1093/glycob/cwh149; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Mehta DP, 1997, J BIOL CHEM, V272, P28638, DOI 10.1074/jbc.272.45.28638; Moody-Haupt S, 2000, J MOL BIOL, V297, P409, DOI 10.1006/jmbi.2000.3577; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pereira-Chioccola VL, 2000, J CELL SCI, V113, P1299; Previato JO, 2004, ADV PARASIT, V56, P1, DOI 10.1016/S0065-308X(03)56001-8; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; RUIZ RD, 1993, PARASITE IMMUNOL, V15, P121, DOI 10.1111/j.1365-3024.1993.tb00591.x; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; Schroter S, 1999, J BIOL CHEM, V274, P29862, DOI 10.1074/jbc.274.42.29862; Srikrishna G, 1998, GLYCOBIOLOGY, V8, P799, DOI 10.1093/glycob/8.8.799; Thomson LM, 2002, J BIOL CHEM, V277, P48899, DOI 10.1074/jbc.M208942200; Todeschini AR, 2001, GLYCOBIOLOGY, V11, P47, DOI 10.1093/glycob/11.1.47; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; YOSHIDA N, 1989, INFECT IMMUN, V57, P1663, DOI 10.1128/IAI.57.6.1663-1667.1989	52	37	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12201	12211		10.1074/jbc.M412939200	http://dx.doi.org/10.1074/jbc.M412939200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15649890	hybrid			2022-12-25	WOS:000227922000018
J	Malli, R; Frieden, M; Trenker, M; Graier, WF				Malli, R; Frieden, M; Trenker, M; Graier, WF			The role of mitochondria for Ca2+ refilling of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERFICIAL BUFFER BARRIER; GREEN FLUORESCENT PROTEINS; BOVINE ENDOTHELIAL-CELLS; SMOOTH-MUSCLE; SARCOPLASMIC-RETICULUM; RELEASE CONTRIBUTES; HEART-MITOCHONDRIA; CAPACITATIVE CA2+; CALCIUM INFLUX; T-LYMPHOCYTES	Endoplasmic reticulum (ER) Ca2+ refilling is an active process to ensure an appropriate ER Ca2+ content under basal conditions and to maintain or restore ER Ca2+ concentration during/after cell stimulation. The mechanisms to achieve successful ER Ca2+ refilling are multiple and built on a concerted action of processes that provide a suitable reservoir for Ca2+ sequestration into the ER. Despite mitochondria having been found to play an essential role in the maintenance of capacitative Ca2+ entry by buffering subplasmalemmal Ca2+, their contribution to ER Ca2+ refilling was not subjected to detailed analysis so far. Thus, this study was designed to elucidate the involvement of mitochondria in Ca2+ store refilling during and after cell stimulation. ER Ca2+ refilling was found to be accomplished even during continuous inositol 1,4,5-trisphosphate (IP3)-triggered ER Ca2+ release by an agonist. Basically, ER Ca2+ refilling depended on the presence of extracellular Ca2+ as the source and sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) activity. Interestingly, in the presence of an IP3-generating agonist, ER Ca2+ refilling was prevented by the inhibition of trans-mitochondrial Ca2+ flux by CGP 37157 (7-chloro-5-(2-chlorophenyl)-1,5-dihydro4,1-benzothiazepin-2(3H)-one) that precludes the mitochondrial Na+/Ca2+ exchanger as well as by mitochondrial depolarization using a mixture of oligomycin and antimycin A. In contrast, after the removal of the agonist, ER refilling was found to be largely independent of trans-mitochondrial Ca2+ flux. Under these conditions, ER Ca2+ refilling took place even without an associated Ca2+ elevation in the deeper cytosol, thus, indicating that superficial ER domains mimic mitochondrial Ca2+ buffering and efficiently sequester subplasmalemmal Ca2+ and consequently facilitate capacitative Ca2+ entry. Hence, these data point to different contribution of mitochondria in the process of ER Ca2+ refilling based on the presence or absence of IP3, which represents the turning point for the dependence or autonomy of ER Ca2+ refilling from trans-mitochondrial Ca2+ flux.	Med Univ Graz, Ctr Mol Med, Dept Mol Biol & Biochem, A-8010 Graz, Austria; Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva, Switzerland	Medical University of Graz; University of Geneva	Graier, WF (corresponding author), Graz Univ, Dept Med Biochem & Med Mol Biol, Harrachgasse 21-3, A-8010 Graz, Austria.	wolfgang.graier@meduni-graz.at	Malli, Roland/B-7369-2008; Graier, Wolfgang F./B-7052-2008	Graier, Wolfgang F./0000-0003-1871-3298; Malli, Roland/0000-0001-6327-8729; Frieden, Maud/0000-0001-7135-0874				ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; CHEN Q, 1992, CAN J PHYSIOL PHARM, V70, P509, DOI 10.1139/y92-066; COX DA, 1993, J BIOL CHEM, V268, P938; COX DA, 1993, J CARDIOVASC PHARM, V21, P595, DOI 10.1097/00005344-199304000-00013; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Frieden M, 2000, J PHYSIOL-LONDON, V524, P715, DOI 10.1111/j.1469-7793.2000.00715.x; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; Frieden M, 2002, J PHYSIOL-LONDON, V540, P73, DOI 10.1113/jphysiol.2002.017053; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gilabert JA, 2001, EMBO J, V20, P2672, DOI 10.1093/emboj/20.11.2672; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; GROSCHNER K, 1994, CIRC RES, V75, P304, DOI 10.1161/01.RES.75.2.304; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; KWAN CY, 1990, J BIOL CHEM, V265, P678; Malli R, 2003, J BIOL CHEM, V278, P10807, DOI 10.1074/jbc.M212971200; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; NAZER MA, 1998, AM J PHYSIOL, pH123; Nilius B, 2003, CELL CALCIUM, V33, P293, DOI 10.1016/S0143-4160(03)00042-3; Nilius B, 2003, ENDOTHELIUM-J ENDOTH, V10, P5, DOI 10.1080/10623320303356; Nilius B, 1997, ANNU REV PHYSIOL, V59, P145, DOI 10.1146/annurev.physiol.59.1.145; NILIUS B, 2004, SCI STKE; Paltauf-Doburzynska J, 1999, CELL CALCIUM, V25, P345, DOI 10.1054/ceca.1999.0038; Paltauf-Doburzynska J, 1998, J PHYSIOL-LONDON, V513, P369, DOI 10.1111/j.1469-7793.1998.369bb.x; Parekh AB, 2003, NEWS PHYSIOL SCI, V18, P252, DOI 10.1152/nips.01458.2003; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney J W Jr, 1991, Adv Pharmacol, V22, P251, DOI 10.1016/S1054-3589(08)60037-X; Putney JW, 2001, NATURE, V410, P648, DOI 10.1038/35070704; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200; VANBREEMEN C, 1986, J CARDIOVASC PHARM, V8, pS111, DOI 10.1097/00005344-198600088-00023; VANBREEMEN C, 1995, TRENDS PHARMACOL SCI, V16, P98, DOI 10.1016/S0165-6147(00)88990-7; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200; Zoratti C, 2003, BRIT J PHARMACOL, V140, P1351, DOI 10.1038/sj.bjp.0705529	45	123	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12114	12122		10.1074/jbc.M409353200	http://dx.doi.org/10.1074/jbc.M409353200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15659398	hybrid			2022-12-25	WOS:000227922000008
J	Niimura, M; Isoo, N; Takasugi, N; Tsuruoka, M; Ui- Tei, K; Saigo, K; Morohashi, Y; Tomita, T; Iwatsubo, T				Niimura, M; Isoo, N; Takasugi, N; Tsuruoka, M; Ui- Tei, K; Saigo, K; Morohashi, Y; Tomita, T; Iwatsubo, T			Aph-1 contributes to the stabilization and trafficking of the gamma-secretase complex through mechanisms involving intermolecular and intramolecular interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE HELIX INTERACTIONS; ALZHEIMERS-DISEASE; MEMBRANE-PROTEINS; GXXXG MOTIF; C-TERMINUS; DROSOPHILA-MELANOGASTER; MUTANT PRESENILIN; PRECURSOR PROTEIN; RNA INTERFERENCE; BETA-APP	gamma-Secretase cleaves type I transmembrane proteins, including beta-amyloid precursor protein and Notch, and requires the formation of a protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2 for its activity. Aph-1 is implicated in the stabilization of this complex, although its precise mechanistic role remains unknown. Substitution of the first glycine within the transmembrane GXXXG motif of Aph-1 causes a loss-of-function phenotype in Caenorhabditis elegans. Here, using an untranslated region-targeted RNA interference/rescue strategy in Drosophila Schneider 2 cells, we show that Aph-1 contributes to the assembly of the gamma-secretase complex by multiple mechanisms involving intermolecular and intramolecular interactions depending on or independent of the conserved glycines. Aph-1 binds to nicastrin forming an early subcomplex independent of the conserved glycines within the endoplasmic reticulum. Certain mutations in the conserved GXXXG motif affect the interaction of the Aph-1(.)nicastrin subcomplex with presenilin that mediates trafficking of the presenilin(.)Aph-1(.)nicastrin tripartite complex to the Golgi. The same mutations decrease the stability of Aph-1 polypeptides themselves, possibly by affecting intramolecular associations through the transmembrane domains. Our data suggest that the proper assembly of the Aph-1(.)nicastrin subcomplex with presenilin is the prerequisite for the trafficking as well as the enzymatic activity of the gamma-secretase complex and that Aph-1 functions as a stabilizing scaffold in the assembly of this complex.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Tomita, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	taisuke@mol.f.u-tokyo.ac.jp; iwatsubo@mol.f.u-tokyo.ac.jp	Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943; TAKASUGI, NOBUMASA/0000-0002-6059-2082				Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; Celotto AM, 2002, RNA, V8, P718, DOI 10.1017/S1355838202021064; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; Dawson JP, 2003, J MOL BIOL, V331, P255, DOI 10.1016/S0022-2836(03)00714-9; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Edbauer D, 2004, J BIOL CHEM, V279, P37311, DOI 10.1074/jbc.M406228200; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Fortna RR, 2004, J BIOL CHEM, V279, P3685, DOI 10.1074/jbc.M310505200; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2004, J BIOL CHEM, V279, P31329, DOI 10.1074/jbc.M401548200; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Kaether C, 2004, EMBO J, V23, P4738, DOI 10.1038/sj.emboj.7600478; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Naito Y, 2004, NUCLEIC ACIDS RES, V32, pW124, DOI 10.1093/nar/gkh442; NATSUGARI H, 2003, J BIOL CHEM, V278, P18664; Nowotny P, 2000, MOL CELL NEUROSCI, V15, P88, DOI 10.1006/mcne.1999.0805; Nufer O, 2002, J CELL SCI, V115, P619; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Roignant JY, 2003, RNA, V9, P299, DOI 10.1261/rna.2154103; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schneider D, 2004, J MOL BIOL, V343, P799, DOI 10.1016/j.jmb.2004.08.083; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 2004, DRUG NEWS PERSPECT, V17, P321, DOI 10.1358/dnp.2004.17.5.829036; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	68	75	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12967	12975		10.1074/jbc.M409829200	http://dx.doi.org/10.1074/jbc.M409829200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15644323	hybrid			2022-12-25	WOS:000227922000106
J	Tandia, BM; Lonez, C; Vandenbranden, M; Ruysschaert, JM; Elouahabi, A				Tandia, BM; Lonez, C; Vandenbranden, M; Ruysschaert, JM; Elouahabi, A			Lipid mixing between lipoplexes and plasma lipoproteins is a major barrier for intravenous transfection mediated by cationic lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA LPD COMPLEXES; GENE-TRANSFER; IN-VIVO; MEMBRANE-FUSION; MOUSE LUNG; DELIVERY; EFFICIENCY; CELLS; EXPRESSION; SERUM	It has been previously shown that transfection activity of cationic liposome/DNA lipoplexes delivered systemically is drastically inhibited by lipoproteins (Tandia, B. M., Vandenbranden, M., Wattiez, R., Lakhdar, Z., Ruysschaert, J. M., and Elouahabi, A. (2003) Mol Ther. 8, 264 273). In this work, we have compared the binding/uptake and transfection activities of DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride) and diC14-amidine (3-tetradecylamino-N-tert-butyl-N'-tetradecylpropionamidine)-containing lipoplexes in the presence or absence of purified low density lipoproteins and high density lipoprotein. Binding/uptake of both lipoplexes by the mouse lung endothelial cell line was inhibited to a similar extent in the presence of lipoproteins. In contrast, transfection activity of diC14-amidine-containing lipoplexes was almost completely inhibited (approximately by 95%), whereas similar to 40% transfection activity of DOTAP-containing lipoplexes was preserved in the presence of lipoproteins. Interestingly, the ability of lipoproteins to inhibit the transfection efficiency of lipoplexes was well correlated with their ability to undergo lipid mixing with the cationic lipid bilayer as revealed by fluorescence resonance energy transfer assay. Incubation of lipoplexes with increased doses of lipoproteins resulted in enhanced lipid mixing and reduced transfection activity of the lipoplexes in mouse lung endothelial cells. The role of lipid mixing in transfection was further demonstrated using lipid-mixing inhibitor, lyso-phosphatidylcholine, or activator (dioleoylphosphatidylethanolamine). Incorporation of Lyso-PC into diC14-amidine-containing lipoplexes completely abolished their capacity to undergo lipid mixing with lipoproteins and allowed them to reach a high transfection efficiency in the presence of lipoproteins. On the other hand, the incorporation of dioleoylphosphatidylethanolamine into DOTAP/DNA lipoplex activated lipid mixing with the lipoproteins and was shown to be detrimental toward the transfection activity of these lipoplexes. Taken together, these results indicate that fusion of lipoplexes with lipoproteins is a limiting factor for in vivo transfection.	Free Univ Brussels, Lab Struct & Funct Biol Membranes, Ctr Struct Biol & Bioinformat, B-1050 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Ruysschaert, JM (corresponding author), Free Univ Brussels, Lab Struct & Funct Biol Membranes, Ctr Struct Biol & Bioinformat, CP 206-2,Campus Plaine,Blvd Triomphe, B-1050 Brussels, Belgium.	jmruyss@ulb.ac.be	Lonez, Caroline/D-3104-2014	Lonez, Caroline/0000-0002-9230-3855				BELLONI PN, 1992, MICROVASC RES, V43, P20, DOI 10.1016/0026-2862(92)90004-9; Bragonzi A, 2000, GENE THER, V7, P1753, DOI 10.1038/sj.gt.3301282; CHAPMAN MJ, 1981, J LIPID RES, V22, P339; ElOuahabi A, 1997, FEBS LETT, V414, P187, DOI 10.1016/S0014-5793(97)00973-3; Elouahabi A, 2003, MOL THER, V7, P81, DOI 10.1016/S1525-0016(02)00032-1; Fasbender A, 1997, GENE THER, V4, P716, DOI 10.1038/sj.gt.3300459; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; Imaoka T, 1998, HUM GENE THER, V9, P1093, DOI 10.1089/hum.1998.9.7-1093; Jenkins RG, 2000, GENE THER, V7, P393, DOI 10.1038/sj.gt.3301095; Li S, 1999, GENE THER, V6, P585, DOI 10.1038/sj.gt.3300865; Li S, 1998, GENE THER, V5, P930, DOI 10.1038/sj.gt.3300683; Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482; Liu F, 1997, GENE THER, V4, P517, DOI 10.1038/sj.gt.3300424; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; Mahato RI, 1998, HUM GENE THER, V9, P2083, DOI 10.1089/hum.1998.9.14-2083; Martin I, 1996, J VIROL, V70, P298, DOI 10.1128/JVI.70.1.298-304.1996; MARTIN I, 1995, BBA-BIOMEMBRANES, V1240, P95, DOI 10.1016/0005-2736(95)00171-4; McLean JW, 1997, AM J PHYSIOL-HEART C, V273, pH387, DOI 10.1152/ajpheart.1997.273.1.H387; Pector V, 2000, J BIOL CHEM, V275, P29533, DOI 10.1074/jbc.M909996199; RUYSSCHAERT JM, 1994, BIOCHEM BIOPH RES CO, V203, P1622, DOI 10.1006/bbrc.1994.2372; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Tandia BM, 2003, MOL THER, V8, P264, DOI 10.1016/S1525-0016(03)00150-3; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Uyechi LS, 2001, GENE THER, V8, P828, DOI 10.1038/sj.gt.3301461; WAKABAYASHI H, 1995, CANCER RES, V55, P4458; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zelphati O, 1998, BBA-LIPID LIPID MET, V1390, P119, DOI 10.1016/S0005-2760(97)00169-0	28	29	36	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12255	12261		10.1074/jbc.M414517200	http://dx.doi.org/10.1074/jbc.M414517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15661732	hybrid			2022-12-25	WOS:000227922000024
J	Yano, M; Okano, HJ; Okano, H				Yano, M; Okano, HJ; Okano, H			Involvement of Hu and heterogeneous nuclear ribonucleoprotein K in neuronal differentiation through p21 mRNA post-transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELAV-LIKE PROTEIN; HNRNP-K; CELL-PROLIFERATION; BINDING PROTEINS; PC12 CELLS; CYTOPLASMIC POLYADENYLATION; ERYTHROID-DIFFERENTIATION; 3'-UNTRANSLATED REGION; P21(WAF1) EXPRESSION; KINASE-ACTIVITY	The Hu family is a group of neuronal RNA-binding proteins required for neuronal differentiation in the developing nervous system. Previously, Hu proteins have been shown to enhance the stabilization and/or translation of target mRNAs, such as p21 ( CIP1), by binding to AU-rich elements in untranslated regions ( UTRs). In this study, we show that Hu induces p21 expression, cell cycle arrest, and neuronal differentiation in mouse neuroblastoma N1E-115 cells. p21 expression is also up-regulated during Me2SO- induced differentiation in N1E-115 cells and is controlled by post-transcriptional mechanisms through its 3'-UTR. To investigate the molecular mechanisms of Hu functions, we used a proteomics strategy to isolate Hu-interacting proteins and identified heterogeneous nuclear ribonucleoprotein (hnRNP) K. hnRNP K also specifically binds to CU-rich sequences in p21 mRNA 3'-UTR and represses its translation in both nonneuronal and neuronal cells. Further, using RNA interference experiments, we show that the Hu-p21 pathway contributes to the regulation of neurite outgrowth and proliferation in N1E-115 cells, and this pathway is antagonized by hnRNP K. Our results suggest a model in which the mutually antagonistic action of two RNA-binding proteins, Hu and hnRNP K, control the timing of the switch from proliferation to neuronal differentiation through the post-transcriptional regulation of p21 mRNA.	Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; CREST JST, Tokyo 1608582, Japan; Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci A1, Suita, Osaka 5650871, Japan	Keio University; Japan Science & Technology Agency (JST); Osaka University	Okano, HJ (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hjokano@sc.itc.keio.ac.jp	Okano, Hideyuki/I-7584-2019; Yano, Masato/L-1299-2013	Yano, Masato/0000-0003-0589-478X; Okano, Hirotaka James/0000-0003-4611-7098				Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Aranda-Abreu GE, 1999, J NEUROSCI, V19, P6907, DOI 10.1523/JNEUROSCI.19-16-06907.1999; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; Charroux B, 1999, MOL CELL BIOL, V19, P7846, DOI 10.1128/mcb.19.11.7846; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; Darnell Robert B., 2002, Cell, V110, P545, DOI 10.1016/S0092-8674(02)00937-6; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOHNE M, 1988, BIOMED BIOCHIM ACTA, V47, P75; HOMYK T, 1985, J NEUROGENET, V2, P309, DOI 10.3109/01677068509102326; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Kasashima K, 1999, GENES CELLS, V4, P667, DOI 10.1046/j.1365-2443.1999.00292.x; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okabe M, 2001, NATURE, V411, P94, DOI 10.1038/35075094; Okano H, 2002, J CELL SCI, V115, P1355; Okano HJ, 1997, J NEUROSCI, V17, P3024; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Ostrowski J, 2003, BRIT J CANCER, V89, P1493, DOI 10.1038/sj.bjc.6601250; Ostrowski J, 2002, J BIOL CHEM, V277, P6303, DOI 10.1074/jbc.M110267200; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SAKAI K, 1994, BIOCHEM BIOPH RES CO, V199, P1200, DOI 10.1006/bbrc.1994.1358; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; van der Giessen K, 2003, J BIOL CHEM, V278, P47119, DOI 10.1074/jbc.M308889200; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000	54	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12690	12699		10.1074/jbc.M411119200	http://dx.doi.org/10.1074/jbc.M411119200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15671036	hybrid			2022-12-25	WOS:000227922000076
J	Appelbaum, L; Anzulovich, A; Baler, R; Gothilf, Y				Appelbaum, L; Anzulovich, A; Baler, R; Gothilf, Y			Homeobox-clock protein interaction in zebrafish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN-N-ACETYLTRANSFERASE; EUKARYOTIC CIRCADIAN SYSTEMS; E-BOX; PINEAL-GLAND; MELATONIN SYNTHESIS; GENE; TRANSCRIPTION; CRX; EXPRESSION; PROMOTER	In non-mammalian vertebrates, the pineal gland is photoreceptive and contains an intrinsic circadian oscillator that drives rhythmic production and secretion of melatonin. These features require an accurate spatiotemporal expression of an array of specific genes in the pineal gland. Among these is the arylalkylamine N-acetyltransferase, a key enzyme in the melatonin production pathway. In zebrafish, pineal specificity of zfaanat2 is determined by a region designated the pineal-restrictive downstream module (PRDM), which contains three photoreceptor conserved elements (PCEs) and an E-box, elements that are generally associated with photoreceptor-specific and rhythmic expression, respectively. Here, by using in vivo and in vitro approaches, it was found that the PCEs and E-box of the PRDM mediate a synergistic effect of the photoreceptor-specific homeobox OTX5 and rhythmically expressed clock protein heterodimer, BMAL/CLOCK, on zfaanat2 expression. Furthermore, the distance between the PCEs and the E-box was found to be critical for PRDM function, suggesting a possible physical feature of this synergistic interaction. OTX5-BMAL/CLOCK may act through this mechanism to simultaneously control pineal-specific and rhythmic expression of zfaanat2 and possibly also other pineal and retinal genes.	Tel Aviv Univ, Dept Zool, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel; Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; NIMH, Unit Temporal Gene Express, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Tel Aviv University; Bar Ilan University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Gothilf, Y (corresponding author), Tel Aviv Univ, Dept Zool, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel.	yoavg@tauex.tau.ac.il		Gothilf, Yoav/0000-0002-6054-4128; Anzulovich, Ana/0000-0001-6989-7168				Appelbaum L, 2004, MOL ENDOCRINOL, V18, P1210, DOI 10.1210/me.2003-0439; ARENDT J, 1995, MELATONIN MAMMALIAN, P27; Baler R, 1999, BIOL CELL, V91, P699, DOI 10.1016/S0248-4900(00)88533-0; Begay V, 1998, ENDOCRINOLOGY, V139, P905, DOI 10.1210/en.139.3.905; Bernard M, 1997, P NATL ACAD SCI USA, V94, P304, DOI 10.1073/pnas.94.1.304; Burke Z, 1999, J NEUROCHEM, V73, P1343, DOI 10.1046/j.1471-4159.1999.0731343.x; Cahill GM, 2002, CELL TISSUE RES, V309, P27, DOI 10.1007/s00441-002-0570-7; Cau E, 2003, DEVELOPMENT, V130, P2455, DOI 10.1242/dev.00452; Cermakian N, 2000, P NATL ACAD SCI USA, V97, P4339, DOI 10.1073/pnas.97.8.4339; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Chen W, 2000, MOL BRAIN RES, V81, P43, DOI 10.1016/S0169-328X(00)00160-1; Chong NW, 2000, J BIOL CHEM, V275, P32991, DOI 10.1074/jbc.M005671200; Coon SL, 1999, J BIOL CHEM, V274, P9076, DOI 10.1074/jbc.274.13.9076; Dunlap JC, 1999, GENES CELLS, V4, P1, DOI 10.1046/j.1365-2443.1999.00239.x; Dunlap JC, 1998, CURR OPIN GENET DEV, V8, P400, DOI 10.1016/S0959-437X(98)80109-3; Ekstrom P, 2003, PHILOS T R SOC B, V358, P1679, DOI 10.1098/rstb.2003.1303; Falcon J, 1999, PROG NEUROBIOL, V58, P121, DOI 10.1016/S0301-0082(98)00078-1; Falcon J, 2003, J NEUROENDOCRINOL, V15, P378, DOI 10.1046/j.1365-2826.2003.00993.x; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Gamse JT, 2002, NAT GENET, V30, P117, DOI 10.1038/ng793; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; Gothilf Y, 2002, DEV DYNAM, V225, P241, DOI 10.1002/dvdy.10152; Gothilf Y, 1999, ENDOCRINOLOGY, V140, P4895, DOI 10.1210/en.140.10.4895; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Ishikawa T, 2002, GENES CELLS, V7, P1073, DOI 10.1046/j.1365-2443.2002.00579.x; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; Klein DC, 2004, J BIOL RHYTHM, V19, P264, DOI 10.1177/0748730404267340; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kyriacou CP, 2000, J BIOL RHYTHM, V15, P483, DOI 10.1177/074873000129001594; Lee SK, 2003, NEURON, V38, P731, DOI 10.1016/S0896-6273(03)00296-4; Li XD, 1998, P NATL ACAD SCI USA, V95, P1876, DOI 10.1073/pnas.95.4.1876; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Munoz E, 2003, CHRONOBIOL INT, V20, P371, DOI 10.1081/CBI-120022525; Munoz E, 2002, J BIOL CHEM, V277, P36009, DOI 10.1074/jbc.M203909200; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Pando MP, 2002, BIOESSAYS, V24, P419, DOI 10.1002/bies.10091; Plouhinec JL, 2003, MOL BIOL EVOL, V20, P513, DOI 10.1093/molbev/msg085; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; Tamai TK, 2003, J NEUROENDOCRINOL, V15, P344; Tauber E, 2004, J BIOL RHYTHM, V19, P445, DOI 10.1177/0748730404268775; Triqueneaux G, 2004, J MOL ENDOCRINOL, V33, P585, DOI 10.1677/jme.1.01554; Westerman BA, 2003, BBA-GENE STRUCT EXPR, V1629, P1, DOI 10.1016/j.bbaexp.2003.08.002; Whitaker SL, 2004, J BIOL CHEM, V279, P49010, DOI 10.1074/jbc.M406080200; Whitmore D, 1998, NAT NEUROSCI, V1, P701, DOI 10.1038/3703; Whitmore D, 2000, NATURE, V404, P87, DOI 10.1038/35003589; Zilberman-Peled B, 2004, GEN COMP ENDOCR, V138, P139, DOI 10.1016/j.ygcen.2004.05.007	49	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11544	11551		10.1074/jbc.M412935200	http://dx.doi.org/10.1074/jbc.M412935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657039	hybrid			2022-12-25	WOS:000227761800080
J	Kato, Y; Lambert, CA; Colige, AC; Mineur, P; Noel, A; Frankenne, F; Foidart, JM; Baba, M; Hata, R; Miyazaki, K; Tsukuda, M				Kato, Y; Lambert, CA; Colige, AC; Mineur, P; Noel, A; Frankenne, F; Foidart, JM; Baba, M; Hata, R; Miyazaki, K; Tsukuda, M			Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase D-mitogen-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; HUMAN PANCREATIC ADENOCARCINOMA; IV COLLAGENASE EXPRESSION; INTERLEUKIN-8 EXPRESSION; IN-VITRO; MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTORS; CANCER-CELLS; SPHINGOSINE 1-PHOSPHATE; CULTURE-CONDITIONS	The extracellular pH (pHe) of tumor tissues is often acidic, which can induce the expression of several proteins. We previously showed that production of matrix metalloproteinase-9 (MMP-9) was induced by culturing cells at acidic pHe (5.4-6.5). Here we have investigated the signal transduction pathway by which acidic pHe induces MMP-9 expression. We found that acidic pHe (5.9) activated phospholipase D (PLD), and inhibition of PLD activity by 1-butanol and Myr-ARF6 suppressed the acidic pHe-induced MMP-9 expression. Exogenous PLD, but not phosphatidylinositol-specific PLC or PLA(2), mimicked MMP-9 induction by acidic pHe. Western blot analysis revealed that acidic pHe increased the steady-state levels of phosphorylated extracellular signal-regulated kinases 1/2 and p38 and that the PLD inhibitors suppressed these increases. Using 5'-deletion mutant constructs of the MMP-9 promoter, we found that the acidic pHe-responsive region was located at nucleotide -670 to -531, a region containing the NF kappa B binding site. A mutation into the NF kappa B binding site reduced, but not completely, the acidic pHe- induced MMP-9 promoter activity, pand NF kappa B activity was induced by acidic pHe. Pharmacological inhibitors specific for mitogen-activated protein kinase kinase 1/2 (PD098059) and p38 (SB203580) attenuated the acidic pHe- induced NF kappa B activity and MMP-9 expression. These data suggest that PLD, mitogen-activated protein kinases (extracellular signal-regulated kinases 1/2 and p38), and NF kappa B mediate the acidic pHe signaling to induce MMP-9 expression. A transcription factor(s) other than NF kappa B may also be involved in the MMP-9 expression.	Kanagawa Dent Coll, Dept Biochem & Mol Biol, Yokosuka, Kanagawa 2388580, Japan; Yokohama City Univ, Grad Sch Med, Dept Otolaryngol, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Grad Sch Med, Dept Urol, Yokohama, Kanagawa 2360004, Japan; Univ Liege, B-4000 Cointe Ougree, Belgium; Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Yokohama, Kanagawa 2440813, Japan	Kanagawa Dental College; Yokohama City University; Yokohama City University; University of Liege; Yokohama City University	Kato, Y (corresponding author), Kanagawa Dent Coll, Dept Biochem & Mol Biol, Yokosuka, Kanagawa 2388580, Japan.	yasumasa@kdcnet.ac.jp	Baba, Masaya/ABE-4893-2020; Baba, Masaya/L-7490-2013; Kato, Yasumasa/H-5312-2012	Baba, Masaya/0000-0002-5308-6683; Kato, Yasumasa/0000-0003-0192-9324; Noel, Agnes/0000-0002-7670-6179				Attiga FA, 2000, CANCER RES, V60, P4629; Baba Y, 2000, CLIN EXP METASTAS, V18, P273, DOI 10.1023/A:1006798900743; Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; Bechoua S, 2001, J BIOL CHEM, V276, P31752, DOI 10.1074/jbc.M101265200; Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Cummings RJ, 2002, J BIOL CHEM, V277, P30227, DOI 10.1074/jbc.M111078200; Eberhardt W, 2002, MOL ENDOCRINOL, V16, P1752, DOI 10.1210/me.2001-0278; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Fukumura D, 2001, CANCER RES, V61, P6020; Griffiths L, 1997, CANCER RES, V57, P570; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Helmlinger G, 2002, CLIN CANCER RES, V8, P1284; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; Hong JH, 2001, BIOCHEM BIOPH RES CO, V281, P1337, DOI 10.1006/bbrc.2001.4517; Hu QH, 2002, BIOCHEM BIOPH RES CO, V292, P325, DOI 10.1006/bbrc.2002.6675; Hwang YS, 2004, ONCOGENE, V23, P6603, DOI 10.1038/sj.onc.1207867; Ieda Y, 2001, RHEUMATOL INT, V21, P45; KATO Y, 1992, J BIOL CHEM, V267, P11424; Kato Y, 1996, CELL BIOL INT, V20, P375, DOI 10.1006/cbir.1996.0044; Kato Y, 1998, EUR J CANCER, V34, P1117, DOI 10.1016/S0959-8049(98)00077-X; Kato Y, 2001, BIOCHEM BIOPH RES CO, V287, P422, DOI 10.1006/bbrc.2001.5622; Kato Y, 1996, J STEROID BIOCHEM, V57, P349, DOI 10.1016/0960-0760(95)00280-4; Kozin SV, 2001, CANCER RES, V61, P4740; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lakka SS, 2002, ONCOGENE, V21, P5601, DOI 10.1038/sj.onc.1205646; Lambert CA, 2001, MATRIX BIOL, V20, P397, DOI 10.1016/S0945-053X(01)00156-1; Le Stunff H, 2000, BIOCHEM J, V352, P491, DOI 10.1042/0264-6021:3520491; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Moon Y, 2002, TOXICOL SCI, V69, P373, DOI 10.1093/toxsci/69.2.373; Roebuck KA, 1999, J LEUKOCYTE BIOL, V65, P291, DOI 10.1002/jlb.65.3.291; ROTIN D, 1986, CANCER RES, V46, P2821; SATO H, 1993, ONCOGENE, V8, P395; Shi Q, 2000, J INTERF CYTOK RES, V20, P1023, DOI 10.1089/10799900050198471; Shi Q, 1999, CLIN CANCER RES, V5, P3711; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Simon C, 1998, CANCER RES, V58, P1135; Simon C, 1999, BRIT J CANCER, V80, P1412, DOI 10.1038/sj.bjc.6690537; Tanaka T, 2000, J MOL CELL CARDIOL, V32, P1955, DOI 10.1006/jmcc.2000.1228; TANNOCK IF, 1989, CANCER RES, V49, P4373; Vogt A, 2002, MOL CANCER THER, V1, P885; Vukovic V, 1997, BRIT J CANCER, V75, P1167, DOI 10.1038/bjc.1997.201; Wakelam MJO, 1997, ADV ENZYME REGUL, V37, P29, DOI 10.1016/S0065-2571(96)00023-4; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; Xiong QH, 2001, J INTERF CYTOK RES, V21, P529, DOI 10.1089/10799900152434411; Xu L, 2002, J BIOL CHEM, V277, P11368, DOI 10.1074/jbc.M108347200; Xu L, 2000, CANCER RES, V60, P4610; Yamagata M, 1996, BRIT J CANCER, V73, P1328, DOI 10.1038/bjc.1996.254; Yamagata M, 1998, BRIT J CANCER, V77, P1726, DOI 10.1038/bjc.1998.289; Zamorano J, 2003, J IMMUNOL, V171, P4203, DOI 10.4049/jimmunol.171.8.4203	51	122	134	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10938	10944		10.1074/jbc.M411313200	http://dx.doi.org/10.1074/jbc.M411313200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657063	hybrid, Green Submitted			2022-12-25	WOS:000227761800009
J	Raina, D; Pandey, P; Ahmad, R; Bharti, A; Ren, J; Kharbanda, S; Weichselbaum, R; Kufe, D				Raina, D; Pandey, P; Ahmad, R; Bharti, A; Ren, J; Kharbanda, S; Weichselbaum, R; Kufe, D			c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELLULAR-RESPONSE; FUNCTIONAL INTERACTION; APAF-1; OLIGOMERIZATION; INHIBITION; PROCASPASE-9; APOPTOSOME; INDUCTION; LETHALITY	Activation of the initiator caspase- 9 is essential for induction of apoptosis by developmental signals, oncogenic transformation, and genotoxic stress. The c- Abl tyrosine kinase is also involved in the apoptotic response to DNA damage. The present results demonstrate that c- Abl binds directly to caspase- 9. We show that cAbl phosphorylates caspase- 9 on Tyr- 153 in vitro and in cells treated with DNA damaging agents. Moreover, inhibition of c- Abl with STI571 blocked DNA damage- induced autoprocessing of caspase- 9 to the p35 subunit and activation of caspase- 3. Caspase- 9( Y153F) also attenuated DNA damage- induced processing of caspase- 9 to p35, activation of caspase- 3, and apoptosis. These findings indicate that caspase- 9 autoprocessing is regulated by c- Abl in the apoptotic response to genotoxic stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Univ Chicago, Sch Med, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Agami R, 1999, NATURE, V399, P809; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Fesik SW, 2001, SCIENCE, V294, P1477, DOI 10.1126/science.1062236; Gong JG, 1999, NATURE, V399, P806; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Raina D, 2002, MOL PHARMACOL, V61, P1489, DOI 10.1124/mol.61.6.1489; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	39	46	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11147	11151		10.1074/jbc.M413787200	http://dx.doi.org/10.1074/jbc.M413787200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657060	hybrid			2022-12-25	WOS:000227761800035
J	Wu, WWH; Wong, JP; Kast, J; Molday, RS				Wu, WWH; Wong, JP; Kast, J; Molday, RS			RS1, a discoidin domain-containing retinal cell adhesion protein associated with X-linked retinoschisis, exists as a novel disulfide-linked octamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VIII; C2 DOMAIN; PHOTORECEPTOR; EXPRESSION; GENE; MUTATIONS; BIPOLAR	RS1, also known as retinoschisin, is an extracellular protein that plays a crucial role in the cellular organization of the retina. Mutations in RS1 are responsible for X-linked retinoschisis, a common, early-onset macular degeneration in males that results in a splitting of the inner layers of the retina and severe loss in vision. RS1 is assembled and secreted from photoreceptors and bipolar cells as a homo-oligomeric protein complex. Each subunit consists of a 157-amino acid discoidin domain flanked by two small segments of 39 and 5 amino acids. To begin to understand how the structure of RS1 relates to its role in retinal cell adhesion and X-linked retinoschisis, we have determined the subunit organization and disulfide bonding pattern of RS1 by SDS gel electrophoresis, velocity sedimentation, and mass spectrometry. Our results indicate that RS1 exists as a novel octamer in which the eight subunits are joined together by Cys(59)-Cys(223) intermolecular disulfide bonds. Subunits within the octamer are further organized into dimers mediated by Cys(40)-Cys(40) bonds. These cysteines lie just outside the discoidin domain indicating that these flanking segments primarily function in the octamerization of RS1. Within the discoidin domain, two cysteine pairs (Cys(63)-Cys(219) and Cys(110)-Cys(142)) form intramolecular disulfide bonds that are important in protein folding, and one cysteine (Cys(83)) exists in its reduced state. Because mutations that disrupt subunit assembly cause X-linked retinoschisis, the assembly of RS1 into a disulfide-linked homo-octamer appears to be critical for its function as a retinal cell adhesion protein.	Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Ctr Macular Res, Dept Ophthalmol & Visual Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Ctr Biomed Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	molday@interchange.ubc.ca			NEI NIH HHS [EY 02422] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1998, Hum Mol Genet, V7, P1185; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Fraternali F, 2003, FEBS LETT, V544, P21, DOI 10.1016/S0014-5793(03)00433-2; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; GEORGE NDL, 1995, BRIT J OPHTHALMOL, V79, P697, DOI 10.1136/bjo.79.7.697; Grayson C, 2000, HUM MOL GENET, V9, P1873, DOI 10.1093/hmg/9.12.1873; Hiriyanna KT, 1999, HUM MUTAT, V14, P423, DOI 10.1002/(SICI)1098-1004(199911)14:5<423::AID-HUMU8>3.0.CO;2-D; Hvarregaard J, 1996, EUR J BIOCHEM, V240, P628, DOI 10.1111/j.1432-1033.1996.0628h.x; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Matese JC, 1997, DEV BIOL, V186, P16, DOI 10.1016/S0012-1606(97)98585-7; Molday LL, 2001, INVEST OPHTH VIS SCI, V42, P816; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Reid SNM, 1999, GENE, V227, P257, DOI 10.1016/S0378-1119(98)00578-2; Reid SNM, 2003, J NEUROSCI, V23, P6030, DOI 10.1523/JNEUROSCI.23-14-06030.2003; Sauer CG, 1997, NAT GENET, V17, P164, DOI 10.1038/ng1097-164; See Y., 1989, PROTEIN STRUCTURE PR, P1; Shur BD, 2004, CURR OPIN CELL BIOL, V16, P477, DOI 10.1016/j.ceb.2004.07.005; SIEVING PA, 1998, GENETIC DIS EYE; Tantri A, 2004, SURV OPHTHALMOL, V49, P214, DOI 10.1016/j.survophthal.2003.12.007; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Wang T, 2002, HUM MOL GENET, V11, P3097, DOI 10.1093/hmg/11.24.3097; Weber BHF, 2002, P NATL ACAD SCI USA, V99, P6222, DOI 10.1073/pnas.092528599; Wu WWH, 2003, J BIOL CHEM, V278, P28139, DOI 10.1074/jbc.M302464200; Yamakawa M, 1999, DEV COMP IMMUNOL, V23, P281, DOI 10.1016/S0145-305X(99)00011-7	25	88	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10721	10730		10.1074/jbc.M413117200	http://dx.doi.org/10.1074/jbc.M413117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644328	hybrid			2022-12-25	WOS:000227559600118
J	McEwen, E; Kedersha, N; Song, BB; Scheuner, D; Gilks, N; Han, AP; Chen, JJ; Anderson, P; Kaufman, RJ				McEwen, E; Kedersha, N; Song, BB; Scheuner, D; Gilks, N; Han, AP; Chen, JJ; Anderson, P; Kaufman, RJ			Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces stress granule formation, and mediates survival upon arsenite exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; GENE-EXPRESSION; IN-VIVO; RNA; EIF-2-ALPHA; MECHANISMS; METALLOTHIONEIN; ACCUMULATION; ACTIVATION; CELLS	Exposure to arsenite inhibits protein synthesis and activates multiple stress signaling pathways. Although arsenite has diverse effects on cell metabolism, we demonstrated that phosphorylation of eukaryotic translation initiation factor 2 at Ser-51 on the alpha subunit was necessary to inhibit protein synthesis initiation in arsenite-treated cells and was essential for stress granule formation. Of the four protein kinases known to phosphorylate eukaryotic translation initiation factor 2 alpha, only the heme-regulated inhibitor kinase (HRI) was required for the translational inhibition in response to arsenite treatment in mouse embryonic fibroblasts. In addition, HRI expression was required for stress granule formation and cellular survival after arsenite treatment. In vivo studies elucidated a fundamental requirement for HRI in murine survival upon acute arsenite exposure. The results demonstrated an essential role for HRI in mediating arsenite stress-induced phosphorylation of eukaryotic translation initiation factor 2 alpha, inhibition of protein synthesis, stress granule formation, and survival.	Univ Michigan, Ctr Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts Institute of Technology (MIT)	Kaufman, RJ (corresponding author), Univ Michigan, Ctr Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.	kaufmanr@umich.edu	Farny, Natalie/ABD-4468-2020	Farny, Natalie/0000-0003-1143-4560	NIAID NIH HHS [R56 AI033600] Funding Source: Medline; NIDDK NIH HHS [R01 DK 16272, R01 DK016272, R01 DK42394] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI033600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042394, R01DK016272] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; *AG TOX SUBST DIS, 2003, TOX SUBST DIS REG; Anderson P, 2002, J CELL SCI, V115, P3227; BAUMAN JW, 1993, FUND APPL TOXICOL, V21, P15, DOI 10.1006/faat.1993.1066; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; Bredfeldt TG, 2004, TOXICOL APPL PHARM, V198, P412, DOI 10.1016/j.taap.2003.10.013; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; Cheng HYY, 2004, ONCOGENE, V23, P3603, DOI 10.1038/sj.onc.1207466; CROSBY JS, 1994, MOL CELL BIOL, V14, P3906, DOI 10.1128/MCB.14.6.3906; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; FEUSSNER JR, 1979, BLOOD, V53, P820; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hayashi T, 2003, BRIT J HAEMATOL, V120, P10, DOI 10.1046/j.1365-2141.2003.03929.x; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hogan B, 1994, MANIPULATING MOUSE E; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2002, MOL BIOL CELL, V13, P195, DOI 10.1091/mbc.01-05-0221; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kimball SR, 2003, AM J PHYSIOL-CELL PH, V284, pC273, DOI 10.1152/ajpcell.00314.2002; KREPPEL H, 1993, FUND APPL TOXICOL, V20, P184, DOI 10.1006/faat.1993.1025; Liu J, 2001, TOXICOL SCI, V61, P314, DOI 10.1093/toxsci/61.2.314; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; MELLOR H, 1994, BBA-GENE STRUCT EXPR, V1219, P693, DOI 10.1016/0167-4781(94)90229-1; MORSE BS, 1980, AM J HEMATOL, V8, P273, DOI 10.1002/ajh.2830080305; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; NOVER L, 1983, MOL CELL BIOL, V3, P1648, DOI 10.1128/MCB.3.9.1648; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; THOMPSON DJ, 1993, CHEM-BIOL INTERACT, V88, P89, DOI 10.1016/0009-2797(93)90086-E; Tseng CH, 2004, TOXICOL APPL PHARM, V197, P67, DOI 10.1016/j.taap.2004.02.009; WESTHOFF DD, 1975, BLOOD, V45, P241; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	53	275	282	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16925	16933		10.1074/jbc.M412882200	http://dx.doi.org/10.1074/jbc.M412882200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15684421	hybrid			2022-12-25	WOS:000228615500047
J	Shivji, M; Burger, S; Moncada, CA; Clarkson, AB; Merali, S				Shivji, M; Burger, S; Moncada, CA; Clarkson, AB; Merali, S			Effect of nicotine on lung S-adenosylmethionine and development of Pneumocystis pneumonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LUNG; ORNITHINE DECARBOXYLASE ACTIVITY; ADENOSYL-L-METHIONINE; CARINII-PNEUMONIA; ALPHA-DIFLUOROMETHYLORNITHINE; N-METHYLTRANSFERASE; SULFA RESISTANCE; AMOEBA-PROTEUS; HIV; INHIBITION	Because S-adenosylmethionine ( AdoMet) is required by Pneumocystis carinii in vitro, Pneumocystis infection depletes plasma AdoMet of rats and humans, nicotine reduces AdoMet of guinea pig lungs, and smoking correlates with reduced episodes of Pneumocystis pneumonia (PCP) in AIDS patients, we tested the effect of nicotine treatment on PCP using a rat model. Intraperitoneal infusion of 400 mu g of R-(+) nicotine kg(-1) h(-1) intraperitoneal for 21 days caused a 15-fold reduction in lung AdoMet although neither plasma nor liver were changed. Infusion of 4 and 400 mu g kg(-1) h(-1) into immunosuppressed rats, beginning when rats were inoculated with P. carinii, caused 85 and 99.88% reductions, respectively, in P. carinii cysts at sacrifice 21 days later; P. carinii nuclei were reduced by 91.2 and >99.99%, respectively. This effect was reversed by concomitant administration of AdoMet with nicotine. Treatment with AdoMet alone increased infection intensity. We conclude that AdoMet is a critical and limiting nutrient for Pneumocystis thus can serve as a therapeutic target for PCP. Regarding the mechanism, nicotine treatment caused no change in rat lung activity of AdoMet synthesizing methionine ATP transferase activity nor was there any evidence of increased AdoMet utilization for methylation reactions. Except of a doubling of putrescine, nicotine treatment also did not change lung polyamine content. However, key polyamine anabolic and catabolic enzymes were up-regulated, and there were corresponding changes in polyamine metabolic intermediates. We conclude that chronic nicotine treatment increases lung polyamine catabolic/anabolic cycling and/or excretion leading to increased AdoMet-consuming polyamine biosynthesis and depletion of lung AdoMet.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA	New York University	Merali, S (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, 341 E 25th St, New York, NY 10010 USA.	merals01@popmail.med.nyu.edu	Moncada, Camilo/L-7468-2018; Burger, Sálmar/ABH-3418-2021; Moncada-Benavides, Camilo/B-9407-2009	Moncada, Camilo/0000-0001-9458-5684; 	PHS HHS [R01A141947, R01A1064017] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKUBUE PI, 1966, J PHARM PHARMACOL, V18, P625, DOI 10.1111/j.2042-7158.1966.tb07946.x; Andersson JO, 1999, MOL BIOL EVOL, V16, P1178, DOI 10.1093/oxfordjournals.molbev.a026208; Ayers JT, 2002, BIOORG MED CHEM LETT, V12, P3067, DOI 10.1016/S0960-894X(02)00687-X; BENOWITZ NL, 1994, CLIN PHARMACOL THER, V56, P483, DOI 10.1038/clpt.1994.169; Chopra S, 1998, BIOCHEM PHARMACOL, V55, P1119, DOI 10.1016/S0006-2952(97)00601-1; Conley LJ, 1996, AIDS, V10, P1121, DOI 10.1097/00002030-199609000-00010; Crooks PA, 2004, BIOORG MED CHEM LETT, V14, P1869, DOI 10.1016/j.bmcl.2003.10.074; CUNDY KC, 1985, BIOCHEM PHARMACOL, V34, P281, DOI 10.1016/0006-2952(85)90137-6; CUNDY KC, 1985, BIOCHEM BIOPH RES CO, V128, P312, DOI 10.1016/0006-291X(85)91680-8; Deresinski S C, 1997, Semin Respir Infect, V12, P79; Ehrlich M, 2003, J CELL BIOCHEM, V88, P899, DOI 10.1002/jcb.10464; ELORANTA TO, 1984, BIOCHEM J, V224, P137, DOI 10.1042/bj2240137; Fisk DT, 2003, CLIN INFECT DIS, V36, P70, DOI 10.1086/344951; Fukada A, 2002, J PHARMACOL EXP THER, V302, P532, DOI 10.1124/jpet.102.034629; GERNER EW, 1993, BIOCHEM J, V294, P491, DOI 10.1042/bj2940491; GODIN CS, 1986, J PHARM SCI, V75, P949, DOI 10.1002/jps.2600751007; GODIN CS, 1986, TOXICOL LETT, V31, P23, DOI 10.1016/0378-4274(86)90190-6; Graham SM, 2003, PEDIATR PULM, V36, P462, DOI 10.1002/ppul.10343; Heby O, 1988, Adv Exp Med Biol, V250, P291; Jeon TJ, 2004, J CELL SCI, V117, P535, DOI 10.1242/jcs.00894; Jeon TJ, 2003, J EUKARYOT MICROBIOL, V50, P61, DOI 10.1111/j.1550-7408.2003.tb00107.x; Jones J L, 1999, MMWR CDC Surveill Summ, V48, P1; Jones JL, 1998, J INFECT DIS, V178, P114, DOI 10.1086/515593; Kazanjian PH, 2004, J INFECT DIS, V189, P1684, DOI 10.1086/382957; Kessl JJ, 2004, J BIOL CHEM, V279, P2817, DOI 10.1074/jbc.M309984200; Konu O, 2004, MOL BRAIN RES, V121, P102, DOI 10.1016/j.molbrainres.2003.11.012; Larson P. S., 1961, TOBACCO EXPT CLIN ST; Levin ED, 2002, CNS NEUROL DISORD-DR, V1, P423, DOI 10.2174/1568007023339102; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev; Merali S, 2000, J BIOL CHEM, V275, P14958, DOI 10.1074/jbc.275.20.14958; Merali S, 1999, P NATL ACAD SCI USA, V96, P2402, DOI 10.1073/pnas.96.5.2402; Merali S, 1999, J BIOL CHEM, V274, P21017, DOI 10.1074/jbc.274.30.21017; Merali S, 1996, J CHROMATOGR B, V675, P321, DOI 10.1016/0378-4347(95)00363-0; Merali S, 1996, ANTIMICROB AGENTS CH, V40, P973, DOI 10.1128/AAC.40.4.973; MERALI S, 1995, ANTIMICROB AGENTS CH, V39, P1442, DOI 10.1128/AAC.39.7.1442; Miguez-Burbano MJ, 2003, ADDICT BIOL, V8, P39, DOI 10.1080/1355621031000069864; Mihailescu S, 2000, ACTA PHARMACOL SIN, V21, P97; Nahimana A, 2003, EMERG INFECT DIS, V9, P864; Navin TR, 2001, LANCET, V358, P545, DOI 10.1016/S0140-6736(01)05705-1; Newhouse PA, 2001, BIOL PSYCHIAT, V49, P268, DOI 10.1016/S0006-3223(00)01069-6; OLSON JW, 1985, LIFE SCI, V37, P2165, DOI 10.1016/0024-3205(85)90567-3; OLSON JW, 1985, CARCINOGENESIS, V6, P1517, DOI 10.1093/carcin/6.10.1517; Palmer ME, 2001, RAPID COMMUN MASS SP, V15, P224, DOI 10.1002/1097-0231(20010215)15:3<224::AID-RCM213>3.3.CO;2-Q; Persson L, 1988, Adv Exp Med Biol, V250, P261; POOL WF, 1986, DRUG METAB DISPOS, V14, P574; Pulvirenti J, 2003, AIDS PATIENT CARE ST, V17, P261, DOI 10.1089/108729103322108139; Robberts F J L, 2002, SADJ, V57, P451; SAAH AJ, 1995, JAMA-J AM MED ASSOC, V273, P1197, DOI 10.1001/jama.273.15.1197; SATO M, 1985, DRUG METAB DISPOS, V13, P348; SHIVAPURKAR N, 1983, CARCINOGENESIS, V4, P1051, DOI 10.1093/carcin/4.8.1051; Skelly M, 2003, LANCET, V361, P1267, DOI 10.1016/S0140-6736(03)12984-4; TABIB A, 1998, METHOD MOL BIOL, V79, P41; Thomas GAO, 2000, POSTGRAD MED J, V76, P273, DOI 10.1136/pmj.76.895.273; Tucker AM, 2003, J BACTERIOL, V185, P3031, DOI 10.1128/JB.185.10.3031-3035.2003; Wakefield AE, 2002, BRIT MED BULL, V61, P175, DOI 10.1093/bmb/61.1.175; Wheeler DL, 2003, CANCER RES, V63, P3037; Wilkin A, 1999, AM FAM PHYSICIAN, V60, P1699; Yildiz D, 1998, TOXICOLOGY, V130, P155, DOI 10.1016/S0300-483X(98)00105-X; Zar HJ, 2004, CURR OPIN PULM MED, V10, P176, DOI 10.1097/00063198-200405000-00006; Zhan XQ, 2003, CLIN CHEM, V49, P1740, DOI 10.1373/49.10.1740; Zingale A, 2003, J CLIN MICROBIOL, V41, P2709, DOI 10.1128/JCM.41.6.2709-2712.2003	62	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15219	15228		10.1074/jbc.M413946200	http://dx.doi.org/10.1074/jbc.M413946200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15668255	hybrid			2022-12-25	WOS:000228236800107
J	De Genest, E; Silence, K; Ghahroudi, MA; Decanniere, K; Loris, R; Kinne, J; Wyns, L; Muyldermans, S				De Genest, E; Silence, K; Ghahroudi, MA; Decanniere, K; Loris, R; Kinne, J; Wyns, L; Muyldermans, S			Strong in vivo maturation compensates for structurally restricted H3 loops in antibody repertoires	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-DOMAIN ANTIBODY; HEAVY-CHAIN ANTIBODIES; PROTEIN-PROTEIN INTERACTIONS; CRYSTAL-STRUCTURE; IMMUNE-RESPONSE; V-H; LYSOZYME; AFFINITY; RECOGNITION; DIVERSITY	A central paradigm in immunology states that successful generation of high affinity antibodies necessitates an immense primary repertoire of antigen-combining sites. Much of the diversity of this repertoire is provided by varying one antigen binding loop, created by inserting randomly a D (diversity) gene out of a small pool between the V and J genes. It is therefore assumed that any particular D-encoded region surrounded by different V and J regions adopts a different conformation. We have solved the structure of two lysozyme-specific variable domains of heavy-chain antibodies isolated from two strictly unrelated dromedaries. These antibodies recombined identical D gene sequences to different V and J precursors with significant variance in their V( D) J junctions. Despite these large differences, the D-encoded loop segments adopt remarkably identical architectures, thus directing the antibodies toward identical epitopes. Furthermore, a striking convergent maturation process occurred in the V region, adapting both binders for their sub-nanomolar affinity association with lysozyme. Hence, on a structural level, humoral immunity may rely more on well developed maturation and selection systems than on the acquisition of large primary repertoires.	Free Univ Brussels VIB, Dept Mol & Cellular Interact, Cellular & Mol Immunol Lab, B-1050 Brussels, Belgium; Cent Vet Res Lab, Dubai, U Arab Emirates	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	De Genest, E (corresponding author), Free Univ Brussels VIB, Dept Mol & Cellular Interact, Cellular & Mol Immunol Lab, Pleinlaan 2, B-1050 Brussels, Belgium.	edegenst@vub.ac.be	Muyldermans, Serge V/C-6418-2016; Loris, Remy/GPG-0894-2022; Muyldermans, Serge/AAC-7374-2019	Muyldermans, Serge V/0000-0002-3678-3575; Muyldermans, Serge/0000-0002-3678-3575; Loris, Remy/0000-0002-8862-3338				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; Conrath KE, 2001, ANTIMICROB AGENTS CH, V45, P2807, DOI 10.1128/AAC.45.10.2807-2812.2001; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Desmyter A, 2001, J BIOL CHEM, V276, P26285, DOI 10.1074/jbc.M102107200; Dumoulin M, 2003, NATURE, V424, P783, DOI 10.1038/nature01870; Flajnik MF, 2002, NAT REV IMMUNOL, V2, P688, DOI 10.1038/nri889; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; FOOTE J, 1995, P NATL ACAD SCI USA, V92, P1254, DOI 10.1073/pnas.92.5.1254; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; Goldbaum FA, 1999, J IMMUNOL, V162, P6040; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; HOLLER E, 1975, BIOCHEMISTRY-US, V14, P1088, DOI 10.1021/bi00676a032; Hoogenboom Hennie R, 2002, Methods Mol Biol, V178, P1; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kabat E. A., 1991, NIH PUBLICATION; KARLSSON R, 1997, J IMMUNOL METHODS; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; Loris R, 2003, J BIOL CHEM, V278, P28252, DOI 10.1074/jbc.M302336200; MANSER T, 1990, MOL IMMUNOL, V27, P503, DOI 10.1016/0161-5890(90)90069-C; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Milstein C, 1996, ADV PROTEIN CHEM, V49, P451, DOI 10.1016/S0065-3233(08)60494-5; Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nguyen VK, 2001, ADV IMMUNOL, V79, P261, DOI 10.1016/S0065-2776(01)79006-2; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; Rajamani D, 2004, P NATL ACAD SCI USA, V101, P11287, DOI 10.1073/pnas.0401942101; ROOST HP, 1995, P NATL ACAD SCI USA, V92, P1257, DOI 10.1073/pnas.92.5.1257; Schaffitzel C, 1999, J IMMUNOL METHODS, V231, P119, DOI 10.1016/S0022-1759(99)00149-0; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Taylor MG, 1998, PROTEIN SCI, V7, P1857, DOI 10.1002/pro.5560070902; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Weill JC, 1996, IMMUNOL TODAY, V17, P92, DOI 10.1016/0167-5699(96)80586-X; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6	44	49	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14114	14121		10.1074/jbc.M413011200	http://dx.doi.org/10.1074/jbc.M413011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15659390	hybrid			2022-12-25	WOS:000228095500114
J	Narasaki, R; Kuribayashi, H; Shimizu, K; Imamura, D; Sato, T; Hasumi, K				Narasaki, R; Kuribayashi, H; Shimizu, K; Imamura, D; Sato, T; Hasumi, K			Bacillolysin MA, a novel bacterial metalloproteinase that produces angiostatin-like fragments from plasminogen and activates protease zymogens in the coagulation and fibrinolysis systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASES GINGIPAINS-R; PORPHYROMONAS-GINGIVALIS; MOLECULAR-CLONING; ANGIOGENESIS; BINDING; ENHANCEMENT; PROTEOLYSIS; GENERATION; INHIBITOR; STAPLABIN	We isolated a novel protease that converts plasminogen to angiostatin-like fragments (BL-angiostatins) from a culture of Bacillus megaterium A9542 through a single-step chromatography on CM-cellulose. The protease, designated bacillolysin MA (BL-MA), belongs to a family of neutral metalloproteinases based on the nucleotide sequence of its gene. At an enzyme: substrate ratio of 1: 540, BL-MA cleaved human plasminogen mainly at Ser(441)-Val(442) to form BL-angiostatin and miniplasminogen with a K-m of 3.0 +/- 0.8 mu M and a k(cat) of 0.70 +/- 0.09 s(-1). The resulting BL-angiostatins inhibited the proliferation, migration, and tube formation of vascular endothelial cells at concentrations of 1-10 mu g/ml. Although BL-MA failed to activate plasminogen, it increased urokinase-catalyzed activation of plasminogen caused by production of miniplasminogen, which is highly susceptible to activation. In addition, BL-MA was active in converting prourokinase, prothrombin, coagulation factor X, and protein C to their active forms. BL-MA enhanced both the clotting of human plasma and clot dissolution in the presence of prourokinase. Thus, BL-MA affects blood coagulation and fibrinolysis systems and can be used to produce angiostatin-like plasminogen fragments and active serine proteases of human plasma.	Tokyo Noko Univ, Dept Appl Biol Sci, Fuchu, Tokyo 1838509, Japan; Tokyo Noko Univ, Dept Int Environm & Agr Sci, Fuchu, Tokyo 1838509, Japan	Tokyo University of Agriculture & Technology; Tokyo University of Agriculture & Technology	Hasumi, K (corresponding author), Tokyo Noko Univ, Dept Appl Biol Sci, 3-5-8 Saiwaicho, Fuchu, Tokyo 1838509, Japan.	hasumi@cc.tuat.ac.jp	Hasumi, Keiji/C-2372-2013	Hasumi, Keiji/0000-0002-3340-7312				Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CARMELIET P, 1995, TRENDS CARDIOVAS MED, V5, P117, DOI 10.1016/1050-1738(95)00050-J; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Cornelius LA, 1998, J IMMUNOL, V161, P6845; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; Hasumi K, 1998, J ANTIBIOT, V51, P1059, DOI 10.7164/antibiotics.51.1059; Hosotaki K, 1999, BIOL CHEM, V380, P75, DOI 10.1515/BC.1999.009; Hu WM, 2000, J ANTIBIOT, V53, P241, DOI 10.7164/antibiotics.53.241; Imamura T, 1997, J BIOL CHEM, V272, P16062, DOI 10.1074/jbc.272.25.16062; Imamura T, 2001, J BIOL CHEM, V276, P18984, DOI 10.1074/jbc.M006760200; Kassam G, 2001, J BIOL CHEM, V276, P8924, DOI 10.1074/jbc.M009071200; Kikuchi T, 2002, BBA-PROTEIN STRUCT M, V1596, P234, DOI 10.1016/S0167-4838(02)00221-2; KUHN S, 1993, J GEN MICROBIOL, V139, P39, DOI 10.1099/00221287-139-1-39; Kwon M, 2001, BIOCHEMISTRY-US, V40, P13246, DOI 10.1021/bi0113420; Lay AJ, 2000, NATURE, V408, P869, DOI 10.1038/35048596; Lijnen HR, 2000, BIOCHEMISTRY-US, V39, P479, DOI 10.1021/bi992014r; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; MORIHARA K, 1971, ARCH BIOCHEM BIOPHYS, V146, P291, DOI 10.1016/S0003-9861(71)80066-8; Morikawa W, 2000, J BIOL CHEM, V275, P38912, DOI 10.1074/jbc.M005402200; Ohyama S, 2004, EUR J BIOCHEM, V271, P809, DOI 10.1111/j.1432-1033.2004.03985.x; Ohyama S, 2002, J ANTIBIOT, V55, P83, DOI 10.7164/antibiotics.55.83; OPDENAKKER G, 1992, CYTOKINE, V4, P251, DOI 10.1016/1043-4666(92)90064-X; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Sim BKL, 1997, CANCER RES, V57, P1329; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Tachikawa K, 1997, THROMB HAEMOSTASIS, V77, P137; Takayasu R, 1997, FEBS LETT, V418, P58, DOI 10.1016/S0014-5793(97)01334-3; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0	36	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14278	14287		10.1074/jbc.M500241200	http://dx.doi.org/10.1074/jbc.M500241200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677446	hybrid			2022-12-25	WOS:000228095500131
J	Hu, QB; Wang, L; Yang, Z; Cool, BH; Zitnik, G; Martin, GM				Hu, QB; Wang, L; Yang, Z; Cool, BH; Zitnik, G; Martin, GM			Endoproteolytic cleavage of FE65 converts the adaptor protein to a potent suppressor of the sAPP alpha pathway in primates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-PRECURSOR PROTEIN; RECEPTOR-RELATED PROTEIN; ALZHEIMERS-DISEASE; BINDING PROTEIN; TRANSGENIC MICE; BETA-PROTEIN; CYTOPLASMIC DOMAIN; TERMINAL FRAGMENT; GAMMA-SECRETASE; EXPRESSION	Adaptor protein FE65 (APBB1) specifically binds to the intracellular tail of the type I transmembrane protein, beta-amyloid precursor protein (APP). The formation of this complex may be important for modulation of the processing and function of APP. APP is proteolytically cleaved at multiple sites. The cleavages and their regulation are of central importance in the pathogenesis of dementias of the Alzheimer type. In cell cultures and perhaps in vivo, secretion of the alpha-cleaved APP ectodomain (sAPP alpha) is the major pathway in the most cells. Regulation of the process may require extracellular/intracellular cues. Neither extracellular ligands nor intracellular mediators have been identified, however. Here, we show novel evidence that the major isoform of FE65 (97-kDa FE65, p97FE65) can be converted to a 65-kDa N-terminally truncated C-terminal fragment (p65FE65) via endoproteolysis. The cleavage region locates immediately after an acidic residue cluster but before the three major protein-protein binding domains. The cleavage activity is particularly high in human and non-human primate cells and low in rodent cells; the activity appears to be triggered/enhanced by high cell density, presumably via cell-cell/cell-substrate contact cues. As a result, p65FE65 exhibits extraordinarily high affinity for APP (up to 40-fold higher than p97FE65) and potent suppression (up to 90%) of secretion of sAPP alpha. Strong p65FE65-APP binding is required for the suppression. The results suggest that p65FE65 may be an intracellular mediator in a signaling cascade regulating alpha-secretion of APP, particularly in primates.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hu, QB (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.	qhu@u.washington.edu			NIA NIH HHS [AG19711, AG05136-19] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019711] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Bruni P, 2002, J BIOL CHEM, V277, P35481, DOI 10.1074/jbc.M205227200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; FUKUCHI K, 1992, J NEUROCHEM, V58, P1863, DOI 10.1111/j.1471-4159.1992.tb10063.x; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; GUENETTE SY, 2003, SOC NEUROSCI ABSTR; HAASS C, 1993, J BIOL CHEM, V268, P3021; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Ho A, 2004, P NATL ACAD SCI USA, V101, P2548, DOI 10.1073/pnas.0308655100; Hu QB, 1998, HUM GENET, V103, P295, DOI 10.1007/s004390050820; Hu QB, 1999, J NEUROSCI RES, V58, P632, DOI 10.1002/(SICI)1097-4547(19991201)58:5<632::AID-JNR4>3.0.CO;2-P; Hu QB, 2002, HUM MOL GENET, V11, P465, DOI 10.1093/hmg/11.4.465; Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139; Kesavapany S, 2002, NEUROSCIENCE, V115, P951, DOI 10.1016/S0306-4522(02)00422-0; KHYOTCHEV M, 2004, J BIOL CHEM, V279, P47101; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kouchi Z, 1998, EUR J BIOCHEM, V258, P291, DOI 10.1046/j.1432-1327.1998.2580291.x; Lambert JC, 2000, NEUROSCI LETT, V293, P29, DOI 10.1016/S0304-3940(00)01477-4; Longo O, 2003, BIOSCI BIOTECH BIOCH, V67, P2048, DOI 10.1271/bbb.67.2048; Magara F, 1999, P NATL ACAD SCI USA, V96, P4656, DOI 10.1073/pnas.96.8.4656; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; MONNING U, 1995, J BIOL CHEM, V270, P7104, DOI 10.1074/jbc.270.13.7104; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; Muresan Z, 2004, HUM MOL GENET, V13, P475, DOI 10.1093/hmg/ddh054; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Schwab C, 2004, EXP NEUROL, V188, P52, DOI 10.1016/j.expneurol.2004.03.016; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shie FS, 2002, NEUROREPORT, V13, P455, DOI 10.1097/00001756-200203250-00019; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Tanahashi H, 2002, BIOCHEM J, V367, P687, DOI 10.1042/BJ20020562; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Thomas M, 2002, P NATL ACAD SCI USA, V99, P14640, DOI 10.1073/pnas.192581499; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wang BP, 2004, J NEUROSCI RES, V75, P12, DOI 10.1002/jnr.10834	52	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12548	12558		10.1074/jbc.M411855200	http://dx.doi.org/10.1074/jbc.M411855200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15647266	hybrid			2022-12-25	WOS:000227922000059
J	Wu, JZ; Neiers, F; Boschi-Muller, S; Branlant, G				Wu, JZ; Neiers, F; Boschi-Muller, S; Branlant, G			The N-terminal domain of PILB from Neisseria meningitidis is a disulfide reductase that can recycle methionine sulfoxide reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; PROTEIN-BOUND METHIONINE; CATALYTIC MECHANISM; SUBSTRATE STEREOSPECIFICITY; KINETIC CHARACTERIZATION; ACTIVE-SITE; OXIDOREDUCTASES; BIOCHEMISTRY; MIMICKING; ENZYME	The PilB protein of the Neisseria genus comprises three domains. Two forms have been recently reported to be produced in vivo. One form, containing the three domains, is secreted from the bacterial cytoplasm to the outer membrane, whereas the second form, which is cytoplasmic, only contains the central and the C-terminal domains. The secreted form was shown to be involved in survival under oxidative conditions. Although previous studies indicated that the central and the C-terminal domains display methionine sulfoxide reductase A and B activities, respectively, no function was described so far for the N-terminal domain. In the present study, the N-terminal domain of the PilB of Neisseria meningitidis was produced as a folded entity, and its biochemical and enzymatic properties have been determined. The data show that the N-terminal domain possesses a disulfide redox-active site with a redox potential in the range of that of thioredoxin. Moreover, the N-terminal domain, either as an isolated form or included in PilB, recycles the oxidized forms of the methionine sulfoxide reductases like thioredoxin. These results, which show that the N-terminal domain exhibits a disulfide reductase activity and probably has a thioredoxin-fold, are discussed in relation to its possible functional role in Neisseria.	UHP, Lab MAEM, UMR 7567, CNRS,Fac Sci, F-54506 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Branlant, G (corresponding author), UHP, Lab MAEM, UMR 7567, CNRS,Fac Sci, Bld Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.	guy.branlant@maem.uhp-nancy.fr	Neiers, Fabrice/AAM-1637-2021	Neiers, Fabrice/0000-0002-8965-4929; Boschi, Sandrine/0000-0001-8962-4749				Antoine M, 2003, J BIOL CHEM, V278, P45352, DOI 10.1074/jbc.M307471200; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; Boschi-Muller S, 2005, BBA-PROTEINS PROTEOM, V1703, P231, DOI 10.1016/j.bbapap.2004.09.016; Boyle EC, 2003, CURR OPIN CELL BIOL, V15, P633, DOI 10.1016/S0955-0674(03)00099-1; Brot N, 2000, BIOPOLYMERS, V55, P288, DOI 10.1002/1097-0282(2000)55:4<288::AID-BIP1002>3.0.CO;2-M; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P14985, DOI 10.1021/bi970071j; Dehio C, 2000, Subcell Biochem, V33, P61; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Kapatral V, 2002, J BACTERIOL, V184, P2005, DOI 10.1128/JB.184.7.2005-2018.2002; Kauffmann B, 2002, ACTA CRYSTALLOGR D, V58, P1467, DOI 10.1107/S0907444902010570; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Lowther WT, 2000, BIOCHEMISTRY-US, V39, P13307, DOI 10.1021/bi0020269; Lowther WT, 2002, NAT STRUCT BIOL, V9, P348, DOI 10.1038/nsb783; Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167; Moskovitz J, 2002, BIOCHEM BIOPH RES CO, V290, P62, DOI 10.1006/bbrc.2001.6171; Mossner E, 1998, PROTEIN SCI, V7, P1233; Olry A, 2004, BIOCHEMISTRY-US, V43, P11616, DOI 10.1021/bi049306z; Olry A, 2002, J BIOL CHEM, V277, P12016, DOI 10.1074/jbc.M112350200; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Skaar EP, 2002, P NATL ACAD SCI USA, V99, P10108, DOI 10.1073/pnas.152334799; Slaby I, 1996, J BIOL CHEM, V271, P3091, DOI 10.1074/jbc.271.6.3091; Stadtman ER, 2003, ANTIOXID REDOX SIGN, V5, P577, DOI 10.1089/152308603770310239; Taylor AB, 2003, J BACTERIOL, V185, P4119, DOI 10.1128/JB.185.14.4119-4126.2003; Tete-Favier F, 2000, STRUCTURE, V8, P1167, DOI 10.1016/S0969-2126(00)00526-8	29	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12344	12350		10.1074/jbc.M500385200	http://dx.doi.org/10.1074/jbc.M500385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668226	hybrid, Green Published			2022-12-25	WOS:000227922000035
J	Yogesha, SD; Khapli, SM; Wani, MR				Yogesha, SD; Khapli, SM; Wani, MR			Interleukin-3 and granulocyte-macrophage colony-stimulating factor inhibits tumor necrosis factor (TNF)-alpha-induced osteoclast differentiation by down-regulation of expression of TNF receptors 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW CULTURES; T-CELL PRODUCTION; KAPPA-B LIGAND; FACTOR-ALPHA; OSTEOPROTEGERIN LIGAND; DENDRITIC CELLS; RHEUMATOID-ARTHRITIS; OVARIECTOMIZED MICE; OSTEOBLASTIC CELLS; RAT BONE	Osteoclasts, the multinucleated cells that resorb bone, differentiate from hemopoietic precursors of monocyte/macrophage lineage, which also give rise to macrophages or dendritic cells. In this study we investigated the mechanism by which interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GMCSF) inhibit tumor necrosis factor (TNF)-alpha-induced osteoclast differentiation in mouse osteoclast precursors. We show here that both IL-3 and GM-CSF potently inhibits TNF-alpha-induced osteoclast differentiation by direct action on osteoclast precursors. The inhibitory effect of IL-3 and GM-CSF on osteoclast differentiation was completely neutralized by anti-IL-3 and anti-GMCSF antibodies, respectively. In addition, the inhibitory effect of IL-3 and GM-CSF on TNF-alpha-induced osteoclast differentiation was irreversible. In osteoclast precursors, IL-3 and GM-CSF inhibited c-Fms expression post-transcriptionally. Interestingly, IL-3 and GM-CSF down-regulated both mRNA and surface expression of TNF receptor 1 (TNFR1) and TNFR2. Furthermore, cells in the presence of IL-3 and GM-CSF showed high expression of macrophage antigen CD11b, and low expression of dendritic cells antigen CD11c and prolong exposure of osteoclast precursors to GM-CSF increased the CD11c expression compare with IL-3. In summary, we provide the first evidence that IL-3 and GM-CSF block TNF-alpha-induced osteoclast differentiation by down-regulation of mRNA and surface expression of TNFR1 and TNFR2.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Wani, MR (corresponding author), Natl Ctr Cell Sci, Univ Pune Campus,Ganeshkhind Rd, Pune 411007, Maharashtra, India.	mohanwani@nccs.res.in	Wani, Mohan/AAK-8516-2020					Abu-Amer Y, 2000, J BIOL CHEM, V275, P27307; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Assuma R, 1998, J IMMUNOL, V160, P403; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BUCHAN G, 1988, CLIN EXP IMMUNOL, V73, P449; CAUX C, 1993, J EXP MED, V177, P1815, DOI 10.1084/jem.177.6.1815; Caux C, 1996, BLOOD, V87, P2376, DOI 10.1182/blood.V87.6.2376.bloodjournal8762376; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; Day CJ, 2004, J CELL BIOCHEM, V91, P303, DOI 10.1002/jcb.10780; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Fuller K, 2000, J CELL SCI, V113, P2445; Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HATTERSLEY G, 1990, J CELL PHYSIOL, V142, P201, DOI 10.1002/jcp.1041420125; HATTERSLEY G, 1988, J CELL PHYSIOL, V137, P199, DOI 10.1002/jcp.1041370125; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Horwood NJ, 1998, J CLIN INVEST, V101, P595, DOI 10.1172/JCI1333; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Khapli SM, 2003, J IMMUNOL, V171, P142, DOI 10.4049/jimmunol.171.1.142; Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890; Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935; KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kohrgruber N, 1999, J IMMUNOL, V163, P3250; Komine M, 2001, BONE, V28, P474, DOI 10.1016/S8756-3282(01)00420-3; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KONIG A, 1988, J BONE MINER RES, V3, P621; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Ledgerwood EC, 1999, LAB INVEST, V79, P1041; LERNER UH, 1993, J BONE MINER RES, V8, P147; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544; Morgan H, 2004, INT J CANCER, V109, P653, DOI 10.1002/ijc.20056; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; PAULNOCK DM, 2000, MACROPHAGES, P31; Rho J, 2004, MOL CELLS, V17, P1; Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698; SHINAR DM, 1990, ENDOCRINOLOGY, V126, P1728, DOI 10.1210/endo-126-3-1728; SHUTO T, 1994, ENDOCRINOLOGY, V134, P831, DOI 10.1210/en.134.2.831; Storozynsky E, 1999, IMMUNOLOGY, V97, P138; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; THOMSON BM, 1987, J IMMUNOL, V138, P775; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; VANDERPLUIJM G, 1991, ENDOCRINOLOGY, V129, P1596; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	60	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11759	11769		10.1074/jbc.M410828200	http://dx.doi.org/10.1074/jbc.M410828200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15653694	hybrid			2022-12-25	WOS:000227761800105
J	Zhao, B; Guengerich, FP; Bellamine, A; Lamb, DC; Izumikawa, M; Lei, L; Podust, LM; Sundaramoorthy, M; Kalaitzis, JA; Reddy, LM; Kelly, SL; Moore, BS; Stec, D; Voehler, M; Falck, JR; Shimada, T; Waterman, MR				Zhao, B; Guengerich, FP; Bellamine, A; Lamb, DC; Izumikawa, M; Lei, L; Podust, LM; Sundaramoorthy, M; Kalaitzis, JA; Reddy, LM; Kelly, SL; Moore, BS; Stec, D; Voehler, M; Falck, JR; Shimada, T; Waterman, MR			Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of Streptomyces coelicolor A3(2) cytochrome P450 158A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III POLYKETIDE SYNTHASE; GLYCOPEPTIDE ANTIBIOTICS; VANCOMYCIN-TYPE; BIOSYNTHESIS; METABOLISM; MODEL; CRYSTALLOGRAPHY; IDENTIFICATION; EXPRESSION; RESOLUTION	Cytochrome P450 158A2 ( CYP158A2) is encoded within a three-gene operon ( sco1206-sco1208) in the prototypic soil bacterium Streptomyces coelicolor A3( 2). This operon is widely conserved among streptomycetes. CYP158A2 has been suggested to produce polymers of flaviolin, a pigment that may protect microbes from UV radiation, in combination with the adjacent rppA gene, which encodes the type III polyketide synthase, 1,3,6,8-tetrahydroxynaphthalene synthase. Following cloning, expression, and purification of this cytochrome P450, we have shown that it can produce dimer and trimer products from the substrate flaviolin and that the structures of two of the dimeric products were established using mass spectrometry and multiple NMR methods. A comparison of the x-ray structures of ligand-free (1.75 angstrom ) and flaviolin-bound (1.62 angstrom) forms of CYP158A2 demonstrates a major conformational change upon ligand binding that closes the entry into the active site, partly due to repositioning of the F and G helices. Particularly interesting is the presence of two molecules of flaviolin in the closed active site. The flaviolin molecules form a quasi-planar three-molecule stack including the heme of CYP158A2, suggesting that oxidative C-C coupling of these phenolic molecules leads to the production of flaviolin dimers.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Struct Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Univ Coll Swansea, Swansea Clin Sch, Swansea SA2 8PP, W Glam, Wales; Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA; Univ Texas, SW Med Ctr, Dallas, TX 75390 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Swansea University; University of Arizona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University	Zhao, B (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 864 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	bin.zhao@vanderbilt.edu	Podust, Larissa/ABB-7940-2020; Kalaitzis, John/B-5553-2009	Podust, Larissa/0000-0002-8537-8760; Shimada, Tsutomu/0000-0003-2552-4348; Falck, John/0000-0002-9219-7845; Kalaitzis, John/0000-0001-9647-7652; Moore, Bradley/0000-0002-4652-1253	NIAID NIH HHS [AI52443] Funding Source: Medline; NIDDK NIH HHS [DK62524] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM69970, GM37942, GM31278] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037942, R37GM037942, R01GM031278, R01GM069970] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANN T, 1991, TETRAHEDRON LETT, V32, P3675, DOI 10.1016/S0040-4039(00)79765-6; Anzenbacher P, 2001, CELL MOL LIFE SCI, V58, P737, DOI 10.1007/PL00000897; Austin MB, 2004, J BIOL CHEM, V279, P45162, DOI 10.1074/jbc.M406567200; BAKER PM, 1968, CHEM COMMUN, V2, P71; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P4688, DOI 10.1002/1521-3773(20011217)40:24<4688::AID-ANIE4688>3.0.CO;2-M; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P1693, DOI 10.1002/1521-3773(20010504)40:9<1693::AID-ANIE16930>3.0.CO;2-8; BRASH AR, 1990, J BIOL CHEM, V265, P6705; BRASH AR, 1988, P NATL ACAD SCI USA, V85, P3382, DOI 10.1073/pnas.85.10.3382; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cortes J, 2002, MOL MICROBIOL, V44, P1213, DOI 10.1046/j.1365-2958.2002.02975.x; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; Dunn AR, 2001, P NATL ACAD SCI USA, V98, P12420, DOI 10.1073/pnas.221297998; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; GOTOH O, 1992, J BIOL CHEM, V267, P83; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; Izumikawa M, 2003, J IND MICROBIOL BIOT, V30, P510, DOI 10.1007/s10295-003-0075-8; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim C, 2000, BIOORG CHEM, V28, P306, DOI 10.1006/bioo.2000.1187; Lamb DC, 2002, J BIOL CHEM, V277, P24000, DOI 10.1074/jbc.M111109200; Moore BS, 2001, CHEMBIOCHEM, V2, P35, DOI 10.1002/1439-7633(20010105)2:1<35::AID-CBIC35>3.3.CO;2-T; Mueller Ernest J., 1995, P83; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PANG YP, 1991, J ORG CHEM, V56, P4499, DOI 10.1021/jo00014a033; Pelzer S, 1999, ANTIMICROB AGENTS CH, V43, P1565, DOI 10.1128/AAC.43.7.1565; Podust LM, 2003, J BIOL CHEM, V278, P12214, DOI 10.1074/jbc.M212210200; PORTER TD, 1992, FASEB J, V6, P669; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; Pylypenko O, 2003, J BIOL CHEM, V278, P46727, DOI 10.1074/jbc.M306486200; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; STADLER R, 1993, J BIOL CHEM, V268, P823; STIPANOVIC RD, 1980, PESTIC BIOCHEM PHYS, V13, P198, DOI 10.1016/0048-3575(80)90072-3; Sussmuth RD, 1999, ANGEW CHEM INT EDIT, V38, P1976, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1976::AID-ANIE1976>3.0.CO;2-3; Taylor M, 1999, BIOCHEM BIOPH RES CO, V263, P838, DOI 10.1006/bbrc.1999.1427; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; ZENK MH, 1989, J CHEM SOC CHEM COMM, P1725, DOI 10.1039/c39890001725; Zerbe K, 2002, J BIOL CHEM, V277, P47476, DOI 10.1074/jbc.M206342200	46	123	134	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11599	11607		10.1074/jbc.M410933200	http://dx.doi.org/10.1074/jbc.M410933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659395	hybrid			2022-12-25	WOS:000227761800087
J	Babilonia, E; Wei, Y; Sterling, H; Kaminski, P; Wolin, M; Wang, WH				Babilonia, E; Wei, Y; Sterling, H; Kaminski, P; Wolin, M; Wang, WH			Superoxide anions are involved in mediating the effect of low K intake on c-Src expression and renal K secretion in the cortical collecting duct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; HYDROGEN-PEROXIDE; REDOX REGULATION; CELLS; ACTIVATION; RECEPTOR; PHOSPHORYLATION; GENERATION; CHANNELS; INTERMEDIATE	We previously demonstrated that low K intake stimulated the expression of c-Src and that stimulation of protein tyrosine kinase inhibited ROMK channel activity (Wei, Y., Bloom, P., Lin, D. H., Gu, R. M., and Wang, W. H. (2001) Am. J. Physiol. 281, F206-F212). Decreases in dietary K content significantly increased O-2(.-) levels and the phosphorylation of c-Jun, a transcription factor, in renal cortex and outer medulla. The role of O-2(.-) and related products such as H2O2 in stimulating the expression of protein tyrosine kinase is suggested by the observation that addition of 50-200 mu M H2O2 increased the phosphorylation of c-Jun and the expression of c-Src in M1 cells, a mouse collecting duct principal cell line. The effect of H2O2 on c-Src expression was completely abolished with cyclohexamide or actinomycin D. The treatment of animals on a K-deficient (KD) diet with tempol for 7 days significantly decreased the production of O-2(.-), c-Jun phosphorylation, and c-Src expression. Moreover, low K intake decreased the activity of ROMK-like small conductance channels from 1.37 (control K diet) to 0.5 in the cortical collecting duct and increased the tyrosine phosphorylation of ROMK in the renal cortex and outer medulla. In contrast, the tempol treatment not only increased channel activity to 1.1 in the cortical collecting duct but also decreased the tyrosine phosphorylation of ROMK from rats on a KD diet. Finally, suppressing O-2(.-) production with tempol significantly increased renal K excretion measured with metabolic cage and lowered the plasma K concentration in comparison with those on a KD diet alone without tempol. We conclude that O-2(.-) and related products play a role in mediating the effect of low K intake on c-Src expression and in suppressing ROMK channel activity and renal K secretion.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Wang, WH (corresponding author), New York Med Coll, Dept Pharmacol, BSB Rm 537, Valhalla, NY 10595 USA.	wenhui_wang@nymc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047402, R01DK054983] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK047402, R01 DK054983-08, R01 DK047402-13, R01 DK054983] Funding Source: Medline; PHS HHS [47402, 54983] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD I, 1992, P NATL ACAD SCI USA, V89, P10262, DOI 10.1073/pnas.89.21.10262; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; Cai H, 2002, J BIOL CHEM, V277, P48311, DOI 10.1074/jbc.M208884200; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; EVAN AP, 1995, KIDNEY INT, V48, P1517, DOI 10.1038/ki.1995.442; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; Hsu FW, 1997, KIDNEY INT, V52, P363, DOI 10.1038/ki.1997.342; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KORBMACHER C, 1993, J GEN PHYSIOL, V102, P761, DOI 10.1085/jgp.102.4.761; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; LETZ B, 1995, J MEMBRANE BIOL, V148, P127; Lin DH, 2002, AM J PHYSIOL-RENAL, V283, pF671, DOI 10.1152/ajprenal.00160.2002; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MOHAZZAB HKM, 1994, AM J PHYSIOL, V267, pL815; MohazzabH KM, 1996, AM J PHYSIOL-HEART C, V270, pH1044, DOI 10.1152/ajpheart.1996.270.3.H1044; Munzel T, 2002, ARTERIOSCL THROM VAS, V22, P1761, DOI 10.1161/01.ATV.0000034022.11764.EC; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Schmid E, 1999, FASEB J, V13, P1491, DOI 10.1096/fasebj.13.12.1491; Sterling H, 2002, J BIOL CHEM, V277, P4317, DOI 10.1074/jbc.M109739200; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wang WH, 2004, ANNU REV PHYSIOL, V66, P547, DOI 10.1146/annurev.physiol.66.032102.112025; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wei Y, 2001, AM J PHYSIOL-RENAL, V281, pF206, DOI 10.1152/ajprenal.2001.281.2.F206; Wei Y, 2000, J BIOL CHEM, V275, P20502, DOI 10.1074/jbc.M000783200; WINGO CS, 1993, ANNU REV PHYSIOL, V55, P323, DOI 10.1146/annurev.physiol.55.1.323; Woda CB, 2002, AM J PHYSIOL-RENAL, V283, pF437, DOI 10.1152/ajprenal.00316.2001; Woda CB, 2001, AM J PHYSIOL-RENAL, V280, pF786, DOI 10.1152/ajprenal.2001.280.5.F786; Yang BC, 1998, AM J PHYSIOL-HEART C, V274, pH1955, DOI 10.1152/ajpheart.1998.274.6.H1955	37	32	32	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10790	10796		10.1074/jbc.M414610200	http://dx.doi.org/10.1074/jbc.M414610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644319	Green Accepted, hybrid			2022-12-25	WOS:000227559600126
J	Tsukada, S; Westwick, JK; Ikejima, K; Sato, N; Rippe, RA				Tsukada, S; Westwick, JK; Ikejima, K; Sato, N; Rippe, RA			SMAD and p38 MAPK signaling pathways independently regulate alpha 1(I) collagen gene expression in unstimulated and transforming growth factor-alpha-stimulated hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA; COLLAGEN GENE; PRIMARY CULTURE; ITO CELLS; FIBROSIS; IDENTIFICATION; TRANSDUCTION; RECEPTOR; MKK3	The hepatic stellate cell (HSC) is the predominant cell type responsible for excess collagen deposition during liver fibrosis. Both transforming growth factor-beta(TGF-beta), the most potent fibrogenic cytokine for HSCs, which classically activates Smad signaling, and p38 MAPK signaling have been shown to influence collagen gene expression; however, the relative contribution and mechanisms that these two signaling pathways have in regulating collagen gene expression have not been investigated. The aim of this study was to investigate the relative roles and mechanisms of both Smad and p38 MAPK signaling in alpha 1(I) collagen gene expression in HSCs. Inhibiting either p38 MAPK or Smad signaling reduced alpha 1(I) collagen mRNA expression in untreated or TGF-beta-treated HSCs, and when both signaling pathways were simultaneously inhibited, alpha 1(I) collagen gene expression was essentially blocked. Both signaling pathways were found to independently and additively increase alpha 1(I) collagen gene expression by transcriptional mechanisms. TGF-beta treatment increased alpha 1(I) collagen mRNA half-life, mediated by increased stability of alpha 1(I) collagen mRNA through p38 MAPK signaling but not through Smad signaling. In conclusion, both p38 MAPK and Smad signaling independently and additively regulate alpha 1(I) collagen gene expression by transcriptional activation, whereas p38 MAPK and not Smad signaling increased alpha 1(I) collagen mRNA stability.	Univ N Carolina, Div Gastroenterol & Hepatol, Dept Med, Chapel Hill, NC 27599 USA; Juntendo Univ, Sch Med, Dept Gastroenterol, Tokyo 1138421, Japan; Odessey Thera Inc, San Ramon, CA 94583 USA	University of North Carolina; University of North Carolina Chapel Hill; Juntendo University	Rippe, RA (corresponding author), Univ N Carolina, Div Gastroenterol & Hepatol, Dept Med, CB 7032,Med Biomol Res Bldg,Rm 7340B, Chapel Hill, NC 27599 USA.	rarippe@med.unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA010459, R01AA010459] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10459] Funding Source: Medline; NIDDK NIH HHS [DK34987] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bamba S, 2003, AM J PHYSIOL-GASTR L, V285, pG529, DOI 10.1152/ajpgi.00050.2003; Cao Q, 2002, AM J PHYSIOL-GASTR L, V283, pG1051, DOI 10.1152/ajpgi.00128.2002; Cui XZ, 2003, J HEPATOL, V39, P731, DOI 10.1016/S0168-8278(03)00216-2; Cutroneo KR, 2003, J CELL BIOCHEM, V90, P1, DOI 10.1002/jcb.10599; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Eng FJ, 2000, AM J PHYSIOL-GASTR L, V279, pG7, DOI 10.1152/ajpgi.2000.279.1.G7; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; Friedman SL, 1999, SEMIN LIVER DIS, V19, P129, DOI 10.1055/s-2007-1007105; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Furukawa F, 2003, HEPATOLOGY, V38, P879, DOI 10.1053/jhep.2003.50384; Garcia-Trevijano ER, 1999, HEPATOLOGY, V29, P960, DOI 10.1002/hep.510290346; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KNITTEL T, 1992, GASTROENTEROLOGY, V102, P1724, DOI 10.1016/0016-5085(92)91736-N; Krempen K, 1999, GENE EXPRESSION, V8, P151; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; MAHER JJ, 1988, J CLIN INVEST, V82, P450, DOI 10.1172/JCI113618; Masamune A, 2003, J PHARMACOL EXP THER, V304, P8, DOI 10.1124/jpet.102.040287; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; Rivera CA, 2001, AM J PHYSIOL-GASTR L, V281, pG200, DOI 10.1152/ajpgi.2001.281.1.G200; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schnabl B, 2001, HEPATOLOGY, V34, P953, DOI 10.1053/jhep.2001.28790; Schnabl B, 2001, HEPATOLOGY, V34, P89, DOI 10.1053/jhep.2001.25349; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; Tanaka N, 2002, EMBO REP, V3, P785, DOI 10.1093/embo-reports/kvf153; TERADA Y, 2002, KIDNEY INT S1, V61, P94, DOI DOI 10.1046/J.1523-1755.2002.0610S1094.X; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yata Y, 2003, HEPATOLOGY, V37, P267, DOI 10.1053/jhep.2003.50067	43	136	150	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10055	10064		10.1074/jbc.M409381200	http://dx.doi.org/10.1074/jbc.M409381200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647278	Green Published, hybrid			2022-12-25	WOS:000227559600040
J	Wolner, B; Peterson, CL				Wolner, B; Peterson, CL			ATP-dependent and ATP-independent roles for the Rad54 chromatin remodeling enzyme during recombinational repair of a DNA double strand break	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; NUCLEOPROTEIN FILAMENT; YEAST RAD54; CONFORMATION; EXCHANGE; LOCI	The efficient and accurate repair of DNA double strand breaks (DSBs) is critical to cell survival, and defects in this process can lead to genome instability and cancers. In eukaryotes, the Rad52 group of proteins dictates the repair of DSBs by the error-free process of homologous recombination (HR). A critical step in eukaryotic HR is the formation of the initial Rad51-single-stranded DNA presynaptic nucleoprotein filament. This presynaptic filament participates in a homology search process that leads to the formation of a DNA joint molecule and recombinational repair of the DSB. Recently, we showed that the Rad54 protein functions as a mediator of Rad51 binding to single-stranded DNA, and here, we find that this activity does not require ATP hydrolysis. We also identify a novel Rad54-dependent chromatin remodeling event that occurs in vivo during the DNA strand invasion step of HR. This ATP-dependent remodeling activity of Rad54 appears to control subsequent steps in the HR process.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Peterson, CL (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Biotech 2,Ste 203, Worcester, MA 01605 USA.	craig.Peterson@umassmed.edu	Wolner, Branden/A-9615-2015	Wolner, Branden/0000-0003-0021-2073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM064233, R01GM054096] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM64233, GM54096] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2004, J BIOL CHEM, V279, P27824, DOI 10.1074/jbc.M402648200; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Kim PM, 2002, NUCLEIC ACIDS RES, V30, P2727, DOI 10.1093/nar/gkf413; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Peters Charles R., 1996, Kaupia Darmstaedter Beitraege zur Naturgeschichte, V6, P175; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Smirnova M, 2004, J BIOL CHEM, V279, P24081, DOI 10.1074/jbc.M402719200; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Weiss K, 1998, MOL CELL BIOL, V18, P5392, DOI 10.1128/MCB.18.9.5392; Wolner B, 2003, MOL CELL, V12, P221, DOI 10.1016/S1097-2765(03)00242-9	29	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10855	10860		10.1074/jbc.M414388200	http://dx.doi.org/10.1074/jbc.M414388200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15653683	hybrid			2022-12-25	WOS:000227559600134
J	Busson, M; Carazo, A; Seyer, P; Grandemange, P; Casas, F; Pessemesse, L; Rouault, JP; Wrutniak-Cabello, C; Cabello, G				Busson, M; Carazo, A; Seyer, P; Grandemange, P; Casas, F; Pessemesse, L; Rouault, JP; Wrutniak-Cabello, C; Cabello, G			Coactivation of nuclear receptors and myogenic factors induces the major BTG1 influence on muscle differentiation	ONCOGENE			English	Article						BTG1; coactivator; myoblast; myogenic factors; nuclear receptors	THYROID-HORMONE RECEPTOR; TRANSCRIPTIONAL ACTIVATION; PROTEIN METHYLTRANSFERASE; MYOBLAST DIFFERENTIATION; NERVOUS-SYSTEM; RETINOIC ACID; TRIIODOTHYRONINE; FAMILY; GENE; COMPONENT	The btg1 (B-cell translocation gene 1) gene coding sequence was isolated from a translocation break point in a case of B-cell chronic lymphocytic leukaemia. We have already shown that BTG1, considered as an antiproliferative protein, strongly stimulates myoblast differentiation. However, the mechanisms involved in this influence remained unknown. In cultured myoblasts, we found that BTG1 stimulates the transcriptional activity of nuclear receptors (T3 and all-trans retinoic acid receptors but not RXRalpha and PPARgamma), c-Jun and myogenic factors (CMD1, Myf5, myogenin). Immunoprecipitation experiments performed in cells or using in vitro-synthesized proteins and GST pull-down assays established that BTG1 directly interacts with T3 and all-trans retinoic acid receptors and with avian MyoD ( CMD1). These interactions are mediated by the transactivation domain of each transcription factor and the A box and C-terminal part of BTG1. NCoR presence induces the ligand dependency of the interaction with nuclear receptors. Lastly, deletion of BTG1 interacting domains abrogates its ability to stimulate nuclear receptors and CMD1 activity, and its myogenic influence. In conclusion, BTG1 is a novel important coactivator involved in the regulation of myoblast differentiation. It not only stimulates the activity of myogenic factors, but also of nuclear receptors already known as positive myogenic regulators.	INRA, UMR 866, Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; Hop Debrousse, INSERM, U418, F-69322 Lyon 05, France	INRAE; Universite de Montpellier; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cabello, G (corresponding author), INRA, UMR 866, Differenciat Cellulaire & Croissance, 2 Pl Viala, F-34060 Montpellier 1, France.	cabello@ensam.inra.fr		Francois, Casas/0000-0002-5535-8195				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Berthet C, 2002, GENES CELLS, V7, P29, DOI 10.1046/j.1356-9597.2001.00497.x; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Casas F, 1999, MOL CELL BIOL, V19, P7913; Casas F, 2000, FEBS LETT, V478, P4, DOI 10.1016/S0014-5793(00)01814-7; CassarMalek I, 1996, J BIOL CHEM, V271, P11392, DOI 10.1074/jbc.271.19.11392; CASSARMALEK I, 1994, ONCOGENE, V9, P2197; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Daury L, 2001, ONCOGENE, V20, P7998, DOI 10.1038/sj.onc.1204967; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; Matsuda S, 1996, ONCOGENE, V12, P705; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Prevot D, 2001, J BIOL CHEM, V276, P9640, DOI 10.1074/jbc.M008201200; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rodier A, 2001, ONCOGENE, V20, P2691, DOI 10.1038/sj.onc.1204398; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; ROWE A, 1991, DEVELOPMENT, V111, P771; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SNEDECOR GW, 1961, STAT METHODS, P534; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805	44	51	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1698	1710		10.1038/sj.onc.1208373	http://dx.doi.org/10.1038/sj.onc.1208373			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674337				2022-12-25	WOS:000227345100006
J	Devchand, PR; Schmidt, BA; Primo, VC; Zhang, QY; Arnaout, MA; Serhan, CN; Nikolic, B				Devchand, PR; Schmidt, BA; Primo, VC; Zhang, QY; Arnaout, MA; Serhan, CN; Nikolic, B			A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils	FASEB JOURNAL			English	Article						eicosanoids; lipoxin; LXA(4) receptor; complex inflammatory diseases	DISEASE; ASPIRIN; INFLAMMATION; TRAFFICKING; RECRUITMENT; INHIBITION; A(4)	Lipoxin A(4) (LXA(4)) and aspirin-triggered 15-epi-LXA(4) are potent endogenous lipid mediators thought to define the inflammatory set-point. We used single prophylactic administrations of a synthetic aspirin-triggered lipoxin A(4) signal mimetic, ATLa, to probe dynamics of early host-donor interactions in a mouse model for the inflammation-associated multifactorial disease of allogeneic bone marrow transplant (BMT) - induced graft-vs.-host disease (GvHD). We first demonstrated that both host and donor are responsive to the ATLa signals. The simple and restricted regimen of a single prophylactic administration of ATLa [ 100 ng/mL to donor cells or 1 mu g (similar to 50 mu g/kg) i. v. to host] was sufficient to delay death. Clinical indicators of weight, skin lesions, diarrhea and eye inflammation were monitored. Histological analyses on day 45 post-BMT showed that the degree of cellular trafficking, particularly neutrophil infiltrate, and protection of end-organ target pathology are different, depending on whether the host or donor was treated with ATLa. Taken together, these results chart some ATLa protective effects on GvHD cellular dynamics over time and identify a previously unrecognized effect of host neutrophils in the early phase post-BMT as important determinants in the dynamics of GvHD onset and progression.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med,Ctr Expt T, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Renal, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Serhan, CN (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med,Ctr Expt T, Thorn Bldg Med Res,75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu; bnikolic@partners.org			NIAMS NIH HHS [K01-AR02219] Funding Source: Medline; NIDDK NIH HHS [K08-DK59919, P01-DK50305] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059919, P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765, R29GM038765, R37GM038765] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blazar BR, 1997, IMMUNOL REV, V157, P79, DOI 10.1111/j.1600-065X.1997.tb00976.x; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Devchand PR, 2003, FASEB J, V17, P652, DOI 10.1096/fj.02-0770com; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gewirtz AT, 2002, J IMMUNOL, V168, P5260, DOI 10.4049/jimmunol.168.10.5260; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kim YM, 2003, J CLIN INVEST, V111, P659, DOI 10.1172/JCI200316950; Leonard MO, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015795.74094.91; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Nikolic B, 1997, CURR OPIN IMMUNOL, V9, P634, DOI 10.1016/S0952-7915(97)80042-8; Nikolic B, 2000, J CLIN INVEST, V105, P1289, DOI 10.1172/JCI7894; Perretti M, 2004, J LEUKOCYTE BIOL, V76, P25, DOI 10.1189/jlb.1103552; Qiu FH, 2001, FASEB J, V15, P2736, DOI 10.1096/fj.01-0576fje; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Souza MHLP, 2003, AM J PHYSIOL-GASTR L, V285, pG54, DOI 10.1152/ajpgi.00525.2002; Wallace JL, 2003, TRENDS PHARMACOL SCI, V24, P323, DOI 10.1016/S0165-6147(03)00166-4	21	24	27	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2005	19	2					203	210		10.1096/fj.04-2565com	http://dx.doi.org/10.1096/fj.04-2565com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15677343				2022-12-25	WOS:000227591900024
J	Pan, D; Estevez-Salmeron, LD; Stroschein, SL; Zhu, XL; He, J; Zhou, SL; Luo, KX				Pan, D; Estevez-Salmeron, LD; Stroschein, SL; Zhu, XL; He, J; Zhou, SL; Luo, KX			The integral inner nuclear membrane protein MAN1 physically interacts with the R-Smad proteins to repress signaling by the transforming growth factor-beta superfamily of cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; FYVE DOMAIN PROTEIN; MAMMALIAN-CELLS; SKI ONCOPROTEIN; CO-REPRESSOR; LEM DOMAIN; 7SK SNRNA; P-TEFB; RECEPTOR; SARA	Smad proteins are critical intracellular mediators of the transforming growth factor-beta, bone morphogenic proteins (BMPs), and activin signaling. Upon ligand binding, the receptor-associated R-Smads are phosphorylated by the active type I receptor serine/threonine kinases. The phosphorylated R-Smads then form heteromeric complexes with Smad4, translocate into the nucleus, and interact with various transcription factors to regulate the expression of downstream genes. Interaction of Smad proteins with cellular partners in the cytoplasm and nucleus is a critical mechanism by which the activities and expression of the Smad proteins are modulated. Here we report a novel step of regulation of the R- Smad function at the inner nuclear membrane through a physical interaction between the integral inner nuclear membrane protein MAN1 and R-Smads. MAN1, through the RNA recognition motif, associates with R- Smads but not Smad4 at the inner nuclear membrane in a ligand-independent manner. Overexpression of MAN1 results in inhibition of R- Smad phosphorylation, heterodimerization with Smad4 and nuclear translocation, and repression of transcriptional activation of the TGF beta, BMP2, and activin-responsive promoters. This repression of TGF beta, BMP2, and activin signaling is dependent on the MAN1-Smad interaction because a point mutation that disrupts this interaction abolishes the transcriptional repression by MAN1. Thus, MAN1 represents a new class of R- Smad regulators and defines a previously unrecognized regulatory step at the nuclear periphery.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Luo, KX (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 237 Hildebrand Hall,Mail Code 3206, Berkeley, CA 94720 USA.	kluo@uclink.berkeley.edu	Pan, Deng/F-8418-2012		NCI NIH HHS [CA87940] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Engel ME, 1998, J CELL BIOCHEM, P111; Escobedo J, 2003, BIOTECHNIQUES, V35, P936, DOI 10.2144/03355bm06; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; Hellemans J, 2004, NAT GENET, V36, P1213, DOI 10.1038/ng1453; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kim RH, 2000, GENE DEV, V14, P1605; Kunzmann S, 2003, FASEB J, V17, P194, DOI 10.1096/fj.02-0550com; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Lee KK, 2000, MOL BIOL CELL, V11, P3089, DOI 10.1091/mbc.11.9.3089; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Liu J, 2003, P NATL ACAD SCI USA, V100, P4598, DOI 10.1073/pnas.0730821100; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Luo KX, 2004, CURR OPIN GENET DEV, V14, P65, DOI 10.1016/j.gde.2003.11.003; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Moustakas A, 2003, GENE DEV, V17, P2855, DOI 10.1101/gad.1161403; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Osada SI, 2003, DEVELOPMENT, V130, P1783, DOI 10.1242/dev.00401; PaulinLevasseur M, 1996, CHROMOSOMA, V104, P367, DOI 10.1007/s004120050128; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Raju GP, 2003, J BIOL CHEM, V278, P428, DOI 10.1074/jbc.M210505200; Reguly T, 2003, TRENDS CELL BIOL, V13, P216, DOI 10.1016/S0962-8924(03)00075-8; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Wu W, 2002, J CELL SCI, V115, P1361; Wurthner JU, 2001, J BIOL CHEM, V276, P19495, DOI 10.1074/jbc.M006473200; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xiao Z, 2003, J BIOL CHEM, V278, P34245, DOI 10.1074/jbc.M301596200; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yik JHN, 2004, MOL CELL BIOL, V24, P5094, DOI 10.1128/MCB.24.12.5094-5105.2004; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605	55	143	151	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15992	16001		10.1074/jbc.M411234200	http://dx.doi.org/10.1074/jbc.M411234200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15647271	hybrid			2022-12-25	WOS:000228444800066
J	Chen, BPC; Chan, DW; Kobayashi, J; Burma, S; Asaithamby, A; Morotomi-Yano, K; Botvinick, E; Qin, J; Chen, DJ				Chen, BPC; Chan, DW; Kobayashi, J; Burma, S; Asaithamby, A; Morotomi-Yano, K; Botvinick, E; Qin, J; Chen, DJ			Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT MAMMALIAN-CELLS; CATALYTIC SUBUNIT; HOMOLOGOUS RECOMBINATION; HISTONE H2AX; REPAIR; DAMAGE; PATHWAYS; ENDS; ATM; PK	DNA-dependent protein kinase (DNA-PK), consisting of Ku and DNA-PKcs subunits, is the key component of the non-homologous end-joining (NHEJ) pathway of DNA double strand break (DSB) repair. Although the kinase activity of DNA-PKcs is essential for NHEJ, thus far, no in vivo substrate has been conclusively identified except for an autophosphorylation site on DNA-PKcs itself (threonine 2609). Here we report the ionizing radiation (IR)-induced autophosphorylation of DNA-PKcs at a novel site, serine 2056, the phosphorylation of which is required for the repair of DSBs by NHEJ. Interestingly, IR-induced DNA-PKcs autophosphorylation is regulated in a cell cycle-dependent manner with attenuated phosphorylation in the S phase. In contrast, DNA replication-associated DSBs resulted in DNA-PKcs autophosphorylation and localization to DNA damage sites. These results indicate that although IR-induced DNA-PKcs phosphorylation is attenuated in the S phase, DNA-PKcs is preferentially activated by the physiologically relevant DNA replication-associated DSBs at the sites of DNA synthesis.	Univ Texas, SW Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Hiroshima Univ, Dept Radiat Biol, Hiroshima 7348553, Japan; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Irvine, Beckman Laser Inst, Irvine, CA 92612 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine; Baylor College of Medicine; Hiroshima University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Irvine	Chen, DJ (corresponding author), Univ Texas, SW Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA.	benjamin.chen@utsouthwestern.edu	Kobayashi, Junya/AAX-6390-2021; Classen, Scott/AAY-8176-2020	Kobayashi, Junya/0000-0003-4645-7500; 	NCI NIH HHS [P01-CA92584, CA86936, CA50519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050519, R01CA086936, R37CA050519, P01CA092584] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Botvinick EL, 2004, BIOPHYS J, V87, P4203, DOI 10.1529/biophysj.104.049528; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Hendrickson EA, 1997, AM J HUM GENET, V61, P795, DOI 10.1086/514895; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; NAGASAWA H, 1991, RADIAT RES, V126, P280, DOI 10.2307/3577917; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Soubeyrand S, 2003, CANCER RES, V63, P1198; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Verkaik NS, 2002, EUR J IMMUNOL, V32, P701, DOI 10.1002/1521-4141(200203)32:3<701::AID-IMMU701>3.0.CO;2-T; Weterings E, 2003, NUCLEIC ACIDS RES, V31, P7238, DOI 10.1093/nar/gkg889; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m	42	269	275	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14709	14715		10.1074/jbc.M408827200	http://dx.doi.org/10.1074/jbc.M408827200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15677476	Green Submitted, hybrid			2022-12-25	WOS:000228236800047
J	Chen, Y; Balakrishnan, M; Roques, BP; Bambara, RA				Chen, Y; Balakrishnan, M; Roques, BP; Bambara, RA			Acceptor RNA cleavage profile supports an invasion mechanism for HIV-1 minus strand transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; STRONG-STOP DNA; RETROVIRAL NUCLEOCAPSID PROTEINS; REVERSE-TRANSCRIPTASE; H ACTIVITY; IN-VITRO; VIRAL REPLICATION; ESCHERICHIA-COLI; SEQUENCES; MUTATIONS	We previously proposed that HIV-1 minus strand transfer occurs by an acceptor invasion-initiated multistep mechanism. During synthesis of minus strong stop DNA, reverse transcriptase (RT) transiently pauses at the base of TAR before continuing synthesis. Pausing promotes RT-RNase H cleavage of the donor RNA, exposing regions of the cDNA. The acceptor RNA then invades at these locations to interact with the minus strong stop DNA. Whereas primer extension continues on the donor RNA, the cDNA-acceptor hybrid expands by branch migration until transfer of the primer terminus is completed. We present results here showing that the interaction of the acceptor RNA and the cDNA can be determined by examining the time-dependent cleavage of the acceptor RNA by RNase H. Our approach utilizes a combination of RT-RNase H and Escherichia coli RNase H to allow assessment of acceptor-cDNA interactions at high sensitivity. Results show an initial interaction of the acceptor RNA with cDNA at the base of TAR. We observe a time-dependent shift in RNase H susceptibility along the length of the acceptor toward the 5' end, suggesting hybrid propagation from the initial invasion point. Control experiments validate that the RNase H cleavage profile represents the formation and expansion of the acceptor-DNA interaction and that the process is promoted by the nucleocapsid. Observations with this new approach lend additional support to the proposed multistep transfer mechanism.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA; CNRS, INSERM, Fac Pharm,U266, Dept Pharmacochim Mol & Struct,UMR 8600, F-75270 Paris, France	University of Rochester; University of Rochester; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Balakrishnan, M (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.	balakrishnan@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 049573] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; Chen Y, 2003, J BIOL CHEM, V278, P38368, DOI 10.1074/jbc.M305700200; Chen Y, 2003, J BIOL CHEM, V278, P8006, DOI 10.1074/jbc.M210959200; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Guo JH, 1998, J VIROL, V72, P6716, DOI 10.1128/JVI.72.8.6716-6724.1998; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KLAVER B, 1994, NUCLEIC ACIDS RES, V22, P137, DOI 10.1093/nar/22.2.137; Kulpa D, 1997, EMBO J, V16, P856, DOI 10.1093/emboj/16.4.856; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LOBEL LI, 1985, J VIROL, V53, P447, DOI 10.1128/JVI.53.2.447-455.1985; Ohi Y, 2000, J VIROL, V74, P8324, DOI 10.1128/JVI.74.18.8324-8334.2000; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; Raja A, 2003, J BIOL CHEM, V278, P10102, DOI 10.1074/jbc.M210201200; RAMSEY CA, 1993, J VIROL, V67, P4114, DOI 10.1128/JVI.67.7.4114-4121.1993; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; TELESNITSKY A, 1992, J VIROL, V66, P615, DOI 10.1128/JVI.66.2.615-622.1992; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; Topping R, 1998, J MOL BIOL, V281, P1, DOI 10.1006/jmbi.1998.1929; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Wisniewski M, 2000, J BIOL CHEM, V275, P37664, DOI 10.1074/jbc.M007381200; Yin PD, 1997, J VIROL, V71, P2487, DOI 10.1128/JVI.71.3.2487-2494.1997; YOU JC, 1993, J BIOL CHEM, V268, P16519; YOU JC, 1994, J BIOL CHEM, V269, P31491	42	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14443	14452		10.1074/jbc.M412190200	http://dx.doi.org/10.1074/jbc.M412190200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15657044	hybrid			2022-12-25	WOS:000228236800013
J	Dong, XS; Shylnova, O; Challis, JRG; Lye, SJ				Dong, XS; Shylnova, O; Challis, JRG; Lye, SJ			Identification and characterization of the protein-associated splicing factor as a negative co-regulator of the progesterone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; ACTIVATION FUNCTION-1; HORMONE RECEPTORS; RESPONSE ELEMENT; MESSENGER-RNA; B-ISOFORM; COACTIVATOR; BINDING; SUPERFAMILY	Progesterone is essential in all species for the maintenance of pregnancy, and its withdrawal is required to activate the myometrium and to initiate labor. However, unlike most other species, progesterone levels do not fall at term in humans, raising the paradox as to how labor can occur under the continued influence of progesterone. We hypothesized that an endogenous (myometrial) repressor of the progesterone receptor (PR) could induce a functional withdrawal of progesterone and hence lead to the initiation of labor. We used the human PR as bait in a protein pull-down assay and identified polypyrimidine tract-binding protein-associated splicing factor (PSF) as a PR-interacting protein. PSF functions as a potent inhibitor of PR (but not estrogen receptor) transcriptional activity in mammalian cells. It acts through two novel mechanisms, inducing degradation of the PR through the proteasomal pathway and also interfering with binding of PR to its DNA response element. Importantly, in vivo studies in rats demonstrated a dramatic increase in myometrial PSF expression at term that was temporally associated with reduced levels of the myometrial PR. Accordingly, we propose that PSF acts as a PR corepressor and contributes to the functional withdrawal of progesterone and the initiation of human labor.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ctr Womens & Infants Hlth, Program Dev & Fetal Hlth, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Obstet & Gynecol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto	Lye, SJ (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ctr Womens & Infants Hlth, Program Dev & Fetal Hlth, 600 Univ Ave,Suite 982, Toronto, ON M5G 1X5, Canada.	lye@mshri.on.ca	Lye, Stephen J/E-7269-2013; Challis, John RG/E-7419-2014	Lye, Stephen J/0000-0002-3305-4406; 				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Challis JRG, 2000, ENDOCR REV, V21, P514, DOI 10.1210/er.21.5.514; CHALLIS JRG, 2004, MATERNAL FETAL MED P, P79; CHEN ZQ, 1995, J BIOL CHEM, V270, P3863, DOI 10.1074/jbc.270.8.4088; Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100; Dong X, 2004, J MOL ENDOCRINOL, V32, P843, DOI 10.1677/jme.0.0320843; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P313; Glass CK, 2000, GENE DEV, V14, P121; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henderson D, 2001, AM J OBSTET GYNECOL, V185, P579, DOI 10.1067/mob.2001.116753; ING NH, 1992, J BIOL CHEM, V267, P17617; Ishitani K, 2003, BIOCHEM BIOPH RES CO, V306, P660, DOI 10.1016/S0006-291X(03)01021-0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; KRAMER A, 1996, ANNU REV BIOCHEM, V65, P331; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924; MEYER ME, 1992, J BIOL CHEM, V267, P10882; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; NEILSON JP, 2000, COCHRANE DATABASE SY; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; ONATE SA, 1995, SCIENCE, V270, P1354; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PEPE GJ, 1974, ENDOCRINOLOGY, V95, P275, DOI 10.1210/endo-95-1-275; Pieber D, 2001, MOL HUM REPROD, V7, P875, DOI 10.1093/molehr/7.9.875; PIERSANTI M, 1995, ENDOCRINOLOGY, V136, P3571, DOI 10.1210/en.136.8.3571; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Shynlova O, 2004, BIOL REPROD, V70, P986, DOI 10.1095/biolreprod.103.023648; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Urban RJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE423, DOI 10.1152/ajpendo.00057.2002; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; Zhao Y, 2002, J BIOL CHEM, V277, P30031, DOI 10.1074/jbc.M203811200	47	62	65	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13329	13340		10.1074/jbc.M409187200	http://dx.doi.org/10.1074/jbc.M409187200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15668243	hybrid			2022-12-25	WOS:000228095500019
J	Zhou, XB; Wang, R; Fan, LB; Li, Y; Ma, L; Yang, ZY; Yu, W; Jing, NH; Zhu, XL				Zhou, XB; Wang, R; Fan, LB; Li, Y; Ma, L; Yang, ZY; Yu, W; Jing, NH; Zhu, XL			Mitosin/CENP-F as a negative regulator of activating transcription factor-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CENP-F; LEUCINE-ZIPPER; NUCLEAR-MATRIX; DNA-BINDING; CELL-CYCLE; KINETOCHORE PROTEIN; TARGETED DISRUPTION; CYTOPLASMIC DYNEIN; MAMMALIAN-CELLS	Mitosin/CENP-F is a human nuclear matrix protein with multiple leucine zipper motifs. Its accumulation in S-G(2) phases and transient kinetochore localization in mitosis suggest a multifunctional protein for cell proliferation. Moreover, its murine and avian orthologs are implicated in myocyte differentiation. Here we report its interaction with activating transcription factor-4 (ATF4), a ubiquitous basic leucine zipper transcription factor important for proliferation, differentiation, and stress response. The C-terminal portion of mitosin between residues 2488 and 3113 bound to ATF4 through two distinct domains, one of which was a leucine zipper motif. Mitosin mutants containing these domains were able to either supershift or disrupt the ATF4-DNA complex. On the other hand, ATF4, but not ATF1-3 or ATF6, interacted with mitosin through a region containing the basic leucine zipper motif. Moreover, overexpression of full-length mitosin repressed the transactivation activity of ATF4 in dual luciferase-based reporter assays, while knocking down mitosin expression manifested the opposite effects. These findings suggest mitosin to be a negative regulator of ATF4 in interphase through direct interaction.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Zhu, XL (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	xlzhu@sibs.ac.cn	Yang, Zhenye/G-9641-2018; yang, zhenye/D-3519-2009; yu, WEI/F-2826-2014; yu, wei/A-2287-2013	Li, Yan/0000-0003-4962-9910				Abel T, 1998, BRAIN RES REV, V26, P360, DOI 10.1016/S0165-0173(97)00050-7; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155; Chen A, 2003, NEURON, V39, P655, DOI 10.1016/S0896-6273(03)00501-4; Clark GM, 1997, CANCER RES, V57, P5505; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; de la Guardia C, 2001, HEAD NECK-J SCI SPEC, V23, P104; Dees E, 2000, DEV DYNAM, V219, P169, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1055>3.3.CO;2-2; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Goodwin RL, 1999, J BIOL CHEM, V274, P18597, DOI 10.1074/jbc.274.26.18597; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Hong S, 2004, CELL DEATH DIFFER, V11, P714, DOI 10.1038/sj.cdd.4401405; Hussein D, 2002, J CELL SCI, V115, P3403; Kato Y, 1999, MOL CELL ENDOCRINOL, V154, P151, DOI 10.1016/S0303-7207(99)00078-7; Konstantinidou AE, 2003, HISTOL HISTOPATHOL, V18, P67, DOI 10.14670/HH-18.67; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Loidl P, 1995, INT REV CYTOL, V162B, P377; Ma YJ, 2003, NAT IMMUNOL, V4, P310, DOI 10.1038/ni0403-310; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Pabon-Pena LM, 2000, J BIOL CHEM, V275, P21453, DOI 10.1074/jbc.M000518200; Podust LM, 2001, J BIOL CHEM, V276, P505, DOI 10.1074/jbc.M005594200; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Stein GS, 2003, TRENDS CELL BIOL, V13, P584, DOI 10.1016/j.tcb.2003.09.009; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wei Y, 1996, DEVELOPMENT, V122, P2779; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yang ZY, 2003, CELL RES, V13, P275, DOI 10.1038/sj.cr.7290172; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; ZHU XL, 1995, J BIOL CHEM, V270, P19545, DOI 10.1074/jbc.270.33.19545; ZHU XL, 1995, MOL CELL BIOL, V15, P5017; Zhu XL, 1999, MOL CELL BIOL, V19, P1016	49	22	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13973	13977		10.1074/jbc.M414310200	http://dx.doi.org/10.1074/jbc.M414310200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15677469	hybrid			2022-12-25	WOS:000228095500099
J	Heo, J; Campbell, SL				Heo, J; Campbell, SL			Superoxide anion radical modulates the activity of Ras and Ras-related GTPases by a radical-based mechanism similar to that of nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SYNTHASE GENERATES SUPEROXIDE; ACTIVATED PROTEIN-KINASE; HA-RAS; XANTHINE-OXIDASE; STRUCTURAL BASIS; ANGIOTENSIN-II; NITROGEN-DIOXIDE; KINETIC-ANALYSIS; P21(RAS)	Ras GTPases cycle between inactive GDP-bound and active GTP-bound states to modulate a diverse array of processes involved in cellular growth control. The activity of Ras is up-regulated by cellular agents, including both protein ( guanine nucleotide exchange factors) and redox-active agents ( nitric oxide ( NO) and superoxide anion radical (O-2(.-))). We have recently elucidated the mechanism by which NO promotes guanine nucleotide dissociation of redox-active NKCD motif-containing Ras and Ras-related GTPases. In this study, we show that guanine nucleotide dissociation is enhanced upon exposure of the redox-active GTPases, Ras and Rap1A, to O-2(.-) and provide evidence for the efficient guanine nucleotide reassociation in the presence of the radical quenching agent ascorbate to complete guanine nucleotide exchange. In vivo, guanine nucleotide reassociation is necessary to populate Ras in its biologically active GTP-bound form after the dissociation of GDP. We further show that treatment of the redox-active GTPases with O-2(.-) releases GDP in the form of an unstable oxygenated GDP adduct, putatively assigned as 5-oxo-GDP. 5-Oxo-GDP was not produced from either the C118S or the F28L Ras variants upon the treatment of O-2(.-), supporting the involvement of residues Cys118 and Phe(28) in O-2(.-)-mediated Ras guanine nucleotide dissociation. These results indicate that the mechanism of O2.- mediated Ras guanine nucleotide dissociation is similar to that of NO/O-2-mediated Ras guanine nucleotide dissociation.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Campbell, SL (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 530 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	campbesl@med.unc.edu		campbell, sharon/0000-0003-0311-409X	NCI NIH HHS [R01CA89614-01A1] Funding Source: Medline; NHLBI NIH HHS [P01 HL45100] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Baker TL, 2000, J BIOL CHEM, V275, P22037, DOI 10.1074/jbc.M001813200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Bonini MG, 2004, BIOCHEMISTRY-US, V43, P344, DOI 10.1021/bi035606p; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; Chuang JI, 2003, ONCOGENE, V22, P1349, DOI 10.1038/sj.onc.1206289; Dawson TM, 1998, PROG BRAIN RES, V118, P3; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; Ford E, 2002, FREE RADICAL BIO MED, V32, P1314, DOI 10.1016/S0891-5849(02)00850-X; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; Heo J, 2005, J MOL BIOL, V346, P1423, DOI 10.1016/j.jmb.2004.12.050; Heo JY, 2000, BIOCHEMISTRY-US, V39, P7956, DOI 10.1021/bi992958g; Heo JY, 2004, BIOCHEMISTRY-US, V43, P2314, DOI 10.1021/bi035275g; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; Hodges GR, 2000, FREE RADICAL BIO MED, V29, P434, DOI 10.1016/S0891-5849(00)00298-7; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Ito Y, 1997, BIOCHEMISTRY-US, V36, P9109, DOI 10.1021/bi970296u; Jourd'heuil D, 2003, J BIOL CHEM, V278, P15720, DOI 10.1074/jbc.M300203200; KHAN AU, 1994, P NATL ACAD SCI USA, V91, P12365, DOI 10.1073/pnas.91.26.12365; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V151, P7182; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LEUSEN JHW, 1996, FRONT BIOSCI, V1, P72; MCCLURE WR, 1969, BIOCHEMISTRY-US, V8, P2782, DOI 10.1021/bi00835a014; Meneshian A, 2002, MICROCIRCULATION, V9, P161, DOI 10.1038/sj.mn.7800136; Misiaszek R, 2004, J BIOL CHEM, V279, P32106, DOI 10.1074/jbc.M313904200; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Mittar D, 2004, BIOCHEM BIOPH RES CO, V322, P203, DOI 10.1016/j.bbrc.2004.07.107; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Saavedra AP, 2002, ONCOGENE, V21, P778, DOI 10.1038/sj.onc.1205123; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheidig AJ, 1999, STRUCTURE, V7, P1311, DOI 10.1016/S0969-2126(00)80021-0; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; SEGEL IH, 1993, ENZYME KINETICS BEHA, P85; Shafirovich V, 2001, CHEM RES TOXICOL, V14, P233, DOI 10.1021/tx000204t; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; STEINMAN HM, 1974, J BIOL CHEM, V249, P7326; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; VAINSHTEIN BK, 1981, NATURE, V293, P411, DOI 10.1038/293411a0; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Yoneyama H, 2001, BIOCHEM J, V360, P247, DOI 10.1042/0264-6021:3600247	69	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12438	12445		10.1074/jbc.M414282200	http://dx.doi.org/10.1074/jbc.M414282200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15684418	Green Published, hybrid			2022-12-25	WOS:000227922000046
J	Matsumura, T; Suzuki, T; Aizawa, K; Munemasa, Y; Muto, S; Horikoshi, M; Nagai, R				Matsumura, T; Suzuki, T; Aizawa, K; Munemasa, Y; Muto, S; Horikoshi, M; Nagai, R			The deacetylase HDAC1 negatively regulates the cardiovascular transcription factor Kruppel-like factor 5 through direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HISTONE DEACETYLASES; 3 FINGERS; GENE; ACETYLATION; FAMILY; CHAIN; SP1; PHOSPHORYLATION; ACTIVATION	Transcription is regulated by a network of transcription factors and related cofactors that act in concert with the general transcription machinery. Elucidating their underlying interactions is important for understanding the mechanisms regulating transcription. Recently, we have shown that Kruppel-like factor KLF5, a member of the Sp/KLF family of zinc finger factors and a key regulator of cardiovascular remodeling, is regulated positively by the acetylase p300 and negatively by the oncogenic regulator SET through coupled interaction and regulation of acetylation. Here, we have shown that the deacetylase HDAC1 can negatively regulate KLF5 through direct interaction. KLF5 interacts with HDAC1 in the cell and in vitro. Gel shift DNA binding assay showed that their interaction inhibits the DNA binding activity of KLF5, suggesting a property of HDAC1 to directly affect the DNA binding affinity of a transcription factor. Reporter assay also revealed that HDAC1 suppresses KLF5-dependent promoter activation. Additionally, overexpression of HDAC1 suppressed KLF5-dependent activation of its endogenous downstream gene, platelet-derived growth factor-A chain gene, when activated by phorbol ester. Further, HDAC1 binds to the first zinc finger of KLF5, which is the same region where p300 interacts with KLF5 and, intriguingly, HDAC1 inhibits binding of p300 to KLF5. Direct competitive interaction between acetylase and deacetylase has been hitherto unknown. Collectively, the transcription factor KLF5 is negatively regulated by the deacetylase HDAC1 through direct effects on its activities (DNA binding activity, promoter activation) and further through inhibition of interaction with p300. These findings suggest a novel role and mechanism for regulation of transcription by deacetylase.	Univ Tokyo, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dept Clin Bioinformat, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Dev Biol Lab, Tokyo 1130032, Japan; Japan Sci & Technol Corp, Horikoshi Gene Selector Project Exploratory Res A, Tsukuba, Ibaraki 3002635, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Suzuki, T (corresponding author), Univ Tokyo, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	torusuzu-tky@umin.ac.jp		Suzuki, Toru/0000-0002-8371-664X				Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kornberg Roger D., 1999, Trends in Cell Biology, V9, pM46, DOI 10.1016/S0962-8924(99)01679-7; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Miyamoto S, 2003, MOL CELL BIOL, V23, P8528, DOI 10.1128/MCB.23.23.8528-8541.2003; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Suzuki T, 2003, J BIOL CHEM, V278, P28758, DOI 10.1074/jbc.M302228200; SUZUKI T, 2003, GENE THER MOL BIOL, V7, P91; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang ZP, 2003, NUCLEIC ACIDS RES, V31, P2196, DOI 10.1093/nar/gkg310; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	38	52	55	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12123	12129		10.1074/jbc.M410578200	http://dx.doi.org/10.1074/jbc.M410578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668237	hybrid			2022-12-25	WOS:000227922000009
J	Tlapak-Simmons, VL; Baron, CA; Gotschall, R; Haque, D; Canfield, WM; Weigel, PH				Tlapak-Simmons, VL; Baron, CA; Gotschall, R; Haque, D; Canfield, WM; Weigel, PH			Hyaluronan biosynthesis by class I streptococcal hyaluronan synthases occurs at the reducing end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DIRECTIONALITY; POLYSACCHARIDE SYNTHESIS; CHAIN GROWTH; EQUISIMILIS; PYOGENES; ACID; GENE; SEQUENCE; GLYCOSYLTRANSFERASES; POLYMERIZATION	Previous studies reached different conclusions about whether class I hyaluronan synthases ( HASs) elongate hyaluronic acid ( HA) by addition to the reducing or the nonreducing end. Here we used two strategies to determine the direction of HA synthesis by purified class I HASs from Streptococcus equisimilis and Streptococcus pyogenes. In the first strategy we used each of the two UDP-sugar substrates separately to pulse label either the beginning or the end of HA chains. We then quantified the relative rates of radioactive HA degradation by treatment with beta- glycosidases that act at the nonreducing end. The results with both purified HASs demonstrated that HA elongation occurred at the reducing end. In the second strategy, we used purified S. equisimilis HAS, UDP- glucuronic acid, and UDP[ beta-P-32]- GlcNAc to radiolabel nascent HA chains. Under conditions of limiting substrate, the P-32-labeled products were separated from the substrates by paper chromatography and identified as HA-[P-32] UDP saccharides based on their degradation by snake venom phosphodiesterase or hyaluronidase and by their binding to a specific HA-binding protein. The P-32 radioactivity was chased ( released) by incubation with unlabeled UDP- sugars, showing that the HA- UDP linkages turn over during HA biosynthesis. In contrast, HA-[P-32] UDP products made by the purified class II Pasteurella multocida HAS were not released by adding unlabeled UDP- sugars, consistent with growth at the nonreducing end for this enzyme. The results demonstrate that the streptococcal class I HAS enzymes polymerize HA chains at the reducing end.	Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Genzyme Glycobiol Res Inst, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Sanofi-Aventis	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA.	paul-weigel@ouhsc.edu			NIGMS NIH HHS [R01 GM035978, GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asplund T, 1998, BBA-GEN SUBJECTS, V1380, P377, DOI 10.1016/S0304-4165(98)00010-5; BODEVINAUTHELET S, 2004, J BIOL CHEM     1224; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Cartee RT, 2000, J BIOL CHEM, V275, P3907, DOI 10.1074/jbc.275.6.3907; CHRISTNER JE, 1979, J BIOL CHEM, V254, P4624; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; Deangelis PL, 2003, J BIOL CHEM, V278, P35199, DOI 10.1074/jbc.M306431200; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7033, DOI 10.1128/jb.175.21.7033-7044.1993; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Hoshi H, 2004, J BIOL CHEM, V279, P2341, DOI 10.1074/jbc.M305723200; IELPI L, 1993, J BACTERIOL, V175, P2490, DOI 10.1128/JB.175.9.2490-2500.1993; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; KONGTAWELERT P, 1990, ANAL BIOCHEM, V185, P313, DOI 10.1016/0003-2697(90)90300-X; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; LI SC, 1970, J BIOL CHEM, V245, P5153; Lipmann F, 1968, Essays Biochem, V4, P1; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; ROBBINS PW, 1967, SCIENCE, V158, P1536, DOI 10.1126/science.158.3808.1536; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 2004, BIOCHEMISTRY-US, V43, P9234, DOI 10.1021/bi049468v; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Tlapak-Simmons VL, 2002, GLYCOBIOLOGY, V12, P707; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Weigel PH, 2002, IUBMB LIFE, V54, P201, DOI 10.1080/15216540214931; WEIGEL PH, 2004, GLYCOFORUM HYALURONA; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497	34	46	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13012	13018		10.1074/jbc.M409788200	http://dx.doi.org/10.1074/jbc.M409788200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15668242	Green Accepted, hybrid			2022-12-25	WOS:000227922000111
J	Gajate, C; Mollinedo, F				Gajate, C; Mollinedo, F			Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LEUKEMIC-CELLS; HUMAN T-LYMPHOCYTES; MEMBRANE RAFTS; SIGNAL-TRANSDUCTION; ANCHORED PROTEINS; FAS; ACTIVATION; MECHANISM; REDISTRIBUTION; RECRUITMENT	While investigating the mechanism of action of the novel antitumor drug Aplidin, we have discovered a potent and novel cell-killing mechanism that involves the formation of Fas/CD95-driven scaffolds in membrane raft clusters housing death receptors and apoptosis-related molecules. Fas, tumor necrosis factor-receptor 1, and tumor necrosis factor-related apoptosis-inducing ligand receptor 2/death receptor 5 were clustered into lipid rafts in leukemic Jurkat cells following Aplidin treatment, the presence of Fas being essential for apoptosis. Preformed membrane-bound Fas ligand (FasL) as well as downstream signaling molecules, including Fas-associated death domain-containing protein, procaspase-8, procaspase-10, c-Jun amino-terminal kinase, and Bid, were also translocated into lipid rafts, connecting death receptor extrinsic and mitochondrial intrinsic apoptotic pathways. Blocking Fas/FasL interaction partially inhibited Aplidin-induced apoptosis. Aplidin was rapidly incorporated into membrane rafts, and drug uptake was inhibited by lipid raft disruption. Actin-linking proteins ezrin, moesin, RhoA, and RhoGDI were conveyed into Fas-enriched rafts in drug-treated leukemic cells. Disruption of lipid rafts and interference with actin cytoskeleton prevented Fas clustering and apoptosis. Thus, Aplidin-induced apoptosis involves Fas activation in both a FasL-independent way and, following Fas/FasL interaction, an autocrine way through the concentration of Fas, membrane-bound FasL, and signaling molecules in membrane rafts. These data indicate a major role of actin cytoskeleton in the formation of Fas caps and highlight the crucial role of the clusters of apoptotic signaling molecule-enriched rafts in apoptosis, acting as concentrators of death receptors and downstream signaling molecules and as the linchpin from which a potent death signal is launched.	Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Mollinedo, F (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	fmollin@usal.es		Gajate, Consuelo/0000-0003-0604-6459				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cuadrado A, 2004, ONCOGENE, V23, P4673, DOI 10.1038/sj.onc.1207636; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2003, CLIN CANCER RES, V9, P1535; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Geldof AA, 1999, CANCER CHEMOTH PHARM, V44, P312, DOI 10.1007/s002800050983; Giurisato E, 2003, J BIOL CHEM, V278, P6771, DOI 10.1074/jbc.M210758200; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Larbi A, 2004, J LEUKOCYTE BIOL, V75, P373, DOI 10.1189/jlb.0703319; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MOLLINEDO F, 2004, FAS SIGNALING, P1; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; van der Luit AH, 2002, J BIOL CHEM, V277, P39541, DOI 10.1074/jbc.M203176200; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4	29	157	169	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11641	11647		10.1074/jbc.M411781200	http://dx.doi.org/10.1074/jbc.M411781200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15659383	hybrid			2022-12-25	WOS:000227761800092
J	Grove, DE; Willcox, S; Griffith, JD; Bryant, FR				Grove, DE; Willcox, S; Griffith, JD; Bryant, FR			Differential single-stranded DNA binding properties of the paralogous SsbA and SsbB proteins from Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SSB; MECHANISM; RECOMBINATION; VISUALIZATION; COMPLEXES; EXCHANGE; GENES	The naturally transformable Gram-positive bacterium Streptococcus pneumoniae has two single-stranded DNA-binding (SSB) proteins, designated SsbA and SsbB. The SsbA protein is similar in size to the well characterized SSB protein from Escherichia coli (SsbEc). The SsbB protein, in contrast, is a smaller protein that is specifically induced during natural transformation and has no counterpart in E. coli. In this report, the single-stranded DNA (ssDNA) binding properties of the SsbA and SsbB proteins were examined and compared with those of the SsbEc protein. The ssDNA binding characteristics of the SsbA protein were similar to those of the SsbEc protein in every ssDNA binding assay used in this study. The SsbB protein differed from the SsbA and SsbEc proteins, however, both in its binding to short homopolymeric dT(n) oligomers (as judged by polyacrylamide gel-shift assays) and in its binding to the longer naturally occurring phi X and M13 ssDNAs (as judged by agarose gel-shift assays and electron microscopic analysis). The results indicate that an individual SsbB protein binds to ssDNA with an affinity that is similar or higher than that of the SsbA and SsbEc proteins. However, the manner in which multiple SsbB proteins assemble onto a ssDNA molecule differs from that observed with the SsbA and SsbEc proteins. These results represent the first analysis of paralogous SSB proteins from any bacterial species and provide a foundation for further investigations into the biological roles of these proteins.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Bryant, FR (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, 615 N Wolfe St, Baltimore, MD 21205 USA.	fbryant@jhsph.edu			NIEHS NIH HHS [ES07141] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; Claverys JP, 2000, MOL MICROBIOL, V35, P251, DOI 10.1046/j.1365-2958.2000.01718.x; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Hedayati MA, 2002, J BIOL CHEM, V277, P24863, DOI 10.1074/jbc.M202041200; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P11611, DOI 10.1021/bi020361m; Lindner C, 2004, J BACTERIOL, V186, P1097, DOI 10.1128/JB.186.4.1097-1105.2004; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Peterson SN, 2004, MOL MICROBIOL, V51, P1051, DOI 10.1046/j.1365-2958.2003.03907.x; Savvides SN, 2004, PROTEIN SCI, V13, P1942, DOI 10.1110/ps.04661904; Steffen SE, 2002, J BIOL CHEM, V277, P14493, DOI 10.1074/jbc.M112444200; Steffen SE, 2001, ARCH BIOCHEM BIOPHYS, V388, P165, DOI 10.1006/abbi.2001.2286	13	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11067	11073		10.1074/jbc.M414057200	http://dx.doi.org/10.1074/jbc.M414057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647253	Green Published, hybrid			2022-12-25	WOS:000227761800024
J	He, LP; Hewavitharana, T; Soboloff, J; Spassova, MA; Gill, DL				He, LP; Hewavitharana, T; Soboloff, J; Spassova, MA; Gill, DL			A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; PHOSPHOLIPASE-C-GAMMA; CA2+ ENTRY; 2-AMINOETHOXYDIPHENYL BORATE; TRISPHOSPHATE RECEPTOR; CALCIUM-ENTRY; ACTIVATION; DEPLETION; INFLUX; CAT1	The coupling between receptor-mediated Ca2+ store release and the activation of "store-operated" Ca2+ entry channels is an important but so far poorly understood mechanism. The transient receptor potential (TRP) superfamily of channels contains several members that may serve the function of store-operated channels (SOCs). The 3,5-bis(trifluoromethyl) pyrazole derivative, BTP2, is a recently described inhibitor of SOC activity in T-lymphocytes. We compared its action on SOC activation in a number of cell types and evaluated its modification of three specific TRP channels, canonical transient receptor potential 3 (TRPC3), TRPC5, and TRPV6, to throw light on any link between SOC and TRP channel function. Using HEK293 cells, DT40 B cells, and A7r5 smooth muscle cells, BTP2 blocked store-operated Ca2+ entry within 10 min with an IC50 of 0.1-0.3 mu M. Store-operated Ca2+ entry induced by Ca2+ pump blockade or in response to muscarinic or B cell receptor activation was similarly sensitive to BTP2. Using the T3-65 clonal HEK293 cell line stably expressing TRPC3 channels, TRPC3-mediated Sr2+ entry activated by muscarinic receptors was also blocked by BTP2 with an IC50 of < 0.3 mu M. Importantly, direct activation of TRPC3 channels by diacylglycerol was also blocked by BTP2 ( IC50 similar to 0.3 mu M). BTP2 still blocked TRPC3 in medium with N-methyl-D- glucamine-chloride replacing Na+, indicating BTP2 did not block divalent cation entry by depolarization induced by activating monovalent cation entry channels. Whereas whole-cell carbachol-induced TRPC3 current was blocked by 3 mu M BTP2, single TRPC3 channel recordings revealed persistent short openings suggesting BTP2 reduces the open probability of the channel rather than its pore properties. TRPC5 channels transiently expressed in HEK293 cells were blocked by BTP2 in the same range as TRPC3. However, function of the highly Ca2+-selective TRPV6 channel, with many channel properties akin to SOCs, was entirely unaffected by BTP2. The results indicate a strong functional link between the operation of expressed TRPC channels and endogenous SOC activity.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	dgill@umaryland.edu	Soboloff, Jonathan/I-6995-2012	Soboloff, Jonathan/0000-0001-5192-1297	NHLBI NIH HHS [HL55426] Funding Source: Medline; NIAID NIH HHS [AI058173] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058173] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 2004, SCI STKE, V243, pPE33; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; GUDERMANN T, 2004, SCI STKE, V243, pPE35; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Ishikawa J, 2003, J IMMUNOL, V170, P4441, DOI 10.4049/jimmunol.170.9.4441; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2003, BIOCHEM J, V376, P667, DOI 10.1042/BJ20031345; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Nilius B, 2003, J BIOL CHEM, V278, P30813, DOI 10.1074/jbc.M305127200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Prakriya M, 2003, CELL CALCIUM, V33, P311, DOI 10.1016/S0143-4160(03)00045-9; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney J W Jr, 2001, Mol Interv, V1, P84; Putney JW, 2001, J CELL SCI, V114, P2223; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; SHORT AD, 1993, J BIOL CHEM, V268, P25887; Shuttleworth TJ, 2003, BIOCHEM SOC T, V31, P916; SHUTTLEWORTH TJ, 2004, SCI STKE, V243, pPE39; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Takezawa R, 2004, FASEB J, V18, pA1281; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; van Rossum DB, 2004, P NATL ACAD SCI USA, V101, P2323, DOI 10.1073/pnas.0308565100; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Venkatachalam Kartik, 2004, Novartis Found Symp, V258, P172; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	48	172	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10997	11006		10.1074/jbc.M411797200	http://dx.doi.org/10.1074/jbc.M411797200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15647288	hybrid			2022-12-25	WOS:000227761800016
J	Tsvetkov, L; Stern, DF				Tsvetkov, L; Stern, DF			Interaction of chromatin-associated Plk1 and Mcm7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE KINASE-1; DNA-DAMAGE; CELL-CYCLE; REPLICATION; PHOSPHORYLATION; PROTEINS; BOX; TARGET; DOMAIN; CHROMOSOMES	Plk1 is a multifunctional protein kinase involved in regulation of mitotic entry, chromosome segregation, centrosome maturation, and mitotic exit. Plk1 is a target of DNA damage checkpoints and aids resumption of the cell cycle during recovery from G(2) arrest. The polo-box domain (PBD) of Plk1 interacts with phosphoproteins and localizes Plk1 to some mitotic structures. In a search for proteins that interact with the PBD of Plk1, we identified two of the minichromosome maintenance (MCM) proteins, Mcm2 and Mcm7. Co-immunoprecipitation and immunoblot analysis showed an interaction between full-length Plk1 and all other members of the MCM2-7 protein complex. Endogenous Plk1 co-immunoprecipitates with basal forms of Mcm7 as well as with slower migrating forms of Mcm7, induced in response to DNA damage. The strongest interaction between endogenous Plk1 and Mcm7 was detected in a soluble chromatin fraction. These findings suggest a new function for Plk1 in coordination of DNA replication and mitotic events.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06511 USA	Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,BML 342, New Haven, CT 06511 USA.	DF.Stern@yale.edu			NCI NIH HHS [01CA82257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Dimitrova DS, 2002, J CELL SCI, V115, P51; Dohrmann PR, 1999, GENETICS, V151, P965; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fitch MJ, 2003, J BIOL CHEM, V278, P25408, DOI 10.1074/jbc.M300699200; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Garber PM, 2002, GENETICS, V161, P521; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Klemm RD, 2001, P NATL ACAD SCI USA, V98, P8361, DOI 10.1073/pnas.131006898; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Lei M, 2001, J CELL SCI, V114, P1447; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shohet JM, 2002, CANCER RES, V62, P1123; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yuan JP, 2002, CANCER RES, V62, P4186	35	42	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11943	11947		10.1074/jbc.M413514200	http://dx.doi.org/10.1074/jbc.M413514200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15654075	hybrid			2022-12-25	WOS:000227761800125
J	Li, YZ; Batra, S; Sassano, A; Majchrzak, B; Levy, DE; Gaestel, M; Fish, EN; Davis, RJ; Platanias, LC				Li, YZ; Batra, S; Sassano, A; Majchrzak, B; Levy, DE; Gaestel, M; Fish, EN; Davis, RJ; Platanias, LC			Activation of mitogen-activated protein kinase kinase (MKK) 3 and MKK6 by Type I interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MEDIATES TYROSINE PHOSPHORYLATION; STAT1 SERINE PHOSPHORYLATION; CRKL ADAPTER PROTEIN; P38 MAP KINASE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; TNF-ALPHA; JAK-STAT; PHOSPHATIDYLINOSITOL 3-KINASE	There is accumulating evidence that the p38 MAP kinase pathway plays important roles in Type I interferon (IFN) signaling, but the mechanisms regulating p38 activation during engagement of the Type I IFN receptor remain to be defined. We sought to identify the events that lead to activation of the p38 MAP kinase in response to Type I IFNs. Our data demonstrate that treatment of sensitive cell lines with IFN alpha results in activation of both MAP kinase kinase 3 (MKK3) and MAP kinase kinase 6 (MKK6). Such IFN-inducible activation of MKK3 and MKK6 is essential for downstream phosphorylation and activation of the p38 MAP kinase, as shown by studies using mouse embryonic fibroblasts (MEFs) with targeted disruption of the Mkk3 and Mkk6 genes (MKK3-/- MKK6-/-). Similarly, IFN-dependent activation of the downstream effectors of p38, MAPKAPK-2 and MAPKAPK-3, is not detectable in cells lacking Mkk3 and Mkk6, demonstrating that the function of these MAP kinase kinases is required for full activation of the p38 pathway. To define the functional relevance of MKK3/6 engagement in Type I IFN signaling, IFN-inducible gene transcription was evaluated in the MKK3/MKK6 double knock-out cells. IFN alpha- and IFN beta-dependent transcription via either interferon-stimulated response element or IFN gamma activated site elements was defective in MKK3 -/-/MKK6 -/- MEFs in luciferase reporter assays. In addition, IFN-dependent induction of two genes known to be of importance in the generation of IFN responses, Isg15 and Irf-9, was diminished in the absence of Mkk3 and Mkk6. The effects of Mkk3 and Mkk6 on IFN-dependent transcription were unrelated to any effects on the phosphorylation and activation of STAT proteins, indicating the presence of a STAT-independent mechanism. Altogether, our findings demonstrate that MKK3 and MKK6 are rapidly activated during engagement of the Type I IFN receptor and play important roles in Type I IFN signaling and the generation of IFN responses.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; Lakeside Vet Affairs Med Ctr, Chicago, IL 60611 USA; Univ Hlth Network, Toronto Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany; Univ Massachusetts, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Program Mol Med, Worcester, MA 01605 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; New York University; Hannover Medical School; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 710 N Fairbanks St,Olson 8250, Chicago, IL 60611 USA.	l-platanias@northwestern.edu	Gaestel, Matthias/A-6560-2013; Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Gaestel, Matthias/0000-0002-4944-4652; Levy, David/0000-0002-7320-7788	NCI NIH HHS [CA77816, CA94079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094079, R01CA077816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Caraglia M, 1999, CELL DEATH DIFFER, V6, P773, DOI 10.1038/sj.cdd.4400550; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Doualla-Bell F, 2001, ENDOCRINOLOGY, V142, P5107, DOI 10.1210/en.142.12.5107; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200; Lekmine F, 2002, BIOCHEM BIOPH RES CO, V291, P744, DOI 10.1006/bbrc.2002.6516; Li YZ, 2004, J BIOL CHEM, V279, P970, DOI 10.1074/jbc.M309927200; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; MORIGUCHI T, 1996, J BIOL CHEM, V271, P13765; MORIGUCHI T, 1996, J BIOL CHEM, V271, P13775; Parmar Simrit, 2003, Current Opinion in Oncology, V15, P431, DOI 10.1097/00001622-200311000-00005; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salojin KV, 1999, J IMMUNOL, V163, P844; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Srivastava KK, 2004, J BIOL CHEM, V279, P29911, DOI 10.1074/jbc.M401997200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Verma A, 2002, LEUKEMIA LYMPHOMA, V43, P703, DOI 10.1080/10428190290016782; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Verma A, 2002, J IMMUNOL, V168, P5984, DOI 10.4049/jimmunol.168.12.5984; WEN Z, 1995, CELL, V28, P241; Winston BW, 1997, J IMMUNOL, V159, P4491; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	66	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10001	10010		10.1074/jbc.M410972200	http://dx.doi.org/10.1074/jbc.M410972200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644321	hybrid			2022-12-25	WOS:000227559600033
J	Ribeiro, CMP; Paradiso, AM; Carew, MA; Shears, SB; Boucher, RC				Ribeiro, CMP; Paradiso, AM; Carew, MA; Shears, SB; Boucher, RC			Cystic fibrosis airway epithelial Ca-i(2+) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CAPACITATIVE CALCIUM-ENTRY; ENDOPLASMIC-RETICULUM; CHLORIDE CONDUCTANCE; ACTIVATION; CLEARANCE; CELLS; CA2+; CFTR	In cystic fibrosis (CF) airways, abnormal epithelial ion transport likely initiates mucus stasis, resulting in persistent airway infections and chronic inflammation. Mucus clearance is regulated, in part, by activation of apical membrane receptors coupled to intracellular calcium (Ca-i(2+)) mobilization. We have shown that Ca-i(2+) signals resulting from apical purinoceptor (P2Y(2)-R) activation are increased in CF compared with normal human airway epithelia. The present study addressed the mechanism for the larger apical P2Y(2)-R-dependent Ca-i(2+) signals in CF human airway epithelia. We show that the increased Ca-i(2+) mobilization in CF was not specific to P2Y(2)-Rs because it was mimicked by apical bradykinin receptor activation, and it did not result from a greater number of P2Y(2)-R or a more efficient coupling between P2Y(2)-Rs and phospholipase C-generated inositol 1,4,5-trisphosphate. Rather, the larger apical P2Y(2)-R activation-promoted Ca-i(2+) signals in CF epithelia resulted from an increased density and Ca2+ storage capacity of apically confined endoplasmic reticulum (ER) Ca2+ stores. To address whether the ER upregulation resulted from ER retention of misfolded Delta F508 CFTR or was an acquired response to chronic luminal airway infection/inflammation, three approaches were used. First, ER density was studied in normal and CF sweat duct human epithelia expressing high levels of Delta F508 CFTR, and it was found to be the same in normal and CF epithelia. Second, apical ER density was morphometrically analyzed in airway epithelia from normal subjects, Delta F508 homozygous CF patients, and a disease control, primary ciliary dyskinesia; it was found to be greater in both CF and primary ciliary dyskinesia. Third, apical ER density and P2Y(2)-R activation-mobilized Ca-i(2+), which were investigated in airway epithelia in a long term culture in the absence of luminal infection, were similar in normal and CF epithelia. To directly test whether luminal infection/inflammation triggers an up-regulation of the apically confined ER Ca2+ stores, normal airway epithelia were chronically exposed to supernatant from mucopurulent material from CF airways. Supernatant treatment expanded the apically confined ER, resulting in larger apical P2Y(2)-R activation-dependent Ca-i(2+) responses, which reproduced the increased Ca-i(2+) signals observed in CF epithelia. In conclusion, the mechanism for the larger Ca-i(2+) signals elicited by apical P2Y(2)-R activation in CF airway epithelia is an expansion of the apical ER Ca2+ stores triggered by chronic luminal airway infection/inflammation. Greater ER-derived Ca-i(2+) signals may provide a compensatory mechanism to restore, at least acutely, mucus clearance in CF airways.	Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; NIEHS, Inositide Signaling Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Ribeiro, CMP (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.	carla_ribeiro@med.unc.edu	Ribeiro, Carla Maria P/A-6955-2009; Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NHLBI NIH HHS [HL60280, HL34322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060280, P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080046, ZIAES080046] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Carew MA, 2000, J BIOL CHEM, V275, P26906; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; ELIASSON R, 1977, NEW ENGL J MED, V297, P1, DOI 10.1056/NEJM197707072970101; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Guo Q, 1997, J NEUROSCI, V17, P4212; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KNOWLES MR, 1992, CHEST, V101, pS60, DOI 10.1378/chest.101.3_Supplement.60S; Knowles MR, 1998, CILIA, MUCUS, AND MUCOCILIARY INTERACTIONS, P307; Korkotian E, 1999, J BIOL CHEM, V274, P21673, DOI 10.1074/jbc.274.31.21673; Lazarowski ER, 2001, NEWS PHYSIOL SCI, V16, P1; LEIGH MW, 1998, DISORDERS RESP TRACT; Leissring MA, 1999, J BIOL CHEM, V274, P32535, DOI 10.1074/jbc.274.46.32535; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Noone PG, 1999, AM J RESP CRIT CARE, V160, P144, DOI 10.1164/ajrccm.160.1.9806146; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Paradiso AM, 1999, EXP LUNG RES, V25, P277; Paradiso AM, 2001, J GEN PHYSIOL, V117, P53, DOI 10.1085/jgp.117.1.53; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PARADISO AM, 1991, AM J PHYSIOL, V261, pL63, DOI 10.1152/ajplung.1991.261.2.L63; Pedrosa CM, 2001, CILIA AND MUCUS: FROM DEVELOPMENT TO RESPIRATORY DEFENSE, P303; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Ribeiro CMP, 2003, J GEN PHYSIOL, V122, P377, DOI 10.1085/jgp.200308893; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; RIBEIRO CP, 2003, PEDIATR PULM, V25, P270; ROBINSON G, 1996, THEORY PRACTICE HIST; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SHEARS SB, 1997, SIGNALLING INOSITIDE; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Weber AJ, 2001, AM J PHYSIOL-LUNG C, V281, pL71, DOI 10.1152/ajplung.2001.281.1.L71; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; Yang XN, 1999, J BIOL CHEM, V274, P18973, DOI 10.1074/jbc.274.27.18973	34	96	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10202	10209		10.1074/jbc.M410317200	http://dx.doi.org/10.1074/jbc.M410317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15647273	hybrid			2022-12-25	WOS:000227559600058
J	Yi, JY; Shin, I; Arteaga, CL				Yi, JY; Shin, I; Arteaga, CL			Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; HUMAN CANCER; 3-KINASE; PROTEIN; SUBSTRATE; PATHWAY; DOMAIN; TRANSFORMING-GROWTH-FACTOR-BETA-1	We have examined the interaction of transforming growth factor (TGF)beta receptors with phosphatidylinositol 3-(PI3) kinase in epithelial cells. In COS7 cells, treatment with TGF beta increased PI3 kinase activity as measured by the ability of p85- associated immune complexes to phosphorylate inositides in vitro. Both type I and type II TGF beta receptors (T beta R) associated with p85, but the association of T beta RII appeared to be constitutive. The interaction of T beta RI with p85 was induced by treatment with TGF beta. The receptor association with PI3 kinase was not direct as S-35-labeled rabbit reticulocyte p85 did not couple with fusion proteins containing type I and type II receptors. A kinase-dead, dominant-negative mutant of T beta RII blocked ligand-induced p85-T beta RI association and PI3 kinase activity. In T beta RI-null R1B cells, TGF beta did not stimulate PI3 kinase activity. This stimulation was restored upon reconstitution of T beta RI by transfection. In R1B and NMuMG epithelial cells, overexpression of a dominant active mutant form of T beta RI markedly enhanced ligand-independent PI3 kinase activity, which was blocked by the addition of the T beta RI kinase inhibitor LY580276, suggesting a causal link between T beta RI function and PI3 kinase. Overexpressed Smad7 also prevented ligand-induced PI3 kinase activity. Taken together, these data suggest that 1) TGF beta receptors can indirectly associate with p85, 2) both receptors are required for ligand-induced PI3 kinase activation, and 3) the activated T beta RI serine-threonine kinase can potently induce PI3 kinase activity.	Vanderbilt Univ, Sch Med, Dept Med, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Vanderbilt Ingram Comprehens Canc Ctr, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Breast Canc Program, Vanderbilt Ingram Comprehens Canc Ctr, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Arteaga, CL (corresponding author), Vanderbilt Univ, Med Ctr, Div Oncol, 2220 Pierce Ave,777 PRB, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu	Yin, Ji-Ye/AAE-6794-2020		NATIONAL CANCER INSTITUTE [P30CA068485, R01CA062212, P50CA098131] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, R01 CA62212, P50 CA98131] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; DOWNING JR, 1991, ONCOGENE, V6, P607; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grignani F, 1998, CANCER RES, V58, P14; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HELLYER NJ, 1995, GENE, V165, P279, DOI 10.1016/0378-1119(95)00436-A; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KIM HH, 1994, J BIOL CHEM, V269, P24747; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; LUI X, 1997, P NATL ACAD SCI USA, V94, P10669; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PELES E, 1992, J BIOL CHEM, V267, P12266; Sawyer JS, 2004, BIOORG MED CHEM LETT, V14, P3581, DOI 10.1016/j.bmcl.2004.04.007; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Singh J, 2004, CURR OPIN DRUG DISC, V7, P437; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Zhu HJ, 1999, J BIOL CHEM, V274, P11773, DOI 10.1074/jbc.274.17.11773	37	177	188	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10870	10876		10.1074/jbc.M413223200	http://dx.doi.org/10.1074/jbc.M413223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15657037	hybrid			2022-12-25	WOS:000227559600136
J	Kostadinova, RM; Nawrocki, AR; Frey, FJ; Frey, BM				Kostadinova, RM; Nawrocki, AR; Frey, FJ; Frey, BM			Tumor necrosis factor alpha and phorbol 12-myristate-13acetate down-regulate human 11 beta-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappa B homodimers and Egr-1	FASEB JOURNAL			English	Article						genomic footprinting; kidney tissue; mineralocorticoid receptor	LIPOPOLYSACCHARIDE TOLERANCE; SALT-SENSITIVITY; ACTIVATION; EXPRESSION; CELLS; SP1; PROMOTER; SUBUNIT; BINDING; GENE	The 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) regulates access of 11beta-hydroxyglucocorticoids to the mineralocorticoid receptor by reducing the hydroxyl group of these steroids at position 11. Previous cell culture studies revealed that tumor necrosis factor-alpha (TNF-alpha) down- regulates 11beta-HSD2 activity. Here, we demonstrate that transgenic mice overexpressing TNF-alpha have decreased mRNA abundance and activity of 11beta-HSD2 in kidney tissue, indicating that this effect may occur also in vivo. The analysis of the transcriptional regulation of 11beta-HSD2 by TNF-alpha and phorbol 12-myristate-13-acetate (PMA) with in vivo genomic footprinting in human colon SW620 cells revealed stimulus-dependent protein-DNA interactions in three promoter regions, kappaB1, Sp1/Egr-1I, and Sp1/Egr-1II. Chromatin immunoprecipitation and electrophoretic mobility shift assays demonstrated the relevance of NF-kappaB binding to kappaB1 and of Egr-1 binding to Sp1/Egr-1 sites for the PMA and TNF-alpha effect. We observed a temporal switch of binding to kappaB1 site from active p65/p50 heterodimers to inactive p50/p50 homodimers. TNF-alpha or PMA treatment for 24 h resulted in accumulation of p50 and decrease of p65 nuclear proteins. Overexpression of p50 inhibited HSD11B2 promoter activity and overexpression of Egr-1 inhibited transactivation of the HSD11B2 promoter by p65/p50. In conclusion, TNF-alpha and PMA down- regulate expression and activity of 11beta-HSD2 most likely by a coordinate binding of p50/p50 and Egr-1 to the HSD11B2 promoter.	Univ Hosp Bern, Dept Hypertens & Nephrol, CH-3010 Bern, Switzerland; Univ Hosp Bern, Dept Clin Res, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Frey, BM (corresponding author), Univ Hosp Bern, Dept Hypertens & Nephrol, Freiburgstr 15, CH-3010 Bern, Switzerland.	brigitte.frey@dkf.unibe.ch						Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; Agarwal AK, 1996, MOL CELL ENDOCRINOL, V121, P93, DOI 10.1016/0303-7207(96)03855-5; Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; Algarte M, 1999, MOL CELL BIOL, V19, P6140; Atanasov AG, 2003, BIOCHEM BIOPH RES CO, V308, P257, DOI 10.1016/S0006-291X(03)01359-7; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; CAO XM, 1993, J BIOL CHEM, V268, P16949; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; Cooper MS, 2001, J BONE MINER RES, V16, P1037, DOI 10.1359/jbmr.2001.16.6.1037; Escher G, 1997, J EXP MED, V186, P189, DOI 10.1084/jem.186.2.189; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; Goldring CE, 1998, EUR J IMMUNOL, V28, P2960, DOI 10.1002/(SICI)1521-4141(199809)28:09<2960::AID-IMMU2960>3.0.CO;2-B; Grundstrom S, 2004, J BIOL CHEM, V279, P8460, DOI 10.1074/jbc.M312398200; Haudek SB, 2001, J MOL CELL CARDIOL, V33, P1263, DOI 10.1006/jmcc.2001.1388; Heiniger CD, 2003, FASEB J, V17, P917, DOI 10.1096/fj.02-0582fje; Heiniger CD, 2001, FEBS LETT, V507, P351, DOI 10.1016/S0014-5793(01)03004-6; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; Knuefermann P, 2002, J BIOL CHEM, V277, P23888, DOI 10.1074/jbc.M202937200; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lovati E, 1999, J CLIN ENDOCR METAB, V84, P3745, DOI 10.1210/jc.84.10.3745; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nawrocki A, 1999, ANAL BIOCHEM, V272, P280, DOI 10.1006/abio.1999.4195; Nawrocki AR, 2002, J BIOL CHEM, V277, P14647, DOI 10.1074/jbc.M111549200; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Quattropani C, 2001, J CLIN INVEST, V108, P1299, DOI 10.1172/JCI200112745; Quinkler M, 2003, J CLIN ENDOCR METAB, V88, P2384, DOI 10.1210/jc.2003-030138; Rabbitt E, 2003, ONCOGENE, V22, P1663, DOI 10.1038/sj.onc.1206293; Schumacher M, 2002, TRANSPLANTATION, V74, P66, DOI 10.1097/00007890-200207150-00012; Stauffer AT, 2002, J BIOL CHEM, V277, P26286, DOI 10.1074/jbc.M201556200; Stewart PM, 1999, VITAM HORM, V57, P249; Takahashi K, 1999, DIGEST DIS SCI, V44, P2516, DOI 10.1023/A:1026699324927; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x	37	44	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					650	+		10.1096/fj.04-2820fje	http://dx.doi.org/10.1096/fj.04-2820fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15659537				2022-12-25	WOS:000226576600020
J	Mabley, JG; Pacher, P; Deb, A; Wallace, R; Elder, RH; Szabo, C				Mabley, JG; Pacher, P; Deb, A; Wallace, R; Elder, RH; Szabo, C			Potential role for 8-oxoguanine DNA glycosylase in regulating inflammation	FASEB JOURNAL			English	Article						OGG-1; diabetes; shock; hypersensitivity; DNA repair	ADP-RIBOSE SYNTHETASE; TUMOR-NECROSIS-FACTOR; PEROXYNITRITE DECOMPOSITION CATALYST; DEPENDENT DIABETES-MELLITUS; BASE EXCISION-REPAIR; NITRIC-OXIDE; POLY(ADP-RIBOSE) POLYMERASE; SACCHAROMYCES-CEREVISIAE; NEUTROPHIL RECRUITMENT; ISCHEMIA-REPERFUSION	OGG-1 DNA glycosylase (OGG-1) is an enzyme involved in DNA repair. It excises 7,8-dihydro-8-oxoguanine, which is formed by oxidative damage of guanine. We have investigated the role of OGG-1 in inflammation using three models of inflammation: endotoxic shock, diabetes, and contact hypersensitivity. We found that OGG-1(-/-) mice are resistant to endotoxin ( lipopolysaccharide, LPS)-induced organ dysfunction, neutrophil infiltration and oxidative stress, when compared with the response seen in wild-type controls ( OGG(+/+)). Furthermore, the deletion of the OGG-1 gene was associated with decreased serum cytokine and chemokine levels and prolonged survival after LPS treatment. Type I diabetes was induced by multiple low-dose streptozotocin treatment. OGG-1(-/-) mice were found to have significantly lower blood glucose levels and incidence of diabetes as compared with OGG-1(+/+) mice. Biochemical analysis of the pancreas showed that OGG-1(-/-) mice had greater insulin content, indicative of a greater beta-cell mass coupled with lower levels of the chemokine MIP-1alpha and Th1 cytokines IL-12 and TNF-alpha. Levels of protective Th2 cytokines, IL-4 and IL-10 were significantly higher in the pancreata of OGG-1(-/-) mice as compared with the levels measured in wild-type mice. In the contact hypersensitivity induced by oxazolone, the OGG-1(-/-) mice showed reduced neutrophil accumulation, chemokine, and Th1 and Th2 cytokine levels in the ear tissue. The current studies unveil a role for OGG-1 in the regulation of inflammation.	Univ Brighton, Sch Pharm & Biomol Sci, Brighton BN2 4GJ, E Sussex, England; Inotek Pharmaceut Corp, Beverly, MA USA; NIAAA, NIH, Lab Physiol Studies, Rockville, MD 20852 USA; Christie Hosp NHS Trust, Paterson Inst Canc Res, CR UK Carcinogenesis Grp, Manchester M20 4BX, Lancs, England; Semmelweis Univ, Inst Human Physiol & Clin Expt Res, H-1085 Budapest, Hungary	University of Brighton; Inotek Pharmaceuticals; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Semmelweis University	Mabley, JG (corresponding author), Univ Brighton, Sch Pharm & Biomol Sci, Cockcroft Bldg,Lewes Rd, Brighton BN2 4GJ, E Sussex, England.	jgmabley@hotmail.com	Szabo, Csaba/ABG-2644-2021; è-, ä/F-9947-2012; Szabo, Csaba/D-1882-2013; Pacher, Pal/B-6378-2008	Pacher, Pal/0000-0001-7036-8108; Mabley, Jon/0000-0001-9423-6230; Elder, Rhoderick/0000-0003-4614-175X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059266, K23HL071246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000375] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AA999999] Funding Source: Medline; NHLBI NIH HHS [R-01-HL59266, R-01-HL/DK-71246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Andreone TL, 2003, J IMMUNOL, V170, P2113, DOI 10.4049/jimmunol.170.4.2113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardinal JW, 2001, MOL CELL BIOL, V21, P5605, DOI 10.1128/MCB.21.16.5605-5613.2001; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Guzik TJ, 2003, J PHYSIOL PHARMACOL, V54, P469; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hasko G, 2002, MOL MED, V8, P283, DOI 10.1007/BF03402154; Hasko G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/jimmunol.164.2.1013; Ishchenko A, 2003, MED SCI MONITOR, V9, pBR16; Karagiozova D, 2003, IMP DAM STRUCT, V1, P1; KARCK U, 1988, J HEPATOL, V7, P352, DOI 10.1016/S0168-8278(88)80008-4; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Lin LH, 2000, J NEUROCHEM, V74, P1098; Liu ZP, 2001, J COMP NEUROL, V432, P35, DOI 10.1002/cne.1087; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Mabley J, 2003, EUR J PHARMACOL, V466, P323, DOI 10.1016/S0014-2999(03)01570-X; Mabley JG, 2003, AM J PHYSIOL-GASTR L, V284, pG138, DOI 10.1152/ajpgi.00060.2002; Mabley JG, 2002, MOL MED, V8, P581, DOI 10.1007/BF03402168; Mabley JG, 2002, J PHARMACOL EXP THER, V300, P876, DOI 10.1124/jpet.300.3.876; Mabley JG, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730457; Mabley JG, 2001, BRIT J PHARMACOL, V133, P909, DOI 10.1038/sj.bjp.0704156; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Moller P, 2001, FASEB J, V15, P1181, DOI 10.1096/fj.00-0703com; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; Phoa N, 2002, CARCINOGENESIS, V23, P469, DOI 10.1093/carcin/23.3.469; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Radak Z, 2003, LIFE SCI, V72, P1627, DOI 10.1016/S0024-3205(02)02476-1; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SALERNO A, 1995, IMMUNOLOGY, V84, P404; Salvemini D, 2003, CRIT CARE MED, V31, pS29, DOI 10.1097/00003246-200301001-00005; SCHLAYER HJ, 1988, J HEPATOL, V7, P239, DOI 10.1016/S0168-8278(88)80488-4; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Suarez-Pinzon WL, 2003, DIABETES, V52, P1683, DOI 10.2337/diabetes.52.7.1683; Szabo C, 2002, MOL MED, V8, P571, DOI 10.1007/BF03402167; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Szabo E, 2001, J INVEST DERMATOL, V117, P74, DOI 10.1046/j.0022-202x.2001.01388.x; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; THOMSON JA, 1993, IMMUNOLOGY, V78, P185; Tsuruya K, 2003, DNA REPAIR, V2, P211, DOI 10.1016/S1568-7864(02)00214-8; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680; Winter DB, 2003, J IMMUNOL, V170, P5558, DOI 10.4049/jimmunol.170.11.5558; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhou ZX, 2004, AM J PATHOL, V164, P1547, DOI 10.1016/S0002-9440(10)63713-3; Zingarelli B, 1999, GASTROENTEROLOGY, V116, P335, DOI 10.1016/S0016-5085(99)70130-7; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	60	92	93	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					290	+		10.1096/fj.04-2278fje	http://dx.doi.org/10.1096/fj.04-2278fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15677345				2022-12-25	WOS:000226091000026
J	Bruck, I; Georgescu, RE; O'Donnell, M				Bruck, I; Georgescu, RE; O'Donnell, M			Conserved interactions in the Staphylococcus aureus DNA PolC chromosome replication machine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; BETA-SLIDING CLAMP; GRAM-POSITIVE EUBACTERIA; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; LAGGING-STRAND; ACCESSORY PROTEINS; EPSILON-SUBUNIT; DELTA-SUBUNIT; TAU	The PolC holoenzyme replicase of the Gram-positive Staphylococcus aureus pathogen has been reconstituted from pure subunits. We compared individual S. aureus replicase subunits with subunits from the Gram-negative Escherichia coli polymerase III holoenzyme for activity and interchangeability. The central organizing subunit, tau, is smaller than its Gram-negative homolog, yet retains the ability to bind single-stranded DNA and contains DNA-stimulated ATPase activity comparable with E. coli tau. S. aureus tau also stimulates PolC, although they do not form as stabile a complex as E. coli polymerase III center dot tau. We demonstrate that the extreme C-terminal residues of PolC bind to and function with beta clamps from different bacteria. Hence, this polymerase-clamp interaction is highly conserved. Additionally, the S. aureus delta wrench of the clamp loader binds to E. coli beta. The S. aureus clamp loader is even capable of loading E. coli and Streptococcus pyogenes beta clamps onto DNA. Interestingly, S. aureus PolC lacks functionality with heterologous beta clamps when they are loaded onto DNA by the S. aureus clamp loader, suggesting that the S. aureus clamp loader may have difficulty ejecting from heterologous clamps. Nevertheless, these overall findings underscore the conservation in structure and function of Gram-positive and Gram-negative replicases despite > 1 billion years of evolutionary distance between them.	Rockefeller Univ, Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	O'Donnell, M (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab DNA Replicat, 1230 York Ave, New York, NY 10021 USA.	odonnel@mail.rockefeller.edu	Georgescu, Roxana/B-9943-2011	O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES MH, 1995, GENE, V165, P45, DOI 10.1016/0378-1119(95)00530-J; Barnes MH, 1998, BIOCHEMISTRY-US, V37, P15254, DOI 10.1021/bi981113m; BARNES MH, 1994, MOL MICROBIOL, V13, P843, DOI 10.1111/j.1365-2958.1994.tb00476.x; BARNES MH, 1992, GENE, V111, P43, DOI 10.1016/0378-1119(92)90601-K; Barnes MH, 2002, J BACTERIOL, V184, P3834, DOI 10.1128/JB.184.14.3834-3838.2002; BAZILL GW, 1973, NATURE-NEW BIOL, V243, P241, DOI 10.1038/newbio243241a0; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; Bruck I, 2000, J BIOL CHEM, V275, P28971, DOI 10.1074/jbc.M003565200; Bruck I, 2003, J BIOL CHEM, V278, P44361, DOI 10.1074/jbc.M308307200; Bruck I, 2002, J BIOL CHEM, V277, P17334, DOI 10.1074/jbc.M110198200; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; COZZARELLI NR, 1973, BIOCHEM BIOPH RES CO, V51, P151, DOI 10.1016/0006-291X(73)90521-4; Dallmann HG, 2000, J BIOL CHEM, V275, P15512, DOI 10.1074/jbc.M909257199; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; De Saro FJL, 2003, P NATL ACAD SCI USA, V100, P14689, DOI 10.1073/pnas.2435454100; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; de Saro FL, 2004, PHILOS T R SOC B, V359, P25, DOI 10.1098/rstb.2003.1361; Dervyn E, 2001, SCIENCE, V294, P1716, DOI 10.1126/science.1066351; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GASS KB, 1973, J BIOL CHEM, V248, P7688; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; GRIEP MA, 1988, BIOCHEMISTRY-US, V27, P5210, DOI 10.1021/bi00414a040; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Indiani C, 2003, J BIOL CHEM, V278, P40272, DOI 10.1074/jbc.M305828200; Inoue R, 2001, MOL GENET GENOMICS, V266, P564, DOI 10.1007/s004380100564; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Klemperer N, 2000, J BIOL CHEM, V275, P26136, DOI 10.1074/jbc.M002566200; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1992, DNA REPLICATION, P169; Larsen B, 2000, P NATL ACAD SCI USA, V97, P1683, DOI 10.1073/pnas.97.4.1683; Le Chatelier E, 2004, J BIOL CHEM, V279, P1757, DOI 10.1074/jbc.M310719200; Leu FP, 2003, MOL CELL, V11, P315, DOI 10.1016/S1097-2765(03)00042-X; Leu FP, 2001, J BIOL CHEM, V276, P47185, DOI 10.1074/jbc.M106780200; LOW RL, 1976, J BIOL CHEM, V251, P1311; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; PACITTI DF, 1995, GENE, V165, P51, DOI 10.1016/0378-1119(95)00377-I; ROWEN L, 1978, J BIOL CHEM, V253, P758; SANJANWALA B, 1991, MOL GEN GENET, V226, P467, DOI 10.1007/BF00260660; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; SLATER SC, 1994, J BACTERIOL, V176, P815, DOI 10.1128/jb.176.3.815-821.1994; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Yurieva O, 1997, J BIOL CHEM, V272, P27131, DOI 10.1074/jbc.272.43.27131; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	70	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18152	18162		10.1074/jbc.M413595200	http://dx.doi.org/10.1074/jbc.M413595200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15647255	hybrid			2022-12-25	WOS:000228807200073
J	Kattapuram, T; Yang, S; Maki, JL; Stone, JR				Kattapuram, T; Yang, S; Maki, JL; Stone, JR			Protein kinase CK1 alpha regulates mRNA binding by heterogeneous nuclear ribonucleoprotein c in response to physiologic levels of hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HNRNP-C; CASEIN KINASE-1; SPATIAL-ORGANIZATION; BETA-CATENIN; I EPSILON; PHOSPHORYLATION; SITES; IDENTIFICATION; TRANSCRIPTION; ACTIVATION	At low concentrations, hydrogen peroxide (H2O2) is a positive endogenous regulator of mammalian cell proliferation and survival; however, the signal transduction pathways involved in these processes are poorly understood. In primary human endothelial cells, low concentrations of H2O2 stimulated the rapid phosphorylation of the acidic C-terminal domain (ACD) of heterogeneous nuclear ribonucleoprotein C (hnRNP-C), a nuclear restricted pre-mRNA-binding protein, at Ser(240) and at Ser(225)-Ser(228). A kinase activity was identified in mouse liver that phosphorylates the ACD of hnRNP-C at Ser(240) and at two sites at Ser(225)-Ser(228). The kinase was purified and identified by tandem mass spectrometry as protein kinase CK1 alpha (formerly casein kinase 1 alpha). Protein kinase CK1 alpha immunoprecipitated from primary human endothelial cell nuclei also phosphorylated the ACD of hnRNP-C at these positions. Pretreatment of endothelial cells with the protein kinase CK1-specific inhibitor IC261 prevented the H2O2-stimulated phosphorylation of hnRNP-C. Utilizing phosphoserine-mimicking Ser-to-Glu point mutations, the effects of phosphorylation on hnRNP-C function were investigated by quantitative equilibrium fluorescence RNA binding analyses. Wild-type hnRNP-C1 and hnRNP-C1 modified at the basal sites of phosphorylation (S247E and S286E) both avidly bound RNA with similar binding constants. In contrast, hnRNP-C1 that was also modified at the CK1 alpha phosphorylation sites exhibited a 14-500-fold decrease in binding affinity, demonstrating that CK1 alpha-mediated phosphorylation modulates the mRNA binding ability of hnRNP-C.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Stone, JR (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Warren 501B,55 Fruit St, Boston, MA 02114 USA.	jrstone@partners.org			NHLBI NIH HHS [HL074324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGOSTINIS P, 1992, FEBS LETT, V305, P121, DOI 10.1016/0014-5793(92)80877-J; BARNETT SF, 1989, MOL CELL BIOL, V9, P492, DOI 10.1128/MCB.9.2.492; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; DeGnore JP, 1998, J AM SOC MASS SPECTR, V9, P1175, DOI 10.1016/S1044-0305(98)00088-9; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Dubois T, 2001, J BIOL CHEM, V276, P18757, DOI 10.1074/jbc.M010005200; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Gross SD, 1999, J CELL SCI, V112, P2647; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Johnson EN, 2003, J BIOL CHEM, V278, P1686, DOI 10.1074/jbc.M210250200; KOCHETKOV NK, 1971, TETRAHEDRON LETT, P1993; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; Marin O, 2002, BIOCHEMISTRY-US, V41, P618, DOI 10.1021/bi0112309; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; McAfee JG, 1996, RNA, V2, P1139; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P1212, DOI 10.1021/bi951974k; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Shahied L, 2001, J MOL BIOL, V305, P817, DOI 10.1006/jmbi.2000.4331; Stone JR, 2004, ARCH BIOCHEM BIOPHYS, V422, P119, DOI 10.1016/j.abb.2003.12.029; Stone JR, 2003, BIOCHEMISTRY-US, V42, P1301, DOI 10.1021/bi0268091; Stone JR, 2002, ENDOTHELIUM-J ENDOTH, V9, P231, DOI 10.1080/10623320214733; Stone JR, 2002, J BIOL CHEM, V277, P15621, DOI 10.1074/jbc.M112153200; Tan JH, 2001, J MOL BIOL, V305, P829, DOI 10.1006/jmbi.2000.4332; Tobin AB, 2002, TRENDS PHARMACOL SCI, V23, P337, DOI 10.1016/S0165-6147(02)02043-6; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Williamson DJ, 2000, MOL CELL BIOL, V20, P4094, DOI 10.1128/MCB.20.11.4094-4105.2000; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474; Zhao Y, 2004, J BIOL CHEM, V279, P30844, DOI 10.1074/jbc.M404651200; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	49	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15340	15347		10.1074/jbc.M500214200	http://dx.doi.org/10.1074/jbc.M500214200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15687492	hybrid			2022-12-25	WOS:000228236800119
J	Onda, M; Belorgey, D; Sharp, LK; Lomas, DA				Onda, M; Belorgey, D; Sharp, LK; Lomas, DA			Latent S49P neuroserpin forms polymers in the dementia familial encephalopathy with neuroserpin inclusion bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SERINE-PROTEASE INHIBITOR; CIRCULAR-DICHROISM SPECTRA; CONFORMATIONAL DISEASE; REACTIVE LOOP; ALPHA(1)-ANTITRYPSIN POLYMERIZATION; ENDOPLASMIC-RETICULUM; PROTEINASE-INHIBITOR; SECONDARY STRUCTURE; TYPE-2 PAI-2	The serpinopathies result from conformational transitions in members of the serine proteinase inhibitor superfamily with aberrant tissue deposition or loss of function. They are typified by mutants of neuroserpin that are retained within the endoplasmic reticulum of neurons as ordered polymers in association with dementia. We show here that the S49P mutant of neuroserpin that causes the dementia familial encephalopathy with neuroserpin inclusion bodies (FENIB) forms a latent species in vitro and in vivo in addition to the formation of polymers. Latent neuroserpin is thermostable and inactive as a proteinase inhibitor, but activity can be restored by refolding. Strikingly, latent S49P neuroserpin is unlike any other latent serine proteinase inhibitor (serpin) in that it spontaneously forms polymers under physiological conditions. These data provide an alternative method for the inactivation of mutant neuroserpin as a proteinase inhibitor in FENIB and demonstrate a second pathway for the formation of intracellular polymers in association with disease.	Univ Cambridge, Cambridge Inst Med Res, Dept Med, Cambridge CB2 2XY, England; Osaka Womens Univ, Fac Sci, Dept Environm Sci, Sakai, Osaka 5900035, Japan	University of Cambridge; Osaka Metropolitan University	Onda, M (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Med, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	onda@center.osaka-wu.ac.jp		Skipper, Lynda/0000-0002-1463-5811				Barker-Carlson K, 2002, J BIOL CHEM, V277, P46852, DOI 10.1074/jbc.M207740200; Belorgey D, 2004, EUR J BIOCHEM, V271, P3360, DOI 10.1111/j.1432-1033.2004.04270.x; Belorgey D, 2002, J BIOL CHEM, V277, P17367, DOI 10.1074/jbc.M200680200; Bottomley SP, 1998, BIOCHEM BIOPH RES CO, V251, P1, DOI 10.1006/bbrc.1998.9254; Bradshaw CB, 2001, ARCH NEUROL-CHICAGO, V58, P1429, DOI 10.1001/archneur.58.9.1429; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1998, J BIOL CHEM, V273, P3695, DOI 10.1074/jbc.273.6.3695; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Dafforn TR, 2001, J BIOL CHEM, V276, P49310, DOI 10.1074/jbc.M108896200; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Davis RL, 2002, LANCET, V359, P2242, DOI 10.1016/S0140-6736(02)09293-0; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Hill RM, 2002, ANN NY ACAD SCI, V971, P406, DOI 10.1111/j.1749-6632.2002.tb04503.x; Im H, 2002, J BIOL CHEM, V277, P46347, DOI 10.1074/jbc.M207682200; Janciauskiene S, 2002, J BIOL CHEM, V277, P26540, DOI 10.1074/jbc.M203832200; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; Madani R, 2003, MOL CELL NEUROSCI, V23, P473, DOI 10.1016/S1044-7431(03)00077-0; Mahadeva R, 2002, J BIOL CHEM, V277, P6771, DOI 10.1074/jbc.C100722200; Makarova A, 2003, J BIOL CHEM, V278, P50250, DOI 10.1074/jbc.M309150200; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; Miranda E, 2004, J BIOL CHEM, V279, P28283, DOI 10.1074/jbc.M313166200; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Osterwalder T, 1998, J BIOL CHEM, V273, P2312, DOI 10.1074/jbc.273.4.2312; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; Parmar PK, 2002, J NEUROCHEM, V82, P1406, DOI 10.1046/j.1471-4159.2002.01100.x; Renatus M, 1997, EMBO J, V16, P4797, DOI 10.1093/emboj/16.16.4797; SIDHAR SK, 1995, J BIOL CHEM, V270, P8393, DOI 10.1074/jbc.270.15.8393; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Strickland S, 2001, THROMB HAEMOSTASIS, V86, P138; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; Wilczynska M, 2003, EMBO J, V22, P1753, DOI 10.1093/emboj/cdg178; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Yepes M, 2000, BLOOD, V96, P569; Zhou AW, 1999, BLOOD, V94, P3388, DOI 10.1182/blood.V94.10.3388.422k20_3388_3396	48	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13735	13741		10.1074/jbc.M413282200	http://dx.doi.org/10.1074/jbc.M413282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15664988	hybrid			2022-12-25	WOS:000228095500069
J	Breece, RM; Costello, A; Bennett, B; Sigdel, TK; Matthews, ML; Tierney, DL; Crowder, MW				Breece, RM; Costello, A; Bennett, B; Sigdel, TK; Matthews, ML; Tierney, DL; Crowder, MW			A five-coordinate metal center in Co(II)-substituted VanX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALA-D-ALA; ENTEROCOCCUS-FAECIUM BM4147; D-ALANINE DIPEPTIDASE; X-RAY-ABSORPTION; VANCOMYCIN RESISTANCE; CAPILLARY-ELECTROPHORESIS; GLYCOPEPTIDE RESISTANCE; AEROMONAS-PROTEOLYTICA; CARBOXYPEPTIDASE-A; CRYSTAL-STRUCTURE	In an effort to structurally probe the metal binding site in VanX, electronic absorption, EPR, and extended x-ray absorption fine structure (EXAFS) spectroscopic studies were conducted on Co(II)-substituted VanX. Electronic spectroscopy revealed the presence of Co(II) ligand field transitions that had molar absorptivities of similar to 100 M-1 cm(-1), which suggests that Co(II) is five-coordinate in Co(II)-substituted VanX. Low temperature EPR spectra of Co(II)-substituted VanX were simulated using spin Hamiltonian parameters of M-S = vertical bar +/- 1/2 >, E/D = 0.14, g(real(x,y)) = 2.37, and g(real(z)) = 2.03. These parameters lead to the prediction that Co(II) in the enzyme is five-coordinate and that there may be at least one solvent-derived ligand. Single scattering fits of EXAFS data indicate that the metal ions in both native Zn(II)containing and Co(II)-substituted VanX have the same coordination number and that the metal ions are coordinated by 5 nitrogen/oxygen ligands at similar to 2.0 angstrom. These data demonstrate that Co(II) (and Zn(II) from EXAFS studies) is five-coordinate in VanX in contrast to previous crystallographic studies (Bussiere, D. E., Pratt, S. D., Katz, L., Severin, J. M., Holzman, T., and Park, C. H. (1998) Mol. Cell 2, 75-84). These spectroscopic studies also demonstrate that the metal ion in Co(II)-substituted VanX when complexed with a phosphinate analog of substrate D-Ala-D-Ala is also five-coordinate.	Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Med Coll Wisconsin, Natl Biomed EPR Ctr, Dept Biophys, Milwaukee, WI 53226 USA	University System of Ohio; Miami University; University of New Mexico; Medical College of Wisconsin	Crowder, MW (corresponding author), Miami Univ, Dept Chem & Biochem, 112 Hughes Hall, Oxford, OH 45056 USA.	crowdemw@muohio.edu	Sigdel, Tara/AAV-5886-2020; Matthews, Megan/W-2217-2017	Sigdel, Tara/0000-0001-8448-0328; Matthews, Megan/0000-0003-1178-4616	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056231, R29AI040052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM040052] Funding Source: NIH RePORTER; NIAID NIH HHS [AI056231, AI40052] Funding Source: Medline; NIBIB NIH HHS [EB001980] Funding Source: Medline; NIGMS NIH HHS [GM40052] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson ME, 1999, J AM CHEM SOC, V121, P2346, DOI 10.1021/ja982280c; Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; Araoz R, 2000, BIOCHEMISTRY-US, V39, P15971, DOI 10.1021/bi001408b; Arthur M, 1996, J INFECTION, V32, P11, DOI 10.1016/S0163-4453(96)80003-X; AULD DS, 1988, METHOD ENZYMOL, V158, P71, DOI 10.1016/0076-6879(88)58048-5; AULD DS, 1995, METHOD ENZYMOL, V248, P228; Bennett B, 1997, BIOCHEMISTRY-US, V36, P9837, DOI 10.1021/bi970735p; Bennett B, 1997, J AM CHEM SOC, V119, P1923, DOI 10.1021/ja963021v; Bennett B., 2002, CURR TOP BIOPHYS, V26, P49; BUGG TDH, 1992, NAT PROD REP, V9, P199, DOI 10.1039/np9920900199; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; Bussiere DE, 1998, MOL CELL, V2, P75, DOI 10.1016/S1097-2765(00)80115-X; Crowder MW, 2001, J BIOL INORG CHEM, V6, P91, DOI 10.1007/s007750000173; D'souza VM, 2000, BIOCHEMISTRY-US, V39, P3817, DOI 10.1021/bi9925827; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; GARMER DR, 1993, J AM CHEM SOC, V115, P10247, DOI 10.1021/ja00075a046; Gilson HSR, 1999, J AM CHEM SOC, V121, P6984, DOI 10.1021/ja990459x; Haldimann A, 1997, J BACTERIOL, V179, P5903, DOI 10.1128/jb.179.18.5903-5913.1997; HOLMAN TR, 1994, BIOCHEMISTRY-US, V33, P4625, DOI 10.1021/bi00181a024; Holz RC, 2002, COORDIN CHEM REV, V232, P5, DOI 10.1016/S0010-8545(01)00470-2; KIEFER LL, 1994, BIOCHEMISTRY-US, V33, P15233, DOI 10.1021/bi00255a003; Kleifeld O, 2004, BIOCHEMISTRY-US, V43, P7151, DOI 10.1021/bi0302696; Kolotilov SV, 2004, INORG CHEM COMMUN, V7, P485, DOI 10.1016/j.inoche.2004.01.009; Lessard IAD, 1998, CHEM BIOL, V5, P489, DOI 10.1016/S1074-5521(98)90005-9; Lessard IAD, 1999, P NATL ACAD SCI USA, V96, P11028, DOI 10.1073/pnas.96.20.11028; MARET W, 1993, METHOD ENZYMOL, V226, P52; MARTINELLI RA, 1989, BIOCHEMISTRY-US, V28, P2251, DOI 10.1021/bi00431a042; McCafferty DG, 1997, BIOCHEMISTRY-US, V36, P10498, DOI 10.1021/bi970543u; McClure CP, 2003, J INORG BIOCHEM, V94, P78, DOI 10.1016/S0162-0134(02)00611-6; McComas CC, 2003, J AM CHEM SOC, V125, P9314, DOI 10.1021/ja035901x; Rajagopalan PTR, 2000, BIOCHEMISTRY-US, V39, P779, DOI 10.1021/bi9919899; RANDALL CR, 1993, BIOCHEMISTRY-US, V32, P6664, DOI 10.1021/bi00077a020; Rao JH, 1997, J AM CHEM SOC, V119, P9336, DOI 10.1021/ja971146+; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REYNOLDS PE, 1994, MOL MICROBIOL, V13, P1065, DOI 10.1111/j.1365-2958.1994.tb00497.x; Tu J, 1998, ANAL BIOCHEM, V264, P293, DOI 10.1006/abio.1998.2870; Ulijasz AT, 2000, BIOCHEMISTRY-US, V39, P11417, DOI 10.1021/bi0012888; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Walsh C, 1999, SCIENCE, V284, P442, DOI 10.1126/science.284.5413.442; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; Walsh CT, 1996, CHEM BIOL, V3, P21, DOI 10.1016/S1074-5521(96)90079-4; Williams DH, 1999, ANGEW CHEM INT EDIT, V38, P1173, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1172::AID-ANIE1172>3.0.CO;2-C; WILLIAMS RJP, 1995, EUR J BIOCHEM, V234, P363, DOI 10.1111/j.1432-1033.1995.363_b.x; Wu Z, 1996, J AM CHEM SOC, V118, P1785, DOI 10.1021/ja953652+; WU Z, 1995, P NATL ACAD SCI USA, V92, P11603, DOI 10.1073/pnas.92.25.11603; WU Z, 1995, BIOCHEMISTRY-US, V34, P2455, DOI 10.1021/bi00008a008; Yang KW, 2000, BIOORG MED CHEM LETT, V10, P1085, DOI 10.1016/S0960-894X(00)00186-4; Yaouancq L, 2002, EUR J ORG CHEM, V2002, P3573, DOI 10.1002/1099-0690(200211)2002:21<3573::AID-EJOC3573>3.0.CO;2-V	48	32	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11074	11081		10.1074/jbc.M412582200	http://dx.doi.org/10.1074/jbc.M412582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15657055	Green Published, hybrid			2022-12-25	WOS:000227761800025
J	Foulon, V; Sniekers, M; Huysmans, E; Asselberghs, S; Mahieu, V; Mannaerts, GP; Van Veldhoven, PP; Casteels, M				Foulon, V; Sniekers, M; Huysmans, E; Asselberghs, S; Mahieu, V; Mannaerts, GP; Van Veldhoven, PP; Casteels, M			Breakdown of 2-hydroxylated straight chain fatty acids via peroxisomal 2-hydroxyphytanoyl-CoA lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTANOYL-COA HYDROXYLASE; ALPHA-OXIDATION; RAT-LIVER; BETA-OXIDATION; MOLECULAR-CLONING; PURIFICATION; EXPRESSION; PROTEIN; IDENTIFICATION; DECARBOXYLASE	Hydroxyfatty acids, constituents of brain cerebro-sides and sulfatides, were previously reported to be degraded by an alpha-oxidation system, generating fatty acids shortened by one carbon atom. In the current study we used labeled and unlabeled 2-hydroxyoctadecanoic acid to reinvestigate the degradation of this class of lipids. Both in intact and broken cell systems formate was identified as a main reaction product. Furthermore, the generation of an n-1 aldehyde was demonstrated. In permeabilized rat hepatocytes and liver homogenates, studies on cofactor requirements revealed a dependence on ATP, CoA, Mg2+, thiamine pyrophosphate, and NAD(+). Together with subcellular fractionation data and studies on recombinant enzymes, this led to the following picture. In a first step, the 2-hydroxyfatty acid is activated to an acyl-CoA; subsequently, the 2-hydroxy fatty acyl-CoA is cleaved by 2-hydroxyphytanoyl-CoA lyase, to formyl-CoA and an n-1 aldehyde. The severe inhibition of formate generation by oxythiamin treatment of intact fibroblasts indicates that cleavage through the thiamine pyrophosphate-dependent 2-hydroxyphytanoyl-CoA lyase is the main pathway for the degradation of 2-hydroxyfatty acids. The latter protein was initially characterized as an essential enzyme in the peroxisomal alpha-oxidation of 3-methyl-branched fatty acids such as phytanic acid. Our findings point to a new role for peroxisomes in mammals, i.e. the breakdown of 2-hydroxyfatty acids, at least the long chain 2-hydroxyfatty acids. Most likely, the more abundant very long chain 2-hydroxyfatty acids are degraded in a similar manner.	Catholic Univ Louvain, Fac Geneeskunde, Dept Celbiol, Afdeling Farmacol, B-3000 Louvain, Belgium	Universite Catholique Louvain	Casteels, M (corresponding author), Catholic Univ Louvain, Fac Geneeskunde, Dept Celbiol, Afdeling Farmacol, Herestr 49,Box 601,Campus Gasthuisberg, B-3000 Louvain, Belgium.	minne.casteels@med.kuleuven.ac.be	, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564; Foulon, Veerle/0000-0002-4053-3915				Alderson NL, 2004, J BIOL CHEM, V279, P48562, DOI 10.1074/jbc.M406649200; Ashton R, 1936, J CHEM SOC, P283, DOI 10.1039/jr9360000283; Baes M, 1997, NAT GENET, V17, P49, DOI 10.1038/ng0997-49; BELMOUDEN A, 1993, EUR J BIOCHEM, V214, P17, DOI 10.1111/j.1432-1033.1993.tb17891.x; Borge GIA, 1998, BBA-LIPID LIPID MET, V1394, P158, DOI 10.1016/S0005-2760(98)00113-1; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; CASTEELS M, 1994, BIOCHEM PHARMACOL, V48, P1973, DOI 10.1016/0006-2952(94)90596-7; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Croes K, 1996, EUR J BIOCHEM, V240, P674, DOI 10.1111/j.1432-1033.1996.0674h.x; Croes K, 2000, J LIPID RES, V41, P629; Croes K, 1999, J LIPID RES, V40, P601; Croes K, 1997, FEBS LETT, V407, P197, DOI 10.1016/S0014-5793(97)00343-8; Croes K, 1997, FEBS LETT, V412, P643, DOI 10.1016/S0014-5793(97)00856-9; CROES K, 1995, BBA-LIPID LIPID MET, V1255, P63, DOI 10.1016/0005-2760(94)00209-H; CROES K, 1998, THESIS; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; DIRKX R, 2005, IN PRESS HEPATOLOGY; Foulon V, 2003, J LIPID RES, V44, P2349, DOI 10.1194/jlr.M300230-JLR200; Foulon V, 1999, P NATL ACAD SCI USA, V96, P10039, DOI 10.1073/pnas.96.18.10039; FOULON V, 2001, THESIS; FULCO AJ, 1967, J BIOL CHEM, V242, P3608; GERHARDT B, 1992, PROG LIPID RES, V31, P417, DOI 10.1016/0163-7827(92)90004-3; HAJRA AK, 1963, J LIPID RES, V58, P270; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; Jones JM, 2000, J BIOL CHEM, V275, P12590, DOI 10.1074/jbc.275.17.12590; KAYA K, 1984, J BIOL CHEM, V259, P3548; KISHIMOTO Y, 1963, J LIPID RES, V4, P139; Koeduka T, 2002, J BIOL CHEM, V277, P22648, DOI 10.1074/jbc.M110420200; Kovacs WJ, 2001, EUR J BIOCHEM, V268, P4850, DOI 10.1046/j.0014-2956.2001.02409.x; Larson TR, 2001, PLANT J, V25, P115, DOI 10.1046/j.1365-313x.2001.00929.x; LEVIS GM, 1964, J BIOL CHEM, V239, P77; LIPPEL K, 1968, BIOCHIM BIOPHYS ACTA, V152, P669, DOI 10.1016/0005-2760(68)90113-6; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; Mukherji M, 2002, CHEM BIOL, V9, P597, DOI 10.1016/S1074-5521(02)00139-4; NOVIKOV DK, 1994, J BIOL CHEM, V269, P27125; Saito M, 1999, BBA-MOL CELL BIOL L, V1438, P55, DOI 10.1016/S1388-1981(99)00037-2; Sandhir R, 2000, LIPIDS, V35, P1127, DOI 10.1007/s11745-000-0628-5; Steinberg SJ, 2000, J BIOL CHEM, V275, P35162, DOI 10.1074/jbc.M006403200; SVENNERHOLM L, 1968, J LIPID RES, V9, P215; Tatsumi K, 2001, BBA-MOL BASIS DIS, V1535, P285, DOI 10.1016/S0925-4439(01)00027-8; Tittmann K, 1998, FEBS LETT, V441, P404, DOI 10.1016/S0014-5793(98)01594-4; Townsend CA, 2002, CURR OPIN CHEM BIOL, V6, P583, DOI 10.1016/S1367-5931(02)00392-7; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VANVELDHOVEN PP, 1993, J INHERIT METAB DIS, V16, P381, DOI 10.1007/BF00710285; VanVeldhoven PP, 1996, FEBS LETT, V388, P80, DOI 10.1016/0014-5793(96)00508-X; Verhoeven NM, 1998, FEBS LETT, V429, P225, DOI 10.1016/S0014-5793(98)00574-2	46	78	81	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9802	9812		10.1074/jbc.M413362200	http://dx.doi.org/10.1074/jbc.M413362200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644336	hybrid			2022-12-25	WOS:000227559600009
J	Takuma, K; Yao, J; Huang, JM; Xu, HW; Chen, X; Luddy, J; Trillat, AC; Stern, DM; Arancio, O; Yan, SSD				Takuma, K; Yao, J; Huang, JM; Xu, HW; Chen, X; Luddy, J; Trillat, AC; Stern, DM; Arancio, O; Yan, SSD			ABAD enhances A beta-induced cell stress via mitochondrial dysfunction	FASEB JOURNAL			English	Article						amyloid-beta peptide binding alcohol dehydrogenase; mitochondria; glucose utilization; reactive oxygen species; oxidant stress	CYTOCHROME-C-OXIDASE; ALZHEIMERS-DISEASE; PERMEABILITY TRANSITION; IN-VIVO; LIVER-MITOCHONDRIA; LIPID-PEROXIDATION; HEART-MITOCHONDRIA; OXIDATIVE STRESS; TRANSGENIC MICE; CYCLOSPORINE-A	Amyloid-beta peptide (Abeta) binding alcohol dehydrogenase (ABAD), an enzyme present in neuronal mitochondria, is a cofactor facilitating Abeta-induced cell stress. We hypothesized that ABAD provides a direct link between A and cytotoxicity via mitochondrial oxidant stress. Neurons cultured from transgenic (Tg) mice with targeted overexpression of a mutant form of amyloid precursor protein and ABAD (Tg mAPP/ABAD) displayed spontaneous generation of hydrogen peroxide and superoxide anion, and decreased ATP, as well as subsequent release of cytochrome c from mitochondria and induction of caspase-3-like activity followed by DNA fragmentation and loss of cell viability. Generation of reactive oxygen species (ROS) was associated with dysfunction at the level of mitochondrial complex IV ( cytochrome c oxidase, or COX). In neurons cultured from Tg mAPP/ABAD mice, COX activity was selectively decreased, and cyanide, an inhibitor of complex IV, exacerbated leakage of ROS, induction of caspase-3-like activity, and DNA fragmentation. In vivo, Tg mAPP/ABAD mice displayed reduced levels of brain ATP and COX activity, diminished glucose utilization, as well as electrophysiological abnormalities in hippocampal slices compared with Tg mAPP mice. In contrast, neither Tg ABAD mice nor nontransgenic (non-TG) littermates showed similar changes in ATP, COX activity, glucose utilization or electrophysiological properties. Each of the genotypes ( Tg ABAD, Tg mAPP and Tg mAPP/ABAD mice, and non-TG littermates) displayed normal reproductive fitness, development and lifespan ( 1) These findings link ABAD-induced oxidant stress to critical aspects of Alzheimer's disease (AD)-associated cellular dysfunction, suggesting a pivotal role for this enzyme in the pathogenesis of AD.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Analyt Chem, Kobe, Hyogo 6512180, Japan; Columbia Univ, Taub Inst Res Alzeheimers Dis & Aging Brain, New York, NY 10032 USA; SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; Med Coll Georgia, Deans Off, Augusta, GA 30912 USA; NYU, Sch Med, Nathan Kline Inst, New York, NY 10016 USA	Columbia University; Columbia University; Columbia University; Kobe Gakuin University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University System of Georgia; Augusta University; Nathan Kline Institute for Psychiatric Research; New York University	Yan, SSD (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 650 W 168th St,Black Bldg,Room 17-07, New York, NY 10032 USA.	sdy1@columbia.edu	arancio, ottavio/AAB-7959-2019	arancio, ottavio/0000-0001-6335-164X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016736, P01AG017490, P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHS [AG08702, AG17490, AG16736] Funding Source: Medline; NINDS NIH HHS [NS42855] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberts B., 1994, MOL BIOL CELL; Bigl M, 2003, J NEURAL TRANSM, V110, P77, DOI 10.1007/s00702-002-0772-x; Bosetti F, 2002, NEUROBIOL AGING, V23, P371, DOI 10.1016/S0197-4580(01)00314-1; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Cardoso SM, 2004, NEUROBIOL AGING, V25, P105, DOI 10.1016/S0197-4580(03)00033-2; Cardoso SM, 2001, FASEB J, V15, P1439, DOI 10.1096/fj.00-0561fje; CHANDRASEKARAN K, 1994, MOL BRAIN RES, V24, P336, DOI 10.1016/0169-328X(94)90147-3; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Clark A., 2000, RES PAPERS ED, V15, P25, DOI DOI 10.1080/026715200362934; CROMPTON M, 1988, BIOCHEM J, V255, P357; Du Yan S, 1999, J BIOL CHEM, V274, P2145, DOI 10.1074/jbc.274.4.2145; Eckert A, 2003, BIOCHEM PHARMACOL, V66, P1627, DOI 10.1016/S0006-2952(03)00534-3; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Furuta S, 1997, BBA-GENE STRUCT EXPR, V1350, P317, DOI 10.1016/S0167-4781(96)00171-6; He XY, 2002, MOL BRAIN RES, V99, P46, DOI 10.1016/S0169-328X(02)00102-X; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Hoffman JM, 2000, J NUCL MED, V41, P1920; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; IMBERTI R, 1995, J RES COMMUN CHEM PA, V78, P27; Kim SH, 2001, LIFE SCI, V68, P2741, DOI 10.1016/S0024-3205(01)01074-8; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Mattson MP, 2001, J MOL NEUROSCI, V17, P205, DOI 10.1385/JMN:17:2:205; Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Ofman R, 2003, AM J HUM GENET, V72, P1300, DOI 10.1086/375116; PARKER WD, 1994, NEUROLOGY, V44, P1086, DOI 10.1212/WNL.44.6.1086; Parks JK, 2001, J NEUROCHEM, V76, P1050, DOI 10.1046/j.1471-4159.2001.00112.x; Petrone A, 2003, EMBO J, V22, P4121, DOI 10.1093/emboj/cdg399; Salim S, 2000, TOXICOLOGY, V144, P163, DOI 10.1016/S0300-483X(99)00203-6; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Silverman DHS, 2001, JAMA-J AM MED ASSOC, V286, P2120, DOI 10.1001/jama.286.17.2120; Smith MA, 1997, J NEUROSCI, V17, P2653; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; Takuma K, 2001, J BIOL CHEM, V276, P48093, DOI 10.1074/jbc.M108622200; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Torroja L, 1998, J CELL BIOL, V141, P1009, DOI 10.1083/jcb.141.4.1009; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Villani G, 2000, FREE RADICAL BIO MED, V29, P202, DOI 10.1016/S0891-5849(00)00303-8; Wiedemann FR, 1998, FEBS LETT, V422, P33, DOI 10.1016/S0014-5793(97)01586-X; Yan SD, 1999, AM J PATHOL, V155, P1403, DOI 10.1016/S0002-9440(10)65452-1; Yan SD, 1997, NATURE, V389, P689; Yan SD, 2000, BBA-MOL BASIS DIS, V1502, P145, DOI 10.1016/S0925-4439(00)00041-7; Yan SD, 2000, J BIOL CHEM, V275, P27100; Young TA, 2002, ARCH BIOCHEM BIOPHYS, V405, P65, DOI 10.1016/S0003-9861(02)00338-7	47	220	243	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2005	19	1					597	+		10.1096/fj.04-2582fje	http://dx.doi.org/10.1096/fj.04-2582fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	891JH	15665036				2022-12-25	WOS:000226576600015
J	Horonchik, L; Tzaban, S; Ben-Zaken, O; Yedidia, Y; Rouvinski, A; Papy-Garcia, D; Barritault, D; Vlodavsky, I; Taraboulos, A				Horonchik, L; Tzaban, S; Ben-Zaken, O; Yedidia, Y; Rouvinski, A; Papy-Garcia, D; Barritault, D; Vlodavsky, I; Taraboulos, A			Heparan sulfate is a cellular receptor for purified infectious prions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-ASSOCIATED FORM; CULTURED-CELLS; SPONGIFORM ENCEPHALOPATHY; MOLECULAR CHARACTERISTICS; FINE-STRUCTURE; BINDING-SITES; IN-VITRO; PROTEIN; PRP; GLYCOSAMINOGLYCAN	Prions replicate in the host cell by the self-propagating refolding of the normal cell surface protein, PrPC, into a beta-sheet-rich conformer, PrPSc. Exposure of cells to prion-infected material and subsequent endocytosis can sometimes result in the establishment of an infected culture. However, the relevant cell surface receptors have remained unknown. We have previously shown that cellular heparan sulfates (HS) are involved in the ongoing formation of scrapie prion protein (PrPSc) in chronically infected cells. Here we studied the initial steps in the internalization of prions and in the infection of cells. Purified prion "rods" are arguably the purest prion preparation available. The only proteinaceous component of rods is PrPSc. Mouse neuroblastoma N2a, hypothalamus GT1 - 1, and Chinese hamster ovary cells efficiently bound both hamster and mouse prion rods ( at 4 degrees C) and internalized them ( at 37 degrees C). Treating cells with bacterial heparinase III or chlorate ( a general inhibitor of sulfation) strongly reduced both binding and uptake of rods, whereas chondroitinase ABC was inactive. These results suggested that the cell surface receptor of prion rods involves sulfated HS chains. Sulfated glycans inhibited both binding and uptake of rods, probably by competing with the binding of rods to cellular HS. Treatments that prevented endocytosis of rods also prevented the de novo infection of GT1 - 1 cells when applied during their initial exposure to prions. These results indicate that HS are an essential part of the cellular receptor used both for prion uptake and for cell infection. Cellular HS thus play a dual role in prion propagation, both as a cofactor for PrPSc synthesis and as a receptor for productive prion uptake.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; OTR3 Sarl, F-94000 Creteil, France; Univ Paris 12, Lab CRRET, CNRS, UMR 7149, F-94010 Creteil, France	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Taraboulos, A (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel.	taraboul@cc.huji.ac.il						BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; BOLTON DC, 1984, BIOCHEMISTRY-US, V23, P5898, DOI 10.1021/bi00320a002; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CLARKE MC, 1970, NATURE, V225, P100, DOI 10.1038/225100a0; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; DIRINGER H, 1983, EUR J BIOCHEM, V134, P555, DOI 10.1111/j.1432-1033.1983.tb07602.x; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Flechsig E, 2001, MOL MED, V7, P679, DOI 10.1007/BF03401958; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; GIBBS CJ, 1969, SCIENCE, V165, P1023, DOI 10.1126/science.165.3897.1023; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KATO M, 1994, J BIOL CHEM, V269, P18881; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Ledoux D, 2000, J BIOL CHEM, V275, P29383, DOI 10.1074/jbc.M000837200; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Luhr KM, 2002, J VIROL, V76, P12259, DOI 10.1128/JVI.76.23.12259-12264.2002; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MCKINLEY MP, 1986, J INFECT DIS, V154, P110, DOI 10.1093/infdis/154.1.110; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Nakato H, 2002, BBA-GEN SUBJECTS, V1573, P312, DOI 10.1016/S0304-4165(02)00398-7; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Schatzl HM, 1997, J VIROL, V71, P8821; Schonberger O, 2003, BIOCHEM BIOPH RES CO, V312, P473, DOI 10.1016/j.bbrc.2003.10.150; Solassol J, 2003, BRIT MED BULL, V66, P87, DOI 10.1093/bmb/66.1.87; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Verdier Y, 2004, CURR PROTEIN PEPT SC, V5, P19, DOI 10.2174/1389203043486937; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; WEINER RI, 1992, FRONT NEUROENDOCRIN, V13, P95; WILESMITH JW, 1988, VET REC, V123, P638; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200	52	138	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17062	17067		10.1074/jbc.M500122200	http://dx.doi.org/10.1074/jbc.M500122200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15668247	hybrid			2022-12-25	WOS:000228615500064
J	Bracken, CP; Whitelaw, ML; Peet, DJ				Bracken, CP; Whitelaw, ML; Peet, DJ			Activity of hypoxia-inducible factor 2 alpha is regulated by association with the NF-kappa B essential modulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; DEPENDENT GENE-EXPRESSION; CREB-BINDING PROTEIN; IKK-GAMMA/NEMO; KINASE COMPLEX; TRANSCRIPTION FACTOR; NEMO/IKK-GAMMA; FACTOR 1-ALPHA; PAS DOMAIN	The hypoxia- inducible factors 1 alpha ( HIF-1 alpha) and 2 alpha ( HIF- 2 alpha) are key regulators of the transcriptional response to low oxygen and are closely related in domain architecture, DNA binding, and activation mechanisms. Despite these similarities, targeted disruption of the HIF- alpha genes in mice results in distinctly different phenotypes demonstrating nonredundancy of function, although the underlying mechanisms remain unclear. Here we report on the novel and specific interaction of HIF- 2 alpha, but not HIF- 1 alpha, with the NF- kappa B essential modulator ( NEMO) using immunoprecipitation, mammalian two- hybrid, and in vitro protein interaction assays. Reporter gene assays demonstrate that this interaction specifically enhances normoxic HIF- 2 alpha transcriptional activity, independently of the HIF- 2 alpha transactivation domain, consistent with a model by which NEMO aids CBP/ p300 recruitment to HIF- 2 alpha. In contrast, HIF- 2 alpha overexpression does not alter NF- kappa B signaling, suggesting that the functional consequence of the HIF- 2 alpha/ NEMO interaction is limited to the HIF pathway. The specificity of NEMO for HIF- 2 alpha represents one of the few known differential protein- protein interactions between the HIF- alpha proteins, which has important implications for the activity of HIF- 2 alpha and is also the first postulated NF- kappa B- independent role for NEMO.	Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Peet, DJ (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.		Peet, Daniel/AAE-6698-2020	Peet, Daniel/0000-0002-6085-8936; Bracken, Cameron/0000-0001-7722-625X				Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bernaudin M, 2002, J BIOL CHEM, V277, P39728, DOI 10.1074/jbc.M204619200; Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x; Blancher C, 2001, CANCER RES, V61, P7349; Brusselmans K, 2001, J BIOL CHEM, V276, P39192, DOI 10.1074/jbc.C100428200; Burke B, 2002, J PATHOL, V196, P204, DOI 10.1002/path.1029; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Carter RS, 2003, J BIOL CHEM, V278, P19642, DOI 10.1074/jbc.M301705200; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Cooke EL, 2001, BIOCHEM J, V359, P403, DOI 10.1042/0264-6021:3590403; COURTOIS G, 2000, SCI STKE, P14; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Haque M, 2003, J VIROL, V77, P6761, DOI 10.1128/JVI.77.12.6761-6768.2003; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Huang J, 2004, J BIOL CHEM, V279, P16847, DOI 10.1074/jbc.M309491200; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jurgensen JS, 2004, FASEB J, V18, P1415, DOI 10.1096/fj.04-1605fje; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Ruas JL, 2002, J BIOL CHEM, V277, P38723, DOI 10.1074/jbc.M205051200; Rudolph D, 2000, GENE DEV, V14, P854; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Schwamborn K, 2000, J BIOL CHEM, V275, P22780, DOI 10.1074/jbc.M001500200; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; Scortegagna M, 2003, BLOOD, V102, P1634, DOI 10.1182/blood-2003-02-0448; Stilo R, 2004, J BIOL CHEM, V279, P34323, DOI 10.1074/jbc.M402244200; Takahashi R, 2004, BIOCHEM BIOPH RES CO, V317, P84, DOI 10.1016/j.bbrc.2004.03.010; Takeda N, 2004, CIRC RES, V95, P146, DOI 10.1161/01.RES.0000134920.10128.b4; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Tarassishin L, 2001, BIOCHEM BIOPH RES CO, V285, P555, DOI 10.1006/bbrc.2001.5197; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200; Xia GB, 2002, UROLOGY, V59, P774, DOI 10.1016/S0090-4295(01)01607-7; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	74	58	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14240	14251		10.1074/jbc.M409987200	http://dx.doi.org/10.1074/jbc.M409987200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15653678	hybrid			2022-12-25	WOS:000228095500127
J	Levy, SF; LeBoeuf, AC; Massie, MR; Jordan, MA; Wilson, L; Feinstein, SC				Levy, SF; LeBoeuf, AC; Massie, MR; Jordan, MA; Wilson, L; Feinstein, SC			Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners - Implications for neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAU-PROTEIN; IN-VITRO; INDIVIDUAL MICROTUBULES; NEURITE OUTGROWTH; NEUROFIBRILLARY TANGLES; KINETIC STABILIZATION; PROTOFILAMENT NUMBER; ASSEMBLED INVITRO; LIGHT-MICROSCOPY; BINDING DOMAINS	The microtubule-associated protein tau is implicated in the pathogenesis of many neurodegenerative diseases, including fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), in which both RNA splicing and amino acid substitution mutations in tau cause dominantly inherited early onset dementia. RNA-splicing FTDP-17 mutations alter the wildtype similar to 50:50 3-repeat (3R) to 4-repeat (4R) tau isoform ratio, usually resulting in an excess of 4R tau. To examine further how splicing mutations might cause dysfunction by misregulation of microtubule dynamics, we used video microscopy to determine the in vitro behavior of individual microtubules stabilized by varying amounts of human 4R and 3R tau. At low tau: tubulin ratios (1: 55 and 1: 45), all 3R isoforms reduced microtubule growth rates relative to the no-tau control, whereas all 4R isoforms increased them; however, at a high tau: tubulin ratio (1: 20), both 4R and 3R tau increased the growth rates. Further analysis revealed two distinct subpopulations of growing microtubules in the absence of tau. Increasing concentrations of both 4R and 3R tau resulted in an increase in the size of the faster growing subpopulation of microtubules; however, 4R tau caused a redistribution to the faster growing subpopulation at lower tau: tubulin ratios than 3R tau. This modulation of discrete growth rate subpopulations by tau suggests that tau causes a conformational shift in the microtubule resulting in altered dynamics. Quantitative and qualitative differences observed between 4R and 3R tau are consistent with a "microtubule misregulation" model in which abnormal tau isoform expression results in the inability to properly regulate microtubule dynamics, leading to neuronal death and dementia.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Feinstein, SC (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Bldg 571,Rm 6129, Santa Barbara, CA 93106 USA.	feinstei@lifesci.ucsb.edu	LeBoeuf, Adria C/F-1837-2017	LeBoeuf, Adria C/0000-0002-2931-1510; Levy, Sasha/0000-0002-0923-1636	NCI NIH HHS [CA57291] Funding Source: Medline; NINDS NIH HHS [NS13560, NS35010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013560, R01NS035010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOHM KJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P119, DOI 10.1016/0304-4165(84)90049-7; BRANDT R, 1993, J BIOL CHEM, V268, P3414; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Bunker JM, 2004, MOL BIOL CELL, V15, P2720, DOI 10.1091/mbc.E04-01-0062; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Carlier MF, 1991, CURR OPIN CELL BIOL, V3, P12, DOI 10.1016/0955-0674(91)90160-Z; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; CHRETIEN D, 1992, J CELL BIOL, V117, P1031, DOI 10.1083/jcb.117.5.1031; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; Diaz JF, 1998, J BIOL CHEM, V273, P33803, DOI 10.1074/jbc.273.50.33803; Downing KH, 1998, EUR BIOPHYS J BIOPHY, V27, P431, DOI 10.1007/s002490050153; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; FRAPPIER TF, 1994, J NEUROCHEM, V63, P2288; GAMBLIN TC, 1995, ANAL BIOCHEM, V232, P43; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P15009, DOI 10.1021/bi035722s; GEUENS G, 1986, J CELL BIOL, V103, P1883, DOI 10.1083/jcb.103.5.1883; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hall GF, 2000, J CELL SCI, V113, P1373; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; JORDAN MA, 2005, IN PRESS MICROTUBULE; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; Kraemer BC, 2003, P NATL ACAD SCI USA, V100, P9980, DOI 10.1073/pnas.1533448100; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Liu CWA, 1999, CELL MOTIL CYTOSKEL, V43, P232, DOI 10.1002/(SICI)1097-0169(1999)43:3<232::AID-CM6>3.0.CO;2-7; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; Makrides V, 2003, J BIOL CHEM, V278, P33298, DOI 10.1074/jbc.M305207200; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; Panda D, 2003, P NATL ACAD SCI USA, V100, P9548, DOI 10.1073/pnas.1633508100; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; Panda D, 2002, BIOCHEMISTRY-US, V41, P1609, DOI 10.1021/bi011767m; Pedigo S, 2002, BIOPHYS J, V83, P1809, DOI 10.1016/S0006-3495(02)73946-5; PIERSON GB, 1978, J CELL BIOL, V76, P223, DOI 10.1083/jcb.76.1.223; Ross JL, 2004, P NATL ACAD SCI USA, V101, P12910, DOI 10.1073/pnas.0402928101; SCOTT CW, 1992, J NEUROSCI RES, V33, P19, DOI 10.1002/jnr.490330104; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; Tran PT, 1997, J STRUCT BIOL, V118, P107, DOI 10.1006/jsbi.1997.3844; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947	70	74	78	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13520	13528		10.1074/jbc.M413490200	http://dx.doi.org/10.1074/jbc.M413490200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15671021	hybrid			2022-12-25	WOS:000228095500043
J	Linggi, MS; Burke, TL; Williams, BB; Harrington, A; Kraemer, R; Hempstead, BL; Yoon, SO; Carter, BD				Linggi, MS; Burke, TL; Williams, BB; Harrington, A; Kraemer, R; Hempstead, BL; Yoon, SO; Carter, BD			Neurotrophin receptor interacting factor (NRIF) is an essential mediator of apoptotic signaling by the p75 neurotrophin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NF-KAPPA-B; CELL-DEATH; C-JUN; SYMPATHETIC NEURONS; HIPPOCAMPAL-NEURONS; P75-MEDIATED DEATH; NGF BINDING; SPINAL-CORD; IN-VIVO	Activation of the p75 neurotrophin receptor leads to a variety of effects within the nervous system, including neuronal apoptosis. Both c-Jun N-terminal kinase (JNK) and the tumor suppressor p53 have been reported to be critical for this receptor to induce cell death; however, the mechanisms by which p75 activates these pathways is undetermined. Here we report that the neurotrophin receptor interacting factor (NRIF) is necessary for p75-dependent JNK activation and apoptosis. Upon nerve growth factor withdrawal, nrif-/- sympathetic neurons underwent apoptosis, whereas p75-mediated death was completely abrogated. The lack of cell death correlated with a lack of JNK activation in the nrif-/- neurons, suggesting that NRIF is a selective mediator for p75-dependent JNK activation and apoptosis. Moreover, we document that NRIF expression is sufficient to induce cell death through a mechanism that requires p53. Taken together, these results establish NRIF as an essential component of the p75 apoptotic pathway.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol, New York, NY 10021 USA	Vanderbilt University; Vanderbilt University; University System of Ohio; Ohio State University; Cornell University; Cornell University; Cornell University	Carter, BD (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 655 Light Hall, Nashville, TN 37232 USA.	bruce.carter@vanderbilt.edu	Williams, Brooke/V-5638-2019; Yoon, Sung Ok/C-5992-2012		NHLBI NIH HHS [T32 HL07328] Funding Source: Medline; NINDS NIH HHS [NS38220, NS39472, NS30687] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030687, R01NS038220, R01NS039472] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Becker EBE, 2004, J NEUROSCI, V24, P8762, DOI 10.1523/JNEUROSCI.2953-04.2004; Benzel I, 2001, GENE, V281, P19, DOI 10.1016/S0378-1119(01)00730-2; Bhakar AL, 2003, J NEUROSCI, V23, P11373; Brennan C, 1999, NAT NEUROSCI, V2, P699, DOI 10.1038/11158; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Dobrowsky RT, 2000, J NEUROSCI RES, V61, P237, DOI 10.1002/1097-4547(20000801)61:3<237::AID-JNR1>3.0.CO;2-M; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Frade JM, 1999, DEVELOPMENT, V126, P683; Frade JM, 1996, NATURE, V383, P166; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gentry JJ, 2004, J BIOL CHEM, V279, P16646, DOI 10.1074/jbc.M309209200; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Harrington AW, 2002, J NEUROSCI, V22, P156, DOI 10.1523/JNEUROSCI.22-01-00156.2002; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Kendall SE, 2003, DEV BRAIN RES, V144, P151, DOI 10.1016/S0165-3806(03)00166-4; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Majdan M, 2001, J CELL BIOL, V155, P1275, DOI 10.1083/jcb.200110017; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Naumann T, 2002, J NEUROSCI, V22, P2409, DOI 10.1523/JNEUROSCI.22-07-02409.2002; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Sadoul R, 1996, J NEUROSCI RES, V43, P594, DOI 10.1002/(SICI)1097-4547(19960301)43:5<594::AID-JNR9>3.3.CO;2-D; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Troy CM, 2002, J BIOL CHEM, V277, P34295, DOI 10.1074/jbc.M205167200; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yeiser EC, 2004, J NEUROSCI, V24, P10521, DOI 10.1523/JNEUROSCI.1390-04.2004; Yoon SO, 1998, J NEUROSCI, V18, P3273	47	52	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13801	13808		10.1074/jbc.M410435200	http://dx.doi.org/10.1074/jbc.M410435200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15668238	hybrid			2022-12-25	WOS:000228095500077
J	Maier, EA; Dusing, MR; Wiginton, DA				Maier, EA; Dusing, MR; Wiginton, DA			Cdx binding determines the timing of enhancer activation in postnatal duodenum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-DEAMINASE GENE; HOMEODOMAIN PROTEIN CDX2; TRANSCRIPTION FACTOR YY1; HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; PHLORHIZIN HYDROLASE GENE; HOMEOBOX GENE; INTESTINAL EPITHELIUM; CALBINDIN-D9K GENE; DEVELOPMENTAL REGULATION; ALIMENTARY-TRACT	In mammalian intestine, adenosine deaminase (ADA) is expressed at high levels only along the villi of the duodenal epithelium. A duodenum-specific enhancer identified in the second intron of the human ADA gene controls this pattern of expression. This enhancer faithfully recapitulates this expression pattern in transgenic mice, when included in CAT reporter gene constructions. Multiple binding sites for PDX-1 and GATA factors were previously identified within the similar to 300-bp region that encompasses the enhancer. Mutation analyses demonstrated that binding of PDX-1 and of GATA-4 was absolutely essential for enhancer function. In the present study, we have identified additional enhancer binding sites for Cdx factors, for YY1, and for NFI family members. Detailed EMSA studies were used to confirm binding at these sites. This brings the number of confirmed binding sites within the enhancer to thirteen, with five different factors or family of factors contributing to the putative enhanceosome complex. Mutation analysis was utilized to examine the specific roles of the newly identified sites. Two sites were identified that bound both Cdx1 and Cdx2. Mutations were identified in these two sites that completely and specifically eliminated Cdx binding. In transgenic mice, these enhancer mutations dramatically changed the developmental timing of enhancer activation (delaying it by 2-3 weeks) without affecting other aspects of enhancer function. In the chromatin context of certain transgenic insertion sites, mutation of the two YY1 sites to specifically ablate binding caused a delay in enhancer activation similar to that observed with the Cdx mutations. No overt changes were observed from mutation of the NFI site.	Cincinnati Childrens Hosp, Res Fdn, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Div Dev Biol, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Wiginton, DA (corresponding author), Cincinnati Childrens Hosp, Res Fdn, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	dan.wiginton@chmcc.org						ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ATCHISON ML, 1988, ANNU REV CELL BIOL, V4, P127, DOI 10.1146/annurev.cellbio.4.1.127; Barbara PD, 2003, CELL MOL LIFE SCI, V60, P1322, DOI 10.1007/s00018-003-2289-3; Barley NF, 1999, BIOCHEM J, V341, P491, DOI 10.1042/0264-6021:3410491; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Brickner AG, 1995, GENE, V167, P261, DOI 10.1016/0378-1119(95)00673-7; Brickner AG, 1999, MAMM GENOME, V10, P95, DOI 10.1007/s003359900951; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; Colnot S, 1998, J BIOL CHEM, V273, P31939, DOI 10.1074/jbc.273.48.31939; Drummond FJ, 1998, FEBS LETT, V423, P218, DOI 10.1016/S0014-5793(98)00103-3; Dusing MR, 1997, J BIOL CHEM, V272, P26634, DOI 10.1074/jbc.272.42.26634; Dusing MR, 2001, J BIOL CHEM, V276, P14434, DOI 10.1074/jbc.M009249200; Dusing MR, 2003, AM J PHYSIOL-GASTR L, V284, pG1053, DOI 10.1152/ajpgi.00483.2002; Dusing MR, 2000, AM J PHYSIOL-GASTR L, V279, pG1080, DOI 10.1152/ajpgi.2000.279.5.G1080; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Gautier-Stein A, 2003, NUCLEIC ACIDS RES, V31, P5238, DOI 10.1093/nar/gkg747; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; GUH E, 2001, AM J PHYSIOL, V280, pG149; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; GUZ Y, 1995, DEVELOPMENT, V121, P11; Heller RS, 1998, GASTROENTEROLOGY, V115, P381, DOI 10.1016/S0016-5085(98)70204-5; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; Lee SY, 1996, J BIOL CHEM, V271, P707, DOI 10.1074/jbc.271.2.707; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McNeil S, 1998, J CELL BIOCHEM, V68, P500, DOI 10.1002/(SICI)1097-4644(19980315)68:4<500::AID-JCB9>3.3.CO;2-T; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; Park J, 2000, GASTROENTEROLOGY, V119, P89, DOI 10.1053/gast.2000.8520; Rankin EB, 2004, AM J PHYSIOL-GASTR L, V286, pG872, DOI 10.1152/ajpgi.00326.2003; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; van den Akker E, 2002, DEVELOPMENT, V129, P2181; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Winston JH, 1996, SOMAT CELL MOLEC GEN, V22, P261, DOI 10.1007/BF02369566; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; Xu PA, 1999, J BIOL CHEM, V274, P10316, DOI 10.1074/jbc.274.15.10316; Yamamoto H, 1999, J BONE MINER RES, V14, P240, DOI 10.1359/jbmr.1999.14.2.240; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001	64	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					13195	13202		10.1074/jbc.M413158200	http://dx.doi.org/10.1074/jbc.M413158200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15677472	hybrid			2022-12-25	WOS:000227922000132
J	Wei, G; Li, AG; Liu, X				Wei, G; Li, AG; Liu, X			Insights into selective activation of p53 DNA binding by c-abl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; PHOSPHORYLATION; REQUIRES; TETRAMER; TERMINUS; LATENT; MDM2; SITE	As a transcription factor, p53 recognizes a specific consensus DNA sequence and activates the expression of the target genes involved in either growth arrest or apoptosis. Despite our wealth of knowledge on the genes that are targeted by p53 in growth arrest and apoptosis, relatively little is known about the promoter specificity triggered by p53 in these processes. Here we show that interaction with c-Abl stabilized p53 tetrameric conformation, and as a consequence c-Abl stimulated p53 DNA binding only when all quarter binding sites (a perfect binding sequence) on p53-responsive promoters were present. This result suggests that in response to DNA damage, c-Abl binding may specifically stimulate p53 DNA binding on the promoters with perfect binding sequences. A sequence comparison of several known p53-responsive elements illustrates the presence of the perfect binding sequences on the p21 but not the Bax promoter. Significantly, we show that c-Abl indeed enhanced p53 DNA binding and transcription from p21 but not Bax. These results suggest that the promoter specificity plays an important role in selective activation of p53 DNA binding by c-Abl. The implications of this with relation to selective activation of p53 target genes involved in either growth arrest or apoptosis are discussed.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Liu, X (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	xuan.liu@ucr.edu			NCI NIH HHS [CA75180] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA075180, R01CA075180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOGA A, 1995, ONCOGENE, V11, P791; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gong JG, 1999, NATURE, V399, P806; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LIU X, 1995, MOL CELL BIOL, V15, P6474; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; MIYASHITA T, 1995, CELL, V80, P293; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	37	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12271	12278		10.1074/jbc.M409522200	http://dx.doi.org/10.1074/jbc.M409522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15661746	hybrid			2022-12-25	WOS:000227922000026
J	Abouzied, MM; El-Tahir, HM; Prenner, L; Haberlein, HH; Gieselmann, V; Franken, S				Abouzied, MM; El-Tahir, HM; Prenner, L; Haberlein, HH; Gieselmann, V; Franken, S			Hepatoma-derived growth factor - Significance of amino acid residues 81-100 in cell surface interaction and proliferative activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; SECRETORY SIGNAL SEQUENCE; NUCLEAR-LOCALIZATION; ANGIOGENIC FACTOR; HEPARAN-SULFATE; GENE FAMILY; PROTEIN; EXPRESSION; MECHANISM; RECEPTOR	Hepatoma-derived growth factor ( HDGF) has proliferative, angiogenic, and neurotrophic activity. It plays a putative role in the development and progression of cancer. When expressed in cells, the mitogenic activity of HDGF depends on its nuclear localization, but it also stimulates proliferation when added to the cell culture medium. A cell surface receptor for HDGF has not been identified so far. We investigated the interaction of various purified recombinant HDGF fusion proteins with the cell surface of NIH 3T3 fibroblasts. We showed that binding of a HDGF-beta-galactosidase fusion protein to the cell surface of NIH 3T3 fibroblasts was saturable, occurred with high affinity (K-D=14nM), and had a proliferative effect. We identified a peptide comprising amino acid residues 81-100 within the amino-terminal part of HDGF that bound to the cell surface of NIH 3T3 cells with saturation and affinity values similar to those of HDGF. When added to primary human fibroblasts, this peptide stimulated proliferation. Substitution of a single amino acid (K96A) within this peptide was sufficient to abolish its binding to the cell surface and its proliferative activity. In contrast, when expressed transiently in NIH 3T3 cells, a HDGF-beta-galactosidase fusion protein in which amino acid residues 81-100 were deleted still had proliferative activity, whereas a fusion protein containing only the 81-100 peptide did not. Our results suggest the existence of a plasma membrane-located HDGF receptor for which signaling depends on amino acid residues 81-100 of HDGF. This region differs from the one that has been recently identified to be essential for mitogenic activity depending on the nuclear localization of HDGF. Thus, HDGF exerts its proliferative activity via two different pathways.	Univ Bonn, Inst Physiol, D-53115 Bonn, Germany	University of Bonn	Franken, S (corresponding author), Univ Bonn, Inst Physiol, Nussallee 11, D-53115 Bonn, Germany.	franken@institut.physiochem.uni-bonn.de	Eltahir, Heba M/S-6533-2019	Abouzied, mekky/0000-0001-5309-3552; Franken, Sebastian/0000-0003-4844-6389				Abouzied MM, 2004, BIOCHEM J, V378, P169, DOI 10.1042/BJ20030916; Berland Keith M, 2004, Methods Mol Biol, V261, P383; Bernard K, 2003, CANCER RES, V63, P6716; Cilley RE, 2000, J PEDIATR SURG, V35, P113, DOI 10.1016/S0022-3468(00)80026-3; CORPS AN, 1993, GROWTH FACTORS PRACT, P35; Dietz F, 2002, BIOCHEM J, V366, P491, DOI 10.1042/BJ20011811; Enomoto H, 2002, J GASTROENTEROL, V37, P158, DOI 10.1007/BF03326437; Enomoto H, 2002, HEPATOLOGY, V36, P1519, DOI 10.1053/jhep.2002.36935; Everett AD, 2000, J CLIN INVEST, V105, P567, DOI 10.1172/JCI7497; Everett AD, 2004, AM J PHYSIOL-LUNG C, V286, pL1194, DOI 10.1152/ajplung.00427.2003; Everett AD, 2003, CURR DRUG TARGETS, V4, P367, DOI 10.2174/1389450033490975; Everett AD, 2001, J BIOL CHEM, V276, P37564, DOI 10.1074/jbc.M105109200; Fatma N, 2000, INVEST OPHTH VIS SCI, V41, P2648; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Haustein E, 2003, METHODS, V29, P153, DOI 10.1016/S1046-2023(02)00306-7; Hegener O, 2004, BIOCHEMISTRY-US, V43, P6190, DOI 10.1021/bi035928t; Hsia E, 2003, J CELL BIOCHEM, V88, P1214, DOI 10.1002/jcb.10470; Hu TH, 2003, CANCER-AM CANCER SOC, V98, P1444, DOI 10.1002/cncr.11653; Ikegame K, 1999, BIOCHEM BIOPH RES CO, V266, P81, DOI 10.1006/bbrc.1999.1733; Izumoto Y, 1997, BIOCHEM BIOPH RES CO, V238, P26, DOI 10.1006/bbrc.1997.7233; Kambe H, 2000, HEPATO-GASTROENTEROL, V47, P1645; Kishima Y, 2002, J BIOL CHEM, V277, P10315, DOI 10.1074/jbc.M111122200; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; Lepourcelet M, 2005, DEVELOPMENT, V132, P415, DOI 10.1242/dev.01579; Levin MK, 2004, DIFFERENTIATION, V72, P1, DOI 10.1111/j.1432-0436.2004.07201002.x; Martz E, 2002, TRENDS BIOCHEM SCI, V27, P107, DOI 10.1016/S0968-0004(01)02008-4; Matsuyama A, 2001, CANCER RES, V61, P5714; Meissner O, 2003, BIOCHEMISTRY-US, V42, P1667, DOI 10.1021/bi0263356; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; Mori M, 2004, AM J RESP CELL MOL, V30, P459, DOI 10.1165/rcmb.2003-0013OC; NAKAMURA H, 1994, J BIOL CHEM, V269, P25143; NAKAMURA H, 1989, CLIN CHIM ACTA, V183, P273, DOI 10.1016/0009-8981(89)90361-6; Nakamura H, 2002, J GASTROENTEROL, V37, P8, DOI 10.1007/BF03326407; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Okuda Y, 2003, CANCER SCI, V94, P1034, DOI 10.1111/j.1349-7006.2003.tb01397.x; Oliver JA, 1998, J CLIN INVEST, V102, P1208, DOI 10.1172/JCI785; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Pramanik A, 2004, CURR PHARM BIOTECHNO, V5, P205, DOI 10.2174/1389201043377002; Ryu J, 2003, MOL CELLS, V16, P385; Singh DP, 2000, BIOCHEM BIOPH RES CO, V267, P373, DOI 10.1006/bbrc.1999.1979; Stachowiak MK, 1997, MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02740663; Sue SC, 2004, J MOL BIOL, V343, P1365, DOI 10.1016/j.jmb.2004.09.014; WALICKE PA, 1991, J NEUROSCI, V11, P2249; Wang DY, 2003, J BIOL CHEM, V278, P43340, DOI 10.1074/jbc.M307789200; Yoshida K, 2003, J GASTROEN HEPATOL, V18, P1293, DOI 10.1046/j.1440-1746.2003.03191.x; Zhou ZW, 2004, J BIOL CHEM, V279, P27320, DOI 10.1074/jbc.M308650200	48	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					10945	10954		10.1074/jbc.M414652200	http://dx.doi.org/10.1074/jbc.M414652200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15655245	hybrid			2022-12-25	WOS:000227761800010
J	Salamon, Z; Devanathan, S; Alves, ID; Tollin, G				Salamon, Z; Devanathan, S; Alves, ID; Tollin, G			Plasmon-waveguide resonance studies of lateral segregation of lipids and proteins into microdomains (rafts) in solid-supported bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ALKALINE-PHOSPHATASE; PROBING MOLECULAR-INTERACTIONS; DELTA-OPIOID RECEPTOR; CHOLESTEROL; MODEL; SPECTROSCOPY; LOCALIZATION; CAVEOLAE; DOMAINS; BINDING	Plasmon- waveguide resonance ( PWR) spectroscopy has been used to examine solid- supported lipid bilayers consisting of dioleoylphosphatidylcholine ( DOPC), palmitoyloleoylphosphatidylcholine ( POPC), sphingomyelin ( SM), and phosphatidylcholine/ SM binary mixtures. Spectral simulation of the resonance curves demonstrated an increase in bilayer thickness, long- range order, and molecular packing density in going from DOPC to POPC to SM single component bilayers, as expected based on the decreasing level of unsaturation in the fatty acyl chains. DOPC/ SM and POPC/ SM binary mixtures yielded PWR spectra that can be ascribed to a superposition of two resonances corresponding to microdomains ( rafts) consisting of phosphatidylcholine- and SM- rich phases coexisting within a single bilayer. These were formed spontaneously over time as a consequence of lateral phase separation. Each microdomain contained a small proportion (< 20%) of the other lipid component, which increased their kinetic and thermodynamic stability. Incorporation of a glycosylphosphatidylinositol- linked protein ( placental alkaline phosphatase) occurred within each of the single component bilayers, although the insertion was less efficient into the DOPC bilayer. Incorporation of placental alkaline phosphatase into a DOPC/ SM binary bilayer occurred with preferential insertion into the SM- rich phase, although the protein incorporated into both phases at higher concentrations. These results demonstrate the utility of PWR spectroscopy to provide insights into raft formation and protein sorting in model lipid membranes.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Arizona	Tollin, G (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA.	gtollin@u.arizona.edu	Alves, Isabel D/R-9613-2016	Alves, Isabel D/0000-0003-3193-2436	NIDA NIH HHS [DA13449, DA06284] Funding Source: Medline; NIGMS NIH HHS [GM59630] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013449, P01DA006284] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alves ID, 2004, J BIOL CHEM, V279, P44673, DOI 10.1074/jbc.M404713200; Angrand M, 1997, EUR J BIOCHEM, V250, P168, DOI 10.1111/j.1432-1033.1997.t01-1-00168.x; Bacia K, 2004, BIOPHYS J, V87, P1034, DOI 10.1529/biophysj.104.040519; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Born M., 1968, PRINCIPLES OPTICS; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; Crane JM, 2004, BIOPHYS J, V86, P2965, DOI 10.1016/S0006-3495(04)74347-7; CUYPERS PA, 1983, J BIOL CHEM, V258, P2426; DEJEU WH, 1978, LIQUID CRYSTAL MONOG, V1, P31; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Eroglu C, 2003, P NATL ACAD SCI USA, V100, P10219, DOI 10.1073/pnas.1737042100; Gimpl G, 2000, EXP PHYSIOL, V85, p41S, DOI 10.1111/j.1469-445X.2000.tb00006.x; Giocondi MC, 2004, ULTRAMICROSCOPY, V100, P135, DOI 10.1016/j.ultramic.2003.11.002; Guzzi F, 2002, ONCOGENE, V21, P1658, DOI 10.1038/sj.onc.1205219; Henderson RA, 2004, NEWS PHYSIOL SCI, V19, P39, DOI 10.1152/nips.01505.2003; Lawrence JC, 2003, BIOPHYS J, V84, P1827, DOI 10.1016/S0006-3495(03)74990-X; MACLEOD HA, 1986, THIN FILM OPTICAL FI; McIntosh TJ, 2003, BIOPHYS J, V85, P1656, DOI 10.1016/S0006-3495(03)74595-0; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; Milhiet PE, 2002, EMBO REP, V3, P485, DOI 10.1093/embo-reports/kvf096; Milhiet PE, 2002, J BIOL CHEM, V277, P875, DOI 10.1074/jbc.C100654200; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nagle JF, 2000, CURR OPIN STRUC BIOL, V10, P474, DOI 10.1016/S0959-440X(00)00117-2; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Salamon Z, 2000, BIOPHYS J, V79, P2463, DOI 10.1016/S0006-3495(00)76489-7; Salamon Z, 1997, BIOPHYS J, V73, P2791, DOI 10.1016/S0006-3495(97)78308-5; Salamon Z, 1999, TRENDS BIOCHEM SCI, V24, P213, DOI 10.1016/S0968-0004(99)01394-8; Salamon Z, 2001, SPECTROSC-INT J, V15, P161, DOI 10.1155/2001/907405; Salamon Z, 2001, BIOPHYS J, V80, P1557, DOI 10.1016/S0006-3495(01)76128-0; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; Saslowsky DE, 2002, J BIOL CHEM, V277, P26966, DOI 10.1074/jbc.M204669200; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Shipley GG, 2000, CURR OPIN STRUC BIOL, V10, P471, DOI 10.1016/S0959-440X(00)00116-0; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200	44	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11175	11184		10.1074/jbc.M411197200	http://dx.doi.org/10.1074/jbc.M411197200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15668234	hybrid			2022-12-25	WOS:000227761800038
J	Sidhu, G; Li, W; Laryngakis, N; Bishai, E; Balla, T; Southwick, F				Sidhu, G; Li, W; Laryngakis, N; Bishai, E; Balla, T; Southwick, F			Phosphoinositide 3-kinase is required for intracellular Listeria monocytogenes actin-based motility and filopod formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARP2/3 COMPLEX; IN-VITRO; CYTOSKELETON; PI(3,4,5)P-3; PHAGOCYTOSIS; CHEMOTAXIS; CALCIUM; BINDING; PROTEIN; ROLES	Motile nonmuscle cells concentrate phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) in areas of new actin filament assembly. There is great interest in assessing the in vivo functional significance of these phosphoinositides, and we have used Listeria monocytogenes to explore the contribution of PtdIns( 3,4,5) P3 and PtdIns( 4,5) P2 to its actin-based motility. In Listeria-infected PtK2 cells Akt-pleckstrin homology (PH)-green fluorescent protein (GFP) and phospholipase C delta(PLC delta)-PH-GFP both first concentrate at the front of motile Listeria, subsequently surrounding the bacterium and then concentrating in the actin filament tail. Surprisingly, Listeria ActA mutant strains lacking the putative phosphoinositide binding site are also able to concentrate these probes. Reduction of available PtdIns( 3,4,5)P-3 by expression of Akt-PH-GFP and available PtdIns(4,5)P-2 by expression of PLC delta-PH-GFP both significantly slow Listeria actin-based movement. Treatment of cells with the PI 3-kinase inhibitor, LY294002, dissociates Akt-PH but not PLC delta-PH, from the bacterial surface and cell membranes, and results in near complete inhibition of Listeria actin-based motility and filopod formation. Removal of LY294002 results in rapid and full recovery of Akt-PH localization, Listeria actin-based motility, and filopod formation. These findings suggest that PtdIns(4,5)P-2 is concentrated at the surface of Listeria and serves as the substrate for PtdIns(3,4,5)P-3 production, indicating a central role for PI 3-kinases in Listeria intracellular actin-based motility and filopod formation.	Univ Florida, Coll Med, Div Infect Dis, Dept Med, Gainesville, FL 32610 USA; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20982 USA	State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Southwick, F (corresponding author), Univ Florida, Coll Med, Div Infect Dis, Dept Med, Box 100277, Gainesville, FL 32610 USA.	southfs@med.mac.ufl.edu		Balla, Tamas/0000-0002-9077-3335	NIAID NIH HHS [R01 AI034276, R01AI34276, R01AI-23262] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023262, R01AI034276] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Botelho RJ, 2004, CURR TOP MICROBIOL, V282, P1; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Cicchetti G, 1999, J BIOL CHEM, V274, P33616, DOI 10.1074/jbc.274.47.33616; Cossart P, 2000, CELL MICROBIOL, V2, P195, DOI 10.1046/j.1462-5822.2000.00053.x; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DILLON SB, 1987, J CELL BIOCHEM, V35, P345, DOI 10.1002/jcb.240350409; Hilpela P, 2004, CURR TOP MICROBIOL, V282, P117; LARSON L, 2005, IN PRESS P NATL ACAD; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; May RC, 1999, CURR BIOL, V9, P759, DOI 10.1016/S0960-9822(99)80337-6; Moreau V, 1998, FEBS LETT, V427, P353, DOI 10.1016/S0014-5793(98)00443-8; Pizarro-Cerda J, 2004, CR BIOL, V327, P115, DOI 10.1016/j.crvi.2003.11.007; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; Postma M, 2004, EMBO REP, V5, P35, DOI 10.1038/sj.embor.7400051; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; Skoble J, 2000, J CELL BIOL, V150, P527, DOI 10.1083/jcb.150.3.527; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Steffen P, 2000, CELL MOTIL CYTOSKEL, V45, P58; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zeile WL, 1996, J CELL BIOL, V133, P49, DOI 10.1083/jcb.133.1.49	26	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11379	11386		10.1074/jbc.M414533200	http://dx.doi.org/10.1074/jbc.M414533200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15642729	hybrid			2022-12-25	WOS:000227761800060
J	Visser, F; Baldwin, SA; Isaac, RE; Young, JD; Cass, CE				Visser, F; Baldwin, SA; Isaac, RE; Young, JD; Cass, CE			Identification and mutational analysis of amino acid residues involved in dipyridamole interactions with human and Caenorhabditis elegans equilibrative nucleoside transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NITROBENZYLTHIOINOSINE BINDING; INTRACELLULAR MEMBRANES; MOLECULAR-CLONING; CELLULAR UPTAKE; ENT FAMILY; INHIBITION; CELLS; ADENOSINE; EI	The equilibrative nucleoside transporters, hENT1 and CeENT1 from humans and Caenorhabditis elegans, respectively, are inhibited by nanomolar concentrations of dipyridamole and share a common 11-transmembrane helix (TM) topology. Random mutagenesis and screening by functional complementation in yeast for clones with reduced sensitivities to dipyridamole yielded mutations at Ile(429) in TM 11 of CeENT1 and Met(33) in TM 1 of hENT1. Mutational analysis of the corresponding residues of both proteins suggested important roles for these residues in competitive inhibition of hENT1 and CeENT1 by dipyridamole. To verify the roles of these residues in dipyridamole interactions, hENT2, which naturally exhibits low dipyridamole sensitivity, was mutated to contain side chains favorable for high affinity dipyridamole binding (i.e. a Met at the TM 1 and/or an Ile at the TM 11 positions). The single mutants exhibited increased hENT2 sensitivity to inhibition by dipyridamole, and the double mutant was the most sensitive, with an IC50 value that was only 2% of that of wild type. Functional analysis of the TM 1 and 11 mutants of hENT1 and CeENT1 revealed that Ala and Thr in the TM 1 and 11 positions, respectively, impaired uridine and adenosine transport and that Leu(442) of hENT1 was involved in permeant selectivity. Mechanistic and structural models of dipyridamole interactions with the TM 1 and 11 residues are proposed. This study demonstrated that the corresponding residues in TMs 1 and 11 of hENT1, hENT2, and CeENT1 are important for dipyridamole interactions and nucleoside transport.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Membrane Prot Res Grp, Dept Oncol, Edmonton, AB T6G 2M7, Canada; Univ Alberta, Membrane Prot Res Grp, Dept Physiol, Edmonton, AB T6G 2M7, Canada; Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Leeds; University of Leeds	Cass, CE (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	carol.cass@cancerboard.ab.ca						Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; Appleford PJ, 2004, MOL MEMBR BIOL, V21, P247, DOI 10.1080/09687680410001712550; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BARCLAY BJ, 1982, CAN J BIOCHEM CELL B, V60, P172, DOI 10.1139/o82-023; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; CASS CE, 1999, MEMBRANE TRANSPORTER, V12, P313; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; GATI WP, 1989, MOL PHARMACOL, V36, P134; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Greener A, 1996, Methods Mol Biol, V57, P375, DOI 10.1385/0-89603-332-5:375; GRENSON M, 1969, EUR J BIOCHEM, V11, P249, DOI 10.1111/j.1432-1033.1969.tb00767.x; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HAMMOND JR, 1991, MOL PHARMACOL, V39, P771; Hogue DL, 1996, J BIOL CHEM, V271, P9801, DOI 10.1074/jbc.271.16.9801; Hogue DL, 1997, BIOCHEM BIOPH RES CO, V238, P811, DOI 10.1006/bbrc.1997.7400; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P31, DOI 10.1113/jphysiol.1982.sp014099; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; JARVIS SM, 1983, BIOCHEM J, V216, P661, DOI 10.1042/bj2160661; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; PATERSON ARP, 1980, MOL PHARMACOL, V18, P40; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHI MM, 1986, BIOCHEM J, V240, P879, DOI 10.1042/bj2400879; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; VANBELLE H, 1993, CARDIOVASC RES, V27, P68; Vickers MF, 2000, J BIOL CHEM, V275, P25931, DOI 10.1074/jbc.M000239200; Vickers MF, 2004, NUCLEOS NUCLEOT NUCL, V23, P361, DOI 10.1081/NCN-120028333; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; VICKERS MF, 2000, EMERGING THERAPEUTIC, V4, P515; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Zhang J, 2003, MOL PHARMACOL, V64, P1512, DOI 10.1124/mol.64.6.1512	41	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11025	11034		10.1074/jbc.M410348200	http://dx.doi.org/10.1074/jbc.M410348200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15649894	hybrid			2022-12-25	WOS:000227761800019
J	Li, HB; Ye, XQ; Mahanivong, C; Bian, DF; Chun, J; Huang, S				Li, HB; Ye, XQ; Mahanivong, C; Bian, DF; Chun, J; Huang, S			Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; MATRIX METALLOPROTEINASES; PHOSPHOLIPASE-D; TUMOR INVASION; MESSENGER-RNA; RECEPTOR UPAR; KINASE; GROWTH; MITOGEN; RAS	Lysophosphatidic acid (LPA) enhances urokinase plasminogen activator (uPA) expression in ovarian cancer cells; however, the molecular mechanisms responsible for this event have not been investigated. In this study, we used the invasive ovarian cancer SK-OV-3 cell line to explore the signaling molecules and pathways essential for LPA-induced uPA up-regulation. With the aid of specific inhibitors and dominant negative forms of signaling molecules, we determined that the Gi-associated pathway mediates this LPA-induced event. Moreover, constitutively active H-Ras and Raf-1-activating H-Ras mutant enhance uPA expression, whereas dominant negative H-Ras and Raf-1 block LPA-induced uPA up-regulation, suggesting that the Ras-Raf pathway works downstream of Gi to mediate this LPA-induced process. Surprisingly, dominant negative MEK1 or Erk2 displays only marginal inhibitory effect on LPA-induced uPA up-regulation, suggesting that a signaling pathway distinct from Raf-MEK1/2-Erk is the prominent pathway responsible for this process. In this report, we demonstrate that LPA activates NF-kappa B in a Ras-Raf-dependent manner and that blocking NF-kappa B activation with either non-phosphorylable I kappa B or dominant negative I kappa B kinase abolished LPA-induced uPA up-regulation and uPA promoter activation. Furthermore, introducing mutations to knock out the NF-kappa B binding site of the uPA promoter results in over 80% reduction in LPA-induced uPA promoter activation, whereas this activity is largely intact with the promoter containing mutations in the AP1 binding sites. Thus these results suggest that the G(i)-Ras-Raf-NF-kappa B signaling cascade is responsible for LPA-induced uPA up-regulation in ovarian cancer cells.	Scripps Res Inst, Dept Immunol, IMM 19, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Biol Mol, IMM 19, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Huang, S (corresponding author), Scripps Res Inst, Dept Immunol, IMM 19, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@scripps.edu	Chun, Jerold/Y-4670-2019		NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA93926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Borgfeldt C, 2001, INT J CANCER, V92, P497, DOI 10.1002/ijc.1215; CHAMBERS SK, 1995, CANCER, V75, P1627, DOI 10.1002/1097-0142(19950401)75:7<1627::AID-CNCR2820750712>3.0.CO;2-V; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Dunn SE, 2001, CANCER RES, V61, P1367; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Fidler IJ, 2003, GYNECOL ONCOL, V88, pS29, DOI 10.1006/gyno.2002.6680; Fischer K, 1998, FEBS LETT, V438, P101, DOI 10.1016/S0014-5793(98)01279-4; Fishman DA, 2001, CANCER RES, V61, P3194; Fishman DA, 1999, BIOCHEM J, V341, P765, DOI 10.1042/0264-6021:3410765; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Fujita T, 2003, CANCER LETT, V192, P161, DOI 10.1016/S0304-3835(02)00713-9; Gondi CS, 2003, ONCOGENE, V22, P5967, DOI 10.1038/sj.onc.1206535; Guerrini L, 1996, FEBS LETT, V393, P69, DOI 10.1016/0014-5793(96)00854-X; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Huang MC, 2002, BBA-MOL CELL BIOL L, V1582, P161, DOI 10.1016/S1388-1981(02)00151-8; Huang S, 2001, J BIOL CHEM, V276, P40977, DOI 10.1074/jbc.M105242200; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Janosch P, 2000, FASEB J, V14, P2008, DOI 10.1096/fj.99-0883com; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; Konecny G, 2001, CLIN CANCER RES, V7, P1743; Kozasa Tohru, 2003, V237, P153; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; KUHN W, 1994, GYNECOL ONCOL, V55, P401, DOI 10.1006/gyno.1994.1313; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Laird AD, 1999, J BIOL CHEM, V274, P4430, DOI 10.1074/jbc.274.7.4430; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Lengyel E, 2001, METHOD ENZYMOL, V333, P105; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Luquain C, 2003, J LIPID RES, V44, P1963, DOI 10.1194/jlr.M300188-JLR200; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Mazumdar A, 2001, CANCER RES, V61, P400; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Moriyama T, 1999, CLIN EXP METASTAS, V17, P873, DOI 10.1023/A:1006729611241; Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E; Murthi P, 2004, GYNECOL ONCOL, V92, P80, DOI 10.1016/j.ygyno.2003.09.016; Paciucci R, 1998, AM J PATHOL, V153, P201, DOI 10.1016/S0002-9440(10)65561-7; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Rabbani SA, 1998, INT J ONCOL, V12, P911; Reuning U, 1999, EUR J BIOCHEM, V259, P143, DOI 10.1046/j.1432-1327.1999.00014.x; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sato S, 2002, FEBS LETT, V528, P212, DOI 10.1016/S0014-5793(02)03311-2; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Suzuki M, 2004, J BIOL CHEM, V279, P14899, DOI 10.1074/jbc.M313130200; Suzuki M, 2003, INT J CANCER, V104, P289, DOI 10.1002/ijc.10950; Tanyi JL, 2003, CANCER RES, V63, P1073; Ueshima S, 1999, CELL STRUCT FUNCT, V24, P71, DOI 10.1247/csf.24.71; van Leeuwen FN, 2003, BIOCHEM SOC T, V31, P1209; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILHELM O, 1995, CLIN EXP METASTAS, V13, P296, DOI 10.1007/BF00133485; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317	79	53	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10564	10571		10.1074/jbc.M412152200	http://dx.doi.org/10.1074/jbc.M412152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15653692	hybrid			2022-12-25	WOS:000227559600101
J	Rubotham, J; Woods, K; Garcia-Salcedo, JA; Pays, E; Nolan, DP				Rubotham, J; Woods, K; Garcia-Salcedo, JA; Pays, E; Nolan, DP			Characterization of two protein disulfide isomerases from the endocytic pathway of bloodstream forms of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; LYSOSOMAL MEMBRANE GLYCOPROTEIN; INDUCIBLE EXPRESSION SYSTEM; PROTIST GIARDIA-LAMBLIA; AFRICAN TRYPANOSOMES; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; BOND FORMATION; SURFACE; INTERFERENCE	Proteins from the endocytic pathway in bloodstream forms of Trypanosome brucei are modified by the addition of linear poly-N-acetyllactosamine side chains, which permits their isolation by tomato lectin affinity chromatography. Antibodies against this tomato lectin binding fraction were employed to screen a cDNA expression library from bloodstream forms of T. brucei. Two cDNAs were prominent among those selected. These cDNAs coded for two putative protein disulfide isomerases (PDIs) that respectively contained one and two double-cysteine redox-active sites and corresponded to a single domain PDI and a class 1 PDI. Assays of the purified recombinant proteins demonstrated that both proteins possess isomerase activity, but only the single domain PDI had a reducing activity. These PDIs possess a number of unusual features that distinguish them from previously characterized PDIs. The expression of both is developmentally regulated, they both co-localize with markers of the endocytic pathway, and both are modified by N-glycosylation. The larger PDI possesses N-glycans containing poly-N-acetyllactosamine, a modification that is indicative of processing in the Golgi and suggests the presence of a novel trafficking pathway for PDIs in trypanosomes. Although generally PDIs are considered essential, neither activity appeared to be essential for the growth of trypanosomes, at least in vitro.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Free Univ Brussels, Mol Parasitol Lab, Inst Mol Biol & Med, B-6041 Gosselies, Belgium	Trinity College Dublin	Nolan, DP (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.	denolan@tcd.ie	Garcia-Salcedo, Jose A/AAA-9434-2019	Garcia-Salcedo, Jose A/0000-0003-3399-1835; Woods, Katherine/0000-0003-3474-3104; Nolan, Derek/0000-0002-3742-4304				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; Bastin P, 2000, J CELL SCI, V113, P3321; Ben Achour Y, 2002, INFECT IMMUN, V70, P3576, DOI 10.1128/IAI.70.7.3576-3585.2002; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; BRICKMAN MJ, 1993, EXP PARASITOL, V76, P329, DOI 10.1006/expr.1993.1041; BRICKMAN MJ, 1994, J CELL SCI, V107, P3191; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; BRUN R, 1979, ACTA TROP, V36, P289; Desilva MG, 1996, DNA CELL BIOL, V15, P9, DOI 10.1089/dna.1996.15.9; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Field MC, 2004, TRAFFIC, V5, P905, DOI 10.1111/j.1600-0854.2004.00234.x; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Garcia-Salcedo JA, 2004, EMBO J, V23, P780, DOI 10.1038/sj.emboj.7600094; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HSU MP, 1989, BIOCHEMISTRY-US, V28, P6440, DOI 10.1021/bi00441a042; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; Kanai S, 1998, J MOL EVOL, V47, P200, DOI 10.1007/PL00006377; Kelley RJ, 1995, MOL BIOCHEM PARASIT, V74, P167, DOI 10.1016/0166-6851(95)02493-X; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; Knodler LA, 1999, J BIOL CHEM, V274, P29805, DOI 10.1074/jbc.274.42.29805; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; LEE MGS, 1994, J BIOL CHEM, V269, P8408; McArthur AG, 2001, MOL BIOL EVOL, V18, P1455, DOI 10.1093/oxfordjournals.molbev.a003931; MIZUNAGA T, 1990, J BIOCHEM, V108, P846, DOI 10.1093/oxfordjournals.jbchem.a123291; Morgan GW, 2002, TRENDS PARASITOL, V18, P540, DOI 10.1016/S1471-4922(02)02392-9; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Nolan DP, 1999, CURR BIOL, V9, P1169, DOI 10.1016/S0960-9822(00)80018-4; O'Beirne C, 1998, MOL BIOCHEM PARASIT, V91, P165, DOI 10.1016/S0166-6851(97)00191-6; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; Padilla A, 2003, J BIOL CHEM, V278, P1872, DOI 10.1074/jbc.M210322200; PAYS E, 1980, NUCLEIC ACIDS RES, V8, P5965, DOI 10.1093/nar/8.24.5965; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WEBSTER P, 1989, EUR J CELL BIOL, V49, P295; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	57	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10410	10418		10.1074/jbc.M409375200	http://dx.doi.org/10.1074/jbc.M409375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15642735	hybrid			2022-12-25	WOS:000227559600082
J	Ward, DMV; Vaughn, MB; Shiflett, SL; White, PL; Pollock, AL; Hill, J; Schnegelberger, R; Sundquist, WI; Kaplan, J				Ward, DMV; Vaughn, MB; Shiflett, SL; White, PL; Pollock, AL; Hill, J; Schnegelberger, R; Sundquist, WI; Kaplan, J			The role of LIP5 and CHMP5 in multivesicular body formation and HIV-1 budding in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR DOWN-REGULATION; SACCHAROMYCES-CEREVISIAE; ENDOCYTIC PATHWAY; ESCRT-I; PROTEIN; ENDOSOMES; COMPLEX; TRANSPORT; INTERACT; TRAFFICKING	We examined the function of LIP5 in mammalian cells, because the yeast homologue Vta1p was recently identified as a protein required for multivesicular body (MVB) formation. LIP5 is predominantly a cytosolic protein. Depletion of LIP5 by small inhibitory RNA (siRNA) does not affect the distribution or morphology of early endosomes, lysosomes, or Golgi but does reduce the degradation of internalized epidermal growth factor receptor ( EGFR), with EGFR accumulating in intracellular vesicles. Depletion of LIP5 by siRNA also decreases human immunodeficiency virus type 1 (HIV-1) budding by 70%. We identify CHMP5 as a LIP5-binding protein and show that CHMP5 is primarily cytosolic. Depletion of CHMP5 by siRNA does not affect the distribution or morphology of early endosomes, lysosomes, or Golgi but does result in reduced degradation of the EGFR similar to silencing of LIP5. Surprisingly, CHMP5 depletion results in an increase in the release of infectious HIV-1 particles. Overexpression of CHMP5 with a large carboxyl-terminal epitope affects the distribution of both early and late endocytic compartments, whereas overexpression of LIP5 does not alter the endocytic pathway. Comparison of overexpression and siRNA phenotypes suggests that the roles of these proteins in MVB formation may be more specifically addressed using RNA interference and that both LIP5 and CHMP5 function in MVB sorting, whereas only LIP5 is required for HIV release.	Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu			NHLBI NIH HHS [HL26922] Funding Source: Medline; NIAID NIH HHS [AI51174] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026922, R01HL026922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amara A, 2003, J CELL BIOL, V162, P371, DOI 10.1083/jcb.200307062; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bache KG, 2004, MOL BIOL CELL, V15, P4337, DOI 10.1091/mbc.E04-03-0250; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Bishop NE, 2003, INT REV CYTOL, V232, P1, DOI 10.1016/S0074-7696(03)32001-7; Bright NA, 2001, TRAFFIC, V2, P631, DOI 10.1034/j.1600-0854.2001.20906.x; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Fujita H, 2004, J CELL SCI, V117, P2997, DOI 10.1242/jcs.01170; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Howard TL, 2001, J CELL SCI, V114, P2395; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kranz A, 2001, MOL BIOL CELL, V12, P711, DOI 10.1091/mbc.12.3.711; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Ono A, 2004, J VIROL, V78, P1552, DOI 10.1128/JVI.78.3.1552-1563.2004; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Shiflett SL, 2004, J BIOL CHEM, V279, P10982, DOI 10.1074/jbc.M312669200; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Tchernev VT, 2002, MOL MED, V8, P56, DOI 10.1007/BF03402003; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Yeo SCL, 2003, J CELL SCI, V116, P3957, DOI 10.1242/jcs.00751; YORIKAWA C, 2004, IN PRESS BIOCH J	37	86	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10548	10555		10.1074/jbc.M413734200	http://dx.doi.org/10.1074/jbc.M413734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15644320	hybrid			2022-12-25	WOS:000227559600099
